<SEC-DOCUMENT>0001558370-22-017874.txt : 20221114
<SEC-HEADER>0001558370-22-017874.hdr.sgml : 20221114
<ACCEPTANCE-DATETIME>20221114172530
ACCESSION NUMBER:		0001558370-22-017874
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		106
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221114
DATE AS OF CHANGE:		20221114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			iBio, Inc.
		CENTRAL INDEX KEY:			0001420720
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262797813
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35023
		FILM NUMBER:		221387960

	BUSINESS ADDRESS:	
		STREET 1:		600 MADISON AVENUE, SUITE 1601
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022-1737
		BUSINESS PHONE:		302 355-0650

	MAIL ADDRESS:	
		STREET 1:		600 MADISON AVENUE, SUITE 1601
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022-1737

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	iBioPharma, Inc.
		DATE OF NAME CHANGE:	20080806

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	InB:Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20071210
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ibio-20220930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/14/2022 9:57:24 PM -->
      <!-- iXBRL Library version: 1.0.8263.24741 -->
      <!-- iXBRL Service Job ID: 455b6960-0237-4e83-b400-7dbfc12bd11c -->

  <html xmlns:ibio="http://www.ibioinc.com/20220930" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_r-l9-B56DkK8GFGRbyXoAQ">8842000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_yhSKRaHIUkS1_3TLlaftHA">8715000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_Doy5vExYEUu9Mr8jwtDtWQ">8842000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_rjhicEeiM0iIWauwVf4RfA">8715000</ix:nonFraction><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityCentralIndexKey" id="Tc_aCnAQKbX_0OKexW2a5T7ng_2_1">0001420720</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:CurrentFiscalYearEndDate" id="Tc_ZBVyyjFJ_kS9Iy9PEPT5fw_3_1">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:DocumentFiscalYearFocus" id="Tc_bF2rRI0PrkGVIvVoWftuvQ_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:DocumentFiscalPeriodFocus" id="Tc_y3aPtTSp2kuHjHNmgRr8bw_5_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:AmendmentFlag" id="Tc_kA6uaDyTvUaR3mtzBp0rcQ_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_njHtyGT4_U6yqIcTgti9cg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_tyE9TMbZgEyWhODfiBHPvA">1000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" xs:nil="true" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" name="us-gaap:PreferredStockValue" id="Hidden_eqD4kNNv-U-K5qj5gfYiFQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" xs:nil="true" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" name="us-gaap:PreferredStockValue" id="Hidden_wTYmbk3_IEuxZyoGomTrdA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="0" name="us-gaap:CommonStockSharesIssued" id="Hidden_XHV-8pD9R02rZnlCS5G2Qw">9006582</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="0" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_-Kg9WQpbq0eBpOgmN66fgA">8727158</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_OpPyzGPfbk6YG5Rr7wMBdg">0.85</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_gMzmk3wLFkK2aHz3MKKD4g">0.60</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_AoT3ZaryAEean7dePk0z3A">1.20</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_Cf2NuHLrfE-uFyMkWX3Uig">0.43</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_99bdrmUalkCbFfGhk6saBA">2.05</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_YTsxMg4SEUaPMK4RepGT4Q">1.03</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" id="Hidden_G92FJIZcG06BIGNnHbTKpg">1151000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="Duration_9_22_2022_To_9_22_2022_CTru4tx0CEOj9arQdgZu6A" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden__0cS0oMu3kKeTj2aafl8jw">0.04</ix:nonFraction><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:LeasePracticalExpedientsPackage" id="Hidden_sGul_1aHN0eDILLvK8AumA">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_8yJ_HfWYO0S9Yen3aE5TWA" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_mylpkjT0LkCiMRV69PIkrw">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember__u8DjlS8KEWaLpv6LnztgQ" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Hidden_u6VUYlS0b0yj9uFRIDrlgA">P23Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_0Gc57JBw0UGHG06Trj7aaw" name="ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm" id="Hidden_9g2_uLeoFka_iS5MEA5Jqw">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_MinimumMember_-6_SwUpb2EmaZh5-_vBL1Q" name="us-gaap:InvestmentMaturityDate" id="Hidden__3BD-NqJOEiqalOgJX0pyg">2022-01-01</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_MaximumMember_s8tVGg0TVkGTdiQRMPEupQ" name="us-gaap:InvestmentMaturityDate" id="Hidden_NaePz8N5I0616M6LaQS5Jg">2023-11-01</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_4qWWKwB8e0-Yy5X_aaxA6w" name="ibio:BaseRentAbatementInFirstYearPeriod" id="Hidden_HTgQ1reF4068PJjjH7wdhg">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_Q5VFP_d1U0Sx8AHkVLyC-g" name="ibio:BaseRentAbatementInFirstYearPeriod" id="Hidden_6jE7_kh_EUe3WSMLLFzfcg">P5Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_UVdxoMmgQkKjhJdoE6VcYg">0.85</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_drCJr6G_BkCKj9KtPlTGNA">0.60</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_Ja0Qe-ca6kSwUGmiTbHIlA">1.20</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_1FZCwCoI6Emocc2F149ZKA">0.43</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_-4hgScTO5E-EP-H2wvkN5w">2.05</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_OTJhXFjeGU-xhjMC2Fzccw">1.03</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_ZaqY31fz2UaBgOG5OgjeFQ" decimals="0" name="us-gaap:SettlementAssetsCurrent" id="Hidden_n27rjvZYL0OlHIzsiufN3A">5100000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_YqxjlA6uoU6BgYmOK-o-eA" decimals="0" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" id="Hidden_KLGwyYKoFUWk37Z8Z7W-QA">900000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ibio-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pjwYstABlU2nhu8zVQax6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_nIO8x0O-D0ajEs1hfec5ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_22_2022_To_9_22_2022_CTru4tx0CEOj9arQdgZu6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-22</xbrli:startDate><xbrli:endDate>2022-09-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mC7BYOTYH0a7Wk8V2O2hrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N4y1JB93p0KE0lNMIY0TKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ONpLrTILEC92ojz2-S9Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VqSPMHJY_kKNvzc7COpAeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B4AZcYK-c0asmfHVM1feAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mG4LbET2DECSO7FdaX63IQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HxjHz6i74k6VEvJSqTEdqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bmsbSdyfUUmoltX5xZjZqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XzvlH8qzzkC_5vSGgF1Uwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XVi69PwJykqe8xvOj7V4FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4SJVQK9LYUSBCSlw5dlipg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_2zacrRBIuEKYll8_FrKwOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GH-5RrH9aUCemJman1Sceg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LANmWQuoxU-cg4DMxrvqag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UIQ-9TQJg02_iffm6LAbPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_45O6JBHOlU2mPcO5JCdPKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bAryvWRFa0ajF3wOujsFkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0tv1Shz8i02Z3bQpOwGtZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2N7RXo2_pUetdE_cG5cZ6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_ZaqY31fz2UaBgOG5OgjeFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_euWJTSKtt0aJwVGdmEINPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_0pi0YCsgSUCH7buV1WBF9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_F4h9j-DOsUyvR-zF7aWpzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_K4UWN_QhQECOHvhw12blGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_54ARR6tb80WIuJ-jyvDHFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_H3Laxbz45UWYB-AJtsQg0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_8yJ_HfWYO0S9Yen3aE5TWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_h3rVauDz3ESYJDDsYgtxFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_ovqbH7S4FkKWmzhQHgtz3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2017_QxVrYRSL_UiOCiGSWO0CFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_h-pYgsijTkKHQ_QNQK-fLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-31</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_l3TXqFcTd0OMoQ1amXL65A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-23</xbrli:startDate><xbrli:endDate>2017-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_J9Qyego6XEGPGcqSDViMZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_L7GZScf59UWcwVJ60pxOUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_H4wahzJ9fkakdBA5brt04w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_nOs84_8GCkueqFiJt1xgmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HRtnDhbFY0iZF8Myn0m59Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FDjxICtcCUCFzo4fnrEFAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_vBxV47t9JkmztS3TPBPfNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_EasternAffiliateMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_MyiAUVo2vkGkyCCsfdBIcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibio:EasternAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_cVkZ8G6vJUqQuiTDjSGGZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_RangeAxis_srt_MinimumMember_-6_SwUpb2EmaZh5-_vBL1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_RangeAxis_srt_MaximumMember_s8tVGg0TVkGTdiQRMPEupQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_ZxIXPbVKrUyMV_ban-OCAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialStandbyLetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_DEoVZtJZY0yz9pSSGN9D5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ab93kNrf80-v2rMyke-vrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember__u8DjlS8KEWaLpv6LnztgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_fXHaqpNPo0ibzA3IIYhZbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_rkj0FZs-fUu4EXJb9_k82g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_YQhUDGnYokGcvtHjtcEqtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_uC1tSKAok0msG1QVWd04rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_dlYgMTALDUmKK5WItuSB3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_WTTx3bX1OkW89C-T4NTf4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:PrincipalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_JT9c6c8IIEOMVOhxR4-gmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_GQ940Ff9F0Sa787zj-1tnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_vIjz2QvLhkmSRzd2SRXhOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_ibio_RubrycTheraputicsInc.Member_6l4R-5WO_UilEL_BSvm5mA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember_xJCS27lRZ0q-02PnngOAUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionPrepaidExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_zieqCNuAYk6lRv2JAfCx8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember__MJTg0K5YECHuCTCCIebng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_ITw1i6YR9UyPpE1bDlnljA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_gsOXphCp7kqOXBi52mrpig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aLCKc_DsZ0mcPYZ4iThlOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_RW522OwZwE2Q8Rhd-pq6hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_6yylM16A906KWG6WH1olXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kOWrKqdXuEqZHagsSxnYmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_awj1_vQ1DUSHyHXaRL7ufw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_U25ZnOgUdEuQ-HzSBdsbxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Cd2Z2zMIHkG4C6QpdIGJ0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-3uXSg1qM0mejJjzOTqnKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_QgEz_8IsUkubKmRBLIhjSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_zK_EuxHxJUWase0Bb6jdgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_QXdJeF316UutTHwstfvd0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_MtHCCTglWES6FXBOwD3GbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_UYTDkmnuYUKjYhuJvrtFBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_97qQQ2NlZkS1QrbYGZ0BWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-04</xbrli:startDate><xbrli:endDate>2021-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_s9c-WnWOxE6g2LweOZs_9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_i04Yf02_rk-EHh765zWa6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_ezl_cu4pZEaWF2orMq4slA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-23</xbrli:startDate><xbrli:endDate>2017-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_XyA_UzbdsEqM1o0uE-Nz6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_RpRam_Iq8kC7AtGMNktNbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_4_1_2021_Cv64n0Mw7E6pyUXZzZXFwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2021_To_9_10_2021_m_dKSYWyjkGt_N2eurcfeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_UM_IWNFT-kCLpCY0YtA3Kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibio:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_7CoQPwcN1U-vHI9EXbbGag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibio:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_2OHxCAB-J0WOw18oKiVXGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibio:IbioCmoPreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Drb-_QNrO0K1RLoc86Un0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fF9KSDzTNUewjtgDUfom4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IurkUKJGTEiNYvvgn9u9qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_0Gc57JBw0UGHG06Trj7aaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:NoBiosimilarProductHasBeenApprovedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_OdZyqlQ0vEmY8lbQusF-8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_6ZrviqcdeEqMylJf6L3J_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_WRviyH3-o0yDEY9X1wSIKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_LZBHDrN9UUGCxpUjpg5lXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_YqxjlA6uoU6BgYmOK-o-eA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_mRyOoO-D5kmgzWk1TetiGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_fdlqH-ydv0qTOi8QNX4gWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedLegalFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_4qWWKwB8e0-Yy5X_aaxA6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_Q5VFP_d1U0Sx8AHkVLyC-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_7_2022_qjzi2byYh0-0owjOCuOBmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_customer_Y0UfwaAMRkCOQV5hDgN0Lw"><xbrli:measure>ibio:customer</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_5KxWaFXlD02dT7QlqBc7JA"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_e4f47eb1_71a3_4d75_9ca4_11bd0a77993f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Washington</b>, <b style="font-weight:bold;">D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:9pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:DocumentType" id="Narr_P7rOSybBnEWP0Z2Ug33nFg"><b style="font-size:9pt;font-weight:bold;">10-Q</b></ix:nonNumeric></p><a id="_78f9c99e_4a1c_46a6_993a_898c0bdb85de"></a><a id="Tc_U30phUhnKUezwEnT3XEBzA_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:DocumentQuarterlyReport" id="Tc_8S5gDCCgAkimMxbY6BmD4Q_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-size:9pt;">For the quarterly period ended </span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:DocumentPeriodEndDate" id="Narr_eN36uKlme0GCti1WemQDfA">September&#160;30,&#160;2022</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">OR</b></p><a id="_2426db59_d74c_4e48_8938_15e2dadd7a8b"></a><a id="Tc_ELsgv4x32UW2xnGsiIVo7Q_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:DocumentTransitionReport" id="Tc_LjSnzpp7BU6PWnCX-hXvYQ_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">For the transition period from ___ to ___</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:9pt;font-weight:bold;">Commission file number </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityFileNumber" id="Narr_OT-Ez9ZIuEOMzwhHny774g"><b style="font-size:9pt;font-weight:bold;">001-35023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityRegistrantName" id="Narr_Uqc_ybKUWkqDXvyRb1hEVA"><b style="font-weight:bold;">iBio,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Exact name of registrant as specified in its charter)</p><a id="_64cc32ea_03df_4de5_8b97_e3f1a1a0de16"></a><a id="Tc_RMMLdGkffUmGP4V7gYHmyA_1_0"></a><a id="Tc_8VyavXJZkEWx48Efugdp_g_1_2"></a><a id="Tc_Nf0ulJ3MGkalAc_DlPmztg_3_0"></a><a id="Tc_2yGNq4P4c0yXzOrqDDRfRQ_3_2"></a><a id="Tc_HYUSRj6YsUmM0VvD-F2o_w_4_0"></a><a id="Tc_m_qok7AbhU2o0d-3Pk7j1Q_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityIncorporationStateCountryCode" id="Tc_KubkwukwR0a5JPYqVu-fQQ_0_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityTaxIdentificationNumber" id="Tc_6o7g8Vf_A06xs6UyMjg6Rw_0_2"><b style="font-size:9pt;font-weight:bold;">26-2797813</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityAddressAddressLine1" id="Narr_Mn4LWgeR4EWkYc2HtAbylg"><b style="font-size:9pt;font-weight:bold;">8800 HSC Parkway</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityAddressCityOrTown" id="Narr_OfYCA9_NikapwqPZzOCaXQ"><b style="font-size:9pt;font-weight:bold;">Bryan</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityAddressStateOrProvince" id="Narr_3d2lrX6XKUGMgEgktws6VQ"><b style="font-size:9pt;font-weight:bold;">TX</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityAddressPostalZipCode" id="Narr_h9ZyA0JhrkennR5iYJycfg"><b style="font-size:9pt;font-weight:bold;">77807</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">-1107</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:CityAreaCode" id="Narr_WUPQTCiWw0W_JzQ5Yma76w"><b style="font-size:9pt;font-weight:bold;">979</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:LocalPhoneNumber" id="Narr_Sky0bxwS20-90cOwk5jD4A"><b style="font-size:9pt;font-weight:bold;">446-0027</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Former name, former address and former fiscal year, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 10pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_69468a9e_bc59_40b1_bd61_01c8e498cc01"></a><a id="Tc_MeQQhbjRxEefsZMNEsSrMQ_1_0"></a><a id="Tc_2aMwJpsYi0CIAV4j18gLKQ_1_2"></a><a id="Tc_xhnSQpezm0SZz4xF3NRN0w_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:52%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:26%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:0.99%;background:#ffffff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:19.99%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ticker symbol(s)</b></p></td><td style="vertical-align:bottom;width:0.99%;background:#ffffff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:52%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:26%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:Security12bTitle" id="Tc_yipRbNn-v0mA8qAEf-LgiQ_2_0"><span style="font-size:9pt;">Common Stock</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:0.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:19.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:TradingSymbol" id="Tc_6EZ8DxSLhkqM0ckrF9GyGg_2_2"><span style="font-size:9pt;">IBIO</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:0.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:SecurityExchangeName" id="Tc_RBVMOky-o0uMz5au5y7Xbg_2_4"><span style="font-size:9pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityCurrentReportingStatus" id="Narr_NvUeC56JR06vGrAa8Y6lZw"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160; </span><span style="font-family:Times New Roman;font-size:9pt;">&#8999;</span><span style="font-size:9pt;"> &#160;&#160;No </span><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityInteractiveDataCurrent" id="Narr_yZkp6mCJeE-NFW--99yv_w"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160; </span><span style="font-family:Times New Roman;font-size:9pt;">&#8999;</span><span style="font-size:9pt;"> &#160;&#160;No </span><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large, accelerated filer,&#8221; &#8220;accelerated filer&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Large accelerated Filer&#160; <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Accelerated Filer&#160; <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityFilerCategory" id="Narr_vlveDWzjLEq0JxQO19ODTA"><span style="font-size:9pt;">Non-accelerated Filer</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Smaller reporting company&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntitySmallBusiness" id="Narr_o_9sNO-6b0arHcBo9ZS_5A"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Emerging growth&#160;company&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityEmergingGrowthCompany" id="Narr_z6avpidJ6kaAbRoUfwOB8g"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-size:9pt;">Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="dei:EntityShellCompany" id="Narr_xRam8wHTEEy6vXunSfie-Q"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> &#160;&#160; No&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Shares of Common Stock outstanding as of November 7, 2022:&#160;<ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_7_2022_qjzi2byYh0-0owjOCuOBmQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_EOLU1irICEq2MaRdEk5rOA">8,988,782</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_10e5e096_de04_41f3_b7fb_a459e1afc4ba"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">iBio, Inc.</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_616298"><span style="font-style:normal;font-weight:normal;">PART&#160;I. FINANCIAL INFORMATION</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_863395"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_863395"><span style="font-style:normal;font-weight:normal;">Financial Statements (Unaudited)</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3</span></a>.</p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_545173"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_545173"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_600713"><span style="font-style:normal;font-weight:normal;">PART&#160;II. OTHER INFORMATION</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_731318"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_731318"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_275295"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_275295"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_186239"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_186239"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">38</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_377876"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_377876"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">38</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_117481"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e31b7acb_1b53_4713_a703_640c879db98d"></a><a id="PARTIFINANCIALINFORMATION_616298"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;I&#160;- FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_863395"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item&#160;1. &#160; Financial Statements (Unaudited).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(In Thousands, except share and per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_75250c54_ee0d_4efe_b108_30bf3749ae52"></a><a id="Tc_D8cirOmSK0qnvTpgqaYUrg_1_2"></a><a id="Tc_1brOZzNL5UiOtBEg_k6SdQ_1_5"></a><a id="Tc_5dzDwkiwaE-iapIuvolLDQ_2_2"></a><a id="Tc_lHvMLH9E-0Gv7Ym9xhfuBw_2_5"></a><a id="Tc_okVauEYMWUmUlDTw01G1mw_3_2"></a><a id="Tc_tkOO5dkVRUSnpScB1VH8OA_3_5"></a><a id="Tc_d8pZhXtrDkemoiE-VTFLIw_4_0"></a><a id="Tc_IMewlC-5pUaMweCWEnZjVw_5_0"></a><a id="Tc_dzz5v247hkuIiGDnfAdCUw_6_0"></a><a id="Tc_gm5M7CDErECzw6rK7CtmpA_6_2"></a><a id="Tc_TGgCvenuHU2KCnUKCWygTg_6_5"></a><a id="Tc_SZ-Sy2_CkE2eSZXnwPn_rQ_7_0"></a><a id="Tc_Odb1isegu0enBqqWAE7Miw_8_0"></a><a id="Tc_LqPU1KWjDE2RtN7Y1HAhXQ_9_0"></a><a id="Tc_3Rls3D2OQ0qN7QgramB-Wg_10_0"></a><a id="Tc_WukGuyK000iwXAvGd-KiRA_11_0"></a><a id="Tc_ZB5pEAPpdE2K9P_7r-jRCg_12_0"></a><a id="Tc_yDq-Jd2YykSIVz822zvTjA_14_0"></a><a id="Tc_4GpyOJlvN02iWsYRxrrcVw_15_0"></a><a id="Tc_qk-XgP2syEe_fsev4C5WYQ_15_3"></a><a id="Tc_NlsrKkYVD0KBsjF0WLXUDQ_16_0"></a><a id="Tc_g0R4AMQw_ki95Kqc0ECQIA_17_0"></a><a id="Tc_SYpy5MjFs0COHEYAumTlUQ_17_6"></a><a id="Tc__xky8WzjV02iCNdZi-mDCg_18_0"></a><a id="Tc_ZVtocYsQNEW_0VM-ZBVhLw_19_0"></a><a id="Tc_tL2hudzF3EmUAS743zcu6Q_20_0"></a><a id="Tc_m1tVAL9E3067-3YnEpbMgw_21_0"></a><a id="Tc_em6oNxD7BkacYIa8Wt_sfQ_22_0"></a><a id="Tc_kcQnEW1exkevGEdTKUqdiQ_23_0"></a><a id="Tc_c30BrFGNAUmRmKmZ80lVhQ_23_2"></a><a id="Tc_MI7AAx2BG0uMbNkGHVFRSg_23_5"></a><a id="Tc_5NxNVpR3pkSaSTsKZ3QXGA_25_0"></a><a id="Tc_pkmMfELZw02gioe0Z1062A_26_0"></a><a id="Tc_AsKzzYdyqEKETv-9GkBHdw_27_0"></a><a id="Tc_ac4ZankrAE2nw8BDzWoI9A_27_2"></a><a id="Tc_8_R2oInKFk-pME69k9BFSg_27_5"></a><a id="Tc_rDQlVS_YuEy0262aaWGaHA_28_0"></a><a id="Tc_iQJ3e8WA_EaWJiUYgEqV7g_29_0"></a><a id="Tc_FTsW-DTw9kCIrOisXCcQRA_29_6"></a><a id="Tc_1II8_7inxUWLAFfUDWio8Q_30_0"></a><a id="Tc_EbhPUJaWQ0qMSOOXdiCTlw_31_0"></a><a id="Tc_w-Daxl6Qs061QACxYSVbgw_32_0"></a><a id="Tc_OhLPpJ5_bE2O_tNabVOeRg_33_0"></a><a id="Tc_hsT_mK86S0eJas0zy7kC4w_34_0"></a><a id="Tc_nOaVU73c3EaHrToko3ylUQ_36_0"></a><a id="Tc_uwUuYBaFdUCXN-JLWYHxew_36_6"></a><a id="Tc_5FrOKmUx1Uu6ZjSxE9-aEA_37_0"></a><a id="Tc_lnAP152S-kSbU25rNXIFoQ_38_0"></a><a id="Tc_C_gTan_Yn0u22gENkAOzPg_38_3"></a><a id="Tc_tPdq1hAU6UWjkugWuu67Vg_40_0"></a><a id="Tc_Nz8pZkZh_EuRRnC0Md4yDw_42_0"></a><a id="Tc_I8LSTWeQuEWJoUbs7kW9VA_43_0"></a><a id="Tc_2eUpjIWmO0a-BDSaw8YUlw_44_0"></a><a id="Tc_sqcqKupPK0qwjEwdtlHfgQ_45_0"></a><a id="Tc_6vt13kw2uESlMvzxTcF_ng_46_0"></a><a id="Tc_kCFZAM9jm0GR-CkPPdKIiQ_47_0"></a><a id="Tc_FSRuBBbBVUyndLRtUBHLRw_48_0"></a><a id="Tc_G-e5i9vSeE-V-QxmHsDiuA_49_0"></a><a id="Tc_7PJef8cKI0a-yOVEtR2cEg_50_0"></a><a id="Tc_d-jWyq8LbkCVndr_oSITQQ_50_2"></a><a id="Tc_qJJSg5N3r0G_rfAQzzpydQ_50_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.1111145%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">September&#160;30,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2022</p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(Unaudited)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(See Note 2)</p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_ALhJZ6BUpESTZYwzhWz_fw_6_3">9,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_gNDkWNfgSkS0tORKI-uvcw_6_6">22,676</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Investments in debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="Tc_-6rYrtlBbU28OaVl_speyw_7_3">7,599</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="Tc_yx1oF3bb8EuV9wmEPhrykw_7_6">10,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accounts receivable - trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_Gn0IhCbQkk2CAYEKS6JQMg_8_3">1,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_ZwPwX39YPky3Nfd7qu3PTQ_8_6">1,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Settlement receivable - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SettlementAssetsCurrent" scale="3" id="Tc_tOIm4PGapE2HnPixffTR_w_9_3">5,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SettlementAssetsCurrent" scale="3" id="Tc_ONQFnh5V10qh4VxHBxhl0Q_9_6">5,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_RXXMKYW5q0Sg_8_lE6BKtA_10_3">1,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_5EIWMdvK6UaPRrp13WDKrw_10_6">1,549</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Current assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="3" id="Tc_WxPhA17WikOXFVs9i3GK2w_11_3">38,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="3" id="Tc_z6HFPG3AF0e-hmpEUU3UYg_11_6">3,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Current Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc__ll8nXQpzkSAYySqTklmgQ_12_3">63,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_t-LtIkn3zkCUTJaxEBGhig_12_6">45,070</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_vH1H6oQNmUGOBH1_Np0NxQ_14_3">5,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_BnH5mb75W06d9ZyxruEzKQ_14_6">5,996</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="3" id="Tc_6YDfuQHRhU-hC-pl3ha4PA_15_6">37,314</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Convertible promissory note receivable and accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest" scale="3" id="Tc_Ny6GkFKvlkK2J9Dbce0xpg_16_3">1,650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest" scale="3" id="Tc_zLWcVDm57k6m1AZTtu9AFw_16_6">1,631</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease right-of-use assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_xaFpFbvQVE21yOtQsfmJDA_17_3">875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_Rgccpee3GUuYFRJtqfoDaA_18_3">2,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_GXGnsbCAkku5DemINKwqTA_18_6">3,068</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Fixed assets, net of accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_qJXOWAFWNUqo3lkSp8Zvzw_19_3">3,464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_V98Pa411hESBdTjl5PIAUg_19_6">1,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_377Rhy4KWUi0amXQoGubFw_20_3">6,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_5tEc4WO5eU-h9mSM9-ot7w_20_6">4,851</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="3" id="Tc_WR00a5B730SFia9RYLm66A_21_3">44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="3" id="Tc_Cf0qmRFXrEWNax3BP__NfA_21_6">74</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="3" id="Tc_Jd9eBQl1F0y81XAVCjzlhA_22_3">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="3" id="Tc_JhrjkEpCxUe6o5Abutixeg_22_6">29</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_ylO3CgFtCkCCYV3sXKLTwA_23_3">84,564</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_Pk5z01gbtUKgPmSgU_sXqw_23_6">99,406</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities and Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_ilSorH2UyEWCTA7dU1-wrw_27_3">4,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_WZOX61iN6EaHLouBWHOpRw_27_6">4,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_kaGEvoZab0e_oh3iTHMgiw_28_3">2,595</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_f9R-oNa-C06vkzibtMeZ7Q_28_6">3,764</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Finance lease obligations - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_sLvNQzXX3Um2Gqqzi1IN_g_29_3">303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_s5Bc-cxKLU-c8fDJ3CSlzQ_30_3">183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_lPJul0wQakyqPmyr7GIR3g_30_6">91</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Current liabilities related to assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale" scale="3" id="Tc_eVhIxbEbB0a_iXRp2J-xJw_31_3">1,949</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale" scale="3" id="Tc_fXIahf4PR0a4uWzncD2Mtg_31_6">56</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Term note payable - net of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_NExyNIjaokyPDtiy72USsg_32_3">22,201</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_ECFAJIEAS0aSCJ9nsNx1Yg_32_6">22,161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="Tc_l4berjRCdkqUkMUB-6pj9g_33_3">161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="Tc_UeMX5w3lAkKSMrtJ4JcZxw_33_6">100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Current Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_xQLpcC6t4EqhiIblamHEEA_34_3">32,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_bW3ewczq2E2P1hkKIPqXSA_34_6">30,436</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease obligations - net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_kpoCTTQxTkeGiPFetbkhJQ_36_3">576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease obligation - net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_ZBt_qq62NU6u21HT4Yhv4A_37_3">3,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_vTNKwt6seEaiV_jlZsepEw_37_6">3,514</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Noncurrent liabilities related to assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:NoncurrentLiabilitiesRelatedToAssetsHeldForSale" scale="3" id="Tc_oOzESy-hKkaF6RR-nWYAFw_38_6">1,971</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_DjvHfOQXEU6N5uPrTVw38g_40_3">36,196</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_T8aEvzvyrE2cOJr4BNYMLg_40_6">35,921</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">iBio, Inc. Stockholders&#8217; Equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Series 2022 Convertible Preferred Stock &#8211; </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_ZZI1JDnltk6tktlr4Q6UGQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_w5V5qWnZOkSvfU97ALIXdw">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_zV2oeTXfREKm68yyEmqo4A"><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_rc25FuYn4kqt8rRDxv6BjA">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> shares authorized; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_yKg8XsLHsEuKWavAlvQCsw">0</ix:nonFraction></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_x5AMusOWY0q-wwREDImWfw">1,000</ix:nonFraction></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_njHtyGT4_U6yqIcTgti9cg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_tyE9TMbZgEyWhODfiBHPvA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of September 30, 2022 and June 30, 2022, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_eqD4kNNv-U-K5qj5gfYiFQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_wTYmbk3_IEuxZyoGomTrdA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Common stock - </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_0lHtJrUGUkyIm8kQu8Wfdw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_U3Kluf0WpEKjO5bYUBrQBw">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_mYjNj50EBkC-obNbutdCcw"><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_lgyprKZW90-2TBeZxChkEQ">275,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> shares authorized at September 30, 2022 and June 30, 2022; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_KlIPYKG5nUyoSPiXfF6Q0A">9,006,582</ix:nonFraction></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_QCCAsugxDEKLiqraXjnqvQ">8,727,158</ix:nonFraction></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_XHV-8pD9R02rZnlCS5G2Qw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_-Kg9WQpbq0eBpOgmN66fgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of September 30, 2022 and June 30,&#160;2022, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_EkgcnPvSdUCRAAdymiBjOA_45_3">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_UlNWGSVW0k2t7jnSXTNt2w_45_6">9</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc__-O5vYBmEES0zR7tWvDFJg_46_3">290,642</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_fzEwrgit-UCbIDUb1_6pTA_46_6">287,619</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_HBYKJCzr_0unGZMGKGijKQ_47_3">223</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_hUrsEeFWr02Rl4EQLmHbPw_47_6">213</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_g6DVAjzbT0mK5tDWib19yw_48_3">242,060</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_6IGwAugdPkOP9UbVVWmm2w_48_6">223,930</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total iBio, Inc. Stockholders&#8217; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_PmNHFX2Ff0u-kh7Zl9eeeA_49_3">48,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_e8lcqBwb5UuO6sK8rA795A_49_6">63,485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Liabilities and Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_viiJ2XHXf0aWFA29ntufjQ_50_3">84,564</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_eLOhqZ6G_EaRWdcczRWF7g_50_6">99,406</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3346d1c0_7c38_460d_b5ad_6f93201e5b18"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Operations and Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited; in Thousands, except per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c5321d8f_6e23_495d_85a2_b363ce9c7edb"></a><a id="Tc_KXeHRmF-uUu8DVUwLRelTQ_1_2"></a><a id="Tc_V35hppG1f02w2BfKx1gEtA_2_2"></a><a id="Tc_w_svzInTkE-NZKyW9jy9bQ_3_2"></a><a id="Tc_N5B98Lkr1U6Vkd5WCB6agg_3_5"></a><a id="Tc_nkA1q2OcnE2FOL9gnImFBw_5_0"></a><a id="Tc_IKOZ70stOEClTDgkcRCQDg_5_2"></a><a id="Tc_hP6fReW_TEyjvSJAVzmZgg_5_5"></a><a id="Tc_0PzobJx4fkWO0_j6tAFv0A_7_0"></a><a id="Tc_rpTMSqEtN0WPUc2MNA4P2g_8_0"></a><a id="Tc_uUDPhPgoFkm98d8kQt3lNQ_9_0"></a><a id="Tc_5OR7X7FT2k-r7NuEQp7zgw_10_0"></a><a id="Tc_bUiKKRzpeEaMwo7Bim-UfQ_12_0"></a><a id="Tc_RuOxVL09sk6Vj4u6-wq85A_14_0"></a><a id="Tc_G6H8JcwWZkGVgdTPKFvfPw_15_0"></a><a id="Tc_LVyz3GNqFUGD4gzh0xRaGw_17_0"></a><a id="Tc_JP5piC_b7kiV0dC2fB7xWA_18_0"></a><a id="Tc_21UgcU1tPEOqYKoRpG41jg_19_0"></a><a id="Tc_ZL6hOP_pI0SyvKaCw29UNQ_21_0"></a><a id="Tc_a7ruE_vkgkaS1HL0tfHtew_22_0"></a><a id="Tc_mBcngo_C-E-YHsbVDDEkjA_24_0"></a><a id="Tc_N-9pMgK1PkyK5ihVJMx4fQ_26_0"></a><a id="Tc_dv3Vn93m5ESK0qa--Uytaw_26_2"></a><a id="Tc_5vueS5nFp0WuN6q7XuFJnQ_26_5"></a><a id="Tc_CJwysviTEk2r-vBBK51whA_28_0"></a><a id="Tc__oDDaVRhB0akVGdz-OXziA_29_0"></a><a id="Tc_r3uB21KZ3Um5bU6ikLkGNg_29_2"></a><a id="Tc_C8F045WTiUeK3QCB3KtfAg_29_5"></a><a id="Tc_PdAM92FJi0qMYbTulgqdtg_30_0"></a><a id="Tc_S-qFr4ugoEi9HBJrvKCcEQ_32_0"></a><a id="Tc_wReqUiKqmEK9cW9aS84raw_32_2"></a><a id="Tc_vZvbnEfcKkymA03AmDUPwQ_32_5"></a><a id="Tc_Yh4DbwhEYk-OBIGPiccQMg_34_0"></a><a id="Tc_SZZi_wBN2Um1zEe0hNHbdA_35_0"></a><a id="Tc_Wy8fQiaoU0CGjUTDHfX4bA_36_0"></a><a id="Tc_k9DvULWSckm6CMIkAzmpvQ_38_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.20833588%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="Tc_R033HGneP0GJHZ17XNWbMA_5_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_DSnbdq-a90evy8AQbIYcpw_5_6">84</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_pTRZ8ubXEEWpvBjWDLtBPA_8_3">2,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_FvP5IPvZsEib2GRnRiPWPg_8_6">1,134</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative (related party of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" scale="3" id="Narr_1f5M8rlgEE6BDX864WP0LQ">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" scale="3" id="Narr_5W-_NmAu1kOY055vhBvUjA">189</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_8Et6v9p3202UU4uc9Bxg6A_9_3">5,088</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_bdtdix_AYUWfJsyxliTTrg_9_6">4,175</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_Jbx5gjuho0SKGJOBwF9KBg_10_3">7,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_T0A0Wv3_-kK4e0v2DGrZZw_10_6">5,309</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_2AkS4foe0EmJXBlpprN4fQ_12_3">7,636</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_1wZZmc8ecEu92axqMfZFzA_12_6">5,225</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_lYR3yXlEn0mHuTF7-pmxOA_15_3">99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_ummrigYer0qdNh-gxn7Fww_15_6">36</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Consolidated net loss from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_oLCEKIDf90KICxjkQrKsfw_17_3">7,537</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_6ZD3xUxt2Uy0PbsKudnt-w_17_6">5,189</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Net loss attributable to noncontrolling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="3" id="Tc_PKEet627r0mlK_4FwbkL3Q_18_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" sign="-" scale="3" id="Tc_bHAfzF-yXU6WqZQE6yKrdQ_18_6">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to iBio, Inc. from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_EqEmF9aXEk6zp05hygeylg_19_3">7,537</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_O7NmbZ3ns0il1XDlL2p8Qw_19_6">5,188</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock dividends - iBio CDMO Tracking Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_CKlJG0O1gkqoFd4ewqibTQ_21_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_DDSPO6Ioj0-sr1yKW_cRZQ_21_6">66</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_mi8PBVLSKUKDA93CWhpVhw_22_3">7,537</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_pNVbJwZ7mEqzeQWZNBA2_Q_22_6">5,254</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_BiGV5RherU235JyqdRXM1g_24_3">10,593</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_nQwP8OE-iUudoWB0c8QDOA_24_6">3,751</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_wtyOjwd8pECGqLagFALi6Q_26_3">18,130</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc__AB5yu7rGUKydu7NB78zmg_26_6">9,005</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Consolidated net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_CtSIFL34XUaENRtQl8wK5w_29_3">18,130</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_Xpwf5PEpJkGzg3wAEwwJlQ_29_6">8,940</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive loss - unrealized loss on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_5DgNxSO2JkOI05Y1gNg2xg_30_3">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_l4G5KHyowEi3315nI95tsQ_30_6">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_3H646P907EedBtSN0lsCKw_32_3">18,140</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_odjTbkaXE0iU690yuz00sA_32_6">8,941</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_OpPyzGPfbk6YG5Rr7wMBdg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_tccmynXft0OthMTcg3qS2w_34_3">0.85</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gMzmk3wLFkK2aHz3MKKD4g;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_YkndjlDtyEmCf2wFb7Pz4Q_34_6">0.60</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_AoT3ZaryAEean7dePk0z3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_r0Cxs-0wAkmigntczPXruQ_35_3">1.20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Cf2NuHLrfE-uFyMkWX3Uig;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_Vp55pPLxuUSS1oiV_XwNZA_35_6">0.43</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_99bdrmUalkCbFfGhk6saBA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_GZlIgss3nkyTtCiENDYWZw_36_3">2.05</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_YTsxMg4SEUaPMK4RepGT4Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_jJxdMVf9RkGbX_RTRtvk0Q_36_6">1.03</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_tNWyJKn2VUC4uCvJ3afNhA_38_3">8,842</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_mLlQRdZIcUGgjrrvoQBaYw_38_6">8,715</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_815ebba6_b959_461c_97b1_f7e784538779"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited; in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Three Months Ended September 30, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2e8a0b0c_723f_45eb_951a_9d7bc96275a4"></a><a id="Tc_OaNgFjyoUU-eFcX5e70xnQ_1_16"></a><a id="Tc_OtoMx127M0-GiMxnbYPq4Q_2_13"></a><a id="Tc_qAeAK_nVAEyAnUjKzrgbMw_2_16"></a><a id="Tc_lvAuwSLxPE-uaise5RBOcw_3_2"></a><a id="Tc_ItT-OeQFkk67KE0fH0pMwQ_3_8"></a><a id="Tc_Tce3vJ4DiEqMy1t_yS0i6A_3_13"></a><a id="Tc_F13KLX7D4EGE7y_zdm4QMQ_3_16"></a><a id="Tc_9v3fUCUjrU6Ngk8tUHowOg_3_19"></a><a id="Tc_kDQzHzcOxkG0EDiEnG00ZQ_4_2"></a><a id="Tc_PsO5MgyfhEK44eS2iCYdmg_4_5"></a><a id="Tc_QOUpVnZMPkOU9xW-qKW50Q_4_8"></a><a id="Tc_FFxcIvkqmEORckjRF9ILVA_4_10"></a><a id="Tc_G1xTMlLquEmEWTI1lGkn0A_4_13"></a><a id="Tc_byUX839HE0uo9_7a4_gevw_4_16"></a><a id="Tc_Og6Ts-9iH0qRgymvzJm6HA_4_19"></a><a id="Tc_w-skfDXcWEqALA3Dgsm70A_4_22"></a><a id="Tc_7tx1rMT8lUK9q78FPHM39w_5_0"></a><a id="Tc_b-urljeeSEO3gh9PTcd3Eg_5_5"></a><a id="Tc_Xd8zdFvr80ORvh5PNHVwrw_5_6"></a><a id="Tc_FU3UINom60KOdWqgz9u0XQ_5_10"></a><a id="Tc_8c0qsAL38UCac-LSBCoosQ_5_13"></a><a id="Tc_eask9Uf7ok2N-Dc2GF-iNw_5_16"></a><a id="Tc_dVR-O3fMK0Sth-lfz1RSLQ_5_19"></a><a id="Tc_QU7ZKHclHUWk6SDlmoXiIQ_5_22"></a><a id="Tc_j-cfM8kSL0CtGJKUKs5zHQ_7_0"></a><a id="Tc_hUXJcqJwcE-MZTW-BqpWxQ_7_3"></a><a id="Tc_zZWfCsTB2ESDL86_BWh4rg_7_6"></a><a id="Tc_yiiDc1WiWkerlSuMPCm2uQ_7_11"></a><a id="Tc_s5cTz_GGvUa3VRL_p4yj3w_7_17"></a><a id="Tc_BzycNa8BmEipmO4ecIxd9g_7_20"></a><a id="Tc_XzvP7mb7-UOaInPm8Z6WTQ_8_0"></a><a id="Tc_smHF1eZQyU6NtFsoUrxpMw_8_6"></a><a id="Tc_s7cf8ZhsPE2OlPf3lwoRYg_8_8"></a><a id="Tc_zLxxiXqY1EC8fkZr8baByw_8_11"></a><a id="Tc_CPdF2I8XJ0CBUckjtodIog_8_14"></a><a id="Tc_-TjD9Err4kilfyGsodU7qA_8_17"></a><a id="Tc_isHLplGRUUqFymEpNFxYtw_8_20"></a><a id="Tc_pRJTiO0X3EmS7OeHA2VbZg_8_23"></a><a id="Tc_BFfYdfuV6UmtDoF-Qjx7xQ_9_0"></a><a id="Tc_gCXTXGc2g0O5UmCl_WY3ug_9_3"></a><a id="Tc_0t6BkrT5v02vEa0s_eWcZA_9_6"></a><a id="Tc_Jn3TOrEWSkG3cNBOaTsnhw_9_11"></a><a id="Tc_dhbcq7rzdUmdVS-hqDi57A_9_17"></a><a id="Tc_aR1KipEnDk6iEv90UkAv8g_9_20"></a><a id="Tc_BrBcrBWwm0OJ0dCjysrkzw_10_0"></a><a id="Tc_Q1dM0g5sSkOMIAyUpucKhA_10_3"></a><a id="Tc_uYsmxAu41kGREwFdJ9UsKg_10_6"></a><a id="Tc_t994J0O200i717hPIvwk-A_10_11"></a><a id="Tc_QoNk6xRWMk-PkSK3VPvheQ_10_14"></a><a id="Tc_uYMR1fMLJUWKN1HSsW3gzw_10_17"></a><a id="Tc_NOZa9pL1dUKUZhsVgsSYZw_10_20"></a><a id="Tc_R2d8VwUngE2PH6GxseoM2g_10_23"></a><a id="Tc_GhobzPCfm0ODgTbQ_ZWXIQ_11_0"></a><a id="Tc_EF86iuxiCEejmHijJSFoLA_11_3"></a><a id="Tc_O7dGP1iqk0ipulxgeMxhGA_11_6"></a><a id="Tc_uitpNCUNFkK6Ksu9-_9l2Q_11_8"></a><a id="Tc_miFfb2d1D0C_bEEqyWXXYQ_11_11"></a><a id="Tc_Yt1g5uAEhkW9b8pHBphOvQ_11_17"></a><a id="Tc_YU5nT5GRA0-_qkiF4rd3DQ_11_20"></a><a id="Tc_G3wxpWRJTkqjO7_ZFU_ECQ_12_0"></a><a id="Tc_Hf67yMXLfkyTdXVXpBcw3Q_12_3"></a><a id="Tc_y0z5LCWGRkOwCKuFOydRWA_12_6"></a><a id="Tc_OvXpY6kxa0WVilw5TVWLGw_12_8"></a><a id="Tc_UbElE5M6Fk2TyKwEpxwxnQ_12_11"></a><a id="Tc_ECduLy0zw0GdFKSrOyZ2lQ_12_14"></a><a id="Tc_Fw4vtyE_kEe_yZc2yEwpvw_12_20"></a><a id="Tc_KOwz5pgJt0iWuaskNgUmZw_13_0"></a><a id="Tc_V1d0zbHLyUuEp94QKn6smw_13_3"></a><a id="Tc_EP1WfT3qPEm4W1rBZPeU-g_13_6"></a><a id="Tc_Z-b46OgPFkix5ENJMRXxpQ_13_8"></a><a id="Tc_U6Oycco2VUWjIPWZgYE98Q_13_11"></a><a id="Tc_6q2QhTVd00KS7UOr4tx64Q_13_14"></a><a id="Tc_DsJcg1UiI0ejYCo-W5kCSw_13_17"></a><a id="Tc_XXSd8u_hWUW0ZkOnxlxS_A_15_0"></a><a id="Tc_urnUhWy7qke-Q57HXKvPCQ_15_3"></a><a id="Tc_sklEKWTRxkCe-vbyg6MH8w_15_5"></a><a id="Tc_WbhkQHO2Rk6xdVwflGMh_g_15_6"></a><a id="Tc_Lgh2DYDlX06CKvwdpOXt5g_15_10"></a><a id="Tc_Hmx2BNcLRECVjXhYwv2szQ_15_13"></a><a id="Tc_yCwc3hLT_kWtOjJt3sY9kw_15_16"></a><a id="Tc_3CU0xdvHz0e-tf2IhUFumQ_15_19"></a><a id="Tc_ZYtZn-rmSkueersialK-Eg_15_22"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of July 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_45O6JBHOlU2mPcO5JCdPKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_xWpBPf3mwE-SD0SgE2jNWw_5_3">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bAryvWRFa0ajF3wOujsFkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_3fFIh9duZ0-HoCOReobOIQ_5_8">8,727</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bAryvWRFa0ajF3wOujsFkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_jLmhbJUeu0Orgd11OGEf8w_5_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B4AZcYK-c0asmfHVM1feAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_zbp5lD1QWEq07HBQ2NQ_nQ_5_14">287,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mG4LbET2DECSO7FdaX63IQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_ZGOUMuvyMEu6JgaJKgKd4Q_5_17">213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VqSPMHJY_kKNvzc7COpAeg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_w2RbauCgj06q_LB5TxQvIw_5_20">223,930</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_oRtPshqLpE-F6NEzyqLxyw_5_23">63,485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Capital raise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IurkUKJGTEiNYvvgn9u9qQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodSharesCapitalRaise" scale="3" id="Tc_LfG-wl7Xq06uUae3xxpoKg_7_8">176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fF9KSDzTNUewjtgDUfom4w" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_lP9kBL8BvESi5ofumKd6MA_7_14">1,151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_P3tAhNzKo0ur_9SHI4iJ5g_7_23">1,151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_nIO8x0O-D0ajEs1hfec5ig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="3" id="Tc_iVnGDtoTM0aLjd7uT-Rs6Q_8_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Common stock issued - RubrYc transaction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IurkUKJGTEiNYvvgn9u9qQ" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionInShares" scale="3" id="Tc_uYIwxA8KKUqcufURmqvhvg_9_8">102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fF9KSDzTNUewjtgDUfom4w" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_6w4Q01Gpb0mhDjNObOUuKQ_9_14">650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_C_znFupWlEaoKis0tTQU7Q_9_23">650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IurkUKJGTEiNYvvgn9u9qQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc_3Jz82B9C6kK7Zl_PzW-Wng_10_8">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fF9KSDzTNUewjtgDUfom4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_WRqjDzT2A0uiXCULf1Pu5g_11_14">1,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_1XAS5ecvTEyCmxxU-d0uJw_11_23">1,222</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized loss on available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_J9Qyego6XEGPGcqSDViMZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_zh4FuBWwxk-CFBhfX4XFnw_12_17">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_8ETF6KY7KkiVqjKF4Hh7TA_12_23">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HRtnDhbFY0iZF8Myn0m59Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_R_9j7VGMuUqqyKYxsfjiyw_13_20">18,130</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_SvolteEgbkeArPanANa2Pw_13_23">18,130</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of September 30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UIQ-9TQJg02_iffm6LAbPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_FWa5kOoD3UO6m1eZIOy3tQ_15_8">9,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UIQ-9TQJg02_iffm6LAbPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_fB8ZOuSKpEy0e_PHO5u9Hw_15_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N4y1JB93p0KE0lNMIY0TKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_oYTQ0EBH8Em57dx7hMaxqQ_15_14">290,642</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ONpLrTILEC92ojz2-S9Sg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_PrLY7UzYQ0mWjrlQgyujTA_15_17">223</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mC7BYOTYH0a7Wk8V2O2hrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_F-xv4FlkwU2ft5O7l_c-vg_15_20">242,060</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_Oq3cjK_yIk6bcjG_6YKiaQ_15_23">48,368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Three Months Ended September 30, 2021</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c6f7d3f6_c336_473e_9c70_22cbb0026f2e"></a><a id="Tc_Md_74i4we0OunK5WOmyeEw_1_16"></a><a id="Tc_hSdSpCIsekyzqEqsnF9kQw_2_13"></a><a id="Tc_ItTO2QrYc0e0-GILZ5uMwQ_2_16"></a><a id="Tc_sQF_lvRxY0CGZP3bSGER-w_3_2"></a><a id="Tc_cy3qoEmsOU2ytaXSAM_kig_3_8"></a><a id="Tc_7VqGA5uY8ECq2_8JJ9MlIw_3_13"></a><a id="Tc__JcqtKNIT0ewpCFfZwnMMA_3_16"></a><a id="Tc_mUJlJKmAl0m1nknl50J-zg_3_19"></a><a id="Tc_6MyS1fgDu0KPjmfebLDnBQ_3_22"></a><a id="Tc_lDN6YuRvn0Cq3c1faH1RqQ_4_2"></a><a id="Tc_eP7ZKTt_GU-kMks9_eePdA_4_5"></a><a id="Tc_--5hCNw6UE2NOfWmIHv8sA_4_8"></a><a id="Tc_-IpKkr2rg0qiOuvc7z10kA_4_10"></a><a id="Tc_0aMGALh05UCCfVmTpS6phQ_4_13"></a><a id="Tc_c85vWyx5skq6ykavRb0Dug_4_16"></a><a id="Tc_hBcZv89xOEyB9cwszRs0Og_4_19"></a><a id="Tc_02qG7rpC1k27uZJ4URlo2A_4_22"></a><a id="Tc_qpVmEml_oECzWyeYMJxAXQ_4_25"></a><a id="Tc_yVQ-zCkOPkaUvU6iCjPjkQ_5_0"></a><a id="Tc_KX6pECalxUe9VrJ2mhwZpA_5_3"></a><a id="Tc_-brAsRx_TkebgbPEzEzICg_5_5"></a><a id="Tc_ebPvZcK9IE2Gv2K43Vau3w_5_6"></a><a id="Tc_eOSAK2EB50G62_bUbcgDlw_5_10"></a><a id="Tc_X-0IkZBmXkSct1LjUT4V9g_5_13"></a><a id="Tc_zAqi2DgTpkGrsyrDL-uqoQ_5_16"></a><a id="Tc_YrK2ugBOfkeMPYCqrx5dnQ_5_19"></a><a id="Tc_ghaueI_Lq0KzGgSdnCGsrg_5_22"></a><a id="Tc_3akUFaBcfk2s4iFR-qyqhg_5_25"></a><a id="Tc_USlhkroasE2NsRj_zpPjFQ_7_0"></a><a id="Tc_lpOyXGzkHEe2wB4563qELw_7_3"></a><a id="Tc_UrhbufTRa0mbP0hdyki8qQ_7_6"></a><a id="Tc_INGFYg6iKUaIiqkEzPBciA_7_11"></a><a id="Tc_m0DuGOlPRE-EYAAnQudoYw_7_17"></a><a id="Tc_2sy3tNVpzU-EBva5gJxYkQ_7_20"></a><a id="Tc_kQ2F_NiR7k21nci7yAzJRg_7_23"></a><a id="Tc_fkbYlax1PEmffxybT3Z3ZA_8_0"></a><a id="Tc_Q8YvFU-Fi0q4NJurL75uCg_8_3"></a><a id="Tc_2hlmjriYykmE6dfdeZ_cCQ_8_6"></a><a id="Tc_9riqQE8HUE67vBf_PoacPQ_8_8"></a><a id="Tc_oCDRg9U3zkipX_z8gEyTsQ_8_11"></a><a id="Tc_4vMorjZUZkyiVmWF4Vr8pg_8_17"></a><a id="Tc_NbaqsSEPx0eZF_XTJ7HMLw_8_20"></a><a id="Tc_Sk7m_s-_Ck6EspHHa1jSlw_8_23"></a><a id="Tc_72C0nj1hK0qqqKu1jsO48A_9_0"></a><a id="Tc_utD_ZzPcZEG0wbZJspvTng_9_3"></a><a id="Tc_1MlFbTtWnEaaGXNABFhj3Q_9_6"></a><a id="Tc_yGzUJ27CwUOxhF_B_IIQLA_9_8"></a><a id="Tc_pDcgp4W5Sk648vvlIQ6QJQ_9_11"></a><a id="Tc_Mmzl0nBV2ESyfSlQlYGvtA_9_14"></a><a id="Tc_KTcRgKAt50O0qeF-EL_XjA_9_20"></a><a id="Tc_ZGKqRM8iJUq8nVyVfS8w9g_9_23"></a><a id="Tc_A3dnHQx6EUebsyCQ4czulQ_10_0"></a><a id="Tc_tqWTsmyL4U-AWiFVTWPNHQ_10_3"></a><a id="Tc_GYHd385h8E-PsMVT3WW_ig_10_6"></a><a id="Tc_DCfteRXXq0miOn44vVLrUQ_10_8"></a><a id="Tc_zxMGmS9K5U-ZgqM6N4JaNw_10_11"></a><a id="Tc_gozFGFAa4kivNjX-EKBykg_10_14"></a><a id="Tc_JZPrWrj7OUW0OCa2cmLCrA_10_17"></a><a id="Tc_tIDzSQB-30ONDpR_TZgTUg_12_0"></a><a id="Tc_QwooBB2kuEaTnFJyyAitfA_12_3"></a><a id="Tc_5xeVXclnpki0quuZjKizWg_12_5"></a><a id="Tc_EpHEaH6y6kO0qHaLy_HW2w_12_6"></a><a id="Tc_ufq1aJ_WREONYiF5DTgJLQ_12_10"></a><a id="Tc_KBMHclqLBEyC9X4UwGUF3A_12_13"></a><a id="Tc_Ab6-EayBLUyHbBierMDomw_12_16"></a><a id="Tc_bHXY8lkS0UacfdjQP3wNVA_12_19"></a><a id="Tc_GlvIm1K89k-cj0cc-QAsww_12_22"></a><a id="Tc_Ff6ZhE32KU-_nGpMdmKN3Q_12_25"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:16.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Noncontrolling</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of July 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2N7RXo2_pUetdE_cG5cZ6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc__uPTgGvplUeEM8Ei7zXOZA_5_8">8,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2N7RXo2_pUetdE_cG5cZ6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_4bzXVCMnpkimNo5AdF544g_5_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GH-5RrH9aUCemJman1Sceg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_Q509FLC_UUGJlpWG3hH6zQ_5_14">282,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LANmWQuoxU-cg4DMxrvqag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_C9d0_xL2oUCyS8F8VWhz-A_5_17">63</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4SJVQK9LYUSBCSlw5dlipg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_6FB1PrsbYk2vqfnQ1Ts1vA_5_20">173,627</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_2zacrRBIuEKYll8_FrKwOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_jaLhC7eTv0OlNnlKYeW4_Q_5_23">17</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2021_GQ940Ff9F0Sa787zj-1tnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_33RSal1ioEOgOAxacKkKmA_5_26">108,568</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pjwYstABlU2nhu8zVQax6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_3yYs-oIjn0GiJ1hTWpKk5A_7_8">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-3uXSg1qM0mejJjzOTqnKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc__1wf1_AVE0GT2APxqssfBg_7_14">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_NXh_FEyZfE-JSdZHRKbTSA_7_26">77</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-3uXSg1qM0mejJjzOTqnKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_y4DehaNVq0e9ZzcQP2l8Ew_8_14">821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_unIYR3Pdwkqm7IZpArD6pQ_8_26">821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized loss on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_L7GZScf59UWcwVJ60pxOUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_XBPUxydvK0KYhpSMk6wKKQ_9_17">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_u1gOw-Ttyk6g1s6XIhdUGg_9_26">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FDjxICtcCUCFzo4fnrEFAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_U3-hfXJrskWR59-wNaX1xg_10_20">8,939</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_nOs84_8GCkueqFiJt1xgmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="Tc_hjqgmVTE_ECZFwQbWND4wA_10_23">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_1JBDo9SOAE6MpMaYMhUEmA_10_26">8,940</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of September&#160;30,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0tv1Shz8i02Z3bQpOwGtZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_mRSfmH8nLU-xrlH3SPspGA_12_8">8,718</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0tv1Shz8i02Z3bQpOwGtZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_xPTvca_zDUC00iy1bnM3yg_12_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XzvlH8qzzkC_5vSGgF1Uwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_LLVLngRC40i0LxdzAcn9rQ_12_14">283,164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XVi69PwJykqe8xvOj7V4FA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_EIG6ykobb0qkk0vyy5qjdw_12_17">64</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HxjHz6i74k6VEvJSqTEdqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_-S7b_RNLg0q5IXLCtFWUoA_12_20">182,566</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bmsbSdyfUUmoltX5xZjZqw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_geRKB15XAUyYz0blTS5eUQ_12_23">18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.55pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2021_JT9c6c8IIEOMVOhxR4-gmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_KqLRq9ykzE2IGvq2dTmnDQ_12_26">100,525</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2f285abd_250c_40eb_8c93_2f028b1276c3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited; in Thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3e80e45b_99d0_4606_bf62_ac31d4e8f20c"></a><a id="Tc_MRFSX_vfSU2KHQqBHzTdYA_1_2"></a><a id="Tc_3CsF5IDNX0aFshW6SnK0HQ_2_2"></a><a id="Tc_hLc6flgy80ybdSCUtXqiiw_3_2"></a><a id="Tc_qvNoKa18Uk2ubM0cIjSnOQ_3_5"></a><a id="Tc_p3z8deEt9kikLgjJC88qig_5_0"></a><a id="Tc_O32zex5ptkqL3L6qVUldXw_6_0"></a><a id="Tc_Q6e7J-hNfUaIsVbLUThIJw_6_2"></a><a id="Tc_90pNDCJec0iWV0sB2JFjQQ_6_5"></a><a id="Tc_hym6EyCG5EqkwU3uZjItlw_7_0"></a><a id="Tc_xn3WkiVH00qV3YyhgLx8EQ_8_0"></a><a id="Tc_OvfG0--BYke3SbljLPBZ-Q_9_0"></a><a id="Tc_X7-n7ukaT0Gw_ZDXm2TMbg_10_0"></a><a id="Tc_Xj2geW-WwkCt3_nxr9op2w_11_0"></a><a id="Tc_4GEfzJeSa0q9pr0-rN04Og_12_0"></a><a id="Tc_IYojldp3rEyWSaQCtOSIpg_13_0"></a><a id="Tc_K9mQGSE0n0udzhbVpkAwNQ_14_0"></a><a id="Tc_hb2JXp5-XEqq1CkgfqqvXw_15_0"></a><a id="Tc_Y9C1SshaUk6DGmnFvVWEIA_16_0"></a><a id="Tc_MDA62qzBQkG__HRRe07zXQ_17_0"></a><a id="Tc_X3pVvKU38UG59XwykIFsmQ_18_0"></a><a id="Tc_vE5pQ5qTMk2w64HXtCdTXw_19_0"></a><a id="Tc_OnB4XzfWGkyFanotWwrXpQ_20_0"></a><a id="Tc_8j6Y-pMpVUa7iEoLRDIYiQ_21_0"></a><a id="Tc_VejHaH3UHECbGnZsaKmkuQ_22_0"></a><a id="Tc_yvLoFd1-gE2Vt4UaZLPEew_23_0"></a><a id="Tc_SEacXrPbREySa173Wr9O7g_24_0"></a><a id="Tc_tfK0oa4PMEmCtPS0qmcf1g_25_0"></a><a id="Tc_LrQLxl-iAEiFkK-Stz12Bg_26_0"></a><a id="Tc_nhsaB7Nrl0OKpuQVE6Akrw_27_0"></a><a id="Tc_jpyARDiA00m8rBAtQgNdTQ_28_0"></a><a id="Tc_tu40TWIdQ0u3Kv7Fp4or3Q_30_0"></a><a id="Tc_TmVnjizgpEK3Qk-nUj-XQA_31_0"></a><a id="Tc_wNTWn1EtTEqcqTNyRm4lug_32_0"></a><a id="Tc_2ZhPh11NeESI9gIVzEcV1A_33_0"></a><a id="Tc_-XjPfwir80Sy1_jS6-GQyg_34_0"></a><a id="Tc_6-8eN40mzUmhUF3Bi_Z7nA_35_0"></a><a id="Tc_bPnl1OFqdUC8GsWlcNeolw_36_0"></a><a id="Tc_al9MUzBePkiYDmE9Jfbwzg_38_0"></a><a id="Tc_LKscLy26hUygf9OPGkvj4Q_40_0"></a><a id="Tc_tvdCBVtbSU6S2UT6OE1EUQ_41_0"></a><a id="Tc_ay8j6Jhv9UCBm1gcciQODg_42_0"></a><a id="Tc_sqV3oSyDs0K3rJUESyX5MQ_43_0"></a><a id="Tc_5SwvkRYDHUuUe8DBfLH1pA_45_0"></a><a id="Tc_oecIboEvYkqbk-G7kVHx1A_46_0"></a><a id="Tc_E6H5M57CUEqaAe57HLeuAA_47_0"></a><a id="Tc_Bq1kjCUYhk2_2ecVlik1AA_47_2"></a><a id="Tc_-NNmdJ13Y0evIVykk3Kyjw_47_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Consolidated net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_jp5haSWFDEGIYVnvCozeIA_6_3">18,130</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_HcYMhZvkX0O5DFDkiMuPEw_6_6">8,940</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile consolidated net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_yd3Ryvlzi0-IgL2P8iWVKg_8_3">1,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_BNZpk_Zedk-RWZqK-aQd2g_8_6">821</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_3s3S5jOoXE6HQa7ZZpFaBg_9_3">67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_9WBt7dXwukauBKEpux7myg_9_6">88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_q4p68913GUWRU0UG2xaiFg_10_3">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_NVEhXeZdzUGYfRhKsfDKug_10_6">416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_6G13xS92OEa-QwRfgD9CDg_11_3">143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:zerodash" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_GHvMyFK06E67L-I4ZRWpGg_11_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Depreciation of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_vwAyPTUo0UGGkSQS2Kqc8w_12_3">271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_1lwi8t9DaEqUky9HNq3zvA_12_6">306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Accrued interest receivable on convertible promissory note receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" scale="3" id="Tc_kntmAU65wUigwHdenOfM5Q_13_3">19</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" scale="3" id="Tc_Mdifd5xTJUuAJI9gob7xgw_13_6">19</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of premiums on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_d1MYA8aOhUqTR6ZCBy-sdA_14_3">36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_eOCgfkTEQkmd6jVmmtHyNA_14_6">102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:DeferredFinancingCostsAmortizationExpense" scale="3" id="Tc_R1NRuZ4tMEGWdaE6WjHj4g_15_3">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:zerodash" name="ibio:DeferredFinancingCostsAmortizationExpense" scale="3" id="Tc_F_k4p66we0-m6DGczLo-Tg_15_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInInventoryReserve" scale="3" id="Tc_NaHNZeY7XkSs-qMT_3UuIg_16_3">4,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:zerodash" name="ibio:IncreaseDecreaseInInventoryReserve" scale="3" id="Tc_WCzDKHty_UCrjQzxP-N5OA_16_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Forgiveness of note payable and accrued interest - SBA loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="ibio:ForgivenessOfNotePayableAndAccruedInterestSbaLoan" scale="3" id="Tc_74nJIhXYbk-U9HzUb1z7yA_17_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:ForgivenessOfNotePayableAndAccruedInterestSbaLoan" scale="3" id="Tc_0jcidspPXkyV2KnBKIw1VA_17_6">607</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Settlement of revenue contract</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="ibio:SettlementOfRevenueContract" scale="3" id="Tc_ozjb-48fv0GDa1FjyB4ZYw_18_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:SettlementOfRevenueContract" scale="3" id="Tc_4R9fbwqdcU2H3bldX92QsQ_18_6">84</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Accounts receivable &#8211; trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_3UFqGONWXUqa3L5oPayw5A_20_3">54</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_B2a9g8LXfkmExPRi85Elqg_20_6">93</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" scale="3" id="Tc_N2k4S6QHtkaOg0LconZNqg_21_3">1,137</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" scale="3" id="Tc_Z8lAXVKawEq3sxxrxzM3Bg_21_6">560</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_3izte1BPMECIGs3L9TMjOA_22_3">403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_QbA3kM1hc02YZ9OLuX8RzA_22_6">325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Prepaid expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="3" id="Tc_osEqUw88ME6VjJk-giN3iQ_23_3">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="Tc_GA6i1Q22fUyJUa22k-0baQ_23_6">912</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_YahypWLogUiyEX-WmeOVrQ_24_3">166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_qGYbRtkZakiSqbKn5iVsxg_24_6">79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_ZGbRtEflb0quhBKSktw0lw_25_3">1,168</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_AVcCNj6kCEScBcJKcZIRvw_25_6">269</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_qIj1anAynUuUA4oPp2PWQA_26_3">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="Tc_cYptTfXNRUiGryTd8cteCw_26_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_bSIOceNRC0aQ1gXl6mvC7Q_27_3">61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_NAHd_hTHxEawgsLoQd3d7Q_27_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;"><span style="white-space:pre-wrap;">     Net cash used in operating activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_9RtwRkqudk-d-z6tk6PKoQ_28_3">13,959</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_yoJMgf8OjUec5URc2AxxGQ_28_6">9,347</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_4Sa9FOAC90CZlKpTu3t_Jw_31_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="Tc_cvt2g2O4gkyVVe_Bj5hKSg_31_6">2,386</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Redemption of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="Tc_Mg61Gtd1WkeqLSITg8DEJg_32_3">3,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="Tc_gAnHP426pUi_JxsiMwUxOA_32_6">2,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Purchase of equity security</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="3" id="Tc_pR1JXAS_LkuCpu4duZ-UAQ_33_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="3" id="Tc_B3XRjdHicEGVFuktK7cHWA_33_6">1,173</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Additions to intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_-SBKKV2UJ0O11ppG5PXRDQ_34_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_4pdC7-Wf20a4t8nOkW7grQ_34_6">2,867</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_0OP-ZUAZX0mYU2413-ZmYA_35_3">2,479</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_EAjPYXUUi0KPycu8Svptwg_35_6">1,123</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Payment for RubrYc asset acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="Tc_2IJpcRSbI0Cw5xCldfM7Gw_36_3">692</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="Tc_QtxzE_Rcb0qqPRCGHGxS_g_36_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;"><span style="white-space:pre-wrap;">     Net cash provided by (used in) investing activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_uQBsc1LIi0S0yuej5p3Kdw_38_3">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_zTFxK4AeP0eQXN3kAfGNlg_38_6">5,149</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from sales of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:ProceedsFromIssuanceOfPreferredAndCommonStock" scale="3" id="Tc_60yrvVjOEEex6qc9DUYPiA_41_3">1,151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:zerodash" name="ibio:ProceedsFromIssuanceOfPreferredAndCommonStock" scale="3" id="Tc_jqe8jf18pEK5pyJUkhQ7Wg_41_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Payment of finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_lXNPdYPJyECr6tTOt2JL4w_42_3">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_8c6wSCqzy0KTDKLD_W0Jng_42_6">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;"><span style="white-space:pre-wrap;">     Net cash provided by (used in) provided by financing activities </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_NVN8YnYu7k-Vj8dEGC89fQ_43_3">1,141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_ZQ2YhXrnlUOQfOtFEPND1w_43_6">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_HH5neNuJMUKimXHC87JS3A_45_3">12,789</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_2zVAbPPMAkGFOkjqxinlkQ_45_6">14,584</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash - beginning </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_uYeET-x1gkabhI6ZN99JUA_46_3">28,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2021_GQ940Ff9F0Sa787zj-1tnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_uuCKALv17UaYuBpFhWXMow_46_6">77,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash - end </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_yv4BBPwG6kS14jICwt7x8w_47_3">15,883</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2021_JT9c6c8IIEOMVOhxR4-gmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ALEBeczex0eyYdP91Ygq0w_47_6">62,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited; in Thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8f6f63e7_b1d2_465e_878f_4b32ffb4565d"></a><a id="Tc_7OZU7OZ1GEWy9GaGEtgGqw_1_2"></a><a id="Tc_rFyYMlPu1Eq7Riv6E2jzOw_2_2"></a><a id="Tc_JbC_AWh9O0iPakDI6WZkYQ_3_2"></a><a id="Tc_VfJ-W_K4tkmtvSzcxB_UeA_3_5"></a><a id="Tc_t6Z3r0l_yUK0E0kmYTbexA_4_0"></a><a id="Tc_xkHX_-Bc3E6AtwdmbYfhfg_5_0"></a><a id="Tc_fq3hEHiR_k6tIV3cUpMPSQ_5_2"></a><a id="Tc_iBvCQJ0G_kW9_h-tT0-U1A_5_5"></a><a id="Tc_WM7P8OXCAUq3Gvi2zSDfyg_6_0"></a><a id="Tc_6oLa-PSXJkSi5nS3st4UgQ_6_2"></a><a id="Tc_a52jcLQg-UObJ4tQ8knW0g_6_5"></a><a id="Tc__5s5k2i1pEOxNQvJfcm0wA_7_0"></a><a id="Tc_bvHc0294_USr7oH27oDCwA_7_2"></a><a id="Tc_iOeg6DbLGke8P2kskgCcXg_7_5"></a><a id="Tc_1DoDrGjd5U25lv1Zb_yfnA_8_0"></a><a id="Tc_wjS8ri7EvUufxAp-LhGDlA_8_2"></a><a id="Tc_8ChJWB-4TkC3cjHWKoorjQ_8_5"></a><a id="Tc_AdKCg8wdHke719_koSIHcw_9_0"></a><a id="Tc_1FGjCt0hMk2dsdgtN6fONQ_9_2"></a><a id="Tc_9XUr8p0U1EqWPfUpWBFGmw_9_5"></a><a id="Tc_j8ZPVWQp2UmXmj3COtLhSA_10_0"></a><a id="Tc_m9tpgcomV0qPBZpU9LD8hQ_10_2"></a><a id="Tc_4cylex8BckuDGjhMS33niA_10_5"></a><a id="Tc_aIld8EsMnkmkSSGU6egXtw_11_0"></a><a id="Tc_PuIW2u7sI06uNwOsEUA1xw_11_2"></a><a id="Tc_cRY2R1674ky5CR4KQY91WQ_11_5"></a><a id="Tc_dV0vZCr73UW4O3bU2dj8LA_12_0"></a><a id="Tc_rpy7kSJ4-0qo94TXTlQJfw_12_2"></a><a id="Tc_Ked55aFQH0y2b2ga8iO1EA_12_5"></a><a id="Tc_5oDC1NfKB0iiJWyyYNwoOQ_13_0"></a><a id="Tc_5_gaR7MyQkmUknsqnJjoRQ_13_2"></a><a id="Tc_-WM64rIFmEGJw1Y_VuDaWQ_13_5"></a><a id="Tc_nwhgHfkuqkuAx34PwDe5bA_14_0"></a><a id="Tc_7vhIoM_YXU-0zZtVKyHFKw_14_2"></a><a id="Tc_78G9H516f0-Tc32UHlhYyQ_14_5"></a><a id="Tc_68gnaNlad0SLKZ9bbIjGSw_15_0"></a><a id="Tc_lGAOnQNbhk69oQw8FSGslw_15_2"></a><a id="Tc_wGIXVSZV0UivSMyJ0Yu7UA_15_5"></a><a id="Tc_2XS_yvhBG0qIBJ0AXlRgww_16_0"></a><a id="Tc_Gccag8oP_0egrzrdok4JUg_16_2"></a><a id="Tc_78fglWvyJEGKWCCYNremfA_16_5"></a><a id="Tc_iF9JWr8jqUC97rDVY8IkIQ_19_0"></a><a id="Tc_bXzqFELoFUW3BL85YV3_bg_20_0"></a><a id="Tc_LC-zgcHn2kODa2LVzHTA-w_20_2"></a><a id="Tc_1FSdFfrKZESQnFTfQTfJrg_20_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Schedule of non-cash activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Increase in operating lease ROU assets for new lease - net of lease incentive</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" scale="3" id="Tc_OB_JCUbL7kiLzwdQccEtSg_5_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" scale="3" id="Tc_vAE-1rR5VEy6DXQtNygDmA_5_6">3,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Increase in operating lease obligation for new lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="ibio:IncreaseDecreaeInOperatingLeaseObligations" scale="3" id="Tc_RwZNeB6L1k6-cuUjk_8asw_6_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaeInOperatingLeaseObligations" scale="3" id="Tc_eBeXkPfhnkylOXTOCCWaKg_6_6">3,603</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Increase in finance lease ROU assets for new leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_-A8A3XJ26EeISyKYvtrwKw_7_3">814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_j9GGEpuabkaIHhXJO174IQ_7_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Increase in finance lease obligation for new leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" scale="3" id="Tc_QTJK45G4_EKSpTdnLgfWxQ_8_3">814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:zerodash" name="ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" scale="3" id="Tc_9A4vRpsKH0uPSuvC9P6syw_8_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Fixed assets included in accounts payable in prior period, paid in current period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid" scale="3" id="Tc_hmLitVfNvkS3_2TaWSkQSw_9_3">1,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid" scale="3" id="Tc_slApatF7VESVWec9w95h-g_9_6">383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Unpaid fixed assets included in accounts payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnpaidFixedAssetsIncludedInAccountsPayable" scale="3" id="Tc_xPCA0UB27Um-Jcgcrh1WCQ_10_3">2,143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnpaidFixedAssetsIncludedInAccountsPayable" scale="3" id="Tc_cbA0k3vTCE24Urs-yvR4tA_10_6">750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Unpaid portion of RubrYc transaction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="ibio:StockPurchaseAgreementValueOfSharesToBePurchased" scale="3" id="Tc_Nltx0UMsGUaFekj7FqhxcA_11_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementValueOfSharesToBePurchased" scale="3" id="Tc_s4Ij7wivU0OtxMuuSpZWeA_11_6">2,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Unrealized loss on available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_ZPfkgfr6F0Ka5HaMg8N0xg_12_3">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_f28h4XV5lUKp8K7wEUjk1w_12_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Lease incentive for construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="ibio:LeaseIncentiveForConstructionInProgress" scale="3" id="Tc_XATt3AiKjE6YCunfyTxBng_13_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:LeaseIncentiveForConstructionInProgress" scale="3" id="Tc_IxSQnP8iuECvcw2mG_x2bA_13_6">82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Settlement of revenue contract</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="ibio:NonCashSettlementOfRevenueContract" scale="3" id="Tc_0PczMHhjOkWG5zF_Tcb_CQ_14_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:NonCashSettlementOfRevenueContract" scale="3" id="Tc_9Ji-HiTKx0W3mKBPE2Oy9Q_14_6">580</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">RubrYc asset acquisition by issuance of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_ZSg7xNtZpku1lO46JVLMVQ_15_3">650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:zerodash" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_UJ0MaQn9Ok20Un7utbsBqQ_15_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from options exercised included in prepaid expenses and OCA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="ibio:ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="Tc_0_DSXJgWPUC_Jd0yWgRpgg_16_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="Tc_pwPh8qZ6VUOBI4GN9KJrdg_16_6">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid during the period for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_kv2hI78g8UO0JRqtoXmWaw_20_3">187</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_6FL_hlzJ6U--RVDkrGHrAQ_20_6">610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:249.03pt;"><a id="_38aaeb69_a4db_4b80_a5cd_bda07833987d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:NatureOfOperations" id="Tb_IJPVqqSkdkK5dZ_0x6oqMQ" continuedAt="Tb_IJPVqqSkdkK5dZ_0x6oqMQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio, Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;iBio&#8221;, &#8220;iBio, Inc&#8221; or the &#8220;Company&#8221;) is an Artificial Intelligence (&#8220;AI&#8221;)-driven innovator of precision antibody immunotherapies. The Company has a pipeline of innovative primarily immuno-oncology antibodies against hard-to-drug targets where we may face reduced competition and with antibodies that may be more selective. The Company plans to use its AI-driven discovery platform to continue adding antibodies against hard-to-drug targets or to work with partners on AI-driven drug development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="ibio-20220930x10q001.jpg" alt="Graphic" style="display:inline-block;height:248.43pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:534.2pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">IBIO-101: </b>an anti-CD25 molecule that works by depletion of immunosuppressive T-regulatory cells (Tregs) via antibody-dependent cellular cytotoxicity (&#8220;ADCC&#8221;), without disrupting activation of effector T-cells (Teffs) in the tumor microenvironment. IBIO-101 could potentially be used to treat solid tumors, hairy cell leukemia, relapsed multiple myeloma, lymphoma, or head and neck cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">EGFRvIII: </b>binds a tumor-specific mutation of EGFR variant III with an afucosylated antibody for high ADCC. Because of its specificity binding to the tumor-specific mutation, it could potentially reduce toxicity and/or expand the therapeutic window compared to simple broad EGFR-targeted alternatives. . EGFRvIII is constantly &#8220;switched on&#8221; which can lead to the development of a range of different cancers. An EGFRvIII antibody could potentially be used to treat glioblastoma, head and neck cancer or non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CCR8:</b> targets depletion of highly immunosuppressive CCR8+ Tregs in the tumor microenvironment via an ADCC mechanism with selective binding to CCR8 over its closely related cousin, CCR4, to avoid off-target effects. A CCR8 program could potentially be broadly applicable in solid tumors and/or as a prospective combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PD-1 Agonist: </b>Selectively binds PD-1 to suppress auto-reactive T-cells without PD-L1/PD-L2 blocking. A PD-1 agonist could potentially be used to treat inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis or other inflammatory diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the programs described above, the Company also has six additional early discovery programs that have the potential to advance into later stages of preclinical development and are designed to tackle hard-to-drug targets.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_IJPVqqSkdkK5dZ_0x6oqMQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IBIO-100 and Endostatin E4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our lead anti-fibrotic candidate is IBIO-100, and its design is based in part upon work by Dr. Carol Feghali-Bostwick, Professor of Medicine at the Medical University of South Carolina and Vice-Chair of the Scleroderma Foundation. Her initial work was conducted at the University of Pittsburgh, and we have licensed the patents relevant for the continued development of the molecule from the university. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As part of the Company&#8217;s review of potential options, the Company intends to continue to review the data from its research and development efforts and determine how to proceed with the development of IBIO-100 in Fibrosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;">To align with the Company&#8217;s focus on the immuno-oncology pipeline, the Company also intends to continue to pursue the E4 endostatin peptide, from which IBIO-100 is derived, as an oncology target in collaboration with University of Texas Southwestern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AI Drug Discovery Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2022, iBio purchased substantially all of the assets of RubrYc Therapeutics (for a complete description of the transaction please see Note 6 &#8211; Significant Transactions). The AI Drug Discovery platform technology is designed to be used to discover antibodies that bind to hard-to-target subdominant and conformational epitopes for further development within our existing portfolio or in partnership with outside entities. The RubrYc AI platform is built upon 3 key technologies. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Epitope Targeting Engine:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> A proprietary machine-learning platform that combines computational biology and 3D-modeling to identify molecules that mimic hard-to-target binding sites on target proteins, specifically, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subdominant and conformational epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The creation of these small mimics enables the engineering of therapeutic antibody candidates that can selectively bind immune and cancer cells better than &#8221;trial and error&#8221; antibody engineering and screening methods that are traditionally focused on dominant epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">RubrYcHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-generated human antibody library free of significant sequence liabilities that provides a unique pool of antibodies to screen. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The combination of the Epitope Targeting Engine and screening with the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">RubrYcHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Library has been shown to reduce the discovery time from ideation to </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> proof-of-concept (PoC) by up to 4 months. This has the potential to enable more, and better, therapeutic candidates to reach the clinic, faster. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">StableHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-powered sequence optimization library used to improve antibody performance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Once an antibody has been advanced to the lead optimization stage, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">StableHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> allows precise and rapid optimization of the antibody binding regions to rapidly move a candidate molecule into the IND-enabling stage.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_gQzdWmB9vUOXc-2YFeppRw" continuedAt="Tb_gQzdWmB9vUOXc-2YFeppRw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">2.&#160;&#160;&#160;Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Interim Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2022, filed with the SEC on October 11, 2022 (the &#8220;Annual Report&#8221;), from which the accompanying condensed consolidated balance sheet dated June 30, 2022 was derived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Non-controlling interest in the consolidated financial statements represented the share of the loss in iBio CDMO, LLC (&#8220;iBio CDMO&#8221;) for an affiliate of Eastern Capital Limited (&#8220;Eastern Capital&#8221;) through November 1, 2021, the date the Company acquired the remaining interest in iBio CDMO. &#160;See Note 6 &#8211; Significant Transactions.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gQzdWmB9vUOXc-2YFeppRw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company&#39;s ability to continue as a going concern. In an effort to remain a going concern and increase cash reserves, the Company recently announced it was selling its CDMO business and facility, reducing its work force by approximately 60% (a reduction of approximately 69 positions), and ceasing operations of its CDMO thereby reducing annual spending by approximately 50%. (See Note 3 &#8211; Discontinued Operations for more information.) Potential options being considered&#160;to further increase liquidity include lowering the Company&#8217;s expenses further, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from capital markets, grant revenue or collaborations, or a combination thereof. During the first quarter of fiscal year 2023, the Company completed at-the-market (&#8220;ATM&#8221;) offerings and raised <span style="-sec-ix-hidden:Hidden_G92FJIZcG06BIGNnHbTKpg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.1M</span></span> selling approximately <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="0" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodSharesCapitalRaise" scale="0" id="Narr_lycA_FTCyUe5nA-cyZrPWw">176,000</ix:nonFraction> shares of common stock. (See Note 16 &#8211; Stockholder&#8217;s Equity for more information.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s cash, cash equivalents, restricted cash and investments in debt securities of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-5" format="ixt:numdotdecimal" name="ibio:CashAndCashEquivalentsPlusDebtSecurities" scale="6" id="Narr__bpmLeai7EqQghemFwEDrQ">23.5</ix:nonFraction> million as of September 30, 2022, is not anticipated to be sufficient to support operations beyond Q3 of Fiscal 2023<b style="font-weight:bold;"> </b>unless the Company reduces its burn rate further or increases its capital as described above. Regardless of whether the Company is able to reduce its burn rate or sell or out-license certain assets or parts of the business, the Company will need to raise additional capital in order to fully execute its longer-term business plan. It is the Company&#8217;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Quarterly Report on Form 10-Q. However, there can be no assurance that the Company will be successful in implementing any of the options that we are evaluating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Reverse Stock Split</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 22, 2022, the Company&#39;s Board of Directors approved the implementation of a reverse stock split at a ratio of one-for-twenty five (1:<span style="-sec-ix-hidden:Hidden__0cS0oMu3kKeTj2aafl8jw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25</span></span>) shares of the Company&#39;s Common Stock (the &#8220;Reverse Split&#8221;). The Reverse Split was effective as of October 7, 2022. All share and per share amounts of our common stock presented have been retroactively adjusted to reflect the Reverse Split. See Note 16 &#8211; Stockholders&#8217; Equity for more information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="Tb_7-8U5Uoi1EyitVJPK-bMpQ" continuedAt="Tb_7-8U5Uoi1EyitVJPK-bMpQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.&#160;&#160;&#160;Discontinued Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In November 2022, the Company announced it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately 60% of the current Company staffing levels (a reduction of approximately 69 positions). The Company expects to substantially complete the employee reduction by January 2, 2023. The Company expects it may be able to complete a transaction for the sale of its contract development and manufacturing organization in calendar 2023, although there is no assurance as to when, or for how much, the Company may be able to sell the iBio CDMO, LLC organization, including the 130,000-square-foot cGMP facility location in Bryan, Texas. &#160;The Company expects to incur pre-tax charges of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-5" format="ixt:numdotdecimal" name="ibio:EmployeeReductionExpenses" scale="6" id="Narr_9Us1aY7-k0Km5Rm-etruOQ">1.7</ix:nonFraction> million for the employee reduction, most of which is expected to be incurred in the second and third quarter of fiscal year 2023. These charges will be substantially settled in cash and almost entirely consist of severance obligations, continuation of salaries and benefits over a 60-day transitional period during which impacted employees remain employed but are not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. The transition to a focused AI-Biotech business is expected to reduce the Company&#8217;s monthly burn rate by approximately half, with an approximate range of $2.5-3.0 million per month. The Company recorded a charge in discontinued operations for $4.1 million for the three months ended September 30, 2022, due to inventory write offs resulting from the winding down of the CDMO business and depending upon the sale price of the facility, the Company may have to incur additional write offs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As such, the results of iBio CDMO&#39;s operations are reported as discontinued operations for the three months ended September 30, 2022. The Company has retrospectively recast its consolidated statement of operations for the three months ended September 30, 2021 presented. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intends to sell have been classified as &#8220;held for sale&#8221; as of September 30, 2022. &#160;The Company has retrospectively recast its consolidated balance sheet as of June 30, 2022 for assets and liabilities held for sale. &#160;The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statement of cash flows. &#160;Supplemental disclosures related to discontinued operations for the statements of cash flows has been provided below. Unless noted otherwise, discussion in the Notes to the Condensed Consolidated Financial Statements refers to the Company&#39;s continuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_075b834f_ea6e_4b6d_918f_dab5057ef1cf"></a><a id="Tc_vj84bSn840-OLs47i5__zQ_1_2"></a><a id="Tc_dqFDMNCsXUKFRECCvroD-w_1_5"></a><a id="Tc_tBuV0z3YhE-qP26r2FczPA_2_2"></a><a id="Tc_GjA34g-ExUOV4EDY_iNBhw_2_5"></a><a id="Tc_fcijIJllbEKQzXCNxzhsrg_3_0"></a><a id="Tc_ZN5nxv0AdkWbXp22Sbbwsw_3_1"></a><a id="Tc_Rjc4y6SqM0SUxNQhMGEfvQ_3_2"></a><a id="Tc_aknZFnWszk-RJ60KP8Q8Iw_3_5"></a><a id="Tc_kg7ai0GPYEmNf_eCzonFKQ_4_0"></a><a id="Tc_xal8uQbsPEGi9_E0x_bgoQ_5_0"></a><a id="Tc_55ITMCSbVU2HXZXVRkinWg_6_0"></a><a id="Tc_CwWSJwh7bE2WiC11BF4nYg_7_0"></a><a id="Tc_Kz0da65ER0KSeQFWSSa2QA_8_0"></a><a id="Tc_SPzI5S8iik6XkPZ_zFhnwQ_9_0"></a><a id="Tc_ifb3xlLnbUqDyp2VWhjDSg_11_0"></a><a id="Tc_MdhSm9B-Tk2SxgX26rig6w_12_0"></a><a id="Tc_kFS2N2Rt8UKD5YNIODhzuA_12_6"></a><a id="Tc_DaD-hokI1EiJy3YDXAy1ug_13_0"></a><a id="Tc_PdhQGWO-lk-DllB8Ki_ZQg_13_3"></a><a id="Tc_X9uUd59XOEyKebCJLKYO-w_14_0"></a><a id="Tc_fj6oCdsv_0-NeLj71i7kDw_14_3"></a><a id="Tc_0vhQroses0CIsaut6SwbwA_15_0"></a><a id="Tc_fF8DKRM5_kSk8Z4qJsYyyA_16_0"></a><a id="Tc_3wCwp1ZkU0eS_ek_s4824A_16_1"></a><a id="Tc_Xja7AsaCH029zWDoVUfwpw_18_0"></a><a id="Tc_Lwjbg6zveUOzJSutDIEqeQ_18_1"></a><a id="Tc_T_ngkNqRukeksw6iNDLt2Q_18_2"></a><a id="Tc_o0R2GyvwkUObJfPj0CHYAQ_18_3"></a><a id="Tc_p6MTBSZpCESLU3cw9MCPXw_18_5"></a><a id="Tc_SGW1dDJti0mJSef3Micpdw_18_6"></a><a id="_33dc10ed_cfbb_4f9f_89c5_fea575d6012f"></a><a id="Tc_CAtJ7K9eUkOrLiG5F2mwIQ_1_2"></a><a id="Tc__7oxB2dpPEKmZVYur9E1yA_1_5"></a><a id="Tc_7p5lc1QVZkyF4OfkRqmNQw_2_2"></a><a id="Tc_01JtFBXXI0a9DxBJL6JL_g_2_5"></a><a id="Tc_wAjnrRaCc0CBv6bbMCpqFg_3_0"></a><a id="Tc__ozlfYBNwk6YmzQSe6Swvw_4_0"></a><a id="Tc_nkR76z0tCUW88pACVvYOfg_4_2"></a><a id="Tc_DIz4OeTGMUKL7PO3t82DQg_4_5"></a><a id="Tc_CSeEPM8ytkuGyUMIfM0QlQ_5_0"></a><a id="Tc_2OaVyppfB0uMVoRTM42slQ_5_6"></a><a id="Tc_su2oDU1VO0Cp41d60Aqh7Q_6_0"></a><a id="Tc_muiixwCG_kmRxOVrl7VK1w_6_6"></a><a id="Tc_NXba_UQxJU6LRzzSi8cAUA_7_0"></a><a id="Tc_gTdJjgPOoUybAYzDJjdClw_7_2"></a><a id="Tc_izhpqrRlz0CANENvdVjdlw_7_5"></a><a id="Tc_x4S4xTXDQUW52oX4qZ3nYA_9_0"></a><a id="Tc_BVIvac42pkOJmO_tXboBRA_10_0"></a><a id="Tc_A50Y-NO4l0W9-AFp8yrqLQ_10_2"></a><a id="Tc_ZUfa0wIBIESD5fFO7WFwQw_10_3"></a><a id="Tc_TeP4tT_Uy0uIXrhMYatMMA_10_5"></a><a id="Tc_t6dEcwooM0eNNzJDBcdPSA_11_0"></a><a id="Tc_4AhMFF02HkKVtRx9N0sbRQ_11_3"></a><a id="Tc_nPJn_G6SY0qvK8jj1-fhbg_12_0"></a><a id="Tc_XMjAMDe9tk6ZSPM1beb5tg_12_2"></a><a id="Tc_d_xX0VJsNkq9YhyOBjMI7g_12_3"></a><a id="Tc_CFbhXZ01e0aobBuLIGs_Jw_12_5"></a><a id="Tc_1pawbo7GxEm9w3BgA7T3Jg_12_6"></a><a id="Tc_qZFS7WRE8kWJ-3alYOdVDw_14_0"></a><a id="Tc_d-odhK4EmUCQ53zqjt9I5A_15_0"></a><a id="Tc_gNnzb4SAR0yCJJa5C1_80A_15_2"></a><a id="Tc_DkhqcgijYEy0cg7FQaK6vQ_15_5"></a><a id="Tc_LuWC5Q4qvEWwlgqUPSNRgg_17_0"></a><a id="Tc_YxAYs1o7uUSahQtCFHJPww_18_0"></a><a id="Tc_3MNUKPjDRU-MnMdl2vJaJA_18_2"></a><a id="Tc_1Jfx-giNqEa4mQvAudWp5Q_18_3"></a><a id="Tc_qAAyl6q8NEGlC0VVpX5Sqg_18_5"></a><a id="_47db2472_f34f_4a92_9f5f_763468402716"></a><a id="Tc_YBT5veYT_0uSPwX2X-7xQQ_1_2"></a><a id="Tc_i0carL5ShEul136THq3nAw_1_5"></a><a id="Tc_oSkImuGVBUW4-8VhpcOwpw_2_2"></a><a id="Tc_t71-X5MW_0qYGv5uDOlfzA_2_5"></a><a id="Tc_Qa07fEB5Q0iDVqMkxRfo-A_3_2"></a><a id="Tc_gzcyra0mTUiZU_-aZQYe2g_3_5"></a><a id="Tc_dhWlTMEgH0Ke9UGUhCg5cw_4_0"></a><a id="Tc_dWY8C_YmvUSGQBfrNTcOFQ_4_1"></a><a id="Tc_3kNsUr5_NkGcOQCsCne0cw_4_2"></a><a id="Tc_QBOUGIc6VkiiY8Sriset2w_4_5"></a><a id="Tc_RMa8UERrjE-ZLgRNQ0eZkg_5_0"></a><a id="Tc_4tIEEGb8KEGL0ZJ5dgpUrg_6_0"></a><a id="Tc_0FV469bwjUeKCJM-8_CciA_7_0"></a><a id="Tc_ttHiTUdURU2KKsxNEUY7GA_8_0"></a><a id="Tc_gPOGTn41206lNQHC8g6Wig_9_0"></a><ix:continuation id="Tb_7-8U5Uoi1EyitVJPK-bMpQ_cont1"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="Tb__1AUVCIGikOjkjlZHXNqoQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="Tc_7rIr4Ezf9E23qGcbPbMqzg_3_3">56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="Tc_zDFt6tAkZk-QiaAvNoQ1ag_3_6">127</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="Tc_SiNV95SkQ0i5gTtbDfl9Kw_4_3">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="Tc_NopjgILMcUeKk0BMuMR3mg_4_6">40</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" id="Tc_DcbjERNMk02XmIspnprInA_5_3">51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" id="Tc_zijjJ13_sUiK8OFViTdxAg_5_6">87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses" scale="3" id="Tc_JUR6RfvnHkCFh4sa18lOeA_7_3">3,062</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses" scale="3" id="Tc_SZGpFbaMekOIWE9HdKeHxw_7_6">1,378</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="Tc_kNWtZszroU-813xsW5DtfA_8_3">7,355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="Tc_bASvw1jDBESAUrWD17IUkQ_8_6">2,458</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="Tc_9j8QbjEGTUCy3qRBaJu02g_9_3">10,417</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="Tc_syLG_N5xGEqvqyxB64a4Sw_9_6">3,836</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expenses):</p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="Tc_amcEOGNP7Eu0kXN29w0tFw_12_3">226</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - related party</span></p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupInterestExpenseRelatedParty" scale="3" id="Tc_NcAZ6nrsLUyKt7H8XD49_Q_13_6">608</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Forgiveness of note payable and accrued interest - SBA loan</span></p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupGainOnDebtForgiveness" scale="3" id="Tc_UxoPYEQdU0OkeWzECDc1dA_14_6">607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsMiscellaneousExpensesIncome" scale="3" id="Tc_XbXsQ_fHm0WX7TTNGmGCrg_15_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsMiscellaneousExpensesIncome" scale="3" id="Tc_h1Z1CHGP8k6Y8_4WYQJObA_15_6">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other expenses</p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="Tc_q5jFlCyj4kK7DvvS8IfNuQ_16_3">227</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="Tc_RB9D4VOChkqq2185lnxvyw_16_6">2</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operation</p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,593)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,751)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents net carrying values related to the major classes of assets that were classified as held for sale at September 30, 2022 and June 30, 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" scale="3" id="Tc_mNJZ7cAflUi9W8vjQ5rSUw_4_3">937</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" scale="3" id="Tc_ffYNPmfNwEC-WqBGCP0y6w_4_6">3,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupOperatingLeaseRightOfUseAssets" scale="3" id="Tc_U8tpzYY52UOhSzwr7m8P1w_5_3">1,949</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" scale="3" id="Tc_tw2-48s0mUWXaal_kmlbCQ_6_3">35,892</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_qFqNKLwkAk-vFUcJW5rilw_7_3">38,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_oM9sln0oAUqXW678ufTvGw_7_6">3,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="3" id="Tc_7tBh1OH43E-JP9SADfAPDw_10_6">35,289</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" scale="3" id="Tc_r0pXZIMehUenf4dqv3GRvw_11_6">1,951</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 37,240</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" scale="3" id="Tc_Q-8DGRtVXUKcy0Q0IS6Mlg_15_3">1,949</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" scale="3" id="Tc_W1LbIBSKKEyYPwYkp8ZO_g_15_6">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupNoncurrentOperatingLeaseObligations" scale="3" id="Tc_JBiN-lgbqE-c0EfzDyQKbQ_18_6">1,941</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:middle;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="Tc_4AaxrkhNNkq7_g92E6Ongw_4_3">271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="Tc_qsCBBcEfnkKNVWRqEW9FPQ_4_6">306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" scale="3" id="Tc_3CYexlgQQkWO_DZsMP01mQ_5_3">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" scale="3" id="Tc_SuFv2TzGs0q3liqYfiMY_w_5_6">416</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="3" id="Tc_-8-5sVwYLU-QXg39xYwUvw_6_3">875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="3" id="Tc_0I4OYGsMI0yPGpKEvb7n9A_6_6">1,082</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing noncash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed assets included in accounts payable in prior period, paid in current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" scale="3" id="Tc_vOqZcO0ipUimEVGpR0NxvA_8_3">1,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" scale="3" id="Tc_VKF1fS_Z8Ua3zCtrFu1C4Q_8_6">383</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Unpaid fixed assets included in accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations" scale="3" id="Tc_9JjuGgmBFkeYlSSHBDce0g_9_3">229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations" scale="3" id="Tc_POR57JI4t02AFYPWpothsw_9_6">750</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_ZZK3GHJwIk2OAubaiC1r1Q" continuedAt="Tb_ZZK3GHJwIk2OAubaiC1r1Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">4.&#160;&#160;&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s significant accounting policies are described in Note&#160;3 of the Notes&#160;to Financial Statements in the Annual Report.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:UseOfEstimates" id="Tb_CoSpvIujn0OWe08dyjP-CQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_yr8hQEuoG0ezSaqMsenBJw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounts Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#8217;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, the Company determined that an allowance for doubtful accounts was not needed.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_Og_9xUqsrUOaukcwGUngoA" continuedAt="Tb_Og_9xUqsrUOaukcwGUngoA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for its revenue recognition under Accounting Standards Codification (&quot;ASC&quot;) 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i)&#160;identify the contract, (ii)&#160;identify the performance obligations, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations and (v)&#160;recognize revenue when a performance obligation is satisfied. The nature of the Company&#8217;s contracts with customers generally falls within the three key elements of the Company&#8217;s business plan: CDMO Facility Activities; Product Candidate Pipeline, and Facility Design and Build-out /Technology Transfer services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and/or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At September 30, 2022 and June 30, 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ProvisionForLossOnContracts" scale="3" id="Narr_aC8S4UEg5EKYXsFnckmgnA"><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:ProvisionForLossOnContracts" scale="3" id="Narr_SMufMbMBdEyBcoQpemwwaQ">no</ix:nonFraction></ix:nonFraction> contract loss provisions. </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ZZK3GHJwIk2OAubaiC1r1Q_cont1" continuedAt="Tb_ZZK3GHJwIk2OAubaiC1r1Q_cont2"><ix:continuation id="Tb_Og_9xUqsrUOaukcwGUngoA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company generates (or may generate in the future) contract revenue under the following types of contracts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fixed-Fee </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue can be recognized either 1) over time or 2) at a point in time. &#160;All revenue was recognized at a point in time for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended September 30, 2021, revenue was from the settlement of a revenue contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Time and Materials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#8217;s billing rate plus other project specific costs incurred.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="ibio:ContractAssetsPolicyTextBlock" id="Tb_91cdxW1rTEi5oQfzjqZIMw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract asset is an entity&#8217;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both September&#160;30,&#160;2022 and June&#160;30,&#160;2022, contract assets were $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_fjoDCUkP8ESYbgHqneNtzA"><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_-UPv4hNOFkmOiDNcO04SGA">0</ix:nonFraction></ix:nonFraction>.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="ibio:ContractLiabilitiesPolicyTextBlock" id="Tb_NRJttDqJj0uzkAPCopN81w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Contract Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract liability is an entity&#8217;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#8217;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, contract liabilities w<span style="background:#ffffff;">ere </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Narr_n4U8HmYmgkKvj50BFWjxTQ">161,000</ix:nonFraction></span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Narr_axYH1xrQPUyaNkZfphukIQ">100,000</ix:nonFraction></span><span style="background:#ffffff;"> r</span>espectively. The Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="Narr_iQ3CiyJSek6tPMWHTZLtDg">56,000</ix:nonFraction> during the three months ended September 30, 2022 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. &#160; The Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="Narr_Yzom1Ucqck6nEt_9efckjQ">84,000</ix:nonFraction> during the three months ended September 30, 2021 that was included in the contract liabilities balance as of June 30, 2021 and reported as part of continuing operations. &#160; </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_K9s4SxTalkGc2KVrM55edg" continuedAt="Tb_K9s4SxTalkGc2KVrM55edg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for leases under the guidance of Accounting Standards Codification (&quot;ASC&quot;) 842, &quot;Leases&quot; (&quot;ASC 842&quot;). The standard established a right-of-use (&#8220;ROU&#8221;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#8217;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, <span style="-sec-ix-hidden:Hidden_sGul_1aHN0eDILLvK8AumA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component</span></span>.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d1abb17b_0533_4c11_b9df_85ab01e76140"></a><a id="Tc_FPP7PqrJekGExkYXNpruww_1_2"></a><a id="Tc_2fzXrTl6uk2UlCMJBw6cbw_1_5"></a><a id="Tc_KG37Hs6FEUujBOfImsPq7Q_2_2"></a><a id="Tc_6GkBeorPVUyhTvHuPne6SQ_2_5"></a><a id="Tc_E_-QyqvOfkKLwo0jgynpaw_3_0"></a><a id="Tc_XmTLxpMvVUO1QMlCASYR8g_3_1"></a><a id="Tc_wxbUt2OX3EK7nlyLnxD8yg_3_2"></a><a id="Tc_iPbii36MckaXqPKq5HKI0Q_3_5"></a><a id="Tc_TpaWblE2qkCS26QXw88e1w_4_0"></a><a id="Tc_JqXAcLGQtE2Vdt94ETl5GA_5_0"></a><a id="Tc_xAZATHqdvUSItna6236Jsw_6_0"></a><a id="Tc_VYvZa1vU20WrQCVX-VQdCg_6_1"></a><a id="Tc_rKazz4cwVk6l_e8t17BaqQ_7_0"></a><a id="Tc_L0O19J07LUCjMj_XoDe7Ig_7_1"></a><a id="Tc_Kmuhq8VdtEi3E2nGbxDgLg_7_2"></a><a id="Tc_IuVEVO2vfUSpnGg8wnSrzg_7_5"></a><ix:continuation id="Tb_ZZK3GHJwIk2OAubaiC1r1Q_cont2" continuedAt="Tb_ZZK3GHJwIk2OAubaiC1r1Q_cont3"><ix:continuation id="Tb_K9s4SxTalkGc2KVrM55edg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#8217;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#8217;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#8217;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_6TSa3e4QoUObgbux5_UanQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at September 30, 2022 and June 30, 2022 consisted of money market accounts. Restricted cash consisted of collateral held for letters of credit obtained to the term note payable for the purchase of the 130,000 square foot cGMP manufacturing facility in Bryan, Texas located at 8800 HSC Parkway, Bryan, Texas 77807 (the &#8220;Facility&#8221;) (see Note 6 &#8211; Significant Transactions) and the San Diego operating lease (see Note 15 &#8211; Operating Lease Obligations) and a Company purchasing card. The Company&#8217;s bank required an additional 5% collateral held above the actual letters of credit issued. Restricted cash was approximately $6 million at both September 30, 2022 and June 30, 2022. On October 11, 2022, the Company, as part of the First Amendment to the Credit Agreement with Woodforest, paid down $5.5M of the term loan and subsequently Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. The change in restricted cash will be reflected in second quarter of fiscal year 2023 financials.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_ojjhTzu_rkSW5fdi0P3aVg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_6sd_umvLdk2krGp1H0xgGQ_3_3">9,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_dwa9mX0XAEmyuJnSc8HEYQ_3_6">22,676</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_euWJTSKtt0aJwVGdmEINPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_FklEncyxWUO6B_s-zGnsvQ_4_3">5,743</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_K4UWN_QhQECOHvhw12blGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_P4FbIvxtHUOIVmNb5lq6MQ_4_6">5,743</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_0pi0YCsgSUCH7buV1WBF9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_0NsHC5H5YUiuew4ZolUXIQ_5_3">198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_54ARR6tb80WIuJ-jyvDHFA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_IY95qI5b1kql_hlYjeGl4Q_5_6">198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_F4h9j-DOsUyvR-zF7aWpzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_AI5VyfFel0GfDdX4csUz9g_6_3">55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_H3Laxbz45UWYB-AJtsQg0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_bisA6NFxZ0KXJINKQ4h8xw_6_6">55</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_hTxOlxsUMkua2PEfvb6Fgg_7_3">15,883</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_zMCzCu8jFEuTQnz1QTivpg_7_6">28,672</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" id="Tb_a9fWP4vqoUGqCoE-DbwCmg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Investments in Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value is calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. See Note 8 &#8211; Investments in Debt Securities.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:InventoryPolicyTextBlock" id="Tb_2bA9vTVGl0i7kivtr2pYjQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';">Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. &#160;Inventory held is related to the CDMO business and has been classified as held for sale. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_iasDYOSq10mLmGF0I9mU1A" continuedAt="Tb_iasDYOSq10mLmGF0I9mU1A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 730-10, <i style="font-style:italic;">Research and Development</i> (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the three month periods ending September 30, 2022 and 2021 research and development expense was reported in both continuing and discontinued operations.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ZZK3GHJwIk2OAubaiC1r1Q_cont3" continuedAt="Tb_ZZK3GHJwIk2OAubaiC1r1Q_cont4"><ix:continuation id="Tb_iasDYOSq10mLmGF0I9mU1A_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="ibio:RightOfUseAssetsPolicyPolicyTextBlock" id="Tb_gXYUcrWmH0GpHKc7iKGNIw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-Use Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 14 - Finance Lease Obligations for additional information.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_nYhtRuSryUauKkiuAeduAw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_mylpkjT0LkCiMRV69PIkrw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_h3rVauDz3ESYJDDsYgtxFw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_SXr7k8kFSEuPdpmVDvdSxg">39 years</ix:nonNumeric>.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="Tb_LZeM4GeWrEiIhyAI5XbHyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_fXHaqpNPo0ibzA3IIYhZbQ" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_8N0uWtQQN0Wtpg8iTwwF5g">10 years</ix:nonNumeric> and other intellectual property is amortized over periods from <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ab93kNrf80-v2rMyke-vrg" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_n8SHmXC68kqQCokHhYuzZQ">16</ix:nonNumeric> to <span style="-sec-ix-hidden:Hidden_u6VUYlS0b0yj9uFRIDrlgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23&#160;years</span></span>. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="0" id="Narr_F83lx8g1xUmL-NufvtuLlA"><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="0" id="Narr_QogOH08y7kmu27P-mTL3eQ">no</ix:nonFraction></ix:nonFraction> impairment charges for the three months ended September&#160;30,&#160;2022 and 2021.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_h1j7OtWbN0GOnm_cjRIWjQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The impact that share-based payment awards will have on the Company&#8217;s results of operations is a function of the number of shares awarded, the trading price of the Company&#8217;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#8217;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Expected volatility is based on historical volatility of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;); the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#8217;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_QjZnejMjcUyNmgx7wGFn8g">zero</ix:nonFraction>. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 17 - Share-Based Compensation for additional information.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_XG0nrxAaukS-EpdE2hCugw" continuedAt="Tb_XG0nrxAaukS-EpdE2hCugw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, amounts in excess of insured limits were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="0" id="Narr_dlBrjbIM2E6FT8LZX8VQ1A">15,372,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="0" id="Narr_SHmNZwU9dES9clK-PgL7qw">18,200,000</ix:nonFraction>, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended September&#160;30,&#160;2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from <ix:nonFraction unitRef="Unit_Standard_customer_Y0UfwaAMRkCOQV5hDgN0Lw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_s9c-WnWOxE6g2LweOZs_9Q" decimals="0" format="ixt-sec:numwordsen" name="ibio:NumberOfMajorCustomers" scale="0" id="Narr_RZJ0W3GCdEO8krUC9KxVLQ">one</ix:nonFraction> customer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended September&#160;30,&#160;2021, the Company reported revenue from continuing operations from one customer related to the settlement of a revenue contract and generated 100% of revenue reported in discontinued operations from <ix:nonFraction unitRef="Unit_Standard_customer_Y0UfwaAMRkCOQV5hDgN0Lw" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_i04Yf02_rk-EHh765zWa6g" decimals="0" format="ixt-sec:numwordsen" name="ibio:NumberOfMajorCustomers" scale="0" id="Narr_Es-nRPJxlk-g4Og8zWHzug">three</ix:nonFraction> customers, each of whom individually accounted for more than 10% of revenue.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ZZK3GHJwIk2OAubaiC1r1Q_cont4"><ix:continuation id="Tb_XG0nrxAaukS-EpdE2hCugw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_hMENetisuEq9JEYIs2UMxw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Recently Issued Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#8217;s condensed consolidated financial statements.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_oozcHYK5VUSDzN3QpMtQvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">5.&#160;&#160;&#160;Financial Instruments and Fair Value Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The carrying values of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and term note payable in the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of September&#160;30,&#160;2022 and June&#160;30,&#160;2022 due to their short-term nature. The carrying value of the convertible promissory note receivable, the term note payable and finance lease obligation approximated fair value as of September&#160;30,&#160;2022 and June&#160;30,&#160;2022 as the interest rates related to the financial instruments approximated market value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of investments that fall under each category, and the valuation methodologies used to measure these investments at fair value. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs are based upon unadjusted quoted prices for identical instruments in active markets. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 2</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs to the valuation include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. &#160;All debt securities were valued using Level 2 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 3</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="ibio:SignificantTransactionsTextBlock" id="Tb_ceMK2G95BEiArJZkONpIIA" continuedAt="Tb_ceMK2G95BEiArJZkONpIIA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">6.   Significant Transactions </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Affiliates of Eastern Capital Limited</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Company and its subsidiary, iBio CDMO (&#8220;iBio CDMO&#8221;, and collectively with the Company, the &#8220;Purchaser&#8221;) entered into a series of agreements (the &#8220;Transaction&#8221;) with College Station Investors LLC (&#8220;College Station&#8221;), and Bryan Capital Investors LLC (&#8220;Bryan Capital&#8221; and, collectively with College Station, &#8220;Seller&#8221;), each affiliates of Eastern Capital Limited (&#8220;Eastern,&#8221; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility&#8217;s ground lease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise terminated all agreements between the Company and the affiliates of Eastern.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ceMK2G95BEiArJZkONpIIA_cont1" continuedAt="Tb_ceMK2G95BEiArJZkONpIIA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&amp;M University System (&#8220;Texas A&amp;M&#8221;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the &#8220;Sublease&#8221;) until the purchase of the Facility described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Purchase and Sale Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Purchaser entered into a Purchase and Sale Agreement (the &#8220;Purchase and Sale Agreement&#8221;) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the &#8220;Ground Lease Agreement&#8221;) that it entered into with Texas A&amp;M (the &#8220;Landlord&#8217;&#8217;) related to the property at which the Facility is located together with all improvements pertaining thereto (the &#8220;Property&#8221;), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA" decimals="0" format="ixt:numdotdecimal" name="ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" scale="0" id="Narr_Mi8OUjEua0SLe8wdFC-I_g">28,750,000</ix:nonFraction>, which was paid $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ" decimals="0" format="ixt:numdotdecimal" name="ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" scale="0" id="Narr_1H8GUeihPUSL63Q5T6juWw">28,000,000</ix:nonFraction> in cash and by the issuance to Seller of warrants (the &#8220;Warrant&#8221;) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA" decimals="0" format="ixt:numdotdecimal" name="ibio:FairMarketValueOfProperty" scale="0" id="Narr__3zvDAcdgk6CwMmp8jojWQ">151,450</ix:nonFraction> for the prior year, is <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ" decimals="3" format="ixt:numdotdecimal" name="ibio:BaseRentPercentageOfFairMarketValueOfProperty" scale="-2" id="Narr_VtMHfNcLUUWtY-bzFta8mA">6.5</ix:nonFraction>% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, iBio CDMO is being accounted for as a discontinued operation. &#160;As such, the assets acquired and/or leased are now classified as assets held for sale on the September 30, 2022 and June 30, 2022 condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Equity Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also entered into an Equity Purchase Agreement with Bryan Capital on November 1, 2021 (the &#8220;Equity Purchase Agreement&#8221;) pursuant to which the Company acquired for $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ" decimals="0" format="ixt:numdotdecimal" name="ibio:EquityAgreementConsiderationTransferredEquityInterestsAcquired" scale="0" id="Narr_t8l6K6VC2EmRhKgYjyQzgg">50,000</ix:nonFraction> cash, plus the Warrant, the <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_2OHxCAB-J0WOw18oKiVXGA" decimals="INF" format="ixt-sec:numwordsen" name="ibio:EquityAgreementWarrantsIssuedOrIssuable" scale="0" id="Narr_4M4LYFFkYUWf-SmfHTrdzQ">one</ix:nonFraction> (1) share of iBio CMO Preferred Tracking Stock and the <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_2OHxCAB-J0WOw18oKiVXGA" decimals="4" format="ixt:numdotdecimal" name="ibio:EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" scale="-2" id="Narr_qGQWgdKB6kegqlO0-T12xA">0.01</ix:nonFraction>% interest in iBio CDMO owned by Bryan Capital. As a result, iBio CDMO is now a wholly-owned subsidiary of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Purchase and Sale Agreement, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Drb-_QNrO0K1RLoc86Un0A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_5KP7wcCiA0qAPtE_G6lNvA">22,375,000</ix:nonFraction> secured term loan (the &#8220;Term Loan&#8221;) to purchase the Facility, which Term Loan is evidenced by a Term Note (the &#8220;Term Note&#8221;). The Term Loan was advanced in full on the closing date. The Term Loan bears interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Drb-_QNrO0K1RLoc86Un0A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_G6Dm7HOAdUeQFgAFagDOMA">3.25</ix:nonFraction>%, with higher interest rates upon an event of default, which interest is payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Credit Agreement contains customary events of default (which are in some cases subject to certain exceptions, thresholds, notice requirements and grace periods), including, but not limited to, nonpayment of principal or interest, failure to perform or observe covenants, breaches of representations and warranties, cross-defaults with certain other indebtedness, certain bankruptcy-related events or proceedings, final monetary judgments or orders and certain change of control events. The covenants include a prohibition on the incurrence of Debt (as defined in the Credit Agreement) except permitted Debt (as defined in the Credit Agreement) and Liens (as defined in the Credit Agreement) and termination of the Ground Lease Agreement. In addition, the Company initially was required to maintain unrestricted cash of no less than $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Drb-_QNrO0K1RLoc86Un0A" decimals="0" format="ixt:numdotdecimal" name="ibio:CreditAgreementThresholdLimitUnrestrictedCash" scale="0" id="Narr_lAJYvd8cN0SDvvPvD9rw2A">10,000,000</ix:nonFraction> which amount has been reduced (see below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company opened an irrevocable letter of credit in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Drb-_QNrO0K1RLoc86Un0A" decimals="0" format="ixt:numdotdecimal" name="ibio:IrrevocableLetterOfCredit" scale="0" id="Narr_bSYd16-ackG5WU-6OksyJA">5,469,000</ix:nonFraction> in favor of Woodforest. &#160;The letter of credit was scheduled to expire on October 29, 2022, but was cancelled (see below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The proceeds of the Term Loan were used (a) to fund a portion of the purchase price under the Purchase Agreement, and (b) to pay closing costs in connection with the Credit Agreement. The term loan is secured by (a) a leasehold deed of trust on the Facility, (b) a letter of credit issued by JPMorgan Chase Bank, and (c) a first lien on all assets of iBio CDMO including the Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 11, 2022, we and Woodforest amended the Credit Agreement to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days &#160;upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (see Note 19 &#8211; Fraunhofer Settlement for more information), (iii) include </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ceMK2G95BEiArJZkONpIIA_cont2" continuedAt="Tb_ceMK2G95BEiArJZkONpIIA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">principal payments of $250,000 per month in debt amortization for a 6 month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast (vi) reduce the liquidity covenant in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5.0 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. If we fail to successfully extend our cash runway via strategic options or other alternatives as described, we would be in violation of the liquidity covenant on December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result of the foregoing, at both September 30, 2022 and June&#160;30,&#160;2022, the Term Loan has been classified as short term. At September 30, 2022, the balance was $22,201,000 which consisted of the Term note of $22,375,000, net of approximately $174,000 of deferred finance costs. &#160; At June 30, 2022, the balance was $22,161,000 which consisted of the Term Note of $22,375,000, net of approximately $214,000 of deferred finance costs. Interest expense incurred under the Credit Agreement for the three months ended September&#160;30,&#160;2022 amounted to $186,000. Amortization of deferred finance costs amounted to $40,000 for the three months ended September 30, 2022 and is included in interest expense. &#160;Both interest expense amounts are classified under loss from discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security and Pledge Agreements, Guaranties and Deed of Trust</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio CDMO also entered into a Security Agreement on November 1, 2021 with Woodforest (the &#8220;Security Agreement&#8221;) providing Woodforest a security interest in the following assets of iBio CDMO (subject to certain exclusions): all personal and fixture property of every kind and nature, including, without limitation, all goods (including, but not limited to, all equipment and any accessions thereto), all inventory, instruments (including promissory notes), documents, accounts, chattel paper (whether tangible or electronic), deposit accounts, securities accounts, letter-of-credit rights (whether or not the letter of credit is evidenced by a writing), money, commercial tort claims, securities and all other investment property, supporting obligations, contracts, contract rights, other rights to the payment of money, insurance claims and proceeds, software, fixtures, vehicles and rolling stock (whether or not subject to a certificate of title statute), leasehold improvements, general intangibles (including all payment intangibles), and all of iBio CDMO&#8217;s company and other business books, reports, memoranda, customer lists, credit files, data compilations, and computer software, in any form, including, without limitation, whether on tape, disk, card, strip, cartridge, or any other form, pertaining to any and all of the foregoing property, and all products and proceeds of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also entered into a Guaranty for the benefit of Woodforest (the &#8220;Guaranty&#8221;) pursuant to which it guaranteed all of the obligations of iBio CDMO to Woodforest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, iBio CDMO entered into a Leasehold Deed of Trust, Assignment of Rents, Security Agreement and UCC Financing Statement for Fixture Filing (the &#8220;Deed of Trust&#8221;) with the trustee named therein and Woodforest as beneficiary, securing all of iBio CDMO&#8217;s obligations to Woodforest by a senior priority security interest in the Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company and iBio CDMO also entered into an Environmental Indemnity Agreement in favor of Woodforest (the &#8220;Environmental Indemnity Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Warrant</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_vCgFVNSHG0ak_sz6iYigJA">51,583</ix:nonFraction> shares of the Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_s4gfAdCDNk60CbAXpekvGg">33.25</ix:nonFraction> per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the shares issued under the Warrant, <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ" decimals="INF" format="ixt:numdotdecimal" name="ibio:WarrantsIssuedForFinalPaymentOfSubleaseRent" scale="0" id="Narr_R3ZLoFQXqEenF46m_d7bfg">11,583</ix:nonFraction>, which were originally valued at $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA" decimals="0" format="ixt:numdotdecimal" name="ibio:WarrantsIssuedForFinalPaymentOfSubleaseRentValue" scale="0" id="Narr_FhP7YIUrPUSJDgrJmyOuvg">217,255</ix:nonFraction>, reflected the final payment of rent due under the Sublease. The Warrant, as shown on the condensed consolidated statements of equity, was recorded in additional paid in capital with the corresponding activity included in the basis of the purchase price allocation of the property acquired. &#160;See Note 16 &#8211; Stockholders&#8217; Equity for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (&#8220;RubrYc&#8221;) described in more detail below:</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_510a9d62_c474_4755_bd29_abe8ac2e0e02"></a><a id="Tc_TFwBrBr4BkKrT62P_YGqhA_1_0"></a><a id="Tc_oErkLv1GGU26h_IosIiMzw_1_1"></a><a id="Tc_y6uvMkPJvUCycWQTmE1XZA_1_2"></a><a id="Tc_cHEbfztUgkOOjhllbYBdLA_2_0"></a><a id="Tc_e6vuQGiqNEKO5V9mbeuVGQ_3_0"></a><a id="Tc_fHfUNFDaU0mHIR7kHwlbfw_3_1"></a><a id="Tc_VzVRaPwtOUqhFyCFDejM3Q_4_1"></a><a id="Tc_Ya3tNFbsDUW1rlxjzJy8zQ_4_2"></a><ix:continuation id="Tb_ceMK2G95BEiArJZkONpIIA_cont3" continuedAt="Tb_ceMK2G95BEiArJZkONpIIA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into a collaboration and licensing agreement (the &#8220;RTX-003 License Agreement&#8221;) with RubrYc to further develop RubrYc&#8217;s immune-oncology antibodies in its RTX-003 campaign. &#160;Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields<span style="color:#0000ff;">. &#160;</span>RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration, Option and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into an agreement with RubrYc (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration, Option and License Agreement&#8221;) </span>to collaborate for up to <ix:nonNumeric contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_OdZyqlQ0vEmY8lbQusF-8g" format="ixt-sec:durwordsen" name="ibio:CollaborationAndLicenseAgreementAgreementTerm" id="Narr_6I6NJZVUK0uA189occ03Eg">five years</ix:nonNumeric> to discover and develop novel antibody therapeutics using RubrYc&#8217;s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. &#160;RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) <span style="-sec-ix-hidden:Hidden_9g2_uLeoFka_iS5MEA5Jqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. &#160;The Collaboration, Option and License Agreement was mostly terminated when the Company acquired substantially all of the assets of RubrYc in September 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-align:justify;margin:0pt;">In connection with the entry into the Collaboration Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (&#8220;Stock Purchase Agreement&#8221;) with RubrYc whereby the Company purchased a total of <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_QgEz_8IsUkubKmRBLIhjSw" decimals="INF" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementNumberOfSharesPurchased" scale="0" id="Narr_TF0TH7VMKkWjbpP5sy8k2A">2,864,345</ix:nonFraction> shares of RubrYc&#8217;s Series A-2 preferred stock &#8220;Series A-2 Preferred&#8221;) for $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_QgEz_8IsUkubKmRBLIhjSw" decimals="0" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementValueOfSharesPurchased" scale="0" id="Narr_WQ9BJtJd2kqNd_cKk9H8zQ">7,500,000</ix:nonFraction>. </p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_vIjz2QvLhkmSRzd2SRXhOA" name="us-gaap:AssetAcquisitionTableTextBlock" id="Tb_nHL3OpmBV0qMYjlmvEgMFA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_8_23_2021_To_8_23_2021_ITw1i6YR9UyPpE1bDlnljA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Narr_g6saaeH7eEKjcz_Riz5kIQ">7,500,000</ix:nonFraction> as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember__MJTg0K5YECHuCTCCIebng" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_XsP_qTFhikK4KLcI4C0R1w_1_3">1,760,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_zieqCNuAYk6lRv2JAfCx8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_YNDPPbVWp0GPjorcf1Vbhg_2_3">4,300,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember_xJCS27lRZ0q-02PnngOAUw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_FuTWx8q0Y02CO1Nb9zG3hg_3_3">1,440,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_8_23_2021_To_8_23_2021_ITw1i6YR9UyPpE1bDlnljA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_3M3QduBDeEe7_57LiY3Ehw_4_3">7,500,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">RubrYc ceased its operations, and the Company recorded an impairment of the investment in the amount of $1,760,000 in 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, in 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The Company issued 102,354 shares of the Company&#8217;s common stock with an approximate market value of $1,000,000 (the &#8220;Closing Shares&#8221;). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Company&#8217;s common stock, at the Company&#8217;s option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. &#160;The assets acquired include an AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, and two additional immuno-oncology candidates plus a partnership-ready PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. &#160;The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ceMK2G95BEiArJZkONpIIA_cont4"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_ibio_RubrycTheraputicsInc.Member_6l4R-5WO_UilEL_BSvm5mA" name="us-gaap:AssetAcquisitionTableTextBlock" id="Tb_ZjYDBCwGu0KIR-mfDgT3dA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:73.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,228,000</span></p></td></tr><tr><td style="vertical-align:middle;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 114,000</span></p></td></tr><tr><td style="vertical-align:middle;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,342,000</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. &#160;See Note 9 &#8211; Finance Lease ROU Assets and Note 14 &#8211; Finance Lease Obligations.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Tb_3qipMro8ykyJ87ng4DIfGw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">7.&#160;&#160;&#160;Convertible Promissory Note Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 1, 2020, the Company entered into a master services agreement with Safi Biosolutions, Inc. (&#8220;Safi&#8221;). In addition, the Company invested $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_RpRam_Iq8kC7AtGMNktNbw" decimals="-5" format="ixt:numdotdecimal" name="ibio:LoansReceivableAmountInvested" scale="6" id="Narr_lhOZODV25U-79chuo3wfpA">1.5</ix:nonFraction> million in Safi in the form of a convertible promissory note (the &quot;Note&quot;). The Note bears interest at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_XyA_UzbdsEqM1o0uE-Nz6Q" decimals="2" format="ixt:numdotdecimal" name="ibio:LoansReceivableFixedRatesOfInterest" scale="-2" id="Narr_qX3lg8wqtUydyhYKtO3J4Q">5</ix:nonFraction>% per annum and is convertible into shares of Safi&#8217;s common stock (as defined). Principal and accrued interest mature on October 1, 2023. &#160;For both of the three months ended September 30, 2022 and 2021, interest income amounted to $19,000. As of September&#160;30,&#160;2022 and June 30, 2022, the Note balance and accrued interest totaled $1,650,000 and $1,631,000, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b3aa3e97_bcf0_437c_bcc9_201d17d46763"></a><a id="Tc_k_stdWCQ_UunXBdd09Y-6w_1_2"></a><a id="Tc_TZYYn3dKq0yoz3e6HlUx4Q_1_5"></a><a id="Tc_Q9JYIaqoBkW9d4JGOD1_QQ_2_2"></a><a id="Tc_dqQII6UOA0mQWe-htVsFdw_2_5"></a><a id="Tc_lHdVwJlm4Ui6zeQgrz4RIw_3_0"></a><a id="Tc_wCX_XaSqAkKO1wh1a-xnMw_3_1"></a><a id="Tc_N5pJ5ugdd0KRvbeZxoFW9w_3_2"></a><a id="Tc_PEDev8vQSU6Z1nTAq0xgSw_3_5"></a><a id="Tc_42iM5BUVJECpoxw3KDjYjQ_4_0"></a><a id="Tc_QvhZ3S08OkWODZ6_JEJCNg_4_1"></a><a id="Tc_YFAhwj5p3UOPvVbTnAQxxw_5_0"></a><a id="Tc_SqV4NeHsDU6Uq6aGA6bPUg_5_1"></a><a id="Tc_tOk-ofzlnU2DrbIK9HXZvw_5_2"></a><a id="Tc_qMuPTb2-7UKaI9MsaEoORg_5_5"></a><a id="_baf04a13_255f_46b1_ba8a_feaaeef4ab79"></a><a id="Tc_go5A0wdkEk2UBjgJa03ROA_1_2"></a><a id="Tc_ADzSCZVjpE6MeE56q2cXNQ_1_5"></a><a id="Tc_Z6g19Bn9w0aEgEnm3SJZrw_2_0"></a><a id="Tc_207rZBVBTkqTBTCQOHZR4Q_2_1"></a><a id="Tc_M36DsiQDUUO74i-qpdIOzA_2_2"></a><a id="Tc_v6dJdcrx4kOUKv4Y7BoFQw_2_5"></a><a id="Tc_xBxCeayvhk-Zvze-A3iInQ_3_0"></a><a id="Tc_R2-4HYtu70GI4mVIjGMYhA_3_1"></a><a id="Tc_HCsp8gx8hEKFXp7zC5Ml6w_3_2"></a><a id="Tc_4dMKDgJFTUivGcHwb40qIw_3_5"></a><a id="Tc_sq3rvSbUREKM2Bv8WQTdVQ_4_0"></a><a id="Tc_Zc4scLzJpkeQUhxMwGT_1A_5_1"></a><a id="Tc_UMvwAttvbk6uLvv4ug8X5g_5_2"></a><a id="Tc_RLFQkVU20U6dTdVnYUho3w_5_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="Tb_LZ1K5TZXo0OueONF_P6xhg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;Investments in Debt and Equity Securities</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="Tb_bChqJvE_00atn1jSV3pqeQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Debt Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Investments in debt securities consist of AA and A rated corporate bonds bearing interest at rates from <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_MinimumMember_-6_SwUpb2EmaZh5-_vBL1Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:InvestmentInterestRate" scale="-2" id="Narr_IFeTFWbK3UKkkZS0uLnRhA">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_MaximumMember_s8tVGg0TVkGTdiQRMPEupQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:InvestmentInterestRate" scale="-2" id="Narr_KCOgdJ2mg0GXku1G3o1H-g">3.5</ix:nonFraction>% with maturities from <span style="-sec-ix-hidden:Hidden__3BD-NqJOEiqalOgJX0pyg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December 2022</span></span> to <span style="-sec-ix-hidden:Hidden_NaePz8N5I0616M6LaQS5Jg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">February 2024</span></span>. The components of investments in debt securities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Adjusted cost</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_5lZQEzp8jUqDk74O-4qNWA_3_3">7,793</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_PSX_u2LpZECbE67g4d4IFg_3_6">11,029</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Gross unrealized losses</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_IwV_Kby3rE23LRQ_ZkedaA_4_3">194</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.46%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_PdpJi6im9kC8KzerFEqf3g_4_6">184</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Fair value</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="Tc_L4qDJY_Pvku1SCIRhMEFQg_5_3">7,599</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="Tc_ZVHIRQ-bgEmxDmM21rJqSw_5_6">10,845</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="Tb_7uVQy6wIrUyv22vYRaVKOA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair value of available-for-sale debt securities, by contractual maturity, was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Fiscal period ending:</b></p></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2023</p></td><td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" scale="3" id="Tc_cmQ8ZCO4sUuudj-BB4FDVA_3_3">5,341</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" scale="3" id="Tc_u6gjztam7U-jRuSSEdQhjQ_3_6">8,054</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2024</p></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="Tc_CUAdo5IKqkqBZGEMcH0yfA_4_3">2,258</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="Tc_ESXAQo4N3EWNPbKwU7uiXg_4_6">2,791</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="Tc_aOMSAZPrmUSf_pqiQeypYA_5_3">7,599</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesCurrent" scale="3" id="Tc_qIoxbSPPQUuyMJzfan35cQ_5_6">10,845</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of premiums paid on the debt securities amounted to $36,000 and $102,000 for the three months ended September&#160;30,&#160;2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock" id="Tb_kiIeaKYN9U6ks5agL49UeQ" continuedAt="Tb_kiIeaKYN9U6ks5agL49UeQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.&#160;&#160;&#160;Finance Lease ROU Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company assumed three equipment leases as part of the RubrYc asset acquisition. &#160;In addition, the Company also leases a mobile office trailer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 14 &#8211; Finance Lease Obligation for more details of the terms of the leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_af606e7e_a5ff_4638_b67a_c1940e015287"></a><a id="Tc_bmA3HjFTJEWtGVFZapB4Kg_1_2"></a><a id="Tc_Ef3Anp-WHE6lgavlYKbvkQ_1_5"></a><a id="Tc_2wNlV_BP0EOtLLTqviQARw_2_2"></a><a id="Tc_ChOknuUsxkeBiRuxcM8BDw_2_5"></a><a id="Tc_5WaIMr6Dw0Sw5juE8awmUQ_3_0"></a><a id="Tc_z8HN2FWog0SSCZDoJF8S0w_3_2"></a><a id="Tc_nFFtrdwWRkmGTRRDbA2ouA_3_5"></a><a id="Tc_tfKnDuXF10KBssXdKWTX0w_4_0"></a><a id="Tc_Q0e1CCvnxkmKyxUIao813A_5_0"></a><a id="Tc_7TO4eZvdKUy9vtoFL0k4gw_5_2"></a><a id="Tc_5xag-NKPDkutYQgBmBzE8Q_5_5"></a><ix:continuation id="Tb_kiIeaKYN9U6ks5agL49UeQ_cont1"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" id="Tb_OJbhIHjGVE-zE-_qBB81_g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ROU - Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_UM_IWNFT-kCLpCY0YtA3Kg" decimals="-3" format="ixt:numdotdecimal" name="ibio:FinanceLeaseRightOfUseAssetGross" scale="3" id="Tc_pP3RZ8bkq0WEeloslJKGRg_3_3">960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_7CoQPwcN1U-vHI9EXbbGag" decimals="-3" format="ixt:numdotdecimal" name="ibio:FinanceLeaseRightOfUseAssetGross" scale="3" id="Tc_3n46H1X6Yku0pQ1An3ZbpA_3_6">146</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="Tc_P5A6G3UFvUS3vmJv0dU3Qg_4_3">85</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="Tc_gfjDJofL7E2IOfseOL0rlw_4_6">72</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net finance lease ROU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_EF7iMduQb0-9TxrHh4vdNw_5_3">875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_yCJ9SHt-ZU6tFoscKcBHcg_5_6">74</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of finance lease ROU assets was approximately $13,000 and $12,000 for three months ended September 30, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock" id="Tb_VMAhK0q4LkOeFd_5z7HEgA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">10.&#160;&#160;&#160;Operating Lease ROU Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">San Diego, California</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 10, 2021, the Company entered into a lease for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_5KxWaFXlD02dT7QlqBc7JA" contextRef="As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_DWU_ZvRTnUiuiqonub3lIA">11,383</ix:nonFraction> square feet of space in San Diego, California. &#160;Based on the terms of the lease payments, the Company recorded an operating lease right-of-use asset of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_0MRa3FMqyEawRBzamI2cXw">3,603,000</ix:nonFraction>. &#160;The net carrying amount of this ROU operating lease asset was $2,928,000 and $3,068,000 at September 30, 2022 and June 30, 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Bryan, Texas</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, as discussed above, iBio CDMO acquired the Facility and became the tenant under the ground lease for the Property upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease right of use asset of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_11_1_2021_H4wahzJ9fkakdBA5brt04w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_P8lVnbZpG02uHUTxhdMmeg">1,967,000</ix:nonFraction>. The net amount of this ROU operating lease asset is included in assets held for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> &#160; &#160;<span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 15 - Operating Lease Obligation for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_NzSSpeyk2kud7QhZo1ePig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Substantially all of the fixed assets at September 30, 2022 are included in assets held for sale. &#160;The depreciation expense for the three months ended September 30, 2022 and 2021 is classified as part of loss from discontinued operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fixed assets at September 30, 2022 and June 30, 2022 reported in continuing operations represents the construction in progress for the new San Diego research facility. &#160;These assets were placed into service on October 1, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="Tb_f7cBEsNRU0mQcG9qDSo1zQ" continuedAt="Tb_f7cBEsNRU0mQcG9qDSo1zQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12.&#160;&#160;&#160;Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has two categories of intangible assets&#160;&#8211; intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December&#160;2003 from Fraunhofer USA&#160;Inc., acting through its Center for Molecular Biotechnology (&#8220;Fraunhofer&#8221;), pursuant to a Technology Transfer Agreement, as amended (the &#8220;TTA&#8221;). The Company designates such technology further developed and acquired from Fraunhofer as <i style="font-style:italic;">iBioLaunch</i><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or <i style="font-style:italic;">LicKM</i><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or <i style="font-style:italic;">FastPharming</i> Technology. The value on the Company&#8217;s books attributed to patents owned or controlled by the Company is based only on payments for services and fees related to the protection of the Company&#8217;s patent portfolio. The intellectual property also includes certain trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) whereby in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T regulatory (T reg) cells while enhancing T effector (T eff) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. &#160;In addition, the Company also received preferred shares and an option for future collaboration licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e0b286f9_c9e0_4a50_9938_a5cf5f2edd93"></a><a id="Tc_vXO2tZqnSkqql6WQNjJjSw_1_2"></a><a id="Tc_Tc1VvbkM_ke5LExekHSu1A_1_5"></a><a id="Tc_HN_gxZW8SkGwhFkHxAkD8g_2_2"></a><a id="Tc_pzyc0oSBL02uXYVJ7UZIuA_2_5"></a><a id="Tc_dYDcNOEwqUaurr99LJJ8vA_3_0"></a><a id="Tc_YTpHDd_VR0y6wx3ZwdcLbw_3_2"></a><a id="Tc_QkYsqEN9D0O1vbOlcf1ftA_3_5"></a><a id="Tc_e0PdKNP450yqKvQPil50KA_4_0"></a><a id="Tc_aXTSDfaCyUq4dMynzbl35Q_6_0"></a><a id="Tc_BV0HAkfjSUuloCD0YtTHFQ_7_0"></a><a id="Tc_TzjFbF0Uj0y4Tfvg5fDjBw_9_0"></a><a id="Tc_0nskY0p8Q0a95wT4Shwc3Q_9_3"></a><a id="Tc_ut_973YbG0mBM9bpGc9Cow_9_6"></a><a id="Tc__rVjaOFskUejqno0-NrcIA_11_0"></a><a id="Tc_2zW6t26LLUSiOvwxcHBANw_11_3"></a><a id="Tc_Zb5-9SUCA0m0mKlSxzwvOQ_11_6"></a><a id="Tc_X7xpkZv28EyZQlfzf1CEBQ_13_0"></a><a id="Tc_aP2m273NZkuZn2KBJuOqow_13_2"></a><a id="Tc_LJLAXElQWEeN9Jp4lCLjgg_13_5"></a><ix:continuation id="Tb_f7cBEsNRU0mQcG9qDSo1zQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The assets acquired include an AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, and two additional immuno-oncology candidates, plus a partnership-ready PD-1 agonist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2014, the Company entered into a license agreement with the University of Pittsburgh<i style="font-style:italic;"> </i>whereby iBio acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the &quot;Licensed Technology&quot;) which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone &#8211; filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology (&quot;IND&quot;) &#8211; initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022 was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_fXHaqpNPo0ibzA3IIYhZbQ" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_UgPi_fpot0KR3P3penjW4w">10 years</ix:nonNumeric> and other intellectual property is amortized over periods from <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ab93kNrf80-v2rMyke-vrg" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_uB6dneiHb0yBb9XMJ3fkQg">16</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember__u8DjlS8KEWaLpv6LnztgQ" format="ixt-sec:durwordsen" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Narr_0jdBvsALu02574rkzHvrzA">23 years</ix:nonNumeric> unless they were determined to have indefinite lives. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no impairments for the three months ended September&#160;30,&#160;2022 and 2021.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_-MRCe5bs70amraYEqD9kqw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_YQhUDGnYokGcvtHjtcEqtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_-2FNCeE_YkulBlhDuQJE0g_3_3">3,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_dlYgMTALDUmKK5WItuSB3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_6j-EyueqYEi6PcDA4_I8VA_3_6">3,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_rkj0FZs-fUu4EXJb9_k82g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_H0wi9KImn065I5eBwpGhAA_4_3">2,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_uC1tSKAok0msG1QVWd04rw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_qA1vY_lSd0Cn0WEs5ioQLg_4_6">2,846</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_CFyzezf7tk--LeT8FzFclg_5_3">6,220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_OfSHvEIva064JBKzPMatCg_5_6">5,946</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_YQhUDGnYokGcvtHjtcEqtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_yksDOmVbxE6tst6slDRb9Q_6_3">2,905</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_dlYgMTALDUmKK5WItuSB3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_2oRgwAjbUE6GIk3ADggSqQ_6_6">2,867</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_rkj0FZs-fUu4EXJb9_k82g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_Tp9QEUhwTUyOQIqvtAkv3A_7_3">2,305</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_uC1tSKAok0msG1QVWd04rw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_BcITh5TdaEqAmc0iLRigVA_7_6">2,403</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_MsltOQqtJ06dRkYgcpe8Cg_8_3">5,210</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_uqAc0r8iEEeKUQCf8a9KsQ_8_6">5,270</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total definite lived intangible assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 676</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License - indefinite lived</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,175</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_vFASVnr8cUqCX-KnIwTyCw_13_3">6,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_Iz33vA60P0ufTerx6p_X_g_13_6">4,851</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization expense of intangible assets was approximately $67,000 and $88,000 for the three&#160;months ended September&#160;30, 2022 and 2021, respectively.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="ibio:NotesPayablePppLoanDisclosureTextblock" id="Tb_IYtO-ucU10eMS_tRAQNArw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">13.&#160;&#160;&#160;Note Payable &#8211; PPP Loan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On April 16, 2020, the Company received $600,000 related to its filing under the Paycheck Protection Program and Coronavirus Aid, Relief, and Economic Security Act (the &quot;CARES Act&quot;). The Company elected to treat the SBA Loans as debt under ASC 470, &#8220;Debt&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July 21, 2021, iBio was granted forgiveness in repaying the loan. &#160;In accordance with ASC 405-20-40, &#8220;<i style="font-style:italic;">Liabilities - Extinguishments of Liabilities &#8211; Derecognition</i>&#8221;, the Company derecognized the liability and accrued interest of approximately $7,000 in the first quarter of Fiscal 2022. &#160;The forgiveness is included in loss from discontinued operations (see Note 3 &#8211; Discontinued Operations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:LesseeFinanceLeasesTextBlock" id="Tb_iLqVWmlH3kmcqy47FvL1gA" continuedAt="Tb_iLqVWmlH3kmcqy47FvL1gA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;Finance Lease Obligation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0151f434_c40d_4f75_b622_875084f5bf99"></a><a id="Tc_dHCQ5_y5D0u6Heg3kADNSg_1_2"></a><a id="Tc_DlzJggODkE6IwyehyIB9Mw_1_5"></a><a id="Tc_CcLfo1AAyU6F3dubbtinKA_2_2"></a><a id="Tc_FZP2YcKsy0ySRe47T0Fy1Q_2_5"></a><a id="Tc_mSwEwTxOKEifAOexcfzyWg_3_2"></a><a id="Tc_mOj--I3ZpkGIcWExaanxfw_3_5"></a><a id="Tc_BgSFcXHzLk-bGIOKPY8l4A_4_0"></a><a id="Tc_5FgEt0ky5EWUi2ISJJBTew_5_0"></a><a id="Tc_F-1PtfMRw0-fuw5l7IrjOQ_5_2"></a><a id="Tc_rDOJp8VZlkqtuj9NH8_wNg_5_3"></a><a id="Tc_PYvo5qIvyU-xvTCkk7HXLw_5_5"></a><a id="Tc_t_IiTBhrX06vgafD_k-5Dg_5_6"></a><a id="Tc_hJvY4hKQUE2Fa4_Fg_k2TQ_6_0"></a><a id="Tc_T47tqbL_L0io_xs-NSueRA_7_0"></a><a id="Tc_TzSyXDFzDEOAbiXrKqkKaw_7_2"></a><a id="Tc_BnN6U6fjvkWPdtr2nUxnPg_7_5"></a><a id="Tc_JZ63iV_DSEGEOVZz4eVC-w_9_0"></a><a id="Tc_zvpHmlKM0UOZ0HBlJ7FBNg_10_0"></a><a id="Tc_D1xHDFAm-k-Qp7qJWHrsQA_11_0"></a><a id="Tc_4xUiE5Mv1EmpDQ6BaVfNjA_11_2"></a><a id="Tc_q8PmLzc5WE2SFx1V2DeY-g_11_3"></a><a id="Tc_2I8IU2oMdkqNrTz9k015vQ_11_5"></a><a id="Tc_1gI0YT2T-ESPaKNU0M-l7Q_11_6"></a><a id="Tc_YUJEqwBQRkeh48Sdoy_yTw_12_0"></a><a id="Tc_uBmYI86os0-N0RDBSs0yeQ_12_2"></a><a id="Tc_RXdno7j2Kk6oKNL-uK5-_g_12_5"></a><a id="Tc_4fWjdapfyU2bjeuhPU4GNw_1_2"></a><a id="Tc_pvskT4mfq0SHI-QxrWbiXw_1_6"></a><a id="Tc_a0DU_MSCxUaTPOdGd6B9Sg_2_2"></a><a id="Tc_Shm_y8zfWkakEU_UF5871g_2_6"></a><a id="Tc_mQpIOQabSkiFksAYUxRC3A_3_0"></a><a id="Tc_Dtdk6dvFe0Ops7t6kzLmjQ_3_2"></a><a id="Tc_HEKVfSdRHEWj4XPJeYnoiw_3_6"></a><a id="Tc_9gnPanpusEyAKRxq9Ak2nw_4_0"></a><a id="Tc_3015C0uXPEily7ravvouAA_4_2"></a><a id="Tc_KsOT8kfRY0u_DfLI6VwZjA_4_6"></a><a id="Tc_go1GHzetMkSzYY2ao3C6Xw_5_0"></a><a id="Tc_t3BhUQPHj0KDS7CbLO2Hsg_5_2"></a><a id="Tc_VaZzFfekuUiBTkQxtKvBJQ_5_6"></a><a id="Tc_Rtw_2D7DokqRkjYVNMixwg_6_0"></a><a id="Tc_mxTu7zHl0kWJTZvdbrm4CA_6_4"></a><a id="Tc_mDsjX2_80kmli91Fjo0cvg_6_8"></a><a id="Tc_T25eNyXXPEuNnnBWFF2guw_7_0"></a><a id="Tc_zToASvJWHUKZ_dOT-Ps2Hw_7_4"></a><a id="Tc_nh_QHqIG3Ey-y15ww02yxg_7_8"></a><a id="_ed0a8d6d_4c25_47ca_a4df_817b0fafa129"></a><a id="Tc_WcbB8m5AwEWfwMpyV6c90Q_1_0"></a><a id="Tc_sIjVoS91TEajFVgAjdiW_Q_1_2"></a><a id="Tc_7RDKbarf80Sn-NXeAiAqtQ_1_5"></a><a id="Tc_ygIufz4nnUelDLwplUJlSQ_1_8"></a><a id="Tc_nSmOo1VY6EyBVrJRT-1VdA_2_0"></a><a id="Tc__fzVENBiLkmkm3OaPK9r7g_2_2"></a><a id="Tc_QepFeaRvhEq9_tUMqBnZ8Q_2_5"></a><a id="Tc_Z_pPz6Dv2Eyhwxuf2u4xQw_2_8"></a><a id="Tc_UITqxRRNjUSwRrW9hVoY5g_3_0"></a><a id="Tc_VUku8yFxv0ivIA1UnvEzlA_4_0"></a><a id="Tc_9nadoCRgp0qarX9aeKjR4g_6_0"></a><a id="Tc_ATp9FD2MOky2JBD9JyzkiA_6_5"></a><a id="Tc_EnDfN08_3EGUdim9j1T4Bw_6_8"></a><a id="Tc_T0pdsdgCREqlDCOOjnigcg_7_0"></a><a id="Tc_WbJKXDb7-EqREnKGG-sxpw_8_0"></a><a id="Tc_j3mLm6ebWEiFcWUAYvDMvg_8_2"></a><ix:continuation id="Tb_iLqVWmlH3kmcqy47FvL1gA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, until November 1, 2021, iBio CDMO leased the Facility as well as certain equipment from College Station under the Sublease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Sublease was terminated on November 1, 2021, when iBio CDMO acquired the Facility and became the tenant under the ground lease for the property upon which the Facility is located. &#160;See Note 15 &#8211; Operating Lease Obligations for additional information related to the ground lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">General and administrative expenses related to College Station, including rent related to the increases in CPI and real estate taxes, were approximately $189,000 for the three months ended September 30, 2021. Interest expense related to College Station was approximately $608,000 for the three months ended September 30, 2021. Such expenses were classified as part of loss from discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the Company assumed three equipment leases that were accounted for as finance leases totaling $813,822 as part of the RubrYc Asset Purchase Agreement. &#160;The monthly rental for the three leases is approximately $14,000 per month and all three expire on August 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mobile Office Trailer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing April 1, 2021, the Company is leasing a mobile office trailer at a monthly rental of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_4_1_2021_To_4_1_2021_Cv64n0Mw7E6pyUXZzZXFwA" decimals="0" format="ixt:numdotdecimal" name="ibio:LessorFinanceLeaseMonthlyRent" scale="0" id="Narr_WBjNWGXQNkedIIzbpRdNmA">3,819</ix:nonFraction> through March 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" id="Tb_HhjxWSFuREmMRh7Mik2Y9g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_RVNRHxBXuE2F1aDdMs82Bw_6_3">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_erABVk-AsUuZqBuO53ECFw_6_6">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_LnYKZO3sjkaKKaDNFsFz8g_7_3">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_8xSzUDRkH0eUZrd0tlLaFQ_7_6">14</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:FinancingCashFlowsFromFinanceLeaseObligation" scale="3" id="Tc_zeWE-E-65k2w-p1MaU1NBA_12_3">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:FinancingCashFlowsFromFinanceLeaseObligation" scale="3" id="Tc_TULBwk5Bd0KuUEu4dnWDjA_12_6">10</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="ibio:ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" id="Tb_-eo3TPstCUKqiHwj815Ftg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_Np5yVVzptUKOiOyw2G82bQ_3_3">875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_D2q4McnLKEm7-yTXa9Vufg_3_7">74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_9wD6VOzSUEeX_PoNdiWZ_g_4_3">303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_MZTZr4S-P0yXOr4j-zrgWg_4_7">46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_7d88KIKxAECrajIjT0lXxw_5_3">576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_vxRqJYHm7EKbqx7n5Oy03A_5_7">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonNumeric contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_frLcAtpf1EWgY675VrUlog_6_3">2.74</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_wBGbfYWlWEOb1VpcpgscSA_6_7"> 1.76</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate - finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_kS07Dn06T0S3SgL-Rdjlzg_7_3">9.26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q" decimals="5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_S6nvC-0HvUObINATWAeS1A_7_7">6.250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="Tb_pt3HmdDK2E2_Tuf1bKN5AA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_x9j9UTlPG0C-F29-8cSTcw_2_3">303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_WTTx3bX1OkW89C-T4NTf4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_7rp4wlpnSk6jJty3A8os-g_2_6">66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_yfBCRrsTckySn9iuRzytkA_2_9">369</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_Yz6n5eiOL02Tw0Sg7yEh6A_3_3">297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_WTTx3bX1OkW89C-T4NTf4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_2jlMUVvMgUC8S5fQJmuCmg_3_6">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_ZyNhBA8Dy0GL-rpN1iirCA_3_9">338</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_nwYjIydu-kyiPoEdUVdaaw_4_3">279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_WTTx3bX1OkW89C-T4NTf4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_BE42r9lGbEO3vBcurJCNRA_4_6">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_pf4NSDHmcEyU-b81Lj-mCQ_4_9">293</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_aQsp1St9CEqGg_PzOvY73w_6_3">879</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_WTTx3bX1OkW89C-T4NTf4g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_psz533uMVE-fsRC6s1Kriw_6_6">121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc__zJkYawv_E6AedgTBFGqwA_6_9">1,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_5xjsVFHHk0SsfNOdChcBuw_7_3">303</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_ukN6d7ejR02OKKdtBTCXwQ_8_3">576</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3a7d19da_b1b9_4ebb_b22e_d2e08e764ab9"></a><a id="Tc_Kv1toSS740iv5Zlg4zuqfQ_1_1"></a><a id="Tc_Wu8brKzpTECEEYCTP2qxQw_1_4"></a><a id="Tc_ozPfRuXz0Uuoda-TeCS9Zw_2_1"></a><a id="Tc_3fXM_uJpM0q92ef4OzobqQ_2_4"></a><a id="Tc_Xp0Ax0HlZkyLpK8fZnms4g_3_1"></a><a id="Tc_g3bjdNrvXUyt5JwHjHpT6g_3_4"></a><a id="Tc_QDddK0NTEke0mr20pwIgHg_4_0"></a><a id="Tc_QBz7GqBEAUCfY-se8sS9QQ_4_1"></a><a id="Tc_JWWWx3vx3EimphZYGQ0rYg_4_4"></a><a id="Tc_DiKDnZdGjkynbgg4MKlnpw_4_5"></a><a id="Tc_ngQS9V7CGkChf6OMkin3FQ_5_0"></a><a id="Tc_ylX7mZbnyUGH4OHWguKR1A_5_1"></a><a id="Tc_Ctsue_BKuUiviBk584Zw-Q_5_4"></a><a id="Tc_RCTH9x9xHEm8tTCrZBgnmw_5_5"></a><a id="Tc_EfS_8_b2i0aM8FtUUGKyLQ_7_0"></a><a id="Tc_oyPGomJ2UUm6dcVD99IEQg_8_0"></a><a id="Tc_m9TbuAJe5k6RJ-U2RuLiqw_9_0"></a><a id="Tc_joWL3y4kSkmQbOJokEupBA_9_1"></a><a id="Tc_kiC47eU-PUC0SldWkOW4ng_9_4"></a><a id="Tc_E-2Wg6DlXUOyiM2hixNCsQ_9_5"></a><a id="Tc_1Sg6ThAZIUWRv2mKCYAvuQ_10_0"></a><a id="Tc_vbYgEJ2BKE-WfLQ2lR3kGg_10_1"></a><a id="Tc_RrR7ekb_eU6sP4LNAADinQ_10_4"></a><a id="Tc_m-zccLBjaEu6BoS35uqqhA_10_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_AQFOe3J9SESpOOjAvNddQw" continuedAt="Tb_AQFOe3J9SESpOOjAvNddQw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15.&#160;&#160;&#160;Operating Lease Obligation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Texas Ground Lease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ" decimals="0" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseMonthlyRent" scale="0" id="Narr_AGdLBYd3pUCJ7cZncGs24Q">151,450</ix:nonFraction> for the prior year, is <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ" decimals="3" format="ixt:numdotdecimal" name="ibio:BaseRentPercentageOfFairMarketValueOfProperty" scale="-2" id="Narr_GcMu6DHmLEiLbEaQKugp7g">6.5</ix:nonFraction>% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">San Diego</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">On September 10, 2021, the Company entered into a lease for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_5KxWaFXlD02dT7QlqBc7JA" contextRef="As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_WOIh7AD_40iabhnMkEwadw">11,383</ix:nonFraction> square feet of space in San Diego, California. &#160;Terms of the lease include the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The length of term of the lease is </span><ix:nonNumeric contextRef="As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_Tpf-6uuUCkmFq8z98N5t3w"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">88 months</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from the lease commencement date (as defined).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease commencement date was estimated to be on or around January 1, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The monthly rent for the first year of the lease is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_9_10_2021_To_9_10_2021_m_dKSYWyjkGt_N2eurcfeg" decimals="0" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseMonthlyRent" scale="0" id="Narr_2jcRICwwXECh91uMuRc8Jw">51,223</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and increases approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="Duration_9_10_2021_To_9_10_2021_m_dKSYWyjkGt_N2eurcfeg" decimals="2" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" scale="-2" id="Narr_krXsXSzAzkKoL-3uT7hHEw">3</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease provides for a base rent abatement for months </span><span style="-sec-ix-hidden:Hidden_HTgQ1reF4068PJjjH7wdhg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> through </span><span style="-sec-ix-hidden:Hidden_6jE7_kh_EUe3WSMLLFzfcg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in the first year of the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The landlord is providing a tenant improvement allowance of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TenantImprovements" scale="0" id="Narr_FTE0U7Rb50-eMxw8FqsDvQ">81,860</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to be used for improvements as specified in the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company is responsible for other expenses such as electric, janitorial, etc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company opened an irrevocable letter of credit in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_ZxIXPbVKrUyMV_ban-OCAg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GuaranteeObligationsMaximumExposure" scale="0" id="Narr_2KISUSa2RkmZsI1oO0jCwA">188,844</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in favor of the landlord. &#160;The letter of credit expires on October 8, 2022 and renews annually as required.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. &#160;Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease ROU asset in the accompanying balance sheet. &#160;As the Company has already started making improvements to the facility, the rent expense will be recognized.</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" id="Tb_mib6xuZba0mZbR7QoXjOOw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_51Q5MaNkckasbuJs6BriMA_4_2">141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:TotalOperatingLeaseCosts" scale="3" id="Tc_7W_5Kno7UEC6GV-1fGqV7A_5_2">141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_eV-YETr4bkm_FUNo1VN66A_9_2">141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:OperatingCashFlowsFromOperatingLeaseObligation" scale="3" id="Tc_NbK2I9lqJUOaVhkB7BmyIQ_10_2">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9968eb3a_9e76_47d9_87e1_96477970609c"></a><a id="Tc_1W9TQpDPskq_pUcvfYsRsQ_1_0"></a><a id="Tc_2TfoQ-6BTUWEtY0B5X1qVg_1_2"></a><a id="Tc_RXhOzuqF4kOUk_8H-xPTxQ_1_5"></a><a id="Tc_YdW-M2AE4UuXL0yK0zmBtw_1_8"></a><a id="Tc_QDha2ejBgkm0dhk4WUXhbg_2_0"></a><a id="Tc_t--bC2yKYU6kVBXQ7EyXMA_2_2"></a><a id="Tc_ucpxJ5N51U-PGHQGxYYt5Q_2_5"></a><a id="Tc_f3FMgGTX6Um7wQldrEfVkQ_2_8"></a><a id="Tc_77XfEzVapESmxVzFYbSTEg_3_0"></a><a id="Tc_SemWxhpbHUGy5-Ym-XqLyA_4_0"></a><a id="Tc_ZrZncgksSkKIiuKOlITRnw_5_0"></a><a id="Tc_QVCqaLlInU2Dyu-0VdyZ_A_6_0"></a><a id="Tc_BWSaTeq4sU-iWVFGQZQcQg_7_0"></a><a id="Tc_yvXkkoLI6UyqqZqGUCIg1g_9_0"></a><a id="Tc_g0Ba1Byv4069A_hc1MpPcQ_9_5"></a><a id="Tc_rFFtk0BH7UWWNSYG7_g3tQ_9_8"></a><a id="Tc_73Kuemxl-kWcxd5o_f9iNg_10_0"></a><a id="Tc_tixXg6ThtU2JKzFkBudvXg_11_0"></a><a id="Tc_YCOWRWDfjUmSNumLdzD_fg_11_2"></a><ix:continuation id="Tb_AQFOe3J9SESpOOjAvNddQw_cont1"><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_vz0xfcdbq0GYxV8vpTltew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the operating lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on September&#160;30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Imputed Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_VyPrhH-drUG2nfWuMIcWPw_2_3">183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearOne" scale="3" id="Tc_SLYwMhQ-J0GnWs1pssB9IA_2_6">281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" scale="3" id="Tc_FC9aSAUUsEy3tVy__vTHYg_2_9">464</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_hWKb0y-fU0WxCzWIT8RDVw_3_3">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearTwo" scale="3" id="Tc_Ko-axYLDH0ilE56DqOKe_A_3_6">235</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" scale="3" id="Tc_6vbUxLjIV0ijRK7b2t0IFA_3_9">635</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_8A7uI_EdYkatvtPaF1W8Aw_4_3">449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearThree" scale="3" id="Tc_aHaWRc_3NE63qAMGmyuqnQ_4_6">204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" scale="3" id="Tc_DpUcdoE1zUui9qWk0Y6Jlg_4_9">653</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_Tmpl1e8JLU-xNxRtY5P7SQ_5_3">504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFour" scale="3" id="Tc_xuaXr3x0DU2XHgGDSDW3QA_5_6">170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" scale="3" id="Tc_pKqDoXr8L0e_ia_tLR_Hng_5_9">674</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_ADICR2YAtkOMBPt7mt2Pkw_6_3">562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFive" scale="3" id="Tc_vp9bwSjdqkCn-CxAIGMCdA_6_6">132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" scale="3" id="Tc_ydcebnN0FEqQn4GEyAO7Gg_6_9">694</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_-rjVJ080WkOJglf6fPzI7g_7_3">1,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" scale="3" id="Tc_DCzMNNsOuEWRNiQkT8ASaw_7_6">132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" scale="3" id="Tc_L3F74biX9EGbWpRg-TgHrg_7_9">1,638</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_aEfi5Uqu5EahtG8MNgbAcA_9_3">3,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidTotal" scale="3" id="Tc_CZrsSyzQ-UayGRl0CCQOow_9_6">1,154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" scale="3" id="Tc_rSV7HAuiF0W84wAd2ktQfg_9_9">4,758</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_4kxBOhSIG0epOWk2i2QWyg_10_3">183</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_gI4uNvhR6EeFEWf8q3WVuQ_11_3">3,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_Z1fqxCq5zkmI2u0LqVq7Vw" continuedAt="Tb_Z1fqxCq5zkmI2u0LqVq7Vw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16.&#160;&#160;&#160;Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_gi74M6zTzkWzoZby0rxxqA">1</ix:nonFraction> million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series 2022 Convertible Preferred Stock (&#8220;Series 2022 Preferred&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 9, 2022, the Board of Directors of the Company created the Series 2022 Preferred, par value $0.001 per share, out of the Company&#8217;s 1 million authorized shares of preferred stock. &#160;Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (1:1) shares of the Company&#39;s Common Stock on a pre-split basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company issued 1,000 shares of Series 2022 Preferred and received proceeds of $270. &#160;Pursuant to the terms of the preferred stock, the Company&#8217;s Board of Directors converted the Preferred Stock to 40 shares of Common Stock on July 19, 2022 on a post-split basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">iBio CMO Preferred Tracking Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Company entered into an exchange agreement with Bryan Capital pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by Bryan Capital and issued <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_ezl_cu4pZEaWF2orMq4slA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Narr_gwOfpf5r20qSZxR6ZsFW3Q">one</ix:nonFraction> share of a newly created Preferred Tracking Stock, in exchange for <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_ezl_cu4pZEaWF2orMq4slA" decimals="INF" format="ixt:numdotdecimal" name="ibio:NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" scale="0" id="Narr_LgBycXa4r0WW8xnz8fwn5w">29,990,000</ix:nonFraction> units of limited liability company interests of iBio CDMO held by Bryan Capital at an original issue price of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_ezl_cu4pZEaWF2orMq4slA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_3gAWvev_0U2YgAfyIMGFXA">13</ix:nonFraction> million. After giving effect to the transaction, the Company owned <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_vBxV47t9JkmztS3TPBPfNQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_6XmEWK5210W7BB20V79n8w">99.99</ix:nonFraction>% and Bryan Capital owned <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_EasternAffiliateMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_MyiAUVo2vkGkyCCsfdBIcw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_YNyo6UDWPkKJduPkVX7E7A">0.01</ix:nonFraction>% of iBio CDMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Board of Directors of the Company created the Preferred Tracking Stock out of the Company&#8217;s <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_2_23_2017_QxVrYRSL_UiOCiGSWO0CFg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_FIlCZD2IhkS7lnBFpb5gUg">1</ix:nonFraction> million authorized shares of preferred stock. The Preferred Tracking Stock accrued dividends at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_l3TXqFcTd0OMoQ1amXL65A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_S5SU9wBAK0arlCICN4lEvw">2</ix:nonFraction>% per annum on the original issue price. Accrued dividends were cumulative and were payable if and when declared by the Board of Directors, upon an exchange of the shares of Preferred Tracking Stock and upon a liquidation, winding up or deemed liquidation (such as a merger) of the Company. <ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_h-pYgsijTkKHQ_QNQK-fLg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Narr_eRGe6HdZJkC9ldMYokCraQ">No</ix:nonFraction> dividends were declared through October 31, 2021. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, iBio purchased the iBio CMO Preferred Tracking Stock held by Bryan Capital. No iBio CMO Preferred Tracking Stock remains outstanding. As a result, the iBio CDMO subsidiary and its intellectual property are now wholly owned by iBio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The number of authorized shares of the Company&#8217;s common stock is 275 million. In addition, the Company has reserved 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the Company&#8217;s 2020 Omnibus Incentive Plan (the &#8220;2020 Plan&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reverse Stock Split</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to effect an amendment to the Company&#39;s certificate of incorporation, as amended, to implement a reverse stock split at a ratio of one-for-twenty </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk87152699"></a><ix:continuation id="Tb_Z1fqxCq5zkmI2u0LqVq7Vw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">five (1:25). On September 22, 2022, the Company&#39;s Board of Directors approved the implementation of the reverse stock split of the Company&#39;s Common Stock. As a result of the reverse stock split, every twenty five (25) shares of the Company&#39;s Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of the Company&#39;s common stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a one-for-twenty five (1:25) reverse stock split of the shares of the Company&#8217;s common stock, either issued or outstanding, effective October 7, 2022. The Company&#8217;s Common Stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent issuances of Common Stock include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Cantor Fitzgerald Underwriting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&quot;Cantor Fitzgerald&quot;) to sell shares of common stock, from time to time, through an &#8220;at the market offering&#8221; program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. &#160;Between July 25, 2022, and August 17, 2022, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 175,973 shares of Common Stock. The Company received net proceeds of approximately $1.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc Transaction</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 19, 2022, iBio issued 102,354 shares valued at approximately $1,000,000 to RubrYc Therapeutics as part of the payment for purchasing the assets of RubrYc Therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Vesting of Restricted Stock Units &#8220;RSUs&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 23, 2022, RSUs for 1,057 shares of Common Stock were vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Warrant</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company issued to Bryan Capital a Warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_0WPW4TEuu0mxFazNz5tTFw">51,583</ix:nonFraction> shares of the Common Stock of the Company at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_-jFZoBEE-UGRxzJhyujjKg">33.25</ix:nonFraction> per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_-XkSspK9OUCdSzq6b05y0A_1_2"></a><a id="Tc_IEyyEOHJ0EeYEtpDwVxW_w_2_2"></a><a id="Tc_8V7TH6K3BkGLrK1RRgJXrg_3_2"></a><a id="Tc_7qmP7UkhLUmBBB12S4C10Q_3_5"></a><a id="Tc_zCD8opRIKkSHnVZNut2ktg_4_0"></a><a id="Tc_EfD1YQ-9sECZvPLxFsqS4A_6_0"></a><a id="Tc_FZlJuyyrVkCk4p9n8uKCnA_6_2"></a><a id="Tc_l__iBCUCbk6V4jFnPVWSVA_6_5"></a><a id="Tc_zvRVZ3fUfUmOe35jd18k3Q_7_0"></a><a id="Tc_erReTscAEkKS6T4-rAUGeQ_8_0"></a><a id="Tc_2rvkz7ZIeEigo8WMN73NXg_8_2"></a><a id="Tc_dr0adeSSjkmAAXZ3iWWJlQ_8_5"></a><a id="Tc_WbR6HeT7gEeuFZM77ct2Vw_10_0"></a><a id="Tc_7l3s-69tEUCl-zOTsDCxdQ_10_2"></a><a id="Tc_hfhph6mzDEaOcoH_09aNpQ_10_5"></a><a id="Tc_JfwODiSjWkmkoO27DjWMUw_12_0"></a><a id="Tc_NkIRC_QWdkO2qJnkPWTx6A_12_2"></a><a id="Tc_mvrnvFIhn0Wj0BZcrH-NBw_12_5"></a><a id="Tc_R-8I-cTeYkWuzfMWGrEEZQ_14_0"></a><a id="Tc_rutWSsVgX0ifWcrFEi8R8Q_16_0"></a><a id="Tc_Pew32mbENE2Hcl90ZVMGOQ_18_0"></a><a id="Tc_BPybBCLKvEiZoYvUsLO38Q_19_0"></a><a id="Tc_rlN3NjbeQUC5-xEiBd5H3A_20_0"></a><a id="Tc_85QKUvwXNUmQMlwZXdLusw_1_2"></a><a id="Tc_mHOKHZ_OLkumzRlP4E9hzg_2_2"></a><a id="Tc_gaqbj8knlkOvpDBNhqLstA_2_4"></a><a id="Tc_wnZQ8cDXn0-gReqWE7oWEw_3_2"></a><a id="Tc_rcHQotvhsUyDncrjCgUiGQ_4_0"></a><a id="Tc_mh0QoTW8xU-gZI125lirEg_5_0"></a><a id="Tc_gsOxwa0qP0u2XPVbl4Ff8w_5_2"></a><a id="Tc_o0GCo3n8DkiVo2K9pX7I9Q_5_4"></a><a id="Tc_mLoL7HFOXESHn_fTC1PL6Q_6_0"></a><a id="Tc_ww_BIgeiO0uc_HPppa39aw_7_0"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:EarningsPerShareTextBlock" id="Tb_Llf4dd3KVkuMi5naidZAUw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17.&#160;&#160;&#160;Earnings (Loss) Per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_C2t6XTFi6E2zz1w4n6T8jw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to iBio, Inc. from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_bDei4A20w02IDYcQxxAErA_6_3">7,537</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperations" sign="-" scale="3" id="Tc_P0GLO56F-U-5kk8WD0vGUw_6_6">5,188</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock dividends &#8211; iBio CMO Preferred Tracking Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_MYK3Br82VU-6ZSMXf5Et2w_7_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_3KMyINrwwUG40Ql27myoBg_7_6">66</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_l_Ljd7Lh4kSdUx6AxurH3Q_8_3">7,537</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_B22WWFXp6062XEejDcFOQA_8_6">5,254</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_ShWQSBhdykytX32eGM8ubA_10_3">10,593</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_jbKy5nAe20-ayhhguo2wxA_10_6">3,751</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_ERP2GzLvl0SZWIqpIzyELg_12_3">18,130</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_gYcc-9Qg1UiaCboOBP7UDQ_12_6">9,005</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_uooe1cZxh0yMZ989Ky1aaA_16_3">8,842</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_X3E-n8n8OUiTEgcRPKYQzA_16_6">8,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_UVdxoMmgQkKjhJdoE6VcYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_uuD2grOrrU2PcHxBO2oL2Q_18_3">0.85</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_drCJr6G_BkCKj9KtPlTGNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_n6aBpM8xQE2ShiKw49hPPQ_18_6">0.60</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ja0Qe-ca6kSwUGmiTbHIlA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_PXDMP6uNPEmOkI5Y9n1EKw_19_3">1.20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1FZCwCoI6Emocc2F149ZKA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_PVcGVCroJEyRVUAEFcNRuA_19_6">0.43</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-4hgScTO5E-EP-H2wvkN5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_8gLC5PC9Q0uzeJnO9XTvcQ_20_3">2.05</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_OTJhXFjeGU-xhjMC2Fzccw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_IJmmKb5hbkedNz1SZsbzfA_20_6">1.03</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In Fiscal 2023 and Fiscal 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September&#160;30,&#160;2022 and 2021, shares issuable which could potentially dilute future earnings were as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_x6lroQbjakCl1abbj70wWg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aLCKc_DsZ0mcPYZ4iThlOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_fIP_n67Nok-IOKog8AeHRA_4_2">923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_6yylM16A906KWG6WH1olXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Vzm_lMM3eUe-ZgoiOk7lFA_4_4">576</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant issued under the Transaction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_gsOXphCp7kqOXBi52mrpig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_sC5ryBwVFUGJX2CFq6v2Cw_6_2">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_RW522OwZwE2Q8Rhd-pq6hw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Q0VTRwJ8tEa91qegw22JYQ_6_4">31</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares excluded from the calculation of diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Q9iCXIuZzE-pEgIfpLhNGg_7_2">1,001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc__LASkG-N_02f9M_JoajCPw_7_4">607</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d477453a_e0a6_41cf_8916_acd71ab546c7"></a><a id="Tc_vUaI1UQVGEm4XZLBx1aB8g_1_2"></a><a id="Tc_GTdxN8LEBEuoXUCEnr976w_2_2"></a><a id="Tc_3ydKRNmOgk207F-U7omBbQ_3_2"></a><a id="Tc_XH72g-oA2EGaJ_c74MeAdA_3_5"></a><a id="Tc_yzfqiJ_hpE-PI8kNNoPqKQ_4_0"></a><a id="Tc_A7SxKgsnV0S8oWi4yXS0kQ_4_2"></a><a id="Tc_e_5wQKcojkOBGaxGPCe5Fg_4_5"></a><a id="Tc_qmEkV1ynZkqWaOAe8YXtgw_5_0"></a><a id="Tc_HvhqoaL18kmFEN0C_ZyCwA_6_0"></a><a id="Tc_zbm_2JVWDEmDEouNKaOH_Q_6_2"></a><a id="Tc_qiemrSx0mEyLSmrFVhALhw_6_5"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_I_BE__KVUUOvDCdRZt_c-g" continuedAt="Tb_I_BE__KVUUOvDCdRZt_c-g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18.</b>&#160;&#160;&#160;<b style="font-weight:bold;">Share-Based Compensation</b></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_ItiboUz-nUOMBLkHzjBhxQ" continuedAt="Tb_ItiboUz-nUOMBLkHzjBhxQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kOWrKqdXuEqZHagsSxnYmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_v-1bGK039k6yZxQzAm6s2g_4_3">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_U25ZnOgUdEuQ-HzSBdsbxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_NfnaRxNFEke92nrgjUZYDw_4_6">14</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_awj1_vQ1DUSHyHXaRL7ufw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_CQpFpGtE60WmNQOI0t1qeA_5_3">1,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Cd2Z2zMIHkG4C6QpdIGJ0w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_mxAxXA6FRUq85nTu28tzPw_5_6">706</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Ij59nDR1aUi2c6u90hbM_g_6_3">1,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_hHavO5xs9kiRpBsT5yceMQ_6_6">720</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $96,000 and $101,000 for the three months ended September 30, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_I_BE__KVUUOvDCdRZt_c-g_cont1"><ix:continuation id="Tb_ItiboUz-nUOMBLkHzjBhxQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">iBio, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is <ix:nonFraction unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ" contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_MtHCCTglWES6FXBOwD3GbQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="Narr_7tZvafKPE02HckoQXbLWWQ">32</ix:nonFraction> million shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_MtHCCTglWES6FXBOwD3GbQ" decimals="0" format="ixt:numdotdecimal" name="ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" scale="0" id="Narr_lNjBnLCd50K1MdS4-ugPoA">500,000</ix:nonFraction>; provided, however, that such amount shall be $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_QXdJeF316UutTHwstfvd0g" decimals="0" format="ixt:numdotdecimal" name="ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" scale="0" id="Narr_WY7BQxmP7UCswtSy-psgFg">750,000</ix:nonFraction> for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors and $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_zK_EuxHxJUWase0Bb6jdgw" decimals="2" format="ixt:numdotdecimal" name="ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" scale="0" id="Narr_OK2MarnSDEOg9vhfd89BZw">1,500,000</ix:nonFraction> for any non-executive chair of our Board of Directors should one be appointed. Notwithstanding the foregoing, the independent members of the Board of Directors may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Vesting of service awards are determined by the Board of Directors and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally three or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock options issued</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Group_BWwG4VpPrk6DiYudAhyz8g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal 2023, the Company granted stock option agreements to various employees to purchase 303,869 shares of the Company&#39;s common stock at exercise prices between $6.75 and $9.50 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">3.21% - 3.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">115.52 - 116.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">RSUs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 29, 2022, the Company issued RSUs to acquire 6,954 shares of common stock to various employees at a market value of $7.06 per share. &#160;The RSU&#8217;s vest over a four-year period. The grant-date fair value of the RSUs totaled approximately $49,000. &#160; </p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="ibio:GainLossRelatedToLitigationSettlementTextBlock" id="Tb_YKfYzFvQnUulzlth-xylCA" continuedAt="Tb_YKfYzFvQnUulzlth-xylCA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19.&#160;&#160;&#160;Fraunhofer Settlement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 4, 2021, the Company and Fraunhofer USA, Inc. (&#8220;FhUSA&#8221;) entered into a Confidential Settlement Agreement and Mutual Release (the &#8220;Settlement Agreement&#8221;) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the &#8220;Lawsuit&#8221;). The Settlement Agreement, among other things, resolves the Company&#8217;s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Settlement Agreement is not an admission of liability or fault of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The terms of the Settlement Agreement provide for cash payments to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_mRyOoO-D5kmgzWk1TetiGg" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_JqmQQMX1FUSq2KUYghyJ1w">28,000,000</ix:nonFraction> as follows: (i) $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_fdlqH-ydv0qTOi8QNX4gWA" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_NZcpmXanmEGTtyOVmceBZg">16,000,000</ix:nonFraction> to be paid no later than May 14, 2021 (which is expected to be paid <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_97qQQ2NlZkS1QrbYGZ0BWQ" decimals="2" format="ixt:numdotdecimal" name="ibio:PercentageOfLegalFeesExpectedToBeReceived" scale="-2" id="Narr_b-vp_oGvH0qDNmdvDAWAWw">100</ix:nonFraction>% to cover legal fees and expenses); (ii) <span style="-sec-ix-hidden:Hidden_n27rjvZYL0OlHIzsiufN3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_UYTDkmnuYUKjYhuJvrtFBQ" decimals="0" format="ixt:numdotdecimal" name="ibio:SettlementAssetsNonCurrent" scale="0" id="Narr_toefTnAi2k6v3WJQsLK0Ig">5,100,000</ix:nonFraction> payable by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, <span style="-sec-ix-hidden:Hidden_KLGwyYKoFUWk37Z8Z7W-QA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_6ZrviqcdeEqMylJf6L3J_w" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_pIm4L9_EvECQ_roSenQacg">900,000</ix:nonFraction> due on March 1, 2022 and 2023. The license provides for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company&#8217;s estimated aggregate net cash recovery as a result of the Settlement Agreement will be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_DEoVZtJZY0yz9pSSGN9D5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainContingencyUnrecordedAmount" scale="0" id="Narr__g2RCTiAnE-XQNXunVZLzw">10,200,000</ix:nonFraction>. &#160;</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0b7d1fd4_6c00_4db2_bf82_9d85239b22c0"></a><a id="Narr_qy5gm90_CEyadLR0EtrEwg"></a><ix:continuation id="Tb_YKfYzFvQnUulzlth-xylCA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2021, the Company held receivables related to the settlement in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_6_30_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_LZBHDrN9UUGCxpUjpg5lXA" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_nDqrnGho_EOtbTn8bY6wLA">10,200,000</ix:nonFraction>. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in Fiscal 2021. &#160;During the quarter ended March 31, 2022, the Company received the first payment of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_ovqbH7S4FkKWmzhQHgtz3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_JWVsb1yhlkKgiqEYR4Vilw">5,100,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company would recognize the $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_cVkZ8G6vJUqQuiTDjSGGZg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="6" id="Narr_tMTCA1usfE67nxjx04ywCg">1.8</ix:nonFraction> million of license revenue when it determined the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_cVkZ8G6vJUqQuiTDjSGGZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_1IxwgpZCzkCeUXE6VHKCbw">900,000</ix:nonFraction> payment under the license agreement. As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, the Company holds a settlement receivable balance of $5,100,000, which has been pledged to Woodforest - see Note 6 - Significant Transactions, related to the settlement and a trade receivable balance of $<ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="As_Of_9_30_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_WRviyH3-o0yDEY9X1wSIKQ" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_eBEcegN6J0qutX638oghQA">900,000</ix:nonFraction> related to the license agreement. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_LZCrRaw3AUykqil9MmJrQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">20.&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recorded <ix:nonFraction unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_GDoZJrlwkUqt2TcrGS_yFw">no</ix:nonFraction> income tax expense for the three months ended September&#160;30,&#160;2022 because the estimated annual effective tax rate was <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_BBFlznZ63EWcXfzXrY0fDw">zero</ix:nonFraction>. As of September 30, 2022, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_rSLGiQrtT02ig_32YxrCCg" continuedAt="Tb_rSLGiQrtT02ig_32YxrCCg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">21.&#160;&#160;&#160;Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">COVID-19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result of the pandemic, the Company has at times experienced reduced capacity to provide CDMO services as a result of instituting social distancing at work procedures in our Texas facility, restricting access to essential workers, as well as taking other precautions. In July 2022 after we experienced a rise in COVID-19 cases within our Texas facility, for approximately one week, we mandated only those involved in mission critical manufacturing activities were to be permitted within our Texas facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has ascertained that certain risks associated with further COVID-19 developments may adversely impact its operations and liquidity, and its business and share price may also be affected by the COVID-19 pandemic. However, the Company does not anticipate any significant threat to its operations at this point in time. <span style="background:#ffffff;">The future progression of the pandemic and its effects on the Company&#8217;s business and operations are uncertain. The Company may face difficulties recruiting or retaining patients in its planned clinical trials if patients are affected by the virus or are fearful of traveling to clinical trial sites because of the outbreak. The Company and its third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to the Company&#8217;s research and development activities, including, for example, medical and laboratory supplies used in preclinical studies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak. &#160;</span>Due to the general unknown nature surrounding the crisis, the Company cannot reasonably estimate the potential for any future impacts on its operations or liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The outbreak and spread of COVID-19 and continued progress in various countries around the world, including the United States, has led authorities around the globe to take various extraordinary measures to stem the spread of the disease, such as emergency travel and transportation restrictions, school closures, quarantines and social distancing measures. The outbreak of COVID-19 has had an adverse effect on global markets and may continue to affect the economy in the United States and globally, especially if new strains of SARS-CoV-2 emerge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">War in Ukraine</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On February 24, 2022, Russia launched an invasion of Ukraine which has resulted in increased volatility in various financial markets and across various sectors. The United States and other countries, along with certain international organizations, have imposed economic sanctions on Russia and certain Russian individuals, banking entities and corporations as a response to the invasion. The extent and duration of the military action, resulting sanctions and future market disruptions in the region are impossible to predict. Moreover, the ongoing effects of the hostilities and sanctions may not be limited to Russia and Russian companies and may spill over to and negatively impact other regional and global economic markets of the world, including Europe and the United States. &#160;Presently, </span>the Company does not have any existing Russian suppliers or contractors. While it is difficult to estimate the impact of current or future sanctions on the Company&#8217;s business and financial position, or global supply chains or service provisions that could have an impact on the availability or price of goods and services that the Company requires, the Company is not aware of any company-specific risks related to the war in Ukraine at this time.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_rSLGiQrtT02ig_32YxrCCg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Inflation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Although the Company has not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on the Company&#8217;s operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_aTj3SMstjUK7xwYzmFe3JA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">22.&#160;&#160;&#160;Employee 401(K)&#160;Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing January&#160;1, 2018, the Company established the iBio,&#160;Inc. 401(K)&#160;Plan (the &#8220;Plan&#8221;). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_hNQuvsKed0CxvwRnp6YSow">100</ix:nonFraction>% matching contribution that is not in excess of <ix:nonFraction unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw" contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_KbsBlxBowkqYD0EIShe0vg">5</ix:nonFraction>% of an eligible employee&#8217;s compensation. In addition, the Company may make qualified non-elective contributions at its discretion. For the three months ended September&#160;30,&#160;2022 and 2021, employer contributions made to the Plan totaled approximately $104,000 and $33,000, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $71,000 and $33,000 for the three months ended September 30, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d71e1f95_83c5_47f3_96f3_d13352a95c63"></a><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w" name="us-gaap:SubsequentEventsTextBlock" id="Tb_wp4-j4uJvkKlzc75q2XPJQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">23.&#160;&#160;&#160;Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an interest rate of 5.6% and securitized by certain assets purchased for the San Diego research site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 10, 2022, as previous disclosed in relation to the Employment Agreement with Thomas F. Isett 3<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">rd</sup>, the Company&#8217;s Chief Executive Officer, dated April 30, 2021, the Company granted Mr. Isett RSUs to acquire 200,000 shares of common stock, $0.001 par value per share (the &#8220;Common Stock&#8221;), on a post-split basis.&#160; The RSUs vest over a three-year period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) outlicensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application.&#160; The grant-date fair value of the RSUs totaled approximately $296,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 11, 2022, the Company granted Mr. Robert Lutz, the Company&#8217;s Chief Financial and Business Officer, RSUs to acquire 100,057 shares of the Company&#8217;s Common Stock in exchange for Mr. Lutz&#8217; agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board of Directors. The grant-date fair value of the RSUs totaled approximately $175,100.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 11, 2022, the Company granted Mr. Martin Brenner, the Company&#8217;s Chief Scientific Officer, RSUs to acquire 95,348 shares of the Company&#8217;s Common Stock in exchange for Mr. Brenner&#8217;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board of Directors. The grant-date fair value of the RSUs totaled approximately $166,860</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The following information should be read together with the financial statements and the notes thereto and other information included elsewhere in this Quarterly Report on Form&#160;10-Q (this &#8220;Report&#8221;) and in our Annual Report on Form&#160;10-K for the&#160;year ended June&#160;30, 2022, as filed with the SEC on October 11, 2022 (the &#8220;Annual Report&#8221;). Unless the context requires otherwise, references in this Report to &#8220;iBio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; and similar terms mean iBio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Forward-Looking Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">This Report contains &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). For this purpose, any statements contained herein regarding our strategy, future operations, financial position, future revenues, projected costs and expenses, </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:249.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">prospects, plans and objectives of management, other than statements of historical facts, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements reflect our current views with respect to future events. Because these forward-looking statements involve known and unknown risks and uncertainties, actual results, performance or achievements could differ materially from those expressed or implied by these forward-looking statements for a number of important reasons, including those discussed in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Report, as well as in the section titled &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report. We cannot guarantee any future results, levels of activity, performance or achievements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Report as anticipated, believed, estimated or expected. The forward-looking statements contained in this Report represent our estimates as of the date of this Report (unless another date is indicated) and should not be relied upon as representing our expectations as of any other date. While we may elect to update these forward-looking statements, we specifically disclaim any obligation to do so unless otherwise required by securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Overview </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We are an Artificial Intelligence (&#8220;AI&#8221;)-driven innovator of precision antibody immunotherapies. We have a pipeline of innovative primarily immuno-oncology antibodies against hard-to-drug targets where we may face reduced competition and with antibodies that may be more selective. We plan to use our AI-driven discovery platform to continue adding antibodies against hard-to-drug targets or to work with partners on AI-driven drug development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="ibio-20220930x10q001.jpg" alt="Graphic" style="display:inline-block;height:248.43pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:534.2pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">IBIO-101: </b>an anti-CD25 molecule that works by depletion of immunosuppressive T-regulatory cells (Tregs) via antibody-dependent cellular cytotoxicity (&#8220;ADCC&#8221;), without disrupting activation of effector T-cells (Teffs) in the tumor microenvironment. IBIO-101 could potentially be used to treat solid tumors, hairy cell leukemia, relapsed multiple myeloma, lymphoma, or head and neck cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">EGFRvIII: </b>binds a tumor-specific mutation of EGFR variant III with an afucosylated antibody for high ADCC. Because of its specificity binding to the tumor-specific mutation, it could potentially reduce toxicity and/or expand the therapeutic window compared to simple broad EGFR-targeted alternatives. . EGFRvIII is constantly &#8220;switched on&#8221; which can lead to the development of a range of different cancers. An EGFRvIII antibody could potentially be used to treat glioblastoma, head and neck cancer or non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CCR8:</b> targets depletion of highly immunosuppressive CCR8+ Tregs in the tumor microenvironment via an ADCC mechanism with selective binding to CCR8 over its closely related cousin, CCR4, to avoid off-target effects. A CCR8 program could potentially be broadly applicable in solid tumors and/or as a prospective combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PD-1 Agonist: </b>Selectively binds PD-1 to suppress auto-reactive T-cells without PD-L1/PD-L2 blocking. A PD-1 agonist could potentially be used to treat inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis or other inflammatory diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the programs described above, we also have six additional early discovery programs that have the potential to advance into later stages of preclinical development and are designed to tackle hard-to-drug targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IBIO-100 and Endostatin E4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our lead anti-fibrotic candidate is IBIO-100, and its design is based in part upon work by Dr. Carol Feghali-Bostwick, Professor of Medicine at the Medical University of South Carolina and Vice-Chair of the Scleroderma Foundation. Her initial work was conducted at the University of Pittsburgh, and we have licensed the patents relevant for the continued development of the molecule from the university. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As part of the Company&#8217;s our review of potential options, we intend to continue to review the data from our research and development efforts and determine how to proceed with the development of IBIO-100 in Fibrosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;">To align with the Company&#8217;s focus on the immuno-oncology pipeline, we also intend to continue to pursue the E4 endostatin peptide, from which IBIO-100 is derived, as an oncology target in collaboration with University of Texas Southwestern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AI Drug Discovery Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2022, we purchased substantially all of the assets of RubrYc Therapeutics (for a complete description of the transaction please see Note 6 &#8211; Significant Transactions). The AI Drug Discovery platform technology is designed to be used to discover antibodies that bind to hard-to-target subdominant and conformational epitopes for further development within our existing portfolio or in partnership with outside entities. The RubrYc AI platform is built upon 3 key technologies. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Epitope Targeting Engine:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> A proprietary machine-learning platform that combines computational biology and 3D-modeling to identify molecules that mimic hard-to-target binding sites on target proteins, specifically, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subdominant and conformational epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The creation of these small mimics enables the engineering of therapeutic antibody candidates that can selectively bind immune and cancer cells better than &#8221;trial and error&#8221; antibody engineering and screening methods that are traditionally focused on dominant epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">RubrYcHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-generated human antibody library free of significant sequence liabilities that provides a unique pool of antibodies to screen. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The combination of the Epitope Targeting Engine and screening with the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">RubrYcHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Library has been shown to reduce the discovery time from ideation to </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> proof-of-concept (PoC) by up to 4 months. This has the potential to enable more, and better, therapeutic candidates to reach the clinic, faster. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">StableHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-powered sequence optimization library used to improve antibody performance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Once an antibody has been advanced to the lead optimization stage, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">StableHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> allows precise and rapid optimization of the antibody binding regions to rapidly move a candidate molecule into the IND-enabling stage.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Recent Developments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 11, 2022, we and Woodforest amended the Credit Agreement to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days &#160;upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (see Note 19 &#8211; Fraunhofer Settlement for more information), (iii) include principal payments of $250,000 per month in debt amortization for a 6 month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast (vi) reduce the liquidity covenant in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5.0 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing was acceptable with or without a &#8220;going concern&#8221; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. If we fail to successfully extend our cash runway via strategic options or other alternatives as described we would be in violation of the liquidity covenant on December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 2, 2022, we announced our plans to divest our contract development and manufacturing organization (iBio CDMO, LLC) in order to complete our transformation into an antibody discovery and development company. In conjunction with the divestment, we </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">have commenced, on October 31, 2022 a workforce reduction of approximately 60% of our current staffing levels (a reduction of 69 positions). We expect to substantially complete the employee reduction within approximately 60 days of November 2, 2022. We expect we may be able to complete a transaction in 2023, although there is no assurance as to when, or for how much, we may be able to sell our CDMO assets. We expect to incur pre-tax charges of approximately $1.7 million for the employee reduction, most of which is expected to be incurred in the second and third quarter of fiscal year 2023. These charges will be substantially settled in cash and almost entirely consist of severance obligations, continuation of salaries and benefits over a 60-day transitional period during which impacted employees remain employed but are not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. The transition to a focused AI-Biotech business is expected to reduce our monthly burn rate by approximately half, with an approximate range of $2.5-3.0 million per month. Although we expect to decrease burn, our long-term business plan would be to increase R&amp;D and commence clinical trials that could be costly if conducted without a licensing partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2022, Mr. Chip Clark was appointed as the Company&#8217;s Chairman of the Board.<span style="background:#ffff00;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 2, 2022, the Company announced that its Board of Directors has initiated a search for a new Chief Executive Officer. It is expected that Mr. Tom Isett will remain as the Chief Executive Officer of the Company through this transformation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;">Results of Operations&#160;- Comparison of the three months ended September 30,&#160;2022 and 2021 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Revenues for the three months ended September&#160;30,&#160;2022 and 2021 were approximately $- million and $0.1 million respectively, a decrease of approximately ($0.1) million. Revenue from the CDMO operations is in now included in discontinued operations and not broken out separately on the financial statements. Our ongoing business is primarily focused on i) development of our pipeline for which we do not expect revenue and ii) on our AI-driven discovery platform. We may have revenue with the AI-driven discovery platform in future. The $.1M in revenue in Q1 FY2022 related to a customer settlement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Research and development expenses for the three months ended September&#160;30,&#160;2022 and 2021 were $2.5 million and $1.1 million, respectively, an increase of approximately $1.4 million. The increase was primarily related to increases in personnel related to a full year of operation, investment into the San Diego facility, investments into our pipeline including IBIO-101, and EGFRIII, and expenses related to our AI-driven discovery platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">General and Administrative Expenses&#160;(&#8220;G&amp;A&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses for the three months ended September&#160;30,&#160;2022 and 2021 were approximately $5.1 million and $4.2 million, respectively, an increase of $0.9 million. The increase resulted primarily from an increase in headcount, and an increase in consulting costs to support the portfolio of proprietary therapeutics and vaccines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Total Operating Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Total operating expenses, consisting primarily of R&amp;D and G&amp;A expenses, for the three months ended September&#160;30,&#160;2022, were approximately $7.6 million, compared to approximately $5.3 million in the same period of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Total Other Income (Expense)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Total Other Income (expense) for the three months ended September&#160;30,&#160;2022 and 2021 was approximately $0.1 million and $0.0 million respectively. For the three months ended September&#160;30,&#160;2022 Total Other Income was from interest income. For September&#160;30,&#160;2021, Total Other Income (expense) primarily included interest expense of approximately ($0.6) million incurred under the finance lease offset by $0.6 million for the forgiveness of the PPP loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Discontinued Operations:</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 2, 2022, iBio, Inc. announced its plans to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an AI-driven precision antibody discovery and development company. In conjunction with the divestment, iBio initiated a workforce reduction of approximately 60% and discontinued CDMO operations. &#160;CDMO operations are now treated as a discontinued operation on our financial statements. Losses for Discontinued Operations for the three months ended September&#160;30,&#160;2022 and 2021 were approximately ($10.6) million and ($3.8) million respectively. &#160;The increase primarily related to a consumables and inventory write-off of ($4.1) million with the remaining variance related to personnel fees and other professional fees.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Loss Attributable to iBio,&#160;Inc. Stockholders</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net loss attributable to iBio,&#160;Inc. stockholders for the three months ended September&#160;30,&#160;2022, was ($7.5) million, or ($0.85) per share. Net loss attributable to iBio,&#160;Inc. stockholders for the three months ended September&#160;30,&#160;2021, was approximately ($5.2) million or ($0.60) per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September&#160;30,&#160;2022, we had cash and cash equivalents plus debt securities of approximately $23.5 million, including approximately $6 million of restricted cash, as compared to $39.5 million as of June&#160;30,&#160;2022. In an effort to improve liquidity and runway, we recently announced we were selling our CDMO business and facility, reducing its work force by approximately 60% (a reduction of approximately 69 positions), and ceasing operations of its CDMO thereby reducing annual spending by approximately 50%. Potential options being considered&#160;to further increase liquidity include lowering our expenses further, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from capital markets, grant revenue or collaborations, or a combination thereof. During the first quarter of fiscal year 2023, we completed at-the-market (&#8220;ATM&#8221;) offerings and raised $1.1M selling approximately 176,000 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s cash, cash equivalents and investments in debt securities is not anticipated to be sufficient to support operations beyond Q3 of Fiscal 2023<b style="font-weight:bold;"> </b>unless the Company reduces its burn rate further or increases its capital as described above. Regardless of whether the Company is able to reduce its burn rate or sell or out-license certain assets or parts of the business, the Company will need to raise additional capital in order to fully execute its longer-term business plan. It is the Company&#8217;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Quarterly Report on Form 10-Q. However, there can be no assurance that the Company will be successful in implementing any of the options that we are evaluating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Used in Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was approximately ($14.0) million for the three months ended September&#160;30,&#160;2022. The use of cash was primarily attributable to funding our net loss for the period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Used in Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities of approximately $0.0 million for the three months ended September&#160;30,&#160;2022 attributable primarily to the redemption of debt securities of $3.2 million, the purchase of fixed assets of ($2.5) million, and ($.7) million associate with the asset purchase of RubrYc Therapeutics, Inc. (Refer to Note 6 &#8211; Significant Transactions for details.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Provided by Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in financing activities during the three months ended September 30,&#160;2022, was approximately $1.1 million and mainly attributable to the proceeds from the sale of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred significant losses and negative cash flows from operations since our spin-off from Integrated BioPharma in August&#160;2008. As of September&#160;30,&#160;2022, our accumulated deficit was approximately $ (242.0) million and we used approximately ($14.0) million of cash for operating activities during the three months ended September&#160;30,&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to fund our future business operations using cash on hand, through proceeds realized in connection with the commercialization of our technologies, through proceeds from the sale of the&#160; iBio CDMO, through the collection or proceeds from our license agreement with Fraunhofer, through potential proceeds from the sale or out-licensing of assets, and through proceeds from the sale of additional equity or other securities. We cannot be certain that such funding will be available on favorable terms or available at all. Based on current trends and activities, there is significant doubt that iBio can continue as a going concern beyond Q3 of Fiscal 2023. If we fail to successfully extend our cash runway via strategic options or other alternatives as described we would be in violation of the liquidity covenant on&#160;December 31, 2022. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution. If we are unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and we may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of our proprietary technologies; b) seek collaborators for our technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that we would otherwise seek to develop or commercialize; or d) possibly cease operations. &#160;</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (SPEs), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually limited purposes. As of September&#160;30,&#160;2022, we were not involved in any SPE transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A critical accounting policy is one that is both important to the portrayal of a company&#8217;s financial condition and results of operations and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our condensed consolidated financial statements are presented in accordance with U.S. GAAP, and all applicable U.S. GAAP accounting standards effective as of September&#160;30,&#160;2022, have been taken into consideration in preparing the condensed consolidated financial statements. The preparation of condensed consolidated financial statements requires estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. Some of those estimates are subjective and complex, and, consequently, actual results could differ from those estimates. The following accounting policies and estimates have been highlighted as significant because changes to certain judgments and assumptions inherent in these policies could affect our condensed consolidated financial statements:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Valuation of intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Revenue recognition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liquidity assertions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Useful lives of fixed assets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease accounting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Legal and contractual contingencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Research and development expenses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Share-based compensation expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We base our estimates, to the extent possible, on historical experience. Historical information is modified as appropriate based on current business factors and various assumptions that we believe are necessary to form a basis for making judgments about the carrying value of assets and liabilities. We evaluate our estimates on an on-going basis and make changes when necessary. Actual results could differ from our estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1d24a094_a427_4b91_aea0_e31303962a6c"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As a smaller reporting company, we are not required to provide the information required by this Item&#160;3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bae7a397_e2da_4da0_807f_3cec0c0ea073"></a><a id="Item4ControlsandProcedures_545173"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our management, under the direction of our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, as amended, as of September&#160;30,&#160;2022. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company&#8217;s disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Based on our evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September&#160;30,&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no changes in our internal control over financial reporting, as such term is defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act, during the quarter ended September&#160;30,&#160;2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_0de26404_5c2a_444f_ae72_3fe18572a2a0"></a><a id="PARTIIOTHERINFORMATION_600713"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;II.&#160;&#160;OTHER INFORMATION</p><a id="Item1LegalProceedings_731318"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1.&#160;&#160;Legal Proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We are not currently subject to any material legal proceedings</span>.</p><a id="_f7e13ade_3273_4e06_bfab_edfe23bb77ff"></a><a id="Item1ARiskFactors_275295"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A.&#160;&#160;Risk Factors<b style="font-weight:bold;white-space:pre-wrap;">  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities.&#160;</i><i style="color:#222222;font-style:italic;">The following information updates, and should be read in conjunction with, the information disclosed in Part&#160;I,&#160;Item&#160;1A, &#8220;Risk Factors,&#8221; contained in the</i><i style="font-style:italic;"> Annual Report. Except as described below, our risk factors as of the date of this Report have not changed materially from those described in &#8220;Part&#160;I, Item&#160;1A. Risk Factors&#8221;&#160;of our Annual Report.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are reviewing potential options to extend our cash runway. This review could impact our future operations and financial position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We are currently evaluating a number of potential options to expand our cash runway, the implementation of which will impact the Company&#8217;s liquidity. In an effort to improve liquidity and runway, we recently announced that we were selling our CDMO business and facility, reducing our work force by approximately 60%, and ceasing operations of our CDMO thereby reducing annual spending by approximately 50%. Potential options being considered&#160;to further increase liquidity include lowering our expenses further, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from capital markets, grant revenue or collaborations, or a combination thereof. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our cash, cash equivalents and investments in debt securities of $23.5 million as of September 30, 2022, is not anticipated to be sufficient to support our operations for at least 12 months from the date of the filing of this Quarterly Report on Form 10-Q unless we reduce our burn rate further or increase our capital. Regardless of whether we are able to reduce our burn rate or sell or out-licensing of certain assets or parts of the business, we will need to raise additional capital in order to fully execute our longer-term business plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 1pt 0pt 0pt;">There can be no assurance that we will be able to sell the CDMO or that if we are able to do so that we do so on favorable terms or that he exploration of potential options will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. Although we expect to be able to sell the CDMO in 2023, no guaranteed timetable has been established for the completion of this process, and we do not expect to disclose developments unless and until we have a material update to provide or the Board of Directors has concluded that disclosure is appropriate or required. If we determine to change our business strategy, our future business, prospects, financial position and operating results could be significantly different than those in historical periods or projected by our management. Because of the significant uncertainty regarding our future plans, we are not able to accurately predict the impact of a potential change in our business strategy and future funding requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 1pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our historical operating results indicate substantial doubt exists related to our ability to operate as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We have incurred net losses and used significant cash in operating activities since inception, and we expect to continue to generate operating losses for the foreseeable future. As of September 30, 2022, we have an accumulated deficit of $242 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We held cash, cash equivalents and investments in debt securities of $23.5 million as of September 30, 2022. Based on current trends and activities, there is significant doubt that we can continue as a going concern beyond Q3 of Fiscal 2023. We have announced that we </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">are implementing cost savings measures to expand our cash runway, the implementation of which will impact our liquidity but these measures alone will not be sufficient to provide the financing needed to meet our long term goals . Potential options being considered&#160;to increase liquidity include further lowering our expenses through decreasing spending and focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates or parts of the business, raising money from capital markets, grant revenue or collaborations, or a combination thereof. Regardless of whether we are able to reduce our burn rate or sell or out-licensing certain assets or parts of the business, we will need to raise additional capital in order to fully execute our longer-term business plan. We believe based on input from expert advisors, that it is likely we will be able to implement one or more options that will extend our cash runway for 12 months or more from the date of the filing of this Quarterly Report on Form 10-Q. However, there can be no assurance that we will be successful in implementing any of the options that we are evaluating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our consolidated audited financial statements as of and for the year ended September 30, 2022, have been prepared under the assumption that we will continue as a going concern for the next 12 months. Our management concluded that our recurring losses from operations and the fact that we have&#160;not generated significant revenue or positive cash flows from operations raise substantial doubt about our ability to continue as a going concern for the next 12 months after issuance of our financial statements. Our auditors also included an explanatory paragraph in its report on our financial statements as of and for the year ended June 30, 2022 with respect to this uncertainty.&#160;If we continue to experience operating losses, and we are not able to generate additional liquidity through a capital raise or other cash infusion, we might need to secure additional sources of funds, which may or may not be available to us. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to further scale back or discontinue the development of our product candidates or other research and development initiatives or initiate steps to cease operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We need additional funding to fully execute our business plan, which funding may not be available on commercially acceptable terms or at all. If we are unable to raise capital when needed, we may be forced to delay, reduce or eliminate the commercialization of our development and manufacturing services and efforts for our product development programs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;background:#ffffff;margin:0pt;">Even if we are able to sell the CDMO upon favorable terms, we will need additional capital to fully implement our current long-term business, operating and development plans as we do not anticipate that any of our product candidates will generate revenue in the next few years, if at all. To the extent that we initiate or continue clinical development without securing collaborator or licensee funding, our research and development expenses could increase substantially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;background:#ffffff;margin:0pt;">When we elect to raise additional funds or additional funds are required, we may raise such funds from time to time through public or private equity offerings, debt financings, corporate collaboration and licensing arrangements or other financing alternatives. Additional equity or debt financing or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at all. We currently have no committed sources of funding. &#160;On November 25, 2020, we entered into a Controlled Equity Offering SM Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&quot;Cantor Fitzgerald&quot;) to sell shares of common stock, from time to time, through an &#8220;at the market offering&#8221; program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent (the &#8220;Sales Agent&#8221;). There can be no assurance that we will meet the requirements to be able to sell securities pursuant to the Sales Agreement, of if we meet the requirements that we will be able to raise sufficient funds on favorable terms. If we are unable to raise capital in sufficient amounts when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or commercialization efforts and our ability to generate revenues and achieve or sustain profitability will be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 6pt 0pt;">If we are unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and we may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of our proprietary technologies; b) seek collaborators for our technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that we would otherwise seek to develop or commercialize; or d) possibly cease operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in general economic conditions, geopolitical conditions, domestic and foreign trade policies, monetary policies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">and other factors beyond our control may adversely impact our business and operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-align:justify;margin:0pt 5.2pt 0pt 2pt;"><span style="background:#ffffff;">The uncertain financial markets, disruptions in supply chains, mobility restraints, and changing priorities as well as volatile asset values could impact our business in the future. We and our third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to our research and development activities, including, for example, medical and laboratory supplies used in our clinical trials or preclinical studies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak.</span> These minor disruptions have had an immaterial effect on business, which we have been able to address with minimal impact to our business operations to date. Further, although we have not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing manufacturing of our drug candidates or services providers, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on our operations.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-align:justify;margin:0pt 5.2pt 0pt 2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-align:justify;margin:0pt 5.2pt 0pt 2pt;">Our<span style="letter-spacing:0.65pt;"> </span>operations<span style="letter-spacing:0.65pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>performance<span style="letter-spacing:0.65pt;"> </span>depend<span style="letter-spacing:0.65pt;"> </span>on<span style="letter-spacing:0.65pt;"> </span>global,<span style="letter-spacing:0.65pt;"> </span>regional<span style="letter-spacing:0.65pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>U.S.<span style="letter-spacing:0.65pt;"> </span>economic<span style="letter-spacing:0.65pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>geopolitical<span style="letter-spacing:0.65pt;"> </span>conditions.<span style="letter-spacing:-0.05pt;"> </span>Russia&#8217;s<span style="letter-spacing:1.05pt;"> </span>invasion<span style="letter-spacing:1.05pt;"> </span>and<span style="letter-spacing:1.05pt;"> </span>military<span style="letter-spacing:1.05pt;"> </span>attacks<span style="letter-spacing:1.05pt;"> </span>on<span style="letter-spacing:1.05pt;"> </span>Ukraine<span style="letter-spacing:1.05pt;"> </span>have<span style="letter-spacing:1.05pt;"> </span>triggered<span style="letter-spacing:1.05pt;"> </span>significant<span style="letter-spacing:1.05pt;"> </span>sanctions<span style="letter-spacing:1.05pt;"> </span>from<span style="letter-spacing:1.05pt;"> </span>U.S.<span style="letter-spacing:1.05pt;"> </span>and<span style="letter-spacing:1.05pt;"> </span>European<span style="letter-spacing:1.05pt;"> </span>leaders.<span style="letter-spacing:-0.05pt;"> </span>These<span style="letter-spacing:0.55pt;"> </span>events<span style="letter-spacing:0.55pt;"> </span>are<span style="letter-spacing:0.55pt;"> </span>currently<span style="letter-spacing:0.55pt;"> </span>escalating<span style="letter-spacing:0.55pt;"> </span>and<span style="letter-spacing:0.55pt;"> </span>creating<span style="letter-spacing:0.55pt;"> </span>increasingly<span style="letter-spacing:0.55pt;"> </span>volatile<span style="letter-spacing:0.55pt;"> </span>global<span style="letter-spacing:0.55pt;"> </span>economic<span style="letter-spacing:0.55pt;"> </span>conditions.<span style="letter-spacing:0.55pt;"> </span>Resulting<span style="letter-spacing:0.55pt;"> </span>changes<span style="letter-spacing:0.55pt;"> </span>in U.S.<span style="letter-spacing:1.75pt;"> </span>trade<span style="letter-spacing:1.75pt;"> </span>policy<span style="letter-spacing:1.75pt;"> </span>could<span style="letter-spacing:1.75pt;"> </span>trigger<span style="letter-spacing:1.75pt;"> </span>retaliatory<span style="letter-spacing:1.75pt;"> </span>actions<span style="letter-spacing:1.75pt;"> </span>by<span style="letter-spacing:1.75pt;"> </span>Russia,<span style="letter-spacing:1.75pt;"> </span>its<span style="letter-spacing:1.75pt;"> </span>allies<span style="letter-spacing:1.75pt;"> </span>and<span style="letter-spacing:1.75pt;"> </span>other<span style="letter-spacing:1.75pt;"> </span>affected<span style="letter-spacing:1.75pt;"> </span>countries,<span style="letter-spacing:1.75pt;"> </span>including<span style="letter-spacing:1.75pt;"> </span>China,<span style="letter-spacing:-0.1pt;"> </span>resulting<span style="letter-spacing:0.5pt;"> </span>in<span style="letter-spacing:0.5pt;"> </span>a<span style="letter-spacing:0.5pt;"> </span>&#8220;trade<span style="letter-spacing:0.5pt;"> </span>war.&#8221;<span style="letter-spacing:0.5pt;"> </span>Furthermore,<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>conflict<span style="letter-spacing:-0.05pt;"> </span>between<span style="letter-spacing:-0.05pt;"> </span>Russia<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>Ukraine<span style="letter-spacing:-0.05pt;"> </span>continues<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>long<span style="letter-spacing:-0.05pt;"> </span>period<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>time,<span style="letter-spacing:0.6pt;"> </span>or<span style="letter-spacing:0.6pt;"> </span>if<span style="letter-spacing:0.6pt;"> </span>other<span style="letter-spacing:0.6pt;"> </span>countries,<span style="letter-spacing:0.6pt;"> </span>including<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:0.6pt;"> </span>U.S.,<span style="letter-spacing:0.6pt;"> </span>become<span style="letter-spacing:0.6pt;"> </span>further<span style="letter-spacing:0.6pt;"> </span>involved<span style="letter-spacing:0.6pt;"> </span>in<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:0.6pt;"> </span>conflict,<span style="letter-spacing:0.6pt;"> </span>we<span style="letter-spacing:0.6pt;"> </span>could<span style="letter-spacing:0.6pt;"> </span>face<span style="letter-spacing:0.6pt;"> </span>significant<span style="letter-spacing:0.6pt;"> </span>adverse effects to our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;text-align:justify;margin:0pt 5.1pt 12pt 0pt;">The<span style="letter-spacing:1.5pt;"> </span>above<span style="letter-spacing:1.5pt;"> </span>factors,<span style="letter-spacing:1.5pt;"> </span>including<span style="letter-spacing:1.5pt;"> </span>a<span style="letter-spacing:1.5pt;"> </span>number<span style="letter-spacing:1.5pt;"> </span>of<span style="letter-spacing:1.5pt;"> </span>other<span style="letter-spacing:1.5pt;"> </span>economic<span style="letter-spacing:1.5pt;"> </span>and<span style="letter-spacing:1.5pt;"> </span>geopolitical<span style="letter-spacing:1.5pt;"> </span>factors<span style="letter-spacing:1.5pt;"> </span>both<span style="letter-spacing:1.5pt;"> </span>in<span style="letter-spacing:1.5pt;"> </span>the<span style="letter-spacing:1.5pt;"> </span>U.S.<span style="letter-spacing:1.5pt;"> </span>and<span style="letter-spacing:1.5pt;"> </span>abroad,<span style="letter-spacing:1.5pt;"> </span>could ultimately have material adverse effects on our business, financial condition, results of operations or cash flows, including the<span style="letter-spacing:-0.05pt;"> </span>following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effects of significant changes in economic, monetary and fiscal policies in the U.S. and abroad including currency fluctuations, inflationary pressures and significant income tax changes;</span></td><td style="width:6.1pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supply chain disruptions;</span></td><td style="width:6.1pt;"></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.05pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>a global or regional economic slowdown in any of our market segments;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.44pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>changes in government policies and regulations affecting the Company or its significant customers;</div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:0pt;margin-top:0.44pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">industrial policies in various countries that favor domestic industries over multinationals or that restrict foreign companies altogether;</span></td><td style="width:5.85pt;"></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.22;margin-bottom:0pt;margin-top:0.1pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:19.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:16.2pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new or stricter trade policies and tariffs enacted by countries, such as China, in response to changes in U.S. trade policies and tariffs;</span></td><td style="width:5.85pt;"></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.05pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>postponement of spending, in response to tighter credit, financial market volatility and other factors;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.44pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>rapid material escalation of the cost of regulatory compliance and litigation;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.44pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>difficulties protecting intellectual property;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.44pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>longer payment cycles;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.44pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>credit risks and other challenges in collecting accounts receivable; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:19.45pt;margin-top:0.44pt;padding-left:19.8pt;text-indent:-19.8pt;"><span style="display:inline-block;font-size:9pt;min-width:16.55pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of each of the foregoing on outsourcing and procurement arrangements.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Due to the discontinuance of the CDMO business, we will not be generating material revenue from CDMO operations going forward.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As a result of the discontinuance of the CDMO business, we will not generate material revenue from the CDMO operations any longer.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d52fab56_7575_44b5_8a21_e8d73d105ee5"></a><a id="Item5OtherInformation_186239"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;5. Other Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 10, 2022, as previous disclosed in relation to the Employment Agreement with Thomas F. Isett 3<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">rd</sup>, the Company&#8217;s Chief Executive Officer, dated April 30, 2021, the Company granted Mr. Isett Restricted Stock Units (the &#8220;RSUs&#8221;) to acquire 200,000 shares of common stock, $0.001 par value per share (the &#8220;Common Stock&#8221;), on a post-split basis.&#160; The RSUs vest over a three-year period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) outlicensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application.&#160; The grant-date fair value of the RSUs totaled approximately $296,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 11, 2022, the Company granted Mr. Robert Lutz, the Company&#8217;s Chief Financial and Business Officer, RSUs to acquire 100,057 shares of the Company&#8217;s Common Stock in exchange for Mr. Lutz&#8217; agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board of Directors. The grant-date fair value of the RSUs totaled approximately $175,100.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 11, 2022, the Company granted Mr. Martin Brenner, the Company&#8217;s Chief Scientific Officer, RSUs to acquire 95,348 shares of the Company&#8217;s Common Stock in exchange for Mr. Brenner&#8217;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board of Directors. The grant-date fair value of the RSUs totaled approximately $166,860.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2a269750_8ef5_4c22_b296_f709ca599b7b"></a><a id="Item6Exhibits_377876"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;6.&#160;&#160;Exhibits.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">HIDDEN_ROW</p></div></div></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.25%;background:#ffffff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;background:#ffffff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;background:#ffffff;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418027689/tv493469_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of iBio,&#160;Inc., Certificate of Merger, Certificate of Ownership and Merger, Certificate of Amendment of the Certificate of Incorporation (incorporated herein by reference to Exhibit&#160;3.1 to the Quarterly Report on Form&#160;10-Q filed with the Securities and Exchange Commission on May&#160;11, 2018&#160;&#8211; File No.&#160;001-35023)</span></a></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418009023/tv484918_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Certificate of Incorporation of iBio,&#160;Inc. (incorporated herein by reference to Exhibit&#160;3.2 to the Quarterly Report on Form&#160;10-Q filed with the Securities and Exchange Commission on February&#160;14, 2018&#160;&#8211; File No.&#160;001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418033574/tv496218_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Certificate of Incorporation of iBio,&#160;Inc. (incorporated herein by reference to the Company&#8217;s Current Report on Form&#160;8-K filed with the Securities and Exchange Commission on June&#160;8, 2018&#160;&#8211; File No.&#160;001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465922009994/tm224794d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Bylaws of iBio,&#160;Inc. (incorporated herein by reference to Exhibit&#160;3.1 to the Company&#8217;s Current Report on Form&#160;8-K filed with the Securities and Exchange Commission on January 26, 2022&#160;&#8211; File No.&#160;000-53125)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000062/ibio-20221007xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Certificate of Incorporation if iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 7, 2022 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000049/ibio-20220916xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement dated September 16, 2022 by and between iBio, Inc. and RubrYc Therapeutics, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2022 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.2*</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="ibio-20220930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Termination Agreement and Release dated September 19, 2022 by and between iBio, Inc. and RubrYc Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.3*</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="ibio-20220930xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease dated September 10, 2021 by and between iBio, Inc., and San Diego Inspire 4, LLC</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.4+*</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="ibio-20220930xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Restricted Stock Unit Award Agreement dated November 10, 2022 by and between iBio, Inc. and Thomas Isett</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">31.1*</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20220930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Chief Executive Officer Pursuant to Rule&#160;13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a> </p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">31.2*</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20220930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Principal Financial Officer Pursuant to Rule&#160;13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a> </p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">32.1*</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20220930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Chief Executive Officer Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a> </p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">32.2*</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="ibio-20220930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0.3pt;margin:0pt 0pt 0pt -0.3pt;">&#160; </p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline &#160; XBRL Instance*</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Schema*</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Calculation*</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Definition*</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Labeled*</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Presentation*</p></td></tr><tr style="height:6.7pt;"><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.22%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Cover page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*&#160;&#160;&#160;Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">+  Certain portions of this exhibit indicated therein by [**] have been omitted in accordance with Item 601(b)(10) of Regulation 8-K.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7d306a60_52a0_4475_a072_db92f8acdb29"></a><a id="SIGNATURES_117481"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">iBio,&#160;Inc.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Registrant)</p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; November 14, 2022</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Thomas F. Isett 3<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">rd</sup></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thomas F. Isett 3<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">rd</sup></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer<br />Principal Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; November 14, 2022</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert Lutz</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert Lutz</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal Financial Officer and Principal Accounting Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>ibio-20220930xex10d2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/14/2022 09:57:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title>TERMINATION AGREEMENT</title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;text-align:right;vertical-align:super;margin:0pt;"><font style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;text-align:right;text-transform:uppercase;margin:0pt 0pt 6pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:none;">Exhibit 10.2</b></p><p style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 0pt 15pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;">TERMINATION AGREEMENT AND RELEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="text-transform:uppercase;">This Termination Agreement AND RELEASE</font> (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination Agreement</u>&#8221;) is entered into as of the 19th day of September, 2022 between iBio, Inc., a Delaware corporation (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">iBio</u>&#8221;) and RubrYc Therapeutics, Inc., a Delaware corporation (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RubrYc</u>&#8221;). Each of iBio and RubrYc are referred to herein as a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Party</u>&#8221; or, collectively, as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Parties</u>.&#8221;</p><p style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">RECITALS</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Parties hereto are parties to that certain Collaboration and License Agreement dated as of August 23, 2021 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration and License Agreement</u>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Parties hereto are parties to that certain Collaboration, Option and License Agreement dated as of August 23, 2021 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Option Agreement</u>&#8221;, and together with the Collaboration and License Agreement, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreements</u>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WHEREAS</b>, in connection with that certain Asset Purchase Agreement, dated September 16, 2022, by and between iBio and RubrYc (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Agreement</u>&#8221;), the Parties hereto desire to terminate the Agreements in accordance with the terms and subject to the conditions set forth in this Termination Agreement.</p><p style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOW, THEREFORE</b>, the undersigned, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, hereby agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recitals</u>. &#160;The foregoing recitals are hereby made part of this Termination Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Agreements</u>. &#160;Effective as of the closing of the transactions contemplated by the Purchase Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</u>&#8221;), each of iBio and RubrYc hereby terminate the Agreements and all terms, agreements and conditions set forth therein, except with respect to any obligations following the termination of the Agreements, which obligations shall continue in full force and effect. The Parties agree that as a result of the execution of this Termination Agreement, the Agreements and all terms, agreements and conditions set forth therein or related thereto shall be rendered null and void and without further legal force or effect, with each of iBio and RubrYc being irrevocably relieved of all future rights and obligations thereunder (except as provided above), all without requiring any further action. &#160;Effective as of the date hereof, each of iBio and RubrYc acknowledges and agrees that it is not entitled to any payments or monetary consideration of any kind relating to the Agreements.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Failure to Close</u>. &#160;If the Closing does not occur, this Termination Agreement shall be null and void and of no further effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representations and Warranties</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.1</font>Each of iBio and RubrYc has all requisite power and authority to enter into this Termination Agreement and has not assigned any of its rights or obligations under the Agreements to any other party.</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;text-align:center;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;text-align:right;vertical-align:super;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.2</font>The execution and delivery of this Termination Agreement by each of iBio and RubrYc has been duly authorized by all necessary action (corporate or otherwise) and no other proceeding is necessary to authorize the execution, delivery and performance of this Termination Agreement and the transactions contemplated herein.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.3</font>This Termination Agreement has been duly executed and delivered by each of iBio and RubrYc and constitutes the legal, valid and binding obligation of iBio and RubrYc, respectively, enforceable against iBio and RubrYc, respectively, in accordance with its terms.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">5.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release</u>. &#160;Effective as of the date hereof, for good and valuable consideration, the receipt and sufficiency of which iBio and RubrYc hereby acknowledge, each of iBio and RubrYc, for itself and on behalf of its successors and assigns, hereby fully, unconditionally and irrevocably releases and forever discharges the other, and each of the other&#8217;s affiliates, contractors, agents, officers, directors, members, employees, shareholders, representatives, attorneys, successors and assigns, of and from any and all manner of actions, causes of action, suits, debts, sums of money, accounts, bonds, bills, specialties, covenants, controversies, agreements, promises, variances, trespasses, damages, judgments, contracts, agreements, claims, demands, losses, obligations, liabilities, proceedings, fines, costs, expenses, fees (including, without limitation, attorneys&#8217; fees, experts fees and court fees) and penalties whatsoever, in law or in equity, which the releasing and discharging party or any successor or assignee of such party ever had, now has or hereafter can, shall or may have against the other party hereto or its successors and assigns for, upon or by reason of any matter, cause or thing whatsoever relating to or arising out of or in connection with the Agreements.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">6.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</u>. &#160;Each Party agrees from time to time, subsequent to the date hereof, to execute and deliver or cause to be executed and delivered such instruments or further assurances as may, in the reasonable opinion of the other Parties, be necessary or desirable to give effect to the provisions of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">7.</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">7.1</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. &#160;This Termination Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware other than conflict of laws principles thereof directing the application of any law other than that of the State of &#160;Delaware. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">7.2</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect; No Oral Modification</u>. &#160;This Termination Agreement shall be binding on and shall inure to the benefit of the Parties and their respective successors and assigns. &#160;This Termination Agreement may not be altered, modified, or amended unless such alteration, modification, or amendment is in writing and executed by the Parties.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">7.3</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. &#160;This Termination Agreement constitutes the entire integrated agreement of the Parties hereto with respect to the subject matter hereof and the transactions contemplated hereby, and supersedes any other prior statements, negotiations, understandings, and agreements by and between the Parties hereto, written or oral, with respect to the subject matter hereof.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;text-align:center;margin:0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;text-align:right;vertical-align:super;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">7.4</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. &#160;This Termination Agreement may be executed and delivered in one or more counterparts (including facsimile, PDF, or other electronic counterparts), each of which when executed and delivered shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature page follows.]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:14.4pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;text-align:center;margin:0pt;">3</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:14.71%;padding-right:14.71%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;text-align:right;vertical-align:super;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the parties hereto have executed this Termination Agreement as of the date first written above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;margin:0pt 0pt 24pt 216pt;"><b style="font-weight:bold;">RUBRYC THERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;margin:0pt 0pt 0pt 216pt;">By:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> /s/ Isaac Bright</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:15.01pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;margin:0pt 0pt 0pt 216pt;">Name: Isaac Bright</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;margin:0pt 0pt 0pt 216pt;">Title: Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;margin:0pt 0pt 0pt 216pt;"><font style="margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;margin:0pt 0pt 0pt 216pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;margin:0pt 0pt 0pt 216pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;margin:0pt 0pt 24pt 216pt;"><b style="font-weight:bold;">IBIO</b><b style="font-weight:bold;text-transform:uppercase;">, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12pt;margin:0pt 0pt 0pt 216pt;">By:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> /s/ Thomas F. Isett</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:34.33pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><br>Name: Thomas F. Isett<br>Title:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u>Chief Executive Officer</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">[<i style="font-style:italic;">Signature Page to Termination Agreement</i>]</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:14.71%;margin-right:14.71%;margin-top:30pt;page-break-after:avoid;width:70.59%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>ibio-20220930xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/14/2022 09:57:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SOVA NORTH SCIENCE DISTRICT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SAN DIEGO INSPIRE 4, LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">a Delaware limited liability company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">as Landlord,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">iBio, INC.</b>,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">a Delaware corporation,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;">as Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PREMISES, BUILDING, PROJECT, AND COMMON AREAS</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LEASE TERM</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BASE RENT</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADDITIONAL RENT</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">5.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USE OF PREMISES</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">6.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SERVICES AND UTILITIES</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">7.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">REPAIRS</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADDITIONS AND ALTERATIONS</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">22</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COVENANT AGAINST LIENS</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INSURANCE</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">24</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">11.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DAMAGE AND DESTRUCTION</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">12.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NONWAIVER</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">13.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CONDEMNATION</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">14.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ASSIGNMENT AND SUBLETTING</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">15.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">16.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HOLDING OVER</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">17.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ESTOPPEL CERTIFICATES</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">18.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SUBORDINATION</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">19.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DEFAULTS; REMEDIES</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COVENANT OF QUIET ENJOYMENT</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">36</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CREDIT ENHANCEMENT</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">22.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTENTIONALLY OMITTED</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">38</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SIGNS</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">38</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COMPLIANCE WITH LAW</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">38</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">25.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LATE CHARGES</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">39</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">26.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD&#8217;S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">27.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROJECT CONTROL BY LANDLORD; ENTRY BY LANDLORD</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">28.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT PARKING</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">41</p></td></tr><tr><td style="vertical-align:top;width:4.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">29.</p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">MISCELLANEOUS PROVISIONS</p></td><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">41</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-i-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EXHIBITS</p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit 1.1.1-1</p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Premises</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit 1.1.1-2</p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work Letter</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit 2.1</p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form of Notice of Lease Term Dates</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit 5.2</p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rules and Regulations</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit 5.3.1.1</p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Environmental Questionnaire</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit 17</p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form of Tenant&#8217;s Estoppel Certificate</p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit 21</p></td><td style="vertical-align:bottom;width:85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form of Letter of Credit</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-ii-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Index of Defined Terms</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Abatement Period</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional Insureds</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additional Rent</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Alterations</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">22</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Applicable Laws</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">39</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bank Prime Loan</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Base Rent</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BMBL</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brokers</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">44</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Builder&#8217;s All Risk</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building Common Areas</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building Hours</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CASp Report</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">39</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CC&amp;Rs</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clean-up</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Closure Letter</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">16</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Code</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Areas</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Company</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contemplated Effective Date</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contemplated Transfer Space</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Control</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DHHS</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Direct Expenses</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emergency Generator</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Environmental Assessment</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Environmental Laws</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">14</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Environmental Questionnaire</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Environmental Report</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimate</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimate Statement</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Estimated Direct Expenses</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Existing Hazardous Materials</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense Objection Notice</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense Year</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Force Majeure</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">43</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hazardous Materials</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hazardous Materials Claims</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Holidays</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">18</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HVAC</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">19</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intention to Transfer Notice</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">L/C Security</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Landlord</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Landlord Indemnitees</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Landlord Parties</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">24</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Landlord Repair Notice</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">26</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease Commencement Date</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease Expiration Date</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease Term</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease Year</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lender</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-iii-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Page</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lines</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">45</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mail</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">43</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Market Value</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Material Service Interruption</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New Improvements</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Notices</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">43</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating Expenses</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PCBs</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permitted Assignee</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permitted Transferee</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Premises</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Project</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Project Common Areas</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proposition 13</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Recapture Notice</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Regulations</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">REIT</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">43</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Release</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Renovations</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">45</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rent</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Review Notice</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rules and Regulations</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Service Interruption</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Service Interruption Notice</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Statement</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subject Space</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Summary</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax Expenses</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant Parties</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">12</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant&#8217;s Share</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant&#8217;s Subleasing Costs</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third Parties</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transfer Notice</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transfer Premium</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transferee</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Transfers</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:bottom;width:93.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Underlying Documents</p></td><td style="vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-iv-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SOVA SCIENCE DISTRICT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">LEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">This Lease (the &#8220;<b style="font-weight:bold;">Lease</b>&#8221;), dated as of the date set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1</u> of the Summary of Basic Lease Information (the &#8220;<b style="font-weight:bold;">Summary</b>&#8221;), below, is made by and between <b style="font-weight:bold;">San Diego Inspire 4, LLC</b>, a Delaware limited liability company (&#8220;<b style="font-weight:bold;">Landlord</b>&#8221;), and <b style="font-weight:bold;">iBio, Inc.</b>, a Delaware corporation (&#8220;<b style="font-weight:bold;">Tenant</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SUMMARY OF BASIC LEASE INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">TERMS OF LEASE</p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">DESCRIPTION</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>Dated as of:</p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">September 10, 2021</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Premises<br>(<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 1</u>).</p></div></div></div></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font>Building:</p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">That certain life sciences building containing approximately 21,142 rentable square feet of space located at 11750 Sorrento Valley Road, San Diego, California 92121.</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font>Premises:</p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Approximately 11,383 rentable square feet of space located in the Building and commonly known as Suite 200, as depicted in <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;1.1.1-1</b> to the Lease.</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.3</font></font>Interim Premises:</p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Approximately 6,374 rentable square feet space, comprising the &#8220;creative&#8221; portion of the Premises, as depicted in <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1.1.1-1</b> to the Lease. &#160;Tenant shall be entitled to early access of the Interim Premises as provided herein.</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Lease Term<br>(<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 2</u>).</p></div></div></div></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</font></font>Length of Term:</p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Seven (7) years and four (4) months (i.e., 88 months).</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;width:36pt;padding:0pt;"></div><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.2</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Lease Commencement<br>Date:</p></div></div></div></td><td style="vertical-align:top;width:3.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The date upon which (i) the Premises are Ready For Occupancy (as defined in the Work Letter attached hereto as <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1.1.1-2</b>), and (ii) Landlord delivers to Tenant the Premises in the condition required by this Lease and the Work Letter; provided however, Tenant shall be entitled to early access of the Interim Premises commencing on the date that this Lease is fully executed and delivered.<sup style="font-size:7.5pt;vertical-align:top;">1</sup> Landlord estimates that the Lease Commencement Date will be on or about January 1, 2022. &#160;The Emergency Generator (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1.8</u> below) will likely be installed after the Lease Commencement Date, and the Lease Commencement Date shall not be contingent or dependent on the Emergency Generator being operational.</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">1</sup><font style="display:inline-block;width:14.75pt;"></font>The existing building permit covers work throughout the Premises; the permit is not limited to work within the Interim Premises. &#160;Tenant&#8217;s right to early access of the Interim Premises (and Tenant&#8217;s obligation to pay rent for the Interim Premises) is subject to the City of San Diego (building inspection department) allowing Tenant&#8217;s occupancy of the Interim Premises prior to the City&#8217;s final signoff of the building permit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:24.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:25.39%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</font></font>Rent Commencement Date:</p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:50.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Same as Lease Commencement Date (but Tenant shall only be obligated to pay rent for the Interim Premises at a reduced base rental rate of $2.00 NNN per rentable square foot per month prior to the Lease Commencement Date (i.e. $12,748 per month, prorated for any partial months, with Tenant&#8217;s Share adjusted as provided below); provided, however, Tenant&#8217;s base rent for the first two (2) full months of early occupancy of the Interim Premises shall be abated). &#160;If Tenant is unable to occupy the Interim Premises because the City of San Diego building inspector will not approve early occupancy of the Interim Premises, then Tenant shall not be required to pay rent for the Interim Premises.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.4</font></font>Lease Expiration Date:</p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The last day of the eighty-eighth (88th) full month after the Lease Commencement Date.</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50.77%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="5" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>Base Rent (<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 3</u>):</p></td></tr><tr><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:24.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:25.39%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lease Year (in Months)</u></p></td><td colspan="2" style="vertical-align:bottom;width:24.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Annual<br><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Base Rent</u></p></td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Monthly<br>Installment<br><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">of Base Rent</u><sup style="font-size:7.5pt;vertical-align:top;">2</sup></p></td><td style="vertical-align:bottom;width:25.39%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Monthly Base<br>Rent<br>per Rentable<br><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Square Foot</u><sup style="font-size:7.5pt;vertical-align:top;">3</sup></p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1 - 12<sup style="font-size:7.5pt;vertical-align:top;">4</sup></p></td><td colspan="2" style="vertical-align:bottom;width:24.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$614,682.00</p></td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$51,223.50</p></td><td style="vertical-align:bottom;width:25.39%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$4.50</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13 - 24</p></td><td colspan="2" style="vertical-align:bottom;width:24.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$633,805.44</p></td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$52,817.12</p></td><td style="vertical-align:bottom;width:25.39%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$4.64</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25 - 36</p></td><td colspan="2" style="vertical-align:bottom;width:24.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$651,562.92</p></td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$54,296.91</p></td><td style="vertical-align:bottom;width:25.39%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$4.77</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37 - 48</p></td><td colspan="2" style="vertical-align:bottom;width:24.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$672,052.32</p></td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$56,004.36</p></td><td style="vertical-align:bottom;width:25.39%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$4.92</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">49 - 60</p></td><td colspan="2" style="vertical-align:bottom;width:24.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$691,175.76</p></td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$57,597.98</p></td><td style="vertical-align:bottom;width:25.39%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$5.06</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">61 - 72</p></td><td colspan="2" style="vertical-align:bottom;width:24.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$713,031.12</p></td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$59,419.26</p></td><td style="vertical-align:bottom;width:25.39%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$5.22</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">73 - 84</p></td><td colspan="2" style="vertical-align:bottom;width:24.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$733,520.52</p></td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$61,126.71</p></td><td style="vertical-align:bottom;width:25.39%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$5.37</p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">85 - 88</p></td><td colspan="2" style="vertical-align:bottom;width:24.22%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$755,375.88<sup style="font-size:7.5pt;vertical-align:top;">5</sup></p></td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$62,947.99</p></td><td style="vertical-align:bottom;width:25.39%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$5.53</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">2</sup><font style="display:inline-block;width:14.75pt;"></font>If the Rent Commencement Date does not occur on the first day of a calendar month, then Lease Year 1 shall include the first twelve&#160;(12) full calendar months of the Lease Term and any partial calendar month in which the Rent Commencement Date occurs, and the Base Rent for such partial calendar month shall be prorated in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1</u> below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">3</sup><font style="display:inline-block;width:14.75pt;"></font>Monthly Base Rent per Rentable Square Foot has been rounded off to the nearest cent using conventional rounding principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">4</sup><font style="display:inline-block;width:14.75pt;"></font>Provided Tenant is not in default of the terms of this Lease after expiration of any applicable notice and cure period, Tenant shall be entitled to receive four&#160;(4) months of Base Rent abatement. &#160;Base Rent shall be abated for the second&#160;(2<sup style="font-size:7.5pt;vertical-align:top;">nd</sup>), third&#160;(3<sup style="font-size:7.5pt;vertical-align:top;">rd</sup>), fourth&#160;(4<sup style="font-size:7.5pt;vertical-align:top;">th</sup>) and fifth (5th) full calendar months of the Lease Term (the &#8220;<b style="font-weight:bold;">Abatement Period</b>&#8220;) in an aggregate amount of $204,894.00. &#160;Tenant shall be obligated to pay Tenant&#8217;s Share of Direct Expenses and all electricity charges attributable to such period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">5</sup><font style="display:inline-block;width:14.75pt;"></font>Based on a twelve (12) month period. &#160;Months 85 &#8211; 88 will be four (4) months, and aggregate Base Rent for such four (4) months will be $251,791.96.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>P.O. Box 894412<br>Los Angeles, CA 90189-4412</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="white-space:pre-wrap;">Account Name:  San Diego Inspire Holdings, LLC</font><br><font style="white-space:pre-wrap;">Account Number:  6794041847</font><br><font style="white-space:pre-wrap;">Routing Number:  021000089</font><br><font style="white-space:pre-wrap;">Origin is outside of U.S.:  Swift code CITIUS33</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</font></font>Payment of Rent:</p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Rent checks shall be made payable to and sent to the following lockbox address:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">San Diego Inspire&#160;4, LLC<br>P.O. Box 894412<br>Los Angeles, CA 90189-4412</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or wired to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Citibank, N.A., New York<br><font style="white-space:pre-wrap;">Account Name:  San Diego Inspire Holdings, LLC</font><br><font style="white-space:pre-wrap;">Account Number:  6794041847</font><br><font style="white-space:pre-wrap;">Routing Number:  021000089</font><br><font style="white-space:pre-wrap;">Origin is outside of U.S.:  Swift code CITIUS33</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">5.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Tenant Improvement Allowance:</p></div></div></div></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Eighty-One Thousand Nine Hundred Sixty Dollars ($81,960.00), of which Fifty Thousand Ninety Dollars ($50,090.00) (i.e., $10.00 per rentable square feet of the lab portion of the Premises) may only be used for improvements to the lab portion of the Premises and Thirty-One &#160;Thousand Eight Hundred Seventy Dollars ($31,870.00) (i.e., $5.00 per rentable square feet of the office portion of the Premises) may only be used for the improvements to the Interim Premises; Landlord shall construct improvements in the Premises in accordance with the terms of the Tenant Work Letter attached hereto as <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1.1.1-2</b>. &#160;</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">6.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">NNN Lease:</p></div></div></div></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the Base Rent, Tenant shall be responsible to pay (i) Tenant&#8217;s Share of Direct Expenses in accordance with the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 4</u> of the Lease, and (ii) separately metered utilities and janitorial expenses pertaining to the Premises. &#160;Initially, Tenant&#8217;s Share of Direct Expenses for the entire Premises are estimated to be $1.10 per rentable square foot per month.</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">7.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Tenant&#8217;s Share<br>(<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 4</u>):</p></div></div></div></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">53.84% of the Building and 19.03% of the Project, based on the calculations set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2.6</u> of this Lease below. &#160;Notwithstanding the foregoing, Tenant&#8217;s Share during the period that Tenant occupies the Interim Premises is 30.15% of the Building and 10.66% of the Project, based on the calculations set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2.6</u> of this Lease below. &#160;</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">8.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Permitted Use<br>(<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 5</u>):</p></div></div></div></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Premises shall be used only for general office and laboratory, administrative offices and, incidental and accessory thereto, storage uses and other lawful accessory uses reasonably related to and incidental to such specified uses, all in compliance with, and subject to, Applicable Laws and the terms of this Lease. </p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">9.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Credit Enhancement<br>(<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 21</u>): </p></div></div></div></td><td style="vertical-align:top;width:4.15%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$188,844, as a letter of credit pursuant to Article 21 of the Lease and subject to possible reduction to the amount of $94,422 pursuant to Article 21.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">10.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Guarantor<br>(<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 21</u>):</p></div></div></div></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:50.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">None</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">11.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Parking Pass Ratio<br>(<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 28</u>):</p></div></div></div></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Two (2) unreserved parking spaces for every 1,000 rentable square feet of the Premises (i.e., 22 parking spaces), subject to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;28</u> of the Lease.</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">12.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Address of Tenant<br>(<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;29.18</u>):</p></div></div></div></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Before Lease Commencement Date:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">iBio, Inc.<br>11750 Sorrento Valley Road, Suite 200</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">San Diego, California 92121</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attention: Martin Brenner</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With a copy by email to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 21.6pt;">Martin Brenner at Martin.Brenner@ibioinc.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 21.6pt;">Paul Levin at PCLevin@venable.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">After Lease Commencement Date:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">iBio, Inc.<br>11750 Sorrento Valley Road, Suite 200</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">San Diego, California 92121</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Attention: Martin Brenner</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">13.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Address of Landlord<br>(<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;29.18</u>):</p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">San Diego Inspire 4, LLC<br>c/o Longfellow Real Estate Partners<br>260 Franklin Street, Suite 1920<br>Boston, MA 02110<br>Attention: Asset Management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">San Diego Inspire 4, LLC<br>c/o Longfellow Property Management Services CA Inc.<br>11772 Sorrento Valley Road, Suite 250<br>San Diego, CA 92121<br>Attention: Property Management</p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div border="0" cellpadding="0" cellspacing="0" style="display:table;"><div style="display:table-row;"><div style="display:table-cell;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">14.</p></div><div style="display:table-cell;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Broker(s)<br>(<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;29.24</u>):</p></div></div></div></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Newmark Knight Frank<br>(representing Landlord)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hughes Marino</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(representing Tenant)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-4-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">PREMISES, BUILDING, PROJECT, AND COMMON AREAS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Premises, Building, Project and Common Areas</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Premises</b>. &#160;Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the premises set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.2</u> of the Summary (the &#8220;<b style="font-weight:bold;">Premises</b>&#8221;). &#160;The outline of the Premises is set forth in <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;1.1.1-1</b> attached hereto. The parties hereto agree that the lease of the Premises is upon and subject to the terms, covenants and conditions herein set forth, and Tenant covenants as a material part of the consideration for this Lease to keep and perform each and all of such terms, covenants and conditions by it to be kept and performed and that this Lease is made upon the condition of such performance. &#160;The parties hereto hereby acknowledge that the purpose of <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;1.1.1-1</b> is to show the approximate location of the Premises in the &#8220;Building&#8221;, as that term is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1.2</u> below, only, and such Exhibit is not meant to constitute an agreement, representation or warranty as to the construction of the Premises, the precise area thereof or the specific location of the &#8220;Common Areas,&#8221; as that term is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1.3</u> below or the elements thereof or of the accessways to the Premises or the &#8220;Project&#8221;, as that term is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;1.1.2</u> below. Tenant shall accept the Premises in its presently existing &#8220;as-is&#8221; condition, provided that the Premises shall be delivered in a &#8220;broom clean&#8221; condition, with the plumbing, electrical systems, fire sprinkler system, lighting, and air conditioning and heating systems serving the Premises in good operating condition and repair, and in compliance with all Applicable Laws, and with Landlord&#8217;s Work and the Tenant Improvements substantially completed in accordance with this Lease and the Tenant Work Letter, and Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the Premises except as otherwise expressly set forth in this Lease or in the Tenant Work Letter attached hereto as <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1.1.1-2</b>. Tenant shall be entitled to full access and occupancy of the Interim Premises commencing on the date that this Lease is fully executed and delivered. &#160;Landlord, at Landlord&#8217;s sole expense, shall deliver the Interim Premises to Tenant in a &#8220;broom clean&#8221; condition, with the plumbing, electrical systems, fire sprinkler system, lighting, and air conditioning and heating systems serving the Premises in good operating condition and repair, in compliance with Applicable Laws. The Premises shall exclude Common Areas, including without limitation exterior faces of exterior walls, the entry, vestibules and main lobby of the Building, elevator lobbies and common lavatories, the common stairways and stairwells, elevators and elevator wells, boiler room, sprinkler rooms, elevator rooms, mechanical rooms, loading and receiving areas, electric and telephone closets, janitor closets, and pipes, ducts, conduits, wires and appurtenant fixtures and equipment serving exclusively or in common with other parts of the Building.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Building and The Project</b>. &#160;The Premises are a part of the building set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1</u> of the Summary (the &#8220;<b style="font-weight:bold;">Building</b>&#8221;). &#160;The term &#8220;<b style="font-weight:bold;">Project</b>&#8221;, as used in this Lease, shall mean (i) the Building and the Common Areas, (ii) the land (which is improved with landscaping, parking facilities and other improvements) upon which the Building and the Common Areas are located, and (iii) the other building (i.e., 11760 Sorrento Valley Road) located in a portion of the project known as &#8220;SOVA North Science District,&#8221; and the land upon which such adjacent buildings are located. For sake of clarity, the SOVA North Science District is a portion of the project known as the &#160;&#8220;SOVA Science District.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Common Areas</b>. &#160;Tenant shall have the non-exclusive right to use in common with other tenants in the Project, and subject to the rules and regulations referred to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 5</u> of this Lease, those portions of the Project which are provided, from time to time, for use in common by Landlord, Tenant and any other tenants of the Project (such areas, together with such other portions of the Project designated by Landlord, in its discretion, including certain areas designated for the exclusive use of certain tenants, including Tenant, or to be shared by Landlord and certain tenants, including Tenant, are collectively referred to herein as the &#8220;<b style="font-weight:bold;">Common Areas</b>&#8221;). The Common Areas shall consist of the &#8220;<b style="font-weight:bold;">Project Common Areas</b>&#8221; and the &#8220;<b style="font-weight:bold;">Building Common Areas</b>&#8221;. The term &#8220;<b style="font-weight:bold;">Project Common Areas</b>&#8221;, as used in this Lease, shall mean the portion of the Project designated as such by Landlord and which are shown in <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1.1.1-1</b>. &#160;The term &#8220;<b style="font-weight:bold;">Building Common Areas</b>&#8221;, as used in this Lease, shall mean the portions of the Common Areas located within the Building designated as such by Landlord. &#160;The manner in which the Common Areas are maintained and operated shall be at the sole discretion of Landlord and the use thereof shall be subject to such rules, regulations and restrictions as Landlord may make from time to time in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2</u> below. &#160;Landlord reserves the right to close temporarily, make alterations or additions to, or change the location of elements of the Project and the Common Areas, provided that, in connection therewith, Landlord shall perform such closures, alterations, additions or changes in a commercially reasonable manner and, in connection therewith, shall use commercially reasonable efforts to minimize any material interference with Tenant&#8217;s use of and access to the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-5-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rentable Square Feet of Premises</b>. &#160;For purposes of this Lease, &#8220;rentable square feet&#8221; of the Premises shall be as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.2</u> of the Summary, which shall not be subject to remeasurement during the Lease Term. &#160;For purposes of this Lease, the &#8220;rentable square feet&#8221; of the Premises and the Building and the other buildings in the Project shall be calculated pursuant to the Standard Methods of Measurement for Industrial Buildings, ANSI Z65.2-2012, or any subsequent updated standard as may be used by Landlord <b style="font-weight:bold;">(</b>&#8220;<b style="font-weight:bold;">BOMA</b>&#8221;), as modified for the Project pursuant to Landlord&#8217;s standard rental area measurements for the Project, to include, among other calculations, a portion of the Common Areas and service areas of the Building and other buildings in the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">LEASE TERM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lease Term</b>. &#160;The terms and provisions of this Lease shall be effective as of the date of this Lease. The term of this Lease (the &#8220;<b style="font-weight:bold;">Lease Term</b>&#8221;) shall be as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.1</u> of the Summary, shall commence on the date set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.2</u> of the Summary (the &#8220;<b style="font-weight:bold;">Lease Commencement Date</b>&#8221;), and shall terminate on the date set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.4</u> of the Summary (the &#8220;<b style="font-weight:bold;">Lease Expiration Date</b>&#8221;) unless this Lease is sooner terminated as hereinafter provided. &#160;For purposes of this Lease, the term &#8220;<b style="font-weight:bold;">Lease Year</b>&#8221; shall mean the consecutive twelve (12) month period following and including the Rent Commencement Date and each subsequent twelve (12) month period during the Lease Term. &#160;At any time during the Lease Term, Landlord may deliver to Tenant a factually correct notice in the form as set forth in <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;2.1</b> attached hereto, as a confirmation only of the information set forth therein, which Tenant shall execute and return to Landlord within ten (10) business days of receipt thereof, but execution of such instrument shall not be a condition to Lease commencement or Tenant&#8217;s obligations hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">BASE RENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment of Rent</b>. &#160;Tenant shall pay, without prior notice or demand, in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.1</u> of the Summary or at such place as Landlord may from time to time designate in writing, by a check for currency which, at the time of payment, is legal tender for private or public debts in the United States of America or pursuant to wire or electronic payment instructions provided by Landlord, base rent (&#8220;<b style="font-weight:bold;">Base Rent</b>&#8221;) as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</u> of the Summary, payable in equal monthly installments as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4</u> of the Summary, &#160;in advance, on or before the first day of each and every calendar month during the Lease Term, without any setoff or deduction whatsoever. &#160;Base Rent for the first full month of the Lease Term shall be paid at the time of Tenant&#8217;s execution of this Lease. &#160;If any Rent payment date (including the Rent Commencement Date) falls on a day of the month other than the first day of such month or if any payment of Rent is for a period which is shorter than one month, the Rent for any fractional month shall accrue on a daily basis for the period from the date such payment is due to the end of such calendar month or to the end of the Lease Term at a rate per day which is equal to 1/365 of the applicable annual Rent. &#160;All other payments or adjustments required to be made under the terms of this Lease that require proration on a time basis shall be prorated on the same basis. &#160;Base Rent and Additional Rent shall together be denominated &#8220;<b style="font-weight:bold;">Rent</b>&#8221;. Without limiting the foregoing, Tenant&#8217;s obligation to pay Rent shall be absolute, unconditional and independent of any Landlord covenants and shall not be discharged or otherwise affected by any law or regulation now or hereafter applicable to the Premises, or any other restriction on Tenant&#8217;s use, or (except as expressly provided herein) any casualty or taking, or any failure by Landlord to perform any covenant contained herein (except as expressly provided herein), or any other occurrence; and Tenant assumes the risk of the foregoing and waives all rights now or hereafter existing to terminate or cancel this Lease or quit or surrender the Premises or any part thereof, or to assert any defense in the nature of constructive eviction or to any action seeking to recover rent. &#160;Tenant&#8217;s covenants contained herein are independent and not dependent, and Tenant hereby waives the benefit of any statute or judicial law to the contrary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rents from Real Property</b>. &#160;Landlord and Tenant hereby agree that it is their intent that all Base Rent, Additional Rent and other rent and charges payable to the Landlord under this Lease (hereinafter individually and collectively referred to as &#8220;<b style="font-weight:bold;">Rent</b>&#8221;) shall qualify as &#8220;rents from real property&#8221; within the meaning of Section 856(d) of the Internal Revenue Code of 1986, as amended (the &#8220;<b style="font-weight:bold;">Code</b>&#8221;), and the Department of the U.S. Treasury Regulations promulgated thereunder (the &#8220;<b style="font-weight:bold;">Regulations</b>&#8221;). &#160;Should the Code or the Regulations, or interpretations thereof by the Internal Revenue Service contained in revenue rulings or other similar public pronouncements, be changed so that any Rent no longer so qualifies as &#8220;rent from real property&#8221; for purposes of Section 856(d) of the Code and the Regulations promulgated thereunder, the manner of payment of such Rent shall be adjusted in such manner as the Landlord may require so that it will so qualify; provided, however, that any adjustments required pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.2</u> shall be made so as to produce the equivalent (in economic terms) Rent as payable prior to such adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-6-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">ADDITIONAL RENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Terms</b>. &#160;In addition to paying the Base Rent specified in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 3</u> of this Lease, Tenant shall pay &#8220;<b style="font-weight:bold;">Tenant&#8217;s Share</b>&#8221; of the annual &#8220;<b style="font-weight:bold;">Direct Expenses</b>&#8221; as those terms are defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 4.2.6</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.2.2</u> of this Lease, respectively. &#160;Such payments by Tenant, together with any and all other amounts payable by Tenant to Landlord pursuant to the terms of this Lease other than Base Rent, are hereinafter collectively referred to as the &#8220;<b style="font-weight:bold;">Additional Rent</b>&#8221;. &#160;All amounts due under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 4</u> as Additional Rent shall be payable for the same periods and in the same manner as the Base Rent. &#160;Without limitation on other obligations of Tenant which survive the expiration of the Lease Term, the obligations of Tenant to pay the Additional Rent provided for in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 4</u> shall survive the expiration of the Lease Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions of Key Terms Relating to Additional Rent</b>. &#160;As used in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;4</u>, the following terms shall have the meanings hereinafter set forth:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2.1</font></font>Intentionally Omitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2.2</font></font>&#8220;<b style="font-weight:bold;">Direct Expenses</b>&#8221; shall mean &#8220;<b style="font-weight:bold;">Operating Expenses</b>&#8221; and &#8220;<b style="font-weight:bold;">Tax Expenses</b>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2.3</font></font>&#8220;<b style="font-weight:bold;">Expense Year</b>&#8221; shall mean each calendar year in which any portion of the Lease Term falls, through and including the calendar year in which the Lease Term expires, provided that Landlord, upon notice to Tenant, may change the Expense Year from time to time to any other twelve (12) consecutive month period, and, in the event of any such change, Tenant&#8217;s Share of Direct Expenses shall be equitably adjusted for any Expense Year involved in any such change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2.4</font></font>&#8220;<b style="font-weight:bold;">Operating Expenses</b>&#8221; shall mean all reasonable expenses, costs and amounts of every kind and nature which Landlord pays or accrues during any Expense Year because of or in connection with the ownership, management, maintenance, security, repair, replacement, restoration or operation of (i) the Project or any portion thereof, and (ii) the amenities within the SOVA Science District (including, without limitation, market rent for the fitness and conference centers) to which Tenant enjoys a right to use in common with other tenants of buildings within the SOVA Science District. &#160;Without limiting the generality of the foregoing, Operating Expenses shall specifically include any and all of the following: &#160;(i) the cost of supplying all utilities to the Common Areas, the cost of operating, repairing, maintaining, and renovating the utility, telephone, mechanical, sanitary, storm drainage, and elevator systems, and the cost of maintenance and service contracts in connection therewith; (ii) the cost of licenses, certificates, permits and inspections and the cost of contesting any governmental enactments which may affect Operating Expenses, and the costs incurred in connection with any federal, state or municipal governmentally mandated transportation demand management program or similar program; (iii) the cost of all insurance carried by Landlord in connection with the Project; (iv) the cost of landscaping, re-lamping, and all supplies, tools, equipment and materials used in the operation, repair and maintenance of the Project, or any portion thereof; (v) the cost of parking area operation, repair, restoration, and maintenance; (vi) fees and other costs, including reasonable consulting fees, legal fees, accounting fees, and contractor fees, in connection with the management, operation, maintenance and repair of the Project; (vii) payments under any equipment rental agreements and the fair rental value of any management office space; (viii) subject to item (f), below, wages, salaries and other compensation and benefits, including taxes levied thereon, of all persons engaged in the operation, maintenance and security of the Project; (ix) intentionally omitted; (x) operation, repair, maintenance and replacement of all systems and equipment and components thereof of the Project; (xi) the cost of janitorial, alarm, security and other services, replacement of wall and floor coverings, ceiling tiles and fixtures in Common Areas, maintenance and replacement of curbs and walkways, repair to roofs and re-roofing; (xii) amortization (including reasonable interest on the unamortized cost) over the useful life of such item as reasonably determined by Landlord, of the cost of acquiring or the rental expense of personal property used in the maintenance, operation and repair of the Project, or any portion thereof; (xiii) the cost of capital improvements or other costs incurred in connection with the Project (A) which are intended to reduce expenses in the operation or maintenance of the Project, or any portion thereof, or to reduce current or future Operating Expenses or to enhance the safety or security of the Project or its occupants, (B) that are required to comply with present or anticipated mandatory energy conservation programs, (C) which are replacements or modifications of nonstructural items located in the Common Areas required to keep the Common Areas in the same good order or condition as on the Lease Commencement Date, or (D) that are required under any federal, state or municipal governmental law or regulation that was enacted after the Lease Commencement Date; provided, however, that the costs of any capital improvement shall be amortized (including reasonable interest on the amortized cost as reasonably determined by</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-7-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Landlord) over the useful life of such items as reasonably determined by Landlord; and (xiv) costs, fees, charges or assessments imposed by, or resulting from any mandate imposed on Landlord by, any federal, state or municipal government for fire and police protection, trash removal, community services, or other services which do not constitute &#8220;Tax Expenses&#8221; as that term is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2.5</u> below, (xv)&#160;cost of tenant relation programs reasonably established by Landlord, and (xvi)&#160;payments under any easement, license, operating agreement, declaration, restrictive covenant, or instrument pertaining to the sharing of costs by the Building, including, without limitation, any covenants, conditions, restrictions, and reciprocal easement agreements affecting the Project, and any agreements with governmental agencies affecting the Project (any of the foregoing that now or hereafter affect the Property, collectively, the &#8220;<b style="font-weight:bold;">Underlying Documents</b>&#8221;); provided, however, that as of the date of this Lease there are no Underlying Documents. In the event that Landlord or Landlord&#8217;s managers or agents perform services for the benefit of the Building off-site which would otherwise be performed on-site (e.g., accounting), the cost of such services shall be reasonably allocated among the properties benefitting from such service and shall be included in Operating Expenses. Notwithstanding the foregoing, for purposes of this Lease, Operating Expenses shall not, however, include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>costs, including legal fees, space planners&#8217; fees, advertising and promotional expenses, and brokerage fees incurred in connection with the original construction or development, or original, current, or future leasing of the Project, and costs, including permit, license and inspection costs, incurred with respect to the installation of tenant improvements made for tenants or incurred in renovating or otherwise improving, decorating, painting or redecorating vacant space for tenants of the Project (excluding, however, such costs relating to any common areas of the Project);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>except as set forth in items (xii), (xiii) and (xiv) above, depreciation, interest and principal payments on mortgages and other debt costs, if any, penalties and interest, and costs of capital improvements (as distinguished from repairs or replacements);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>costs for which Landlord is reimbursed by or otherwise due from any tenant or occupant of the Project (other than as Direct Expenses) or by insurance by its carrier or any tenant&#8217;s carrier or by anyone else, and electric power costs for which any tenant directly contracts with the local public service company;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(d)<font style="display:inline-block;width:24.34pt;"></font>any bad debt loss, rent loss, or reserves for bad debts or rent loss;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(e)<font style="display:inline-block;width:24.9pt;"></font>costs associated with the operation of the business of the partnership or entity which constitutes Landlord, as the same are distinguished from the costs of operation of the Project (which shall specifically include, but not be limited to, accounting costs associated with the operation of the Project). Costs associated with the operation of the business of the partnership or entity which constitutes Landlord include costs of partnership accounting and legal matters, costs of defending any lawsuits with any mortgagee (except as the actions of Tenant may be in issue), costs of selling, syndicating, financing, mortgaging or hypothecating any of Landlord&#8217;s interest in the Project, and costs incurred in connection with any disputes between Landlord and its employees, between Landlord and Project management, or between Landlord and other tenants or occupants;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(f)<font style="display:inline-block;width:26.01pt;"></font>the wages and benefits of any employee who does not devote substantially all of his or her employed time to the Project unless such wages and benefits are prorated to reflect time spent on operating and managing the Project vis-a-vis time spent on matters unrelated to operating and managing the Project; provided, that in no event shall Operating Expenses for purposes of this Lease include wages and/or benefits attributable to personnel above the level of Project manager;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(g)<font style="display:inline-block;width:24.34pt;"></font>amount paid as ground rental for the Project by Landlord;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(h)<font style="display:inline-block;width:24.34pt;"></font>except for a property management fee, overhead and profit increment paid to Landlord or to subsidiaries or affiliates of Landlord for services in the Project to the extent the same exceeds the costs of such services rendered by qualified, first-class unaffiliated third parties on a competitive basis;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>any compensation paid to clerks, attendants or other persons in commercial concessions operated by Landlord; provided that any reasonable compensation paid to any concierge at the Project shall be includable as an Operating Expense;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-8-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(j)<font style="display:inline-block;width:26.56pt;"></font>all items and services for which Tenant or any other tenant in the Project reimburses Landlord (other than as Direct Expenses) or which Landlord provides selectively to one or more tenants (other than Tenant) without reimbursement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(k)<font style="display:inline-block;width:24.34pt;"></font>rent for any office space occupied by Project management personnel to the extent the size or rental rate of such office space exceeds the size or fair market rental value of office space occupied by management personnel of comparable buildings in the vicinity of the Building, with adjustment where appropriate for the size of the applicable project;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(l)<font style="display:inline-block;width:26.56pt;"></font>costs incurred to comply with laws relating to the removal of Hazardous Materials (excluding construction materials that were legally permissible when used and are not known to Landlord as of the date of this Lease as requiring removal);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(m)<font style="display:inline-block;width:21.56pt;"></font>Landlord&#8217;s general overhead expenses not related to the Project;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(n)<font style="display:inline-block;width:24.34pt;"></font>any costs expressly excluded from Operating Expenses elsewhere in this Lease;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(o)<font style="display:inline-block;width:24.34pt;"></font>legal fees, accountants&#8217; fees (other than normal bookkeeping expenses) and other expenses incurred in connection with disputes of tenants or other occupants of the Project or associated with the enforcement of the terms of any leases with tenants or the defense of Landlord&#8217;s title to or interest in the Project or any part thereof; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(p)<font style="display:inline-block;width:24.34pt;"></font>any reserve funds;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">If Landlord is not furnishing any particular work of services (the cost of which, if performed by Landlord would be included in Operating Expenses) to a tenant who has undertaken to perform such work or service in lieu of the performance thereof by Landlord, Operating Expenses shall be deemed to be increased by an amount equal to the additional Operating Expenses which would reasonably have been incurred during such period by Landlord if it had at its own expense furnished such work or service to such tenant. &#160;If the Project is not at least one hundred percent (100%) occupied during all or a portion of any Expense Year, Landlord shall make an appropriate adjustment to the components of Operating Expenses for such year to determine the amount of Operating Expenses that would have been incurred had the Project been one hundred percent (100%) occupied (provided, however, in no event shall Landlord make a profit pursuant to the foregoing); and the amount so determined shall be deemed to have been the amount of Operating Expenses for such year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2.5</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">4.2.5.1<font style="display:inline-block;width:8.5pt;"></font>&#8220;<b style="font-weight:bold;">Tax Expenses</b>&#8221; shall mean all federal, state, county, or local governmental or municipal taxes, fees, charges or other impositions of every kind and nature, whether general, special, ordinary or extraordinary (including, without limitation, real estate taxes, general and special assessments, transit taxes, payments in lieu of taxes, business improvement district charges, leasehold taxes or taxes based upon the receipt of rent, including gross receipts or sales taxes applicable to the receipt of rent, unless required to be paid by Tenant, personal property taxes imposed upon the fixtures, machinery, equipment, apparatus, systems and equipment, appurtenances, furniture and other personal property used in connection with the Project, or any portion thereof), which shall be paid or accrued during any Expense Year (without regard to any different fiscal year used by such governmental or municipal authority) because of or in connection with the ownership, leasing and operation of the Project, or any portion thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">4.2.5.2<font style="display:inline-block;width:8.5pt;"></font>Tax Expenses shall include, without limitation: &#160;(i) Any tax on the rent, right to rent or other income from the Project, or any portion thereof, or as against the business of leasing the Project, or any portion thereof; (ii) any assessment, tax, fee, levy or charge in addition to, or in substitution, partially or totally, of any assessment, tax, fee, levy or charge previously included within the definition of real property tax, it being acknowledged by Tenant and Landlord that Proposition 13 was adopted by the voters of the State of California in the June 1978 election (&#8220;<b style="font-weight:bold;">Proposition 13</b>&#8221;) and that assessments, taxes, fees, levies and charges may be imposed by governmental agencies for such services as fire protection, street, sidewalk and road maintenance, refuse removal and for other governmental services formerly provided without charge to property owners or occupants, and, in further recognition of the decrease in the level and quality of governmental services and amenities as a result of Proposition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-9-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">13, Tax Expenses shall also include any governmental or private assessments or the Project&#39;s contribution towards a governmental or private cost-sharing agreement for the purpose of augmenting or improving the quality of services and amenities normally provided by governmental agencies (provided that there are no such cost-sharing agreements as of the date of this Lease), and it being further acknowledged that the voters of the State of California may amend, modify, repeal or reject Proposition 13 during the Lease Term resulting in increases in real property taxes assessed or levied against the Project, (iii) any assessment, tax, fee, levy, or charge allocable to or measured by the area of the Premises or the Rent payable hereunder, including, without limitation, any business or gross income tax or excise tax with respect to the receipt of such rent, or upon or with respect to the possession, leasing, operating, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises, or any portion thereof; and (iv) any assessment, tax, fee, levy or charge, upon this transaction or any document to which Tenant is a party, creating or transferring an interest or an estate in the Premises or the improvements thereon. &#160;If at any time during the Lease Term there shall be assessed on Landlord, in addition to or lieu of the whole or any part of the ad valorem tax on real or personal property, a capital levy or other tax on the gross rents or other measures of building operations, or a governmental income, franchise, excise or similar tax, assessment, levy, charge or fee measured by or based, in whole or in part, upon building valuation, gross rents or other measures of building operations or benefits of governmental services furnished to the Building, then any and all of such taxes, assessments, levies, charges and fees, to the extent so measured or based, shall be included within the term Tax Expenses, but only to the extent that the same would be payable if the Building and Land were the only property of Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">4.2.5.3<font style="display:inline-block;width:8.5pt;"></font>Any costs and expenses (including, without limitation, reasonable attorneys&#8217; and consultants&#8217; fees) incurred in attempting to protest, reduce or minimize Tax Expenses shall be included in Tax Expenses in the Expense Year such expenses are incurred. &#160;Tax refunds shall be credited against Tax Expenses and refunded to Tenant regardless of when received, based on the Expense Year to which the refund is applicable, provided that in no event shall the amount to be refunded to Tenant for any such Expense Year exceed the total amount paid by Tenant as on account of Tax Expenses under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 4</u> for such Expense Year. &#160;The foregoing sentence shall survive the expiration or earlier termination of this Lease. &#160;If Tax Expenses for any period during the Lease Term or any extension thereof are increased after payment thereof for any reason, including, without limitation, error or reassessment by applicable governmental or municipal authorities, Tenant shall pay Landlord upon demand Tenant&#8217;s Share of any such increased Tax Expenses. &#160;Notwithstanding anything to the contrary contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2.5</u>, there shall be excluded from Tax Expenses (i) all excess profits taxes, franchise taxes, gift taxes, capital stock taxes, inheritance and succession taxes, estate taxes, transfer tax or fee, federal and state income taxes, and other taxes to the extent applicable to Landlord&#8217;s general or net income (as opposed to rents, receipts or income attributable to operations at the Project), (ii) any items included as Operating Expenses, and (iii) any items paid by Tenant under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.5</u> of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2.6</font></font>&#8220;<b style="font-weight:bold;">Tenant&#8217;s Share</b>&#8221; is based upon the following, as applicable: (i)&#160;for the Building, the ratio that the rentable square feet of the Premises bears to the rentable square feet of the Building (i.e., 11,383 &#247; 21,142), and (ii)&#160;for the Project, the ratio that the rentable square feet of the Premises bears to the rentable square feet of the Project (i.e., 11,383 &#247; 59,818); provided, however, during Tenant&#8217;s occupancy of the Interim Premises only, for the Building, the ratio that the rentable square feet of the Interim Premises bears to the rentable square feet of the Building (i.e., 6,374 &#247; &#160;21,142), and for the Project, the ratio that the rentable square feet of the Interim Premises bears to the rentable square feet of the Project (i.e., 6,374 &#247; 59,818), as applicable. &#160;Tenant&#8217;s Share shall mean the applicable percentages set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;7</u> of the Summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation of Direct Expenses</b>. &#160;The parties acknowledge that the Building is a part of a multi-building project and that the costs and expenses incurred in connection with the Project (i.e., the Direct Expenses) should be shared among the tenants of the Building and the tenants of the other buildings in the Project. &#160;Accordingly, as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2</u> above, Direct Expenses (which consist of Operating Expenses and Tax Expenses) are determined annually for the Project as a whole, and a portion of the Direct Expenses, which portion shall be determined by Landlord on an equitable basis, shall be allocated to the tenants of the Building (as opposed to the tenants of any other buildings in the Project). &#160;Such portion of Direct Expenses allocated to the tenants of the Building shall include all Direct Expenses attributable solely to the Building and an equitable portion of the Direct Expenses attributable to the Project as a whole, provided that the Direct Expenses attributable to the Project as a whole shall not include Direct Expenses attributable solely to the Building. &#160;Further, Landlord shall have the right, from time to time, to allocate equitably some or all of the Direct Expenses for the Building or the Project among different portions or occupants of the Building or Project, in Landlord&#8217;s reasonable discretion, in a manner reflecting commercially reasonable cost pools</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-10-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">for such Direct Expenses so allocated. The Direct Expenses within each cost pool shall be allocated and charged to the tenants within such cost pool in an equitable manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Calculation and Payment of Additional Rent</b>. &#160;Tenant shall pay to Landlord, in the manner set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.4.1</u> below, and as Additional Rent, Tenant&#8217;s Share of Direct Expenses for each Expense Year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Statement of Actual Direct Expenses and Payment by Tenant</b>. &#160;Landlord shall endeavor to give to Tenant within six (6) months following the end of each Expense Year, a statement (the &#8220;<b style="font-weight:bold;">Statement</b>&#8221;) which shall state the Direct Expenses incurred or accrued for such preceding Expense Year, and which shall indicate the amount of Tenant&#8217;s Share of Direct Expenses. &#160;Upon receipt of the Statement for each Expense Year commencing or ending during the Lease Term, Tenant shall pay, with its next installment of Base Rent due, the full amount of Tenant&#8217;s Share of Direct Expenses for such Expense Year, less the amounts, if any, paid during such Expense Year as &#8220;<b style="font-weight:bold;">Estimated Direct Expenses</b>&#8221;, as that term is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.4.2</u>, below, and if Tenant paid more as Estimated Direct Expenses than the actual Tenant&#8217;s Share of Direct Expenses, Tenant shall receive a credit in the amount of Tenant&#8217;s overpayment against Rent next due under this Lease or, if Landlord elects, Landlord shall reimburse such overpayment amount to Tenant. &#160;The failure of Landlord to timely furnish the Statement for any Expense Year shall not prejudice Landlord or Tenant from enforcing its rights under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 4</u>. &#160;Even though the Lease Term has expired and Tenant has vacated the Premises, when the final determination is made of Tenant&#8217;s Share of Direct Expenses for the Expense Year in which this Lease terminates, Tenant shall pay to Landlord such amount within thirty (30) days, and if Tenant paid more as Estimated Direct Expenses than the actual Tenant&#8217;s Share of Direct Expenses, Landlord shall, within thirty (30) days, pay to Tenant the amount of the overpayment. &#160;The provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.4.1</u> shall survive the expiration or earlier termination of the Lease Term for twelve (12) months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Statement of Estimated Direct Expenses</b>. &#160;In addition, Landlord shall endeavor to give Tenant a yearly expense estimate statement (the &#8220;<b style="font-weight:bold;">Estimate Statement</b>&#8221;) which shall set forth Landlord&#8217;s reasonable estimate (the &#8220;<b style="font-weight:bold;">Estimate</b>&#8221;) of what the total amount of Direct Expenses for the then-current Expense Year shall be and the estimated Tenant&#8217;s Share of Direct Expenses (the &#8220;<b style="font-weight:bold;">Estimated Direct Expenses</b>&#8221;). &#160;The failure of Landlord to timely furnish the Estimate Statement for any Expense Year shall not preclude Landlord from enforcing its rights to collect any Estimated Direct Expenses under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 4</u>, nor shall Landlord be prohibited from revising any Estimate Statement or Estimated Direct Expenses theretofore delivered to the extent necessary. &#160;Thereafter, Tenant shall pay, with its next installment of Base Rent due, a fraction of the Estimated Direct Expenses for the then-current Expense Year (reduced by any amounts paid pursuant to the last sentence of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.4.2</u>). &#160;Such fraction shall have as its numerator the number of months which have elapsed in such current Expense Year, including the month of such payment, and twelve (12) as its denominator. &#160;Until a new Estimate Statement is furnished (which Landlord shall have the right to deliver to Tenant at any time), Tenant shall pay monthly, with the monthly Base Rent installments, an amount equal to one-twelfth (1/12) of the total Estimated Direct Expenses set forth in the previous Estimate Statement delivered by Landlord to Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.4.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audit Right</b><b style="font-weight:bold;">. &#160;</b>Tenant may, within sixty (60) days after receiving a Statement, give Landlord written notice (&#8220;<b style="font-weight:bold;">Review Notice</b>&#8221;) that Tenant intends to review Landlord&#8217;s records of the Direct Expenses for that calendar year. &#160;Within thirty (30) days after receipt of the Review Notice, Landlord shall make all pertinent records available for inspection that are reasonably necessary for Tenant to conduct its review; the review will be conducted at Landlord&#8217;s Southern California property manager&#8217;s office located in the greater San Diego area during normal business hours. &#160;If Tenant retains an agent to review Landlord&#8217;s records, the agent must be with an independent firm of licensed certified public accountants (i) reasonably acceptable to Landlord, (ii) which is not compensated on a contingency fee basis or in any other manner which is dependent upon the results of such audit or inspection (and Tenant shall certify same upon request), and (iii) which agrees with Landlord in writing to keep the results of such audit or inspection confidential (except under customary circumstances, such as litigation between Landlord and Tenant regarding such audit). &#160;Tenant shall be solely responsible for all costs, expenses and fees incurred for the audit. &#160;Within sixty (60) days after the records are made available to Tenant, Tenant shall have the right to give Landlord written notice (an &#8220;<b style="font-weight:bold;">Expense Objection Notice</b>&#8221;) stating in reasonable detail any objection to Landlord&#8217;s statement of Direct Expenses for that period. &#160;If Tenant fails to give Landlord an Expense Objection Notice within the 60-day period or fails to provide Landlord with a Review Notice within the 60-day period described above, Tenant shall be deemed to have approved Landlord&#8217;s statement of Direct Expenses and shall be barred from raising any claims regarding the Direct Expenses for that year. &#160;If Tenant provides Landlord with a timely Expense Objection Notice, Landlord and Tenant shall work together in good faith to resolve any issues raised in Tenant&#8217;s Expense Objection</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-11-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Notice. If Landlord and Tenant determine that Direct Expenses for the calendar year are less than reported, Landlord shall provide Tenant with a credit against the next installment of Rent in the amount of the overpayment by Tenant. &#160;Likewise, if Landlord and Tenant determine that Expenses for the calendar year are greater than reported, Tenant shall pay Landlord the amount of any underpayment within 30 days. &#160;If such finding occurs after the expiration of the Term, Tenant shall pay the underpayment within 30 days of receipt of invoice from Landlord. &#160;The records obtained or viewed by Tenant or its auditors and agents shall be treated as confidential. &#160;If Landlord has overcharged Tenant for Direct Expenses by more than five percent (5%), then Landlord shall be responsible for all of Tenant&#8217;s reasonable costs related to Tenant&#8217;s review of Direct Expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.5</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes and Other Charges for Which Tenant Is Directly Responsible</b>. &#160;Tenant shall be liable for and shall pay ten (10) days before delinquency, taxes levied against Tenant&#8217;s equipment, furniture, fixtures and any other personal property located in or about the Premises. &#160;If any such taxes on Tenant&#8217;s equipment, furniture, fixtures and any other personal property are levied against Landlord or Landlord&#8217;s property or if the assessed value of Landlord&#8217;s property is increased by the inclusion therein of a value placed upon such equipment, furniture, fixtures or any other personal property and if Landlord pays the taxes based upon such increased assessment, which Landlord shall have the right to do regardless of the validity thereof but only under proper protest if requested by Tenant, Tenant shall upon demand (together with reasonable back-up evidencing the same) repay to Landlord the taxes so levied against Landlord or the proportion of such taxes resulting from such increase in the assessment, as the case may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-weight:bold;">USE OF PREMISES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Use</b>. &#160;Tenant shall use the Premises solely for the Permitted Use set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8</u> of the Summary and Tenant shall not use or permit the Premises or the Project to be used for any other purpose or purposes whatsoever.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prohibited Uses</b>. &#160;Tenant further covenants and agrees that Tenant shall not use, or suffer or permit any person or persons claiming by, through, or under Tenant to use, the Premises or any part thereof for any use or purpose contrary to the provisions of the Rules and Regulations attached hereto as <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 5.2</b>, as the same may be amended by Landlord from time to time (the &#8220;<b style="font-weight:bold;">Rules and Regulations</b>&#8221;), or in violation of Applicable Laws or any Underlying Documents. &#160;Tenant shall not do or permit anything to be done in or about the Premises which will in any way damage the reputation of the Project or obstruct or interfere with the rights of other tenants or occupants of the Building, or injure or annoy them or use or allow the Premises to be used for any improper, unlawful or objectionable purpose, nor shall Tenant cause, maintain or permit any nuisance in, on or about the Premises. &#160;Tenant shall comply with, and Tenant&#8217;s rights and obligations under the Lease and Tenant&#8217;s use of the Premises shall be subject and subordinate to, all Underlying Documents. &#160;Tenant shall only place equipment within the Premises with floor loading consistent with the Building&#39;s structural design (so long as Landlord has provided such information to Tenant), and such equipment shall be placed in a location designed to carry the weight of such equipment. &#160;Tenant shall cause any equipment or machinery to be installed in the Premises so as to reasonably prevent sounds or vibrations therefrom from extending into the Common Areas or other offices in the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hazardous Materials</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Obligations</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">5.3.1.1<font style="display:inline-block;width:8.5pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prohibitions</b>. &#160;As a material inducement to Landlord to enter into this Lease with Tenant, Tenant has fully and accurately completed Landlord&#8217;s Pre-Leasing Environmental Exposure Questionnaire (the &#8220;<b style="font-weight:bold;">Environmental Questionnaire</b>&#8221;), which is attached as <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 5.3.1.1</b>. &#160;Tenant hereby represents, warrants and covenants that except for those chemicals or materials, and their respective quantities, specifically listed on the Environmental Questionnaire, neither Tenant nor Tenant&#8217;s subtenants or assigns, or any of their respective employees, contractors and subcontractors of any tier, entities with a contractual relationship with such parties (other than Landlord), or any entity acting as an agent or sub-agent of such parties or any of the foregoing (collectively, &#8220;<b style="font-weight:bold;">Tenant Parties</b>&#8221;) will produce, use, store or generate any &#8220;Hazardous Materials&#8221;, as that term is defined below, on, under or about the Premises, nor cause or permit any Hazardous Material to be brought upon, placed, stored, manufactured, generated, blended, handled, recycled, used or &#8220;Released&#8221;, as that term is defined below, on, in, under or about the Premises or Project, excepting typical office cleaning supplies in limited quantities. &#160;Landlord shall not unreasonably withhold or delay consent in connection with Tenant&#8217;s need from time to time to use Hazardous Materials as reasonably required for Tenant&#8217;s current or future operations provided such Hazardous Materials are commonly used</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-12-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">by life science lessees within San Diego County and do not involve work above the risk category Biosafety Level 2 as established by DHHS &#160;and as further described in the DHHS publication BMBL (as defined in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3.1.1</u> below), unless approved in writing by Landlord in connection with Landlord&#8217;s review and approval of the Environmental Questionnaire as completed by Tenant.. &#160;If any information provided to Landlord by Tenant on the Environmental Questionnaire, or otherwise relating to information concerning Hazardous Materials is false, incomplete, or misleading in any material respect, then provided Tenant does not provide a corrected Environmental Questionnaire within ten (10) days after request, the same shall be deemed a default by Tenant under this Lease. Upon Landlord&#8217;s request, or in the event of any material change in Tenant&#8217;s use of Hazardous Materials at the Premises, Tenant shall deliver to Landlord an updated Environmental Questionnaire. &#160;Landlord&#8217;s prior written consent shall be required for any Hazardous Materials use for the Premises not described on the initial Environmental Questionnaire, such consent not to be unreasonably withheld, conditioned or delayed, and Landlord agrees not to withhold consent unless the proposed Hazardous Materials might pose a material risk or threat to the safety of persons or property within the Premises (or Building) despite Tenant&#8217;s implementation of mitigation measures. &#160;Tenant&#8217;s use or storage of Hazardous Materials within the Premises shall be done so in accordance with Applicable Laws. &#160;Tenant shall not install or permit any underground storage tank on the Premises. &#160;In addition, Tenant agrees that it: (i)&#160;shall not cause or suffer to occur, the Release (as defined below) of any Hazardous Materials at, upon, under or within the Premises or any contiguous or adjacent premises; and (ii)&#160;shall not engage in activities at the Premises that give rise to, or lead to the imposition of, liability upon Tenant or Landlord or the creation of an environmental lien or use restriction upon the Premises. &#160;For purposes of this Lease, &#8220;<b style="font-weight:bold;">Hazardous Materials</b>&#8221; means all flammable explosives, petroleum and petroleum products, oil, radon, radioactive materials, toxic pollutants, asbestos, polychlorinated biphenyls (&#8220;<b style="font-weight:bold;">PCBs</b>&#8221;), medical waste, chemicals known to cause cancer or reproductive toxicity, pollutants, contaminants, hazardous wastes, toxic substances or related materials, including without limitation any chemical, element, compound, mixture, solution, substance, object, waste or any combination thereof, which is or may hereafter be determined to be hazardous to human health, safety or to the environment due to its radioactivity, ignitability, corrosiveness, reactivity, explosiveness, toxicity, carcinogenicity, infectiousness or other harmful or potentially harmful properties or effects, or defined as, regulated as or included in, the definition of &#8220;hazardous substances&#8221;, &#8220;hazardous wastes&#8221;, &#8220;hazardous materials&#8221;, or &#8220;toxic substances&#8221; under any Environmental Laws. &#160;The term &#8220;Hazardous Materials&#8221; for purposes of this Lease shall also include any mold, fungus or spores, whether or not the same is defined, listed, or otherwise classified as a &#8220;hazardous material&#8221; under any Environmental Laws, if such mold, fungus or spores may pose a risk to human health or the environment or negatively impact the value of the Premises. &#160;Hazardous Materials shall also include any &#8220;biohazardous waste,&#8221; &#8220;medical waste,&#8221; or other waste under California Health and Safety Code Division 20, Chapter 6.1 (Medical Waste Management Act). &#160;For purposes of this Lease, &#8220;<b style="font-weight:bold;">Release</b>&#8221; or &#8220;<b style="font-weight:bold;">Released</b>&#8221; or &#8220;<b style="font-weight:bold;">Releases</b>&#8221; shall mean any release, deposit, discharge, emission, leaking, spilling, seeping, migrating, injecting, pumping, pouring, emptying, escaping, dumping, disposing, or other movement of Hazardous Materials into the environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Any use or storage of Hazardous materials by Tenant permitted pursuant to this Article 5 shall not exceed Tenant&#8217;s proportionate share (measured on a per floor basis) of similarly classed Hazardous Materials. &#160;Notwithstanding anything contained herein to the contrary, in no event shall Tenant or anyone claiming by through or under Tenant perform work above the risk category Biosafety Level 2 as established by the Department of Health and Human Services (&#8220;<b style="font-weight:bold;">DHHS</b>&#8221;) and as further described in the DHHS publication Biosafety in Microbiological and Biomedical Laboratories (5<sup style="font-size:7.5pt;vertical-align:top;">th</sup> Edition) (as it may be or may have been further revised, the &#8220;<b style="font-weight:bold;">BMBL</b>&#8221;) or such nationally recognized new or replacement standards as Landlord may reasonable designate. Tenant shall comply with all applicable provisions of the standards of the BMBL to the extent applicable to Tenant&#8217;s operations in the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">5.3.1.2<font style="display:inline-block;width:8.5pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices to Landlord</b>. &#160;Unless Tenant is required by Applicable Laws to give earlier notice to Landlord, Tenant shall notify Landlord in writing as soon as possible but in no event later than five (5)&#160;days after (i)&#160;the occurrence of any actual, alleged or threatened Release by Tenant of any Hazardous Material in, on, under, from, about or in the vicinity of the Premises (whether past or present), regardless of the source or quantity of any such Release, or (ii)&#160;Tenant becomes aware of any regulatory actions, inquiries, inspections, investigations, directives, or any cleanup, compliance, enforcement or abatement proceedings (including any threatened or contemplated investigations or proceedings) relating to or potentially affecting the Premises, or (iii)&#160;Tenant becomes aware of any claims by any person or entity relating to any Hazardous Materials in, on, under, from, about or in the vicinity of the Premises, whether relating to damage, contribution, cost recovery, compensation, loss or injury. &#160;Collectively, the matters set forth in clauses&#160;(i), (ii) and (iii) above are hereinafter referred to as &#8220;<b style="font-weight:bold;">Hazardous Materials Claims</b>&#8221;. &#160;Tenant shall promptly forward to Landlord copies of all orders, notices, permits, applications and other</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-13-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">communications and reports in connection with any Hazardous Materials Claims. &#160;Additionally, Tenant shall promptly advise Landlord in writing of Tenant&#8217;s discovery of any occurrence or condition on, in, under or about the Premises that could subject Tenant or Landlord to any liability, or restrictions on ownership, occupancy, transferability or use of the Premises under any &#8220;Environmental Laws&#8221;, as that term is defined below. &#160;Tenant shall not enter into any legal proceeding or other action, settlement, consent decree or other compromise with respect to any Hazardous Materials Claims without first notifying Landlord of Tenant&#8217;s intention to do so and affording Landlord the opportunity to join and participate, as a party if Landlord so elects, in such proceedings and in no event shall Tenant enter into any agreements which are binding on Landlord or the Project without Landlord&#8217;s prior written consent. &#160;Landlord shall have the right to appear at and participate in, any and all legal or other administrative proceedings concerning any Hazardous Materials Claim. &#160;For purposes of this Lease, &#8220;<b style="font-weight:bold;">Environmental Laws</b>&#8221; means all applicable present and future laws relating to the protection of human health, safety, wildlife or the environment, including, without limitation, (i)&#160;all requirements pertaining to reporting, licensing, permitting, investigation and/or remediation of emissions, discharges, Releases, or threatened Releases of Hazardous Materials, whether solid, liquid, or gaseous in nature, into the air, surface water, groundwater, or land, or relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport, or handling of Hazardous Materials; and (ii)&#160;all requirements pertaining to the health and safety of employees or the public. &#160;Environmental Laws include, but are not limited to, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42&#160;USC &#167;&#160;9601, et seq., the Hazardous Materials Transportation Authorization Act of 1994, 49&#160;USC &#167;&#160;5101, et seq., the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976, and Hazardous and Solid Waste Amendments of 1984, 42&#160;USC &#167;&#160;6901, et seq., the Federal Water Pollution Control Act, as amended by the Clean Water Act of 1977, 33&#160;USC &#167;&#160;1251, et seq., the Clean Air Act of 1966, 42&#160;USC &#167;&#160;7401, et seq., the Toxic Substances Control Act of 1976, 15&#160;USC &#167;&#160;2601, et seq., the Safe Drinking Water Act of 1974, 42&#160;USC &#167;&#167;&#160;300f through 300j, the Occupational Safety and Health Act of 1970, as amended, 29&#160;USC &#167;&#160;651 et seq., the Oil Pollution Act of 1990, 33&#160;USC &#167;&#160;2701 et seq., the Emergency Planning and Community Right-To-Know Act of 1986, 42&#160;USC &#167;&#160;11001 et seq., the National Environmental Policy Act of 1969, 42&#160;USC &#167;&#160;4321 et seq., the Federal Insecticide, Fungicide and Rodenticide Act of 1947, 7&#160;USC &#167;&#160;136 et seq.; oil and hazardous materials as defined in any federal, state or local law, as such Applicable Laws, are in effect as of the Lease Commencement Date, or thereafter amended, adopted, published or promulgated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">5.3.1.3<font style="display:inline-block;width:8.5pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Releases of Hazardous Materials</b>. &#160;If any Release by Tenant or any Tenant Parties of any Hazardous Material occurs in, on, under, from or about the Premises in violation of, or requiring any Clean-Up (as defined below), in addition to notifying Landlord as specified above, Tenant, at its own sole cost and expense, shall (i)&#160;immediately comply with any and all reporting requirements imposed pursuant to any and all Environmental Laws, (ii)&#160;provide a written certification to Landlord indicating that Tenant has complied with all applicable reporting requirements, (iii)&#160;take any and all necessary investigation, corrective, remedial and other Clean-up action in accordance with any and all applicable Environmental Laws, utilizing an environmental consultant approved by Landlord, all in accordance with the provisions and requirements of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</u>, including, without limitation, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.3.4</u>, and (iv)&#160;take any such additional investigative, remedial and corrective actions as Landlord shall in its reasonable discretion deem necessary such that the Premises and Project are remediated to a condition as the Premises and Project were in on the Lease Commencement Date, all in accordance with the provisions and requirements of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</u>. &#160;Landlord may, as required by any and all Environmental Laws, report the Release of any Hazardous Material to the appropriate governmental authority, identifying Tenant as the responsible party. &#160;Tenant shall deliver to Landlord copies of all administrative orders, notices, demands, directives or other communications directed to Tenant from any governmental authority with respect to any Release of Hazardous Materials in, on, under, from, or about the Premises, together with copies of all investigation, assessment, and remediation plans and reports prepared by or on behalf of Tenant in response to any such regulatory order or directive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">5.3.1.4<font style="display:inline-block;width:8.5pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">5.3.1.4.1<font style="display:inline-block;width:15.4pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">In General &#8211; Tenant Indemnification of Landlord</b>. &#160;Without limiting in any way Tenant&#8217;s obligations under any other provision of this Lease, Tenant shall be solely responsible for and shall protect, defend, indemnify and hold the Landlord Parties harmless from and against any and all claims, judgments, losses, damages, costs, expenses, penalties, enforcement actions, taxes, fines, remedial actions, liabilities (including, without limitation, actual attorneys&#8217; fees, litigation, arbitration and administrative proceeding costs, expert and consultant fees and laboratory costs) including, without limitation, sums paid in settlement of claims, which arise during or after the Lease Term, whether foreseeable or unforeseeable, directly or indirectly arising out of or attributable to the presence, use, generation, manufacture, treatment, handling, refining, production, processing, storage, Release</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-14-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">or presence of Hazardous Materials in, on, under or about the Premises or Project by any Tenant Party, except to the extent such liabilities result from the negligence or willful misconduct of Landlord or any other tenant of the Project. &#160;The foregoing obligations of Tenant shall include, without limitation: &#160;(i)&#160;the costs of any required or necessary removal, repair, cleanup or remediation of the Premises and Project, and the preparation and implementation of any closure, removal, remedial or other required plans; (ii)&#160;judgments for personal injury or property damages; and (iii)&#160;all costs and expenses incurred by Landlord in connection therewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 10pt 0pt;">5.3.1.4.2<font style="display:inline-block;width:15.4pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitations</b>. &#160;Notwithstanding anything in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3.1.4</u> to the contrary, Tenant&#8217;s indemnity of Landlord shall not be applicable to claims based upon Existing Hazardous Materials except to the extent that Tenant&#8217;s negligent acts or omissions caused or exacerbated the subject claim. &#160;&#8220;<b style="font-weight:bold;">Existing Hazardous Materials</b>&#8221; shall mean Hazardous Materials located within the Project as of the date of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">5.3.1.5<font style="display:inline-block;width:8.5pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Environmental Laws</b>. &#160;Without limiting the generality of Tenant&#8217;s obligation to comply with Applicable Laws as otherwise provided in this Lease, Tenant shall, at its sole cost and expense, comply with all Environmental Laws. &#160;Tenant shall obtain and maintain any and all necessary permits, licenses, certifications and approvals appropriate or required for the use, handling, storage, and disposal of any Hazardous Materials used, stored, generated, transported, handled, blended, or recycled by Tenant on the Premises. &#160;Landlord shall have a continuing right, without obligation, to require Tenant to obtain, and to review and inspect any and all such permits, licenses, certifications and approvals, together with copies of any and all Hazardous Materials management plans and programs, any and all Hazardous Materials risk management and pollution prevention programs, and any and all Hazardous Materials emergency response and employee training programs respecting Tenant&#8217;s use of Hazardous Materials. &#160;Upon request of Landlord, Tenant shall deliver to Landlord a narrative description explaining the nature and scope of Tenant&#8217;s activities involving Hazardous Materials and showing to Landlord&#8217;s satisfaction compliance with all Environmental Laws and the terms of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assurance of Performance</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">5.3.2.1<font style="display:inline-block;width:8.5pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Assessments In General</b>. &#160;Landlord may, but shall not be required to, engage from time to time such contractors as Landlord determines to be appropriate to perform &#8220;Environmental Assessments&#8221;, as that term is defined below, to ensure Tenant&#8217;s compliance with the requirements of this Lease with respect to Hazardous Materials. &#160;For purposes of this Lease, &#8220;<b style="font-weight:bold;">Environmental Assessment</b>&#8221; means an assessment including, without limitation: &#160;(i)&#160;an environmental site assessment conducted in accordance with the then-current standards of the American Society for Testing and Materials and meeting the requirements for satisfying the &#8220;all appropriate inquiries&#8221; requirements; and (ii)&#160;sampling and testing of the Premises based upon potential recognized environmental conditions or areas of concern or inquiry identified by the environmental site assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">5.3.2.2<font style="display:inline-block;width:8.5pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Costs of Environmental Assessments</b>. &#160;All costs and expenses incurred by Landlord in connection with any such Environmental Assessment initially shall be paid by Landlord; provided that if any such Environmental Assessment shows that Tenant has failed to comply with the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</u>, then all of the costs and expenses of such Environmental Assessment shall be reimbursed by Tenant as Additional Rent within thirty (30)&#160;days after receipt of written demand therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Obligations upon Surrender</b>. &#160;At the expiration or earlier termination of the Lease Term, Tenant, at Tenant&#8217;s sole cost and expense, shall: &#160;(i)&#160;cause an Environmental Assessment of the Premises to be conducted in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15.3</u>; (ii)&#160;cause all Hazardous Materials to be removed from the Premises and disposed of in accordance with all Environmental Laws and as necessary to allow the Premises to be used for any purpose; and (iii)&#160;cause to be removed all containers installed or used by any Tenant Parties to store any Hazardous Materials on the Premises, and cause to be repaired any damage to the Premises caused by such removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3.4</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clean-up</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">5.3.4.1<font style="display:inline-block;width:8.5pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Reports; Clean-Up</b>. &#160;If any written report, including any report containing results of any Environmental Assessment (an &#8220;<b style="font-weight:bold;">Environmental Report</b>&#8221;) shall indicate (i)&#160;the presence of any Hazardous Materials as to which Tenant has a removal or remediation obligation under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</u>, and (ii)&#160;that as a result of same, the investigation, characterization, monitoring, assessment, repair, closure, remediation, removal, or other clean-up (the &#8220;<b style="font-weight:bold;">Clean-up</b>&#8221;) of any Hazardous Materials is required, Tenant shall immediately prepare and submit to Landlord within thirty (30)&#160;days after receipt of the Environmental Report a comprehensive plan, subject</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-15-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">to Landlord&#8217;s written approval, specifying the actions to be taken by Tenant to perform the Clean-up so that the Premises are restored to the conditions required by this Lease; provided, however, that Tenant shall have the right to have its own Environmental Report completed by a separate consultant, and if the results of Tenant&#8217;s Environmental Report differ from the results of Landlord&#8217;s Environmental Report, the parties shall use good faith efforts to resolve the discrepancies prior to any required Clean-up. &#160;Upon Landlord&#8217;s approval of the Clean-up plan, Tenant shall, at Tenant&#8217;s sole cost and expense, without limitation of any rights and remedies of Landlord under this Lease, immediately implement such plan with a consultant reasonably acceptable to Landlord and proceed to Clean-Up Hazardous Materials in accordance with all Applicable Laws and as required by such plan and this Lease. &#160;If, within thirty (30)&#160;days after receiving a copy of such Environmental Report, Tenant fails either (a)&#160;to complete such Clean-up, or (b)&#160;with respect to any Clean-up that cannot be completed within such 30-day period, fails to proceed with diligence to prepare the Clean-up plan and complete the Clean-up as promptly as practicable, then Landlord shall have the right, but not the obligation, and without waiving any other rights under this Lease, to carry out any Clean-up recommended by the Environmental Report or required by any governmental authority having jurisdiction over the Premises, and recover all of the costs and expenses thereof from Tenant as Additional Rent, payable within ten (10)&#160;days after receipt of written demand therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">5.3.4.2<font style="display:inline-block;width:8.5pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Rent Abatement</b>. &#160;Tenant shall continue to pay all Rent due or accruing under this Lease during any Clean-up, and shall not be entitled to any reduction, offset or deferral of any Base Rent or Additional Rent due or accruing under this Lease during any such Clean-up.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">5.3.4.3<font style="display:inline-block;width:8.5pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surrender of Premises</b>. &#160;Tenant shall complete any Clean-up prior to surrender of the Premises upon the expiration or earlier termination of this Lease and shall fully comply with all Environmental Laws and requirements of any governmental authority with respect to such completion, including, without limitation, fully comply with any requirement to file a risk assessment, mitigation plan or other information with any such governmental authority in conjunction with the Clean-up prior to such surrender. &#160;Tenant shall obtain and deliver to Landlord a letter or other written determination from the overseeing governmental authority confirming that the Clean-up has been completed in accordance with all requirements of such governmental authority and that no further response action of any kind is required for the unrestricted use of the Premises (&#8220;<b style="font-weight:bold;">Closure Letter</b>&#8221;). &#160;Upon the expiration or earlier termination of this Lease, Tenant shall also be obligated to close all permits obtained in connection with Hazardous Materials in accordance with Applicable Laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">5.3.4.4<font style="display:inline-block;width:8.5pt;"></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Failure to Timely Clean-Up</b>. &#160;Should any Clean-up for which Tenant is responsible not be completed, or should Tenant not receive the Closure Letter and any governmental approvals required under Environmental Laws in conjunction with such Clean-up prior to the expiration or earlier termination of this Lease, and Tenant&#8217;s failure to receive the Closure Letter is prohibiting Landlord from leasing the Premises or any part thereof to a third party, or prevents the occupancy or use of the Premises or any part thereof by a third party, then Tenant shall be liable to Landlord as a holdover tenant (as more particularly provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;16</u>) until Tenant has fully complied with its obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3.5</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</b>. &#160;Unless compelled to do so by Applicable Law, Tenant agrees that Tenant shall not disclose, discuss, disseminate or copy any information, data, findings, communications, conclusions and reports regarding the environmental condition of the Premises to any Person (other than Tenant&#8217;s consultants, attorneys, property managers and employees that have a need to know such information), including any governmental authority, without the prior written consent of Landlord. &#160;In the event Tenant reasonably believes that disclosure is compelled by Applicable Laws, it shall provide Landlord ten (10)&#160;days&#8217; advance notice of disclosure of confidential information (or such shorter period to allow Tenant to comply with Applicable Law) so that Landlord may attempt to obtain a protective order. &#160;Tenant may additionally release such information to bona fide prospective purchasers or lenders, subject to any such parties&#8217; written agreement to be bound by the terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3.6</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Copies of Environmental Reports</b>. &#160;Within thirty (30)&#160;days of receipt thereof, Tenant shall provide Landlord with a copy of any and all environmental assessments, audits, studies and reports regarding Tenant&#8217;s activities with respect to the Premises, or ground water beneath the Land, or the environmental condition or Clean-up thereof. &#160;Tenant shall be obligated to provide Landlord with a copy of such materials without regard to whether such materials are generated by Tenant or prepared for Tenant, or how Tenant comes into possession of such materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-16-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3.7</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Signs, Response Plans, Etc</b>. &#160;Tenant shall be responsible for posting on the Premises any signs required under applicable Environmental Laws. &#160;Tenant shall also complete and file any business response plans or inventories required by any applicable Environmental Laws. &#160;Tenant shall concurrently file a copy of any such business response plan or inventory with Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3.8</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</b>. &#160;Each covenant, agreement, representation, warranty and indemnification made by Tenant set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</u> shall survive the expiration or earlier termination of this Lease and shall remain effective until all of Tenant&#8217;s obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</u> have been completely performed and satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.4</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Premises Compliance with ADA</b>. &#160;Notwithstanding any other provision herein to the contrary, Tenant shall be responsible for all liabilities, costs and expenses arising out of or in connection with the compliance of the Premises with the ADA first applicable to the Premises after the Lease Commencement Date due to any Alterations or other improvements to the Premises performed by Tenant after the Lease Commencement Date (and specifically not including the Tenant Improvements), and Tenant shall indemnify, save, defend (at Landlord&#8217;s option and with counsel reasonably acceptable to Landlord) and hold Landlord and its affiliates, employees, agents and contractors; and any lender, mortgagee or beneficiary (each, a &#8220;<b style="font-weight:bold;">Lender</b>&#8221; and, collectively with Landlord its partners and subpartners, and their respective officers, members, directors, shareholders, agents, property managers, employees and independent contractors, the &#8220;<b style="font-weight:bold;">Landlord Indemnitees</b>&#8221;) harmless from and against any demands, claims, liabilities, losses, costs, expenses, actions, causes of action, damages or judgments, and all reasonable expenses (including reasonable attorneys&#8217; fees, charges and disbursements) incurred in investigating or resisting the same (collectively, &#8220;<b style="font-weight:bold;">Claims</b>&#8221;) arising out of any such failure of the Premises to comply with the ADA as the result of any Alterations made or constructed by Tenant after the Lease Commencement Date. &#160;The provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4</u> shall survive the expiration or earlier termination of this Lease. Notwithstanding the foregoing, the terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4</u> shall not apply to the extent that any issue with the ADA is caused by any action taken by the Landlord or any other tenant of the Project, or which is related to the Building or the Project generally and not the Premises specifically.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rules and Regulations, CC&amp;Rs, Parking Facilities and Common Areas</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5.1</font></font>Tenant shall have the non-exclusive right, in common with others, to use the Common Areas, subject to the Rules and Regulations. &#160;The manner in which the Common Areas are maintained and operated shall be at the sole discretion of Landlord and the use thereof shall be subject to the Rules and Regulations, as Landlord may make from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5.2</font></font>This Lease is subject to any recorded covenants, conditions or restrictions on the Project or Property (the &#8220;<b style="font-weight:bold;">CC&amp;Rs</b>&#8221;), as the same may be amended, amended and restated, supplemented or otherwise modified from time to time; provided that any such amendments, restatements, supplements or modifications do not materially modify Tenant&#8217;s rights or obligations hereunder. Tenant shall comply with the CC&amp;Rs; provided, however, as of the date of this Lease, the Project is not subject to any CC&amp;Rs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5.3</font></font>Tenant shall have a non-exclusive, irrevocable license to use throughout the Lease Term the number of unreserved parking passes set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of the Summary at such locations in the parking facilities serving the Building as may be determined by Landlord from time to time in common with the other occupants of the Building, on an unreserved basis at no cost to Tenant. Tenant shall use only such parking facilities to park Tenant&#8217;s vehicles or as parking for Tenant&#8217;s employees, agents, contractors or invitees. In no event shall Tenant park or store any items other than automotive vehicles at such parking facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5.4</font></font>Tenant agrees not to unreasonably overburden the parking facilities and agrees to cooperate with Landlord and other tenants in the use of the parking facilities, and Landlord reserves the right to determine that parking facilities are becoming overcrowded, and Landlord may reasonably allocate parking spaces among Tenant and other tenants of the Building or the Project provided Tenant shall be entitled to use throughout the Lease Term the number of unreserved parking passes set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 11</u> of the Summary. Nothing in this Section, however, is intended to create an affirmative duty on Landlord&#8217;s part to monitor parking.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5.5</font></font>Landlord reserves the right to modify the Common Areas, including the right to add or remove exterior and interior landscaping and to subdivide real property, in accordance with the terms and conditions of this Lease. Tenant acknowledges that Landlord specifically reserves the right to allow the exclusive use of corridors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-17-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">and restroom facilities located on specific floors to one or more tenants occupying such floors; provided, however, that Tenant shall not be deprived of the use of the corridors reasonably required to serve the Premises or of restroom facilities serving the floor upon which the Premises are located. Landlord reserves the right to close temporarily, make alterations or additions to, or change the location of elements of the Project and the Common Areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;">SERVICES AND UTILITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord Provided Services</b>. Landlord shall provide the following services on all days (unless otherwise stated below) during the Lease Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1.1</font></font>Landlord shall provide HVAC when necessary for normal comfort in the Building Common Areas from 8:00&#160;A.M. to 6:00&#160;P.M. Monday through Friday, and on Saturdays from 9:00&#160;A.M. to 1:00&#160;P.M. (collectively, the &#8220;<b style="font-weight:bold;">Building Hours</b>&#8221;), except for the date of observance of New Year&#8217;s Day, Independence Day, Labor Day, Memorial Day, Thanksgiving Day, Christmas Day and, at Landlord&#8217;s discretion, other locally or nationally recognized holidays which are observed by other buildings comparable to and in the vicinity of the Building (collectively, the &#8220;<b style="font-weight:bold;">Holidays</b>&#8221;). &#160;Tenant shall have complete control of the hours of operation of the HVAC systems serving the Premises. &#160;Excepting emergencies and casualties, Tenant shall have 24/7 access to the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1.2</font></font>Landlord shall provide adequate electrical wiring and facilities for connection to Tenant&#8217;s lighting fixtures and incidental use equipment. &#160;Tenant shall bear the cost of replacement of lamps, starters and ballasts for non-Building standard lighting fixtures within the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1.3</font></font>Landlord shall provide city water from the regular Building outlets for drinking, lavatory and toilet purposes in the Building Common Areas and to the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1.4</font></font>Landlord shall provide a dumpster and/or trash compactor at the Building for use by Tenant and other tenants for ordinary office waste (and not for Hazardous Materials) and janitorial, trash services and cleaning to Building Common Areas consistent with Comparable Buildings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1.5</font></font>Intentionally Omitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1.6</font></font>Landlord agrees to provide and maintain utility connections to the Building and the Premises, and, where applicable, Common Areas, for electricity, water and sewer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1.7</font></font>Subject to the provisions of this Article, Landlord shall furnish the electric energy that Tenant shall reasonably require in the Premises for the purposes permitted under this Lease. &#160;Such electric energy shall be furnished through a meter or meters and related equipment installed, serviced, maintained, monitored and, as appropriate from time to time, upgraded by Landlord, in each case at Landlord&#8217;s expense, measuring the amount of electric energy furnished to the Premises; provided, however, if the electricity is measured on a meter or submeter serving more than the Premises, Landlord shall determine Tenant&#8217;s charges for electricity based on Tenant&#8217;s pro rata share with respect to other jointly metered premises; and provided further, that Landlord shall pay for the cost of installing any such new meters for the Premises to the extent Landlord determines that Tenant&#8217;s usage will be separately metered or submetered. &#160;Tenant shall pay for electric energy (for which it is liable for payment under this Article) in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.2</u> below within ten (10) days after receipt of any bills related thereto. &#160;The amount charged for electric energy furnished to the Premises shall be one hundred percent (100%) of Landlord&#8217;s cost (including those charges applicable to or computed on the basis of electric consumption, demand and hours of use, any sales or other taxes regularly passed on to Landlord by such public utility company, fuel rate adjustments and surcharges, weighted in each case to reflect differences in consumption or demand applicable to each rate level). &#160;Tenant and its authorized representatives may have access to such meter or meters (if any) on at least three (3) days&#8217; prior notice to Landlord for the purpose of verifying Landlord&#8217;s meter readings (if any). &#160;From time to time during the Lease Term, Landlord may, in its sole discretion and at Landlord&#8217;s cost, (a) install or eliminate such meters, (b) increase or reduce the number of such meters, (c) vary the portions of the Premises that such meters serve or (d) replace any or all of such meters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1.8</font></font>Landlord has installed, or shall install, a common 100 kW emergency generator for the Building and an adjacent building (the &#8220;<b style="font-weight:bold;">Emergency Generator</b>&#8221;) prior to the Lease Commencement Date, and Tenant may connect to it. &#160;Tenant shall be allocated power equivalent to Tenant&#8217;s Share times the capacity of the Emergency</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-18-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Generator allocated to lessees connected to it (as opposed to any capacity of the Emergency Generator allocated to the Common Area); Tenant&#8217;s Share is 25 kW available for serving the lab portion of the Premises. &#160;Landlord shall be responsible for (i) obtaining and maintaining all operational permits and any annual maintenance contract for the Emergency Generator, (ii) maintaining and repairing the Emergency Generator, and (iii) arranging and paying for the annual cost of testing required for the APCD (or equivalent) permit for the Emergency Generator, all as part of the Operating Expenses of the Building. &#160;Landlord shall be responsible for obtaining and maintaining any APCD (Air Pollution Control District) permits required to connect and to allow Tenant to use the Emergency Generator.<sup style="font-size:7.5pt;vertical-align:top;">6</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant Provided Services and Utilities</b>. &#160;Except as otherwise expressly set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;6.1</u>, above, Tenant will be responsible, at its sole cost and expense, for the furnishing of telephone, janitorial and Premises security services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2.1</font></font>Tenant shall be solely responsible for performing all janitorial and trash services and other cleaning of the Premises, all in compliance with Applicable Laws. &#160;In the event such service is provided by a third-party janitorial service, and not by employees of Tenant, such service shall be a janitorial service approved in advance by Landlord (Landlord shall provide Tenant with a list of approved vendors upon Tenant&#8217;s request). &#160;The janitorial and cleaning of the Premises shall be adequate to maintain the Premises in a manner consistent with Comparable Buildings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2.2</font></font>Subject to Applicable Laws and the other provisions of this Lease (including, without limitation, the Rules and Regulations, and except in the event of an emergency) and Landlord&#8217;s reasonable security measures, Tenant shall have access to the Building, the Premises and the Common Areas of the Building, other than Common Areas requiring access with a Building engineer, twenty-four (24) hours per day, seven (7) days per week, every day of the year; provided, however, that Tenant shall only be permitted to have access to and use of the limited-access areas of the Building during the normal operating hours of such portions of the Building.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Tenant shall cooperate fully with Landlord at all times and abide by all regulations and requirements that Landlord may reasonably prescribe for the proper functioning and protection of the HVAC, electrical, mechanical and plumbing systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2.3</font></font>Tenant shall pay for all water (including the cost to service, repair and replace any reverse osmosis, de-ionized and other treated water), gas, heat, light, power, telephone, internet service, cable television, other telecommunications and other utilities supplied to the Premises, together with any fees, surcharges and taxes thereon, and utilities and services provided to the Premises that are separately metered, which shall be paid by Tenant directly to the supplier of such utility or service. &#160;If any such utility is not separately metered to Tenant, Tenant shall pay Tenant&#8217;s Share of all charges of such utility jointly metered with other premises as Additional Rent or, in the alternative, Landlord may, at its option, monitor the usage of such utilities by Tenant and charge Tenant with the cost of monitoring such metering equipment, provided that Landlord shall pay for the cost of the initial purchase and installation (only) of any such metering equipment. &#160;As of the date of this Lease, electricity is provided to the Premises through a single meter serving the entire Building. To the extent that Tenant uses more than Tenant&#8217;s Pro Rata Share of any utilities, then Tenant shall pay Landlord Tenant&#8217;s Share of Operating Expenses to reflect such excess. In the event that the Building or the Project is less than fully occupied, Tenant acknowledges that Landlord may extrapolate utility usage that vary depending on the occupancy of the Building or Project, as applicable, by dividing (a) the total cost of utility usage by (b) the Rentable Area of the Building or Project (as applicable) that is occupied, then multiplying (y) the resulting quotient by (z) ninety-five percent (95%) of the total Rentable Area of the Building or Project (as applicable). &#160;Tenant shall pay Tenant&#8217;s Share of the product of (y) and (z), subject to adjustment based on actual usage as reasonably determined by Landlord; provided, however, that Landlord shall not recover more than one hundred percent (100%) of such utility costs and Landlord shall only charge Tenant for its actual usage and consumption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2.4</font></font>For the Premises, Tenant shall (a) maintain and operate the heating, ventilating and air conditioning systems used for the Permitted Use only (&#8220;<b style="font-weight:bold;">HVAC</b>&#8221;) and (b) subject to clause (a) above, furnish HVAC as reasonably required (except as this Lease otherwise provides) for reasonably comfortable occupancy of the Premises</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">6</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Neither Landlord nor Tenant are aware of any other permit required for Tenant to connect to and use the Emergency Generator.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-19-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">twenty-four (24) hours a day, every day during the Lease Term, subject to casualty, eminent domain or as otherwise specified in this Article. Notwithstanding anything to the contrary in this Section except as expressly provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.4</u> below, Landlord shall have no liability, and Tenant shall have no right or remedy, on account of any interruption or impairment in HVAC services; provided, however, that Landlord shall be responsible for replacement of the HVAC system serving the office portion of the Premises in the event such system is no longer functioning and Tenant shall be responsible for replacement of the HVAC System serving the lab portion of the Premises (such units being new as of the Effective Date and dedicated to the lab portion of the Premises) in the event such system is no longer functioning. If requested in writing by Landlord, Tenant shall provide Landlord, on a quarterly basis, copies of HVAC maintenance contracts and HVAC maintenance reports for any such dedicated HVAC units. &#160;In the event Landlord determines that Tenant is not properly maintaining the HVAC, Landlord may take over the responsibilities in (a) and (b) above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2.5</font></font>For any utilities serving the Premises for which Tenant is billed directly by such utility provider, Tenant agrees to furnish to Landlord within thirty (30) days after Landlord&#8217;s request, any utility usage information reasonably requested by Landlord. &#160;Tenant shall retain records of utility usage at the Premises, including invoices and statements from the utility provider, for at least sixty (60) months, or such other shorter period as may be requested by Landlord. &#160;Tenant acknowledges that any utility information for the Premises, the Building and the Project may be shared with third parties, including Landlord&#8217;s consultants and Governmental Authorities (to the extent required by Applicable Law). &#160;In the event that Tenant fails to comply with this Section, Tenant hereby authorizes Landlord to collect utility usage information directly from the applicable utility providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2.6</font></font>Tenant, at its sole cost, shall furnish and install all replacement lighting tubes, lamps, bulbs and ballasts required in the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2.7</font></font>Tenant&#8217;s use of electric energy in the Premises shall not at any time exceed the capacity of any of the electrical conductors and equipment in or otherwise serving the Premises. &#160;In order to ensure that such capacity is not exceeded, and to avert a possible adverse effect upon the Project&#8217;s distribution of electricity via the Project&#8217;s electric system, Tenant shall not, without Landlord&#8217;s prior written consent in each instance (which consent Landlord may condition upon the availability of electric energy in the Project as allocated by Landlord to various areas of the Project) connect any fixtures, appliances or equipment (other than normal business machines) to the Building&#8217;s or Project&#8217;s electric system or make any alterations or additions to the electric system of the Premises existing on the Lease Commencement Date. &#160;Should Landlord grant such consent, all additional risers, distribution cables or other equipment required therefor shall be provided by Landlord and the cost thereof shall be paid by Tenant to Landlord on demand (or, at Tenant&#8217;s option, shall be provided by Tenant pursuant to plans and contractors approved by Landlord, and otherwise in accordance with the provisions of this Lease). &#160;Landlord shall have the right to require Tenant to pay sums on account of such cost prior to the installation of any such risers or equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2.8</font></font>Landlord reserves the right, upon reasonable, prior written notice to Tenant absent exigent circumstances in which the giving of such notice is not reasonably possible, to stop service of the elevator, plumbing, ventilation, air conditioning and electric systems, when Landlord deems reasonably necessary, due to accident, emergency or the need to make emergency repairs, alterations or improvements, until such repairs, alterations or improvements shall have been completed, and Landlord shall further have no responsibility or liability for failure to supply elevator facilities, plumbing, ventilation, air conditioning or electric service when prevented from doing so by Force Majeure or the failure by a third party to deliver gas, oil or other suitable fuel supply (so long as Landlord is using commercially reasonably efforts to obtain a replacement source for such fuel). &#160;If any such repairs, alterations or improvements might require or cause an interruption in electrical service to the Premises or any portion thereof, Landlord will give to Tenant at least three (3) business days prior written notice whenever practicable. &#160;Without limiting the foregoing, it is expressly understood and agreed that any covenants on Landlord&#8217;s part to furnish any service pursuant to any of the terms, covenants, conditions, provisions or agreements of this Lease, or to perform any act or thing for the benefit of Tenant, shall not be deemed breached if Landlord is unable to furnish or perform the same by virtue of Force Majeure or Landlord&#8217;s negligence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capacities; Overstandard Tenant Use</b>. &#160;If Tenant uses water, electricity, heat or air conditioning in excess of that supplied by Landlord pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</u> of this Lease, Tenant shall pay to Landlord, within thirty (30) days after Tenant&#8217;s receipt of an invoice therefor, the actual cost of such excess consumption; and if Tenant does not cease such excessive usage promptly following written notice from Landlord, Landlord may install devices to separately meter any utility use (or use other reasonable industry standard methods to reasonably estimate such use)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-20-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">and in such event Tenant shall pay the cost directly to Landlord, within thirty (30) days after Tenant&#8217;s receipt of an invoice therefor, at the rates charged by the public utility company furnishing the same, including the cost of installing, testing and maintaining of such additional metering devices. &#160;Tenant&#8217;s use of electricity and any other utility serving the Premises shall never exceed the capacity of the feeders to the Project or the risers or wiring installation or Tenant&#8217;s Share of the per floor limits. &#160;If Tenant desires to use heat, ventilation or air conditioning during hours other than those for which Landlord is obligated to supply such utilities pursuant to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</u> of this Lease, Tenant shall give Landlord such prior notice, if any, as Landlord shall from time to time establish as appropriate, of Tenant&#8217;s desired use in order to supply such utilities, and Landlord shall supply such utilities to Tenant at such hourly cost per zone to Tenant (which shall be treated as Additional Rent) as Landlord shall from time to time establish based upon its reasonably estimated out-of-pocket costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interruption of Use</b>. &#160;Tenant agrees that, to the extent permitted pursuant to Applicable Laws, Landlord shall not be liable for damages, by abatement of Rent or otherwise, for failure to furnish or delay in furnishing any service required to be provided by Landlord under this Lease, or for any diminution in the quality or quantity thereof, when such failure or delay or diminution is occasioned, in whole or in part, by breakage, repairs, replacements, or improvements, by any strike, lockout or other labor trouble, by inability to secure electricity, gas, water, or other fuel at the Building or Project after reasonable effort to do so, by any riot or other dangerous condition, emergency, accident or casualty whatsoever, by act or default of Tenant or other parties, or by any other cause; and such failures or delays or diminution shall never be deemed to constitute an eviction or disturbance of Tenant&#8217;s use and possession of the Premises or relieve Tenant from paying Rent or performing any of its obligations under this Lease. Furthermore, Landlord shall not be liable under any circumstances for a loss of, or injury to, property or for injury to, or interference with, Tenant&#8217;s business, including, without limitation, loss of profits, however occurring, through or in connection with or incidental to a failure to furnish any of the services or utilities as set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 6</u>. Notwithstanding the foregoing to the contrary, in the event that there shall be an interruption, curtailment or suspension of any service required to be provided by Landlord pursuant to Section 6.1 (and no reasonably equivalent alternative service or supply is provided by Landlord) that shall materially interfere with Tenant&#8217;s use and enjoyment of a material portion of the Premises, and Tenant actually ceases to use the affected portion of the Premises (any such event, a &#8220;<b style="font-weight:bold;">Service Interruption</b>&#8221;), and if (i) such Service Interruption shall continue for eight (8) consecutive business days following receipt by Landlord of written notice from Tenant describing such Service Interruption (the &#8220;<b style="font-weight:bold;">Service Interruption Notice</b>&#8221;), and (ii) such Service Interruption shall not have been caused, in whole or in part, by reasons beyond Landlord&#8217;s reasonable control or by an act or omission in violation of this Lease by any Tenant Party or by any negligence of Tenant any Tenant Parties, (a Service Interruption that satisfies the foregoing conditions being referred to hereinafter as a &#8220;<b style="font-weight:bold;">Material Service Interruption</b>&#8221;) then, as liquidated damages and Tenant&#8217;s sole remedy at law or equity, Tenant shall be entitled to an equitable abatement of Base Rent and Tenant&#8217;s Share of Direct Expenses, based on the nature and duration of the Material Service Interruption, the area of the Premises affected, and the then current Rent amounts, for the period that shall begin on the commencement of such Material Service Interruption and that shall end on the day such Material Service Interruption shall cease. To the extent a Material Service Interruption is caused by an event covered by Articles 11 or 13 of this Lease, then Tenant&#8217;s right to abate rent shall be governed by the terms of such Article 11 or 13, as applicable, and the provisions of this paragraph shall not apply. &#160;If the entire Premises have not been rendered untenantable by the Service Interruption, the amount of abatement shall be equitably prorated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.5</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Triple Net Lease</b>. &#160;Landlord and Tenant acknowledge that, except as otherwise provided to the contrary in this Lease, it is their intent and agreement that this Lease be a &#8220;TRIPLE NET&#8221; lease and that as such, the provisions contained in this Lease are intended to pass on to Tenant or reimburse Landlord for the costs and expenses reasonably associated with this Lease, the Building and the Project, and Tenant&#8217;s operation therefrom subject to the inclusions and exclusions from Operating Expenses and Taxes described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2.4</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2.5</u> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">7.</b></font><b style="font-weight:bold;">REPAIRS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Tenant shall, at Tenant&#8217;s own expense, keep the Premises, including all improvements, fixtures, furnishings, and systems and equipment within the Premises or elsewhere exclusively serving the Premises, in good order, repair and condition at all times during the Lease Term. &#160;In addition, Tenant shall, at Tenant&#8217;s own expense, but under the supervision and subject to the prior reasonable approval of Landlord, and within any reasonable period of time specified by Landlord, promptly and adequately repair all damage to the Premises and replace or repair all damaged, broken, or worn fixtures and appurtenances, except for damage caused by ordinary wear and tear; provided however,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-21-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">that if Tenant fails to make such repairs within applicable notice and cure periods, Landlord may, but need not, make such repairs and replacements, and Tenant shall pay Landlord the cost thereof, including a management fee of five percent (5%) of such costs. Without limitation, subject to Landlord&#8217;s obligation set forth in Section 1.1.1 above, Tenant shall be responsible for electrical, plumbing, heating, ventilating and air-conditioning systems and other utility services serving the Premises from the Building connection point to the Premises (to the extent serving Tenant exclusively), and Tenant shall secure, pay for, and keep in force contracts with appropriate and reputable service companies reasonably approved by Landlord providing for the regular maintenance of such systems. Notwithstanding the foregoing, Landlord shall be responsible for repairs to the exterior walls, foundation and roof (including roof membrane) of the Building, the structural portions of the Building, and the base building systems and equipment of the Building (including the electrical, plumbing, heating, ventilating and air-conditioning systems and other utility services serving the Premises (to the extent not serving Tenant exclusively) and Common Areas, except to the extent that such repairs are required due to the negligence or willful misconduct of Tenant; provided, however, that if such repairs are due to the negligence or willful misconduct of Tenant, Landlord shall nevertheless make such repairs at Tenant&#8217;s expense, or, if covered by Landlord&#8217;s insurance, Tenant shall only be obligated to pay any deductible in connection therewith. &#160;Subject to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 27</u> below, Landlord may, but shall not be required to, enter the Premises at all reasonable times and upon reasonable prior notice to make such repairs, alterations, improvements or additions to the Premises or to the Project or to any equipment located in the Project as Landlord shall desire or deem necessary or as Landlord may be required to do by governmental or quasi-governmental authority or court order or decree. &#160;Tenant hereby waives and releases its right to make repairs at Landlord&#8217;s expense under Sections 1941 and 1942 of the California Civil Code or under any similar law, statute or ordinance now or hereafter in effect. &#160;Tenant&#8217;s obligation hereunder shall include maintenance and repair of all telecommunications wire and cabling with the Building&#8217;s network cabling connections to the Building&#8217;s existing network cabling which are located within the Premises, but only to the extent that Tenant has, or is provided, access to such connections; provided, however, if Tenant desires or requires additional network cabling not otherwise presently available as part of the telecommunications and cabling of the Building&#8217;s existing network, such installation shall be at Tenant&#8217;s cost to the extent the utility provider is unwilling to install such cabling without cost to Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">8.</b></font><b style="font-weight:bold;">ADDITIONS AND ALTERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Consent to Alterations</b>. &#160;Tenant may not make any improvements, alterations, additions or changes to the Premises or any mechanical, plumbing, HVAC facilities or other utility or Building systems pertaining to the Premises (collectively, the &#8220;<b style="font-weight:bold;">Alterations</b>&#8221;), but expressly excluding the Tenant Improvements, without first procuring the prior written consent of Landlord to such Alterations, which consent shall be requested by Tenant not less than fifteen (15) business days prior to the commencement thereof. &#160;Landlord shall not unreasonably withhold or delay its consent to any proposed nonstructural Alterations, provided that such Alterations (1) are not visible from the outside of the Building, (2) do not affect the use of or require access to any part of the Building other than the Premises, (3) do not violate any certificate of occupancy for the Building or any other permits or licenses relating to the Project, (4) do not adversely affect any service required to be furnished to Tenant or to any other tenant or occupant of the Building, (5) do not affect any Building systems or Common Areas, (6) do not reduce the value or utility of the Building, and (7) otherwise comply with the Rules and Regulations and this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 8</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Alterations Affecting Air Distribution</b>. &#160;Prior to commencing any Alterations affecting air distribution or disbursement from ventilation systems serving Tenant or the Building, including without limitation the installation of Tenant&#8217;s exhaust systems, Tenant shall provide Landlord with a third party report from a consultant, and in a form reasonably acceptable to Landlord, showing that such work will not adversely affect the ventilation systems or air quality of the Building (or of any other tenant in the Building) and shall, upon completion of such work, provide Landlord with a certification reasonably satisfactory to Landlord from such consultant confirming that no such adverse effects have resulted from such work.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manner of Construction</b>. &#160;Landlord may impose, as a condition of its consent to any and all Alterations or repairs of the Premises or about the Premises, such requirements as Landlord in its reasonable discretion may deem desirable, including, but not limited to, the requirement that Tenant utilize for such purposes only contractors, subcontractors, materials, mechanics and materialmen selected by Tenant and approved by Landlord (which approval shall not be unreasonably withheld, conditioned or delayed) and the requirement that upon Landlord&#8217;s request (subject to the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;8.5</u>, below), Tenant shall, at Tenant&#8217;s expense, remove such Alterations upon the expiration or any early termination of the Lease Term; provided, however, Tenant shall have no obligation to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-22-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">remove any of the Tenant Improvements. &#160;Tenant shall construct such Alterations and perform such repairs in a good and workmanlike manner, in conformance with any and all Applicable Laws and, where required by Applicable Law, pursuant to a valid building permit. &#160;Tenant shall not use (and upon notice from Landlord shall cease using) contractors, services, workmen, labor, materials or equipment that, in Landlord&#8217;s reasonable judgment, would disturb labor harmony with the workforce or trades engaged in performing other work, labor or services in or about the Building or the Common Areas. &#160;Upon completion of any Alterations (or repairs), Tenant shall deliver to Landlord final lien waivers from all contractors, subcontractors, design professionals, service providers, suppliers and materialmen who performed such work and whose labor, supplies or services give rise to a lien under California law. &#160;In addition to Tenant&#8217;s obligations under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 9</u> of this Lease, upon completion of any Alterations, Tenant shall deliver to the Project construction manager a reproducible copy of the &#8220;<b style="font-weight:bold;">as built</b>&#8221; drawings of the Alterations in CAD format as well as copies of all permits, approvals and other documents issued by any governmental agency in connection with the Alterations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.4</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payment for Improvements</b>. &#160;If Tenant orders any work directly from Landlord, Tenant shall pay to Landlord an amount equal to five percent (5%) of the cost of such work to compensate Landlord for all overhead, general conditions, fees and other costs and expenses arising from Landlord&#8217;s involvement with such work. &#160;If Tenant does not order any work directly from Landlord, Tenant shall reimburse Landlord for Landlord&#8217;s reasonable, actual, out-of-pocket costs and expenses actually incurred in connection with Landlord&#8217;s review of any proposed Alterations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.5</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction Insurance</b>. &#160;In addition to the requirements of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u> of this Lease, in the event that Tenant makes any Alterations, prior to the commencement of such Alterations, Tenant shall provide Landlord with evidence that Tenant or Tenant&#8217;s general contractor carries &#8220;<b style="font-weight:bold;">Builder&#8217;s All Risk</b>&#8221; insurance (to the extent that the cost of the work shall exceed $100,000.00) in an amount approved by Landlord covering the construction of such Alterations, and such other insurance as Landlord may reasonably require, it being understood and agreed that all of such Alterations shall be insured by Tenant pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u> of this Lease immediately upon completion thereof. &#160;In addition, Tenant&#8217;s contractors and subcontractors shall be required to carry Commercial General Liability Insurance, Auto Liability Insurance, and Workers&#8217; Compensation Insurance in commercially reasonable amounts approved by Landlord and otherwise in accordance with the requirements of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u> of this Lease and such Commercial General Liability and Auto Liability insurance shall name Tenant and the Landlord Parties (as defined below) as additional insureds on a primary and non-contributory basis for both ongoing and completed operations. &#160;Tenant shall require its contractors and subcontractors to maintain products-completed operations coverage for not less than the greater of (i) ten (10) years after substantial completion of the Alterations or (ii) the time in which a claim may be properly brought under the applicable statute of limitations or repose. Landlord may, in its discretion, require Tenant to obtain and record a statutory form of lien bond, or obtain performance and payment bonds, or some alternate form of security satisfactory to Landlord in an amount sufficient to ensure the lien-free completion of such Alterations and naming Landlord as a co-obligee, in each case in form and substance reasonably satisfactory to Landlord. &#160;In addition, Tenant&#8217;s contractors and subcontractors shall be required to carry workers compensation insurance with a waiver of subrogation in favor of Landlord Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.6</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Property</b>. &#160;All Alterations, improvements, fixtures, equipment and/or appurtenances which may be installed or placed in or about the Premises, from time to time, shall be at the sole cost of Tenant and shall be and become the property of Landlord and remain in place at the Premises following the expiration or earlier termination of this Lease. Notwithstanding the foregoing to the contrary, Landlord may, by written notice to Tenant given at the time that Landlord consents to the Alterations<i style="font-style:italic;">,</i> require Tenant, at Tenant&#8217;s expense, to remove any Alterations and/or improvements and/or systems and equipment within the Premises and to repair any damage to the Premises and Building caused by such removal. If Tenant fails to complete any required removal and/or to repair any damage caused by the removal of any Alterations and/or improvements and/or systems and equipment in the Premises, Landlord may do so and may charge the actual and reasonable cost thereof to Tenant. &#160;Tenant hereby protects, defends, indemnifies and holds Landlord harmless from any liability, cost, obligation, expense or claim of lien in any manner relating to the installation, placement, removal or financing of any such Alterations, improvements, fixtures and/or equipment in, on or about the Premises, which obligations of Tenant shall survive the expiration or earlier termination of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">9.</b></font><b style="font-weight:bold;">COVENANT AGAINST LIENS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Within ten (10) business days following a request in writing by Landlord, Tenant shall keep the Project and Premises free from any liens or encumbrances arising out of the work performed, materials or services furnished or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-23-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">obligations incurred by or on behalf of Tenant (which expressly excludes the Landlord Work and the Tenant Improvements), and shall protect, defend, indemnify and hold Landlord harmless from and against any claims, liabilities, judgments or costs (including, without limitation, reasonable attorneys&#8217; fees and costs) arising out of same or in connection therewith. &#160;Tenant shall give Landlord notice at least twenty (20) days prior to the commencement of any work, services or obligations related to the Premises giving rise to any such liens or encumbrances (or such additional time as may be necessary under Applicable Laws) to afford Landlord the opportunity of posting and recording appropriate notices of non-responsibility (to the extent applicable pursuant to then Applicable Laws). &#160;Tenant shall remove any such lien or encumbrance by statutory lien bond or otherwise within ten (10) business days after notice by Landlord, and if Tenant shall fail to do so, Landlord may pay the amount necessary to remove such lien or encumbrance, without being responsible for investigating the validity thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">10.</b></font><b style="font-weight:bold;">INSURANCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification and Waiver</b>. &#160;To the maximum extent permitted pursuant to Applicable Laws and except for the gross negligence or willful misconduct of the Landlord Parties, Tenant hereby assumes all risk of damage to property or injury to persons in, upon or about the Premises from any cause whatsoever (including, but not limited to, any personal injuries resulting from a slip and fall in, upon or about the Premises) and agrees that, to the extent permitted pursuant to Applicable Laws, Landlord, its lenders, partners, subpartners, the Additional Insureds, and each of their respective officers, agents, servants, employees, and independent contractors (collectively, &#8220;<b style="font-weight:bold;">Landlord Parties</b>&#8221;) shall not be liable for, and are hereby released from any responsibility for, any damage either to person or property or resulting from the loss of use thereof, which damage is sustained by Tenant or by other persons claiming through Tenant. &#160;Tenant shall indemnify, defend, protect, and hold harmless the Landlord Parties from any and all loss, cost, damage, injury, expense and liability (including without limitation court costs and reasonable attorneys&#8217; fees) during the Lease Term, or any period of Tenant&#8217;s occupancy of the Premises prior to the commencement or after the expiration of the Lease Term, incurred in connection with or arising from (i) any cause in, on or about the Premises (including, but not limited to, a slip and fall), provided that the terms of the foregoing indemnity shall not apply to the extent of any gross negligence or willful misconduct of Landlord, (ii) any negligent acts or omissions of Tenant or of any person claiming by, through or under Tenant, or of the contractors, agents, servants, employees, invitees, guests or licensees of Tenant or any such person, in, on or about the Project (including without limitation on account of Tenant&#8217;s use of the Special Systems), or (iii) any breach of the terms of this Lease by Tenant during the Lease Term or any period of Tenant&#8217;s occupancy of the Premises prior to, or after the expiration of the Lease Term. &#160;Should Landlord be named as a defendant in any suit brought against Tenant in connection with or arising out of Tenant&#8217;s occupancy of the Premises, Tenant shall pay to Landlord its reasonable costs and expenses incurred in such suit, including without limitation, its actual professional fees such as reasonable appraisers&#8217;, accountants&#8217; and attorneys&#8217; fees. &#160;The provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10.1</u> shall survive the expiration or sooner termination of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Compliance With Landlord&#8217;s Property Insurance</b>. &#160;Tenant shall, at Tenant&#8217;s expense, comply with all insurance company requirements pertaining to the use of the Premises and provided by Landlord to Tenant which do not materially impact the Permitted Use. If Tenant&#8217;s conduct or use of the Premises for any purpose other than the Permitted Use causes any increase in the premium for such insurance policies then Tenant shall reimburse Landlord for any such increase. Tenant, at Tenant&#8217;s expense, shall comply with all rules, orders, regulations or requirements of the American Insurance Association (formerly the National Board of Fire Underwriters) and with any similar body.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Insurance</b>. &#160;Tenant shall maintain, at its cost and expense, the following coverages with limits of not less than the greater of (i) those set forth hereunder, and (ii) those required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3.1</font></font>Commercial General Liability Insurance issued on terms no less broad than the most current ISO CG 00 01 occurrence form covering the insured against claims of bodily injury, personal and advertising injury and property damage (including loss of use thereof) arising out of Tenant&#8217;s operations, products/completed operations, social or host liquor liability (if applicable), and &#8220;insured contracts&#8221; (as defined by the most current ISO CG 00 01 form), including a Separation of Insureds provision with no exclusion for cross-liability, and including the Additional Insureds (as defined hereunder) as additional insureds with respect to both ongoing and completed operations coverage on a primary and non-contributory basis, for limits of liability of not less than:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-24-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$1,000,000 each occurrence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$2,000,000 annual aggregate</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">per location</p></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$1,000,000 personal and advertising injury</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$2,000,000 products completed operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">No deductible or self-insured retention</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3.2</font></font>Property Insurance covering (i) all office furniture, business and trade fixtures, office equipment, free-standing cabinet work, movable partitions, merchandise and all other items of Tenant&#8217;s property on the Premises installed by, for, or at the expense of Tenant, and (ii) the Tenant Improvements described in <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1.1.1-2</b> and any other tenant improvements that exist in the Premises as of the Lease Commencement Date (the &#8220;<b style="font-weight:bold;">New Improvements</b>&#8221;). Such insurance shall be written on an &#8220;<b style="font-weight:bold;">all risks</b>&#8221; of physical loss or damage basis, for the full replacement cost value (subject to reasonable deductible amounts) new without deduction for depreciation of the covered items and in amounts that meet any co-insurance clauses of the policies of insurance and shall include coverage for damage or other loss caused by fire or other peril including, but not limited to, hail, windstorm, flood, earthquake, vandalism and malicious mischief, theft, water damage, including sprinkler leakage, earthquake sprinkler leakage, bursting or stoppage of pipes, and explosion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3.3</font></font>Business income interruption for one (1) year plus extra expense insurance in such amounts as will reimburse Tenant for actual direct or indirect loss of earning and continue expense, including rent attributable to the risks outlined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 10.3.2</u> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3.4</font></font>Auto Liability Insurance covering liability arising out of any auto, including owned (if any), non-owned, leased, and hired autos, with a limit of not less than $1,000,000 combined single limit each accident for bodily injury and property damage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3.5</font></font>Worker&#8217;s Compensation and Employer&#8217;s Liability or other similar insurance pursuant to all applicable state and local statutes and regulations, together with Employer&#8217;s Liability Insurance with limits of not less than $1,000,000 bodily injury (each accident), $1,000,000 bodily injury by disease (each employee), and $1,000,000 bodily injury by disease (policy limit) or such greater amounts as may be required by Tenant&#8217;s Umbrella/Excess Liability policy in order to effect such coverage. &#160;The policy will include a waiver of subrogation in favor of the Landlord Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3.6</font></font>Umbrella and/or Excess Liability Insurance policy in excess of Commercial General Liability, Auto Liability, and Employer&#8217;s Liability Insurance policies, concurrent to, and at least as broad as the underlying primary insurance policies, which must &#8220;drop down&#8221; over reduced or exhausted aggregate limits as to such underlying policies and contain a &#8220;follow form&#8221; statement. &#160;The limits must be no less than $4,000,000 each occurrence and $4,000,000 in the aggregate. &#160;Such Umbrella/Excess Liability policy must be endorsed to provide that this insurance is primary to, and non-contributory with, any other insurance on which the Additional Insureds are an insured, whether such other insurance is primary, excess, contingent, self-insurance, or insurance on any other basis. &#160;This endorsement must cause the Umbrella/Excess coverage to be vertically exhausted, whereby such coverage is not subject to any &#8220;Other Insurance&#8221; clause under this Umbrella and/or Excess Liability policy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.3.7</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Agents/Contractors</u>. &#160;In the case of Tenant&#8217;s contractors, subcontractors, and any vendors/consultants brought on to the Premises for any Alterations or other improvements (collectively, for purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u>, Tenant&#8217;s &#8220;<b style="font-weight:bold;">Third Parties</b>&#8221;), Tenant shall cause such Third Parties to obtain and maintain such insurance as is required under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections&#160;10.3.1</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3.4</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3.5</u> herein, unless granted written approval from Landlord to waive such requirements. &#160;Such Third Parties&#8217; coverage under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections&#160;10.3.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3.4</u> shall include Tenant and the Additional Insureds each as additional insureds on a primary and non-contributory basis for both ongoing and completed operations. &#160;Additionally, the commercial general liability limit required to be carried by any contractor or subcontractors of Tenant shall be not less than the following: (x) general contractors &#8211; $5,000,000, (y)&#160;any subcontractors for work costing $250,000 or more &#8211; $2,000,000, and (z) any subcontractors for work costing less than $250,000 &#8211; $1,000,000. &#160;The foregoing limits may be satisfied by a combination of primary and/or excess policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.4</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Form of Policies</b>. &#160;The minimum limits of policies of insurance required of Tenant and its agents/contractors under this Lease shall in no event limit the liability of Tenant under this Lease. &#160;Such insurance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-25-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">shall name Landlord, its subsidiaries and affiliates, Longfellow Property Management Services CA Inc.; Longfellow Strategic Value Fund, LLC; San Diego Inspire Holdings, LLC; LSVF Americas, LP; LSVF Pacific, LP; Longfellow Capital Partners II, LP; Longfellow Real Estate Partners, LLC; Invesco CMI Investments, LP; and any other party the Landlord so specifies (collectively, the &#8220;<b style="font-weight:bold;">Additional Insureds</b>&#8221;), as additional insureds under the policies listed in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 10.3.1</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3.2</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3.3</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3.4</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3.6</u>. &#160;All insurance policies required to be maintained by Tenant shall (i) be issued by an insurance company having a rating of not less than A:VIII in Best&#8217;s Insurance Guide or which is otherwise acceptable to Landlord and licensed to do business in the State of California; (ii) be primary insurance as to all claims thereunder and provide that any insurance carried by Landlord is excess and is non-contributing with any insurance required of Tenant; (iii) (Tenant shall provide full and complete copies of any policies that Landlord reasonably requests); (iv) be endorsed with waiver of subrogation endorsements in favor of the Additional Insureds; (v) not contain deductible or self-insured retention in excess of $25,000 unless otherwise approved by Landlord in writing; and (vi) provide that said insurer shall provide thirty&#160;(30) days&#8217; written notice to Landlord and any mortgagee of Landlord, to the extent such names are furnished to Tenant prior to the cancellation of such policy (ten (10) days&#8217; for nonpayment of premium). &#160;Tenant shall deliver said policy or policies or certificates thereof to Landlord on or before the earlier to occur of (A)&#160;the Lease Commencement Date, and (B)&#160;the date upon which Tenant is first provided access to the Premises, and at least ten&#160;(10) days before the expiration dates thereof. &#160;In the event Tenant shall fail to procure such insurance, or to deliver such policies or certificate within ten&#160;(10) days after written notice from Landlord, Landlord may, at its option, procure such policies for the account of Tenant, and the cost thereof shall be paid to Landlord within five&#160;(5) days after delivery to Tenant of bills therefor. &#160;Landlord and the Additional Insureds will not be responsible for any deductibles or self-insured retentions related to any insurance under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.5</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subrogation</b>. &#160;Landlord and Tenant intend that their respective property loss risks shall be borne by reasonable insurance carriers to the extent such insurance is required by this Lease or otherwise maintained by the parties, and Landlord and Tenant hereby agree to look solely to, and seek recovery only from, their respective insurance carriers in the event of a property loss to the extent that such coverage is agreed to be provided hereunder. &#160;The parties each hereby waive all rights and claims against each other for such losses and waive all rights of subrogation of their respective insurers, provided such waiver of subrogation shall not affect the right of the insured to recover thereunder. &#160;The parties agree that their respective insurance policies are now or shall specify that the waiver of subrogation shall not affect the right of the insured to recover thereunder. &#160;Tenant will waive, and shall use commercially reasonable efforts to cause its Third Parties to waive, all causes of action or claims they may have against the Additional Insureds for any liability and workers compensation claims they incur in relation to the Lease or any Alterations, or any other work or activities performed in connection with the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.6</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Additional Insurance Obligations</b>. &#160;Landlord reserves the right to require such other reasonable insurance against other insurable hazards that at the time are commonly insured against in case of projects similar in nature, construction type, and geographic location to the Project which Landlord also requires other tenants at the Project to insure against, which are required by any lender or mortgagee entering into a new mortgage secured by the Building or at the time are otherwise commonly insured against in case of projects similar to the Project. &#160;Tenant shall carry and maintain during the entire Lease Term, at Tenant&#8217;s sole cost and expense, increased amounts of insurance and such additional coverages as required pursuant to the preceding sentence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.7</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Insurance</b><b style="font-weight:bold;">. &#160;</b>Landlord shall maintain its usual liability insurance as well as property insurance for the Building (excluding any Alterations and Tenant Improvements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">11.</b></font><b style="font-weight:bold;">DAMAGE AND DESTRUCTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Repair of Damage to Premises by Landlord</b>. &#160;Tenant shall promptly notify Landlord of any damage to the Premises resulting from fire or any other casualty. &#160;If the Premises or any Common Areas serving or providing access to the Premises shall be damaged by fire or other casualty, Landlord shall promptly and diligently, subject to reasonable delays for insurance adjustment or other matters beyond Landlord&#8217;s reasonable control, and subject to all other terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 11</u>, restore such Common Areas and the Premises to substantially the same condition as existed prior to the casualty, except for modifications required by zoning and building codes and other laws or by the holder of a mortgage on the Building or Project or any other modifications to the Common Areas deemed desirable by Landlord, which are consistent with the character of the Project, provided that access to the Premises shall not be materially impaired. &#160;Upon the occurrence of any damage to the Premises, upon notice (the &#8220;<b style="font-weight:bold;">Landlord Repair Notice</b>&#8221;) to Tenant from Landlord, Tenant shall assign to Landlord (or to any party designated by Landlord) all insurance proceeds payable to Tenant under Tenant&#8217;s insurance required under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;10.3.2(ii)</u> of this</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-26-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Lease and Landlord&#8217;s obligation to restore any Alterations or Tenant Improvements shall be limited to the extent of such proceeds received by Landlord. &#160;To the extent permitted pursuant to Applicable Laws, Landlord shall not be liable for any inconvenience or annoyance to Tenant or its visitors, or injury to Tenant&#8217;s business resulting in any way from such damage or the repair thereof; provided however, that if such fire or other casualty shall have damaged the Premises or Common Areas necessary to Tenant&#8217;s occupancy, and the Premises are not occupied by Tenant as a result thereof, then during the time and to the extent the Premises are unfit for occupancy, the Rent shall be abated in proportion to the ratio that the amount of rentable square feet of the Premises which is unfit for occupancy for the Permitted Use bears to the total rentable square feet of the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Option to Repair</b>. &#160;Notwithstanding the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11.1</u> of this Lease, Landlord may elect not to rebuild and/or restore the Premises, Building and/or Project, and instead terminate this Lease, by notifying Tenant in writing of such termination within sixty (60) days after the date of discovery of the damage, such notice to include a termination date giving Tenant sixty (60) days to vacate the Premises, but Landlord may so elect only if the Premises or Building shall be damaged by fire or other casualty or cause and one or more of the following conditions is present: (i) in Landlord&#8217;s reasonable judgment, repairs cannot reasonably be completed within two hundred ten (210) days after the date of discovery of the damage (when such repairs are made without the payment of overtime or other premiums); (ii) the holder of any mortgage on the Building or Project or ground lessor with respect to the Building or Project shall require that the insurance proceeds or any portion thereof be used to retire the mortgage debt, or shall terminate the ground lease, as the case may be; (iii) such damage is not fully covered by Landlord&#8217;s insurance policies; (iv) Landlord decides to rebuild the Building or Common Areas so that they will be substantially different structurally or architecturally; or (v) the damage occurs during the last twelve (12) months of the Lease Term; however, that if Landlord does not elect to terminate this Lease pursuant to Landlord&#8217;s termination right as provided above, and the repairs cannot, in the reasonable opinion of Landlord, be completed within two hundred ten (210) days after being commenced, Tenant may elect, no earlier than sixty (60) days after the date of the damage and not later than ninety (90) days after the date of such damage, to terminate this Lease by written notice to Landlord effective as of the date specified in the notice, which date shall not be less than thirty (30) days nor more than sixty (60) days after the date such notice is given by Tenant. Notwithstanding the provisions of this Section 11.2, Tenant shall have the right to terminate this Lease under this Section 11.2 only if each of the following conditions is satisfied: &#160;(a) the damage to the Project by fire or other casualty was not caused by the negligence or intentional act of Tenant or any Tenant Party; (b) as a result of the damage, Tenant cannot reasonably conduct business from the Premises; and (c) as a result of the damage to the Project, Tenant does not occupy or use the Premises. In addition, Tenant may terminate this Lease if the damage to the Premises occurs during the last twelve (12) months of the Lease Term, and, as a result of such damage, Tenant cannot reasonably conduct business from the Premises for a period of at least one-half (1/2) of the then-remaining term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waiver of Statutory Provisions</b>. &#160;The provisions of this Lease, including this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 11</u>, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the Premises, the Building or the Project, and any statute or regulation of the State of California, including, without limitation, Sections 1932(2) and 1933(4) of the California Civil Code, with respect to any rights or obligations concerning damage or destruction in the absence of an express agreement between the parties, and any other statute or regulation, now or hereafter in effect, shall have no application to this Lease or any damage or destruction to all or any part of the Premises, the Building or the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">12.</b></font><b style="font-weight:bold;">NONWAIVER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">No provision of this Lease shall be deemed waived by either party hereto unless expressly waived in a writing signed thereby. &#160;The waiver by either party hereto of any breach of any term, covenant or condition herein contained shall not be deemed to be a waiver of any subsequent breach of same or any other term, covenant or condition herein contained. &#160;The subsequent acceptance of Rent hereunder by Landlord shall not be deemed to be a waiver of any preceding breach by Tenant of any term, covenant or condition of this Lease, other than the failure of Tenant to pay the particular Rent so accepted, regardless of Landlord&#8217;s knowledge of such preceding breach at the time of acceptance of such Rent. &#160;No acceptance of a lesser amount than the Rent herein stipulated shall be deemed a waiver of Landlord&#8217;s right to receive the full amount due, nor shall any endorsement or statement on any check or payment or any letter accompanying such check or payment be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord&#8217;s right to recover the full amount due. &#160;No receipt of monies by Landlord from Tenant after the termination of this Lease shall in any way alter the length of the Lease Term or of Tenant&#8217;s right of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-27-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">possession hereunder, or after the giving of any notice shall reinstate, continue or extend the Lease Term or affect any notice given Tenant prior to the receipt of such monies, it being agreed that after the service of notice or the commencement of a suit, or after final judgment for possession of the Premises, Landlord may receive and collect any Rent due, and the payment of said Rent shall not waive or affect said notice, suit or judgment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">13.</b></font><b style="font-weight:bold;">CONDEMNATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.1</font></font>If the whole or substantially all of the Premises, Building or Project shall be taken by power of eminent domain or condemned by any competent authority for any public or quasi-public use or purpose, or if all reasonable access to the Building is so taken or condemned, both Landlord and Tenant shall each have the option to terminate this Lease effective as of the date possession is required to be surrendered to the authority. &#160;Tenant shall not because of such taking assert any claim against Landlord or the authority for any compensation because of such taking and Landlord shall be entitled to the entire award or payment in connection therewith, except that Tenant shall have the right to file any separate claim available to Tenant for any taking of Tenant&#8217;s personal property and fixtures belonging to Tenant and removable by Tenant upon expiration of the Lease Term pursuant to the terms of this Lease, and for moving expenses, so long as such claims do not diminish the award available to Landlord, its ground lessor with respect to the Building or Project or its mortgagee, and such claim is payable separately to Tenant. &#160;All Rent shall be apportioned as of the date of such termination. &#160;If any part of the Premises shall be taken, and this Lease shall not be so terminated, the Rent shall be proportionately abated. &#160;Notwithstanding anything to the contrary contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 13</u>, in the event of a temporary taking of all or any portion of the Premises for a period of one hundred eighty (180) days or less, and provided that such temporary taking does not materially preclude or unreasonably diminish Tenant&#8217;s ability to conduct business from the Premises, then this Lease shall not terminate but the Base Rent and Tenant&#8217;s Share of Direct Expenses shall be abated for the period of such taking in proportion to the ratio that the amount of rentable square feet of the Premises taken bears to the total rentable square feet of the Premises. &#160;Tenant hereby waives any and all rights it might otherwise have pursuant to Section 1265.130 of The California Code of Civil Procedure. &#160;Landlord shall be entitled to receive the entire award made in connection with any such temporary taking, provided, however, that Tenant shall be entitled to a share of the award for any loss of fixtures and improvements and for moving and other reasonable expenses that do not otherwise reduce Landlord&#8217;s recovery. &#160; If this Lease does not terminate on account of any such eminent domain or condemnation proceeding, then Landlord shall, to the extent practicable, restore the affected area of the Premises, Building or Project. In no event shall Landlord have any obligation to undertake restoration on account of any condemnation or eminent domain proceeding except to the extent of the award actually received by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">14.</b></font><b style="font-weight:bold;">ASSIGNMENT AND SUBLETTING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfers</b>. &#160;Tenant shall not, without the prior written consent of Landlord, assign, mortgage, pledge, hypothecate, encumber, or permit any lien to attach to, or otherwise transfer, this Lease or any interest hereunder, permit any assignment, or other transfer of this Lease or any interest hereunder by operation of law, sublet the Premises or any part thereof, or enter into any license or concession agreements or otherwise permit the occupancy or use of the Premises or any part thereof by any persons other than Tenant and its employees and contractors (all of the foregoing are hereinafter sometimes referred to collectively as &#8220;<b style="font-weight:bold;">Transfers</b>&#8221; and any person to whom any Transfer is made or sought to be made is hereinafter sometimes referred to as a &#8220;<b style="font-weight:bold;">Transferee</b>&#8221;). &#160;If Tenant desires Landlord&#8217;s consent to any Transfer, Tenant shall notify Landlord in writing, which notice (the &#8220;<b style="font-weight:bold;">Transfer Notice</b>&#8221;) shall include (i) the proposed effective date of the Transfer, which shall not be less than twenty (20) days nor more than one hundred eighty (180) days after the date of delivery of the Transfer Notice, (ii) a description of the portion of the Premises to be transferred (the &#8220;<b style="font-weight:bold;">Subject Space</b>&#8221;), (iii) all of the terms of the proposed Transfer and the consideration therefor, including calculation of the &#8220;<b style="font-weight:bold;">Transfer Premium</b>&#8221;, as that term is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;14.3</u> below, in connection with such Transfer, the name and address of the proposed Transferee, and a copy of all existing executed and/or proposed documentation pertaining to the proposed Transfer, and (iv) current financial statements of the proposed Transferee certified by an officer, partner or owner thereof, business credit and personal references and history of the proposed Transferee and any other information reasonably required by Landlord which will enable Landlord to determine the financial responsibility, character, and reputation of the proposed Transferee, nature of such Transferee&#8217;s business and proposed use of the Subject Space. &#160;Any Transfer made without Landlord&#8217;s prior written consent shall, at Landlord&#8217;s option, be null, void and of no effect, and shall, at Landlord&#8217;s option, constitute a default by Tenant under this Lease. &#160;Whether or not Landlord consents to any proposed Transfer, Tenant shall pay Landlord&#8217;s reasonable review and processing fees, as well as any reasonable professional fees (including, without limitation, attorneys&#8217;, accountants&#8217;,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-28-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">architects&#8217;, engineers&#8217; and consultants&#8217; fees) incurred by Landlord, within thirty (30) days after written request by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Consent</b>. &#160;Landlord shall not unreasonably withhold, condition or delay its consent to any proposed sublet of the Subject Space or assignment of this Lease on the terms specified in the Transfer Notice. &#160;Without limitation as to other reasonable grounds for withholding consent, the parties hereby agree that it shall be reasonable under this Lease and under any Applicable Law for Landlord to withhold consent to any proposed sublet or assignment where one or more of the following apply:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.2.1</font></font>Intentionally deleted;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.2.2</font></font>The Transferee is either a governmental agency or instrumentality thereof;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.2.3</font></font>The Transferee is not a party of reasonable financial worth and/or financial stability in light of the responsibilities to be undertaken in connection with the Transfer on the date consent is requested;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.2.4</font></font>The proposed Transfer would cause a violation of another lease for space in the Project, or would give an occupant of the Project a right to cancel its lease; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.2.5</font></font>Either the proposed Transferee, or any person or entity which directly or indirectly, controls, is controlled by, or is under common control with, the proposed Transferee, is negotiating with Landlord or has negotiated with Landlord during the six (6) month period immediately preceding the date Landlord receives the Transfer Notice, to lease space in the Project, and such space in the Project remains available for lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.2.6</font></font>In Landlord&#8217;s reasonable determination, the sub-rent, additional rent or other amounts received or accrued by Tenant from subleasing, assigning or otherwise Transferring all or any portion of the Premises is based on the income or profits of any person, or the assignment or sublease could cause any portion of the amounts received by Landlord pursuant to this Lease to fail to qualify as &#8220;rents from real property&#8221; within the meaning of section 856(d) of the Internal Revenue Code of 1986, as amended (the &#8220;<b style="font-weight:bold;">Code</b>&#8221;), or any similar or successor provision thereto or which would cause any other income of Landlord to fail to qualify as income described in section 856(c)(2) of the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">If Landlord consents to any Transfer pursuant to the terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;14.2</u> (and does not exercise any recapture rights Landlord may have under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;14.4</u> of this Lease), Tenant may within six (6) months after Landlord&#8217;s consent, but not later than the expiration of said six-month period, enter into such Transfer of the Premises or portion thereof, upon substantially the same terms and conditions as are set forth in the Transfer Notice furnished by Tenant to Landlord pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;14.1</u> of this Lease, provided that if there are any changes in the terms and conditions from those specified in the Transfer Notice (i) such that Landlord would initially have been entitled to refuse its consent to such Transfer under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;14.2</u>, Tenant shall again submit the Transfer to Landlord for its approval and other action under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 14</u> (including Landlord&#8217;s right of recapture, if any, under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;14.4</u> of this Lease). &#160;Notwithstanding anything to the contrary in this Lease, if Tenant or any proposed Transferee claims that Landlord has withheld or delayed its consent in violation of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;14.2</u> or otherwise has breached its obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 14</u>, their sole remedies shall be a suit for contract damages (other than damages for injury to, or interference with, Tenant&#8217;s business including, without limitation, loss of profits, however occurring) or declaratory judgment and an injunction for the relief sought, and Tenant hereby waives all other remedies, including, without limitation, any right at law or equity to terminate this Lease, on its own behalf and, to the extent permitted under all Applicable Laws, on behalf of the proposed Transferee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer Premium</b>. &#160;If Landlord consents to a Transfer, as a condition thereto which the parties hereby agree is reasonable, Tenant shall pay to Landlord fifty percent (50%) of any &#8220;<b style="font-weight:bold;">Transfer Premium</b>&#8221;, as that term is defined in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;14.3</u>, received by Tenant from such Transferee. &#160;&#8220;<b style="font-weight:bold;">Transfer Premium</b>&#8221; shall mean all rent, additional rent and other consideration payable by such Transferee in connection with the Transfer in excess of the Rent and Additional Rent payable by Tenant under this Lease during the term of the Transfer on a per rentable square foot basis if less than all of the Premises is transferred, after deducting the reasonable third party expenses incurred by Tenant for (i)&#160;any design and construction costs incurred on account of changes, alterations and improvements to the Premises in connection with the Transfer, (ii)&#160;any free base rent, tenant improvement allowances reasonably provided to the Transferee in connection with the Transfer (provided that such free rent, tenant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-29-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">improvement allowances shall be deducted only to the extent the same is included in the calculation of total consideration payable by such Transferee), (iii)&#160;any brokerage commissions in connection with the Transfer, and (iv) legal fees and disbursements reasonably incurred in connection with the Transfer (collectively, &#8220;<b style="font-weight:bold;">Tenant&#8217;s Subleasing Costs</b>&#8221;). &#160;&#8220;<b style="font-weight:bold;">Transfer Premium</b>&#8221; shall also include, but not be limited to, any lump sum payment, key money, bonus money or other cash consideration paid by Transferee to Tenant in connection with such Transfer, and any payment in excess of fair market value for services rendered by Tenant to Transferee or for assets, fixtures, inventory, equipment, or furniture transferred by Tenant to Transferee in connection with such Transfer. &#160;The determination of the amount of Landlord&#8217;s applicable share of the Transfer Premium shall be made on a monthly basis as rent or other consideration is received by Tenant under the Transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.4</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Option as to Subject Space</b>. &#160;Notwithstanding anything to the contrary contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 14</u>, in the event Tenant contemplates a Transfer<i style="font-style:italic;">,</i> Tenant shall give Landlord notice (the &#8220;<b style="font-weight:bold;">Intention to Transfer Notice</b>&#8221;) of such contemplated Transfer (whether or not the contemplated Transferee or the terms of such contemplated Transfer have been determined). &#160;The Intention to Transfer Notice shall specify the portion of and amount of rentable square feet of the Premises which Tenant intends to Transfer (the &#8220;<b style="font-weight:bold;">Contemplated Transfer Space</b>&#8221;), the contemplated date of commencement of the Contemplated Transfer (the &#8220;<b style="font-weight:bold;">Contemplated Effective Date</b>&#8221;), and the contemplated length of the term of such contemplated Transfer, and shall specify that such Intention to Transfer Notice is delivered to Landlord pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;14.4</u> in order to allow Landlord to elect to recapture the Contemplated Transfer Space. &#160;Thereafter, Landlord shall have the option, by giving written notice to Tenant (a &#8220;<b style="font-weight:bold;">Recapture Notice</b>&#8221;) within ten (10) days after receipt of any Intention to Transfer Notice, to recapture the Contemplated Transfer Space. &#160;Such recapture shall cancel and terminate this Lease with respect to such Contemplated Transfer Space as of the Contemplated Effective Date. &#160;In the event of a recapture by Landlord, if this Lease shall be canceled with respect to less than the entire Premises, the Rent reserved herein shall be prorated on the basis of the number of rentable square feet retained by Tenant in proportion to the number of rentable square feet contained in the Premises, and this Lease as so amended shall continue thereafter in full force and effect, and upon request of either party, the parties shall execute written confirmation of the same. &#160;Landlord and Tenant shall share equally in the costs to demise any such portion of the Premises recaptured by Landlord pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.4</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.5</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effect of Transfer</b>. &#160;If Landlord consents to a Transfer, (i) the terms and conditions of this Lease shall in no way be deemed to have been waived or modified, (ii) such consent shall not be deemed consent to any further Transfer by either Tenant or a Transferee, (iii) Tenant shall deliver to Landlord, promptly after execution, an original executed copy of all documentation pertaining to the Transfer in form reasonably acceptable to Landlord, (iv) Tenant shall furnish upon Landlord&#8217;s request a complete statement, certified by an independent certified public accountant, or Tenant&#8217;s chief financial officer, setting forth in detail the computation of any Transfer Premium Tenant has derived and shall derive from such Transfer, and (v) no Transfer relating to this Lease or agreement entered into with respect thereto, whether with or without Landlord&#8217;s consent, shall relieve Tenant or any guarantor of the Lease from any liability under this Lease, including, without limitation, in connection with the Subject Space. &#160;Landlord or its authorized representatives shall have the right at all reasonable times to audit the books, records and papers of Tenant relating to any Transfer, and shall have the right to make copies thereof. &#160;If the Transfer Premium respecting any Transfer shall be found understated, Tenant shall, within thirty (30) days after demand, pay the deficiency, and if understated by more than two percent (2%), Tenant shall pay Landlord&#8217;s costs of such audit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.6</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease/Transfer Restrictions</b>. &#160;Notwithstanding anything contained herein to the contrary and without limiting the generality of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.1</u> above, Tenant shall not: &#160;(a) sublet all or part of the Premises or assign or otherwise Transfer this Lease on any basis such that the rental or other amounts to be paid by the subtenant or assignee thereunder would be based, in whole or in part, on the income or profits derived by the business activities of the subtenant or assignee; (b) sublet all or part of the Premises or assign this Lease to any person or entity in which, under Section 856(d)(2)(B) of the Code, Longfellow Atlantic REIT, Inc., a Delaware corporation (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), or any affiliate of the Company owns, directly or indirectly (by applying constructive ownership rules set forth in Section 856(d) (5) of the Code), a ten percent (10%) or greater interest; or (c) sublet all or part of the Premises or assign this Lease in any other manner or otherwise derive any income which could cause any portion of the amounts received by Landlord pursuant hereto or any sublease to fail to qualify as &#8220;rents from real property&#8221; within the meaning of Section 856(d) of the Code, or which could cause any other income received by Landlord to fail to qualify as income described in Section 856(c) (2) of the Code. &#160;The requirements of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14.6</u> shall likewise apply to any further subleasing, assignment or other Transfer by any subtenant or assignee. &#160;All references herein to Section 856 of the Code also shall refer to any amendments thereof or successor provisions thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-30-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.7</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Occurrence of Default</b>. &#160;Any Transfer hereunder shall be subordinate and subject to the provisions of this Lease, and if this Lease shall be terminated during the term of any Transfer, Landlord shall have the right to (and each sublease shall provide Landlord with the ability to): &#160;(i) treat such Transfer as cancelled and repossess the Subject Space by any lawful means, or (ii) require that such Transferee attorn to and recognize Landlord as its landlord under any such Transfer. &#160;If Tenant shall be in default under this Lease, Landlord is hereby irrevocably authorized, as Tenant&#8217;s agent and attorney-in-fact, to direct any Transferee to make all payments under or in connection with the Transfer directly to Landlord (which Landlord shall apply towards Tenant&#8217;s obligations under this Lease) until such default is cured. &#160;Such Transferee shall rely on any representation by Landlord that Tenant is in default hereunder, without any need for confirmation thereof by Tenant. &#160;Upon any assignment, the assignee shall assume in writing all obligations and covenants of Tenant thereafter to be performed or observed under this Lease. &#160;No collection or acceptance of rent by Landlord from any Transferee shall be deemed a waiver of any provision of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 14</u> or the approval of any Transferee or a release of Tenant from any obligation under this Lease, whether theretofore or thereafter accruing. &#160;In no event shall Landlord&#8217;s enforcement of any provision of this Lease against any Transferee be deemed a waiver of Landlord&#8217;s right to enforce any term of this Lease against Tenant or any other person. &#160;If Tenant&#8217;s obligations hereunder have been guaranteed, Landlord&#8217;s consent to any Transfer shall not be effective unless the guarantor also consents to such Transfer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.8</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deemed Consent Transfers</b>. &#160;Notwithstanding anything to the contrary contained in this Article 14, (i) an assignment of this Lease, or a subletting of all or a portion of the Premises, to an affiliate of Tenant (an entity which is controlled by, controls, or is under common control with Tenant), (ii) an assignment of the Lease by Tenant to an entity which acquires all or substantially all of the assets or interest (partnership, stock or other) of Tenant, or (iii) an assignment of the Lease to an entity which is the resulting entity of a merger or consolidation of Tenant or (iv) a sale of corporate shares of capital stock in Tenant in connection with an initial public offering of Tenant&#8217;s stock, or any other transfer of Tenant&#8217;s stock, on a nationally-recognized stock exchange (each, a &#8220;<b style="font-weight:bold;">Permitted Transferee</b>&#8221;), shall not be deemed a Transfer requiring Landlord&#8217;s consent under this Article 14, provided that (A) Tenant notifies Landlord of any such assignment or sublease within ten (10) days thereafter, and promptly supplies Landlord with any documents or information requested by Landlord regarding such assignment or sublease or such affiliate, (B) such assignment or sublease is not a subterfuge by Tenant to avoid its obligations under this Lease, and (C) with respect to an assignment to a Permitted Transferee or a Transfer pursuant to clauses (ii) or (iii) above, the resulting Tenant under this Lease shall have a market value (computed in accordance with generally accepted accounting principles if such resulting Tenant entity is a private company or computed based on the share price of outstanding shares of the resulting Tenant entity if such entity is a public company) (&#8220;<b style="font-weight:bold;">Market Value</b>&#8221;) at least equal to the Market Value of Tenant on the day that is three (3) months prior to the effective date of such assignment or sublease. &#160;An assignee of Tenant&#8217;s entire interest that is also a Permitted Transferee may also be known as a &#8220;<b style="font-weight:bold;">Permitted Assignee</b>&#8221;. &#160;&#8220;<b style="font-weight:bold;">Control</b>,&#8221; as used in this Section 14.8, shall mean the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities of, or possession of the right to vote, in the ordinary direction of its affairs, of more than fifty percent (50%) of the voting interest in, any person or entity, or the power to direct the policies or operations of any person or entity (by contract or otherwise). &#160;No such permitted assignment or subletting or other Transfer permitted with or without Landlord&#8217;s consent pursuant to this Article 14 shall serve to release Tenant from any of its obligations under this Lease<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">15.</b></font><b style="font-weight:bold;">SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Surrender of Premises</b>. &#160;No act or thing done by Landlord or any agent or employee of Landlord during the Lease Term shall be deemed to constitute an acceptance by Landlord of a surrender of the Premises unless such intent is specifically acknowledged in writing by Landlord. &#160;The delivery of keys to the Premises to Landlord or any agent or employee of Landlord shall not constitute a surrender of the Premises or effect a termination of this Lease, whether or not the keys are thereafter retained by Landlord, and notwithstanding such delivery Tenant shall be entitled to the return of such keys at any reasonable time upon request until this Lease shall have been properly terminated. &#160;The voluntary or other surrender of this Lease by Tenant, whether accepted by Landlord or not, or a mutual termination hereof, shall not work a merger, and at the option of Landlord shall operate as an assignment to Landlord of all subleases or subtenancies affecting the Premises or terminate any or all such sublessees or subtenancies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal of Tenant Property by Tenant</b>. &#160;Upon the expiration of the Lease Term, or upon any earlier termination of this Lease, Tenant shall, subject to the provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 15</u>, quit and surrender possession</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-31-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">of the Premises to Landlord in as good order and condition as when Tenant took possession and as thereafter improved by Landlord and/or Tenant, reasonable wear and tear and repairs which are specifically made the responsibility of Landlord hereunder, casualty and condemnation excepted, and Tenant shall have no obligation to remove the Tenant Improvements. &#160;Upon such expiration or termination, Tenant shall, without expense to Landlord, remove or cause to be removed from the Premises all Alterations that Tenant is required to remove in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.3</u> of this Lease, any debris and rubbish, and such items of furniture, equipment, free-standing cabinet work, movable partitions and other articles of personal property owned by Tenant or installed or placed by Tenant at its expense in the Premises, and such similar articles of any other persons claiming under Tenant (unless Landlord, in its sole discretion, waives the requirement that any item of personal property be removed), and Tenant shall repair at its own expense all damage to the Premises and Building resulting from such removal. Tenant&#8217;s personal property includes only those items that are not built into the Premises and that have not been constructed or installed by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Assessment</b>. &#160;Prior to the expiration of the Lease (or within thirty (30) days after any earlier termination), Tenant shall clean and otherwise decommission all interior surfaces (including floors, walls, ceilings, and counters), piping, supply lines, waste lines and plumbing in or serving the Premises, and all exhaust or other ductwork in or serving the Premises, in each case that has carried, released or otherwise been exposed to any Hazardous Materials due to Tenant&#8217;s use or occupancy of the Premises, and shall otherwise clean the Premises so as to permit the Environmental Assessment called for by this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15.3</u> to be issued. Prior to the expiration of this Lease (or within thirty (30) days after any earlier termination), Tenant, at Tenant&#8217;s expense, shall obtain for Landlord a report (an &#8220;<b style="font-weight:bold;">Environmental Assessment</b>&#8221;) addressed to Landlord (and, at Tenant&#8217;s election, Tenant) by a reputable licensed environmental engineer or industrial hygienist that is designated by Tenant and acceptable to Landlord in Landlord&#8217;s reasonable discretion, which report shall be based on the environmental engineer&#8217;s inspection of the Premises and shall state, to Landlord&#8217;s reasonable satisfaction, that (a) the Hazardous Materials described in the first sentence of this paragraph, to the extent, if any, existing prior to such decommissioning, have been removed in accordance with Applicable Laws; (b) all Hazardous Materials described in the first sentence of this paragraph, if any, have been removed in accordance with Applicable Laws from the interior surfaces of the Premises (including floors, walls, ceilings, and counters), piping, supply lines, waste lines and plumbing, and all such exhaust or other ductwork in the Premises, may be reused by a subsequent tenant or disposed of in compliance with Applicable Laws without incurring special costs or undertaking special procedures for demolition, disposal, investigation, assessment, cleaning or removal of such Hazardous Materials and without giving notice in connection with such Hazardous Materials; and (c) the Premises may be reoccupied for office, research and development, or laboratory use, demolished or renovated without incurring special costs or undertaking special procedures for disposal, investigation, assessment, cleaning or removal of Hazardous Materials described in the first sentence of this paragraph and without giving notice in connection with Hazardous Materials. &#160;Further, for purposes of clauses (b) and (c), &#8220;special costs&#8221; or &#8220;special procedures&#8221; shall mean costs or procedures, as the case may be, that would not be incurred but for the nature of the Hazardous Materials as Hazardous Materials instead of non-hazardous materials. &#160;The report shall also include reasonable detail concerning the clean-up measures taken, the clean-up locations, the tests run and the analytic results. &#160;Tenant shall submit to Landlord the identity of the applicable consultants and the scope of the proposed Environmental Assessment for Landlord&#8217;s reasonable review and approval at least 30 days prior to commencing the work described therein or at least 60 days prior to the expiration of the Lease Term, whichever is earlier.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">If Tenant fails to perform its obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15.3</u>, without limiting any other right or remedy, Landlord may, on five (5) business days&#8217; prior written notice to Tenant perform such obligations at Tenant&#8217;s expense if Tenant has not commenced to do so within said five day period, and Tenant shall within 10 days of written demand reimburse Landlord for all reasonable out-of-pocket costs and expenses incurred by Landlord in connection with such work. &#160;Tenant&#8217;s obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15.2</u> shall survive the expiration or earlier termination of this Lease. &#160;In addition, at Landlord&#8217;s election, Landlord may inspect the Premises and/or the Project for Hazardous Materials at Landlord&#8217;s cost and expense within twenty (20) days of Tenant&#8217;s surrender of the Premises at the expiration or earlier termination of this Lease. &#160;Tenant shall pay for all such costs and expenses incurred by Landlord in connection with such inspection if such inspection reveals that a release or threat of release of Hazardous Materials exists at the Project or Premises as a result of the acts or omission of Tenant, its officers, employees, contractors, and agents (except to the extent resulting from (i) Hazardous Materials existing in the Premises as at the delivery of possession to Tenant (in which event Landlord shall be responsible for any Clean-up, as provided in this Lease), or (ii) the acts or omissions of Landlord or Landlord&#8217;s agents, employees or contractors).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-32-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">16.</b></font><b style="font-weight:bold;">HOLDING OVER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">If Tenant holds over after the expiration of the Lease Term or earlier termination thereof, with the express written consent of Landlord, such tenancy shall be from month-to-month only and shall not constitute a renewal hereof or an extension for any further term. &#160;If Tenant holds over after the expiration of the Lease Term or earlier termination thereof, without the express written consent of Landlord, such tenancy shall be deemed to be a tenancy by sufferance only and shall not constitute a renewal hereof or an extension for any further term. &#160;In either case, Base Rent shall be payable at a monthly rate equal to (x) one hundred fifty percent (150%) of the Base Rent applicable during the last rental period of the Lease Term for the first 30 days of such hold over, and (y) the higher of one hundred fifty percent (150%) of the Base Rent applicable during the last rental period of the Lease Term and the fair market rent for each day thereafter. &#160;Such month-to-month tenancy or tenancy by sufferance, as the case may be, shall be subject to every other applicable term, covenant and agreement contained herein, including without limitation the obligation to pay Additional Rent. &#160;Nothing contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 16</u> shall be construed as consent by Landlord to any holding over by Tenant, and Landlord expressly reserves the right to require Tenant to surrender possession of the Premises to Landlord as provided in this Lease upon the expiration or other termination of this Lease. &#160;The provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 16</u> shall not be deemed to limit or constitute a waiver of any other rights or remedies of Landlord provided herein or at law. &#160;If Tenant fails to surrender the Premises upon the termination or expiration of this Lease, in addition to any other liabilities to Landlord accruing therefrom, Tenant shall protect, defend, indemnify and hold Landlord harmless from all loss, costs (including reasonable attorneys&#8217; fees) and liability resulting from such failure, including, without limiting the generality of the foregoing, any claims made by any succeeding tenant founded upon such failure to surrender and/or any lost profits and consequential or indirect damages to Landlord resulting therefrom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">17.</b></font><b style="font-weight:bold;">ESTOPPEL CERTIFICATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Tenant shall execute, acknowledge and deliver to Landlord an estoppel certificate, which, as submitted by Landlord, shall be substantially in the form of <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;17</b> attached hereto (or such other form as may be reasonably required by any prospective mortgagee or purchaser of the Project, or any portion thereof), indicating therein any exceptions thereto that may exist at that time, and shall also contain any other information reasonably requested by Landlord or Landlord&#8217;s mortgagee or prospective mortgagee. &#160;Any such certificate may be relied upon by any prospective mortgagee or purchaser of all or any portion of the Project. &#160;Failure of Tenant to timely object to or execute, acknowledge and deliver such estoppel certificate or other instruments shall constitute an acknowledgment by Tenant that statements included in the estoppel certificate are true and correct. At any time during the Lease Term, within ten (10) business days following a request in writing by Landlord, Landlord may require Tenant to provide Landlord with a current financial statement and financial statements of the two (2) years prior to the current financial statement year. &#160;Such statements shall be prepared in accordance with generally accepted accounting principles and, if such is the normal practice of Tenant, shall be audited by an independent certified public accountant. &#160;If no audited financial statement is prepared, such statement will be certified by the CFO or Treasurer of Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Landlord shall execute, acknowledge and deliver to Tenant a commercially reasonable estoppel certificate, as submitted by Tenant in such other form as may be reasonably required by any prospective lender, investor, or other party involved with Tenant. &#160;Any such certificate may be relied upon by third parties designated by Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">18.</b></font><b style="font-weight:bold;">SUBORDINATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">This Lease shall be subject and subordinate to all future ground or underlying leases of the Building or Project and to the lien of any mortgage, trust deed or other encumbrances now or hereafter in force against the Building or Project or any part thereof, if any, and to all renewals, extensions, modifications, consolidations and replacements thereof, and to all advances made or hereafter to be made upon the security of such mortgages or trust deeds, unless the holders of such mortgages, trust deeds or other encumbrances, or the lessors under such ground lease or underlying leases require in writing that this Lease be superior thereto. &#160;Tenant covenants and agrees that in the event any proceedings are brought for the foreclosure of any such mortgage or deed in lieu thereof (or if any ground lease is terminated), to attorn, without any deductions or set-offs whatsoever, to the lienholder or purchaser or any successors thereto upon any such foreclosure sale or deed in lieu thereof (or to the ground lessor), if so requested to do so by such purchaser or lienholder or ground lessor. Notwithstanding any other provision of this Lease to the contrary, no holder of any such mortgage, trustee deed or other encumbrance and no such ground lessor, shall be obligated to perform or liable in damages for failure to perform any of Landlord&#8217;s obligations under this Lease unless and until such holder shall foreclose such mortgage, trust deed or other encumbrance, or the lessors under such ground lease or underlying</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-33-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">leases otherwise acquire title to the Property, and then shall only be liable for Landlord&#8217;s obligations arising or accruing after such foreclosure or acquisition of title, provided the foregoing shall not release any such holder or ground lessor from performing ongoing obligations of Landlord from and after the date of such foreclosure or acquisition of title, such as repair and maintenance obligations. &#160;No such holder shall ever be obligated to perform or be liable in damages for any of Landlord&#8217;s obligations arising or accruing before such foreclosure or acquisition of title. &#160;Tenant shall, within ten (10) business days of request by Landlord, execute such further instruments or assurances as Landlord may reasonably deem necessary to evidence or confirm the subordination or superiority of this Lease to any such mortgages, trust deeds, ground leases or underlying leases. Tenant waives the provisions of any current or future statute, rule or law which may give or purport to give Tenant any right or election to terminate or otherwise adversely affect this Lease and the obligations of Tenant hereunder in the event of any foreclosure proceeding or sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Landlord&#8217;s interest herein may be assigned as security at any time to any Mortgagee. Notwithstanding the foregoing or anything to the contrary herein, no Mortgagee succeeding to the interest of Landlord hereunder shall be (i) liable in any way to Tenant for any act or omission, neglect or default on the part of Landlord under this Lease, (ii) responsible for any monies owing by or on deposit with Landlord to the credit of Tenant (except to the extent any such deposit is actually received by such mortgagee or ground lessor), (iii) subject to any counterclaim or setoff which theretofore accrued to Tenant against Landlord, (iv) bound (A) by any amendment or modification of this Lease if such Mortgagee held a loan secured by the Property at the time the amendment or modification of this Lease was made and Mortgagee did not consent to such amendment or modification, if required by any applicable documents, or (B) by any previous prepayment of Rent for more than one (1) month, which was not approved in writing by the Mortgagee, (v) liable beyond such Mortgagee&#8217;s interest in the Project or (vi) responsible for the payment or performance of any work to be done by Landlord under this Lease to render the Premises ready for occupancy by Tenant or for the payment of any tenant improvements allowances. &#160;Nothing in clause (i), above, shall be deemed to relieve any Mortgagee succeeding to the interest of Landlord hereunder of its obligation to comply with the obligations of Landlord under this Lease from and after the date of such succession.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">No Mortgagee shall, either by virtue of the Mortgage or any assignment of leases executed by Landlord for the benefit of such Mortgagee, be or become a mortgagee in possession or be or become subject to any liability or obligation under the Lease or otherwise until such Mortgagee shall have acquired the interest of Landlord in the Property, by foreclosure or otherwise, or in fact have taken possession of the Property as a mortgagee in possession and then such liability or obligation of Mortgagee under the Lease shall extend only to those liability or obligations accruing subsequent to the date that such Mortgagee has acquired the interest of Landlord in the Premises, or in fact taken possession of the Property as a mortgagee in possession.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">19.</b></font><b style="font-weight:bold;">DEFAULTS; REMEDIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Events of Default</b>. &#160;The occurrence of any of the following shall constitute a default of this Lease by Tenant:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.1.1</font></font>Any failure by Tenant to pay any Rent or any other charge required to be paid under this Lease, or any part thereof, when due and such failure shall continue for five (5) days after notice of such failure is given to Tenant, except that if Landlord shall have given two (2) such notices in any twelve (12) month period, Tenant shall not be entitled to any further notice of its delinquency in the payment of Rent or any other charge required to be paid under this Lease until such time as twelve (12) consecutive months shall have elapsed without Tenant having defaulted in any such payment; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.1.2</font></font>Except where a specific time period is otherwise set forth for Tenant&#8217;s performance in this Lease, in which event the failure to perform by Tenant within such time period shall be a default by Tenant under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;19.1.2</u>, any failure by Tenant to observe or perform any other provision, covenant or condition of this Lease to be observed or performed by Tenant where such failure continues for thirty (30) days after written notice thereof from Landlord to Tenant; provided that if the nature of such default is such that the same cannot reasonably be cured within a thirty (30) day period, Tenant shall not be deemed to be in default if it diligently commences such cure within such period and thereafter diligently proceeds to rectify and cure such default; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.1.3</font></font>Abandonment of the Premises by Tenant; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-34-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.1.4</font></font>The failure by Tenant to observe or perform according to the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Articles 5</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">17</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18</u> of this Lease where such failure continues for more than five (5) business days after notice from Landlord;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.1.5</font></font>If a receiver, guardian, conservator, trustee in bankruptcy or similar officer shall be appointed by a court of competent jurisdiction to take charge of all or any part of Tenant&#8217;s or any guarantor&#8217;s property and such appointment is not discharged within 90&#160;days thereafter or if a petition including, without limitation, a petition for reorganization or arrangement is filed by Tenant or any guarantor under any bankruptcy law or is filed against Tenant or any guarantor and, in the case of a filing against Tenant only, the same shall not be dismissed within 90&#160;days from the date upon which it is filed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The notice periods provided herein are in lieu of, and not in addition to, any notice periods provided by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Remedies Upon Default</b>. &#160;Upon the occurrence of any event of default by Tenant beyond applicable notice and cure periods, Landlord shall have, in addition to any other remedies available to Landlord at law or in equity (all of which remedies shall be distinct, separate and cumulative), the option to pursue any one or more of the following remedies, each and all of which shall be cumulative and nonexclusive, without any notice or demand whatsoever. Tenant hereby waives, for Tenant and for all those claiming under Tenant, any and all rights now or hereafter existing to redeem by order or judgment of any court or by any legal process or writ, Tenant&#8217;s right of occupancy of the Premises after any termination of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.2.1</font></font>Terminate this Lease (pursuant to Section 1951.2 of the California Civil Code), in which event Tenant shall immediately surrender the Premises to Landlord, and if Tenant fails to do so, Landlord may, without prejudice to any other remedy which it may have for possession or arrearages in rent, enter upon and take possession of the Premises and expel or remove Tenant and any other person who may be occupying the Premises or any part thereof, without being liable for prosecution or any claim or damages therefor; and Landlord may recover from Tenant the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 36pt;">(i)<font style="display:inline-block;width:26.56pt;"></font>The worth at the time of award of the unpaid rent which has been earned at the time of such termination; plus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 36pt;">(ii)<font style="display:inline-block;width:23.78pt;"></font>The worth at the time of award of the amount by which the unpaid rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 36pt;">(iii)<font style="display:inline-block;width:21pt;"></font>The worth at the time of award of the amount by which the unpaid rent for the balance of the Lease Term after the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 36pt;">(iv)<font style="display:inline-block;width:21.56pt;"></font>Any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant&#8217;s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, specifically including but not limited to, brokerage commissions and advertising expenses incurred, expenses of remodeling the Premises or any portion thereof for a new tenant, whether for the same or a different use, and any special concessions made to obtain a new tenant; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 36pt;">(v)<font style="display:inline-block;width:24.34pt;"></font>At Landlord&#8217;s election, such other amounts in addition to or in lieu of the foregoing as may be permitted from time to time by Applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The term &#8220;<b style="font-weight:bold;">rent</b>&#8221; as used in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 19.2</u> shall be deemed to be and to mean all sums of every nature required to be paid by Tenant pursuant to the terms of this Lease, whether to Landlord or to others. &#160;As used in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 19.2.1(i)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(ii)</u>, above, the &#8220;worth at the time of award&#8221; shall be computed by allowing interest at the rate set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 25</u> of this Lease, but in no case greater than the maximum amount of such interest permitted by law. &#160;As used in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 19.2.1(iii)</u> above, the &#8220;<b style="font-weight:bold;">worth at the time of award</b>&#8221; shall be computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one percent (1%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.2.2</font></font>Landlord shall have the remedy described in California Civil Code Section 1951.4 (lessor may continue lease in effect after lessee&#8217;s breach and abandonment and recover rent as it becomes due, if lessee has</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-35-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">the right to sublet or assign, subject only to reasonable limitations). &#160;Accordingly, if Landlord does not elect to terminate this Lease on account of any default by Tenant, Landlord may, from time to time, without terminating this Lease, enforce all of its rights and remedies under this Lease, including the right to recover all rent as it becomes due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.2.3</font></font>Landlord shall at all times have the rights and remedies (which shall be cumulative with each other and cumulative and in addition to those rights and remedies available under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 19.2</u>, or any law or other provision of this Lease), without prior demand or notice except as required by Applicable Law, to seek any declaratory, injunctive or other equitable relief, and specifically enforce this Lease, or restrain or enjoin a violation or breach of any provision hereof. &#160;The provisions of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 19.2.3</u> are not dependent upon the occurrence of a default.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.2.4</font></font>Nothing herein shall limit or prejudice the right of Landlord to prove and obtain in a proceeding for bankruptcy, insolvency, arrangement or reorganization, by reason of the termination, an amount equal to the maximum allowed by a statute of law in effect at the time when, and governing the proceedings in which, the damages are to be proved, whether or not the amount is greater to, equal to, or less than the amount of the loss or damage which Landlord has suffered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subleases of Tenant</b>. &#160;Whether or not Landlord elects to terminate this Lease on account of any default by Tenant, as set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 19</u>, Landlord shall have the right to terminate any and all subleases, licenses, concessions or other consensual arrangements for possession entered into by Tenant and affecting the Premises or may, in Landlord&#8217;s sole discretion, succeed to Tenant&#8217;s interest in such subleases, licenses, concessions or arrangements. &#160;In the event of Landlord&#8217;s election to succeed to Tenant&#8217;s interest in any such subleases, licenses, concessions or arrangements, Tenant shall, as of the date of notice by Landlord of such election, have no further right to or interest in the rent or other consideration receivable thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.4</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Efforts to Relet</b>. &#160;No re-entry or repossession, repairs, maintenance, changes, alterations and additions, appointment of a receiver to protect Landlord&#8217;s interests hereunder, or any other action or omission by Landlord shall be construed as an election by Landlord to terminate this Lease or Tenant&#8217;s right to possession, or to accept a surrender of the Premises, nor shall same operate to release Tenant in whole or in part from any of Tenant&#8217;s obligations hereunder, unless express written notice of such intention is sent by Landlord to Tenant. &#160;Tenant hereby irrevocably waives any right otherwise available under any law to redeem or reinstate this Lease. &#160;Notwithstanding the foregoing, Tenant does not waive any requirement that the Landlord has under Applicable Law to re-let the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.5</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord Default</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.5.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</b>. &#160;Notwithstanding anything to the contrary set forth in this Lease, Landlord shall not be in default in the performance of any obligation required to be performed by Landlord pursuant to this Lease unless Landlord fails to perform such obligation within thirty (30) days after the receipt of notice from Tenant specifying in detail Landlord&#8217;s failure to perform; provided, however, if the nature of Landlord&#8217;s obligation is such that more than thirty (30) days are required for its performance, then Landlord shall not be in default under this Lease if it shall commence such performance within such thirty (30) day period and thereafter diligently pursue the same to completion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">20.</b></font><b style="font-weight:bold;">COVENANT OF QUIET ENJOYMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Landlord covenants that Tenant, on paying the Rent, charges for services and other payments herein reserved and on keeping, observing and performing all the other terms, covenants, conditions, provisions and agreements herein contained on the part of Tenant to be kept, observed and performed, shall, during the Lease Term, peaceably and quietly have, hold and enjoy the Premises subject to the terms, covenants, conditions, provisions and agreements hereof without interference by any persons lawfully claiming by or through Landlord. &#160;The foregoing covenant is in lieu of any other covenant express or implied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-36-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">21.</b></font><b style="font-weight:bold;">CREDIT ENHANCEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">21.1</font></font><b style="font-weight:bold;">Letter of Credit</b>. &#160;Within ten (10) business days after Tenant&#8217;s execution of this Lease, Tenant shall deposit with Landlord a letter of credit (the &#8220;<b style="font-weight:bold;">L/C Security</b>&#8221;) in the amount set forth in Section 9 of the Summary as credit enhancement for the faithful performance by Tenant of all its obligations under this Lease as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(a)<font style="display:inline-block;width:24.9pt;"></font>Tenant shall provide Landlord and maintain in full force and effect throughout the Term and until the date that is ninety (90) days after the Lease Expiration Date, an evergreen letter of credit substantially in the form of <b style="font-weight:bold;">Exhibit 21</b> issued by an issuer reasonably satisfactory to Landlord, in the amount set forth in Section 9 of the Summary; provided, however, the initial letter of credit may be issued by JP Morgan Chase Bank in the form already approved by Landlord. &#160;If at any time during the Term (i) Landlord determines in its sole discretion that the financial condition of such issuer has changed in any materially adverse way from the financial condition of such issuer as of the date of execution of this Lease including, without limitation, if such issuer is declared insolvent or is placed into receivership or conservatorship by the Federal Deposit Insurance Corporation, or any successor or similar entity, if a trustee, receiver or liquidator is appointed for such issuer, if the credit rating of the long-term debt of the issuer of the letter of credit (according to Moody&#8217;s, Standard &amp; Poor&#8217;s or similar national rating agency reasonably identified by Landlord) is downgraded to a grade below investment grade, if the issuer enters into any supervisory agreement with any governmental authority or fails to meet any capital requirements imposed by Applicable Law, Landlord may require the L/C Security to be replaced by an L/C Security issued by a different issuer, in which event Tenant shall within twenty (20) days after written notice from Landlord deliver to Landlord a replacement L/C Security issued by a commercial bank or savings and loan association acceptable to Landlord in its sole discretion and that meets all other requirements of this Article. &#160;If Tenant has actual notice, or Landlord notifies Tenant at any time, that any issuer of the L/C Security has become insolvent or placed into FDIC receivership, then Tenant shall promptly deliver to Landlord (without the requirement of further notice from Landlord) substitute L/C Security issued by a commercial bank or savings and loan association acceptable to Landlord in its sole discretion and that meets all other requirements of this Article. &#160;As used herein with respect to the issuer of the L/C Security, &#8220;insolvent&#8221; shall mean the determination of insolvency as made by such issuer&#8217;s primary bank regulator (i.e., the state bank supervisor for state-chartered banks; the OCC or OTS, respectively, for federally chartered banks or thrifts; or the Federal Reserve for its member banks).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(b)<font style="display:inline-block;width:24.34pt;"></font>Landlord may draw upon the L/C Security, and hold and apply the proceeds for the payment of any Rent or any other sum in default, or to compensate Landlord for any other loss or damage that Landlord may suffer by reason of Tenant&#8217;s default, if: &#160;(i) a default beyond applicable notice and cure periods exists (or would have existed with the giving of notice and passage of applicable cure periods, but only if transmittal of a default notice is stayed or barred by applicable bankruptcy or other similar law); (ii) as of the date forty-five (45) days before any L/C Security expires Tenant has not delivered to Landlord an amendment or replacement for such L/C Security, reasonably satisfactory to Landlord, extending the expiry date to the date that is ninety (90) days after the then-current Lease Expiration Date; (iii) Tenant fails to pay any bank charges for Landlord&#8217;s transfer of the L/C Security when due; or (iv) the issuer of the L/C Security ceases, or announces that it will cease, to maintain an office in the city where Landlord may present drafts under the L/C Security (and fails to permit drawing upon the L/C Security by overnight courier or facsimile). &#160;This Section does not limit any other provisions of this Lease allowing Landlord to draw the L/C Security under specified circumstances. &#160;In the event of any such draw upon the L/C Security, Tenant shall within 10 business days thereafter provide Landlord with a replacement letter of credit, or amendment to the existing letter of credit increasing the amount of such letter of credit, in the amount of L/C Security, and in the form, required hereunder, and Tenant&#8217;s failure to do so shall be a material breach of this Lease. &#160;Landlord shall hold the proceeds of any draw not applied as set forth above as a cash Security Deposit as further described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(c)<font style="display:inline-block;width:24.9pt;"></font>If Landlord transfers its interest in the Premises, then Landlord shall transfer the L/C Security to the transferee of its interest and notify Tenant of such transfer, and Tenant shall at Landlord&#8217;s expense, within fifteen (15) business days after receiving a request from Landlord, deliver (and, if the issuer requires, Landlord shall consent to) an amendment to the L/C Security naming Landlord&#8217;s grantee as substitute beneficiary. &#160;If the required Security Deposit changes while L/C Security is in force, then Tenant shall deliver (and, if the issuer requires, Landlord shall consent to) a corresponding amendment to the L/C Security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(d)<font style="display:inline-block;width:24.34pt;"></font>If and to the extent Landlord is holding the proceeds of the L/C Security in cash from time to time, such cash shall be held by Landlord as security for the faithful performance by Tenant of all of the terms, covenants and conditions of this Lease to be kept and performed by Tenant during the period commencing on</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-37-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">the Execution Date and ending upon the expiration or termination of Tenant&#8217;s obligations under this Lease. &#160;If Tenant defaults (beyond applicable notice and cure periods) with respect to any provision of this Lease, including any provision relating to the payment of Rent, then Landlord may (but shall not be required to) use, apply or retain all or any part of the Security Deposit for the payment of any Rent or any other sum in default, or to compensate Landlord for any other loss or damage that Landlord may suffer by reason of Tenant&#8217;s default as provided in this Lease. &#160;The provisions of this Article shall survive the expiration or earlier termination of this Lease. &#160;In the event of bankruptcy or other debtor-creditor proceedings against Tenant, any cash security then being held by Landlord shall be deemed to be applied first to the payment of Rent and other charges due Landlord for all periods prior to the filing of such proceedings. &#160;Landlord shall deliver or credit to any purchaser of Landlord&#8217;s interest in the Premises the funds then held hereunder by Landlord, and thereupon (and upon confirmation by the transferee of such funds, whether expressly or by written assumption of this Lease, generally) Landlord shall be discharged from any further liability with respect to such funds. &#160;This provision shall also apply to any subsequent transfers. If Tenant shall fully and faithfully perform every provision of this Lease to be performed by it, then the cash security, if any, or any balance thereof, shall be returned to Tenant (or, at Landlord&#8217;s option, to the last assignee of Tenant&#8217;s interest hereunder) within 90 days after the expiration or earlier termination of this Lease. &#160;If and to the extent the security held by Landlord hereunder shall be in cash, Landlord shall hold such cash in an account at a banking organization selected by Landlord; provided, however, that Landlord shall not be required to maintain a separate account for the cash security but may intermingle it with other funds of Landlord. &#160;Landlord shall be entitled to all interest and/or dividends, if any, accruing on such cash security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 10pt 0pt;">(e)<font style="display:inline-block;width:24.9pt;"></font>Notwithstanding anything to the contrary contained in this Lease, if the Market Value of Tenant as of the last day of the seventy-sixth (76) full month of the Lease Term is more than double the Market Value of Tenant as of the date of this Lease, then the required amount of the L/C Security shall be reduced to $94,422.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">22.</b></font><b style="font-weight:bold;">INTENTIONALLY OMITTED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">23.</b></font><b style="font-weight:bold;">SIGNS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Signage</b>. Tenant shall not install any signage (including, without limitation, any signs identifying Tenant&#8217;s name or advertising Tenant&#8217;s merchandise or otherwise) in or about the Premises that is visible from the exterior of the Premises or in any other part of the Project except as expressly permitted in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 23.1</u> or by Landlord&#8217;s prior written approval. &#160;Tenant, at its sole cost and expense, shall be entitled to (i) one sign identifying Tenant at the entry to the Premises, which identification signage shall be consistent with building standard signage, and (ii) one (1) exterior Building-top sign at a location approved by Landlord and in compliance with Applicable Laws.. &#160;Such entry signage shall be comparable to that used by Landlord for other similar floors in the Building, and all signage shall comply with Landlord&#8217;s then-current Building standard signage program. &#160;All permitted signs shall be maintained by Tenant at its expense in a first-class and safe condition and appearance. &#160;The installation and eventual removal of Tenant&#8217;s entry door signage and exterior Building signage shall be the responsibility of Landlord. &#160;Tenant shall repair any damage to the Premises or Building, inside or outside, resulting from the erection, maintenance or removal of any signs. Tenant&#8217;s signage must also comply with all Applicable Laws. &#160;All Building signage shall be subject to the existing rights of other tenants in the Building and any declaration of covenants for the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prohibited Signage and Other Items</b>. &#160;Any signs, notices, logos, pictures, names or advertisements which are installed and that have not been separately approved by Landlord may be removed without notice by Landlord at the sole expense of Tenant. &#160;Except as expressly permitted pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 23.1</u> above, Tenant may not install any signs on the exterior or roof of the Project or the Common Areas. &#160;Any signs, displays, window coverings, window lettering, or blinds (even if the same are located behind the Landlord-approved window coverings for the Building), or other items or Alterations visible from the exterior of the Premises or Building, shall be subject to the prior approval of Landlord, in its reasonable discretion. &#160;Tenant shall not place or install any projections, antennae, aerials, or similar devices inside or outside of the Building, without the prior written approval of Landlord, subject to Tenant&#8217;s rights pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 23.1</u> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">24.</b></font><b style="font-weight:bold;">COMPLIANCE WITH LAW</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Tenant shall not do anything or suffer anything to be done by any Tenant Party in or about the Premises or the Project which will in any way conflict with any law, statute, ordinance or other federal, state or local governmental</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-38-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">rule, regulation or requirement now in force or which may hereafter be enacted or promulgated (collectively, &#8220;<b style="font-weight:bold;">Applicable Laws</b>&#8221;). &#160;At its sole cost and expense, Tenant shall promptly comply with all such Applicable Laws which relate to (i)&#160;Tenant&#8217;s use of the Premises, (ii) any Alterations, or (iii)&#160;the Building, but as to the Building, only to the extent such obligations are triggered by Alterations or Tenant&#8217;s particular use of the Premises for any use other than office and laboratory use. Tenant shall be responsible, at its sole cost and expense, to make all alterations to the Premises as are required to comply with the Applicable Laws to the extent required in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 24</u>. &#160;Notwithstanding the foregoing terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 24</u> to the contrary, Tenant may defer such compliance with Applicable Laws while Tenant contests, in a court of proper jurisdiction, in good faith, the applicability of such Applicable Laws to the Premises or Tenant&#8217;s specific use or occupancy of the Premises; provided, however, Tenant may only defer such compliance if such deferral shall not (a)&#160;prohibit Tenant from obtaining or maintaining a certificate of occupancy for the Premises, (b)&#160;prohibit Landlord from obtaining or maintaining a certificate of occupancy for the Building or any portion thereof, (c)&#160;unreasonably and materially affect the safety of the employees and/or invitees of Landlord or of any tenant in the Building (including Tenant), (d)&#160;create a significant health hazard for the employees and/or invitees of Landlord or of any tenant in the Building (including Tenant), (e)&#160;otherwise materially and adversely affect Tenant&#8217;s use of or access to the Buildings or the Premises, or (f)&#160;impose material obligations, liability, fines, or penalties upon Landlord or any other tenant of the Building, or would materially and adversely affect the use of or access to the Building by Landlord or other tenants or invitees of the Building. &#160;The judgment of any court of competent jurisdiction or the admission of Tenant in any judicial action, regardless of whether Landlord is a party thereto, that Tenant has violated any of said governmental measures, shall be conclusive of that fact as between Landlord and Tenant. &#160;Landlord shall comply with all Applicable Laws relating to the Common Areas of the Building, provided that compliance with such Applicable Laws is not the responsibility of Tenant under this Lease, and provided further that Landlord&#8217;s failure to comply therewith would prohibit Tenant from obtaining or maintaining a certificate of occupancy for the Premises, or would unreasonably and materially affect the safety of Tenant&#8217;s employees or create a significant health hazard for Tenant&#8217;s employees, or would otherwise materially and adversely affect Tenant&#8217;s use of or access to the Premises. &#160;Landlord shall be permitted to include in Operating Expenses any costs or expenses incurred by Landlord under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;24</u> to the extent not prohibited by the terms of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.2.7</u>, above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">For purposes of Section 1938 of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that neither the Premises, the Building nor the Common Areas have undergone inspection by a Certified Access Specialist (CASp). &#160;Pursuant to California Civil Code Section 1938, Tenant is hereby notified that<b style="font-weight:bold;">: &#160;&#8220;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. &#160;Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy of the lessee or tenant, if requested by the lessee or tenant. &#160;The parties shall mutually agree on the arrangements for the time and manner of any CASp inspection, the payment of the fee for the CASp inspection and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#8221;</b> If Tenant requests to perform a CASp inspection of the Premises, Tenant shall, at its cost, retain a CASp approved by Landlord (provided that Landlord may designate the CASp, at Landlord&#8217;s option) to perform the inspection of the Premises at a time agreed upon by the parties. &#160;Tenant shall provide Landlord with a copy of any report or certificate issued by the CASp (the &#8220;<b style="font-weight:bold;">CASp Report</b>&#8221;). &#160;Landlord and Tenant agree that any modifications necessary to correct violations of construction related accessibility standards identified in the CASp Report shall be the responsibility of Tenant. &#160;Tenant agrees to keep the information in the CASp Report confidential except as necessary for the Tenant to complete such modifications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">25.</b></font><b style="font-weight:bold;">LATE CHARGES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">If any installment of Rent or any other sum due from Tenant shall not be received by Landlord or Landlord&#8217;s designee within five (5) business days after the date due, then Tenant shall pay to Landlord a late charge equal to five percent (5%) of the overdue amount plus any reasonable attorneys&#8217; fees incurred by Landlord by reason of Tenant&#8217;s failure to pay Rent and/or other charges when due hereunder. &#160;Notwithstanding the foregoing, Landlord shall not charge Tenant a late charge for the first (1<sup style="font-size:7.5pt;vertical-align:top;">st</sup>) late payment in any twelve (12) month period unless Tenant fails to timely pay such amount within five (5) business days following notice from Landlord that such amount is past due. &#160;The late charge shall be deemed Additional Rent and the right to require it shall be in addition to all of Landlord&#8217;s other rights and remedies hereunder or at law and shall not be construed as liquidated damages or as limiting Landlord&#8217;s remedies in any manner. &#160;In addition to the late charge described above, any Rent or other amounts owing hereunder which are</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-39-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">not paid when due shall bear interest from the date when due until paid at a rate per annum equal to the lesser of (i) the annual &#8220;<b style="font-weight:bold;">Bank Prime Loan</b>&#8221; rate cited in the Federal Reserve Statistical Release Publication H.15, published on the first Tuesday of each calendar month (or such other comparable index as Landlord and Tenant shall reasonably agree upon if such rate ceases to be published) plus nine (9) percentage points, and (ii) the highest rate permitted by Applicable Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">26.</b></font><b style="font-weight:bold;">LANDLORD&#8217;S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">26.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Cure</b>. &#160;All covenants and agreements to be kept or performed by Tenant under this Lease shall be performed by Tenant at Tenant&#8217;s sole cost and expense and without any reduction of Rent, except to the extent, if any, otherwise expressly provided herein. &#160;If Tenant shall fail to perform any obligation under this Lease, and such failure shall continue in excess of the time allowed under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;19.1.2</u> above, unless a specific time period is otherwise stated in this Lease, Landlord may, but shall not be obligated to, make any such payment or perform any such act on Tenant&#8217;s part without waiving its rights based upon any default of Tenant and without releasing Tenant from any obligations hereunder. Except as may be specifically provided to the contrary in this Lease, Tenant shall pay to Landlord, upon delivery by Landlord to Tenant of statements therefor: &#160;(i) sums equal to expenditures reasonably made and obligations incurred by Landlord in connection with the remedying by Landlord of Tenant&#8217;s defaults pursuant to the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;26.1</u>; (ii) sums equal to all losses, costs, liabilities, damages and expenses referred to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u> of this Lease; and (iii) sums equal to all expenditures made and obligations incurred by Landlord in collecting or attempting to collect the Rent or in enforcing or attempting to enforce any rights of Landlord under this Lease or pursuant to law, including, without limitation, all reasonable legal fees and other amounts so expended. &#160;Tenant&#8217;s obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;26.1</u> shall survive the expiration or sooner termination of the Lease Term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">27.</b></font><b style="font-weight:bold;">PROJECT CONTROL BY LANDLORD; ENTRY BY LANDLORD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">27.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Project Control</b>. &#160;Landlord reserves full control over the Building and the Project to the extent not inconsistent with Tenant&#8217;s enjoyment of the Premises as provided by this Lease. &#160;This reservation includes Landlord&#8217;s right to subdivide the Project; convert the Building to condominium units; change the size of the Project by selling all or a portion of the Project or adding real property and any improvements thereon to the Project; grant assessments and licenses to third parties; maintain or establish ownership of the Building separate from fee title to the Property; make additions to or reconstruct portions of the Building and the Project; install, use, maintain, repair, replace and relocate for service to the Premises and other parts of the Building or the Project pipes, ducts, conduits, wires and appurtenant fixtures, wherever located in the Premises, the Building or elsewhere at the Project; and alter or relocate any other Common Area or facility, including private drives, lobbies and entrances, at no cost to Tenant. &#160;Landlord&#8217;s right pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 27.1</u>, including without limitation the rights to construct, maintain, relocate, alter, improve, or adjust the Building or the Project shall be subject to the condition that (i) the exercise of any of such rights shall not materially and adversely interfere with Tenant&#8217;s use of the Premises, materially increase Tenant&#8217;s costs or Rent related to the Premises, or materially decrease the number of Tenant&#8217;s parking spaces, (ii) Landlord shall provide reasonable prior notice to Tenant before exercising any such rights which may materially and adversely interfere with Tenant&#8217;s use of the Premises, provided that such use of the Premises is in accordance with the Permitted Use, and (iii) Landlord shall use reasonable efforts to minimize to the extent possible any interference with Tenant&#8217;s business, provided that such business is in accordance with the Permitted Use, including, when reasonable, scheduling such work after business hours or on weekends. &#160;Possession of areas of the Premises necessary for utilities, services, safety and operation of the Building is reserved to Landlord. &#160;Notwithstanding the foregoing, Landlord shall provide Tenant reasonable prior notice of required access to the Premises for such activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">27.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entry by Landlord</b>. &#160;Landlord reserves the right at all reasonable times and upon not less than one (1) business day&#8217;s prior notice to Tenant which may be given by telephone or electronic mail (except in the case of an emergency or with respect to regularly scheduled services) to enter the Premises to (i) inspect them; (ii) show the Premises to prospective purchasers, or to current or prospective mortgagees, ground or underlying lessors or insurers or, during the last twelve (12) months of the Lease Term, to prospective tenants; (iii) post notices of nonresponsibility (to the extent applicable pursuant to then Applicable Law); or (iv) alter, improve or repair the Premises or the Building, or for structural alterations, repairs or improvements to the Building or the Building&#8217;s systems and equipment. &#160;Provided that Landlord employs commercially reasonable efforts to minimize interference with the conduct of Tenant&#8217;s business in connection with entries into the Premises, Landlord may make any such entries without creating a default by Landlord and shall take such reasonable steps as required to accomplish the stated purposes. &#160;In an emergency, Landlord shall have the right to use any means that Landlord may deem proper to open the doors in and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-40-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">to the Premises. &#160;Landlord also shall have the right at any time, without the same constituting an actual or constructive eviction and without incurring any liability to Tenant therefor, to change the arrangement or location of entrances or passageways, doors and doorways, and corridors, elevators, stairs, toilets, or other public parts of the Building and to change the name, address, number or designation by which the Premises is commonly known, provided any such change does not (A) unreasonably reduce, interfere with or deprive Tenant of access to the Premises, or (B) reduce the rentable area (except by a <i style="font-style:italic;">de minimis</i> amount) of the Premises. &#160;Any entry into the Premises by Landlord in the manner hereinbefore described shall not be deemed to be a forcible or unlawful entry into, or a detainer of, the Premises, or an actual or constructive eviction of Tenant from any portion of the Premises and the Base Rent (and any other item of Rent) shall under no circumstances abate while said repairs, alterations, improvements, additions or restorations are being made, by reason of loss or interruption of business of Tenant, or otherwise. &#160;If Tenant shall not be present when for any reason entry into the Premises shall be necessary or permissible, Landlord or Landlord&#8217;s agents, representatives, contractors or employees may enter the same without rendering Landlord or such agents liable therefor if during such entry Landlord or Landlord&#8217;s agents shall accord reasonable care under the circumstances to Tenant&#8217;s Property, and without in any manner affecting this Lease. &#160;Tenant shall, at all times during the Term, be responsible for ensuring that Landlord has any and all keys, cards, codes or other means necessary to access the Premises. Landlord and Landlord&#8217;s agents, representatives, contractors, employees, and other invitees and permittees entering the Premises shall keep any information relating to the Tenant acquired during such entry on to the Premises strictly confidential and shall not disclose such information to any person or entity except as may be required by Applicable Law and as otherwise permitted pursuant to Section 29.27 of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">28.</b></font><b style="font-weight:bold;">TENANT PARKING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">During the Term, Landlord shall provide Tenant with parking passes for use by standard size automobiles and small utility vehicles in an amount equal to the number of parking passes set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;11</u> of the Summary, which parking passes shall pertain to the on-site and/or off-site parking facilities which serve the Project. &#160;All such parking shall be on a first-come, first-serve basis in common with others entitled to use the same. &#160;Parking shall be free of charge for the duration of the Lease Term. &#160;Tenant&#8217;s continued right to use the parking passes is conditioned upon Tenant abiding by all rules and regulations which are prescribed from time to time for the orderly operation and use of the parking facility where the parking passes provide access (including any sticker or other identification system established by Landlord and the prohibition of vehicle repair and maintenance activities in the parking facilities), and Tenant shall cooperate in seeing that any Tenant Parties and Tenant visitors also comply with such rules and regulations. &#160;Tenant&#8217;s use of the parking passes for parking at the Project shall be at Tenant&#8217;s sole risk and Tenant acknowledges and agrees that Landlord shall have no liability whatsoever for damage to the vehicles of Tenant, its employees and/or visitors, or for other personal injury or property damage or theft relating to or connected with the parking rights granted herein or any of Tenant&#8217;s, its employees&#8217; and/or visitors&#8217; use of the parking facilities. &#160;Landlord shall have the right to assign its obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;28</u> to an affiliate of Landlord or a third-party parking manager or operator, in which case Tenant shall make any payments due under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;28</u> directly to such other entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">29.</b></font><b style="font-weight:bold;">MISCELLANEOUS PROVISIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Terms; Captions</b>. &#160;The words &#8220;<b style="font-weight:bold;">Landlord</b>&#8221; and &#8220;<b style="font-weight:bold;">Tenant</b>&#8221; as used herein shall include the plural as well as the singular. &#160;The necessary grammatical changes required to make the provisions hereof apply either to corporations or partnerships or individuals, men or women, as the case may require, shall in all cases be assumed as though in each case fully expressed. &#160;The captions of Articles and Sections are for convenience only and shall not be deemed to limit, construe, affect or alter the meaning of such Articles and Sections.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect</b>. &#160;Subject to all other provisions of this Lease, each of the covenants, conditions and provisions of this Lease shall extend to and shall, as the case may require, bind or inure to the benefit not only of Landlord and of Tenant, but also of their respective heirs, personal representatives, successors or assigns, provided this clause shall not permit any assignment by Tenant contrary to the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 14</u> of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Air Rights</b>. &#160;No rights to any view or to light or air over any property, whether belonging to Landlord or any other person, are granted to Tenant by this Lease. &#160;If at any time any windows of the Premises are temporarily darkened or the light or view therefrom is obstructed by reason of any repairs, improvements, maintenance or cleaning in or about the &#160;Project, the same shall be without liability to Landlord and without any reduction or diminution of Tenant&#8217;s obligations under this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-41-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.4</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Modification of Lease</b>. &#160;Should any current or prospective mortgagee or ground lessor for the Building or Project require a modification of this Lease, which modification will not cause an increased cost or expense to Tenant or in any other way materially and adversely change the rights and obligations of Tenant hereunder, then and in such event, Tenant agrees that this Lease may be so modified and agrees to execute whatever documents are reasonably required therefor and to deliver the same to Landlord within ten (10) business days following a request therefor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.5</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer of Landlord&#8217;s Interest</b>. &#160;Tenant acknowledges that Landlord has the right to transfer all or any portion of its interest in the Project or Building and in this Lease, and Tenant agrees that in the event of any such transfer, Landlord shall automatically be released from all liability under this Lease and Tenant agrees to look solely to such transferee for the performance of Landlord&#8217;s obligations hereunder after the date of transfer and such transferee shall be deemed to have fully assumed and be liable for all obligations of this Lease to be performed by Landlord and Tenant shall attorn to such transferee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.6</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prohibition Against Recording</b>. &#160;Landlord and Tenant agree not to record this Lease or a memorandum thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.7</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Title</b>. &#160;Landlord&#8217;s title is and always shall be paramount to the title of Tenant. &#160;Nothing herein contained shall empower Tenant to do any act which can, shall or may encumber the title of Landlord. &#160;Landlord owns fee title to the Building.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.8</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Relationship of Parties</b>. &#160;Nothing contained in this Lease shall be deemed or construed by the parties hereto or by any third party to create the relationship of principal and agent, partnership, joint venturer or any association between Landlord and Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.9</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Application of Payments</b>. &#160;Landlord shall have the right to apply payments received from Tenant pursuant to this Lease, regardless of Tenant&#8217;s designation of such payments, to satisfy any obligations of Tenant hereunder, in such order and amounts as Landlord, in its sole discretion, may elect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.10</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time of Essence</b>. &#160;Time is of the essence with respect to the performance of every provision of this Lease in which time of performance is a factor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.11</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Partial Invalidity</b>. &#160;If any term, provision or condition contained in this Lease shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term, provision or condition to persons or circumstances other than those with respect to which it is invalid or unenforceable, shall not be affected thereby, and each and every other term, provision and condition of this Lease shall be valid and enforceable to the fullest extent possible permitted by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.12</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Warranty</b>. &#160;In executing and delivering this Lease, Tenant has not relied on any representations, including, but not limited to, any representation as to the amount of any item comprising Additional Rent or the amount of the Additional Rent in the aggregate or that Landlord is furnishing the same services to other tenants, at all, on the same level or on the same basis, or any warranty or any statement of Landlord which is not expressly set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.13</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exculpation</b>. &#160;The liability of Landlord or the Landlord Parties to Tenant for any default by Landlord under this Lease or arising in connection herewith or with Landlord&#8217;s operation, management, leasing, repair, renovation, alteration or any other matter relating to the Project or the Premises shall be limited solely and exclusively to an amount which is equal to the interest of Landlord in the Project. &#160;Neither Landlord, nor any of the Landlord Parties shall have any personal liability therefor, and Tenant hereby expressly waives and releases such personal liability on behalf of itself and all persons claiming by, through or under Tenant. &#160;The limitations of liability contained in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;29.13</u> shall inure to the benefit of Landlord&#8217;s and the Landlord Parties&#8217; present and future partners, beneficiaries, officers, directors, trustees, shareholders, agents and employees, and their respective partners, heirs, successors and assigns. &#160;Under no circumstances shall any present or future partner of Landlord (if Landlord is a partnership), or trustee or beneficiary (if Landlord or any partner of Landlord is a trust), have any liability for the performance of Landlord&#8217;s obligations under this Lease. &#160;Notwithstanding any contrary provision herein, (1) neither Landlord nor any Landlord Parties shall be liable under any circumstances for consequential or indirect damages, including without limitation injury or damage to, or interference with, Tenant&#8217;s business, loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, in each case, however occurring, and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-42-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">(2) Tenant shall not be liable under any circumstances for consequential or indirect damages, including without limitation injury or damage to, or interference with, Landlord&#8217;s business, loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, in each case, however occurring, except as expressly provided in Section 5.3 (Hazardous Materials) and Section 16 (Holding Over).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.14</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</b>. &#160;It is understood and acknowledged that there are no oral agreements between the parties hereto affecting this Lease and this Lease constitutes the parties&#8217; entire agreement with respect to the leasing of the Premises and supersedes and cancels any and all previous negotiations, arrangements, brochures, agreements and understandings, if any, between the parties hereto or displayed by Landlord to Tenant with respect to the subject matter thereof, and none thereof shall be used to interpret or construe this Lease. &#160;None of the terms, covenants, conditions or provisions of this Lease can be modified, deleted or added to except in writing signed by the parties hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.15</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">REIT</b><b style="font-weight:bold;">.</b> &#160;Tenant acknowledges that the Company, an affiliate of Landlord, elects to be taxed as a real estate investment trust (a &#8220;<b style="font-weight:bold;">REIT</b>&#8221;) under the Code. &#160;Tenant hereby agrees to modifications of this Lease required to retain or clarify the Company&#8217;s status as a REIT, provided such modifications: (a) are reasonable, (b) do not adversely affect in a material manner Tenant&#8217;s use of the Premises as herein permitted, and (c) do not increase the Base Rent, Additional Rent and other sums to be paid by Tenant or Tenant&#8217;s other obligations pursuant to this Lease, or reduce any rights of Tenant under this Lease, then Landlord may submit to Tenant an amendment to this Lease incorporating such required modifications, and Tenant shall execute, acknowledge and deliver such amendment to Landlord within ten (10) days after Tenant&#8217;s receipt thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.16</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Lease</b>. &#160;Landlord reserves the absolute right to effect such other tenancies in the Project as Landlord in the exercise of its sole business judgment shall determine to best promote the interests of the Building or Project. &#160;Tenant does not rely on the fact, nor does Landlord represent, that any specific tenant or type or number of tenants shall, during the Lease Term, occupy any space in the Building or Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.17</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure</b>. &#160;Any prevention, delay or stoppage due to strikes, lockouts, labor disputes, acts of God, acts of war, terrorist acts, governmental action or inaction, inability to obtain services, labor, or materials or reasonable substitutes therefor, governmental actions, civil commotions, fire or other casualty, epidemic or pandemic (including COVID-19) and other causes beyond the reasonable control of the party obligated to perform, except with respect to the obligations imposed with regard to Rent and other charges to be paid by Tenant pursuant to this Lease (collectively, a &#8220;<b style="font-weight:bold;">Force Majeure</b>&#8221;), notwithstanding anything to the contrary contained in this Lease, shall excuse the performance of such party for a period equal to any such prevention, delay or stoppage and, therefore, if this Lease specifies a time period for performance of an obligation of either party, that time period shall be extended by the period of any delay in such party&#8217;s performance caused by a Force Majeure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.18</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</b>. &#160;All notices, demands, statements, designations, approvals or other communications (collectively, &#8220;<b style="font-weight:bold;">Notices</b>&#8221;) given or required to be given by either party to the other hereunder or by law shall be in writing, shall be (A) sent by United States certified or registered mail, postage prepaid, return receipt requested (&#8220;<b style="font-weight:bold;">Mail</b>&#8221;), (B) delivered by a nationally recognized overnight courier, or (C) delivered personally. &#160;Any Notice shall be sent, transmitted, or delivered, as the case may be, to Tenant at the appropriate address set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;12</u> of the Summary, or to such other place as Tenant may from time to time designate in a Notice to Landlord, and to Landlord at the addresses set forth below, or to such other places as Landlord may from time to time designate in a Notice to Tenant. &#160;Any Notice will be deemed given (i) three (3) days after the date it is posted if sent by Mail, (ii) the date the overnight courier delivery is made, or (iii) the date personal delivery is made. &#160;As of the date of this Lease, any Notices to Landlord must be sent, transmitted, or delivered, to Landlord at the appropriate address set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13</u> of the Summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.19</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Joint and Several</b>. &#160;If there is more than one Tenant, the obligations imposed upon Tenant under this Lease shall be joint and several.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.20</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authority</b>. &#160;If Tenant is a corporation, trust or partnership, Tenant hereby represents and warrants that Tenant (a) is a duly formed and existing entity qualified to do business in the <i style="font-style:italic;">State of California </i>and is qualified as a foreign entity authorized to do business in the State of California and (b) has full right and authority to execute and deliver this Lease, and (c) each person signing on behalf of Tenant is authorized to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-43-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.21</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attorneys&#8217; Fees</b>. &#160;If either Landlord or Tenant should bring suit for the possession of the Premises, for the recovery of any sum due under this Lease, or because of the breach of any provision of this Lease or for any other relief against the other, then all costs and expenses, including reasonable attorneys&#8217; fees, incurred by the prevailing party therein shall be paid by the other party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.22</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law; WAIVER OF TRIAL BY JURY</b>. &#160;This Lease shall be construed and enforced in accordance with the laws of the State of California. &#160;IN ANY ACTION OR PROCEEDING ARISING HEREFROM, LANDLORD AND TENANT HEREBY CONSENT TO (I) THE JURISDICTION OF ANY COMPETENT COURT WITHIN THE STATE OF CALIFORNIA, (II) SERVICE OF PROCESS BY ANY MEANS AUTHORIZED BY CALIFORNIA LAW, AND (III) IN THE INTEREST OF SAVING TIME AND EXPENSE, TRIAL WITHOUT A JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER OF THE PARTIES HERETO AGAINST THE OTHER OR THEIR SUCCESSORS IN RESPECT OF ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, TENANT&#39;S USE OR OCCUPANCY OF THE PREMISES, AND/OR ANY CLAIM FOR INJURY OR DAMAGE, OR ANY EMERGENCY OR STATUTORY REMEDY. &#160;IN THE EVENT LANDLORD COMMENCES ANY SUMMARY PROCEEDINGS OR ACTION FOR NONPAYMENT OF BASE RENT OR ADDITIONAL RENT, TENANT SHALL NOT INTERPOSE ANY COUNTERCLAIM OF ANY NATURE OR DESCRIPTION (UNLESS SUCH COUNTERCLAIM SHALL BE MANDATORY) IN ANY SUCH PROCEEDING OR ACTION BUT SHALL BE RELEGATED TO AN INDEPENDENT ACTION AT LAW.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.23</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Submission of Lease</b>. &#160;Submission of this instrument for examination or signature by Tenant does not constitute a reservation of, option for or option to lease, and it is not effective as a lease or otherwise until execution and delivery by both Landlord and Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.24</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers</b>. &#160;Landlord and Tenant hereby warrant to each other that they have had no dealings with any real estate broker or agent in connection with the negotiation of this Lease, excepting only the real estate brokers or agents specified in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;14</u> of the Summary (the &#8220;<b style="font-weight:bold;">Brokers</b>&#8221;), and that they know of no other real estate broker or agent who is entitled to a commission in connection with this Lease. &#160;Each party agrees to indemnify and defend the other party against and hold the other party harmless from any and all claims, demands, losses, liabilities, lawsuits, judgments, costs and expenses (including without limitation reasonable attorneys&#8217; fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of any dealings with any real estate broker or agent, other than the Brokers, occurring by, through, or under the indemnifying party. &#160;The terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 29.24</u> shall survive the expiration or earlier termination of the Lease Term. &#160;Landlord shall pay a commission to the Brokers pursuant to a separate written agreement between Landlord and the Brokers<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.25</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Project or Building Name, Address and Signage</b>. &#160;Landlord shall have the right at any time to change the name and/or address of the Project or Building and to install, affix and maintain any and all signs on the exterior and on the interior of the Project or Building as Landlord may, in Landlord&#8217;s sole discretion, desire. &#160;Tenant shall not use the name of the Project or Building or use pictures or illustrations of the Project or Building in advertising or other publicity or for any purpose other than as the address of the business to be conducted by Tenant in the Premises, without the prior written consent of Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.26</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</b>. &#160;This Lease may be executed in counterparts with the same effect as if both parties hereto had executed the same document. &#160;The parties may execute and deliver this Lease using electronic signature technology (e.g., via DocuSign or other similar electronic signature technology), and any such electronic signature shall be deemed the same as a &#8220;wet&#8221; original signature delivered to the other party. &#160;Both counterparts shall be construed together and shall constitute a single lease. Delivery by fax or by electronic mail file attachment of any executed counterpart to this Lease will be deemed the equivalent of the delivery of the original executed instrument.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.27</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</b>. &#160;Landlord and Tenant acknowledge that the content of this Lease, any information regarding the Building or Project received from Landlord or Tenant, and any related documents are confidential information. &#160;The parties shall keep such confidential information strictly confidential and shall not disclose such confidential information to any person or entity other than to each party&#8217;s financial, legal, and space planning consultants on a &#8216;need to know&#8217; basis, provided that such other parties are made aware of the obligations under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 29.27</u> and Landlord and Tenant shall be responsible for any disclosure by such parties in violation of this paragraph.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-44-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.28</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development of the Project</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.28.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Subdivision</b>. &#160;Landlord reserves the right to subdivide all or a portion of the Building or Project. &#160;Tenant agrees to execute and deliver, upon demand by Landlord and in the form requested by Landlord, any additional documents needed to conform this Lease to the circumstances resulting from a subdivision and any all maps in connection therewith. &#160;Notwithstanding anything to the contrary set forth in this Lease, the separate ownership of any buildings and/or Common Areas by an entity other than Landlord shall not affect the calculation of Direct Expenses or Tenant&#8217;s payment of Tenant&#8217;s Share of Direct Expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.28.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction of Property and Other Improvements</b>. &#160;Tenant acknowledges that portions of the Project may be under construction following Tenant&#8217;s occupancy of the Premises, and that such construction may result in levels of noise, dust, obstruction of access, etc. which are in excess of that present in a fully constructed project. &#160;Tenant hereby waives any and all rent offsets or claims of constructive eviction which may arise in connection with such construction. &#160;However, Tenant hereby acknowledges that Landlord is currently renovating or may during the Lease Term renovate, improve, alter, or modify (collectively, the &#8220;<b style="font-weight:bold;">Renovations</b>&#8221;) the Project, the Building and/or the Premises. &#160;Landlord shall use commercially reasonable efforts to complete any Renovations in a manner which does not materially, adversely affect Tenant&#8217;s use of or access to the Premises. &#160;Notwithstanding the foregoing, Tenant hereby agrees that such Renovations shall in no way constitute a constructive eviction of Tenant nor entitle Tenant to any abatement of Rent. &#160;Landlord shall have no responsibility and shall not be liable to Tenant for any injury to or interference with Tenant&#8217;s business arising from the Renovations, nor shall Tenant be entitled to any compensation or damages from Landlord for loss of the use of the whole or any part of the Premises or of Tenant&#8217;s personal property or improvements resulting from the Renovations, or for any inconvenience or annoyance occasioned by such Renovations, provided that the foregoing shall not limit Landlord&#8217;s liability, if any, pursuant to Applicable Law for personal injury and property damage to the extent caused by the gross negligence or willful misconduct of Landlord, its agents, employees or contractors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.29</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Violation</b>. &#160;Tenant hereby warrants and represents that neither its execution of nor performance under this Lease shall cause Tenant to be in violation of any agreement, instrument, contract, law, rule or regulation by which Tenant is bound, and Tenant shall protect, defend, indemnify and hold Landlord harmless against any claims, demands, losses, damages, liabilities, costs and expenses, including, without limitation, reasonable attorneys&#8217; fees and costs, arising from Tenant&#8217;s breach of this warranty and representation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.30</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Communications and Computer Lines</b>. &#160;Tenant may install, maintain, replace, remove or use any communications or computer wires and cables serving the Premises (collectively, the &#8220;<b style="font-weight:bold;">Lines</b>&#8221;), provided that Tenant shall obtain Landlord&#8217;s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed), use an experienced and qualified contractor approved in writing by Landlord, and comply with all of the other provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Articles 7</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8</u> of this Lease. &#160;Tenant shall pay all costs in connection therewith. &#160;Landlord reserves the right, upon notice to Tenant prior to Tenant&#8217;s installation of any Lines, to require that Tenant, at Tenant&#8217;s sole cost and expense, remove any Lines located in or serving the Premises prior to the expiration or earlier termination of this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.31</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transportation Management</b>. &#160;Tenant shall fully comply with all present or future programs intended to manage parking, transportation or traffic in and around the Project and/or the Building, and in connection therewith, Tenant shall take responsible action for the transportation planning and management of all employees located at the Premises by working directly with Landlord, any governmental transportation management organization or any other transportation-related committees or entities. &#160;Such programs may include, without limitation: (i) restrictions on the number of peak-hour vehicle trips generated by Tenant; (ii) increased vehicle occupancy; (iii) implementation of an in-house ridesharing program and an employee transportation coordinator; (iv) working with employees and any Project, Building or area-wide ridesharing program manager; (v) instituting employer-sponsored incentives (financial or in-kind) to encourage employees to rideshare; and (vi) utilizing flexible work shifts for employees<i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-45-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.32</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Special Appurtenant Rights</b>. &#160;Tenant shall have the right in common with others to connect to and use the Emergency Generator located, or to be installed by Landlord pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1.8</u> above, at the Building subject to the following conditions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">(1) Tenant&#8217;s use of the Emergency Generator shall be at Tenant&#8217;s sole risk to the extent permitted pursuant to Applicable Laws (Landlord making no representation or warranty regarding the sufficiency of the Emergency Generator for Tenant&#8217;s use);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">(2) Tenant&#8217;s use of the Emergency Generator shall be undertaken by Tenant in compliance with all Applicable Laws, including Environmental Laws, and Landlord shall obtain any and all permits required in connection with its use (other than any permit needed for Tenant to connect to the generator);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">(3) Landlord shall be responsible for connecting to the central distribution point for the Emergency Generator prior to the Lease Commencement Date;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">(4) The costs to operate and maintain the Emergency Generator shall be included in Operating Expenses. &#160;Tenant use of the Special Systems shall not exceed Tenant&#8217;s Share of the capacity available to tenants of any such Emergency Generator, but which allocation to the lab portion of the Premises shall be as listed in Section 6.1.8 above;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">(5) The use of the Emergency Generator shall be subject to the Rules and Regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">(6) Tenant acknowledges and agrees that there are no warranties of any kind, whether express or implied, made by Landlord or otherwise with respect to the Emergency Generator, and Tenant disclaims all such warranties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Landlord may, at its sole election and by prior written notice to Tenant, add additional special systems to the Building in the future and make the same available to all laboratory tenants, in which case such additional systems shall be treated as special systems hereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-46-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">IN WITNESS WHEREOF, Landlord and Tenant have caused this Lease to be executed the day and date first above written as a sealed California instrument.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:37.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:37.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LANDLORD:</p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:top;width:48.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">TENANT:</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.38%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.55%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">SAN DIEGO INSPIRE 4, LLC</b>,<br>a Delaware limited liability company</p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">iBio, Inc</b>.,<br>a Delaware corporation</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td colspan="2" style="vertical-align:top;width:43.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jessica Brock</p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td colspan="2" style="vertical-align:top;width:43.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Rob Lutz</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:37.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jessica Brock</p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:37.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rob Lutz</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its: </p></td><td style="vertical-align:top;width:37.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Authorized Signatory</p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its: </p></td><td style="vertical-align:top;width:37.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial and Business Officer</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td colspan="2" style="vertical-align:top;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Martin Brenner</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: </p></td><td style="vertical-align:top;width:37.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Martin Brenner</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:48.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its: </p></td><td style="vertical-align:top;width:37.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Scientific Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">-47-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT 1.1.1-1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PREMISES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><img src="ibio-20220930xex10d3004.jpg" alt="Graphic" style="display:inline-block;height:259.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:470.88pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT 1.1.1-2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TENANT WORK LETTER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">This Tenant Work Letter sets forth the terms and conditions relating to the construction of the initial tenant improvements in the Premises. &#160;This Tenant Work Letter is essentially organized chronologically and addresses the issues of the construction of the Premises, in sequence, as such issues will arise during the actual construction of the Premises. &#160;All references in this Tenant Work Letter to Articles or Sections of &#8220;this Lease&#8221; shall mean the relevant portion of the Lease to which this Tenant Work Letter is attached as <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit 1.1.1-2</b> and of which this Tenant Work Letter forms a part, and all references in this Tenant Work Letter to Sections of &#8220;this Tenant Work Letter&#8221; shall mean the relevant portion of this Tenant Work Letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></font><b style="font-weight:bold;">LANDLORD&#8217;S INITIAL CONSTRUCTION IN THE PREMISES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord Work</b>. &#160;Landlord has caused, or shall cause, at Landlord&#8217;s sole cost and expense, the construction, renovation or installation of the improvements described on the attached <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment 1</u> (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord Work</u>&#8221;) in connection with the improvement of the Premises prior to the date of this Lease and as otherwise required to deliver the Premises to Tenant as required by this Lease.<sup style="font-size:7.5pt;vertical-align:top;">7</sup> &#160;Landlord acknowledges and agrees that the Tenant Improvement Allowance will not be used to cover the cost of the Landlord Work; provided, however, if Tenant decides to convert two (2) existing rooms into three (3) rooms or move the location of any doors, the additional costs associated with such changes to the existing spec design shall be deducted from Tenant&#8217;s TI Allowance. &#160;The Landlord Work shall be performed in a first-class, workmanlike manner using new materials of good quality and in accordance with all Applicable Laws. &#160;The Landlord Work shall comply with all building codes applicable to Title 24, seismic, fire and life safety, structural support of existing MEP items and ceilings, exit lighting with the Premises and egress lighting at all exit doors leaving the Premises and American with Disabilities Act (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ADA</u>&#8221;) requirements (including path of travel to and from the Premises and parking areas).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></font><b style="font-weight:bold;">TENANT IMPROVEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant Improvement Allowance</b>. &#160;Tenant shall be entitled to an improvement allowance as follows: &#160;Eighty-One Thousand Nine Hundred Sixty Dollars ($81,960.00) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maximum Allowance Amount</u>&#8221;), of which Fifty Thousand Ninety Dollars ($50,090.00) thereof must be used for improvements to the lab portion of the Premises (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lab Premises TI Allowance</u>&#8221;) and the remainder [i.e., Thirty-One Thousand Eight Hundred Seventy Dollars ($31,870.00)] must be used for the improvements to the Interim Premises (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interim Premises TI Allowance</u>&#8221; and together with the Lab Premises TI Allowance, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TI Allowance</u>&#8221;). &#160;The Lab Premises TI Allowance will be used for the hard costs and customary soft costs incurred by Landlord including, without limitation actual and reasonable out-of-pocket architectural and engineering fees and a project management fee equal to five percent (5%) of the cost of the Tenant Improvements (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Project Management Fee</u>&#8221;) payable to Landlord or its affiliates and permits, relating to the initial design and construction of Tenant&#8217;s improvements which are to be permanently affixed to the lab portion of the Premises (including, without limitation, power distribution, voice and data cabling, WIFI and security systems, Tenant&#8217;s construction manager and licenses and permits in accordance with this Work Letter) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lab Premises Tenant Improvements</u>&#8221;). &#160;The Interim Premises TI Allowance must be used for the hard costs and customary soft costs incurred by Landlord including, without limitation Landlord&#8217;s Project Management Fee, relating to the initial design and construction of Tenant&#8217;s improvements which are to be permanently affixed to the Interim Premises (including, without limitation, power distribution within the Interim Premises), Tenant&#8217;s construction manager and licenses and permits in accordance with this Work Letter (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Interim Premises Tenant Improvements</u>&#8221; and together with the Lab Premises Tenant Improvements, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant Improvements</u>&#8221;); provided, however, the use of the Maximum Allowance Amount for costs attributable to voice and data cabling and wifi and security systems and other technology systems within the Premises shall be limited to $22,766.00. &#160;Notwithstanding the foregoing or anything otherwise provided elsewhere herein, there shall be no project management fee with respect to any hard costs of construction related to improvements performed in connection with the Landlord Work (but design costs related to the Tenant Improvements, other than design costs associated with the Landlord Work, shall be subject to the project management fee, even if such design costs arise out of services performed prior to the Effective Date).</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">7</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note to Draft</u>: Landlord Work to include installation of freight lift at Landlord&#8217;s cost.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Landlord agrees to keep Tenant advised as to the progress of the work by providing copies of the Contractor&#8217;s applications for payment. The Tenant Improvements are more particularly described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment 2</u> attached hereto (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TI Requirements</u>&#8221;), and Landlord and Tenant acknowledge and agree that the Maximum Allowance Amount shall be used subject to and pursuant to this Tenant Work Letter to construct the Tenant Improvements as described in the TI Requirements<b style="font-weight:bold;">.</b> &#160;In no event shall Landlord be obligated to make disbursements pursuant to this Tenant Work Letter in a total amount which exceeds the Maximum Allowance Amount. &#160;The Tenant Improvements shall be constructed by Landlord in a good and workmanlike manner, in accordance with all Applicable Laws and the Approved Working Drawings (as defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.4</u> below), and as otherwise reasonably directed by Tenant. &#160;All Tenant Improvements for which the TI Allowance has been paid shall be deemed Landlord&#8217;s property under the terms of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disbursement of the TI Allowance</b>. &#160;Except as otherwise set forth in this Tenant Work Letter, the TI Allowance shall be disbursed by Landlord (each of which disbursements shall be made pursuant to Landlord&#8217;s reasonable disbursement process) for costs incurred by Landlord related to the construction of the Tenant Improvements and for the following items and costs (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant Improvement Allowance Items</u>&#8221;): &#160;(i) payment of the fees of the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Architect</u>&#8221; (as that term is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1</u> of this Tenant Work Letter) in connection with the preparation and review of the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction Documents</u>&#8221; (as that term is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1</u> of this Tenant Work Letter); (ii) payment of the project management fee described above, (iii) the cost of any changes to the Construction Documents or Tenant Improvements required by all applicable building codes (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Code</u>&#8221;) enacted after approval of the Construction Documents, (iv) costs payable to the Contractor and any subcontractors, and (v) other costs incurred in connection with the Tenant Improvements to the extent the same can be paid using the TI Allowance pursuant to the specific provisions of this Tenant Work Letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Notwithstanding anything to the contrary herein, the cost of the Tenant Improvements shall not include (and Landlord shall be solely responsible for and the TI Allowance shall not be used for) costs incurred in connection with complying with building codes applicable to Title 24, seismic, fire and life safety, structural support of existing MEP items and ceilings, exit lighting with the Premises and egress lighting at all exit doors leaving the Premises and American with Disabilities Act (&#8220;ADA&#8221;) requirements (including path of travel to and from the Premises and parking areas). &#160;Such compliance costs shall constitute part of the Landlord Work, and the TI Allowance will only be used for compliance costs, if any, directly relating to the construction work relating to the TI Requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></font><b style="font-weight:bold;">CONSTRUCTION DOCUMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Selection of Architect/Construction Documents</b>. &#160;Landlord shall cause Ferguson Pape Baldwin Architects (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Architect</u>&#8221;) to prepare the &#8220;Construction Documents&#8221;, as that term is defined in this Section 3.1 for the Tenant Improvements, together with the consulting engineers selected by the Architect and reasonably approved by Landlord. &#160;The plans and drawings to be prepared by Architect hereunder shall be known collectively as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction Documents</u>&#8221;. &#160;All Construction Documents shall comply with the drawing format and specifications as determined by Landlord, and shall be subject to Landlord&#8217;s and Tenant&#8217;s approval. &#160;Tenant may hire an architectural firm reasonably approved by Landlord to conduct a peer review, and the fees associated with this peer review shall be paid solely by Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Landlord has no obligation to approve or perform any Tenant Change or any Tenant Improvements not shown on the plans previously approved by Landlord and Tenant or reasonably inferable therefrom if, in Landlord&#8217;s reasonable judgment, such Tenant Improvements (i)&#160;would delay completion of the Tenant Improvements beyond the date that the Tenant Improvements are then-scheduled to be completed, unless Tenant agrees in writing that such work constitutes a Tenant Delay (to the extent such work causes Substantial Completion to be delayed beyond such date), and Landlord and Tenant agree in writing to the amount of such Tenant Delay, (ii)&#160;would materially increase the cost of performing any other work in the Building, unless in each case Tenant agrees to pay such costs based on Landlord&#8217;s Change Estimate Notice (as defined below), (iii)&#160;are incompatible with the design, quality, equipment or systems of the Building or otherwise require a change to the existing Building systems or structure, each in a manner that would not otherwise be required in connection with the improvements contemplated by the Fit Plan (as defined below) and would have a material adverse affect on the Building structure or systems, or (iv)&#160;otherwise do not comply with the provisions of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Final Space Plan</b>. &#160;Tenant has approved the preliminary space plan prepared by the Architect attached as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment 3</u> hereto (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fit Plan</u>&#8221;). &#160;On or before the date set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment 4</u> attached hereto, Landlord shall use commercially reasonable efforts to cause the Contractor to have the Architect prepare a space plan for Tenant for the Premises which space plan shall be reasonably consistent with the Fit Plan and shall include a layout and designation of all labs, offices, rooms and other partitioning, their intended use, and equipment to be contained therein, and shall deliver the space plan to Landlord and Tenant for their approval. Landlord and Tenant shall review and provide any changes to the space plan within five (5) Business Days of receipt thereof (and if Tenant shall fail to object thereto within such five (5) Business Day period, then such space plan shall be deemed approved by Tenant), and Landlord shall use reasonable efforts to cause the Architect prepare and circulate a modified plan within five (5) Business Days after its receipt of any requested changes from Tenant or Landlord. &#160;Such process of submittal and response within the time frame specified in the preceding sentence shall continue until each of Landlord and Tenant gives written approval to such space plan, with the understanding the Final Space Plan shall be approved no later than the date set forth for such approval on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment 4</u>. &#160;Once Landlord and Tenant approve the final space plan, the space plan shall be considered final (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Final Space Plan</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.3</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction Documents</b>. &#160;On or before the date set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment 4</u>, Landlord shall use commercially reasonable efforts to cause Landlord&#8217;s design/build contractor to cause the Architect to complete final Construction Documents consistent with the Final Space Plan and shall submit the same to Landlord and Tenant for their approval. &#160;Landlord and Tenant shall review and provide any changes to the construction documents within five (5) Business Days of receipt thereof, and Landlord shall use reasonable efforts to cause the Architect to prepare and circulate modified documents within five (5) Business Days of its receipt of any requested changes from Tenant or Landlord. Such process of submittal and response within the time frame specified in the preceding sentence shall continue until each of Landlord and Tenant gives written approval to such documents, and the Construction Documents shall be considered final once approved by Landlord and Tenant, with the understanding the Construction Documents shall be approved no later than the date set forth for such approval on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment 4</u>. In no event may either Tenant or Landlord require any changes that are inconsistent with the Final Space Plan. &#160;The Construction Documents shall comply with Applicable&#160;Laws existing on the date of this Tenant Work Letter and which may be enacted prior to Tenant&#8217;s approval of completed Construction Documents. Subject to the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 3.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.4</u> of this Work Letter, Tenant may, from time to time, by written order to Landlord on a form reasonably specified by Landlord (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant Change</u>&#8221;), request a change in the Tenant Improvements shown on the Construction Documents, which approval shall not be unreasonably withheld or conditioned, and shall be granted or denied within five (5) business days after delivery of such Tenant Change to Landlord. &#160;The Over-Allowance Amount shall be adjusted for any Tenant Change as further contemplated by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4</u> below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.4</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permits</b>. &#160;The Construction Documents as approved (or deemed approved) pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.3</u> shall be the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Approved Working Drawings</u>&#8221;. &#160;Following Tenant&#8217;s approval or deemed approval of the Cost Proposal, as described below, Landlord shall promptly thereafter submit or cause to be submitted, the Approved Working Drawings to the appropriate municipal authorities for all applicable building permits necessary to allow &#8220;Contractor&#8221; (as that term is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.1</u> below), to commence and fully complete the construction of the applicable Tenant Improvements (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permits</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.5</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time Deadlines</b>. &#160;The applicable dates for approval of items, plans and drawings as described in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4</u> below, and in this Tenant Work Letter are set forth and further elaborated upon in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment 4</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time Deadlines</u>&#8221;) attached hereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></font><b style="font-weight:bold;">CONSTRUCTION OF THE TENANT IMPROVEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contractor</b>. &#160;A design/build contractor designated by Landlord and approved by Tenant (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contractor</u>&#8221;) shall construct the Tenant Improvements based on a competitive bidding process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.2</font></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cost Proposal</b>. &#160;After the Approved Working Drawings are approved by Landlord and Tenant, Landlord shall provide Tenant with a cost proposal (or cost proposals) in accordance with the Approved Working Drawings, which cost proposal(s) shall include, as nearly as possible, the cost of all Tenant Improvements Allowance Items to be incurred in connection with the design and construction of the Tenant Improvements and shall include a so-called guaranteed maximum price proposal from Landlord&#8217;s Contractor together with a construction schedule (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cost Proposal</u>&#8221;), which Cost Proposal shall include, among other things, the Contractor&#8217;s fee,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">general conditions, and a reasonable contingency. &#160;The Cost Proposal may include early trade release packages for long lead time matters such as mechanical equipment. &#160;In connection with the Cost Proposal, Landlord shall cause the Contractor to solicit at least three bids from each subcontractor trade for which the total cost is expected to exceed $10,000. &#160;No work shall be bid or performed by any party that is an affiliate of or otherwise related to Landlord without Tenant&#8217;s prior written consent. Tenant shall have the right to propose one subcontractor to be included in the bidding for each trade, subject to Landlord&#8217;s reasonable approval. &#160;Landlord will consult with Tenant prior to approving the subcontractors to whom it will be bid and Tenant may review bid packages at Tenant&#8217;s request. &#160;In the case of each bid request, Landlord will accept the lowest responsible bid, unless Landlord and Tenant reasonably determine otherwise. &#160;Tenant shall approve (or reasonably disapprove) and deliver the Cost Proposal to Landlord within five (5) Business Days after the receipt of the same (and if Tenant fails to comment on the Cost Proposal within such five (5) Business Day period, then Tenant shall be deemed to have approved the Cost Proposal), provided, however, Tenant shall have the right to request Tenant Changes to the Approved Working Drawings within such five (5) Business Days, following its receipt of the Cost Proposal for the purpose of value engineering (in which event Landlord will cause its contractor to provide a new Cost Proposal to Landlord and Tenant following its receipt and approval of modified drawing showing such Tenant Change (such approval not to be unreasonably withheld, conditioned or delayed)).&#160; Upon Tenant&#8217;s approval, or deemed approval, of a Cost Proposal by Landlord, Landlord shall be released by Tenant to cause the Contractor to purchase the items set forth in the Cost Proposal and to commence the construction relating to such items (the date on which Tenant approves or is deemed to approve the Cost Proposal shall be known hereafter as the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cost Proposal Delivery Date</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction of Tenant Improvements by Contractor</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Over-Allowance Amount</u>. &#160;The difference between (i) the amount of the Cost Proposal and (ii) the amount of the remaining unused Tenant Improvements Allowance is referred to as the &#8220;Over-Allowance Amount.&#8221; &#160;On the Cost Proposal Delivery Date, Tenant shall deliver to Landlord cash in an amount (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Over-Allowance Amount</u>&#8221;), if any, equal to fifty percent (50%) of any Over-Allowance Amount. &#160;The Over-Allowance Amount shall be disbursed by Landlord following the disbursement of any then remaining portion of the Tenant Improvements Allowance, and such disbursement shall be pursuant to the same procedure as the Tenant Improvements Allowance. &#160;The remaining fifty percent (50%) of the Over-Allowance Amount shall be paid by Tenant to Landlord once the Tenant Improvements Allowance is expended (and at least twenty (20) days prior to Landlord&#8217;s scheduled use of the first installment of the Over-Allowance Amount). &#160;In the event that, after the applicable Cost Proposal Delivery Date, any revisions, changes, or substitutions shall be made to the Construction Documents or the Tenant Improvements, then, subject to Section 5.4 below, to the extent that the amount of the Cost Proposal plus any additional costs which arise in connection with such revisions, changes or substitutions or any other additional costs exceeds the sum of the Tenant Improvements Allowance and any Over-Allowance Amounts previously funded by Tenant, such excess costs shall be paid by Tenant to Landlord immediately upon Landlord&#8217;s request as an addition to the Over-Allowance Amount (whether or not the Tenant Improvements Allowance has then been fully utilized). &#160;In the event that, after the date of Substantial Completion, any Over-Allowance Amount is held by Landlord that will not be needed to pay for Tenant Improvements in accordance with this Work Letter, such amount shall be returned to Tenant within fifteen (15) days after Substantial Completion. &#160;Unless otherwise agreed by the parties, all Tenant Improvements paid for by the Over-Allowance Amount shall be deemed Landlord&#8217;s property under the terms of the Lease. &#160;Tenant hereby acknowledges and agrees that Tenant shall be responsible for all costs associated with the Tenant Improvements and approved by Tenant, to the extent the same exceed the Tenant Improvements Allowance (notwithstanding the content of the Cost Proposal).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.3.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Retention of Contractor</u>. Except as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2</u>, Landlord shall independently retain Contractor to construct the Tenant Improvements in accordance with the applicable Approved Working Drawings and the applicable Cost Proposal. Tenant shall be entitled to review Landlord&#8217;s construction contract with the Contractor upon Tenant&#8217;s written request. Landlord shall manage the Contractor in its performance of the construction work and endeavor to oversee the Contractor&#8217;s performance of its work to protect Tenant from construction defects. &#160;The Tenant Improvements shall be constructed by Landlord in a good and workmanlike manner, in accordance with all Applicable Laws and the Approved Working Drawings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-4-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.</b></font><b style="font-weight:bold;">COMPLETION OF THE TENANT IMPROVEMENTS;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> LEASE COMMENCEMENT DATE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Substantial Completion</u>. &#160;The Premises shall be &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ready for Occupancy</u>&#8221; on the date that Substantial Completion of the Tenant Improvements occurs. For purposes of this Lease, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Substantial Completion</u>&#8221; shall occur upon the completion of the last of the following to occur: (i) the completion of construction of the Tenant Improvements pursuant to the Approved Working Drawings for such Tenant Improvements (each as reasonably determined by Landlord), with the exception of (1) any punch list items which do not impair Tenant&#8217;s ability to use and occupy the Premises for their contemplated use, and (2) the installation of the Emergency Generator, (ii) the acquisition of a certificate of occupancy or its legal equivalent allowing occupancy of the Premises for their contemplated use (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sign Off</u>&#8221;), (iii) all base building systems are operational and fully-commissioned, (iv) delivery of the Premises to Tenant in the condition required by the Lease and this Tenant Work Letter, and (v) delivery of a certificate of substantial completion from the Architect on behalf of the Contractor confirming the matters set forth in the foregoing clause (i). &#160;In the event that the Sign Off is not a final certificate of occupancy, Landlord shall diligently prosecute the work necessary to achieve a full certificate of occupancy and use commercially reasonable efforts to obtain such full certificate of occupancy as soon as reasonably practicable following Substantial Completion. &#160;Landlord shall give Tenant at least ten (10) days prior written notice of the date that Landlord reasonably anticipates that the Landlord Work and Tenant Improvements will be Substantially Complete (as defined below); provided, however, Landlord&#8217;s failure to accurately estimate such date shall in no event affect the actual date of Substantial Completion or any other obligations of Landlord or Tenant hereunder. &#160;Tenant acknolwedges that Landlord has disclosed to it that the Emergency Generator is a long lead time delivery item; Landlord will install the Emergency Generator as soon as is reasonably practicable following the delivery of same to the site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delay of the Substantial Completion of the Premises</u>. &#160;Except as provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2</u>, the Rent Commencement Date shall occur as set forth in the Lease. &#160;Each of the following shall constitute a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant Delay</u>&#8221; to the extent such matter actually causes a delay in Substantial Completion beyond January 1, 2022 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expected Completion Date</u>&#8221;), or such later date if the estimated date of Substantial Completion is revised for any reason(s) unrelated to a Tenant Delay, and cannot reasonably be avoided without additional cost:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2.1</font></font>Tenant&#8217;s failure to comply with the Time Deadlines;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2.2</font></font>Tenant&#8217;s failure to timely approve or reasonably reject any matter requiring Tenant&#8217;s response within the time periods set forth herein (which, for avoidance of doubt, shall mean any period longer than five (5) business days or such shorter time period as may be required hereunder) except to the extent that Tenant is deemed to consent to any such request for approval in accordance with the terms of this Work Letter;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2.3</font></font>A breach by Tenant of the material terms of this Tenant Work Letter or the Lease (provided that Landlord shall provide Tenant prior written notice specifying the nature of the breach and resulting delay under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2.3</u>);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2.4</font></font>Any Tenant Change (including value engineering changes described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2</u> above);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2.5</font></font>Tenant&#8217;s insistence on materials, components, finishes or improvements which are not available in a commercially reasonable time given the anticipated date of Substantial Completion, as set forth in the Lease, after having been informed, in writing, by Landlord that such materials, components, finishes or improvements will cause a delay in completion of the Tenant Improvements; or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2.6</font></font>Any other act or omission of Tenant or anyone acting by, through or under Tenant that causes a delay in construction work or any process described in this Tenant Work Letter (provided that Landlord shall provide Tenant prior written notice specifying the nature of the acts or omissions giving rise to the delay and the resulting delay under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2.6</u>, and a two (2) business day cure period); and/or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.2.7</font></font>Any act or omission of Tenant or anyone acting by, through or under Tenant that causes a delay in the issuance of the Sign Off (provided that Landlord shall provide Tenant prior written notice specifying the acts or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-5-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">omissions giving rise to the delay and the resulting delay under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2.7</u>, and a two (2) business day cure period).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Upon any Tenant Delay, only for the purpose of determining the commencement of Tenant&#8217;s obligation to pay Rent, &#160;the date of the Substantial Completion shall be deemed to be the date the Substantial Completion of the Premises would have occurred if no Tenant Delays, as set forth above, had occurred and the Rent Commencement Date shall be deemed to have occurred accordingly (but only for the purpose of determining the commencement of Tenant&#8217;s obligation to pay Rent). &#160;Any increased costs of the Tenant Improvements resulting from Tenant Delay shall be paid by Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Landlord and Tenant have agreed to determine the length of any Tenant Delay as follows: &#160;(i) any delays pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 5.2.1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.2.2</u> in the definition of Tenant Delay in the definition of Tenant Delay shall be equal to one day for each day that the applicable Tenant Delay continues beyond the applicable time period required under this Lease, and (ii) with respect to any other Delay, Landlord shall notify Tenant in writing of the claimed estimated length of such Tenant Delay within ten (10) business days after its occurrence and Tenant may elect by written notice delivered to Landlord within ten (10) business days thereafter to dispute the claimed estimated Delay. &#160;Unless such estimate is disputed by written notice delivered within such ten (10) business day period, the length of such Delay shall be no less the claimed estimated Delay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Walk-through and Punchlist</u>. &#160;After the Tenant Improvements are Substantially Completed and prior to Tenant&#8217;s move-in into the Premises, following no less than two (2) days&#8217; advance written notice from Tenant to Landlord, Landlord shall cause the Contractor to inspect the Premises with a representative of Tenant and complete a punch list of unfinished or defective items of construction of the Tenant Improvements. &#160;The items listed on such punch list shall be completed by the Contractor within thirty (30) days after the approval of such punch list or as soon thereafter as reasonably practicable, provided that in the event a punch list item reasonably requires longer than thirty (30) days to complete, then Landlord shall cause Contractor to commence the completion of such particular item within thirty (30) days and diligently pursue the same to completion. &#160;The terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</u> will not affect the occurrence of the Substantial Completion of the Premises or the occurrence of the Rent Commencement Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant Changes</u>. &#160;Landlord may, but shall not be obligated to, approve any Tenant Change on the condition that Tenant deliver to Landlord, in advance pursuant to Section 4.3.1 (or cause to be paid in full from the Tenant Improvements Allowance), any and all additional costs or expenses associated with the approval of said Tenant Change; provided, however, if the additional costs associated with the approval of a Tenant Change is less than $25,000 (on a cumulative basis) and such Tenant Change will not result in a Tenant Delay of more than ten (10) days, then Landlord shall approve such Tenant Change. &#160;If Tenant shall request any Tenant Change, Landlord shall provide Tenant in writing (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Change Estimate Notice</u>&#8221;) the estimated costs of design and/or construction of the Tenant Improvements or Landlord Work that Landlord determines will be incurred as a consequence of such Tenant Change on an order of magnitude basis and shall provide Tenant with the estimated Tenant Delay, if any, on account of such proposed Tenant Change. Tenant shall, within three (3) Business Days following receipt of Landlord&#8217;s Change Estimate Notice, notify Landlord in writing whether it desires to proceed with the applicable Tenant Change or withdraw such Tenant Change. Tenant&#8217;s failure to respond in such three (3) Business Day period shall be deemed to be a withdrawal of the applicable Tenant Change. &#160;The cost of any Tenant Change shall be determined on a net basis; i.e. taking into account the savings, if any, resulting from such Tenant Change. &#160;To the extent that there is no remaining unused Tenant Improvements Allowance, the Over-Allowance Amount shall be adjusted for any Tenant Change. If and to the extent that Landlord initiates any change orders in the Tenant Improvements, such change orders shall be at Landlord&#8217;s sole cost and expense to the extent that the net cost of such changes exceed the costs that would have been incurred but for such change. &#160;Without limiting the generality of any provisions of this Tenant Work Letter, Tenant acknowledges that any extension of time due to a Tenant Change will not cause an extension of any Rent Commencement Date. Landlord shall be authorized to proceed with work described in a Tenant Change upon receipt of Tenant&#8217;s notice to proceed following the giving of Landlord&#8217;s Change Estimate Notice. &#160;All change orders shall specify any change in the Cost Proposal and the amount of any delay in the substantial completion of the Tenant Improvements as a consequence of the change order.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delay Not Caused by Parties</u>. &#160;Neither Landlord nor Tenant shall be considered to be in default of the provisions of this Tenant Work Letter for delays in performance due to Force Majeure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-6-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.6</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warranty</u>. &#160;Except for uncompleted items of Tenant Improvements specified in the punchlist described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.3</u> above and for latent defects, Tenant shall be deemed to have accepted all elements of Tenant Improvements on the date that Tenant takes possession of the Premises. &#160;In the case of a dispute concerning the completion of items of Tenant Improvements specified in the punchlist, such items shall be deemed completed and accepted by Tenant upon the delivery to Tenant of a certificate of the Architect on behalf of the Contractor that such items have been completed unless the certification reasonably is disputed by Tenant by a notice to Landlord given within ten (10) Business Days of Landlord&#8217;s delivery of the certification to Tenant. In the case of latent defects in Tenant Improvements appearing after the Lease Commencement Date, Tenant shall be deemed to have waived the requirement that Landlord make any claim for correction or cure thereof to the applicable contractor on the date that is at least twenty (20) days prior to the deadline date by which Landlord is required to make any such claim to the applicable contractor related to such defect (and if requested in writing by Tenant following the date of Substantial Completion, Landlord shall provide Tenant with written notice of any such dates) if Tenant has not then given notice of such defect to Landlord. &#160;For the purposes of this Lease, &#8220;latent defects&#8221; shall mean defects in the construction of the Landlord Work that are not readily observable by visible inspection at the time the punchlist is prepared or cannot be ascertained by reason of seasonality. &#160;Landlord shall cause Landlord&#8217;s contractor so to remedy, repair or replace any such latent defects identified by Tenant, together with any damage caused to the Landlord Work on account of such defects, such action to occur as soon as practicable during normal working hours and so as to avoid any unreasonable interruption of Tenant&#8217;s use of the Premises. &#160;If timely and adequate notice has been given and if Landlord has other guarantees, contract rights, or other claims against contractors, materialmen, architects, suppliers or manufacturers with respect to the Tenant Improvements or any portion thereof, Landlord shall also exercise commercially reasonable efforts to enforce such guarantees or contract rights for Tenant&#8217;s benefit upon its request. &#160;The foregoing shall constitute Landlord&#8217;s entire obligation with respect to all latent defects in the Tenant Improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.7</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery</u>. Landlord&#8217;s failure to Substantially Complete the Landlord Work or Tenant Improvements on or before the Expected Completion Date, or to substantially complete any element of the Landlord Work or Tenant Improvements by any particular time, shall not give rise to any liability of Landlord hereunder, shall not constitute Landlord&#8217;s default, and shall not affect the validity of this Lease, except as expressly provided in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.7</u>. &#160;Notwithstanding the foregoing, Landlord agrees to use commercially reasonable efforts to cause the completion of the Tenant Improvements so that the Premises shall be Ready for Occupancy on or before the Expected Completion Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></font><b style="font-weight:bold;">MISCELLANEOUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.1</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Entry Into the Premises Prior to Substantial Completion</u>. Landlord shall allow Tenant access to the Premises no less than three (3) days prior to Substantial Completion for the purpose of installing Tenant&#8217;s furniture, fixtures and equipment provided such access may be given without causing any delay in Substantial Completion. Prior to Tenant&#8217;s entry into the Premises (other than the Interim Premises) as permitted by the terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</u>, if required by Landlord or Contractor, Tenant shall submit a schedule to Landlord and Contractor, for their approval, which schedule shall detail the timing and purpose of Tenant&#8217;s entry. &#160;Tenant&#8217;s entry pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</u> shall be subject to all applicable provisions of the Lease other than the obligation to pay Base Rent and Additional Rent for Tenant&#8217;s Share of Direct Expenses (except with respect to the Interim Premises). &#160;Further, Landlord and Contractor shall allow Tenant access to the Interim Premises for its beneficial use prior to the Lease Commencement Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As a condition to Tenant&#8217;s entry into the Premises (other than the Interim Premises) prior to the Rent Commencement Date, Tenant shall comply with and perform, and shall cause its employees, agents, contractors, subcontractors, material suppliers and laborers to comply with and perform, all of Tenant&#8217;s insurance and indemnity obligations and other obligations governing the conduct of Tenant at the Property under this Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Any independent contractor of Tenant (or any employee or agent of Tenant) performing any work or inspections in the Premises prior to the Rent Commencement Date shall be subject to all of the terms, conditions and requirements contained in the Lease (including without limitation the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u>) and, prior to such entry, Tenant shall provide Landlord with evidence of the insurance coverages required pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 10</u>. &#160;Tenant and any Tenant contractor performing any work or inspections in the Premises prior to the Lease Commencement Date shall use reasonable efforts not to interfere in any way with construction of, and shall not damage the Landlord Work or the common areas or other parts of the Building. &#160;Neither Tenant, nor any Tenant contractor performing any work</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-7-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">or inspections in the Premises prior to the Lease Commencement Date shall cause any labor disharmony, and Tenant shall be responsible for all costs required to produce labor harmony in connection with an entry under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</u>. &#160;Without limiting the generality of the foregoing, to the extent that the commencement or performance of Landlord Work or Tenant Improvements is delayed on account in whole or in part of any act or negligent omission, neglect, or default by Tenant or any Tenant contractor, then such delay shall constitute a Tenant Delay to the extent set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2</u> above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Any requirements of any Tenant contractor performing any work or inspections in the Premises prior to the Rent Commencement Date for services from Landlord or Landlord&#8217;s contractor, such as hoisting, electrical or mechanical needs, shall be paid for by Tenant and arranged between such Tenant contractor and Landlord or Landlord&#8217;s contractor based on the actual, reasonable cost thereof determined on a time and materials basis. &#160;Should the work of any Tenant contractor performing any work or inspections in the Premises prior to the Rent Commencement Date depend on the installed field conditions of any item of Landlord Work or Tenant Improvements, such Tenant contractor shall ascertain such field conditions after installation of such item of Landlord Work or Tenant Improvements, provided, however, both parties shall cooperate with each other in order to maximize cost and scheduling efficiencies wherever reasonably practicable so long as Landlord is not delayed in the performance of the Tenant Improvements or Landlord Work or required to incur any additional expense not borne by Tenant hereunder. &#160;Neither Landlord nor Landlord&#8217;s contractor shall ever be required or obliged to alter the method, time or manner for performing Landlord Work or Tenant Improvements or work elsewhere in the Building, on account of the work of any such Tenant contractor. &#160;Tenant shall cause each Tenant contractor performing work on the Premises prior to the Rent Commencement Date to clean up regularly and remove its debris from the Premises and Building. &#160;Any work performed by Tenant pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 6.1</u> shall be performed in accordance with the applicable provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 8</u> of the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.2</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tenant&#8217;s Representative</u>. &#160;Tenant has designated Martin Brenner as its sole representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Landlord, shall have full authority and responsibility to act on behalf of the Tenant as required in this Tenant Work Letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.3</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord&#8217;s Representative</u>. &#160;Landlord has designated Peter Fritz as its sole representative with respect to the matters set forth in this Tenant Work Letter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of Landlord as required in this Tenant Work Letter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.4</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Time of the Essence in This Tenant Work Letter</u>. &#160;Unless otherwise indicated, all references herein to a &#8220;number of days&#8221; shall mean and refer to calendar days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.5</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u>. &#160;This Work Letter shall not be deemed applicable to any additional space added to the Premises at any time or from time to time, whether by any options under the Lease or otherwise, or to any additions to the Premises in the event of a renewal or extension of the original Lease Term, whether by any options under the Lease or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-8-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment 1 to Tenant Work Letter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Landlord Work</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Landlord Scope Description:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exterior Improvements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Symbol';">&#183;</font> New elevator located at the north side of the building.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">extending from level 1 to level 2. Additional 86 sf for elevator</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level 1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Symbol';">&#183;</font> New sidewalk, connecting the elevator</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Symbol';">&#183;</font> New landing (additional 110 sf for landing), connecting the elevator to the level 2 tenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Symbol';">&#183;</font> Interior lab/office speculative ti of suite 200 in existing 2 story</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Building, as follows: new interior walls, doors, ceilings, casework,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">finishes, electrical, plumbing and mechanical for the lab half.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Only a few minor adjustments to the office half.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Note: The building permit for the Landlord Work is for a spec lab/ office space only. Hazardous materials are limited to the amounts specified in cbc table 307.1(1) and 307.1(2). A separate tenant improvement permit will be required to be submitted for review if a tenant chooses to exceed the allowable amounts of if a system requiring a tank application (ta) permit is proposed. (see ib-1 16) for requirements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-9-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment 2 to Tenant Work Letter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TI Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tenant Scope Description:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following requirements are based on the current test fit plan (see Attachment 3 to Tenant Work Letter) and subject to change and approval by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New fixed lab bench with sink and deck mounted eye wash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provide floor boxes in open office for furniture connection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provide seismic restraint for co2 cylinders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provide new mobile lab casework with storage below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basis of Design for casework is Hanson agility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provide lab sinks where shown in plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provide j-box above ceiling in center of automation room for future power connection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provide floor drain for ice maker and clinical analyzer. <font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font>New sink in existing lab bench.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provide Landlord standard controls and fixtures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provide power/data for monitors if not existing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-10-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment 3 to Tenant Work Letter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20220930xex10d3006.jpg" alt="Diagram  Description automatically generated" style="display:inline-block;height:334.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:516.96pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-11-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Attachment 4 to Tenant Work Letter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20220930xex10d3007.jpg" alt="Graphical user interface, application, table  Description automatically generated" style="display:inline-block;height:545.04pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:454.32pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-12-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20220930xex10d3008.jpg" alt="Chart  Description automatically generated with low confidence" style="display:inline-block;height:601.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:405.36pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-13-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20220930xex10d3009.jpg" alt="Application, table  Description automatically generated" style="display:inline-block;height:556.56pt;width:452.16pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-14-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="ibio-20220930xex10d3010.jpg" alt="A picture containing diagram  Description automatically generated" style="display:inline-block;height:585pt;width:445.65pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 1.1.1-2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-15-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT 2.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FORM OF NOTICE OF LEASE TERM DATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr><td style="vertical-align:top;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">To:</p></td><td style="vertical-align:top;width:46.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.66%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:6.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Re:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;text-align:justify;">Lease dated ____________, 20__ between ____________________, a _____________________ (&#8220;<b style="font-weight:bold;">Landlord</b>&#8221;), and _______________________, a _______________________ (&#8220;<b style="font-weight:bold;">Tenant</b>&#8221;) concerning Suite ______ on floor(s) __________ of the building located at <b style="font-weight:bold;">[INSERT BUILDING ADDRESS]</b>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Gentlemen:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In accordance with the Lease (the &#8220;<b style="font-weight:bold;">Lease</b>&#8221;), we wish to advise you and/or confirm as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The Lease Term shall commence on or has commenced on _____________ for a term of _______________ ending on _______________.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The Rent Commencement Date occurred on _____________..</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Your rent checks should be made payable to __________ at ______________.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="3" style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8220;Landlord&#8221;:</b></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SAN DIEGO INSPIRE __, LLC,<br>a Delaware limited liability company</p></td></tr><tr><td colspan="3" style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td colspan="2" style="vertical-align:top;width:44.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:41.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agreed to and Accepted as<br>of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;</u>, 20 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>.</p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#8220;Tenant&#8221;:</b></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:46.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a</p></td><td colspan="2" style="vertical-align:top;width:43.37%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td colspan="2" style="vertical-align:top;width:43.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td style="vertical-align:top;width:40.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 2.1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT 5.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RULES AND REGULATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Tenant shall faithfully observe and comply with the following Rules and Regulations. &#160;Landlord shall not be responsible to Tenant for the nonperformance of any of said Rules and Regulations by or otherwise with respect to the acts or omissions of any other tenants or occupants of the Project. &#160;In the event of any conflict between the Rules and Regulations and the other provisions of this Lease, the latter shall control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>Tenant shall not alter any lock or install any new or additional locks or bolts on any doors or windows of the Premises without obtaining Landlord&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed. &#160;If Tenant shall affix additional locks on doors then Tenant shall furnish Landlord with copies of keys or pass cards or similar devices for said locks. &#160;Tenant shall bear the cost of any lock changes or repairs required by Tenant. &#160;Initial keys will be furnished by Landlord for the Premises, and any additional keys required by Tenant must be obtained from Landlord at a reasonable cost to be established by Landlord. &#160;Upon the termination of this Lease, Tenant shall restore to Landlord all keys of stores, offices, and toilet rooms, either furnished to, or otherwise procured by, Tenant and in the event of the loss of keys so furnished, Tenant shall pay to Landlord the cost of replacing same or of changing the lock or locks opened by such lost key if Landlord shall deem it necessary to make such changes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>All doors opening to public corridors shall be kept closed at all times except for normal ingress and egress to the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Landlord reserves the right to close and keep locked all entrance and exit doors of the Building during such hours as are customary for comparable buildings in the vicinity of the Building. &#160;Tenant, its employees and agents must be sure that the doors to the Building are securely closed and locked when leaving the Premises if it is after the normal hours of business for the Building. &#160;Any tenant, its employees, agents or any other persons entering or leaving the Building at any time when it is so locked, or any time when it is considered to be after normal business hours for the Building, may be required to sign the Building register. &#160;Access to the Building may be refused unless the person seeking access has proper identification or has a previously arranged pass for access to the Building. &#160;Landlord will furnish passes to persons for whom Tenant requests same in writing. &#160;Tenant shall be responsible for all persons for whom Tenant requests passes and shall be liable to Landlord for all acts of such persons. &#160;Landlord and its agents shall in no case be liable for damages for any error with regard to the admission to or exclusion from the Building of any person. &#160;In case of invasion, mob, riot, public excitement, or other commotion, Landlord reserves the right to prevent access to the Building or the Project during the continuance thereof by any means it deems appropriate for the safety and protection of life and property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>No furniture, freight or equipment of any kind shall be brought into the Building without prior notice to Landlord. &#160;All moving activity into or out of the Building shall be scheduled with Landlord and done only at such time and in such manner as Landlord designates. &#160;Landlord shall have the right to prescribe the weight, size and position of all safes and other heavy property brought into the Building and also the times and manner of moving the same in and out of the Building. &#160;Safes and other heavy objects shall, if considered necessary by Landlord, stand on supports of such thickness as is necessary to properly distribute the weight. &#160; Landlord will not be responsible for loss of or damage to any such safe or property in any case. &#160;Any damage to any part of the Building, its contents, occupants or visitors by moving or maintaining any such safe or other property shall be the sole responsibility and expense of Tenant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>No furniture, packages, supplies, equipment or merchandise will be received in the Building or carried up or down in the elevators, except between such hours, in such specific elevator and by such personnel as shall be designated by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font>The requirements of Tenant will be attended to only upon application at the management office for the Project or at such office location designated by Landlord. &#160;Employees of Landlord shall not perform any work or do anything outside their regular duties unless under special instructions from Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 5.2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font>No sign, advertisement, notice or handbill shall be exhibited, distributed, painted or affixed by Tenant on any part of the Premises or the Building without the prior written consent of Landlord. &#160;Tenant shall not disturb, solicit, peddle, or canvass any occupant of the Project and shall cooperate with Landlord and its agents of Landlord to prevent same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font>The toilet rooms, urinals, wash bowls and other apparatus shall not be used for any purpose other than that for which they were constructed, and no foreign substance of any kind whatsoever shall be thrown therein. &#160;The expense of any breakage, stoppage or damage resulting from the violation of this rule shall be borne by the tenant who, or whose servants, employees, agents, visitors or licensees shall have caused same.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9. </font></font>Discharge of industrial sewage to the Building plumbing system shall only be permitted if Tenant, at its sole expense, shall have obtained all necessary permits and licenses therefor, including without limitation permits from state and local authorities having jurisdiction thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font>Tenant shall not overload the floor of the Premises, nor mark, drive nails or screws, or drill into the partitions, woodwork or drywall or in any way deface the Premises or any part thereof without Landlord&#8217;s prior written consent; provided, however, that Landlord&#8217;s prior written consent shall not be required for the hanging of normal and customary office artwork and personal items. &#160;Tenant shall not purchase spring water, ice, towel, linen, maintenance or other like services from any person or persons not included on an approved list that Landlord shall provide to Tenant upon request. Landlord reserves the right to have Landlord&#8217;s structural engineer review Tenant&#8217;s floor loads on the Building at Landlord&#8217;s expense, unless such study reveals that Tenant has exceeded the floor loads, in which case Tenant shall pay the cost of such survey.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font>Except for vending machines intended for the sole use of Tenant&#8217;s employees and invitees, no vending machine or machines other than fractional horsepower office machines shall be installed, maintained or operated upon the Premises without the written consent of Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font>Tenant shall not use or keep in or on the Premises, the Building, or the Project any kerosene, gasoline or other inflammable or combustible fluid, chemical, substance or material, unless otherwise permitted by the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font>Tenant shall not without the prior written consent of Landlord use any method of heating or air conditioning other than that supplied by Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.</font></font>Tenant shall not use, keep or permit to be used or kept, any foul or noxious gas or substance in or on the Premises, or permit or allow the Premises to be occupied or used in a manner offensive or objectionable to Landlord or other occupants of the Project by reason of noise, odors, or vibrations, or interfere with other tenants or those having business therein, whether by the use of any musical instrument, radio, phonograph, or in any other way. &#160;Tenant shall not throw anything out of doors, windows or skylights or down passageways.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">15.</font></font>Tenant shall not bring into or keep within the Project, the Building or the Premises any animals, birds, aquariums, or, except in areas designated by Landlord, bicycles or other vehicles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">16.</font></font>No cooking shall be done or permitted on the Premises, nor shall the Premises be used for the storage of merchandise, for lodging or for any improper, objectionable or immoral purposes. &#160;Notwithstanding the foregoing, Underwriters&#8217; laboratory-approved equipment and microwave ovens may be used in the Premises for heating food and brewing coffee, tea, hot chocolate and similar beverages for employees and visitors, provided that such use is in accordance with all applicable federal, state, county and city laws, codes, ordinances, rules and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">17.</font></font>The Premises shall not be used for manufacturing or for the storage of merchandise except as such storage may be incidental to the use of the Premises provided for in the Summary. &#160;Tenant shall not occupy or permit any portion of the Premises to be occupied as an office for a messenger-type operation or dispatch office, public stenographer or typist, or for the manufacture or sale of liquor, narcotics, or tobacco in any form, or as a medical office, or as a barber or manicure shop, or as an employment bureau without the express prior written consent of Landlord. &#160;Tenant shall not engage or pay any employees on the Premises except those actually working for such tenant on the Premises nor advertise for laborers giving an address at the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 5.2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">18.</font></font>Landlord reserves the right to exclude or expel from the Project any person who, in the judgment of Landlord, is intoxicated or under the influence of liquor or drugs, or who shall in any manner do any act in violation of any of these Rules and Regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">19.</font></font>Tenant, its employees and agents shall not loiter in or on the entrances, corridors, sidewalks, lobbies, courts, halls, stairways, elevators, vestibules or any Common Areas for the purpose of smoking tobacco products or for any other purpose, nor in any way obstruct such areas, and shall use them only as a means of ingress and egress for the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20.</font></font>Tenant shall not waste electricity, water or air conditioning and agrees to cooperate fully with Landlord to ensure the most effective operation of the Building&#8217;s heating and air conditioning system, and shall refrain from attempting to adjust any controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">21.</font></font>Tenant shall store all its trash and garbage within the interior of the Premises unless otherwise provided in the Lease. &#160;No material shall be placed in the trash boxes or receptacles if such material is of such nature that it may not be disposed of in the ordinary and customary manner of removing and disposing of trash and garbage in San Diego, California without violation of any law or ordinance governing such disposal. &#160;All trash, garbage and refuse disposal shall be made only through entry-ways and elevators provided for such purposes at such times as Landlord shall designate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">22.</font></font>Tenant shall comply with all safety, fire protection and evacuation procedures and regulations established by Landlord or any governmental agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23.</font></font>Any persons employed by Tenant to do janitorial work shall be subject to the prior written approval of Landlord, and while in the Building and outside of the Premises, shall be subject to and under the control and direction of the Building manager (but not as an agent or servant of such manager or of Landlord), and Tenant shall be responsible for all acts of such persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24.</font></font>No awnings or other projection shall be attached to the outside walls of the Building without the prior written consent of Landlord, and no curtains, blinds, shades or screens shall be attached to or hung in, or used in connection with, any window or door of the Premises other than Landlord standard drapes. &#160;All electrical ceiling fixtures hung in the Premises or spaces along the perimeter of the Building must be fluorescent and/or of a quality, type, design and a warm white bulb color approved in advance in writing by Landlord. &#160;Neither the interior nor exterior of any windows shall be coated or otherwise sunscreened without the prior written consent of Landlord. &#160;Tenant shall abide by Landlord&#8217;s regulations concerning the opening and closing of window coverings which are attached to the windows in the Premises, if any, which have a view of any interior portion of the Building or Building Common Areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25.</font></font>The sashes, sash doors, skylights, windows, and doors that reflect or admit light and air into the halls, passageways or other public places in the Building shall not be covered or obstructed by Tenant, nor shall any bottles, parcels or other articles be placed on the windowsills.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">26.</font></font>Tenant must comply with requests by Landlord concerning the informing of their employees of items of importance to Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">27.</font></font>No smoking is permitted in the Building or on the Project. &#160;Tenant must comply with the State of California &#8220;No-Smoking&#8221; law set forth in California Labor Code Section 6404.5, and any local &#8220;No-Smoking&#8221; ordinance which may be in effect from time to time and which is not superseded by such state law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">28.</font></font>Tenant hereby acknowledges that Landlord shall have no obligation to provide guard service or other security measures for the benefit of the Premises, the Building or the Project. &#160;Tenant hereby assumes all responsibility for the protection of Tenant and its agents, employees, contractors, invitees and guests, and the property thereof, from acts of third parties, including keeping doors locked and other means of entry to the Premises closed, whether or not Landlord, at its option, elects to provide security protection for the Project or any portion thereof. &#160;Tenant further assumes the risk that any safety and security devices, services and programs which Landlord elects, in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 5.2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">its sole discretion, to provide may not be effective, or may malfunction or be circumvented by an unauthorized third party, and Tenant shall, in addition to its other insurance obligations under this Lease, obtain its own insurance coverage to the extent Tenant desires protection against losses related to such occurrences. &#160;Tenant shall cooperate in any reasonable safety or security program developed by Landlord or required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">29.</font></font>All non-standard office equipment of any electrical or mechanical nature shall be placed by Tenant in the Premises in settings approved by Landlord, to absorb or prevent any vibration, noise and annoyance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30.</font></font>Tenant shall not use in any space or in the public halls of the Building, any hand trucks except those equipped with rubber tires and rubber side guards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">31.</font></font>No auction, liquidation, fire sale, going-out-of-business or bankruptcy sale shall be conducted in the Premises without the prior written consent of Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">32.</font></font>No tenant shall use or permit the use of any portion of the Premises for living quarters, sleeping apartments or lodging rooms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">Landlord reserves the right at any time to change or rescind any one or more of these Rules and Regulations, or to make such other and further reasonable Rules and Regulations as in Landlord&#8217;s judgment may from time to time be necessary for the management, safety, care and cleanliness of the Premises, Building, the Common Areas and the Project, and for the preservation of good order therein, as well as for the convenience of other occupants and tenants therein. &#160;Landlord may waive any one or more of these Rules and Regulations for the benefit of any particular tenants, but no such waiver by Landlord shall be construed as a waiver of such Rules and Regulations in favor of any other tenant, nor prevent Landlord from thereafter enforcing any such Rules or Regulations against any or all tenants of the Project. &#160;Tenant shall be deemed to have read these Rules and Regulations and to have agreed to abide by them as a condition of its occupancy of the Premises.</p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 5.2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-4-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT 5.3.1.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SOVA Central Science District</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ENVIRONMENTAL QUESTIONNAIRE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ENVIRONMENTAL QUESTIONNAIRE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FOR COMMERCIAL AND INDUSTRIAL PROPERTIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.9%;" align="center"><tr><td style="vertical-align:top;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property Name:</b></p></td><td style="vertical-align:top;width:80.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property Address:</b></p></td><td style="vertical-align:top;width:80.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:19.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:80.81%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Instructions</b><font style="white-space:pre-wrap;">:  The following questionnaire is to be completed by the Lessee representative with knowledge of the planned operations for the specified building/location.  Please print clearly and attach additional sheets as necessary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.0</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PROCESS INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Describe planned use, and include brief description of manufacturing processes employed.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.9%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.0</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">HAZARDOUS MATERIALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Are hazardous materials used or stored? If so, continue with the next question. &#160;If not, go to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;3.0</u>.</p><div style="margin-bottom:10pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:7.14%;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.1</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Are any of the following materials handled on the Property?</font></font><font style="display:block;height:1px;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Yes&#160;&#160;&#160;&#160;No</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">(A material is handled if it is used, generated, processed, produced, packaged, treated, stored, emitted, discharged, or disposed.) If so, complete this section. If this question is not applicable, skip this section and go on to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.0</u>.</p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:50%;"><tr><td style="vertical-align:top;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Explosives</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fuels</p></td><td style="vertical-align:top;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Oils</p></td></tr><tr><td style="vertical-align:top;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Solvents</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Oxidizers</p></td><td style="vertical-align:top;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Organics/Inorganics</p></td></tr><tr><td style="vertical-align:top;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Acids</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bases</p></td><td style="vertical-align:top;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Pesticides</p></td></tr><tr><td style="vertical-align:top;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Gases</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PCBs</p></td><td style="vertical-align:top;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Radioactive Materials</p></td></tr><tr><td style="vertical-align:top;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Other (please specify)</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:41.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2-2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">If any of the groups of materials checked in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;2.1</u><font style="white-space:pre-wrap;">, please list the specific material(s), use(s), and quantity of each chemical used or stored on the site in the Table below.  If convenient, you may substitute a chemical inventory and list the uses of each of the chemicals in each category separately.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:84.76%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.67%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Material</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:32.7%;border-bottom:3px double #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Physical State (Solid, Liquid, or Gas)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.43%;border-bottom:3px double #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Usage</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.6%;border-bottom:3px double #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Container Size</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:20.89%;border-bottom:3px double #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of Containers</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.68%;border-bottom:3px double #000000;border-left:1px solid #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total Quantity</b></p></th></tr><tr><td style="vertical-align:top;width:9.67%;border-bottom:1px solid #000000;border-left:3px double #000000;border-right:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:32.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.67%;border-bottom:1px solid #000000;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:32.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.67%;border-bottom:1px solid #000000;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:32.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.67%;border-bottom:1px solid #000000;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:32.7%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.43%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.6%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.89%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.67%;border-bottom:3px double #000000;border-left:3px double #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:32.7%;border-bottom:3px double #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:7.43%;border-bottom:3px double #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.6%;border-bottom:3px double #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20.89%;border-bottom:3px double #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.68%;border-bottom:3px double #000000;border-left:1px solid #000000;border-right:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 5.3.1.1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2-3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="white-space:pre-wrap;">Describe the planned storage area location(s) for these materials.  Please include site maps and drawings as appropriate.</font></p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.9%;" align="center"><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.0</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">HAZARDOUS WASTES</b></p><div style="margin-bottom:10pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Are hazardous wastes generated?</font></font><font style="display:block;height:1px;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Yes  No</font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;">If yes, continue with the next question.  If not, skip this section and go to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4.0</u>.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Are any of the following wastes generated, handled, or disposed of (where applicable) on the Property?</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:50%;"><tr><td style="vertical-align:top;width:42.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Hazardous wastes</p></td><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:51.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Industrial Wastewater</p></td></tr><tr><td style="vertical-align:top;width:42.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Waste oils</p></td><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>PCBs</p></td></tr><tr><td style="vertical-align:top;width:42.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Air emissions</p></td><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Sludges</p></td></tr><tr><td style="vertical-align:top;width:42.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Regulated Wastes</p></td><td style="vertical-align:top;width:5.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:51.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Other (please specify)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3-2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">List and quantify the materials identified in Question&#160;3-1 of this section.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:29.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:23.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASTE </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">GENERATED</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:14.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RCRA listed </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Waste?</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:6.65%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SOURCE</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:29.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">APPROXIMATE </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">MONTHLY QUANTITY</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:23.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASTE </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">CHARACTERIZATION</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DISPOSITION</b></p></th></tr><tr><td style="vertical-align:top;width:16.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:23.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:16.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:23.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:16.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:23.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:16.16%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:14.01%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.65%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:29.58%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:23.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.41%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3-3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="white-space:pre-wrap;">Please include name, location, and permit number (e.g. EPA ID No.) for transporter and disposal facility, if applicable).  Attach separate pages as necessary.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:32.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transporter/Disposal Facility Name</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:16.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Facility Location</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:35.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Transporter (T) or Disposal (D) Facility</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:15.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Permit Number</b></p></th></tr><tr><td style="vertical-align:top;width:32.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:32.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:32.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:32.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:16.63%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:35.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:15.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:7.14%;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3-4.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Are pollution controls or monitoring employed in the process to prevent or minimize the release of wastes into the environment?</font></font><font style="display:block;height:1px;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Yes&#160;&#160;&#160;No</font></font></p></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3-5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">If so, please describe.</p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.0</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">USTS/ASTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.1</font></font>Are underground storage tanks (USTs), aboveground storage tanks (ASTs), or associated pipelines used for the storage of petroleum products, chemicals, or liquid wastes present on site (lease renewals) or required for planned operations (new tenants)?<font style="display:inline-block;width:35.91pt;"></font>Yes<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;</u><font style="display:inline-block;width:5.45pt;"></font>No<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;</u> </p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 36pt;">If not, continue with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;5.0</u><font style="white-space:pre-wrap;">.  If yes, please describe capacity, contents, age, type of the USTs or ASTs, as well any associated leak detection/spill prevention measures.  Please attach additional pages if necessary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 5.3.1.1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="font-size:1pt;visibility:hidden;">&#8203;</font><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:23.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capacity</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contents</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Installed</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:23.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Type (Steel, Fiberglass,</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;"> etc.)</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:44.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Associated Leak Detection / Spill </b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Prevention Measures</b><sup style="font-size:7.5pt;font-weight:bold;vertical-align:top;">*</sup></p></th></tr><tr><td style="vertical-align:top;width:9.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:23.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:23.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:9.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:9.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:13.15%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:23.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.74%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">*</sup>Note:</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The following are examples of leak detection / spill prevention measures:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:60%;"><tr><td style="vertical-align:top;width:33.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Integrity testing</p></td><td style="vertical-align:top;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inventory reconciliation</p></td><td style="vertical-align:top;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Leak detection system</p></td></tr><tr><td style="vertical-align:top;width:33.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Overfill spill protection</p></td><td style="vertical-align:top;width:34.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Secondary containment</p></td><td style="vertical-align:top;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cathodic protection</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">4-2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;">Please provide copies of written tank integrity test results and/or monitoring documentation, if available.</p></td></tr></table><div style="margin-bottom:10pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="display:inline-block;margin-left:36.0pt;position:relative;width:100%;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:7.14%;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4-3.</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Is the UST/AST registered and permitted with the appropriate regulatory agencies?</font></font><font style="display:block;height:1px;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Yes&#160;&#160;No </font></font></font><font style="display:inline-block;position:relative;text-indent:0pt;width:100%;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If so, please attach a copy of the required permits.</font></font></font></p></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4-4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">If this Questionnaire is being completed for a lease renewal, and if any of the USTs/ASTs have leaked, please state the substance released, the media(s) impacted (e.g., soil, water, asphalt, etc.), the actions taken, and all remedial responses to the incident.</p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4-5.</font></font>If this Questionnaire is being completed for a lease renewal, have USTs/ASTs been removed from the Property?<font style="display:inline-block;width:18.42pt;"></font><font style="white-space:pre-wrap;">Yes  No</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 36pt;">If yes, please provide any official closure letters or reports and supporting documentation (e.g., analytical test results, remediation report results, etc.).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4-6.</font></font>For Lease renewals, are there any above or below ground pipelines on site used to transfer chemicals or wastes?<font style="display:inline-block;width:20.1pt;"></font><font style="white-space:pre-wrap;">Yes  No</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 36pt;">For new tenants, are installations of this type required for the planned operations?</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;">Yes  No</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If yes to either question, please describe.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.0</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ASBESTOS CONTAINING BUILDING MATERIALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Please be advised that an asbestos survey may have been performed at the Property. &#160;If provided, please review the information that identifies the locations of known asbestos containing material or presumed asbestos containing material. &#160;All personnel and appropriate subcontractors should be notified of the presence of these materials, and informed not to disturb these materials. &#160;Any activity that involves the disturbance or removal of these materials must be done by an appropriately trained individual/contractor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.0</b></font><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">REGULATORY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6-1.</font></font>Does the operation have or require a National Pollutant Discharge Elimination System (NPDES) or equivalent permit?<font style="display:inline-block;width:334.58pt;"></font>Yes&#160;&#160;No <br>If so, please attach a copy of this permit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 5.3.1.1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6-2.</font></font>Has a Hazardous Materials Business Plan been developed for the site?<font style="display:inline-block;width:53.56pt;"></font>Yes&#160;&#160;No <br>If so, please attach a copy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I am familiar with the real property described in this questionnaire. &#160;By signing below, I represent and warrant that the answers to the above questions are complete and accurate to the best of my knowledge. &#160;I also understand that Lessor will rely on the completeness and accuracy of my answers in assessing any environmental liability risks associated with the property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.9%;" align="center"><tr><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signature:</p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:44.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Telephone:</p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 5.3.1.1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-4-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT 17</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SOVA Central Science District</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FORM OF TENANT&#8217;S ESTOPPEL CERTIFICATE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The undersigned as Tenant under that certain Lease (the &#8220;<b style="font-weight:bold;">Lease</b>&#8221;) made and entered into as of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>, 20 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;</u> by and between <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> as Landlord, and the undersigned as Tenant, for Premises on the <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>&#160;floor(s) of the office building located at <b style="font-weight:bold;">[INSERT BUILDING ADDRESS]</b>, San Diego, California, certifies as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.</font></font>Attached hereto as <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</b> is a true and correct copy of the Lease and all amendments and modifications thereto. &#160;The documents contained in <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</b> represent the entire agreement between the parties as to the Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2.</font></font>The undersigned currently occupies the Premises described in the Lease, the Lease Term commenced on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>, and the Lease Term expires on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>, and the undersigned has no option to terminate or cancel the Lease or to purchase all or any part of the Premises, the Building and/or the Project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.</font></font>Base Rent became payable on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4.</font></font>The Lease is in full force and effect and has not been modified, supplemented or amended in any way except as provided in <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</b>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.</font></font>Tenant has not transferred, assigned, or sublet any portion of the Premises nor entered into any license or concession agreements with respect thereto except as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6.</font></font>Intentionally Omitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7.</font></font>All monthly installments of Base Rent, all Additional Rent and all monthly installments of estimated Additional Rent have been paid when due through <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>. The current monthly installment of Base Rent is $<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8.</font></font>All conditions of the Lease to be performed by Landlord necessary to the enforceability of the Lease have been satisfied and Landlord is not in default thereunder. &#160;In addition, the undersigned has not delivered any notice to Landlord regarding a default by Landlord thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">9.</font></font>No rental has been paid more than thirty (30) days in advance and no security has been deposited with Landlord except as provided in the Lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10.</font></font>As of the date hereof, there are no existing defenses or offsets, or, to the undersigned&#8217;s knowledge, claims or any basis for a claim, that the undersigned has against Landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">11.</font></font>If Tenant is a corporation or partnership, each individual executing this Estoppel Certificate on behalf of Tenant hereby represents and warrants that Tenant is a duly formed and existing entity qualified to do business in California and that Tenant has full right and authority to execute and deliver this Estoppel Certificate and that each person signing on behalf of Tenant is authorized to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12.</font></font>There are no actions pending against the undersigned under the bankruptcy or similar laws of the United States or any state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">13.</font></font>To the best of Tenant&#8217;s knowledge, Tenant is in full compliance with all federal, state and local laws, ordinances, rules and regulations affecting its use of the Premises, including, but not limited to, those laws, ordinances, rules or regulations relating to hazardous or toxic materials. &#160;Tenant has never permitted or suffered, nor does Tenant have any knowledge of, the generation, manufacture, treatment, use, storage, disposal or discharge of any</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 17</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">hazardous, toxic or dangerous waste, substance or material in, on, under or about the Project or the Premises or any adjacent premises or property in violation of any federal, state or local law, ordinance, rule or regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">14.</font></font>To the undersigned&#8217;s knowledge, all tenant improvement work to be performed by Landlord under the Lease has been completed in accordance with the Lease and has been accepted by the undersigned and all reimbursements and allowances due to the undersigned under the Lease in connection with any tenant improvement work have been paid in full. &#160;All work (if any) in the common areas required by the Lease to be completed by Landlord has been completed and all parking spaces required by the Lease have been furnished and/or all parking ratios required by the Lease have been met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The undersigned acknowledges that this Estoppel Certificate may be delivered to Landlord or to a prospective mortgagee or prospective purchaser and acknowledges that said prospective mortgagee or prospective purchaser will be relying upon the statements contained herein in making the loan or acquiring the property of which the Premises are a part and that receipt by it of this certificate is a condition of making such loan or acquiring such property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Executed at <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> on the <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> day of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>, 20 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:top;width:42.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8220;Tenant&#8221;:</b></p></td></tr><tr><td style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:top;width:48.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">,</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">a</p></td><td colspan="3" style="vertical-align:top;width:45.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td colspan="3" style="vertical-align:top;width:45.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:42.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="4" style="vertical-align:top;width:49.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td colspan="3" style="vertical-align:top;width:45.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:46.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:3.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Its:</p></td><td colspan="2" style="vertical-align:top;width:42.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 17</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 21</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM LETTER OF CREDIT</b><sup style="font-size:7.5pt;font-weight:bold;vertical-align:top;">8</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">IRREVOCABLE STANDBY LETTER OF CREDIT NO. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">DATE: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>, 20 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">BENEFICIARY:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">APPLICANT:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">AMOUNT: US$ <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> ($ <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> and 00/100 U.S. DOLLARS)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">EXPIRATION DATE: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>, 20 <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">LOCATION: AT OUR COUNTERS IN <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">DEAR SIR/MADAM:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">WE HEREBY ESTABLISH OUR IRREVOCABLE STANDBY LETTER OF CREDIT NO. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> IN YOUR FAVOR AVAILABLE BY YOUR DRAFT IN THE FORM OF &#8220;ANNEX 1&#8221; ATTACHED DRAWN ON US AT SIGHT AND ACCOMPANIED BY THE FOLLOWING DOCUMENTS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">A DATED STATEMENT SIGNED BY AN AUTHORIZED OFFICER OF THE BENEFICIARY </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">READING AS FOLLOWS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(A)</font></font>WE ARE ENTITLED TO DRAW ON THE LETTER OF CREDIT PURSUANT TO THE TERMS OF THAT CERTAIN LEASE BY AND BETWEEN <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>, AS LANDLORD, AND <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>, AS TENANT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">OR</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(B)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> HEREBY CERTIFIES THAT IT HAS RECEIVED NOTICE FROM <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> THAT THE LETTER OF CREDIT NO. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> WILL NOT BE RENEWED, AND THAT IT HAS NOT RECEIVED A REPLACEMENT OF THIS LETTER OF CREDIT FROM</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">8</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Note to Draft: L/C Form to be provided by the issuing bank.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 21</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-1-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> SATISFACTORY TO<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> AT LEAST FORTY-FIVE (45) DAYS &#160;PRIOR TO THE EXPIRATION DATE OF THIS LETTER OF CREDIT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">THE LEASE MENTIONED IN THIS LETTER OF CREDIT IS FOR IDENTIFICATION PURPOSES ONLY AND IT IS NOT INTENDED THAT SAID AGREEMENT BE INCORPORATED HEREIN OR FORM PART OF THIS LETTER OF CREDIT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">DRAFT(S) AND DOCUMENTS MUST INDICATE THE NUMBER AND DATE OF THIS LETTER OF CREDIT. &#160;PARTIAL DRAWINGS ARE PERMITTED.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">THIS LETTER OF CREDIT SHALL BE AUTOMATICALLY EXTENDED FOR AN ADDITIONAL PERIOD OF ONE YEAR, WITHOUT AMENDMENT OR CONDITION, FROM THE PRESENT OR EACH FUTURE EXPIRATION DATE UNLESS AT LEAST FORTY-FIVE (45) DAYS PRIOR TO THE THEN CURRENT EXPIRATION DATE WE NOTIFY YOU AND THE APPLICANT BY REGISTERED MAIL/OVERNIGHT COURIER SERVICE AT THE ABOVE ADDRESSES THAT THIS LETTER OF CREDIT WILL NOT BE EXTENDED BEYOND THE CURRENT EXPIRATION DATE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">THIS LETTER OF CREDIT MAY BE TRANSFERRED (AND THE PROCEEDS HEREOF ASSIGNED), AT THE EXPENSE OF THE APPLICANT (WHICH PAYMENT SHALL NOT BE A CONDITION TO ANY TRANSFER), ONE OR MORE TIMES BUT IN EACH INSTANCE ONLY IN THE FULL AMOUNT AVAILABLE TO BE DRAWN UNDER THE LETTER OF CREDIT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">ALL DEMANDS FOR PAYMENT SHALL BE MADE BY PRESENTATION OF &#160;THE DATED CERTIFICATION PRIOR TO <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> A.M. <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u> TIME, ON A BUSINESS DAY AT OUR OFFICE (THE &#8220;BANK&#8217;S OFFICE&#8221;) AT: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>, ATTENTION: STANDBY LETTER OF CREDIT SECTION OR BY FACSIMILE TRANSMISSION AT: (<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;</u>) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>; AND SIMULTANEOUSLY UNDER TELEPHONE ADVICE TO: (<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;</u>) <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</u>, ATTENTION: STANDBY LETTER OF CREDIT NEGOTIATION SECTION WITH ORIGINALS TO FOLLOW BY OVERNIGHT COURIER SERVICE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">PAYMENT AGAINST CONFORMING PRESENTATIONS HEREUNDER SHALL BE MADE BY BANK IN IMMEDIATELY AVAILABLE U.S. FUNDS DURING NORMAL BUSINESS HOURS OF THE BANK&#8217;S OFFICE WITHIN TWO (2) BUSINESS DAYS AFTER PRESENTATION NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THE UNIFORM CUSTOMS AND PRACTICE FOR DOCUMENTARY CREDITS (1997 REVISION), INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION NO. 600.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">WE HEREBY CERTIFY THAT THIS IS AN UNCONDITIONAL AND IRREVOCABLE CREDIT AND AGREE WITH THE DRAWERS, ENDORSERS AND BONAFIDE HOLDERS THAT THE DRAFTS DRAWN UNDER AND IN ACCORDANCE WITH THE TERMS AND CONDITIONS OF THIS LETTER OF CREDIT SHALL BE DULY HONORED UPON PRESENTATION TO THE DRAWEE, IF NEGOTIATED ON OR BEFORE THE EXPIRATION DATE OF THIS CREDIT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">EXCEPT TO THE EXTENT INCONSISTENT WITH THE EXPRESS TERMS HEREOF, THIS LETTER OF CREDIT IS SUBJECT TO THE UNIFORM CUSTOMS AND PRACTICE FOR DOCUMENTARY CREDITS (1997 REVISION), INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION NO. 600.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">___________________________</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.9%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AUTHORIZED SIGNATURE</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AUTHORIZED SIGNATURE</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 21</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-2-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ANNEX 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:-2.25pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.49%;"><tr><td colspan="3" style="vertical-align:top;width:100%;border-left:4.5pt double #000000;border-right:4.5pt double #000000;border-top:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BILL OF EXCHANGE</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">DATE:</p></td></tr><tr><td style="vertical-align:top;width:5.83%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-right:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">A</b>T</p></td><td style="vertical-align:top;width:50%;border-right:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SIGHT OF THIS BILL OF EXCHANGE</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">P</b>AY TO THE ORDER OF</p></td><td style="vertical-align:top;width:50%;border-right:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">DOLLARS (US $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;)</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">US</p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-right:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-right:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">DRAWN UNDER</b></p></td><td style="vertical-align:top;width:50%;border-right:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-right:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CREDIT NUMBER NO.</b></p></td><td style="vertical-align:top;width:50%;border-right:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">DATED</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5.83%;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">T</b>O:</p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-right:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;border-left:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-bottom:4.5pt double #000000;border-left:4.5pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><b style="font-weight:bold;">Authorized Signature</b></p></td><td style="vertical-align:top;width:50%;border-bottom:4.5pt double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">EXHIBIT 21</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">-3-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>ibio-20220930xex10d4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/14/2022 09:57:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY </b><b style="font-size:11pt;font-weight:bold;"><br></b><b style="font-size:11pt;font-weight:bold;">[***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF </b><b style="font-size:11pt;font-weight:bold;"><br></b><b style="font-size:11pt;font-weight:bold;">INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">IBIO, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RESTRICTED STOCK UNIT AWARD AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">UNDER THE IBIO, INC. 2020 OMNIBUS INCENTIVE PLAN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:59.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name of Grantee:</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:59.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Thomas Isett</font></p></td></tr><tr><td style="vertical-align:top;width:37.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">No. of Restricted Stock Units:</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Five Million (5,000,000) (pre-split basis)</font></p></td></tr><tr><td style="vertical-align:top;width:37.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Grant Date:</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">November 10, 2022</font></p></td></tr><tr><td style="vertical-align:top;width:37.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:37.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Vesting Commencement Date:</font></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">April 30, 2021</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Pursuant to the iBio, Inc. 2020 Omnibus Incentive Plan, as amended through the date hereof (the &#8220;Plan&#8221;), iBio, Inc. (the &#8220;Company&#8221;) hereby grants an award of the number of Restricted Stock Units listed above (an &#8220;Award&#8221;) to the Grantee named above. &#160;Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.001 per share (the &#8220;Stock&#8221;), of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictions on Transfer of Award</u><font style="font-size:12pt;">. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Section 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Vesting of Restricted Stock Units</u><font style="font-size:12pt;">. The restrictions and conditions of Section&#160;1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains in a Service Relationship with the Company or a Subsidiary on such Vesting Dates, provided that any of the Performance Conditions (as defined below) has been satisfied as of the Vesting Date. &#160;If a series of Vesting Dates is specified, then the restrictions and conditions in Section&#160;1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:52.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:14.85pt;"><td style="vertical-align:top;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Incremental Percentage of </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Restricted Stock Units Vested</font></p></td><td style="vertical-align:top;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;width:52.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">Vesting Date</font></p></td></tr><tr style="height:14.85pt;"><td style="vertical-align:top;width:44.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">1/3</font></p></td><td style="vertical-align:top;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:52.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">1</font><sup style="font-size:9pt;vertical-align:top;">st</sup><font style="font-size:12pt;"> anniversary of Vesting </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Commencement Date</font></p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">1/3</font></p></td><td style="vertical-align:top;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:52.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;"> anniversary of Vesting </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Commencement Date</font></p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">1/3</font></p></td><td style="vertical-align:top;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:52.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">3</font><sup style="font-size:9pt;vertical-align:top;">rd</sup><font style="font-size:12pt;"> anniversary of Vesting </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Commencement Date</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:12pt;font-style:italic;">Alternative Performance Conditions</i><font style="font-size:12pt;">. Notwithstanding the foregoing, Grantee shall become vested in the number of Restricted Stock Units determined above as of a Vesting Date</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">only if, as of such Vesting Date, the first to occur of the following performance conditions (&#8220;Performance Conditions&#8221;) has been satisfied:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IND Application</u><font style="font-size:12pt;">. This Performance Condition is satisfied if the Company or a Subsidiary has submitted to the U.S. Food and Drug Administration (FDA) an Investigational New Drug (IND) application, and only with the exceptions set forth in Section 3 below, such application has gone into effect, or alternatively, if the Board approves not to file an IND (&#8220;IND Condition&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sale of CDMO Subsidiary</u><font style="font-size:12pt;">. This Performance Condition is satisfied upon consummation of a Disposition of iBio CDMO, LLC, provided that a definitive transaction agreement is executed by March 31, 2023, and the Gross Sales Proceeds of the Disposition is at least $30,000,000. &#160;The following definitions shall apply for purposes of this Performance Condition:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(I)</font></font><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disposition</u><font style="font-size:12pt;">&#8221; shall have the same meaning as the term &#8220;Sale Event&#8221; as defined in the Plan, with references in such definition to &#8220;Company&#8221; substituted with references to iBio CDMO, LLC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(II)</font></font><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Gross Sales Proceeds</u><font style="font-size:12pt;">&#8221; shall mean the total consideration including without limitation cash proceeds and the fair market value of any non-cash consideration (as reasonably determined in good faith by the Board) to be paid to iBio CDMO, LLC and/or the Company from the Disposition (including any additional consideration with respect to working capital or other adjustments and including any hold backs, any amounts escrowed for indemnification or other purposes, any amounts paid by promissory note and contingent payments, earn-outs and deferred performance-based payments).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Out License Asset</u><font style="font-size:12pt;">. This Performance Condition is satisfied if the Company or a Subsidiary has outlicensed, with full global rights, any of its investigational product candidates prior to the Company or a Subsidiary submitting to the FDA an IND application.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Satisfaction of Any Performance Condition</u><font style="font-size:12pt;">. If, as of the first or second Vesting Dates set forth above, none of the Performance Conditions has been satisfied, but any of the Performance Conditions has been satisfied as of a later Vesting Date set forth above, then as of such later Vesting Date, Grantee shall become vested in the cumulative number of Restricted Stock Units determined under the vesting schedule above. &#160;However, if as of the third Vesting Date set forth above none of the Performance Conditions has been satisfied, Grantee shall forfeit all of the Restricted Stock Units.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:12pt;font-style:italic;">Discretionary Vesting Acceleration. </i><font style="font-size:12pt;">The Administrator may at any time accelerate the vesting schedule specified in this Section 2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">3.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of Service Relationship</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:12pt;font-style:italic;">Certain Terminations in Connection with Sale Event. </i><font style="font-size:12pt;">Upon termination of the Grantee&#8217;s Service Relationship within twelve (12) months following a Sale Event, on an involuntary basis without Cause or on a voluntary basis with Good Reason, the Restricted Stock Units shall</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">immediately vest (regardless of whether any of the Performance Conditions has been satisfied at such time).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:12pt;font-style:italic;">Termination for Cause</i><font style="font-size:12pt;">. Upon termination for Cause of the Grantee&#8217;s Service Relationship, all Restricted Stock Units granted hereunder, including those that already vested, shall be forfeited, regardless of the Grantee&#8217;s period of service following the Vesting Commencement Date, and the Grantee shall have no further rights hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:12pt;font-style:italic;">Termination Upon Death or Disability.</i><font style="font-size:12pt;"> Upon the termination of the Grantee&#8217;s Service Relationship (i) due to the death of the Grantee, or (ii) due to the Company terminating the employment of Grantee due to Total Disability under the Employment Agreement, the Restricted Stock Units shall vest; provided that if the operative Performance Condition is the IND Condition, the Company or a Subsidiary has submitted to the FDA an IND application prior to the third anniversary of the Vesting Commencement Date and prior to the Grantee&#8217;s termination of employment, and provided further that the IND application goes into effect (whether before or after Grantee&#8217;s termination of employment).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-size:12pt;font-style:italic;">Termination for Any Other Reason. </i><font style="font-size:12pt;">If the Grantee&#8217;s Service Relationship with the Company or a Subsidiary terminates for any reason (other than the death or disability of the Grantee or for Cause) prior to the satisfaction of the vesting conditions set forth in Section 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">4.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Issuance of Shares of Stock</u><font style="font-size:12pt;">. As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the calendar year in which the Vesting Date occurs) and provided that any Performance Condition has been satisfied as of such Vesting Date, the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Section 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">5.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Incorporation of Plan</u><font style="font-size:12pt;">. Unless stated herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. &#160;Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein. The Grantee and the Company are parties to an employment agreement entered into effective as of April 30, 2021 (the &#8220;Employment Agreement&#8221;). &#160;The terms &#8220;Cause&#8221; and &#8220;Good Reason&#8221;, when used in this Agreement, shall have the meanings set forth in the Employment Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">6.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Withholding</u><font style="font-size:12pt;">. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. &#160;The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i) withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">amount due; or (ii) causing its transfer agent to sell from the number of shares of Stock to be issued to the Grantee, the number of shares of Stock necessary to satisfy the Federal, state and local taxes required by law to be withheld from the Grantee on account of such transfer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">7.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 409A of the Code.</u><font style="font-size:12pt;"> This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as &#8220;short-term deferrals&#8221; as described in Section 409A of the Code.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">8.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Obligation to Continue Service Relationship</u><font style="font-size:12pt;">. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee&#8217;s Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee&#8217;s Service Relationship with the Company or a Subsidiary at any time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Integration</u><font style="font-size:12pt;">. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">10.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Privacy Consent</u><font style="font-size:12pt;">. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#8220;Relevant Information&#8221;). &#160;By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. &#160;The Grantee shall have access to, and the right to change, the Relevant Information. &#160;Relevant Information will only be used in accordance with applicable law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">11.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clawback</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">In General</u><font style="font-size:12pt;">. Notwithstanding anything to the contrary in this Agreement, this Agreement is expressly made subject to the terms of the clawback and forfeiture provisions set forth below and in the Plan; provided, however, that if the Employment Agreement includes differing clawback and forfeiture provisions, such provisions shall prevail. &#160;As a result, the Grantee may be required to forfeit the Restricted Stock Units and/or return to the Company any proceeds received in settlement thereof in the situations described below. &#160;The Grantee agrees that the Company may enforce the forfeiture by all legal means available, including, without limitation, by withholding the forfeited amount from other sums owed to the Grantee by the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restatement of Financial Statements</u><font style="font-size:12pt;">. In the event of a restatement of the Company&#8217;s financial results within three years of original reporting to correct a material error, then, if the Administrator determines that Grantee&#8217;s acts or omissions were a significant</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">contributing factor to the need to issue such restatement and that all or any portion of the Restricted Stock Units, if the award was made prior to the restatement, would not have been awarded based upon the restated financial results, or that the Grantee derived more economic benefit from the Restricted Stock Units than would have occurred absent the financial statement errors, then the Grantee agrees to forfeit and return to the Company the portion (which may be all) of the Restricted Stock Units and/or any proceeds received in settlement thereof that the Administrator, in its discretion, determines to be appropriate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination for Cause</u><font style="font-size:12pt;">. In the event that (i) the Grantee&#8217;s Service Relationship is terminated by the Company for Cause, or (ii) following the termination of the Grantee&#8217;s Service Relationship, the Company is or becomes aware that the Grantee committed an act that would have given rise to a termination for Cause, then the Grantee agrees to forfeit to the Company all or part of the Restricted Stock Units and/or any proceeds received in settlement thereof, that the Administrator, in its discretion, determines to be appropriate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(d)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Law or Company Policy</u><font style="font-size:12pt;">. The Restricted Stock Units and/or any proceeds received in settlement thereof shall also be subject to forfeiture to the extent required by applicable law or Company policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">12.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="font-size:12pt;">. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">13.</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protective Provisions</u><font style="font-size:12pt;">. As a condition to receipt of this Award, the Grantee acknowledges having read and understood the Company protective provisions attached as Exhibit A (individually and collectively referred to as the &#8220;Protective Provisions&#8221;), and agrees to be bound by such Protective Provisions, and in the event of violation of any of such Protective Provisions, to forfeit to the Company this Award and/or return to the Company any Shares (or net proceeds thereof, if sold). &#160;If any protective provision is included within the Employment Agreement conflicts with any of the Protective Provisions, the protective provision included within the Employment Agreement shall prevail; provided however, if any Protective Provision is not included within the Employment Agreement, such Protective Provision shall be in addition to those within the Employment Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:99.9%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">iBio, Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Marc Banjak</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td><td style="vertical-align:top;width:44.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">General Counsel and Corporate Secretary</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Grantee (including through an online acceptance process) is acceptable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:43.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Dated:</font></p></td><td style="vertical-align:top;width:43.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">10 November 2022</font></p></td><td style="vertical-align:top;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:48.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Thomas Isett</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Grantee&#8217;s Signature</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Grantee&#8217;s name and address:</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Thomas Isett</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">[***]</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">6</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT A TO iBIO, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">COMPANY PROTECTIVE PROVISIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8.05pt 0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment of Intellectual Property Rights</u><font style="font-size:12pt;">. In consideration of the grant of the Award of Restricted Stock Units under the Agreement to which this Exhibit is attached, Grantee agrees to be bound by the provisions of this Exhibit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:22.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u><font style="font-size:12pt;">. Grantee agrees to assign, and hereby assigns, to the Company all of his or her rights in any Inventions (as hereinafter defined) (including all Intellectual Property Rights (as hereinafter defined) therein or related thereto) that are made, conceived or reduced to practice, in whole or in part and whether alone or with others, by him or her during his or her employment by, or service with, the Company or which arise out of any activity conducted by, for or under the direction of the Company (whether or not conducted at the Company&#39;s facilities, working hours or using any of the Company&#39;s assets), or which are useful with, or relate directly or indirectly to, any Company Interest (as defined below). Grantee will promptly and fully disclose and provide all of the Inventions described above (the &#8220;Assigned Inventions&#8221;) to the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:22.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assurances</u><font style="font-size:12pt;">. Grantee hereby agrees, during Grantee&#8217;s employment or service with the Company and thereafter, to further assist the Company, at the Company&#8217;s expense, to evidence, record and perfect the Company&#8217;s rights in and ownership of the Assigned Inventions, to perfect, obtain, maintain, enforce and defend any rights specified to be so owned or assigned and to provide and execute all documentation necessary to effect the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:22.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="font-size:12pt;">. &#8220;Company Interest&#8221; means any business of the Company or any product, service, Invention or Intellectual Property Right that is used or under consideration or development by the Company. &#8220;Intellectual Property Rights&#8221; means any and all intellectual property rights and other similar proprietary rights in any jurisdiction, whether registered or unregistered, and whether owned or held for use under license with any third party, including all rights and interests pertaining to or deriving from: (a) patents and patent applications, reexaminations, extensions and counterparts claiming property therefrom; inventions, invention disclosures, discoveries and improvements, whether or not patentable; (b) computer software and firmware, including data files, source code, object code and software-related specifications and documentation; (c) works of authorship, whether or not copyrightable; (d) trade secrets (including those trade secrets defined in the Uniform Trade Secrets Act and under corresponding statutory law and common law), business, technical and know-how information, non-public information, and confidential information and rights to limit the use of disclosure thereof by any person; (e) trademarks, trade names, service marks, certification marks, service names, brands, trade dress and logos and the goodwill associated therewith; (f) proprietary databases and data compilations and all documentation relating to the foregoing, including manuals, memoranda and record; (g) domain names; and (h) licenses of any of the foregoing; including in each case any registrations of, applications to register, and renewals and extensions of, any of the foregoing with or by any governmental authority in any jurisdiction. &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Invention</u><font style="font-size:12pt;">&#8221; means any products, process, ideas, improvements, discoveries, inventions, designs, algorithms, financial models, writings, works of authorship, content, graphics, data, software, specifications, instructions, text, images, photographs, illustration, audio clips, trade secrets and other works, material and information, tangible or intangible, whether or not it may be patented, copyrighted or otherwise protected (including all versions, modifications, enhancements and derivative work thereof).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">7</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8.05pt 0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictive Covenants</u><font style="font-size:12pt;">. Grantee acknowledges and agrees that he or she has and will have access to secret and confidential information of the Company, its affiliates, and its subsidiaries (&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u><font style="font-size:12pt;">&#8221;) and that the following restrictive covenants are necessary to protect the interests and continued success of the Company. As used in this Agreement, Confidential Information includes, without limitation, all information of a technical or commercial nature (such as research and development information, patents, trademarks and copyrights and applications thereto, formulas, codes, computer programs, software, methodologies, processes, innovations, software tools, know-how, knowledge, designs, drawings specifications, concepts, data, reports, techniques, documentation, pricing information, marketing plans, customer and prospect lists, trade secrets, financial information, salaries, business affairs, suppliers, profits, markets, sales strategies, forecasts and personnel information), whether written or oral, relating to the business and affairs of the Company, its customers and/or other business associates which has not been made available to the general public.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8.05pt 0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u><font style="font-size:12pt;">. Grantee shall not disclose any Confidential Information to any person or entity at any time during Grantee&#8217;s employment or service with the Company or at any time thereafter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8.05pt 0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Compete</u><font style="font-size:12pt;">. In consideration of the Service Relationship hereunder, Grantee agrees that during his or her employment and for a period of one (1) year thereafter, Grantee will not (and will cause any entity controlled by Grantee not to), directly or indirectly, whether or not for compensation and whether or not as an employee, be engaged in or have any financial interest in any business competing with or which may compete with the business of the Company within any state &#160;within the United States or solicit, advise, provide services or products of the same or similar nature to services or products of the Company to any person or entity. &#160;For purposes of this Agreement, Grantee will be deemed to be engaged in or to have a financial interest in such competitive business if he or she is an officer, director, shareholder, joint venturer, salesperson, consultant, investor, advisor, principal or partner, of any person, partnership, corporation, trust or other entity which is engaged in such a competitive business, or if he or she directly or indirectly performs services for such an entity in a capacity the same as or similar to that which Grantee performed for the Company; </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, however,</u><font style="font-size:12pt;"> that the foregoing will not prohibit Grantee from owning, for the purpose of passive investment, less than 2% of any class of securities of a publicly held corporation or performing work for competitive business if such work is not similar to the work performed by Grantee for the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Solicitation/Non-Interference</u><font style="font-size:12pt;">. Grantee agrees that while Grantee remains employed by the Company and for an additional one (1) year after the separation of Grantee from a Service Relationship with the Company, Grantee shall not (and shall cause any entity controlled by Grantee not to), directly or indirectly: (i) solicit, request or otherwise attempt to induce or influence, directly or indirectly, any present client, distributor, licensor or supplier, or prospective client, distributor, licensor or supplier, of the Company, or other persons sharing a business relationship with the Company, to cancel, limit or postpone their business with the Company, or otherwise take action which might cause a financial disadvantage of the &#160;Company; or (ii) hire or solicit for employment, directly or indirectly, or induce or actively attempt to influence, any employee, officer, director, agent, contractor or other business associate of the Company, to terminate his or her or her employment or discontinue such person&#8217;s consultant, contractor or other business association with the Company. For purposes </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">8</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">of this Agreement the term &#8220;prospective client&#8221; shall mean any person, group of associated persons or entity whose business the Company has directly solicited within the one year period prior to the termination of his or her Service Relationship.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8.05pt 0pt;"><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Disparagement</u><font style="font-size:12pt;">. &#160;Grantee agrees that he or she will not in any way disparage the Company, including current or former officers, directors and employees, nor will he or she make or solicit any comments, statements or the like to the media or to others that may be considered to be disparaging, derogatory or detrimental to the good name or business reputation of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If the Company, in its reasonable discretion, determines that Grantee violated any of the restrictive covenants contained in this Exhibit A, the applicable restrictive period shall be increased by the period of time from the commencement of any such violation until the time such violation shall be cured by Grantee to the satisfaction of the Company. &#160;Grantee agrees that a violation of any of the restrictive covenants contained in this Exhibit A shall constitute grounds for forfeiture of any equity-based awards granted to Grantee by the Company (regardless of the extent to which Grantee has vested in such awards), and grounds for the Company to recoup from Grantee any proceeds of equity-based awards granted to Grantee by the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(a)</font></font><font style="font-size:12pt;">In the event that either any scope or restrictive period set forth in this Exhibit A is deemed to be unreasonably restrictive or unenforceable in any court proceeding, the scope and/or restrictive period shall be reduced to equal the maximum scope and/or restrictive period allowable under the circumstances.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(b)</font></font><font style="font-size:12pt;">Grantee acknowledges and agrees that in the event of a breach or threatened breach of the provisions of this Exhibit A by Grantee, the Company may suffer irreparable harm and, therefore, the Company shall be entitled to seek immediate injunctive relief restraining Grantee from such breach or threatened breach of the restrictive covenants contained in this Exhibit A in a court of competent jurisdiction. &#160;Nothing herein shall be construed as prohibiting the Company from pursuing any other remedies available to it for such breach or threatened breach, including the recovery of damages from Grantee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><font style="font-size:12pt;">Under the federal Defend Trade Secrets Act of 2016 (18 U.S.C. &#167;&#160;1833(b)), &#8220;An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that&#8212;(A) is made&#8212;(i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.&#8221; Nothing in this Agreement is intended to conflict with 18 U.S.C. &#167;&#160;1833(b) or create liability for disclosures of trade secrets that are expressly allowed by 18 U.S.C. &#167;&#160;1833(b). Accordingly, the parties to this Agreement have the right to disclose in confidence trade secrets to federal, state, and local government officials, or to an attorney, for the sole purpose of reporting or investigating a suspected violation of law. The parties also have the right to disclose trade secrets in a document filed in a lawsuit or other proceeding, but only if the filing is made under seal and protected from public disclosure.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">9</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ibio-20220930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/14/2022 09:57:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:9.56%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;">Exhibit</b>&#160;<b style="font-weight:bold;">31.1 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;text-transform:uppercase;">Certification Pursuant to Section</b><font style="text-transform:uppercase;">&#160;</font><b style="font-weight:bold;text-transform:uppercase;">302 of </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;text-transform:uppercase;">the Sarbanes-Oxley Act of 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">I, Thomas F. Isett 3<sup style="font-size:7.5pt;vertical-align:top;">rd</sup>, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:89.98%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">1.</p></td><td style="vertical-align:top;width:89.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the &#8220;report&#8221;) of iBio, Inc. (the &#8220;registrant&#8221;);</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.</p></td><td style="vertical-align:top;width:89.56%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.</p></td><td style="vertical-align:top;width:89.56%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.</p></td><td style="vertical-align:top;width:89.56%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b.</p></td><td style="vertical-align:top;width:83.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">c.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">d.</p></td><td style="vertical-align:top;width:83.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5.</p></td><td style="vertical-align:top;width:89.56%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.4289856%;padding-left:0pt;padding-right:0pt;width:100.85%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:56.72%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:11.3pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: <a name="led148333F20215171623961419318"></a>November 14, 2022</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.72%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:11.3pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.1%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:56.72%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Thomas F. Isett 3<sup style="font-size:7.5pt;vertical-align:top;">rd</sup></p></td></tr><tr style="height:11.3pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.72%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:&#160;Thomas F. Isett 3<sup style="font-size:7.5pt;vertical-align:top;">rd</sup></p></td></tr><tr style="height:34.35pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.72%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:&#160;  Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:9.56%;margin-top:30pt;page-break-after:avoid;width:84.56%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ibio-20220930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/14/2022 09:57:32 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;">Exhibit</b>&#160;<b style="font-weight:bold;">31.2 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;text-transform:uppercase;">Certification Pursuant to Section</b><font style="text-transform:uppercase;">&#160;</font><b style="font-weight:bold;text-transform:uppercase;">302 of </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;text-transform:uppercase;">the Sarbanes-Oxley Act of 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">I, Robert Lutz, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">1.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the &#8220;report&#8221;) of iBio, Inc. (the &#8220;registrant&#8221;);</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">c.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">d.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: <a name="led148333F20215171623961450661"></a>November 14, 2022</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert Lutz</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:&#160;Robert Lutz</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:&#160;&#160;Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ibio-20220930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/14/2022 09:57:33 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Quarterly Report on Form 10-Q of iBio, Inc. (the &#8220;Company&#8221;) for the quarterly period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Thomas F. Isett 3<sup style="font-size:7.5pt;vertical-align:top;">rd</sup>&#160;, Chief Executive Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1.25pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td></tr><tr style="height:15.7pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 14, 2022</p></td><td style="vertical-align:top;width:49.16%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Thomas F. Isett 3<sup style="font-size:7.5pt;vertical-align:top;">rd</sup></p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thomas F. Isett 3<sup style="font-size:7.5pt;vertical-align:top;">rd</sup></p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 1.5pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ibio-20220930xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 11/14/2022 09:57:34 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">18 U.S.C. &#167;1350,</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Quarterly Report on Form 10-Q of iBio, Inc. (the &#8220;Company&#8221;) for the quarterly period ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Robert Lutz, Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.2%;"><tr><td style="vertical-align:middle;width:6.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1.</p></td><td style="vertical-align:middle;width:89.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:6.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p></td><td style="vertical-align:middle;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.97%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1.25pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"></td></tr><tr style="height:15.7pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 14, 2022</p></td><td style="vertical-align:top;width:50.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Robert Lutz</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Robert Lutz</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer and Principal Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ibio-20220930x10q001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20220930x10q001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'T!#,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#A?B=_P45^
M.?AKXE>+-(L/%%G%8V&KW=I;QG1[5BL:3.JC)CR< #DUS/\ P\O^/W_0UV7_
M ();3_XW7AWQL_Y+-X]_[#]__P"E$E<77T<:-.R]U'DNI.^Y]2_\/+_C]_T-
M=E_X);3_ .-T?\/+_C]_T-=E_P""6T_^-U\M457L:?\ *A>TGW/J7_AY?\?O
M^AKLO_!+:?\ QNC_ (>7_'[_ *&NR_\ !+:?_&Z^6J*/8T_Y4'M)]SZE_P"'
ME_Q^_P"AKLO_  2VG_QNC_AY?\?O^AKLO_!+:?\ QNOEJBCV-/\ E0>TGW/J
M7_AY?\?O^AKLO_!+:?\ QNC_ (>7_'[_ *&NR_\ !+:?_&Z^6J*/8T_Y4'M)
M]SZE_P"'E_Q^_P"AKLO_  2VG_QNC_AY?\?O^AKLO_!+:?\ QNOEJBCV-/\
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MC_AY?\?O^AKLO_!+:?\ QNOEJBCV-/\ E0>TGW/J7_AY?\?O^AKLO_!+:?\
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MC_AY?\?O^AKLO_!+:?\ QNOEG//7FC/.,\^E'L:?\J#VD^Y]3?\ #R_X_?\
M0UV7_@EM/_C='_#R_P"/W_0UV7_@EM/_ (W7RRK*Z[E8,OJIR*6CV-/^5![2
M?<^I?^'E_P ?O^AKLO\ P2VG_P ;H_X>7_'[_H:[+_P2VG_QNOEJBCV-/^5!
M[2?<^I?^'E_Q^_Z&NR_\$MI_\;H_X>7_ !^_Z&NR_P#!+:?_ !NOEJBCV-/^
M5![2?<^I?^'E_P ?O^AKLO\ P2VG_P ;H_X>7_'[_H:[+_P2VG_QNOEJHVGB
M5MK2QJW]TN :/8T_Y4'M)]SZI_X>7_'[_H:[+_P2VG_QNC_AY?\ '[_H:[+_
M ,$MI_\ &Z^6>E->6.+&^1$STW,!FCV-/^5![2?<^J/^'E_Q^_Z&NR_\$MI_
M\;H_X>7_ !^_Z&NR_P#!+:?_ !NOEG<..1STYZ_2C(SC(SZ4>QI_RH/:3[GU
M-_P\O^/W_0UV7_@EM/\ XW1_P\O^/W_0UV7_ ();3_XW7RR"#G!!QP<4U)HY
M&VI(CMZ*P)H]C3_E0>TGW/JC_AY?\?O^AKLO_!+:?_&Z/^'E_P ?O^AKLO\
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M7/%+1[&G_*@]I/N?4O\ P\O^/W_0UV7_ ();3_XW1_P\O^/W_0UV7_@EM/\
MXW7RU2 @]"#]*/8T_P"5![2?<^IO^'E_Q^_Z&NR_\$MI_P#&Z/\ AY?\?O\
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MU<95E8>JG-'L:?\ *@]I/N?4_P#P\O\ C]_T-=E_X);3_P"-T?\ #R_X_?\
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M[S602S%3+*SRN[LS!$7EL!44 #G/*UK%-*S,Y.["BBBK)"BBB@ KZ#\0:O\
MV#\,/AU!:>-K'PQ]J\-O-/IW]@M</<N;RY7>TRP,,L%"Y+9 4=*^?*[JZ^)U
MIJOAO0]*U7P?I>I3:-8-IUKJ#7E[#*(S+)*"RQS!"P:5N=O(QG-9S5[%Q=KG
MLW[/'P5MM<^&TLNL>&KC4I/'D\NB:;J:P[ET6.)=WVTMV#7/DQ9_N)-S53X(
M^ _%5Y\,/&FD:!/I.A>,[?Q1:6;_ -JB))6$=M=M-;Q&2*0ELQYV*,ML&,G
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M''7H?G6!OL[1E>3'C&?:O5M4^/YO_&=_XPA\#>&[3Q9=W)O/[49KNY$%P?\
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M5)[)D,@NHK"9XBHZL'"[<>^<5O\ A#QOJ'@;2O$>ER:#8ZMINK)!!?VNK07
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M7[/G_0F7/_@ZO?\ X[1]>AV8?5I=S\2<48K]MO\ AVE^SY_T)ES_ .#J]_\
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M  [4_9[_ .A+N?\ P<WO_P =H^O0[,/JTNY^)6*,5^VO_#M3]GO_ *$NY_\
M!S>__':/^':G[/?_ $)=S_X.;W_X[1]>AV8?5I=S\2L48K]M?^':G[/?_0EW
M/_@YO?\ X[1_P[4_9[_Z$NY_\'-[_P#':/KT.S#ZM+N?B5BC%?M7JO\ P39^
M %OIEW+#X+NO-2)F3&L7I.0#C_EK6+\-?^"=7P&U_P"'7A;4[_P?<RWU[I5I
M<SR?VO>+ND>%&8X$F!DD]*/KT.S#ZM+N?C=BC%?MK_P[4_9[_P"A+N?_  <W
MO_QVC_AVI^SW_P!"7<_^#F]_^.T?7H=F'U:7<_$K%&*_;7_AVI^SW_T)=S_X
M.;W_ ..T?\.U/V>_^A+N?_!S>_\ QVCZ]#LP^K2[GXE8HQ7[:_\ #M3]GO\
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M#![I(Q*VX$@G=D]R:_7G_AVI^SW_ -"7<_\ @YO?_CM'_#M3]GO_ *$NY_\
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M.#(0>?6NK_X=I?L^?]"9<_\ @ZO?_CM'UZ'9A]6EW/Q*Q1BOVV_X=I?L^?\
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M*** "BBB@ HHHH *\Z^+W_'YX%_[&6T_]!EKT6O.?C"VVY\#'T\26A_\=EH
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M,=L5PL96.(F0>9*K2H"&V+R3NX(H=2BG9[^GG;\PYH(XS_A-_$/_ $'-2_\
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MC;_X3?Q#_P!!S4O_  ,E_P#BJ/\ A-_$/_0<U+_P,E_^*K$HHY(]@LNQM_\
M";^(?^@YJ7_@9+_\51_PF_B'_H.:E_X&2_\ Q58E%')'L%EV-O\ X3?Q#_T'
M-2_\#)?_ (JC_A-_$/\ T'-2_P# R7_XJL2BCDCV"R[&W_PF_B'_ *#FI?\
M@9+_ /%4?\)OXA_Z#FI?^!DO_P 56)11R1[!9=C;_P"$W\0_]!S4O_ R7_XJ
MC_A-_$/_ $'-2_\  R7_ .*K$HHY(]@LNQM_\)OXA_Z#FI?^!DO_ ,51_P )
MOXA_Z#FI?^!DO_Q58E%')'L%EV-=/&&NQR2.FLZ@KR$%V6[D!8XQR=W/%2?\
M)OXA_P"@YJ7_ (&2_P#Q58E%')'L%EV-O_A-_$/_ $'-2_\  R7_ .*H_P"$
MW\0_]!S4O_ R7_XJL2BCDCV"R[&W_P )OXA_Z#FI?^!DO_Q5'_";^(?^@YJ7
M_@9+_P#%5B44<D>P678V_P#A-_$/_0<U+_P,E_\ BJ/^$W\0_P#0<U+_ ,#)
M?_BJQ**.2/8++L;?_";^(?\ H.:E_P"!DO\ \51_PF_B'_H.:E_X&2__ !58
ME%')'L%EV-O_ (3?Q#_T'-2_\#)?_BJ/^$W\0_\ 0<U+_P #)?\ XJL2BCDC
MV"R[&W_PF_B'_H.:E_X&2_\ Q5'_  F_B'_H.:E_X&2__%5B44<D>P678V_^
M$W\0_P#0<U+_ ,#)?_BJ/^$W\0_]!S4O_ R7_P"*K$HHY(]@LNQM_P#";^(?
M^@YJ7_@9+_\ %5&WC#7'E25M8U!I$SL<W4A*YZX.[BLBBCDCV"R[&XGCOQ'$
MX9-?U1''(9;V4$?^/5ZQ\)OVR?B1\,-2MS+KESXDT=6'FZ;J\IF#+GG9(V60
M]<8./4&O"Z*RJ8>E6CRU(IHF5.$U:2/VQ^%7Q/T;XO\ @C3_ !-H<I:TNEP\
M3_?@D'WXW'J#^8P1P:Z^O@?_ ()D^*;O^T/&/AUG+V9ABOT4]$<-L;'U##/^
MZ*^^*_+\?AEA,1*DMEMZ,^8KT_95'!!1117GG.%%%% !1110 4444 %%%% !
M1110!P?QW_Y(WXR_[!<__H!KNQTKA/CO_P D;\9?]@N?_P! -=V.E "T444
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M"C_J9;3_ -!EKT6O.OB]_P ?G@7_ +&6T_\ 09: /S!_:H^%5Y\*/C-K]E+
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M.03[E61 X!PF,@-1_:N"_P"?B_$/K5'^8^3J*^Q?^'9OC?\ Z&GP_P#E<?\
MQ%'_  [-\;_]#3X?_*X_^(H_M7!?\_%^(?6J/\Q\=45]B_\ #LWQO_T-/A_\
MKC_XBC_AV;XW_P"AI\/_ )7'_P 11_:N"_Y^+\0^M4?YCXZHK[%_X=F^-_\
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M1@>!];9(;)9 03 A)+_1F/'^Y[U]C5%:VL-C;16]O$D$$2!(XHU"JB@8  '
M ':I:_/,7B)8JM*M+J?/5:CJS<WU"BBBN0R"BBB@ HHHH **** "BBB@ HHH
MH X/X[_\D;\9?]@N?_T UW8Z5PGQW_Y(WXR_[!<__H!KNQTH 6BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I#TI:0]* /D6__P"0QK'_ &$KO_THDHHO
M_P#D,:Q_V$KO_P!*)** /#_V6_\ D^35O^OW6?\ VK7Z5U^:G[+?_)\FK?\
M7[K/_M6OTKKZ'._X\/\ "OU/0QOQKT04445\\>>%%%% !1110 4444 %%%%
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M\QSBK"MC).&RLON/F<9-3K-Q.QHHHKQ3B"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#S_P !?\E"^(W_ &$+7_TDCKT"O/\ P%_R4+XC?]A"U_\ 22.O
M0* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSKQA_R5[X?_34/_1%>
MBUYUXP_Y*]\/_IJ'_HB@#T6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH X/X[_\ )&_&7_8+G_\ 0#7=CI7"?'?_ )(WXR_[!<__ * :[L=* %HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *0]*6D/2@#Y%O_P#D,:Q_V$KO
M_P!*)**+_P#Y#&L?]A*[_P#2B2B@#P_]EO\ Y/DU;_K]UG_VK7Z5U^:G[+?_
M "?)JW_7[K/_ +5K]*Z^ASO^/#_"OU/0QOQKT04445\\>>%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)?]6WTI],E_U;?2@#A/
M@%_R17P1_P!@BV_] %=]7 _ +_DBO@C_ +!%M_Z *[Z@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KSKXO?\?G@7_L9;3_T&6O1:\Z^+
MW_'YX%_[&6T_]!EH [G5=)LM=TVXT_4;6&^L;A#'-;W"!XY%/4,IX(KYE\8_
M\$[/AIXBU![O3+C5O#@=BS6UE,DD(S_=616('MFOI^\O;?3K26ZNYX[:VA0O
M)-,X1$4#)))X 'J:^>?%_P"WS\)O"M[-:PZA?^()(B59](M=\>?9W9%;Z@D>
M]>E@Y8Q-_5+^=OUZ'31=9/\ =7.%_P"'9O@O_H:M?_[XM_\ XBC_ (=F^"_^
MAJU__OBW_P#B*T?^'EGPT_Z 7BK_ ,!;;_X_1_P\L^&G_0"\5?\ @+;?_'Z]
M?FSG^]^!UWQGF9W_  [-\%_]#5K_ /WQ;_\ Q%'_  [-\%_]#5K_ /WQ;_\
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MX=F^"_\ H:M?_P"^+?\ ^(K1_P"'EGPT_P"@%XJ_\!;;_P"/T?\ #RSX:?\
M0"\5?^ MM_\ 'Z.;.?[WX!?&>9G?\.S?!?\ T-6O_P#?%O\ _$4?\.S?!?\
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M_C]']F8S_GVP^K5OY3ZVHKY)_P"'EGPT_P"@%XJ_\!;;_P"/T?\ #RSX:?\
M0"\5?^ MM_\ 'Z/[,QG_ #[8?5JW\I];45\E)_P4K^&;. =$\4J">6-K;\?^
M1Z]*^&G[8?PP^*.HQ:=IVNG3M3E(6*SU:(V[R$] K$E&/L&S6=3+\52CS3IN
MQ,L/5BKN+/:Z*3K2UYYSA1110 4444 %%%% 'G_@+_DH7Q&_["%K_P"DD=>@
M5Y_X"_Y*%\1O^PA:_P#I)'7H% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5YUXP_Y*]\/_ *:A_P"B*]%KSKQA_P E>^'_ --0_P#1% 'HM%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!P?QW_ .2-^,O^P7/_ .@&N['2
MN$^._P#R1OQE_P!@N?\ ] -=V.E "T444 %%%% !1110 4444 %%%% !1110
M 4444 %(>E+2'I0!\BW_ /R&-8_["5W_ .E$E%%__P AC6/^PE=_^E$E% 'A
M_P"RW_R?)JW_ %^ZS_[5K]*Z_-3]EO\ Y/DU;_K]UG_VK7Z5U]#G?\>'^%?J
M>AC?C7H@HHHKYX\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "F2_P"K;Z4^F2_ZMOI0!PGP"_Y(KX(_[!%M_P"@"N^K@?@%_P D
M5\$?]@BV_P#0!7?4 %%%% '*?$#QE?>"=-.H0>'[G6;.*-Y;F6WN(8O(5<<D
M2,"V>?N@]*U?#6JW^L:8+C4=(FT2X+D?99YHI6V\8;=&Q7GTSFL?XM_\DT\2
M_P#7C+_*L/XF/:3ZCX6T_6[J2T\,7DDB7;>:8HII@@,,,K@C"-\YQD!BJ@]<
M4 >DY%&:\)FTCPEX?^*.BV7A>>&(_P!G7[W.G6<Y>"+,:[7V D(S<].H&3TJ
MMI7AO3_"WPB\+W\<LUC'JWV./7-965A.MJP)(,F<HF=B9& JD].M 'O^:*\'
M\4^&O WAO7O!9\-RV]C?SZU:9M=.N2Z7*!^6D0,0<<8<\Y.,\UC:II-[XI\4
M^);K5HO"=U=65[)&@U_4KF">S@'^J,:J-J*5 <.O)).3D8 ![SXD\2Q>'&TH
M20O-_:%]%8KL(&QGSACGL,=JN:SK%KH&D7>I7LGE6EK$TTKXSA5&3QW/M7BF
ML>'+;Q/X*^'K^(5L-?E;6(H([J-I)D>W=GPH>0!F!55!8CYMH/.<UZ_K^KVW
M@[PU/?M:RR6=E$I:*U0,R1C ) ST4<GV!H Q-!^(LVHZQ:6&I^'=3T!K\,UA
M)>F)EG"KN*GRV8QOMYVM@\'TKM*\BU"2QB^)WAK6=*\0MK\^I3/"-,DN$N([
M>W:(EIX O,8&U<DYR&QGD5ZX.E "T444 %%%% !1110 5YU\7O\ C\\"_P#8
MRVG_ *#+7HM>=?%__C\\"_\ 8RVG_H,M 'Q/^W_\?]0\0>-)OAYI5T]OH>E;
M?MZQ,1]JN" VUL=40$<?WLD]!7QY7H_[1]G=6'QX\>17F?/_ +8N7Y&/E9RR
M?^.E:\V?[C?0U^M8&C"CAX0AV7X]3ZRA",*<5$FGM9K69HIX9(95QNCD0JPR
M,C(/(X(/XU'@^AKZ \37FC6VIZE=3Z1HVL7EYXDTVR:XOT6<I:FQB\Q4YP,G
M^/JI'!!IFE67A2:]UNYE\.Z&UOHNI:I:6EHPPLT$=G,\/G-NS,1)&A#DY))&
M<$ -8GW;N(>UTO8\"VGG@\48/I7LR?V!K&GZ3#)H.AVDFI^&+W4+RXMH%C=;
MN+S_ "C%@XA_U*91<!MQR#D5L6/@/0[/QOJ=UJ&DZ>OAO4];TR/16=T\F>"2
MY1I1%AON>3N#'^'.#@\4WB5'=?U>W]>0_:I;H\!(([4$$=1BO:]&MO#/BF[F
MNK_1=#T_[)K\UG9V=J!:P3H;>=H89FW99#+'$ID8Y^8@L >,/Q?HNFP:5HLG
MBNPC\(:_)+<":TT/3XBSVX"^5));B5%C.XR*"""RJ#@XW&E73ERM#517L<!I
M'AS5O$!E&EZ5?ZF8@#)]AM9)]@/3=L4X_&J#1LCLC*592592,$$=01ZUZI?Z
M5J_BGPEX8M_!,EU?Z;81.MY96D@AGBO#*Y,\T0?/SIY>V3)4!2NX8YW_ !+J
MVE6WA/7]3N;/0_$GBVSATFRN=1O$6[7[23<><R\[9F"+"C.0P+*3R>:7MW?:
M^MO-:VU_K[Q<YX6 3VH )Z#->YZEX3M;>2_;P=X<T?7M2-_$UW:74:7*V=N]
MM#(HCB=\+&TCRAI!DIM5=R]ZOA[P_#+:VYT;PMX>UMVU:>/6Q<2K<Q6, 91&
ML<KN#'"4,C>>ISE?O?* 3ZS&U[?E^/;R#VBM<\?NM,N[&*TEN+:2&.[B\^!G
M7 ECW,NY?4;E8?4&JP!)QCFO?=2TO2;K3[9/#5E9>*-3M-*\O1[/4$2</;?V
MA=[Y1$Q DD$?ED*P. Y;:<<4KOPQ91?VY-X>\-Z5J?BE!8I<:0T2W5M8L\;F
MZ\B-F*.0XC!&6\L,V.!D2L2GNOZ_K]1*J>'X/I17OWB+PQX9CU[4+J[T32M*
MC\.V-GJ]WI]@^Z"[$MK&/LZMD[LW)3^+[LDF#A:\"=B[%B%!)R0@PH^@["MJ
M5555=+^F7&7,)1116YH%%%% !1110 4444 %*K%""I((Y!%)10!^F/[!'Q]O
M_B9X2O?"VOW+WFLZ$B-#=2G<\]J3M&X]V0X&3U!7T-?5]?FG_P $W+*ZF^,^
MKW$2M]FAT:42L.F6DCVC\P:_2ROS'-Z,*.+DH;.S^\^9Q<%"LU$****\4X@H
MHHH **** //_  %_R4+XC?\ 80M?_22.O0*\_P# 7_)0OB-_V$+7_P!)(Z]
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O.O&'_)7OA_]-0_]$5Z+
M7G7C#_DKWP_^FH?^B* /1:*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#@_CO_P D;\9?]@N?_P! -=V.E<)\=_\ DC?C+_L%S_\ H!KNQTH 6BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ I#TI:0]* /D6__ .0QK'_82N__
M $HDHHO_ /D,:Q_V$KO_ -*)** /#_V6_P#D^35O^OW6?_:M?I77YJ?LM_\
M)\FK?]?NL_\ M6OTKKZ'._X\/\*_4]#&_&O1!1117SQYX4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %,E_U;?2GTR7_5M]* .$^
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M$]\.?^"Z/_"C_6*C_(_P#^T(?RL_&IX1)C?&KXZ;ESBEV'(.WD=#CI7[*?\
M#-'PJ_Z)[X<_\%T?^%'_  S1\*O^B>^'/_!='_A1_K%1_D?X!_:$/Y6?C4T*
ML &B5@.@*@XH:$.06C#$=-RYQ7[*_P##-'PJ_P"B>^'/_!='_A1_PS1\*O\
MHGOAS_P71_X4_P#6*C_(_P !_P!HP_E9^-31!@0T88'D@KG-;.@^*M6\,Q7,
M.GW CMKD+YUM-;Q3P2;3E2T4JLA*\X.,C)P:_7S_ (9H^%7_ $3WPY_X+H_\
M*/\ AFCX5?\ 1/?#G_@NC_PJ7Q#0DK.F_P !/,*;WBS\@;_Q1K&J#41=W\\X
MU"6.:[#X_?.F=A/'1<G & ...!65M/H:_9/_ (9H^%7_ $3WPY_X+H_\*/\
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M8Y(A Y=&8[55EQD$D@ 'DGBG_96 ?_+M?>_\P^JT/Y3[._X><Z[_ -"/IO\
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M0/\ @IUK@(SX&TXCN!?RC_V2O2?AE_P4<\(^)]1AL/%6C7/A5Y2%6]27[3;
MD_QD ,H]\$>N*_.5].NXWF1[6='@022JT3 QKQAF&/E'(Y/'(]:K]*F>38*<
M;*%O--BE@Z,E9*Q^Y>J7D&H>&;JYM9H[FVFM6DCFB8,CJ4)#*1P01W%8?P:_
MY)#X'_[ 5C_Z3QU\A_L ?&&]UCPIXG\ :G<-.FGV;WVFF1LF.,\21C_9#,K
M=LM7UY\&O^20^!_^P%8_^D\=?G^,PTL)6E1EK;\CP*U)T9N#.QHHHKC,0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH \_\!?\E"^(W_80M?\ TDCKT"O/
M_ 7_ "4+XC?]A"U_])(Z] H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "O.O&'_ "5[X?\ TU#_ -$5Z+7G7C#_ )*]\/\ Z:A_Z(H ]%HHHH ****
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M* .#^.__ "1OQE_V"Y__ $ UW8Z5PGQW_P"2-^,O^P7/_P"@&N['2@!:***
M"BBB@ HHHH **** "BBB@ HHHH **** "D/2EI#TH ^1;_\ Y#&L?]A*[_\
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M7"?'?_DC?C+_ +!<_P#Z :[L=* %HHHH **** "BBB@ HHHH **** "BBB@
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M@BK-% '+>&/AAX7\'7SWND:-;VEVRE?/^9W53U"EB2H/H,5U&,TM% !1110
MF,4M%% !1110 4444 %%%% !7G7Q>_X_/ O_ &,MI_Z#+7HM>=?%[_C\\"_]
MC+:?^@RT 8_[17[.6A?M!^%TM+U_[.UJS#-8:K&@9H2>JL/XD/&5SV!&#7Y\
M>,?V'OBWX4U&2"#PX=>M0Q"7FE3)(CCL=I(9?Q%?K&.E(<'MG\*]C!YKB,''
MDC9Q[/\ 0[*.*J45RK5'X^?\,F?%W_H0M7_[]K_\51_PR9\7?^A"U?\ []K_
M /%5^P>%]/THPOI^E>E_K#B/Y%^/^9T_VA4[(_'S_ADSXN_]"%J__?M?_BJ/
M^&3/B[_T(6K_ /?M?_BJ_8/"^GZ487T_2C_6'$?R+\?\P_M"IV1^/G_#)GQ=
M_P"A"U?_ +]K_P#%4?\ #)GQ=_Z$+5_^_:__ !5?L'A?3]*,+Z?I1_K#B/Y%
M^/\ F']H5.R/Q\_X9,^+O_0A:O\ ]^U_^*H_X9,^+O\ T(6K_P#?M?\ XJOV
M#POI^E&%]/TH_P!8<1_(OQ_S#^T*G9'X^?\ #)GQ=_Z$+5_^_:__ !5'_#)G
MQ=_Z$+5_^_:__%5^P>%]/THPOI^E'^L.(_D7X_YA_:%3LC\?/^&3/B[_ -"%
MJ_\ W[7_ .*I?^&3?B[_ -"%J_\ W[7_ .*K]@L+Z?I1A?3]*/\ 6'$?R+\?
M\P_M"IV1^/G_  R9\7?^A"U?_OVO_P 57HGPM_X)_P#Q%\8:G"WB6WC\(Z0&
M!EENI%DN&7/(2)">?]X@?6OT_P +Z?I2@@=!^E1/B#$RC:,4O/\ IDRQ]5JR
M21Q/A;X<Z'\*?AHWASP_:_9M/M;:3ECF25RIW2.W=B>I_ 8  J;X-?\ )(?
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M_P#(8UC_ +"5W_Z42447_P#R&-8_["5W_P"E$E% 'A_[+?\ R?)JW_7[K/\
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M* "BBB@ KSKQA_R5[X?_ $U#_P!$5Z+7G7C#_DKWP_\ IJ'_ *(H ]%HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .#^._\ R1OQE_V"Y_\ T UW
M8Z5PGQW_ .2-^,O^P7/_ .@&N['2@!:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "D/2EI#TH ^1;_P#Y#&L?]A*[_P#2B2BB_P#^0QK'_82N_P#THDHH
M \/_ &6_^3Y-6_Z_=9_]JU^E=?FI^RW_ ,GR:M_U^ZS_ .U:_2NOH<[_ (\/
M\*_4]#&_&O1!1117SQYX4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %,E_P!6WTI],E_U;?2@#A/@%_R17P1_V"+;_P! %=]7 _ +
M_DBO@C_L$6W_ * *[Z@ HHHH ^3_ /@HK\+/&'Q3^'/@2'P;X1?QK>:/XNL]
M6N])6:&(2V\4<V\,9B%P2RKT/WNA&:P[KX,:M^T]\#/'?@O5O@S;_L]ZD\EI
M=Z5>6]S9W"W-U$SO'(PM47A"H4[LG$IV\@U]ED ]>:  .@Q0!^<WQJ^'WQP_
M:)\*Z3X,^)/[.NF^(_%>D12V]AXWM_&1L])CDD1 UTUO$RR-G8IV'^(<  D5
MTVN?L2ZMX(\#_LS^!]+TM?&NF^%?%(U+Q-=3")H"D@+3.8Y6^:/<Q4+@G &1
MFOO/ SG'-&* /E']LS]GBX\;_#_X>>&_ O@JQN=,LO&UAJ>HZ9806]M MJN\
M32,A**PP0"!DG/0TG[*GP5\5?!36/B?\(]:\/M??"6XNIM1\-ZLTD;QM;W/$
MUC(H;?E=W!*X.'.>0*^K\9HQSF@#XD_8Q_9"\8?"/XL^*=:\<74FHZ5X7AE\
M-^ S/(KE-,DF>=Y0 3M.'6/YN>''W0*\Z;]F#XH']EN;PO\ \(C<_P!O-\66
M\0BR^T0;C8>:&\_/F;<8'3.[VK](*,#TH ^;/A5\+O%.@?MJ?&GQIJ&CRVWA
MC7=-TJ#3M1:2,K</%&!( H8L,'^\![5]*4F*6@ HHHH **** "BBB@ KSKXO
M?\?G@7_L9;3_ -!EKT6O.OB]_P ?G@7_ +&6T_\ 09: /SR_;I^$M]X ^,^H
M:VMN_P#8OB)OMMO<!?D$Q \V,G^\&^;Z./>OG C((]:_;WQ]\//#_P 3_#-S
MH/B738M3TV<9,<G#(W9T8<JP[$<U\;^+O^"9$4NHR2>&O&AM[)F)6WU2S\QT
M'IYB,-W_ 'R*^[R[.:*I1IXAV:TOT9[N'QD.11J:-'QOJGQ,U?5Y"\Z6H8ZC
M!JGR1$?OHHEB3^+[NU!D=SGD4^V^*.LVB:LJ):8U.ZN;N?="3AYXI(GV_-P-
MLC8'.#CK7U1_P['\0?\ 0[:9_P" 4O\ \51_P['\0?\ 0[:9_P" 4O\ \57H
M_P!I9?:W.ON?^1T?6</M<^3+7Q_J=H-/$:VW^@Z7/I$68S_J9O-WD\\M^^?!
M[<<'%;)^,VLK>1WL-CI5MJ!N[:^N[R&V<27TL#!HS-ERN-P#$($W'D\U]-?\
M.Q_$'_0[:9_X!2__ !5'_#L?Q!_T.VF?^ 4O_P 50\QRZ6KFON?^0/$X=]3Y
M0T?XCZQH2RBT-L!+J!U&020[P[F.2-D8$X,;)*X*GJ#UJMKWC*YUJUL[."SL
M]$TZT9Y(K+2UDCC\Q\;G8N[NS$*HR6. H  KZX_X=C^(/^AVTS_P"E_^*H_X
M=C^(/^AVTS_P"E_^*I_VGE]^;G5_1_Y#^LX>]^8^3].\>SV^DVVFZCI6F>(+
M2T9FM1JL4C/;[CEE1XY$;83R48E<DG )-)J_Q%UG7=.U6RO'@>#49+9W5(0@
MA6W#B&.)5PJ1J'(V@>GOGZQ_X=C^(/\ H=M,_P# *7_XJC_AV/X@_P"AVTS_
M , I?_BJ/[2R^]^=?<_\A?6</OS'R]-\5]0U SKJNE:1K5N\L5Q';WUO(4@E
M2)(MZ%)%8;DC0,I)5L#(J&P^)]_; ?:M+T?56BNWO;0WMF<6<SD%C$J,BA25
M4[&#)E1\O7/U/_P['\0?]#MIG_@%+_\ %4?\.Q_$'_0[:9_X!2__ !5+^T<N
MM;G7W/\ R#ZQA^_YGRW_ ,+6UBXC$.I6]CK5HUO]GGMK^)V2?]_).)'*.K"0
M/*Y#*R\$CH3G8T/XGZ=J":O;^*K(7%I=FW-M;6]H);2V$(*HBPB:)UPK$!EE
M!Y;<'W&OHS_AV/X@_P"AVTS_ , I?_BJ/^'8_B#_ *';3/\ P"E_^*J7F&7-
M:3M\G_D)XC#O[1\Z^(/B^FHOXP>PMI+/^V;.STN!%CC1([6%55B57A794"X7
M@!W&3W\RK[7_ .'8_B#_ *';3/\ P"E_^*H_X=C^(/\ H=M,_P# *7_XJKAF
M> IJT:GX/T[#CB</':1\445]HWG_  30UZSM)IV\;:85B0N1]BE[#/\ >K/\
M)_\ !.;7/%GA;1M;B\8Z=!%J5E#>)$]G*2@DC5PI.[DC=BM/[6P7_/S\'_D5
M];H?S'Q]17VO_P .Q_$'_0[:9_X!2_\ Q5'_  ['\0?]#MIG_@%+_P#%4?VM
M@O\ GY^#_P @^MT/YCXHHK[7_P"'8_B#_H=M,_\  *7_ .*H_P"'8_B#_H=M
M,_\  *7_ .*H_M;!?\_/P?\ D'UNA_,?%%%?:_\ P['\0?\ 0[:9_P" 4O\
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M_P"2-^,O^P7/_P"@&N['2@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 %%%% !1110 5YU\7O\ C\\"_P#8RVG_ *#+7HM>=?%[_C\\"_\
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M3D^IHR?4T?ZNT?YW^ ?V?#^9G[+?\-*?"O\ Z*%X;_\ !E'_ (T?\-*?"O\
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M&'_)7OA_]-0_]$4 >BT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV"Y__0#7=CI0 M%%% !1110 4444 %%%% !1110 4444 %%%% !2'I2TAZ4
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M[1^&W_0?\5?^!-M_\8H_X=H_#;_H/^*O_ FV_P#C%4O^'F/@?_H5O$/YV_\
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M *#_ (J_\";;_P",5]<44?VIC/\ GXP^M5OYCY'_ .':/PV_Z#_BK_P)MO\
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M* "BBB@ KSKQA_R5[X?_ $U#_P!$5Z+7G7C#_DKWP_\ IJ'_ *(H ]%HHHH
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M &,MI_Z#+0!\Q_MW?LMZEXFO6^(OA.R>^N5A":M86Z[I'5!A9T'5B%PK <X
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M@U6V6-;D*,ML*LV& YVMAL=N#78T %%%% !1110 4444 %>=?%[_ (_/ O\
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M'_[ 5C_Z3QU^?8S#2P=>5&6MOR/GZU)T9N#.QHHHKB,0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \_\!?\ )0OB-_V$+7_TDCKT"O/_  %_R4+XC?\
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M.:*(1#&(U+&(!1@# .!C->0?\(;KW_0%U'_P$D_^)H_X0W7O^@+J/_@))_\
M$UU?5Z-K7_(V]G"UCT>'XKI=V&B6>HZW=7-O'X8OK"^BE\QQ-=/Y_DB7C]ZP
M_<8=L[<#D8K:L?B#X9TCQMJ?B-=>2YCUS6M-OC;1VTPELHXKE)Y3-N3:2NW:
M A?=UX'%>/?\(;KW_0%U'_P$D_\ B:/^$-U[_H"ZC_X"2?\ Q--T*3Z_EWN'
MLX=ST[0?BS:37=S>Z_K%W>:@=?FN[2[N$>=[..2WG1;A > $D:%M@P?D! R*
MP_$OB[35T31=/U6]3XAW]I+<2O>R7-W$L4;[=L(E8)*_S*SX(V@O@9YKC?\
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MR>)GCT"TTTV5SX2,$JFXD(8.WEJOD8D<B8N6W*1@#*K7DW_"&Z]_T!=1_P#
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M_@U_R2'P/_V K'_TGCK\US+%1Q>)E4AMLOD?-XFJJM1R6QV-%%%>6<H4444
M%%%% !1110 4444 %%%% !1110 4444 >?\ @+_DH7Q&_P"PA:_^DD=>@5Y_
MX"_Y*%\1O^PA:_\ I)'7H% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5YUXP_Y*]\/_IJ'_HBO1:\Z\8?\E>^'_P!-0_\ 1% 'HM%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!P?QW_P"2-^,O^P7/_P"@&N['2N$^._\
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M .,5Z/CZ_G1CZ_G0!YQ_PT)X)_Y_=1_\$E__ /&*/^&A/!/_ #^ZC_X)+_\
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M8KT?'U_.C'U_.@#SC_AH3P3_ ,_NH_\ @DO_ /XQ1_PT)X)_Y_=1_P#!)?\
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M_#0G@G_G]U'_ ,$E_P#_ !BC_AH3P3_S^ZC_ ."2_P#_ (Q7H^/K^=&/K^=
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M445\Z>L%%%% !1110!Y_X"_Y*%\1O^PA:_\ I)'7H%>?^ O^2A?$;_L(6O\
MZ21UZ!0 4444 %%%% !1110 4444 %%%% !1110 4444 %>=>,/^2O?#_P"F
MH?\ HBO1:\Z\8?\ )7OA_P#34/\ T10!Z+1110 4444 %%%% !1110 4444
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M*X+_ (6=JO\ T3?Q=^5A_P#)='_"SM5_Z)OXN_*P_P#DN@#O:*X+_A9VJ_\
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MK:^Z^9X^*RREB9<Z?*S\??\ A#M=_P"@-J'_ ("2?_$T?\(=KO\ T!M0_P#
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M_B[\K#_Y+H [ZBN!_P"%GZK_ -$W\7?E8?\ R71_PL_5?^B;^+ORL/\ Y+H
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MB2Y:>_\ $NI2LQSL2X:-!]%7  ^@JE\0]>N/$_CC7=4N6+2W-Y*_/9=Q"K^
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M,X:SAC9D9YODP/F4J%&6)Q@5,:N&:OI]Q*J8=J^GW&7_ ,)IK_\ T&]2_P#
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M -!O4O\ P,D_^*H_X337_P#H-ZE_X&2?_%5C45M[*G_*C7V</Y4;/_"::_\
M]!O4O_ R3_XJC_A--?\ ^@WJ7_@9)_\ %5C44>RI_P J#V</Y4;/_"::_P#]
M!O4O_ R3_P"*H_X337_^@WJ7_@9)_P#%5C44>RI_RH/9P_E1L_\ "::__P!!
MO4O_  ,D_P#BJ/\ A--?_P"@WJ7_ (&2?_%5C44>RI_RH/9P_E1L_P#"::__
M -!O4O\ P,D_^*H_X337_P#H-ZE_X&2?_%5C44>RI_RH/9P_E1L_\)IK_P#T
M&]2_\#)/_BJ/^$TU_P#Z#>I?^!DG_P 56-11[*G_ "H/9P_E1L_\)IK_ /T&
M]2_\#)/_ (JC_A--?_Z#>I?^!DG_ ,56-11[*G_*@]G#^5&S_P )IK__ $&]
M2_\  R3_ .*H_P"$TU__ *#>I?\ @9)_\56-11[*G_*@]G#^5&K'XKUJ&262
M/5KY))2&D=;EP7(& 2<\\<<U)_PFFO\ _0;U+_P,D_\ BJQJ*/94_P"5![.'
M\J-G_A--?_Z#>I?^!DG_ ,51_P )IK__ $&]2_\  R3_ .*K&HH]E3_E0>SA
M_*C9_P"$TU__ *#>I?\ @9)_\51_PFFO_P#0;U+_ ,#)/_BJQJ*/94_Y4'LX
M?RHV?^$TU_\ Z#>I?^!DG_Q5'_"::_\ ]!O4O_ R3_XJL:BCV5/^5![.'\J-
MG_A--?\ ^@WJ7_@9)_\ %4?\)IK_ /T&]2_\#)/_ (JL:BCV5/\ E0>SA_*C
M9_X337_^@WJ7_@9)_P#%4?\ "::__P!!O4O_  ,D_P#BJQJ*/94_Y4'LX?RH
MV?\ A--?_P"@WJ7_ (&2?_%4?\)IK_\ T&]2_P# R3_XJL:BCV5/^5![.'\J
M-G_A--?_ .@WJ7_@9)_\55FQ^(OBG39UEM?$6JP2*<@I>2?XUSM%)T:;5G%?
M<)TJ;T<5]Q]3_ O]JR^N-6M="\9S)<17#".'52H5T8\ 2XX(/3=U'?->W>+\
M'XO?#_Z7_P#Z(K\ZU8JP(."*^X? ^NS>);GX,:C<L7N);*^61SU8I"4R?<[<
MU^=\19=2PW+B**LI.S72Y\!G^7TL-RUZ*LF[-=+GO&*,4M%?%GQPF*,4M% "
M8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% '!_'<?\6;\9?]@N
M?_T UW8'%<)\=_\ DC?C+_L%S_\ H!KNQTH ,48I:* $Q1BEHH 3%&*6B@!,
M48I:* $Q1BEHH 3%&*6B@!,48I:* $Q01Q2TAZ4 ?(M__P AC6/^PE=_^E$E
M%%__ ,AC6/\ L)7?_I1)10!A? G_ ).DU#_KZU+_ -GK[8KXG^!/_)TFH?\
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M _\ /U'SO17T1_PQ)XO_ .@UHG_?<W_QNC_AB3Q?_P!!K1/^^YO_ (W1_;&
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MB*]%KSKQA_R5[X?_ $U#_P!$4 >BT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '!_'?_ )(WXR_[!<__ * :[L=*X3X[_P#)&_&7_8+G_P#0#7=C
MI0 M%%% !1110 4444 %%%% !1110 4444 %%%% !2'I2TAZ4 ?(M_\ \AC6
M/^PE=_\ I1)11?\ _(8UC_L)7?\ Z4244 87P)_Y.DU#_KZU+_V>OMBOG'X9
M? 'Q-X1^-EUXKOI-/;3)9KR0"*=FDQ+NV_+M [C/-?1U?09U7IUZ\)4I72BE
M\]3WLYK4Z]>$J4KI12_,****^?/!"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IDO^K;Z4^F2_ZMOI0!PGP"_P"2*^"/^P1;?^@"
MN^K@?@%_R17P1_V"+;_T 5WU !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7G7Q?&;OP*/^IEM/\ T&6O1:\Z^+W_ !^>!?\ L9;3_P!!
MEH ^(_C9X*N/ GQ)UK3Y8RL$D[7-LY'#PN2RD>N,E3[@UQ,$OD3QR@;BC!L'
MO@YK]'_BE\(="^+.D)::K&T5S#DVU[#@2PD]<=B#W4\?CS7S'K/[%7BVUNV7
M3=4TN_ML_+),[POCW7:P_(U^HY=GN&JT8PQ$N625G?9^=S],R_.\-5HJ%>7+
M)*SOL_,\DNO&]OJ[W8U;1DOH9;Z:_A2.Z>%H6E(+IN .Y#A>" >."*OZC\5)
M-4N+GSM'MELKJ24SV<4SJK(\<*;%;JNWR$8-R<]<CKWO_#&GCS_GMH__ (%O
M_P#&Z/\ AC3QY_SVT?\ \"W_ /C==OUW++I^T6GFSL^N9;I^\7WLX/3?'FFQ
MZ=JEG/I:+IYTX6EIIYE=RS-.DCLTP (<[20V,# &/7/7QVD*1646DQ)H:V\E
MM)8-<,S2AV5V<RX!#[D0@A0!L P><^F?\,:>//\ GMH__@6__P ;H_X8T\>?
M\]M'_P# M_\ XW0L;EJ;?M5][_J_GOY@L9ER;?M5]_\ 6OGN><+\08;27P]]
M@T6&S@T:6:5$:Y>1YVD !,CD#GY>P ]JI)XUE2\T^X%I&39Z4VE!=YPZF.1-
MY]_WA..G%>J?\,:>//\ GMH__@6__P ;H_X8T\>?\]M'_P# M_\ XW5+'98O
M^7B^_P!?\V4L;ER_Y>+[_7_-GG&I>/[;7IS)JVA0WQCG>>W5;IXA&'P6C? .
M]"PSCY3R>>:P8]:\O1]4T_[+#Y5_+%*<# B\MF8!5]/FQ[8KV7_AC3QY_P ]
MM'_\"W_^-T?\,:>//^>VC_\ @6__ ,;IQS#+H*T:JMZ]M1QQ^7P5E45O4\LT
M#QC%H]E9P7&EQZ@UA=&\LW-PT7ER$+D,%!WKE$..#QUP33]5\>7&KZ.EC-:Q
M@J8&:8,<L8S*<XQ@;C,?I@5ZA_PQIX\_Y[:/_P"!;_\ QNC_ (8T\>?\]M'_
M / M_P#XW2^OY:Y<WM%?U%]>RYOF]HK^IYM'\2+J#4=3O([* -?:@+YXV9F4
M#;(K1=LJRRL,\&DM?'L6DQ"VTO2$L['R[@/#)=-,SO+$8MY<J/NJW"X]<DYK
MTK_AC3QY_P ]M'_\"W_^-T?\,:>//^>VC_\ @6__ ,;I?7<L_P"?B^_Y"^NY
M;_S\7WGENG>-3:Z1;:5<:?'>:<D,L$T1E9&E#2+(&# ?(RLHP<$=<@U9U'Q_
M%<:$-(L]&AL+1;1[12+AY7.Z9)2[,0,MF/'0#!Z#%>D_\,:>//\ GMH__@6_
M_P ;H_X8T\>?\]M'_P# M_\ XW3>.RUOF]JM[[]>X_KN7-W]HM[[]>YY7XJ\
M2IJ^FZ%80MOBL;4"639L,LY^\3Z[46- ?1*CM_%SV^M>'M2^QQ-+H\,4**6/
M[T([-DG&1G=CCTKU.Y_8\\=6EO+.\VC[(U+MB[;. ,_W*I^'?V4/&GB?P_IF
ML6<VE"TU"UBNX1+=,'V2('7("'!P1WIK,,N4>7VJMKU[[C6/R]1Y?:JVO7ON
M<6/B#:K<Z=?C0(!J^GVT=O!=?:GV%D&$D>+&&8=1R!P,@XJFOC8RW#B[L$N;
M.:P@L)[<3,A<1 ;9 X!*ME0>A'48(KU'_AC3QY_SVT?_ ,"W_P#C='_#&GCS
M_GMH_P#X%O\ _&ZE8[+%_P O5][)6-RY?\O%][//--^) TK4HKJ#2MD5K;BV
MM+9+V146/+%EEX_?*S,2P(&>V!3#\1F^P7L(TX"6ZL8[!S]J?R2BQK&&:'&U
MF&W<IR-I/?%>C?\ #&GCS_GMH_\ X%O_ /&Z/^&-/'G_ #VT?_P+?_XW2^NY
M9>_M%][%]<RV]_:+[V>#T5[Q_P ,:>//^>VC_P#@6_\ \;H_X8T\>?\ /;1_
M_ M__C==/]K8'_G\OO.G^U,%_P _5]YX/17O'_#&GCS_ )[:/_X%O_\ &Z/^
M&-/'G_/;1_\ P+?_ .-T_P"UL#_S^7WA_:F"_P"?J^\\'HKWC_AC3QY_SVT?
M_P "W_\ C='_  QIX\_Y[:/_ .!;_P#QNC^UL#_S^7WA_:F"_P"?J^\\'I54
MLP &2?2O>$_8R\=LP!N-&4$\G[6YQ_Y#KV#X2?LEZ7X*U&#5_$%VFMZC P>&
M!$*V\3#HV#RY';.![&N7$9Y@J$')3YGV1SU\ZP5&#DI\S[([3]G+P7<>!_A5
MI=I>1F*\NBU[-&W!0OC /H0H7(]:].I!Q2U^45ZTL15E5EO)W/RVO5E7JRJR
MWD[A1116!@>?^ O^2A?$;_L(6O\ Z21UZ!7G_@+_ )*%\1O^PA:_^DD=>@4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7G7C#_ )*]\/\ Z:A_Z(KT
M6O.O&'_)7OA_]-0_]$4 >BT444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '!_'?_DC?C+_ +!<_P#Z :[L=*X3X[_\D;\9?]@N?_T UW8Z4 +1110
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M4?\ #4GQ!_Z"-K_X!1_X444 '_#4GQ!_Z"-K_P" 4?\ A1_PU)\0?^@C:_\
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M^(/_ $$;7_P"C_PH_P"&I/B#_P!!&U_\ H_\*** #_AJ3X@_]!&U_P# */\
MPH_X:D^(/_01M?\ P"C_ ,*** #_ (:D^(/_ $$;7_P"C_PH_P"&I/B#_P!!
M&U_\ H_\*** #_AJ3X@_]!&U_P# */\ PH_X:D^(/_01M?\ P"C_ ,*** #_
M (:D^(/_ $$;7_P"C_PH_P"&I/B#_P!!&U_\ H_\*** #_AJ3X@_]!&U_P#
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M#_T$;7_P"C_PHHH /^&I/B#_ -!&U_\  */_  H_X:D^(/\ T$;7_P  H_\
M"BB@ _X:D^(/_01M?_ */_"C_AJ3X@_]!&U_\ H_\*** #_AJ3X@_P#01M?_
M  "C_P */^&I/B#_ -!&U_\  */_  HHH BNOVG?'UU;2POJ-KLD0J<6470C
M'I5'PQ^T5XY\.>&M)TFTU& VMA:0VL1DLXBVQ$"KDA1DX HHH T_^&I/B#_T
M$;7_ , H_P#"C_AJ3X@_]!&U_P# */\ PHHH /\ AJ3X@_\ 01M?_ */_"C_
M (:D^(/_ $$;7_P"C_PHHH /^&I/B#_T$;7_ , H_P#"C_AJ3X@_]!&U_P#
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M ?\ #4GQ!_Z"-K_X!1_X4?\ #4GQ!_Z"-K_X!1_X444 '_#4GQ!_Z"-K_P"
M4?\ A1_PU)\0?^@C:_\ @%'_ (444 '_  U)\0?^@C:_^ 4?^%'_  U)\0?^
M@C:_^ 4?^%%% !_PU)\0?^@C:_\ @%'_ (4?\-2?$'_H(VO_ (!1_P"%%% !
M_P -2?$'_H(VO_@%'_A1_P -2?$'_H(VO_@%'_A110 ?\-2?$'_H(VO_ (!1
M_P"%'_#4GQ!_Z"-K_P" 4?\ A110!T7@JSD\1>'8-4O;R9[N\EGGE*+&HW-,
+Y. %X'-%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ibio-20220930xex10d3009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20220930xex10d3009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /N S$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"!TG^- 'Z(T5^=W_"W/&W_ $-NL_\ @=)_C1_PMSQM_P!#;K/_ ('2?XT
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M_P!"U%_X$S__ !='_#.7PY_Z%J+_ ,"9_P#XNNG_ .$HU/\ Z%#6?^_UE_\
M)%'_  E&I_\ 0H:S_P!_K+_Y(H YC_AG+X<_]"U%_P"!,_\ \71_PSE\.?\
MH6HO_ F?_P"+KI_^$HU/_H4-9_[_ %E_\D4?\)1J?_0H:S_W^LO_ )(H YC_
M (9R^'/_ $+47_@3/_\ %T?\,Y?#G_H6HO\ P)G_ /BZZ?\ X2C4_P#H4-9_
M[_67_P D4?\ "4:G_P!"AK/_ '^LO_DB@#F/^&<OAS_T+47_ ($S_P#Q='_#
M.7PY_P"A:B_\"9__ (NNG_X2C4_^A0UG_O\ 67_R11_PE&I_]"AK/_?ZR_\
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MA_T+&J?]_;3_ ./T <G_ ,,Y?#G_ *%J+_P)G_\ BZ/^&<OAS_T+47_@3/\
M_%UUG_"0ZA_T+&J?]_;3_P"/T?\ "0ZA_P!"QJG_ ']M/_C] ')_\,Y?#G_H
M6HO_  )G_P#BZRO"GP!\ ZKX7T>]NO#T<UU<V<,TLAN)AN=D!8X#XY)->@_\
M)#J'_0L:I_W]M/\ X_6/X+UV^A\':%&GAW4IT6P@42QR6P5P(UY&9@<'W /M
M0!E_\,Y?#G_H6HO_  )G_P#BZ/\ AG+X<_\ 0M1?^!,__P 776?\)#J'_0L:
MI_W]M/\ X_1_PD.H?]"QJG_?VT_^/T <G_PSE\.?^A:B_P# F?\ ^+K*\-_
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M_P##.7PY_P"A:B_\"9__ (NBNL_X2'4/^A8U3_O[:?\ Q^B@#=HHHH ****
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M #\:Q_X.[W_X]0!T5%<[_P ('IG_ #\:Q_X.[W_X]1_P@>F?\_&L?^#N]_\
MCU '145SO_"!Z9_S\:Q_X.[W_P"/4?\ "!Z9_P _&L?^#N]_^/4 =%17._\
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MG8VW@[794FU(O'83N!)JERZDB-CRID((]B,&MC_A#=/_ .>^J?\ @WN__CM
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M;!IVA23Z=96R7L^J:=(W_+,32?;82-[!20,D\X/4G!)YN^)/#-UJ\E^]M=O
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M+)R+?."L:+CI@$="0=F7X-6,NE1::O@7P]!:0ZA_:L2VVMW4+1W?D&W,RND
M8,86:/@_=)'>O%?$G@;]K&[N[J\TWQK86UX)M2AM=DMKY$4$CVK6V83;8?;Y
M<J[W)=59B!D[7[?PU\-?BMX8M-&OKB_M]=U&T\:S:W<V;:O+''/I\FC36@AW
M%#PMS(LHC(V_)N^]B@#J_#_P)T?PKJMGJ6D_#OPQ8WEI,UQ!)%J]QA)&5%+!
M3;XX$<8''RA%QC:*)O@5H]P\SS?#KPM-)-<&YDDDU:X9V8F0E=QM\[#YTV8_
MN'S'ROS&N'^'G@G]H.U\?:-JOBWQ7;7UC'?7*7,4,ELL/V!EMRL;1K "[!XY
M]CJ4?$B;^,H,[6_AU\?='2<^#=6M+'5I-4,E[J^HZW)?IJ,/F7,BXM9XF2V3
M;) A$15EVA5W)&I(!Z-_PH+01I5YI@^&GA-;"\*&>W74YPKA5V*IQ;?=" 1A
M1P$ 3&T;:W%^'6SQS)XR'@CPT/%$BE6U3^U)O.(,:Q-S]F_B2.-3ZB./.=BX
M\,L_!O[72364C^/] 9+6&65X9[2U(O9E$K)'*R0 QQN_V>,&,;M@E<E&*H-K
M2? O[3?VO2K?5?B1IS0M+:IJ%]86MG&%MTN<3M%&]LQ^T2PJK@L3&IDD4)E4
M:@#M)_V<?#-S T,OPP\)21E!$H;5)SY<89'6)#]G^2-3&NU%PJC(  8@OTW]
MGG0-(C6.T^''AF.)%NT2)M:NG2,72,ER%5H"%\Q78-C&<UTW[/GAWQIX/^%>
MCZ+\0-6@UKQ)8QB"2_MWW)+&J@)C*AL@?*2Y9F*EBQW8'HV]?[P_.@#R?X7?
M"W4?A)'KJ:+I5C*-8OVU"<WFMR/L8J%"(%M%"HH4 #!/J37<?;?%G_0&T7_P
M;S?_ "+70;U_O#\Z-Z_WA^= '/\ VWQ9_P! ;1?_  ;S?_(M'VWQ9_T!M%_\
M&\W_ ,BUT&]?[P_.C>O]X?G0!S_VWQ9_T!M%_P#!O-_\BT?;?%G_ $!M%_\
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M@8="$0'A5P?V_EG_ #_0>SGV,OX@?%GX.?#KQ5/X9O\ 0;6[U^WBBN9M/L=
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M*[\*?]"SHW_@!%_\36)I%[K.@:7::;IOAG0['3[2)88+:WU*1(XD48"J!;8
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M;:Z?)\//"K6-M;/:0VXO7"+"\<T3QX%MRK)<3@@]?-;N:</!%F--L=/_ .$
M\,FQL8I8+:W.H2%(XY P= /LWW3O;@\9.>H%3_;^6?\ /]#]G/L<[\-OB7X'
M^)'B32-(M_AK%9-J5G<7L5T]M8S1>7#,T1D!B=B86*C9,!L?>H!/./8/^%=^
M%/\ H6=&_P# "+_XFO/?"O@+3_!&J)J7A_X?>%])OUMUM5N+34)$?R1G:F1;
M?=&YL#MDXZUV7_"2^)_^@)I/_@UE_P#D:C^W\L_Y_H/9S[&A_P *[\*?]"SH
MW_@!%_\ $UP/C"U\)^!-3\0:E<^$['4+>"RTN*"PMK&#=)<7%W/ @7=A5+.T
M0+$@  $G KKO^$E\3_\ 0$TG_P &LO\ \C5RU]-J7B'Q%X@L=3\-Z+J-K=Z7
M9PW-E=7[O"\?FW1&<VYSDEN,#&T$$YXI9[ELDVJZT_X87LY]CB3\9?A\UD\L
M?PS/V@VEC=06\UC91>>+B"ZG.UV<(%B6QN [LP4&-L$CDU;?XU>#KB)G'PAD
M^?3[74+9/LEB&N!.92B EPH/EV]S+DD+Y<6XD!TSW6I^!=/UG3DL+[X=^$[F
MQ2RCTY;:2\;RUM4614A"_9L!%664 = )&'<TEWX%T^_TF33+GX?>%KC3Y 5D
MMY;^1DD!@DMR&S;?,/)EDCY_A<CO4_V]EG_/]#]G/L9/PQ\=^"?B9XF@T:'X
M;Q:8T^EOJL5U<V=D\3Q++'&&_=LS!)#(3$Y 658Y&7A>?5O^%=^%/^A9T;_P
M B_^)KA/"OA"W\$ZM<:GH/@3PWI6H7,*P37-MJ,JO)& H"L?L_( 10/]T5U?
M_"2^)_\ H":3_P"#67_Y&H_M_+/^?Z#V<^QH?\*[\*?]"SHW_@!%_P#$U@>$
M_!N@2:WXPB?0]-:*WU5(X4:TC*QJ;&U8JHQP-S,<#NQ/>K__  DOB?\ Z FD
M_P#@UE_^1JP?#>N>(H-9\5O'I&F.\VI(\BMJ4BA&^QVRX!^SG<,*IR<<DC'&
M32SW+9)M5UI_PPO9S['9_P#"#>&_^A?TK_P"C_\ B:/^$&\-_P#0OZ5_X!1_
M_$UE?\)+XG_Z FD_^#67_P"1J/\ A)?$_P#T!-)_\&LO_P C5/\ ;^6?\_T/
MV<^Q'XT\&Z!:^#M=FAT/389H["=TDCM(U96$;$$$#@@]ZV?^$&\-_P#0OZ5_
MX!1__$USFNZCXGUO0]1T[^R-)A^UV\EOYG]J2MLWJ5SC[.,XSTJ]_P )+XG_
M .@)I/\ X-9?_D:C^W\L_P"?Z#V<^QJ_\(-X;_Z%_2O_  "C_P#B:/\ A!O#
M?_0OZ5_X!1__ !-97_"2^)_^@)I/_@UE_P#D:C_A)?$__0$TG_P:R_\ R-1_
M;^6?\_T'LY]C5_X0;PW_ -"_I7_@%'_\36-X+\&Z!=>#M"FFT/39II+"!WDD
MM(V9F,:DDDCDD]ZD_P"$E\3_ /0$TG_P:R__ "-5'0M1\3Z)H>G:=_9&DS?9
M+>.W\S^U)5W[%"YQ]G.,XZ4?V_EG_/\ 0>SGV.C_ .$&\-_]"_I7_@%'_P#$
MT?\ "#>&_P#H7]*_\ H__B:RO^$E\3_] 32?_!K+_P#(U'_"2^)_^@)I/_@U
ME_\ D:C^W\L_Y_H/9S[&K_P@WAO_ *%_2O\ P"C_ /B:QO"?@W0+C2YWET/3
M96%_>H&>TC)"K=2JHY'0   =@!4G_"2^)_\ H":3_P"#67_Y&JCHVH^)](M)
M(/[(TF7?<3W&[^U)1CS)GDQ_Q[]M^,]\4?V_EG_/]![.?8Z/_A!O#?\ T+^E
M?^ 4?_Q-'_"#>&_^A?TK_P  H_\ XFLK_A)?$_\ T!-)_P#!K+_\C4?\)+XG
M_P"@)I/_ (-9?_D:C^W\L_Y_H/9S[&K_ ,(-X;_Z%_2O_ */_P")K&M?!N@-
MXQU2$Z'IIA2PM'6,VD>U6,ER"0,=2%7)]AZ5)_PDOB?_ * FD_\ @UE_^1JH
MPZCXGBUR[U'^R-)/VBWAM_+_ +4E^7RVE;.?L_.?-Z?[/O1_;^6?\_T'LY]C
MH_\ A!O#?_0OZ5_X!1__ !-<YX!\(:%>:'=23Z)IT[C5=2C#26D;$*M].JKD
MCH%  '8 "KW_  DOB?\ Z FD_P#@UE_^1JS/#EUXG\/Z?+:_V5I,_F7EU=[_
M .TY5QYUQ)-MQ]G/W?,VY[XSQG%']OY9_P _T'LY]CJ/^$&\-_\ 0OZ5_P"
M4?\ \36-=>#= 7QCI<(T/31"]A=NT8M(]K,)+8 D8Z@,V#[GUJ3_ (27Q/\
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MWQ5[_A)?$_\ T!-)_P#!K+_\C4?V_EG_ #_0>SGV-7_A!O#?_0OZ5_X!1_\
MQ-'_  @WAO\ Z%_2O_ */_XFLK_A)?$__0$TG_P:R_\ R-1_PDOB?_H":3_X
M-9?_ )&H_M_+/^?Z#V<^Q'H7@W0)M4\1I)H>FNL5^B1JUI&0B_98&P..!EB<
M>I/K6S_P@WAO_H7]*_\  */_ .)KG-.U'Q/87>J3_P!D:2_VVX%QM_M24;,0
MQQX_X]^?]7G/O[5>_P"$E\3_ /0$TG_P:R__ "-1_;^6?\_T'LY]C5_X0;PW
M_P!"_I7_ (!1_P#Q-'_"#>&_^A?TK_P"C_\ B:RO^$E\3_\ 0$TG_P &LO\
M\C4?\)+XG_Z FD_^#67_ .1J/[?RS_G^@]G/L1VO@W0&\8ZI"=#TTPI86CK&
M;2/:K&2Y!(&.I"KD^P]*V?\ A!O#?_0OZ5_X!1__ !-<Y#J/B>+7+O4?[(TD
M_:+>&W\O^U)?E\MI6SG[/SGS>G^S[U>_X27Q/_T!-)_\&LO_ ,C4?V_EG_/]
M![.?8U?^$&\-_P#0OZ5_X!1__$UY?\5/"FCQ>*?#LD&E6%LNER?V@L<5I&%G
M=DEB*2C;\R;6)P,<\YKN_P#A)?$__0$TG_P:R_\ R-65JT6IZY<K/>^&M)FE
M5 @;^V9U^7)..+<>IK2'$&5)OFKK\SEQ%"O.%J6C^XY/^V[/_H6/#W_@N7_&
MBM_^PI_^A5TG_P 'ES_\8HK7_6+*?^@A?^ H\SZEC^__ ),_\CU.BBBO6/8"
MBBB@ HHHH YOQ)X5DUN2_>.X>)KG3WM%_?2*%?<&1L X SUQU'!R.*Y;7?#5
M[H=EK-W<W2S07VL:?)#$&)V_\3!6+'@<X=5[X$:C.  .I\1^+9-"N)H5L1+L
MMUG2228(LA,@0H  S9Y&  220 #7,^)O$D?BSPY?65SIXA2._P!/5X9F$@=#
MJ B*NN,#YH7XY&"/4@<V*_@5+]G^14=T='O7^\/SHWK_ 'A^=8G_  @GAK_H
M7M*_\ HO_B:/^$$\-?\ 0O:5_P" 47_Q-?S?RX?^:7_@*_\ DCU=3;WK_>'Y
MU\^_M-?!#QK\6]?\/7?A?6K'3[&PM;J*Y@N;V2V=Y)%VQNC+!*,H3N&1P0,<
MX(]G_P"$$\-?]"]I7_@%%_\ $UP7Q!UCPYX)U[3=)M_ VFZK<7%E<ZI.[):V
ML4%K!) DC;Y=JE\W"$+D# 8EEXSVX24*=92HR;EKO%=M?M$N[6IQ7@/X4?&/
M1H=4TS7O&6FWVEW.GZE$@AF8KYUP[-"?FA$@96=V:0R-PP4(2-]9WCKX<?'[
MQ9JUC]DU[0=$\/VMOIXETNQUB1I)Y;>[BF=TG>RRC.D17YE(Y S@MC5'[0_P
M7:!9ET)FA*+(77PXQ"J]N+F$G]W_ ,M8F5D]=P'!R ]/V@O@O+JLNEQ:*)]5
MCWAK"'P^7F#I&LLL>T(262-PQ ZC.W<00/47M5/VGLW?_KVOO^+\2--K_B3>
M*?A;\2=1N-+U&/4=+U7Q%#X<L;(:G+JMQ91V.J0F9KBZB@2)D=9S)&I#  "(
M!E=?EKB)?AG^U0NFS11?$7P]]I-H\:N6)!D-XSQD9M\J5@(0YW<C[S9R/14^
M)/@B30]*U1?!%JD6HZ>NH10RVD"R!6NXK8*1CKF96X/0>]>=G]J_X;?8(+O_
M (0& 1S:+'K>TV<>Z.)IS"0X$9QL(!8C/WAM#<D5155JT8<UGUA%_+XM/D)V
M-2Z^&/[222WKK\3-'N8M\@LXH0L#8=)$C,K-;."(V2VE(4#?ON%X&S/>_";X
M<?$/P?\ $+5=6\3>+H=?T/4;%0;3S?GAO 8\N!Y*@H5#*!D; @X<R$KE>&_C
ME\%O%GC'3?#.G6-A+J>HW,UK:AM(58Y&C0/D,5QA@3CO\IR!BF:%\4_!<FMR
M:5XA\#V&B73ZQ)HUL8+1;Q))$GM[=G=DB C0S7EJ@)ZF7/ 5B,:G/.+A*%KK
M_GW%.WE[U^G0:_K4]]WK_>'YT;U_O#\Z\'O_ (O_  OT/1+"_P!7\/6%A+J.
MOZCX>L[7[#$[S3VNHR6!/"\!Y$4^H#Y/"L1A>*/C[X!\/_#71_&5O\/C?VMW
M+*EU9+I:I<68BMS<2%AY9&/+ (8E4PP+.HR1P1P',[)2WM\*W_\  O(OF/I7
M>O\ >'YT;U_O#\Z^;K[]IKX$:;<7L=Q96ZI9"9[B=="+QQQQLJ^82$/#,Z*H
MZDL.*+W]HSX0Z+>:K;ZUX7?1WL[F2UB6YT'YKEXHH))U4!/O1_:%RO<89=P(
MIK+I/[,__ ?_ +8.8^D=Z_WA^=&]?[P_.O-?AOK?PY^*]GJMUX=T?3KF+3;Z
M33[CS=-2-EE0 GY67(!!!&0#[5U__"">&O\ H7M*_P# *+_XFN.=*C3DXS<D
MU_=7_P D.[9M[U_O#\Z-Z_WA^=8G_"">&O\ H7M*_P# *+_XFC_A!/#7_0O:
M5_X!1?\ Q-1RX?\ FE_X"O\ Y(>IM[U_O#\Z-Z_WA^=8G_"">&O^A>TK_P
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MNO? OB&VT&;2+%)99+FY=%\T_9&C=HU1A*H2*X0J2I_>@9*&16]&^!?A#7_
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MZ%[2O_ *+_XFCEP_\TO_  %?_)!J;>]?[P_.C>O]X?G6)_P@GAK_ *%[2O\
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M\ZQ/^$$\-?\ 0O:5_P" 47_Q-'_"">&O^A>TK_P"B_\ B:.7#_S2_P# 5_\
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M5OM,LM20I>6EO=)C&V>-7&,Y[CUKF?B!I\=KX78:?:VT=Q+J.GD+@1J[_:X
MNYE!..@S@X'8U)XP\'3Z^]Q);/ ))[86S"Z!= /,5LA>1D ''&,X)!QBLS6/
M#8\/:7<R"3<EWK.E2!2[.4VW%LA&6Y/*G'M43BIQ<);,-BU]B\6?] W1?_!G
M-_\ (]51/X@,GEBW\/E\[=O]KR9SZ?\ 'O7>[U_O#\Z\2/A'Q6?B!_:?]I3_
M -@_9/(_LKR#CS/7/3K\V[KVZ5\U_JQE/_/G_P FE_F;>VGW.Y-IXK! .G:*
M">@_M27_ .1ZR-?\ WOBN6QDUOPCX4UB2QD\ZT?4+AIS;R<?/&7M3M;@<C!X
M%<C\:O@MXM\<_$33]?\ #NI:3:B%=.$5WJ-Q*)M,-O<S2S-;Q+&RL9UEC5OG
MC)\E0QD0E*\];X$_M'?V#:)'\6+%-42**&;=>RM$T8FNGF4-]GW;G5[5!*1N
M0*^/NC<UPUE47>-&W_;TO_D@]M/N>NV?P9L]-MY8+3X=>!;6"602R1PA45W
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M\6?] W1?_!G-_P#(]'V+Q9_T#=%_\&<W_P CUV>]?[P_.C>O]X?G1_JQE/\
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M:CIEA!<Z;>ZQ?+:^;:C4I(H(Y$7?' LUQIXW1A&9()255B,O_5W+/^?;_P#
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M]8\/:7?RZU=)+=6L4[JL<> 60,0/EZ<T?ZL93_SY_P#)I?YA[:?<?_PFDO\
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ML93_ ,^?_)I?YA[:?<?_ ,)I+_T$?"'_ (4!_P#C%'_":2_]!'PA_P"% ?\
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M"O\ T+.C_P#@!%_\32?;/%G_ $!]%_\ !K-_\C4?;/%G_0'T7_P:S?\ R-0
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M_(U "_\ "O/"O_0LZ/\ ^ $7_P 31_PKSPK_ -"SH_\ X 1?_$TGVSQ9_P!
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MB_\ @UF_^1JYO_B?W_B_7K>YT31+E)]*M(KBVGU"1H7B,EV,'-N=V<N"I&,
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M$KLK2! EJ  S*I;'4J">@K8^V>+/^@/HO_@UF_\ D:@!?^%>>%?^A9T?_P
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MG=D8&,#DYXV/M7B7_H%Z5_X,I?\ XQ0!XY_:MW_T*VA_^$U)_P#%4?VK=_\
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M!ZW\$O@9?_#F]\+ZGJ4UC'J-CH^IZ??PZ?>2R6KR7-[!=(UO$4C2*-2LXVA
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M[T ,_P"%/:;_ -!O5?\ ON#_ .-4?\*>TW_H-ZK_ -]P?_&JZ?\ X0?PY_T
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M#;9%D4DJRG@KP,]3FL'6/#,7@GP]=W5QJ\]W%/JNF7$TUZ441[+J ,Q8 <8
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M_DFC_A8WA3_H9=)_\#8_\:/^%C>%/^AETG_P-C_QH /[/\5_]!S2?_!1)_\
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M:/\ A8WA3_H9=)_\#8_\:/\ A8WA3_H9=)_\#8_\: #^S_%?_0<TG_P42?\
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M$G&!@ ^E=+\-:OI44<.G:AX>LXXTV)':Z(R!4R3@!;C@9)./4FK_ /9_BO\
MZ#FD_P#@HD_^2:^?_@+\.=%^%/C9M9O_ !%X.:*+1SIMO)IMVJ3EY'ADG>7Y
M55@[PJ55=J1A0J(NYR?H#_A8WA3_ *&72?\ P-C_ ,: #^S_ !7_ -!S2?\
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M6Q_PG7AO_H/:;_X%I_C6/X+\9Z!:^#M"AFUO3XIH["!'C>Y0,K"-001G@@T
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M7AO_ *#VF_\ @6G^-8^N^,] FU3PZ\>MZ>ZQ7[O(RW*$(OV6=<GG@98#ZD4
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MT-6F_P#@FG_^/5E_\(IX+_Z'>3_P-M?_ (W1_P (IX+_ .AWD_\  VU_^-T
M:G_"Q4_Z&K3?_!-/_P#'J*R_^$4\%_\ 0[R?^!MK_P#&Z* /7**** "BBB@
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M ./T?8O$G_07TW_P6/\ _'Z -VL+QE_R"+?_ +"-A_Z5PT?8O$G_ $%]-_\
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MI;WXL>.M%T)O^$=FBO=.N;Y_[,O7>98XYWCBF9'4;!*%#"')D4;BX3&#](T
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ME-I]N+%4MYP\CPR7,TK[\2-*\*$\!4"(J*@W;O>/^%C>%?\ H9-)_P# V/\
MQKQ_X"_M*7GQ>\<KH,BZ&RKH;:M.-/NV>>#,T:6_F(1A3*C.YC!8PA8PYS(
M/H*@#G?^%C>%?^ADTG_P-C_QK \)^,] CUKQA,^M:>L5QJJ20N;E )%%E:J6
M4YY&Y6&1W4CM7H-<OX0_Y&#QO_V&(_\ TWV= %O_ (3KPY_T'M-_\"D_QH_X
M3KPY_P!![3?_  *3_&MVB@#BO&GC/0+KP=KL,.M:?+-)83HD:7*%F8QL  ,\
MDFMC_A.O#G_0>TW_ ,"D_P :/'?_ "(_B'_L'7'_ **:MV@#"_X3KPY_T'M-
M_P# I/\ &C_A.O#G_0>TW_P*3_&MVB@#"_X3KPY_T'M-_P# I/\ &L?P7XST
M"U\':%#-K6GQ31V$"/&]R@96$:@@C/!!KM:PO G_ "(_A[_L'6__ **6@ _X
M3KPY_P!![3?_  *3_&C_ (3KPY_T'M-_\"D_QK=HH PO^$Z\.?\ 0>TW_P "
MD_QK'\)^,] MM+G276M/C8W]ZX5[E 2K74K*>O0@@CV-=K6%X-_Y!%Q_V$;_
M /\ 2N:@ _X3KPY_T'M-_P# I/\ &C_A.O#G_0>TW_P*3_&MVB@#"_X3KPY_
MT'M-_P# I/\ &L>U\9Z OC'4YCK6GB%["T19#<IM+"2Y) .>H#+^8]:[6L*S
M_P"1XU;_ +!UE_Z-NJ #_A.O#G_0>TW_ ,"D_P :YWP%XPT*ST.ZCGUFPA<Z
MKJ4@62Y125:^G96Y/0J00>X(-=_7+_#G_D7[O_L,:K_Z<+B@"W_PG7AS_H/:
M;_X%)_C6/=>,] ;QCIDPUK3S"EA=HT@N4VAC);$ G/4A6_(^E=K6%>?\CQI/
M_8.O?_1MK0 ?\)UX<_Z#VF_^!2?XT?\ "=>'/^@]IO\ X%)_C6[10!A?\)UX
M<_Z#VF_^!2?XUCZ[XST";5/#KIK6GNL5^[R,MRA"+]EG7)YX&6 ^I%=K6%XA
M_P"0OX8_["+_ /I)<4 '_"=>'/\ H/:;_P"!2?XT?\)UX<_Z#VF_^!2?XUNT
M4 87_"=>'/\ H/:;_P"!2?XUC^+/&>@7.EP)%K6GR,+^R<JERA(5;J)F/7H
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M/[/\5?\ 0<TG_P %$G_R31_PL;PK_P!#)I7_ (&1_P"-'_"QO"O_ $,FE?\
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M_P"@YI/_ (*)/_DFC_A8WA7_ *&32O\ P,C_ ,:/^%C>%?\ H9-*_P# R/\
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M FJZ>LJZJ@F<Z>Y#M]BM2"H\[Y1M*C!)Y!.><#?_ .%C>%?^ADTK_P #(_\
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M"[/7V\':$8=5T^.$V$!1'T]V95\M< GSADX[X'TK8_X3KPY_T'=._P# I/\
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M"@#8^P^(_P#H,:;_ ."Q_P#X_1]A\1_]!C3?_!8__P ?H_X3KPY_T'=._P#
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M (%)_C0!CVMGKY\8ZF!JNGB86%H6<Z>^TKYES@ >=P0=W.><C@8YV/L/B/\
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M?]!W2O\ P4R?_)% 'F_Q)^)GC?P[\3YM,T;389?#-CIVF7=U=/8B8M)<W=Q
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MZ/L/B/\ Z#&G?^"Q_P#X_0!NUA6?_(\:M_V#K+_T;=4?8?$?_08T[_P6/_\
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MX]_P/MC_ (6-X5_Z&32O_ R/_&C_ (6-X5_Z&32O_ R/_&F45X?^N[_Z!_\
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M<OGHMNI=I'4RM$6:2-,JAV@2-G%?5%>;B>+JF$J>SJ8=7\I__:EJ@I*Z8_\
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M7_@9'_C6/X4\?>&;;2YTFU_38G-_>N%>Z0$JUU*RGKT(((]B*U:*/]=W_P!
M_P#Y-_\ :A]7\Q__  L;PK_T,FE?^!D?^-'_  L;PK_T,FE?^!D?^-,HH_UW
M?_0/_P"3?_:A]7\Q_P#PL;PK_P!#)I7_ (&1_P"-8]KX^\,KXPU.<Z_IHA>P
MM$60W2;699+@L <]0&7/U'K6K11_KN_^@?\ \F_^U#ZOYC_^%C>%?^ADTK_P
M,C_QKG? ?COPW9:'<QW&O:=!(VJZE(%DND4E'O9V1N3T*L"#W!!K?HH_UW?_
M $#_ /DW_P!J'U?S'_\ "QO"O_0R:5_X&1_XUCW7C[PRWC#3)QK^FF%+"[1I
M!=)M5FDMRH)SU(5L?0^E:M%'^N[_ .@?_P F_P#M0^K^8_\ X6-X5_Z&32O_
M  ,C_P :/^%C>%?^ADTK_P #(_\ &F44?Z[O_H'_ /)O_M0^K^8__A8WA7_H
M9-*_\#(_\:Q]=\?>&9M4\.O'K^FND-^[R,MTA"+]EG7)YX&64?4BM6BC_7=_
M] __ )-_]J'U?S'_ /"QO"O_ $,FE?\ @9'_ (T?\+&\*_\ 0R:5_P"!D?\
MC3**/]=W_P! _P#Y-_\ :A]7\Q__  L;PK_T,FE?^!D?^-8_BOQ]X9N=+@2'
M7]-E<7]DY5+I"0JW43,>O0 $GV!K5HH_UW?_ $#_ /DW_P!J'U?S'_\ "QO"
MO_0R:5_X&1_XT?\ "QO"O_0R:5_X&1_XTRBC_7=_] __ )-_]J'U?S'_ /"Q
MO"O_ $,FE?\ @9'_ (T?\+&\*_\ 0R:5_P"!D?\ C3**/]=W_P! _P#Y-_\
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M5Y%M"JBY9L,1T)("CG%3**FG&6S TO\ A%_$G_0?T[_P5/\ _)%'_"+^)/\
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M_P"-T?\ "=6/_/EK7_@FNO\ XW1_866?\^(A[2?<H_\ "+^)/^@_IW_@J?\
M^2*/^$7\2?\ 0?T[_P %3_\ R15[_A.K'_GRUK_P377_ ,;H_P"$ZL?^?+6O
M_!-=?_&Z/["RS_GQ$/:3[E'_ (1?Q)_T']._\%3_ /R11_PB_B3_ *#^G?\
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M_P"-T?\ "=6/_/EK7_@FNO\ XW1_866?\^(A[2?<H_\ "+^)/^@_IW_@J?\
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M /R147C3Q5:7'@[78EM=35I+"=09--N$4$QL.6*8 ]SQ6Q_PF%G_ ,^FJ_\
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M5S_\;H_X3"S_ .?35?\ P57/_P ;H_L++/\ GQ$/:3[F9_PB_B3_ *#^G?\
M@J?_ .2*/^$7\2?]!_3O_!4__P D5I_\)A9_\^FJ_P#@JN?_ (W1_P )A9_\
M^FJ_^"JY_P#C=']A99_SXB'M)]SGM!TKQ)K>AZ=J)UK383=VT=QY?]ENVS>H
M;&?/YQFKW_"+^)/^@_IW_@J?_P"2*B\%^*K2W\':%$UKJ;-'80*3'IMPZDB-
M1PP3!'N.*V/^$PL_^?35?_!5<_\ QNC^PLL_Y\1#VD^YF?\ "+^)/^@_IW_@
MJ?\ ^2*R[BR\20>*-/TC^V=-87=G<W?G?V8_R^4\"[<>?SGS\YSQM[YXZ?\
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MYM?_ (Q0!T5%<[_PBM]_T->M?]\VO_QBC_A%;[_H:]:_[YM?_C% '145SO\
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M_,B%RHQY&.#(_P"?TH ZJBN=_P"$5OO^AKUK_OFU_P#C%'_"*WW_ $->M?\
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M8^#YM-LK>TMO$.JQ6]O&L4:8MSM51@#)AST% '1T5A?\(Y>?]#)JO_?-M_\
M&:/^$<O/^ADU7_OFV_\ C- &[6%X-_Y!%Q_V$;__ -*YJ/\ A'+S_H9-5_[Y
MMO\ XS4-GX/FL(FB@\0ZK&C222D8MS\SN78\P]V8G\: .CHK"_X1R\_Z&35?
M^^;;_P",T?\ ".7G_0R:K_WS;?\ QF@#=K"L_P#D>-6_[!UE_P"C;JC_ (1R
M\_Z&35?^^;;_ .,U"G@^:.]ENU\0ZJ+B6-(G?%ORJ%BHQY.."[?G0!T=<O\
M#G_D7[O_ +#&J_\ IPN*M_\ ".7G_0R:K_WS;?\ QFJVG>"GTJW>"UU_58HG
MFEG*_P"CG+R2-(YYB[L['\>.* .FK"O/^1XTG_L'7O\ Z-M:/^$<O/\ H9-5
M_P"^;;_XS4+^#YI+V*[;Q#JIN(HWB1\6_"N5+#'DXY*+^5 '1T5A?\(Y>?\
M0R:K_P!\VW_QFC_A'+S_ *&35?\ OFV_^,T ;M87B'_D+^&/^PB__I)<4?\
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MYJW:YRS\'S6$310>(=5C1I))2,6Y^9W+L>8>[,3^-3?\(Y>?]#)JO_?-M_\
M&: -VBL+_A'+S_H9-5_[YMO_ (S1_P (Y>?]#)JO_?-M_P#&: #P]_R%_$__
M &$4_P#22WK=KG+?P?-:RW,L7B'54>YD$LIQ;G<P14S_ *GCY44<>E3?\(Y>
M?]#)JO\ WS;?_&: -VBL+_A'+S_H9-5_[YMO_C-'_".7G_0R:K_WS;?_ !F@
M L_^1XU;_L'67_HVZK=KG$\'S1WLMVOB'51<2QI$[XM^50L5&/)QP7;\ZF_X
M1R\_Z&35?^^;;_XS0!NT5A?\(Y>?]#)JO_?-M_\ &:/^$<O/^ADU7_OFV_\
MC- &[16%_P (Y>?]#)JO_?-M_P#&:* -VBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ibio-20220930xex10d3004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20220930xex10d3004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (' ZX# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%\4_"\B@X)744//YT >QT5YYX5_:%^&GCE-8?P_XXT36%T>U-[J!M+M7%K
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MQL_Z);;_ /@6O_QR@#KOV@=!TR/X+^,F33K1&&EW!#+ H(_=M[5^:/B+Q_\
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MZFJ!  %Q>SXP*&!Z(W[,WPO;Q9H/B<^#-..OZ%%%#IM_A_,M4C4)&J_-C"J
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MO_";^'_^@S8_]_U_QH \8M;W]I+[3%Y^D>#/(W#?MU*3.W/./W%?0";BB[P
MV.0.F:QT\::#(P5=8LF8G  G7)_6MKK0 4444 <E\3OBAH'PC\&ZMXF\0W7D
M:=ID)N)Q&09-H]%)&:\Z\'_MD?#/XC7VNV/A76EU>[TG3AJ,NS"QLI#X4$G[
MWR'(QW%?.?QZ^ ?AW]HK]O2'PGXKN]5CT5_"\ETT.G70A+.A@ !RI&/F.1BN
M7_:7_8:^&OAKXT?"FUT;^V-)M_%5Q/INI)9W@C#11B/;M^3ACYC9/.>* /K/
M]G+]JS0OC]I4C_8I_#^IH'E6UOBJK/"LK1"6)L_,NY2N<#D$5[?]IB_YZI_W
MT*_/G]L;]A[PGX3^"OA:Y\'ZAK=CKOA=+;1=&DDO@5*2WWF?O<(-S;YVPW&.
M..*BL/"/AJ#X53WVH>/_ (EQ>.;.<:1)H*ZZHEEO^0-B>3G8VUI%_P!D=>]
M'Z"G5+(,5-Y &!P095R#^=.BU"UGSY=S#)@X.V0'%?F#\(?V6?!>D_#KQ9XQ
M^./C[Q%8:A:>)+K2KNZMM66&+S4<C))4Y).>?:O+/AMK/PO\#?'3Q597'Q>\
M16GPYO\ 4'@T^?2M;2.>(JBD2S-M.]6)"Y 7&T]: /V.O=6LM.MI+BYNH8(8
MU+,[N   ,FOBKXB_\%0_#'@WQCK.C67AN^U&"P@:6*Z?""YVNJDI@G();@]Q
MBOD3X\ZS\,O'7Q%T/P[HOQ@\1WO@RUN574[S6=:2?S"RG/DX5<#:0-W(SD5[
MQ)\!?V-OBAXH\-VL/CR]N=7MXH+&SAM-9B!F\L*$##8=Q^09H ^[OA?\6=$^
M*OA>WUC37>U9V,<UC>;4N+>4 %HW3)PPR,UV#74*@DS1@#DDL.*_'WXS?#+4
M-._X*!>*QX7U'7;>RBMWU[4K?2;KR[J2(EC.L!VG!*H,#!KV+X\?#K3;WX<K
M;?#3XD>.]:\0:II$^IL+S7%FM[:SC1S*9E$8^]Y<D8Y'S#\* /T:_M>QQG[;
M;X_ZZK_C4L=Y;RH'2>-U/(97!!K\J] _9"\/?\);X;T*Z\2^)I;>_P#AY)XC
ME,>H[?\ 2?DP!\APF'/'ZUM_LJ?#/3K/P!I^E_$GXD>-/#]ZVD)K.G3Z?K*V
MUG/9%02$5HVP8PR!OF/+#I0!^BWC_P")&A_#?PS>ZUJ]T!!;)D0Q$-+*Q^ZB
M+D99CP!ZU\<>#_\ @JWX5\3>--/T.3POJ,"W%V]M(T8#20JH)WE<] !D\\#/
M6O+?@O\ LS0_%_\ :=BUCQ-KOBFY\-6EO;ZMHEKJM]ONI(TD<Q-*VP<;D/R[
M1]>:W?@9^QO\/(?VVOBG8JFI&WTFRD>V4W*\&ZB$<I/R<\3/CT..N* /T6TK
M7M.UNPM[VRO(+FVGC66-XY 0589!_$&K$M];0*&DN(HU)QEG &:_+GPE^S]8
M?![XZ>)-'F\7^,M+^&4=Q;:<MWI^K"*2UN'BW(9G,9!3"L,X&"0*M_'#X%CQ
MG\2/#?AKP[XY\::CX*MO%%CHVLWNJ:L)UDN99&4+"1&H#1[6SU^\.!0!^FS:
MQ8("6OK8 =S,O^--_MW3?^@C:?\ ?]?\:_.?X._L&> OBEXQ^*WA[Q!KGBV;
M3_#^O_8+18=5"%D6*%P7/EG)W.>>.U>G_P##H_X);L_VEXTSZ_VTO_QJ@#VW
M]H_]J;PU^SSX,FUBY5M:O?+,D5C8LKML4@-(_/RH"0">>HXKRK]GG_@HOX7^
M./CV\\-3Z1/H80JEO?2,&A9R2 KL2-I/&.N:9H__  3+^$'@+1_%,EC<>)KK
M^U-%N=,G6^U-90(G*NQ7]V,-F->?K7SG^Q;^QOX!^)G['WB75M3?5H=2U&^9
MI)[2["%3:_/%M^4XY=L^O'2@#]2([RWE0.D\;J>C*X(-,DU&TA8+)=0HQ&0&
MD -?F?\ LQ_":PTOP]-HGQ ^(/C;P^([>?4=)GT_65@MKBR1G#!5:,_."DA(
MST&>]>6>,?AWI-[\1]2UGQQ\1-?T/PM<^';J]\+QZ[K"I=SF.9(U^<JH82<R
M!0O0CD]: /V"35+.1PB7<#.1D*LBDG]:E:ZA4$F:, <DEA7XZ>'_ ()W%IIW
MP.\5^&?$'BFYOM5\.7FL:]%8ZC_I$D47V<R1VYV'8Q\SIAN@KV?X]> =*NOA
MLD'PS^)/CO7=?U+2Y=39;O7%FM[:S1&:1IE$8^\%=0,C)4B@#Z'_ &COV\O"
M_P  _$=EHRZ=<:Y,\CQW5Q;D>1;N(C((RV?OE0#C'0]:Z3]F']L#PU^TCH4M
MS!;R:%J$9+"UO"%$L>>'C.?F'3/3!-?'_P 9OV+_  7X0_8-?5)+W5]0UAK^
MQUR2ZGN@=UQ,T5LW&W.WRW.!GKSGM6K\>/V$_!V@_LZ>"=4\)7VLZ9X@LH8U
MM)3> H3.!(^X!1GY@,<\>] 'Z2_:8O\ GJG_ 'T*@.JV2L5-Y;AAP095R/UK
M\^-,\':#8_"2XOM7\=_$A?B!8S#2YO#</B!1)+?GA40>3G8S<!L&OFK4?V>-
M2\/^'(M5\2^*]<N?$%YX]L]#NO+N]H$$KVP;/!RX64C=[#B@#]GXM0M9\^7<
MPR;>#MD!Q27.I6EG"TL]S%%&HR6=P!7Y?>&_@38_"G]H3QKI=SXN\::=\-UU
M"UTW[;I^K".6VNI+9)5DN',9!0\H#@<LHS3_ (Y_ A/'OQ#\/>&O#OCKQCJG
M@:#Q!;Z1K-YJFK"X62ZD$F%APBX9/+D#=<$B@#VOXD?\%//#?@OQ7JFE6'AF
M^U2UMEM3;7?"B\$TCH'C&>4RG![\\5]1?"7XQ>'_ (P>#['7M)N/)^T+^\L[
M@JLT+]U9<G'K]"*^%_VCOV(_AUI'QD_9[T2)M8:SG@DT67?>*6:"TV21<[/O
M;IWR>_'3%9'[1/[']C\*?CAH>M?#_5/$MI'/;?;M6MK34 LS1*&1S"P3Y=J)
MG&#G!]: /TT:ZA126FC4#J2PJ#^U[#&?MMOCU\U?\:_.;XZ?#?2=5\$6.F_#
M;XC^/-;U[6K'[:WVS6UFM[*V &]YT$8.0Q5=N1RWM7C?PS_9BTO5OB_X*\%Z
MGXE\12V&J>!WURY:WOO+/VD)&1MRIPF6/'/UH _8..\MY4#I/&ZGHRN"#7/>
M/OB)HGPX\,7VN:O=I':VJ!BB,#(Y9@JJHSR2Q 'N:_.G]EGX7:=9^%%T?X@?
M$'QOX>*V<VJ:7<6&LK;VDUDA?<JAHS\Z"-V89Z$4WX7_ ++4/QO_ &EH+CQ9
MX@\5W/A*#2%US08-1U$/=,D5X(P9&V %&=2X&T<$<]Z /8=(_P""G6AW7B33
MM/O_  AJ=E!<7%Y%<G ,UHD$PB+.F>#DC(SQ7V7IWB;2M6L8+RTU&VFMYD#Q
MNLJX(/XU\ >&/V(_ /BO]L+XS6MS/JRVX@@N5"70!66\7SYB#MX&[H.P]:]'
M\/?\$N?AQHL30OXG\9- %"QQPZJ$" =O]6: /L ZM8CK>6__ ']7_&D&L6!_
MY?;;T_UJ_P"-?(7BC_@FU\,+/0[N[?Q9XSLH+6)IYIY=85E1%&YB?W8Z &OS
MH^&?P\T3Q5\/OBQXAN_&.L6D/AS7A;:9?+>?NS!Y@"NRX^8[>>"* /W<^TQ?
M\]4_[Z%>0_M$?M)Z/\!?#$E[]CF\0:PT%Q/!IEB59RD*;Y'?GY553DGGCM7Y
M(^-?BWXF\.^'-=F\/?%#Q)XDBM+H):ZJ=96U+Q_-D"T969AP/G#8]N:]C_X)
MP? I_P!H#QK\3?'/B]]7NM%O;.?1K6\?4!*[M/&T=R&?9AF",F" ,$]#0!]M
M?#']M31/'/Q,OO"&H:5-H^V:&VL]2+!K:>9[2.Y,18D88*YXQVKZ&?6M/C(W
M7]LN?691_6OSUG^!O[)6E^%KKP4WCG6Q!;:R=2ED75XS<)=+$(<;]G0*HXQU
MK$UC]G7]D/7IH'U#XC^*960B-&DUZ, ;B!C_ %?KB@#])!KNFDX&HVG_ '_7
M_&KB.LJ!D8.IZ,IR#7YW_&S_ ()C?"'X<_!WQ=XLT34_%W]IZ3IDU[:&;5P\
M?F(I*Y'EC(_&OK3]DB66;]F[P"\TTEQ*=.&Z65LLWSMU- 'KU%%% 'E'QQ_:
M1\,_  :8?$-CJ]X-0+B+^R[43;=N,[LL,?>%>2S?\%)_AG%#(_\ 8?B\[5+8
M_LM><?\ ;2OJV6WBGQYD:28Z;E!J/[!:_P#/M#_W[% 'YJW7[7GA+XOZ[>:Q
M\4(/&-EX>MYB-/\ #NDVQ6W:(' >X82+O)')4@@9Z\58\+:C^S-J_P 7-=UH
M:&;;3[S2[+[+I/\ 8\4;P?*V9E96R&;(.1Z5]X?&.QME^%_B0BWB!%FW1![5
MX-^R[)X/D^(45K#IEP/%B^$M(:ZNY) T#Q&%M@5-ORD<Y.3GVH \]\._M):1
M\!_%MC;Z#JNN>)_A[>R"*6QU"-I;K36)PK1NS$NG(R"0% )&<U[Z/VT?AP0#
MYVH_^ O_ ->O<38VQZV\7_? KP7]J&?75UOX8Z#X;UJ7PVVNZU-:W5U:* YC
M6UDD _-10!ZO\.OB5HWQ0T0ZKHCS/:AS&?.38V02.GX5U5> Q_L^^/(AA/B[
MKB#T4X_K3O\ A07C_P#Z+!KW_?1_QH [G]H3_DBGC3_L%7/_ **:ORW^('CO
MX;Q_ML>#K3X@V<4OAZS\.6%O?F^@62'+6,;JV#GL1SZU^@&O?LR^,_$NCW>E
MZC\6M<N+&[C:&:)F.'1A@CKZ&OG#XN>$/AWX(^-&MZ?<>$M/\4^.+G3[?2-(
MEO2(C%(MDJ"624@A0$5N2.N!WH ^3?VT_AO\+9[CPMXG^"=A+/X>U>ROTN);
M?<\32PR1+A0.%^\WUKO_ /@F+\8?"7[/WQ!^*#>.=3&@)?P6<=L;B-AYA1I2
MP'';</SK[O\ ^">GP;U3X-_LUZ=X8\1_V;=ZC#J-Y-YEA.ES%L>3(PXXSZBO
M=[WX8^$]1OYKVY\/V$]U-_K)7A!9OK0!\W?$S]NGP=XD@TCPO\-/$MO>^*->
MO$LHIQ$66U0D;Y"#WV[L>^.E?.W[#7[1WASX/?$#XW6WQ/\ %SC59?$;P0WE
M^K;[A(2\88=<#@<=J_1:#X4^#[74;2_A\.:?'>VC%X)UA :-B,$@_0XIC?"/
MP8UY=79\-:<;FZ?S)I3 -TC>I]Z /G7XB_MP>$O&USX>\$_##Q3#-XJ\2ZC%
MI\=XL.];.-SAI<'JPR,#OSR*^?/V'_VCO"?P@\7?%./XC>*VCU:[U=F^U7RL
M9+@@*"QZ^E?HA:_"GP?9:I::E!X<T^&_M6W07"0@/&?4'\*8?A)X,:[NKD^&
MM.-Q=2F:>0P#,CD %C[\"@#RD_M[_ ['_([VO_?+?X5\X?L<?M8?##X>R_%$
MZ_XEAT\:IXJO;ZT\Q&_>PO/*RN..A# _C7W/_P *G\'?]"WIW_?@4?\ "I_!
MW_0MZ=_WX% 'R3K'[9EW^T#\=5^$/PPOX;/2+G3Q?R>+(-SR;5SYT2H0 &QM
MPP;/->1_\$XOVDO GP3\"?$#2/'7B4:?JUQXJN9T-TK%YDV1IO\ Q*G\J_1C
M2?AGX5T'64U;3M!L;/4D1HUNH8@KA3U&?0U4MO@[X(LT9(?"^FQJS%R%@'))
MR3^= 'E%S^WK\#WMY5'C:U)*$ ;6]/I7PY^S;\?-9^'OB?XR?$:S\033?#^Q
M\71^=I;Q%HY[>Y:=VEC)^ZP\L< <[NHQ7Z?_ /"I_!W_ $+>G?\ ?@41?"?P
M=#H^H:5'X<T]--OVWW5J(1LF;GEAWZG\Z /)(?V^_@?)$CGQK:J6 )4JW'MT
MKY[^,/[6GPN\0?M4_!SQ+8>)H;C1=&^U?;KI4;;#N@G5<\=RRC\:^WE^$W@U
M5 'AK3@ , >0*7_A4_@[_H6]._[\"@#R<_M\? X#_D=[7_OEO\*BM_V__@=<
M(6_X32WCP2,.C UZ[_PJ?P=_T+>G?]^!1_PJ?P=_T+>G?]^!0!\G?&/]IJ']
MH&Q\6>%OA7XJ-MI^D>&KS5]3U2UBW.^V&4QPH>""6CY(/1N]<K^P7^U]\,?A
MQ^R[X2T'Q9XJBL-?MVNGNH)U8N&>XD<$_4,#^-?<&F_#+PIH]Q?3V.@6-K-?
M6_V6Y>*( RQ<_(WJ/F/YU5MO@]X)LX5A@\+Z;%&O15@&!0!Y9_PWQ\#O^AWM
M?^^6_P *\-^/O[1+?M(^$?BAI'PT\3-:^&O"OAB74]1O[6,[[N1XY-D*G@J
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M^'M=\;^/O$GBWQ-8W*ZE.MQJ$S68NL$GRXB^T*I9@#M!Q0!XAXI^)-A\*_\
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MD0#(S[@U]44 4-?_ .0%J7_7M)_Z":^-?^"<_P#R9-J'_7[?_P#H"5]E:_\
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M_P )'JLZ^&KOPEI36=C%&\I63R3O;:H.,Y% 'KG_  SW\4_^B\^)?_ >T_\
MC%<=\2?V'/$OQ>L]/M?%OQB\1ZM#83FYM05@B,4A4J6#1Q*>A(Z]Z] _X;4^
M''_/QJ'_ ( R_P#Q-5K[]N7X7Z9$);J^OH(R<;GL9<?^@T 87PY_8#\#^$M#
M-IKM_K'BF\+EOMEYJ4ZL!DX&$=1^E=7_ ,,6?"W_ *!-[_X-;O\ ^.U8\/\
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ME?M ?L,0?"[X,^+?%>G?%;QU<WVDZ?)=117%Y%Y;,HR V$!Q]#7BGP&UK7_
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M#Y#D$>6N#7NU>(_L5?\ )KGPY_[!%O\ ^BUKVZ@#YT_X*"?\FI>+?^OC3_\
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M,#G-=M<?&74/!UK<:O<? @Z1;6T9>:]FU*VB2) .2S%  /<T =A^QC8KIWP
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M_%;P'HJ7]G\1O$_B*1I-AMK(+O ]?N&@#Z._X0#PW_T ['_OPM'_  @'AO\
MZ =C_P!^%KYT^&GQP\<^#]!:SUWP9XL\3WA<M]KNS\P&3QQ&*Z[_ (:<U[_H
ME'B+\S_\10!)^U;X(T"T_9[\<S0Z/9Q2IIDY5UA (.QJ^-_AEHXMO^"@'PYN
MH+RXC:X\)Z?)-$KD(V+&)0I'<=#CUKWW]HOX^Z_XG^"GB_3/^%9:]9"XTZ9#
M<2D[8P4/)^3H*^.;[2?BG-^W'X%@\&WMGI^HS>&]-%E/>_O8HHAI\6_>BL#]
M\'C(ZB@#]=O$_B;3/!N@7VM:Q=QV.F649EGN)3A44=R:^6?V6O[7\6?M0?%_
MQ]_PC>KZ3X4UO3]/BTO4-2M3"EYLDN"Q3KD8=?SKQK]KOP+^U.OP1U:;5?%^
M@7VF0R))<Q:7:O!+L .26>5AMY&>/2O5/^"??A/]H;0'\1W?QG\0#7-"N[2U
M_L,QZC!=(I!?S"OE=,@IU]* /LNOCWX7^.7^$W[27Q*_X3+0M6\/:7XIU"V3
M2M8N[8K9SLD.PKYA.,G!Q]*^PJ_*G]N+P-^U./&&N72>*8_^%=7=W$MCIXU&
MW5I/F&U4A)\QF!&3CG@GI0!^JU?*G[*W_)Q?[1'_ &,A_P#1458VB_#O]KF/
M2;19OB!X4641J&$NG2NX..Y$V":J?L(67B/3OBI\<;;Q=>VVH^)(]=Q?75G&
M8XI)/+CY5220,8[F@#[/HHHH **** "OE;]BG_D<_CK_ -CE>?\ HZ6OJFOE
M;]BG_D<_CK_V.5Y_Z.EH ^J:^-?^"9/_ "3SX@?]C7>?^AFOLJOC7_@F3_R3
MSX@?]C7>?^AF@#[*KA_CC_R1_P 8?]@R;_T$UW%<)\=3(OP<\9&*"6YD&ES[
M884+NYVG@ <DT ?FS^S9X3^(_P $O@OX.^*?@'X=77B[6K_5+P7=EILC![VP
M90L1<!#G#^81UQC->G7GQ!^-_P"T?\:_A3+K_P  ]<\!Z3X<U=[^?4+MWDC*
MFWECP<QKCF05D?LT_P#!0GPW\*/@CX)\'W/@OQ-J=U86\L$US:6,IC+"1V^7
M$9W=>QXKW_X2_P#!0CPA\5)O&T?_  CVLZ$WA?3O[3G6_A96EBW*O"E 0=S@
M8/UH ^JATKSG]H'X<^'?B9\+->TWQ'ID&I6R6LDL0E4%HI IPZ$]&'8UXS=?
M\%#/!L?[-UK\8;?1-1N]+N=4_LF/3H_]<TWS]]O3Y#VKS[Q3_P %-?"^MZ->
M:2G@#Q=$U]:3*)7T^;Y3M]/+R1SU'2@#V_\ 8,M([']E#P'!%GRXX;E%W')P
M+J8#^5>U^*6"^&=7)( ^R3<G_<->)_L%70OOV3/ %PJLBRP7+A7&",W4QP16
M%_P46O;FS_9=\5&!0JF-=TQG$6WYU_.@#\1O'\5N_B?7)#&AE\R?YB.?O#%?
MT _LK_\ )O'@+_L&1_UK\=- ^%O@_4?@-X@\4ZMJ/ABVO;;2;@6=I'JT+7TU
MS\NPF+?N['MWK]B_V5_^3>/ ?_8,C_K0!S/[3GPY\%_\(SJ?CGQ%X2T;Q*^D
MVQE:/4[-)SQW7<.#7I_PFUBU\0_"_P ):I8VD=A97NDVMQ#:Q+M2%&B5E0 =
M  0,>U<9^UP"?V<O'8!P?[/?G\17SA\&?V8/C)K/PC\%W]A^T'XATNQN=&M)
MH+&)4V6\;0J5C'R=%! _"@#VO]N[P!XF^)O[-_B'0/"6G_VGK,[(4MLX+* V
M<<')Y'%?/'@+Q#^W!K/AF*TLH/"6FZC8$6[6.JV@AQ"J*%;?@Y.<C&.U;W[8
MFJ>/_@U^R9)8)XDU7Q-XJT_5K::?59T+-<6V3OW;0/DP.?3/6OLKP!8PVOA'
M298T"RW%I%+*W=F* F@#\E/V^%_:>7PAX';XP'PJVE#Q#%_9PT)LR?:]C;=W
MRCY=N[\<5][_ !);4W_9_P#A8VM!5U8ZCIAN@@X$ODONQ^.:\K_X*W:%J6J_
M"#P%>V%L\\>F>*8+JX95)$:;'4,WH-S*/QKU[XS?VSJOP \$:CI^DSZS>VU[
M87LUI9@EBHB?<0 #W(H ^B+?_CWB_P!T?RJ2O#O#7[1FJ:QJ^FZ;)\-_$-BM
MQ*D#7,T;!(@2!N;Y.@ZU[C0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %5=5E:#3;F1(Q*RQDA",AN.E6JK:BLKV%PL#!)BAV,3
M@ XXH ^8OAI^V-H%EX&TFWUCPWJ^EZG'&RSVEII4XBB8.W"_)T[_ (UTW_#:
M'@[_ *!6O_\ @JG_ /B*]+^#%IK-C\+_  ]!XANUO]:2W(N;E)#()&WMSN/7
MC%=K0!X):_MD^#[JYBA73->5I&" MI<X )/^Y7O*.)$##H1D4ZB@ HHHH ^-
M7_Y2F6O_ &)%S_Z%;5]E5\ ^,/BKI7@[_@K'H.G7EO=R3:AX=&CQ-#&&437'
MDLA)S]T"-LGMD5]B?&SXJ6GP6^'&J^+[ZUN+VTT]=\D-JFZ1A[#(]* .ZHK,
M\,Z]!XH\.Z;J]LK+!?6Z7"*XPP#*#@^_-:= $<\R6\+RR,%1!DD]A6!X0\4G
MQ&ER)4$4L;Y5-K#Y.QY_&N:^-?QLT'X*Z5I5WX@M+VZL]2O8[ ?9(!*$+_Q.
M,C"UZ!:"":..YBC5?,C4AMN#MZ@?K0M]098HHHH **** /F[6O\ D_/0?^Q*
MN/\ TLBKW7Q!J$UM>6D$5PEMY@9B[XP<8XY^M?&OQU_: T_X2_MSZ+-/X?UO
M795\+R60M](MEED9VGCD! ++P ,$^M>4^-OB)\;?C%^TKJGBSX?^&_%.G>'M
M*T(26^BZS;+Y5Q<+M!C\K>R@MR0W7@TF,_2[1;]]2TR"XD55=QR%Z?A7RW\$
MO^3Z_C7_ ->%M_*&O(_@C\<?&G[._P 1?B-X<\;Z'XX\<Q)J -A=6=L)HECP
M#\JM( @SD8'I7"^$/V[_  A\+_VKOB;XI\1^%O%MI#K%K##%8QZ<CW,141_Z
MQ?,P!\OJ>HJF(_2KQ=JEQIEO9BV+!IIQ$2I4$#!/\7':N>^+GQ9T_P"#'PVN
M_%.JJUR(5"10>8B-<3,#LC#$A021U) KY0U7_@KM\#_W<6H^'/&')W(ESI,7
M)Z9 ,M>,?M0_MF^%?VE_!NG62^'-9M/A%I6MZ>?$8O+7R+R9'9\+" 3C 5^0
MPZBD@/K7]C+3_$=SK7Q,\4Z[%I=M'XCUHZA#!IUXEP4!BB7!*,P'"]"<YKZ@
MK\7OV3_VI;+]G?QO\2-:\%Z7J#_ ZSN[=VT^Z3?>H)V6)2K$G<P;G&[IBOL(
M?\%<OA$0"/#/CK!_Z@Z?_': /M#7_P#D!:E_U[2?^@FOD_\ X)8_\FJVW_87
MNOY1URNJ_P#!6GX2W>EWD">&?'(>6%T4MHZ 9*D<_O:\%_8;_P""AG@'X#_
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M\:]450J@ 8 X KY_M=9_:.-S%Y_AGPD(-PWE=6;(7/./W->_H6*+O #8Y H
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MXVAF>+D$YR=F:_-3]C6+]GJ]TFYUOQ1X7UH^+/"MM'?"6UU)I%OYC+A L.T
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M2*%^R2$'*OSSMP#^-8_PZN?!.A>-F_X3/2[GQ)X>1F0Q65V;5W'(#!@#['%
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M<$'.>$_NGW%?T,?L>1+#^S+\/4085=-  _X&U 'L=%%% !7A7[,__(Q?%O\
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M%/B)K-_KWBA;22 :A>ZA/<+<31F(, 5"Q@G[YR.M>N:U_P GYZ#_ -B5<?\
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M@S-Y2>;_ &?>CS-HW8\F?C->\_&.WAN_A;XGAN+J.Q@>QD$EQ+G:BXY)Q[4
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MTR: ._\ BO\ #NR^*/@;4M NP \J>9;3=X+A?FBD'NKA6_"N5_9U^(EUXO\
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M/$/AP2I:30L%#I(CH5<8Y'SL1TYKO*** "BBB@ KPWQ+^TIJ&F_$#7_"^B>
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M'[LS)\N,X[GM7T4.E>6FFK^=OR_S/I%*7.XO:R:_']4+1110:!1110 4444
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MS%\2?"VM_P#!0GX\ZY9:[93Z1>:7:_9[SS0L<N/)!VDXSR#^5>EP_P#!+/X
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M,ML/]W8S_P# Z]VU72K37-/GL;^WCN[28;9(95#*PSGD'W IT^G6US=6US+
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M;'197N%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJGJZ1R:7=+,YCB,;!F'4#%7*IZPZ)I5VSQ^:@B8E/[W'2@#PCX+?L[_"C4OA
M=X?NK/1H==MI8"R:C<>8DD_SMEB,C!SD=.U=M_PS3\,O^A0LO^^Y/_BJ\=^#
M/B+XYW7PQT"7PKX1\ Z;X=:%C96E[?WWG1Q[VP'^0\YR>O>NT_MK]I/_ *%_
MX;_^!U]_\;H [&']F[X:02I)'X2LU="&5@\G!'_ J])50J@ 8 Z"O";;6?VC
MFN8A/H'PZ6 L-Y2^OBP7/.,Q]:]U3=L&[&['..E #J*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q+XL?LA?#_XS_$/2O&7B
M2TN)]7TZ$V\30S&,,F6."5P>K'H:MR_LG?#>;68=4;1YC>Q(L:O]MGP J;!Q
MOQTKV*B@#Q:S_9!^&5A+>R0Z+.KWD+V\Q^W3G<C8W#[_ !T[5Q-M_P $Y_@S
M:>+9/$$6C7*74@(=%NY &R,9+!MQ_.OI^B@#Q6^_8^^&.HV=C:SZ+.T-G&8X
M5%].-JEBQYW\\D]:FO/V2OAM?ZE;W\VCS-<P1)#&_P!MG&%1=JC&_'05[)10
M!\Z>%OV#?A5X2\3Z_K=GIMU]HUJ-HKF,W3JNUL[L;2#DYZDUOVO['?PPL["\
MLXM%G6WNPHE7[?.=VUMPYW\<^E>V44 >'ZA^QK\+M3T>+3)]%G-I$&5%^W3\
M;LY_CYZGK7,>"/\ @GK\'O 4EPVGZ/<D2R"0(;N1%0C/0*P]>]?2]% 'E?AO
M]F7X?^%/'$7B[3]&9-=BW^7<R7,K[-X ; 9B!D =J]4HHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HKS_XK?"4?%!+!3XAU/0OLA8YTZ4IY
MF['WL$=,?K7GG_#(P_Z*'XH_\"F_^*H ]0^,O_)+O$O_ %YM_2OD#X7_ !5\
M)_"3XAV5]<KKVLZ]=^$=)233=+TZ>Y2",0MM8E$89.?7M7H_Q/\ V5AI?P_U
MV[_X3[Q+/Y-L7\J2Y8JW(X/S55_98U?P];>/(-,71VAUZ+PAH[3:S)*VV>,P
MMM3!. 1ST'>@#K?^&TO#_P#T)_C+_P $%W_\:H_X;2\/_P#0G^,O_!!=_P#Q
MJOH'[=;?\_$7_?8H^W6W_/Q%_P!]B@#A/AUXG\.?%_1GUN/PU+:-YAC9=8TL
MP3'!(SB1 2.*[BPTJRTM&6RL[>T5CDK!$J _7 JQ'(DJ[D=77U4Y%.H ****
M "BBB@ K)U[Q5I7AF73DU.\CLSJ%R+2V,AP'E*E@N?HI_*L3P[\4-+\0^./$
M/A18IK/5M'92T=P !<1,JD2QX/*Y8KSSE34/QC^&]M\4O =_HTI,5U@36=RG
M#P3+RK*>Q[?0F@#M702(5/0C!KP+X-ZE=_"?XD:K\+-6ED?39MVH>';J9B=\
M!SOM]QZLFUF/LXKKOV??B3>^//![VFOJMOXNT64V&KVXXQ.G!=1_=8@X/M47
M[0_PXO/&OA.#5=#8P>*O#\O]HZ;*G#.R89H<^D@78?8T >K5XO\ M&>"+^2S
MTWQ[X:A+>*O#$GVB.-.#=V__ "T@/L?E;_@%=K\(_B+:?%#P-I^MVYVSNIBN
MH#PT,Z$K(I';#*WX5V,B+*C(P#*PP0>XH Y_X?\ CC3?B/X.TOQ'I,OFV-_"
MLR$\%<CH1U!]C715\^^"H[GX'_&V\\)&-AX-\4M)?Z2RJ2MK=?\ +:+_ &5(
M,>T=.O2OH*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'^-'_#&GA'_H:/'7_A2W'^-._P"%E?';_HC-E_X55M_\11_PLKX[?]$9LO\
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M<;_T#_\ DZ_R#DI?S_@=317+?\(%%_T$[_\ [[7_  H_X0*+_H)W_P#WVO\
MA1]9QO\ T#_^3K_(.2E_/^!U-%<M_P (%%_T$[__ +[7_"C_ (0*+_H)W_\
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MI$\":6KI!(RD0+P0I]JL_P#"P/CO_P!$ML?_  <V_P#\75/6O'_QT;1[\/\
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MMI?Q>^'GQ'\:WOA_P79Z[I&LW,<\-Q)J4,3?+OR"K.#_ !4 ;_\ PP]\$O\
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MKQ/X2_L??"3Q'X \6:GJ'@VPN;S3]1O8[>1XE.Q1&A Z=NU>U/X\^.[HR_\
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M&?Q,F\9Z[XLT/4+(:=JV@7@AEAW[MT3[FA?H/O( ?QKSWXU63?!SXA:?\6[
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MPU_T,.E?^!L7_P 51_PG7AK_ *&'2O\ P-B_^*KS3_ACWX2_]"A8_P#?M?\
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ML+2=>3%/=(C#\"<UJUYIXS_9R^'OQ UZ76==\.6M_J,JA7GD0$D#IVH Z_\
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M1P#U//:@#]!O@Y_R2+P/_P!@.Q_])TKL*X_X.?\ )(O _P#V ['_ -)TKL*
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M>LQW7B#2[:0^+=?<)->QH2IU*<J<%NA!!!KW[_A8OA/_ *&?1O\ P81?_%4
M>3?\)U\??^B7Z3_X4,/_ ,37MNB3WUUI-K+J5JME?O&#-;I() C=P&'6LO\
MX6+X3_Z&?1O_  81?_%5O6]Q%=PI-!*DT3C*R1L&5AZ@CK0!)1110!SGC_4?
M$FE^&YY_"ND0ZWK 91':7%TMNC#(W'>P(&!DUY/_ ,)U\??^B7Z3_P"%##_\
M37N.HZI9:/:M<W]W!8VZX!FN95C09Z<D@5C_ /"Q?"?_ $,^C?\ @PB_^*H
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M^&%SBX3@E5!QVK[8KY6_X*;S1P?L=^+VD<(IEM5!8XY,R@"@#WGX.?\ )(O
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M#X8?]"U#_P!]&O4]*TNVT73K>QLXQ#:P((XXQT51T%?.7_"9?M2?]$V\(?\
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M%?1U>8_M"_#F7XA_#Z<:>637=)D75-->/AC/"PD6//HY0*?8T >G45Q?P?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *YWP#_R*UK_ +TO_HQJZ*N=\ _\BM:_[TO_ *,:
MO,J?[_2_P3_.F;Q_A2]5^IT5%>&_M;?M5:/^R5X#TWQ/K.D7NM07M^M@L%B4
M#J2CON.X@8^3U[U\Q:9_P68\%ZQM6Q^&'C2]<\8M8H9,GVP]>F8'7>+8]W_!
M6KP2W]WP5-_*YK[AK\?=&_;OTSXE?MT:+\5-%\!^([VPTWP_)I4FDVZ1/=EL
M3?/@-MQ^\]>QKZV?_@I5IEE<V2:E\)?'&EV]S<Q6OVJZA@6.-I'" L=_3+"@
M#ZZ\2?\ (NZK_P!>LO\ Z :_/']B;]@?X6>//@#'XIUK3[C4=;\0V^#--,0+
M1L'YHMN,'YOXL]!7Z&>('$GAG4G' :TE/_CAKYE_8#\>^&=*_9<\(6M[XCTF
MSN4B(>&XOHD=>!U4MD4 ?._[-G['7@'P[\<]=^'7C[PCJVMZU;V OEO;W5!)
M820M(X1XXT =#\NT[F/2OK67]A3X&V8-U%\/]/6>!7:-C)*V"5([OZ$UR>G>
M/O#"?MQZO>-XCTE;-O!]O&+@WT7EEOM4QV[MV,X/2OH"]^*'@TV<X'BW0B3&
MW']I0^G^]0!X5_P3X\.:=X4^%/BK2]*M5L[&T\7:K;PPIG"1I.0JCZ"OJ*OF
MS]A&YBO/AQXRG@E2>&3QGK#))&P96!N#@@C@BOI.@#GO'_@#0?BAX2U#PSXF
MT^/5-%OT"3VLA(5\$$="#P0#^%4/A1\*/#7P5\%6GA3PG8+INB6KR21VZG(#
M.Q9C^))-=A10 5\>?\%9#C]BCQ5_U_Z?_P"E25]AU\@?\%7;:6Z_8K\5)$AD
M87U@Q ]!<H2: /H_X.?\DB\#_P#8#L?_ $G2NPK\^OA/_P %-](T[X<^%=.F
M^%OC&XDM=-AMFGMXH?+;RXPFX;GS@[?3O78>!/\ @IMH?CGXP>$_ !^'GB;0
MK[Q#=K;03:HL2J@(.6.'.1TZ9H ^U:YCPE_R&_%'_7^/_125T]<QX2_Y#?BC
M_K_'_HI*\G%_[SAO\3_](D=%/X*GHOS1T]5=3>2/3[EH0#*(R5!Z9Q5JJNJ1
M&?3KF,2"(M&1O/1>.M>L<YX+\)_VHO!D'P[T2+Q5XLTFU\0I$5O85N(P$D#M
MQ@'TQ76_\-3_  L_Z'/2O_ E/\:K_!'X/>%=(^%7ARSN]*T#Q!<Q6Y$FII8Q
MR"X.]CNW,F3UQSZ5W'_"K_!O_0I:%_X+8?\ XF@#DX/VH/A?<S1Q1^,M+:1V
M"J/M*<D].]>I*P=00<@\@BN;3X9>#D8,OA/0U8'((TV$$'_OFND "@ # '84
M +1110!XM\&?^2R?%W_KXL/_ $":O::\1^$<XM?BU\8YR"PCEL7('?$<QKXW
MN/\ @M%8#Q)<Z;:_#K4+E1/Y%O&A5II&SC&T/R3Z"@#Z3_X*5Z;9WG['_C>6
MXMHII8UMMDC("R_Z1'T/45W7P0^$'@J[^"_@">;PQILLTOA_3W=V@!+,;:,D
MG\:_-K]J_P#X*@CXS?"#7? !\!WV@W6I^6&EOQL*!)%;INS_  XZ5^I_[/TY
MN?@3\.W*E/\ BGM/&#[6T= &A:?"OP?HMU%?V/AG3X;RW821210A65AT(/8U
MP/QH^%_P]_:"L]'M/'&AMJD6F2O<VL1R0A( 9CCV7]*]L8;@1ZUS,G@>,NC1
M7TT+*AC)55.Y3G(Y^M);Z[#Z&E%)IWA3PLCK_H^DZ;9 CC[D,:?T5:\5@_;P
M^"%Q"DJ^.K *ZA@&;!_$=J]3^)T'E?"GQ9"F6VZ+=H/4_N'%>&_L:?"3P9J?
M[-G@:YU'P?HEU>OI\1EEN=-A>1FV+G<2N<_6F(^??VG_ (W?#_XV_M-_LSCP
MGKMMK<ECXE+7 A8'9ND@V9^N#^5?H_TKX._;(\#^'?"/[2?[+S:'H.FZ.TWB
M63S386D<._#V^-VT#.,GKZU]Y4 ,FD\F%WV[MH)QZUX9XI^#OP[\5?&+0_B)
MK'A\S>+M/$4UC>!]S*4'R#:.E>Z2)YD;(3@,",US5SX(%Q<6TPU&9'MU B*Q
MIQCH>G/XTM;E:6\S?L+Z/4;2.XBSL<9&X8(_"K%5-,L!IME';B1I2HY=A@L?
M6K=4R#XD\#1(/^"KOQ'DP-__  A]J,^VRVK[;K\P/B_^T'>_L_?\%._%FIVO
MA>\\4I?:#964EM8J#*JM!"VX$D ?<QR<<UZUJ/\ P4RGM-/EF3X/>*#*J,VS
M?;.1COA923^ I#/JSX[?\D1^(/\ V+VH?^DTE6O@_P#\DG\&?]@:S_\ 1"5\
M]?"S]J _M7?LE_%3Q5_8CZ$+.QU33Q;N<D[;,MNZG^_C\*^A?@__ ,DG\&?]
M@:S_ /1"4 =?5>_U&UTJU>YO;F&TMD&6FG<(B_4G@58K-\1>'=/\5Z1/IFJ6
MXNK*<;9(B2-P^HH R_\ A9O@_P#Z&K1/_!A#_P#%4?\ "S?!_P#T-6B?^#"'
M_P"*KC_^&7/AG_T+,7_?^3_XJC_AESX9_P#0LQ?]_P"3_P"*H \I_:B\?>&;
MWQ[\%'M_$6E3I#XOLY)6CO8V"*"<LV&X'N:^AO\ A9O@_P#Z&K1/_!A#_P#%
M5\I?M+?L^> M$\<_!R&RT%(8[WQ9:6\ZB5SO0DY'+5[[_P ,N?#/_H68O^_\
MG_Q5 '8?\+-\'_\ 0U:)_P"#"'_XJKVD^,M UZY-OIFMZ=J,X7<8K6ZCE8#U
MPI)Q7 _\,N?#/_H68O\ O_)_\56]X,^"W@[X?:J^HZ#HZ6%XT9B,BR.WRD@D
M8)/H* .XHHHH *Y?6?BEX,\.W[V.J^+=#TR]0 M;WFHPQ2+GIE68$5U%>0>/
M?V3/A9\3?$D^O>)/"\>HZK.H62X-Q*A8#IPK 4 =5_PN[X=_]#YX9_\ !O;_
M /Q=>+_M)_%SP-J,?@O[)XR\/W/EZS$[^3J<#[5R.3AN!6[_ ,,&? [_ *$F
M+_P+G_\ BZ9)^P/\#)<;_ \+8.1F[G_^+H POBE\7_ E]\;/AI=6WC3P]<6T
M$\GFS1:I R1\-]XAL#\:]K_X7=\._P#H?/#/_@WM_P#XNOD;]F3]D'X+^(OA
MAJFL^)/#-LTEMXCUFV%S<7DL:I%%?3(@SO X50/PJOXL^&/P"EU1]"^'?PMN
M/B!KP.UA87,R6L'^T\KR*K+_ +A)H ^P#\;_ (= 9/CWPR .YU>W_P#BZZW3
M]1M-7LXKNQNH;RTE&Z.>WD#HX]0PX-?#_@S_ ()F>&M>UA=:\=P6UK;.,CPU
MHLTOV9/]Z1B),_1L<5]I^%?"VF>"O#]EHFCVWV33+*,100ABVQ1VR22?QH U
MJ*** /"_VL/^1=\*?]C!8_\ I1'7N8Z5X1^US<Q6?A7PQ//*D,,>O63O)(P"
MJ!<1DDD]*J^(?CQKWQ)UN?PO\)-/74&0F.\\4W:E;&S/?;GYG;TPK+[T >B?
M%7XU^&OA'IRRZM<M<ZC+Q;:39*9KRX/^Q$N6(Z<@8&17%_#'P[XJ\6_$P_$?
MQ!I*^'(;G3TM(=+>59)E0%R"Q!X/S],=JVOA9^SWI'@*\?7-7NI?%?C"?YKC
M6]2PS[NXC3[L8S_= [5ZQ0 4444 %%%<)\4?C/X9^$^FB;5[LRWTORVVFVJF
M6YN'/"JJ+DC)P,G ]30!YKH=U;? ?X\:EH]W.EGX5\9 WU@\C!8K>\1?WD0)
MX&Y4DD/U-2^)/C[K/Q$UBZ\+?"'3UU:\C.RY\372G^SK3L=K<"8^R-QBN1\0
M_!'QA^UJ=,U3X@3S>!_#=C<+=Z;H=CM-VQZ;IY.=NY2PPC=&Y[U]->&_"^E>
M$-)@TS1K"#3K&%0J0VZ!1]3CJ?<T ><?"[]GK2_!6H/XAUVZE\5^-+@?Z1K.
MH'<P_P!F-< *HR<<9YZUZT!@4M% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<[X!_P"16M?]Z7_T8U=%7.^ ?^16M?\ >E_]&-7F5/\
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MW.!RP&,FO'K?]L#X/W4\<,7CS1VDD8*JBZ3DGH.M>QJP=0RG*D9!% "T444
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MVI6X\#Z5)/Y6-6B(N54=7\DE6QSQZT ?6G_!/F^?4_V!/C!>2!5>X;6)BJ]
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M/X2MK?@3P=974?BBU?3TM/$$\JS3Y.U)";<;%/=AD^U>Y?\ ":?M/?\ 1-/
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M]I;V[WVJW>X6UJG\1 Y+'LH[GGBL"?Q/XL\/M#>:UI=D=,9@LYM+AGD@R<#
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MTO\ !/\ .F;Q_A2]5^IY?^T]8VU_>?#!+H1.@\41D)*F\,?L\W&*[SQ7\%/
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MK/P%H\.E_%/3;[3UB/D7'V-)MZ[V_C>/<WID^E=3_P ('\>?^BD:;_X+8?\
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M@H$D;J593B+.""1Q70?\(K^V5YF?^$N\ ;,=/+?_ .1Z?_PBW[9'_0V> /\
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M(K<I:1,SYD=4'#0 8RPKN9O#7[8\,,DA\6> <*I;B-^W_;O0!G_\,W_M2?\
M1Q$?_@O3_P"-55U7]GO]J#3M,O+N7]HR*&*"%Y6D.G*0H522<"+MBO-_@C^T
M[^T%^T%H>F:!X7UG18/&^G:MJ$6MW%_9A+3[*D<7V<Y$1P2_FC@>F:]?O/!W
M[8]W:3P'Q9\/\2HR'="[#D8Y!M\$>QH \C_8)\%>*O%7[2/CSQUXB^(5K\3+
M9=+32;O58K-K8R3?NRB[653A5C*\#M7Z,1QK$@1!M4# %?F]^ROXF\=?!?\
M:_\ B1X7^*GB'P\EOIWAN/5+\Z%9I:698^24D"I&@R%<@G')/>OK+X/_ +97
MPQ^-%AJEWI&NQ6<=A=/:L+]UC,@!XD7GE3V[^U '%>#[.WLOV=_CFEOY84C5
MF(C3: ?L5>[_  ?_ .23^#/^P-9_^B$KY[^'/B2P\4?LV_'*\TV[AO;;&K*)
M8/NG_0A7T)\'_P#DD_@S_L#6?_HA* .OK&\6^#M&\=Z+)I&O:?'J>G2,&>WE
M)"DCH>"#6S6)XRN-?M/#MW+X9M;*]UI5S!!J,CQPL?1F4$C\!0!Q _9@^%X
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MZAN*M%CD! ,# /J#UYKI?#O@?1O"[226%FL<\AW23,2S,>YY/&?;%;H4*
M .@%+3OV%;N%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.^ ?^16M?\
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M^(]/\6W_ (DOH-&UG6K+41!:Z2L5@WE*0 PW 0QJ>1SFO,?@3\/M"\!?M_\
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M6#3I;.<K;O)F.+V1?X1[5LT44[W ****0!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7.^ ?^16M?]Z7_ -&-715SO@'_ )%:U_WI?_1C5YE3_?Z7^"?Y
MTS>/\*7JOU.&_:0_9K\-?M.^%--\/>*)KF*PL;Y;]!;$ LZJRX/MAC7FJ_\
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M0?\ QVOE_P#X*3_M2?"CXH_LF^(O#WA3QQIFN:U/>V+QV5J7+LJ7",Q&5'0
MF@#J?AO_ ,$N?@OKWP\\,:I=6%X;F_TRUNYBMPX!=XE9C@-ZDUZ5\+_^"<OP
M@^$WCW2?%^C:9<?VQI<OGVTDL[D+)V;[W/XU[I\'/^21>!_^P'8_^DZ5V% !
M7,>$O^0WXH_Z_P ?^BDKIZYCPE_R&_%'_7^/_125Y.+_ -YPW^)_^D2.BG\%
M3T7YHZ>JNI^=_9]S]G_U_EG9GUQQ5JJFK+OTRZ'F^3F-OWF?N\=:]8YSYH^'
MWPY^/>I^#=,NM1^(\&F7DJ%I+06D)\KYCA<I&5Z8Z&NB_P"%5_&[_HJT'_@%
M'_\ &JYSX4?M9_"/P'\/=%\/ZE\1;34[_3XFAFN]LK^8V]CG=MYZX_"NL_X;
MA^"W_0[6G_?J3_XF@"*U^%WQJCN8GE^*<,D2L"Z?8X_F&>1_JJ]Z0%4 8[B!
MR?6O#[;]MGX,W=Q%!%XUM6DD8(H\J3DG@?PU[@CB1 RG*D9!H =1110!XE\(
MH%NOBY\8X6)"R2V*$CT,<PKQGPM_P2D^$7A^XOYKJ?5-7:[E\TB>8QA#DG V
M$9Z]Z]J^#/\ R63XN_\ 7Q8?^@35[30!^9/[=G[ 'PV^&G[.NO\ BWPZ+ZQU
M'27BE1#.TB2[Y%0A@Q/9L\5]O_LS^'=,L?@7\/)X;"V2X.@V3><(EWY,"$_-
MC->;?\%+9E@_8S\>NX)7;:CCWN(Z]8_9OD67X!?#PJ<C^P+$?^2Z4 >D5Y5^
MT/\ &?0_V=?AW-XQU70[C6+=+F"S^S:?&AF9I9!&N-V,\MTKU6OG+]NNUEU#
MX1Z/;VR&:=?$VCSF->H1+V)G;Z  F@#S^W_X*1:-%$HA^$?CE(R,@)IZ@?I4
MG_#R;2O^B3>//_  ?XU]?:2P;2K(CD&%"/\ OD5;H _-[XU_\%!_"6K>(/!]
MQ=_"GQFNMVUQ(-,$UNB,9&V9"!F&3PO2O68_^"B%KID4=M-\+_&NHRHHW7-O
M8X1SC/ ;!XSC\*S_ -NQPG[1_P"RP#W\3R?^AV]?;% 'YM_M1?MFGXP?#)M
MTWX5^-;6Y:\MIM]Q9 KA)48CC/85[_\ "G]N+2?BO\4K3P(?AKXIT.ZFB8_;
M=1MD-M& 0-I921SG]*^I" P((R#P17S%\1?B<OPW_:P^&O@NQ68VWB2&ZDG$
M0R(F#Q;01TVG>>>V.G- 'TW%#' FR*-8U_NH,"GT44 ?F7\5_P!F?PU^TQ_P
M4N\<:#XGN+F*R@\-6EZHMCABZQ0*/PPQKU&7_@D;\(YP1+J&LRACEM\V<_7F
MI_!%RC?\%8/B'",[U\&VQ/\ WS;5]N4 ?.FE_L[^&?V:/V5_B+X6\+><UC+H
M^I7<CSMEFD-JRD_DHKUSX/\ _))_!G_8&L__ $0E5?CM_P D1^(/_8O:A_Z3
M25:^#_\ R2?P9_V!K/\ ]$)0!U]8OC";7;?P_=2>&X+*XUA5S!%J!80L?]K;
MS6U574M3M=(LY+N]G2VMHQEY9#A5'O0!X=_PD?[1/_0N>!_^_P!=?XT?\)'^
MT3_T+G@?_O\ 77^->F_\+;\&_P#0R:?_ -_A1_PMOP;_ -#)I_\ W^% 'QW^
MTG<_&S7O&'PDL]8M?"^@SR>*+5;*]T]IW,<V3M+!\C'X5]$^ OV8=$T/4_[>
M\6WUSX[\4/R]_JYW1J?]B$8C7'J%S7GW[2'C?0?$OQ(^"$&E:K;7\R^,+-BD
M#[B!D\U]54 -CC2&-4C5411@*HP /84ZBB@ HJO?ZA;:7:275Y/';6\8W/+*
MVU5'UKY_UKXX>)_B]J<N@?""S5[)',5YXNODQ:P#^(0C!\QP.Q"CIS0!Z)\5
M/CEX<^%5LL=W*^HZW/\ +::/8J9;F=ST&!]T>[8'O7FVG_"KQG\?+RWUKXFW
M$N@>&P0\'@RREV[AV-S(IR6QV5]O)XZ5WOPJ^ &A?#6XEU:>6;Q#XJN?FN=<
MU(F6=B>H0L28T_V5.*]0H H:)H6G^&]-AT_2[*"PLH1A(+= BK^ J_110 44
M5Y[\4_CCX;^%-O%'?RR7^L7)V6>CV"B2ZN7[*BY ].I'6@#NKZ_MM,M)+J\N
M(K6VC!9Y9G"JH]23TKP+7?CGXC^*NL7/AGX26 GB0F.\\67J%;.U]1&#R[^A
M"LM5K'X6^-?C_<1ZG\3YWT#PP'$EKX2TZ9E,B]0;F0;2V>\9W+@>YKW_ $+0
M=.\,Z5;Z;I5E!I]A;J$BM[>,(BCV XH \Z^%7[/VB_#N9]6OYY?$_BRX^:YU
MS4OGE9N^P?=C'LH%>J444 %%%% !1110 4A('4XH/2O+?&.LW'BKX<ZC<F6;
M39+:]DB+6DS(P"2E <C!YX-*^J7FOQ=AI?U\CM?$/B.3P_J&F"6%3I]U)Y$D
M^>8W.-GX'G\JR_']K<6:V7B&P&ZXTYMTJCH\!X?/KA=Q%<CJ/BJ"&>Y\$^*K
MQ9TN(]EOJL(Y&>!OQ]QO3!/>MC0[_P 6:[:PZ4]E_9L4 \NZU"Y0.LZ^D:GA
M@1@$G&.:-U>/JG_7;KY/J+;27S_KSZ>G0VO%6K:)K7AZ.UNKI!_:**;=0"[!
MN&4X4$C! YJIH7@K5[F:TN?$VIK>26@ AM[0LD1(X#MT)8]QTYK3\+?#W2/"
M3R2VD<DUPY)\ZYD,C)DY(0G[JY[#BNFJM$[K^OZ[BU:LPHHHI#"BBB@ HHHH
M **\T^*OQY\/_# PV#>;K/B6[^6RT/3U$EQ.WTR !ZDFD^#7_"Q-3&I:YX]:
MTT[[=L^QZ#:#>+%!G.Z0@%F.1D$<;>O- 'IE%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5SO@'_ )%:U_WI?_1C5T5<[X!_Y%:U_P!Z7_T8U>94_P!_I?X)_G3-
MX_PI>J_4Z*BBBO3,#Y)N@#_P4PA/<>"(?_1EU7UM7Q5XC\0SZ;_P5:\+:7'&
MC0ZEX)82NV=R^7]I88_&OM6@ I"H8$$ @]0:6B@!L<21+A$5!Z*,4ZBB@!JH
MJ9VJ%R<G Q3J** &O&LJ%74.IZAAD&OG_P#;+\->$;;X,ZOXK\3>%M-\3Z?X
M:A^V#3+^$/&_S!>!V/S=:^@J\#_;T_Y,_P#BC_V"O_:J4 1_ SX1_"GXA?!W
MP=XEM?AUH>G6VJZ9#=QVB6PQ$K*"%'TKQ7_@I7\%_ WA']D?Q1J>B^%M,TW4
M(KFS"7-O %=09U!P?<5]"?L9_P#)J7PI_P"Q=M/_ $6*\I_X*L2O#^Q;XK9
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M[_U\6'_H$U>TT ?+W_!2X@?L9^/<\?+;?^E$=>L_LW!E^ /P\WMN/]@6//\
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M8D;S(BRD!U)/49R/I6-X _X)M? ?P=X6M=)O_ ]AXDN82Q;4=3!>>3)R-Q!
MXZ=*^I** / 5_8*^ *@!?AAHH Z *_'_ (]7,^/_ /@FU\!_&/A>ZTJP\#6'
MARZF*E=2TU2D\>#D[221STZ5]244 9GAC0H?"_AK2=&MV9[?3K2*SC9SEBL:
M! 3[X%:=%% !7,>$O^0WXH_Z_P ?^BDKIZYCPE_R&_%'_7^/_125Y.+_ -YP
MW^)_^D2.BG\%3T7YHZ>J6L^5_9-WYQ(B\IMQ'7&*NU4U:7R-,NI/+\[;&Q\O
M&=W'2O6.<^4O@O\ "/QYJOPO\/W?A7XHW.G^'9H6:RM9;<EHX][<'D=\UVO_
M  I3XN_]%=F_\!C_ (U@?##]M'X;:=X"T>UU:+4?#NI11%)]+M= U!X[=@[?
M*K"$Y'?J>M=3_P -O?"7_H*ZQ_X3FH?_ !B@"*U^#'Q9AN8GD^+4LL:L"R&V
M/S#/(ZU[X@*H 3N(')]:\,MOVUOA3=W$4$>J:N9)&"*#X>U #).!R8*]S1Q(
M@9>A&10 ZBBB@#Q;X,_\ED^+O_7Q8?\ H$U>TUXM\&?^2R?%W_KXL/\ T":O
M:: /E[_@I=,D'[&7CUY,[=MJ./4W$>*]7_9KF\[X ?#QL;<:#8C!]H$KRO\
MX*4J'_8V\>AL8VVW4?\ 3Q'7K'[.0 ^ ?P[QQ_Q(+#_TG2@#T:OEC_@HUIEC
MJ/P(TP:C+Y-FOB;25F9G"KL:\B#%CZ 9KZGKD?BA\*/"OQF\*R^&_&.E)K.B
MR2QS-:O*\8+HP93E"#P0#UH M^ =<T76O"^G_P!A:E::G9VT$<'F6<ZRJNU
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MP4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXS7NR$L@)7:2.1Z5D+XT\/NP5==TPL> !>1\_K6P"",CD4 +1110!XM\&?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,<V*]LKP'QY%+\*?VA/#WB^+$/A_Q2JZ-JN. ;OC[,Y]@JS<^]>^@A@".0:
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M[+2[&WT^TC "PVT811CZ?SJ_110 4444 %%%% !1110 4444 %%%% !1110
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MA1_P@/AS_H"V?_?H5OT4?V;@?^?$/_ 5_D'MZO\ ._O9@?\ " ^'/^@+9_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#P.F:Y;Q-XIU_2H7_L
MCP7J&N3C[H%[:6\9_P"!/+D?]\T44 >2ZC#^T%\1+LQPC1/AAI9.'65AJ=TR
M_P"S)&Z!#^!J_IO[(?A._N8;_P ;WVJ_$'4T._S-?N1+$C?["A1M'L2:** /
M9-%\.Z9X=LX[73+""QMXQA(X4"@"M&BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
8@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ibio-20220930xex10d3006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20220930xex10d3006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (1 S$# 2(  A$! Q$!_\0
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M:*X;_A+?&G_0@_\ E9@_PH_X2WQI_P!"#_Y68/\ "@#N:*X;_A+?&G_0@_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0!'_ ,+M\%_]!K_R5G_^(H_X7;X+_P"@U_Y*S_\ Q%;G_"">&O\ H7M*_P#
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M/G220,5 W(2 55 <-_"3D%N #WVN&\)?\E/\??\ ;A_Z(:NX&<#/6N'\)?\
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MCR^X_P#*-0!ZM17E7_"1_&__ *)Y\/\ _P +R^_^4U'_  D?QO\ ^B>?#_\
M\+R^_P#E-0!ZK17E7_"1_&__ *)Y\/\ _P +R^_^4U'_  D?QO\ ^B>?#_\
M\+R^_P#E-0!ZK17E7_"1_&__ *)Y\/\ _P +R^_^4U'_  D?QO\ ^B>?#_\
M\+R^_P#E-0!ZK17E7_"1_&__ *)Y\/\ _P +R^_^4U'_  D?QO\ ^B>?#_\
M\+R^_P#E-0!ZK17E7_"1_&__ *)Y\/\ _P +R^_^4U'_  D?QO\ ^B>?#_\
M\+R^_P#E-0!ZK17E7_"1_&__ *)Y\/\ _P +R^_^4U'_  D?QO\ ^B>?#_\
M\+R^_P#E-0!ZK17E7_"1_&__ *)Y\/\ _P +R^_^4U'_  D?QO\ ^B>?#_\
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MHHT%]IEK+-<QXG02*9(Q$-O3< @)).-Q/3H >MH"J@%BQ P6/>N(\)?\E/\
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M"7_)3_'W_;A_Z(:MSQW_ ,B/XA_[!UQ_Z*:@ \"?\B/X>_[!UO\ ^BEHO/\
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M]F1-Z'S.6S<0S X)/5< ,P]DL/"^C:5<K<V6D6-G<*K()K>V1'"D@L,@9P2
M2.^!4$W@?PY<69M)?#^ERVI))@>RC*$G;D[2N.=B?]\+Z"@#S_Q,&TNPBBO?
M'][:S^'W>ZU*=;.8M-'-,K0[UC89&,QC&0V) H7:0MOS[&^UZ._T[QKJ(L[J
M]CN!;P)-<6[*\\$2QESN5$:2VG5=I4'SFQE00WH$OA[2I[5K:73+.2V>..%H
M7MT*&-"3&A&,;5)) Z DXJI<>"/#EVB)/H&ES*A)59+.-@I+ESC*_P!]F;ZD
MGJ: /-6UFV\&Z-#INI_$.YFGM=/ODN[Z:PN)'.9!")RP<A&CEC91DG=NP,9!
M,8B71$MWNOB5>"#Q#SIT<UO<%0SW%JBJC&0N/O+'M+ XE9@1B1CZ9=>!/#5]
M-+-<^'M*N)9=YDDELHF9]WWLDKSGOZU:E\+Z-<?8/-TFQD_L]M]GOMD/V9O6
M/CY#P.1B@#QFQ\A[."W@^*&L/=VMO>375Q<6=UY<GG0^9$PRPP(XXGD1=S%A
MN(.*Z'3M9C\6>(=-N;'QK+<PW+17\-G9Z==(K1!H8W)/F8$9>"0?.,+YSYR<
M-7>P^!_#EM,\L7A_2XI7C,3NEE&&9"""I.WD$,1CT)]:L-X8T=I[6<Z38F:T
M1([>0VR;H50Y14./E"GH!T[4 >4V6HV,'AV]TYOB-J%W/JR2R6.J?9K@K!':
ML3/L<'!;Y7R=PRNS 88W45FL#+>7,7Q1U=)M/%ZVH6\T%Q^Z+LBH1$2&01&1
M0,[LG=R-K >PIX2T.-8U71=/58U94 M8P%#((V XX!154^J@#H*C7P3X=1'1
M=!TQ4=2K*+.,!@65B#QSDHA^J*>PH \^N[U]"N+J.?QI<0/$L-TB-IE[+&BL
M4EY+2L9$,=G." WR[Y22!Q2ZI);>'(],L-<\>WT%_H^H1ZC/>30SP)=Q.LLI
M@8AA&ZL8IMH&[:J! I(Y](N_#6D7\0CN=*LKB-51 DMNC *FX(,$=%WO@=MS
M8ZFIKO1M/U"1GNK&VN7=-C--"KDKM=<$D=,22#'H[#^(T >7^&;0ZMK&;+Q]
MJ&JK>Z7=6UNOV>?R<Q3-$9PX<)O3=$IP07*[QC>,9FD^)M*AAF@NOB)?7<=M
M;07<JFRNXIA"SVYWLV[=AUB.",$?:';D&O8;#0=,TIE:RTZTLRBE%,$"IA2$
M! P.F(XQ]$7T%9T7@#PO K+%X;TB-601D)8Q %0<A>%Z \@>M '">#=?TOPM
M>ZC->>.KG5[2*.WMY$OH+@K;M&(K=VWNS %I65V)Z>9DG&6JU;?#G5M2TB\E
MTWX@:L+/4W:[LW??)]GBDE@E159G\PX2-TY;I*<!>0W;P^#/#]O([Q:%IL;N
M-K,EI&"PW!\'C^\JM]5!ZBM*QL+;3+.&TL[>*TM85"1P0($1%'0*HX ]A0 ^
MWC:&WBC=S(ZJ%+G^(@=:DHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /*O$WQVA\/KJ/EZ9'?26MU+;"UBNF>Y'E)<,[RPQQ.\8;[,Q0X8,K!B4 .
M)=2^-Z:=J5W:R:*T<=J7WSS7D:K.56.3RK?&?-F:*>!U3@,6=0V4.9WC\?7U
M_K\/F7.GVRZE9G3[J+['^\M3<%;@!&5\!8<-ESN9N@7E*QQ-\67U'3BML%LU
M6*2^\Z2T5C+YT0F2$*&W0B,RE S1R'!W.#M# 'L-%>3Z#JGQ4?7(/[9T6*.Q
M:\1E^Q7=N42VD):03EAO+PJR(HB #%&8LP(!ZGX73>*)O"ZMXOMYK;6M_P"\
M266WD'W%SL\D !=V[ ;+>I/% &3JWQFM-(\;R^&IM+N?M O(+6*XW#RIO,-L
M&93ZH;N/<#V*XSGC&F^/<^FZE):ZCX<91&;@,UC<O/GRFO$P"843<S64@"LR
MD[TV[CD"YXRN?B1'K&LC0+.XGM!+$+7Y[-(S#_HWF&-G)<2Y-U_K%*84$#.
MU/7KGXM*\RZ39Q- ;!?):=[9I5N#;;SO.54E9H#$=H"G[:K#Y8C@ BUG]H_3
MM!M;V6ZL[:3[&A9WM;XS179*,RBT=8_WP&W;(S!!&3CYC@'5TGXXV>HZQH>G
MM8;O[62/R;RSF,ML)'DN%$>YD1MVVV=N5&<,/X1N/A^_Q%?Q+N\1V\D.B%)4
M5+BXM)9E8+"49A#&@Y8SC<"> H*#[Y].H ***X31?CM\.O$7B./0=+\;Z#?Z
MO+(\,5I;ZA&[32)G?''@X=UP=RKDK@Y H Q?&7_)6+?_ +!UA_Z=(:/V3O\
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M06XZ\ GCB@#S_P#X2FT_Z);I7_(._M;_ %UO_P >O_/3_5?^._>]J]5\"?\
M(C^'O^P=;_\ HI:\YLYI8_L.S4OLNSP&73YI!]F;Y/WOR@XS@<KEOW?3A<^C
M>!/^1'\/?]@ZW_\ 12T ;M%%% !1110 4444 87B'_D+^&/^PB__ *27%1^!
M@&T:XE,1ADEU&]>16QNS]ID'S$$@D  =3T':JOCW6[+PX_A[4=1F^SV<.HGS
M)-C-C-M.HX4$]2.U1> /$VDZCI.(-0MWDN+V\EBB,@61E:YE93L.&Y!!Z=Z
M.HO=/M=2B$5Y;0W48;<$GC#@'UP>_)_.I8HDMXDBB18XT4*J(,!0.@ ["GT4
M 0W5I!?0-!<PQW$+8W1RJ&4X.1D'W%4/^$3T3_H#:?\ ^ J?X5JT4 <5;^ M
M U35-8:?38_W5RL:+$S1*J^1$V JD#JQ/XUD:YIMAX7L_&UC80^3%)H:2"!7
M+,6/VE6;YCG  7/H!6EJ'B:;2-;UJVMV@A*R_:IY[F-Y%1!! H 5.22S#)[
M$\US1\6_\)7I/C*Y2!8[M=!2*16!"\?:2Y4C/9A@'OQVS0!Z\"& (.0>17#^
M$O\ DI_C[_MP_P#1#5W-<-X2_P"2G^/O^W#_ -$-0!N>._\ D1_$/_8.N/\
MT4U'@3_D1_#W_8.M_P#T4M'CO_D1_$/_ &#KC_T4U'@3_D1_#W_8.M__ $4M
M !>?\CQI/_8.O?\ T;:UNUA7G_(\:3_V#KW_ -&VM;M '#?!+_DF&B_]MO\
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MD@G'FEBG0C(4D9SM-1:5JGCEHYQJ&DV:R+IOFQF$*%:\\J(^7S,>/,:9<'
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MC[5D<'G)/X5;U;QMX@UG2KW3YM(UA8;J%X':/PS(&"LI4D9NCS@T >A^!/\
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M2'1/?I_P_P MS[>69X/W\0DN:4;<MGS)V:LG:W)9V^)OET273J?!O_((N/\
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MIJ:-XQL(;>XO6AGL+IY([F]FG4LLEN%.)';! =N1ZT =/1110 4444 %%%%
M'#>$O^2G^/O^W#_T0U=S7RQ\0_C5X&^$W[5&EV_C+Q/8>&CJ1?[/-J4GE0';
M9J"7E(V1C+* 7902<#)KU+_AK'X(?]%D^'__ (5%C_\ ': /5:*^:7^.,GQ1
MF\0>(?#GQ'M-%^'>D:M_8=MJ/AF&TU&:^N4MEGFEEFE$D20J&VK&B[WVY#$R
M(M>K?"7Q9KFLGQ+H'B=[2Y\0^&=1%A<7UA$88;Z-X(IX9Q&68QL4F"LFX@.C
M8^4K0!Z!16!XZ36)/"UXNA&3^T=T6! 4$S1>8OG"(R?()3%Y@0OA0Q7) S7
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M"9"Q=,Q*I9F(6-AG+DBKI?PVUS3(](4^-]3NC93^9,]R&<W:%H&:-\OT_<N
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M']B$_,[EV/-GW9B?QJ?^T?\ J8/%?_@C_P#N.NYHH X;^T?^I@\5_P#@C_\
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MBV0>F'0YZ8=3W%9=IX \.Q:A=:G#INR[O9(YYI6>0,S+*)E.TGY?G 8@ 9P
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M3C(;&O>:5J]YX<32+/Q]"FL7%Y]I6X%XID&F2,T$1CP,E_*>-PY!#3C[V",
M%/0OBIXVU'6-"L]1\'7FD1W#*MY.NG3W$:$K PPVY!&")FRS;MC1LI!*DUU=
MQKTWB7X0ZAJ%U97&G7LVCRM<VES;R0-%*8"73;(H; )(ST..M<196.MLUS-?
M^/=,_MR[TJ[EMXK?6I!;Q3RVMNR2)%P&AC<7;*Q4D(T;<D?+U^^[F^%_B>>[
MUFTUX307TD-[8G,1BVN%48) VX((!/(/- &-X2U[4_#[Z_Y>DFY6[UB[N?N7
M9V'?L*YCMI$;!0\AN_;%;<_Q"UB&"21/#CSNJEA%&E\&<@=!FS R>G) ]ZX#
MPQXIBU/XM>$Q#K6L6L.H0W]TFCK&/LDJM/>L&E(FX< =-C<HO/I[Y79B,,\.
MJ;;OSQ4MFNK77?;=:$IWN9%EXDMY?"]EK=U_H<%Q;Q7#+DOY>\*0,@9/+ 9Q
M6O7C^O\ B70?#?@[3M&\=^*- \%65O9Q0.FJ:M!#)-*L8 )+.JJH8!@ 23@=
M!U9HG[47A'7-/C_LJ#7O%&H*H69/#OA^]O(!)T.+A8O) /5=T@R.1WKC*.Q\
M9?$0>%M7M=.ALOMLK6TEW<R,TJI:PKP)'V12':2&&0.,#. <U\>P^ O%OAVZ
M\5C2_B/X*AT+Q/KMWX@6SU3PYJLT@6:_ENO*\V.>(.@D9D+!5SM[$<>TZCXV
M\9^*_BI<6VF_"F^B2Z\.M;/'XIUFUT^-XFG(9]ULUU(J\X^X&Z\="9+GX%>.
M/$\-K'>2>"O"EO;Q>3'!9V^H:O+&A9G(69[BV7.]V.6A;KC'3&4_:?8M\ST,
M,L&U_M3DG?[*3TMYM:W_  /%=.\)^/QXUL=:L_B5\/9-1AE_T.T3PGK#1H[R
MHY"I]KRQ;RT7!)XZ8;##@_A9\)M;_9]^'-GX(M/C+X ET6ZO8XXAK/AW4UEN
M9O.:=80R74>[<0WRJ,D*<<C-?5>E?L=Z7%>Q7FK>._%VHRQN)%@L[N+3H8V!
MR"AMXDF&,<9E8^]6)_V%_@C>7^EW]YX-EU"_TRZCO+2[O]:U"YFCE0Y4[Y)V
M9AGDJ202 2#@5,?:_:M^)I567I_N7-[;J*ZZ[-]-O,\!N_"OCB\NY)V^)WP[
M7,IFBB3PMJ^R%B'&5'VSD?.#AMP/EKG(W!L_PC\$_%?PTEU>V\/?$OPK#;R:
M+8:1?V^J^&]3F>/[-I=KI;R$QRQ;-_V=7VL#M9PN6P"?LS_A1O@C_H"?^3<_
M_P 75^?X4^%KFYU.>32]TNI9^UM]HE'F9D60_P 7'SJIXQTQTXJ4Z_5+[W_D
M=$HY3=<LJEO\,>Z_O=K_ #L?%W_"%>,E=C'\3/AW#$)FGAA7POK!2%VWY*YO
M"3RX.&+ [%!R-P/O7P<\73_#CP1%HVHZEHVNZE=7^JZY/?6<-]9PRM=W]S>2
MF*%H)2L:-+(O,C<1DD]<>D?\*-\$?] 3_P FY_\ XNK\?PI\+0_9]FEX^SVT
MMI%_I$ORQ2>9O7[W.?-DY/(W<'@8$Z_5+[W_ )!..4V]R52_G&/;_%WM\CE?
M^%]Z=_SUTG_P*N__ )$J1OCI9K DY_LP0NS(LAN;O:S  L ?L>"0&4D>X]:U
M_P#A1O@C_H"?^3<__P 75A_@WX/DL(;-M(S;0R/,B?:9N'<(&.=^>1&GY>YI
M7Q'9?>_\BG'*+JTZGG[L?_DNYR]UXSO+Z\O]4M)IK)85^SW9M?/>.(Q;B0Y?
M3FVE=Y)&1C/-0:9XZU/6_-_L[6KN_P#*QYGV56DV9SC.W3#C.#^1KU32="L=
M#^V?8H/(^V7+W<_SLV^5\;FY)QG X''M5^NE7MJ>+4Y.9^SO;SW/._ACXKU>
M\U'4=#\13//JD*K=P3M;/;B6 X4X1HD("MQDC)+''"YKT2N&_P":W_\ <N_^
MW-=1KNJ_V58EHP)+R4^5;0]Y)3T'T[D]@">U,S+&GZA;ZK:)=6LGFP.2%< C
M."0>ON#7+?%WQ#!X=\ ZHTHWO>1M91)DC+2*0><'&%W-SUVXSS5SPC;#PTI\
M/2REVB!FMI6&/.C8Y<^[*Y;([!D]:Q?C'8P:I8>&;.Z3S;:XUZUAE3)&Y&#@
MC(Y'!/2D[]"H\O,N;8P=/^+^G:)9RK%<:=<6<M[=20W,DEW'OWS-*5Q]E8;E
M$JY )ZCU%3_\+[T[_GKI/_@5=_\ R)71O\&_!\EA#9MI&;:&1YD3[3-P[A Q
MSOSR(T_+W-5_^%&^"/\ H"?^3<__ ,77,WB.B7WO_(]R,<HM[TZG_@,?E]KL
M9<WQM@MS<>;%I\7V>00S%Y[P>7(=WR-_H?#?*W!_NGT-4+_]HS0]*MFN;V^T
M.SMU(4S3WUTB D@ $FTQR2 /<UV5Y\*?"VH?;_M&E^9]NN1=W'^D2C?*-^&X
M;C_6/P,#GIP*XKXB?LB_"GXJ>&WT+Q)X8-]IK2I-Y:ZA<QD.IR"&60$=Q]":
MK]]?96^9@UEOLVU*IS=-(VO;J[WWOTV-/_A=D'G>3Y>G>;Y?G>7Y]YN\O9OW
MX^Q_=V?-GICGI5?_ (7WIW_/72?_  *N_P#Y$KS^/PY;_ ;4DC\=6<OB'P5Y
M'V"T\<*\@GTZ#R?(6'4XT(4((_D%VBA<8\U8R/,?U>W^"O@.[MXIX-)2:"50
M\<L=[,RNI&000^"".])NOT2^]_Y&D(Y5]N539;1COU^UMV*"?&R"62UC2/3G
MDNL>0BSWA,V6*C8/L?S?,"O'<$5''\<(KJ"Z>SMK'4'MH7N'BMI[MF"*.3S:
M  =!EB ,\D5TT'PI\+6USID\>E[9=-Q]D;[1*?+Q(T@_BY^=F/.>N.G%6/#7
MPX\.^#[^2\TC3OLER\9A9_/D?*$@D89B.JC\JI.M=72M\S*I'+N27LY3YNEU
M&V[W][M;;K<\[TW]HN75+^WM(?#1,LSA%Q=L^,GKM6$L<=> 3[&NAOOBZVF(
M[WEE:6BI((F:=[U K[0VTYL^NT@X]"#7I%>4^*/"6IS>*=9O5\-G7[:[EB*)
M+/'$B!8HP'1O,#*=ZD,NW#!5Y%;GDFQ!\2-0N3((=&CE,9"OL%^=I*A@#BRX
M.&4_0@]ZY[3/$7C;2K"&TA@TQHXEVAGTC5"Q]2?W74UU_P ,]"O-!TW4TO;4
MV;W-\UPD)" *ICC!"JCN%4,&"C.< 56_X7;X+_Z#7_DK/_\ $4 87_":>.!)
M$CIHL/FRI"K3:9J4:;G8*H+-& ,D@<GO7I&@ZG_;>AZ=J/E>3]KMH[CR]V[9
MO4-C.!G&>N*\_P#$WQ<\,:IIT-OIU[+J%Y]MM)([6"UE\R79<1N57<H!;"G
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M#!48 "C@"@#Y5\#?!C3KGXK_  [MCXC\8(MQI=R[/'XEO5D3#WO",),J/E'
M]3ZFOI8?LV>$+H8U:[\4^(X^?W&M>*M2NH"#V,+3^6WU92?>N%^&?V__ (3?
MX?>7_97]G_V=<^9YWV3[;N\V\_U>[]_M^[]SY?O?[5?1U>UF37)AK6_AK9_W
MI;]GY&<.OJ<EX1^$?@?P!)YGAGP=H/A^4Y)ETS38;=V)ZDLB@DGJ23D]ZV=2
MT)+R?[7;SR6&H!=HN8,98=E=3PX^O(R<$9K4HKQ30Y+3_#&JQ^/SKM[<V<\
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MUO+9K>)I7N9UC83-*N]<!_E58UDR1O\ FDCP&"MD YW_ (:Q^"'_ $63X?\
M_A46/_QVC_AK'X(?]%D^'_\ X5%C_P#':U-(USX@W'AR]GU#0+:TU97@\BV3
MRV!4S$2\"YPVV+# ETR21CCE?#&M_$&[EMAKN@6FGHUS(LIM627;$&4(>9QC
M*ER2 2-H^0YH RO^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VM%-=^(_V;P\7\-Z=]IN)_+U5%N%V6D?FPGS$;S,O^Z\\8 SOV?P@EB?7?
MB*NB.\7AZR?5&#B-&9!&C8@*EAY_*\W R#D[$)"Y- &=_P -8_!#_HLGP_\
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M',#N4EB ;=]\3?&T6GV\G_"(36<YOK6UN?\ 0Y[P0),))'D58\-*L4?D!F7
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M0B,KLXY);@BO8:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\J_:._Y$>Q_["*?^BI:]5KRK]H[_D1['_L(I_Z*EH ]5HHHH **** .6^(-
M_'IVGZ9++K4NB1+J$,LDD5L\WGQQ[I9(FV<HI2-B7Z *<Y!(/G^H7FE>+[F;
M5-/^(VKV0N8SJD<=M'.ELMM#!Y;@)Q\ID!=AN!/08)#5Z'X]FMX-.L#<^'&\
M3(;V,>0+<3?9QAM\^"K?=3?C RQ(4<M7&>"]5M]7UJWTV;X7CP_!]G6!IY;+
M:D:O$[.@/DA#'G*8W GS!E!\P !2EN+75-5=[?XBWELNKR306MOY%PH+,P9
MA9P RFXM<%=H:-&&"&=EDLI8(?&']MR?$6X_LNV87<VG2PSI;M%=R@V^YWD*
M@ 2(@P H &54[LVFUN*PMM+DM_AF',WVF[:."R=3:S1)"Z!LVX_>.P0 CC,(
MPS;>$O/%RZ4UA<V'PQN[D76GV\\CP6)CD@E6152!E,0/[O8"#VV(0 OS* 84
M5S::YXI2YL?BQ=M9WLES;VVGI#+M\V5D=55]X!,8NHMH()&&Q@(526]NK?4O
M QT^V^)>JV]\LL]W)K"6-P76$0SHT87/!"1R,N23OB+A20 .JTY]-6#0IE\
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M[=!D1L #FL'4/$,5I'+:'X3/-;W, EE"V.^*3=#!(R.%A)+;P$((Y,2G/!"
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MNMQZ###?W/ABYB-X+C4VM?M<OGS307Q-O D30!BLES>QR*3L8;\,-JA3T?\
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M !6%X[_Y$?Q#_P!@ZX_]%-6[6%X[_P"1'\0_]@ZX_P#134 ?.>@-!J7[1?\
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MR>+O^B$_$#_P.\/?_+6C_A<GB[_HA/Q _P# [P]_\M:/^$C^-_\ T3SX?_\
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MD;/J['N: ,FS^*/A>^M8[F+5%$,D\-M&TL,D?F22R-'&%#*"P+(XR,@;&R0
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M-#\7^+]#\+^']-T?P_JFE1Q:)X@N=3FGEN[G3I0Q$EC;!%5;%QG+$EQP,$T
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M>J_;/$O_ $"=*_\ !I+_ /(]4=&M_$ND6<D']FZ5+ON9[C=_:4JX\R9Y,?\
M'N>F_&>^,\4 <K_P@D/_ $+VJ_\ @%HG_P 36%XX\"LGA34I+70]0@EBC\TR
M3VVE1HJJ0SDM"!)]T-]WKTZ$UZK]L\2_] G2O_!I+_\ (]4=>M_$NMZ'J.G?
MV;I4/VNVDM_,_M*5MF]2N<?9QG&>F: .KHHHH X;XV_\DPUK_MC_ .CXZW/
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MI).21V]^G- 'E7PSUCR?&_P^T[^W-5@\W3KE_P"R84S93?O;SYY&\T8;Y?\
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MZ6[\-P:? DTUU;W$=Y,L<+LL<1650S.!M&2",$YX- 'K=%%% !1110 4444
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M2+Q-)I][J.EP6DMQY":1J-V$074$T8S+:Q9.PG (!&:/^%-^+O\ HNWQ _\
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M?\*;\7?]%V^('_@#X>_^55'_  IOQ=_T7;X@?^ /A[_Y55\J_P#"_P#X(?\
M/;X@?^']L?\ YJ:/^%__  0_Y[?$#_P_MC_\U- 'NO@#PAX\\5>*_B5IEW\<
M?'$=OX:\00Z59M#I_A\-)$VE:?>%I"=+(+>9=R#( &U4&,@D\9\0/@'\;/&_
MQPT+PS??$KQ)J7P26QCU34-3N4T);PZG#,SP0B)=/4/&&2!RKQNAP<G("U\9
M_LR?'SPJGQ<^.[^,]<\<:CH5QX@6;0H(?BQ%I;0Q!YXAYEQ+K=NMZWD0V<?F
MQRW VP)\^TH7^BO^%_\ P0_Y[?$#_P /[8__ #4T ?57_"F_%W_1=OB!_P"
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MX!%>UUY5XC_Y.G^'G_8F>)?_ $NT*@#U6BBB@#A/%6J:S_PE\.FZ;=RPK+%
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M6O\ MC_Z/CK<\"?\B/X>_P"P=;_^BEH W:*** "BBB@ HHHH **** "BBB@
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M L< G.00".FK+\5:C=Z/X8UB_P!/M&O[^ULYI[>T1"YFD5"RH%7DDD 8'/-
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M_P  ?#W_ ,JJ/^&:?"/_ $%_B!_X<?Q#_P#)U'_#-/A'_H+_ ! _\./XA_\
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M=X0\6Q_$FTU">=4T&UBF+Q#4)KAEW)M6(EXP'&XE]S'=R%&%0[_F99C76/\
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MOAT^1%=?;8])-_<G2HY]VX2K8&3[,K[L-N$6=P!ZC- %#PG\<-5-CX'B\8>
M_$'AJ[\0F"S;4)VL6LX[Q[=I=I$=TTRJS1LB[HP=S(&"YX]=KR_]IBVD'P7U
M[5[=&>Z\.-;^)850$LS6%Q'>%5 ZEA R8[[B.]>F6]Q%=V\4\,BRPRJ'21#E
M64C((/H10!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 <-\;?\
MDF&M?]L?_1\=;G@3_D1_#W_8.M__ $4M8?QM_P"28:U_VQ_]'QUN>!/^1'\/
M?]@ZW_\ 12T ;M<8WQB\()9K=OK BM2>99;:9%1<1'S')0;(\3PGS&PI$BG/
M-=G7S!>>,/AM=^"M-34_AX[6%M^ZBL;2*5Y(;=X;:7[0<HC9,AM(S*>"6R)&
M&[(![Q<_$OPU9:?+>W6J+9PQ([RBYBDBDC"-&K!XV4,IS-#@$ D2*0""#21_
M$SP[-KRZ+%>32ZDTCQK!'93MG9)Y3L&"8V+)\K/G:#P2*\FO/$'A'79O^$<N
MM$L];;[+<:NPM]=GO&O)1'<0[(Y@N9CL@"_O&780FT%HUQFP^*? NHZ]IOB"
MV\)ZI=ZM_:#BUD.I7+) T\BW"RE=QCBCD:?3Y&X"@7BYSL84 >XW?Q!T"PUQ
M](N-0$-^I9=CQ2!2RP^<RA]NTL(B'*@Y (..:L6?C+1+^^-G;ZE#+="=;8PJ
M3N\QH#.JX]X@6STX(Z@BO'?&VM^#7T[1_&&L>'-6$&O"6^69=2GB\B%845YR
MB2;48V*R2$*-Q2)T/+$47EQX=T/Q4I7P4]C<+=12W=Q8ZG/'=K<,8!C9$/WN
MTZPR@%ON[P!@(* /7)?'V@07$\,NHI$T,C0L\B.L;.JR,ZJY&URHADW;2=I0
M@X/%1W'Q(\,6C.LVM6L12XCM&#MC$LD/G1I]63D>IX'/%8>A^#?"OCW0H-7N
M-'F>WU!Y+O[#>W,SQQR.)5=A"S;$9O.E)PHY;)Y (L3?!/P3/#=Q/H,6V[#?
M:")9 TI(F7+,&R6 N9@K$Y7<-I&U< %W2OBGX6UUM-&F:JNI'45WVWV.&2;<
MN5!9MJG8 74$M@*3@XKH].U"WU;3[6^LY5GM+F)9H95Z.C %6'U!!KC-.^!W
M@G2+[3[RRT7[-<6#(ULT=W. A1(D4XWX/RP19R#DJ2<EF)ZCP[X=L?"ND6^F
M::DT=E;J$BCFN))RB@ !0TC,0   !G H TZ*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** .<UEV@\9^&Y!]R5+JV)]RB./_ $4:Z.N=
M\6R_9KSPY<8'R:FB$^@>*2/^;"NBH *S->\,:/XIMH[?6M)LM7@C?S$BOK=)
ME5L$9 8$ X)'T)'>M.B@"FFC:?'Y6RQME\F=[J/;"HV3/NWR#CAVWOEAR=[9
MZFJ5SX+\/WE[:WD^A:;-=VLK3V\\EI&SQ2,X=G5B,JQ<!B1R2 >HK9HH RM"
M\*Z+X6CECT71[#2(Y2#(MA:I '(Z$A0,XR:U:** ,+QW_P B/XA_[!UQ_P"B
MFJKX)GNKF?Q!+?6PL[MK]#) KAPA^R6_&X=:M>._^1'\0_\ 8.N/_134SPO"
MMOJ/B2),[$OXU7<Q8X%G;#DGD_4T ?/W[77[6DOP3U;3O"FA65E>Z]>6XNYY
M-04O%!$Q=4 0$;F8Q2'DX 7H=W'+_LC_ +:MU\5_&5MX*\06MB;J\@>6POM,
M@:)&9$WLDB\J"4!;C!& -O.1H_MI?LE:O\:=<TWQ9X9AAO\ 5;:Q.G7&GRSB
M$RQEB0\;$A=WSL#N88 &WJ<\O^Q]^Q5KOPS^(D7C3Q59QZ(VGB7['I<-TLWF
M2R(4,CA&:, *S8P=V<= .?4C'#_5^9VYOQ/@:M3-_P"V%"//[*ZZ>YR];OO;
MYW/MF]OK;3;9[F[N(K6W3&Z6=PB+DX&2>!R0/QJO:Z_IE[,(;?4;2XE;&(XI
MU9CG?C@'_IE)_P!^V_NG"ZSHMEXATV;3]0@%S9S;=\18KG#!AR"#U -<_IGP
MG\+:->VMW8::]G<V[I(DD-W,I+*GEKOP_P _REAAL_?<]68GRS[XWIO$&EV_
MV7S=2LXOM:A[??.@\Y2R("F3\P+2Q+D=Y$'5AF!/%VA2P33IK6G/#""99%NX
MRL8"LQW'/&%1VY[*Q[&LRX^&'AJ\@T"&XT][B/0G633Q-=3.82&5ER2^7 *(
M0&R!M7'05';_  I\+VK2F/3Y/WL7D.K7D[!D\IH0,%\<1NR ]0"<8H UF\8Z
M EVUJVN::+E'6)H3=Q[P[;@JE<YR=CX'?:WH:<OB[0FL8KT:UIYLI9?)CN!=
M1^6\F,[ V<%L G'6LE?A5X62&SB72]L=G,D]NJW$H$;JTS*1\W0&XFP.GS8Q
MA5P\?#+PXNC1Z5]BF-C'+YH0WDY8MY/D8+[]S+Y7R;22,<8H T_^$MT/[))=
M_P!LZ?\ 98]Q>?[5'L7:5#9;.!@N@/IN7U%/'B;1S;Q3C5K$P32K#'+]I3:\
MC+N5 <X+%>0!SCFL*[^$GA6^TQM.GTZ22S961HC>3C<I6-=I._)4"&+ Z#RU
MQC%+;_"7PM:V\%O%ITBP074=[%$;R<K'-'&8T=07P,(<8'!XSG H Z)=;TYK
MF.V%_:FXD<QI")EWLPWY4#.21Y4G'_3-O[IQ5;Q?H*)$[:WIP25G2-C=QX=D
M7<X'/)5?F('0<FJ9^'OA\ZNFJ?V>!?I<O=I,LT@*2OLWLH#8&[RUR!P<OD?.
M^Z3_ (0713I$.EO;2RV$.X10RW4K[ T+0E5)8D+Y;LH4' SD 'F@"Q)XOT**
M2Z1]:TY'M#MN%:[C!A.X+AQGY?F91SW('>BV\7Z#>RP16^MZ=/+<2-#"D5W&
MQDD499% /+  D@<@"L=/A)X23[;G1HYC?,'NS/+)(;DATD!D+,=_S1*?FS_%
M_>;-OP]\._#_ (6CC33+%K=8[IKU=UQ+(?.9'1G)=B22LCCGCGU H Z2BBB@
M HHHH **** "BBB@ K+UCPKHOB%6&JZ/8:F&,987EJDN3&6,>=P/W2[D>A8X
MZFM2B@#!N/ /AB\;=/X<TF=O)6WS)8Q-^Z4J53E?N@HA Z#:OH*OVN@Z99:=
M%I]OIUI;V$3B6.UB@58D</Y@8*!@$/\ -D?Q<]:OT4 8LG@GP[*MNKZ#ICK;
M-&\(:SC(B9 JH5XX*A% QT"C'054'PS\'JJ*/"FB (@C4#3H1M4$D*/EX&2>
M/<UTM% $-G9P:?:06MK!';6L"+%%#"@1(T PJJHX     K(\=_\ (C^(?^P=
M<?\ HIJW:PO'?_(C^(?^P=<?^BFH ^?O!]C;W'[3 OFU*V@N%O;\+ITJ3>?(
M"D_((0Q@#)ZN#\IXZ9^GJ^6_ 6LQ3_M&V\<VC6RWES=7LWVN4S"XM\I,2@7>
M$[$?,A/S'GICZDKW,SOR8:]_X:WM_-+:W3UU,X;OU"BBBO#-#YU_;)O_  5I
MS?!F3XAZ;;ZSX3E\<K;7&GW.D/JJW,LNCZI';QBU2.1I6,[PA55&.[:>V1S_
M /8G[,7_ $03_P PAJG_ ,K*Y_\ X*>7TVF> /@O>6^IV^BW%O\ %/19H]3N
M[N.TAM&6*Z(F>:2*9(E0C<7>*15 )*. 5/%?\+P\7?\ 1R_P_P#_  ZWA[_Y
ME: /5?[$_9B_Z()_YA#5/_E97FFDC]FB+]I+Q5I-S\(+<V\_A+2+K3]$;X1W
M[3!H[S4EN[A;3^S]Z*1+9(TVP*Q"+N)3"U?^%X>+O^CE_A__ .'6\/?_ #*U
MXI_PM3Q'_P -H?VQ_P +Q\'_ &__ (5_]D_X27_A8&C?8_+_ +1W_9/MO]@>
M1YN?WGD?9?,V_/Y^W]W0!]@?V)^S%_T03_S"&J?_ "LH_L3]F+_H@G_F$-4_
M^5E>5?\ "\/%W_1R_P /_P#PZWA[_P"96C_A>'B[_HY?X?\ _AUO#W_S*T '
MP=U7]EKQ'\0/C)91?"S3]>^P^)H1;V5G\*+Z]?3H!IEE"T3Q)I[-;?Z7;WX\
MMPA+K*VWYLGU7^Q/V8O^B"?^80U3_P"5E?!7[)OQ&UW0/C1^T%>67Q>\+^%;
MC4?$ FN-3U+QMI6G0ZNWVF]/G033Z+<I=+EV;?#%;+B53LPZK']0?\+P\7?]
M'+_#_P#\.MX>_P#F5H ]5_L3]F+_ *()_P"80U3_ .5E>/\ QX\5_LF?#[Q7
M\*)]8^'&C^#]-/B"YN-1&K_"V\TU;JR72KZ,C;+8)YZK<SV1**&VL8W(&W<+
M?_"\/%W_ $<O\/\ _P .MX>_^96OE#]M/Q]XE\5_$KX'RM\8?"WB?4K/5YFL
M=5T[QEIFJPZ-*9K,K-/);:58+;KN56W2^8"(F(V!&W@'GLOB[X2?&SQAXI^&
MEY-X7^'OA&;Q]?Z]H7Q!L_#$$$MMH@BU*4V<K PRNCN;(0Q$;EW,O2.*,?7W
M[!'P>\'?!?\ :ZT33?!/B:T\:Z;J?PBGU6X\1V(*PW]P^NB-F5"[[-BPQPE0
M1S$25#%A6'_P3V^#)\2:!JOQ7\ Z!H.I>,M$^*.H#S_$.KR1F;2?[)FA6W2[
MB@N.?,U$2,RIB7RU+$[4Q]2>%_"_C?\ X;ZTOQEXRTOP_HG]J?#._P!(M++0
MM8GU+_CTU6RE>21Y;2VV[OMR *%;[C$D9 H ^JJ*** .4N-!TS6_'&I?VCIU
MI?\ E:=:>7]J@639F6YSC<#C.!^0J]_P@GAK_H7M*_\  *+_ .)HL_\ D>-6
M_P"P=9?^C;JMV@#SNYT3POI7C&_AN/#UO+";"U>..VTAKA58R7 8XCC;:2 O
M)QG;WQQ;^S>"_P#H5O\ RVI__C-4?%VIW&G>.+GR-9M-(WZ=;9^U7T-MYF);
MCIYD$N[&>VW&1UR,4?\ A);_ /Z'+2O_  >VG_R#0!N?9O!?_0K?^6U/_P#&
M:QO%0\&P6-HL?A]+::6_M$3=H$L1D'GH70$Q#)*!_E')&1@]*9_PDM__ -#E
MI7_@]M/_ )!KF_&FN7ES_87F>)M/O/+U6"1?*U:WE\HC=B1MMJFU1W8[@,\J
M: /0/LW@O_H5O_+:G_\ C-'V;P7_ -"M_P"6U/\ _&:P_P#A);__ *'+2O\
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ME;V12>.E<G'\6_%?C%?^*'^'>HRVKY":QXP<Z):D?WEA9'NSZX:",'CYADD
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MM;QI_P! [_R0@_\ EA1_:WC3_H'?^2$'_P L* .YHKAO[6\:?] [_P D(/\
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MK)V;4F4_NXCU^R*>1Q,QRT0]FL[.WTZS@M+2".UM8(UBA@A0(D:*,*JJ.
M  .E 'DWBWX<Z#\,O@IK6EZ#:-#'))%<75U/(TUU>SM/'OGN)G)>61N[L2>
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MD"JOT XH 9IMA'I>GV]I$69(8P@9SEFP.I/<GJ:LT44 %%%% !1110 4444
M87CO_D1_$/\ V#KC_P!%-7/_  =25= O'FNKB]FFF@G>:ZD,DC,]G;.06/4
MM@>P%=!X[_Y$?Q#_ -@ZX_\ 135A_"/_ )%Z;_MT_P#3?:T <Q=B\?\ : OG
M,<DUS#I=L;$((BT=NTA$I3S2!M9]PE,?SX6#VS7LUUF#XI>#GU2../Q+<"X%
MWY#HQ;3!:9?S-BKD+>&$*&!QN;:[9-=1XWU3P)KNK?V-K\N[5--5[J-HEGBG
MM<1&1VCGB 9#Y8.=C D<<]*Q/"WC;X6>#7N9=*OC'=76W[1>W,=W<W4^W[OF
M3RAI'QDXW,<9/K7E2C%3UFK7OOYWM;\-S[ZG4JU,.G'#3<G3Y%:F[6<7%24K
M[/XK<NKZ]3TGQ#/J-MI,LFDVZW5\&0)&X!&TNH<X+("0I8@;AD@#-<A<:Y\0
MVTZ5[?P]8)=K>@(D\JX:T$;Y.%E($ID0$+NV@2H"W#,-2#XK>%KFYTR"/5-T
MNI8^R+]GE'F9D:,?P\?.K#G'3/3FJ'_"\O!'_0;_ /)2?_XBN]UJ2WDOO/DU
MEF.D[*A-_P#;K_R\F1C6/B&_A:VG70]/76S= 3VTS!5$'D%F*A9F&_S?D7+X
M(P3M!.VE;>(_B<VGV37'A:RCNGA3[0(98W\N5I@#M4SJ"JQ*Y/SY+.F. U=1
MX?\ B/X=\4S"+3-1^U2&18<>1(GSE)' ^91_#%(?^ ^XSL:WJL>@Z+J&IS1R
M30V5O)<O'" 7944L0N2!D@<9('O6D91FKQ=SDK4*N'GR5H.+[--/\3@[O7/B
M;YLHMO#NE[%-N5,DP.Y3;;IP,2CYA-\BY !')./FKTFO.I?CMX=C=E2#4)@+
M4W>4A4907+V^,,P(;?&QP0,#K@Y GU/XSZ'I6C:3JDT%Z;74X9KBWVK&',<;
MHN[:7!;=YB$;<_*=QP 35&!WU%<-IOQE\-:KKZZ3%<.DSW7V.*:4*L,TF)#B
M-MWS\1J>,_ZZ+^]Q+J/Q8T;2X+V::*[=+2YEM7$"+,^^-)G8E$8LJXMWP7"C
MH>F2 #M**\WA^/7ANYW"&'4)&^SRW*+Y"J9%1)Y,#+##,D&]0V,K)&>F[;-X
M<^.7AGQ/K,FG6K7,,BWHT\2W2+$C2E'< 9;=SL(P0#D@8H ]"HKSJY^.OAZR
MU.\L;FWU*":UEGB9I+<!6$1=6D4[N4+IY:G^)W51SNQ-J'QJT/3;CR)+>\ED
M%DE__HYAF7RVF:$ ,LA4MN0D@$X'?.10!W]%>?Z9\:]"UAL6EKJ,A+0*O[@#
M<9FVQXRW(RT&2.%%Q$20"Q7T"@ HHHH **** "BBB@ HHHH **** "BBB@ K
M"\=_\B/XA_[!UQ_Z*:MVO(=6\+:WI?A._DUZQA\06]O;J\D::_>J7" %G9'^
M5N1OP-N,8 )Q0!YG\/O^2R?#'_L$77_HR_KZJKY?^%E^8OB_X707FHZ:M]IC
ML;"VB06=\RRWY+R;91@J-H&8S_JP!@ &OJ"O<S.3E##76U-=_P":7=+\+KS,
MX;OU"BN=N)M4NO%-[:6E_';006=M,L<MN)5+/).&/!4](U'6K$&MW%E<Q6NK
MVZ6[2MLBNX6W02-GA3GE&/8'@] 2>*\,T-JBBN3\?^*-3\-6]FVFV2W+3.0\
MDB,Z)@K\N 0<D%B/79@ DC !UE%0V<SW%I!++$;>21%9HF.2A(R5/TZ5-0 4
M444 %%%% !1110 45S]GX<OK;QE?ZS)K5Q/8W$(BCTMMWE0MA/G'S8S\C=%'
MWSSZ]!0 4444 %%<YXU^(WA;X;Z>E]XJ\1:9X>M7;9')J-TD/FMT"H&(+L20
M JY))  KB$^-VL^+G$?@'X?:WKD+YVZQX@5M"TT>AS.AN7![-';NI SGD9 /
M6JYWQI\1?"_PYT];WQ1X@T[0;9SMC:_N4B,K=EC4G+L<@!5!))  KS*3PK\2
MO']Q+#JOCE=+LE;;+;>$;;[' ISAHVNY?,GF8<Y:'[-@X&<@@S_#WX8:%\._
MBW+;V.G64MY+HQNI=5FA,]_*WG;/GNYVDN'&TD8:4CD\9)- %P?&OQ#XN&WP
M!\.=9UB%\;-8\39T'3N>AQ,C73#OE+9E(_BY%/B^&_Q!\8$OXS^(3Z99OUT;
MP/;?8$V_W9+R0R7#G_;B-N?:O6:* ..\%_!_P9\/;N6]T+P]:6NJ3+MGU:8-
M<7]P/^FMU*6FD_X&YKL:** "BBO(_$/Q4U?QOKE]X3^%ZVUY?V<OV;5O%=W&
M9=,T=_XHU (^U70'_+%&"H<>:R<*P!T'Q'^+=AX$N[/1;*RG\2^,]20OIWAO
M3R/M$Z@[3-(Q^6"!21NFDPHZ#<Q53D^#/A+?7GB*W\9_$2\MO$7B^#<=/M;=
M3_9NA*PP4M(VY:0CAKEQYC9('EH?+KH/AO\ "S2/AI:7C6LEUJNMZBXFU37]
M4D$U_J,H& TLF!\J@D+&H6-!\J*HXK<\+:/<Z#H5K87FHRZM<Q;M]Y/G?)EB
MPSEF/ ('7M0!K4444 <-\;?^28:U_P!L?_1\=;G@3_D1_#W_ &#K?_T4M><_
MM&S2K8Z- NI?8X)O/\VV+2!9]H1ER%!!PP &[H7!Z;B/1O G_(C^'O\ L'6_
M_HI: -VBBB@ HHHH **** "BBB@ HHHH **** "N;_X2FY_X27^S_L$7V/[;
M]A^T_:3YF_[+]HSY>S&W'R_>SGM725QO_" W/_"P/^$B_MJ7['YGG?V7Y9\O
M?]G\G=G?C..^W..* .RHHHH **** "BBB@ HHHH **** "BBB@ K"\9?\@BW
M_P"PC8?^E<-;M<Q\2+.34/"DEK#<-:33W=G$EPF=T3-<Q ,,$'()SU'3K0!R
M/P&_Y!"?]@Z'_P!*[VO5:\J^ W_((3_L'0_^E=[7JM !1110 45Y_P#%3P-X
MA\9PLF@^()M ;^R-0M \$@4O/,(A"6W1OA 4?++AUR-IY-<_KWPY\9ZG/=0)
M=V4NGQSW,L*RZE/&;Q)M1MKHQ2@1'RPD44T((+Y$@X4$B@#V"BOGVS^"WCR&
M#6D_M2SM;B[EOY+:[CUJ[D>"":SEBM[+!B&8XI7C<29R/*!" GCL[KP5XIUC
MXD:/XDOEL8+.VM8H9+&WU1G6.199BSJ'M?GW(\?0Q'*X)( - 'I]%%% &%X[
M_P"1'\0_]@ZX_P#135S_ ,')XKGPY.\4B2H&MD+(P(#+8VJL..X((([$&I/C
M#ITE]X3:1;/[;%:^?/*OR?(/LLZK)AB,[79#QD\9 )%<SX!TFYU/199+#1EM
M#Y@:5AKMS9B9WBCD$GDP*44%'3@'CIVH [74KKP0FO727\WA]=:$3&X6Y:#[
M2(_*);>#\VWRLYSQM]JQ?[1^$_\ S\^#/^_EI3-%^"FAR.^IZ_8"^\17"3PW
M-VM_<R!HI%>+8"S#.(6"9(SQG.>:B_X9N^'/_0N_^3US_P#'*]>G2REI>U<[
MV5[1COUWEMVZFJQ.*CI&;^][=#9M+WX>S2:9):S^&9)/.^SV#PO;D^:&#;(B
M/X@TBMA><N#WK._M'X3_ //SX,_[^6E6]/\ @EX+TO\ LW[+HWE?V;=F^M?]
M*F/ESGR\OR_/^JCX.1\O3DYS/^&;OAS_ -"[_P"3US_\<JHTLGN^9U+?X8^?
M][M;\0^M8M;3?WLZ+PW=>")IP- F\/O-YJ@?V:T!;S-DFW[G\6P38[[0_;-=
M57(>%_A)X3\&7 GT;2OL<HF6<-]IE?YUCDC!^9S_  S2C'3YO4#'7UY^(CAH
MSMA;\O\ >23_  ;1$JE2H^:J[O[S,L/$^CZJJM9:M8WBL0 ;>Y1P20Q'0^B.
M?HK>AJ1=?TQ]/:_74;1K%0K-<B=?* 95926SCD.I'J&![BO'-$L+!O#.L7I^
M'.L6EW;VL<2V%Q>73M=HXEMPJL022D)(R5R@?'"X8S65W-I,,]C#\-]7M],O
MY)IQY.H7#!6M2ODE4 S 7V($ V<(,9 KF)/5Y/%>B0P"9]8T](2K.)&ND"E5
M#ECG/0"*4D]A&_\ =."Z\6:'8;OM.LZ?;[2H;S;I%P2SJ,Y/=HY%'NC#L:\K
MU_PKH-C!IVH1> ;G5+R^BNQ</;37@EC.6<[V,8<M(SLNYPI(8CYDS65XKT#2
M'T"UNH/A;?:K!::J;"&V%S=P3+!O:9+A4"%O++RN2IP%.T?P@* >W7/B'2K*
MTCNKC4[."UDD,*32W"*C.,Y4,3@D;6XZ_*?2H[WQ3HNFF47>KV%J8G,<GG7*
M)L8*K%3D\$*RL1Z,#W%97_"O?#^I:)#976FO):FX;4%@GN)7,,\@;<REFRI_
M>.1C&TG( /-1W?PJ\,7C:@SV$J'4!.+OR;R>(3"8YEW!7&=W /LJCHH  -NV
M\2Z1>3K#!JME/,P!6..X1F(*[@0 ?[H)^@S4;>+=#CLY+MM9T];2.,2O.;J,
M(J$*0Q;. ")$(/3#KZBLB/X4>%8II)5TH>8]HUDS&>4GR601E?O<'8-NX<@9
MP>34S_#7PT^FW>GG2T%I=0PV\L:RN-T<4CR1)D-D*K.V ,8!"]   #6G\1:3
M:H7FU.SA0,%+27"* 264#D]<HX^J,.QJ&]\7Z%ILHCN]:TZUD*NVR>[C0X4E
M6.">@*L#Z$'TK+MOA=X;LFMVM;.XM#;C;"+>^N(Q&-TK<!9 !S/,!Z!RHXP*
M@U;X0^%-=ENY+[3I9S=K)',OVVX575Y/-9=H<#'F?/C& W(P: .B@\0Z5<W<
M%K#J=G+<SQ>=%"DZ,\D?/SJH.2ORMR..#Z5H5@67@71=.O[&\M[5TGL85@M\
MW$K*B*) OREMI($TH#$$X<C-;] !1110 4444 %%%% !1574M4L]&LWN]0NX
M+&U3 :>YD6-%R<#+$@#)(%5XO$VCSW,]O'JMC)<6\GE31)<H7C?#':PSD'".
M<'LK>AH TJ*Q$\<>')+TV:>(-+:[$H@-N+V,R>83@)MW9W$]NM6+/Q1HVHM*
MMIJUC=&)ML@AN4?8=I;!P>#M5C]%)[4 :=87CO\ Y$?Q#_V#KC_T4U2R^,=
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MH:E?G4-MM/)+%;[X(0\,9< ^6LJRA>/N[20"2!V=% !1110!A>._^1'\0_\
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MO[$NKN[GUB6WD$L,7^D "U@$BJ6C7S"5 0,HR:\,^@/=**** "BBB@ HHHH
M**\G_:9_:2\+?LL_#"Y\9^*?/N(_.6TLM/M #/>7# E8UR0 ,*S,QZ*I/)P#
M\D_ ?_@L9X1^*?Q)TOPKXI\#W/@:WU69;2UU8:JM]"L[L%03#R8C&A)QO&X
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M_A4>D_\ /;_RFZ?_ /(U '<T5PW_  J/2?\ GM_Y3=/_ /D:C_A4>D_\]O\
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MA=Z=]JMM7MYUD2>82@;%97Y5H]V' (!&>>E.L[GQFPMS<0:<-T6956(@J[7
M"8_?'[D&XN.[XVL1D  T?&_A@>,O"U_H[21Q?:0H#RH[*I5U8$A'1NJ]5=6'
M4$$5YK9?L^WMKITFGOXEMWLI9)[J0)I>R3[1)8RV0((EQY8CD4[2"[,A+2$L
M:[KP!?>,=2@NYO%FGV.E.LAC@M;3YV=0 ?,+B1A@Y(VX!!4\G(K/^!?Q?TGX
MZ_"SPYXRTF6U U*QMKB[L[6[6Y%A<201RR6SR #+Q^8%.0IR.0.E &-XF^!$
M.NM/+;ZA;VEQ+J<&HL[6C_-Y=F;8H3%-&_))?(<<\$$9SVOB3P3I_C/P)?\
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MQ.!Q\J^@K,D^'_A>:X2>3PYI+S);&S61K&(LL!5E,0.W[FUW&WIAF'<T /\
M!OB.;Q5H<>H3:=/I;N[*+>X1T< =\.B'GZ5N50T;0=,\.6?V32=.M-+M-Q?R
M+*!88]QZG:H SP.:OT 87CO_ )$?Q#_V#KC_ -%-1X>_Y"_B?_L(I_Z26]'C
MO_D1_$/_ &#KC_T4U8?PEN+V\T?4+K4;O[;>7-S#<23>6L>=]G;L!M7C@$+G
MOC/>@#N:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7 D7Y.CT7P&ND:'(/$MU#J\[*+XHDCQ6A:-SO_U*DA7\K<%+'[X7?PU?K/\
MLD> +:'XI10216ES9)]OL]0M+^XA\UV$FH0/"T#$,X4*(V&TXV'=R&->V:=_
MP3B_9TTOQDOB6#X:6+7JS?:%MIKJXELUDW$Y^S-(8BO/W"I0 #"C%>CG$.2I
M2CS<WN_=[\E_P?F5DF"G@,(J%1ZW;TV5^BN>E_LU:QK7B#]GWX=:EXB%P-9N
M]!LYKAKQ]\[DQ*0\IP/WC+AFX'S$UZ5117@'OA6#X^\'67Q$\">(_"FI-(FG
M:[IMSI=RT1PXBFB:-ROOACBMZB@#Y\U+2_BUKMO#87?A/28O&$5JU@OC==98
MZ9&"CH;Q+$8D\W;)(1"5 !;9YQ7YJ]M\)>&K3P9X4T7P_8&0V.DV4-A;F5MS
M^7%&J+N/<X49K6HH \4;PKXR^'FI:W8Z1X8LO&WA74-8DUZPB.J_8;G3[J67
M[1*DH92LD7V@O*KJ=PWD%&VAC2T/]ES1_$4&OZ]X^@$WCGQ)=M?W][H6HW-N
MEBWDQP0QVTBE&_=10PJ)2H9F4MA<A1[Q10!Y+X+\=ZOX$U[3? ?Q%O5NM3NV
M:+0O%'E"*#6U4$^5* -L5ZJ@EHQA9 "\?1XX_6JP?''@?1?B/X8O?#_B"R6^
MTRZ W)N*/&ZD,DD;J0T<B, RNI#*R@@@BOC/]DV]_: ^*#:?:>-?&_CFPT"Y
M\+Z;K]AXRTZVT);.\:ZMX91:B*;39)"\?FNC.9&R8"Q"^8HH ]L_9QO(K[5=
M2DAL8-/3[7?#R;9I"N?(TOGYW8Y_&N[^)UGXMNM?\--H'VTZ5'Y[:BMDT08M
MNA\K(>>$XQYW(+8[J>,>+?L)WVJZQ\._#FK:T)3J6J:=_:$TTL0B\YI;#2',
M@4 ##$DC:,>E?5E84$U2BF>KFLXU,=5G#9NZZ_YGC_B<?$2_T$65E8ZG;WL.
MOW+R7D,MJ?M&GL]T81&/M,;853; AF1O][#"M[P!;^*(?$%T=>CU<*4FQ+-/
M:FQ*>8GV=4C5FE$@CR')(!?S.7!C(]"HK<\H*\F_9TF6+PQJ5A('CNX[M;AH
MG0J1')$GEMR.0P4D>V#W%>LUY5\%_P#D+ZY_V#M'_P#22@#U0D $DX I$=9$
M5T8,K#(8'((K*\57C6NBSQQ'_3+H?9K9>[2N,+^7WCZ!2>U1>#G\K1(=/<;;
MC30+*5#U^0 *W_ DVM_P*@";Q)XITOPC8I>:M=?9+9Y!$K^6SY8@D#"@GHI_
M*M:O(_CG;)=ZEH*.%(%EJDGSH&&5M@PX/?(&#V.".17KE !7F]OX3\<1Z?XR
MB&L645WJ,MP=,NFN+F8Q1L9O*4J2%A*!X1F,$?(<AC@UZ110!Y#<?#SX@V,5
MPFF>*TFN$F,]M=WEU/M,> RVC0L),)YG/G%WDV?(<BH=:^'?Q'FT/3[6Q\30
MS7D"7D,ES<W]S"6'[J.SF_=*-SB.(O(K97S)7P&!!'LE% 'E<G@+QR+?18H_
M$L.;"[N)IV\^Y'VB-KJ&2)!EF(Q"LR?O3, 6'# _(GAOP9X[T_2=%AU34;:]
MNK>8O=F'6+M1*W[G;-N9&+8V39@PL;>8.F./5:* /(_ ?PV\;6>HP3^*/$HD
MMX;=(Y(+#4+R4W4ACE21F:1E$>2\;#:O!C!7R^=S].\"_$'3X$A/B.WN+7^S
MK:TDMI+NX,DDJ-$\TOVA@SJ92UW'D#*J86'*[1ZS10!Y1I7A/XA)<>&1?7EA
M]ET^ZN7NT&M7<KS1/<(\(+"*/S&CC#)B3*MG)'/'5_#C1?$&A:5?0>(KV.^N
M'O&DMY$N9)V$)1!AV=5^;>'.%55 (P!TKK** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** &2RI#&\DCK'&@+,[' 4#J2:Q8M7U'5]KZ9:
M1Q69Y6[O2P\P>J1@9(Z<L5]@:J^*]2T[^T]-TS4KRUM;24/<S+<RJ@E"%0L9
M#=068-[^61T)KH+6]M[Y-]M<17"?WHG##]* ,#2O#^M67B6XU.ZU6SN8;J)(
MIH(K%HB F[9M)E;'+L3G/I[CIJ** "BBB@ HHHH **** ,+QW_R(_B'_ +!U
MQ_Z*:L/X1_\ (O3?]NG_ *;[6MSQW_R(_B'_ +!UQ_Z*:L/X1_\ (O3?]NG_
M *;[6@#N:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KSC[#XAU/0_L>K)XEDDN+;RKM(#I8C8LN'"G[
MP7DX[XKT>B@#YUUSX"+J.L?VG:Z3XCTZZ\A+ 2:9K][I;&T2XGFCCD^QZM$L
MIC:ZGVEES\Y&1FM'XF?"&Z^+WVA/$UAX@GM+FR;3[BPT_6+W3[.X@;?N26WM
MM8CBDW!V5BRDLN%)(  ]YHH X)=5\<F)"VG!9 ,D+8P$$^F?MW3\*98ZSX^D
MM4:\TB*"Y.=\<%K%*@YXPQO5)XQV']:] HH X;^UO&G_ $#O_)"#_P"6%?)W
MQG_8GOM9\%Z%9^#M+UM9- *)9:9J&M3W-NELJA1#"+K4;@0J-D1"1J@/EJ"2
M%45]U45I3FZ<E./0Y,7AJ>,H2P]3:7;<_*_X4?L.?$"[\7:?+J.@:GI&EVEV
M)KN>Y>!GD *%U5)'7=O,8R5( R2".E?<6B?#2_T#Q_<^-(--UBY\0SPW-L)]
M2O[B]A@BN)8I9HX+>?5GB@5G@A.V)% $:@8 Q7MU%:UJ\J[3:M8X<LRNEE<)
M0IR<G+=O?\+'A'C+X:ZGXLUUM5N_"-M>7D\!@N)VM;6)V08VJ<W$A8' SR -
MJ\'MEQ? WS=$U[39/!\-K!K=E)IMYY-K:EV@:,*"KK<QD.N %/.W:I!!&*Z+
M1;_XPG3HDUO3PK%?,EFTHVAN5!,V(U623RRX*PDD_*4D('SJ35CQ;J?Q9^QR
M#0](W7,-Q*,B6T43(3<M$5WN?E4"U5P0K'+;3U8>-]0H>W^L6][UTOWL?5?7
M\1[#ZO?W?36W:YXQ\+/A7\0/%_PC\,OJ>MZ[HOBW2?%.J:Y_PD&EZ7IXN9KH
MO?61=TNII(RK6\[#!CX^4JV "?6?&OA'XB^,? L'AD>)->TEO)$%YK5AIFD_
M;;Y/*,;K*LLLD*^9N+L8HXR& V[5RM;B/\4+[1XYI8H-,U2.^N)4MX9()89+
M9K9Y8(YBRYRD_EP,8R,KE@3G<*?F_%7^VI&@AD_L6-=L)O39F[?,4^3+&A",
M1*(<;)8QL*Y#'?CT4W%IIV:/./,OA'^S!?\ P6U:PU/1Y=<U>]M'G?SM6@L?
MWK3S7$LS.(KA!G-U(0%"CA1Q@D^UG6/'YND7^R8A;%,O(+6'>&S]T+]MP1[Y
M!]JZ'P%+KDWA6S;Q' ]MK&Z43)))%(VT2,$8F(!,E IP!QG'45T%;5:]2M;V
MDKV5E?M=O\VQ));'GMKK7Q >:87.CP11 +Y316T3LQQ\VX&]7;@],$Y]NE6?
M[6\:?] [_P D(/\ Y85W-%8#.&_M;QI_T#O_ "0@_P#EA1_:WC3_ *!W_DA!
M_P#+"NYHH X;^UO&G_0._P#)"#_Y851USQ-XWTC1[R^33(G^S1F5A/9Q(@5>
M6)*WKGA03PISC%>CUA>._P#D1_$/_8.N/_134 8>I:QXMT[5+&P0V-_/<6TE
MPZVNGD&/8T:X_>72 C,G7.>!QSQ3E\1>.$N_LXTR'S7CDDB1K2,%PNP<_P"F
MD 9?!YSTP#SB31+"PT+QK:,\MU]NCTFX2\N=1NFE=U26#:Y)=E4'+M@$8W<@
M5TRWMO?^(].FM9XKF(V=T!)$X93^\@[B@#SX_%#7K&ZO+35?[/TZ]M=GF0O#
M#GYHU?C=?+NY)'RYX Z$E1YQX3_9XMK7PKHT.DP^-=.TJ.RA2TL[#QIK4=O!
M"$ 2.)?[<7:BK@*-JX ' Z5]1T4 ?/?P4^$>O_!;P_:Z7IEG*8+96B@A-E"R
M11>5;1*@+7^YL+:1\DYY;.>*V+_XZW&EZC<6=S+Y<\$C12H='!V.IP1Q>8/(
M/.:]LK!CG&A:_<1W#;+/4G62"5ONK-M"M&3T&X*I7U.[VJ8Q459&M6K.O-U*
MCNW\OR/,+;XZ7NIR_9M.#7EZZMY4":(Q+D G'RW;''') .!VK9E\5_$BYN)O
M[*T*RO;-"JK/=6KV;L2BEAY<LP; )(ST.#@UZI15&1Y5_P )#\6?^A8TK_OZ
MO_Q^K'P\\.^(_#MSJ%Q)I<,1N;:QM@EU=*"I@MQ&S?NP^06SCD'CG%>FT4 9
M.G:-*MX+_4;@7=^%*)L4K% IQE47)ZXY8Y)]AQ2ZGHTEQ=)?6-Q]BOU4(9"F
M])4&2$D7(R 22""",G!Y(.K10!X[\9_MUM8V.L:O%9VMG907=JSQ7HS))<0^
M7'M#A"3OP-@W,<X ;I7-:3\??&>K:C:V(T"#3KJ[;9:IK.G7.G"Y?!.R(W#1
MB1L G:I)P,XKJO&\T\_QBL0XD*:9ID4]HRVK71MS-).EQ<)$H)9U\FVB!P=B
MW+GH6J376U;Q89]+\168_P"$0NXO*NKJ6U>!HP+-9O. Y:%EER0Y;"&/;D.%
M)X)5Y\SY>CM_6NGW/]#ZRCE>&]E!UF[N/,VFDDNB2<7S.UG;FBV]-/B9<^+O
MB?IUI<W=]X=TR"TMX9)I)$*N5"J6Z?:.G'.,G'0'H=I=7\>><=VE1B/?@$6D
M).W'7'V[KGC&<8YSVJ/2M5U#7OV?+/4]6!&JWOA=+F[!7:?.>T#/QV^8FGZ/
MK_B[4]<M=.E_L^T\S2HM1ED?39OW#NQ7R&'G#YN&Y)!^4\<5VQDIQ4EU/FJ]
M%X>K.C)ZQ;6FVCL3#5O&VXYTT;>Q^PPY/_D_45YK'CQ+9VM=)BFN!C:DUI#&
MIY[L+YB./8U-H^M^)=5_L/\ TW2HO[3TYK__ )!\I\O'D_)_K^?]=UX^[TYX
M-'UOQ+JO]A_Z;I47]IZ<U_\ \@^4^7CR?D_U_/\ KNO'W>G/%& ?VMXT_P"@
M=_Y(0?\ RPJC=^,?$]CJEAIT]ILO+_S/LT?]FQ'?L7<_(O\  P#W(J#0?&?B
M[6O^$7W1Z?;_ -M1W,SYT^8_9DBQM<_OAE7W+@\#YAUR*CT.;5_%-]X#\3:L
MUO;N\US%'9P6KQD*\$I#EF=L@B)2, <-WH V#JWC;>,::"O.3]AAR/P^WUD7
M'C+Q5<VWBB));.PN=%M_.F$UAB0!H7D4KMN)$S\HZY SGG&*]1KQ_6M,AOM>
M^*TLCW"O;V$#H(;F2)2?LCGYE5@'' X8$=?4T 3P6OQ(:",S:GJ<<Q4%TCTW
M3F56QR 3.,C/? ^@J3['\1/^@MJO_@KTW_Y(KU6B@#RK['\1/^@MJO\ X*]-
M_P#DBC['\1/^@MJO_@KTW_Y(KU6B@#RK['\1/^@MJO\ X*]-_P#DBHVM?B1Y
MZ :GJ9A*L6<Z;IP8-D8 'G\@C=DY&,#@YX]9HH \DFMOB6KQB+4M1=#G>7T_
M3E*^F )SG]*D>T^(H1MNJZH6QP#IFG $_7[17J]% 'D\5I\1S&ADU75%D(&Y
M5TW3F /< _:!G\A2K:?$8EMVJZH!GY<:9IQR/?\ TCBO5Z* /)TM/B.6??JF
MIJH;Y"NFZ<21@<G_ $C@YSQST'K@1VMM\37\[[3J.H18D(B\JPT^3<G9FS,N
MUCW49 ]37KE% 'E7V/XB?]!;5?\ P5Z;_P#)%'V/XB?]!;5?_!7IO_R17JM%
M 'E7V/XB?]!;5?\ P5Z;_P#)%'V/XB?]!;5?_!7IO_R17JM% 'DTUK\2%0&+
M4]3=]R@A]-TY1MR-QR)SR!D@=R ,C.0Y[3XC KMU75&!/S9TS3A@>H_TCGM7
MJ]% 'D=_IWQ&GL;B./5-5>1XV55^P:?%DD<#>MQN7_>'(ZBJFE:+\0;.><PS
MZ[I\+J@"7-S::HS,"V3F1X]@P1P <]SP*]GHH \FFTSQ_<H4EU+4Y4/\+Z3I
MI'ZW%94WP_\ $EP29(9'8]6.@:5G\_/KVZB@#P_0O"'CSPU=SPZ;=:G;:=,O
MF,?LUDQ$NXDA8FN"JK@DY4CG V\ UM_8_B)_T%M5_P#!7IO_ ,D5ZK10!Y5]
MC^(G_06U7_P5Z;_\D4?8_B)_T%M5_P#!7IO_ ,D5ZK10!Y5]C^(G_06U7_P5
MZ;_\D4?8_B)_T%M5_P#!7IO_ ,D5ZK10!Y!:6_Q1>VC:ZOKZ&X+8>.&RT^1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM[R>5!%'.PBC^;@_,N53ENZCTX]'BU&TGG:".YADF7[T:R L/J* *7]C7?\
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MIL<-):;BQV,$;"C/&1GDX]Q5V+?L'F;0_<+TI /HHHH **** "BBB@ HHHH
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M]H%GXX>(3R>;)YFG+.S/M5<EI)&;HBCKVH ]$HKAO^$2\:?]#]_Y1H/\:/\
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M8>%=0\.^/_$NBZ?,9+.#7?AKKUU]G4.QB12VG<B)6\M"<L%499CDFKXV\?\
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MJ#Y>AZM1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ibio-20220930xex10d3007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20220930xex10d3007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /= S$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXZ]17@'C_P#;,_;*^%GA#4?%/BOX(^$M#T#3D#W-]=7)"1@L%4<7A))9E4
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M/8;F(%<[\1_B=I7P[^%?B7QU(\>I:9HNE7.J;+:9/])$,3R>6C9QN;9@>YH
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MN0.VU<S1W=PL>6(4%D(RRCJ1D _2>BOGKQ#\9/BAXX7X'>)O@WX7TKQ!\/\
MQ9)%=^*+S5Y$CN=,L)'MB&B4W$>9!&]SD!9?FC7CH&]WUC7--\/69N]4U"UT
MVU! ,]W,L2 GH-S$"@"]14=O<17<*302)-$XW+)&P96'J".M24 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %</\ &'X+^$OCSX17POXVTYM6T'[5%>/9K.\(D>,DJ&9"
M&QD\@$9KN** /S6_9-\+:/X(_P""L'QMT+0--M='T:P\*&&UL;.(1Q0H'TKA
M5'XGW))/)KZ9_:V_9P^'?C7POX\^)NO^&[?6?%^D^";^QT^ZO6:2.T2.&YE1
MTB)V>8'E8AR"PPNTC%<W\)OV6_&'@G]OOXH_&;4)M,;PEXET8V%E'#.S70D+
M6)^="@ '^C2<AC_#Z\?0_P 7?"UYXY^$_C7PWIS1)J&L:)>Z?;M.Q6,22P/&
MA8@$@989.#Q0!\K_ /!(;_DS;3?^PS?_ /H:UY=_P4#U/4?VF_VK?A9^S)I%
MV]OHWFIK'B"6W<;ERKN<C'#1VR2.H/#&=?05]-_L%? 'Q+^S5^SY9^"O%DMA
M-J\6HW5TS:=,TL6R1@5^9E4YX]*X[X._LJ>,_#/[=_Q.^-OB>729=$UNQDL=
M(BMKAY+A!NMT1G4H I$5N1]XXWX'% %/_@H7^SAK?Q<_9^\'_#GP!/X=\-Z;
MIFIV\JP:K>_8XEMX('AAAC^4Y ,J\?[*U\P?'GX;_'O_ ()V^'/"/Q+TWX[:
MOX[TU=0@TW4- U3SOL:YC9EC6*2:1&B*Q-'N C=/D*X_A^T?V[OV1'_:V^&.
MGZ=I6IPZ+XNT*[-]I%]<[A#N8!9(I&4%E5@%.Y02&1>#7SAXH_9(_:D_:OU#
MPIX7^.OB3P]I7P^T"Z2XNWT5E-SJ;(NWS0JKCS&5G4,VQ5WL=AX4@$7[+_B.
MS\>_\%7/B;XEDC9%U+P3;ZC8I<_+(BRP:4T0 ]?(?\LFM7QX(8O^"T/PX^Q8
M$LOAR;[=Y7.3]@OMN_T.%CZ_[/M7=_M,_L>>/K7XW^&OC9^S_>Z3H_C'2[%-
M-OM&U ^7;7T"1^6@Z8/[O;&58K@1QE2&6K/[)/[(7C_PY\<_%'QV^-NKZ;JO
MQ#UB VMI8Z8-T-C&51"V[  81QB-0N0%+$LS-P =M_P4L2]?]B#XHBP9EG^S
M6A8H3GRA?6YE''8Q[P?:E_X)KII:?L3_  S_ +*V>4UK<&<KC)G^U3>;G'??
MD<]@*^A?%7AC3/&WAC5O#VM6JWVD:K:2V-Y;/D"6&1"CJ<<C*DCBOSE\+_LA
M_M8_LD7FJZ)\#O&NB>(_ E]=-<066L>6LL#$ ;W25=JMC )C?#;02HX  /IS
MXX_%?X*_"+QSXIUNX@\,-\<-,\+7>L6(N[13J$T4-K.R1I,5R-RQR HK!BG4
M8(KXS_8X_8;\,_MG_!W7?BO\6/$>O:YXQ\2:A=16]_%? -9B,A Y4@[FW!L*
MWRA @"CK7O'[,O[ /B/3_B)XI^*GQ_\ $5KXW\>^(+*?3S;VA)@MH9X3#*2^
MU!N,),2HBA$0L!G(V^>^#OV2_P!K#]EFU\1>!_@SXM\.:QX#UFZ>:TO=7(2[
MTQG4*9=K+A7P%!V^8I*!@JDD4 ?(OBGXI^*?$'[!OBSP!XDU2;66\"?$#3[*
MQOIY#(P@>WOE$(8\E$:!BH.<!\=  /0_VK_V+O#/[,_[+'PZ^*_AO7M>/Q"N
M=0L'O=2>\PK2SV\D[/$%4,A21 5.[."<Y."/>/$W_!+KQ/I'[' ^&WAS6M*U
M?QYJ?B:W\0:QJ5Y(\%L0D$L8BC;8695,F06 +%G/' 'N/[:'[+'C'X__ +*G
MA+X=>&I]+BU_2KK3YIWO[AHX"L-M)$^U@C$G<XQP.,T ?%O[<NF>)+WX\^$/
MB/\ %KP=XA\?_!Z7PY8201Z%<M;06LCP(9Q(ZHRQL9B[[24+J4 ?"X&7\$_!
M?PE^(GP%_:2TWPEX[U^?P[:Z#>>*M/\ A_K5J;>[TV>TB=X+GSUE>.50Q6-]
MH!8>7OQA<_4'Q&_9,^/?PV^,>C_%?X)^(=*O-5E\/VNCZQX=UNX8VY:."*-Q
M#N 7RV,,;_>1@X)Y#$"/X!?L!>.I->^,7CGXK:IH6G>*_B#X=OO#T6G>'(0+
M6Q2ZC"22NJJB[@$0 *3G+,S%CF@#X<\1_!?PUX:_X)HZ!\2;&.Z7Q/XA\3Q6
M-](]P6B,4)O @5.BGCGUKT+]I+]B+PE^S]^Q7HOQ*T[5M:U#Q;XCMM*BU(7E
MQ&ULK3J+B7RE6-6 WHH&YFX'KFN]/_!/O]IS5?V>)_@UJ>H^$)/#.FZK%J>D
MG[:01)F?S3O$.\JWG9 ?!&.!7VK^T'^RO??'7]C^T^%)U&TTWQ#9:=IZVM[+
MN>V6[MD0?,0-VQMKKN ) ;.TXP0#P/\ X*$W*'_@F=X.<2K^]AT'8P;[_P"X
M4\>O )KQ+4M&N_VN_P!I/X&_ OQ%J^H:?\._#_@/2=0N;"QG$1N9CI:3F49!
MRY\R*+)!VJK[<%F)W?'/[%/[8?QL^$NC?#KQ=XB\*6WA;PJMO'I=CYZJ;PPI
MY43O)'$6.R)G'S$9P"5)^:O7_BW^PS\3-,UGX0_%'X1ZWI6F_%/P;X>L=$U*
MSOW)M+X0VWDLR,5YRK/&0VW*;2"K+R <%\5/^";=G\*)_B==^%O%HM?A1=>$
M[O4;OPC<WTCWK75M#)-;NG&"B3Q1,'8EMIE3OFO!/AU\'_#ND_\ !*7XJ?$B
MWBN?^$GU>XM=*N9&G)B\B+6+-E"IT!SU-?6WPY_8B^*WQ=^+>O?%7]H/7-)B
MUVY\/W>@Z3H^B'S([%9[>6W+-_#M5)YF"JS$M(6++C!\]\ ?L&_M':?^SI\2
M/@7JVL>$8_".I10SZ-.URY47JZC:3NS.L)D"&*&88*_>9>,$D 'FUM8WO[6G
MQO\ V=_@)KFMZAIGP[T7X>:)>WNGV4PB^U3?V1'<L^.=SD-%&"0=BARH&23W
MGBGX61?\$^OVY_@U;_##5=1@\%_$2\ATG4_#]Y=F6/+W"0,3D#<J_:$D0G+*
MROSM;%>F?$G]@7XDZ))\&_B'\*/$^D:1\6/ WAC3_#^H17.YK+4#;VH@9XW9
M,\J7C(=1N0J<HR\W?A5^Q]\9/BI^TAX<^-'[1&LZ)Y_AE$_L?PUH>62*1"S1
MEB/E4+(WF9W.S, "0H H ^4_V%/V,_!O[67COXQ77CJ^U;[!H.I^3:V>G7 A
MS)/).6E9BK?=$*X&,$GG.,5](_\ !'K6]8L_#WQ>\!WFI3ZAI'A378XM/69R
MPB\PSK($!^ZK&$-M'&68]22?4OV OV4?&?[,FJ_%>X\6SZ7-'XGU."[L?[-N
M'E(1&N"=^Y%P?WJ],]ZG_80_98\8_LW>(OB_?>*Y]+EA\5ZO%?6 TZX:4K&K
MW!/F;D7!Q,O SWH U/\ @H%\/OAG\8OA?HW@3Q[XXLO NL:GJ2S^&[VZ(9GO
M$Q&5$>09$(N K $8+HW85\K^+?#W[<7[-/@O5+74[G0OC7\.[;3YH[^UOU34
M%:SV$2+*KB*ZD!CR& +C&>W-?7_[<'[(EK^UU\,;32;?4UT/Q5HUR;W1M3D4
MF-)",/%)CD(X"Y*\J55L'!4_,%[\&/V_O$7ABX\ :CX\\-C0KJV:QGUR2:$S
M26[*493*L)FR5ZOMW\YW9H \P_:#_:8M?CI^S3\$/ _PKTFT^%NC^/O$-WHV
MMZ3I$*6]O:S1/;!X<1*@:)S>I*< %L 'G(/NNL?\$Q+'X.^/?AOXO^"'C1_"
M&N:/>JNI2^)+UY1J<>0< (HRS@,C1C:K*PQM(YN^/O\ @ES87/[*/A;X>^$_
M$"6_COPQ?RZU:^(+I6BCN[N4*)E<+N,:$1PA6 9E\A.N6SSEY^R/^TG^U+XP
M\#VO[0FM>'+3P)X4NEN9K72'!GU9@!N9E0;=SA=A8E H9BJ<T >&_LH?L<^#
M/VL/VD_VBI?&]UJ8TWP[XAF6*RTZ<0^=+<7=YAW?!.$$!P!U+]<#!Q/A/\8_
M%7[-?[-O[5_A'P]X@O?+\.:_8:-H=T[GS+,W5Q=PW$J8^X[16^05QM?YAS7W
MI^Q3^RWXP_9]^*7QX\0^)IM,EL/&VLQ7^F"PG:1UC6>]<^:"B[3BYCX!/?TY
M\U^'_P#P3KUS4M,_::T+QW?:?:Z9\2M2M[[1+S3)6GELY(;B[FCDD0JO0S19
M4'YAO7(ZT ?G;_8_PTE^"]C<Z3X6^**_%X)'J">*$C!L9+DLKX51\WE]=L@(
M?.&/]VOH'Q-X[\;_ +:/BW]EOX.>.]5U/1--UG1WU'7QM:WFOI8;J]A,KA\*
MSM%8!D8@@/.Q /2O5_\ AE_]M.7X4)\#&\4^$T\ QQK9+XA%RPG%DN-ML&">
M;L  &-F<#;NV\5Z#\9_^"<_B&+P=\(]6^$_C'['\4/AO;"V@U;5W?&ICSFG)
M8G?LQ+).50AE*RE&. * /GCXP?LE^&?V5_V_/V>H?!DMVGAO7M;LIX[&]N/.
M>VGCNHUD"L>2C!HR,Y.=W., >U?\$ZR3^V?^U^"2<>)IP/;_ (F-]6/9?L@_
MM/?%K]I;X8_%SXK:EX50>'-1LWDTJQNF4VMK#,LC"-$1E9G)<D[R2>,@!0-7
MQ7^R)^TA\&/VB_B)XX^ WB#06T?Q]=37=XNK,GF6<DLC2LS)(A!V22.4*[L@
MX9: /EWQJ<^&?^"@_?'BFU ^G_"2-_C7%>,/BUJ,O[+_ .S1\)II]7A\&7L.
MH:SK=MH7-U?H=;O8UC53PQ00NRJV5W.K$':,?5W@C_@FI\8K#X1?'OPMKWB'
MPS>>(/'S:9+:ZJUY.89)8-06ZG>;$&Y=P!QA3DGD <UT>L?\$TO'=E^S]\'(
MO#?BC2-(^-'PVN+N6VU*WED:QN8Y+^:[C4.\08,AD!&Z/:2SJP((8 'R/H'C
M#0/A%\?OAUXO^ ?@_P")/AB.&]BM=>TO7(FFBOK8O&K(NP$G>OF;@V0&V,@4
MJ*_;7XA>-;+X;> ?$OB[4H;BXT[0-,N=5N8;15:9XH(FE=4#%06*H0 2!G&2
M.M?"NF?LN?M,?M$_%KP1KGQY\2:/H/A'PE<?:$TKPU<%);Z0$$D^7QB38JL6
M<;5)"*"Q-?H50!\0?#W_ (*Y?"3XD^/O#7A'3?"WCBWU'7]3MM*MIKNQM%A2
M6>58D9RMTQ"AG!) )QG /2OHK]K'_DUCXR?]B9K/_I#-7JM<5\;O!-[\2O@Q
MX^\(:9+;V^I:_P"']0TJVENV984EGMI(D9RH8A0S@D@$XS@'I0!^+?Q,CU&7
M]C+]C!-(DCAU9M6\1+9R2C*),=63RRV0> V,\&O9/VPOAS^VU=?!37?^%C^(
MM'\3> +9([S5[30/LL3>7$X<,^(8Y&5656(7(& 2/ER/0/B/_P $Y?B]?_LZ
M_ 'P7X?U;PPWBCX>W>KW=W=M=RBV9[F]6X@,1:'+8 ^8,HY'<<UI>.?V;?VY
M_C1X<N_"'B_XI^$;;PQJ:B'4$M$2(R19!*EHK0.<XQM# -T)P30!YI\1?''A
MKX@G_@G5JGA+3I]'T2+Q#_9\6GW4PFEMVM[_ $N!U=P%WDM&6W[5W!@V!G V
M_A7\';/_ (*'?M>_''4_BKJNIWGAOP+J']E:5H-I<M#&D;S3QQ8/.T!+4LX3
M;O=PV< @^V>)O^">&JZ6?V6--\&:UICZ-\)M9?5-8N-7>2*XU R7EI<RO"B1
MN-Q,$V%=@%!C7<0"1C>.OV0/CC\#_P!H7Q=\5?V=];T2ZM?%\LEQJWAK73L7
MS7?S&QGY6 D9W5@R,NXKR"<@'+?L5P:G^S)^WK\2OV>-/US4-;\ BP_M+3K>
M]DW_ &25HX+A6Q]U3LG>-RH7>51B!@"OTIKX[_8U_8Z\9_"[XG^,/C%\7/$M
MIXD^)OB:$VSII^3;VL)9&;YBJ@M^ZC0!5"HJ$ L&X^Q* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8_\  V3_ !H_X6QXT_Z&O6/_  -D_P : /T3HK\[/^%L>-/^AKUC_P #9/\
M&C_A;'C3_H:]8_\  V3_ !H _1.BOSL_X6QXT_Z&O6/_  -D_P :/^%L>-/^
MAKUC_P #9/\ &@#]$Z*_.S_A;'C3_H:]8_\  V3_ !K1T#X@^--<U(6I\9:M
M:J(9IFE>\E8*L<32-P"2>$- 'Z!45\1W5K\68+9+V/Q%J4VER[3%J!U8Q0NC
M+N5LR.I4$#^(#GCKQ7$M\5O&JL0?%>L9!Q_Q_2?XT ?HE17YV?\ "V/&G_0U
MZQ_X&R?XT?\ "V/&G_0UZQ_X&R?XT ?HG17YV?\ "V/&G_0UZQ_X&R?XT?\
M"V/&G_0UZQ_X&R?XT ?HG17YV?\ "V/&G_0UZQ_X&R?XT?\ "V/&G_0UZQ_X
M&R?XT ?HG17YV?\ "V/&G_0UZQ_X&R?XU*OQ5\9FW=O^$JUC<'4 _;I.X/O[
M4 ?H=17YV?\ "V/&G_0UZQ_X&R?XT?\ "V/&G_0UZQ_X&R?XT ?HG17YV?\
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MPU.YCN(+;9L;R$5SM78NY@,G"\<FN;HH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#HM,\9:GX9DNHK!X4#70N%:6W24QR
MKN"NNX'##<<&I&^(FN/IAL6N(C$T9B=_(3S)%\IHAN?&6PC%02>*Y^\_X^Y_
M]]OYU#0!U5_\3=?U.R%I<W,,MOY#V[1FW3#JWE9W<<G-O"0>H*#%-N_B3K][
M#/%+=1D3B42N($#NKB0%2P&2/WTF!GC/L,<O10!;U35+C6+PW5TXDF*)'N
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M940W!'E!B@+ ;\\&O6#KNA"665)]*AGF.9)HO+61_F#'+9R<D UXG\1?V<O
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M/YZGWR#V6"_EC]R,?_A5WA;_ * \7_?;_P"-'_"KO"W_ $!XO^^W_P :V/\
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M !K%U3PAX.T!]9O-3L[>TTC3;!+Z:661@D*#SC(Y.>FV,9_W:[+_ (232?\
MH)6G_?Y?\:Y#QOIOA_XA:1XL\-ZEJ4,>FZUHPTZ6:*9=RA_/5BI/&Y=P(]\5
M="MF+YN>=2UEUE_,MOD34IX16Y8Q_#LSAM*^(_P-UF]L+.UO;8W-ZCLD<D5Q
M&8RGFY67<!Y3_N)L(^UCL. :IV?Q>^ FH:7'?V]]%+!++%!"JVMWYDSR"0J(
MX]NY_P#4S*=H.UHW4X((KEO%O[*%GXS3=J'Q6+7,UQ<WES<)9PH_G3K)'.82
MK@Q+)$Z1LN6R(D((.<M\3_L=^$O$1N(E\:6D-@DMS_9UC/8P7$-E#<27DLJ
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M']J1_P"@>I_X'/\ S#ZF_P#G[#_P&)RO_"$Z%_T =+_\#Y/_ (FC_A"="_Z
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M_P -C_EOIG_?4=']J1_Z!ZG_ ('/_,/J;_Y^P_\  8G*_P#"$Z%_T =+_P#
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M4?V=\1/[NJ_^!5I_\57H_P!A\1_]!C3O_!8__P ?H^P^(_\ H,:=_P""Q_\
MX_0!Y5H=AXXDT33VTY-5&GM;QFV N;48BVC9U;/3'6KW]G?$3^[JO_@5:?\
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M \X_L[XB?W=5_P# JT_^*H_L[XB?W=5_\"K3_P"*KT?[#XC_ .@QIW_@L?\
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M  F%G_SZ:K_X*KG_ .-T?\)A9_\ /IJO_@JN?_C=;M% &%_PF%G_ ,^FJ_\
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M$3&UU,B2_1@%TVX) ^RP#D!.#QT/.,'H16Q_PF%G_P ^FJ_^"JY_^-T>'O\
MD+^)_P#L(I_Z26];M &%_P )A9_\^FJ_^"JY_P#C='_"86?_ #Z:K_X*KG_X
MW6[10!Q5KXJM%\8ZG+]EU/:UA:* --N"P(DN3RNS('S#!/!YQT-;'_"86?\
MSZ:K_P""JY_^-T6?_(\:M_V#K+_T;=5NT 87_"86?_/IJO\ X*KG_P"-T?\
M"86?_/IJO_@JN?\ XW6[10!A?\)A9_\ /IJO_@JN?_C=%;M% !1110 4444
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M\#_!_P *?%L7B#39O%-[=QQ7,8-]ILKNWGR!WW2"$,5X&$SMW%GQN;->R?\
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M*S_Y\]6_\%5S_P#$4?\ "96?_/GJW_@JN?\ XBC^T\Z_Y^3#DI]BS_9>J_\
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M^^+7_P",U6_X3*S_ .?/5O\ P57/_P 11_PF5G_SYZM_X*KG_P"(H_M/.O\
MGY,.2GV+/]EZK_T-.K_]\6O_ ,9H_LO5?^AIU?\ [XM?_C-5O^$RL_\ GSU;
M_P %5S_\11_PF5G_ ,^>K?\ @JN?_B*/[3SK_GY,.2GV.6TC7;?PQX,\)_VG
MXWN](%]9PQVENYME\QEM_,*1AHBS;41CC).%-)X<^*7ASQ=J,6GZ1\4GOK^6
M.25+6*:S\TI'(T;G;Y.<!U93[J?0U4TQ-'UWPUX%FO+/5#=:(EO=P2PZ7,^7
M$&PJ'\LY4[L_*><"O,-4_9:\ ZE)8R;_ !/&]M8V=HV=)>07+V[AQ+,&@/F>
M81F1&^5S\Q&1FO6EC\?[2<9UJD=7:RNMWY=K$<L;+1'T%I)N=<TNSU*P\8ZG
M=V%Y"EQ;W$0M2DL;J&5E/D\@@@CZU;_LO5?^AIU?_OBU_P#C-<]X.O-+\%^$
M=#\/6EOK4UII-C!80R2Z7<;V2*-44MB/&2%&:V/^$RL_^?/5O_!5<_\ Q%>7
M+,LY4GRU)V+Y*?8L_P!EZK_T-.K_ /?%K_\ &:YJZDFT/Q!XAU#4/%U]86=E
MI-M<W-]/]F14B5[HL7)BVA5"L<X'4Y)XQN?\)E9_\^>K?^"JY_\ B*XWQ-)I
M?C.Y\5:/>0:Q%::GH]O:,\&FS^;'E[GYP#&<$%@06!!(/7!%=%#,<WDI\]2>
MR_\ 2E^EQ.$.P_\ X6[X4\J>4_%E1';P1W4S&YL@(XG=$5V_=<#=+&#GIYBY
M^\*;'\7_  G*<+\6E+"V%XR_:;+*PF58MY'E<#S&5#GHQ ZUY/<?LK>"+W6]
M6U&[U#Q?=_VRMZ-3@DTR39<M=(OFGB$;0)(XY47D*P/!SQ9M_P!FOPI:>*KC
MQ!#JWBQ=0O+B>]O7.CL1<7$D_P!H#G]Q]U)DA=4.5_=#().:[OKV+M_O%3[O
M^!_6A/+'LCV/PUXWTKQE/;0:'\2)]4GN+>6ZBBM9+-V:*.7R9'P(<X63Y#[Y
M%=-_9>J_]#3J_P#WQ:__ !FO,_A]X)T'P!<:-=Q-K^HZCIUE>V37USI$WG78
MNKB*XD>9A%EWWQ9SZR.>]>A_\)E9_P#/GJW_ (*KG_XBO-K9EFRE^ZJS:\_^
M&[%*$.J+/]EZK_T-.K_]\6O_ ,9KEM0NF\.>(-=U#5/&%[IUG;:;9O/?3FV0
M!3+<@!B8L  ].,Y8]>,=!_PF5G_SYZM_X*KG_P"(KBO%/]F>--0US3KJ'5X(
MIK33I8I8=,F:2*:"YFFC?88SP'5#\PPVTCL:TH9CF\E/VE2=K+_TJ/Z7!PAV
M-"X^)/A^TM)KJ7XHLEM#:VU]),;BRV)!<"0P2D^3@*XBD*GH0A]*I'XP^$EM
M[R<_%M1!9P0W5Q)]ILML44NSRW8^5P#YD?/^VOJ*\OL_V7? 6GS7$T-QXO:X
MN8;87,LUE/(9;B""XABN"#%M#*+EB% V#:H"@9%,T_\ 9D\*Z3X@GURSUOQC
M%JLYFEDN&TIGS-+;K$9-I@V_*R)*BD%5<'@@X';]>Q>O^T5/N_X#\]2>6/9'
MLOAKQ[H_C'4QIVB?$J;4[\VYNOLUM+9O((U959BHAS\K.@/H77.,BNI_LO5?
M^AIU?_OBU_\ C->2?#'X<:1\,_$2ZK#J'B75/*TW^S+>VO-)FV0(7621U(CW
M%Y'4,[L2SG;N)VKCU+_A,K/_ )\]6_\ !5<__$5Y]?,<UC.U&K-KS_X8I0AU
M19_LO5?^AIU?_OBU_P#C-<(NN7/A_P 1^)+=M9UUI'O8Y'DMH[4B0FU@&6S'
MUP . !@#ODGLO^$RL_\ GSU;_P %5S_\17#P1Z5K/BOQ#?7\.LRPFZC6.VAL
M+E "+:$%G*+NSZ*<<<\Y%>CEF98[GJ/'3J.*CI;>]X[?B3.$=.6QH?\ "<W'
M_09\3?\ ?FS_ /C5'_"<W'_09\3?]^;/_P"-5)_9OA7_ *!.N?\ @-?_ .%'
M]F^%?^@3KG_@-?\ ^%>K_;%'_I_]Z(Y'Y%2^\6'4K*XM+G5O$LMO<1M%(GE6
M@W*PP1D1YZ&I_P#A.;C_ *#/B;_OS9__ !JI/[-\*_\ 0)US_P !K_\ PH_L
MWPK_ - G7/\ P&O_ /"C^V*/_3_[T'(_(C_X3FX_Z#/B;_OS9_\ QJC_ (3F
MX_Z#/B;_ +\V?_QJI/[-\*_] G7/_ :__P */[-\*_\ 0)US_P !K_\ PH_M
MBC_T_P#O0<C\B/\ X3FX_P"@SXF_[\V?_P :J"Q\6'3;*WM+;5O$L5O;QK%&
MGE6AVJHP!DQYZ"K?]F^%?^@3KG_@-?\ ^%']F^%?^@3KG_@-?_X4?VQ1_P"G
M_P!Z#D?D1_\ "<W'_09\3?\ ?FS_ /C5'_"<W'_09\3?]^;/_P"-5)_9OA7_
M *!.N?\ @-?_ .%']F^%?^@3KG_@-?\ ^%']L4?^G_WH.1^1'_PG-Q_T&?$W
M_?FS_P#C506?BPV$310:MXEC1I'E(\JT/S.Y=CS'W9B?QJW_ &;X5_Z!.N?^
M U__ (4?V;X5_P"@3KG_ (#7_P#A1_;%'_I_]Z#D?D1_\)S<?]!GQ-_WYL__
M (U1_P )S<?]!GQ-_P!^;/\ ^-5)_9OA7_H$ZY_X#7_^%']F^%?^@3KG_@-?
M_P"%']L4?^G_ -Z#D?D1_P#"<W'_ $&?$W_?FS_^-5 GBPQWLMVNK>)1<2QI
M$[^5:<JA8J,>7C@NWYU;_LWPK_T"=<_\!K__  H_LWPK_P! G7/_  &O_P#"
MC^V*/_3_ .]!R/R(_P#A.;C_ *#/B;_OS9__ !JJVG^)QI5N\%KJOB6*)YI9
MRHBM#EY)&D<\Q]V=C^/%7?[-\*_] G7/_ :__P */[-\*_\ 0)US_P !K_\
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M'_PG-Q_T&?$W_?FS_P#C5'_"<W'_ $&?$W_?FS_^-5)_9OA7_H$ZY_X#7_\
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M#D?D5+?Q8;66YEBU;Q*CW,@EE/E6AW,$5,_ZOCY44<>E3_\ "<W'_09\3?\
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M /QFC_A&KS_H9-6_*W_^,T>RI_\ /Q?=+_(+OL;M%87_  C5Y_T,FK?E;_\
MQFC_ (1J\_Z&35ORM_\ XS1[*G_S\7W2_P @N^QNT5A?\(U>?]#)JWY6_P#\
M9H_X1J\_Z&35ORM__C-'LJ?_ #\7W2_R"[[&[16%_P (U>?]#)JWY6__ ,9H
M_P"$:O/^ADU;\K?_ .,T>RI_\_%]TO\ (+OL;M%87_"-7G_0R:M^5O\ _&:/
M^$:O/^ADU;\K?_XS1[*G_P _%]TO\@N^QNT5A?\ "-7G_0R:M^5O_P#&:/\
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MY:M_X*[C_P"(H_X3&T_Y\M6_\%=Q_P#$5NT4N>A_(_\ P+_[4>IA?\)C:?\
M/EJW_@KN/_B*/^$QM/\ GRU;_P %=Q_\16[11ST/Y'_X%_\ :AJ87_"8VG_/
MEJW_ (*[C_XBC_A,;3_GRU;_ ,%=Q_\ $5NT4<]#^1_^!?\ VH:F%_PF-I_S
MY:M_X*[C_P"(H_X3&T_Y\M6_\%=Q_P#$5NT4<]#^1_\ @7_VH:F%_P )C:?\
M^6K?^"NX_P#B*/\ A,;3_GRU;_P5W'_Q%;M%'/0_D?\ X%_]J&IA?\)C:?\
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M_"VW9S2^TUU5OQ,D[6/I7_A,;3_GRU;_ ,%=Q_\ $4?\)C:?\^6K?^"NX_\
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MMY2-JJ 6BD*LXP1[37CXETXU&JB;>OVO-_W>Y:O;0PO^$QM/^?+5O_!7<?\
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M_P#M0U,+_A,;3_GRU;_P5W'_ ,11_P )C:?\^6K?^"NX_P#B*W:*.>A_(_\
MP+_[4-3"_P"$QM/^?+5O_!7<?_$4?\)C:?\ /EJW_@KN/_B*W:*.>A_(_P#P
M+_[4-3"_X3&T_P"?+5O_  5W'_Q%'_"8VG_/EJW_ (*[C_XBMVBCGH?R/_P+
M_P"U#4PO^$QM/^?+5O\ P5W'_P 11_PF-I_SY:M_X*[C_P"(K=HHYZ'\C_\
M O\ [4-3"_X3&T_Y\M6_\%=Q_P#$4?\ "8VG_/EJW_@KN/\ XBMVBCGH?R/_
M ,"_^U#4PO\ A,;3_GRU;_P5W'_Q%'_"8VG_ #Y:M_X*[C_XBMVBCGH?R/\
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M)C:_\^.K?^"RX_\ B*+8O^3_ ,E7^0:!_P (U=_]#)JW_DO_ /&J/^$:N_\
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M[_Z&35O_ "7_ /C5'_"-7?\ T,FK?^2__P :H_X3&U_Y\=6_\%EQ_P#$4?\
M"8VO_/CJW_@LN/\ XBBV+_D_\E7^0:!_PC5W_P!#)JW_ )+_ /QJC_A&KO\
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MX++C_P"(H_X3&U_Y\=6_\%EQ_P#$46Q?\G_DJ_R#0/\ A&KO_H9-6_\ )?\
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M_D&@?\(U=_\ 0R:M_P"2_P#\:HH_X3&U_P"?'5O_  67'_Q%%%L7_)_Y*O\
M(-#T.BBBOZ./*"BBB@ HHHH S/$JWS:!J']F2&+4!"S0,%#'>!D  \<]/QKB
MO$)UC^S]3&HF0VHU;3_LYD"@#_B8CA<=5\OR>N>2WT'>:MJEOHFFW%]=L4MX
M%WNRJ6('T%<EX^U2VUKP[?V=M/)'-:ZKI]O+(BX:-S=0'*Y!!(##L1FN;%?P
M*GH_R*CNC3HK"_X1FZ_Z&/5O_('_ ,:H_P"$9NO^ACU;_P @?_&J_F_V5/\
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MAC&%+8YQ[9J2L+_A&;K_ *&/5O\ R!_\:H_X1FZ_Z&/5O_('_P :KQ/94_\
MGXON?^1I=]C=K@/',VM6Z>.)?#@+:\GA^!K(! Y\T-=[=JGAFST!X)Q71?\
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MK*\7FY4F##;$^9\9V#[V*E?XM^$!IMS?)XZUF>*WL].OG2"V223RK[>;7""
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M _\ C5'_  C-U_T,>K?^0/\ XU1[*G_S\7W/_(+OL;M%87_",W7_ $,>K?\
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M#_XU1[*G_P _%]S_ ,@N^QNT5A?\(S=?]#'JW_D#_P"-4?\ ",W7_0QZM_Y
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MR^/X?!^G-\/)+Z/5?MC>=]ACC=GC\B7:K%T?8ID\OY@C<X!P"6'FOB[XE?M
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M3&U_Y\=6_P#!9/\ _$5NT4<]#^1_^!?\ -3"_P"$QM?^?'5O_!9/_P#$4?\
M"8VO_/CJW_@LG_\ B*W:*.>A_(__  +_ ( :F%_PF-K_ ,^.K?\ @LG_ /B*
M/^$QM?\ GQU;_P %D_\ \16[11ST/Y'_ .!?\ -3"_X3&U_Y\=6_\%D__P 1
M1_PF-K_SXZM_X+)__B*W:*.>A_(__ O^ &IY0;#P_P".?AKH&C:YI>K7=I'8
MQ!EAL9]K$VS1-AE7D%9'Y![YK7\!6NB_#O06TK3K77[B-[F>\EGN]/F>66::
M0R2.Q$8'+,3@  =A7/>*;?QS)\,_!$O@6]6"]CM%\ZW>%66?-BXBWLWW467R
MR<#)XY !!Y7P)XL^-UOXMT'1K_PXU]X6N;B3SM>U81QWL,!ED9!-'&0NX1V[
M*2H S<V_'#5[=:$*CJ:Z7;LYVV;Z6,T[6/;O^$QM?^?'5O\ P63_ /Q%'_"8
MVO\ SXZM_P""R?\ ^(K=HKQ.>A_(_P#P+_@&FIA?\)C:_P#/CJW_ (+)_P#X
MBL6T\5VR^,M4E^Q:F5:PM%"C3IMPQ)<G)&W('S<'O@^AKMZX#QS_ &UL\<?\
M(X[1Z]_PC\'V)D4,PEW7>W:&X+9Z9XSC/%=F'="2J1Y6M%]K^]'R)=]#D]%^
M$_@;0/$FAZU9Z9XB2?1HTCM8&LYS#\MM#;;F7R_F8QVUMWZP(1@[MVA>>!/"
M-Y;:1 -/\16ZZ5!]GMFAL[A65=V]<G9R5<*X/9D4]J\<@U7]H,>*-2AG36E\
M.SP7#VEVEM;M=01QF*:W!C\L*9Y8H;B-B6QYEPB[(\!FBT74OVAAJEI'=2:Q
M+IUY9&66<V</FV1%RLABV&)1)*(4FB$A*JY*?NUR&;UG1O9NHM/[_K_=]2+^
M1[GX'\+^&/A_:Z)#IEAK[_V/:75E:R7-C.[^7<2Q2R[B(QN8O"AW'DG))))-
M=G_PF-K_ ,^.K?\ @LG_ /B*\U^#7_"Q)K[PU=^)KW49-.N-(U$WMEJ-M&DU
MO="\A:V$CJB;F\AY$^554^43SD&O9Z\?$.E&HU-.3UUYO-_W>^I:O8PO^$QM
M?^?'5O\ P63_ /Q%<^?$-E>^)];CFL=4:"YTRU@9%T^;?C?<YR-N0"&X/?!]
M#7>UQOB"WU&[U+Q;#I%T;'5)-#MUM;D1B0Q2EKO:P4\$@XX/%5AY4'&I[K6B
MZ_WH^0.^AQ?AWX7^"/"_B^S\1V.F>(5O++!M87LIS#"WV?[.S*OE_>9/O$DY
M//'-277PX\'7&GV%I'8^);-;'3K;2X);6VN(Y$A@@NH(L-LR&5;V8AASNVG^
M&O-=4O\ XXW]W?V^FS:[9XMK82O/96^-R6C/.]L=FW+2A(P'8DLSG"*HW8]K
MJO[1$.N:O'>IK9T6:U)M9;:TM7NH5BMHYHR 5"^=,\<L3 Y56D'"#;GU?9<V
MKJ*]E]OI_P" ^;(OY'O?@G1/#?@"WL8M*T[7 ++3X]+A:73IB1 CLZK@1@<%
MSSBNL_X3&U_Y\=6_\%D__P 17"?!I?'OVN"7Q7?W5W93:/$PBNK587ANOM$V
M]7(52[",Q#=M0$*"%&:]8KQ\1*E&HU).3[\W_P!J:*]C"_X3&U_Y\=6_\%D_
M_P 16+H/BNVBU7Q(QLM3(DOT8!=.F)'^BVXP0%X/'0]B#W%=O7G^N1WLOB'4
M_P"SUN&42H)?LV<;_*3[V.^W;^&*]G)<%A\RJU:#?)[M[M_WHZ;(X<7B)86"
MFHWN[?@SH_\ A,;7_GQU;_P63_\ Q%'_  F-K_SXZM_X+)__ (BN0^S:[_<U
M#\WH^S:[_<U#\WKZ7_5/"?\ 00OO7^9YG]K2_P"??]?<=?\ \)C:_P#/CJW_
M (+)_P#XBC_A,;7_ )\=6_\ !9/_ /$5R'V;7?[FH?F]'V;7?[FH?F]'^J>$
M_P"@A?>O\P_M:7_/O^ON.O\ ^$QM?^?'5O\ P63_ /Q%'_"8VO\ SXZM_P""
MR?\ ^(KD/LVN_P!S4/S>C[-KO]S4/S>C_5/"?]!"^]?YA_:TO^??]?<=?_PF
M-K_SXZM_X+)__B*/^$QM?^?'5O\ P63_ /Q%<A]FUW^YJ'YO1]FUW^YJ'YO1
M_JGA/^@A?>O\P_M:7_/O^ON.O_X3&U_Y\=6_\%D__P 11_PF-K_SXZM_X+)_
M_B*Y#[-KO]S4/S>C[-KO]S4/S>C_ %3PG_00OO7^8?VM+_GW_7W'7_\ "8VO
M_/CJW_@LG_\ B*/^$QM?^?'5O_!9/_\ $5R'V;7?[FH?F]'V;7?[FH?F]'^J
M>$_Z"%]Z_P P_M:7_/O^ON.O_P"$QM?^?'5O_!9/_P#$4?\ "8VO_/CJW_@L
MG_\ B*Y#[-KO]S4/S>C[-KO]S4/S>C_5/"?]!"^]?YA_:TO^??\ 7W'7_P#"
M8VO_ #XZM_X+)_\ XBC_ (3&U_Y\=6_\%D__ ,17(?9M=_N:A^;T?9M=_N:A
M^;T?ZIX3_H(7WK_,/[6E_P ^_P"ON.O_ .$QM?\ GQU;_P %D_\ \11_PF-K
M_P ^.K?^"R?_ .(KD/LVN_W-0_-Z/LVN_P!S4/S>C_5/"?\ 00OO7^8?VM+_
M )]_U]QU_P#PF-K_ ,^.K?\ @LG_ /B*/^$QM?\ GQU;_P %D_\ \17(?9M=
M_N:A^;T?9M=_N:A^;T?ZIX3_ *"%]Z_S#^UI?\^_Z^XZ_P#X3&U_Y\=6_P#!
M9/\ _$4?\)C:_P#/CJW_ (+)_P#XBN0^S:[_ '-0_-Z?9>)Y/".KV?\ ;B:F
MEO?R)9Q3&VFEB6:26..,.P!";F=5!; YKDQ7#.&P]"=6%92:5[)J[\NIM1S*
M56HH>SM?^NQUG_"8VO\ SXZM_P""R?\ ^(H_X3&U_P"?'5O_  63_P#Q%;M%
M?!\]#^1_^!?\ ]S4PO\ A,;7_GQU;_P63_\ Q%'_  F-K_SXZM_X+)__ (BM
MVBCGH?R/_P "_P" &IA?\)C:_P#/CJW_ (+)_P#XBC_A,;7_ )\=6_\ !9/_
M /$5NT4<]#^1_P#@7_ #4PO^$QM?^?'5O_!9/_\ $4?\)C:_\^.K?^"R?_XB
MMVBCGH?R/_P+_@!J87_"8VO_ #XZM_X+)_\ XBC_ (3&U_Y\=6_\%D__ ,16
M[11ST/Y'_P"!?\ -3"_X3&U_Y\=6_P#!9/\ _$4?\)C:_P#/CJW_ (+)_P#X
MBMVBCGH?R/\ \"_X :F%_P )C:_\^.K?^"R?_P"(H_X3&U_Y\=6_\%D__P 1
M6[11ST/Y'_X%_P  -3"_X3&U_P"?'5O_  63_P#Q%'_"8VO_ #XZM_X+)_\
MXBMVBCGH?R/_ ,"_X :F%_PF-K_SXZM_X+)__B*/^$QM?^?'5O\ P63_ /Q%
M;M%'/0_D?_@7_ #4PO\ A,;7_GQU;_P63_\ Q%'_  F-K_SXZM_X+)__ (BM
MVBCGH?R/_P "_P" &IA?\)C:_P#/CJW_ (+)_P#XBC_A,;7_ )\=6_\ !9/_
M /$5NT4<]#^1_P#@7_ #4PO^$QM?^?'5O_!9/_\ $4?\)C:_\^.K?^"R?_XB
MMVBCGH?R/_P+_@!J87_"8VO_ #XZM_X+)_\ XBC_ (3&U_Y\=6_\%D__ ,16
M[11ST/Y'_P"!?\ -3"_X3&U_Y\=6_P#!9/\ _$45NT4<]#^1_P#@7_ #4Z:B
MBBOZ9/("BBB@ HHHH IZQJL&AZ9<W]SO\BW0N_EJ6./H*X[QUK%IKVAZCIH$
MR26NI:=%.K;HVPUY$ 01@C.#@C!Q@CJ#7;WEI#J%I/:W">9!.C12(3C<I&".
M/8UQGC_2+;2?#]W?6EL\EW<:AI[2#S26D(O8V51N.%Y=L#@#=7-B;^PG;L_R
M''=%7_A"=+_Z?O\ P8W'_P <H_X0G2_^G[_P8W'_ ,<H_M[5/^A:O?\ P(M_
M_CE']O:I_P!"U>_^!%O_ /'*_GKFQ?\ S]_\G7_R1ZGN]@_X0G2_^G[_ ,&-
MQ_\ '*/^$)TO_I^_\&-Q_P#'*/[>U3_H6KW_ ,"+?_XY2'Q#J:G!\.7@/O<V
M_P#\<HOC/^?O_DZ_^2#W>QQ7Q0\4^"_A#9:?=Z^=8$-[++'']CGO+AAY<+S2
M,51R<!(W/3M52Y^(7PW@\5>&/#T6L7-[J7B(RK9)::C<RC]V,MO(D^3N!GJ5
M/I71>)]"M?&EYHUUK?@>74WTBX:[LUN9;9TCE:-HRVTR8)VNV,]#SU%<CIGP
M1\-Z5XOL_$\7@G5)-9LKJ:[M9Y=2B80-*27"J9<;>3@=LUW4Y/D7M*LN:SVG
M&U];?:]+D_(M:5\1OAMJ91I-5OM,@GDCCLKC4[R[M8K_ ,PNJ&W:1P)03&W*
MY['HRDU9OC'\%X;:WG7Q[I]Q'<-"(OL^O2R%A+*D2, LA.W=(N6Z ')XJ!_@
M/X=DDC9_">O/'%(#% VLJ8HH0Q;[.B>=A8B6Y4>BC.% &?>?LS>"KS5(-0_X
M0/5(+N"WMK>.2'4HE*BWCBC@/^MZHL*>Q(R02 1LG3;UK2M_CC_\D+7L=5%\
M0/A/-I5OJ<?C6Q?3[@E8;E=?E*2$#)"GS>< @UFZ%\7_ (/Z_IL5]!XQ@@MY
MHEGC^U:S/"SQE X?:T@.,9[=58=C5*X_9]\+SW8N4\'ZW:RIL$)M=72+R +<
M6S"/;+\F^$%&QSR2"#@ANF_L[^$=*N["XA\#ZL7LO),2OJD97,*R) Q'FX)C
M2655]I#G/&%>%G^^E?\ QQ_^2_KL/Y'0:MXU\!:9-IJQW6JZI%?VD5_'<:9<
M7ES"EM*^R*9W1BJH[<!B><,>BDBE9?%GX.WNF:??#QS8PPW]L+N 3:]*C-&6
MV9VF7/#@J?<$58OOA3H]Z-*4>$M8M(=.MTM$AL]5CA2:%)/,2.4+,-ZJ^2 ?
M[S#D,0<-/V=/!L?C"P\3#P#J/]JV,MM/;N=1B*1R6^/*8+YO!&!GL<#()I1<
M;>]5E?\ QQ_^2#Y&\/B1\(F9%'CK3MSM JC_ (2&3YC,I:$#][_&%)7UP:SK
MSXN?"_2/%>M:#JVKWVC3:2[1W-YJ%Y=0V@91 67SV?9G_28>,Y._C.#7(6W[
M)'A(ZI)-?^$=2U'383;_ -GZ9)=0>39B(2 @9E.XN)7!/'KUYKNO$OP=\,>+
M+3Q%#J/P[DEDU^[COK^Z\VU,TDJ",(=Y<G \I,+]WKQR:M^SC))5I-?XXZ;?
MWO7^M1:]AT?Q1^#LNI_V<GCW3'O_ #OL_P!G'B&0OYF]DV8\WKN1EQZJ?2MK
MX<ZKX*^*_AI-=\,W]WJ&G&1H3(NH7(VR* 60@OU&17.6WP1\*6=G#:6_P]NH
M;>'B-([V$!1NO&P/WO3.HW?_ '\]A74> O#L?PTT!=%T'PIJ%MIB/NC@>\@<
M1_*JX!,F<?+GGN37/5;Y7[*K*_G./Z2&O-'1_P#"$Z7_ -/W_@QN/_CE'_"$
MZ7_T_?\ @QN/_CE']O:I_P!"U>_^!%O_ /'*/[>U3_H6KW_P(M__ (Y7%S8O
M_G[_ .3K_P"2*]WL'_"$Z7_T_?\ @QN/_CE'_"$Z7_T_?^#&X_\ CE']O:I_
MT+5[_P"!%O\ _'*/[>U3_H6KW_P(M_\ XY1S8O\ Y^_^3K_Y(/=[!_PA.E_]
M/W_@QN/_ (Y1_P (3I?_ $_?^#&X_P#CE']O:I_T+5[_ .!%O_\ '*/[>U3_
M *%J]_\  BW_ /CE'-B_^?O_ ).O_D@]WL'_  A.E_\ 3]_X,;C_ ..4?\(3
MI?\ T_?^#&X_^.4?V]JG_0M7O_@1;_\ QRC^WM4_Z%J]_P# BW_^.4<V+_Y^
M_P#DZ_\ D@]WL'_"$Z7_ -/W_@QN/_CE'_"$Z7_T_?\ @QN/_CE']O:I_P!"
MU>_^!%O_ /'*/[>U3_H6KW_P(M__ (Y1S8O_ )^_^3K_ .2#W>P?\(3I?_3]
M_P"#&X_^.4?\(3I?_3]_X,;C_P".4?V]JG_0M7O_ ($6_P#\<H_M[5/^A:O?
M_ BW_P#CE'-B_P#G[_Y.O_D@]WL<%;:GX2\(^&?!$>MW=Y:SZU;1QP$7MP$W
M+;^:[-M?:B!5/)P!D#TK:\!7?@_XF:')K'AV]N]0TU+NXLA<QZC<['>&1HW*
MGS.5W*<$<&LR+1(/&_PXT#2M9\)W6J:<MC%@"YA19 ;<Q$_ZP'!21A@^OK6O
MX(T9OA_H9TO2O#.J>0UQ+=227-[!+))+*Y>1V8R<DLQ/ISQ7HXJ57FG:H^;F
M?VU:UWY^A,;::&__ ,(3I?\ T_?^#&X_^.4?\(3I?_3]_P"#&X_^.4?V]JG_
M $+5[_X$6_\ \<H_M[5/^A:O?_ BW_\ CE>=S8O_ )^_^3K_ .2*]WL'_"$Z
M7_T_?^#&X_\ CE<])X=T?3_$NN2W+WD=I:Z7;7#O]NN,J-]R6)(?)&%''UQU
M-=#_ &]JG_0M7O\ X$6__P <K%M-:U(>,M4<>'[LN;"T4Q>?!E0)+G!SYF.<
MG_ODY[5TT98KDJ7J=/YU_-'S$[::'GEW\<?A;I^E1ZE>7>N6EC)I5OK2SSF^
M5&M9?LY#@EL$J+N L!R,M_=;#?\ A>OPK_M6XTPWNMC4;>'SI;4F_$BD7:6C
M1XS_ *P32*I3KSTXJVWP#\*R7XN9? ^JS@:=%I/V>75(VB^RQVS6Z1;3-P C
MN>,?,Q;J<U5L_P!G3PI8ZVNKQ>#M:_M'=-*]PVJQ%Y)I7WR3,WFYWEPKY! #
M(I &*[E*E;6K+_P./_R1.O;\#I/!?C+P)X]U6UTS2I]7^WW%K=78M[F>\A9$
MM[D6TH;<PP1*<8/)'/3FNZ_X0G2_^G[_ ,&-Q_\ '*Y'P7X)L? %KHUOH_@_
M488](M;BRL_,OH7,<4\D4DJY,O.6AC.3SP?4UUW]O:I_T+5[_P"!%O\ _'*\
MZM*OS?N:KMYS7?\ Q=K%*W5!_P (3I?_ $_?^#&X_P#CE<OJ>EZ%X<UCQ%J&
MH27L6G6&E6UU*ZWEPS!0]SNZ/N;A1@<^PY.>H_M[5/\ H6KW_P "+?\ ^.5@
M?VC?7GBC6HI?#MW(L^FVL4D(N( 0A>Y&<^9CG)'!SP?:M*$L5RU.:IT7VU_-
M'S!VTT.'U/XS_#'1Q+]KNM;B9(K>9%+7Q,ZS1^8GE?-^\.T'(7."".H-0)\=
M?A5-/>P07NN7%S:*I>WB^WM*S9A$D:*#EY(_M$6]%RR[CD9!Q=_X43X9-_=7
M;>"]7>:Y2-&WZI&P3R[=K>(IF7Y"D;N%VXP68]22<^U_9K\&V6M3ZQ#X&U:+
M5IX&MY+Y-4C6<JUNUNYWB7<&9&SD'A@&&#DGL4J5M:LMOYX[_P#@1.O8ZWP+
MXH\$?$6]>ST:?59+J*T6\EBFN;R(QJ99(L'<P^8/$X(ZC /0C/:?\(3I?_3]
M_P"#&X_^.5S'@[PM;>!+>RAT?PA?VZ6=@FF0;KR!MENCLZ)S)T!<X]N*Z?\
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M_P "K;_XY1_MG_/S_P G7_R0>[V'_P#"$Z7_ -/W_@QN/_CE'_"$Z7_T_?\
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M<H_X274/^A>N_P#P*MO_ (Y1_MG_ #\_\G7_ ,D'N]A__"$Z7_T_?^#&X_\
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M\&-Q_P#'*/\ A"=+_P"G[_P8W'_QRF?\)+J'_0O7?_@5;?\ QRC_ (274/\
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M_P"3_P"(K,_MN#_GP7_P=W5']MP?\^"_^#NZHMG_ &_\EI__ "8?NOZN:?\
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M /CE']O:K_T+5Y_X$6__ ,<K=HH]M#_GU'_R;_Y(+>9QFM17FN,OVGPQ/*@
M_=S/;2+D9P<&3KR:S]:\-GQ%X?72+[PUJ/V9+B*YC-K>0P-&\94QE2LF1@J*
M]#HKTGF]>5".&:7)'5+WM/QOU(Y%>YX+I?[.'@O2/$[>(+?P#J@U22=;F:9]
M7#>?(LPG!D!F^<>:JN5;()5>,"KWBOX$>$_&SZE_;/@'4;R+4)7FFMFU8"#>
M[*TK+&)]BERH+$ $G)X))KT+XJ:5K>N?#KQ#I_AN[EL->NK-XK.ZA95>&0C
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M>?\ @1;_ /QRC^WM5_Z%J\_\"+?_ ..5P_P#U+XGZE8ZW)\2=-MM/8W(?2S
MR!G@)8_.BLQ0@;!AN<YX'0>JUY]64*4W!TXNW5.37_I12U,+^WM5_P"A:O/_
M  (M_P#XY1_;VJ_]"U>?^!%O_P#'*W:*Q]M#_GU'_P F_P#DAV\S"_M[5?\
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M#[C_ .+H_P"$)TK^[>?^!]Q_\71_;NJ_]"W>?^!-O_\ '*/[=U7_ *%N\_\
M FW_ /CE?SS?%_\ /W_R=?\ R1ZGN]@_X0G2O[MY_P"!]Q_\71_PA.E?W;S_
M ,#[C_XNC^W=5_Z%N\_\";?_ ..4?V[JO_0MWG_@3;__ !RB^+_Y^_\ DZ_^
M2#W>P?\ "$Z5_=O/_ ^X_P#BZ/\ A"=*_NWG_@?<?_%T?V[JO_0MWG_@3;__
M !RC^W=5_P"A;O/_  )M_P#XY1?%_P#/W_R=?_)![O8QO&5EX?\ !'A35O$%
M_'J#V>FVTEU*L-[<,[*HS@#?U->:>&?CU\*_$,,GFWU_I=R@'^CW-[<%I#YH
MB C*R$2$NP VD[L@C(YKU773<>)='N]+U+PI=W-C=QF*:+[7"A*GT99 0>X(
M((/(-<.OP4\)K8"T7X=7:QB9K@.NJXE$K.KM)YGG[]Y9%);.<]^37=1F^1JM
M4=[]*D=OG(E^2_ 6+XC_  [U/0=0U31+R\U]+.>TMC%87UPS2O<W1M8=A,@#
M*TH9=V<?(W/%8L?QY^$<=IYFH:M?:5<)</9SVMW<W2R0W"3/"\38?&Y9$*G'
M<K_>&=K0/@UX<\-^'M3T6S\"WXL-1N%N)D_M-%92ET]S"L;+,#&L<LC% F,=
M3DDDQ7GP*\%Z@-/%S\,I9OL%V+^ OJ"DBX!4^:Q\_+L2BL2V=QR3DDD[*4$V
MG4E:^GOQO:W^+N'R,J[^/WP8M+N&'_A)GGCD2Y<S07]RZ(8)"DBMA^"-KG_=
M4GH1G:TGXG?"O7/%\'ABRUZ6?6YY&CBMA?7.7*@'(._&#D8/0]JI:7^SSX T
M2VC@L/A0MI%''<1*L5XB_+/:)9S _ON=T$2(<^A/WB2:O@[]GCPUX/\ $C:^
M/".KZKK":@^HVUSJ&IQ/]D=AM"QHLBJ$ SA2#C)QBJDZ3B^6K.]M/?COT^U]
MXM>QZ[_PA.E?W;S_ ,#[C_XNC_A"=*_NWG_@?<?_ !=']NZK_P!"W>?^!-O_
M /'*/[=U7_H6[S_P)M__ (Y7DWQ?_/W_ ,G7_P D7[O8/^$)TK^[>?\ @?<?
M_%T?\(3I7]V\_P# ^X_^+H_MW5?^A;O/_ FW_P#CE']NZK_T+=Y_X$V__P <
MHOB_^?O_ ).O_D@]WL'_  A.E?W;S_P/N/\ XNC_ (0G2O[MY_X'W'_Q=']N
MZK_T+=Y_X$V__P <H_MW5?\ H6[S_P ";?\ ^.47Q?\ S]_\G7_R0>[V#_A"
M=*_NWG_@?<?_ !='_"$Z5_=O/_ ^X_\ BZ/[=U7_ *%N\_\  FW_ /CE']NZ
MK_T+=Y_X$V__ ,<HOB_^?O\ Y.O_ )(/=[!_PA.E?W;S_P #[C_XNC_A"=*_
MNWG_ ('W'_Q=']NZK_T+=Y_X$V__ ,<H_MW5?^A;O/\ P)M__CE%\7_S]_\
M)U_\D'N]@_X0G2O[MY_X'W'_ ,71_P (3I7]V\_\#[C_ .+H_MW5?^A;O/\
MP)M__CE']NZK_P!"W>?^!-O_ /'*+XO_ )^_^3K_ .2#W>P?\(3I7]V\_P#
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MIH=/_P (3I7]V\_\#[C_ .+H_P"$)TK^[>?^!]Q_\71_;NJ_]"W>?^!-O_\
M'*/[=U7_ *%N\_\  FW_ /CE>7?%_P#/W_R=?_)%^[V#_A"=*_NWG_@?<?\
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M?H647$ V'[+;C!R_/ !X]?7-:4GBN2I>KT_G7\T?[P.VFAM?\(3I7]V\_P#
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M/_ FW_\ CE%\7_S]_P#)U_\ )![O8/\ A"=*_NWG_@?<?_%T?\(3I7]V\_\
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MNWG_ ('W'_Q=']NZK_T+=Y_X$V__ ,<H_MW5?^A;O/\ P)M__CE%\7_S]_\
M)U_\D'N]@_X0G2O[MY_X'W'_ ,71_P (3I7]V\_\#[C_ .+H_MW5?^A;O/\
MP)M__CE']NZK_P!"W>?^!-O_ /'*+XO_ )^_^3K_ .2#W>P?\(3I7]V\_P#
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MG_@3;_\ QRB^+_Y^_P#DZ_\ D@]WL'_"$Z5_=O/_  /N/_BZ/^$)TK^[>?\
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MTG^Y=_\ @?/_ /%T<N'_ )Y?^ K_ .2#4W:*PO\ A"=)_N7?_@?/_P#%T?\
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MVN-U[3+C6M3\6V%I=SV-U<Z';PQ7-JX66)V:[ 9200"#W(-:O_"$Z3_<N_\
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M'^\7:Z<FTDM6V[>7YL]MHKQ/^T=1_P"@+:?^#R\_^)H_M'4?^@+:?^#R\_\
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M\_\ B:/]5\;_ "2^Z/\ \F'MJ/\ S]C_ .!(]LHKQ/\ M'4?^@+:?^#R\_\
MB:/[1U'_ * MI_X/+S_XFC_5?&_R2^Z/_P F'MJ/_/V/_@2/;**\3_M'4?\
MH"VG_@\O/_B:/[1U'_H"VG_@\O/_ (FC_5?&_P DONC_ /)A[:C_ ,_8_P#@
M2/;**\3_ +1U'_H"VG_@\O/_ (FC^T=1_P"@+:?^#R\_^)H_U7QO\DONC_\
M)A[:C_S]C_X$CVRBO$_[1U'_ * MI_X/+S_XFC^T=1_Z MI_X/+S_P")H_U7
MQO\ )+[H_P#R8>VH_P#/V/\ X$CVRBO$_P"T=1_Z MI_X/+S_P")H_M'4?\
MH"VG_@\O/_B:/]5\;_)+[H__ "8>VH_\_8_^!(]LHKQ/^T=1_P"@+:?^#R\_
M^)H_M'4?^@+:?^#R\_\ B:/]5\;_ "2^Z/\ \F'MJ/\ S]C_ .!(]LHKQ/\
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M^T=1_P"@+:?^#R\_^)H_M'4?^@+:?^#R\_\ B:/]5\;_ "2^Z/\ \F'MJ/\
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M6Z?*\:\?\\ZB<%4BX2V>@UH:7VG7O^A9NO\ P*M__BZ/M.O?]"S=?^!5O_\
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MR/\ \"8>VF<A]IU[_H6;K_P*M_\ XNC[3KW_ $+-U_X%6_\ \777_P!IV?\
MS]P?]_!_C1_:=G_S]P?]_!_C1_JGE?\ (_\ P)A[:9R'VG7O^A9NO_ JW_\
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M?^#6P_PH_P"$+'_/QKG_ (-;#_"NI_X4[:_]#!9?^ 2?_%T?\*=M?^A@LO\
MP"3_ .+H_LR'_/V?_@;#ZQ+^6/\ X!'_ ".03PM&]Y+:BXU[S8XTD;_B9V.,
M,6 P<8)^0\?3UJ;_ (0L?\_&N?\ @UL/\*VH?A=!+KEW8'6[(1P6T,XE^QI\
MQ=I5(^_V\L?]]5?_ .%.VO\ T,%E_P" 2?\ Q=']F0_Y^S_\#8?6)?RQ_P#
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M*/\ A"_#W_0"TS_P#C_PJMYWBS_GST7_ ,"IO_C='G>+/^?/1?\ P*F_^-T
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M;QU/S7$C9^YTYX/<8- '<?\ "*:)_P! ?3__  %3_"C_ (131/\ H#Z?_P"
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M'T__ ,!4_P *Y^UD\0?\)CJ9%OIGG?8+3<#<2;=OF7.,'9USNS^%;'F^)?\
MGUTK_P "9?\ XW0!8_X131/^@/I__@*G^%'_  BFB?\ 0'T__P !4_PJOYOB
M7_GUTK_P)E_^-T>;XE_Y]=*_\"9?_C= %C_A%-$_Z ^G_P#@*G^%%5_-\2_\
M^NE?^!,O_P ;HH W:*** "BBB@ HHHH QO%^E76MZ#<65F85GE*@-.S!5&02
M?EYSZ=L]:XZ]\-W?AG2+I[JZ66WFU?37C#2%V3_3T)+,5'9E&.<;>O-=OXCU
M=]"T>XO4A$[1 $1[L;N?Y^U<7J_BF#QCH4L#VJB%=1TTE'(=9(VU%8\,.G/E
M,<>C#UH [W^U++_G[@_[^K_C1_:EE_S]P?\ ?U?\:H?\(9X?_P"@%IO_ ("1
M_P"%'_"&>'_^@%IO_@)'_A0!?_M2R_Y^X/\ OZO^->2_%CP]J_BC5[%]%UTZ
M5';W<<\K0D,)D"@$=>V#P>#GFO2_^$,\/_\ 0"TW_P !(_\ "O-?B7XL\,?#
MK4;*"[T"P*7EPMM'Y6FI(02 2QP.@R..M $?Q1\):EXP\*>&X-.FM;@65]+/
M>:7-J4EDMRCP3HF9(B&^1Y(WV]/E)Z@5Y3<^ /VC!K-ZUE\3](MM/-Z[VD#2
M(Z10^9)L0DQ[B@C,?7YMRXZ$O7J?Q(\;:'\.]+\-RCP7I^K7>L3W,*Q1QV\"
MJ(+>:=V+/@<K P SU(KFK+]ISX,WLB1C22DC;7*G1#\L9G-N93\GW%G5HR>Q
M'IS0!R&G_#;]I"."V27XQZ3)%]EN1+YT40G\UV=HOF5"HV>3;)D \7-P>=J5
MO>&?AK\7+;Q[X<\2:O\ $F.[M+*_NDNM*:YBVR:;(;0QQ$K$ 9E,<K._\6P*
MNS>2._\ A1\3/AI\9=4UO3?#^C0B^T>.WENH+[2!;NJ3JS1, RC((4G\O45Z
M1_PAGA__ * 6F_\ @)'_ (4 7_[4LO\ G[@_[^K_ (T?VI9?\_<'_?U?\:H?
M\(9X?_Z 6F_^ D?^%'_"&>'_ /H!:;_X"1_X4 7_ .U++_G[@_[^K_C1_:EE
M_P _<'_?U?\ &J'_  AGA_\ Z 6F_P#@)'_A1_PAGA__ * 6F_\ @)'_ (4
M7_[4LO\ G[@_[^K_ (T?VI9?\_<'_?U?\:H?\(9X?_Z 6F_^ D?^%'_"&>'_
M /H!:;_X"1_X4 7_ .U++_G[@_[^K_C1_:EE_P _<'_?U?\ &J'_  AGA_\
MZ 6F_P#@)'_A1_PAGA__ * 6F_\ @)'_ (4 7_[4LO\ G[@_[^K_ (T?VI9?
M\_<'_?U?\:H?\(9X?_Z 6F_^ D?^%'_"&>'_ /H!:;_X"1_X4 7_ .U++_G[
M@_[^K_C1_:EE_P _<'_?U?\ &J'_  AGA_\ Z 6F_P#@)'_A1_PAGA__ * 6
MF_\ @)'_ (4 7_[4LO\ G[@_[^K_ (T?VI9?\_<'_?U?\:H?\(9X?_Z 6F_^
M D?^%'_"&>'_ /H!:;_X"1_X4 7_ .U++_G[@_[^K_C1_:EE_P _<'_?U?\
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M'2U?2XM4BN+BV@:.='GEB!C*YW*?*#ANA61??'I?_"&>'_\ H!:;_P" D?\
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M.V_\!4_^+JAHOPWBU.SDFDU^VB9;FX@"_95Y$<SQ@_?[A0?QKU/_ (171?\
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M,>X-;V@^&](DU7Q(KZ59,L>H(J VZ$*/LMN<#C@9)/XFMK_A%=%_Z ]A_P"
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MNEZG97\%K?RR6[R7%[%<Q&%)/NJ@69.>0&09(&:]K_M:Q_Y_+?\ [^K_ (T
M9'G>+/\ GUT7_P "9O\ XW7/0GQ'-XUUM'M-'=WTNS65'N)=A3S+O'\'.?FS
MQZ>]=Q_:UC_S^6__ ']7_&N)U^TL?%&L>,-)>_2&/4-!M;7S8KGRR-SW@.'4
MY!Y'(Y&: )H=(O[2\@O(](\,1W-K#'!%,)W#11*'$:@^7P )) /9V]36#_PJ
MW3&%T/\ A$/!A6X@6&<;FP\1A^SJ"/+Z&+]V/]GY>G%>/W/[.7B_[?=%/%.B
MWUJ\" Q7NI7*I=R)9"*)9@F"L<<P#C8<L 0>IJM8_LU^,82T5UK_ (>N;,:=
M#9F+^V+P&\DC@+;IV !53<QVQ41XV1HX&3(U 'T5HFB:IHB0C2](\.6JI (8
MS!<2C$6XL%!\O[NYF/U)K6\[Q9_SZZ+_ .!,W_QNO.?@G\,KKX;7%O=ZMXBM
MM0NFT:*PNECO7DB,ZW$\K/&KX"(1,  !D !>0H->N_VM8_\ /Y;_ /?U?\:
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MQ^-=9_:5I_S]0?\ ?P?XUB7>H6I\:Z4WVF':-/O 3Y@P#YEM_@: )_-\2_\
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M]!GMO[2M/^?J#_OX/\:YG4+^V/Q+T%Q<1;!I&H@MO& 3-98'Z'\J (?"<GB
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M#8_X0[0/^@'IO_@)'_A1_P (=H'_ $ ]-_\  2/_  JKYOBS_GVT7_P(F_\
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M7_P(F_\ C='F^+/^?;1?_ B;_P"-T 6O^$.T#_H!Z;_X"1_X4?\ "':!_P!
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ME1OI,6J0W310O'<*\\T0* #.TB)7!8#(D'<''I__  AV@?\ 0#TW_P !(_\
M"L'1=/U/38H5TG2O"]K&L(2(64C(!%N+ +MC^[N+'CC)-:GF^+/^?;1?_ B;
M_P"-T 6O^$.T#_H!Z;_X"1_X5SWA+PWI#ZYXRC;2[)HXM6C2-3;IA%^PVC8
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M/>+J38-SP'!.S@G;P/9O2@#T'_A%M%_Z!%A_X#)_A1_PBVB_] BP_P# 9/\
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M_"+:+_T"+#_P&3_"N>\%R>(!X.T+R8-,,/V"#89)I Q7RUQD!.N*V/,\2_\
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M1_PBVB_] BP_\!D_PJMYGB7_ )]]*_[_ ,O_ ,11YGB7_GWTK_O_ "__ !%
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M5)&$%=W\:/B!IWPA\ :3K<'A#2]:N+JYEA>-K=5PD<,TK, J$DXB Z8&[)P
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M_P#"@"Y_:]C_ ,_MO_W]7_&C^U['_G]M_P#OZO\ C5/_ (0_0?\ H":=_P"
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M1M,EQ-*70-@(I\[A0HQTZ 5Z[_:]C_S^V_\ W]7_ !KR/X3^+;/X@ZDEI?\
M@73=*1](BU.*Y6.*1)P\\T7RC;N5<1*PW '#X(!!KU#_ (0_0?\ H":=_P"
MD?\ A0!<_M>Q_P"?VW_[^K_C7E?_  C$/BOQ]XKN9=5BM-/CO(D'E.OF2/\
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MFO1_^$7T;_H$V/\ X#)_A6+X)\.:3/X,T"232[.21]/MV9VMT)8F-<DG')H
MPO\ A6.B_P#0>G_[^Q_X4?\ "L=%_P"@]/\ ]_8_\*[?_A%]&_Z!-C_X#)_A
M1_PB^C?] FQ_\!D_PH XC_A6.B_]!Z?_ +^Q_P"%9^@_#_2]1L999]<F1UNK
MF$ 2(/E2=T4].ZJ#7H__  B^C?\ 0)L?_ 9/\*Q?"/AS29M*G:32[-V&H7R@
MM;H3@74H Z=  !^% &%_PK'1?^@]/_W]C_PH_P"%8Z+_ -!Z?_O['_A7;_\
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MN<\$^'-)G\&:!))I=G)(^GV[,[6Z$L3&N23CDUM?\(OHW_0)L?\ P&3_  H
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M:79LJ:@BH#;H0H^RVYP..!DD_B:VO^$7T;_H$V/_ (#)_A0!9_M.S_Y^X/\
MOXO^-']IV?\ S]P?]_%_QJM_PB^C?] FQ_\  9/\*/\ A%]&_P"@38_^ R?X
M4 9MIJ-H/&NJM]JAVG3[, ^8,$^9<_XBMO\ M.S_ .?N#_OXO^-<Y:>'-)/C
M/5(SI=F8UT^T8(;=, F2YR0,=3@?D*VO^$7T;_H$V/\ X#)_A0!9_M.S_P"?
MN#_OXO\ C1_:=G_S]P?]_%_QJM_PB^C?] FQ_P# 9/\ "C_A%]&_Z!-C_P"
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MOV>O!&I?";P3=:/XE\;+XMOY;YKE;VXN-Q5#%$F!NY&YHWE(Z!I6 X KT_\
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MF"WV6?K\O3&?QQ75_P!JV7_/Y;_]_5_QK$\0:E:-JWADBZ@(74')(D' ^R7
M]?<4 6/,\2_\\-*_[_2__$4>9XE_YX:5_P!_I?\ XBM/^U;+_G\M_P#OZO\
MC1_:ME_S^6__ ']7_&@#,\SQ+_SPTK_O]+_\16/XL?Q =+@\V'3 GV^RQLFD
M)W?:HMO5>F<9]LUU?]JV7_/Y;_\ ?U?\:Q/&&I6CZ3;A;J!C_:%B<"0'@7<1
M/>@"QYGB7_GAI7_?Z7_XBCS/$O\ SPTK_O\ 2_\ Q%:?]JV7_/Y;_P#?U?\
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M+>8, F:RP/T/Y4 1>$W\0#2Y_*ATPI]OO<[YI =WVJ7=T7IG./;%;'F>)?\
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MR_!7_"<ZW!X>T^^;2O#UO>Q6C6Z!&=6O#SA3@':N2!G ]J[;^R/$?_0Q6_\
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M_P"%BQ?]#)_Y2C_\56;!XZ1/$=]<G7BJ26EO&)O[,.&*O,2N-W&-X.>^[VH
MQ]GB3_H G_P2K6?H<>LBRD^Q:2]S#]IN-SMI <B3SG\Q<_[+[EQVVX[5W7_"
MQ8O^AD_\I1_^*K&\)^-ETW2YXGUPVK-?WLVPZ:7R'NI7#9W?Q!@V.V[':@#.
MV>)/^@"?_!*M5)8]=_M:VW:,RW7D2^7%_8ZX9-T>]L=\'8,]MWO7:_\ "Q8O
M^AD_\I1_^*K-G\=(_B.QN1KQ9([2XC,W]F'"EGA(7&[G.PG/;;[T 8^SQ)_T
M 3_X)5HV>)/^@"?_  2K75?\+%B_Z&3_ ,I1_P#BJ/\ A8L7_0R?^4H__%4
M<KL\2?\ 0!/_ ()5JI>QZ[]IT_SM&:.3SSY"C1U'F/Y;Y4CO\N\X_P!G/:NU
M_P"%BQ?]#)_Y2C_\56;JOCI+B^T:1=>,H@NVD9AIA'ECR)5W8W<\L!C_ &L]
MJ ,?9XD_Z )_\$JT;/$G_0!/_@E6NJ_X6+%_T,G_ )2C_P#%4?\ "Q8O^AD_
M\I1_^*H Y79XD_Z )_\ !*M5-4CUTVR?:=&:&/SX<,-'5<OYB[%S[MM&.^<=
MZ[7_ (6+%_T,G_E*/_Q59NO^.DO;&*-=>,Y%W;2;1IA7 6=&+9W=@N<=\8H
MQ]GB3_H G_P2K1L\2?\ 0!/_ ()5KJO^%BQ?]#)_Y2C_ /%4?\+%B_Z&3_RE
M'_XJ@#E=GB3_ * )_P#!*M&SQ)_T 3_X)5KJO^%BQ?\ 0R?^4H__ !5'_"Q8
MO^AD_P#*4?\ XJ@#BM(CUT:39?9-&:XM?(3R96T=6+IM&UB>^1@YJWL\2?\
M0!/_ ()5K8\->.DL/#FE6SZ\;=X;2*,PG3"Q0A -N=W.,8S6E_PL6+_H9/\
MRE'_ .*H Y79XD_Z )_\$JUGSQZS_;]F7TEUOOLT_E6_]D !X]\6]MO?:?+&
M>V\^M=U_PL6+_H9/_*4?_BJQKKQLLGC'2[T:X6CAL+N$W']FD!"\EL0NW=SN
M\LG/;9[T 8>EQZZ+9_LVC--'Y\V6.CJV'\QMZY]FW#';&.U6]GB3_H G_P $
MJUL:!XZ2RL98VUXP$W=S)M.F%LAIW8-G=W#9QVSBNM\/:I>^*()Y=/\ $,4B
MPOY;[M.VD' /=_0B@#SK9XD_Z )_\$JT;/$G_0!/_@E6O6O[,UW_ *#D/_@
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M'X<_Z"T'Z_X5T5% '._\+#\.?]!:#]?\*/\ A8?AS_H+0?K_ (5T5% '._\
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M(?\ (P>-_P#L,1_^F^SH Y'_ (1CP5_T'KS_ +_C_P"(H_X1CP5_T'KS_O\
MC_XBO5J* /&?$.@>$[/0-3N++7+MKR*UE>%3,#EPA*C[GKBM#_A&/!7_ $'K
MS_O^/_B*[GQW_P B/XA_[!UQ_P"BFK=H \I_X1CP5_T'KS_O^/\ XBC_ (1C
MP5_T'KS_ +_C_P"(KU:B@#RG_A&/!7_0>O/^_P"/_B*S_#V@>$[S0-,N+W7+
MM;R6UB>91,!AR@+#[GKFO9JPO G_ "(_A[_L'6__ **6@#AO^$8\%?\ 0>O/
M^_X_^(H_X1CP5_T'KS_O^/\ XBO5J* /*?\ A&/!7_0>O/\ O^/_ (BL_0]
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M)OH7_01B_)O\*Q_!?C'1K7P=H4,M_&DL=A CJ0>"(U!'2@#8_LO7?^@[%_X
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M(.1?\_E][_S.<L_%6K:?:06MO?R16\"+''&,850, =/05-_PFNN?]!.;]/\
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MQCD&2YP,;N,8//O[5L?V7KG_ $'8_P#P!7_XJ@#=HK"_LO7/^@['_P" *_\
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MX<OM8O/#%]X7BANC;P0:@-LLR;1(L@7LICDB/U+#^&@#J?\ A87AW_H*1?\
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MWQ9XCUFZAU6"WBBG2%3*K'S,01-N&!TRQ'/=37LU<OX0_P"1@\;_ /88C_\
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M;Q%_T,<7_@O7_P"*H_L;Q%_T,<7_ (+U_P#BJ/\ A87A[_H)Q_\ ?#?X4?\
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M()_WRW^%8_@OQAH]KX.T*&6^1)8["!&4JW!$:@CI0!L?V5KG_0=C_P# %?\
MXJC^RM<_Z#L?_@"O_P 51_PF^A_]!!/^^6_PH_X3?0_^@@G_ 'RW^% !_96N
M?]!V/_P!7_XJL?PGINLOI<YCUI(U^WWH*FS4Y(NI03][N<G';-;'_";Z'_T$
M$_[Y;_"L?PGXPT>WTN=)+Y%8W]ZX&UNC74K ]/0B@#8_LK7/^@['_P" *_\
MQ5']E:Y_T'8__ %?_BJ/^$WT/_H()_WRW^%'_";Z'_T$$_[Y;_"@ _LK7/\
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MM_A1_P )OH?_ $$$_P"^6_PH Q]"TW66U3Q$$UI$9;] [?8U.\_98#G[W'!
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M@$-VLKSWJ2RNMJN&;[- O0MQ\JJ,>V>]5&K&6B+C7A-VB?0E%>$_\+.\6?\
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M_@&G_P 51S>0<_D>[5A>#?\ D$7'_81O_P#TKFKR;_A9WBS_ )[C_P  T_\
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M\HLL4PVVB#YHY%=?XO[RBCF\@Y_(]_HKPG_A9WBS_GN/_ -/_BJ/^%G>+/\
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MK2M U768=1O+(SK]H-QO)C::1HQN8Y.U&1>?2NS_ +4LO^?N#_OZO^->M?\
M"+Z-_P! FQ_\!D_PH_X1?1O^@38_^ R?X5F\/?6YB\'=WYCR7^U++_G[@_[^
MK_C1_:EE_P _<'_?U?\ &O6O^$7T;_H$V/\ X#)_A1_PB^C?] FQ_P# 9/\
M"E]67<7U-?S'DO\ :EE_S]P?]_5_QH_M2R_Y^X/^_J_XUZU_PB^C?] FQ_\
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M,/JTOYV>5_V5X?\ [T'_ ($'_P"*H_LKP_\ WH/_  (/_P 57M__  B^C?\
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M;'_P&3_"CV+_ )F'U:7\[/$/[*\/_P!Z#_P(/_Q5']E>'_[T'_@0?_BJ]O\
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M@D+EGE'). .G<D"OG:Z_9XUO0_A[I6B^$/B=!IFJ06$<=U<75V7BFNLVXED
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MY5\&_A:GP\U#PYJFI>(=(GU.STG4=/U#[%<L(9Y+B\AN4>-';"*A6<!>PD4
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MR,@C\#0!KY\2_P!W2O\ OJ7_  HSXE_NZ5_WU+_A5_\ MS3O^@A:_P#?Y?\
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M6)P)E/ NHB3U]!0!;SXE_NZ5_P!]2_X49\2_W=*_[ZE_PJ__ &YIW_00M?\
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M"<]3@_D: &^$SX@_LN?RETS9]OO<[S)G=]JEW=!TSG'MBMC/B7^[I7_?4O\
MA53PAK%A'I,X>^ME/]H7QP9E'!NI2#U]#6U_;FG?]!"U_P"_R_XT 4,^)?[N
ME?\ ?4O^%&?$O]W2O^^I?\*O_P!N:=_T$+7_ +_+_C1_;FG?]!"U_P"_R_XT
M <QH1\0?VIXB\M=,W_;T\S<9,;OLL'3CIC'XYK8SXE_NZ5_WU+_A530-8L$U
M;Q*6OK90VH(5)F7D?9;<9'/J#^5;7]N:=_T$+7_O\O\ C0!0SXE_NZ5_WU+_
M (49\2_W=*_[ZE_PJ_\ VYIW_00M?^_R_P"-']N:=_T$+7_O\O\ C0!S%J?$
M'_"8ZIA=,\[[!:;LF3;M\RYQCCKG=G\*V,^)?[NE?]]2_P"%5+36+ >--5<W
MUL$.GV8#><N"1)<Y'7W'YUM?VYIW_00M?^_R_P"- %#/B7^[I7_?4O\ A1GQ
M+_=TK_OJ7_"K_P#;FG?]!"U_[_+_ (T?VYIW_00M?^_R_P"- %#/B7^[I7_?
M4O\ A15_^W-._P"@A:_]_E_QHH O4444 %%%% !1110!A>-/$$WAG0);ZW@6
MYF5XT6-B0#N8 YQZ DUQMUXN?QGHUY#<V20P0ZKIBJK9(D1K]$.X'_KF?P(K
MTF\:W6W<W1B$'&XS8V]>,YXZUR_CMXF\/'^SS;-<_P!IZ=W&W?\ ;(<;]O/]
M: -O_A&='_Z!-C_X#)_A1_PC.C_] FQ_\!D_PJAGQ9Z:-^<M&?%GIHWYRT >
M6_%'XL:+\-?%]]I]SX?T<:7I.EV^K7TMPJ+<312R7"%;6/'[QT^S$L/]M1WK
MRZP_;;\%ZMXKT?3K+P0)K347N(5;R(_-\V)1\@&,'<W /3&#7T?>Z/J6KZFC
MW=AX7O=0MH\JT\;22Q(^X<$@E0VUAZ'!]*JP^#I;26/RM"\'PR6H\Q-EJ5,0
M.>1\ORYP>?8T >;:3^T5X.\4:-XKN=%\*1O=Z'HLFK>1=PQ1B1DC1C$>,K@R
MJNX\'G'2N>TG]K;P0GA:TNM7\,VL>MRWD=BUC;Q1*I>2[>V1@7Z)N0$D\+NZ
M\5ZEH_P_T_1=:UOQ!I^E>$(;W6K<IJ%TA<K<0Q (P8?=V+@ \8'&:MZO\,[;
M4K."VU#PQX,DMD>%8HY+0A04E$L:CY>@D ;;T)[<T >5>'_VPOAEXCCM7MO"
M]PJW+IY7F648/EF1XRQ'9@T9^0_,>PKG;_\ ;"TF7[(=,^'"NL\T89)+=99H
MH9=/AOK>0QH,_O(WFP/^F)KWVQ^'ZZ!"PM_#_A"TCDO/M9)MV&;EY&8/DC[V
M^5L>F_ QTJ\GAR^TV47*:5X5M9-T*B98&0[D4QQ#.WJJN47T#$#KB@#Q'2/V
MOOA[>:/87-SX3,=W/;17$D,%O%(J'R6DF4,.I0HR@=7X*YS6I-\;3IOA7P#X
MCU#P1I,.F>(]$NM>N4C0/-;00P&Y*J-OS,82F/\ :)[5Z/\ V+::?>C3_P"S
M_ UM>9CE%KY023*C$;;<9X!P#VSQ6ZVBZV\$$+:=X<:&WC,,,9B<K'&5VE%&
M.%*\8'&.* /*] _:'\$>)YM;M;#PP@O=,TV^OF62WB*,]H=LJ9';<1M?[K#D
M&N.LOVL=%T6^2R\9?#U=#N;R6P33%$"#[8ET9P) &'RJ&@8<]<$]*]NT7P@-
M.O[NZTK2/",-U?6R+,]M&V9;?&U1P/\ 5D+T'RG%/\1VOD-;S:_!X-C;Y5@D
MU(8/R9P%+C^'>V,=-Q]: /!/!G[97A;6K>)]7\ BRN+QK065O;0QRF07%MYL
M63C&6:.9>.%PF>7%=IHG[1GA/7M,\37,'@6XBDT;1;[6!%):1'[2+6"VF>)"
M!]\K>6^/]_VKTNS\)S,()K31/"!$&4BDAMC^[P<$*0O&"N,#T]JM6NF:G;R@
M6UEX7CDEC? B1@73Y%?H.1\L0/\ NH#T% 'A^K?M6>"_!6K6^A^(="TF]UN<
MRF/^P/+N('"VYF0!B/O$*R'T(']X57US]M+X8>&F6+4O"MQ!<YNMT2V<;[1
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M ,!D_P *H9\6>FC?G+1GQ9Z:-^<M %__ (1G1_\ H$V/_@,G^%'_  C.C_\
M0)L?_ 9/\*H9\6>FC?G+1GQ9Z:-^<M %_P#X1G1_^@38_P#@,G^%'_",Z/\
M] FQ_P# 9/\ "J&?%GIHWYRT9\6>FC?G+0!?_P"$9T?_ *!-C_X#)_A1_P (
MSH__ $";'_P&3_"J&?%GIHWYRT9\6>FC?G+0!?\ ^$9T?_H$V/\ X#)_A1_P
MC.C_ /0)L?\ P&3_  JAGQ9Z:-^<M&?%GIHWYRT >*>,OBWH?P6\(_#234_#
M<%[IVJ:;')>WZ6JR/ JBUC&% W,[M<KCK]UB:] ^#/BC1_BWX0GUW_A&;/3
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MV[>O?- '5?VQX)_Y_M _[_0?XT?VQX)_Y_M _P"_T'^-9_\ P@*?]"WX3_\
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MY: +O]@:7_T#;3_OPO\ A1_8&E_] VT_[\+_ (52SXE]-*_.6C/B7TTK\Y:
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M"$_QH_X2+2O^@G9_^!"?XTG_  C6D?\ 0*LO_ =/\*/^$:TC_H%67_@.G^%
M"_\ "1:5_P!!.S_\"$_QH_X2+2O^@G9_^!"?XTG_  C6D?\ 0*LO_ =/\*/^
M$:TC_H%67_@.G^% "_\ "1:5_P!!.S_\"$_QH_X2+2O^@G9_^!"?XTG_  C6
MD?\ 0*LO_ =/\*/^$:TC_H%67_@.G^% "_\ "1:5_P!!.S_\"$_QH_X2+2O^
M@G9_^!"?XTG_  C6D?\ 0*LO_ =/\*/^$:TC_H%67_@.G^% "_\ "1:5_P!!
M.S_\"$_QH_X2+2O^@G9_^!"?XTG_  C6D?\ 0*LO_ =/\*/^$:TC_H%67_@.
MG^% "_\ "1:5_P!!.S_\"$_QH_X2+2O^@G9_^!"?XTG_  C6D?\ 0*LO_ =/
M\*/^$:TC_H%67_@.G^% 'COB/P!HWQ4^%W@>TEUVWTJ]T^Q39<I<A9(1+8O
M^T!A\P\P'GIMKG_AG\%;WP9\1=)\1:AXRT>?3[,W<HTNTF9(;=IC+B*%2<",
M>9G)^;.1TQ5KQS\3M.^#7P\^'.H2^'++5[:_M;9+U$M]]UL*P*TD:@?-CS<G
M/MZY'=_!;Q-IWQ7\'3ZY/X9L-+9-3O;%8$6.4%89WC5MX&#N"@Y''- '??\
M"1:5_P!!.S_\"$_QH_X2+2O^@G9_^!"?XTG_  C6D?\ 0*LO_ =/\*/^$:TC
M_H%67_@.G^% "_\ "1:5_P!!.S_\"$_QKS[QO:6'C9_'.AQZS:6AU3P];V<=
MPTR[59GO!S@\CYAD#G!]Z] _X1K2/^@59?\ @.G^%>?>-[BP\%-XYUN#0K.^
M?2_#UO>1VAA4*S*]X><#@?*,D<X'M0!X=8?LJW-OXPO]7G\<Z++9:B+E[C3M
MY,*&0PS0PHN?]5%<6\1 )R4RO'=-'_96O-,EC63QQHES:R237%S%+*S%MUPL
M\=L#D?N%>&'(X)S+P-U:7A']I>3Q)\1?^$0_X5_IDM[+-)!9S6\>(;OR9K=)
M94<C 1TDNI(\\D6Q)^]4DW[27V:]T>TE\$:*+K4]'BO5BP +>X,UNKI(VW 1
M8I9I<_W8#ZT =W\(/A78_#S4?#VK7NMZ-)JUEI6HZ=?O8SE8KE[F\AN5=48X
M0*R3?*!QYH X KV/_A(M*_Z"=G_X$)_C7C7P?^)7_"Q]0\.QWGA#2+;3M9TG
M4-2M]1M=KI+]FO(H%"H1E0\4\4@W<_-CL:]D_P"$:TC_ *!5E_X#I_A0 O\
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MZ7P7H#O86KNVGV[,S0J228UR2<4 ;?\ ;FF_]!"U_P"_R_XT?VYIO_00M?\
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M7J.G7<UM:2QK=&ZO(KK>%VX4*Z2X4# \W'85Z_\ \+!T#_G_ /\ R#)_\30
M?\59_P!0;_R+7-,NNOXMU];M=$:,Z3:?:1<>9Y/E>9=]<_\  \YXQCWKI?\
MA8.@?\__ /Y!D_\ B:X[6M;\-^)M8\5Z=>78>PU+1+:S;=%)ALO=A@0!GHX_
M.@#0BU Z;+<74=SX-M984C,TRR;#&I3]WN;L"GW<]NG%,G15M)KF9?!8MOL\
M1EF?[GDL"D18GC81N5<\$9 KY_U']F[1-1N)%D\9HUD(U*Q-92$S2K:"%!-\
MOSQK(H8+V!(K=F^"NAIIMQ%;>);4S7EK:17D=S82O;S26XU%H<QXQL26]@8)
MTQ; =Z /<=#?4/)A31CX6\H0AHUL2VWRBQP5"_PEMW3C.:UO^*L_Z@W_ )%K
MROX/^$/#'PMNH;Q=7CFNSI,>G7+1P2XF=;B:8R<KQDS'@ #K7JG_  L'0/\
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MW_XFLGPUXP\7V^G3*MWX74&]NWP\5X3EKB0GH.G/'MC/- &S\$/^$@_X4OX
M\G^S/)_X1_3]GF>9NV_9H\9QWQ7:_P#%2_\ 4*_\BUQ7P0\8:1;?!?P!#+=[
M9(_#^GHR^4YP1;1@]J[7_A-M%_Y_?_(3_P#Q- !_Q4O_ %"O_(M8]K_PD'_"
M8ZGC^S/.^P6F[/F;=OF7.,>^=V?PK8_X3;1?^?W_ ,A/_P#$UCVOC#2%\8ZG
M,;O]V]A:(K>4_)$ER3V_VA^= &Q_Q4O_ %"O_(M<[X"_M_\ L.Z^S_V;Y?\
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MPFVB_P#/[_Y"?_XF@ _XJ7_J%?\ D6C_ (J7_J%?^1:/^$VT7_G]_P#(3_\
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M:_\ ]#*?_ "/_&@#HJ*YW^Q-?_Z&4_\ @!'_ (T?V)K_ /T,I_\  "/_ !H
MZ*BN=_L37_\ H93_ . $?^-']B:__P!#*?\ P C_ ,: .BHKG?[$U_\ Z&4_
M^ $?^-']B:__ -#*?_ "/_&@#SKQ#\1=<^&WPI\!WVCZ"NNQ36")<1AR)!LL
M'E18U'5G>,+SP,^XKG_A7^T_J?CWQ[HWA.Z\/0Q3SF[%UJMM(XMI!$9=CP*X
MW,C>6!N/&<CTKN_!]O>V_@OP@LWBB"S-W9VR6=O-:Q%F?R P1,G+$*#TYP":
MV=-T&ZNCYUAXBM9#;.]KYD&G0_NF5B'CR.F&R"/7- '9T5SO]B:__P!#*?\
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M/2O6JX70H6OUC31_%]C,/($J)9V<!Q$68 X4\+N##Z@]P:V/[$U__H93_P"
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M#H?6][-?N$;[(@V'[+.<^_ (_'VH [6BL+^R-:_Z#_\ Y)I_C1_9&M?]!_\
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M'\_:MC^R-:_Z#_\ Y)I_C0!NT5A?V1K7_0?_ /)-/\:/[(UK_H/_ /DFG^-
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M>*M*\,WGP\U"ZU*_N)[2*YMW/DEHI;J'>YV_(K/92XR>CQGOSE3?MVWMK/\
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M]^9/_B:YWP%XMTJTT.Z26Z*L=5U*0#RG/RM?3LIX'<$&N_KE_AS_ ,B_=_\
M88U7_P!.%Q0!;_X3;1?^?P_]^9/_ (FL>Z\8:0WC'3)A=GRTL+M&/E/P3);$
M=O\ 9/Y5VM85Y_R/&D_]@Z]_]&VM !_PFVB_\_A_[\R?_$T?\)MHO_/X?^_,
MG_Q-;M% &%_PFVB_\_A_[\R?_$UCZ[XPTB75/#K)=DK%?N[GRGX'V6<>GJ17
M:UA>(?\ D+^&/^PB_P#Z27% !_PFVB_\_A_[\R?_ !-'_";:+_S^'_OS)_\
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MK8_X3;1?^?P_]^9/_B:/!O\ R"+C_L(W_P#Z5S5NT 87_";:+_S^'_OS)_\
M$T?\)MHO_/X?^_,G_P 36[10!Q6A>,-(BU3Q$SW9"RWZ.A\I^1]E@'IZ@UL?
M\)MHO_/X?^_,G_Q-'A[_ )"_B?\ ["*?^DEO6[0!A?\ ";:+_P _A_[\R?\
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MIV.ER>,K5;Z[#QVMM]CA+2!5+.JCV5"2/1:U5\.ZVHP/$0 R#@:?%VZ?R%>
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MZW_@/+_\31_PL'0?^?UO_ >7_P")H /[#U__ *&9O_ &.C^P]?\ ^AF;_P
M8Z/^%@Z#_P _K?\ @/+_ /$T?\+!T'_G];_P'E_^)H /[#U__H9F_P# &.C^
MP]?_ .AF;_P!CH_X6#H/_/ZW_@/+_P#$T?\ "P=!_P"?UO\ P'E_^)H /[#U
M_P#Z&9O_  !CH_L/7_\ H9F_\ 8Z/^%@Z#_S^M_X#R__ !-'_"P=!_Y_6_\
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M9F_\ 8Z/[#U__H9F_P# &.C_ (6#H/\ S^M_X#R__$T?\+!T'_G];_P'E_\
MB: #^P]?_P"AF;_P!CKF7M=2TSQ9X@N;OQ0EK!;:3:3W%W-:1*BQ"2[/S9X
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M#R__ !- !_8>O_\ 0S-_X QURUU#?:1XH\076H>*$M+>#2[)Y[J:TC"[#+=
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M!_PJ>VFM-:FO;M-+CTR:XDLF1KC;-+-YKX7ERTS9]3D]S7I/_"P=!_Y_6_\
M >7_ .)H /[#U_\ Z&9O_ &.L#PGI>K-K7C!5ULK(FJHLC_94/F-]BM3NQVX
M*C _NY[UO_\ "P=!_P"?UO\ P'E_^)K \)^+])CUKQA*UTPCGU5)(SY+_,HL
MK5<_=XY5ASZ4 =)_9&M?]!\_^ <=']D:U_T'S_X!QT?\)MHW_/VW_?B3_P")
MH_X3;1O^?MO^_$G_ ,30!C^--+U:/P=KKR:V98UL)RT?V5!N'EMD9'3-;']D
M:U_T'S_X!QUC^-/%^DW/@[788[IFDDL)T4>2XR3&P'5:V/\ A-M&_P"?MO\
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M^_$G_P 31_PFVC?\_;?]^)/_ (F@#'\%Z7JTG@[0GCULQ1M80%8_LJ':/+7
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MCH_LC6O^@^?_  #CH_X3;1O^?MO^_$G_ ,31_P )MHW_ #]M_P!^)/\ XF@
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M>)H?$*Z:=.\?V]W_ &D'-F([2+,X4$L5'4@;6YZ<4 >AT5SO]AZ]_P!#,_\
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M@;_P#CH W:*PO['UG_H8&_\  ..C^Q]9_P"A@;_P#CH W:*PO['UG_H8&_\
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M11_KM4_Y\+_P+_@!]77<7_A8WA[_ *"!_P"_$O\ \31_PL;P]_T$#_WXE_\
MB:2BC_7:I_SX7_@7_ #ZNNXO_"QO#W_00/\ WXE_^)H_X6-X>_Z"!_[\2_\
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M.P\):);7%XT4\-C!')&UO)E6$:@@_+V(K6HH_P!=JG_/A?\ @7_ #ZNNXO\
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MX?DCO&=+>^:24BWD^13;3KD_+_>91^-:U%'^NU3_ )\+_P "_P" 'U==Q?\
MA8WA[_H('_OQ+_\ $T?\+&\/?]! _P#?B7_XFDHH_P!=JG_/A?\ @7_ #ZNN
MXO\ PL;P]_T$#_WXE_\ B:R/%'CO0[W3(8X+QI'6^LY"!;R<*ES&S'[O95)_
M"M:BC_7:I_SX7_@7_ #ZNNXO_"QO#W_00/\ WXE_^)H_X6-X>_Z"!_[\2_\
MQ-)11_KM4_Y\+_P+_@!]77<7_A8WA[_H('_OQ+_\31_PL;P]_P!! _\ ?B7_
M .)I**/]=JG_ #X7_@7_   ^KKN9/@_QWH=AX2T2VN+QHIX;&".2-K>3*L(U
M!!^7L16O_P +&\/?]! _]^)?_B:2BC_7:I_SX7_@7_ #ZNNXO_"QO#W_ $$#
M_P!^)?\ XFN?O?&^C2>/]&O5NG-K#IE]#)+]GDPKO+:%%^[W$;G_ (":WZ*/
M]=JG_/A?^!?\ /JZ[F3X7\=Z'9:9-'/>-&[7UY( ;>3E7N9&4_=[JP/XUK_\
M+&\/?]! _P#?B7_XFDHH_P!=JG_/A?\ @7_ #ZNNXO\ PL;P]_T$#_WXE_\
MB:/^%C>'O^@@?^_$O_Q-)11_KM4_Y\+_ ,"_X ?5UW,G1/'>AVVI^())+QD2
MXOEDB)MY/G46T"Y'R_WE8?A6O_PL;P]_T$#_ -^)?_B:2BC_ %VJ?\^%_P"!
M?\ /JZ[B_P#"QO#W_00/_?B7_P")H_X6-X>_Z"!_[\2__$TE%'^NU3_GPO\
MP+_@!]77<R;;QWH:>+=2N6O&$$EC:QI)]GDP662X+#[O8.OYUK_\+&\/?]!
M_P#?B7_XFDHH_P!=JG_/A?\ @7_ #ZNNXO\ PL;P]_T$#_WXE_\ B:/^%C>'
MO^@@?^_$O_Q-)11_KM4_Y\+_ ,"_X ?5UW%_X6-X>_Z"!_[\2_\ Q-%)11_K
MM4_Y\+_P+_@!]77<Z:BBBOU<X@HHHH **** *FJ:I;:-9M=7<HBA4A2V">2<
M 8'N:X[QOKUEXA\*W$>F7JO+%J.GJ9$7.PF]B4, >"-RL/3*FNJ\0:%;^)-*
MEL+HNL,A4DQG!!!!'/X5Q/BCPII?@KPQ>75J)$26_P!.:0L2VU$O8V  ]!O;
MIZUS8F_L)V[/\BH[HE_L;6O^AA?_ , XZ/[&UK_H87_\ XZ/^$XT;_GZD_\
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MO_X!QT?V-K7_ $,+_P#@''1_PG&C?\_4G_@/+_\ $T?\)QHW_/U)_P" \O\
M\34\N+_Y]?\ DB_^1#3N']C:U_T,+_\ @''1_8VM?]#"_P#X!QT?\)QHW_/U
M)_X#R_\ Q-'_  G&C?\ /U)_X#R__$T<N+_Y]?\ DB_^1#3N']C:U_T,+_\
M@''1_8VM?]#"_P#X!QT?\)QHW_/U)_X#R_\ Q-'_  G&C?\ /U)_X#R__$T<
MN+_Y]?\ DB_^1#3N']C:U_T,+_\ @''1_8VM?]#"_P#X!QT?\)QHW_/U)_X#
MR_\ Q-'_  G&C?\ /U)_X#R__$T<N+_Y]?\ DB_^1#3N']C:U_T,+_\ @''1
M_8VM?]#"_P#X!QT?\)QHW_/U)_X#R_\ Q-'_  G&C?\ /U)_X#R__$T<N+_Y
M]?\ DB_^1#3N']C:U_T,+_\ @''1_8VM?]#"_P#X!QT?\)QHW_/U)_X#R_\
MQ-'_  G&C?\ /U)_X#R__$T<N+_Y]?\ DB_^1#3N']C:U_T,+_\ @''1_8VM
M?]#"_P#X!QT?\)QHW_/U)_X#R_\ Q-'_  G&C?\ /U)_X#R__$T<N+_Y]?\
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MSL?&%U;6VC^.XKZZN+>:ZC@2T02&**7R9&*D J%D.WD#FNG_ +&UK_H87_\
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M7_0PO_X!QT?V-K7_ $,+_P#@''1_PG&C?\_4G_@/+_\ $T?\)QHW_/U)_P"
M\O\ \31RXO\ Y]?^2+_Y$-.X?V-K7_0PO_X!QT?V-K7_ $,+_P#@''1_PG&C
M?\_4G_@/+_\ $T?\)QHW_/U)_P" \O\ \31RXO\ Y]?^2+_Y$-.X?V-K7_0P
MO_X!QT?V-K7_ $,+_P#@''1_PG&C?\_4G_@/+_\ $T?\)QHW_/U)_P" \O\
M\31RXO\ Y]?^2+_Y$-.X?V-K7_0PO_X!QT?V-K7_ $,+_P#@''1_PG&C?\_4
MG_@/+_\ $T?\)QHW_/U)_P" \O\ \31RXO\ Y]?^2+_Y$-.X?V-K7_0PO_X!
MQT?V-K7_ $,+_P#@''1_PG&C?\_4G_@/+_\ $T?\)QHW_/U)_P" \O\ \31R
MXO\ Y]?^2+_Y$-.X?V-K7_0PO_X!QT?V-K7_ $,+_P#@''1_PG&C?\_4G_@/
M+_\ $T?\)QHW_/U)_P" \O\ \31RXO\ Y]?^2+_Y$-.X?V-K7_0PO_X!QT?V
M-K7_ $,+_P#@''1_PG&C?\_4G_@/+_\ $T?\)QHW_/U)_P" \O\ \31RXO\
MY]?^2+_Y$-.X?V-K7_0PO_X!QT?V-K7_ $,+_P#@''1_PG&C?\_4G_@/+_\
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MB264?(W&(SZUV/A?XX_$I_#GC>75O!>;[1+:S?3G$+C[;)*<2[U!X"Y!PO\
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M_ YJ/^%?6O\ T%-8_P# YJ/]2\7_ ,_8_C_D'UB/8?13/^%?6O\ T%-8_P#
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MX;N_N?\ D>ET5Y]_;.F?W]=_\&1_PJ!]6M#?0NMQK8M1&XDC.H'<SDKM(..
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M]"_K7_@.G_Q='_"82?\ 0OZU_P" Z?\ Q==%10!SO_"82?\ 0OZU_P" Z?\
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M<)\%-4^(&HW5O)XN=GLIM&BF5'MEB>&Y-Q,&1R/O,(Q$">AQD?>KUV@#G?\
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M (3"3_H7M:_[\)_\70 C>"8F!!U?62#P0;]^:;#X$M[:)8HM5U>*-1A42^8
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MV6SC)( 7@#U/K76?\)A)_P!"]K7_ 'X3_P"+KF9-<&H^*_$$,^@ZL\5UI-I
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M"XDPOWOX1A?PH Q?^$]C_P">6K?^#C_ZU'_">Q_\\M6_\''_ -:NO_LW0_\
MH3;S_P !4_\ BZ/[-T/_ *$V\_\  5/_ (N@#D/^$]C_ .>6K?\ @X_^M5*+
MQ@(]9NKLQ:EY<MO#$,:M\^4:0G)QR/G&!VY]:[S^S=#_ .A-O/\ P%3_ .+K
M*MM/T8^*M14^%+IHA96Q6'[.N5.^?+8W=\ ?\!]J ,7_ (3V/_GEJW_@X_\
MK5FZ!XK_ +*L98)(M0+/=7,X\G5=BXDG>09&/O8<9/<Y/>O0?[-T/_H3;S_P
M%3_XNL+P78:1)H]P9O"UU=/_ &E?@2+;JP"B\F"IRW51A<=MN* ,W_A/8_\
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M'0VZCS!]GF^4?-SSAO\ @- &+_PGL?\ SRU;_P ''_UJ/^$]C_YY:M_X./\
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M#L3DUS?B7Q'8>,/#<L5C+,$CU33HFF0[#S>Q#<ASGL<'U% '?45SO_"%1?\
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M/O=.>>HR.:Y[1?C/\.=7MX)Y?&.L:1%/;QW43:I?/ 'B=49&&3T*.K?[N2<
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MG;R\TST,-6P^&BX\][N^S78]GHK@_"C6_BG[5LN]8M_(V9W7[-G=G_XFM_\
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M4U7_ ,#7H W:*PO^$3C_ .@IJO\ X&O1_P (G'_T%-5_\#7H / G_(C^'O\
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M,1WY4?Z>G"CL-OE_CF@#K?\ A+Y?^A>UK_OQ'_\ %T?\)?+_ -"]K7_?B/\
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M-$\0?M&V_P!KO[K2H6N19VUQ):W2)]G,WFR-+!%M.0OER(-_7*8YQ0!UVN_
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M +\I_P#%T?\ "3R?] /5?^_*?_%UNT4 87_"3R?] /5?^_*?_%T?\)/)_P!
M/5?^_*?_ !=;M% '%>"_$<D'@[0HQH^IRA+"!=\<2%6Q&O(^;I6Q_P )/)_T
M ]5_[\I_\71X$_Y$?P]_V#K?_P!%+6[0!A?\)/)_T ]5_P"_*?\ Q=<[?>(7
M;XB:)-_9&I II5^GE&)=[9FLSD#=T&W!_P!X5W]<OJ'_ "4[0/\ L#ZE_P"C
MK&@"EX3\1R0Z7.HT?4Y,W]ZV4B0CFZE./O=1G!]P:V/^$GD_Z >J_P#?E/\
MXNCP;_R"+C_L(W__ *5S5NT 87_"3R?] /5?^_*?_%T?\)/)_P! /5?^_*?_
M !=;M% '%:%XCDCU3Q$W]CZF^^_1L+$F5_T6 8/S=>,_0BMC_A)Y/^@'JO\
MWY3_ .+H\/?\A?Q/_P!A%/\ TDMZW: ,+_A)Y/\ H!ZK_P!^4_\ BZ/^$GD_
MZ >J_P#?E/\ XNMVB@#BK7Q'(/&.IR?V/J9+6%HNP1)N&)+GD_-T.>/H:V/^
M$GD_Z >J_P#?E/\ XNBS_P"1XU;_ +!UE_Z-NJW: ,+_ (2>3_H!ZK_WY3_X
MNC_A)Y/^@'JO_?E/_BZW:* ,+_A)Y/\ H!ZK_P!^4_\ BZ*W:* "BBB@ HHH
MH **** ,/6O%UIH=R\$L-Q+*L:R!8DSNRX4 9(YR?RKGO$^OVOBOP_-;VZW4
M*1ZGIB&?[F=]W P*,#G.TJ<\8W"NMU30K'65(NX%ERH3/0@;@W!^H!K \;VE
MOHGA93:6I"C5-/E,,"C<Y%Y , >N  /PH N_\(5%_P!!?6O_  82?XT?\(5%
M_P!!?6O_  82?XT?\)?-_P!"[K7_ 'YC_P#CE'_"7S?]"[K7_?F/_P".4 '_
M  A47_07UK_P82?XUQ_CKQ+X1^&M[86WB3Q3K&F&]MY[B&1[V9E*PM"KCY<G
M.9T[=,GM78?\)?-_T+NM?]^8_P#XY7(^-_#6@_$.^TZ\UWP?K5W/I\-S;V[;
M$4*DX02C DYSY:?3% &/_P +5^&/FS(?B-<KY,L\,CMJ4P1&AQYNY\;0%W*,
MDX)( ))IEC\5OAQJU[HMIIOCG5-4FUBX2UM!9W=Q(#(V[AB!A"-A#!L%>,@9
M%<I-^R_\-[C5;VZG\$^(I[2^CGCN]/E=6@N/-,9.Y?,Y"^6NU>@(SUKH/#?P
M6\%>$M2L+_2_!WB.VN;*X-Y&PE&&N"P9YF'F?,[X 9C]X<&@##N_VD?AE;3F
MU3Q+XDN;]3=*]G'=LLD9@OH[)MY=U5=TLJE22 RY/:EO_P!HKX?Z;J5SI]QJ
M?BM+R".)VB^W)U<VX"[O.PI!NHN6(4_-M+8K0N?@!\/KC5+_ %-/ NO6FI7S
M;YKRV=4E)\V*7.X2<8>",_@?4UU%IX)\,VMC]E;P3J]R#=P7LDUS%')+-+$(
MPC.Y?+?ZI"0>"10 DOC/P=9Z]IVBW_BC6=.U34([=[:VN+Z3+F8JJ+E25!W.
MB<G&YU ))%9%W\6/ NER:G+JGB+Q#I&D6-S/9'6KVZD6RGG@G,$\4;@DEDE#
M*00/N,1D*2-K6/!OAO7?%2>(KSP9K,FJI';Q+*$0 +#<P7,0"B3'$MM"W_ <
M=ZYSQ+\#O OBV>^EU+P5XAF^U7$UUY8E"QP2S/OG>)1+A#(V2Y'WLG/4T +I
MOQL^&VH:MJ>GOXQUFRFT^[@L9'N;V41M+*KN@5E)&W:C$L< #J:O:C\3O ]K
MX;AUNP\2:]KMK/>-81)IUZ^]Y5MFNG_UC( JP(9"Q(&W!R<BLZV^!'P^M+G6
M)XO .M(^K8^U#Y</B.2,8'F<?)*XX]:I^"O@3X>\)_#Y/"EQI7BO5XX[_P#M
M&+4)O+BN8I/LRVBA&1QM MU$6!U4D'K0!;7XY_#*2T:XC\9ZW,@@@FQ'<SEF
M\T$H@'=L*2<<#N:];_X0J+_H+ZU_X,)/\:\D'P'^'\=A86<'@37;6"Q18H!
MP0K&-_R9$G*D.P([BO6_^$OF_P"A=UK_ +\Q_P#QR@ _X0J+_H+ZU_X,)/\
M&C_A"HO^@OK7_@PD_P :/^$OF_Z%W6O^_,?_ ,<H_P"$OF_Z%W6O^_,?_P <
MH /^$*B_Z"^M?^#"3_&C_A"HO^@OK7_@PD_QH_X2^;_H7=:_[\Q__'*/^$OF
M_P"A=UK_ +\Q_P#QR@ _X0J+_H+ZU_X,)/\ &C_A"HO^@OK7_@PD_P :/^$O
MF_Z%W6O^_,?_ ,<H_P"$OF_Z%W6O^_,?_P <H /^$*B_Z"^M?^#"3_&C_A"H
MO^@OK7_@PD_QH_X2^;_H7=:_[\Q__'*/^$OF_P"A=UK_ +\Q_P#QR@ _X0J+
M_H+ZU_X,)/\ &C_A"HO^@OK7_@PD_P :/^$OF_Z%W6O^_,?_ ,<H_P"$OF_Z
M%W6O^_,?_P <H /^$*B_Z"^M?^#"3_&C_A"HO^@OK7_@PD_QH_X2^;_H7=:_
M[\Q__'*/^$OF_P"A=UK_ +\Q_P#QR@ _X0J+_H+ZU_X,)/\ &C_A"HO^@OK7
M_@PD_P :/^$OF_Z%W6O^_,?_ ,<H_P"$OF_Z%W6O^_,?_P <H \P?Q/X=^'7
M@GP++K^K:]9V^JVEK$MS!=.+:W9A"@WG<-B[I5P!G #'&U6(ZOP#>:!\3-"E
MUC0==UZXL$N[BR\R6[FC)DAD:-_E;!QN4XR!7(2^"M"^)/@_P*VO>'?$%Z-(
MTU4A%K((X)EE@C20.HD =65<?,.C-TR:['P'8Z?\.- _L?1O#?B 6IN)KIVN
M=LTCRRN7D=F:3))9B?QH Z+_ (0J+_H+ZU_X,)/\:/\ A"HO^@OK7_@PD_QH
M_P"$OF_Z%W6O^_,?_P <H_X2^;_H7=:_[\Q__'* #_A"HO\ H+ZU_P"#"3_&
MN:?P]:Z=XL\033ZKK"V]KI-I</)'>2M(5\R[)'&2V O '<G'6NE_X2^;_H7=
M:_[\Q_\ QRL&S\4RKXZU>7^P=6);3;)?+$4>Y<2W1R?GZ'/'T- 'G%]\?/A]
MIFEKJ5WK7BRWL7T:#74F>67YK646Y! W9)47<1/&.),$E& ED^-GA"WF>.XE
M\;6Y6%Y?F=VRZ7B63Q85R?,%P_EXQR5;!(4FK,'P1\$0ZA]I;P?XDN(O[/AT
MPV4\P>V-O%:M:HOEF7'$3./JQ/4UHV_PP\)VME);IX0\0YDC5))V<&60K-=3
MAV?S,E_-O;B3=UW,#U44 2^ _'GA7XB:M::7IFK>)XM0N+.ZO1!=7$J!$M[K
M[+*"X)0L)>,*QXP3C(SZ#_PA47_07UK_ ,&$G^-<?X*\,:-X!M=#@TOPSXB*
MZ+97&GV3W++*T<$TD4DB9:3GYH(L9Z;?>NP_X2^;_H7=:_[\Q_\ QR@ _P"$
M*B_Z"^M?^#"3_&N1U73;#PUKWB?4;[5-:%GI^CVMU*\-U*\I427>0 .6^[P/
M4GUKKO\ A+YO^A=UK_OS'_\ '*YL:^;WQAKT<V@:N\5QI5G"\(B3>%\R[R3\
M_0[B!]#0!P>J_''P)HOGBZU;Q8C+#;SP*)I"UT)HRZ"(;LDX#=<?=;&<&JEM
M^T-\.KR^U.P@UOQ9-J.GI$TMC'+(T[.XB)B5 Q)=!,NX=!AL$[3C6B^"O@N.
MYO9G\)>)IQ=*H:*:??'&RVQM4=%,OR,L)*@CIGUJD/V?/AZEW/=1^"/$45S-
M!+ TT<VU_P![;?9I7!$N0[QX#-U)4'J* .G^'OC+PO\ $V\>TT;6/$OVA+)+
MYUN+F5 (VEEB #9*L=T+\J2,8()S7=_\(5%_T%]:_P#!A)_C7,>$=)TSP4MH
M-.\->("]K8)IL<MQLD?R$=G523)S@N?PP.U=/_PE\W_0NZU_WYC_ /CE !_P
MA47_ $%]:_\ !A)_C6!X3\,1OK7C"/\ M'4P(=51 RWCAG_T*U;+'/)^;&3V
M ':M_P#X2^;_ *%W6O\ OS'_ /'*P/"?B*1-:\82?V-J;&754<HL:;H_]"M5
MPWS\'Y<\9X8?2@#I/^$3B_Z">J_^!S_XUQ7QO\,1V_P7\?RC4=3<IX?U!MLE
MX[*<6TAP1GD>U=K_ ,)/+_T M5_[]1__ !=<5\;_ !%)/\%_'\9T;4X@_A_4
M%\R2- JYMI.3\_2@#=\:>&([?P=KLHU'4W*6$[;9+QV4XC8X(SR/:MC_ (1.
M+_H)ZK_X'/\ XUC^-/$4D_@[78SHVIQ!["=?,DC0*N8VY/S]*V/^$GE_Z 6J
M_P#?J/\ ^+H /^$3B_Z">J_^!S_XT?\ ")Q?]!/5?_ Y_P#&C_A)Y?\ H!:K
M_P!^H_\ XNC_ (2>7_H!:K_WZC_^+H XKX(>&([CX+^ )3J.IH7\/Z>VV.\=
M5&;:,X SP/:MWP7X8CN/!VA2G4=30O80-MCO'51F-3@#/ ]JPO@AXBD@^"_@
M",:-J<H3P_IZ^9'&A5L6T?(^?I6[X+\120>#M"C&C:G*$L(%\R.-"K8C7D?/
MTH V/^$3B_Z">J_^!S_XT?\ ")Q?]!/5?_ Y_P#&C_A)Y?\ H!:K_P!^H_\
MXNC_ (2>7_H!:K_WZC_^+H /^$3B_P"@GJO_ ('/_C6/X3\,1SZ7.QU'4TQ?
MWJX2\<#BZE&>O4XR3W.:V/\ A)Y?^@%JO_?J/_XNL?PGXBDATN=1HVIR9O[U
MLI&A S=2G'W^HS@^X- &Q_PB<7_03U7_ ,#G_P :/^$3B_Z">J_^!S_XT?\
M"3R_] +5?^_4?_Q='_"3R_\ 0"U7_OU'_P#%T '_  B<7_03U7_P.?\ QK'M
M?#$;>,=3B_M'4P%L+1MPO'W',ER,$YY'' ]SZUL?\)/+_P! +5?^_4?_ ,76
M/:^(I!XQU.3^QM3):PM%\L1IN&)+GD_/T.>/H: -C_A$XO\ H)ZK_P"!S_XU
MSO@+PW'<Z'=.=0U*/&JZDF([MU'RWTZYP.YQDGN23WKHO^$GE_Z 6J_]^H__
M (NN=\!>()+?0[I1H^I39U74GW1QH0-U].<<OU&<'W!ZT =%_P (G%_T$]5_
M\#G_ ,:Q[KPQ&OC'3(O[1U,AK"[;<;Q]PQ);# .>!SR/8>E;'_"3R_\ 0"U7
M_OU'_P#%UCW7B*0^,=,D_L;4P5L+M?+,:;CF2VY'S]!CGZB@#D/VB]-CT3X*
M^,)!?ZI(TVE7<(#7C,O-O(?F!X((4@CWJ2V\5V\-M$DLVM3RJ@#RG46&\@<G
M X&:/V@[MM?^#7BZ!M'U>)TTN[>,K C9?R)%4$!B<9;L*&\&V.K::?+M?$20
MW,/RR1Q1QN%9>"#NRIP?J*Z(>STYK>>_Z'F8A8KF?L=OE^IZ'_PB<7_03U7_
M ,#G_P :Q]=\,1QZIX=7^T=3;S+]URUXY*_Z+.<CG@\8SZ$^M<__ ,(=%_S\
M?$#_ ,&[_P#QRLK6?!\0U'0?]*\=#_36XDU9RQ_T>;[G[SAOZ;JYSTSTW_A$
MXO\ H)ZK_P"!S_XT?\(G%_T$]5_\#G_QKA_^$.B_Y^/B!_X-W_\ CE'_  AT
M7_/Q\0/_  ;O_P#'* .X_P"$3B_Z">J_^!S_ .-8_BSPQ'!I<##4=3?-_9+A
M[QR.;J(9Z]1G(/8XKG_^$.B_Y^/B!_X-W_\ CE97B;P?$-.A_P!*\=#_ $VT
MYFU9RO\ Q\1]/WGWO3WQ0!Z;_P (G%_T$]5_\#G_ ,:/^$3B_P"@GJO_ ('/
M_C7#_P#"'1?\_'Q _P#!N_\ \<H_X0Z+_GX^('_@W?\ ^.4 =Q_PB<7_ $$]
M5_\  Y_\:/\ A$XO^@GJO_@<_P#C7#_\(=%_S\?$#_P;O_\ '*/^$.B_Y^/B
M!_X-W_\ CE '0>"_#$=QX.T*4ZCJ:%["!ML=XZJ,QJ< 9X'M6Q_PB<7_ $$]
M5_\  Y_\:\R\)^#XCX5T8_:O'3?Z%#S!JSB,_(/NCS!A?3VK5_X0Z+_GX^('
M_@W?_P".4 =Q_P (G%_T$]5_\#G_ ,:YV^\-QK\1-$@_M#4B'TJ_?>;M]XVS
M68P#V!W<CO@>E9/_  AT7_/Q\0/_  ;O_P#'*P;SP?%_PG6D#[5XX'_$MO?E
M;57\X_O;7E3YGW?[W/4IUQP =]X3\,1SZ7.QU'4TQ?WJX2\<#BZE&>O4XR3W
M.:V/^$3B_P"@GJO_ ('/_C7F7AKP?$=.F_TKQT?]-N^8=6<+_P ?$G7]Y][U
M]\UJ_P#"'1?\_'Q _P#!N_\ \<H [C_A$XO^@GJO_@<_^-'_  B<7_03U7_P
M.?\ QKA_^$.B_P"?CX@?^#=__CE'_"'1?\_'Q _\&[__ !R@#H-"\,1R:IXB
M7^T=37R[]%RMXX+?Z+ <GGD\XSZ >E;'_")Q?]!/5?\ P.?_ !KS+1O!\1U'
M7O\ 2O'1_P!-7B/5G##_ $>'[_[SEOZ;:U?^$.B_Y^/B!_X-W_\ CE '<?\
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M_C1_PKSPW_T![;\C_C0!T5%<[_PKSPW_ - >V_(_XT?\*\\-_P#0'MOR/^-
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M_0+@_(T?\(/H/_0+@_(T 8?P)_Y(A\//^Q=T[_TFCK<\"?\ (C^'O^P=;_\
MHI:XKX(>#M%NO@OX FETZ%Y9/#^GN[$'))MHR36[X+\':+=>#M"FETZ%Y9+"
M!W8@Y),:DF@#M:*PO^$'T'_H%P?D:/\ A!]!_P"@7!^1H W:PO!O_((N/^PC
M?_\ I7-1_P (/H/_ $"X/R-8_A/P=HMQI<[R:="["_O4!(/1;J50/P  H [6
MBL+_ (0?0?\ H%P?D:/^$'T'_H%P?D: -VL*S_Y'C5O^P=9?^C;JC_A!]!_Z
M!<'Y&L>U\':*WC'4X3IT)B2PM'5<' )DN03^.T?E0!VM<O\ #G_D7[O_ +#&
MJ_\ IPN*M_\ "#Z#_P! N#\C7.^ O".C7FAW4DVGPR.-5U*,%A_"M].JC\
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M9Z K(W(YSSV%/G<XN*;^;\UY#6%A@Y1K2EMV7D_,]MK"\9?\@BW_ .PC8?\
MI7#7E_\ PD%C_P!"_IWY/_C5>_U2RO8%C&B6,.V6.7<@;)V.K;>O0[<'V)K'
MD7\R.KZ_1\_N/=:*\2_X2"Q_Z%_3OR?_ !K4\,W6FZYKEM8RZ%8QQR[LL@;(
MPI;N?:CV=]FAQQU*34===-NYZS16%_P@^@_] N#\C1_P@^@_] N#\C61Z >!
M/^1'\/?]@ZW_ /12UNUQ7@OP=HMUX.T*:73H7EDL('=B#DDQJ2:V/^$'T'_H
M%P?D: -VN7U#_DIV@?\ 8'U+_P!'6-6_^$'T'_H%P?D:YV^\(Z,GQ$T2V&GP
MB"32K^1DQP66:S"G\ S?G0!T7@W_ )!%Q_V$;_\ ]*YJW:XKPGX.T6XTN=Y-
M.A=A?WJ D'HMU*H'X  5L?\ "#Z#_P! N#\C0!NT5A?\(/H/_0+@_(T?\(/H
M/_0+@_(T 'A[_D+^)_\ L(I_Z26];M<5H7@[19M4\1(^G0LL5^B("#\H^RP-
MC\V)_&MC_A!]!_Z!<'Y&@#=HK"_X0?0?^@7!^1H_X0?0?^@7!^1H +/_ )'C
M5O\ L'67_HVZK=KBK7P=HK>,=3A.G0F)+"T=5P< F2Y!/X[1^5;'_"#Z#_T"
MX/R- &[16%_P@^@_] N#\C1_P@^@_P#0+@_(T ;M%87_  @^@_\ 0+@_(T4
M;M%%% !1110 4444 4=2T.QU<$7ELEP"NP[QVW!OY@'\*YCQEHEIH7AZ272[
M"&.XFU33G9%.P2N+V' )P<<D_3)K0\2:#J&I27[V=W)"9M/>",+,5"S;@4/L
M#T)]*P=7TO4]/M[Z6]E#V\^LZ<T \PL?^0DK9P?N_(T2X_Z9T =#_:_B3_H7
MK;_P9#_XW4 \2:X7V#1;$MG&W^U5SG_OW74UY!_97B,Z_P";]H_XE?3[']E^
M?.W'^L_WN: .]_M?Q)_T+UM_X,A_\;KF/%W@QO'5[87>M^#;.]N+&&X@MW;4
M\;$F""4?ZON$7\JPOBRWQ1T_7O$4W@6RCNA?:1IL%A<W%POEV=Q'=737+F%E
M(8M#+$!R,E0.,9JE^SAI_P 7]/EOU^)ES#<)+;QS_(8R%NVP91%M4$1YW<-G
M'R[<"@#-U/\ 9;\'ZO&Z77PVL75YIIR!JS#YI1&L@^YT(B08]!71Q?![3K;0
M7T>#P-:6]FVH#55\G5BKQW0B$/FJP3*GRQLX[$CO7L5% 'A]Q\ _#\]O;0_\
M*[T^*.UDAFMQ#J93R)(8V2%TQ'\I0,=I'0X/:I=(^!NC>'])U33=,\!6=A:Z
MDUL\XM]5*-NMY?.A96$>05E)DR/XB3WKVNB@#PF;]G?PU-()/^%=6$<H.]9(
M]5*LLI<.TP(3_6$CE^I'%:&D?!/1=!U"RO+#X>:;:RV5K<65NL>I86.&>262
M50/+Q@M/-]-YKV:B@#P73/V<?#6CZ:MC:?#VSAA6:"Y0C5VWI+"LPBD5MF0R
M_:9B#V+9K6U'X,Z5JUGX>M+OP#836VA6MO8V<3:F=H@@*F&-QY?SJA0$ ]#G
MU->R44 ?.NG?LI^"M*=6MOAGIZ!7A?:=68C]T\DB#&SH'ED;'JU>F>"]"O?A
M]X:M-!T+PI:V6EVID:*$:GG!>1I'.3'R2[L?QKOJ* .=_M?Q)_T+UM_X,A_\
M;H_M?Q)_T+UM_P"#(?\ QNNBHH YW^U_$G_0O6W_ (,A_P#&Z/[7\2?]"];?
M^#(?_&ZZ*B@#G?[7\2?]"];?^#(?_&Z/[7\2?]"];?\ @R'_ ,;KHJ* .=_M
M?Q)_T+UM_P"#(?\ QNC^U_$G_0O6W_@R'_QNNBHH YW^U_$G_0O6W_@R'_QN
MC^U_$G_0O6W_ (,A_P#&ZZ*B@#G?[7\2?]"];?\ @R'_ ,;H_M?Q)_T+UM_X
M,A_\;KHJ* .=_M?Q)_T+UM_X,A_\;H_M?Q)_T+UM_P"#(?\ QNNBHH \17X>
M6OQ)\$^#?^$@\%V.N6]AID*6_P!IU#"NC)"QW)LP06AB?!SAD4]JZWP3X>O?
MA]H?]DZ)X6@M[,SRW+!]5+LTLCEY'+&/))9B3]:YW5?#7B'7?AU\-[KP_?WD
M#:?;137-G:77V<7<;6+H%+X/(<H1V!.[^$5Y7HW@7]HC1%TV_M];B$,.EW$#
M:;-<?:)899-2MYF*O*&61EMEEBC+@X"^K9 !]*_VOXD_Z%ZV_P#!D/\ XW1_
M:_B3_H7K;_P9#_XW3?AKIVK:/\.?"MAKTQN-=M=*M(+^4OO+W"PJLK;N^7#'
M/>NDH YW^U_$G_0O6W_@R'_QNL&SU3Q /'6KL-"MS,=-L@T?]H#"J);K!SY?
M.26X[8]Z] KE6M6OO&?B2V2>2U>;1K*-9X3AXR9+P!E]QG(^E '":#\&]/\
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M[;@1M]BM0 #L^;Y0ISQ][';)]!KE_"'_ ",'C?\ [#$?_IOLZ +?]IZ]_P!
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MXJNE\7:E*+6PW-8VJE3J:A0!)<$$-MY/)X[8'K6+_P *7U'_ *"%A_X#/_\
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M06\,YD^SO\P=I5Q][MY9_.KW_"E]1_Z"%A_X#/\ _%4 0?\ "+'_ *#&L_\
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MRL*LSJG^KZ LQ_&MS9XF_P"@':?^#'_[77+5RG/'-NE&:7^-?_)%*=/J4_\
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M  A&A?\ 0,@_(U<V>)O^@':?^#'_ .UT;/$W_0#M/_!C_P#:Z/[)X@[2_P#
MU_\ )!STBG_PA&A?] R#\C2-X%T!QAM*MV&0<%>XY%7=GB;_ * =I_X,?_M=
M5=1OO$.F6Z33:';;&FB@&W4,G=)(L:_\L^F6%']D\0=I?^!K_P"2#GI#?^$(
MT+_H&0?D:/\ A"-"_P"@9!^1JYL\3?\ 0#M/_!C_ /:Z-GB;_H!VG_@Q_P#M
M=']D\0=I?^!K_P"2#GI%/_A"-"_Z!D'Y&C_A"-"_Z!D'Y&KFSQ-_T [3_P &
M/_VNC9XF_P"@':?^#'_[71_9/$':7_@:_P#D@YZ127P+H"*%72K=5 P %P *
M7_A"-"_Z!D'Y&G:7?>(=7TRTOH-#MO(NH4GCWZA@[64$9'E]<&K6SQ-_T [3
M_P &/_VNC^R>(.TO_ U_\D'/2*?_  A&A?\ 0,@_(TA\": 7#G2K<N 0&V\@
M'&1^@_*KNSQ-_P! .T_\&/\ ]KJC-JFOPZU::6VAV_VJYMYKE,:A\NR)HE;)
M\OKF9,?C1_9/$':7_@:_^2#GI"KX%T!!A=*MU&2<!>YY-+_PA&A?] R#\C3M
M.OO$.IV[S0Z';;%FE@.[4,'='(T;?\L^F5-6MGB;_H!VG_@Q_P#M=']D\0=I
M?^!K_P"2#GI%/_A"-"_Z!D'Y&C_A"-"_Z!D'Y&KFSQ-_T [3_P &/_VNC9XF
M_P"@':?^#'_[71_9/$':7_@:_P#D@YZ12'@70%+$:5;@L<DA>IZ?TI?^$(T+
M_H&0?D:=:7WB&]N+V&/0[;?:3""3.H<;C&DG'[OIB1?UJUL\3?\ 0#M/_!C_
M /:Z/[)X@[2_\#7_ ,D'/2*?_"$:%_T#(/R-'_"$:%_T#(/R-7-GB;_H!VG_
M (,?_M=&SQ-_T [3_P &/_VNC^R>(.TO_ U_\D'/2*7_  @N@!BW]E6^X@ G
M;R1_DFE_X0C0O^@9!^1IT=]XAEU.XL1H=MY\,,<[9U#C:[.%P?+ZYC;]*M;/
M$W_0#M/_  8__:Z/[)X@[2_\#7_R0<](I_\ "$:%_P! R#\C1_PA&A?] R#\
MC5S9XF_Z =I_X,?_ +71L\3?] .T_P#!C_\ :Z/[)X@[2_\  U_\D'/2*?\
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M_#7_ $!K3_OBC_A7?AK_ * UI_WQ0!T5%<[_ ,*[\-?] :T_[XH_X5WX:_Z
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M.:/^TE\.-:OI;*W\"WDEXD:[8DB&)Y6N8H46)VVJZLLT<JOD91@Q '- '?\
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M (/_ /[GJ3PGX.T2XTN=Y=,MW87]Z@)7LMU*H'X  ?A6Q_P@^@?] JV_[XH
MP_\ A)/'O_0D:;_X/_\ [GH_X23Q[_T)&F_^#_\ ^YZW/^$'T#_H%6W_ 'Q1
M_P (/H'_ $"K;_OB@#BM"\1>.5U3Q$4\&:>[-?H7!UW&T_98.!^XYXP<^^.U
M:D7CSQ)8^(_#VFZYX6MM.MM9O)+**ZMM6^T%)%MI[CE/*7@K;L,YZD59T+P=
MHDVJ>(D?3+=EBOT1 5^Z/LL#8'XL3^-87C_P=HD/BOX:HFF6ZK+X@F1P%^\/
M[*U!L'\5!_"@#U*BL+_A!] _Z!5M_P!\4?\ "#Z!_P! JV_[XH +/_D>-6_[
M!UE_Z-NJW:XJU\':(WC'5(3IEN8DL+1U3;P"9+D$_CM'Y5L?\(/H'_0*MO\
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MJW807_\ JP+>&';GR^?]3G_@6.U=G10!A?VEK_\ T!+;_P &'_VNC^TM?_Z
MEM_X,/\ [76[10!R?B >(-:T'4M/72+6)KNVDMQ(;_(7<I7./+YQFK_]I:__
M - 2V_\ !A_]KK=HH PO[2U__H"6W_@P_P#M=']I:_\ ] 2V_P#!A_\ :ZW:
M* ,+^TM?_P"@);?^##_[75#P^/$&BZ#INGMI%K*UI;1VYD%_@-M4+G'E\9Q7
M644 87]I:_\ ] 2V_P#!A_\ :Z/[2U__ * EM_X,/_M=;M% &%_:6O\ _0$M
MO_!A_P#:ZH:(/$&DV<D#:1:R%[FXN-PO\8\R9Y,?ZOMOQ^%=910!A?VEK_\
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M1_P&KG_"H- _Z)SHG_@5_P#:Z]5HH \J_P"%0:!_T3G1/_ K_P"UT?\ "H-
M_P"B<Z)_X%?_ &NO5:* /*O^%0:!_P!$YT3_ ,"O_M=%>JT4 %%%% !1110
M5YO^T;\1-2^$WP0\7>+M(C@EU+2K/SX$N4+QEMZK\R@@D?-T!KTBN>^('@32
M/B=X-U7PMKT,L^D:G%Y-S'#,T3E<@\.I!4Y Y!H \'TS]IR]^&O@J^\4?$J[
MDU31Q>QV27>E>&[G3_LKM%(R"2.9V9_,=4C4KP'=0>N1KZO^V=X8\*7>J?\
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M5]F:;X/TO2?$FLZ];6Y74]7\G[7*SD[O*0HF >%PI/3K7F-W^Q]\++YYY)M
M=YI[.]L'E^UR[S#=7SWTPSNZF>20@]5#LHP"10!R7[1?[0'BGX:?%'3?#FA7
MNDV-L_AZXUEAJ&CW>HR7<R3K$L"+;,&7=N^\>,BN67]ICXJ0:3X\\97ND:#8
M>'_!D>DR:OX;N;>;^T$$^F6-[=JDPDVAXS=2*H*'/E@=Z^GI? FC3^.X?&#V
MQ;7H=.?2DG+G:+=I5E*[>F=Z*<XS7$>(?V9/!'BGQAJ_B+48]5FFU>]MM0U#
M3AJMPNGW<\$4443R6P;RVPD$0Y'.T9H YCP)XM^*VI_M"^*/"&KZUX9F\/\
MAZSL-2F^RZ7-'<7$-XUXL<:L9B%9#: EB"&W< 8KWZL'3O!&D:5XTUOQ5;0.
MFM:S:6EE>3&1BKQ6S3M" N<#!N9>1UW#/05O4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ibio-20220930xex10d3008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20220930xex10d3008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2S RL# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXT^+?\
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M%% !1110 5^2OA]0W_!6&ZR,_P#%3W'_ *):OUJK\E?#Y _X*PW6?^AGN/\
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MU"W+Q"0#J/;.<5C_ !@_;O\ "UIX'N?"7P4LKCQ%XDF@^S6D6GV;-%:AN-V
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M[C_P,7_XB@#Z2HKYM_X;2T__ *%>X_\  Q?_ (BC_AM+3_\ H5[C_P #%_\
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M[C_P,7_XB@#Z2HKYM_X;2T__ *%>X_\  Q?_ (BC_AM+3_\ H5[C_P #%_\
MB* /I*BOFW_AM+3_ /H5[C_P,7_XBC_AM+3_ /H5[C_P,7_XB@#Z2HKYM_X;
M2T__ *%>X_\  Q?_ (BC_AM+3_\ H5[C_P #%_\ B* /I*BOFW_AM+3_ /H5
M[C_P,7_XBC_AM+3_ /H5[C_P,7_XB@#Z2HKYM_X;2T__ *%>X_\  Q?_ (BC
M_AM+3_\ H5[C_P #%_\ B* /I*BOFW_AM+3_ /H5[C_P,7_XBC_AM+3_ /H5
M[C_P,7_XB@#Z2HKYM_X;2T__ *%>X_\  Q?_ (BC_AM+3_\ H5[C_P #%_\
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MW26UG9W5W</PD,'SNWT 7)HFLVM[:&XEL[F*WG+"*5^%DVXW;3MP<9&<=,T
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M8:0UMJ>,_:75&V,<[\?4G/"CWR1D['_"I_#?_/IK/_?:4?\ "I_#?_/IK/\
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M8SCD\UD^/O&]GXOM[ 061MIXBS2L41>JJ @V@;@-I.YOF^;'85WG_"I_#?\
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MM:!>6NG:W8W5];F[M()EEDMP<>: <[2?0XP?:O<Q\#?#H0KYE]M)!(\Y>W_
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MS^3\#-_L$?\ /]>?]]K_ /$T?V"/^?Z\_P"^U_\ B:TO)T[_ *'&#_P32_\
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MJ./[(E&Q2>6_UG;TJQY.G?\ 0XP?^":7_P".T?V?GW_/W_R8/K>6?R?@9O\
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M'F?V<>[%<8\[VH_U9Q_9?>']L87S^XPZ*ZO_ (5+JG_0Q6W_ (+3_P#'J/\
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MDBIN_P!;VSG%'^K./[+[P_MC"^?W&1175_\ "I=4_P"ABMO_  6G_P"/4?\
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ME'_"G;K_ *#R?^ /_P!LKL/^$:N/^A@U7_OJ'_XW1_PC5Q_T,&J_]]0__&Z
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M*=NO^@\G_@#_ /;*[#_A&KC_ *&#5?\ OJ'_ .-T?\(U<?\ 0P:K_P!]0_\
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M*=NO^@\G_@#_ /;*[#_A&KC_ *&#5?\ OJ'_ .-T?\(U<?\ 0P:K_P!]0_\
MQN@#C_\ A3MU_P!!Y/\ P!_^V5+X#\(ZMX;\8W9O466U^R,D5Y%PLA+J<$=5
M/'3]:ZO_ (1JX_Z&#5?^^H?_ (W1_P (U<?]#!JO_?4/_P ;H /#'_'QKO\
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M_H8-5_[ZA_\ C= &[16%_P (U<?]#!JO_?4/_P ;H_X1JX_Z&#5?^^H?_C=
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M?\(U<?\ 0P:K_P!]0_\ QNC_ (1JX_Z&#5?^^H?_ (W0 >!?^1,T/_KSB_\
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M+_C1_:=G_P _<'_?Q?\ &JW_  B^C?\ 0)L?_ 9/\*/^$7T;_H$V/_@,G^%
M%G^T[/\ Y^X/^_B_XT?VG9_\_<'_ '\7_&JW_"+Z-_T";'_P&3_"C_A%]&_Z
M!-C_ . R?X4 9O@[4;1-#PUU"I^U71P9 /\ EXDK;_M.S_Y^X/\ OXO^-<YX
M0\.:3-HFZ32[-V^U70RUNA.!/( .GH,5M?\ "+Z-_P! FQ_\!D_PH L_VG9_
M\_<'_?Q?\:/[3L_^?N#_ +^+_C5;_A%]&_Z!-C_X#)_A1_PB^C?] FQ_\!D_
MPH L_P!IV?\ S]P?]_%_QK$\+ZC:+_:^ZZA&=0F(S(.1Q6E_PB^C?] FQ_\
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MD&#C'7D_F: .C_M.S_Y^X/\ OXO^-']IV?\ S]P?]_%_QJM_PB^C?] FQ_\
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M/\*/^$7T;_H$V/\ X#)_A0!9_M.S_P"?N#_OXO\ C6(FHVG_  FLS?:H=O\
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MB^C?] FQ_P# 9/\ "C_A%]&_Z!-C_P" R?X4 9O@C4;1/!VBJUU"K"SB!!D
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M#-K6ARIJ,;1PS2M(P5L*#"X!/'J0*U_^%C>&_P#H*Q?]\M_A7DO_  G>M?\
M02B_\ Z/^$[UK_H)1?\ @'1];S/_ )\P_P#!G_VH<L.[^X[KP%XXT/3O"]O;
MW.H)!,LT[%'1@0#,[#MW!!_&N@_X6-X;_P"@K%_WRW^%>2_\)WK7_02B_P#
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M4( ''K6G%\1?#@B0'58@0H_A;_"O)_\ A.]:_P"@E%_X!T?\)WK7_02B_P#
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MO)?^$[UK_H)1?^ ='_"=ZU_T$HO_  #H^MYG_P ^8?\ @S_[4.6'=_<>M?\
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M&H(*MP<?2I_^%C>&_P#H*Q?]\M_A7DO_  G>M?\ 02B_\ Z/^$[UK_H)1?\
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M?\ /JZ[CO^%C>&_^@K%_WRW^%'_"QO#?_05B_P"^6_PIM%'^NT_^?"_\"_X
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M\)%'_P! '4__  $'^-'_  D4?_0!U/\ \!!_C70T5_-'MJ?\GXL]:S[G/?\
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M1_\ 0!U/_P !!_C1_P )%'_T =3_ / 0?XUT-%'MJ?\ )^+"S[G/?\)%'_T
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M-JW_ (##_P"*K=HH]I2_Y]_BPL^YA?\ "5'_ * VK?\ @,/_ (JC_A*C_P!
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M_0!A_P# \?\ Q%']JZ]_T 8?_ \?_$5NT4>VA_SZC_Y-_P#)!;S,+^U=>_Z
M,/\ X'C_ .(H_M77O^@##_X'C_XBMVBCVT/^?4?_ ";_ .2"WF87]JZ]_P!
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M (BC^U=>_P"@##_X'C_XBMVBCVT/^?4?_)O_ )(+>9A?VKKW_0!A_P# \?\
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M@##_ .!X_P#B*W:*/;0_Y]1_\F_^2"WF87]JZ]_T 8?_  /'_P 11_:NO?\
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M_P#&J/[ U3_H9K__ ,![;_XU6[11]9GVC_X#'_(+&%_8&J?]#-?_ /@/;?\
MQJC^P-4_Z&:__P# >V_^-5NT4?69]H_^ Q_R"QA?V!JG_0S7_P#X#VW_ ,:H
M_L#5/^AFO_\ P'MO_C5;M%'UF?:/_@,?\@L87]@:I_T,U_\ ^ ]M_P#&J/[
MU3_H9K__ ,![;_XU6[11]9GVC_X#'_(+&%_8&J?]#-?_ /@/;?\ QJC^P-4_
MZ&:__P# >V_^-5NT4?69]H_^ Q_R"QA?V!JG_0S7_P#X#VW_ ,:H_L#5/^AF
MO_\ P'MO_C5;M%'UF?:/_@,?\@L87]@:I_T,U_\ ^ ]M_P#&J/[ U3_H9K__
M ,![;_XU6[11]9GVC_X#'_(+&%_8&J?]#-?_ /@/;?\ QJC^P-4_Z&:__P#
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M_P#X#VW_ ,:H_L#5/^AFO_\ P'MO_C5;M%'UF?:/_@,?\@L87]@:I_T,U_\
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M_P# >V_^-5NT4?69]H_^ Q_R"QA?V!JG_0S7_P#X#VW_ ,:H_L#5/^AFO_\
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MX2FYY<V[?$]DEV['!7^,****^T.<**** "BBB@#SS_A#;'_GZU;_ ,&UU_\
M'*/^$-L?^?K5O_!M=?\ QRC_ (3SPS_T,6E?^!L7_P 51_PGGAG_ *&+2O\
MP-B_^*K^</\ A0_O_B>K[H?\(;8_\_6K?^#:Z_\ CE'_  AMC_S]:M_X-KK_
M ..4?\)YX9_Z&+2O_ V+_P"*H_X3SPS_ -#%I7_@;%_\51_PH?W_ ,0]T/\
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M*/\ A//#/_0Q:5_X&Q?_ !5'_">>&?\ H8M*_P# V+_XJC_A0_O_ (A[H?\
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M_P )YX9_Z&+2O_ V+_XJC_A0_O\ XA[H?\(;8_\ /UJW_@VNO_CE'_"&V/\
MS]:M_P"#:Z_^.4?\)YX9_P"ABTK_ ,#8O_BJ/^$\\,_]#%I7_@;%_P#%4?\
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M0VQ_Y^M6_P#!M=?_ !RC_A#;'_GZU;_P;77_ ,<H_P"$\\,_]#%I7_@;%_\
M%4?\)YX9_P"ABTK_ ,#8O_BJ/^%#^_\ B'NA_P (;8_\_6K?^#:Z_P#CE'_"
M&V/_ #]:M_X-KK_XY1_PGGAG_H8M*_\  V+_ .*H_P"$\\,_]#%I7_@;%_\
M%4?\*']_\0]T/^$-L?\ GZU;_P &UU_\<H_X0VQ_Y^M6_P#!M=?_ !RC_A//
M#/\ T,6E?^!L7_Q5'_">>&?^ABTK_P #8O\ XJC_ (4/[_XA[H?\(;8_\_6K
M?^#:Z_\ CE'_  AMC_S]:M_X-KK_ ..4?\)YX9_Z&+2O_ V+_P"*H_X3SPS_
M -#%I7_@;%_\51_PH?W_ ,0]T/\ A#;'_GZU;_P;77_QRC_A#;'_ )^M6_\
M!M=?_'*/^$\\,_\ 0Q:5_P"!L7_Q5'_">>&?^ABTK_P-B_\ BJ/^%#^_^(>Z
M'_"&V/\ S]:M_P"#:Z_^.4?\(;8_\_6K?^#:Z_\ CE'_  GGAG_H8M*_\#8O
M_BJ/^$\\,_\ 0Q:5_P"!L7_Q5'_"A_?_ !#W0_X0VQ_Y^M6_\&UU_P#'*/\
MA#;'_GZU;_P;77_QRC_A//#/_0Q:5_X&Q?\ Q5'_  GGAG_H8M*_\#8O_BJ/
M^%#^_P#B'NA_PAMC_P _6K?^#:Z_^.4?\(;8_P#/UJW_ (-KK_XY1_PGGAG_
M *&+2O\ P-B_^*H_X3SPS_T,6E?^!L7_ ,51_P *']_\0]T/^$-L?^?K5O\
MP;77_P <H_X0VQ_Y^M6_\&UU_P#'*/\ A//#/_0Q:5_X&Q?_ !5'_">>&?\
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MW_@VNO\ XY1_PGGAG_H8M*_\#8O_ (JC_A//#/\ T,6E?^!L7_Q5'_"A_?\
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M;77_ ,<H_P"$\\,_]#%I7_@;%_\ %4?\)YX9_P"ABTK_ ,#8O_BJ/^%#^_\
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M $+5[_X$6_\ \<H^K3[Q_P# H_YA<W:*PO[>U7_H6KW_ ,"+?_XY1_;VJ_\
M0M7O_@1;_P#QRCZM/O'_ ,"C_F%S=HK"_M[5?^A:O?\ P(M__CE']O:K_P!"
MU>_^!%O_ /'*/JT^\?\ P*/^87-VBL+^WM5_Z%J]_P# BW_^.4?V]JO_ $+5
M[_X$6_\ \<H^K3[Q_P# H_YA<W:*PO[>U7_H6KW_ ,"+?_XY1_;VJ_\ 0M7O
M_@1;_P#QRCZM/O'_ ,"C_F%S=HK"_M[5?^A:O?\ P(M__CE']O:K_P!"U>_^
M!%O_ /'*/JT^\?\ P*/^87-VBL+^WM5_Z%J]_P# BW_^.4?V]JO_ $+5[_X$
M6_\ \<H^K3[Q_P# H_YA<W:*PO[>U7_H6KW_ ,"+?_XY1_;VJ_\ 0M7O_@1;
M_P#QRCZM/O'_ ,"C_F%S=HK"_M[5?^A:O?\ P(M__CE']O:K_P!"U>_^!%O_
M /'*/JT^\?\ P*/^87-VBL+^WM5_Z%J]_P# BW_^.4?V]JO_ $+5[_X$6_\
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M ,"C_F%S=HK"_M[5?^A:O?\ P(M__CE']O:K_P!"U>_^!%O_ /'*/JT^\?\
MP*/^87-VBL+^WM5_Z%J]_P# BW_^.4?V]JO_ $+5[_X$6_\ \<H^K3[Q_P#
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M ,"+?_XY1_;VJ_\ 0M7O_@1;_P#QRCZM/O'_ ,"C_F%S=HK"_M[5?^A:O?\
MP(M__CE']O:K_P!"U>_^!%O_ /'*/JT^\?\ P*/^87-VBL+^WM5_Z%J]_P#
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MD=917)_\))JG_/;0O_ R3_XBC_A)-4_Y[:%_X&2?_$4?4:WE]X<R.LHKD_\
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M_P"IJC_\%P_^*K\F_M//OYO_ "G+_P"0.WDI?TRE_P *TU3TTK\F_P#B:/\
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M /!</_BJ/[3S[^;_ ,IR_P#D Y*7],I?\*TU3TTK\F_^)H_X5IJGII7Y-_\
M$U=_X2S_ *FJ/_P7#_XJC_A+/^IJC_\ !</_ (JC^T\^_F_\IR_^0#DI?TRE
M_P *TU3TTK\F_P#B:/\ A6FJ>FE?DW_Q-7?^$L_ZFJ/_ ,%P_P#BJ/\ A+/^
MIJC_ /!</_BJ/[3S[^;_ ,IR_P#D Y*7],I?\*TU3TTK\F_^)H_X5IJGII7Y
M-_\ $U=_X2S_ *FJ/_P7#_XJC_A+/^IJC_\ !</_ (JC^T\^_F_\IR_^0#DI
M?TRE_P *TU3TTK\F_P#B:/\ A6FJ>FE?DW_Q-7?^$L_ZFJ/_ ,%P_P#BJ/\
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M\*TU3TTK\F_^)H_X5IJGII7Y-_\ $U=_X2S_ *FJ/_P7#_XJC_A+/^IJC_\
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M!Z/_ , 5_P#BJ/[*UW_H/1_^ *__ !5'L8?\_8_^3?\ R(7\C=HK"_LK7?\
MH/1_^ *__%4?V5KO_0>C_P# %?\ XJCV,/\ G['_ ,F_^1"_D;M%87]E:[_T
M'H__  !7_P"*H_LK7?\ H/1_^ *__%4>QA_S]C_Y-_\ (A?R-VBL+^RM=_Z#
MT?\ X K_ /%4?V5KO_0>C_\  %?_ (JCV,/^?L?_ ";_ .1"_D;M%87]E:[_
M -!Z/_P!7_XJC^RM=_Z#T?\ X K_ /%4>QA_S]C_ .3?_(A?R-VBL+^RM=_Z
M#T?_ ( K_P#%4?V5KO\ T'H__ %?_BJ/8P_Y^Q_\F_\ D0OY&[16%_96N_\
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M_P#@"O\ \51_96N_]!Z/_P  5_\ BJ/8P_Y^Q_\ )O\ Y$+^1NT5A?V5KO\
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M+_C1_P *TF_Z#4G_ (#+_C6Y_P (H/\ H,:M_P"!7_UJ/^$4'_08U;_P*_\
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M+_C1_P *TF_Z#4G_ (#+_C6Y_P (H/\ H,:M_P"!7_UJ/^$4'_08U;_P*_\
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MH_X10?\ 08U;_P "O_K4>SH_\_/P879NT5A?\(H/^@QJW_@5_P#6H_X10?\
M08U;_P "O_K4>SH_\_/P879NT5A?\(H/^@QJW_@5_P#6H_X10?\ 08U;_P "
MO_K4>SH_\_/P879NT5A?\(H/^@QJW_@5_P#6H_X10?\ 08U;_P "O_K4>SH_
M\_/P879NT5A?\(H/^@QJW_@5_P#6H_X10?\ 08U;_P "O_K4>SH_\_/P879N
MT5A?\(H/^@QJW_@5_P#6H_X10?\ 08U;_P "O_K4>SH_\_/P879NT5A?\(H/
M^@QJW_@5_P#6H_X10?\ 08U;_P "O_K4>SH_\_/P879NT5A?\(H/^@QJW_@5
M_P#6H_X10?\ 08U;_P "O_K4>SH_\_/P879NT5A?\(H/^@QJW_@5_P#6H_X1
M0?\ 08U;_P "O_K4>SH_\_/P879NT5A?\(H/^@QJW_@5_P#6H_X10?\ 08U;
M_P "O_K4>SH_\_/P879NT5A?\(H/^@QJW_@5_P#6H_X10?\ 08U;_P "O_K4
M>SH_\_/P879NT5A?\(H/^@QJW_@5_P#6H_X10?\ 08U;_P "O_K4>SH_\_/P
M879NT5A?\(H/^@QJW_@5_P#6H_X10?\ 08U;_P "O_K4>SH_\_/P879NT5A?
M\(H/^@QJW_@5_P#6H_X10?\ 08U;_P "O_K4>SH_\_/P879NT5A?\(H/^@QJ
MW_@5_P#6H_X10?\ 08U;_P "O_K4>SH_\_/P879NT5A?\(H/^@QJW_@5_P#6
MH_X10?\ 08U;_P "O_K4>SH_\_/P879U.E?\?8_W36U7)>&="_L_4Q+_ &A?
MW/R$;+B?>OUQBNMK]EX248Y<U%W]Y_H<%?XPHHHK[0YPHHHH **** .9HK"_
MX0;0?^@;%^;?XT?\(-H/_0-B_-O\:_F;EP_\\O\ P%?_ "1Z^INT5A?\(-H/
M_0-B_-O\:/\ A!M!_P"@;%^;?XT<N'_GE_X"O_D@U-VBL+_A!M!_Z!L7YM_C
M1_P@V@_] V+\V_QHY</_ #R_\!7_ ,D&INT5A?\ "#:#_P! V+\V_P :/^$&
MT'_H&Q?FW^-'+A_YY?\ @*_^2#4W:*PO^$&T'_H&Q?FW^-'_  @V@_\ 0-B_
M-O\ &CEP_P#/+_P%?_)!J;M%87_"#:#_ - V+\V_QH_X0;0?^@;%^;?XT<N'
M_GE_X"O_ )(-3=HK"_X0;0?^@;%^;?XT?\(-H/\ T#8OS;_&CEP_\\O_  %?
M_)!J;M%87_"#:#_T#8OS;_&C_A!M!_Z!L7YM_C1RX?\ GE_X"O\ Y(-3=HK"
M_P"$&T'_ *!L7YM_C1_P@V@_] V+\V_QHY</_/+_ ,!7_P D&INT5A?\(-H/
M_0-B_-O\:/\ A!M!_P"@;%^;?XT<N'_GE_X"O_D@U-VBL+_A!M!_Z!L7YM_C
M1_P@V@_] V+\V_QHY</_ #R_\!7_ ,D&INT5A?\ "#:#_P! V+\V_P :/^$&
MT'_H&Q?FW^-'+A_YY?\ @*_^2#4W:*PO^$&T'_H&Q?FW^-'_  @V@_\ 0-B_
M-O\ &CEP_P#/+_P%?_)!J;M%87_"#:#_ - V+\V_QH_X0;0?^@;%^;?XT<N'
M_GE_X"O_ )(-3=HK"_X0;0?^@;%^;?XT?\(-H/\ T#8OS;_&CEP_\\O_  %?
M_)!J;M%87_"#:#_T#8OS;_&C_A!M!_Z!L7YM_C1RX?\ GE_X"O\ Y(-3=HK"
M_P"$&T'_ *!L7YM_C1_P@V@_] V+\V_QHY</_/+_ ,!7_P D&INT5A?\(-H/
M_0-B_-O\:/\ A!M!_P"@;%^;?XT<N'_GE_X"O_D@U-VBL+_A!M!_Z!L7YM_C
M1_P@V@_] V+\V_QHY</_ #R_\!7_ ,D&INT5A?\ "#:#_P! V+\V_P :/^$&
MT'_H&Q?FW^-'+A_YY?\ @*_^2#4W:*PO^$&T'_H&Q?FW^-'_  @V@_\ 0-B_
M-O\ &CEP_P#/+_P%?_)!J;M%87_"#:#_ - V+\V_QH_X0;0?^@;%^;?XT<N'
M_GE_X"O_ )(-3=HK"_X0;0?^@;%^;?XT?\(-H/\ T#8OS;_&CEP_\\O_  %?
M_)!J;M%87_"#:#_T#8OS;_&C_A!M!_Z!L7YM_C1RX?\ GE_X"O\ Y(-3=HK"
M_P"$&T'_ *!L7YM_C1_P@V@_] V+\V_QHY</_/+_ ,!7_P D&INT5A?\(-H/
M_0-B_-O\:/\ A!M!_P"@;%^;?XT<N'_GE_X"O_D@U-VBL+_A!M!_Z!L7YM_C
M1_P@V@_] V+\V_QHY</_ #R_\!7_ ,D&INT5A?\ "#:#_P! V+\V_P :/^$&
MT'_H&Q?FW^-'+A_YY?\ @*_^2#4W:*PO^$&T'_H&Q?FW^-'_  @V@_\ 0-B_
M-O\ &CEP_P#/+_P%?_)!J;M%87_"#:#_ - V+\V_QH_X0;0?^@;%^;?XT<N'
M_GE_X"O_ )(-3=HK"_X0;0?^@;%^;?XT?\(-H/\ T#8OS;_&CEP_\\O_  %?
M_)!J;M%87_"#:#_T#8OS;_&C_A!M!_Z!L7YM_C1RX?\ GE_X"O\ Y(-3=HK"
M_P"$&T'_ *!L7YM_C1_P@V@_] V+\V_QHY</_/+_ ,!7_P D&INT5A?\(-H/
M_0-B_-O\:/\ A!M!_P"@;%^;?XT<N'_GE_X"O_D@U-VBL+_A!M!_Z!L7YM_C
M1_P@V@_] V+\V_QHY</_ #R_\!7_ ,D&INT5A?\ "#:#_P! V+\V_P :/^$&
MT'_H&Q?FW^-'+A_YY?\ @*_^2#4W:*PO^$&T'_H&Q?FW^-'_  @V@_\ 0-B_
M-O\ &CEP_P#/+_P%?_)!J;M%87_"#:#_ - V+\V_QH_X0;0?^@;%^;?XT<N'
M_GE_X"O_ )(-3=HK"_X0;0?^@;%^;?XT?\(-H/\ T#8OS;_&CEP_\\O_  %?
M_)!J;M%87_"#:#_T#8OS;_&C_A!M!_Z!L7YM_C1RX?\ GE_X"O\ Y(-3=HK"
M_P"$&T'_ *!L7YM_C1_P@V@_] V+\V_QHY</_/+_ ,!7_P D&INT5A?\(-H/
M_0-B_-O\:/\ A!M!_P"@;%^;?XT<N'_GE_X"O_D@U-VBL+_A!M!_Z!L7YM_C
M1_P@V@_] V+\V_QHY</_ #R_\!7_ ,D&INT5A?\ "#:#_P! V+\V_P :/^$&
MT'_H&Q?FW^-'+A_YY?\ @*_^2#4W:*PO^$&T'_H&Q?FW^-'_  @V@_\ 0-B_
M-O\ &CEP_P#/+_P%?_)!J;M%87_"#:#_ - V+\V_QH_X0;0?^@;%^;?XT<N'
M_GE_X"O_ )(-3=HK"_X0;0?^@;%^;?XT?\(-H/\ T#8OS;_&CEP_\\O_  %?
M_)!J=3I7_'V/]TUM5R7AGPQI>DZF)[2S2";85WJ3G!_&NMK]EX24%ESY&VN9
M[JW;S9P5_C"BBBOM#G"BBB@ HHHH \\_X3?2/^>MS_X!3_\ Q%'_  F^D?\
M/6Y_\ I__B*W:*_F;FP_\DO_  )?_(GKZF%_PF^D?\];G_P"G_\ B*/^$WTC
M_GK<_P#@%/\ _$5NT4<V'_DE_P"!+_Y$-3"_X3?2/^>MS_X!3_\ Q%'_  F^
MD?\ /6Y_\ I__B*W:*.;#_R2_P# E_\ (AJ87_";Z1_SUN?_  "G_P#B*/\
MA-](_P">MS_X!3__ !%;M%'-A_Y)?^!+_P"1#4PO^$WTC_GK<_\ @%/_ /$4
M?\)OI'_/6Y_\ I__ (BMVBCFP_\ )+_P)?\ R(:F%_PF^D?\];G_ , I_P#X
MBC_A-](_YZW/_@%/_P#$5NT4<V'_ ))?^!+_ .1#4PO^$WTC_GK<_P#@%/\
M_$4?\)OI'_/6Y_\  *?_ .(K=HHYL/\ R2_\"7_R(:F%_P )OI'_ #UN?_ *
M?_XBC_A-](_YZW/_ (!3_P#Q%;M%'-A_Y)?^!+_Y$-3"_P"$WTC_ )ZW/_@%
M/_\ $4?\)OI'_/6Y_P# *?\ ^(K=HHYL/_)+_P "7_R(:F%_PF^D?\];G_P"
MG_\ B*/^$WTC_GK<_P#@%/\ _$5NT4<V'_DE_P"!+_Y$-3"_X3?2/^>MS_X!
M3_\ Q%'_  F^D?\ /6Y_\ I__B*W:*.;#_R2_P# E_\ (AJ87_";Z1_SUN?_
M  "G_P#B*/\ A-](_P">MS_X!3__ !%;M%'-A_Y)?^!+_P"1#4PO^$WTC_GK
M<_\ @%/_ /$4?\)OI'_/6Y_\ I__ (BMVBCFP_\ )+_P)?\ R(:F%_PF^D?\
M];G_ , I_P#XBC_A-](_YZW/_@%/_P#$5NT4<V'_ ))?^!+_ .1#4PO^$WTC
M_GK<_P#@%/\ _$4?\)OI'_/6Y_\  *?_ .(K=HHYL/\ R2_\"7_R(:F%_P )
MOI'_ #UN?_ *?_XBC_A-](_YZW/_ (!3_P#Q%;M%'-A_Y)?^!+_Y$-3"_P"$
MWTC_ )ZW/_@%/_\ $4?\)OI'_/6Y_P# *?\ ^(K=HHYL/_)+_P "7_R(:F%_
MPF^D?\];G_P"G_\ B*/^$WTC_GK<_P#@%/\ _$5NT4<V'_DE_P"!+_Y$-3"_
MX3?2/^>MS_X!3_\ Q%'_  F^D?\ /6Y_\ I__B*W:*.;#_R2_P# E_\ (AJ8
M7_";Z1_SUN?_  "G_P#B*/\ A-](_P">MS_X!3__ !%;M%'-A_Y)?^!+_P"1
M#4PO^$WTC_GK<_\ @%/_ /$4?\)OI'_/6Y_\ I__ (BMVBCFP_\ )+_P)?\
MR(:F%_PF^D?\];G_ , I_P#XBC_A-](_YZW/_@%/_P#$5NT4<V'_ ))?^!+_
M .1#4PO^$WTC_GK<_P#@%/\ _$4?\)OI'_/6Y_\  *?_ .(K=HHYL/\ R2_\
M"7_R(:F%_P )OI'_ #UN?_ *?_XBC_A-](_YZW/_ (!3_P#Q%;M%'-A_Y)?^
M!+_Y$-3"_P"$WTC_ )ZW/_@%/_\ $4?\)OI'_/6Y_P# *?\ ^(K=HHYL/_)+
M_P "7_R(:F%_PF^D?\];G_P"G_\ B*/^$WTC_GK<_P#@%/\ _$5NT4<V'_DE
M_P"!+_Y$-3"_X3?2/^>MS_X!3_\ Q%'_  F^D?\ /6Y_\ I__B*W:*.;#_R2
M_P# E_\ (AJ87_";Z1_SUN?_  "G_P#B*/\ A-](_P">MS_X!3__ !%;M%'-
MA_Y)?^!+_P"1#4PO^$WTC_GK<_\ @%/_ /$4?\)OI'_/6Y_\ I__ (BMVBCF
MP_\ )+_P)?\ R(:F%_PF^D?\];G_ , I_P#XBC_A-](_YZW/_@%/_P#$5NT4
M<V'_ ))?^!+_ .1#4PO^$WTC_GK<_P#@%/\ _$4?\)OI'_/6Y_\  *?_ .(K
M=HHYL/\ R2_\"7_R(:F%_P )OI'_ #UN?_ *?_XBC_A-](_YZW/_ (!3_P#Q
M%;M%'-A_Y)?^!+_Y$-3"_P"$WTC_ )ZW/_@%/_\ $4?\)OI'_/6Y_P# *?\
M^(K=HHYL/_)+_P "7_R(:F%_PF^D?\];G_P"G_\ B*/^$WTC_GK<_P#@%/\
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MD?\ /6Y_\ I__B*W:*.;#_R2_P# E_\ (AJ87_";Z1_SUN?_  "G_P#B*/\
MA-](_P">MS_X!3__ !%;M%'-A_Y)?^!+_P"1#4PO^$WTC_GK<_\ @%/_ /$4
M?\)OI'_/6Y_\ I__ (BMVBCFP_\ )+_P)?\ R(:F%_PF^D?\];G_ , I_P#X
MBC_A-](_YZW/_@%/_P#$5NT4<V'_ ))?^!+_ .1#4PO^$WTC_GK<_P#@%/\
M_$4?\)OI'_/6Y_\  *?_ .(K=HHYL/\ R2_\"7_R(:D'AGQ+8:KJ8@MGF:38
M6P]M+&,?5E KK:Q=*_X^Q_NFMJOV7A)P>7>XFES/=W[>2."O\84445]H<X44
M44 %%%% 'GG_  DUU_T+NK?E!_\ ':/^$FNO^A=U;\H/_CM>7?8;C_H-:W_X
M-;C_ .+H^PW'_0:UO_P:W'_Q=?E'^J&(_N??,W_M/ ?SS_\  5_\D>H_\)-=
M?]"[JWY0?_':/^$FNO\ H7=6_*#_ ..UY=]AN/\ H-:W_P"#6X_^+H^PW'_0
M:UO_ ,&MQ_\ %T?ZH8C^Y]\P_M/ ?SS_ / 5_P#)'J/_  DUU_T+NK?E!_\
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MWV&X_P"@UK?_ (-;C_XNC[#<?]!K6_\ P:W'_P 71_JAB/[GWS#^T\!_//\
M\!7_ ,D>H_\ "377_0NZM^4'_P =H_X2:Z_Z%W5OR@_^.UY=]AN/^@UK?_@U
MN/\ XNC[#<?]!K6__!K<?_%T?ZH8C^Y]\P_M/ ?SS_\  5_\D>H_\)-=?]"[
MJWY0?_':/^$FNO\ H7=6_*#_ ..UY=]AN/\ H-:W_P"#6X_^+H^PW'_0:UO_
M ,&MQ_\ %T?ZH8C^Y]\P_M/ ?SS_ / 5_P#)'J/_  DUU_T+NK?E!_\ ':/^
M$FNO^A=U;\H/_CM>7?8;C_H-:W_X-;C_ .+H^PW'_0:UO_P:W'_Q='^J&(_N
M??,/[3P'\\__  %?_)'J/_"377_0NZM^4'_QVC_A)KK_ *%W5OR@_P#CM>7?
M8;C_ *#6M_\ @UN/_BZ/L-Q_T&M;_P#!K<?_ !='^J&(_N??,/[3P'\\_P#P
M%?\ R1ZC_P )-=?]"[JWY0?_ !VC_A)KK_H7=6_*#_X[7EWV&X_Z#6M_^#6X
M_P#BZ/L-Q_T&M;_\&MQ_\71_JAB/[GWS#^T\!_//_P !7_R1ZC_PDUU_T+NK
M?E!_\=H_X2:Z_P"A=U;\H/\ X[7EWV&X_P"@UK?_ (-;C_XNC[#<?]!K6_\
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M ,D>H_\ "377_0NZM^4'_P =H_X2:Z_Z%W5OR@_^.UY=]AN/^@UK?_@UN/\
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M\=H_X2:Z_P"A=U;\H/\ X[6[11[6G_S[7WO_ #"S[F%_PDUU_P!"[JWY0?\
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M***^T.<**** "BBB@#R+_A4L/_0@>$_^_P#_ /<U'_"I8?\ H0/"?_?_ /\
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M#PG_ -__ /[FK'_X5!K'_0%TO_O^/_B*/^%0:Q_T!=+_ ._X_P#B*/[ R_\
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M_P"/_B*/[ R_^5_^!S_^2#^T<9_S]E][-C_A4L/_ $('A/\ [_\ _P!S4?\
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M_P"!S_\ D@_M'&?\_9?>SHO^%2P_]"!X3_[_ /\ ]S4?\*EA_P"A \)_]_\
M_P"YJQ_^%0:Q_P! 72_^_P"/_B*/^%0:Q_T!=+_[_C_XBC^P,O\ Y7_X'/\
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M5J/_ *-LZ/[ R_\ E?\ X'/_ .2#^T<9_P _9?>SBO\ A4L/_0@>$_\ O_\
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M/6SXU_Y%J[_WH_\ T8M;E'^J^4_\^?\ R:7^8>VGW.*^S>*O^@1I7_@TD_\
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MC=+U+5K#Q+86&IZ=:6XO(Y6CEMKQIL% I((,2_WO6NRKE]<_Y'OPO_URO/\
MT&.NHKW,'@L/@*7L<-'EC>^[?YW,Y2<G=A1117<2%%%% !1110!A?8_$O_06
MTK_P5R__ "11]C\2_P#06TK_ ,%<O_R16[10!A?8_$O_ $%M*_\ !7+_ /)%
M'V/Q+_T%M*_\%<O_ ,D5NT4 <5K%KX@&N:"'U33&<SR[&739 %/DOG(\\YXS
MW']*V/L?B7_H+:5_X*Y?_DBEUO\ Y&#P[_U\3?\ HAZW* . ^'UKK[^%;<V^
MI:;%%YUQA9=.D=L^?)GD3COGMQ[]:Z+['XE_Z"VE?^"N7_Y(JI\-?^1/M?\
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M7I7_ &$8/_0JW: ,+['XE_Z"VE?^"N7_ .2*/L?B7_H+:5_X*Y?_ )(K=HH
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M^ADU7_OFV_\ C-'_  CEY_T,FJ_]\VW_ ,9K<HH P_\ A'+S_H9-5_[YMO\
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M]\VW_P 9I/!?_("_[>[K_P!*)*W: ,/_ (1R\_Z&35?^^;;_ .,T?\(Y>?\
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M8[(^3F(\_3BNG\,?\?&N_P#81?\ ]%QU1\!_\?'BG_L-3?\ HN.H?Q([*/\
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MT@U_4E*B#+A;?+94]?W6./8"MG_A'+S_ *&35?\ OFV_^,T:3_R-&O?2W_\
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M_P#%T?\ "%Z7_P!/O_@PN/\ XNM3^T;3_GZA_P"_@H_M&T_Y^H?^_@H R_\
MA"]+_P"GW_P87'_Q='_"%Z7_ -/O_@PN/_BZU/[1M/\ GZA_[^"C^T;3_GZA
M_P"_@H Y/Q-X2TZ"/3=GVOYK^!#NOISP6]WX^M;'_"%Z7_T^_P#@PN/_ (NH
M/%5_;-'I>+F(XU" G#CINK;_ +1M/^?J'_OX* ,O_A"]+_Z??_!A<?\ Q='_
M  A>E_\ 3[_X,+C_ .+K4_M&T_Y^H?\ OX*/[1M/^?J'_OX* ,O_ (0O2_\
MI]_\&%Q_\76=XE\(:;#X<U61?MFY+25ANOYR,A#U!?!_&NE_M&T_Y^H?^_@K
M,\4ZA:MX9U<"YA)-G, !(.?D- %>P\&Z8]C;L?MF3&I.-0N!V_WZG_X0O2_^
MGW_P87'_ ,75W3]1M!86P-S#GRE_Y:#T%3_VC:?\_4/_ '\% &7_ ,(7I?\
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MPT:=])V7\;;+^-VP#P &YZ4 =#_PBVB_] BP_P# 9/\ "C_A%M%_Z!%A_P"
MR?X56_X3?0_^@C'^3?X4?\)OH?\ T$8_R;_"@"S_ ,(MHO\ T"+#_P !D_PH
M_P"$6T7_ *!%A_X#)_A5;_A-]#_Z",?Y-_A1_P )OH?_ $$8_P F_P * */C
M#PWI$/A+6Y(]*LHY$L9V5UMT!4B-L$'%:D/A?1C$G_$HL/NC_EV3_"L/Q=XQ
MT:X\*:U%'?QO))93*J@-R3&P Z5J1>-]#$2 ZC']T=F_PH M_P#"+:+_ - B
MP_\  9/\*/\ A%M%_P"@18?^ R?X56_X3?0_^@C'^3?X4?\ ";Z'_P!!&/\
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M .A_X1;1?^@18?\ @,G^%'_"+:+_ - BP_\  9/\*K?\)OH?_01C_)O\*/\
MA-]#_P"@C'^3?X4 6?\ A%M%_P"@18?^ R?X4?\ "+:+_P! BP_\!D_PJM_P
MF^A_]!&/\F_PH_X3?0_^@C'^3?X4 9WAOPWI$L^M!]+LG":@ZKNMT.!L3@<=
M*H>!O#>D2S^)]^EV3[=8F5=UNAP/+CX''2K'AWQAHT,^LE[^-1)?NZ\'D;$&
M>GL:H>"/&&C03^)B]_&N_6)77@\CRX^>GM4/XD=E'^#5^7YG8?\ "+:+_P!
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M_7Q-_P"B'K<KBM8U35FUS02VB;66>4JOVM#N/DOQGMQS6S_:^M?]  _^!B4
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M4 )X+_Y 7_;W=?\ I1)6[7%>$M4U9-%Q'HGFK]IN3N^UH.?/DR/P.1^%;/\
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M\:-OB7_GII7_ '[E_P : -VBL+;XE_YZ:5_W[E_QHV^)?^>FE?\ ?N7_ !H
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M+_C0!NT5A;?$O_/32O\ OW+_ (T;?$O_ #TTK_OW+_C0 >!?^1,T/_KSB_\
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MT>*VN;;7/.5Y&/V?4&5,-(S# #CG!&??-:?_  FFF?\ /MXC_P#!F_\ \<H
M]?K#\4??T7_L(Q?^@M7GG_"::9_S[>(__!F__P <JCJGBFQNVLC%;:]^ZN%E
M?S-18_* <X^?@\]: /;:*\@_X333/^?;Q'_X,W_^.4?\)IIG_/MXC_\ !F__
M ,<H ]?HKR#_ (333/\ GV\1_P#@S?\ ^.4?\)IIG_/MXC_\&;__ !R@#T;Q
MI_R)VN_]>$__ *+:M:'_ %,?^Z*\7UKQ58WVCW]M#;:_YTT$D:>;J+LFXJ0-
MP+\C)Y%6T\9Z:J*#;>(L@8XU-_\ XY0![!17D'_"::9_S[>(_P#P9O\ _'*/
M^$TTS_GV\1_^#-__ (Y0!Z_17D'_  FFF?\ /MXC_P#!F_\ \<H_X333/^?;
MQ'_X,W_^.4 >A>"_^0%_V]W7_I1)6[7B6C>*;&QL?*FMM>W^;*_[K465<-(S
M#C?UP1GWS5[_ (333/\ GV\1_P#@S?\ ^.4 >OT5Y!_PFFF?\^WB/_P9O_\
M'*/^$TTS_GV\1_\ @S?_ ..4 >OUA>%?^8Q_V$9OZ5Y[_P )IIG_ #[>(_\
MP9O_ /'*HZ7XIL;3[9YMMKW[VX>5/+U%A\IQC/S\GWH ]%\<?ZWPW_V&(?\
MT"2NHKPW7/$EG?OII@MM<Q;WB32>=J#-\@# [<OPW(Y^M:?_  FFF?\ /MXC
M_P#!F_\ \<H ]?HKR#_A--,_Y]O$?_@S?_XY1_PFFF?\^WB/_P &;_\ QR@#
MT.#_ )'>^_[!UO\ ^C9JW*\2C\4V*ZW/=&VU[R'MXXAC46W[@SDY._IAA@?6
MKW_"::9_S[>(_P#P9O\ _'* /7Z*\@_X333/^?;Q'_X,W_\ CE'_  FFF?\
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M*D\.?\\;S_P/G_\ BZUO^$&\._\ 0"T[_P !D_PH_P"$&\._] +3O_ 9/\*
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M_P#"I/#G_/&\_P# ^?\ ^+K*T#X9:%??VEYR7C^3>R0I_ITPPHQ@?>]ZZO\
MX0;P[_T M._\!D_PK&\-^#=!G_M7S-&L9-E_*B[K=#M48P!QTH Q?%/PWT73
M9-$%NMX@N=1BMY?]-F.Y"KDCEN.@K=_X5)X<_P">-Y_X'S__ !=4O&/A#0[:
M7P^(='L8A+JL4;[+=1N4J^0>.1P.*Z/_ (0;P[_T M._\!D_PH R?^%2>'/^
M>-Y_X'S_ /Q='_"I/#G_ #QO/_ ^?_XNM;_A!O#O_0"T[_P&3_"C_A!O#O\
MT M._P# 9/\ "@#E(OAEH3>*;JS*7GV=+.&55^W3<,SR G.[T4?E6K_PJ3PY
M_P \;S_P/G_^+ID/@W03XPO(3HUB85L('"?9TVAC)*"<8Z\#\JV?^$&\._\
M0"T[_P !D_PH R?^%2>'/^>-Y_X'S_\ Q='_  J3PY_SQO/_  /G_P#BZUO^
M$&\._P#0"T[_ ,!D_P */^$&\._] +3O_ 9/\* ,G_A4GAS_ )XWG_@?/_\
M%UE3_#+0D\4V5F$O!;R6<\K)]NFY97A"G.[T=OSKJ_\ A!O#O_0"T[_P&3_"
ML:X\&Z"OC#3X1HUB(6L+EV3[.FTL)( #C'49/YF@!_\ PJ3PY_SQO/\ P/G_
M /BZ/^%2>'/^>-Y_X'S_ /Q=:W_"#>'?^@%IW_@,G^%'_"#>'?\ H!:=_P"
MR?X4 9/_  J3PY_SQO/_  /G_P#BZ/\ A4GAS_GC>?\ @?/_ /%UK?\ "#>'
M?^@%IW_@,G^%'_"#>'?^@%IW_@,G^% '*>(/AEH5BE@84O$,M[#"_P#ITQRK
M'!'WJU?^%2>'/^>-Y_X'S_\ Q=,\3>#=!@CTWR]&L8]]_ C;;=!E2W(/'2MG
M_A!O#O\ T M._P# 9/\ "@#)_P"%2>'/^>-Y_P"!\_\ \71_PJ3PY_SQO/\
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MX36)47=;H=J[(^!QTYJ'\2.RC_!J_+\ST2BL/_A!O#O_ $ M._\  9/\*/\
MA!O#O_0"T[_P&3_"K.,W*PD_Y'B;_L')_P"C7I?^$&\._P#0"T[_ ,!D_P *
MQD\&Z"?&,L/]C6/DBP1Q']G3;N\QAG&.O% ':T5A_P#"#>'?^@%IW_@,G^%'
M_"#>'?\ H!:=_P" R?X4 ;E%8?\ P@WAW_H!:=_X#)_A1_P@WAW_ * 6G?\
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M^$&\._\ 0"T[_P !D_PH W**P_\ A!O#O_0"T[_P&3_"C_A!O#O_ $ M._\
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MBBB@ HHHH P_^$Z\-?\ 0PZ5_P"!L7_Q5'_"=>&O^AATK_P-B_\ BJV\48H
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MX,'_ !(O^WNZ_P#2B2MS% &)_P )UX:_Z&'2O_ V+_XJC_A.O#7_ $,.E?\
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MF-E_SZZK_P""JY_^-T>"_P#D!?\ ;W=?^E$E;M &%_PF-E_SZZK_ ."JY_\
MC='_  F-E_SZZK_X*KG_ .-UNT4 87_"8V7_ #ZZK_X*KG_XW6/X;\56D/\
M:NZVU,[[^5ALTRX; ..N$X/L>:[6L+PK_P QC_L(S?TH YWQCXHM+B7P^5MM
M27R]5B<^9IMPN0%?@93D\]!S71?\)C9?\^NJ_P#@JN?_ (W53QQ_K?#?_88A
M_P#0)*ZB@#"_X3&R_P"?75?_  57/_QNC_A,;+_GUU7_ ,%5S_\ &ZW:* .*
MA\5V@\87DOV;4]IL(%Q_9EQNR))3]W9G'/7IU]*V/^$QLO\ GUU7_P %5S_\
M;I8/^1WOO^P=;_\ HV:MR@#"_P"$QLO^?75?_!5<_P#QNC_A,;+_ )]=5_\
M!5<__&ZW:* ,+_A,;+_GUU7_ ,%5S_\ &ZQ[CQ7:'QAI\OV;4]JV%RI!TRXW
M9,D!X79DCCKT''J*[6L.Y_Y'?3?^P==?^C;>@!/^$QLO^?75?_!5<_\ QNC_
M (3&R_Y]=5_\%5S_ /&ZW:* ,+_A,;+_ )]=5_\ !5<__&Z/^$QLO^?75?\
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M )]=5_\ !5<__&Z/^$QLO^?75?\ P57/_P ;K=HH PO^$QLO^?75?_!5<_\
MQNC_ (3&R_Y]=5_\%5S_ /&ZW:* .*\&^*[2W\):/$UMJ;,EI&I,>F7#J?E'
M0A,$>XK8_P"$QLO^?75?_!5<_P#QNCP+_P B9H?_ %YQ?^@BMV@#"_X3&R_Y
M]=5_\%5S_P#&Z/\ A,;+_GUU7_P57/\ \;K=HH PO^$QLO\ GUU7_P %5S_\
M;K'\/^*[2*^UXFVU,B2_W#;IEPQ \B(<X3@\=#ST/>NUK"\-_P#'_P"(O^PC
M_P"T(: #_A,;+_GUU7_P57/_ ,;H_P"$QLO^?75?_!5<_P#QNMVB@#"_X3&R
M_P"?75?_  57/_QNC_A,;+_GUU7_ ,%5S_\ &ZW:* .*TSQ7:)XCUJ0VVIE7
M$& -,N"1A3U&S(_&MC_A,;+_ )]=5_\ !5<__&Z72?\ D:->^EO_ .@&MR@#
MB;G6(=6\>>&Q#%=Q>7%=D_:K26#.53IO49_"NVKE]<_Y'OPO_P!<KS_T&.NH
MH **** "BBB@ HHHH POM'B7_GQTK_P-E_\ C5'VCQ+_ ,^.E?\ @;+_ /&J
MW:* ,+[1XE_Y\=*_\#9?_C5'VCQ+_P ^.E?^!LO_ ,:K=HH XK6)_$!US0=]
MEI@<3R[ MW(03Y+YR?*XXSZUL?:/$O\ SXZ5_P"!LO\ \:I=;_Y&#P[_ -?$
MW_HAZW* . ^'TVOKX5MQ;V>FO%YUQAI;N16SY[YX$1[Y[UT7VCQ+_P ^.E?^
M!LO_ ,:JI\-?^1/M?^N]S_Z425U% &%]H\2_\^.E?^!LO_QJL?Q'/X@+Z3YE
MEIB_Z?'MV7<ARV&P#^ZX%=K6'XH^_HO_ &$8O_06H 3[1XE_Y\=*_P# V7_X
MU1]H\2_\^.E?^!LO_P :K=HH POM'B7_ )\=*_\  V7_ .-4?:/$O_/CI7_@
M;+_\:K=HH XSQ=/XA/A36A-9:8L1LIM[)>2%@OEMG ,0R?Q%:D5QXE\I,6.E
M8VC_ )?9?_C53>-/^1.UW_KPG_\ 1;5K0_ZF/_=% &+]H\2_\^.E?^!LO_QJ
MC[1XE_Y\=*_\#9?_ (U6[10!A?:/$O\ SXZ5_P"!LO\ \:H^T>)?^?'2O_ V
M7_XU6[10!Q7A*?Q -%_<V6F,GVFYY>[D!SY\F>!$>^:V/M'B7_GQTK_P-E_^
M-4>"_P#D!?\ ;W=?^E$E;M &%]H\2_\ /CI7_@;+_P#&J/M'B7_GQTK_ ,#9
M?_C5;M% &%]H\2_\^.E?^!LO_P :K'\-S^(!_:OE66F-_I\N[?=R##<9 _='
M(KM:PO"O_,8_[",W]* .=\8S:^9?#_G6>FJ1JL1C\N[D;+;7P#F(8'7GGZ5T
M7VCQ+_SXZ5_X&R__ !JJGCC_ %OAO_L,0_\ H$E=10!A?:/$O_/CI7_@;+_\
M:H^T>)?^?'2O_ V7_P"-5NT4 <5#/X@_X3"\(LM,\[[!!E?M<FW;YDN#GRNN
M<]O2MC[1XE_Y\=*_\#9?_C5+!_R.]]_V#K?_ -&S5N4 87VCQ+_SXZ5_X&R_
M_&J/M'B7_GQTK_P-E_\ C5;M% &%]H\2_P#/CI7_ (&R_P#QJL>XG\0?\)AI
MY-EIGG?8+G:HNY-I7S(,DGRNN<<8[GTY[6L.Y_Y'?3?^P==?^C;>@!/M'B7_
M )\=*_\  V7_ .-4?:/$O_/CI7_@;+_\:K=HH POM'B7_GQTK_P-E_\ C5'V
MCQ+_ ,^.E?\ @;+_ /&JW:* .*\33^(#'IOFV6F+_I\&W9=R'+;N ?W0XK8^
MT>)?^?'2O_ V7_XU1XK_ -7I7_81@_\ 0JW: ,+[1XE_Y\=*_P# V7_XU1]H
M\2_\^.E?^!LO_P :K=HH POM'B7_ )\=*_\  V7_ .-5G>)9_$1\.:J);+3%
MC^R2[BEY(2!L.<#RADUUU97BK_D5]8_Z\YO_ $ T 4+&?Q)]AM]MCI97RUQF
M]DSC'_7*I_M'B7_GQTK_ ,#9?_C5:NG?\@^V_P"N2_R%6* ,+[1XE_Y\=*_\
M#9?_ (U7.ZA-K_\ PL'0RUGIHN!IM_L47<A0KYEIN)/E9!SMP,'.3R,<]_7+
MZE_R4KP__P!@K4?_ $;9T 6S<>)?^?'2O_ V7_XU6/X,G\0CP?H0ALM,:$6$
M&QI+N16*^6N"0(C@X]S7:'I6)X%_Y$GP]_V#K?\ ]%+0 GVCQ+_SXZ5_X&R_
M_&J/M'B7_GQTK_P-E_\ C5;M% &%]H\2_P#/CI7_ (&R_P#QJC[1XE_Y\=*_
M\#9?_C5;M% '%>'9_$ GUGR[+3&/V]]^Z[D&&V)P/W7(Z50\$3^(!/XF\NRT
MQC_;$N_?=R##;(^!^ZY'3FNG\,?\?&N_]A%__1<=4? ?_'QXI_[#4W_HN.H?
MQ([*/\&K\OS+WVCQ+_SXZ5_X&R__ !JC[1XE_P"?'2O_  -E_P#C5;M%6<9A
M?:/$O_/CI7_@;+_\:K'2?Q!_PF,I^Q:9YWV!,K]KDV[?,;G/E=<^U=K6$G_(
M\3?]@Y/_ $:] !]H\2_\^.E?^!LO_P :H^T>)?\ GQTK_P #9?\ XU6[10!A
M?:/$O_/CI7_@;+_\:H^T>)?^?'2O_ V7_P"-5NT4 <5=S^(/^$OTLFRTP3?8
MKK:HNY-I7?;YR?*Z_=QQW/3'.Q]H\2_\^.E?^!LO_P :HO?^1VTC_KPO/_1E
MM6[0!A?:/$O_ #XZ5_X&R_\ QJC[1XE_Y\=*_P# V7_XU6[10!A?:/$O_/CI
M7_@;+_\ &JYWQQ-KYL=,\^STU%_M6R*F.[D8EO/3:#F(<9QD]O0UW]<O\0/^
M0?I/_88L?_2A* +?VCQ+_P ^.E?^!LO_ ,:H^T>)?^?'2O\ P-E_^-5NT4 8
M7VCQ+_SXZ5_X&R__ !JC[1XE_P"?'2O_  -E_P#C5;M% '%>+Y_$!\/7(FLM
M,6/,>2EW(3]]<<&(5L?:/$O_ #XZ5_X&R_\ QJE\:_\ (M7?^]'_ .C%K<H
MPOM'B7_GQTK_ ,#9?_C5'VCQ+_SXZ5_X&R__ !JMVB@#"^T>)?\ GQTK_P #
M9?\ XU1]H\2_\^.E?^!LO_QJMVB@#BO!L_B >$M'$-EIC0_9(]C27<BL1M&,
M@1'!_&MC[1XE_P"?'2O_  -E_P#C5'@7_D3-#_Z\XO\ T$5NT 87VCQ+_P ^
M.E?^!LO_ ,:H^T>)?^?'2O\ P-E_^-5NT4 87VCQ+_SXZ5_X&R__ !JL?P_/
MX@%]KWEV6F,QO_GW7<@ ;R(N!^ZY&,>G>NUK"\-_\?\ XB_["/\ [0AH /M'
MB7_GQTK_ ,#9?_C5'VCQ+_SXZ5_X&R__ !JMVB@#"^T>)?\ GQTK_P #9?\
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M_KPG_P#1;5K0_P"IC_W10!C?V=K_ /T&[7_P7_\ VRC^SM?_ .@W:_\ @O\
M_ME;E% &'_9VO_\ 0;M?_!?_ /;*/[.U_P#Z#=K_ ."__P"V5N44 <5X2L-;
M?1<Q:O;QI]IN1M-CNY\^3)SYG<Y-;/\ 9VO_ /0;M?\ P7__ &RD\%_\@+_M
M[NO_ $HDK=H P_[.U_\ Z#=K_P""_P#^V4?V=K__ $&[7_P7_P#VRMRB@##_
M +.U_P#Z#=K_ ."__P"V5C>&[#6V_M7R]7MTQ?RALV.<GC)_UG'TKM:PO"O_
M #&/^PC-_2@#G?&-CK*2^'_-U:WD)U6()MLMNUMKX)^<Y[\5T?\ 9VO_ /0;
MM?\ P7__ &RJ?CC_ %OAO_L,0_\ H$E=10!A_P!G:_\ ]!NU_P#!?_\ ;*/[
M.U__ *#=K_X+_P#[96Y10!Q4-AK?_"87BC5[<2BP@)?[#P1YDN!CS/KS[UL_
MV=K_ /T&[7_P7_\ VRB#_D=[[_L'6_\ Z-FK<H P_P"SM?\ ^@W:_P#@O_\
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M!/F#/UKM#TK$\"_\B3X>_P"P=;_^BEH /[.U_P#Z#=K_ ."__P"V4?V=K_\
MT&[7_P %_P#]LK<HH P_[.U__H-VO_@O_P#ME']G:_\ ]!NU_P#!?_\ ;*W*
M* .*\.V&MM/K/EZO;H1?N&S8YW'8G/\ K..W%4/ ]AK;3^)O+U>W0C6)0V;'
M.X[(^?\ 6<?2NG\,?\?&N_\ 81?_ -%QU1\!_P#'QXI_[#4W_HN.H?Q([*/\
M&K\OS+_]G:__ -!NU_\ !?\ _;*/[.U__H-VO_@O_P#ME;E%6<9A_P!G:_\
M]!NU_P#!?_\ ;*QDL-;_ .$QE7^U[?S?L"$O]AXQYC<8\S]:[6L)/^1XF_[!
MR?\ HUZ %_L[7_\ H-VO_@O_ /ME']G:_P#]!NU_\%__ -LK<HH P_[.U_\
MZ#=K_P""_P#^V4?V=K__ $&[7_P7_P#VRMRB@#BKNPUL>+]+4ZO;F4V5T5?[
M#P!OM\C'F<YXY[8]ZV?[.U__ *#=K_X+_P#[927O_([:1_UX7G_HRVK=H P_
M[.U__H-VO_@O_P#ME']G:_\ ]!NU_P#!?_\ ;*W** ,/^SM?_P"@W:_^"_\
M^V5SGCBQUE+'3#-JUO*#JMD%"V6W#>>F#]\YP><=Z[^N7^('_(/TG_L,6/\
MZ4)0!<_L[7_^@W:_^"__ .V4?V=K_P#T&[7_ ,%__P!LK<HH P_[.U__ *#=
MK_X+_P#[91_9VO\ _0;M?_!?_P#;*W** .*\7V&MIX>N3+J]O(F8\JMCM)^=
M>_F&MG^SM?\ ^@W:_P#@O_\ ME'C7_D6KO\ WH__ $8M;E &'_9VO_\ 0;M?
M_!?_ /;*/[.U_P#Z#=K_ ."__P"V5N44 8?]G:__ -!NU_\ !?\ _;*/[.U_
M_H-VO_@O_P#ME;E% '%>#+#6W\):.T6KV\41M(RJ-8[BHVC SY@S6S_9VO\
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MJ_\ ?Y/_ (BMVB@#"_X1>3_H-ZK_ -_D_P#B*/\ A%Y/^@WJO_?Y/_B*W:*
M.*\.^''EGUD?VQJ:;+]U^251N^1.3\O6J'@CPX\L_B;_ (G&IIMUB5?DE4;O
MDCY/R]:Z?PQ_Q\:[_P!A%_\ T7'5'P'_ ,?'BG_L-3?^BXZA_$CLH_P:OR_,
MO?\ "+R?]!O5?^_R?_$4?\(O)_T&]5_[_)_\16[15G&87_"+R?\ 0;U7_O\
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M/#SP6.F$ZOJ4N[5;),22J0,SH,CY>HZBN_KE_B!_R#])_P"PQ8_^E"4 6_\
MA%Y/^@WJO_?Y/_B*/^$7D_Z#>J_]_D_^(K=HH PO^$7D_P"@WJO_ '^3_P"(
MH_X1>3_H-ZK_ -_D_P#B*W:* .*\7^''A\/7+G6-3DP8_E>52#\Z_P"S6Q_P
MB\G_ $&]5_[_ "?_ !%+XU_Y%J[_ -Z/_P!&+6Y0!A?\(O)_T&]5_P"_R?\
MQ%'_  B\G_0;U7_O\G_Q%;M% &%_PB\G_0;U7_O\G_Q%'_"+R?\ 0;U7_O\
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M?_%4?\(3HW_/F?\ O])_\55S_A(=*_Z"=G_X$)_C1_PD.E?]!.S_ / A/\:
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ML_\ P(3_ !K%N==TT^,].D&HVA0:?<J6\]< F2# SGV/Y4 7O^$)T;_GS/\
MW^D_^*H_X0G1O^?,_P#?Z3_XJKG_  D.E?\ 03L__ A/\:/^$ATK_H)V?_@0
MG^- %/\ X0G1O^?,_P#?Z3_XJC_A"=&_Y\S_ -_I/_BJN?\ "0Z5_P!!.S_\
M"$_QH_X2'2O^@G9_^!"?XT <UXF\(:3!'INRU*[K^!#^]<Y!;GO6S_PA.C?\
M^9_[_2?_ !54/%&NZ;)'IFS4+1MNH0,=LZG W<GK6W_PD.E?]!.S_P# A/\
M&@"G_P (3HW_ #YG_O\ 2?\ Q5'_  A.C?\ /F?^_P!)_P#%5<_X2'2O^@G9
M_P#@0G^-'_"0Z5_T$[/_ ,"$_P : *?_  A.C?\ /F?^_P!)_P#%5F^)?!VD
M0>'-5D2T(=+25E/FN<$(?]JM[_A(=*_Z"=G_ .!"?XUF>)]>TR3PUJR)J-HS
M-:3 *)U))V'CK0 6'@O1WL;=C:$DQJ3^^?T_WJG_ .$)T;_GS/\ W^D_^*J3
M3_$&EK86P.I68(C7(,Z>@]ZL?\)#I7_03L__  (3_&@"G_PA.C?\^9_[_2?_
M !5<YJ'A/2D^(.AVXM2(9--OW9?-?DK): '.?]H_G77_ /"0Z5_T$[/_ ,"$
M_P :YK4=<TYOB+H,HU"U,2Z9?JSB9=H)EM, G/4X/Y&@#8/@G1L?\>9_[_2?
M_%5C^#/"&DW/@_0II+4M))80.Q\UQDF-2>]=(?$.E8_Y"=G_ .!"?XUC>"==
MTV'P;H,<FHVB.MA;JRM.H((C7((S0!>_X0G1O^?,_P#?Z3_XJC_A"=&_Y\S_
M -_I/_BJN?\ "0Z5_P!!.S_\"$_QH_X2'2O^@G9_^!"?XT 4_P#A"=&_Y\S_
M -_I/_BJ/^$)T;_GS/\ W^D_^*JY_P )#I7_ $$[/_P(3_&C_A(=*_Z"=G_X
M$)_C0!S7AWPAI,T^LA[4D)?NB_O7X&Q/?WJAX(\(:3-/XF#VI.S6)47]Z_ V
M1^_O6SX;UW38Y];+:A:+NU!V7,ZC(\M.1S5'P+KNFQW'B?=J-HN[69F&9U&1
MY<?(YJ'\2.RC_!J_+\S=_P"$)T;_ )\S_P!_I/\ XJC_ (0G1O\ GS/_ '^D
M_P#BJN?\)#I7_03L_P#P(3_&C_A(=*_Z"=G_ .!"?XU9QE/_ (0G1O\ GS/_
M '^D_P#BJQD\(:2?&,L/V4^6+!'QYK]?,8>M=+_PD.E?]!.S_P# A/\ &L1-
M=TW_ (32:3^T;39_9Z+N\]<9\QN,YH O_P#"$Z-_SYG_ +_2?_%4?\(3HW_/
MF?\ O])_\55S_A(=*_Z"=G_X$)_C1_PD.E?]!.S_ / A/\: *?\ PA.C?\^9
M_P"_TG_Q5'_"$Z-_SYG_ +_2?_%5<_X2'2O^@G9_^!"?XT?\)#I7_03L_P#P
M(3_&@#FKOPAI*^+]+A%J?+>RNF8>:_)#V^._^T:V?^$)T;_GS/\ W^D_^*JA
M>:[II\9:3(-0M"BV-V"WGK@$O;X&<^Q_*MO_ (2'2O\ H)V?_@0G^- %/_A"
M=&_Y\S_W^D_^*H_X0G1O^?,_]_I/_BJN?\)#I7_03L__  (3_&C_ (2'2O\
MH)V?_@0G^- %/_A"=&_Y\S_W^D_^*KG/''A/2K6QTQHK4J7U6RC/[USE6G0$
M<GT-=?\ \)#I7_03L_\ P(3_ !KFO'>N:=-8:6(]0M9"NK63$+,IP!.A)Z]
M* -G_A"=&_Y\S_W^D_\ BJ/^$)T;_GS/_?Z3_P"*JY_PD.E?]!.S_P# A/\
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M72_\)#I7_03L_P#P(3_&L3P[KNFQWWB MJ%HH?4-RDSJ,CR(1D<^Q_*@"_\
M\(3HW_/F?^_TG_Q5'_"$Z-_SYG_O])_\55S_ (2'2O\ H)V?_@0G^-'_  D.
ME?\ 03L__ A/\: *?_"$Z-_SYG_O])_\51_PA.C?\^9_[_2?_%5<_P"$ATK_
M *"=G_X$)_C1_P )#I7_ $$[/_P(3_&@#FM,\(:2_B/6HVM2400;1YK\94Y[
MUL_\(3HW_/F?^_TG_P 55'2]=TU?$NN.=1M K"#:QG7!PISCFMK_ (2'2O\
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M,_\ 01?_ ,!9O_B*+H.9=RO\.=*LI?"5LSV<#L9KGYFB4G_7R>U=-_8VG_\
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M,NYO?V-I_P#SXVW_ 'Y7_"L3PQI-B_\ :^ZSMVQJ$P&8E.!QQTIG_"T/#/\
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MH.9=S>_L;3_^?&V_[\K_ (4?V-I__/C;?]^5_P *P?\ A:'AG_H(O_X"S?\
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M_A:'AG_H(O\ ^ LW_P 11=!S+N;W]C:?_P ^-M_WY7_"C^QM/_Y\;;_ORO\
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M&T__ )\;;_ORO^%<7XJ^(OA^_P!!N((+UY)6*846TO.'4G^'T%:W_"T/#/\
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MH>&?^@B__@+-_P#$470<R[F]_8VG_P#/C;?]^5_PK$\.Z38O?^( UG;L%U#
MS$O \B'CI3/^%H>&?^@B_P#X"S?_ !%9&A?$7P_:WFMO+>NBSWOFQDVTOS+Y
M,2Y^[ZJ1^%%T',NYVO\ 8VG_ //C;?\ ?E?\*/[&T_\ Y\;;_ORO^%8/_"T/
M#/\ T$7_ / 6;_XBC_A:'AG_ *"+_P#@+-_\11=!S+N;W]C:?_SXVW_?E?\
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MN/\ G_OO_ 5O_B:/[4N/^?\ OO\ P%;_ .)KI/\ A(])_P"@I9?^!"?XT?\
M"1Z3_P!!2R_\"$_QH]I_<#VW_3M'-_VI<?\ /_??^ K?_$T?VI<?\_\ ??\
M@*W_ ,372?\ "1Z3_P!!2R_\"$_QH_X2/2?^@I9?^!"?XT>T_N![;_IVCF_[
M4N/^?^^_\!6_^)H_M2X_Y_[[_P !6_\ B:Z3_A(])_Z"EE_X$)_C1_PD>D_]
M!2R_\"$_QH]I_<#VW_3M'-_VI<?\_P#??^ K?_$T?VI<?\_]]_X"M_\ $UTG
M_"1Z3_T%++_P(3_&C_A(])_Z"EE_X$)_C1[3^X'MO^G:.;_M2X_Y_P"^_P#
M5O\ XFC^U+C_ )_[[_P%;_XFND_X2/2?^@I9?^!"?XT?\)'I/_04LO\ P(3_
M !H]I_<#VW_3M'-_VI<?\_\ ??\ @*W_ ,31_:EQ_P _]]_X"M_\372?\)'I
M/_04LO\ P(3_ !H_X2/2?^@I9?\ @0G^-'M/[@>V_P"G:.;_ +4N/^?^^_\
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M?].T<W_:EQ_S_P!]_P" K?\ Q-']J7'_ #_WW_@*W_Q-=)_PD>D_]!2R_P#
MA/\ &C_A(])_Z"EE_P"!"?XT>T_N![;_ *=HYO\ M2X_Y_[[_P !6_\ B:/[
M4N/^?^^_\!6_^)KI/^$CTG_H*67_ ($)_C1_PD>D_P#04LO_  (3_&CVG]P/
M;?\ 3M'-_P!J7'_/_??^ K?_ !-']J7'_/\ WW_@*W_Q-=)_PD>D_P#04LO_
M  (3_&C_ (2/2?\ H*67_@0G^-'M/[@>V_Z=HYO^U+C_ )_[[_P%;_XFC^U+
MC_G_ +[_ ,!6_P#B:Z3_ (2/2?\ H*67_@0G^-'_  D>D_\ 04LO_ A/\:/:
M?W ]M_T[1S?]J7'_ #_WW_@*W_Q-8_AW4ITDU?%]>+F^<G;;L<_*G)^6N\_X
M2/2?^@I9?^!"?XUA>%M?TR.77-^I6B[M1D9=TZC(V)R.:EU-5[AW4:O[BK^[
M73\R#^U+C_G_ +[_ ,!6_P#B:/[4N/\ G_OO_ 5O_B:Z3_A(])_Z"EE_X$)_
MC1_PD>D_]!2R_P# A/\ &J]I_<.'VW_3M'-_VI<?\_\ ??\ @*W_ ,31_:EQ
M_P _]]_X"M_\372?\)'I/_04LO\ P(3_ !H_X2/2?^@I9?\ @0G^-'M/[@>V
M_P"G:.;_ +4N/^?^^_\  5O_ (FC^U+C_G_OO_ 5O_B:Z3_A(])_Z"EE_P"!
M"?XT?\)'I/\ T%++_P "$_QH]I_<#VW_ $[1S?\ :EQ_S_WW_@*W_P 31_:E
MQ_S_ -]_X"M_\372?\)'I/\ T%++_P "$_QH_P"$CTG_ *"EE_X$)_C1[3^X
M'MO^G:.;_M2X_P"?^^_\!6_^)H_M2X_Y_P"^_P# 5O\ XFND_P"$CTG_ *"E
ME_X$)_C1_P )'I/_ $%++_P(3_&CVG]P/;?].T<W_:EQ_P _]]_X"M_\35[P
M]J<USJR1_;7NH'@D<AU *LK(.F,@_,>#6M_PD>D_]!2R_P# A/\ &JD=]X?B
MU%KY+ZQ2Z=/+9Q<(,C(///L*3FFFN44JBE%KDL;E%9W_  D>D_\ 04LO_ A/
M\:/^$CTG_H*67_@0G^-86?8Y.5]C1HK._P"$CTG_ *"EE_X$)_C1_P )'I/_
M $%++_P(3_&BS[!ROL:-%9W_  D>D_\ 04LO_ A/\:/^$CTG_H*67_@0G^-%
MGV#E?8T:*SO^$CTG_H*67_@0G^-'_"1Z3_T%++_P(3_&BS[!ROL:-%9W_"1Z
M3_T%++_P(3_&C_A(])_Z"EE_X$)_C19]@Y7V-&BL[_A(])_Z"EE_X$)_C1_P
MD>D_]!2R_P# A/\ &BS[!ROL:-%9W_"1Z3_T%++_ ,"$_P :/^$CTG_H*67_
M ($)_C19]@Y7V-&BL[_A(])_Z"EE_P"!"?XT?\)'I/\ T%++_P "$_QHL^P<
MK[&C16=_PD>D_P#04LO_  (3_&C_ (2/2?\ H*67_@0G^-%GV#E?8T:*SO\
MA(])_P"@I9?^!"?XT?\ "1Z3_P!!2R_\"$_QHL^P<K[&C16=_P )'I/_ $%+
M+_P(3_&C_A(])_Z"EE_X$)_C19]@Y7V-&BL[_A(])_Z"EE_X$)_C1_PD>D_]
M!2R_\"$_QHL^P<K['8^!_P#D.#_KFW]*]#KS'X>ZQ87OB$1V][;7$GE,=D4J
ML<<=@:].KT*&D#V,*FJ>H4445TG8%%%% !1110!7^P6O_/M#_P!\"C[!:_\
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M6O\ S[0_]\"C[!:_\^T/_? K+_X3+3O[FH_^"RY_^-T?\)EIW]S4?_!9<_\
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MT?\ "9:=_<U'_P %ES_\;H @\&V-LVAY-O$3]JNN2@_Y^)*V_L%K_P ^T/\
MWP*Y+PEXLL+?1=CI?%OM-RWR:=<,,&>0CD1^_P"'2MG_ (3+3O[FH_\ @LN?
M_C= &I]@M?\ GVA_[X%'V"U_Y]H?^^!67_PF6G?W-1_\%ES_ /&Z/^$RT[^Y
MJ/\ X++G_P"-T :GV"U_Y]H?^^!6)X7L;9O[7S;Q'&HS 90>U3_\)EIW]S4?
M_!9<_P#QNL;PWXLL(?[5W)??/?RN-NG7#<''7$?!]CS0!/XVLK=9?#F((AG5
MX0<(.1L>NF^P6O\ S[0_]\"N(\8^*K&XE\/E$OAY>JQ.V_3[A> K],H,GGH.
M:Z/_ (3+3O[FH_\ @LN?_C= &I]@M?\ GVA_[X%'V"U_Y]H?^^!67_PF6G?W
M-1_\%ES_ /&Z/^$RT[^YJ/\ X++G_P"-T 006-M_PFMZ/L\6/[/@.-@_YZ35
MM_8+7_GVA_[X%<E#XLL!XPO)=E]L:P@4?\2ZXW9$DIZ>7G'(YZ?E6S_PF6G?
MW-1_\%ES_P#&Z -3[!:_\^T/_? H^P6O_/M#_P!\"LO_ (3+3O[FH_\ @LN?
M_C='_"9:=_<U'_P67/\ \;H U/L%K_S[0_\ ? K$N;&V_P"$UTX?9XL?V?='
M&P?\]+>I_P#A,M._N:C_ ."RY_\ C=8UQXLL#XPT^4)?;%L+E#_Q+KC=DR0$
M<>7DC@\]!QZB@#K?L%K_ ,^T/_? H^P6O_/M#_WP*R_^$RT[^YJ/_@LN?_C=
M'_"9:=_<U'_P67/_ ,;H U/L%K_S[0_]\"C[!:_\^T/_ 'P*R_\ A,M._N:C
M_P""RY_^-T?\)EIW]S4?_!9<_P#QN@"#Q58VRQZ7BWB&=1@'"#^]6W]@M?\
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ML+CP]<QHE\&)C^_IUPH^^IZF/%;/_"9:=_<U'_P67/\ \;H U/L%K_S[0_\
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MY16'_P )#?\ _0LZK_W\M/\ X_1_PD-__P!"SJO_ '\M/_C] !K?_(P>'?\
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M/_C] &Y16'_PD-__ -"SJO\ W\M/_C]'_"0W_P#T+.J_]_+3_P"/T )X+_Y
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M40F2VWN#):98?OL8& #D@_,, \X .^/2L3P+_P B3X>_[!UO_P"BEI#XAO\
M'_(LZK_W\M/_ (_6/X,UV]A\'Z%&GAW4IU6P@42QR6P5P(UY&9@<'W /M0!V
MM%8?_"0W_P#T+.J_]_+3_P"/T?\ "0W_ /T+.J_]_+3_ ./T ;E%8?\ PD-_
M_P!"SJO_ '\M/_C]'_"0W_\ T+.J_P#?RT_^/T )X8_X^-=_["+_ /HN.J/@
M/_CX\4_]AJ;_ -%QU5\.Z[>QSZR5\.ZE)NOW8A9+;Y3L3@YF'/TR.>M4/!&N
MWL<_B;;X=U*7=K$K';);?*=D?!S,.?ID<]:A_$CLH_P:OR_,]$HK#_X2&_\
M^A9U7_OY:?\ Q^C_ (2&_P#^A9U7_OY:?_'ZLXS<K"3_ )'B;_L')_Z->E_X
M2&__ .A9U7_OY:?_ !^L9-=O?^$QED_X1W4MWV!%\KS+;<!YC<_Z[&/QS[4
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M^/T?\)#?_P#0LZK_ -_+3_X_0!N45A_\)#?_ /0LZK_W\M/_ (_1_P )#?\
M_0LZK_W\M/\ X_0 G@7_ )$S0_\ KSB_]!%;M<5X,UV]A\):.B^'=2F5;2,"
M2.2VVL-HY&9@<?4"MG_A(;__ *%G5?\ OY:?_'Z -RBL/_A(;_\ Z%G5?^_E
MI_\ 'Z/^$AO_ /H6=5_[^6G_ ,?H W*PO#?_ !_^(O\ L(_^T(:7_A(;_P#Z
M%G5?^_EI_P#'ZQO#^NWL=]KQ7P[J4A>_W$+);90^1$,',PYXSQD<CG.0 #M:
M*P_^$AO_ /H6=5_[^6G_ ,?H_P"$AO\ _H6=5_[^6G_Q^@#<HK#_ .$AO_\
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M$/6Y7%:Q9Z^-<T$/JNGLYGEV,-.<!3Y+YR/.YXSW%;'V+Q)_T%]-_P#!8_\
M\?H J?#7_D3[7_KO<_\ I1)745P'P^M-=?PK;FWU.PBB\ZXPDFGNYSY[YY$P
M[Y/3\^M=%]B\2?\ 07TW_P %C_\ Q^@#=K#\4??T7_L(Q?\ H+4GV+Q)_P!!
M?3?_  6/_P#'ZQ_$=GKZOI/F:KI[YOXPNW3G7#8;!/[XY'MQ]: .UHK"^Q>)
M/^@OIO\ X+'_ /C]'V+Q)_T%]-_\%C__ !^@#=HK"^Q>)/\ H+Z;_P""Q_\
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M8O$G_07TW_P6/_\ 'Z -VL.Y_P"1WTW_ +!UU_Z-MZ3[%XD_Z"^F_P#@L?\
M^/UCW%GK_P#PF&G@ZKIYF-A<E7&G/M"^9!D$>=R<XYSQ@\'/ !VM%87V+Q)_
MT%]-_P#!8_\ \?H^Q>)/^@OIO_@L?_X_0!NT5A?8O$G_ $%]-_\ !8__ ,?H
M^Q>)/^@OIO\ X+'_ /C] !XK_P!7I7_81@_]"K=KBO$UGKZQZ;YNJ:>^;^ +
MMTYUPV[@G]\<CV_6MC[%XD_Z"^F_^"Q__C] &[16%]B\2?\ 07TW_P %C_\
MQ^C[%XD_Z"^F_P#@L?\ ^/T ;M97BK_D5]8_Z\YO_0#5?[%XD_Z"^F_^"Q__
M (_6=XEL_$"^'-5,FJZ<\8M)=RKISJ2-AR ?/./K@T =-IW_ "#[;_KDO\A5
MBN;L;+Q$;&WVZOIH7RUP#IKDCC_KO4_V+Q)_T%]-_P#!8_\ \?H W:Y?4O\
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MH^Q>)/\ H+Z;_P""Q_\ X_5G&;M82?\ (\3?]@Y/_1KT?8O$G_07TW_P6/\
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MVJZ?)'F/*IISJ3\Z]_./\JV/L7B3_H+Z;_X+'_\ C] &[16%]B\2?]!?3?\
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M\(W=?]#%JO\ Y _^-4?\(W=?]#%JO_D#_P"-4 ;E%8?_  C=U_T,6J_^0/\
MXU1_PC=U_P!#%JO_ ) _^-4 &M_\C!X=_P"OB;_T0];E<5K&@7*:YH*G7M2<
MO/* S>3E/W+G(_=_ASFMG_A&[K_H8M5_\@?_ !J@"G\-?^1/M?\ KO<_^E$E
M=17 ?#[0KBX\*V[KKFHP S7 \N+R=HQ/(,\QD\]>O>NC_P"$;NO^ABU7_P @
M?_&J -RL/Q1]_1?^PC%_Z"U'_"-W7_0Q:K_Y _\ C58WB/0+F-])SKVI2;K^
M-1N\GY>&Y&(^M ':T5A_\(W=?]#%JO\ Y _^-4?\(W=?]#%JO_D#_P"-4 ;E
M%8?_  C=U_T,6J_^0/\ XU1_PC=U_P!#%JO_ ) _^-4 /\:?\B=KO_7A/_Z+
M:M:'_4Q_[HKD/%WA^YB\*:T[:]J<H6RF8QOY&UL1MP<1 X/L:TX?#ET8D_XJ
M'51\H_YX?_&J -^BL/\ X1NZ_P"ABU7_ ,@?_&J/^$;NO^ABU7_R!_\ &J -
MRBL/_A&[K_H8M5_\@?\ QJC_ (1NZ_Z&+5?_ "!_\:H 3P7_ ,@+_M[NO_2B
M2MVN*\):!<S:+N77=2B'VFY&U/)QQ/(,\QGKU_&MG_A&[K_H8M5_\@?_ !J@
M#<HK#_X1NZ_Z&+5?_('_ ,:H_P"$;NO^ABU7_P @?_&J -RL+PK_ ,QC_L(S
M?TI?^$;NO^ABU7_R!_\ &JQO#>@7,G]JXUW4H]M_*IV>3\W3DYCZT 7?''^M
M\-_]AB'_ - DKJ*X#QCH-Q#+X?W:YJ,V_58E&_R?D.U_F&(QS]<CGI71_P#"
M-W7_ $,6J_\ D#_XU0!N45A_\(W=?]#%JO\ Y _^-4?\(W=?]#%JO_D#_P"-
M4 $'_([WW_8.M_\ T;-6Y7%0Z!<GQA>1_P!O:D&%A WF?N=QS)+Q_J\8&/3N
M:V?^$;NO^ABU7_R!_P#&J -RBL/_ (1NZ_Z&+5?_ "!_\:H_X1NZ_P"ABU7_
M ,@?_&J -RL.Y_Y'?3?^P==?^C;>C_A&[K_H8M5_\@?_ !JL:XT"Y'C#3X_[
M=U(L;"Y;S#Y.X8D@X'[O&#GT[#WH [6BL/\ X1NZ_P"ABU7_ ,@?_&J/^$;N
MO^ABU7_R!_\ &J -RBL/_A&[K_H8M5_\@?\ QJC_ (1NZ_Z&+5?_ "!_\:H
M3Q7_ *O2O^PC!_Z%6[7%>)M N8H]-SKNI2;K^!1O\GY<MU&(QR*V?^$;NO\
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MNO\ H8M5_P#('_QJC_A&[K_H8M5_\@?_ !JK.,W*PD_Y'B;_ +!R?^C7I?\
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M\@?_ !JC_A&[K_H8M5_\@?\ QJ@#<HK#_P"$;NO^ABU7_P @?_&J/^$;NO\
MH8M5_P#('_QJ@!/ O_(F:'_UYQ?^@BMVN*\&:!<S>$M'D77=2A5K2,B./R=J
M_*.!F,G'U-;/_"-W7_0Q:K_Y _\ C5 &Y16'_P (W=?]#%JO_D#_ .-4?\(W
M=?\ 0Q:K_P"0/_C5 &Y6%X;_ ./_ ,1?]A'_ -H0TO\ PC=U_P!#%JO_ ) _
M^-5C>'] N9+[7@-=U*/9?[25\G+_ +B(Y.8^O..,=!0!VM%8?_"-W7_0Q:K_
M .0/_C5'_"-W7_0Q:K_Y _\ C5 &Y16'_P (W=?]#%JO_D#_ .-4?\(W=?\
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M5A?\(7I7]RZ_\#I__BZ/^$+TK^Y=?^!T_P#\70!NT5A?\(7I7]RZ_P# Z?\
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M5_<NO_ Z?_XN@#=K"\*_\QC_ +",W]*/^$+TK^Y=?^!T_P#\76/X;\(Z;/\
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M6/<>$=,'C#3X0ESL:PN7/^F39R)( .=^>YX_PH [6BL+_A"]*_N77_@=/_\
M%T?\(7I7]RZ_\#I__BZ -VBL+_A"]*_N77_@=/\ _%T?\(7I7]RZ_P# Z?\
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M@!\#Z"@#M:*PO^$+TK^Y=?\ @=/_ /%T?\(7I7]RZ_\  Z?_ .+H W:*PO\
MA"]*_N77_@=/_P#%T?\ "%Z5_<NO_ Z?_P"+H /#'_'QKO\ V$7_ /1<=4?
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MX!?5;*,[KN9N#.@/5_0]>HH [^BL+_A"]*_N77_@=/\ _%T?\(7I7]RZ_P#
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M^?RW_P"_J_XURGC30=,AE\.^7IUHF_5H4;; HW#:_!XY%=)_PC6D?] JR_\
M =/\* )_[6L?^?RW_P"_J_XT?VM8_P#/Y;_]_5_QJ#_A&M(_Z!5E_P" Z?X4
M?\(UI'_0*LO_  '3_"@#,@U.S'C2];[7!M.GP 'S!C/F3>];7]K6/_/Y;_\
M?U?\:YZ#P_I9\9WL?]FV?EC3X&">0F 3)-DXQ[#\JVO^$:TC_H%67_@.G^%
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M@59?^ Z?X4 3_P!K6/\ S^6__?U?\:/[6L?^?RW_ ._J_P"-0?\ "-:1_P!
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M+?\ [^K_ (T?VM8_\_EO_P!_5_QJ#_A&M(_Z!5E_X#I_A1_PC6D?] JR_P#
M=/\ "@#,\9ZG9OX;NE6[@9BT? D!/^L7WK:_M:Q_Y_+?_OZO^-<]XQ\/Z7#X
M=NGCTVS1P8\,L" C]XOM6U_PC6D?] JR_P# =/\ "@"?^UK'_G\M_P#OZO\
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MGX5MXIKP)()K@D;&/!GD([>A%=%_PF^B?\_P_P"_;_X54^&O_(GVO_7>Y_\
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M_P#"B]_Y';2/^O"\_P#1EM6[0!A?\)OHG_/\/^_;_P"%'_";Z)_S_#_OV_\
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M ,)0W_0%U7_OPO\ \51_PE#?] 75?^_"_P#Q5;E% &'_ ,)0W_0%U7_OPO\
M\51_PE#?] 75?^_"_P#Q5;E% '%:QXC9]<T%O[)U)=D\IVM",M^Y<<?-6S_P
ME#?] 75?^_"__%4:W_R,'AW_ *^)O_1#UN4 <!\/O$+6WA6WC_LK49L37!WQ
M0@J<SR'^][XKH_\ A*&_Z NJ_P#?A?\ XJJ?PU_Y$^U_Z[W/_I1)744 8?\
MPE#?] 75?^_"_P#Q58WB/Q&TKZ3_ ,2G4DVW\;?-"!GAN!\W6NUK#\4??T7_
M +",7_H+4 '_  E#?] 75?\ OPO_ ,51_P )0W_0%U7_ +\+_P#%5N44 8?_
M  E#?] 75?\ OPO_ ,51_P )0W_0%U7_ +\+_P#%5N44 <;XN\2--X4UJ/\
MLC4X]]E,N]X %7,;<GYNE:</BAA$G_$FU7[H_P"6"_\ Q53>-/\ D3M=_P"O
M"?\ ]%M6M#_J8_\ =% &-_PE#?\ 0%U7_OPO_P 51_PE#?\ 0%U7_OPO_P 5
M6Y10!A_\)0W_ $!=5_[\+_\ %4?\)0W_ $!=5_[\+_\ %5N44 <5X2\1M#HN
MW^R=2D_TFY.Y(01S/(<?>[9Q6S_PE#?] 75?^_"__%4G@O\ Y 7_ &]W7_I1
M)6[0!A_\)0W_ $!=5_[\+_\ %4?\)0W_ $!=5_[\+_\ %5N44 8?_"4-_P!
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M"+L\D;O]8W.-W2NUK"3_ )'B;_L')_Z->@!?^$H;_H"ZK_WX7_XJC_A*&_Z
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M+JO_ 'X7_P"*K&\/^(VCOM>/]DZD^^_W86$$K^XB&#\W7C/XBNUK"\-_\?\
MXB_["/\ [0AH 7_A*&_Z NJ_]^%_^*H_X2AO^@+JO_?A?_BJW** ,/\ X2AO
M^@+JO_?A?_BJ/^$H;_H"ZK_WX7_XJMRB@#BM,\1LGB/6G_LG4FWB#Y1",KA3
MU^:MG_A*&_Z NJ_]^%_^*HTG_D:->^EO_P"@&MR@#B;G5#J7CSPWFRN[/9%=
MG_2HPN[*ITP37;5R^N?\CWX7_P"N5Y_Z#'744 %%%% !1110 4444 87]IZ]
M_P! .#_P/'_Q%']IZ]_T X/_  /'_P 16[10!A?VGKW_ $ X/_ \?_$4?VGK
MW_0#@_\  \?_ !%;M% '%:QJ.M-KF@EM'A5Q/+L47H.X^2^>=G''-;']IZ]_
MT X/_ \?_$4NM_\ (P>'?^OB;_T0];E ' ?#[4-9C\*VZP:1#-'YUQAVO-I)
M\^3/&P]#D5T7]IZ]_P! .#_P/'_Q%5/AK_R)]K_UWN?_ $HDKJ* ,+^T]>_Z
M <'_ ('C_P"(K'\1ZCK3/I/F:/"F+^,KB]!W'#<?<X^M=K6'XH^_HO\ V$8O
M_06H 3^T]>_Z <'_ ('C_P"(H_M/7O\ H!P?^!X_^(K=HH PO[3U[_H!P?\
M@>/_ (BC^T]>_P"@'!_X'C_XBMVB@#C/%VHZV_A36EET:&.,V4P9Q>ABH\ML
MG&SGZ5J1:GKWE)C0X"-H_P"7\?\ Q%3>-/\ D3M=_P"O"?\ ]%M6M#_J8_\
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M!P?^!X_^(H\5_P"KTK_L(P?^A5NT 87]IZ]_T X/_ \?_$4?VGKW_0#@_P#
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MA>AL?.O;96Q_:>O?] .#_P #Q_\ $4OC7_D6KO\ WH__ $8M;E &%_:>O?\
M0#@_\#Q_\11_:>O?] .#_P #Q_\ $5NT4 87]IZ]_P! .#_P/'_Q%']IZ]_T
M X/_  /'_P 16[10!Q7@W4-:3PEHZQ:/#+$+2,*YO=I8;1SC9Q6Q_:>O?] .
M#_P/'_Q%'@7_ )$S0_\ KSB_]!%;M &%_:>O?] .#_P/'_Q%']IZ]_T X/\
MP/'_ ,16[10!A?VGKW_0#@_\#Q_\16/X?U'6EOM>*:/"Y-_EP;T#:?(BX^YS
MQ@Y]Z[6L+PW_ ,?_ (B_["/_ +0AH /[3U[_ * <'_@>/_B*/[3U[_H!P?\
M@>/_ (BMVB@#"_M/7O\ H!P?^!X_^(H_M/7O^@'!_P"!X_\ B*W:* .*TS4=
M:'B/6F71X6D(@W+]M V_*<<[.:V/[3U[_H!P?^!X_P#B*72?^1HU[Z6__H!K
M<H XFYN;^Y\>>&_MUC'9;8KO9LG\W=\J9_A&*[:N7US_ )'OPO\ ]<KS_P!!
MCKJ* "BBB@ HHHH **** ,/R?$O_ #^:5_X"2_\ QVCR?$O_ #^:5_X"2_\
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M_':W** .*\30^(!'IOFW>FM_I\&W9;2##;N,_O.E;/D^)?\ G\TK_P !)?\
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M .#2X_\ BZ3P7_R O^WNZ_\ 2B2MV@##_P"$0M/^?S5?_!I<?_%T?\(A:?\
M/YJO_@TN/_BZW** ,/\ X1"T_P"?S5?_  :7'_Q=8WAOPM:S?VKFZU)=E_*H
MV:C.N0,=</R?>NUK"\*_\QC_ +",W]* .=\8^&+:WE\/A;K46\S58D._4)VP
M"K\C+\'CJ.:Z/_A$+3_G\U7_ ,&EQ_\ %U3\<?ZWPW_V&(?_ $"2NHH P_\
MA$+3_G\U7_P:7'_Q='_"(6G_ #^:K_X-+C_XNMRB@#BH?"UJ?&%Y%]JU+:+"
M!L_VC/NR9)1UWYQQT^OK6S_PB%I_S^:K_P"#2X_^+H@_Y'>^_P"P=;_^C9JW
M* ,/_A$+3_G\U7_P:7'_ ,71_P (A:?\_FJ_^#2X_P#BZW** ,/_ (1"T_Y_
M-5_\&EQ_\76-<>%K4>,-/B^U:EM:PN6).HS[LB2 <'?D#GIWX]!7:UAW/_([
MZ;_V#KK_ -&V] !_PB%I_P _FJ_^#2X_^+H_X1"T_P"?S5?_  :7'_Q=;E%
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M_P B3X>_[!UO_P"BEH /^$0M/^?S5?\ P:7'_P 71_PB%I_S^:K_ .#2X_\
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M<L,/;]#OR!SR._'H*V?^$0M/^?S5?_!I<?\ Q=)>_P#([:1_UX7G_HRVK=H
MP_\ A$+3_G\U7_P:7'_Q='_"(6G_ #^:K_X-+C_XNMRB@##_ .$0M/\ G\U7
M_P &EQ_\77.>./#%M;6.F,MUJ+%M5LD/F:A.X ,Z D9?@^AZCM7?UR_Q _Y!
M^D_]ABQ_]*$H N?\(A:?\_FJ_P#@TN/_ (NC_A$+3_G\U7_P:7'_ ,76Y10!
MA_\ "(6G_/YJO_@TN/\ XNC_ (1"T_Y_-5_\&EQ_\76Y10!Q7B_PM:P>'KEU
MNM28@Q\/J,[#[Z]B^*V?^$0M/^?S5?\ P:7'_P 71XU_Y%J[_P!Z/_T8M;E
M&'_PB%I_S^:K_P"#2X_^+H_X1"T_Y_-5_P#!I<?_ !=;E% &'_PB%I_S^:K_
M .#2X_\ BZ/^$0M/^?S5?_!I<?\ Q=;E% '%>#?"UK<>$M'E:ZU)6>TC8B/4
M9U4?*.@#X ]A6S_PB%I_S^:K_P"#2X_^+I/ O_(F:'_UYQ?^@BMV@##_ .$0
MM/\ G\U7_P &EQ_\71_PB%I_S^:K_P"#2X_^+K<HH P_^$0M/^?S5?\ P:7'
M_P 76-X?\+6LM]KP-UJ0$=_M&W49P2/(B/.'Y//4^WI7:UA>&_\ C_\ $7_8
M1_\ :$- "_\ "(6G_/YJO_@TN/\ XNC_ (1"T_Y_-5_\&EQ_\76Y10!A_P#"
M(6G_ #^:K_X-+C_XNC_A$+3_ )_-5_\ !I<?_%UN44 <5IGA:U?Q'K49NM2
M008(U&<$Y4]3OR?QK9_X1"T_Y_-5_P#!I<?_ !=&D_\ (T:]]+?_ - -;E '
M$W.CPZ3X\\-F*:[E\R*[!^U74DV,*G3>QQ^%=M7+ZY_R/?A?_KE>?^@QUU%
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M  #C_P */^$]\-?]#!I?_@9'_C1_PGOAK_H8-+_\#(_\:+YA_?\ _)@]T/\
MA O#7_0O:7_X!Q_X4?\ "!>&O^A>TO\ \ X_\*/^$]\-?]#!I?\ X&1_XT?\
M)[X:_P"A@TO_ ,#(_P#&B^8?W_\ R8/=#_A O#7_ $+VE_\ @''_ (4?\(%X
M:_Z%[2__  #C_P */^$]\-?]#!I?_@9'_C1_PGOAK_H8-+_\#(_\:+YA_?\
M_)@]T/\ A O#/_0O:7_X!Q_X4?\ "!>&O^A>TO\ \ X_\*/^$]\-?]#!I?\
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M\*/^$]\-?]#!I?\ X&1_XT?\)[X:_P"A@TO_ ,#(_P#&B^8?W_\ R8/=#_A
MO#/_ $+VE_\ @''_ (4?\(%X:_Z%[2__  #C_P */^$]\-?]#!I?_@9'_C1_
MPGOAK_H8-+_\#(_\:+YA_?\ _)@]T/\ A O#7_0O:7_X!Q_X4?\ "!>&O^A>
MTO\ \ X_\*/^$]\-?]#!I?\ X&1_XT?\)[X:_P"A@TO_ ,#(_P#&B^8?W_\
MR8/=#_A O#7_ $+VE_\ @''_ (4?\(%X:_Z%[2__  #C_P */^$]\-?]#!I?
M_@9'_C1_PGOAK_H8-+_\#(_\:+YA_?\ _)@]T/\ A O#7_0O:7_X!Q_X4?\
M"!>&O^A>TO\ \ X_\*/^$]\-?]#!I?\ X&1_XT?\)[X:_P"A@TO_ ,#(_P#&
MB^8?W_\ R8/=#_A O#7_ $+VE_\ @''_ (4?\(%X:_Z%[2__  #C_P */^$]
M\-?]#!I?_@9'_C1_PGOAK_H8-+_\#(_\:+YA_?\ _)@]T/\ A O#7_0O:7_X
M!Q_X4?\ "!>&O^A>TO\ \ X_\*/^$]\-?]#!I?\ X&1_XT?\)[X:_P"A@TO_
M ,#(_P#&B^8?W_\ R8/=#_A O#7_ $+VE_\ @''_ (4?\(%X:_Z%[2__  #C
M_P */^$]\-?]#!I?_@9'_C1_PGOAK_H8-+_\#(_\:+YA_?\ _)@]T/\ A O#
M7_0O:7_X!Q_X4?\ "!>&O^A>TO\ \ X_\*/^$]\-?]#!I?\ X&1_XT?\)[X:
M_P"A@TO_ ,#(_P#&B^8?W_\ R8/=#_A O#7_ $+VE_\ @''_ (4?\(%X:_Z%
M[2__  #C_P */^$]\-?]#!I?_@9'_C1_PGOAK_H8-+_\#(_\:+YA_?\ _)@]
MT/\ A O#7_0O:7_X!Q_X4?\ "!>&?^A>TO\ \ X_\*/^$]\-?]#!I?\ X&1_
MXT?\)[X:_P"A@TO_ ,#(_P#&B^8?W_\ R8/=#_A O#7_ $+VE_\ @''_ (4?
M\(%X:_Z%[2__  #C_P */^$]\-?]#!I?_@9'_C1_PGOAK_H8-+_\#(_\:+YA
M_?\ _)@]T/\ A O#7_0O:7_X!Q_X4?\ "!>&O^A>TO\ \ X_\*/^$]\-?]#!
MI?\ X&1_XT?\)[X:_P"A@TO_ ,#(_P#&B^8?W_\ R8/=#_A O#7_ $+VE_\
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M_P :QOF']_\ \F./W0_X0+PU_P!"]I?_ (!Q_P"%'_"!>&O^A>TO_P  X_\
M"C_A/?#7_0P:7_X&1_XT?\)[X:_Z&#2__ R/_&B^8?W_ /R8/=#_ (0+PU_T
M+VE_^ <?^%'_  @7AK_H7M+_ / ./_"C_A/?#7_0P:7_ .!D?^-'_">^&O\
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MK_H8-+_\#(_\:/\ A/?#7_0P:7_X&1_XT7S#^_\ ^3![H?\ "!>&?^A>TO\
M\ X_\*/^$"\-?]"]I?\ X!Q_X4?\)[X:_P"A@TO_ ,#(_P#&C_A/?#7_ $,&
ME_\ @9'_ (T7S#^__P"3![H?\(%X:_Z%[2__  #C_P */^$"\-?]"]I?_@''
M_A1_PGOAK_H8-+_\#(_\:/\ A/?#7_0P:7_X&1_XT7S#^_\ ^3![H?\ "!>&
MO^A>TO\ \ X_\*/^$"\-?]"]I?\ X!Q_X4?\)[X:_P"A@TO_ ,#(_P#&C_A/
M?#7_ $,&E_\ @9'_ (T7S#^__P"3![H?\(%X:_Z%[2__  #C_P */^$"\-?]
M"]I?_@''_A1_PGOAK_H8-+_\#(_\:/\ A/?#7_0P:7_X&1_XT7S#^_\ ^3![
MH?\ "!>&O^A>TO\ \ X_\*/^$"\-?]"]I?\ X!Q_X4?\)[X:_P"A@TO_ ,#(
M_P#&C_A/?#7_ $,&E_\ @9'_ (T7S#^__P"3![H?\(%X:_Z%[2__  #C_P *
M/^$"\,_]"]I?_@''_A1_PGOAK_H8-+_\#(_\:/\ A/?#7_0P:7_X&1_XT7S#
M^_\ ^3![H?\ "!>&O^A>TO\ \ X_\*/^$"\-?]"]I?\ X!Q_X4?\)[X:_P"A
M@TO_ ,#(_P#&C_A/?#7_ $,&E_\ @9'_ (T7S#^__P"3![H?\(%X:_Z%[2__
M  #C_P */^$"\-?]"]I?_@''_A1_PGOAK_H8-+_\#(_\:/\ A/?#7_0P:7_X
M&1_XT7S#^_\ ^3![H?\ "!>&?^A>TO\ \ X_\*/^$"\-?]"]I?\ X!Q_X4?\
M)[X:_P"A@TO_ ,#(_P#&C_A/?#7_ $,&E_\ @9'_ (T7S#^__P"3![IJ^&?"
MVC:1J8N+'2;&SGV%?-M[=$;!ZC(&:ZZN2\,^*=&U?4Q;V.K65Y/L+>5!<([8
M'4X!KK:_7N%O;?V?^^O?F>][].YPUK<V@4445]@8!1110 4444 <S16%_P )
MC:?\^6K?^"NX_P#B*/\ A,;3_GRU;_P5W'_Q%?S-]5K_ ,C^X]>Z-VBL+_A,
M;3_GRU;_ ,%=Q_\ $4?\)C:?\^6K?^"NX_\ B*/JM?\ D?W!=&[16%_PF-I_
MSY:M_P""NX_^(H_X3&T_Y\M6_P#!7<?_ !%'U6O_ "/[@NC=HK"_X3&T_P"?
M+5O_  5W'_Q%'_"8VG_/EJW_ (*[C_XBCZK7_D?W!=&[16%_PF-I_P ^6K?^
M"NX_^(H_X3&T_P"?+5O_  5W'_Q%'U6O_(_N"Z-VBL+_ (3&T_Y\M6_\%=Q_
M\11_PF-I_P ^6K?^"NX_^(H^JU_Y']P71NT5A?\ "8VG_/EJW_@KN/\ XBC_
M (3&T_Y\M6_\%=Q_\11]5K_R/[@NC=HK"_X3&T_Y\M6_\%=Q_P#$4?\ "8VG
M_/EJW_@KN/\ XBCZK7_D?W!=&[16%_PF-I_SY:M_X*[C_P"(H_X3&T_Y\M6_
M\%=Q_P#$4?5:_P#(_N"Z-VBL+_A,;3_GRU;_ ,%=Q_\ $4?\)C:?\^6K?^"N
MX_\ B*/JM?\ D?W!=&[16%_PF-I_SY:M_P""NX_^(H_X3&T_Y\M6_P#!7<?_
M !%'U6O_ "/[@NC=HK"_X3&T_P"?+5O_  5W'_Q%'_"8VG_/EJW_ (*[C_XB
MCZK7_D?W!=&[16%_PF-I_P ^6K?^"NX_^(H_X3&T_P"?+5O_  5W'_Q%'U6O
M_(_N"Z-VBL+_ (3&T_Y\M6_\%=Q_\11_PF-I_P ^6K?^"NX_^(H^JU_Y']P7
M1NT5A?\ "8VG_/EJW_@KN/\ XBC_ (3&T_Y\M6_\%=Q_\11]5K_R/[@NC=HK
M"_X3&T_Y\M6_\%=Q_P#$4?\ "8VG_/EJW_@KN/\ XBCZK7_D?W!=&[16%_PF
M-I_SY:M_X*[C_P"(H_X3&T_Y\M6_\%=Q_P#$4?5:_P#(_N"Z-VBL+_A,;3_G
MRU;_ ,%=Q_\ $4?\)C:?\^6K?^"NX_\ B*/JM?\ D?W!=&[16%_PF-I_SY:M
M_P""NX_^(H_X3&T_Y\M6_P#!7<?_ !%'U6O_ "/[@NC=HK"_X3&T_P"?+5O_
M  5W'_Q%'_"8VG_/EJW_ (*[C_XBCZK7_D?W!=&[16%_PF-I_P ^6K?^"NX_
M^(H_X3&T_P"?+5O_  5W'_Q%'U6O_(_N"Z-VBL+_ (3&T_Y\M6_\%=Q_\11_
MPF-I_P ^6K?^"NX_^(H^JU_Y']P71NT5A?\ "8VG_/EJW_@KN/\ XBC_ (3&
MT_Y\M6_\%=Q_\11]5K_R/[@NC=HK"_X3&T_Y\M6_\%=Q_P#$4?\ "8VG_/EJ
MW_@KN/\ XBCZK7_D?W!=&[16%_PF-I_SY:M_X*[C_P"(H_X3&T_Y\M6_\%=Q
M_P#$4?5:_P#(_N"Z-VBL+_A,;3_GRU;_ ,%=Q_\ $4?\)C:?\^6K?^"NX_\
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M (*[C_XBC_A,;3_GRU;_ ,%=Q_\ $4?5:_\ (_N"Z-VBL+_A,;3_ )\M6_\
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MJW_@KN/_ (BC_A,;3_GRU;_P5W'_ ,11]5K_ ,C^X+HW:*PO^$QM/^?+5O\
MP5W'_P 11_PF-I_SY:M_X*[C_P"(H^JU_P"1_<%T=3I7_'V/]TUM5R7AGQ#!
MJ>IB&.VOXFV%MUQ92Q+_ -],H%=;7[+PE"5/+K35GS/]#@KZS"BBBOM#G"BB
MB@ HHHH YFBLS[5KW_0L77_@7;__ !='VK7O^A8NO_ NW_\ BZ_GW_5_-/\
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M[6'<VZ*P=0U[5=,:U%QX;NT-S.MO%BY@.7() ^_QT-6_M6O?]"Q=?^!=O_\
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M !='VK7O^A8NO_ NW_\ BZ/]7\T_Y\/\/\P]K#N:=%9GVK7O^A8NO_ NW_\
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M6'_?9_PJ'X?/KP\*V_V>+3C%YUQ@RRR!L^?)GHOKFNCW^)?^>.E?]_I?_B:
M,+_A>'@/_H:+#_OL_P"%8_B/XT^!YGTG9XFL6V7\;MASP,-STKM=_B7_ )XZ
M5_W^E_\ B:QO$;^(-^D^9#IH_P!/CV[99/O8;&?EZ4 1_P#"\/ ?_0T6'_?9
M_P */^%X> _^AHL/^^S_ (5N[_$O_/'2O^_TO_Q-&_Q+_P \=*_[_2__ !-
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M -#18?\ ?9_PK=W^)?\ GCI7_?Z7_P")HW^)?^>.E?\ ?Z7_ .)H PO^%X>
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M_H:+#_OL_P"%;N_Q+_SQTK_O]+_\31O\2_\ /'2O^_TO_P 30!A?\+P\!_\
M0T6'_?9_PK'N/C3X';QAI\P\36)B6PN4+;S@$R0$#I['\J[7?XE_YXZ5_P!_
MI?\ XFL:X?Q!_P )AI^8=-\[[!<[0)9-NWS(,Y^7KG'ZT 1_\+P\!_\ 0T6'
M_?9_PH_X7AX#_P"AHL/^^S_A6[O\2_\ /'2O^_TO_P 31O\ $O\ SQTK_O\
M2_\ Q- &%_PO#P'_ -#18?\ ?9_PH_X7AX#_ .AHL/\ OL_X5N[_ !+_ ,\=
M*_[_ $O_ ,31O\2_\\=*_P"_TO\ \30!Q7B;XT^!YX]-\OQ-8OLOX';#G@!N
M3TK8_P"%X> _^AHL/^^S_A4GB9_$'EZ;YL.FC_3X-NR60_-NXS\O2MG?XE_Y
MXZ5_W^E_^)H PO\ A>'@/_H:+#_OL_X4?\+P\!_]#18?]]G_  K=W^)?^>.E
M?]_I?_B:-_B7_GCI7_?Z7_XF@#"_X7AX#_Z&BP_[[/\ A6=XE^-?@:?PYJL<
M?B:P9WM)550YR24.!TKKM_B7_GCI7_?Z7_XFLWQ*_B'_ (1S5?-ATP1_9)=Q
M260G&PYQ\O6@#-L/C=X$2QMU/B>P!$:@C>?3Z5/_ ,+P\!_]#18?]]G_  K6
ML'\1_8;?;#I>WRUQF63/3_=J??XE_P">.E?]_I?_ (F@#"_X7AX#_P"AHL/^
M^S_A7.ZA\9O!#_$'0[A?$MB8(]-OT=]YP&:2T*CIWVM^5=_O\2_\\=*_[_2_
M_$USFH/KW_"P=#+1:=]H_LV_V 2R;-OF6F[)VYSG;C\: )C\;_ >/^1HL/\
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M\\=*_P"_TO\ \31O\2_\\=*_[_2__$U9QFY6$G_(\3?]@Y/_ $:]+O\ $O\
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MX"NVH **** "BBB@ HHHH **PO[)UO\ Z#R_^ 2?XT?V3K?_ $'E_P# )/\
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MK?\ T'E_\ D_QH_LG6_^@\O_ (!)_C0 >&/^/C7?^PB__HN.J/@/_CX\4_\
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M^OB;_P!$/6Y7%:QX/T>/7-!1;)0LD\H8;VY A<^OJ*V?^$)T3_GP7_OMO\:
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M_GP7_OMO\: -RBL/_A"=$_Y\%_[[;_&C_A"=$_Y\%_[[;_&@!+W_ )';2/\
MKPO/_1EM6[7%7?@_1U\7Z7"+)1&]E=,R[VY(>W [_P"T?SK9_P"$)T3_ )\%
M_P"^V_QH W**P_\ A"=$_P"?!?\ OMO\:/\ A"=$_P"?!?\ OMO\: -RN7^(
M'_(/TG_L,6/_ *4)5S_A"=$_Y\%_[[;_ !KG/''A+2;6QTQHK-4+ZK91L=[<
MJTZ CKZ&@#OZ*P_^$)T3_GP7_OMO\:/^$)T3_GP7_OMO\: -RBL/_A"=$_Y\
M%_[[;_&C_A"=$_Y\%_[[;_&@ \:_\BU=_P"]'_Z,6MRN*\7^#]'M_#US)'9*
MK@QX.]O[ZCUK9_X0G1/^?!?^^V_QH W**P_^$)T3_GP7_OMO\:/^$)T3_GP7
M_OMO\: -RBL/_A"=$_Y\%_[[;_&C_A"=$_Y\%_[[;_&@!/ O_(F:'_UYQ?\
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MSYV__?I?\*/[*LO^?.W_ ._2_P"% %;_ (2;1_\ H+6/_@2G^-'_  DVC_\
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M*LO^?.W_ ._2_P"%8GB;3;1'T?;:P#.H1@XC'(VM[4 :7_"3:/\ ]!:Q_P#
ME/\ &C_A)M'_ .@M8_\ @2G^-6?[*LO^?.W_ ._2_P"%']E67_/G;_\ ?I?\
M* *W_"3:/_T%K'_P)3_&C_A)M'_Z"UC_ .!*?XU9_LJR_P"?.W_[]+_A1_95
ME_SYV_\ WZ7_  H Y_QAXBTJ;PEK<<>IV;R/8SJJK<(228VP ,UJP^)M'$2?
M\36Q^Z/^7E/\:I>,M,LT\(:XRVD"L+&<@B, @^6WM6K#I5EY*?Z'!]T?\LE_
MPH A_P"$FT?_ *"UC_X$I_C1_P )-H__ $%K'_P)3_&K/]E67_/G;_\ ?I?\
M*/[*LO\ GSM_^_2_X4 5O^$FT?\ Z"UC_P"!*?XT?\)-H_\ T%K'_P "4_QJ
MS_95E_SYV_\ WZ7_  H_LJR_Y\[?_OTO^% '.>$/$.E0Z)MDU.S1OM5T<-<(
M#@SR$'KZ&MK_ (2;1_\ H+6/_@2G^-9O@[3;1]#RUK Q^U70R8P?^7B3VK;_
M +*LO^?.W_[]+_A0!6_X2;1_^@M8_P#@2G^-'_"3:/\ ]!:Q_P# E/\ &K/]
ME67_ #YV_P#WZ7_"C^RK+_GSM_\ OTO^% %;_A)M'_Z"UC_X$I_C6+X9\0Z5
M%_:V_4[--VH2LNZX09''(YKH_P"RK+_GSM_^_2_X5B>%]-M'_M?=:P-C4)@,
MQC@<>U &;XS\0:7-+X>\O4K239JT+MMG4[5VOR>>!72?\)-H_P#T%K'_ ,"4
M_P :PO&NG6B2^'-MK"N[5X0<1@9&U^*Z;^RK+_GSM_\ OTO^% %;_A)M'_Z"
MUC_X$I_C1_PDVC_]!:Q_\"4_QJS_ &59?\^=O_WZ7_"C^RK+_GSM_P#OTO\
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MTO\ A0!6_P"$FT?_ *"UC_X$I_C1_P )-H__ $%K'_P)3_&K/]E67_/G;_\
M?I?\*/[*LO\ GSM_^_2_X4 <YXH\0Z5+'IFS4[-]NH0,=MPAP W)Z]*VO^$F
MT?\ Z"UC_P"!*?XUF^*=-M$CTO;:P+G4( <1CD;OI6W_ &59?\^=O_WZ7_"@
M"M_PDVC_ /06L?\ P)3_ !H_X2;1_P#H+6/_ ($I_C5G^RK+_GSM_P#OTO\
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M7_/G;_\ ?I?\*/[*LO\ GSM_^_2_X4 5O^$FT?\ Z"UC_P"!*?XT?\)-H_\
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M/3;1/#=TRVL"D-'R(P/^6B^U;?\ 95E_SYV__?I?\* *W_"3:/\ ]!:Q_P#
ME/\ &C_A)M'_ .@M8_\ @2G^-6?[*LO^?.W_ ._2_P"%']E67_/G;_\ ?I?\
M* *W_"3:/_T%K'_P)3_&C_A)M'_Z"UC_ .!*?XU9_LJR_P"?.W_[]+_A1_95
ME_SYV_\ WZ7_  H YSP5XATJ'PAHT<FIV<<BVD096N$!!VC@C-;7_"3:/_T%
MK'_P)3_&LWP1IMI)X.T5FM8&8V<1),8)/RCVK;_LJR_Y\[?_ +]+_A0!6_X2
M;1_^@M8_^!*?XT?\)-H__06L?_ E/\:L_P!E67_/G;_]^E_PH_LJR_Y\[?\
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M)-H__06L?_ E/\:S=*TVT/B;75-K 5 M\#RQ@?(?:MO^RK+_ )\[?_OTO^%
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MH_X332O[UW_X S__ !%;E% &'_PFFE?WKO\ \ 9__B*/^$TTK^]=_P#@#/\
M_$5N44 <;XN\7:;<>%-:B1KG>]E,J[K*91DQL.24P/J:TX?&>EB)!NNONC_E
MQG_^(J;QI_R)VN_]>$__ *+:M:'_ %,?^Z* ,;_A--*_O7?_ ( S_P#Q%'_"
M::5_>N__  !G_P#B*W** ,/_ (332O[UW_X S_\ Q%'_  FFE?WKO_P!G_\
MB*W** .*\)>+=-M]%V.USN^TW+?+9S,,&>0CD)Z&MG_A--*_O7?_ ( S_P#Q
M%)X+_P"0%_V]W7_I1)6[0!A_\)II7]Z[_P# &?\ ^(H_X332O[UW_P" ,_\
M\16Y10!A_P#"::5_>N__  !G_P#B*QO#?BW38?[5WM<_/?RN,6<QX./1./I7
M:UA>%?\ F,?]A&;^E '.^,?%>G7$OA\HUS^[U6*1MUG,O 5^F4Y//0<UT?\
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MS_$'0[@-<^5'IM^C9LY@<M):$8&S)^Z>0,#C/45W]<OJ7_)2O#__ &"M1_\
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M /$4E[_R.VD?]>%Y_P"C+:MV@##_ .$TTK^]=_\ @#/_ /$4?\)II7]Z[_\
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M+_L(_P#M"&@!?^$TTK^]=_\ @#/_ /$4?\)II7]Z[_\  &?_ .(K<HH P_\
MA--*_O7?_@#/_P#$4?\ "::5_>N__ &?_P"(K<HH XK3/%NFIXCUJ0M<[7$&
MW%G,3PISD;,C\:V?^$TTK^]=_P#@#/\ _$4:3_R-&O?2W_\ 0#6Y0!Q-SK5K
MK'CSPV+4RGRXKLMYL$D754QC>HS^%=M7+ZY_R/?A?_KE>?\ H,==10 4444
M%%%% !1110!A?\))=_\ 0N:K_P"2_P#\=H_X22[_ .A<U7_R7_\ CM9'_"[/
MAW_T/OAC_P '%O\ _%T?\+L^'?\ T/OAC_P<6_\ \70!K_\ "27?_0N:K_Y+
M_P#QVC_A)+O_ *%S5?\ R7_^.UD?\+L^'?\ T/OAC_P<6_\ \71_PNSX=_\
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M_&7P!;Z+LE\<^&XG^TW+;7U>W!P9Y"#]_N"#^-;/_"[/AW_T/OAC_P '%O\
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M_P )A+)_8.I[OL"+Y?[C=CS&Y_UN,?C7:UA)_P CQ-_V#D_]&O0 ?\))=_\
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MO3]D5V1]J\OY\JG38[=/?%=M7+ZY_P CWX7_ .N5Y_Z#'744 %%%% !1110
M4444 <]OUW_H!Z1_X,7_ /D>C?KO_0#TC_P8O_\ (]=#10!SV_7?^@'I'_@Q
M?_Y'HWZ[_P! /2/_  8O_P#(]=#10!PVL-K1UO0=^C:6KB>78JW[D,?)?.3Y
M''&>Q_K6QOUW_H!Z1_X,7_\ D>I=;_Y&#P[_ -?$W_HAZW* ///A^VL+X5MQ
M!H^F31>=<8>6^9&)\]\\" ]#D=?RZ5T6_7?^@'I'_@Q?_P"1Z@^&O_(GVO\
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MIT(1WU%U9E\H8)'D'!QVR?K7;GI6!X._Y$'0_P#L&0?^BEH Y+X,W>OK\'_
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M&.NHH **** "BBB@ HHHH P_L?B3_H+Z7_X+)/\ Y(H^Q^)/^@OI?_@LD_\
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M_P D53\<?ZWPW_V&(?\ T"2NHH P_L?B3_H+Z7_X+)/_ )(H^Q^)/^@OI?\
MX+)/_DBMRB@#BH;37_\ A,+P#5-.\[[! 2_]G/M*^9+@8\_KG/.>XXXYV?L?
MB3_H+Z7_ ."R3_Y(H@_Y'>^_[!UO_P"C9JW* /+OA+::^WAS5/*U33D7_A(-
M8!#Z<[$M_:-QD_Z\<$Y('8<9/6NU^Q^)/^@OI?\ X+)/_DBL/X/_ /(M:K_V
M,6M?^G*YKN* ,/['XD_Z"^E_^"R3_P"2*QKBTU__ (3#3P=4TXS&PN2KC3GV
MA?,@R"//Y.<<YXP>#GCM:P[G_D=]-_[!UU_Z-MZ #['XD_Z"^E_^"R3_ .2*
M/L?B3_H+Z7_X+)/_ )(K<HH P_L?B3_H+Z7_ ."R3_Y(H^Q^)/\ H+Z7_P""
MR3_Y(K<HH XKQ-::^J:;YNJ:<^;^ +MTYUPV[@G]^<CVX^M;/V/Q)_T%]+_\
M%DG_ ,D4GBO_ %>E?]A&#_T*MV@##^Q^)/\ H+Z7_P""R3_Y(H^Q^)/^@OI?
M_@LD_P#DBMRB@##^Q^)/^@OI?_@LD_\ DBLWQ+:>(5\.:J9-5TUXQ:2[E739
M%)&PY /GG!]\&NNK*\5?\BOK'_7G-_Z : *-A9^(S8V^W5M,"^6N =,D)Z?]
M?%3_ &/Q)_T%]+_\%DG_ ,D5J:=_R#[;_KDO\A5B@##^Q^)/^@OI?_@LD_\
MDBN<U"UUX?$'0U;4]/-P=-ORD@T]PJKYEIN!7SLDD[<'(Q@\'/'?UR^I?\E*
M\/\ _8*U'_T;9T 6S9^),?\ (7TS_P %DG_R16)X4M-?;P1HYAU33HX3IT)1
M'TYV95\H8!/GC)QWP/I7;GI6!X._Y$'0_P#L&0?^BEH Y+X,VGB!O@_X%,.J
M:='$="L2B/ITC,J_9TP"?/&3[X'TKL?L?B3_ *"^E_\ @LD_^2*QO@E_R1CP
M#_V +#_TFCKM: ,/['XD_P"@OI?_ (+)/_DBC['XD_Z"^E_^"R3_ .2*W**
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MM87AO_C_ /$7_81_]H0T +]C\2?]!?2__!9)_P#)%'V/Q)_T%]+_ /!9)_\
M)%;E% &']C\2?]!?2_\ P62?_)%'V/Q)_P!!?2__  62?_)%;E% '%:9::^?
M$>M!=4TX2 0;V.G.0?E.,#S^/S/X5L_8_$G_ $%]+_\ !9)_\D4:3_R-&O?2
MW_\ 0#6Y0!Q-S#J4/CSPW_:-W:W0,5WY?V:U:':=J9SF1\_I7;5R^N?\CWX7
M_P"N5Y_Z#'744 %%%% !1110 4444 >2?\)]!_T$O$O_ '[M?_C='_"?0?\
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MO_H):I_W\C_^-T?\*>TO_H):I_W\C_\ C= &!_PGT'_02\2_]^[7_P"-T?\
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M?]!+Q+_W[M?_ (W1_P )]!_T$O$O_?NU_P#C=;__  I[2_\ H):I_P!_(_\
MXW1_PI[2_P#H):I_W\C_ /C= '):OXRCO%M E]XAD\NYCE/F1VW !Y(PG7T[
M5>_X3Z#_ *"7B7_OW:__ !NKFN_"ZPTY+$Q:EJ69KN*!MSQGY6.#_!UK3_X4
M]I?_ $$M4_[^1_\ QN@# _X3Z#_H)>)?^_=K_P#&Z/\ A/H/^@EXE_[]VO\
M\;K?_P"%/:7_ -!+5/\ OY'_ /&Z/^%/:7_T$M4_[^1__&Z ,#_A/H/^@EXE
M_P"_=K_\;JKJWC:*\TJ]MTO_ !%(\L+QJDD=L%8E2 #A,X^E=3_PI[2_^@EJ
MG_?R/_XW5'7/A3I^GZ)J%U%J6I>;!;R2INDC(RJDC/[OVH RK;QW#%;Q(=1\
M2*54 A8[7 X[?NZD_P"$^@_Z"7B7_OW:_P#QNMFT^$6FS6L,C:EJ>YT5CB2/
MJ1_USJ;_ (4]I?\ T$M4_P"_D?\ \;H P/\ A/H/^@EXE_[]VO\ \;K+NO%R
MR^)].OA>:^T,%I<PM*R6WF*SO"0%&S&#Y;9R,_*N,<Y[/_A3VE_]!+5/^_D?
M_P ;K%O/AI90>,M)TQ=2U'[-<V-W<29>/=NC>W5<'9TQ*V?PH B_X3Z#_H)>
M)?\ OW:__&ZSM'\91Z?X<LK26^\0Q206B1-'%';%%(0 A<H3@8XR<UUY^#VE
M_P#02U/_ +^1_P#QNLK0/A=8:KX4TV_GU+4O/N;*.=]KQ@;FC#''R=,F@#C/
MA1XWAM?A;X.A.H>(4,>C6:%88[;8,0(,+E,X],\UU7_"?0?]!+Q+_P!^[7_X
MW5#X0_"G3=0^$W@JZ?4-11Y]$LI65)(]H)@0X&4Z<UUW_"GM+_Z"6J?]_(__
M (W0!@?\)]!_T$O$O_?NU_\ C='_  GT'_02\2_]^[7_ .-UO_\ "GM+_P"@
MEJG_ '\C_P#C='_"GM+_ .@EJG_?R/\ ^-T <EI?C*.TDOV>^\0H)KDRJ8X[
M;Y@549;*=>#TXX%9WA+QO#!-KQ.H>(5\S4Y''EQVW/R)RV4Z\=N.E=7HOPNL
M+^74UEU+4L6]VT";7C'RA%//R=<L:SO!OPJTZ[G\1!M0U%?)U66(;9(^0$C.
M3\G7FH?Q([*/\&K\OS)?^$^@_P"@EXE_[]VO_P ;H_X3Z#_H)>)?^_=K_P#&
MZW_^%/:7_P!!+5/^_D?_ ,;H_P"%/:7_ -!+5/\ OY'_ /&ZLXS _P"$^@_Z
M"7B7_OW:_P#QNJ*^,HQKKW?V[Q#Y9MEB\SR[;?D,3C[F,<^F:ZW_ (4]I?\
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ML(O$EA8KJ6I>1/:W$SY>/.Y&A"X^3_IHWZ5I_P#"GM+_ .@EJG_?R/\ ^-T
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M .T(: #_ (1N[_Z&/5?RM_\ XU1_PC=W_P!#'JOY6_\ \:K=HH PO^$;N_\
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M1\_6E_X3?0O^@G#^O^%(WCG05QG5(!DX&2>31[7.?YJOWS"U/R'_ /"(Z?\
MWK[_ ,&-Q_\ '*/^$1T_^]??^#&X_P#CE-_X3?0O^@G#^O\ A1_PF^A?]!.'
M]?\ "CVN<_S5?OF%J?D._P"$1T_^]??^#&X_^.4?\(CI_P#>OO\ P8W'_P <
MIO\ PF^A?]!.']?\*/\ A-]"_P"@G#^O^%'M<Y_FJ_?,+4_(27P9I<\3QR"\
MDC<%61M0N"&!Z@C?R*</"&G 8#7V/^PC<?\ QRFMXYT%%+-JD"J!DDDX _*E
M_P"$WT+_ *"</YG_  H]KG/\U7[YA:GY#O\ A$=/_O7W_@QN/_CE'_"(Z?\
MWK[_ ,&-Q_\ '*;_ ,)OH7_03A_7_"C_ (3?0O\ H)P_K_A1[7.?YJOWS"U/
MR'?\(CI_]Z^_\&-Q_P#'*/\ A$=/_O7W_@QN/_CE-_X3?0O^@G#^O^%'_";Z
M%_T$X?U_PH]KG/\ -5^^86I^0D7@O2X$V1B\C7).U=0N ,DY)^_W))I__"(Z
M?_>OO_!C<?\ QRF+XYT%QE=4@8=,@FE_X3?0O^@G#^O^%'M<Y_FJ_?,+4_(=
M_P (CI_]Z^_\&-Q_\<H_X1'3_P"]??\ @QN/_CE-_P"$WT+_ *"</Z_X4?\
M";Z%_P!!.']?\*/:YS_-5^^86I^0[_A$=/\ [U]_X,;C_P".4R/P7I<.[8+Q
M-S%FVZA<#)/4GY^M+_PF^A?]!.']?\*1?'.@MG;JD!P<'!/!H]KG/\U7[YA:
MGY"2^"=*N#'YJW<GEL'3??W!VL.A'S\'GK4G_"(Z?_>OO_!C<?\ QRHV\=:
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M-Q_\<IO_  F^A?\ 03A_7_"C_A-]"_Z"</Z_X4>USG^:K]\PM3\AW_"(Z?\
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MM3\AW_"(Z?\ WK[_ ,&-Q_\ '*/^$1T_^]??^#&X_P#CE-_X3?0O^@G#^O\
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M>#1[7.?YJOWS"U/R'_\ "(Z?_>OO_!C<?_'*/^$1T_\ O7W_ (,;C_XY3?\
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M]><7_H(K=KBO!OB58/"6CQ_V9J<FRTC7=':DJ?E'(/<5L?\ "5K_ - G5?\
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M\&\G_P 51_PJC1?^A'7_ ,&\G_Q5 '>>-/\ D3M=_P"O"?\ ]%M6M#_J8_\
M=%>1:O\ !W2K[2KVV@\%I#-- \:2'57(1BI .-W.":LI\)]&50#X'4D#K_:T
MG_Q5 'J]%>5?\*HT7_H1U_\ !O)_\51_PJC1?^A'7_P;R?\ Q5 'JM%>5?\
M"J-%_P"A'7_P;R?_ !5'_"J-%_Z$=?\ P;R?_%4 =QX+_P"0%_V]W7_I1)6[
M7CND_!S2[&R\J?P8DTGFROO&JN.&D9@/O=@0/PJ[_P *HT7_ *$=?_!O)_\
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MI[T =916%_:VM_\ 0!'_ (&I_A1_:VM_] $?^!J?X4 ;M%87]K:W_P! $?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ibio-20220930xex10d3010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20220930xex10d3010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1\ S$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\?SHWM_>/YU)]DD]%_[['^-'V23T7_OL?XT 1[V_O'\Z-[?WC^=2?9)/1?\
MOL?XT?9)/1?^^Q_C0!'O;^\?SHWM_>/YU)]DD]%_[['^-*;.4$@@ CL6'^-
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M?@%\2KW;]HT6YFV_=\R=#CIZM[#\J7_A0GQ+V.G]C76QU5&7[0F&51@ _-T
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MX&_%"(@II5XI'0BY4=E'][T5?^^1Z4NJ_ WXF:R]NUUH4K_9X5@B DC 1!G
M SZDGZDF@"IXD^&^FZ?I/B.>R:X:;3KR94\W[@@1X5&6Q@N3*>/I^/G-G_Q]
MP?[Z_P Z]+?X"?$N6.2-]&N621M[J;A,,?4_-S567X!^.]*C>]NM!DBMK8&:
M5S*AVHO+'KZ T ><5[=JWP(L$EU!;*\E*RSPI8$@.0J@BY+#(SAQ@=,X-<U_
MPSI\0O\ H7I?^_J?_%5<'P+^)X8,-)NPP.[/VE>N<_WO7F@#%\8_"N7PAI]Y
M>2ZE'/#;RK;8$15FF8*X3!/'[I@^?P]ZZ2'X5Z8UQ"DNG:O$!:&XN01DP1Y
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M%]NY%U%@?<[G SVSF@#M:*PO[2U__H"6W_@P_P#M=']I:_\ ] 2V_P#!A_\
M:Z -VBL+^TM?_P"@);?^##_[71_:6O\ _0$MO_!A_P#:Z -VL+P)_P B/X>_
M[!UO_P"BEH_M+7_^@);?^##_ .UUC^"]0UM/!VA+%H]O+$+" ([7VTL/+7!Q
ML./I0!VM%87]I:__ - 2V_\ !A_]KH_M+7_^@);?^##_ .UT ;M%87]I:_\
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MENDZAK8^-'BIAH]N93X?T@,GV[@#[3J6#G9SG)X[8]Z[7^TM?_Z EM_X,/\
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M7_\ H"6W_@P_^UT ;M%87]I:_P#] 2V_\&'_ -KH_M+7_P#H"6W_ (,/_M=
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M,N-,+_;W\O;!( &^RS]?GY&,_CBMCRO$O_/SI7_@/+_\70!AZ/\ \EO\6_\
M8NZ-_P"E.J5W->6Z3'X@_P"%T>*@+C3/._X1_2-Q,$FW;]IU+&!OZYW9_"NU
M\KQ+_P _.E?^ \O_ ,70!NUA>,O^01;_ /81L/\ TKAH\KQ+_P _.E?^ \O_
M ,76/XLC\0#2X/-N-,*?;[+&R"0'=]JBV]7Z9QGVS0!VM%87E>)?^?G2O_ >
M7_XNCRO$O_/SI7_@/+_\70!NT5A>5XE_Y^=*_P# >7_XNCRO$O\ S\Z5_P"
M\O\ \70!NUA>!/\ D1_#W_8.M_\ T4M'E>)?^?G2O_ >7_XNL?P7'X@/@[0C
M#<:8L/V"#8)()"P7RUQDA^N* .UHK"\KQ+_S\Z5_X#R__%T>5XE_Y^=*_P#
M>7_XN@#=HK"\KQ+_ ,_.E?\ @/+_ /%T>5XE_P"?G2O_  'E_P#BZ #P]_R%
M_$__ &$4_P#22WK=KBM"C\0'5/$7EW&F!_MZ>9N@D(+?98.GS\#&/QS6QY7B
M7_GYTK_P'E_^+H W:Y?XI_\ ),?%_P#V![S_ -$O5ORO$O\ S\Z5_P" \O\
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MH!<:9YWV"TW$P2;=OF7.,#?USNS^% ':T5A>5XE_Y^=*_P# >7_XNCRO$O\
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M03C5?&0NFC>Z_M=/,:%2J$_8;3& 22.,=^N: .NHHHH **** "BBB@ HHHH
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M<5H6CZF^J>(@NO7"%;] S"WA.\_98#DY7C@@<>E;']B:K_T,=S_X#0?_ !%
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M?^E.J5W->6Z3H^IGXT>*D&O7 D'A_2"9/L\.6!N=2P,;<<8/Y_2NU_L35?\
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M\%Z/J<O@[0GCUZXAC:P@*QK;PD(/+7 R5R<>] ':T5A?V)JO_0QW/_@-!_\
M$4?V)JO_ $,=S_X#0?\ Q% &[16%_8FJ_P#0QW/_ (#0?_$4?V)JO_0QW/\
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M?_$4?V)JO_0QW/\ X#0?_$4 ;M87CO\ Y$?Q#_V#KC_T4U']B:K_ -#'<_\
M@-!_\16/XTT?4XO!VNO)KUQ-&MA.6C:WA <>6V02%R,^U ':T5A?V)JO_0QW
M/_@-!_\ $4?V)JO_ $,=S_X#0?\ Q% &[16%_8FJ_P#0QW/_ (#0?_$4?V)J
MO_0QW/\ X#0?_$4 ;M87@3_D1_#W_8.M_P#T4M']B:K_ -#'<_\ @-!_\16/
MX+T?4Y?!VA/'KUQ#&UA 5C6WA(0>6N!DKDX]Z .UKE_"'_(P>-_^PQ'_ .F^
MSJW_ &)JO_0QW/\ X#0?_$5G>!(I+?5?&44T[74RZN@:=U"E_P#0;0@D  #
M(' [4 ==1110 4444 %%%% !1110 45Y%_PEUG_=UC_P:R4?\)=9_P!W6/\
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M *".J_\ @PE_QH W:*PO^$2@_P"@CJO_ (,)?\:/^$2@_P"@CJO_ (,)?\:
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M83L%DOI&4XC8X()Y'M0!VM%87_")0?\ 01U7_P &$O\ C1_PB4'_ $$=5_\
M!A+_ (T ;M%87_")0?\ 01U7_P &$O\ C1_PB4'_ $$=5_\ !A+_ (T ;M87
M@3_D1_#W_8.M_P#T4M'_  B4'_01U7_P82_XUC^"_"\-QX.T*4W^IH7L(&*Q
MWTBJ,QJ<  \#VH [6BL+_A$H/^@CJO\ X,)?\:/^$2@_Z".J_P#@PE_QH W:
M*PO^$2@_Z".J_P#@PE_QH_X1*#_H(ZK_ .#"7_&@"IX0_P"1@\;_ /88C_\
M3?9UU%<!X6\-0S:YXP0WVI*(M5C0%+V12W^@VK98@\GYL9/8 =JZ+_A$H/\
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M]J'U?S-7_A,_#_\ T'=,_P# R/\ QH_X3/P__P!!W3/_  ,C_P :RO[.M?\
MGVA_[]BC^SK7_GVA_P"_8H_UWC_T#_\ DW_VH?5_,BT'Q=H4>J^)&?6M.59+
M]&0M=1@,/LMN,CGD9!'X&MK_ (3/P_\ ]!W3/_ R/_&LK^SK7_GVA_[]BC^S
MK7_GVA_[]BC_ %WC_P! _P#Y-_\ :A]7\S5_X3/P_P#]!W3/_ R/_&C_ (3/
MP_\ ]!W3/_ R/_&LK^SK7_GVA_[]BC^SK7_GVA_[]BC_ %WC_P! _P#Y-_\
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MP_\ ]!W3/_ R/_&LK^SK7_GVA_[]BC^SK7_GVA_[]BC_ %WC_P! _P#Y-_\
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M?Z[Q_P"@?_R;_P"U#ZOYD6@^+M"CU7Q(SZUIRK)?HR%KJ,!A]EMQD<\C((_
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M '[%>+CN):V6S4,3AK-J_P :?Z&ZP\)P52G44HMM75]U:^]NZ-7_ (3/P_\
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MEU:-XV:Z0!U^PVBY'/(RK#/J#Z5TG_"9^'_^@[IG_@9'_C65_9UK_P ^T/\
MW[%']G6O_/M#_P!^Q1_KO'_H'_\ )O\ [4/J_F:O_"9^'_\ H.Z9_P"!D?\
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M])_Y+-XI_P"P!I'_ *4:E751E0Y*GNO;^9?S1_NDN^AK_P#";Z3_ '[K_P
M9_\ XBC_ (3?2?[]U_X S_\ Q%;M%<O-A_Y)?^!+_P"1*U,+_A-])_OW7_@#
M/_\ $4?\)OI/]^Z_\ 9__B*W:*.;#_R2_P# E_\ (AJ87_";Z3_?NO\ P!G_
M /B*/^$WTG^_=?\ @#/_ /$5NT4<V'_DE_X$O_D0U,+_ (3?2?[]U_X S_\
MQ%'_  F^D_W[K_P!G_\ B*W:*.;#_P DO_ E_P#(AJ87_";Z3_?NO_ &?_XB
MC_A-])_OW7_@#/\ _$5NT4<V'_DE_P"!+_Y$-3"_X3?2?[]U_P" ,_\ \11_
MPF^D_P!^Z_\  &?_ .(K=HHYL/\ R2_\"7_R(:F%_P )OI/]^Z_\ 9__ (BC
M_A-])_OW7_@#/_\ $5NT4<V'_DE_X$O_ )$-3"_X3?2?[]U_X S_ /Q%'_";
MZ3_?NO\ P!G_ /B*W:*.;#_R2_\  E_\B&IA?\)OI/\ ?NO_  !G_P#B*/\
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MJS_\$MY_C1_9^H_]!JS_ /!+>?XU[911_K1C?YY??'_Y /8T?^?4?_ 3Q/\
ML_4?^@U9_P#@EO/\:/[/U'_H-6?_ ();S_&O;**/]:,;_/+[X_\ R >QH_\
M/J/_ (">&W.A7E\;9)=?A@2*Y@N/,M]%NO,4QRK(-N[*YR@Z@CVKN/!7C^WN
M=")U*\NKN[BN[N S_P!GR@ND=S(B$A$P#L5<@=\]ZTOB9JUYHO@^XN+"?[-=
M-<VENLNQ7VK)<Q1MPP(/RN>M>;:#%K7AK3A8Z=X@FM[8.\FP6D!^9F+,<E.Y
M)KOI8;%\24G7E[SB[:R2>U^D/,ZY5\-A\)[.I*,+RNDHOHO>U2>]X_<>J?\
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M\ 9__B*W:*.;#_R2_P# E_\ (AJ87_";Z3_?NO\ P!G_ /B*/^$WTG^_=?\
M@#/_ /$5NT4<V'_DE_X$O_D0U,+_ (3?2?[]U_X S_\ Q%'_  F^D_W[K_P!
MG_\ B*W:*.;#_P DO_ E_P#(AJ87_";Z3_?NO_ &?_XBC_A-])_OW7_@#/\
M_$5NT4<V'_DE_P"!+_Y$-3"_X3?2?[]U_P" ,_\ \11_PF^D_P!^Z_\  &?_
M .(K=HHYL/\ R2_\"7_R(:F%_P )OI/]^Z_\ 9__ (BC_A-])_OW7_@#/_\
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M1?\ @2W_ ,5574H?$8MT^V?V^8?.BV[[AB/,\Q?+_BZ[]N/?%'^J&6_WOO\
M^ 'MYGHO]L7_ /T+6K_]\P__ !RC^V+_ /Z%K5_^^8?_ (Y7">1XN]?$7_@2
MW_Q5'D>+O7Q%_P"!+?\ Q5'^J&6_WOO_ . 'MYG=_P!L7_\ T+6K_P#?,/\
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MK5_^^8?_ (Y1_;%__P!"UJ__ 'S#_P#'*X3R/%WKXB_\"6_^*H\CQ=Z^(O\
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M &Q?_P#0M:O_ -\P_P#QRJVI>*)](TZZO[SP_JT%I:Q//-*4B(1%!9CQ)G@
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MD_ZST%>@UA>._P#D1_$/_8.N/_134?ZH9;_>^_\ X >WF8/]L7__ $+6K_\
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MG/=7'A[5HK>"-I9'*0D*JC)/^L]!7H-87CO_ )$?Q#_V#KC_ -%-1_JAEO\
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MW7CFB?#G5=8LI)[73+%(DN;BW(:Z(^>*9XW/W.[(QSWS5_\ X5+KW_0/T_\
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M_P ;KR"R^&>L7=S?Q1:;8*]K.(92;LC+&-'R/DY^5U_*K?\ PJ77O^@?I_\
MX&-_\10!ZI_:.O\ _0$M?_!@?_C=']HZ_P#] 2U_\&!_^-UY7_PJ77O^@?I_
M_@8W_P 11_PJ77O^@?I__@8W_P 10!ZI_:.O_P#0$M?_  8'_P"-UCVM_K@\
M8ZFPTBV,IL+0,GV[@#S+G!SY?.<GC'&/?C@O#6@7?AKXD^'K:^L?LDKS2E9(
MV+Q2+]FFSAL#D'L0.E>JV?\ R/&K?]@ZR_\ 1MU0!SOQ(OM:D^'?BE+C2;>&
M!M*NA)*M[O*+Y+9(7RQD@=LC-=%_:.O_ /0$M?\ P8'_ .-U4^*?_),?%_\
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M\"?\B/X>_P"P=;_^BEH /[1U_P#Z EK_ .# _P#QNC^T=?\ ^@):_P#@P/\
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M.<GC'&/?CM:PK/\ Y'C5O^P=9?\ HVZH XK2;_7!\:/%3#2+8RGP_I 9/MW
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MS7:UA>!/^1'\/?\ 8.M__12T ']HZ_\ ] 2U_P#!@?\ XW1_:.O_ /0$M?\
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M_P"-T?VCK_\ T!+7_P &!_\ C=;M% &%_:.O_P#0$M?_  8'_P"-T?VCK_\
MT!+7_P &!_\ C=;M% '%:[?ZXVJ>'2^D6R,M^Y0"^SN/V6?@_N^.,G//3'>M
MC^T=?_Z EK_X,#_\;H\0_P#(7\,?]A%__22XK=H PO[1U_\ Z EK_P"# _\
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M_P C!XW_ .PQ'_Z;[.@#J**** "BBB@ HHHH **** ,+R?$O_/WI7_@++_\
M'*/)\2_\_>E?^ LO_P <K=HH PO)\2_\_>E?^ LO_P <KBM)B\0?\+H\5 7.
MF>=_PC^D;B;>3:5^TZEC \SKG=G\*]2KAM'_ .2W^+?^Q=T;_P!*=4H DUV+
MQ -4\.^9<Z87-^_EE;>0 -]EGZ_O.1C/XXK8\GQ+_P _>E?^ LO_ ,<H\0_\
MA?PQ_P!A%_\ TDN*W: . \!1:^=#NOL]SIJQ_P!JZED26\A.[[=/N/#CC=G
M[#'7K71>3XE_Y^]*_P# 67_XY53X<_\ (OW?_88U7_TX7%=10!A>3XE_Y^]*
M_P# 67_XY6/XLB\0#2X/-N=,9/M]E@);R [OM46WK)TSC/MFNUK"\9?\@BW_
M .PC8?\ I7#0 >3XE_Y^]*_\!9?_ (Y1Y/B7_G[TK_P%E_\ CE;M% &%Y/B7
M_G[TK_P%E_\ CE'D^)?^?O2O_ 67_P".5NT4 87D^)?^?O2O_ 67_P".5C^"
MXO$!\':$8;G3%A^P0;!);R%@OEKC)$@R<5VM87@3_D1_#W_8.M__ $4M !Y/
MB7_G[TK_ ,!9?_CE'D^)?^?O2O\ P%E_^.5NT4 87D^)?^?O2O\ P%E_^.4>
M3XE_Y^]*_P# 67_XY6[10!Q6A1>(#JGB+R[G3 XOT\PM;R$%OLL'3]YP,8_'
M-;'D^)?^?O2O_ 67_P".4>'O^0OXG_["*?\ I);UNT 87D^)?^?O2O\ P%E_
M^.4>3XE_Y^]*_P# 67_XY6[10!@-:^(G9&:YTAF0Y4FUDR#C''[ST)K)M8O$
M'_"8ZF!<Z9YWV"TW$V\FTKYESC \SKG=G\*[6L*S_P"1XU;_ +!UE_Z-NJ .
M=^)$6OCX=^*3<W.FO;C2KKS5BMY%<KY+9"DN0#CH2#71>3XE_P"?O2O_  %E
M_P#CE5/BG_R3'Q?_ -@>\_\ 1+UU% &%Y/B7_G[TK_P%E_\ CE'D^)?^?O2O
M_ 67_P".5NT4 <5KL7B :IX=\RYTPN;]_+*V\@ ;[+/U_><C&?QQ6QY/B7_G
M[TK_ ,!9?_CE'B'_ )"_AC_L(O\ ^DEQ6[0!Y;I,7B#_ (71XJ N=,\[_A']
M(W$V\FTK]IU+&!YG7.[/X5VOD^)?^?O2O_ 67_XY6'H__);_ !;_ -B[HW_I
M3JE=S0!A>3XE_P"?O2O_  %E_P#CE8_BR+Q -+@\VYTQD^WV6 EO(#N^U1;>
MLG3.,^V:[6L+QE_R"+?_ +"-A_Z5PT 'D^)?^?O2O_ 67_XY1Y/B7_G[TK_P
M%E_^.5NT4 87D^)?^?O2O_ 67_XY1Y/B7_G[TK_P%E_^.5NT4 87D^)?^?O2
MO_ 67_XY6/X+B\0'P=H1AN=,6'[!!L$EO(6"^6N,D2#)Q7:UA>!/^1'\/?\
M8.M__12T 'D^)?\ G[TK_P !9?\ XY1Y/B7_ )^]*_\  67_ ..5NT4 87D^
M)?\ G[TK_P !9?\ XY1Y/B7_ )^]*_\  67_ ..5NT4 <5H47B ZIXB\NYTP
M.+]/,+6\A!;[+!T_><#&/QS6QY/B7_G[TK_P%E_^.4>'O^0OXG_["*?^DEO6
M[0!A>3XE_P"?O2O_  %E_P#CE<[\2(M?'P[\4FYN=->W&E77FK%;R*Y7R6R%
M)<@''0D&N_KE_BG_ ,DQ\7_]@>\_]$O0!;\GQ+_S]Z5_X"R__'*Q[6+Q!_PF
M.I@7.F>=]@M-Q-O)M*^9<XP/,ZYW9_"NUK"L_P#D>-6_[!UE_P"C;J@#BM)B
M\0?\+H\5 7.F>=_PC^D;B;>3:5^TZEC \SKG=G\*[7R?$O\ S]Z5_P" LO\
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M<JIX0_Y&#QO_ -AB/_TWV==15G$87D^)?^?O2O\ P%E_^.4>3XE_Y^]*_P#
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MTX+<H>6(+>G/&!@5T7]AZK_T,=W_ . \'_Q%5/AS_P B_=_]AC5?_3A<5U%
M&%_8>J_]#'=_^ \'_P 16/XLT;4H]+@+Z_<R@W]D-K00C!-U$ >$[$@_AS7:
MUA>,O^01;_\ 81L/_2N&@ _L/5?^ACN__ >#_P"(H_L/5?\ H8[O_P !X/\
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M9#:T$(P3=1 'A.Q(/X<UVM87C+_D$6__ &$;#_TKAH /[#U7_H8[O_P'@_\
MB*/[#U7_ *&.[_\  >#_ .(K=HH PO[#U7_H8[O_ ,!X/_B*/[#U7_H8[O\
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MX_\ 134 ']AZK_T,=W_X#P?_ !%']AZK_P!#'=_^ \'_ ,16[10!A?V'JO\
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M8>J_]#'=_P#@/!_\11_8>J_]#'=_^ \'_P 16[10!A?V'JO_ $,=W_X#P?\
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M]NU,!?#^D-N%_+N.;G4A@G=DCC@=LGUKM?\ A$;?_H(:K_X,9O\ XJL/1_\
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MH_X1&W_Z"&J_^#&;_P"*K=HH \[^%GA>"X^&/A"4WVIH7T>S8K'?RJHS"AP
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M/^$TTO\ O7?_ ( 3_P#Q%'_"::7_ 'KO_P  )_\ XB@ _P"$&\/_ /0(M/\
MOV*/^$&\/_\ 0(M/^_8H_P"$TTO^]=_^ $__ ,11_P )II?]Z[_\ )__ (B@
M _X0;P__ - BT_[]BL?P7X-T.Z\':%--I=M)+)80.[M&"6)C4DFMC_A--+_O
M7?\ X 3_ /Q%8_@OQ=IMMX.T*&1KK?'80(VVRF89$:@X(3!^HH V/^$&\/\
M_0(M/^_8H_X0;P__ - BT_[]BC_A--+_ +UW_P" $_\ \11_PFFE_P!Z[_\
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M BT_[]BN'\O5?^BD>(?_  GX/_D6CR]5_P"BD>(?_"?@_P#D6@#N/^$&\/\
M_0(M/^_8H_X0;P__ - BT_[]BN'\O5?^BD>(?_"?@_\ D6CR]5_Z*1XA_P#"
M?@_^1: .X_X0;P__ - BT_[]BL?P7X-T.Z\':%--I=M)+)80.[M&"6)C4DFN
M?\O5?^BD>(?_  GX/_D6LGPG!JL?A71D_P"%B:_#MLH1Y4>A0.J?(. WV8Y
M]<G/K0!Z=_P@WA__ *!%I_W[%'_"#>'_ /H$6G_?L5P_EZK_ -%(\0_^$_!_
M\BT>7JO_ $4CQ#_X3\'_ ,BT =Q_P@WA_P#Z!%I_W[%'_"#>'_\ H$6G_?L5
MP_EZK_T4CQ#_ .$_!_\ (M'EZK_T4CQ#_P"$_!_\BT =!H7@W0YM4\1(^EVS
M+%?HB QCY1]E@; _%B?QK8_X0;P__P! BT_[]BO,=&@U5=1UX_\ "Q-?CW7J
MG<NA0,7_ -'A&2/LQVGC&.. #CG)UO+U7_HI'B'_ ,)^#_Y%H [C_A!O#_\
MT"+3_OV*YWXD>$-%L?AWXIN;?3+:&>'2KJ2.1$ *L(6((]P163Y>J_\ 12/$
M/_A/P?\ R+6#X^M]5F\"^(X_^%A:[<[M-N5\F70X(TDS$WRLWV8;0>A.1CU%
M 'JW_"#>'_\ H$6G_?L5CVO@W0V\8ZG"=+MC$EA:.J>6, F2Y!/X[5_*N?\
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M_P#] BT_[]BC_A--+_O7?_@!/_\ $4?\)II?]Z[_ / "?_XB@ _X0;P__P!
MBT_[]BL?QIX-T.U\':[-#I=M'+'83NCK& 5(C8@BMC_A--+_ +UW_P" $_\
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MFFE_WKO_ , )_P#XB@ _X0;P_P#] BT_[]BC_A!O#_\ T"+3_OV*/^$TTO\
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M_>N__ "?_P"(K.\"74=_JOC*YAW&*75T*[T*-Q8V@.58 CD'J/?O0!UU%%%
M!1110 4444 %%%% !16%_P )+<?]"_JO_?,/_P <H_X26X_Z%_5?^^8?_CE
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M (26X_Z%_5?^^8?_ (Y6/XL\0SS:7 IT/4X@+^R;<ZQ8.+J(XXDZG&![D=*
M.UHK"_X26X_Z%_5?^^8?_CE'_"2W'_0OZK_WS#_\<H W:*PO^$EN/^A?U7_O
MF'_XY1_PDMQ_T+^J_P#?,/\ \<H W:PO G_(C^'O^P=;_P#HI:/^$EN/^A?U
M7_OF'_XY6/X+\0SP>#M"C&AZG,$L(%$D:Q;6Q&O(S(#@^XH [6BL+_A);C_H
M7]5_[YA_^.4?\)+<?]"_JO\ WS#_ /'* -VBL+_A);C_ *%_5?\ OF'_ ..4
M?\)+<?\ 0OZK_P!\P_\ QR@ \/?\A?Q/_P!A%/\ TDMZW:XK0O$,\>J>(F&A
MZFY>_1BJK%E/]%@&#^\Z\9XSP16Q_P )+<?]"_JO_?,/_P <H W:*PO^$EN/
M^A?U7_OF'_XY1_PDMQ_T+^J_]\P__'* -VL*S_Y'C5O^P=9?^C;JC_A);C_H
M7]5_[YA_^.5CVOB&<>,=3D_L/4R6L+1?+"Q;EQ)<\G]YC!SQSV/MD N_%/\
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M&O(S(#@^XH [6BL+_A);C_H7]5_[YA_^.4?\)+<?]"_JO_?,/_QR@"A\)?\
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M0!NT5A?\)+<?]"_JO_?,/_QRC_A);C_H7]5_[YA_^.4 'B'_ )"_AC_L(O\
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M !JC^T?$'_0%L_\ P8G_ .-4 ;M%87]H^(/^@+9_^#$__&J/[1\0?] 6S_\
M!B?_ (U0 >(?^0OX8_["+_\ I)<5Y)^T#=S1?$#X>*DK*L>HM*@!^Z_V*^^8
M>_ _(5Z'KM_KC:IX=+Z1:HPOW* 7Y.YOLL_!/E\<9.>>F.^1R_Q)@U#4/%WP
MXDN_#UA)*==EC7=>;MX_LR_.TGRN!U;OR!ZY&D)*-[G-B*<JL.6+_JQD?\)3
MK'_04N_^_IH_X2G6/^@I=_\ ?TUZ%_8D_P#T*.D_^!G_ -JH_L2?_H4=)_\
M S_[56OM/[[^[_@GD_4:W=?>_P#(\]_X2G6/^@I=_P#?TUW37<U]\']4FN)7
MFF;3KS<[G).!(!S]!5C^Q)_^A1TG_P #/_M55O%,FK6G@?6[9-#LK2T%A< ^
M5>D[%*,20OEC/4G&12G-.-KM_P!>IU8;"U*-3GF]+=WY'=T5A?VCX@_Z MG_
M .#$_P#QJC^T?$'_ $!;/_P8G_XU7.>J;M%87]H^(/\ H"V?_@Q/_P :H_M'
MQ!_T!;/_ ,&)_P#C5 &[6%X$_P"1'\/?]@ZW_P#12T?VCX@_Z MG_P"#$_\
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M1A?N4 OR=S?99^"?+XXR<\],=\C8_M'Q!_T!;/\ \&)_^-4 ;M%87]H^(/\
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MTQAL#/&#T'7';- '74444 %%%% !1110 4444 %%87D>)?\ G\TK_P !)?\
MX[1Y'B7_ )_-*_\  27_ ..T ;M>#^(7*^)-58,0QN95)!YP'; KUOR/$O\
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M5NUQ6NP^(!JGAWS+O3"YOW\LK:R !OLL_7]YR,9].<?2MCR/$O\ S^:5_P"
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MW4A:_<*Q@@&P_99SD83G@$<^OKBMC^PM4_Z&2\_\![?_ .-T 8?_  LK4?\
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MI:J:7#<ZU;M/9>*KN>)6V%A;0#!P#CF/W%4O!>C:E+X.T)X]?NH4:P@*QK!
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ML/V6<Y&$YX!'/KZXK8_L+5/^ADO/_ >W_P#C= &[16%_86J?]#)>?^ ]O_\
M&Z/["U3_ *&2\_\  >W_ /C= &[6%X[_ .1'\0_]@ZX_]%-1_86J?]#)>?\
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M+_T%-9_\&<__ ,57PG^N67?RS^Y?_)'3["1WM%<%_P (TO\ T%-9_P#!G/\
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M .#.?_XJC_A&E_Z"FL_^#.?_ .*H_P!<LN_EG]R_^2#V$CO:PO G_(C^'O\
ML'6__HI:Y_\ X1I?^@IK/_@SG_\ BJBMO"4%G;Q6\&H:O#!$@2.--2G"JH&
M -W0"C_7++OY9_<O_D@]A(]"HK@O^$:7_H*:S_X,Y_\ XJC_ (1I?^@IK/\
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M/]<LN_EG]R_^2#V$CO:*X+_A&E_Z"FL_^#.?_P"*H_X1I?\ H*:S_P"#.?\
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M_P &<_\ \51_PC2_]!36?_!G/_\ %4?ZY9=_+/[E_P#)!["1T'A[_D+^)_\
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M^6?W+_Y(X/82.]HK@O\ A&E_Z"FL_P#@SG_^*H_X1I?^@IK/_@SG_P#BJ/\
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M:/\ A7'A?_H :?\ ]^%H_P!2)?\ 01_Y+_\ ;!]8\AE%/_X5QX7_ .@!I_\
MWX6C_A7'A?\ Z &G_P#?A:/]2)?]!'_DO_VP?6/(913_ /A7'A?_ * &G_\
M?A:Q_!O@'PY>>$-#N)]$L9IY;&!Y)'A4LS&-223ZDT?ZD2_Z"/\ R7_[8/K'
MD:M%/_X5QX7_ .@!I_\ WX6C_A7'A?\ Z &G_P#?A:/]2)?]!'_DO_VP?6/(
M913_ /A7'A?_ * &G_\ ?A:/^%<>%_\ H :?_P!^%H_U(E_T$?\ DO\ ]L'U
MCR&45E:'X!\.3ZIXA231+%TAOD2-6A4A%^S0-@>@RS'ZDUL?\*X\+_\ 0 T_
M_OPM'^I$O^@C_P E_P#M@^L>0RBG_P#"N/"__0 T_P#[\+1_PKCPO_T -/\
M^_"T?ZD2_P"@C_R7_P"V#ZQY#**?_P *X\+_ /0 T_\ [\+6/:^ ?#C>+]3M
MSHEB8$L;1UC,*[59I+@,0/4A5_(4?ZD2_P"@C_R7_P"V#ZQY&K16!\1O OA[
M3OA[XHN[71K*WN8-+NI8I8X0&1UB8JP/8@@&NB_X5QX7_P"@!I__ 'X6C_4B
M7_01_P"2_P#VP?6/(913_P#A7'A?_H :?_WX6C_A7'A?_H :?_WX6C_4B7_0
M1_Y+_P#;!]8\AE%96N> ?#D&J>'DCT2Q1)KYTD585 =?LT[8/J,JI^H%;'_"
MN/"__0 T_P#[\+1_J1+_ *"/_)?_ +8/K'D,HI__  KCPO\ ] #3_P#OPM'_
M  KCPO\ ] #3_P#OPM'^I$O^@C_R7_[8/K'D,HI__"N/"_\ T -/_P"_"UC^
M*_ /ARUTN!X=$L8G-]9(62%02K7,2L/H02#[&C_4B7_01_Y+_P#;!]8\C5HI
M_P#PKCPO_P! #3_^_"T?\*X\+_\ 0 T__OPM'^I$O^@C_P E_P#M@^L>0RBG
M_P#"N/"__0 T_P#[\+1_PKCPO_T -/\ ^_"T?ZD2_P"@C_R7_P"V#ZQY#**?
M_P *X\+_ /0 T_\ [\+6/X-\ ^'+SPAH=Q/HEC-/+8P/)(\*EF8QJ22?4FC_
M %(E_P!!'_DO_P!L'UCR-6BG_P#"N/"__0 T_P#[\+1_PKCPO_T -/\ ^_"T
M?ZD2_P"@C_R7_P"V#ZQY#**?_P *X\+_ /0 T_\ [\+1_P *X\+_ /0 T_\
M[\+1_J1+_H(_\E_^V#ZQY#**RM#\ ^')]4\0I)HEBZ0WR)&K0J0B_9H&P/09
M9C]2:V/^%<>%_P#H :?_ -^%H_U(E_T$?^2__;!]8\AE%/\ ^%<>%_\ H :?
M_P!^%KG?B-X%\/:=\/?%%W:Z-96]S!I=U+%+'" R.L3%6![$$ T?ZD2_Z"/_
M "7_ .V#ZQY&_13_ /A7'A?_ * &G_\ ?A:Q[7P#X<;Q?J=N=$L3 EC:.L9A
M7:K-)<!B!ZD*OY"C_4B7_01_Y+_]L'UCR-6BG_\ "N/"_P#T -/_ ._"T?\
M"N/"_P#T -/_ ._"T?ZD2_Z"/_)?_M@^L>0RBG_\*X\+_P#0 T__ +\+1_PK
MCPO_ - #3_\ OPM'^I$O^@C_ ,E_^V#ZQY#**RM<\ ^'(-4\/)'HEBB37SI(
MJPJ Z_9IVP?4953]0*V/^%<>%_\ H :?_P!^%H_U(E_T$?\ DO\ ]L'UCR&4
M4_\ X5QX7_Z &G_]^%H_X5QX7_Z &G_]^%H_U(E_T$?^2_\ VP?6/(913_\
MA7'A?_H :?\ ]^%K'\9> ?#EGX0URX@T2QAGBL9WCD2%0RL(V((/J#1_J1+_
M *"/_)?_ +8/K'D:M%/_ .%<>%_^@!I__?A:/^%<>%_^@!I__?A:/]2)?]!'
M_DO_ -L'UCR&44__ (5QX7_Z &G_ /?A:/\ A7'A?_H :?\ ]^%H_P!2)?\
M01_Y+_\ ;!]8\AE%/_X5QX7_ .@!I_\ WX6L?P;X!\.7GA#0[B?1+&:>6Q@>
M21X5+,QC4DD^I-'^I$O^@C_R7_[8/K'D:M<M\2_ -I\2?"5UHMTYA+D203KS
MY4HSM;'<<D$>A-=9_P *X\+_ /0 T_\ [\+1_P *X\+_ /0 T_\ [\+6E/@R
MI2FIPQ-FO[O_ -L;4<=/#U(U:6DHNZ?F>>_!?X61?"SPM]C:07&I73"6\F7.
MTMCA5]@./?DUW]/_ .%<>%_^@!I__?A:/^%<>%_^@!I__?A:JMP;5KU'4J8F
M[?\ =_\ MB\3F-3%UI5ZVLI.[&45@>%_ OAZZUOQ?'-HUE)';ZHD4*M""(T-
ME:N5'H-SL?JQKHO^%<>%_P#H :?_ -^%K'_4B7_01_Y+_P#;'-]8\AE%/_X5
MQX7_ .@!I_\ WX6C_A7'A?\ Z &G_P#?A:/]2)?]!'_DO_VP?6/(913_ /A7
M'A?_ * &G_\ ?A:Q[7P#X<;Q?J=N=$L3 EC:.L9A7:K-)<!B!ZD*OY"C_4B7
M_01_Y+_]L'UCR-6BG_\ "N/"_P#T -/_ ._"T?\ "N/"_P#T -/_ ._"T?ZD
M2_Z"/_)?_M@^L>0RBG_\*X\+_P#0 T__ +\+1_PKCPO_ - #3_\ OPM'^I$O
M^@C_ ,E_^V#ZQY#**RM<\ ^'(-4\/)'HEBB37SI(JPJ Z_9IVP?4953]0*V/
M^%<>%_\ H :?_P!^%H_U(E_T$?\ DO\ ]L'UCR&44_\ X5QX7_Z &G_]^%H_
MX5QX7_Z &G_]^%H_U(E_T$?^2_\ VP?6/(913_\ A7'A?_H :?\ ]^%K'\9>
M ?#EGX0URX@T2QAGBL9WCD2%0RL(V((/J#1_J1+_ *"/_)?_ +8/K'D:M%/_
M .%<>%_^@!I__?A:/^%<>%_^@!I__?A:/]2)?]!'_DO_ -L'UCR&44__ (5Q
MX7_Z &G_ /?A:/\ A7'A?_H :?\ ]^%H_P!2)?\ 01_Y+_\ ;!]8\AE%/_X5
MQX7_ .@!I_\ WX6L?P;X!\.7GA#0[B?1+&:>6Q@>21X5+,QC4DD^I-'^I$O^
M@C_R7_[8/K'D:M;&C_\ 'LW^^?Y"LK_A7'A?_H :?_WX6J?@&QM]+U/QC9VD
M*6UK#JZ".&,85 ;&T8@#MRQ/U)KV\HX9>5XI8EUN;1JW+;?YLB=;GC:QU]%%
M%?<G,%%%% !1110 4444 87_  FFE_\ 3[_X+[C_ .(H_P"$TTO_ *??_!?<
M?_$5NT4 87_"::7_ -/O_@ON/_B*/^$TTO\ Z??_  7W'_Q%;M% '%:[XMTZ
M75/#K+]KQ%?N[9L9P<?99QP"G/)' ]ST!K8_X332_P#I]_\ !?<?_$4>(?\
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M/_B*Q_!?BW3K;P=H4+_:]\=A C;;&=AD1J#@A,'ZBNUK"\"?\B/X>_[!UO\
M^BEH /\ A--+_P"GW_P7W'_Q%'_"::7_ -/O_@ON/_B*W:* ,+_A--+_ .GW
M_P %]Q_\11_PFFE_]/O_ (+[C_XBMVB@#BM"\6Z=%JGB)F^UXEOT=<6,Y./L
ML Y 3CD'@^QZ$5L?\)II?_3[_P""^X_^(H\/?\A?Q/\ ]A%/_22WK=H PO\
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MZXTN!4^UY%_9/\UC.O"W41/)3T!X[]!S7:UA>,O^01;_ /81L/\ TKAH /\
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M ."^X_\ B*W:* ,+_A--+_Z??_!?<?\ Q%'_  FFE_\ 3[_X+[C_ .(K=HH
MXK7?%NG2ZIX=9?M>(K]W;-C.#C[+.. 4YY(X'N>@-;'_  FFE_\ 3[_X+[C_
M .(H\0_\A?PQ_P!A%_\ TDN*W: ,+_A--+_Z??\ P7W'_P 11_PFFE_]/O\
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MBJGA#_D8/&__ &&(_P#TWV==10!A?\)II?\ T^_^"^X_^(H_X332_P#I]_\
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M\)+<_P#0O:K^4'_QVMVB@#"_X26Y_P"A>U7\H/\ X[1_PDMS_P!"]JOY0?\
MQVMVB@#"_P"$EN?^A>U7\H/_ ([6;X9U2^T?PWI-A/X?U,SVMI%!(4\DKN5
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MC/[SIDUU]% &%_PDMS_T+VJ_E!_\=H_X26Y_Z%[5?R@_^.UNT4 87_"2W/\
MT+VJ_E!_\=H_X26Y_P"A>U7\H/\ X[6[10!A?\)+<_\ 0O:K^4'_ ,=K-\,Z
MI?:/X;TFPG\/ZF9[6TB@D*>25W*@4X_>=,BNOHH PO\ A);G_H7M5_*#_P".
MT?\ "2W/_0O:K^4'_P =K=HH PO^$EN?^A>U7\H/_CM'_"2W/_0O:K^4'_QV
MMVB@#B=!O=0TS5?$ES-X?U(QZA?I=0[?))""UMXCN_><'=$WX8K9_P"$EN?^
MA>U7\H/_ ([6[10!A?\ "2W/_0O:K^4'_P =H_X26Y_Z%[5?R@_^.UNT4 87
M_"2W/_0O:K^4'_QVLVWU2^B\27U^?#^I^1/:6\"@>3NW(\S-G]YTQ(OZUU]%
M &%_PDMS_P!"]JOY0?\ QVC_ (26Y_Z%[5?R@_\ CM;M% &%_P )+<_]"]JO
MY0?_ !VC_A);G_H7M5_*#_X[6[10!R&K:I?7M_HLT?A_4PEG=M/)N\G)4P2Q
M\?O.N9%_#-:7_"2W/_0O:K^4'_QVMVB@#"_X26Y_Z%[5?R@_^.T?\)+<_P#0
MO:K^4'_QVMVB@#"_X26Y_P"A>U7\H/\ X[6;XFU2^UCPWJUA!X?U,3W5I+!&
M7\D+N9"HS^\Z9-=?10!A?\)+<_\ 0O:K^4'_ ,=H_P"$EN?^A>U7\H/_ ([6
M[10!A?\ "2W/_0O:K^4'_P =H_X26Y_Z%[5?R@_^.UNT4 87_"2W/_0O:K^4
M'_QVLWPSJE]H_AO2;"?P_J9GM;2*"0IY)7<J!3C]YTR*Z^B@#"_X26Y_Z%[5
M?R@_^.U7\'VMTE]XFO;FTELEO]26XACG*[]@M+>+)VD@?-$W>NEHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y/XG?$W1?A)X6.OZ]
M]L>S-U;V,<6GV<EW<33SRK%#''%&K.[,[JH !.3765XS^U=X+U?Q]\.M"TC1
M?[1BNV\6Z!.]WI2JUS9PQZG;O+<IN5E!B16DRRLHVY((R* .C^&?QV\*_%74
M]8TK2CJFG:WI"12WVD:]I5SIEY#'+N\J0Q7"(Q1MC88 CBO0/-3;NWKM]<\5
M\@_'K]FJ[\,>!]9U?2W\1_%;Q+KM]I5CJM[XB(OI;72X)G<A+.T%J+B-6=G:
MWR!(6);<!BO!/!?@:_\ !T>BZ+\2/ ^IZYX$'BCQ#/8>"'@@L)KB*2RTZ6UN
MX+!K@*8HG%Z"JN?(:<%MI!( /TY,J#'SKSTYZUR?Q.^*OA[X1Z%:ZIXAFN@E
MY>1Z=96MA9RW=U>7,@8I###$K/(Y".<*#PK'H#7Y?>$O@QXY\9?"/P-?OX=U
MK7M%OO!LD/AV33K(:G)I^H/?WLC.LGVF(6DK++;L+IMPPO7Y2I^]OV@/&/CC
MX8_!KPY)X<\(7GCWQTSV]B+NUT\WITZ0PD37[1@Y;: V%#+N9PI8 DT >H_#
M;XF>'_BSX6CU_P -W<ES8F:6UE2X@DMY[>>)RDL,L4@5XY$8$%6 /X$4OQ&^
M)&A?"OP5J7BKQ!<R1:3IX3S6MH6GD9GD6.-$C0%F9G=5  ZD5XCX%\$ZO)^Q
MWXPT/P5:^*=%\::G8:LR7GBZ 6>IWFJSJ[-=. V(_,E?*D'"C']VOF?QC^SI
M-XR\&Z_#X1^#>O>%_#PT_P /0W>B:M;_ #7^JQZO;F>YC@WOO,=H;I9)^-ZR
MMRPR: /NOQM\=/#7P]\.>'-4UJ/5H[CQ"R1Z;HMKI5Q<ZG<2&(RM&+6)&DW(
M@8N,?+M.><5T'P\^(.@_%3P;IGBKPS?#4=$U%&:"X\MHSE79'5D8!E975E96
M (92",BO(/VH?%7B?X6^!O#.F?#/P)?ZKJDSG3;;4]&T@7__  C=F(PKSQPC
M&Y]NU8XRRJ2/F.%VMVG[-.@Z9X8^"/AG3=)TGQ!HMG"DY-KXJB\O4VE:XD::
M:X7)^>61GEXX(D!  .* /3J*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YSQM\-_"?Q*L(+'Q=X9TC
MQ/9P2":*WUBQBNDC<?Q*LBD ]O<<=*Z.B@""RLK?3;."TM((K6TMXUBA@@0)
J'&BC"JJC@    #IBIZ** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>ibio-20220930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/14/2022 9:57:43 PM-->
<!--Modified on: 11/14/2022 9:57:43 PM-->
<xsd:schema xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" targetNamespace="http://www.ibioinc.com/20220930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ibio="http://www.ibioinc.com/20220930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2">
        <link:definition>00201 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss CALC2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>40403 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details" id="DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details">
        <link:definition>40702 - Disclosure - Investments in Debt and Equity Securities (Components of Investments in Debt Securities2) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails" id="DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails">
        <link:definition>40803 - Disclosure - Investments in Debt and Equity Securities (Debt Securities, Contractual Maturity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" id="DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails">
        <link:definition>40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" id="DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails">
        <link:definition>41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" id="DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2">
        <link:definition>41304 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Finance Lease Obligation) (Details) (Calc2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" id="DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2">
        <link:definition>41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" id="DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3">
        <link:definition>41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" id="DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails">
        <link:definition>41404 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" id="DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails">
        <link:definition>41503 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical">
        <link:definition>00205 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" id="StatementCondensedConsolidatedStatementsOfEquity">
        <link:definition>00300 - Statement - Condensed Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>10101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10201 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10401 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" id="DisclosureFinancialInstrumentsAndFairValueMeasurement">
        <link:definition>10501 - Disclosure - Financial Instruments and Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactions" id="DisclosureSignificantTransactions">
        <link:definition>10601 - Disclosure - Significant Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable" id="DisclosureConvertiblePromissoryNoteReceivable">
        <link:definition>10701 - Disclosure - Convertible Promissory Note Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecurities" id="DisclosureInvestmentsInDebtAndEquitySecurities">
        <link:definition>10801 - Disclosure - Investments in Debt and Equity Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets" id="DisclosureFinanceLeaseRouAssets">
        <link:definition>10901 - Disclosure - Finance Lease ROU Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets" id="DisclosureOperatingLeaseRouAssets">
        <link:definition>11001 - Disclosure - Operating Lease ROU Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssets" id="DisclosureFixedAssets">
        <link:definition>11101 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
        <link:definition>11201 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureNotePayablePppLoan" id="DisclosureNotePayablePppLoan">
        <link:definition>11301 - Disclosure - Note Payable - PPP Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation" id="DisclosureFinanceLeaseObligation">
        <link:definition>11401 - Disclosure - Finance Lease Obligation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation" id="DisclosureOperatingLeaseObligation">
        <link:definition>11501 - Disclosure - Operating Lease Obligation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11601 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare" id="DisclosureEarningsLossPerCommonShare">
        <link:definition>11701 - Disclosure - Earnings (Loss) Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>11801 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlement" id="DisclosureFraunhoferSettlement">
        <link:definition>11901 - Disclosure - Fraunhofer Settlement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>12001 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureContingencies" id="DisclosureContingencies">
        <link:definition>12101 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlan" id="DisclosureEmployee401KPlan">
        <link:definition>12201 - Disclosure - Employee 401(K) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>12301 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20402 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30403 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" id="DisclosureSignificantTransactionsTables">
        <link:definition>30603 - Disclosure - Significant Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesTables" id="DisclosureInvestmentsInDebtAndEquitySecuritiesTables">
        <link:definition>30803 - Disclosure - Investments in Debt and Equity Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables" id="DisclosureFinanceLeaseRouAssetsTables">
        <link:definition>30903 - Disclosure - Finance Lease ROU Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables" id="DisclosureIntangibleAssetsTables">
        <link:definition>31203 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables" id="DisclosureFinanceLeaseObligationTables">
        <link:definition>31403 - Disclosure - Finance Lease Obligation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables" id="DisclosureOperatingLeaseObligationsTables">
        <link:definition>31503 - Disclosure - Operating Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables" id="DisclosureEarningsLossPerCommonShareTables">
        <link:definition>31703 - Disclosure - Earnings (Loss) Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>31803 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" id="DisclosureBasisOfPresentationNarrativeDetails">
        <link:definition>40201 - Disclosure - Basis of Presentation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" id="DisclosureDiscontinuedOperationsNarrativeDetails">
        <link:definition>40301 - Disclosure - Discontinued Operations (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRevenueDetails">
        <link:definition>40402 - Disclosure - Summary of Significant Accounting Policies - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" id="DisclosureSignificantTransactionsNarrativeDetails">
        <link:definition>40601 - Disclosure - Significant Transactions (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" id="DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails">
        <link:definition>40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsAmendedCreditAgreementDetails" id="DisclosureSignificantTransactionsAmendedCreditAgreementDetails">
        <link:definition>40603 - Disclosure - Significant Transactions - Amended Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" id="DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails">
        <link:definition>40701 - Disclosure - Convertible Promissory Note Receivable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails" id="DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails">
        <link:definition>40801 - Disclosure - Investments in Debt and Equity Securities (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails" id="DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails">
        <link:definition>40802 - Disclosure - Investments in Debt and Equity Securities (Components of Investments in Debt Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" id="DisclosureFinanceLeaseRouAssetsNarrativeDetails">
        <link:definition>40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails" id="DisclosureOperatingLeaseRouAssetsNarrativeDetails">
        <link:definition>41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" id="DisclosureFixedAssetsNarrativeDetails">
        <link:definition>41101 - Disclosure - Fixed Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" id="DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails">
        <link:definition>41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" id="DisclosureIntangibleAssetsNarrativeDetails">
        <link:definition>41201 - Disclosure - Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails" id="DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails">
        <link:definition>41203 - Disclosure - Intangible Assets (Estimated Annual Amortization Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureNotePayablePppLoanNarrativeDetails" id="DisclosureNotePayablePppLoanNarrativeDetails">
        <link:definition>41301 - Disclosure - Note Payable - PPP Loan (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" id="DisclosureFinanceLeaseObligationNarrativeDetails">
        <link:definition>41401 - Disclosure - Finance Lease Obligation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails" id="DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails">
        <link:definition>41403 - Disclosure - Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" id="DisclosureOperatingLeaseObligationNarrativeDetails">
        <link:definition>41501 - Disclosure - Operating Lease Obligation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" id="DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails">
        <link:definition>41502 - Disclosure - Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails">
        <link:definition>41601 - Disclosure - Stockholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingNarrativeDetails" id="DisclosureStockholdersEquityCantorFitzgeraldUnderwritingNarrativeDetails">
        <link:definition>41602 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" id="DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails">
        <link:definition>41701 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" id="DisclosureShareBasedCompensationNarrativeDetails">
        <link:definition>41801 - Disclosure - Share-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" id="DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>41802 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" id="DisclosureShareBasedCompensationStockOptionActivityDetails">
        <link:definition>41803 - Disclosure - Share-Based Compensation (Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" id="DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails">
        <link:definition>41805 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" id="DisclosureFraunhoferSettlementNarrativeDetails">
        <link:definition>41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>42001 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" id="DisclosureEmployee401KPlanNarrativeDetails">
        <link:definition>42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" id="DisclosureSubsequentEventsNarrativeDetails">
        <link:definition>42301 - Disclosure - Subsequent Events (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsCategoryNetCarryingValuesOfOperatingLeaseRouDetails" id="DisclosureOperatingLeaseRouAssetsCategoryNetCarryingValuesOfOperatingLeaseRouDetails">
        <link:definition>9941002 - Disclosure - Operating Lease ROU Assets (Category the net carrying values of operating lease ROU) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" id="DisclosureDiscontinuedOperations">
        <link:definition>10301 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables" id="DisclosureDiscontinuedOperationsTables">
        <link:definition>30303 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:element id="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" name="CapitalExpenditureIncurredForIntangibleAssetsPaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="UnpaidFixedAssetsIncludedInAccountsPayable" id="ibio_UnpaidFixedAssetsIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ContractAssetsPolicyTextBlock" id="ibio_ContractAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchaseAgreementAxis" id="ibio_PurchaseAgreementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchaseAgreementDomain" id="ibio_PurchaseAgreementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_EasternAffiliateMember" name="EasternAffiliateMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SummaryOfSignificantAccountingPoliciesLineItems" id="ibio_SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityTable" id="ibio_StockholdersEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredTrackingStockMember" id="ibio_PreferredTrackingStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityLineItems" id="ibio_StockholdersEquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EarningsLossPerCommonShareTable" id="ibio_EarningsLossPerCommonShareTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EarningsLossPerCommonShareLineItems" id="ibio_EarningsLossPerCommonShareLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_PrincipalMember" name="PrincipalMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_InterestMember" name="InterestMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ContractLiabilitiesPolicyTextBlock" name="ContractLiabilitiesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_IbioCdmoMember" name="IbioCdmoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" name="ProceedsFromIssuanceOfPreferredAndCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_RightOfUseAssetsPolicyPolicyTextBlock" name="RightOfUseAssetsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" name="FinanceLeaseRightOfUseAssetDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" name="FinanceLeaseRightOfUseAssetDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" name="SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" name="FinanceLeaseRightOfUseAssetDisclosureTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FacilityMember" name="FacilityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" name="FinanceLeaseRightOfUseAssetDisclosureLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetGross" name="FinanceLeaseRightOfUseAssetGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" name="ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseObligationOtherInformationAbstract" name="FinanceLeaseObligationOtherInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinancingCashFlowsFromFinanceLeaseObligation" name="FinancingCashFlowsFromFinanceLeaseObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_StockIssuedDuringPeriodValueCapitalRaise" name="StockIssuedDuringPeriodValueCapitalRaise" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_StockIssuedDuringPeriodSharesCapitalRaise" name="StockIssuedDuringPeriodSharesCapitalRaise" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioTwoMember" name="ScenarioTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_NumberOfMajorCustomers" name="NumberOfMajorCustomers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_NotesPayablePppLoanDisclosureTextblock" name="NotesPayablePppLoanDisclosureTextblock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" name="IbioInc.2020OmnibusEquityIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioOneMember" name="ScenarioOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" name="ConvertiblePromissoryNoteReceivableAndAccruedInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" name="AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LoansReceivableAmountInvested" name="LoansReceivableAmountInvested" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LoansReceivableFixedRatesOfInterest" name="LoansReceivableFixedRatesOfInterest" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashAndCashEquivalentsPlusDebtSecurities" name="CashAndCashEquivalentsPlusDebtSecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" name="ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SettlementAssetsNonCurrent" name="SettlementAssetsNonCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" name="ForgivenessOfNotePayableAndAccruedInterestSbaLoan" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_ExchangeAgreementMember" name="ExchangeAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CollaborationOptionAndLicenseAgreementMember" name="CollaborationOptionAndLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_RubrycTheraputicsInc.Member" name="RubrycTheraputicsInc.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" name="CollaborationAndLicenseAgreementRoyaltyPaymentTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_ImmuneOncologyAntibodiesRtx003Member" name="ImmuneOncologyAntibodiesRtx003Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_Series2PreferredStockMember" name="Series2PreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockPurchaseAgreementNumberOfSharesPurchased" name="StockPurchaseAgreementNumberOfSharesPurchased" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockPurchaseAgreementValueOfSharesPurchased" name="StockPurchaseAgreementValueOfSharesPurchased" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_StockPurchaseAgreementValueOfSharesToBePurchased" name="StockPurchaseAgreementValueOfSharesToBePurchased" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_CollaborationAndLicenseAgreementAgreementTerm" name="CollaborationAndLicenseAgreementAgreementTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_GainLossRelatedToLitigationSettlementTextBlock" name="GainLossRelatedToLitigationSettlementTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" name="AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" name="IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" name="CashPaymentsReceivablesRelatedToLitigationSettlement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ScenarioPlanExpectedLegalFeesMember" name="ScenarioPlanExpectedLegalFeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioPlanExpectedPaymentOneMember" name="ScenarioPlanExpectedPaymentOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioPlanExpectedPaymentTwoMember" name="ScenarioPlanExpectedPaymentTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_PercentageOfLegalFeesExpectedToBeReceived" name="PercentageOfLegalFeesExpectedToBeReceived" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" name="LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" name="NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SettlementOfRevenueContract" name="SettlementOfRevenueContract" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LeaseIncentiveForConstructionInProgress" name="LeaseIncentiveForConstructionInProgress" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_NonCashSettlementOfRevenueContract" name="NonCashSettlementOfRevenueContract" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_SignificantTransactionsAbstract" name="SignificantTransactionsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SignificantTransactionsTextBlock" name="SignificantTransactionsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_NoBiosimilarProductHasBeenApprovedMember" name="NoBiosimilarProductHasBeenApprovedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" name="OperatingLeaseRightOfUseAssetDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" name="ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_LessorFinanceLeaseMonthlyRent" name="LessorFinanceLeaseMonthlyRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseMonthlyRent" name="LesseeOperatingLeaseMonthlyRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_BaseRentAbatementInFirstYearPeriod" name="BaseRentAbatementInFirstYearPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_OperatingLeaseObligationOtherInformationAbstract" name="OperatingLeaseObligationOtherInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_OperatingCashFlowsFromOperatingLeaseObligation" name="OperatingCashFlowsFromOperatingLeaseObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_TotalOperatingLeaseCosts" name="TotalOperatingLeaseCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" name="CollegeStationInvestorsLlcAndBryanCapitalMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_IbioCmoPreferredTrackingStockMember" name="IbioCmoPreferredTrackingStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SecuredTermLoanMember" name="SecuredTermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" name="PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" name="PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_BaseRentPercentageOfFairMarketValueOfProperty" name="BaseRentPercentageOfFairMarketValueOfProperty" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FairMarketValueOfProperty" name="FairMarketValueOfProperty" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" name="EquityAgreementConsiderationTransferredEquityInterestsAcquired" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_EquityAgreementWarrantsIssuedOrIssuable" name="EquityAgreementWarrantsIssuedOrIssuable" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" name="EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_CreditAgreementThresholdLimitUnrestrictedCash" name="CreditAgreementThresholdLimitUnrestrictedCash" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" name="WarrantsIssuedForFinalPaymentOfSubleaseRent" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" name="WarrantsIssuedForFinalPaymentOfSubleaseRentValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_OperatingLeaseCostsAbstract" name="OperatingLeaseCostsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets" name="ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" name="LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" name="LesseeOperatingLeaseImputedInterestToBePaidYearOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" name="LesseeOperatingLeaseImputedInterestToBePaidYearTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" name="LesseeOperatingLeaseImputedInterestToBePaidYearThree" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" name="LesseeOperatingLeaseImputedInterestToBePaidYearFour" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" name="LesseeOperatingLeaseImputedInterestToBePaidYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" name="LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" name="LesseeOperatingLeaseImputedInterestToBePaidTotal" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_IrrevocableLetterOfCredit" name="IrrevocableLetterOfCredit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_LetterOfCreditTermLoanMember" name="LetterOfCreditTermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LetterOfCreditSanDiegoLeaseMember" name="LetterOfCreditSanDiegoLeaseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" name="NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_DeferredFinancingCostsAmortizationExpense" name="DeferredFinancingCostsAmortizationExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element name="CompanyPurchasingCardMember" id="ibio_CompanyPurchasingCardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionIntangibleAssetsMember" id="ibio_AssetAcquisitionIntangibleAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionPrepaidExpensesMember" id="ibio_AssetAcquisitionPrepaidExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CurrentLiabilitiesRelatedToAssetsHeldForSale" id="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NoncurrentLiabilitiesRelatedToAssetsHeldForSale" id="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="UnconsolidatedGainLossAttributableToStockholders" id="ibio_UnconsolidatedGainLossAttributableToStockholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CommonStockIssuedInRubrycTransactionInShares" id="ibio_CommonStockIssuedInRubrycTransactionInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonStockIssuedInRubrycTransactionValue" id="ibio_CommonStockIssuedInRubrycTransactionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInInventoryReserve" id="ibio_IncreaseDecreaseInInventoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncreaseDecreaeInOperatingLeaseObligations" id="ibio_IncreaseDecreaeInOperatingLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" id="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EmployeeReductionExpenses" id="ibio_EmployeeReductionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DiscontinuedOperationsResearchAndDevelopmentExpenses" id="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupInterestExpenseRelatedParty" id="ibio_DisposalGroupInterestExpenseRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupGainOnDebtForgiveness" id="ibio_DisposalGroupGainOnDebtForgiveness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DiscontinuedOperationsMiscellaneousExpensesIncome" id="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupOperatingLeaseRightOfUseAssets" id="ibio_DisposalGroupOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" id="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" id="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupNoncurrentOperatingLeaseObligations" id="ibio_DisposalGroupNoncurrentOperatingLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" id="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" id="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="UnpaidFixedAssetsAttributableToDiscontinuedOperations" id="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>ibio-20220930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/14/2022 9:57:43 PM-->
<!--Modified on: 11/14/2022 9:57:43 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" />
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638040598584737726" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638040598584737726" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638040598584737726" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638040598584737726" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638040598584737726" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638040598584737726" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638040598584747771" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638040598584747771" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638040598584747771" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_SecurityDeposit_638040598584747771" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SettlementAssetsNonCurrent" xlink:label="ibio_SettlementAssetsNonCurrent_638040598584747771" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="ibio_SettlementAssetsNonCurrent_638040598584747771" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638040598584747771" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638040598584747771" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_638040598584747771" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent_638040598584747771" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638040598584747771" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638040598584747771" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638040598584757536" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638040598584757536" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638040598584757536" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638040598584757536" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638040598584757536" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638040598584757536" xlink:to="us-gaap_AccountsReceivableNetCurrent_638040598584757536" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638040598584757536" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638040598584757536" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638040598584757536" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638040598584757536" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638040598584757536" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638040598584757536" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638040598584757536" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638040598584757536" xlink:to="us-gaap_DebtSecuritiesCurrent_638040598584757536" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent_638040598584757536" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638040598584757536" xlink:to="us-gaap_SettlementAssetsCurrent_638040598584757536" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638040598584767499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638040598584757536" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638040598584767499" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638040598584767499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638040598584767499" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638040598584767499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638040598584767499" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638040598584767499" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638040598584767499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638040598584767499" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638040598584767499" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_638040598584767499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638040598584767499" xlink:to="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_638040598584767499" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638040598584767499" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638040598584767499" xlink:to="us-gaap_LiabilitiesCurrent_638040598584767499" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638040598584777727" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638040598584767499" xlink:to="us-gaap_AccountsPayableCurrent_638040598584777727" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638040598584777727" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638040598584767499" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638040598584777727" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638040598584777727" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638040598584767499" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638040598584777727" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638040598584777727" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638040598584767499" xlink:to="us-gaap_NotesPayableCurrent_638040598584777727" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638040598584777727" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638040598584767499" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638040598584777727" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638040598584777727" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638040598584767499" xlink:to="us-gaap_DeferredRevenueCurrent_638040598584777727" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638040598584787726" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638040598584767499" xlink:to="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638040598584787726" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638040598584787726" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638040598584787726" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638040598584787726" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638040598584787726" xlink:to="us-gaap_PreferredStockValue_638040598584787726" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638040598584787726" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638040598584787726" xlink:to="us-gaap_CommonStockValue_638040598584787726" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638040598584787726" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638040598584787726" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638040598584787726" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638040598584787726" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638040598584787726" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638040598584787726" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638040598584797721" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638040598584787726" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638040598584797721" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638040598584797721" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638040598584797721" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638040598584797721" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638040598584797721" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock_638040598584797721" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638040598584797721" xlink:to="us-gaap_DividendsPreferredStockStock_638040598584797721" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638040598584807509" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638040598584797721" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638040598584807509" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_638040598584807509" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations_638040598584807509" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_638040598584807509" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638040598584807509" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations_638040598584807509" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638040598584807509" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638040598584807509" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638040598584807509" xlink:to="us-gaap_InvestmentIncomeInterest_638040598584807509" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638040598584807509" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638040598584807509" xlink:to="us-gaap_OperatingIncomeLoss_638040598584807509" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638040598584807509" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638040598584807509" xlink:to="us-gaap_OperatingExpenses_638040598584807509" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638040598584807509" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638040598584807509" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638040598584807509" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638040598584807509" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638040598584807509" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638040598584807509" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638040598584817736" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638040598584807509" xlink:to="us-gaap_Revenues_638040598584817736" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" xlink:type="extended" xlink:title="00201 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss CALC2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638040598584817736" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638040598584817736" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638040598584817736" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss_638040598584817736" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638040598584817736" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_ProfitLoss_638040598584817736" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IncreaseDecreaseInInventoryReserve" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_638040598584817736" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="ibio_IncreaseDecreaseInInventoryReserve_638040598584817736" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638040598584827712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638040598584827712" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638040598584827712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638040598584827712" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_638040598584827712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_638040598584827712" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638040598584827712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_ShareBasedCompensation_638040598584827712" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638040598584827712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638040598584827712" order="7" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638040598584827712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638040598584827712" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_638040598584827712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_638040598584827712" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638040598584827712" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638040598584827712" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SettlementOfRevenueContract" xlink:label="ibio_SettlementOfRevenueContract_638040598584837508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="ibio_SettlementOfRevenueContract_638040598584837508" order="11" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638040598584837508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_Depreciation_638040598584837508" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638040598584837508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638040598584837508" order="13" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638040598584837508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638040598584837508" order="14" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638040598584837508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638040598584837508" order="15" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638040598584837508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638040598584837508" order="16" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638040598584837508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638040598584837508" order="17" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638040598584847728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638040598584847728" order="18" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638040598584847728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638040598584847728" order="19" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638040598584847728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598584817736" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638040598584847728" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638040598584847728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638040598584847728" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638040598584847728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638040598584847728" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638040598584847728" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_638040598584857583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638040598584847728" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_638040598584857583" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638040598584857583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638040598584847728" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638040598584857583" order="3" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_638040598584857583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638040598584847728" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_638040598584857583" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638040598584857583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638040598584847728" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638040598584857583" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638040598584857583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638040598584847728" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638040598584857583" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638040598584857583" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638040598584857583" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638040598584867721" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638040598584857583" xlink:to="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638040598584867721" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638040598584867721" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638040598584857583" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638040598584867721" order="2" use="optional" weight="-1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638040598584867721" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638040598584867721" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638040598584867721" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638040598584867721" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details" xlink:type="extended" xlink:title="40702 - Disclosure - Investments in Debt and Equity Securities (Components of Investments in Debt Securities2) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638040598584877514" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638040598584877514" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638040598584877514" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_DebtSecuritiesCurrent_638040598584877514" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Investments in Debt and Equity Securities (Debt Securities, Contractual Maturity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_638040598584877514" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_638040598584877514" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638040598584877514" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638040598584877514" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638040598584877514" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638040598584877514" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_638040598584887734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross_638040598584887734" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638040598584887734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638040598584887734" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638040598584887734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_638040598584887734" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638040598584887734" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638040598584887734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_638040598584887734" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638040598584887734" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" xlink:type="extended" xlink:title="41304 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Finance Lease Obligation) (Details) (Calc2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638040598584887734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638040598584887734" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638040598584887734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638040598584887734" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" xlink:type="extended" xlink:title="41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638040598584897736" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638040598584897736" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638040598584897736" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638040598584897736" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" xlink:type="extended" xlink:title="41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 3)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638040598584897736" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638040598584897736" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638040598584897736" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638040598584897736" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638040598584897736" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638040598584897736" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638040598584897736" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638040598584897736" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638040598584907777" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638040598584907777" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638040598584907777" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638040598584907777" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638040598584907777" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638040598584907777" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638040598584907777" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638040598584907777" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638040598584907777" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638040598584907777" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638040598584917730" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638040598584917730" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638040598584917730" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638040598584917730" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638040598584917730" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638040598584917730" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638040598584917730" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638040598584917730" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638040598584917730" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638040598584917730" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" xlink:type="extended" xlink:title="41404 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638040598584927728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638040598584927728" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638040598584927728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638040598584927728" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638040598584927728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638040598584927728" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638040598584927728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638040598584927728" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638040598584937793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638040598584937793" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638040598584937793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638040598584937793" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638040598584937793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638040598584937793" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638040598584937793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638040598584937793" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638040598584937793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638040598584937793" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638040598584937793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638040598584937793" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638040598584937793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638040598584937793" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638040598584937793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638040598584937793" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638040598584947773" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638040598584947773" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638040598584947773" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638040598584947773" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638040598584947773" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638040598584947773" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638040598584947773" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638040598584947773" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638040598584947773" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638040598584947773" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638040598584947773" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638040598584947773" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638040598584957568" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638040598584957568" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638040598584957568" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638040598584957568" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638040598584957568" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638040598584957568" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>ibio-20220930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/14/2022 9:57:43 PM-->
<!--Modified on: 11/14/2022 9:57:43 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#StatementCondensedConsolidatedStatementsOfEquity" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSignificantTransactionsTables" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSignificantTransactionsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureIntangibleAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureOperatingLeaseObligationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureShareBasedCompensationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFraunhoferSettlementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="ibio-20220930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1" xlink:title="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_1" xlink:title="us-gaap_ReceivableTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1" xlink:to="us-gaap_ReceivableTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1 To us-gaap_ReceivableTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:title="us-gaap_GuaranteeObligationsByNatureAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_1" xlink:title="us-gaap_GuaranteeObligationsNatureDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GuaranteeObligationsByNatureAxis_1 To us-gaap_GuaranteeObligationsNatureDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_1" xlink:title="srt_LitigationCaseAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_1" xlink:title="srt_LitigationCaseTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_LitigationCaseAxis_1" xlink:to="srt_LitigationCaseTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_LitigationCaseAxis_1 To srt_LitigationCaseTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_1" xlink:title="us-gaap_LitigationStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_1" xlink:title="us-gaap_LitigationStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LitigationStatusAxis_1" xlink:to="us-gaap_LitigationStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LitigationStatusAxis_1 To us-gaap_LitigationStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis_1" xlink:title="us-gaap_OtherComprehensiveIncomeLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain_1" xlink:title="us-gaap_OtherComprehensiveIncomeLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis_1" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OtherComprehensiveIncomeLocationAxis_1 To us-gaap_OtherComprehensiveIncomeLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeAxis" xlink:label="us-gaap_ReclassificationTypeAxis_1" xlink:title="us-gaap_ReclassificationTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationTypeDomain" xlink:label="us-gaap_ReclassificationTypeDomain_1" xlink:title="us-gaap_ReclassificationTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ReclassificationTypeAxis_1" xlink:to="us-gaap_ReclassificationTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ReclassificationTypeAxis_1 To us-gaap_ReclassificationTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_1" xlink:title="us-gaap_FairValueByAssetClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByAssetClassAxis_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByAssetClassAxis_1 To us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis_1" xlink:title="us-gaap_TimingOfTransferOfGoodOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" xlink:title="us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis_1" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TimingOfTransferOfGoodOrServiceAxis_1 To us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PurchaseAgreementAxis" xlink:label="ibio_PurchaseAgreementAxis_1" xlink:title="ibio_PurchaseAgreementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PurchaseAgreementDomain" xlink:label="ibio_PurchaseAgreementDomain_1" xlink:title="ibio_PurchaseAgreementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ibio_PurchaseAgreementAxis_1" xlink:to="ibio_PurchaseAgreementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ibio_PurchaseAgreementAxis_1 To ibio_PurchaseAgreementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1" xlink:title="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" xlink:title="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1 To us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:label="us-gaap_UnusualOrInfrequentItemAxis_1" xlink:title="us-gaap_UnusualOrInfrequentItemAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:label="us-gaap_UnusualOrInfrequentItemDomain_1" xlink:title="us-gaap_UnusualOrInfrequentItemDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_UnusualOrInfrequentItemAxis_1" xlink:to="us-gaap_UnusualOrInfrequentItemDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_UnusualOrInfrequentItemAxis_1 To us-gaap_UnusualOrInfrequentItemDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:title="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_1" xlink:title="us-gaap_AdjustmentsForErrorCorrectionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1 To us-gaap_AdjustmentsForErrorCorrectionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis_1" xlink:to="us-gaap_AssetAcquisitionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AssetAcquisitionAxis_1 To us-gaap_AssetAcquisitionDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CommonStockIssuedInRubrycTransactionInShares" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CommonStockIssuedInRubrycTransactionInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Significant Transactions (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_StockPurchaseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_RubrycTheraputicsInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetAcquisitionTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLossOnContracts" xlink:label="us-gaap_ProvisionForLossOnContracts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProvisionForLossOnContracts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LeasePracticalExpedientsPackage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashUninsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NumberOfMajorCustomers" xlink:label="ibio_NumberOfMajorCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ibio_NumberOfMajorCustomers" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LetterOfCreditTermLoanMember" xlink:label="ibio_LetterOfCreditTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="ibio_LetterOfCreditTermLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LetterOfCreditSanDiegoLeaseMember" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="ibio_LetterOfCreditSanDiegoLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CompanyPurchasingCardMember" xlink:label="ibio_CompanyPurchasingCardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="ibio_CompanyPurchasingCardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Significant Transactions (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ibio_Series2PreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollaborationOptionAndLicenseAgreementMember" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_CollaborationOptionAndLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_StockPurchaseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_NoBiosimilarProductHasBeenApprovedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTheraputicsInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IbioCmoPreferredTrackingStockMember" xlink:label="ibio_IbioCmoPreferredTrackingStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="ibio_IbioCmoPreferredTrackingStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_SecuredTermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_FairMarketValueOfProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EquityAgreementWarrantsIssuedOrIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IrrevocableLetterOfCredit" xlink:label="ibio_IrrevocableLetterOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_IrrevocableLetterOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CollaborationAndLicenseAgreementAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockPurchaseAgreementNumberOfSharesPurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockPurchaseAgreementValueOfSharesPurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementValueOfSharesToBePurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesToBePurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockPurchaseAgreementValueOfSharesToBePurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_Series2PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_AssetAcquisitionIntangibleAssetsMember" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetAcquisitionIntangibleAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_AssetAcquisitionPrepaidExpensesMember" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetAcquisitionPrepaidExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Promissory Note Receivable (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember" xlink:label="us-gaap_NotesReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_NotesReceivableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LoansReceivableAmountInvested" xlink:label="ibio_LoansReceivableAmountInvested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ibio_LoansReceivableAmountInvested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LoansReceivableFixedRatesOfInterest" xlink:label="ibio_LoansReceivableFixedRatesOfInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ibio_LoansReceivableFixedRatesOfInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Investments in Debt and Equity Securities (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentMaturityDate" xlink:label="us-gaap_InvestmentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FacilityMember" xlink:label="ibio_FacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ibio_FacilityMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Intangible Assets (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" xlink:type="extended" xlink:title="41404 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_PrincipalMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_InterestMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Operating Lease Obligation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_FairMarketValueOfProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseMonthlyRent" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_LesseeOperatingLeaseMonthlyRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_BaseRentAbatementInFirstYearPeriod" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_BaseRentAbatementInFirstYearPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TenantImprovements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Stockholders' Equity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockholdersEquityTable" xlink:label="ibio_StockholdersEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ExchangeAgreementMember" xlink:label="ibio_ExchangeAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ibio_ExchangeAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EasternAffiliateMember" xlink:label="ibio_EasternAffiliateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ibio_EasternAffiliateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PreferredTrackingStockMember" xlink:label="ibio_PreferredTrackingStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ibio_PreferredTrackingStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ibio_StockholdersEquityTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ibio_StockholdersEquityTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="ibio_StockholdersEquityTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IbioCdmoMember" xlink:label="ibio_IbioCdmoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="ibio_IbioCdmoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockholdersEquityLineItems" xlink:label="ibio_StockholdersEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_StockholdersEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EarningsLossPerCommonShareTable" xlink:label="ibio_EarningsLossPerCommonShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_EarningsLossPerCommonShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EarningsLossPerCommonShareLineItems" xlink:label="ibio_EarningsLossPerCommonShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="ibio_EarningsLossPerCommonShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Share-Based Compensation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioOneMember" xlink:label="ibio_ScenarioOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_ScenarioOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioTwoMember" xlink:label="ibio_ScenarioTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_ScenarioTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_SettledLitigationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioPlanExpectedLegalFeesMember" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="ibio_ScenarioPlanExpectedLegalFeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioPlanExpectedPaymentOneMember" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="ibio_ScenarioPlanExpectedPaymentOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="ibio_ScenarioPlanExpectedPaymentTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_LicenseAndMaintenanceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PercentageOfLegalFeesExpectedToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SettlementAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SettlementAssetsNonCurrent" xlink:label="ibio_SettlementAssetsNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SettlementAssetsNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainContingencyUnrecordedAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLegalSettlements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>ibio-20220930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/14/2022 9:57:43 PM-->
<!--Modified on: 11/14/2022 9:57:43 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesCurrent" xlink:to="us-gaap_DebtSecuritiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesCurrent_lbl" xml:lang="en-US">Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesCurrent_lbl" xml:lang="en-US">Fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesCurrent_lbl" xml:lang="en-US">Fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtSecuritiesCurrent_lbl" xml:lang="en-US">Investments in debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementAssetsCurrent" xlink:to="us-gaap_SettlementAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettlementAssetsCurrent_lbl" xml:lang="en-US">Settlement Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SettlementAssetsCurrent_lbl" xml:lang="en-US">Settlement receivable - current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xml:lang="en-US">Current assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xml:lang="en-US">Noncurrent assets held for sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:to="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" xml:lang="en-US">Amount of convertible Promissory Note Receivable and Accrued Interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" xml:lang="en-US">Convertible Promissory Note Receivable and Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" xml:lang="en-US">Convertible promissory note receivable and accrued interest</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SettlementAssetsNonCurrent" xlink:label="ibio_SettlementAssetsNonCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SettlementAssetsNonCurrent" xlink:to="ibio_SettlementAssetsNonCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SettlementAssetsNonCurrent_lbl" xml:lang="en-US">Settlement receivables, Non current portion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SettlementAssetsNonCurrent_lbl" xml:lang="en-US">Settlement Assets Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SettlementAssetsNonCurrent_lbl" xml:lang="en-US">Settlement receivable - noncurrent portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance lease right-of-use assets, net of accumulated amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Net finance lease ROU</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance lease ROU assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease ROU assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Net fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net of accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Total net intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid Expense, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses - noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease obligations - current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease obligation - current portion</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:to="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Current liabilities related to assets held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Current Liabilities Related To Assets Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Current liabilities related to assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Term note payable - net of deferred financing costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Note payable PPP loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligation - non-current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligations - net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligation - net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease obligation - net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term portion of minimum lease obligation</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:to="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Noncurrent liabilities related to assets held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Noncurrent Liabilities Related To Assets Held For Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Noncurrent liabilities related to assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">iBio, Inc. Stockholders' Equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series 2022 Convertible Preferred Stock - $.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Value of common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - $0.001 par value; 275,000,000 shares authorized at September 30, 2022 and June 30, 2022; 9,006,582 and 8,727,158 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total iBio, Inc. Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Reverse stock split, shares received per share tendered</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Operations and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative (related party of $0 and $189)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Consolidated Gain (Loss) From Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Consolidated net loss from continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" xml:lang="en-US">Net loss attributable to noncontrolling interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Net loss attributable to iBio, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Net loss attributable to iBio, Inc. from continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Dividends, Preferred Stock, Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Preferred stock dividends- iBio CDMO Tracking Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Preferred stock dividends - iBio CMO Preferred Tracking Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to iBio, Inc. stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to iBio, Inc. stockholders from continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Loss from discontinued operations</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:to="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" xml:lang="en-US">The unconsolidated net gain (loss) attributable to stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" xml:lang="en-US">Unconsolidated Gain (Loss) Attributable To Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" xml:lang="en-US">Net loss available to iBio, Inc. stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Consolidated net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss including portion attributable to noncontrolling interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Consolidated net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">Other comprehensive loss - unrealized loss on debt securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">Unrealized loss on available-for-sale debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - basic - total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Per share amount basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - diluted - total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Per share amount diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average common shares outstanding - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average common shares outstanding - diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Operating expenses general and administrative, related party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements of Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" xml:lang="en-US">Equity impact of the value of capital raise during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" xml:lang="en-US">Stock Issued During Period, Value, Capital Raise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" xml:lang="en-US">Capital raise</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" xml:lang="en-US">Number of new shares raised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Capital Raise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" xml:lang="en-US">Capital raise (in shares)</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CommonStockIssuedInRubrycTransactionValue" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">The value of common stock issued in the RubrYc transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">Common Stock Issued In RubrYc Transaction, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">Common stock issued - RubrYc transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">RubrYc asset acquisition by issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CommonStockIssuedInRubrycTransactionInShares" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CommonStockIssuedInRubrycTransactionInShares" xlink:to="ibio_CommonStockIssuedInRubrycTransactionInShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares_lbl" xml:lang="en-US">The number of shares of common stock issued in the RubrYc transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares_lbl" xml:lang="en-US">Common Stock Issued In RubrYc Transaction (In Shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares_lbl" xml:lang="en-US">Common stock issued - RubrYc transaction (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Vesting of RSU's (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock Options, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss attributable to noncontrolling interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile consolidated net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of ROU assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of finance lease right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of finance lease ROU assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of fixed assets</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:to="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" xml:lang="en-US">Amount of accrued interest receivable on convertible promissory note receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" xml:lang="en-US">Accrued Interest Receivable on Convertible Promissory Note Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" xml:lang="en-US">Accrued interest receivable on convertible promissory note receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of premiums on debt securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of premiums on debt securities</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DeferredFinancingCostsAmortizationExpense" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_lbl" xml:lang="en-US">Amortization of loan and debt issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_lbl" xml:lang="en-US">Deferred Financing Costs, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_lbl" xml:lang="en-US">Amortization of deferred financing costs</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IncreaseDecreaseInInventoryReserve" xlink:label="ibio_IncreaseDecreaseInInventoryReserve" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInInventoryReserve" xlink:to="ibio_IncreaseDecreaseInInventoryReserve_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_lbl" xml:lang="en-US">The increase (decrease) in inventory valuation reserve during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_lbl" xml:lang="en-US">Increase (Decrease) In Inventory Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_lbl" xml:lang="en-US">Inventory reserve</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" xlink:to="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_lbl" xml:lang="en-US">Forgiveness of note payable and accrued interest - SBA loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_lbl" xml:lang="en-US">Forgiveness of note payable and accrued interest - SBA loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_lbl" xml:lang="en-US">Forgiveness of note payable and accrued interest - SBA loan</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SettlementOfRevenueContract" xlink:label="ibio_SettlementOfRevenueContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SettlementOfRevenueContract" xlink:to="ibio_SettlementOfRevenueContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SettlementOfRevenueContract_lbl" xml:lang="en-US">Settlement of revenue contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SettlementOfRevenueContract_lbl" xml:lang="en-US">Settlement of revenue contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_SettlementOfRevenueContract_lbl" xml:lang="en-US">Settlement of revenue contract</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable - trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:to="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_lbl" xml:lang="en-US">Increase (Decrease) in Finished Goods and Work in Process Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_lbl" xml:lang="en-US">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses - noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Purchases of debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Redemption of debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_lbl" xml:lang="en-US">Purchase of equity security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Additions to intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Payment for RubrYc asset acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:to="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" xml:lang="en-US">Proceeds From Issuance Of Preferred And Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" xml:lang="en-US">Proceeds from sales of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payment of finance lease obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash - end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents - beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Schedule of non-cash activities:</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" xlink:to="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US">The amount of increase in Right Of Use Assets under the ASU 842, for which no cash outflow was incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US">Non Cash Transaction Increase In Right Of Use Assets And Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_lbl" xml:lang="en-US">Increase in operating lease ROU assets for new lease - net of lease incentive</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IncreaseDecreaeInOperatingLeaseObligations" xlink:label="ibio_IncreaseDecreaeInOperatingLeaseObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaeInOperatingLeaseObligations" xlink:to="ibio_IncreaseDecreaeInOperatingLeaseObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaeInOperatingLeaseObligations_lbl" xml:lang="en-US">Increae (decrease) in operating lease obligations for new leases during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaeInOperatingLeaseObligations_lbl" xml:lang="en-US">Increase (Decreae) In Operating Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IncreaseDecreaeInOperatingLeaseObligations_lbl" xml:lang="en-US">Increase in operating lease obligation for new lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Increase in finance lease ROU assets for new leases</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" xlink:to="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" xml:lang="en-US">The increase (decrease) in finance lease obligations for new leases incurred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" xml:lang="en-US">Increase (Decrease) In Finance Lease Obligations For New Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" xml:lang="en-US">Increase in finance lease obligation for new leases</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" xlink:to="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" xml:lang="en-US">The amount paid for capital expenditures incurred for intangible assets during the previous year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" xml:lang="en-US">Capital Expenditure Incurred For Intangible Assets Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" xml:lang="en-US">Fixed assets included in accounts payable in prior period, paid in current period</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LeaseIncentiveForConstructionInProgress" xlink:label="ibio_LeaseIncentiveForConstructionInProgress" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LeaseIncentiveForConstructionInProgress" xlink:to="ibio_LeaseIncentiveForConstructionInProgress_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LeaseIncentiveForConstructionInProgress_lbl" xml:lang="en-US">Lease incentive for construction in progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LeaseIncentiveForConstructionInProgress_lbl" xml:lang="en-US">Lease incentive for construction in progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LeaseIncentiveForConstructionInProgress_lbl" xml:lang="en-US">Lease incentive for construction in progress</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_UnpaidFixedAssetsIncludedInAccountsPayable" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_UnpaidFixedAssetsIncludedInAccountsPayable" xlink:to="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_lbl" xml:lang="en-US">The amount of unpaid fixed assets included in accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_lbl" xml:lang="en-US">Unpaid Fixed Assets Included In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_lbl" xml:lang="en-US">Unpaid fixed assets included in accounts payable</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementValueOfSharesToBePurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesToBePurchased" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementValueOfSharesToBePurchased" xlink:to="ibio_StockPurchaseAgreementValueOfSharesToBePurchased_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementValueOfSharesToBePurchased_lbl" xml:lang="en-US">Stock purchase agreement, value of shares to be purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementValueOfSharesToBePurchased_lbl" xml:lang="en-US">Stock purchase agreement, value of shares to be purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockPurchaseAgreementValueOfSharesToBePurchased_lbl" xml:lang="en-US">Stock purchase agreement, value of shares to be purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_StockPurchaseAgreementValueOfSharesToBePurchased_lbl" xml:lang="en-US">Unpaid portion of RubrYc transaction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Unrealized loss on available-for-sale debt securities</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NonCashSettlementOfRevenueContract" xlink:label="ibio_NonCashSettlementOfRevenueContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NonCashSettlementOfRevenueContract" xlink:to="ibio_NonCashSettlementOfRevenueContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NonCashSettlementOfRevenueContract_lbl" xml:lang="en-US">Non cash Settlement of revenue contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NonCashSettlementOfRevenueContract_lbl" xml:lang="en-US">Non cash Settlement of revenue contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_NonCashSettlementOfRevenueContract_lbl" xml:lang="en-US">Settlement of revenue contract</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:label="ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:to="ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US">Proceeds from options exercised included in prepaid expenses and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets_lbl" xml:lang="en-US">Proceeds from options exercised included in prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid during the period for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of Business [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Business</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_BasisOfPresentationAbstract" xlink:label="ibio_BasisOfPresentationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BasisOfPresentationAbstract" xlink:to="ibio_BasisOfPresentationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BasisOfPresentationAbstract_lbl" xml:lang="en-US">Represents the information pertaining to Basis of Presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BasisOfPresentationAbstract_lbl" xml:lang="en-US">Basis of Presentation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Discontinued Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Financial Instruments and Fair Value Measurement [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Financial Instruments and Fair Value Measurement</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="ibio_SignificantTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SignificantTransactionsAbstract_lbl" xml:lang="en-US">Significant Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SignificantTransactionsAbstract_lbl" xml:lang="en-US">Significant Transactions [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SignificantTransactionsTextBlock" xlink:label="ibio_SignificantTransactionsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SignificantTransactionsTextBlock" xlink:to="ibio_SignificantTransactionsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">Significant Transactions [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">Significant Transactions [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">Significant Transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Convertible Promissory Note Receivable [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Convertible Promissory Note Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments in Debt and Equity Securities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Investments in Debt Securities</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract_lbl" xml:lang="en-US">Finance Lease ROU [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for lessee's right to use underlying asset under finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Finance Lease ROU Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Operating Lease ROU Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" xlink:to="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for lessee's right to use underlying asset under operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Operating Lease Right Of Use Asset Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Operating Lease ROU Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Fixed Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NotesPayablePppLoanDisclosureTextblock" xlink:label="ibio_NotesPayablePppLoanDisclosureTextblock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NotesPayablePppLoanDisclosureTextblock" xlink:to="ibio_NotesPayablePppLoanDisclosureTextblock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NotesPayablePppLoanDisclosureTextblock_lbl" xml:lang="en-US">Tabular disclosure of notes payable PPP loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NotesPayablePppLoanDisclosureTextblock_lbl" xml:lang="en-US">Notes Payable Ppp Loan Disclosure Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_NotesPayablePppLoanDisclosureTextblock_lbl" xml:lang="en-US">Note Payable - PPP Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US">Finance Lease Obligation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Finance Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xml:lang="en-US">Finance Lease Obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US">Operating Lease, Liability [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating Lease Obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings (Loss) Per Common Share [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings (Loss) Per Common Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Compensation [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:to="us-gaap_GainLossRelatedToLitigationSettlementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract_lbl" xml:lang="en-US">Fraunhofer Settlement [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_GainLossRelatedToLitigationSettlementTextBlock" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_GainLossRelatedToLitigationSettlementTextBlock" xlink:to="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" xml:lang="en-US">Entire disclosure on gain (Loss) related to litigation settlement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" xml:lang="en-US">Gain Loss Related To Litigation Settlement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" xml:lang="en-US">Fraunhofer Settlement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee 401(K) Plan [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Employee 401(K) Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ContractAssetsPolicyTextBlock" xlink:label="ibio_ContractAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractAssetsPolicyTextBlock" xlink:to="ibio_ContractAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractAssetsPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for contract assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractAssetsPolicyTextBlock_lbl" xml:lang="en-US">Contract Assets [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ContractAssetsPolicyTextBlock_lbl" xml:lang="en-US">Contract Assets</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ContractLiabilitiesPolicyTextBlock" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractLiabilitiesPolicyTextBlock" xlink:to="ibio_ContractLiabilitiesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contract Liabilities [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contract Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:to="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Premium on Purchased Options [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" xml:lang="en-US">Investments in Debt Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_RightOfUseAssetsPolicyPolicyTextBlock" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_RightOfUseAssetsPolicyPolicyTextBlock" xlink:to="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">The disclosure of accounting policy for right-of-use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Right Of Use Assets Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Right-of-Use Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of discontinued operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of of total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementMember" xlink:to="ibio_StockPurchaseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_RubrycTheraputicsInc.Member" xlink:to="ibio_RubrycTheraputicsInc.Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_RubrycTheraputicsInc.Member_lbl" xml:lang="en-US">RubrYc Theraputics, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_RubrycTheraputicsInc.Member_lbl" xml:lang="en-US">RubrYc Theraputics, Inc. [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTableTextBlock" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Asset Acquisition [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Summary of Purchase Price Allocation of Asset Acquisition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of investments in debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of available-for-sale debt securities, by contractual maturity</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" xlink:to="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">Summary Of Gross Carrying Value And Accumulated Amortization Of Finance Lease, Right Of Use Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">Summary of the gross carrying value and accumulated amortization of finance lease ROU</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Category the gross carrying value and accumulated amortization of intangible assets</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expense And Supplemental Balance Sheet Information Related To Finance Lease Obligation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" xlink:label="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" xlink:to="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock_lbl" xml:lang="en-US">Represents information pertaining to schedule of finance lease right of use assets and obligation and weighted average information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Finance Lease Right of use Assets and Obligation and Weighted average Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of finance lease and weighted average information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Finance Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Future Minimum Payments Under the Finance Lease Obligation</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Future Minimum Payments under the Operating Lease Obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings (loss) Per Share, Basic and Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair value of options granted using the Black-Scholes option pricing model</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CashAndCashEquivalentsPlusDebtSecurities" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashAndCashEquivalentsPlusDebtSecurities" xlink:to="ibio_CashAndCashEquivalentsPlusDebtSecurities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities_lbl" xml:lang="en-US">Cash and cash equivalents plus debt securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities_lbl" xml:lang="en-US">Cash and cash equivalents plus debt securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities_lbl" xml:lang="en-US">Cash and cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EmployeeReductionExpenses" xlink:label="ibio_EmployeeReductionExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EmployeeReductionExpenses" xlink:to="ibio_EmployeeReductionExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EmployeeReductionExpenses_lbl" xml:lang="en-US">Expected amount of expenses to be incurred due to employee reductions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EmployeeReductionExpenses_lbl" xml:lang="en-US">Employee Reduction Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EmployeeReductionExpenses_lbl" xml:lang="en-US">Expected employee reduction charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_lbl" xml:lang="en-US">Results of operations for discontinued operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xml:lang="en-US">Gross profit</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:to="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Discontinued Operations, Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xml:lang="en-US">Interest expense - term note payable</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupInterestExpenseRelatedParty" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupInterestExpenseRelatedParty" xlink:to="ibio_DisposalGroupInterestExpenseRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense to related party from discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty_lbl" xml:lang="en-US">Disposal Group, Interest Expense, Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense - related party</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupGainOnDebtForgiveness" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupGainOnDebtForgiveness" xlink:to="ibio_DisposalGroupGainOnDebtForgiveness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness_lbl" xml:lang="en-US">Gain (loss) on forgiveness of debt to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness_lbl" xml:lang="en-US">Disposal Group, Gain On Debt Forgiveness</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness_lbl" xml:lang="en-US">Forgiveness of note payable and accrued interest - SBA loan</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" xlink:to="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" xml:lang="en-US">Miscellaneous expenses (income) attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" xml:lang="en-US">Discontinued Operations, Miscellaneous Expenses (Income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_lbl" xml:lang="en-US">Total other expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_lbl" xml:lang="en-US">Inventory</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupOperatingLeaseRightOfUseAssets" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Current operating lease ROU assets attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Disposal Group, Operating Lease Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" xml:lang="en-US">Other assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_lbl" xml:lang="en-US">Noncurrent operating lease ROU assets attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_lbl" xml:lang="en-US">Disposal Group, Operating Lease Right Of Use Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" xlink:to="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" xml:lang="en-US">Current operating lease obligations attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" xml:lang="en-US">Disposal Group, Current Liabilities, Operating Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" xml:lang="en-US">Operating lease obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_lbl" xml:lang="en-US">Long-term liabilities:</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupNoncurrentOperatingLeaseObligations" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupNoncurrentOperatingLeaseObligations" xlink:to="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_lbl" xml:lang="en-US">Noncurrent operating lease obligations attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_lbl" xml:lang="en-US">Disposal Group, Noncurrent Operating Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_lbl" xml:lang="en-US">Operating lease obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" xml:lang="en-US">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" xlink:to="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amortization of finance lease ROU assets attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Disposal Group, Amortization Of Finance Lease Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amortization of finance lease ROU assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" xml:lang="en-US">Capital Expenditure, Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" xml:lang="en-US">Purchase of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Investing noncash transactions:</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" xlink:to="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" xml:lang="en-US">Fixed asset charges incurred but not yet paid attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" xml:lang="en-US">Disposal Group, Fixed Assets Incurred But Not Yet Paid In Current Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" xml:lang="en-US">Fixed assets included in accounts payable in prior period, paid in current period</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" xlink:to="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" xml:lang="en-US">Unpaid fixed assets included in accounts payable, attributable to discontinued operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" xml:lang="en-US">Unpaid Fixed Assets Attributable To Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" xml:lang="en-US">Unpaid fixed assets included in accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents and Licenses [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US">Intellectual Property [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US">Revenue [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ibio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLossOnContracts" xlink:label="us-gaap_ProvisionForLossOnContracts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForLossOnContracts" xlink:to="us-gaap_ProvisionForLossOnContracts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForLossOnContracts_lbl" xml:lang="en-US">Provision for Loss on Contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForLossOnContracts_lbl" xml:lang="en-US">Provisions for contract loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract with Customer, Asset, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Revenue recognized included in contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientsPackage" xlink:to="us-gaap_LeasePracticalExpedientsPackage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xml:lang="en-US">Lease, Practical Expedients, Package [true false]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Fixed assets, useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible asset, useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US">Goodwill and Intangible Asset Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_lbl" xml:lang="en-US">Intangible asset impairment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Amount in excess of insured limit</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NumberOfMajorCustomers" xlink:label="ibio_NumberOfMajorCustomers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfMajorCustomers" xlink:to="ibio_NumberOfMajorCustomers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfMajorCustomers_lbl" xml:lang="en-US">Represents the information pertaining to number of major customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfMajorCustomers_lbl" xml:lang="en-US">Number of Major Customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfMajorCustomers_lbl" xml:lang="en-US">Number of major customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LetterOfCreditTermLoanMember" xlink:label="ibio_LetterOfCreditTermLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LetterOfCreditTermLoanMember" xlink:to="ibio_LetterOfCreditTermLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LetterOfCreditTermLoanMember_lbl" xml:lang="en-US">Represents the information pertaining to letter of credit term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LetterOfCreditTermLoanMember_lbl" xml:lang="en-US">Letter Of Credit - Term Loan [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LetterOfCreditSanDiegoLeaseMember" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LetterOfCreditSanDiegoLeaseMember" xlink:to="ibio_LetterOfCreditSanDiegoLeaseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember_lbl" xml:lang="en-US">Represents the information pertaining to letter of credit for sandiego lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember_lbl" xml:lang="en-US">Letter Of Credit - San Diego Lease [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CompanyPurchasingCardMember" xlink:label="ibio_CompanyPurchasingCardMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CompanyPurchasingCardMember" xlink:to="ibio_CompanyPurchasingCardMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CompanyPurchasingCardMember_lbl" xml:lang="en-US">Information related to the Company purchasing card.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CompanyPurchasingCardMember_lbl" xml:lang="en-US">Company Purchasing Card [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Collateral held</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_Series2PreferredStockMember" xlink:to="ibio_Series2PreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_Series2PreferredStockMember_lbl" xml:lang="en-US">Series A-2 Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_Series2PreferredStockMember_lbl" xml:lang="en-US">Series A-2 Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollaborationOptionAndLicenseAgreementMember" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborationOptionAndLicenseAgreementMember" xlink:to="ibio_CollaborationOptionAndLicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember_lbl" xml:lang="en-US">Collaboration, Option and License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember_lbl" xml:lang="en-US">Collaboration, Option and License Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_lbl" xml:lang="en-US">Immune-Oncology Antibodies (RTX-003) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_lbl" xml:lang="en-US">Immune-Oncology Antibodies (RTX-003) [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:to="ibio_NoBiosimilarProductHasBeenApprovedMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember_lbl" xml:lang="en-US">No Biosimilar Product has been Approved [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember_lbl" xml:lang="en-US">No Biosimilar Product has been Approved [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_lbl" xml:lang="en-US">Represents the information pertaining to College Station Investors LLC And Bryan Capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_lbl" xml:lang="en-US">College Station Investors LLC And Bryan Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IbioCmoPreferredTrackingStockMember" xlink:label="ibio_IbioCmoPreferredTrackingStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IbioCmoPreferredTrackingStockMember" xlink:to="ibio_IbioCmoPreferredTrackingStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IbioCmoPreferredTrackingStockMember_lbl" xml:lang="en-US">Represents the information pertaining to IBio CMO Preferred Tracking Stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IbioCmoPreferredTrackingStockMember_lbl" xml:lang="en-US">IBio CMO Preferred Tracking Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SecuredTermLoanMember" xlink:to="ibio_SecuredTermLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SecuredTermLoanMember_lbl" xml:lang="en-US">Represents the information pertaining to secured term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SecuredTermLoanMember_lbl" xml:lang="en-US">Secured Term Loan</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" xml:lang="en-US">Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" xml:lang="en-US">Purchase Price For Property, Termination of Sublease And Equity Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" xml:lang="en-US">Total purchase price</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" xml:lang="en-US">Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" xml:lang="en-US">Purchase Price For Property, Termination of Sublease And Equity Interest, Cash Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" xml:lang="en-US">Cash payment</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FairMarketValueOfProperty" xlink:to="ibio_FairMarketValueOfProperty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FairMarketValueOfProperty_lbl" xml:lang="en-US">Fair market value of the property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FairMarketValueOfProperty_lbl" xml:lang="en-US">Fair Market Value of Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FairMarketValueOfProperty_lbl" xml:lang="en-US">Fair market value of property</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" xml:lang="en-US">Amount of base rent payable on percentage of fair Market Value of the Property.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" xml:lang="en-US">Base Rent, Percentage of Fair Market Value of Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" xml:lang="en-US">Percentage of base rent</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:to="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" xml:lang="en-US">Consideration transferred for equity interest acquired under the equity agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" xml:lang="en-US">Equity Agreement, Consideration Transferred Equity Interests Acquired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" xml:lang="en-US">Cash consideration for equity interest acquired</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:to="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" xml:lang="en-US">Warrants issued or issuable under the equity agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" xml:lang="en-US">Equity Agreement, Warrants Issued or Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" xml:lang="en-US">Warrants issuable</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:to="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" xml:lang="en-US">Equity agreement, percentage of equity interest issued or issuable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" xml:lang="en-US">Equity Agreement, Percentage of Equity Interest Issued or Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" xml:lang="en-US">Percentage of equity interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Secured term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as percent)</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" xml:lang="en-US">Threshold limit of unrestricted cash to be maintained.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" xml:lang="en-US">Credit Agreement, Threshold Limit, Unrestricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" xml:lang="en-US">Unrestricted cash</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IrrevocableLetterOfCredit" xlink:label="ibio_IrrevocableLetterOfCredit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IrrevocableLetterOfCredit" xlink:to="ibio_IrrevocableLetterOfCredit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IrrevocableLetterOfCredit_lbl" xml:lang="en-US">Irrevocable letter of credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IrrevocableLetterOfCredit_lbl" xml:lang="en-US">Irrevocable letter of credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IrrevocableLetterOfCredit_lbl" xml:lang="en-US">Irrevocable letter of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares of Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants, exercise price per share</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" xml:lang="en-US">Number of warrants issued for the final payment of rent due under sublease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" xml:lang="en-US">Warrants Issued for Final Payment of Sublease Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" xml:lang="en-US">Shares issued under the Warrant</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" xml:lang="en-US">Value of warrants issued for the final payment of rent due under sublease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" xml:lang="en-US">Warrants Issued for Final Payment of Sublease Rent, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" xml:lang="en-US">Fair value of the warrant</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:to="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" xml:lang="en-US">Collaboration and license agreement, royalty payment term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" xml:lang="en-US">Collaboration and License Agreement, Royalty payment term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" xml:lang="en-US">Collaboration and license agreement, royalty payment term</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:to="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" xml:lang="en-US">Collaboration and license agreement, agreement term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" xml:lang="en-US">Collaboration and license agreement, agreement term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" xml:lang="en-US">Collaboration and license agreement, agreement term</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:to="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, number of shares purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, number of shares purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, number of shares purchased</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:to="ibio_StockPurchaseAgreementValueOfSharesPurchased_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, value of shares purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, value of shares purchased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferential dividend rate percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset Acquisition [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_AssetAcquisitionIntangibleAssetsMember" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionIntangibleAssetsMember" xlink:to="ibio_AssetAcquisitionIntangibleAssetsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Intangible Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Intangible Assets [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_AssetAcquisitionPrepaidExpensesMember" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionPrepaidExpensesMember" xlink:to="ibio_AssetAcquisitionPrepaidExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember_lbl" xml:lang="en-US">Asset Acquisition Prepaid Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember_lbl" xml:lang="en-US">Asset Acquisition Prepaid Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Purchase price allocated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US">Receivable Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US">Receivable [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember" xlink:label="us-gaap_NotesReceivableMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableMember" xlink:to="us-gaap_NotesReceivableMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableMember_lbl" xml:lang="en-US">Convertible Promissory Note Receivable [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LoansReceivableAmountInvested" xlink:label="ibio_LoansReceivableAmountInvested" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LoansReceivableAmountInvested" xlink:to="ibio_LoansReceivableAmountInvested_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LoansReceivableAmountInvested_lbl" xml:lang="en-US">Represents the face amount of notes receivable invested.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LoansReceivableAmountInvested_lbl" xml:lang="en-US">Loans Receivable, Amount Invested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LoansReceivableAmountInvested_lbl" xml:lang="en-US">Amount invested</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LoansReceivableFixedRatesOfInterest" xlink:label="ibio_LoansReceivableFixedRatesOfInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LoansReceivableFixedRatesOfInterest" xlink:to="ibio_LoansReceivableFixedRatesOfInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_lbl" xml:lang="en-US">Percentage of fixed rate of interest on notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_lbl" xml:lang="en-US">Loans Receivable, Fixed Rates of Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_lbl" xml:lang="en-US">Interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US">Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US">Debt securities, interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentMaturityDate" xlink:label="us-gaap_InvestmentMaturityDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentMaturityDate" xlink:to="us-gaap_InvestmentMaturityDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentMaturityDate_lbl" xml:lang="en-US">Investment Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentMaturityDate_lbl" xml:lang="en-US">Debt securities, maturity date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Adjusted cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Gross unrealized losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after Two Years, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_lbl" xml:lang="en-US">Disclosure of information about activity in the balance of lessee's right to use underlying asset under finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FacilityMember" xlink:label="ibio_FacilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FacilityMember" xlink:to="ibio_FacilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FacilityMember_lbl" xml:lang="en-US">This member stands for facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FacilityMember_lbl" xml:lang="en-US">Facility [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetGross" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">Gross amount of lessee's right to use underlying asset under finance lease, before accumulated amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">ROU, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Area of Real Estate Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Area of lab and office</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, gross carrying value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total definite lived intangible assets, net of accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Notes Payable [Abstract]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LessorFinanceLeaseMonthlyRent" xlink:label="ibio_LessorFinanceLeaseMonthlyRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LessorFinanceLeaseMonthlyRent" xlink:to="ibio_LessorFinanceLeaseMonthlyRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_lbl" xml:lang="en-US">The amount of rent receivable monthly by the lessor under the finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_lbl" xml:lang="en-US">Lessor, Finance Lease Monthly Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_lbl" xml:lang="en-US">Mobile office trailer monthly rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Finance lease cost:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseObligationOtherInformationAbstract" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseObligationOtherInformationAbstract" xlink:to="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Finance Lease Obligation, Other Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Other Information</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Lease Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement lease liabilities:</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinancingCashFlowsFromFinanceLeaseObligation" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinancingCashFlowsFromFinanceLeaseObligation" xlink:to="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" xml:lang="en-US">The amount of cash outflow for finance lease obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" xml:lang="en-US">Financing Cash Flows From Finance Lease Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" xml:lang="en-US">Financing cash flows from finance lease obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term - finance lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate - Finance lease obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PrincipalMember" xlink:to="ibio_PrincipalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PrincipalMember_lbl" xml:lang="en-US">Information pertaining to principal portion of the obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PrincipalMember_lbl" xml:lang="en-US">Principal [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_InterestMember" xlink:to="ibio_InterestMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_InterestMember_lbl" xml:lang="en-US">Information pertaining to interest portion of the obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_InterestMember_lbl" xml:lang="en-US">Interest [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Finance Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Finance Lease, Liability, Payment, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_lbl" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_lbl" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember_lbl" xml:lang="en-US">Letter of Credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Term of lease</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseMonthlyRent" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseMonthlyRent" xlink:to="ibio_LesseeOperatingLeaseMonthlyRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_lbl" xml:lang="en-US">The amount of rent payable monthly by the lessee under the operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_lbl" xml:lang="en-US">Lessee, Operating Lease Monthly Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_lbl" xml:lang="en-US">Operating lease monthly rent payable</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:to="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" xml:lang="en-US">Lessee Operating Lease, Annual percentage increase in base rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" xml:lang="en-US">Lessee Operating Lease, Annual percentage increase in base rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" xml:lang="en-US">Annual percentage increase in base rent</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_BaseRentAbatementInFirstYearPeriod" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BaseRentAbatementInFirstYearPeriod" xlink:to="ibio_BaseRentAbatementInFirstYearPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_lbl" xml:lang="en-US">Base rent abatement period in the first year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_lbl" xml:lang="en-US">Base Rent Abatement In the First Year, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_lbl" xml:lang="en-US">Base rent abatement period in the first year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Tenant Improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Tenant improvement allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_lbl" xml:lang="en-US">Guarantor Obligations, Maximum Exposure, Undiscounted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_lbl" xml:lang="en-US">Irrevocable letter of credit</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_OperatingLeaseCostsAbstract" xlink:label="ibio_OperatingLeaseCostsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingLeaseCostsAbstract" xlink:to="ibio_OperatingLeaseCostsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingLeaseCostsAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingLeaseCostsAbstract_lbl" xml:lang="en-US">Operating Lease Costs [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_OperatingLeaseCostsAbstract_lbl" xml:lang="en-US">Operating lease cost:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_TotalOperatingLeaseCosts" xlink:label="ibio_TotalOperatingLeaseCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_TotalOperatingLeaseCosts" xlink:to="ibio_TotalOperatingLeaseCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_TotalOperatingLeaseCosts_lbl" xml:lang="en-US">Total operating lease costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_TotalOperatingLeaseCosts_lbl" xml:lang="en-US">Total Operating Lease Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_TotalOperatingLeaseCosts_lbl" xml:lang="en-US">Total lease cost</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_OperatingLeaseObligationOtherInformationAbstract" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingLeaseObligationOtherInformationAbstract" xlink:to="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Operating Lease Obligation Other Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Other information:</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Operating Lease Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement lease liability:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating lease</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_OperatingCashFlowsFromOperatingLeaseObligation" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingCashFlowsFromOperatingLeaseObligation" xlink:to="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" xml:lang="en-US">Operating cash flows from operating lease obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" xml:lang="en-US">Operating Cash Flows From Operating Lease Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" xml:lang="en-US">Operating cash flows from operating lease obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Operating Lease Obligation, Principal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Imputed Interest Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Operating Lease Obligation, Imputed Interest</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year One.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">2027</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" xml:lang="en-US">Imputed Interest, Total</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Operating Lease Obligation, Total</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">2027</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" xml:lang="en-US">Lessee Operating Lease Liability Principal And Imputed Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" xml:lang="en-US">Lessee Operating Lease Liability Principal And Imputed Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" xml:lang="en-US">Principal and imputed interest, Total</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockholdersEquityTable" xlink:label="ibio_StockholdersEquityTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockholdersEquityTable" xlink:to="ibio_StockholdersEquityTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockholdersEquityTable_lbl" xml:lang="en-US">Stockholders' Equity [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ExchangeAgreementMember" xlink:label="ibio_ExchangeAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ExchangeAgreementMember" xlink:to="ibio_ExchangeAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EasternAffiliateMember" xlink:label="ibio_EasternAffiliateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EasternAffiliateMember" xlink:to="ibio_EasternAffiliateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EasternAffiliateMember_lbl" xml:lang="en-US">Information pertaining to Eastern affiliate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EasternAffiliateMember_lbl" xml:lang="en-US">Eastern Affiliate [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PreferredTrackingStockMember" xlink:label="ibio_PreferredTrackingStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PreferredTrackingStockMember" xlink:to="ibio_PreferredTrackingStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PreferredTrackingStockMember_lbl" xml:lang="en-US">iBio CMO Preferred Tracking Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:to="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_lbl" xml:lang="en-US">After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_lbl" xml:lang="en-US">After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IbioCdmoMember" xlink:label="ibio_IbioCdmoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IbioCdmoMember" xlink:to="ibio_IbioCdmoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IbioCdmoMember_lbl" xml:lang="en-US">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IbioCdmoMember_lbl" xml:lang="en-US">Bioprocessing (iBio CDMO) [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockholdersEquityLineItems" xlink:label="ibio_StockholdersEquityLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_StockholdersEquityLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockholdersEquityLineItems_lbl" xml:lang="en-US">Stockholders' Equity [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:to="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" xml:lang="en-US">Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" xml:lang="en-US">Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" xml:lang="en-US">Number of LLC interest units exchanged for each share of preferred tracking stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Proceeds from sale of shares, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Basic and diluted numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Basic and diluted denominator:</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EarningsLossPerCommonShareTable" xlink:label="ibio_EarningsLossPerCommonShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EarningsLossPerCommonShareTable" xlink:to="ibio_EarningsLossPerCommonShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EarningsLossPerCommonShareTable_lbl" xml:lang="en-US">Earnings Loss Per Common Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EarningsLossPerCommonShareLineItems" xlink:label="ibio_EarningsLossPerCommonShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="ibio_EarningsLossPerCommonShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EarningsLossPerCommonShareLineItems_lbl" xml:lang="en-US">Earnings Loss Per Common Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioOneMember" xlink:label="ibio_ScenarioOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioOneMember" xlink:to="ibio_ScenarioOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioOneMember_lbl" xml:lang="en-US">This member stands for scenario one in which the value of maximum award in calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioOneMember_lbl" xml:lang="en-US">Scenario One [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioTwoMember" xlink:label="ibio_ScenarioTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioTwoMember" xlink:to="ibio_ScenarioTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioTwoMember_lbl" xml:lang="en-US">This represents Preferred tracking stock exchanged for units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioTwoMember_lbl" xml:lang="en-US">Scenario Two [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">This member stands for iBio, Inc. 2020 Omnibus Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">2020 Omnibus Equity Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Total number of shares of common stock reserved</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:to="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" xml:lang="en-US">Maximum value of all awards awarded under the Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US">Litigation Case [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US">Litigation Case [Domain]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_lbl" xml:lang="en-US">I Bio Inc Versus Fraunhofer United States of America Incorporated [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_lbl" xml:lang="en-US">iBio, Inc. v. Fraunhofer USA, Inc. [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusAxis_lbl" xml:lang="en-US">Litigation Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_LitigationStatusDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusDomain_lbl" xml:lang="en-US">Litigation Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettledLitigationMember" xlink:to="us-gaap_SettledLitigationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettledLitigationMember_lbl" xml:lang="en-US">Settled Litigation [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US">Scenario, Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioPlanExpectedLegalFeesMember" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioPlanExpectedLegalFeesMember" xlink:to="ibio_ScenarioPlanExpectedLegalFeesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember_lbl" xml:lang="en-US">Scenario Plan, Expected Legal Fees [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember_lbl" xml:lang="en-US">Scenario Plan Expected Legal Fees [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioPlanExpectedPaymentOneMember" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioPlanExpectedPaymentOneMember" xlink:to="ibio_ScenarioPlanExpectedPaymentOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment One [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment One [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:to="ibio_ScenarioPlanExpectedPaymentTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment Two [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment Two [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceMember_lbl" xml:lang="en-US">Service [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndMaintenanceMember" xlink:to="us-gaap_LicenseAndMaintenanceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndMaintenanceMember_lbl" xml:lang="en-US">License and Maintenance [Member]</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:to="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" xml:lang="en-US">Cash payments receivables related to litigation settlement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" xml:lang="en-US">Cash Payments Receivables Related to Litigation Settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" xml:lang="en-US">Cash payments receivables related to litigation settlement</label>
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:to="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" xml:lang="en-US">Percentage of legal fees expected to be received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" xml:lang="en-US">Percentage Of Legal Fees Expected to be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" xml:lang="en-US">Percentage of legal fees expected to be received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingencyUnrecordedAmount" xlink:to="us-gaap_GainContingencyUnrecordedAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainContingencyUnrecordedAmount_lbl" xml:lang="en-US">Gain Contingency, Unrecorded Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainContingencyUnrecordedAmount_lbl" xml:lang="en-US">Estimated net cash recovery</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US">Litigation settlement, amount awarded from other party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US">Settlement income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLegalSettlements" xlink:to="us-gaap_ProceedsFromLegalSettlements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLegalSettlements_lbl" xml:lang="en-US">Proceeds from Legal Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLegalSettlements_lbl" xml:lang="en-US">Settlement payment received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>ibio-20220930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.1.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/14/2022 9:57:43 PM-->
<!--Modified on: 11/14/2022 9:57:43 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#StatementCondensedConsolidatedStatementsOfEquity" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureNatureOfBusiness" roleURI="http://www.ibioinc.com/role/DisclosureNatureOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureBasisOfPresentation" roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentation" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureDiscontinuedOperations" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurement" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSignificantTransactions" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactions" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureConvertiblePromissoryNoteReceivable" roleURI="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureInvestmentsInDebtAndEquitySecurities" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecurities" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseRouAssets" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureOperatingLeaseRouAssets" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFixedAssets" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureIntangibleAssets" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureNotePayablePppLoan" roleURI="http://www.ibioinc.com/role/DisclosureNotePayablePppLoan" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseObligation" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureOperatingLeaseObligation" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureStockholdersEquity" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureEarningsLossPerCommonShare" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureShareBasedCompensation" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensation" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFraunhoferSettlement" roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlement" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureIncomeTaxes" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureContingencies" roleURI="http://www.ibioinc.com/role/DisclosureContingencies" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureEmployee401KPlan" roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlan" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSubsequentEvents" roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureDiscontinuedOperationsTables" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSignificantTransactionsTables" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureInvestmentsInDebtAndEquitySecuritiesTables" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseRouAssetsTables" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureIntangibleAssetsTables" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseObligationTables" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureOperatingLeaseObligationsTables" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureEarningsLossPerCommonShareTables" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureBasisOfPresentationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureDiscontinuedOperationsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRevenueDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSignificantTransactionsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSignificantTransactionsAmendedCreditAgreementDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsAmendedCreditAgreementDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseRouAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureOperatingLeaseRouAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFixedAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureIntangibleAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureNotePayablePppLoanNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureNotePayablePppLoanNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseObligationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureOperatingLeaseObligationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureStockholdersEquityCantorFitzgeraldUnderwritingNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureShareBasedCompensationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureFraunhoferSettlementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureEmployee401KPlanNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureSubsequentEventsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20220930.xsd#DisclosureOperatingLeaseRouAssetsCategoryNetCarryingValuesOfOperatingLeaseRouDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsCategoryNetCarryingValuesOfOperatingLeaseRouDetails" />
  <presentationLink xlink:role="http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638040598585767805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638040598585767805" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638040598585767805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638040598585767805" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638040598585767805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638040598585767805" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638040598585767805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638040598585767805" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638040598585767805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638040598585767805" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638040598585767805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638040598585767805" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638040598585767805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638040598585767805" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638040598585767805" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638040598585767805" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638040598585777727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638040598585777727" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638040598585777727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638040598585777727" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638040598585777727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638040598585777727" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638040598585777727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638040598585777727" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638040598585777727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638040598585777727" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638040598585777727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638040598585777727" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638040598585777727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638040598585777727" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638040598585777727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638040598585777727" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638040598585777727" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638040598585777727" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638040598585787733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638040598585787733" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638040598585787733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638040598585787733" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638040598585787733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638040598585787733" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638040598585787733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638040598585787733" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638040598585787733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638040598585787733" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638040598585787733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638040598585787733" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638040598585787733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638040598585787733" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638040598585797791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638040598585797791" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638040598585797791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638040598585797791" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638040598585797791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638040598585797791" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638040598585797791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638040598585797791" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638040598585797791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638040598585797791" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_26" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638040598585807506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26" xlink:to="us-gaap_AssetsAbstract_638040598585807506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638040598585807506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638040598585807506" xlink:to="us-gaap_AssetsCurrentAbstract_638040598585807506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638040598585807506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638040598585807506" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638040598585807506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638040598585807506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638040598585807506" xlink:to="us-gaap_DebtSecuritiesCurrent_638040598585807506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638040598585807506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638040598585807506" xlink:to="us-gaap_AccountsReceivableNetCurrent_638040598585807506" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent_638040598585807506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638040598585807506" xlink:to="us-gaap_SettlementAssetsCurrent_638040598585807506" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638040598585807506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638040598585807506" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638040598585807506" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638040598585807506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638040598585807506" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638040598585807506" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638040598585807506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638040598585807506" xlink:to="us-gaap_AssetsCurrent_638040598585807506" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638040598585807506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638040598585807506" xlink:to="us-gaap_RestrictedCashNoncurrent_638040598585807506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638040598585817758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638040598585807506" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638040598585817758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638040598585817758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638040598585807506" xlink:to="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638040598585817758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SettlementAssetsNonCurrent" xlink:label="ibio_SettlementAssetsNonCurrent_638040598585817758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638040598585807506" xlink:to="ibio_SettlementAssetsNonCurrent_638040598585817758" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638040598585817758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638040598585807506" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638040598585817758" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638040598585817758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638040598585807506" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638040598585817758" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638040598585817758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638040598585807506" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638040598585817758" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638040598585817758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638040598585807506" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638040598585817758" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent_638040598585817758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638040598585807506" xlink:to="us-gaap_PrepaidExpenseNoncurrent_638040598585817758" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638040598585817758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638040598585807506" xlink:to="us-gaap_SecurityDeposit_638040598585817758" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638040598585827758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638040598585807506" xlink:to="us-gaap_Assets_638040598585827758" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638040598585827758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638040598585827758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638040598585827758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638040598585827758" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638040598585827758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638040598585827758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638040598585827758" xlink:to="us-gaap_AccountsPayableCurrent_638040598585827758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638040598585827758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638040598585827758" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638040598585827758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638040598585827758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638040598585827758" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638040598585827758" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638040598585827758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638040598585827758" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638040598585827758" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638040598585837757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638040598585827758" xlink:to="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638040598585837757" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638040598585837757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638040598585827758" xlink:to="us-gaap_NotesPayableCurrent_638040598585837757" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638040598585837757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638040598585827758" xlink:to="us-gaap_DeferredRevenueCurrent_638040598585837757" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638040598585837757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638040598585827758" xlink:to="us-gaap_LiabilitiesCurrent_638040598585837757" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638040598585837757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638040598585827758" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638040598585837757" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638040598585837757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638040598585827758" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638040598585837757" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_638040598585847517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638040598585827758" xlink:to="ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale_638040598585847517" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638040598585847517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638040598585827758" xlink:to="us-gaap_Liabilities_638040598585847517" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638040598585847517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638040598585827758" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638040598585847517" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638040598585847517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638040598585847517" xlink:to="us-gaap_StockholdersEquityAbstract_638040598585847517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638040598585847517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638040598585847517" xlink:to="us-gaap_PreferredStockValue_638040598585847517" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638040598585847517" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638040598585847517" xlink:to="us-gaap_CommonStockValue_638040598585847517" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638040598585857729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638040598585847517" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638040598585857729" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638040598585857729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638040598585847517" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638040598585857729" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638040598585857729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638040598585847517" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638040598585857729" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638040598585857729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638040598585847517" xlink:to="us-gaap_StockholdersEquity_638040598585857729" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638040598585857729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638040598585827758" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638040598585857729" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638040598585867505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638040598585867505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638040598585867505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638040598585867505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638040598585867505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638040598585867505" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638040598585867505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638040598585867505" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638040598585867505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638040598585867505" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638040598585867505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638040598585867505" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638040598585867505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638040598585867505" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638040598585877746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638040598585877746" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638040598585877746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638040598585877746" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_636900514088604338" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638040598585877746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_Revenues_638040598585877746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638040598585877746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_OperatingExpensesAbstract_638040598585877746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638040598585877746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638040598585877746" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638040598585877746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638040598585877746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638040598585877746" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638040598585877746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638040598585877746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638040598585877746" xlink:to="us-gaap_OperatingExpenses_638040598585877746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638040598585877746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_OperatingIncomeLoss_638040598585877746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638040598585877746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638040598585877746" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638040598585887513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638040598585877746" xlink:to="us-gaap_InvestmentIncomeInterest_638040598585887513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638040598585887513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638040598585887513" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_638040598585887513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_638040598585887513" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638040598585887513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638040598585887513" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock_638040598585887513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_DividendsPreferredStockStock_638040598585887513" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638040598585887513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638040598585887513" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638040598585887513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638040598585887513" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_638040598585887513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="ibio_UnconsolidatedGainLossAttributableToStockholders_638040598585887513" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638040598585887513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638040598585887513" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638040598585897767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638040598585887513" xlink:to="us-gaap_ProfitLoss_638040598585897767" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638040598585897767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638040598585887513" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638040598585897767" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_638040598585897767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_638040598585897767" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638040598585897767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638040598585897767" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638040598585897767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638040598585897767" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638040598585897767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638040598585897767" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638040598585897767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638040598585897767" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638040598585897767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_EarningsPerShareBasic_638040598585897767" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638040598585907767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_EarningsPerShareDiluted_638040598585907767" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638040598585907767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638040598585907767" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638040598585907767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638040598585907767" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical" xlink:type="extended" xlink:title="00205 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_343" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_638040598585907767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_343" xlink:to="us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_638040598585907767" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638040598585907767" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_343" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638040598585907767" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_637045036841541064" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638040598585917758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_637045036841541064" xlink:to="us-gaap_StatementTable_638040598585917758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638040598585917758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598585917758" xlink:to="us-gaap_StatementEquityComponentsAxis_638040598585917758" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638040598585917758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638040598585917758" xlink:to="us-gaap_PreferredStockMember_638040598585917758" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638040598585917758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638040598585917758" xlink:to="us-gaap_CommonStockMember_638040598585917758" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638040598585917758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638040598585917758" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638040598585917758" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638040598585917758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638040598585917758" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638040598585917758" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638040598585917758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638040598585917758" xlink:to="us-gaap_RetainedEarningsMember_638040598585917758" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember_638040598585917758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638040598585917758" xlink:to="us-gaap_NoncontrollingInterestMember_638040598585917758" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638040598585917758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638040598585917758" xlink:to="us-gaap_EquityComponentDomain_638040598585917758" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638040598585917758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598585917758" xlink:to="us-gaap_StatementLineItems_638040598585917758" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638040598585917758" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638040598585917758" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638040598585927500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_SharesOutstanding_638040598585927500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_638040598585927500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise_638040598585927500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_638040598585927500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise_638040598585927500" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_638040598585927500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue_638040598585927500" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CommonStockIssuedInRubrycTransactionInShares" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares_638040598585927500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="ibio_CommonStockIssuedInRubrycTransactionInShares_638040598585927500" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638040598585927500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638040598585927500" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638040598585927500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638040598585927500" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638040598585927500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638040598585927500" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638040598585937486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638040598585937486" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638040598585937486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638040598585937486" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638040598585937486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638040598585937486" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638040598585937486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_NetIncomeLoss_638040598585937486" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_638040598585937486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_638040598585937486" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638040598585937486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_ProfitLoss_638040598585937486" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638040598585937486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638040598585937486" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638040598585937486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598585917758" xlink:to="us-gaap_SharesOutstanding_638040598585937486" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638040598585947781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="us-gaap_ProfitLoss_638040598585947781" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638040598586037711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="us-gaap_ShareBasedCompensation_638040598586037711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638040598586037711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638040598586037711" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638040598586037711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638040598586037711" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638040598586037711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638040598586037711" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638040598586037711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="us-gaap_Depreciation_638040598586037711" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638040598586037711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638040598586037711" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638040598586037711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638040598586037711" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_638040598586047710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_638040598586047710" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IncreaseDecreaseInInventoryReserve" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_638040598586047710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="ibio_IncreaseDecreaseInInventoryReserve_638040598586047710" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan" xlink:label="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_638040598586047710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan_638040598586047710" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SettlementOfRevenueContract" xlink:label="ibio_SettlementOfRevenueContract_638040598586047710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="ibio_SettlementOfRevenueContract_638040598586047710" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638040598586047710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638040598586047710" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638040598586047710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638040598586047710" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638040598586047710" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638040598586047710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638040598586047710" xlink:to="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638040598586047710" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638040598586047710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638040598586047710" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638040598586047710" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638040598586047710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638040598586047710" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638040598586047710" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638040598586057730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638040598586047710" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638040598586057730" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638040598586057730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638040598586047710" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638040598586057730" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638040598586057730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638040598586047710" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638040598586057730" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638040598586057730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638040598586047710" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638040598586057730" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598586067549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638040598585947781" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638040598586067549" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638040598586067549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638040598586067549" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_638040598586067549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638040598586067549" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_638040598586067549" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638040598586077712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638040598586067549" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638040598586077712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:label="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_638040598586077712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638040598586067549" xlink:to="us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_638040598586077712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638040598586077712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638040598586067549" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638040598586077712" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638040598586077712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638040598586067549" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638040598586077712" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638040598586077712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638040598586067549" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638040598586077712" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638040598586077712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638040598586067549" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638040598586077712" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638040598586077712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638040598586077712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638040598586087500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638040598586077712" xlink:to="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638040598586087500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638040598586087500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638040598586077712" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638040598586087500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638040598586087500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638040598586077712" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638040598586087500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638040598586087500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638040598586087500" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638040598586087500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638040598586087500" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6380405985860875001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6380405985860875001" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities" xlink:label="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_638040598586097722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities_638040598586097722" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IncreaseDecreaeInOperatingLeaseObligations" xlink:label="ibio_IncreaseDecreaeInOperatingLeaseObligations_638040598586097722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="ibio_IncreaseDecreaeInOperatingLeaseObligations_638040598586097722" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638040598586097722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638040598586097722" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_638040598586097722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_638040598586097722" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_638040598586107733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_638040598586107733" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LeaseIncentiveForConstructionInProgress" xlink:label="ibio_LeaseIncentiveForConstructionInProgress_638040598586107733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="ibio_LeaseIncentiveForConstructionInProgress_638040598586107733" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_UnpaidFixedAssetsIncludedInAccountsPayable" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_638040598586107733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_638040598586107733" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementValueOfSharesToBePurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesToBePurchased_638040598586107733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="ibio_StockPurchaseAgreementValueOfSharesToBePurchased_638040598586107733" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_638040598586107733" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_638040598586107733" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LeaseIncentiveForConstructionInProgress" xlink:label="ibio_LeaseIncentiveForConstructionInProgress_6380405985861077331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="ibio_LeaseIncentiveForConstructionInProgress_6380405985861077331" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NonCashSettlementOfRevenueContract" xlink:label="ibio_NonCashSettlementOfRevenueContract_638040598586117729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="ibio_NonCashSettlementOfRevenueContract_638040598586117729" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_638040598586117729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue_638040598586117729" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets" xlink:label="ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets_638040598586117729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638040598586097722" xlink:to="ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets_638040598586117729" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638040598586117729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638040598586117729" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638040598586127508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638040598586117729" xlink:to="us-gaap_InterestPaidNet_638040598586127508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of Business">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638040598586127508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638040598586127508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of Presentation">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_BasisOfPresentationAbstract" xlink:label="ibio_BasisOfPresentationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638040598586127508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638040598586127508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" xlink:type="extended" xlink:title="10301 - Disclosure - Discontinued Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_638040598586137730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_638040598586137730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10401 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638040598586137730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638040598586137730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" xlink:type="extended" xlink:title="10501 - Disclosure - Financial Instruments and Fair Value Measurement">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638040598586137730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638040598586137730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactions" xlink:type="extended" xlink:title="10601 - Disclosure - Significant Transactions">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SignificantTransactionsTextBlock" xlink:label="ibio_SignificantTransactionsTextBlock_638040598586137730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="ibio_SignificantTransactionsTextBlock_638040598586137730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable" xlink:type="extended" xlink:title="10701 - Disclosure - Convertible Promissory Note Receivable">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638040598586147725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638040598586147725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecurities" xlink:type="extended" xlink:title="10801 - Disclosure - Investments in Debt and Equity Securities">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638040598586147725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638040598586147725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets" xlink:type="extended" xlink:title="10901 - Disclosure - Finance Lease ROU Assets">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_638040598586147725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_638040598586147725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets" xlink:type="extended" xlink:title="11001 - Disclosure - Operating Lease ROU Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_638040598586147725" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_638040598586147725" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssets" xlink:type="extended" xlink:title="11101 - Disclosure - Fixed Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638040598586157730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638040598586157730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssets" xlink:type="extended" xlink:title="11201 - Disclosure - Intangible Assets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_638040598586157730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_638040598586157730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureNotePayablePppLoan" xlink:type="extended" xlink:title="11301 - Disclosure - Note Payable - PPP Loan">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NotesPayablePppLoanDisclosureTextblock" xlink:label="ibio_NotesPayablePppLoanDisclosureTextblock_638040598586157730" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="ibio_NotesPayablePppLoanDisclosureTextblock_638040598586157730" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation" xlink:type="extended" xlink:title="11401 - Disclosure - Finance Lease Obligation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_638040598586167494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_638040598586167494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation" xlink:type="extended" xlink:title="11501 - Disclosure - Operating Lease Obligation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638040598586167494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638040598586167494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11601 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638040598586167494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638040598586167494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare" xlink:type="extended" xlink:title="11701 - Disclosure - Earnings (Loss) Per Common Share">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638040598586167494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638040598586167494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="11801 - Disclosure - Share-Based Compensation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638040598586177717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638040598586177717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFraunhoferSettlement" xlink:type="extended" xlink:title="11901 - Disclosure - Fraunhofer Settlement">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_GainLossRelatedToLitigationSettlementTextBlock" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_638040598586177717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:to="ibio_GainLossRelatedToLitigationSettlementTextBlock_638040598586177717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="12001 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638040598586177717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638040598586177717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureContingencies" xlink:type="extended" xlink:title="12101 - Disclosure - Contingencies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638040598586177717" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638040598586177717" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEmployee401KPlan" xlink:type="extended" xlink:title="12201 - Disclosure - Employee 401(K) Plan">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638040598586187738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638040598586187738" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="12301 - Disclosure - Subsequent Events">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638040598586187738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638040598586187738" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20402 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638040598586187738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638040598586187738" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638040598586187738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638040598586187738" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638040598586187738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638040598586187738" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ContractAssetsPolicyTextBlock" xlink:label="ibio_ContractAssetsPolicyTextBlock_638040598586187738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibio_ContractAssetsPolicyTextBlock_638040598586187738" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ContractLiabilitiesPolicyTextBlock" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_638040598586197722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibio_ContractLiabilitiesPolicyTextBlock_638040598586197722" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638040598586197722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638040598586197722" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638040598586197722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638040598586197722" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_638040598586197722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_638040598586197722" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638040598586197722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_638040598586197722" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638040598586197722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638040598586197722" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_RightOfUseAssetsPolicyPolicyTextBlock" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_638040598586197722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibio_RightOfUseAssetsPolicyPolicyTextBlock_638040598586197722" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638040598586197722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638040598586197722" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_638040598586197722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_638040598586197722" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638040598586197722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638040598586197722" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638040598586197722" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638040598586197722" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638040598586207732" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638040598586207732" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Discontinued Operations (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_638040598586207732" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_638040598586207732" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638040598586207732" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638040598586207732" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Significant Transactions (Tables)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638040598586217710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="us-gaap_StatementTable_638040598586217710" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638040598586217710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586217710" xlink:to="us-gaap_TypeOfArrangementAxis_638040598586217710" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638040598586217710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638040598586217710" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638040598586217710" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember_638040598586217710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638040598586217710" xlink:to="ibio_StockPurchaseAgreementMember_638040598586217710" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638040598586217710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638040598586217710" xlink:to="ibio_RubrycTheraputicsInc.Member_638040598586217710" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638040598586217710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586217710" xlink:to="us-gaap_StatementLineItems_638040598586217710" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_638040598586217710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586217710" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_638040598586217710" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Investments in Debt and Equity Securities (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_638040598586227737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_638040598586227737" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_638040598586227737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_638040598586227737" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables" xlink:type="extended" xlink:title="30903 - Disclosure - Finance Lease ROU Assets (Tables)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_638040598586227737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_638040598586227737" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables" xlink:type="extended" xlink:title="31203 - Disclosure - Intangible Assets (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638040598586227737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638040598586227737" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables" xlink:type="extended" xlink:title="31403 - Disclosure - Finance Lease Obligation (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_638040598586227737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_638040598586227737" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock" xlink:label="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock_638040598586237776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock_638040598586237776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638040598586237776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638040598586237776" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables" xlink:type="extended" xlink:title="31503 - Disclosure - Operating Lease Obligations (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_638040598586237776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_638040598586237776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638040598586237776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638040598586237776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables" xlink:type="extended" xlink:title="31703 - Disclosure - Earnings (Loss) Per Common Share (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638040598586237776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638040598586237776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638040598586237776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638040598586237776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="31803 - Disclosure - Share-Based Compensation (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638040598586247505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638040598586247505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638040598586247505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638040598586247505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_BasisOfPresentationAbstract" xlink:label="ibio_BasisOfPresentationAbstract_637045036841780422" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CashAndCashEquivalentsPlusDebtSecurities" xlink:label="ibio_CashAndCashEquivalentsPlusDebtSecurities_638040598586247505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract_637045036841780422" xlink:to="ibio_CashAndCashEquivalentsPlusDebtSecurities_638040598586247505" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638040598586247505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract_637045036841780422" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638040598586247505" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_638040598586247505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract_637045036841780422" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise_638040598586247505" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_638040598586247505" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract_637045036841780422" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise_638040598586247505" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Discontinued Operations (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EmployeeReductionExpenses" xlink:label="ibio_EmployeeReductionExpenses_638040598586257523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" xlink:to="ibio_EmployeeReductionExpenses_638040598586257523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638040598586257523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638040598586257523" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_638040598586257523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_638040598586257523" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_638040598586257523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_638040598586257523" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_638040598586257523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" xlink:to="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_638040598586257523" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_638040598586257523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_638040598586257523" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638040598586257523" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638040598586257523" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_638040598586267556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_638040598586267556" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupInterestExpenseRelatedParty" xlink:label="ibio_DisposalGroupInterestExpenseRelatedParty_638040598586267556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" xlink:to="ibio_DisposalGroupInterestExpenseRelatedParty_638040598586267556" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupGainOnDebtForgiveness" xlink:label="ibio_DisposalGroupGainOnDebtForgiveness_638040598586267556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" xlink:to="ibio_DisposalGroupGainOnDebtForgiveness_638040598586267556" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_638040598586267556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" xlink:to="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_638040598586267556" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_638040598586267556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_638040598586267556" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638040598586267556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638040598586257523" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638040598586267556" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638040598586267556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638040598586267556" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638040598586267556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638040598586267556" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638040598586267556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_638040598586267556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638040598586267556" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_638040598586267556" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_638040598586267556" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638040598586267556" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_638040598586267556" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_638040598586277745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638040598586267556" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_638040598586277745" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_638040598586277745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638040598586267556" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_638040598586277745" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638040598586277745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638040598586267556" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638040598586277745" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_638040598586277745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638040598586277745" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_638040598586277745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_638040598586277745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638040598586277745" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent_638040598586277745" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638040598586277745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638040598586277745" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_638040598586277745" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638040598586277745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638040598586267556" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638040598586277745" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_638040598586287530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638040598586277745" xlink:to="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_638040598586287530" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638040598586287530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638040598586267556" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638040598586287530" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupNoncurrentOperatingLeaseObligations" xlink:label="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_638040598586287530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_638040598586287530" xlink:to="ibio_DisposalGroupNoncurrentOperatingLeaseObligations_638040598586287530" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638040598586287530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638040598586267556" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638040598586287530" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_638040598586287530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638040598586287530" xlink:to="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_638040598586287530" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_638040598586287530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638040598586287530" xlink:to="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_638040598586287530" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_638040598586287530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638040598586287530" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_638040598586287530" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638040598586297496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638040598586287530" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638040598586297496" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_638040598586297496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638040598586297496" xlink:to="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_638040598586297496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_638040598586297496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638040598586297496" xlink:to="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_638040598586297496" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_189" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638040598586297496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_189" xlink:to="us-gaap_StatementTable_638040598586297496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638040598586297496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586297496" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638040598586297496" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638040598586307753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638040598586297496" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638040598586307753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember_638040598586307753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638040598586307753" xlink:to="us-gaap_PatentsMember_638040598586307753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638040598586307753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638040598586307753" xlink:to="us-gaap_IntellectualPropertyMember_638040598586307753" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638040598586307753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586297496" xlink:to="srt_RangeAxis_638040598586307753" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638040598586307753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638040598586307753" xlink:to="srt_RangeMember_638040598586307753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638040598586307753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638040598586307753" xlink:to="srt_MinimumMember_638040598586307753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638040598586307753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638040598586307753" xlink:to="srt_MaximumMember_638040598586307753" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638040598586307753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586297496" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638040598586307753" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638040598586307753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638040598586307753" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638040598586307753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_638040598586307753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638040598586307753" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_638040598586307753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638040598586317514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586297496" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638040598586317514" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638040598586317514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638040598586317514" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638040598586317514" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638040598586317514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638040598586317514" xlink:to="us-gaap_CustomerConcentrationRiskMember_638040598586317514" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586297496" xlink:to="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLossOnContracts" xlink:label="us-gaap_ProvisionForLossOnContracts_638040598586317514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" xlink:to="us-gaap_ProvisionForLossOnContracts_638040598586317514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_638040598586317514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_638040598586317514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638040598586317514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" xlink:to="us-gaap_DeferredRevenueCurrent_638040598586317514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638040598586317514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638040598586317514" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage_638040598586317514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" xlink:to="us-gaap_LeasePracticalExpedientsPackage_638040598586317514" order="5" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638040598586327498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638040598586327498" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638040598586327498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638040598586327498" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:label="us-gaap_GoodwillAndIntangibleAssetImpairment_638040598586327498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" xlink:to="us-gaap_GoodwillAndIntangibleAssetImpairment_638040598586327498" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638040598586327498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638040598586327498" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638040598586327498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638040598586327498" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount_638040598586327498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" xlink:to="us-gaap_CashUninsuredAmount_638040598586327498" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NumberOfMajorCustomers" xlink:label="ibio_NumberOfMajorCustomers_638040598586327498" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638040598586317514" xlink:to="ibio_NumberOfMajorCustomers_638040598586327498" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Summary of Significant Accounting Policies - Revenue (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638040598586337487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_Revenues_638040598586337487" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638040598586337487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638040598586337487" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638040598586337487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586337487" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638040598586337487" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638040598586337487" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638040598586337487" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638040598586337487" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LetterOfCreditTermLoanMember" xlink:label="ibio_LetterOfCreditTermLoanMember_638040598586347772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638040598586337487" xlink:to="ibio_LetterOfCreditTermLoanMember_638040598586347772" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LetterOfCreditSanDiegoLeaseMember" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember_638040598586347772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638040598586337487" xlink:to="ibio_LetterOfCreditSanDiegoLeaseMember_638040598586347772" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CompanyPurchasingCardMember" xlink:label="ibio_CompanyPurchasingCardMember_638040598586347772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638040598586337487" xlink:to="ibio_CompanyPurchasingCardMember_638040598586347772" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638040598586347772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586337487" xlink:to="us-gaap_StatementLineItems_638040598586347772" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638040598586347772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586347772" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638040598586347772" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638040598586347772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638040598586347772" xlink:to="us-gaap_RestrictedCashNoncurrent_638040598586347772" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638040598586347772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638040598586347772" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638040598586347772" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638040598586347772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638040598586347772" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638040598586347772" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638040598586347772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638040598586347772" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638040598586347772" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Significant Transactions (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638040598586357772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="us-gaap_StatementTable_638040598586357772" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638040598586357772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586357772" xlink:to="us-gaap_StatementClassOfStockAxis_638040598586357772" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638040598586357772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638040598586357772" xlink:to="us-gaap_ClassOfStockDomain_638040598586357772" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember_638040598586357772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638040598586357772" xlink:to="ibio_Series2PreferredStockMember_638040598586357772" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638040598586357772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586357772" xlink:to="us-gaap_TypeOfArrangementAxis_638040598586357772" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638040598586357772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638040598586357772" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638040598586357772" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollaborationOptionAndLicenseAgreementMember" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember_638040598586357772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638040598586357772" xlink:to="ibio_CollaborationOptionAndLicenseAgreementMember_638040598586357772" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember_638040598586357772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638040598586357772" xlink:to="ibio_StockPurchaseAgreementMember_638040598586357772" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638040598586357772" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586357772" xlink:to="srt_ProductOrServiceAxis_638040598586357772" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638040598586367578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638040598586357772" xlink:to="srt_ProductsAndServicesDomain_638040598586367578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_638040598586367578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638040598586367578" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member_638040598586367578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638040598586367578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586357772" xlink:to="srt_StatementScenarioAxis_638040598586367578" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638040598586367578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638040598586367578" xlink:to="srt_ScenarioUnspecifiedDomain_638040598586367578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember_638040598586367578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638040598586367578" xlink:to="ibio_NoBiosimilarProductHasBeenApprovedMember_638040598586367578" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638040598586367578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586357772" xlink:to="srt_CounterpartyNameAxis_638040598586367578" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638040598586367578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638040598586367578" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638040598586367578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_RubrycTheraputicsInc.Member" xlink:label="ibio_RubrycTheraputicsInc.Member_638040598586367578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638040598586367578" xlink:to="ibio_RubrycTheraputicsInc.Member_638040598586367578" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638040598586377759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638040598586367578" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638040598586377759" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638040598586377759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586357772" xlink:to="dei_LegalEntityAxis_638040598586377759" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638040598586377759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638040598586377759" xlink:to="dei_EntityDomain_638040598586377759" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IbioCmoPreferredTrackingStockMember" xlink:label="ibio_IbioCmoPreferredTrackingStockMember_638040598586377759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638040598586377759" xlink:to="ibio_IbioCmoPreferredTrackingStockMember_638040598586377759" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638040598586377759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586357772" xlink:to="us-gaap_DebtInstrumentAxis_638040598586377759" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638040598586377759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638040598586377759" xlink:to="us-gaap_DebtInstrumentNameDomain_638040598586377759" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember_638040598586377759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638040598586377759" xlink:to="ibio_SecuredTermLoanMember_638040598586377759" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638040598586377759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586357772" xlink:to="us-gaap_StatementLineItems_638040598586377759" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_638040598586387756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_638040598586387756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_638040598586387756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_638040598586387756" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty_638040598586387756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_FairMarketValueOfProperty_638040598586387756" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638040598586387756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638040598586387756" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_638040598586387756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_638040598586387756" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_638040598586387756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_EquityAgreementWarrantsIssuedOrIssuable_638040598586387756" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_638040598586387756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_638040598586387756" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638040598586397777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="us-gaap_DebtInstrumentFaceAmount_638040598586397777" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638040598586397777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638040598586397777" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638040598586397777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638040598586397777" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IrrevocableLetterOfCredit" xlink:label="ibio_IrrevocableLetterOfCredit_638040598586397777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_IrrevocableLetterOfCredit_638040598586397777" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_638040598586397777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_638040598586397777" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638040598586407496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638040598586407496" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638040598586407496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638040598586407496" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_638040598586407496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_638040598586407496" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_638040598586407496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_638040598586407496" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_638040598586407496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_638040598586407496" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_638040598586407496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_CollaborationAndLicenseAgreementAgreementTerm_638040598586407496" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_638040598586417514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_StockPurchaseAgreementNumberOfSharesPurchased_638040598586417514" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased_638040598586417514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_StockPurchaseAgreementValueOfSharesPurchased_638040598586417514" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockPurchaseAgreementValueOfSharesToBePurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesToBePurchased_638040598586417514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="ibio_StockPurchaseAgreementValueOfSharesToBePurchased_638040598586417514" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638040598586417514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586377759" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638040598586417514" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638040598586427777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="us-gaap_StatementTable_638040598586427777" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638040598586427777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586427777" xlink:to="us-gaap_AssetAcquisitionAxis_638040598586427777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638040598586427777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638040598586427777" xlink:to="us-gaap_AssetAcquisitionDomain_638040598586427777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember_638040598586427777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638040598586427777" xlink:to="ibio_Series2PreferredStockMember_638040598586427777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_AssetAcquisitionIntangibleAssetsMember" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember_638040598586427777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638040598586427777" xlink:to="ibio_AssetAcquisitionIntangibleAssetsMember_638040598586427777" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_AssetAcquisitionPrepaidExpensesMember" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember_638040598586427777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638040598586427777" xlink:to="ibio_AssetAcquisitionPrepaidExpensesMember_638040598586427777" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638040598586427777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586427777" xlink:to="us-gaap_StatementLineItems_638040598586427777" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_638040598586427777" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586427777" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_638040598586427777" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsAmendedCreditAgreementDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Significant Transactions - Amended Credit Agreement (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638040598586437780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract_1" xlink:to="us-gaap_NotesPayableCurrent_638040598586437780" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Promissory Note Receivable (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638040598586437780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638040598586437780" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638040598586437780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638040598586437780" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638040598586437780" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_638040598586437780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638040598586437780" xlink:to="us-gaap_ReceivableTypeDomain_638040598586437780" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesReceivableMember" xlink:label="us-gaap_NotesReceivableMember_638040598586437780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain_638040598586437780" xlink:to="us-gaap_NotesReceivableMember_638040598586437780" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_638040598586437780" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638040598586437780" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_638040598586437780" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LoansReceivableAmountInvested" xlink:label="ibio_LoansReceivableAmountInvested_638040598586447723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638040598586437780" xlink:to="ibio_LoansReceivableAmountInvested_638040598586447723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LoansReceivableFixedRatesOfInterest" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_638040598586447723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638040598586437780" xlink:to="ibio_LoansReceivableFixedRatesOfInterest_638040598586447723" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638040598586447723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638040598586437780" xlink:to="us-gaap_InvestmentIncomeInterest_638040598586447723" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Investments in Debt and Equity Securities (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638040598586447723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_StatementTable_638040598586447723" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638040598586447723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586447723" xlink:to="srt_RangeAxis_638040598586447723" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638040598586447723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638040598586447723" xlink:to="srt_RangeMember_638040598586447723" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638040598586447723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638040598586447723" xlink:to="srt_MinimumMember_638040598586447723" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638040598586447723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638040598586447723" xlink:to="srt_MaximumMember_638040598586447723" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638040598586447723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586447723" xlink:to="us-gaap_StatementLineItems_638040598586447723" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate" xlink:label="us-gaap_InvestmentInterestRate_638040598586457710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586447723" xlink:to="us-gaap_InvestmentInterestRate_638040598586457710" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentMaturityDate" xlink:label="us-gaap_InvestmentMaturityDate_638040598586457710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586447723" xlink:to="us-gaap_InvestmentMaturityDate_638040598586457710" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638040598586457710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586447723" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638040598586457710" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Investments in Debt and Equity Securities (Components of Investments in Debt Securities) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638040598586457710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638040598586457710" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638040598586457710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638040598586457710" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638040598586457710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesCurrent_638040598586457710" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Investments in Debt and Equity Securities (Debt Securities, Contractual Maturity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638040598586467940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638040598586467940" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_638040598586467940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638040598586467940" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_638040598586467940" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638040598586467940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638040598586467940" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638040598586467940" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrent" xlink:label="us-gaap_DebtSecuritiesCurrent_638040598586467940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract_638040598586467940" xlink:to="us-gaap_DebtSecuritiesCurrent_638040598586467940" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638040598586477495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638040598586477495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638040598586477495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638040598586477495" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638040598586477495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638040598586477495" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638040598586477495" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638040598586477495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638040598586477495" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638040598586477495" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FacilityMember" xlink:label="ibio_FacilityMember_638040598586477495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638040598586477495" xlink:to="ibio_FacilityMember_638040598586477495" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638040598586477495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638040598586477495" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638040598586477495" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_638040598586477495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638040598586477495" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross_638040598586477495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638040598586487712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638040598586477495" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638040598586487712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638040598586487712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638040598586477495" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638040598586487712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_638040598586487712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty_638040598586487712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638040598586487712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638040598586487712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Fixed Assets (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637045036842019774" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638040598586487712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637045036842019774" xlink:to="us-gaap_Depreciation_638040598586487712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637045036841999830" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638040598586497502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637045036841999830" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638040598586497502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Intangible Assets (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842069641" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638040598586497502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842069641" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638040598586497502" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638040598586497502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638040598586497502" xlink:to="srt_RangeAxis_638040598586497502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638040598586497502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638040598586497502" xlink:to="srt_RangeMember_638040598586497502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638040598586497502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638040598586497502" xlink:to="srt_MaximumMember_638040598586497502" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638040598586497502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638040598586497502" xlink:to="srt_MinimumMember_638040598586497502" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638040598586497502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638040598586497502" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638040598586497502" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638040598586507504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638040598586497502" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638040598586507504" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember_638040598586507504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638040598586507504" xlink:to="us-gaap_PatentsMember_638040598586507504" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638040598586507504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638040598586507504" xlink:to="us-gaap_IntellectualPropertyMember_638040598586507504" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638040598586507504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638040598586497502" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638040598586507504" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638040598586507504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638040598586507504" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638040598586507504" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638040598586507504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638040598586507504" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638040598586507504" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842049705" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638040598586507504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842049705" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638040598586507504" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638040598586507504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638040598586507504" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638040598586507504" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638040598586507504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638040598586507504" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638040598586507504" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638040598586517773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638040598586507504" xlink:to="us-gaap_IntellectualPropertyMember_638040598586517773" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember_638040598586517773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638040598586507504" xlink:to="us-gaap_PatentsMember_638040598586517773" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638040598586517773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638040598586507504" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638040598586517773" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638040598586517773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638040598586517773" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638040598586517773" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638040598586517773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638040598586517773" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638040598586517773" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638040598586517773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638040598586517773" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638040598586517773" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638040598586517773" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638040598586517773" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638040598586517773" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Intangible Assets (Estimated Annual Amortization Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638040598586527509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638040598586527509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureNotePayablePppLoanNarrativeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Note Payable - PPP Loan (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638040598586527509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableCurrent_638040598586527509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Finance Lease Obligation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract_637567665964848090" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LessorFinanceLeaseMonthlyRent" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_638040598586527509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_637567665964848090" xlink:to="ibio_LessorFinanceLeaseMonthlyRent_638040598586527509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638040598586537509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract_638040598586537509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638040598586537509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638040598586537509" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638040598586537509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638040598586537509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638040598586537509" xlink:to="us-gaap_FinanceLeaseInterestExpense_638040598586537509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638040598586537509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638040598586537509" xlink:to="us-gaap_LeaseCost_638040598586537509" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinanceLeaseObligationOtherInformationAbstract" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_638040598586537509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ibio_FinanceLeaseObligationOtherInformationAbstract_638040598586537509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638040598586537509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseObligationOtherInformationAbstract_638040598586537509" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638040598586537509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FinancingCashFlowsFromFinanceLeaseObligation" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_638040598586537509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638040598586537509" xlink:to="ibio_FinancingCashFlowsFromFinanceLeaseObligation_638040598586537509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638040598586537509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638040598586537509" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638040598586537509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638040598586537509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638040598586537509" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638040598586537509" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638040598586537509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638040598586537509" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638040598586537509" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638040598586537509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638040598586537509" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638040598586537509" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638040598586547531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638040598586537509" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638040598586547531" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" xlink:type="extended" xlink:title="41404 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638040598586547531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_StatementTable_638040598586547531" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638040598586547531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586547531" xlink:to="us-gaap_LeaseContractualTermAxis_638040598586547531" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638040598586547531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638040598586547531" xlink:to="us-gaap_LeaseContractualTermDomain_638040598586547531" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember_638040598586547531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638040598586547531" xlink:to="ibio_PrincipalMember_638040598586547531" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember_638040598586547531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638040598586547531" xlink:to="ibio_InterestMember_638040598586547531" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638040598586547531" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586547531" xlink:to="us-gaap_StatementLineItems_638040598586547531" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638040598586557474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586547531" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638040598586557474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638040598586557474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586547531" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638040598586557474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638040598586557474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586547531" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_638040598586557474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638040598586557474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586547531" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638040598586557474" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638040598586557474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586547531" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638040598586557474" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638040598586557474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586547531" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638040598586557474" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Operating Lease Obligation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638040598586557474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_StatementTable_638040598586557474" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638040598586568012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586557474" xlink:to="srt_CounterpartyNameAxis_638040598586568012" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638040598586568012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638040598586568012" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638040598586568012" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638040598586568012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638040598586568012" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638040598586568012" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638040598586568012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586557474" xlink:to="srt_RangeAxis_638040598586568012" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638040598586568012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638040598586568012" xlink:to="srt_RangeMember_638040598586568012" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638040598586568012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638040598586568012" xlink:to="srt_MinimumMember_638040598586568012" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638040598586568012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638040598586568012" xlink:to="srt_MaximumMember_638040598586568012" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_638040598586568012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586557474" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis_638040598586568012" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_638040598586568012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis_638040598586568012" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_638040598586568012" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember_638040598586568012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsNatureDomain_638040598586568012" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember_638040598586568012" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638040598586568012" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586557474" xlink:to="us-gaap_StatementLineItems_638040598586568012" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty_638040598586577711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586568012" xlink:to="ibio_FairMarketValueOfProperty_638040598586577711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638040598586577711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586568012" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638040598586577711" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_638040598586577711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586568012" xlink:to="us-gaap_AreaOfRealEstateProperty_638040598586577711" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638040598586577711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586568012" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638040598586577711" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseMonthlyRent" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_638040598586577711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586568012" xlink:to="ibio_LesseeOperatingLeaseMonthlyRent_638040598586577711" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_638040598586577711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586568012" xlink:to="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_638040598586577711" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_BaseRentAbatementInFirstYearPeriod" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_638040598586577711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586568012" xlink:to="ibio_BaseRentAbatementInFirstYearPeriod_638040598586577711" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements_638040598586577711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586568012" xlink:to="us-gaap_TenantImprovements_638040598586577711" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_638040598586577711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586568012" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure_638040598586577711" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_OperatingLeaseCostsAbstract" xlink:label="ibio_OperatingLeaseCostsAbstract_638040598586587710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_OperatingLeaseCostsAbstract_638040598586587710" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638040598586587710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_OperatingLeaseCostsAbstract_638040598586587710" xlink:to="us-gaap_OperatingLeaseCost_638040598586587710" order="1" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_TotalOperatingLeaseCosts" xlink:label="ibio_TotalOperatingLeaseCosts_638040598586587710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_OperatingLeaseCostsAbstract_638040598586587710" xlink:to="ibio_TotalOperatingLeaseCosts_638040598586587710" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_OperatingLeaseObligationOtherInformationAbstract" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_638040598586587710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_OperatingLeaseObligationOtherInformationAbstract_638040598586587710" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638040598586587710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_OperatingLeaseObligationOtherInformationAbstract_638040598586587710" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638040598586587710" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638040598586587710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638040598586587710" xlink:to="us-gaap_OperatingLeasePayments_638040598586587710" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_OperatingCashFlowsFromOperatingLeaseObligation" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_638040598586587710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638040598586587710" xlink:to="ibio_OperatingCashFlowsFromOperatingLeaseObligation_638040598586587710" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638040598586587710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638040598586587710" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638040598586597711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638040598586597711" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638040598586597711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638040598586597711" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638040598586597711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638040598586597711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638040598586597711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638040598586597711" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638040598586597711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638040598586597711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638040598586597711" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638040598586597711" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638040598586597711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638040598586597711" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638040598586597711" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638040598586597711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638040598586597711" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638040598586597711" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638040598586607500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638040598586597711" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638040598586607500" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638040598586607500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638040598586597711" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638040598586607500" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638040598586607500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638040598586597711" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638040598586607500" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638040598586607500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638040598586597711" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638040598586607500" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638040598586607500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638040598586597711" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638040598586607500" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638040598586607500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638040598586607500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638040598586607500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638040598586607500" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638040598586607500" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638040598586607500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638040598586607500" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638040598586607500" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638040598586607500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638040598586607500" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638040598586607500" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638040598586607500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638040598586607500" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638040598586607500" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638040598586607500" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638040598586607500" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638040598586607500" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638040598586617734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638040598586607500" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638040598586617734" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638040598586617734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638040598586607500" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638040598586617734" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638040598586617734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638040598586617734" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638040598586617734" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638040598586617734" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638040598586617734" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638040598586677810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638040598586617734" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638040598586677810" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638040598586677810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638040598586617734" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638040598586677810" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638040598586677810" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638040598586617734" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638040598586677810" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638040598586687502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638040598586617734" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638040598586687502" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638040598586687502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638040598586617734" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638040598586687502" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_638040598586687502" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638040598586617734" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_638040598586687502" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Stockholders' Equity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_355" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockholdersEquityTable" xlink:label="ibio_StockholdersEquityTable_638040598586697737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_355" xlink:to="ibio_StockholdersEquityTable_638040598586697737" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638040598586697737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638040598586697737" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638040598586697737" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638040598586697737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638040598586697737" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638040598586697737" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ExchangeAgreementMember" xlink:label="ibio_ExchangeAgreementMember_638040598586697737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638040598586697737" xlink:to="ibio_ExchangeAgreementMember_638040598586697737" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638040598586697737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638040598586697737" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638040598586697737" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638040598586697737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638040598586697737" xlink:to="us-gaap_RelatedPartyDomain_638040598586697737" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EasternAffiliateMember" xlink:label="ibio_EasternAffiliateMember_638040598586697737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638040598586697737" xlink:to="ibio_EasternAffiliateMember_638040598586697737" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638040598586697737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638040598586697737" xlink:to="us-gaap_StatementClassOfStockAxis_638040598586697737" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638040598586697737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638040598586697737" xlink:to="us-gaap_ClassOfStockDomain_638040598586697737" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PreferredTrackingStockMember" xlink:label="ibio_PreferredTrackingStockMember_638040598586697737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638040598586697737" xlink:to="ibio_PreferredTrackingStockMember_638040598586697737" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638040598586697737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638040598586697737" xlink:to="srt_CounterpartyNameAxis_638040598586697737" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638040598586697737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638040598586697737" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638040598586697737" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638040598586707710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638040598586697737" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638040598586707710" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638040598586707710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638040598586697737" xlink:to="srt_StatementScenarioAxis_638040598586707710" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638040598586707710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638040598586707710" xlink:to="srt_ScenarioUnspecifiedDomain_638040598586707710" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_638040598586707710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638040598586707710" xlink:to="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_638040598586707710" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638040598586707710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638040598586697737" xlink:to="srt_OwnershipAxis_638040598586707710" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638040598586707710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638040598586707710" xlink:to="srt_OwnershipDomain_638040598586707710" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IbioCdmoMember" xlink:label="ibio_IbioCdmoMember_638040598586707710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638040598586707710" xlink:to="ibio_IbioCdmoMember_638040598586707710" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_StockholdersEquityLineItems" xlink:label="ibio_StockholdersEquityLineItems_638040598586707710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638040598586697737" xlink:to="ibio_StockholdersEquityLineItems_638040598586707710" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638040598586707710" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_PreferredStockSharesAuthorized_638040598586707710" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638040598586717712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638040598586717712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_638040598586717712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_638040598586717712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638040598586717712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638040598586717712" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_638040598586717712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_638040598586717712" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_638040598586717712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_638040598586717712" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638040598586717712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638040598586717712" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_638040598586717712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_638040598586717712" order="8" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638040598586717712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_PreferredStockSharesOutstanding_638040598586717712" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638040598586727496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638040598586727496" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638040598586727496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_CommonStockSharesAuthorized_638040598586727496" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638040598586727496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638040598586727496" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638040598586727496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638040598586727496" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638040598586727496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638040598586727496" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638040598586727496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638040598586707710" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638040598586727496" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingNarrativeDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting) (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638040598586737515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638040598586737515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638040598586737515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_638040598586737515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638040598586737515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638040598586737515" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638040598586737515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock_638040598586747746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638040598586737515" xlink:to="us-gaap_DividendsPreferredStockStock_638040598586747746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638040598586747746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638040598586737515" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638040598586747746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638040598586747746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638040598586737515" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638040598586747746" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_638040598586747746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638040598586737515" xlink:to="ibio_UnconsolidatedGainLossAttributableToStockholders_638040598586747746" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_638040598586747746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_638040598586747746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638040598586747746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638040598586747746" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638040598586747746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638040598586747746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638040598586747746" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638040598586747746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638040598586747746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638040598586747746" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638040598586747746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638040598586747746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638040598586747746" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638040598586747746" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638040598586747746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638040598586747746" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638040598586747746" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638040598586747746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638040598586747746" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638040598586747746" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638040598586757720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638040598586747746" xlink:to="us-gaap_EarningsPerShareBasic_638040598586757720" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638040598586757720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638040598586747746" xlink:to="us-gaap_EarningsPerShareDiluted_638040598586757720" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637045036842717904" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EarningsLossPerCommonShareTable" xlink:label="ibio_EarningsLossPerCommonShareTable_638040598586757720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637045036842717904" xlink:to="ibio_EarningsLossPerCommonShareTable_638040598586757720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638040598586757720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareTable_638040598586757720" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638040598586757720" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638040598586757720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638040598586757720" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638040598586757720" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638040598586757720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638040598586757720" xlink:to="us-gaap_EmployeeStockOptionMember_638040598586757720" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638040598586757720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638040598586757720" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638040598586757720" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_EarningsLossPerCommonShareLineItems" xlink:label="ibio_EarningsLossPerCommonShareLineItems_638040598586767499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareTable_638040598586757720" xlink:to="ibio_EarningsLossPerCommonShareLineItems_638040598586767499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638040598586767499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareLineItems_638040598586767499" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638040598586767499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638040598586767499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareLineItems_638040598586767499" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638040598586767499" order="2" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Share-Based Compensation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_495" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638040598586767499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_495" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638040598586767499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638040598586767499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638040598586767499" xlink:to="srt_StatementScenarioAxis_638040598586767499" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638040598586767499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638040598586767499" xlink:to="srt_ScenarioUnspecifiedDomain_638040598586767499" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioOneMember" xlink:label="ibio_ScenarioOneMember_638040598586767499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638040598586767499" xlink:to="ibio_ScenarioOneMember_638040598586767499" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioTwoMember" xlink:label="ibio_ScenarioTwoMember_638040598586777501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638040598586767499" xlink:to="ibio_ScenarioTwoMember_638040598586777501" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638040598586777501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638040598586767499" xlink:to="us-gaap_PlanNameAxis_638040598586777501" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638040598586777501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638040598586777501" xlink:to="us-gaap_PlanNameDomain_638040598586777501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638040598586777501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638040598586777501" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638040598586777501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638040598586777501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638040598586767499" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638040598586777501" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638040598586777501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638040598586777501" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638040598586777501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_638040598586777501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638040598586777501" xlink:to="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_638040598586777501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842727870" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638040598586787536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842727870" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638040598586787536" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638040598586787536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638040598586787536" xlink:to="us-gaap_IncomeStatementLocationAxis_638040598586787536" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638040598586787536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638040598586787536" xlink:to="us-gaap_IncomeStatementLocationDomain_638040598586787536" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638040598586787536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638040598586787536" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638040598586787536" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638040598586787536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638040598586787536" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638040598586787536" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638040598586787536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638040598586787536" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638040598586787536" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638040598586787536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638040598586787536" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638040598586787536" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41803 - Disclosure - Share-Based Compensation (Stock Option Activity) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638040598586787536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638040598586787536" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" xlink:type="extended" xlink:title="41805 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638040598586797729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638040598586797729" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638040598586797729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:to="us-gaap_StatementTable_638040598586797729" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_638040598586797729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586797729" xlink:to="srt_LitigationCaseAxis_638040598586797729" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638040598586797729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_638040598586797729" xlink:to="srt_LitigationCaseTypeDomain_638040598586797729" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638040598586797729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638040598586797729" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638040598586797729" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_638040598586797729" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586797729" xlink:to="us-gaap_LitigationStatusAxis_638040598586797729" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_638040598586807718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis_638040598586797729" xlink:to="us-gaap_LitigationStatusDomain_638040598586807718" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember_638040598586807718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusDomain_638040598586807718" xlink:to="us-gaap_SettledLitigationMember_638040598586807718" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638040598586807718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586797729" xlink:to="srt_StatementScenarioAxis_638040598586807718" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638040598586807718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638040598586807718" xlink:to="srt_ScenarioUnspecifiedDomain_638040598586807718" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638040598586807718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638040598586807718" xlink:to="us-gaap_ScenarioPlanMember_638040598586807718" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioPlanExpectedLegalFeesMember" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember_638040598586807718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_638040598586807718" xlink:to="ibio_ScenarioPlanExpectedLegalFeesMember_638040598586807718" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioPlanExpectedPaymentOneMember" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember_638040598586807718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_638040598586807718" xlink:to="ibio_ScenarioPlanExpectedPaymentOneMember_638040598586807718" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember_638040598586807718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_638040598586807718" xlink:to="ibio_ScenarioPlanExpectedPaymentTwoMember_638040598586807718" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638040598586807718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586797729" xlink:to="srt_ProductOrServiceAxis_638040598586807718" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638040598586817501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638040598586807718" xlink:to="srt_ProductsAndServicesDomain_638040598586817501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember_638040598586817501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638040598586817501" xlink:to="us-gaap_ServiceMember_638040598586817501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember_638040598586817501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ServiceMember_638040598586817501" xlink:to="us-gaap_LicenseAndMaintenanceMember_638040598586817501" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638040598586817501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638040598586797729" xlink:to="us-gaap_StatementLineItems_638040598586817501" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_638040598586817501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586817501" xlink:to="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_638040598586817501" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_638040598586817501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586817501" xlink:to="ibio_PercentageOfLegalFeesExpectedToBeReceived_638040598586817501" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent_638040598586817501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586817501" xlink:to="us-gaap_SettlementAssetsCurrent_638040598586817501" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ibio-20220930.xsd#ibio_SettlementAssetsNonCurrent" xlink:label="ibio_SettlementAssetsNonCurrent_638040598586817501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586817501" xlink:to="ibio_SettlementAssetsNonCurrent_638040598586817501" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount_638040598586817501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586817501" xlink:to="us-gaap_GainContingencyUnrecordedAmount_638040598586817501" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_638040598586827719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586817501" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_638040598586827719" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements_638040598586827719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586817501" xlink:to="us-gaap_ProceedsFromLegalSettlements_638040598586827719" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638040598586827719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638040598586817501" xlink:to="us-gaap_Revenues_638040598586827719" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="42001 - Disclosure - Income Taxes (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_605" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638040598586827719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_605" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638040598586827719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638040598586827719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_605" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638040598586827719" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" xlink:type="extended" xlink:title="42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638040598586837532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638040598586837532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638040598586837532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638040598586837532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" xlink:type="extended" xlink:title="42301 - Disclosure - Subsequent Events (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638040598586847492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_CommonStockValue_638040598586847492" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638040598586847492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638040598586847492" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsCategoryNetCarryingValuesOfOperatingLeaseRouDetails" xlink:type="extended" xlink:title="9941002 - Disclosure - Operating Lease ROU Assets (Category the net carrying values of operating lease ROU) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638040598586847492" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638040598586847492" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643141779792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 07, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">iBio,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2797813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8800 HSC Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bryan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">446-0027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IBIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001420720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,988,782<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643141868528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,887,000<span></span>
</td>
<td class="nump">$ 22,676,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Investments in debt securities</a></td>
<td class="nump">7,599,000<span></span>
</td>
<td class="nump">10,845,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - trade</a></td>
<td class="nump">1,055,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementAssetsCurrent', window );">Settlement receivable - current portion</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,146,000<span></span>
</td>
<td class="nump">1,549,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Current assets held for sale</a></td>
<td class="nump">38,778,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">63,565,000<span></span>
</td>
<td class="nump">45,070,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">5,996,000<span></span>
</td>
<td class="nump">5,996,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Noncurrent assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,314,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest', window );">Convertible promissory note receivable and accrued interest</a></td>
<td class="nump">1,650,000<span></span>
</td>
<td class="nump">1,631,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets, net of accumulated amortization</a></td>
<td class="nump">875,000<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,928,000<span></span>
</td>
<td class="nump">3,068,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="nump">3,464,000<span></span>
</td>
<td class="nump">1,373,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization</a></td>
<td class="nump">6,013,000<span></span>
</td>
<td class="nump">4,851,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses - noncurrent</a></td>
<td class="nump">44,000<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">84,564,000<span></span>
</td>
<td class="nump">99,406,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,807,000<span></span>
</td>
<td class="nump">4,264,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,595,000<span></span>
</td>
<td class="nump">3,764,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations - current portion</a></td>
<td class="nump">303,000<span></span>
</td>
<td class="nump">46,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation - current portion</a></td>
<td class="nump">183,000<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale', window );">Current liabilities related to assets held for sale</a></td>
<td class="nump">1,949,000<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Term note payable - net of deferred financing costs</a></td>
<td class="nump">22,201,000<span></span>
</td>
<td class="nump">22,161,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Contract liabilities</a></td>
<td class="nump">161,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">32,199,000<span></span>
</td>
<td class="nump">30,436,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations - net of current portion</a></td>
<td class="nump">576,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation - net of current portion</a></td>
<td class="nump">3,421,000<span></span>
</td>
<td class="nump">3,514,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale', window );">Noncurrent liabilities related to assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,971,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">36,196,000<span></span>
</td>
<td class="nump">35,921,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>iBio, Inc. Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series 2022 Convertible Preferred Stock - $.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.001 par value; 275,000,000 shares authorized at September 30, 2022 and June 30, 2022; 9,006,582 and 8,727,158 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">290,642,000<span></span>
</td>
<td class="nump">287,619,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(223,000)<span></span>
</td>
<td class="num">(213,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(242,060,000)<span></span>
</td>
<td class="num">(223,930,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total iBio, Inc. Stockholders' Equity</a></td>
<td class="nump">48,368,000<span></span>
</td>
<td class="nump">63,485,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="nump">$ 84,564,000<span></span>
</td>
<td class="nump">$ 99,406,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible Promissory Note Receivable and Accrued Interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current liabilities related to assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent liabilities related to assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982154&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643145827296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">9,006,582<span></span>
</td>
<td class="nump">8,727,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">9,006,582<span></span>
</td>
<td class="nump">8,727,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643145757952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,548<span></span>
</td>
<td class="nump">1,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative (related party of $0 and $189)</a></td>
<td class="nump">5,088<span></span>
</td>
<td class="nump">4,175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,636<span></span>
</td>
<td class="nump">5,309<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(7,636)<span></span>
</td>
<td class="num">(5,225)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Consolidated net loss from continuing operations</a></td>
<td class="num">(7,537)<span></span>
</td>
<td class="num">(5,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss attributable to iBio, Inc. from continuing operations</a></td>
<td class="num">(7,537)<span></span>
</td>
<td class="num">(5,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends- iBio CDMO Tracking Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to iBio, Inc. stockholders from continuing operations</a></td>
<td class="num">(7,537)<span></span>
</td>
<td class="num">(5,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(10,593)<span></span>
</td>
<td class="num">(3,751)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnconsolidatedGainLossAttributableToStockholders', window );">Net loss available to iBio, Inc. stockholders</a></td>
<td class="num">(18,130)<span></span>
</td>
<td class="num">(9,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
<td class="num">(18,130)<span></span>
</td>
<td class="num">(8,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive loss - unrealized loss on debt securities</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (18,140)<span></span>
</td>
<td class="num">$ (8,941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations</a></td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations</a></td>
<td class="num">(0.85)<span></span>
</td>
<td class="num">(0.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations</a></td>
<td class="num">(1.20)<span></span>
</td>
<td class="num">(0.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations</a></td>
<td class="num">(1.20)<span></span>
</td>
<td class="num">(0.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - total</a></td>
<td class="num">(2.05)<span></span>
</td>
<td class="num">(1.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - total</a></td>
<td class="num">$ (2.05)<span></span>
</td>
<td class="num">$ (1.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">8,842<span></span>
</td>
<td class="nump">8,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">8,842<span></span>
</td>
<td class="nump">8,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnconsolidatedGainLossAttributableToStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The unconsolidated net gain (loss) attributable to stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnconsolidatedGainLossAttributableToStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144122416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Operating expenses general and administrative, related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643139333840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 282,266<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
<td class="num">$ (173,627)<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="nump">$ 108,568<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,715,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionValue', window );">Common stock issued - RubrYc transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss including portion attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,940)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">283,164<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(182,566)<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="nump">100,525<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">287,619<span></span>
</td>
<td class="num">(213)<span></span>
</td>
<td class="num">(223,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,485<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">8,727,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodValueCapitalRaise', window );">Capital raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise', window );">Capital raise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionValue', window );">Common stock issued - RubrYc transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionInShares', window );">Common stock issued - RubrYc transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss including portion attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,130)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 290,642<span></span>
</td>
<td class="num">$ (223)<span></span>
</td>
<td class="num">$ (242,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,368<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,006,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonStockIssuedInRubrycTransactionInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of common stock issued in the RubrYc transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonStockIssuedInRubrycTransactionInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonStockIssuedInRubrycTransactionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of common stock issued in the RubrYc transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonStockIssuedInRubrycTransactionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares raised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodSharesCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodValueCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of capital raise during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodValueCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144364496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
<td class="num">$ (18,130)<span></span>
</td>
<td class="num">$ (8,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile consolidated net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of fixed assets</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable', window );">Accrued interest receivable on convertible promissory note receivable</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premiums on debt securities</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DeferredFinancingCostsAmortizationExpense', window );">Amortization of deferred financing costs</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInInventoryReserve', window );">Inventory reserve</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan', window );">Forgiveness of note payable and accrued interest - SBA loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(607)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SettlementOfRevenueContract', window );">Settlement of revenue contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable - trade</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories', window );">Inventory</a></td>
<td class="num">(1,137)<span></span>
</td>
<td class="num">(560)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses - noncurrent</a></td>
<td class="nump">30<span></span>
</td>
<td class="num">(912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,168)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease obligations</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,959)<span></span>
</td>
<td class="num">(9,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Redemption of debt securities</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Purchase of equity security</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,173)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="num">(2,479)<span></span>
</td>
<td class="num">(1,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payment for RubrYc asset acquisition</a></td>
<td class="num">(692)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">29<span></span>
</td>
<td class="num">(5,149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ProceedsFromIssuanceOfPreferredAndCommonStock', window );">Proceeds from sales of common stock</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligation</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="nump">1,141<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(12,789)<span></span>
</td>
<td class="num">(14,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents - beginning</a></td>
<td class="nump">28,672<span></span>
</td>
<td class="nump">77,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - end</a></td>
<td class="nump">15,883<span></span>
</td>
<td class="nump">62,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Schedule of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities', window );">Increase in operating lease ROU assets for new lease - net of lease incentive</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaeInOperatingLeaseObligations', window );">Increase in operating lease obligation for new lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Increase in finance lease ROU assets for new leases</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases', window );">Increase in finance lease obligation for new leases</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid', window );">Fixed assets included in accounts payable in prior period, paid in current period</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LeaseIncentiveForConstructionInProgress', window );">Lease incentive for construction in progress</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnpaidFixedAssetsIncludedInAccountsPayable', window );">Unpaid fixed assets included in accounts payable</a></td>
<td class="nump">2,143<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementValueOfSharesToBePurchased', window );">Unpaid portion of RubrYc transaction</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized loss on available-for-sale debt securities</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LeaseIncentiveForConstructionInProgress', window );">Lease incentive for construction in progress</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NonCashSettlementOfRevenueContract', window );">Settlement of revenue contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionValue', window );">RubrYc asset acquisition by issuance of common stock</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets', window );">Proceeds from options exercised included in prepaid expenses and other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">$ 610<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest receivable on convertible promissory note receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid for capital expenditures incurred for intangible assets during the previous year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonStockIssuedInRubrycTransactionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of common stock issued in the RubrYc transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonStockIssuedInRubrycTransactionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DeferredFinancingCostsAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DeferredFinancingCostsAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forgiveness of note payable and accrued interest - SBA loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaeInOperatingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increae (decrease) in operating lease obligations for new leases during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaeInOperatingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in finance lease obligations for new leases incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInInventoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in inventory valuation reserve during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInInventoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LeaseIncentiveForConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease incentive for construction in progress</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LeaseIncentiveForConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NonCashSettlementOfRevenueContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash Settlement of revenue contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NonCashSettlementOfRevenueContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in Right Of Use Assets under the ASU 842, for which no cash outflow was incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ProceedsFromIssuanceOfPreferredAndCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ProceedsFromIssuanceOfPreferredAndCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from options exercised included in prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SettlementOfRevenueContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of revenue contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SettlementOfRevenueContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementValueOfSharesToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement, value of shares to be purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementValueOfSharesToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnpaidFixedAssetsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unpaid fixed assets included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnpaidFixedAssetsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643141776368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio, Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;iBio&#8221;, &#8220;iBio, Inc&#8221; or the &#8220;Company&#8221;) is an Artificial Intelligence (&#8220;AI&#8221;)-driven innovator of precision antibody immunotherapies. The Company has a pipeline of innovative primarily immuno-oncology antibodies against hard-to-drug targets where we may face reduced competition and with antibodies that may be more selective. The Company plans to use its AI-driven discovery platform to continue adding antibodies against hard-to-drug targets or to work with partners on AI-driven drug development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img alt="Graphic" src="ibio-20220930x10q001.jpg" style="display:inline-block;height:248.43pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:534.2pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">IBIO-101: </b>an anti-CD25 molecule that works by depletion of immunosuppressive T-regulatory cells (Tregs) via antibody-dependent cellular cytotoxicity (&#8220;ADCC&#8221;), without disrupting activation of effector T-cells (Teffs) in the tumor microenvironment. IBIO-101 could potentially be used to treat solid tumors, hairy cell leukemia, relapsed multiple myeloma, lymphoma, or head and neck cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">EGFRvIII: </b>binds a tumor-specific mutation of EGFR variant III with an afucosylated antibody for high ADCC. Because of its specificity binding to the tumor-specific mutation, it could potentially reduce toxicity and/or expand the therapeutic window compared to simple broad EGFR-targeted alternatives. . EGFRvIII is constantly &#8220;switched on&#8221; which can lead to the development of a range of different cancers. An EGFRvIII antibody could potentially be used to treat glioblastoma, head and neck cancer or non-small cell lung cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CCR8:</b> targets depletion of highly immunosuppressive CCR8+ Tregs in the tumor microenvironment via an ADCC mechanism with selective binding to CCR8 over its closely related cousin, CCR4, to avoid off-target effects. A CCR8 program could potentially be broadly applicable in solid tumors and/or as a prospective combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PD-1 Agonist: </b>Selectively binds PD-1 to suppress auto-reactive T-cells without PD-L1/PD-L2 blocking. A PD-1 agonist could potentially be used to treat inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis or other inflammatory diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the programs described above, the Company also has six additional early discovery programs that have the potential to advance into later stages of preclinical development and are designed to tackle hard-to-drug targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IBIO-100 and Endostatin E4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our lead anti-fibrotic candidate is IBIO-100, and its design is based in part upon work by Dr. Carol Feghali-Bostwick, Professor of Medicine at the Medical University of South Carolina and Vice-Chair of the Scleroderma Foundation. Her initial work was conducted at the University of Pittsburgh, and we have licensed the patents relevant for the continued development of the molecule from the university. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As part of the Company&#8217;s review of potential options, the Company intends to continue to review the data from its research and development efforts and determine how to proceed with the development of IBIO-100 in Fibrosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;">To align with the Company&#8217;s focus on the immuno-oncology pipeline, the Company also intends to continue to pursue the E4 endostatin peptide, from which IBIO-100 is derived, as an oncology target in collaboration with University of Texas Southwestern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AI Drug Discovery Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2022, iBio purchased substantially all of the assets of RubrYc Therapeutics (for a complete description of the transaction please see Note 6 &#8211; Significant Transactions). The AI Drug Discovery platform technology is designed to be used to discover antibodies that bind to hard-to-target subdominant and conformational epitopes for further development within our existing portfolio or in partnership with outside entities. The RubrYc AI platform is built upon 3 key technologies. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Epitope Targeting Engine:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> A proprietary machine-learning platform that combines computational biology and 3D-modeling to identify molecules that mimic hard-to-target binding sites on target proteins, specifically, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subdominant and conformational epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The creation of these small mimics enables the engineering of therapeutic antibody candidates that can selectively bind immune and cancer cells better than &#8221;trial and error&#8221; antibody engineering and screening methods that are traditionally focused on dominant epitopes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">RubrYcHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-generated human antibody library free of significant sequence liabilities that provides a unique pool of antibodies to screen. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The combination of the Epitope Targeting Engine and screening with the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">RubrYcHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Library has been shown to reduce the discovery time from ideation to </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> proof-of-concept (PoC) by up to 4 months. This has the potential to enable more, and better, therapeutic candidates to reach the clinic, faster. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">StableHu</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> Library:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> An </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-powered sequence optimization library used to improve antibody performance</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Once an antibody has been advanced to the lead optimization stage, </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">StableHu</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> allows precise and rapid optimization of the antibody binding regions to rapidly move a candidate molecule into the IND-enabling stage.</span></td></tr></table><div style="margin-top:10pt;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643145713504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">2.&#160;&#160;&#160;Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Interim Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended June 30, 2022, filed with the SEC on October 11, 2022 (the &#8220;Annual Report&#8221;), from which the accompanying condensed consolidated balance sheet dated June 30, 2022 was derived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Non-controlling interest in the consolidated financial statements represented the share of the loss in iBio CDMO, LLC (&#8220;iBio CDMO&#8221;) for an affiliate of Eastern Capital Limited (&#8220;Eastern Capital&#8221;) through November 1, 2021, the date the Company acquired the remaining interest in iBio CDMO. &#160;See Note 6 &#8211; Significant Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company's ability to continue as a going concern. In an effort to remain a going concern and increase cash reserves, the Company recently announced it was selling its CDMO business and facility, reducing its work force by approximately 60% (a reduction of approximately 69 positions), and ceasing operations of its CDMO thereby reducing annual spending by approximately 50%. (See Note 3 &#8211; Discontinued Operations for more information.) Potential options being considered&#160;to further increase liquidity include lowering the Company&#8217;s expenses further, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from capital markets, grant revenue or collaborations, or a combination thereof. During the first quarter of fiscal year 2023, the Company completed at-the-market (&#8220;ATM&#8221;) offerings and raised <span style="-sec-ix-hidden:Hidden_G92FJIZcG06BIGNnHbTKpg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.1M</span></span> selling approximately 176,000 shares of common stock. (See Note 16 &#8211; Stockholder&#8217;s Equity for more information.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s cash, cash equivalents, restricted cash and investments in debt securities of $23.5 million as of September 30, 2022, is not anticipated to be sufficient to support operations beyond Q3 of Fiscal 2023<b style="font-weight:bold;"> </b>unless the Company reduces its burn rate further or increases its capital as described above. Regardless of whether the Company is able to reduce its burn rate or sell or out-license certain assets or parts of the business, the Company will need to raise additional capital in order to fully execute its longer-term business plan. It is the Company&#8217;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Quarterly Report on Form 10-Q. However, there can be no assurance that the Company will be successful in implementing any of the options that we are evaluating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Reverse Stock Split</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 22, 2022, the Company's Board of Directors approved the implementation of a reverse stock split at a ratio of one-for-twenty five (1:<span style="-sec-ix-hidden:Hidden__0cS0oMu3kKeTj2aafl8jw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25</span></span>) shares of the Company's Common Stock (the &#8220;Reverse Split&#8221;). The Reverse Split was effective as of October 7, 2022. All share and per share amounts of our common stock presented have been retroactively adjusted to reflect the Reverse Split. See Note 16 &#8211; Stockholders&#8217; Equity for more information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to Basis of Presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643141843568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.&#160;&#160;&#160;Discontinued Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In November 2022, the Company announced it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately 60% of the current Company staffing levels (a reduction of approximately 69 positions). The Company expects to substantially complete the employee reduction by January 2, 2023. The Company expects it may be able to complete a transaction for the sale of its contract development and manufacturing organization in calendar 2023, although there is no assurance as to when, or for how much, the Company may be able to sell the iBio CDMO, LLC organization, including the 130,000-square-foot cGMP facility location in Bryan, Texas. &#160;The Company expects to incur pre-tax charges of approximately $1.7 million for the employee reduction, most of which is expected to be incurred in the second and third quarter of fiscal year 2023. These charges will be substantially settled in cash and almost entirely consist of severance obligations, continuation of salaries and benefits over a 60-day transitional period during which impacted employees remain employed but are not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. The transition to a focused AI-Biotech business is expected to reduce the Company&#8217;s monthly burn rate by approximately half, with an approximate range of $2.5-3.0 million per month. The Company recorded a charge in discontinued operations for $4.1 million for the three months ended September 30, 2022, due to inventory write offs resulting from the winding down of the CDMO business and depending upon the sale price of the facility, the Company may have to incur additional write offs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As such, the results of iBio CDMO's operations are reported as discontinued operations for the three months ended September 30, 2022. The Company has retrospectively recast its consolidated statement of operations for the three months ended September 30, 2021 presented. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intends to sell have been classified as &#8220;held for sale&#8221; as of September 30, 2022. &#160;The Company has retrospectively recast its consolidated balance sheet as of June 30, 2022 for assets and liabilities held for sale. &#160;The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statement of cash flows. &#160;Supplemental disclosures related to discontinued operations for the statements of cash flows has been provided below. Unless noted otherwise, discussion in the Notes to the Condensed Consolidated Financial Statements refers to the Company's continuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 127</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 40</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,378</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 7,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,458</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 10,417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,836</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expenses):</p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - related party</span></p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (608)</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Forgiveness of note payable and accrued interest - SBA loan</span></p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 607</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other expenses</p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (227)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operation</p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,593)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,751)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents net carrying values related to the major classes of assets that were classified as held for sale at September 30, 2022 and June 30, 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">937</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35,892</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 38,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35,289</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,951</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 37,240</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,941</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:middle;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 306</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 416</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,082</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing noncash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed assets included in accounts payable in prior period, paid in current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 383</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Unpaid fixed assets included in accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 750</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143212688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">4.&#160;&#160;&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s significant accounting policies are described in Note&#160;3 of the Notes&#160;to Financial Statements in the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounts Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#8217;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, the Company determined that an allowance for doubtful accounts was not needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for its revenue recognition under Accounting Standards Codification ("ASC") 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i)&#160;identify the contract, (ii)&#160;identify the performance obligations, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations and (v)&#160;recognize revenue when a performance obligation is satisfied. The nature of the Company&#8217;s contracts with customers generally falls within the three key elements of the Company&#8217;s business plan: CDMO Facility Activities; Product Candidate Pipeline, and Facility Design and Build-out /Technology Transfer services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and/or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At September 30, 2022 and June 30, 2022, the Company had no contract loss provisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company generates (or may generate in the future) contract revenue under the following types of contracts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fixed-Fee </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue can be recognized either 1) over time or 2) at a point in time. &#160;All revenue was recognized at a point in time for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended September 30, 2021, revenue was from the settlement of a revenue contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Time and Materials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#8217;s billing rate plus other project specific costs incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract asset is an entity&#8217;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both September&#160;30,&#160;2022 and June&#160;30,&#160;2022, contract assets were $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Contract Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract liability is an entity&#8217;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#8217;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, contract liabilities w<span style="background:#ffffff;">ere </span><span style="background:#ffffff;">$161,000</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">$100,000</span><span style="background:#ffffff;"> r</span>espectively. The Company recognized revenue of $56,000 during the three months ended September 30, 2022 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. &#160; The Company recognized revenue of $84,000 during the three months ended September 30, 2021 that was included in the contract liabilities balance as of June 30, 2021 and reported as part of continuing operations. &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for leases under the guidance of Accounting Standards Codification ("ASC") 842, "Leases" ("ASC 842"). The standard established a right-of-use (&#8220;ROU&#8221;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#8217;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, <span style="-sec-ix-hidden:Hidden_sGul_1aHN0eDILLvK8AumA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#8217;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#8217;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#8217;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at September 30, 2022 and June 30, 2022 consisted of money market accounts. Restricted cash consisted of collateral held for letters of credit obtained to the term note payable for the purchase of the 130,000 square foot cGMP manufacturing facility in Bryan, Texas located at 8800 HSC Parkway, Bryan, Texas 77807 (the &#8220;Facility&#8221;) (see Note 6 &#8211; Significant Transactions) and the San Diego operating lease (see Note 15 &#8211; Operating Lease Obligations) and a Company purchasing card. The Company&#8217;s bank required an additional 5% collateral held above the actual letters of credit issued. Restricted cash was approximately $6 million at both September 30, 2022 and June 30, 2022. On October 11, 2022, the Company, as part of the First Amendment to the Credit Agreement with Woodforest, paid down $5.5M of the term loan and subsequently Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. The change in restricted cash will be reflected in second quarter of fiscal year 2023 financials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 22,676</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,743</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,672</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Investments in Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value is calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. See Note 8 &#8211; Investments in Debt Securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';">Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. &#160;Inventory held is related to the CDMO business and has been classified as held for sale. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 730-10, <i style="font-style:italic;">Research and Development</i> (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the three month periods ending September 30, 2022 and 2021 research and development expense was reported in both continuing and discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-Use Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 14 - Finance Lease Obligations for additional information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_mylpkjT0LkCiMRV69PIkrw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to 39 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of 10 years and other intellectual property is amortized over periods from 16 to <span style="-sec-ix-hidden:Hidden_u6VUYlS0b0yj9uFRIDrlgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23&#160;years</span></span>. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges for the three months ended September&#160;30,&#160;2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The impact that share-based payment awards will have on the Company&#8217;s results of operations is a function of the number of shares awarded, the trading price of the Company&#8217;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#8217;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Expected volatility is based on historical volatility of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;); the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#8217;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 17 - Share-Based Compensation for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, amounts in excess of insured limits were approximately $15,372,000 and $18,200,000, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended September&#160;30,&#160;2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from one customer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended September&#160;30,&#160;2021, the Company reported revenue from continuing operations from one customer related to the settlement of a revenue contract and generated 100% of revenue reported in discontinued operations from three customers, each of whom individually accounted for more than 10% of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Recently Issued Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#8217;s condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143324128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments and Fair Value Measurement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">5.&#160;&#160;&#160;Financial Instruments and Fair Value Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The carrying values of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and term note payable in the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of September&#160;30,&#160;2022 and June&#160;30,&#160;2022 due to their short-term nature. The carrying value of the convertible promissory note receivable, the term note payable and finance lease obligation approximated fair value as of September&#160;30,&#160;2022 and June&#160;30,&#160;2022 as the interest rates related to the financial instruments approximated market value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of investments that fall under each category, and the valuation methodologies used to measure these investments at fair value. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs are based upon unadjusted quoted prices for identical instruments in active markets. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 2</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs to the valuation include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. &#160;All debt securities were valued using Level 2 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 3</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143012544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SignificantTransactionsAbstract', window );"><strong>Significant Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SignificantTransactionsTextBlock', window );">Significant Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">6.   Significant Transactions </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Affiliates of Eastern Capital Limited</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Company and its subsidiary, iBio CDMO (&#8220;iBio CDMO&#8221;, and collectively with the Company, the &#8220;Purchaser&#8221;) entered into a series of agreements (the &#8220;Transaction&#8221;) with College Station Investors LLC (&#8220;College Station&#8221;), and Bryan Capital Investors LLC (&#8220;Bryan Capital&#8221; and, collectively with College Station, &#8220;Seller&#8221;), each affiliates of Eastern Capital Limited (&#8220;Eastern,&#8221; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility&#8217;s ground lease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise terminated all agreements between the Company and the affiliates of Eastern.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&amp;M University System (&#8220;Texas A&amp;M&#8221;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the &#8220;Sublease&#8221;) until the purchase of the Facility described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Purchase and Sale Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Purchaser entered into a Purchase and Sale Agreement (the &#8220;Purchase and Sale Agreement&#8221;) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the &#8220;Ground Lease Agreement&#8221;) that it entered into with Texas A&amp;M (the &#8220;Landlord&#8217;&#8217;) related to the property at which the Facility is located together with all improvements pertaining thereto (the &#8220;Property&#8221;), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $28,750,000, which was paid $28,000,000 in cash and by the issuance to Seller of warrants (the &#8220;Warrant&#8221;) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, iBio CDMO is being accounted for as a discontinued operation. &#160;As such, the assets acquired and/or leased are now classified as assets held for sale on the September 30, 2022 and June 30, 2022 condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Equity Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also entered into an Equity Purchase Agreement with Bryan Capital on November 1, 2021 (the &#8220;Equity Purchase Agreement&#8221;) pursuant to which the Company acquired for $50,000 cash, plus the Warrant, the one (1) share of iBio CMO Preferred Tracking Stock and the 0.01% interest in iBio CDMO owned by Bryan Capital. As a result, iBio CDMO is now a wholly-owned subsidiary of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Purchase and Sale Agreement, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan (the &#8220;Term Loan&#8221;) to purchase the Facility, which Term Loan is evidenced by a Term Note (the &#8220;Term Note&#8221;). The Term Loan was advanced in full on the closing date. The Term Loan bears interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest is payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Credit Agreement contains customary events of default (which are in some cases subject to certain exceptions, thresholds, notice requirements and grace periods), including, but not limited to, nonpayment of principal or interest, failure to perform or observe covenants, breaches of representations and warranties, cross-defaults with certain other indebtedness, certain bankruptcy-related events or proceedings, final monetary judgments or orders and certain change of control events. The covenants include a prohibition on the incurrence of Debt (as defined in the Credit Agreement) except permitted Debt (as defined in the Credit Agreement) and Liens (as defined in the Credit Agreement) and termination of the Ground Lease Agreement. In addition, the Company initially was required to maintain unrestricted cash of no less than $10,000,000 which amount has been reduced (see below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company opened an irrevocable letter of credit in the amount of approximately $5,469,000 in favor of Woodforest. &#160;The letter of credit was scheduled to expire on October 29, 2022, but was cancelled (see below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The proceeds of the Term Loan were used (a) to fund a portion of the purchase price under the Purchase Agreement, and (b) to pay closing costs in connection with the Credit Agreement. The term loan is secured by (a) a leasehold deed of trust on the Facility, (b) a letter of credit issued by JPMorgan Chase Bank, and (c) a first lien on all assets of iBio CDMO including the Facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 11, 2022, we and Woodforest amended the Credit Agreement to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days &#160;upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (see Note 19 &#8211; Fraunhofer Settlement for more information), (iii) include </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">principal payments of $250,000 per month in debt amortization for a 6 month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast (vi) reduce the liquidity covenant in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5.0 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. If we fail to successfully extend our cash runway via strategic options or other alternatives as described, we would be in violation of the liquidity covenant on December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result of the foregoing, at both September 30, 2022 and June&#160;30,&#160;2022, the Term Loan has been classified as short term. At September 30, 2022, the balance was $22,201,000 which consisted of the Term note of $22,375,000, net of approximately $174,000 of deferred finance costs. &#160; At June 30, 2022, the balance was $22,161,000 which consisted of the Term Note of $22,375,000, net of approximately $214,000 of deferred finance costs. Interest expense incurred under the Credit Agreement for the three months ended September&#160;30,&#160;2022 amounted to $186,000. Amortization of deferred finance costs amounted to $40,000 for the three months ended September 30, 2022 and is included in interest expense. &#160;Both interest expense amounts are classified under loss from discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Security and Pledge Agreements, Guaranties and Deed of Trust</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio CDMO also entered into a Security Agreement on November 1, 2021 with Woodforest (the &#8220;Security Agreement&#8221;) providing Woodforest a security interest in the following assets of iBio CDMO (subject to certain exclusions): all personal and fixture property of every kind and nature, including, without limitation, all goods (including, but not limited to, all equipment and any accessions thereto), all inventory, instruments (including promissory notes), documents, accounts, chattel paper (whether tangible or electronic), deposit accounts, securities accounts, letter-of-credit rights (whether or not the letter of credit is evidenced by a writing), money, commercial tort claims, securities and all other investment property, supporting obligations, contracts, contract rights, other rights to the payment of money, insurance claims and proceeds, software, fixtures, vehicles and rolling stock (whether or not subject to a certificate of title statute), leasehold improvements, general intangibles (including all payment intangibles), and all of iBio CDMO&#8217;s company and other business books, reports, memoranda, customer lists, credit files, data compilations, and computer software, in any form, including, without limitation, whether on tape, disk, card, strip, cartridge, or any other form, pertaining to any and all of the foregoing property, and all products and proceeds of the foregoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also entered into a Guaranty for the benefit of Woodforest (the &#8220;Guaranty&#8221;) pursuant to which it guaranteed all of the obligations of iBio CDMO to Woodforest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, iBio CDMO entered into a Leasehold Deed of Trust, Assignment of Rents, Security Agreement and UCC Financing Statement for Fixture Filing (the &#8220;Deed of Trust&#8221;) with the trustee named therein and Woodforest as beneficiary, securing all of iBio CDMO&#8217;s obligations to Woodforest by a senior priority security interest in the Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company and iBio CDMO also entered into an Environmental Indemnity Agreement in favor of Woodforest (the &#8220;Environmental Indemnity Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Warrant</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the shares issued under the Warrant, 11,583, which were originally valued at $217,255, reflected the final payment of rent due under the Sublease. The Warrant, as shown on the condensed consolidated statements of equity, was recorded in additional paid in capital with the corresponding activity included in the basis of the purchase price allocation of the property acquired. &#160;See Note 16 &#8211; Stockholders&#8217; Equity for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (&#8220;RubrYc&#8221;) described in more detail below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into a collaboration and licensing agreement (the &#8220;RTX-003 License Agreement&#8221;) with RubrYc to further develop RubrYc&#8217;s immune-oncology antibodies in its RTX-003 campaign. &#160;Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields<span style="color:#0000ff;">. &#160;</span>RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration, Option and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company entered into an agreement with RubrYc (the &#8220;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration, Option and License Agreement&#8221;) </span>to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYc&#8217;s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. &#160;RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) <span style="-sec-ix-hidden:Hidden_9g2_uLeoFka_iS5MEA5Jqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. &#160;The Collaboration, Option and License Agreement was mostly terminated when the Company acquired substantially all of the assets of RubrYc in September 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-align:justify;margin:0pt;">In connection with the entry into the Collaboration Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (&#8220;Stock Purchase Agreement&#8221;) with RubrYc whereby the Company purchased a total of 2,864,345 shares of RubrYc&#8217;s Series A-2 preferred stock &#8220;Series A-2 Preferred&#8221;) for $7,500,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,760,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,300,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,440,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,500,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">RubrYc ceased its operations, and the Company recorded an impairment of the investment in the amount of $1,760,000 in 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, in 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The Company issued 102,354 shares of the Company&#8217;s common stock with an approximate market value of $1,000,000 (the &#8220;Closing Shares&#8221;). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Company&#8217;s common stock, at the Company&#8217;s option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. &#160;The assets acquired include an AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, and two additional immuno-oncology candidates plus a partnership-ready PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. &#160;The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:73.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,228,000</span></p></td></tr><tr><td style="vertical-align:middle;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 114,000</span></p></td></tr><tr><td style="vertical-align:middle;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,342,000</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. &#160;See Note 9 &#8211; Finance Lease ROU Assets and Note 14 &#8211; Finance Lease Obligations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Transactions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SignificantTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Transactions [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SignificantTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143012544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Note Receivable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Convertible Promissory Note Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Convertible Promissory Note Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">7.&#160;&#160;&#160;Convertible Promissory Note Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 1, 2020, the Company entered into a master services agreement with Safi Biosolutions, Inc. (&#8220;Safi&#8221;). In addition, the Company invested $1.5 million in Safi in the form of a convertible promissory note (the "Note"). The Note bears interest at the rate of 5% per annum and is convertible into shares of Safi&#8217;s common stock (as defined). Principal and accrued interest mature on October 1, 2023. &#160;For both of the three months ended September 30, 2022 and 2021, interest income amounted to $19,000. As of September&#160;30,&#160;2022 and June 30, 2022, the Note balance and accrued interest totaled $1,650,000 and $1,631,000, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143242272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt and Equity Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Debt Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;Investments in Debt and Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Debt Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Investments in debt securities consist of AA and A rated corporate bonds bearing interest at rates from 0.25% to 3.5% with maturities from <span style="-sec-ix-hidden:Hidden__3BD-NqJOEiqalOgJX0pyg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December 2022</span></span> to <span style="-sec-ix-hidden:Hidden_NaePz8N5I0616M6LaQS5Jg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">February 2024</span></span>. The components of investments in debt securities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Adjusted cost</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,029</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Gross unrealized losses</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (194)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.46%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (184)</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Fair value</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,845</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair value of available-for-sale debt securities, by contractual maturity, was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Fiscal period ending:</b></p></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2023</p></td><td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,054</p></td></tr><tr><td style="vertical-align:middle;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2024</p></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,791</p></td></tr><tr><td style="vertical-align:middle;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,845</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of premiums paid on the debt securities amounted to $36,000 and $102,000 for the three months ended September&#160;30,&#160;2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143242272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease ROU Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract', window );"><strong>Finance Lease ROU [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock', window );">Finance Lease ROU Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.&#160;&#160;&#160;Finance Lease ROU Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company assumed three equipment leases as part of the RubrYc asset acquisition. &#160;In addition, the Company also leases a mobile office trailer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 14 &#8211; Finance Lease Obligation for more details of the terms of the leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ROU - Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 146</p></td></tr><tr><td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (85)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (72)</p></td></tr><tr><td style="vertical-align:bottom;width:70.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net finance lease ROU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 74</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of finance lease ROU assets was approximately $13,000 and $12,000 for three months ended September 30, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143012544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease ROU Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Operating Lease ROU Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock', window );">Operating Lease ROU Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">10.&#160;&#160;&#160;Operating Lease ROU Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">San Diego, California</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. &#160;Based on the terms of the lease payments, the Company recorded an operating lease right-of-use asset of $3,603,000. &#160;The net carrying amount of this ROU operating lease asset was $2,928,000 and $3,068,000 at September 30, 2022 and June 30, 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Bryan, Texas</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, as discussed above, iBio CDMO acquired the Facility and became the tenant under the ground lease for the Property upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease right of use asset of $1,967,000. The net amount of this ROU operating lease asset is included in assets held for sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> &#160; &#160;<span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 15 - Operating Lease Obligation for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643228392416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Substantially all of the fixed assets at September 30, 2022 are included in assets held for sale. &#160;The depreciation expense for the three months ended September 30, 2022 and 2021 is classified as part of loss from discontinued operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fixed assets at September 30, 2022 and June 30, 2022 reported in continuing operations represents the construction in progress for the new San Diego research facility. &#160;These assets were placed into service on October 1, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144144880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12.&#160;&#160;&#160;Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has two categories of intangible assets&#160;&#8211; intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December&#160;2003 from Fraunhofer USA&#160;Inc., acting through its Center for Molecular Biotechnology (&#8220;Fraunhofer&#8221;), pursuant to a Technology Transfer Agreement, as amended (the &#8220;TTA&#8221;). The Company designates such technology further developed and acquired from Fraunhofer as <i style="font-style:italic;">iBioLaunch</i><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or <i style="font-style:italic;">LicKM</i><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> or <i style="font-style:italic;">FastPharming</i> Technology. The value on the Company&#8217;s books attributed to patents owned or controlled by the Company is based only on payments for services and fees related to the protection of the Company&#8217;s patent portfolio. The intellectual property also includes certain trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) whereby in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T regulatory (T reg) cells while enhancing T effector (T eff) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. &#160;In addition, the Company also received preferred shares and an option for future collaboration licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The assets acquired include an AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, and two additional immuno-oncology candidates, plus a partnership-ready PD-1 agonist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2014, the Company entered into a license agreement with the University of Pittsburgh<i style="font-style:italic;"> </i>whereby iBio acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the "Licensed Technology") which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone &#8211; filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology ("IND") &#8211; initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022 was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of 10 years and other intellectual property is amortized over periods from 16 to 23 years unless they were determined to have indefinite lives. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no impairments for the three months ended September&#160;30,&#160;2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,100</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,846</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,946</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,905)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,867)</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,305)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,403)</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,210)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,270)</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total definite lived intangible assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 676</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License - indefinite lived</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,175</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,851</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization expense of intangible assets was approximately $67,000 and $88,000 for the three&#160;months ended September&#160;30, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643141744560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable - PPP Loan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NotesPayablePppLoanDisclosureTextblock', window );">Note Payable - PPP Loan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">13.&#160;&#160;&#160;Note Payable &#8211; PPP Loan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On April 16, 2020, the Company received $600,000 related to its filing under the Paycheck Protection Program and Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"). The Company elected to treat the SBA Loans as debt under ASC 470, &#8220;Debt&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On July 21, 2021, iBio was granted forgiveness in repaying the loan. &#160;In accordance with ASC 405-20-40, &#8220;<i style="font-style:italic;">Liabilities - Extinguishments of Liabilities &#8211; Derecognition</i>&#8221;, the Company derecognized the liability and accrued interest of approximately $7,000 in the first quarter of Fiscal 2022. &#160;The forgiveness is included in loss from discontinued operations (see Note 3 &#8211; Discontinued Operations).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NotesPayablePppLoanDisclosureTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of notes payable PPP loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NotesPayablePppLoanDisclosureTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144144880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Finance Lease Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Finance Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;Finance Lease Obligation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, until November 1, 2021, iBio CDMO leased the Facility as well as certain equipment from College Station under the Sublease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Sublease was terminated on November 1, 2021, when iBio CDMO acquired the Facility and became the tenant under the ground lease for the property upon which the Facility is located. &#160;See Note 15 &#8211; Operating Lease Obligations for additional information related to the ground lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">General and administrative expenses related to College Station, including rent related to the increases in CPI and real estate taxes, were approximately $189,000 for the three months ended September 30, 2021. Interest expense related to College Station was approximately $608,000 for the three months ended September 30, 2021. Such expenses were classified as part of loss from discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the Company assumed three equipment leases that were accounted for as finance leases totaling $813,822 as part of the RubrYc Asset Purchase Agreement. &#160;The monthly rental for the three leases is approximately $14,000 per month and all three expire on August 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mobile Office Trailer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing April 1, 2021, the Company is leasing a mobile office trailer at a monthly rental of $3,819 through March 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 10</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 1.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate - finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 9.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 6.250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 369</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 338</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 293</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,000</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (303)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143212688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Obligation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15.&#160;&#160;&#160;Operating Lease Obligation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Texas Ground Lease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">San Diego</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. &#160;Terms of the lease include the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The length of term of the lease is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">88 months</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from the lease commencement date (as defined).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease commencement date was estimated to be on or around January 1, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The monthly rent for the first year of the lease is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$51,223</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and increases approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease provides for a base rent abatement for months </span><span style="-sec-ix-hidden:Hidden_HTgQ1reF4068PJjjH7wdhg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> through </span><span style="-sec-ix-hidden:Hidden_6jE7_kh_EUe3WSMLLFzfcg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in the first year of the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The landlord is providing a tenant improvement allowance of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$81,860</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to be used for improvements as specified in the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company is responsible for other expenses such as electric, janitorial, etc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company opened an irrevocable letter of credit in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$188,844</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in favor of the landlord. &#160;The letter of credit expires on October 8, 2022 and renews annually as required.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. &#160;Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease ROU asset in the accompanying balance sheet. &#160;As the Company has already started making improvements to the facility, the rent expense will be recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the operating lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on September&#160;30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Imputed Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 464</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 635</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 653</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 674</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 694</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,638</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,758</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144155584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16.&#160;&#160;&#160;Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series 2022 Convertible Preferred Stock (&#8220;Series 2022 Preferred&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 9, 2022, the Board of Directors of the Company created the Series 2022 Preferred, par value $0.001 per share, out of the Company&#8217;s 1 million authorized shares of preferred stock. &#160;Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (1:1) shares of the Company's Common Stock on a pre-split basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company issued 1,000 shares of Series 2022 Preferred and received proceeds of $270. &#160;Pursuant to the terms of the preferred stock, the Company&#8217;s Board of Directors converted the Preferred Stock to 40 shares of Common Stock on July 19, 2022 on a post-split basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">iBio CMO Preferred Tracking Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Company entered into an exchange agreement with Bryan Capital pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by Bryan Capital and issued one share of a newly created Preferred Tracking Stock, in exchange for 29,990,000 units of limited liability company interests of iBio CDMO held by Bryan Capital at an original issue price of $13 million. After giving effect to the transaction, the Company owned 99.99% and Bryan Capital owned 0.01% of iBio CDMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Board of Directors of the Company created the Preferred Tracking Stock out of the Company&#8217;s 1 million authorized shares of preferred stock. The Preferred Tracking Stock accrued dividends at the rate of 2% per annum on the original issue price. Accrued dividends were cumulative and were payable if and when declared by the Board of Directors, upon an exchange of the shares of Preferred Tracking Stock and upon a liquidation, winding up or deemed liquidation (such as a merger) of the Company. No dividends were declared through October 31, 2021. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, iBio purchased the iBio CMO Preferred Tracking Stock held by Bryan Capital. No iBio CMO Preferred Tracking Stock remains outstanding. As a result, the iBio CDMO subsidiary and its intellectual property are now wholly owned by iBio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The number of authorized shares of the Company&#8217;s common stock is 275 million. In addition, the Company has reserved 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the Company&#8217;s 2020 Omnibus Incentive Plan (the &#8220;2020 Plan&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reverse Stock Split</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to effect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio of one-for-twenty </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">five (1:25). On September 22, 2022, the Company's Board of Directors approved the implementation of the reverse stock split of the Company's Common Stock. As a result of the reverse stock split, every twenty five (25) shares of the Company's Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of the Company's common stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a one-for-twenty five (1:25) reverse stock split of the shares of the Company&#8217;s common stock, either issued or outstanding, effective October 7, 2022. The Company&#8217;s Common Stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent issuances of Common Stock include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Cantor Fitzgerald Underwriting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. ("Cantor Fitzgerald") to sell shares of common stock, from time to time, through an &#8220;at the market offering&#8221; program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. &#160;Between July 25, 2022, and August 17, 2022, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 175,973 shares of Common Stock. The Company received net proceeds of approximately $1.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc Transaction</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 19, 2022, iBio issued 102,354 shares valued at approximately $1,000,000 to RubrYc Therapeutics as part of the payment for purchasing the assets of RubrYc Therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Vesting of Restricted Stock Units &#8220;RSUs&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 23, 2022, RSUs for 1,057 shares of Common Stock were vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Warrant</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock of the Company at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144040672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17.&#160;&#160;&#160;Earnings (Loss) Per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to iBio, Inc. from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,537)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,188)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock dividends &#8211; iBio CMO Preferred Tracking Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (66)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,537)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,254)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,593)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,751)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,130)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,005)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 8,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 8,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_UVdxoMmgQkKjhJdoE6VcYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.85)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_drCJr6G_BkCKj9KtPlTGNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.60)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ja0Qe-ca6kSwUGmiTbHIlA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1FZCwCoI6Emocc2F149ZKA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-4hgScTO5E-EP-H2wvkN5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.05)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_OTJhXFjeGU-xhjMC2Fzccw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In Fiscal 2023 and Fiscal 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September&#160;30,&#160;2022 and 2021, shares issuable which could potentially dilute future earnings were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 576</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant issued under the Transaction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares excluded from the calculation of diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 607</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143252000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18.</b>&#160;&#160;&#160;<b style="font-weight:bold;">Share-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 1,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 706</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 1,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 720</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $96,000 and $101,000 for the three months ended September 30, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">iBio, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is 32 million shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors and $1,500,000 for any non-executive chair of our Board of Directors should one be appointed. Notwithstanding the foregoing, the independent members of the Board of Directors may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Vesting of service awards are determined by the Board of Directors and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally three or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock options issued</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal 2023, the Company granted stock option agreements to various employees to purchase 303,869 shares of the Company's common stock at exercise prices between $6.75 and $9.50 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">3.21% - 3.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">115.52 - 116.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">RSUs </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 29, 2022, the Company issued RSUs to acquire 6,954 shares of common stock to various employees at a market value of $7.06 per share. &#160;The RSU&#8217;s vest over a four-year period. The grant-date fair value of the RSUs totaled approximately $49,000. &#160; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643141708272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fraunhofer Settlement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlementAbstract', window );"><strong>Fraunhofer Settlement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_GainLossRelatedToLitigationSettlementTextBlock', window );">Fraunhofer Settlement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19.&#160;&#160;&#160;Fraunhofer Settlement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 4, 2021, the Company and Fraunhofer USA, Inc. (&#8220;FhUSA&#8221;) entered into a Confidential Settlement Agreement and Mutual Release (the &#8220;Settlement Agreement&#8221;) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the &#8220;Lawsuit&#8221;). The Settlement Agreement, among other things, resolves the Company&#8217;s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Settlement Agreement is not an admission of liability or fault of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The terms of the Settlement Agreement provide for cash payments to the Company of $28,000,000 as follows: (i) $16,000,000 to be paid no later than May 14, 2021 (which is expected to be paid 100% to cover legal fees and expenses); (ii) <span style="-sec-ix-hidden:Hidden_n27rjvZYL0OlHIzsiufN3A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $5,100,000 payable by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, <span style="-sec-ix-hidden:Hidden_KLGwyYKoFUWk37Z8Z7W-QA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $900,000 due on March 1, 2022 and 2023. The license provides for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company&#8217;s estimated aggregate net cash recovery as a result of the Settlement Agreement will be approximately $10,200,000. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2021, the Company held receivables related to the settlement in the amount of $10,200,000. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in Fiscal 2021. &#160;During the quarter ended March 31, 2022, the Company received the first payment of $5,100,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company would recognize the $1.8 million of license revenue when it determined the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $900,000 payment under the license agreement. As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, the Company holds a settlement receivable balance of $5,100,000, which has been pledged to Woodforest - see Note 6 - Significant Transactions, related to the settlement and a trade receivable balance of $900,000 related to the license agreement. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_GainLossRelatedToLitigationSettlementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure on gain (Loss) related to litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_GainLossRelatedToLitigationSettlementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643141708272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">20.&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recorded no income tax expense for the three months ended September&#160;30,&#160;2022 because the estimated annual effective tax rate was zero. As of September 30, 2022, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144155584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">21.&#160;&#160;&#160;Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">COVID-19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result of the pandemic, the Company has at times experienced reduced capacity to provide CDMO services as a result of instituting social distancing at work procedures in our Texas facility, restricting access to essential workers, as well as taking other precautions. In July 2022 after we experienced a rise in COVID-19 cases within our Texas facility, for approximately one week, we mandated only those involved in mission critical manufacturing activities were to be permitted within our Texas facility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has ascertained that certain risks associated with further COVID-19 developments may adversely impact its operations and liquidity, and its business and share price may also be affected by the COVID-19 pandemic. However, the Company does not anticipate any significant threat to its operations at this point in time. <span style="background:#ffffff;">The future progression of the pandemic and its effects on the Company&#8217;s business and operations are uncertain. The Company may face difficulties recruiting or retaining patients in its planned clinical trials if patients are affected by the virus or are fearful of traveling to clinical trial sites because of the outbreak. The Company and its third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to the Company&#8217;s research and development activities, including, for example, medical and laboratory supplies used in preclinical studies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak. &#160;</span>Due to the general unknown nature surrounding the crisis, the Company cannot reasonably estimate the potential for any future impacts on its operations or liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The outbreak and spread of COVID-19 and continued progress in various countries around the world, including the United States, has led authorities around the globe to take various extraordinary measures to stem the spread of the disease, such as emergency travel and transportation restrictions, school closures, quarantines and social distancing measures. The outbreak of COVID-19 has had an adverse effect on global markets and may continue to affect the economy in the United States and globally, especially if new strains of SARS-CoV-2 emerge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">War in Ukraine</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On February 24, 2022, Russia launched an invasion of Ukraine which has resulted in increased volatility in various financial markets and across various sectors. The United States and other countries, along with certain international organizations, have imposed economic sanctions on Russia and certain Russian individuals, banking entities and corporations as a response to the invasion. The extent and duration of the military action, resulting sanctions and future market disruptions in the region are impossible to predict. Moreover, the ongoing effects of the hostilities and sanctions may not be limited to Russia and Russian companies and may spill over to and negatively impact other regional and global economic markets of the world, including Europe and the United States. &#160;Presently, </span>the Company does not have any existing Russian suppliers or contractors. While it is difficult to estimate the impact of current or future sanctions on the Company&#8217;s business and financial position, or global supply chains or service provisions that could have an impact on the availability or price of goods and services that the Company requires, the Company is not aware of any company-specific risks related to the war in Ukraine at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Inflation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Although the Company has not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on the Company&#8217;s operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143172800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee 401(K) Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee 401(K) Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee 401(K) Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">22.&#160;&#160;&#160;Employee 401(K)&#160;Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing January&#160;1, 2018, the Company established the iBio,&#160;Inc. 401(K)&#160;Plan (the &#8220;Plan&#8221;). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a 100% matching contribution that is not in excess of 5% of an eligible employee&#8217;s compensation. In addition, the Company may make qualified non-elective contributions at its discretion. For the three months ended September&#160;30,&#160;2022 and 2021, employer contributions made to the Plan totaled approximately $104,000 and $33,000, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $71,000 and $33,000 for the three months ended September 30, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643146578224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">23.&#160;&#160;&#160;Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an interest rate of 5.6% and securitized by certain assets purchased for the San Diego research site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 10, 2022, as previous disclosed in relation to the Employment Agreement with Thomas F. Isett 3<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">rd</sup>, the Company&#8217;s Chief Executive Officer, dated April 30, 2021, the Company granted Mr. Isett RSUs to acquire 200,000 shares of common stock, $0.001 par value per share (the &#8220;Common Stock&#8221;), on a post-split basis.&#160; The RSUs vest over a three-year period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) outlicensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application.&#160; The grant-date fair value of the RSUs totaled approximately $296,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 11, 2022, the Company granted Mr. Robert Lutz, the Company&#8217;s Chief Financial and Business Officer, RSUs to acquire 100,057 shares of the Company&#8217;s Common Stock in exchange for Mr. Lutz&#8217; agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board of Directors. The grant-date fair value of the RSUs totaled approximately $175,100.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 11, 2022, the Company granted Mr. Martin Brenner, the Company&#8217;s Chief Scientific Officer, RSUs to acquire 95,348 shares of the Company&#8217;s Common Stock in exchange for Mr. Brenner&#8217;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#8217;s 2023 objectives, as defined by the Board of Directors. The grant-date fair value of the RSUs totaled approximately $166,860</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643141724288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounts Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#8217;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, the Company determined that an allowance for doubtful accounts was not needed.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for its revenue recognition under Accounting Standards Codification ("ASC") 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i)&#160;identify the contract, (ii)&#160;identify the performance obligations, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations and (v)&#160;recognize revenue when a performance obligation is satisfied. The nature of the Company&#8217;s contracts with customers generally falls within the three key elements of the Company&#8217;s business plan: CDMO Facility Activities; Product Candidate Pipeline, and Facility Design and Build-out /Technology Transfer services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and/or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At September 30, 2022 and June 30, 2022, the Company had no contract loss provisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company generates (or may generate in the future) contract revenue under the following types of contracts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fixed-Fee </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue can be recognized either 1) over time or 2) at a point in time. &#160;All revenue was recognized at a point in time for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended September 30, 2021, revenue was from the settlement of a revenue contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Time and Materials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#8217;s billing rate plus other project specific costs incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractAssetsPolicyTextBlock', window );">Contract Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract asset is an entity&#8217;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both September&#160;30,&#160;2022 and June&#160;30,&#160;2022, contract assets were $0.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractLiabilitiesPolicyTextBlock', window );">Contract Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Contract Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract liability is an entity&#8217;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#8217;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, contract liabilities w<span style="background:#ffffff;">ere </span><span style="background:#ffffff;">$161,000</span><span style="background:#ffffff;"> and </span><span style="background:#ffffff;">$100,000</span><span style="background:#ffffff;"> r</span>espectively. The Company recognized revenue of $56,000 during the three months ended September 30, 2022 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. &#160; The Company recognized revenue of $84,000 during the three months ended September 30, 2021 that was included in the contract liabilities balance as of June 30, 2021 and reported as part of continuing operations. &#160; </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for leases under the guidance of Accounting Standards Codification ("ASC") 842, "Leases" ("ASC 842"). The standard established a right-of-use (&#8220;ROU&#8221;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#8217;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, <span style="-sec-ix-hidden:Hidden_sGul_1aHN0eDILLvK8AumA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#8217;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#8217;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#8217;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at September 30, 2022 and June 30, 2022 consisted of money market accounts. Restricted cash consisted of collateral held for letters of credit obtained to the term note payable for the purchase of the 130,000 square foot cGMP manufacturing facility in Bryan, Texas located at 8800 HSC Parkway, Bryan, Texas 77807 (the &#8220;Facility&#8221;) (see Note 6 &#8211; Significant Transactions) and the San Diego operating lease (see Note 15 &#8211; Operating Lease Obligations) and a Company purchasing card. The Company&#8217;s bank required an additional 5% collateral held above the actual letters of credit issued. Restricted cash was approximately $6 million at both September 30, 2022 and June 30, 2022. On October 11, 2022, the Company, as part of the First Amendment to the Credit Agreement with Woodforest, paid down $5.5M of the term loan and subsequently Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. The change in restricted cash will be reflected in second quarter of fiscal year 2023 financials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 22,676</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,743</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,672</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy', window );">Investments in Debt Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Investments in Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value is calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. See Note 8 &#8211; Investments in Debt Securities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';">Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. &#160;Inventory held is related to the CDMO business and has been classified as held for sale. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 730-10, <i style="font-style:italic;">Research and Development</i> (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the three month periods ending September 30, 2022 and 2021 research and development expense was reported in both continuing and discontinued operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_RightOfUseAssetsPolicyPolicyTextBlock', window );">Right-of-Use Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-Use Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 14 - Finance Lease Obligations for additional information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_mylpkjT0LkCiMRV69PIkrw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to 39 years.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of 10 years and other intellectual property is amortized over periods from 16 to <span style="-sec-ix-hidden:Hidden_u6VUYlS0b0yj9uFRIDrlgA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">23&#160;years</span></span>. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges for the three months ended September&#160;30,&#160;2022 and 2021.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The impact that share-based payment awards will have on the Company&#8217;s results of operations is a function of the number of shares awarded, the trading price of the Company&#8217;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#8217;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Expected volatility is based on historical volatility of the Company&#8217;s common stock (the &#8220;Common Stock&#8221;); the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#8217;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 17 - Share-Based Compensation for additional information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, amounts in excess of insured limits were approximately $15,372,000 and $18,200,000, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended September&#160;30,&#160;2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from one customer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended September&#160;30,&#160;2021, the Company reported revenue from continuing operations from one customer related to the settlement of a revenue contract and generated 100% of revenue reported in discontinued operations from three customers, each of whom individually accounted for more than 10% of revenue.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Recently Issued Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#8217;s condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contract assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_RightOfUseAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policy for right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_RightOfUseAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=6435544&amp;loc=d3e41834-113960<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143236080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of discontinued operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 127</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 40</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 87</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,378</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 7,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,458</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 10,417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,836</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expenses):</p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - related party</span></p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (608)</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Forgiveness of note payable and accrued interest - SBA loan</span></p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 607</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other expenses</p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (227)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td></tr><tr><td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operation</p></td><td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,593)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,751)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents net carrying values related to the major classes of assets that were classified as held for sale at September 30, 2022 and June 30, 2022 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Inventory</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">937</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35,892</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 38,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,900</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35,289</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,951</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 37,240</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:19.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 10</p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:21.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,941</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:middle;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 306</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 416</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,082</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing noncash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed assets included in accounts payable in prior period, paid in current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 383</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Unpaid fixed assets included in accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 750</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143230032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of of total cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 22,676</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,743</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,743</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,883</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,672</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144048816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Purchase Price Allocation of Asset Acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,760,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,300,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,440,000</p></td></tr><tr><td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,500,000</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_RubrycTheraputicsInc.Member', window );">RubrYc Theraputics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Purchase Price Allocation of Asset Acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:73.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,228,000</span></p></td></tr><tr><td style="vertical-align:middle;width:73.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 114,000</span></p></td></tr><tr><td style="vertical-align:middle;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:4.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,342,000</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643141778128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt and Equity Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of components of investments in debt securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Debt Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Investments in debt securities consist of AA and A rated corporate bonds bearing interest at rates from 0.25% to 3.5% with maturities from <span style="-sec-ix-hidden:Hidden__3BD-NqJOEiqalOgJX0pyg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">December 2022</span></span> to <span style="-sec-ix-hidden:Hidden_NaePz8N5I0616M6LaQS5Jg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">February 2024</span></span>. The components of investments in debt securities are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Adjusted cost</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,793</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,029</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Gross unrealized losses</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.48%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (194)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.46%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (184)</p></td></tr><tr><td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Fair value</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:16.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,845</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of fair value of available-for-sale debt securities, by contractual maturity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The fair value of available-for-sale debt securities, by contractual maturity, was as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:59.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:15.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Fiscal period ending:</b></p></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2023</p></td><td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,054</p></td></tr><tr><td style="vertical-align:middle;width:59.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">2024</p></td><td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,791</p></td></tr><tr><td style="vertical-align:middle;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:15.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,845</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143241456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease ROU Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract', window );"><strong>Finance Lease ROU [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock', window );">Summary of the gross carrying value and accumulated amortization of finance lease ROU</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ROU - Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 146</p></td></tr><tr><td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (85)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (72)</p></td></tr><tr><td style="vertical-align:bottom;width:70.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net finance lease ROU</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 74</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643146594976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Category the gross carrying value and accumulated amortization of intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,100</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 2,846</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,946</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,905)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,867)</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents and licenses &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,305)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,403)</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,210)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,270)</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total definite lived intangible assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 676</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License - indefinite lived</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,175</p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 6,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,851</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643146778672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Finance Lease Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock', window );">Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 12</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 10</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock', window );">Schedule of finance lease and weighted average information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 2.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 1.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate - finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 9.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 6.250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Payments Under the Finance Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 303</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 369</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 297</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 338</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 293</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,000</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (303)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to schedule of finance lease right of use assets and obligation and weighted average information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643145915968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease, Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock', window );">Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Payments under the Operating Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the operating lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on September&#160;30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Imputed Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 464</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 635</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 653</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 674</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 562</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 694</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,638</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,154</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 4,758</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 3,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643142451024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings (loss) Per Share, Basic and Diluted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to iBio, Inc. from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,537)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,188)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Preferred stock dividends &#8211; iBio CMO Preferred Tracking Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (66)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,537)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,254)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,593)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,751)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,130)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,005)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 8,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 8,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_UVdxoMmgQkKjhJdoE6VcYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.85)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_drCJr6G_BkCKj9KtPlTGNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.60)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ja0Qe-ca6kSwUGmiTbHIlA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1FZCwCoI6Emocc2F149ZKA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-4hgScTO5E-EP-H2wvkN5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.05)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_OTJhXFjeGU-xhjMC2Fzccw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 576</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant issued under the Transaction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 31</p></td></tr><tr><td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares excluded from the calculation of diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 1,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"> 607</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643145713376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 14</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 1,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 706</p></td></tr><tr><td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 1,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"> 720</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $96,000 and $101,000 for the three months ended September 30, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair value of options granted using the Black-Scholes option pricing model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal 2023, the Company granted stock option agreements to various employees to purchase 303,869 shares of the Company's common stock at exercise prices between $6.75 and $9.50 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:79.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">3.21% - 3.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">115.52 - 116.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643139361696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 22, 2022</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashAndCashEquivalentsPlusDebtSecurities', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, shares received per share tendered</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodValueCapitalRaise', window );">Capital raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise', window );">Capital raise (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to Basis of Presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashAndCashEquivalentsPlusDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents plus debt securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashAndCashEquivalentsPlusDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares raised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodSharesCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodValueCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of capital raise during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodValueCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643138245696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EmployeeReductionExpenses', window );">Expected employee reduction charges</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Results of operations for discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenues</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross profit</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="nump">3,062<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,355<span></span>
</td>
<td class="nump">2,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">10,417<span></span>
</td>
<td class="nump">3,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense - term note payable</a></td>
<td class="num">(226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupInterestExpenseRelatedParty', window );">Interest expense - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupGainOnDebtForgiveness', window );">Forgiveness of note payable and accrued interest - SBA loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DiscontinuedOperationsMiscellaneousExpensesIncome', window );">Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Total other expenses</a></td>
<td class="num">(227)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(10,593)<span></span>
</td>
<td class="num">(3,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="nump">937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent', window );">Property and equipment, net</a></td>
<td class="nump">35,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets</a></td>
<td class="nump">38,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract', window );"><strong>Other assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations', window );">Operating lease obligation</a></td>
<td class="nump">1,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupNoncurrentOperatingLeaseObligations', window );">Operating lease obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract', window );"><strong>Net Cash Provided by (Used in) Discontinued Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation expense</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets', window );">Amortization of finance lease ROU assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpenditureDiscontinuedOperations', window );">Purchase of fixed assets</a></td>
<td class="nump">875<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Investing noncash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod', window );">Fixed assets included in accounts payable in prior period, paid in current period</a></td>
<td class="nump">1,542<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations', window );">Unpaid fixed assets included in accounts payable</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DiscontinuedOperationsMiscellaneousExpensesIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous expenses (income) attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DiscontinuedOperationsMiscellaneousExpensesIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of finance lease ROU assets attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current operating lease obligations attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed asset charges incurred but not yet paid attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupGainOnDebtForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on forgiveness of debt to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupGainOnDebtForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupInterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense to related party from discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupInterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupNoncurrentOperatingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent operating lease obligations attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupNoncurrentOperatingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current operating lease ROU assets attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent operating lease ROU assets attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EmployeeReductionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected amount of expenses to be incurred due to employee reductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EmployeeReductionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid fixed assets included in accounts payable, attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpenditureDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital expenditure attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpenditureDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1063-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643139486912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>customer </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForLossOnContracts', window );">Provisions for contract loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Contract liabilities</a></td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized included in contract liabilities</a></td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientsPackage', window );">Lease, Practical Expedients, Package [true false]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Intangible asset impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Amount in excess of insured limit</a></td>
<td class="nump">$ 15,372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfMajorCustomers', window );">Number of major customers | customer</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to number of major customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientsPackage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientsPackage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLossOnContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative provision for contract losses not offset against related costs accumulated on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 35<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126916656&amp;loc=d3e57777-111642<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLossOnContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143978176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643139486528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 5,996<span></span>
</td>
<td class="nump">$ 5,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">9,887<span></span>
</td>
<td class="nump">22,676<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">15,883<span></span>
</td>
<td class="nump">28,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember', window );">Letter Of Credit - Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="nump">5,743<span></span>
</td>
<td class="nump">5,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember', window );">Letter Of Credit - San Diego Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember', window );">Company Purchasing Card [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643137907248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2021</div></th>
<th class="th"><div>Aug. 23, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DeferredFinancingCostsAmortizationExpense', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementValueOfSharesToBePurchased', window );">Stock purchase agreement, value of shares to be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest', window );">Total purchase price</a></td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment', window );">Cash payment</a></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FairMarketValueOfProperty', window );">Fair market value of property</a></td>
<td class="nump">$ 151,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty', window );">Percentage of base rent</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired', window );">Cash consideration for equity interest acquired</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued</a></td>
<td class="nump">51,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share</a></td>
<td class="nump">$ 33.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent', window );">Shares issued under the Warrant</a></td>
<td class="nump">11,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue', window );">Fair value of the warrant</a></td>
<td class="nump">$ 217,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="nump">$ 22,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as percent)</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CreditAgreementThresholdLimitUnrestrictedCash', window );">Unrestricted cash</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IrrevocableLetterOfCredit', window );">Irrevocable letter of credit</a></td>
<td class="nump">$ 5,469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member] | IBio CMO Preferred Tracking Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquityAgreementWarrantsIssuedOrIssuable', window );">Warrants issuable</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable', window );">Percentage of equity interest</a></td>
<td class="nump">0.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CollaborationAndLicenseAgreementAgreementTerm', window );">Collaboration and license agreement, agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Theraputics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm', window );">Collaboration and license agreement, royalty payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember', window );">Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementNumberOfSharesPurchased', window );">Stock purchase agreement, number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,864,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementValueOfSharesPurchased', window );">Stock purchase agreement, value of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent payable on percentage of fair Market Value of the Property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BaseRentPercentageOfFairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CollaborationAndLicenseAgreementAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement, agreement term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CollaborationAndLicenseAgreementAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement, royalty payment term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CreditAgreementThresholdLimitUnrestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold limit of unrestricted cash to be maintained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CreditAgreementThresholdLimitUnrestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DeferredFinancingCostsAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DeferredFinancingCostsAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration transferred for equity interest acquired under the equity agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity agreement, percentage of equity interest issued or issuable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquityAgreementWarrantsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued or issuable under the equity agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquityAgreementWarrantsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair market value of the property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IrrevocableLetterOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Irrevocable letter of credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IrrevocableLetterOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementNumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement, number of shares purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementNumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementValueOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement, value of shares purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementValueOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementValueOfSharesToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement, value of shares to be purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementValueOfSharesToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued for the final payment of rent due under sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of warrants issued for the final payment of rent due under sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibio_IbioCmoPreferredTrackingStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibio_IbioCmoPreferredTrackingStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTheraputicsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_NoBiosimilarProductHasBeenApprovedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_NoBiosimilarProductHasBeenApprovedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143932560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Transactions (Summary of Asset Acquisition) (Details)<br></strong></div></th>
<th class="th">
<div>Aug. 23, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember', window );">Series A-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">1,760,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember', window );">Asset Acquisition Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">4,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionPrepaidExpensesMember', window );">Asset Acquisition Prepaid Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">$ 1,440,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionPrepaidExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionPrepaidExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643141776368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Transactions - Amended Credit Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SignificantTransactionsAbstract', window );"><strong>Significant Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Term note payable - net of deferred financing costs</a></td>
<td class="nump">$ 22,201<span></span>
</td>
<td class="nump">$ 22,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Transactions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643137844832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Note Receivable (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Promissory Note Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LoansReceivableAmountInvested', window );">Amount invested</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LoansReceivableFixedRatesOfInterest', window );">Interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LoansReceivableAmountInvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the face amount of notes receivable invested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LoansReceivableAmountInvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LoansReceivableFixedRatesOfInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fixed rate of interest on notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LoansReceivableFixedRatesOfInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643137844512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt and Equity Securities (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premiums on debt securities</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Debt securities, interest rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentMaturityDate', window );">Debt securities, maturity date</a></td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Debt securities, interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentMaturityDate', window );">Debt securities, maturity date</a></td>
<td class="text">Nov.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of investment, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144131424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Debt and Equity Securities (Components of Investments in Debt Securities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted cost</a></td>
<td class="nump">$ 7,793<span></span>
</td>
<td class="nump">$ 11,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Fair value</a></td>
<td class="nump">$ 7,599<span></span>
</td>
<td class="nump">$ 10,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643139528320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Debt and Equity Securities (Debt Securities, Contractual Maturity) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue', window );">2022</a></td>
<td class="nump">$ 5,341<span></span>
</td>
<td class="nump">$ 8,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">2023</a></td>
<td class="nump">2,258<span></span>
</td>
<td class="nump">2,791<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrent', window );">Fair value</a></td>
<td class="nump">$ 7,599<span></span>
</td>
<td class="nump">$ 10,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643141749872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease ROU Assets (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract', window );"><strong>Finance Lease ROU [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease ROU assets</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643142159104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems', window );"><strong>Finance Lease, Right Of Use Asset, Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">$ (85)<span></span>
</td>
<td class="num">$ (72)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Net finance lease ROU</a></td>
<td class="nump">875<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibio_FacilityMember', window );">Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems', window );"><strong>Finance Lease, Right Of Use Asset, Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetGross', window );">ROU, gross</a></td>
<td class="nump">$ 960<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of lessee's right to use underlying asset under finance lease, before accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibio_FacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibio_FacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643139648368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease ROU Assets (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Operating Lease ROU Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lab and office | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset | $</a></td>
<td class="nump">$ 2,928,000<span></span>
</td>
<td class="nump">$ 3,068,000<span></span>
</td>
<td class="nump">$ 1,967,000<span></span>
</td>
<td class="nump">$ 3,603,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143222560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643139621712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets (Carrying Value and Accumulated Depreciation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net fixed assets</a></td>
<td class="nump">$ 3,464<span></span>
</td>
<td class="nump">$ 1,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643145899104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144457936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Carrying Value and Accumulated Amortization) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, gross carrying value</a></td>
<td class="nump">$ 6,220<span></span>
</td>
<td class="nump">$ 5,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, accumulated amortization</a></td>
<td class="num">(5,210)<span></span>
</td>
<td class="num">(5,270)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total definite lived intangible assets, net of accumulated amortization</a></td>
<td class="nump">6,013<span></span>
</td>
<td class="nump">4,851<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total net intangible assets</a></td>
<td class="nump">6,013<span></span>
</td>
<td class="nump">4,851<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, gross carrying value</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, accumulated amortization</a></td>
<td class="num">(2,905)<span></span>
</td>
<td class="num">(2,867)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, gross carrying value</a></td>
<td class="nump">2,720<span></span>
</td>
<td class="nump">2,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, accumulated amortization</a></td>
<td class="num">$ (2,305)<span></span>
</td>
<td class="num">$ (2,403)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643145818224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Estimated Annual Amortization Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 6,013<span></span>
</td>
<td class="nump">$ 4,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643138424688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note Payable - PPP Loan (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable PPP loan</a></td>
<td class="nump">$ 22,201<span></span>
</td>
<td class="nump">$ 22,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643142462096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finance Lease Obligation (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Finance Lease Obligation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LessorFinanceLeaseMonthlyRent', window );">Mobile office trailer monthly rent</a></td>
<td class="nump">$ 3,819<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LessorFinanceLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of rent receivable monthly by the lessor under the finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LessorFinanceLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144445744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligation (Finance Lease Cost and Other Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of ROU assets</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinancingCashFlowsFromFinanceLeaseObligation', window );">Financing cash flows from finance lease obligation</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease ROU assets</a></td>
<td class="nump">875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations - current portion</a></td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligation - non-current portion</a></td>
<td class="nump">$ 576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - finance lease</a></td>
<td class="text">2 years 8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - Finance lease obligation</a></td>
<td class="nump">9.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinancingCashFlowsFromFinanceLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for finance lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinancingCashFlowsFromFinanceLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643138457424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(303)<span></span>
</td>
<td class="num">$ (46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligation - net of current portion</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember', window );">Principal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligation - net of current portion</a></td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember', window );">Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643139470800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease Obligation (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lab and office | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">88 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseMonthlyRent', window );">Operating lease monthly rent payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent', window );">Annual percentage increase in base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Irrevocable letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentAbatementInFirstYearPeriod', window );">Base rent abatement period in the first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentAbatementInFirstYearPeriod', window );">Base rent abatement period in the first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FairMarketValueOfProperty', window );">Fair market value of property</a></td>
<td class="nump">$ 151,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty', window );">Percentage of base rent</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseMonthlyRent', window );">Operating lease monthly rent payable</a></td>
<td class="nump">$ 151,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BaseRentAbatementInFirstYearPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base rent abatement period in the first year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BaseRentAbatementInFirstYearPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent payable on percentage of fair Market Value of the Property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BaseRentPercentageOfFairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair market value of the property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease, Annual percentage increase in base rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of rent payable monthly by the lessee under the operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643139256752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
<th class="th"><div>Sep. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_OperatingLeaseCostsAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">$ 141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_TotalOperatingLeaseCosts', window );">Total lease cost</a></td>
<td class="nump">141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement lease liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating lease</a></td>
<td class="nump">141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_OperatingCashFlowsFromOperatingLeaseObligation', window );">Operating cash flows from operating lease obligation</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,928,000<span></span>
</td>
<td class="nump">$ 3,068,000<span></span>
</td>
<td class="nump">$ 1,967,000<span></span>
</td>
<td class="nump">$ 3,603,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation - current portion</a></td>
<td class="nump">183,000<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation - net of current portion</a></td>
<td class="nump">$ 3,421,000<span></span>
</td>
<td class="nump">$ 3,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_OperatingCashFlowsFromOperatingLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating cash flows from operating lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_OperatingCashFlowsFromOperatingLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_OperatingLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_OperatingLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_TotalOperatingLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total operating lease costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_TotalOperatingLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643138350224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Obligation, Principal</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">3,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">$ (91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of minimum lease obligation</a></td>
<td class="nump">3,421<span></span>
</td>
<td class="nump">$ 3,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract', window );"><strong>Operating Lease Obligation, Imputed Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne', window );">2023</a></td>
<td class="nump">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo', window );">2024</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree', window );">2025</a></td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour', window );">2026</a></td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive', window );">2027</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive', window );">Thereafter</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal', window );">Imputed Interest, Total</a></td>
<td class="nump">1,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract', window );"><strong>Operating Lease Obligation, Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne', window );">2023</a></td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo', window );">2024</a></td>
<td class="nump">635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree', window );">2025</a></td>
<td class="nump">653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour', window );">2026</a></td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive', window );">2027</a></td>
<td class="nump">694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest', window );">Principal and imputed interest, Total</a></td>
<td class="nump">$ 4,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year One.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Imputed Interest Payment, Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Principal And Imputed Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643138963712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Sep. 22, 2022</div></th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 23, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ibio_PreferredTrackingStockMember', window );">iBio CMO Preferred Tracking Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Preferred Stock, Dividends Per Share, Declared | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember', window );">Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | Bioprocessing (iBio CDMO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock', window );">Number of LLC interest units exchanged for each share of preferred tracking stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of shares, net of issuance cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember', window );">Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling Interest, Ownership Percentage by Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember', window );">Exchange Agreement [Member] | Eastern Affiliate [Member] | iBio CMO Preferred Tracking Stock [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ibio_PreferredTrackingStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ibio_PreferredTrackingStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ibio_IbioCdmoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ibio_IbioCdmoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibio_EasternAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibio_EasternAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144451504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Basic and diluted numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss attributable to iBio, Inc.</a></td>
<td class="num">$ (7,537)<span></span>
</td>
<td class="num">$ (5,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends - iBio CMO Preferred Tracking Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to iBio, Inc. stockholders</a></td>
<td class="num">(7,537)<span></span>
</td>
<td class="num">(5,254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(10,593)<span></span>
</td>
<td class="num">(3,751)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnconsolidatedGainLossAttributableToStockholders', window );">Net loss available to iBio, Inc. stockholders</a></td>
<td class="num">$ (18,130)<span></span>
</td>
<td class="num">$ (9,005)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic and diluted denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">8,842<span></span>
</td>
<td class="nump">8,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">8,842<span></span>
</td>
<td class="nump">8,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations</a></td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations</a></td>
<td class="num">(0.85)<span></span>
</td>
<td class="num">(0.60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations</a></td>
<td class="num">(1.20)<span></span>
</td>
<td class="num">(0.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations</a></td>
<td class="num">(1.20)<span></span>
</td>
<td class="num">(0.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Per share amount basic</a></td>
<td class="num">(2.05)<span></span>
</td>
<td class="num">(1.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Per share amount diluted</a></td>
<td class="num">$ (2.05)<span></span>
</td>
<td class="num">$ (1.03)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnconsolidatedGainLossAttributableToStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The unconsolidated net gain (loss) attributable to stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnconsolidatedGainLossAttributableToStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643139404128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 22, 2022</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EarningsLossPerCommonShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EarningsLossPerCommonShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143952560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation (Narrative) (Details) - 2020 Omnibus Equity Incentive Plan [Member]<br> shares in Millions</strong></div></th>
<th class="th">
<div>Dec. 09, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total number of shares of common stock reserved | shares</a></td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized', window );">Maximum value of all awards awarded under the Plan</a></td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ibio_ScenarioOneMember', window );">Scenario One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized', window );">Maximum value of all awards awarded under the Plan</a></td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ibio_ScenarioTwoMember', window );">Scenario Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized', window );">Maximum value of all awards awarded under the Plan</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643139248320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Share Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 1,126<span></span>
</td>
<td class="nump">$ 720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">$ 706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643144015328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Fair Value of Options Granted) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643138714992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fraunhofer Settlement (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2022</div></th>
<th class="th"><div>May 04, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementAssetsCurrent', window );">Settlement receivable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfLegalFeesExpectedToBeReceived', window );">Percentage of legal fees expected to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Estimated net cash recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Settlement payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | License and Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Settlement income</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Settlement payment received</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Legal Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment One [Member] | License and Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementAssetsCurrent', window );">Settlement receivable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment Two [Member] | License and Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SettlementAssetsNonCurrent', window );">Settlement receivable - noncurrent portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments receivables related to litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashPaymentsReceivablesRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfLegalFeesExpectedToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of legal fees expected to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfLegalFeesExpectedToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SettlementAssetsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement receivables, Non current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SettlementAssetsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedLegalFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedLegalFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643147706352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643147816112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee 401(K) Plan (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee 401(K) Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643143989776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Value of common stock issued</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139643147660240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease ROU Assets (Category the net carrying values of operating lease ROU) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
<th class="th"><div>Sep. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Operating Lease ROU Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease ROU assets</a></td>
<td class="nump">$ 2,928,000<span></span>
</td>
<td class="nump">$ 3,068,000<span></span>
</td>
<td class="nump">$ 1,967,000<span></span>
</td>
<td class="nump">$ 3,603,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>ibio-20220930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ibio="http://www.ibioinc.com/20220930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ibio-20220930.xsd" xlink:type="simple"/>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pjwYstABlU2nhu8zVQax6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_nIO8x0O-D0ajEs1hfec5ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_22_2022_To_9_22_2022_CTru4tx0CEOj9arQdgZu6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-09-22</startDate>
            <endDate>2022-09-22</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mC7BYOTYH0a7Wk8V2O2hrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N4y1JB93p0KE0lNMIY0TKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ONpLrTILEC92ojz2-S9Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VqSPMHJY_kKNvzc7COpAeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B4AZcYK-c0asmfHVM1feAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mG4LbET2DECSO7FdaX63IQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HxjHz6i74k6VEvJSqTEdqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bmsbSdyfUUmoltX5xZjZqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XzvlH8qzzkC_5vSGgF1Uwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XVi69PwJykqe8xvOj7V4FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4SJVQK9LYUSBCSlw5dlipg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_2zacrRBIuEKYll8_FrKwOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GH-5RrH9aUCemJman1Sceg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LANmWQuoxU-cg4DMxrvqag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UIQ-9TQJg02_iffm6LAbPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_45O6JBHOlU2mPcO5JCdPKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bAryvWRFa0ajF3wOujsFkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0tv1Shz8i02Z3bQpOwGtZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2N7RXo2_pUetdE_cG5cZ6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_ZaqY31fz2UaBgOG5OgjeFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_euWJTSKtt0aJwVGdmEINPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_0pi0YCsgSUCH7buV1WBF9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_F4h9j-DOsUyvR-zF7aWpzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_K4UWN_QhQECOHvhw12blGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_54ARR6tb80WIuJ-jyvDHFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_H3Laxbz45UWYB-AJtsQg0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_8yJ_HfWYO0S9Yen3aE5TWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_h3rVauDz3ESYJDDsYgtxFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_ovqbH7S4FkKWmzhQHgtz3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_2_23_2017_QxVrYRSL_UiOCiGSWO0CFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2017-02-23</instant>
        </period>
    </context>
    <context id="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_h-pYgsijTkKHQ_QNQK-fLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-31</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_l3TXqFcTd0OMoQ1amXL65A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-23</startDate>
            <endDate>2017-02-23</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_J9Qyego6XEGPGcqSDViMZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_L7GZScf59UWcwVJ60pxOUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2021_H4wahzJ9fkakdBA5brt04w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_nOs84_8GCkueqFiJt1xgmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HRtnDhbFY0iZF8Myn0m59Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FDjxICtcCUCFzo4fnrEFAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_vBxV47t9JkmztS3TPBPfNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-23</instant>
        </period>
    </context>
    <context id="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_EasternAffiliateMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_MyiAUVo2vkGkyCCsfdBIcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibio:EasternAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-23</instant>
        </period>
    </context>
    <context id="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_cVkZ8G6vJUqQuiTDjSGGZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_RangeAxis_srt_MinimumMember_-6_SwUpb2EmaZh5-_vBL1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_RangeAxis_srt_MaximumMember_s8tVGg0TVkGTdiQRMPEupQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_ZxIXPbVKrUyMV_ban-OCAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialStandbyLetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-10</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_DEoVZtJZY0yz9pSSGN9D5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ab93kNrf80-v2rMyke-vrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember__u8DjlS8KEWaLpv6LnztgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_fXHaqpNPo0ibzA3IIYhZbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_rkj0FZs-fUu4EXJb9_k82g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_YQhUDGnYokGcvtHjtcEqtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_uC1tSKAok0msG1QVWd04rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_dlYgMTALDUmKK5WItuSB3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_WTTx3bX1OkW89C-T4NTf4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:PrincipalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_JT9c6c8IIEOMVOhxR4-gmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_GQ940Ff9F0Sa787zj-1tnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_vIjz2QvLhkmSRzd2SRXhOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_ibio_RubrycTheraputicsInc.Member_6l4R-5WO_UilEL_BSvm5mA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember_xJCS27lRZ0q-02PnngOAUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionPrepaidExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_zieqCNuAYk6lRv2JAfCx8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember__MJTg0K5YECHuCTCCIebng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_ITw1i6YR9UyPpE1bDlnljA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-09-10</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_gsOXphCp7kqOXBi52mrpig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aLCKc_DsZ0mcPYZ4iThlOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_RW522OwZwE2Q8Rhd-pq6hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_6yylM16A906KWG6WH1olXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kOWrKqdXuEqZHagsSxnYmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_awj1_vQ1DUSHyHXaRL7ufw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_U25ZnOgUdEuQ-HzSBdsbxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Cd2Z2zMIHkG4C6QpdIGJ0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-3uXSg1qM0mejJjzOTqnKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_QgEz_8IsUkubKmRBLIhjSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_zK_EuxHxJUWase0Bb6jdgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_QXdJeF316UutTHwstfvd0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_MtHCCTglWES6FXBOwD3GbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_UYTDkmnuYUKjYhuJvrtFBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_97qQQ2NlZkS1QrbYGZ0BWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-04</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_s9c-WnWOxE6g2LweOZs_9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_i04Yf02_rk-EHh765zWa6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_ezl_cu4pZEaWF2orMq4slA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-23</startDate>
            <endDate>2017-02-23</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_XyA_UzbdsEqM1o0uE-Nz6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="As_Of_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_RpRam_Iq8kC7AtGMNktNbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_4_1_2021_Cv64n0Mw7E6pyUXZzZXFwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2021_To_9_10_2021_m_dKSYWyjkGt_N2eurcfeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_UM_IWNFT-kCLpCY0YtA3Kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibio:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_7CoQPwcN1U-vHI9EXbbGag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibio:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_2OHxCAB-J0WOw18oKiVXGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibio:IbioCmoPreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Drb-_QNrO0K1RLoc86Un0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fF9KSDzTNUewjtgDUfom4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IurkUKJGTEiNYvvgn9u9qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_0Gc57JBw0UGHG06Trj7aaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:NoBiosimilarProductHasBeenApprovedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_OdZyqlQ0vEmY8lbQusF-8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTheraputicsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_6ZrviqcdeEqMylJf6L3J_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_WRviyH3-o0yDEY9X1wSIKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_LZBHDrN9UUGCxpUjpg5lXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_YqxjlA6uoU6BgYmOK-o-eA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_mRyOoO-D5kmgzWk1TetiGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_fdlqH-ydv0qTOi8QNX4gWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedLegalFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_4qWWKwB8e0-Yy5X_aaxA6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_Q5VFP_d1U0Sx8AHkVLyC-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_7_2022_qjzi2byYh0-0owjOCuOBmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-11-07</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_customer_Y0UfwaAMRkCOQV5hDgN0Lw">
        <measure>ibio:customer</measure>
    </unit>
    <unit id="Unit_Standard_sqft_5KxWaFXlD02dT7QlqBc7JA">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Hidden_r-l9-B56DkK8GFGRbyXoAQ"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8842000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Hidden_yhSKRaHIUkS1_3TLlaftHA"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8715000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Hidden_Doy5vExYEUu9Mr8jwtDtWQ"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8842000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Hidden_rjhicEeiM0iIWauwVf4RfA"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8715000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tc_aCnAQKbX_0OKexW2a5T7ng_2_1">0001420720</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tc_ZBVyyjFJ_kS9Iy9PEPT5fw_3_1">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tc_bF2rRI0PrkGVIvVoWftuvQ_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tc_y3aPtTSp2kuHjHNmgRr8bw_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tc_kA6uaDyTvUaR3mtzBp0rcQ_6_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="INF"
      id="Hidden_njHtyGT4_U6yqIcTgti9cg"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="INF"
      id="Hidden_tyE9TMbZgEyWhODfiBHPvA"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">1000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      id="Hidden_eqD4kNNv-U-K5qj5gfYiFQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      id="Hidden_wTYmbk3_IEuxZyoGomTrdA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="0"
      id="Hidden_XHV-8pD9R02rZnlCS5G2Qw"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">9006582</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="0"
      id="Hidden_-Kg9WQpbq0eBpOgmN66fgA"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8727158</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Hidden_OpPyzGPfbk6YG5Rr7wMBdg"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-0.85</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="2"
      id="Hidden_gMzmk3wLFkK2aHz3MKKD4g"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Hidden_AoT3ZaryAEean7dePk0z3A"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-1.20</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="2"
      id="Hidden_Cf2NuHLrfE-uFyMkWX3Uig"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-0.43</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Hidden_99bdrmUalkCbFfGhk6saBA"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-2.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="2"
      id="Hidden_YTsxMg4SEUaPMK4RepGT4Q"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-1.03</us-gaap:EarningsPerShareDiluted>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Hidden_G92FJIZcG06BIGNnHbTKpg"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1151000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_9_22_2022_To_9_22_2022_CTru4tx0CEOj9arQdgZu6A"
      decimals="INF"
      id="Hidden__0cS0oMu3kKeTj2aafl8jw"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:LeasePracticalExpedientsPackage
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Hidden_sGul_1aHN0eDILLvK8AumA">false</us-gaap:LeasePracticalExpedientsPackage>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_8yJ_HfWYO0S9Yen3aE5TWA"
      id="Hidden_mylpkjT0LkCiMRV69PIkrw">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember__u8DjlS8KEWaLpv6LnztgQ"
      id="Hidden_u6VUYlS0b0yj9uFRIDrlgA">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_0Gc57JBw0UGHG06Trj7aaw"
      id="Hidden_9g2_uLeoFka_iS5MEA5Jqw">P10Y</ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm>
    <us-gaap:InvestmentMaturityDate
      contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_MinimumMember_-6_SwUpb2EmaZh5-_vBL1Q"
      id="Hidden__3BD-NqJOEiqalOgJX0pyg">2022-01-01</us-gaap:InvestmentMaturityDate>
    <us-gaap:InvestmentMaturityDate
      contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_MaximumMember_s8tVGg0TVkGTdiQRMPEupQ"
      id="Hidden_NaePz8N5I0616M6LaQS5Jg">2023-11-01</us-gaap:InvestmentMaturityDate>
    <ibio:BaseRentAbatementInFirstYearPeriod
      contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_4qWWKwB8e0-Yy5X_aaxA6w"
      id="Hidden_HTgQ1reF4068PJjjH7wdhg">P2Y</ibio:BaseRentAbatementInFirstYearPeriod>
    <ibio:BaseRentAbatementInFirstYearPeriod
      contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_Q5VFP_d1U0Sx8AHkVLyC-g"
      id="Hidden_6jE7_kh_EUe3WSMLLFzfcg">P5Y</ibio:BaseRentAbatementInFirstYearPeriod>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Hidden_UVdxoMmgQkKjhJdoE6VcYg"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-0.85</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="2"
      id="Hidden_drCJr6G_BkCKj9KtPlTGNA"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Hidden_Ja0Qe-ca6kSwUGmiTbHIlA"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-1.20</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="2"
      id="Hidden_1FZCwCoI6Emocc2F149ZKA"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-0.43</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Hidden_-4hgScTO5E-EP-H2wvkN5w"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-2.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="2"
      id="Hidden_OTJhXFjeGU-xhjMC2Fzccw"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-1.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SettlementAssetsCurrent
      contextRef="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_ZaqY31fz2UaBgOG5OgjeFQ"
      decimals="0"
      id="Hidden_n27rjvZYL0OlHIzsiufN3A"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5100000</us-gaap:SettlementAssetsCurrent>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_YqxjlA6uoU6BgYmOK-o-eA"
      decimals="0"
      id="Hidden_KLGwyYKoFUWk37Z8Z7W-QA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">900000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <dei:DocumentType
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_P7rOSybBnEWP0Z2Ug33nFg">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tc_8S5gDCCgAkimMxbY6BmD4Q_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_eN36uKlme0GCti1WemQDfA">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tc_LjSnzpp7BU6PWnCX-hXvYQ_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_OT-Ez9ZIuEOMzwhHny774g">001-35023</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_Uqc_ybKUWkqDXvyRb1hEVA">iBio,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tc_KubkwukwR0a5JPYqVu-fQQ_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tc_6o7g8Vf_A06xs6UyMjg6Rw_0_2">26-2797813</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_Mn4LWgeR4EWkYc2HtAbylg">8800 HSC Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_OfYCA9_NikapwqPZzOCaXQ">Bryan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_3d2lrX6XKUGMgEgktws6VQ">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_h9ZyA0JhrkennR5iYJycfg">77807</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_WUPQTCiWw0W_JzQ5Yma76w">979</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_Sky0bxwS20-90cOwk5jD4A">446-0027</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tc_yipRbNn-v0mA8qAEf-LgiQ_2_0">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tc_6EZ8DxSLhkqM0ckrF9GyGg_2_2">IBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tc_RBVMOky-o0uMz5au5y7Xbg_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_NvUeC56JR06vGrAa8Y6lZw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_yZkp6mCJeE-NFW--99yv_w">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_vlveDWzjLEq0JxQO19ODTA">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_o_9sNO-6b0arHcBo9ZS_5A">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_z6avpidJ6kaAbRoUfwOB8g">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Narr_xRam8wHTEEy6vXunSfie-Q">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_7_2022_qjzi2byYh0-0owjOCuOBmQ"
      decimals="INF"
      id="Narr_EOLU1irICEq2MaRdEk5rOA"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8988782</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_ALhJZ6BUpESTZYwzhWz_fw_6_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">9887000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_gNDkWNfgSkS0tORKI-uvcw_6_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">22676000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_-6rYrtlBbU28OaVl_speyw_7_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">7599000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_yx1oF3bb8EuV9wmEPhrykw_7_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">10845000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_Gn0IhCbQkk2CAYEKS6JQMg_8_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1055000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_ZwPwX39YPky3Nfd7qu3PTQ_8_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:SettlementAssetsCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_tOIm4PGapE2HnPixffTR_w_9_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5100000</us-gaap:SettlementAssetsCurrent>
    <us-gaap:SettlementAssetsCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_ONQFnh5V10qh4VxHBxhl0Q_9_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5100000</us-gaap:SettlementAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_RXXMKYW5q0Sg_8_lE6BKtA_10_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1146000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_5EIWMdvK6UaPRrp13WDKrw_10_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1549000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_WxPhA17WikOXFVs9i3GK2w_11_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">38778000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_z6HFPG3AF0e-hmpEUU3UYg_11_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3900000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc__ll8nXQpzkSAYySqTklmgQ_12_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">63565000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_t-LtIkn3zkCUTJaxEBGhig_12_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">45070000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_vH1H6oQNmUGOBH1_Np0NxQ_14_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5996000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_BnH5mb75W06d9ZyxruEzKQ_14_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5996000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_6YDfuQHRhU-hC-pl3ha4PA_15_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">37314000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_Ny6GkFKvlkK2J9Dbce0xpg_16_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1650000</ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest>
    <ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_zLWcVDm57k6m1AZTtu9AFw_16_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1631000</ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_xaFpFbvQVE21yOtQsfmJDA_17_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">875000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_Rgccpee3GUuYFRJtqfoDaA_18_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2928000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_GXGnsbCAkku5DemINKwqTA_18_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3068000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_qJXOWAFWNUqo3lkSp8Zvzw_19_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3464000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_V98Pa411hESBdTjl5PIAUg_19_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1373000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_377Rhy4KWUi0amXQoGubFw_20_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">6013000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_5tEc4WO5eU-h9mSM9-ot7w_20_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">4851000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_WR00a5B730SFia9RYLm66A_21_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">44000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_Cf0qmRFXrEWNax3BP__NfA_21_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">74000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_Jd9eBQl1F0y81XAVCjzlhA_22_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">29000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_JhrjkEpCxUe6o5Abutixeg_22_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">29000</us-gaap:SecurityDeposit>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_ylO3CgFtCkCCYV3sXKLTwA_23_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">84564000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_Pk5z01gbtUKgPmSgU_sXqw_23_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">99406000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_ilSorH2UyEWCTA7dU1-wrw_27_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">4807000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_WZOX61iN6EaHLouBWHOpRw_27_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">4264000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_kaGEvoZab0e_oh3iTHMgiw_28_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2595000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_f9R-oNa-C06vkzibtMeZ7Q_28_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3764000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_sLvNQzXX3Um2Gqqzi1IN_g_29_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">303000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_s5Bc-cxKLU-c8fDJ3CSlzQ_30_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">183000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_lPJul0wQakyqPmyr7GIR3g_30_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">91000</us-gaap:OperatingLeaseLiabilityCurrent>
    <ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_eVhIxbEbB0a_iXRp2J-xJw_31_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1949000</ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale>
    <ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_fXIahf4PR0a4uWzncD2Mtg_31_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">56000</ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_NExyNIjaokyPDtiy72USsg_32_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">22201000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_ECFAJIEAS0aSCJ9nsNx1Yg_32_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">22161000</us-gaap:NotesPayableCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_l4berjRCdkqUkMUB-6pj9g_33_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">161000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_UeMX5w3lAkKSMrtJ4JcZxw_33_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">100000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_xQLpcC6t4EqhiIblamHEEA_34_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">32199000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_bW3ewczq2E2P1hkKIPqXSA_34_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">30436000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_kpoCTTQxTkeGiPFetbkhJQ_36_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">576000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_ZBt_qq62NU6u21HT4Yhv4A_37_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3421000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_vTNKwt6seEaiV_jlZsepEw_37_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3514000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <ibio:NoncurrentLiabilitiesRelatedToAssetsHeldForSale
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_oOzESy-hKkaF6RR-nWYAFw_38_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1971000</ibio:NoncurrentLiabilitiesRelatedToAssetsHeldForSale>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_DjvHfOQXEU6N5uPrTVw38g_40_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">36196000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_T8aEvzvyrE2cOJr4BNYMLg_40_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">35921000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="INF"
      id="Narr_ZZI1JDnltk6tktlr4Q6UGQ"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="INF"
      id="Narr_w5V5qWnZOkSvfU97ALIXdw"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="INF"
      id="Narr_zV2oeTXfREKm68yyEmqo4A"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="INF"
      id="Narr_rc25FuYn4kqt8rRDxv6BjA"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="INF"
      id="Narr_yKg8XsLHsEuKWavAlvQCsw"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="INF"
      id="Narr_x5AMusOWY0q-wwREDImWfw"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">1000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="INF"
      id="Narr_0lHtJrUGUkyIm8kQu8Wfdw"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="INF"
      id="Narr_U3Kluf0WpEKjO5bYUBrQBw"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="0"
      id="Narr_mYjNj50EBkC-obNbutdCcw"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">275000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="0"
      id="Narr_lgyprKZW90-2TBeZxChkEQ"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">275000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="INF"
      id="Narr_KlIPYKG5nUyoSPiXfF6Q0A"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">9006582</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="0"
      id="Narr_QCCAsugxDEKLiqraXjnqvQ"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8727158</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_EkgcnPvSdUCRAAdymiBjOA_45_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_UlNWGSVW0k2t7jnSXTNt2w_45_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">9000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc__-O5vYBmEES0zR7tWvDFJg_46_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">290642000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_fzEwrgit-UCbIDUb1_6pTA_46_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">287619000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_HBYKJCzr_0unGZMGKGijKQ_47_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-223000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_hUrsEeFWr02Rl4EQLmHbPw_47_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-213000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_g6DVAjzbT0mK5tDWib19yw_48_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-242060000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_6IGwAugdPkOP9UbVVWmm2w_48_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-223930000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_PmNHFX2Ff0u-kh7Zl9eeeA_49_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">48368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_e8lcqBwb5UuO6sK8rA795A_49_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">63485000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_viiJ2XHXf0aWFA29ntufjQ_50_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">84564000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_eLOhqZ6G_EaRWdcczRWF7g_50_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">99406000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_R033HGneP0GJHZ17XNWbMA_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_DSnbdq-a90evy8AQbIYcpw_5_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">84000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_pTRZ8ubXEEWpvBjWDLtBPA_8_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2548000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_FvP5IPvZsEib2GRnRiPWPg_8_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1134000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Narr_1f5M8rlgEE6BDX864WP0LQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Narr_5W-_NmAu1kOY055vhBvUjA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">189000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_8Et6v9p3202UU4uc9Bxg6A_9_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5088000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_bdtdix_AYUWfJsyxliTTrg_9_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">4175000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_Jbx5gjuho0SKGJOBwF9KBg_10_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">7636000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_T0A0Wv3_-kK4e0v2DGrZZw_10_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5309000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_2AkS4foe0EmJXBlpprN4fQ_12_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-7636000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_1wZZmc8ecEu92axqMfZFzA_12_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-5225000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_lYR3yXlEn0mHuTF7-pmxOA_15_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">99000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_ummrigYer0qdNh-gxn7Fww_15_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">36000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_oLCEKIDf90KICxjkQrKsfw_17_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-7537000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_6ZD3xUxt2Uy0PbsKudnt-w_17_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-5189000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_PKEet627r0mlK_4FwbkL3Q_18_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_bHAfzF-yXU6WqZQE6yKrdQ_18_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-1000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_EqEmF9aXEk6zp05hygeylg_19_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-7537000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_O7NmbZ3ns0il1XDlL2p8Qw_19_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-5188000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_CKlJG0O1gkqoFd4ewqibTQ_21_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_DDSPO6Ioj0-sr1yKW_cRZQ_21_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">66000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_mi8PBVLSKUKDA93CWhpVhw_22_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-7537000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_pNVbJwZ7mEqzeQWZNBA2_Q_22_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-5254000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_BiGV5RherU235JyqdRXM1g_24_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-10593000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_nQwP8OE-iUudoWB0c8QDOA_24_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-3751000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_wtyOjwd8pECGqLagFALi6Q_26_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-18130000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc__AB5yu7rGUKydu7NB78zmg_26_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-9005000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_CtSIFL34XUaENRtQl8wK5w_29_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-18130000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_Xpwf5PEpJkGzg3wAEwwJlQ_29_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-8940000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_5DgNxSO2JkOI05Y1gNg2xg_30_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_l4G5KHyowEi3315nI95tsQ_30_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_3H646P907EedBtSN0lsCKw_32_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-18140000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_odjTbkaXE0iU690yuz00sA_32_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-8941000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Tc_tccmynXft0OthMTcg3qS2w_34_3"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-0.85</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="2"
      id="Tc_YkndjlDtyEmCf2wFb7Pz4Q_34_6"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Tc_r0Cxs-0wAkmigntczPXruQ_35_3"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-1.20</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="2"
      id="Tc_Vp55pPLxuUSS1oiV_XwNZA_35_6"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-0.43</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Tc_GZlIgss3nkyTtCiENDYWZw_36_3"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-2.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="2"
      id="Tc_jJxdMVf9RkGbX_RTRtvk0Q_36_6"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-1.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_tNWyJKn2VUC4uCvJ3afNhA_38_3"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8842000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_mLlQRdZIcUGgjrrvoQBaYw_38_6"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8715000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_45O6JBHOlU2mPcO5JCdPKg"
      decimals="-3"
      id="Tc_xWpBPf3mwE-SD0SgE2jNWw_5_3"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">1000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bAryvWRFa0ajF3wOujsFkg"
      decimals="-3"
      id="Tc_3fFIh9duZ0-HoCOReobOIQ_5_8"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8727000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_bAryvWRFa0ajF3wOujsFkg"
      decimals="-3"
      id="Tc_jLmhbJUeu0Orgd11OGEf8w_5_11"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_B4AZcYK-c0asmfHVM1feAg"
      decimals="-3"
      id="Tc_zbp5lD1QWEq07HBQ2NQ_nQ_5_14"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">287619000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_mG4LbET2DECSO7FdaX63IQ"
      decimals="-3"
      id="Tc_ZGOUMuvyMEu6JgaJKgKd4Q_5_17"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VqSPMHJY_kKNvzc7COpAeg"
      decimals="-3"
      id="Tc_w2RbauCgj06q_LB5TxQvIw_5_20"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-223930000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_oRtPshqLpE-F6NEzyqLxyw_5_23"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">63485000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ibio:StockIssuedDuringPeriodSharesCapitalRaise
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IurkUKJGTEiNYvvgn9u9qQ"
      decimals="-3"
      id="Tc_LfG-wl7Xq06uUae3xxpoKg_7_8"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">176000</ibio:StockIssuedDuringPeriodSharesCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fF9KSDzTNUewjtgDUfom4w"
      decimals="-3"
      id="Tc_lP9kBL8BvESi5ofumKd6MA_7_14"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1151000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_P3tAhNzKo0ur_9SHI4iJ5g_7_23"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1151000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_nIO8x0O-D0ajEs1hfec5ig"
      decimals="-3"
      id="Tc_iVnGDtoTM0aLjd7uT-Rs6Q_8_3"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">-1000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <ibio:CommonStockIssuedInRubrycTransactionInShares
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IurkUKJGTEiNYvvgn9u9qQ"
      decimals="-3"
      id="Tc_uYIwxA8KKUqcufURmqvhvg_9_8"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">102000</ibio:CommonStockIssuedInRubrycTransactionInShares>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fF9KSDzTNUewjtgDUfom4w"
      decimals="-3"
      id="Tc_6w4Q01Gpb0mhDjNObOUuKQ_9_14"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">650000</ibio:CommonStockIssuedInRubrycTransactionValue>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_C_znFupWlEaoKis0tTQU7Q_9_23"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">650000</ibio:CommonStockIssuedInRubrycTransactionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IurkUKJGTEiNYvvgn9u9qQ"
      decimals="-3"
      id="Tc_3Jz82B9C6kK7Zl_PzW-Wng_10_8"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">1000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_fF9KSDzTNUewjtgDUfom4w"
      decimals="-3"
      id="Tc_WRqjDzT2A0uiXCULf1Pu5g_11_14"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_1XAS5ecvTEyCmxxU-d0uJw_11_23"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_J9Qyego6XEGPGcqSDViMZA"
      decimals="-3"
      id="Tc_zh4FuBWwxk-CFBhfX4XFnw_12_17"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_8ETF6KY7KkiVqjKF4Hh7TA_12_23"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HRtnDhbFY0iZF8Myn0m59Q"
      decimals="-3"
      id="Tc_R_9j7VGMuUqqyKYxsfjiyw_13_20"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-18130000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_SvolteEgbkeArPanANa2Pw_13_23"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-18130000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UIQ-9TQJg02_iffm6LAbPQ"
      decimals="-3"
      id="Tc_FWa5kOoD3UO6m1eZIOy3tQ_15_8"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">9006000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UIQ-9TQJg02_iffm6LAbPQ"
      decimals="-3"
      id="Tc_fB8ZOuSKpEy0e_PHO5u9Hw_15_11"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_N4y1JB93p0KE0lNMIY0TKA"
      decimals="-3"
      id="Tc_oYTQ0EBH8Em57dx7hMaxqQ_15_14"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">290642000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7ONpLrTILEC92ojz2-S9Sg"
      decimals="-3"
      id="Tc_PrLY7UzYQ0mWjrlQgyujTA_15_17"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-223000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mC7BYOTYH0a7Wk8V2O2hrw"
      decimals="-3"
      id="Tc_F-xv4FlkwU2ft5O7l_c-vg_15_20"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-242060000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_Oq3cjK_yIk6bcjG_6YKiaQ_15_23"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">48368000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2N7RXo2_pUetdE_cG5cZ6w"
      decimals="-3"
      id="Tc__uPTgGvplUeEM8Ei7zXOZA_5_8"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8715000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2N7RXo2_pUetdE_cG5cZ6w"
      decimals="-3"
      id="Tc_4bzXVCMnpkimNo5AdF544g_5_11"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GH-5RrH9aUCemJman1Sceg"
      decimals="-3"
      id="Tc_Q509FLC_UUGJlpWG3hH6zQ_5_14"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">282266000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_LANmWQuoxU-cg4DMxrvqag"
      decimals="-3"
      id="Tc_C9d0_xL2oUCyS8F8VWhz-A_5_17"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-63000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4SJVQK9LYUSBCSlw5dlipg"
      decimals="-3"
      id="Tc_6FB1PrsbYk2vqfnQ1Ts1vA_5_20"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-173627000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_2zacrRBIuEKYll8_FrKwOA"
      decimals="-3"
      id="Tc_jaLhC7eTv0OlNnlKYeW4_Q_5_23"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_GQ940Ff9F0Sa787zj-1tnA"
      decimals="-3"
      id="Tc_33RSal1ioEOgOAxacKkKmA_5_26"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">108568000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_pjwYstABlU2nhu8zVQax6Q"
      decimals="-3"
      id="Tc_3yYs-oIjn0GiJ1hTWpKk5A_7_8"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">3000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-3uXSg1qM0mejJjzOTqnKQ"
      decimals="-3"
      id="Tc__1wf1_AVE0GT2APxqssfBg_7_14"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_NXh_FEyZfE-JSdZHRKbTSA_7_26"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-3uXSg1qM0mejJjzOTqnKQ"
      decimals="-3"
      id="Tc_y4DehaNVq0e9ZzcQP2l8Ew_8_14"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">821000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_unIYR3Pdwkqm7IZpArD6pQ_8_26"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">821000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_L7GZScf59UWcwVJ60pxOUQ"
      decimals="-3"
      id="Tc_XBPUxydvK0KYhpSMk6wKKQ_9_17"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_u1gOw-Ttyk6g1s6XIhdUGg_9_26"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FDjxICtcCUCFzo4fnrEFAA"
      decimals="-3"
      id="Tc_U3-hfXJrskWR59-wNaX1xg_10_20"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-8939000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_nOs84_8GCkueqFiJt1xgmw"
      decimals="-3"
      id="Tc_hjqgmVTE_ECZFwQbWND4wA_10_23"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_1JBDo9SOAE6MpMaYMhUEmA_10_26"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-8940000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0tv1Shz8i02Z3bQpOwGtZA"
      decimals="-3"
      id="Tc_mRSfmH8nLU-xrlH3SPspGA_12_8"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8718000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_0tv1Shz8i02Z3bQpOwGtZA"
      decimals="-3"
      id="Tc_xPTvca_zDUC00iy1bnM3yg_12_11"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_XzvlH8qzzkC_5vSGgF1Uwg"
      decimals="-3"
      id="Tc_LLVLngRC40i0LxdzAcn9rQ_12_14"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">283164000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_XVi69PwJykqe8xvOj7V4FA"
      decimals="-3"
      id="Tc_EIG6ykobb0qkk0vyy5qjdw_12_17"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-64000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HxjHz6i74k6VEvJSqTEdqA"
      decimals="-3"
      id="Tc_-S7b_RNLg0q5IXLCtFWUoA_12_20"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-182566000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bmsbSdyfUUmoltX5xZjZqw"
      decimals="-3"
      id="Tc_geRKB15XAUyYz0blTS5eUQ_12_23"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2021_JT9c6c8IIEOMVOhxR4-gmw"
      decimals="-3"
      id="Tc_KqLRq9ykzE2IGvq2dTmnDQ_12_26"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">100525000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_jp5haSWFDEGIYVnvCozeIA_6_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-18130000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_HcYMhZvkX0O5DFDkiMuPEw_6_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-8940000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_yd3Ryvlzi0-IgL2P8iWVKg_8_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1222000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_BNZpk_Zedk-RWZqK-aQd2g_8_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">821000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_3s3S5jOoXE6HQa7ZZpFaBg_9_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">67000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_9WBt7dXwukauBKEpux7myg_9_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">88000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_q4p68913GUWRU0UG2xaiFg_10_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">13000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_NVEhXeZdzUGYfRhKsfDKug_10_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">416000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_6G13xS92OEa-QwRfgD9CDg_11_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">143000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_GHvMyFK06E67L-I4ZRWpGg_11_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_vwAyPTUo0UGGkSQS2Kqc8w_12_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">271000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_1lwi8t9DaEqUky9HNq3zvA_12_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">306000</us-gaap:Depreciation>
    <ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_kntmAU65wUigwHdenOfM5Q_13_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">19000</ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable>
    <ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_Mdifd5xTJUuAJI9gob7xgw_13_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">19000</ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_d1MYA8aOhUqTR6ZCBy-sdA_14_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">36000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_eOCgfkTEQkmd6jVmmtHyNA_14_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">102000</us-gaap:AmortizationOfDebtDiscountPremium>
    <ibio:DeferredFinancingCostsAmortizationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_R1NRuZ4tMEGWdaE6WjHj4g_15_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">40000</ibio:DeferredFinancingCostsAmortizationExpense>
    <ibio:DeferredFinancingCostsAmortizationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_F_k4p66we0-m6DGczLo-Tg_15_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:DeferredFinancingCostsAmortizationExpense>
    <ibio:IncreaseDecreaseInInventoryReserve
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_NaHNZeY7XkSs-qMT_3UuIg_16_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">4100000</ibio:IncreaseDecreaseInInventoryReserve>
    <ibio:IncreaseDecreaseInInventoryReserve
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_WCzDKHty_UCrjQzxP-N5OA_16_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:IncreaseDecreaseInInventoryReserve>
    <ibio:ForgivenessOfNotePayableAndAccruedInterestSbaLoan
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_74nJIhXYbk-U9HzUb1z7yA_17_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:ForgivenessOfNotePayableAndAccruedInterestSbaLoan>
    <ibio:ForgivenessOfNotePayableAndAccruedInterestSbaLoan
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_0jcidspPXkyV2KnBKIw1VA_17_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">607000</ibio:ForgivenessOfNotePayableAndAccruedInterestSbaLoan>
    <ibio:SettlementOfRevenueContract
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_ozjb-48fv0GDa1FjyB4ZYw_18_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:SettlementOfRevenueContract>
    <ibio:SettlementOfRevenueContract
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_4R9fbwqdcU2H3bldX92QsQ_18_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">84000</ibio:SettlementOfRevenueContract>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_3UFqGONWXUqa3L5oPayw5A_20_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">54000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_B2a9g8LXfkmExPRi85Elqg_20_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">93000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_N2k4S6QHtkaOg0LconZNqg_21_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1137000</us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories>
    <us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_Z8lAXVKawEq3sxxrxzM3Bg_21_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">560000</us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_3izte1BPMECIGs3L9TMjOA_22_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-403000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_QbA3kM1hc02YZ9OLuX8RzA_22_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-325000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_osEqUw88ME6VjJk-giN3iQ_23_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-30000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_GA6i1Q22fUyJUa22k-0baQ_23_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">912000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_YahypWLogUiyEX-WmeOVrQ_24_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">166000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_qGYbRtkZakiSqbKn5iVsxg_24_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">79000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_ZGbRtEflb0quhBKSktw0lw_25_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-1168000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_AVcCNj6kCEScBcJKcZIRvw_25_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-269000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_qIj1anAynUuUA4oPp2PWQA_26_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-3000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_cYptTfXNRUiGryTd8cteCw_26_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_bSIOceNRC0aQ1gXl6mvC7Q_27_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">61000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_NAHd_hTHxEawgsLoQd3d7Q_27_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_9RtwRkqudk-d-z6tk6PKoQ_28_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-13959000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_yoJMgf8OjUec5URc2AxxGQ_28_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-9347000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_4Sa9FOAC90CZlKpTu3t_Jw_31_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_cvt2g2O4gkyVVe_Bj5hKSg_31_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2386000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_Mg61Gtd1WkeqLSITg8DEJg_32_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3200000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_gAnHP426pUi_JxsiMwUxOA_32_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2400000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_pR1JXAS_LkuCpu4duZ-UAQ_33_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_B3XRjdHicEGVFuktK7cHWA_33_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1173000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_-SBKKV2UJ0O11ppG5PXRDQ_34_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_4pdC7-Wf20a4t8nOkW7grQ_34_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2867000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_0OP-ZUAZX0mYU2413-ZmYA_35_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2479000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_EAjPYXUUi0KPycu8Svptwg_35_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1123000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_2IJpcRSbI0Cw5xCldfM7Gw_36_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">692000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_QtxzE_Rcb0qqPRCGHGxS_g_36_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_uQBsc1LIi0S0yuej5p3Kdw_38_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">29000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_zTFxK4AeP0eQXN3kAfGNlg_38_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-5149000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ibio:ProceedsFromIssuanceOfPreferredAndCommonStock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_60yrvVjOEEex6qc9DUYPiA_41_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1151000</ibio:ProceedsFromIssuanceOfPreferredAndCommonStock>
    <ibio:ProceedsFromIssuanceOfPreferredAndCommonStock
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_jqe8jf18pEK5pyJUkhQ7Wg_41_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:ProceedsFromIssuanceOfPreferredAndCommonStock>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_lXNPdYPJyECr6tTOt2JL4w_42_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">10000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_8c6wSCqzy0KTDKLD_W0Jng_42_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">88000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_NVN8YnYu7k-Vj8dEGC89fQ_43_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1141000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_ZQ2YhXrnlUOQfOtFEPND1w_43_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-88000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_HH5neNuJMUKimXHC87JS3A_45_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-12789000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_2zVAbPPMAkGFOkjqxinlkQ_45_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-14584000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_uYeET-x1gkabhI6ZN99JUA_46_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">28672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2021_GQ940Ff9F0Sa787zj-1tnA"
      decimals="-3"
      id="Tc_uuCKALv17UaYuBpFhWXMow_46_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">77404000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_yv4BBPwG6kS14jICwt7x8w_47_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">15883000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2021_JT9c6c8IIEOMVOhxR4-gmw"
      decimals="-3"
      id="Tc_ALEBeczex0eyYdP91Ygq0w_47_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">62820000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_OB_JCUbL7kiLzwdQccEtSg_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities>
    <ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_vAE-1rR5VEy6DXQtNygDmA_5_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3487000</ibio:NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities>
    <ibio:IncreaseDecreaeInOperatingLeaseObligations
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_RwZNeB6L1k6-cuUjk_8asw_6_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:IncreaseDecreaeInOperatingLeaseObligations>
    <ibio:IncreaseDecreaeInOperatingLeaseObligations
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_eBeXkPfhnkylOXTOCCWaKg_6_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3603000</ibio:IncreaseDecreaeInOperatingLeaseObligations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_-A8A3XJ26EeISyKYvtrwKw_7_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">814000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_j9GGEpuabkaIHhXJO174IQ_7_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_QTJK45G4_EKSpTdnLgfWxQ_8_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">814000</ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases>
    <ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_9A4vRpsKH0uPSuvC9P6syw_8_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases>
    <ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_hmLitVfNvkS3_2TaWSkQSw_9_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1769000</ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid>
    <ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_slApatF7VESVWec9w95h-g_9_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">383000</ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid>
    <ibio:UnpaidFixedAssetsIncludedInAccountsPayable
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_xPCA0UB27Um-Jcgcrh1WCQ_10_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2143000</ibio:UnpaidFixedAssetsIncludedInAccountsPayable>
    <ibio:UnpaidFixedAssetsIncludedInAccountsPayable
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_cbA0k3vTCE24Urs-yvR4tA_10_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">750000</ibio:UnpaidFixedAssetsIncludedInAccountsPayable>
    <ibio:StockPurchaseAgreementValueOfSharesToBePurchased
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_Nltx0UMsGUaFekj7FqhxcA_11_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:StockPurchaseAgreementValueOfSharesToBePurchased>
    <ibio:StockPurchaseAgreementValueOfSharesToBePurchased
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_s4Ij7wivU0OtxMuuSpZWeA_11_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2500000</ibio:StockPurchaseAgreementValueOfSharesToBePurchased>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_ZPfkgfr6F0Ka5HaMg8N0xg_12_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">10000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_f28h4XV5lUKp8K7wEUjk1w_12_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <ibio:LeaseIncentiveForConstructionInProgress
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_XATt3AiKjE6YCunfyTxBng_13_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:LeaseIncentiveForConstructionInProgress>
    <ibio:LeaseIncentiveForConstructionInProgress
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_IxSQnP8iuECvcw2mG_x2bA_13_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">82000</ibio:LeaseIncentiveForConstructionInProgress>
    <ibio:NonCashSettlementOfRevenueContract
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_0PczMHhjOkWG5zF_Tcb_CQ_14_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:NonCashSettlementOfRevenueContract>
    <ibio:NonCashSettlementOfRevenueContract
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_9Ji-HiTKx0W3mKBPE2Oy9Q_14_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">580000</ibio:NonCashSettlementOfRevenueContract>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_ZSg7xNtZpku1lO46JVLMVQ_15_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">650000</ibio:CommonStockIssuedInRubrycTransactionValue>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_UJ0MaQn9Ok20Un7utbsBqQ_15_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:CommonStockIssuedInRubrycTransactionValue>
    <ibio:ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_0_DSXJgWPUC_Jd0yWgRpgg_16_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</ibio:ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets>
    <ibio:ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_pwPh8qZ6VUOBI4GN9KJrdg_16_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">77000</ibio:ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:InterestPaidNet
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_kv2hI78g8UO0JRqtoXmWaw_20_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">187000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_6FL_hlzJ6U--RVDkrGHrAQ_20_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">610000</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_IJPVqqSkdkK5dZ_0x6oqMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;1.&#160;&#160;&#160;Nature of Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;iBio, Inc. (&#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;, &#x201c;iBio&#x201d;, &#x201c;iBio, Inc&#x201d; or the &#x201c;Company&#x201d;) is an Artificial Intelligence (&#x201c;AI&#x201d;)-driven innovator of precision antibody immunotherapies. The Company has a pipeline of innovative primarily immuno-oncology antibodies against hard-to-drug targets where we may face reduced competition and with antibodies that may be more selective. The Company plans to use its AI-driven discovery platform to continue adding antibodies against hard-to-drug targets or to work with partners on AI-driven drug development. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Therapeutics Pipeline&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&lt;img alt="Graphic" src="ibio-20220930x10q001.jpg" style="display:inline-block;height:248.43pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:534.2pt;"/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;IBIO-101: &lt;/b&gt;an anti-CD25 molecule that works by depletion of immunosuppressive T-regulatory cells (Tregs) via antibody-dependent cellular cytotoxicity (&#x201c;ADCC&#x201d;), without disrupting activation of effector T-cells (Teffs) in the tumor microenvironment. IBIO-101 could potentially be used to treat solid tumors, hairy cell leukemia, relapsed multiple myeloma, lymphoma, or head and neck cancer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EGFRvIII: &lt;/b&gt;binds a tumor-specific mutation of EGFR variant III with an afucosylated antibody for high ADCC. Because of its specificity binding to the tumor-specific mutation, it could potentially reduce toxicity and/or expand the therapeutic window compared to simple broad EGFR-targeted alternatives. . EGFRvIII is constantly &#x201c;switched on&#x201d; which can lead to the development of a range of different cancers. An EGFRvIII antibody could potentially be used to treat glioblastoma, head and neck cancer or non-small cell lung cancer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CCR8:&lt;/b&gt; targets depletion of highly immunosuppressive CCR8+ Tregs in the tumor microenvironment via an ADCC mechanism with selective binding to CCR8 over its closely related cousin, CCR4, to avoid off-target effects. A CCR8 program could potentially be broadly applicable in solid tumors and/or as a prospective combination therapy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PD-1 Agonist: &lt;/b&gt;Selectively binds PD-1 to suppress auto-reactive T-cells without PD-L1/PD-L2 blocking. A PD-1 agonist could potentially be used to treat inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis or other inflammatory diseases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In addition to the programs described above, the Company also has six additional early discovery programs that have the potential to advance into later stages of preclinical development and are designed to tackle hard-to-drug targets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;IBIO-100 and Endostatin E4&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Our lead anti-fibrotic candidate is IBIO-100, and its design is based in part upon work by Dr. Carol Feghali-Bostwick, Professor of Medicine at the Medical University of South Carolina and Vice-Chair of the Scleroderma Foundation. Her initial work was conducted at the University of Pittsburgh, and we have licensed the patents relevant for the continued development of the molecule from the university. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As part of the Company&#x2019;s review of potential options, the Company intends to continue to review the data from its research and development efforts and determine how to proceed with the development of IBIO-100 in Fibrosis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;To align with the Company&#x2019;s focus on the immuno-oncology pipeline, the Company also intends to continue to pursue the E4 endostatin peptide, from which IBIO-100 is derived, as an oncology target in collaboration with University of Texas Southwestern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AI Drug Discovery Platform&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In September 2022, iBio purchased substantially all of the assets of RubrYc Therapeutics (for a complete description of the transaction please see Note 6 &#x2013; Significant Transactions). The AI Drug Discovery platform technology is designed to be used to discover antibodies that bind to hard-to-target subdominant and conformational epitopes for further development within our existing portfolio or in partnership with outside entities. The RubrYc AI platform is built upon 3 key technologies. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Epitope Targeting Engine:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; A proprietary machine-learning platform that combines computational biology and 3D-modeling to identify molecules that mimic hard-to-target binding sites on target proteins, specifically, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;subdominant and conformational epitopes.&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The creation of these small mimics enables the engineering of therapeutic antibody candidates that can selectively bind immune and cancer cells better than &#x201d;trial and error&#x201d; antibody engineering and screening methods that are traditionally focused on dominant epitopes.&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;RubrYcHu&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; Library:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; An &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;AI-generated human antibody library free of significant sequence liabilities that provides a unique pool of antibodies to screen. &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The combination of the Epitope Targeting Engine and screening with the &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;RubrYcHu&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; Library has been shown to reduce the discovery time from ideation to &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;in vivo&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; proof-of-concept (PoC) by up to 4 months. This has the potential to enable more, and better, therapeutic candidates to reach the clinic, faster. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;StableHu&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; Library:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; An &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;AI-powered sequence optimization library used to improve antibody performance&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;. Once an antibody has been advanced to the lead optimization stage, &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;StableHu&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; allows precise and rapid optimization of the antibody binding regions to rapidly move a candidate molecule into the IND-enabling stage.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;</us-gaap:NatureOfOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_gQzdWmB9vUOXc-2YFeppRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;2.&#160;&#160;&#160;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Interim Financial Statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended June 30, 2022, filed with the SEC on October 11, 2022 (the &#x201c;Annual Report&#x201d;), from which the accompanying condensed consolidated balance sheet dated June 30, 2022 was derived.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Non-controlling interest in the consolidated financial statements represented the share of the loss in iBio CDMO, LLC (&#x201c;iBio CDMO&#x201d;) for an affiliate of Eastern Capital Limited (&#x201c;Eastern Capital&#x201d;) through November 1, 2021, the date the Company acquired the remaining interest in iBio CDMO. &#160;See Note 6 &#x2013; Significant Transactions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Going Concern&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on its ability to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company's ability to continue as a going concern. In an effort to remain a going concern and increase cash reserves, the Company recently announced it was selling its CDMO business and facility, reducing its work force by approximately 60% (a reduction of approximately 69 positions), and ceasing operations of its CDMO thereby reducing annual spending by approximately 50%. (See Note 3 &#x2013; Discontinued Operations for more information.) Potential options being considered&#160;to further increase liquidity include lowering the Company&#x2019;s expenses further, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from capital markets, grant revenue or collaborations, or a combination thereof. During the first quarter of fiscal year 2023, the Company completed at-the-market (&#x201c;ATM&#x201d;) offerings and raised &lt;span style="-sec-ix-hidden:Hidden_G92FJIZcG06BIGNnHbTKpg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.1M&lt;/span&gt;&lt;/span&gt; selling approximately 176,000 shares of common stock. (See Note 16 &#x2013; Stockholder&#x2019;s Equity for more information.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s cash, cash equivalents, restricted cash and investments in debt securities of $23.5 million as of September 30, 2022, is not anticipated to be sufficient to support operations beyond Q3 of Fiscal 2023&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;unless the Company reduces its burn rate further or increases its capital as described above. Regardless of whether the Company is able to reduce its burn rate or sell or out-license certain assets or parts of the business, the Company will need to raise additional capital in order to fully execute its longer-term business plan. It is the Company&#x2019;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Quarterly Report on Form 10-Q. However, there can be no assurance that the Company will be successful in implementing any of the options that we are evaluating.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Reverse Stock Split&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 22, 2022, the Company's Board of Directors approved the implementation of a reverse stock split at a ratio of one-for-twenty five (1:&lt;span style="-sec-ix-hidden:Hidden__0cS0oMu3kKeTj2aafl8jw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;25&lt;/span&gt;&lt;/span&gt;) shares of the Company's Common Stock (the &#x201c;Reverse Split&#x201d;). The Reverse Split was effective as of October 7, 2022. All share and per share amounts of our common stock presented have been retroactively adjusted to reflect the Reverse Split. See Note 16 &#x2013; Stockholders&#x2019; Equity for more information. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ibio:StockIssuedDuringPeriodSharesCapitalRaise
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="0"
      id="Narr_lycA_FTCyUe5nA-cyZrPWw"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">176000</ibio:StockIssuedDuringPeriodSharesCapitalRaise>
    <ibio:CashAndCashEquivalentsPlusDebtSecurities
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-5"
      id="Narr__bpmLeai7EqQghemFwEDrQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">23500000</ibio:CashAndCashEquivalentsPlusDebtSecurities>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_7-8U5Uoi1EyitVJPK-bMpQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;3.&#160;&#160;&#160;Discontinued Operations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In November 2022, the Company announced it is seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately 60% of the current Company staffing levels (a reduction of approximately 69 positions). The Company expects to substantially complete the employee reduction by January 2, 2023. The Company expects it may be able to complete a transaction for the sale of its contract development and manufacturing organization in calendar 2023, although there is no assurance as to when, or for how much, the Company may be able to sell the iBio CDMO, LLC organization, including the 130,000-square-foot cGMP facility location in Bryan, Texas. &#160;The Company expects to incur pre-tax charges of approximately $1.7 million for the employee reduction, most of which is expected to be incurred in the second and third quarter of fiscal year 2023. These charges will be substantially settled in cash and almost entirely consist of severance obligations, continuation of salaries and benefits over a 60-day transitional period during which impacted employees remain employed but are not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. The transition to a focused AI-Biotech business is expected to reduce the Company&#x2019;s monthly burn rate by approximately half, with an approximate range of $2.5-3.0 million per month. The Company recorded a charge in discontinued operations for $4.1 million for the three months ended September 30, 2022, due to inventory write offs resulting from the winding down of the CDMO business and depending upon the sale price of the facility, the Company may have to incur additional write offs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As such, the results of iBio CDMO's operations are reported as discontinued operations for the three months ended September 30, 2022. The Company has retrospectively recast its consolidated statement of operations for the three months ended September 30, 2021 presented. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intends to sell have been classified as &#x201c;held for sale&#x201d; as of September 30, 2022. &#160;The Company has retrospectively recast its consolidated balance sheet as of June 30, 2022 for assets and liabilities held for sale. &#160;The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statement of cash flows. &#160;Supplemental disclosures related to discontinued operations for the statements of cash flows has been provided below. Unless noted otherwise, discussion in the Notes to the Condensed Consolidated Financial Statements refers to the Company's continuing operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 127&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,062&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,378&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 7,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 10,417&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,836&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income (expenses):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - term note payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (226)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (608)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Forgiveness of note payable and accrued interest - SBA loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (227)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,593)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,751)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table presents net carrying values related to the major classes of assets that were classified as held for sale at September 30, 2022 and June 30, 2022 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt;937&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,949&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 35,892&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 38,778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 35,289&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,951&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 37,240&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,949&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 271&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 416&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Purchase of fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,082&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investing noncash transactions:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Fixed assets included in accounts payable in prior period, paid in current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 383&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Unpaid fixed assets included in accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 229&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <ibio:EmployeeReductionExpenses
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-5"
      id="Narr_9Us1aY7-k0Km5Rm-etruOQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1700000</ibio:EmployeeReductionExpenses>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb__1AUVCIGikOjkjlZHXNqoQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 127&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,062&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,378&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 7,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,458&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 10,417&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,836&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other income (expenses):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - term note payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (226)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (608)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Forgiveness of note payable and accrued interest - SBA loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (227)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,593)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,751)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table presents net carrying values related to the major classes of assets that were classified as held for sale at September 30, 2022 and June 30, 2022 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt;937&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,949&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 35,892&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 38,778&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,900&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 35,289&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,951&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 37,240&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,949&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:48.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:21.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 271&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 416&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Purchase of fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,082&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investing noncash transactions:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Fixed assets included in accounts payable in prior period, paid in current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 383&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Unpaid fixed assets included in accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 229&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 750&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_7rIr4Ezf9E23qGcbPbMqzg_3_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">56000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_zDFt6tAkZk-QiaAvNoQ1ag_3_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">127000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_SiNV95SkQ0i5gTtbDfl9Kw_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_NopjgILMcUeKk0BMuMR3mg_4_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">40000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_DcbjERNMk02XmIspnprInA_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">51000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_zijjJ13_sUiK8OFViTdxAg_5_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">87000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_JUR6RfvnHkCFh4sa18lOeA_7_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3062000</ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses>
    <ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_SZGpFbaMekOIWE9HdKeHxw_7_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1378000</ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_kNWtZszroU-813xsW5DtfA_8_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">7355000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_bASvw1jDBESAUrWD17IUkQ_8_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2458000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_9j8QbjEGTUCy3qRBaJu02g_9_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">10417000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_syLG_N5xGEqvqyxB64a4Sw_9_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3836000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_amcEOGNP7Eu0kXN29w0tFw_12_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">226000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <ibio:DisposalGroupInterestExpenseRelatedParty
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_NcAZ6nrsLUyKt7H8XD49_Q_13_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">608000</ibio:DisposalGroupInterestExpenseRelatedParty>
    <ibio:DisposalGroupGainOnDebtForgiveness
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_UxoPYEQdU0OkeWzECDc1dA_14_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">607000</ibio:DisposalGroupGainOnDebtForgiveness>
    <ibio:DiscontinuedOperationsMiscellaneousExpensesIncome
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_XbXsQ_fHm0WX7TTNGmGCrg_15_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1000</ibio:DiscontinuedOperationsMiscellaneousExpensesIncome>
    <ibio:DiscontinuedOperationsMiscellaneousExpensesIncome
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_h1Z1CHGP8k6Y8_4WYQJObA_15_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1000</ibio:DiscontinuedOperationsMiscellaneousExpensesIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_q5jFlCyj4kK7DvvS8IfNuQ_16_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">227000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_RB9D4VOChkqq2185lnxvyw_16_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_mNJZ7cAflUi9W8vjQ5rSUw_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">937000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_ffYNPmfNwEC-WqBGCP0y6w_4_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <ibio:DisposalGroupOperatingLeaseRightOfUseAssets
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_U8tpzYY52UOhSzwr7m8P1w_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1949000</ibio:DisposalGroupOperatingLeaseRightOfUseAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_tw2-48s0mUWXaal_kmlbCQ_6_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">35892000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_qFqNKLwkAk-vFUcJW5rilw_7_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">38778000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_oM9sln0oAUqXW678ufTvGw_7_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3900000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_7tBh1OH43E-JP9SADfAPDw_10_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">35289000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <ibio:DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_r0pXZIMehUenf4dqv3GRvw_11_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1951000</ibio:DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent>
    <ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_Q-8DGRtVXUKcy0Q0IS6Mlg_15_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1949000</ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations>
    <ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_W1LbIBSKKEyYPwYkp8ZO_g_15_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">10000</ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations>
    <ibio:DisposalGroupNoncurrentOperatingLeaseObligations
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_JBiN-lgbqE-c0EfzDyQKbQ_18_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1941000</ibio:DisposalGroupNoncurrentOperatingLeaseObligations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_4AaxrkhNNkq7_g92E6Ongw_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">271000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_qsCBBcEfnkKNVWRqEW9FPQ_4_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">306000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_3CYexlgQQkWO_DZsMP01mQ_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">13000</ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets>
    <ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_SuFv2TzGs0q3liqYfiMY_w_5_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">416000</ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets>
    <us-gaap:CapitalExpenditureDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_-8-5sVwYLU-QXg39xYwUvw_6_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">875000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <us-gaap:CapitalExpenditureDiscontinuedOperations
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_0I4OYGsMI0yPGpKEvb7n9A_6_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1082000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_vOqZcO0ipUimEVGpR0NxvA_8_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1542000</ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod>
    <ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_VKF1fS_Z8Ua3zCtrFu1C4Q_8_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">383000</ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod>
    <ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_9JjuGgmBFkeYlSSHBDce0g_9_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">229000</ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations>
    <ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_POR57JI4t02AFYPWpothsw_9_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">750000</ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_ZZK3GHJwIk2OAubaiC1r1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;4.&#160;&#160;&#160;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s significant accounting policies are described in Note&#160;3 of the Notes&#160;to Financial Statements in the Annual Report.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accounts Receivable&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#x2019;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, the Company determined that an allowance for doubtful accounts was not needed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for its revenue recognition under Accounting Standards Codification ("ASC") 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt;. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i)&#160;identify the contract, (ii)&#160;identify the performance obligations, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations and (v)&#160;recognize revenue when a performance obligation is satisfied. The nature of the Company&#x2019;s contracts with customers generally falls within the three key elements of the Company&#x2019;s business plan: CDMO Facility Activities; Product Candidate Pipeline, and Facility Design and Build-out /Technology Transfer services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and/or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At September 30, 2022 and June 30, 2022, the Company had no contract loss provisions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company generates (or may generate in the future) contract revenue under the following types of contracts:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Fixed-Fee &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Revenue can be recognized either 1) over time or 2) at a point in time. &#160;All revenue was recognized at a point in time for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For the three months ended September 30, 2021, revenue was from the settlement of a revenue contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Time and Materials&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#x2019;s billing rate plus other project specific costs incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A contract asset is an entity&#x2019;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both September&#160;30,&#160;2022 and June&#160;30,&#160;2022, contract assets were $0.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Contract Liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A contract liability is an entity&#x2019;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#x2019;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, contract liabilities w&lt;span style="background:#ffffff;"&gt;ere &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$161,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$100,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; r&lt;/span&gt;espectively. The Company recognized revenue of $56,000 during the three months ended September 30, 2022 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. &#160; The Company recognized revenue of $84,000 during the three months ended September 30, 2021 that was included in the contract liabilities balance as of June 30, 2021 and reported as part of continuing operations. &#160; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for leases under the guidance of Accounting Standards Codification ("ASC") 842, "Leases" ("ASC 842"). The standard established a right-of-use (&#x201c;ROU&#x201d;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#x2019;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, &lt;span style="-sec-ix-hidden:Hidden_sGul_1aHN0eDILLvK8AumA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#x2019;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#x2019;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#x2019;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at September 30, 2022 and June 30, 2022 consisted of money market accounts. Restricted cash consisted of collateral held for letters of credit obtained to the term note payable for the purchase of the 130,000 square foot cGMP manufacturing facility in Bryan, Texas located at 8800 HSC Parkway, Bryan, Texas 77807 (the &#x201c;Facility&#x201d;) (see Note 6 &#x2013; Significant Transactions) and the San Diego operating lease (see Note 15 &#x2013; Operating Lease Obligations) and a Company purchasing card. The Company&#x2019;s bank required an additional 5% collateral held above the actual letters of credit issued. Restricted cash was approximately $6 million at both September 30, 2022 and June 30, 2022. On October 11, 2022, the Company, as part of the First Amendment to the Credit Agreement with Woodforest, paid down $5.5M of the term loan and subsequently Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. The change in restricted cash will be reflected in second quarter of fiscal year 2023 financials.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 22,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,743&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - San Diego lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for Company purchasing card&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,883&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Investments in Debt Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value is calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. See Note 8 &#x2013; Investments in Debt Securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt;Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. &#160;Inventory held is related to the CDMO business and has been classified as held for sale. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 730-10, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt; (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the three month periods ending September 30, 2022 and 2021 research and development expense was reported in both continuing and discontinued operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Right-of-Use Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 14 - Finance Lease Obligations for additional information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fixed Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:Hidden_mylpkjT0LkCiMRV69PIkrw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to 39 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of 10 years and other intellectual property is amortized over periods from 16 to &lt;span style="-sec-ix-hidden:Hidden_u6VUYlS0b0yj9uFRIDrlgA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;23&#160;years&lt;/span&gt;&lt;/span&gt;. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges for the three months ended September&#160;30,&#160;2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Share-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The impact that share-based payment awards will have on the Company&#x2019;s results of operations is a function of the number of shares awarded, the trading price of the Company&#x2019;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#x2019;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Expected volatility is based on historical volatility of the Company&#x2019;s common stock (the &#x201c;Common Stock&#x201d;); the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#x2019;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 17 - Share-Based Compensation for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, amounts in excess of insured limits were approximately $15,372,000 and $18,200,000, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the three months ended September&#160;30,&#160;2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from one customer. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the three months ended September&#160;30,&#160;2021, the Company reported revenue from continuing operations from one customer related to the settlement of a revenue contract and generated 100% of revenue reported in discontinued operations from three customers, each of whom individually accounted for more than 10% of revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_CoSpvIujn0OWe08dyjP-CQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_yr8hQEuoG0ezSaqMsenBJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accounts Receivable&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#x2019;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, the Company determined that an allowance for doubtful accounts was not needed.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_Og_9xUqsrUOaukcwGUngoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for its revenue recognition under Accounting Standards Codification ("ASC") 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt;. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In general, the Company applies the following steps when recognizing revenue from contracts with customers: (i)&#160;identify the contract, (ii)&#160;identify the performance obligations, (iii)&#160;determine the transaction price, (iv)&#160;allocate the transaction price to the performance obligations and (v)&#160;recognize revenue when a performance obligation is satisfied. The nature of the Company&#x2019;s contracts with customers generally falls within the three key elements of the Company&#x2019;s business plan: CDMO Facility Activities; Product Candidate Pipeline, and Facility Design and Build-out /Technology Transfer services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Recognition of revenue is driven by satisfaction of the performance obligations using one of two methods: revenue is either recognized over time or at a point in time. Contracts containing multiple performance obligations classify those performance obligations into separate units of accounting either as standalone or combined units of accounting. For those performance obligations treated as a standalone unit of accounting, revenue is generally recognized based on the method appropriate for each standalone unit. For those performance obligations treated as a combined unit of accounting, revenue is generally recognized as the performance obligations are satisfied, which generally occurs when control of the goods or services have been transferred to the customer or client or once the client or customer is able to direct the use of those goods and/or services as well as obtaining substantially all of its benefits. As such, revenue for a combined unit of accounting is generally recognized based on the method appropriate for the last delivered item but due to the specific nature of certain project and contract items, management may determine an alternative revenue recognition method as appropriate, such as a contract whereby one deliverable in the arrangement clearly comprises the overwhelming majority of the value of the overall combined unit of accounting. Under this circumstance, management may determine revenue recognition for the combined unit of accounting based on the revenue recognition guidance otherwise applicable to the predominant deliverable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer indicates a loss will be incurred, a provision for the entire loss on the contract is made. At September 30, 2022 and June 30, 2022, the Company had no contract loss provisions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company generates (or may generate in the future) contract revenue under the following types of contracts:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Fixed-Fee &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Revenue can be recognized either 1) over time or 2) at a point in time. &#160;All revenue was recognized at a point in time for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For the three months ended September 30, 2021, revenue was from the settlement of a revenue contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Time and Materials&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer&#x2019;s billing rate plus other project specific costs incurred.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ProvisionForLossOnContracts
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Narr_aC8S4UEg5EKYXsFnckmgnA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:ProvisionForLossOnContracts>
    <us-gaap:ProvisionForLossOnContracts
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Narr_SMufMbMBdEyBcoQpemwwaQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:ProvisionForLossOnContracts>
    <ibio:ContractAssetsPolicyTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_91cdxW1rTEi5oQfzjqZIMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A contract asset is an entity&#x2019;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both September&#160;30,&#160;2022 and June&#160;30,&#160;2022, contract assets were $0.&lt;/p&gt;</ibio:ContractAssetsPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="0"
      id="Narr_fjoDCUkP8ESYbgHqneNtzA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="0"
      id="Narr_-UPv4hNOFkmOiDNcO04SGA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <ibio:ContractLiabilitiesPolicyTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_NRJttDqJj0uzkAPCopN81w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Contract Liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A contract liability is an entity&#x2019;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#x2019;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, contract liabilities w&lt;span style="background:#ffffff;"&gt;ere &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$161,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$100,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; r&lt;/span&gt;espectively. The Company recognized revenue of $56,000 during the three months ended September 30, 2022 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations. &#160; The Company recognized revenue of $84,000 during the three months ended September 30, 2021 that was included in the contract liabilities balance as of June 30, 2021 and reported as part of continuing operations. &#160; &lt;/p&gt;</ibio:ContractLiabilitiesPolicyTextBlock>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="0"
      id="Narr_n4U8HmYmgkKvj50BFWjxTQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">161000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="0"
      id="Narr_axYH1xrQPUyaNkZfphukIQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">100000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="0"
      id="Narr_iQ3CiyJSek6tPMWHTZLtDg"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">56000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="0"
      id="Narr_Yzom1Ucqck6nEt_9efckjQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">84000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_K9s4SxTalkGc2KVrM55edg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for leases under the guidance of Accounting Standards Codification ("ASC") 842, "Leases" ("ASC 842"). The standard established a right-of-use (&#x201c;ROU&#x201d;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#x2019;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, &lt;span style="-sec-ix-hidden:Hidden_sGul_1aHN0eDILLvK8AumA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#x2019;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#x2019;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#x2019;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_6TSa3e4QoUObgbux5_UanQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at September 30, 2022 and June 30, 2022 consisted of money market accounts. Restricted cash consisted of collateral held for letters of credit obtained to the term note payable for the purchase of the 130,000 square foot cGMP manufacturing facility in Bryan, Texas located at 8800 HSC Parkway, Bryan, Texas 77807 (the &#x201c;Facility&#x201d;) (see Note 6 &#x2013; Significant Transactions) and the San Diego operating lease (see Note 15 &#x2013; Operating Lease Obligations) and a Company purchasing card. The Company&#x2019;s bank required an additional 5% collateral held above the actual letters of credit issued. Restricted cash was approximately $6 million at both September 30, 2022 and June 30, 2022. On October 11, 2022, the Company, as part of the First Amendment to the Credit Agreement with Woodforest, paid down $5.5M of the term loan and subsequently Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. The change in restricted cash will be reflected in second quarter of fiscal year 2023 financials.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 22,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,743&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - San Diego lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for Company purchasing card&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,883&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_ojjhTzu_rkSW5fdi0P3aVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 22,676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,743&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,743&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - San Diego lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for Company purchasing card&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,883&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,672&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_6sd_umvLdk2krGp1H0xgGQ_3_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">9887000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_dwa9mX0XAEmyuJnSc8HEYQ_3_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">22676000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_euWJTSKtt0aJwVGdmEINPg"
      decimals="-3"
      id="Tc_FklEncyxWUO6B_s-zGnsvQ_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5743000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_K4UWN_QhQECOHvhw12blGQ"
      decimals="-3"
      id="Tc_P4FbIvxtHUOIVmNb5lq6MQ_4_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5743000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_0pi0YCsgSUCH7buV1WBF9A"
      decimals="-3"
      id="Tc_0NsHC5H5YUiuew4ZolUXIQ_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">198000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_54ARR6tb80WIuJ-jyvDHFA"
      decimals="-3"
      id="Tc_IY95qI5b1kql_hlYjeGl4Q_5_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">198000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_F4h9j-DOsUyvR-zF7aWpzQ"
      decimals="-3"
      id="Tc_AI5VyfFel0GfDdX4csUz9g_6_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">55000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2022_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_H3Laxbz45UWYB-AJtsQg0g"
      decimals="-3"
      id="Tc_bisA6NFxZ0KXJINKQ4h8xw_6_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">55000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_hTxOlxsUMkua2PEfvb6Fgg_7_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">15883000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_zMCzCu8jFEuTQnz1QTivpg_7_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">28672000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_a9fWP4vqoUGqCoE-DbwCmg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Investments in Debt Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Debt investments are classified as available-for-sale. Changes in fair value are recorded in other comprehensive income (loss). Fair value is calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities are acquired are amortized to interest income over the terms of the debt securities. See Note 8 &#x2013; Investments in Debt Securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_2bA9vTVGl0i7kivtr2pYjQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt;Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. &#160;Inventory held is related to the CDMO business and has been classified as held for sale. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_iasDYOSq10mLmGF0I9mU1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 730-10, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt; (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. For the three month periods ending September 30, 2022 and 2021 research and development expense was reported in both continuing and discontinued operations.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ibio:RightOfUseAssetsPolicyPolicyTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_gXYUcrWmH0GpHKc7iKGNIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Right-of-Use Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 - Finance Lease ROU Assets and Note 14 - Finance Lease Obligations for additional information.&lt;/span&gt;&lt;/p&gt;</ibio:RightOfUseAssetsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_nYhtRuSryUauKkiuAeduAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fixed Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:Hidden_mylpkjT0LkCiMRV69PIkrw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to 39 years.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_h3rVauDz3ESYJDDsYgtxFw"
      id="Narr_SXr7k8kFSEuPdpmVDvdSxg">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_LZeM4GeWrEiIhyAI5XbHyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of 10 years and other intellectual property is amortized over periods from 16 to &lt;span style="-sec-ix-hidden:Hidden_u6VUYlS0b0yj9uFRIDrlgA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;23&#160;years&lt;/span&gt;&lt;/span&gt;. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges for the three months ended September&#160;30,&#160;2022 and 2021.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_fXHaqpNPo0ibzA3IIYhZbQ"
      id="Narr_8N0uWtQQN0Wtpg8iTwwF5g">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ab93kNrf80-v2rMyke-vrg"
      id="Narr_n8SHmXC68kqQCokHhYuzZQ">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="0"
      id="Narr_F83lx8g1xUmL-NufvtuLlA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="0"
      id="Narr_QogOH08y7kmu27P-mTL3eQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_h1j7OtWbN0GOnm_cjRIWjQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Share-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The impact that share-based payment awards will have on the Company&#x2019;s results of operations is a function of the number of shares awarded, the trading price of the Company&#x2019;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#x2019;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Expected volatility is based on historical volatility of the Company&#x2019;s common stock (the &#x201c;Common Stock&#x201d;); the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#x2019;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 17 - Share-Based Compensation for additional information.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Narr_QjZnejMjcUyNmgx7wGFn8g"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_XG0nrxAaukS-EpdE2hCugw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At September&#160;30,&#160;2022 and June&#160;30,&#160;2022, amounts in excess of insured limits were approximately $15,372,000 and $18,200,000, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the three months ended September&#160;30,&#160;2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from one customer. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the three months ended September&#160;30,&#160;2021, the Company reported revenue from continuing operations from one customer related to the settlement of a revenue contract and generated 100% of revenue reported in discontinued operations from three customers, each of whom individually accounted for more than 10% of revenue.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="0"
      id="Narr_dlBrjbIM2E6FT8LZX8VQ1A"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">15372000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="0"
      id="Narr_SHmNZwU9dES9clK-PgL7qw"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">18200000</us-gaap:CashUninsuredAmount>
    <ibio:NumberOfMajorCustomers
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_s9c-WnWOxE6g2LweOZs_9Q"
      decimals="0"
      id="Narr_RZJ0W3GCdEO8krUC9KxVLQ"
      unitRef="Unit_Standard_customer_Y0UfwaAMRkCOQV5hDgN0Lw">1</ibio:NumberOfMajorCustomers>
    <ibio:NumberOfMajorCustomers
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_i04Yf02_rk-EHh765zWa6g"
      decimals="0"
      id="Narr_Es-nRPJxlk-g4Og8zWHzug"
      unitRef="Unit_Standard_customer_Y0UfwaAMRkCOQV5hDgN0Lw">3</ibio:NumberOfMajorCustomers>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_hMENetisuEq9JEYIs2UMxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company does not expect the adoption of ASU 2016-13 to have a significant impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_oozcHYK5VUSDzN3QpMtQvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;5.&#160;&#160;&#160;Financial Instruments and Fair Value Measurement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The carrying values of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and term note payable in the Company&#x2019;s condensed consolidated balance sheets approximated their fair values as of September&#160;30,&#160;2022 and June&#160;30,&#160;2022 due to their short-term nature. The carrying value of the convertible promissory note receivable, the term note payable and finance lease obligation approximated fair value as of September&#160;30,&#160;2022 and June&#160;30,&#160;2022 as the interest rates related to the financial instruments approximated market value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of investments that fall under each category, and the valuation methodologies used to measure these investments at fair value. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 1&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; Inputs are based upon unadjusted quoted prices for identical instruments in active markets. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 2&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; Inputs to the valuation include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. &#160;All debt securities were valued using Level 2 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 3&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <ibio:SignificantTransactionsTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_ceMK2G95BEiArJZkONpIIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;6.   Significant Transactions &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Affiliates of Eastern Capital Limited&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 1, 2021, the Company and its subsidiary, iBio CDMO (&#x201c;iBio CDMO&#x201d;, and collectively with the Company, the &#x201c;Purchaser&#x201d;) entered into a series of agreements (the &#x201c;Transaction&#x201d;) with College Station Investors LLC (&#x201c;College Station&#x201d;), and Bryan Capital Investors LLC (&#x201c;Bryan Capital&#x201d; and, collectively with College Station, &#x201c;Seller&#x201d;), each affiliates of Eastern Capital Limited (&#x201c;Eastern,&#x201d; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility&#x2019;s ground lease;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(iii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;otherwise terminated all agreements between the Company and the affiliates of Eastern.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&amp;amp;M University System (&#x201c;Texas A&amp;amp;M&#x201d;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the &#x201c;Sublease&#x201d;) until the purchase of the Facility described below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Purchase and Sale Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 1, 2021, the Purchaser entered into a Purchase and Sale Agreement (the &#x201c;Purchase and Sale Agreement&#x201d;) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the &#x201c;Ground Lease Agreement&#x201d;) that it entered into with Texas A&amp;amp;M (the &#x201c;Landlord&#x2019;&#x2019;) related to the property at which the Facility is located together with all improvements pertaining thereto (the &#x201c;Property&#x201d;), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity described below is $28,750,000, which was paid $28,000,000 in cash and by the issuance to Seller of warrants (the &#x201c;Warrant&#x201d;) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, iBio CDMO is being accounted for as a discontinued operation. &#160;As such, the assets acquired and/or leased are now classified as assets held for sale on the September 30, 2022 and June 30, 2022 condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Equity Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company also entered into an Equity Purchase Agreement with Bryan Capital on November 1, 2021 (the &#x201c;Equity Purchase Agreement&#x201d;) pursuant to which the Company acquired for $50,000 cash, plus the Warrant, the one (1) share of iBio CMO Preferred Tracking Stock and the 0.01% interest in iBio CDMO owned by Bryan Capital. As a result, iBio CDMO is now a wholly-owned subsidiary of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Credit Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the Purchase and Sale Agreement, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan (the &#x201c;Term Loan&#x201d;) to purchase the Facility, which Term Loan is evidenced by a Term Note (the &#x201c;Term Note&#x201d;). The Term Loan was advanced in full on the closing date. The Term Loan bears interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest is payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Credit Agreement contains customary events of default (which are in some cases subject to certain exceptions, thresholds, notice requirements and grace periods), including, but not limited to, nonpayment of principal or interest, failure to perform or observe covenants, breaches of representations and warranties, cross-defaults with certain other indebtedness, certain bankruptcy-related events or proceedings, final monetary judgments or orders and certain change of control events. The covenants include a prohibition on the incurrence of Debt (as defined in the Credit Agreement) except permitted Debt (as defined in the Credit Agreement) and Liens (as defined in the Credit Agreement) and termination of the Ground Lease Agreement. In addition, the Company initially was required to maintain unrestricted cash of no less than $10,000,000 which amount has been reduced (see below).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company opened an irrevocable letter of credit in the amount of approximately $5,469,000 in favor of Woodforest. &#160;The letter of credit was scheduled to expire on October 29, 2022, but was cancelled (see below).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The proceeds of the Term Loan were used (a) to fund a portion of the purchase price under the Purchase Agreement, and (b) to pay closing costs in connection with the Credit Agreement. The term loan is secured by (a) a leasehold deed of trust on the Facility, (b) a letter of credit issued by JPMorgan Chase Bank, and (c) a first lien on all assets of iBio CDMO including the Facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On October 11, 2022, we and Woodforest amended the Credit Agreement to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days &#160;upon our receipt of such amount owed to us by Fraunhofer as part of our legal settlement with them (see Note 19 &#x2013; Fraunhofer Settlement for more information), (iii) include &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;principal payments of $250,000 per month in debt amortization for a 6 month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast (vi) reduce the liquidity covenant in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5.0 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#x201c;going concern&#x201d; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment. If we fail to successfully extend our cash runway via strategic options or other alternatives as described, we would be in violation of the liquidity covenant on December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As a result of the foregoing, at both September 30, 2022 and June&#160;30,&#160;2022, the Term Loan has been classified as short term. At September 30, 2022, the balance was $22,201,000 which consisted of the Term note of $22,375,000, net of approximately $174,000 of deferred finance costs. &#160; At June 30, 2022, the balance was $22,161,000 which consisted of the Term Note of $22,375,000, net of approximately $214,000 of deferred finance costs. Interest expense incurred under the Credit Agreement for the three months ended September&#160;30,&#160;2022 amounted to $186,000. Amortization of deferred finance costs amounted to $40,000 for the three months ended September 30, 2022 and is included in interest expense. &#160;Both interest expense amounts are classified under loss from discontinued operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Security and Pledge Agreements, Guaranties and Deed of Trust&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;iBio CDMO also entered into a Security Agreement on November 1, 2021 with Woodforest (the &#x201c;Security Agreement&#x201d;) providing Woodforest a security interest in the following assets of iBio CDMO (subject to certain exclusions): all personal and fixture property of every kind and nature, including, without limitation, all goods (including, but not limited to, all equipment and any accessions thereto), all inventory, instruments (including promissory notes), documents, accounts, chattel paper (whether tangible or electronic), deposit accounts, securities accounts, letter-of-credit rights (whether or not the letter of credit is evidenced by a writing), money, commercial tort claims, securities and all other investment property, supporting obligations, contracts, contract rights, other rights to the payment of money, insurance claims and proceeds, software, fixtures, vehicles and rolling stock (whether or not subject to a certificate of title statute), leasehold improvements, general intangibles (including all payment intangibles), and all of iBio CDMO&#x2019;s company and other business books, reports, memoranda, customer lists, credit files, data compilations, and computer software, in any form, including, without limitation, whether on tape, disk, card, strip, cartridge, or any other form, pertaining to any and all of the foregoing property, and all products and proceeds of the foregoing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company also entered into a Guaranty for the benefit of Woodforest (the &#x201c;Guaranty&#x201d;) pursuant to which it guaranteed all of the obligations of iBio CDMO to Woodforest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In addition, iBio CDMO entered into a Leasehold Deed of Trust, Assignment of Rents, Security Agreement and UCC Financing Statement for Fixture Filing (the &#x201c;Deed of Trust&#x201d;) with the trustee named therein and Woodforest as beneficiary, securing all of iBio CDMO&#x2019;s obligations to Woodforest by a senior priority security interest in the Property.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company and iBio CDMO also entered into an Environmental Indemnity Agreement in favor of Woodforest (the &#x201c;Environmental Indemnity Agreement&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Warrant&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the shares issued under the Warrant, 11,583, which were originally valued at $217,255, reflected the final payment of rent due under the Sublease. The Warrant, as shown on the condensed consolidated statements of equity, was recorded in additional paid in capital with the corresponding activity included in the basis of the purchase price allocation of the property acquired. &#160;See Note 16 &#x2013; Stockholders&#x2019; Equity for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;RubrYc&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (&#x201c;RubrYc&#x201d;) described in more detail below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Collaboration and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company entered into a collaboration and licensing agreement (the &#x201c;RTX-003 License Agreement&#x201d;) with RubrYc to further develop RubrYc&#x2019;s immune-oncology antibodies in its RTX-003 campaign. &#160;Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields&lt;span style="color:#0000ff;"&gt;. &#160;&lt;/span&gt;RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Collaboration, Option and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company entered into an agreement with RubrYc (the &#x201c;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Collaboration, Option and License Agreement&#x201d;) &lt;/span&gt;to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYc&#x2019;s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. &#160;RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) &lt;span style="-sec-ix-hidden:Hidden_9g2_uLeoFka_iS5MEA5Jqw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ten&lt;/span&gt;&lt;/span&gt; (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. &#160;The Collaboration, Option and License Agreement was mostly terminated when the Company acquired substantially all of the assets of RubrYc in September 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 4.5pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-align:justify;margin:0pt;"&gt;In connection with the entry into the Collaboration Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (&#x201c;Stock Purchase Agreement&#x201d;) with RubrYc whereby the Company purchased a total of 2,864,345 shares of RubrYc&#x2019;s Series A-2 preferred stock &#x201c;Series A-2 Preferred&#x201d;) for $7,500,000. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,760,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,300,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,440,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;RubrYc ceased its operations, and the Company recorded an impairment of the investment in the amount of $1,760,000 in 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, in 2022. The amount was recorded in the consolidated statement of operations and comprehensive loss under research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The Company issued 102,354 shares of the Company&#x2019;s common stock with an approximate market value of $1,000,000 (the &#x201c;Closing Shares&#x201d;). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Company&#x2019;s common stock, at the Company&#x2019;s option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. &#160;The assets acquired include an AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, and two additional immuno-oncology candidates plus a partnership-ready PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. &#160;The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 1,228,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 114,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 1,342,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. &#160;See Note 9 &#x2013; Finance Lease ROU Assets and Note 14 &#x2013; Finance Lease Obligations.&lt;/p&gt;</ibio:SignificantTransactionsTextBlock>
    <ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA"
      decimals="0"
      id="Narr_Mi8OUjEua0SLe8wdFC-I_g"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">28750000</ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest>
    <ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ"
      decimals="0"
      id="Narr_1H8GUeihPUSL63Q5T6juWw"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">28000000</ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment>
    <ibio:FairMarketValueOfProperty
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA"
      decimals="0"
      id="Narr__3zvDAcdgk6CwMmp8jojWQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">151450</ibio:FairMarketValueOfProperty>
    <ibio:BaseRentPercentageOfFairMarketValueOfProperty
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ"
      decimals="3"
      id="Narr_VtMHfNcLUUWtY-bzFta8mA"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.065</ibio:BaseRentPercentageOfFairMarketValueOfProperty>
    <ibio:EquityAgreementConsiderationTransferredEquityInterestsAcquired
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ"
      decimals="0"
      id="Narr_t8l6K6VC2EmRhKgYjyQzgg"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">50000</ibio:EquityAgreementConsiderationTransferredEquityInterestsAcquired>
    <ibio:EquityAgreementWarrantsIssuedOrIssuable
      contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_2OHxCAB-J0WOw18oKiVXGA"
      decimals="INF"
      id="Narr_4M4LYFFkYUWf-SmfHTrdzQ"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">1</ibio:EquityAgreementWarrantsIssuedOrIssuable>
    <ibio:EquityAgreementPercentageOfEquityInterestIssuedOrIssuable
      contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_2OHxCAB-J0WOw18oKiVXGA"
      decimals="4"
      id="Narr_qGQWgdKB6kegqlO0-T12xA"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.0001</ibio:EquityAgreementPercentageOfEquityInterestIssuedOrIssuable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Drb-_QNrO0K1RLoc86Un0A"
      decimals="0"
      id="Narr_5KP7wcCiA0qAPtE_G6lNvA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">22375000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Drb-_QNrO0K1RLoc86Un0A"
      decimals="4"
      id="Narr_G6Dm7HOAdUeQFgAFagDOMA"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ibio:CreditAgreementThresholdLimitUnrestrictedCash
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Drb-_QNrO0K1RLoc86Un0A"
      decimals="0"
      id="Narr_lAJYvd8cN0SDvvPvD9rw2A"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">10000000</ibio:CreditAgreementThresholdLimitUnrestrictedCash>
    <ibio:IrrevocableLetterOfCredit
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_Drb-_QNrO0K1RLoc86Un0A"
      decimals="0"
      id="Narr_bSYd16-ackG5WU-6OksyJA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5469000</ibio:IrrevocableLetterOfCredit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA"
      decimals="INF"
      id="Narr_vCgFVNSHG0ak_sz6iYigJA"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">51583</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA"
      decimals="2"
      id="Narr_s4gfAdCDNk60CbAXpekvGg"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">33.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ibio:WarrantsIssuedForFinalPaymentOfSubleaseRent
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ"
      decimals="INF"
      id="Narr_R3ZLoFQXqEenF46m_d7bfg"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">11583</ibio:WarrantsIssuedForFinalPaymentOfSubleaseRent>
    <ibio:WarrantsIssuedForFinalPaymentOfSubleaseRentValue
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA"
      decimals="0"
      id="Narr_FhP7YIUrPUSJDgrJmyOuvg"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">217255</ibio:WarrantsIssuedForFinalPaymentOfSubleaseRentValue>
    <ibio:CollaborationAndLicenseAgreementAgreementTerm
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_OdZyqlQ0vEmY8lbQusF-8g"
      id="Narr_6I6NJZVUK0uA189occ03Eg">P5Y</ibio:CollaborationAndLicenseAgreementAgreementTerm>
    <ibio:StockPurchaseAgreementNumberOfSharesPurchased
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_QgEz_8IsUkubKmRBLIhjSw"
      decimals="INF"
      id="Narr_TF0TH7VMKkWjbpP5sy8k2A"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">2864345</ibio:StockPurchaseAgreementNumberOfSharesPurchased>
    <ibio:StockPurchaseAgreementValueOfSharesPurchased
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTheraputicsInc.Member_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_QgEz_8IsUkubKmRBLIhjSw"
      decimals="0"
      id="Narr_WQ9BJtJd2kqNd_cKk9H8zQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">7500000</ibio:StockPurchaseAgreementValueOfSharesPurchased>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_vIjz2QvLhkmSRzd2SRXhOA"
      id="Tb_nHL3OpmBV0qMYjlmvEgMFA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,760,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,300,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,440,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_ITw1i6YR9UyPpE1bDlnljA"
      decimals="0"
      id="Narr_g6saaeH7eEKjcz_Riz5kIQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">7500000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember__MJTg0K5YECHuCTCCIebng"
      decimals="0"
      id="Tc_XsP_qTFhikK4KLcI4C0R1w_1_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1760000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_zieqCNuAYk6lRv2JAfCx8w"
      decimals="0"
      id="Tc_YNDPPbVWp0GPjorcf1Vbhg_2_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">4300000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember_xJCS27lRZ0q-02PnngOAUw"
      decimals="0"
      id="Tc_FuTWx8q0Y02CO1Nb9zG3hg_3_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1440000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_ITw1i6YR9UyPpE1bDlnljA"
      decimals="0"
      id="Tc_3M3QduBDeEe7_57LiY3Ehw_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">7500000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_ibio_RubrycTheraputicsInc.Member_6l4R-5WO_UilEL_BSvm5mA"
      id="Tb_ZjYDBCwGu0KIR-mfDgT3dA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 1,228,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 114,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 1,342,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_3qipMro8ykyJ87ng4DIfGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;7.&#160;&#160;&#160;Convertible Promissory Note Receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On October 1, 2020, the Company entered into a master services agreement with Safi Biosolutions, Inc. (&#x201c;Safi&#x201d;). In addition, the Company invested $1.5 million in Safi in the form of a convertible promissory note (the "Note"). The Note bears interest at the rate of 5% per annum and is convertible into shares of Safi&#x2019;s common stock (as defined). Principal and accrued interest mature on October 1, 2023. &#160;For both of the three months ended September 30, 2022 and 2021, interest income amounted to $19,000. As of September&#160;30,&#160;2022 and June 30, 2022, the Note balance and accrued interest totaled $1,650,000 and $1,631,000, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <ibio:LoansReceivableAmountInvested
      contextRef="As_Of_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_RpRam_Iq8kC7AtGMNktNbw"
      decimals="-5"
      id="Narr_lhOZODV25U-79chuo3wfpA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1500000</ibio:LoansReceivableAmountInvested>
    <ibio:LoansReceivableFixedRatesOfInterest
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_XyA_UzbdsEqM1o0uE-Nz6Q"
      decimals="2"
      id="Narr_qX3lg8wqtUydyhYKtO3J4Q"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.05</ibio:LoansReceivableFixedRatesOfInterest>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_LZ1K5TZXo0OueONF_P6xhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8.&#160;&#160;&#160;Investments in Debt and Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Debt Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Investments in debt securities consist of AA and A rated corporate bonds bearing interest at rates from 0.25% to 3.5% with maturities from &lt;span style="-sec-ix-hidden:Hidden__3BD-NqJOEiqalOgJX0pyg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;December 2022&lt;/span&gt;&lt;/span&gt; to &lt;span style="-sec-ix-hidden:Hidden_NaePz8N5I0616M6LaQS5Jg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;February 2024&lt;/span&gt;&lt;/span&gt;. The components of investments in debt securities are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Adjusted cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Gross unrealized losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt; (194)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.46%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt; (184)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,599&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The fair value of available-for-sale debt securities, by contractual maturity, was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5,341&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8,054&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7,599&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortization of premiums paid on the debt securities amounted to $36,000 and $102,000 for the three months ended September&#160;30,&#160;2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_bChqJvE_00atn1jSV3pqeQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Debt Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Investments in debt securities consist of AA and A rated corporate bonds bearing interest at rates from 0.25% to 3.5% with maturities from &lt;span style="-sec-ix-hidden:Hidden__3BD-NqJOEiqalOgJX0pyg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;December 2022&lt;/span&gt;&lt;/span&gt; to &lt;span style="-sec-ix-hidden:Hidden_NaePz8N5I0616M6LaQS5Jg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;February 2024&lt;/span&gt;&lt;/span&gt;. The components of investments in debt securities are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Adjusted cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,793&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Gross unrealized losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt; (194)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.46%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"&gt; (184)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,599&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:InvestmentInterestRate
      contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_MinimumMember_-6_SwUpb2EmaZh5-_vBL1Q"
      decimals="4"
      id="Narr_IFeTFWbK3UKkkZS0uLnRhA"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.0025</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate
      contextRef="As_Of_9_30_2022_srt_RangeAxis_srt_MaximumMember_s8tVGg0TVkGTdiQRMPEupQ"
      decimals="4"
      id="Narr_KCOgdJ2mg0GXku1G3o1H-g"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.035</us-gaap:InvestmentInterestRate>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_5lZQEzp8jUqDk74O-4qNWA_3_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">7793000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_PSX_u2LpZECbE67g4d4IFg_3_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">11029000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_IwV_Kby3rE23LRQ_ZkedaA_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">194000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_PdpJi6im9kC8KzerFEqf3g_4_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">184000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_L4qDJY_Pvku1SCIRhMEFQg_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">7599000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_ZVHIRQ-bgEmxDmM21rJqSw_5_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">10845000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_7uVQy6wIrUyv22vYRaVKOA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The fair value of available-for-sale debt securities, by contractual maturity, was as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5,341&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;8,054&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,258&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2,791&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:59.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7,599&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:9pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;10,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_cmQ8ZCO4sUuudj-BB4FDVA_3_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5341000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_u6gjztam7U-jRuSSEdQhjQ_3_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">8054000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_CUAdo5IKqkqBZGEMcH0yfA_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2258000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_ESXAQo4N3EWNPbKwU7uiXg_4_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2791000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_aOMSAZPrmUSf_pqiQeypYA_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">7599000</us-gaap:DebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_qIoxbSPPQUuyMJzfan35cQ_5_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">10845000</us-gaap:DebtSecuritiesCurrent>
    <ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_kiIeaKYN9U6ks5agL49UeQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9.&#160;&#160;&#160;Finance Lease ROU Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As discussed above, the Company assumed three equipment leases as part of the RubrYc asset acquisition. &#160;In addition, the Company also leases a mobile office trailer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;See Note 14 &#x2013; Finance Lease Obligation for more details of the terms of the leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ROU - Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (85)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (72)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net finance lease ROU&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortization of finance lease ROU assets was approximately $13,000 and $12,000 for three months ended September 30, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock>
    <ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_OJbhIHjGVE-zE-_qBB81_g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ROU - Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 146&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (85)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (72)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net finance lease ROU&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock>
    <ibio:FinanceLeaseRightOfUseAssetGross
      contextRef="As_Of_9_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_UM_IWNFT-kCLpCY0YtA3Kg"
      decimals="-3"
      id="Tc_pP3RZ8bkq0WEeloslJKGRg_3_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">960000</ibio:FinanceLeaseRightOfUseAssetGross>
    <ibio:FinanceLeaseRightOfUseAssetGross
      contextRef="As_Of_6_30_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_7CoQPwcN1U-vHI9EXbbGag"
      decimals="-3"
      id="Tc_3n46H1X6Yku0pQ1An3ZbpA_3_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">146000</ibio:FinanceLeaseRightOfUseAssetGross>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_P5A6G3UFvUS3vmJv0dU3Qg_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">85000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_gfjDJofL7E2IOfseOL0rlw_4_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">72000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_EF7iMduQb0-9TxrHh4vdNw_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">875000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_yCJ9SHt-ZU6tFoscKcBHcg_5_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">74000</us-gaap:FinanceLeaseRightOfUseAsset>
    <ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_VMAhK0q4LkOeFd_5z7HEgA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10.&#160;&#160;&#160;Operating Lease ROU Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;San Diego, California&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. &#160;Based on the terms of the lease payments, the Company recorded an operating lease right-of-use asset of $3,603,000. &#160;The net carrying amount of this ROU operating lease asset was $2,928,000 and $3,068,000 at September 30, 2022 and June 30, 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Bryan, Texas&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 1, 2021, as discussed above, iBio CDMO acquired the Facility and became the tenant under the ground lease for the Property upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease right of use asset of $1,967,000. The net amount of this ROU operating lease asset is included in assets held for sale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt; &#160; &#160;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;See Note 15 - Operating Lease Obligation for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw"
      decimals="0"
      id="Narr_DWU_ZvRTnUiuiqonub3lIA"
      unitRef="Unit_Standard_sqft_5KxWaFXlD02dT7QlqBc7JA">11383</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw"
      decimals="0"
      id="Narr_0MRa3FMqyEawRBzamI2cXw"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3603000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_11_1_2021_H4wahzJ9fkakdBA5brt04w"
      decimals="0"
      id="Narr_P8lVnbZpG02uHUTxhdMmeg"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1967000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_NzSSpeyk2kud7QhZo1ePig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11.&#160;&#160;&#160;Fixed Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Substantially all of the fixed assets at September 30, 2022 are included in assets held for sale. &#160;The depreciation expense for the three months ended September 30, 2022 and 2021 is classified as part of loss from discontinued operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Fixed assets at September 30, 2022 and June 30, 2022 reported in continuing operations represents the construction in progress for the new San Diego research facility. &#160;These assets were placed into service on October 1, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_f7cBEsNRU0mQcG9qDSo1zQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12.&#160;&#160;&#160;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has two categories of intangible assets&#160;&#x2013; intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December&#160;2003 from Fraunhofer USA&#160;Inc., acting through its Center for Molecular Biotechnology (&#x201c;Fraunhofer&#x201d;), pursuant to a Technology Transfer Agreement, as amended (the &#x201c;TTA&#x201d;). The Company designates such technology further developed and acquired from Fraunhofer as &lt;i style="font-style:italic;"&gt;iBioLaunch&lt;/i&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; or &lt;i style="font-style:italic;"&gt;LicKM&lt;/i&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt; or &lt;i style="font-style:italic;"&gt;FastPharming&lt;/i&gt; Technology. The value on the Company&#x2019;s books attributed to patents owned or controlled by the Company is based only on payments for services and fees related to the protection of the Company&#x2019;s patent portfolio. The intellectual property also includes certain trademarks.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 &#x2013; Significant Transactions) whereby in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T regulatory (T reg) cells while enhancing T effector (T eff) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. &#160;In addition, the Company also received preferred shares and an option for future collaboration licenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 &#x2013; Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The assets acquired include an AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, and two additional immuno-oncology candidates, plus a partnership-ready PD-1 agonist.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In January 2014, the Company entered into a license agreement with the University of Pittsburgh&lt;i style="font-style:italic;"&gt; &lt;/i&gt;whereby iBio acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the "Licensed Technology") which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone &#x2013; filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology ("IND") &#x2013; initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022 was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of 10 years and other intellectual property is amortized over periods from 16 to 23 years unless they were determined to have indefinite lives. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;There were no impairments for the three months ended September&#160;30,&#160;2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; gross carrying value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents and licenses &#x2013; gross carrying value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,720&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 6,220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,946&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,905)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,867)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents and licenses &#x2013; accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,305)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,403)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,210)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,270)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total definite lived intangible assets, net of accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;License - indefinite lived&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,175&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 6,013&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,851&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortization expense of intangible assets was approximately $67,000 and $88,000 for the three&#160;months ended September&#160;30, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_fXHaqpNPo0ibzA3IIYhZbQ"
      id="Narr_UgPi_fpot0KR3P3penjW4w">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ab93kNrf80-v2rMyke-vrg"
      id="Narr_uB6dneiHb0yBb9XMJ3fkQg">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember__u8DjlS8KEWaLpv6LnztgQ"
      id="Narr_0jdBvsALu02574rkzHvrzA">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_-MRCe5bs70amraYEqD9kqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; gross carrying value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents and licenses &#x2013; gross carrying value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,720&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 2,846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 6,220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,946&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,905)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,867)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents and licenses &#x2013; accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,305)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,403)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,210)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,270)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total definite lived intangible assets, net of accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,010&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 676&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;License - indefinite lived&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,175&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 6,013&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,851&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_YQhUDGnYokGcvtHjtcEqtA"
      decimals="-3"
      id="Tc_-2FNCeE_YkulBlhDuQJE0g_3_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_dlYgMTALDUmKK5WItuSB3g"
      decimals="-3"
      id="Tc_6j-EyueqYEi6PcDA4_I8VA_3_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_rkj0FZs-fUu4EXJb9_k82g"
      decimals="-3"
      id="Tc_H0wi9KImn065I5eBwpGhAA_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2720000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_uC1tSKAok0msG1QVWd04rw"
      decimals="-3"
      id="Tc_qA1vY_lSd0Cn0WEs5ioQLg_4_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2846000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_CFyzezf7tk--LeT8FzFclg_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">6220000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_OfSHvEIva064JBKzPMatCg_5_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5946000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_YQhUDGnYokGcvtHjtcEqtA"
      decimals="-3"
      id="Tc_yksDOmVbxE6tst6slDRb9Q_6_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2905000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_dlYgMTALDUmKK5WItuSB3g"
      decimals="-3"
      id="Tc_2oRgwAjbUE6GIk3ADggSqQ_6_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2867000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_9_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_rkj0FZs-fUu4EXJb9_k82g"
      decimals="-3"
      id="Tc_Tp9QEUhwTUyOQIqvtAkv3A_7_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2305000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_uC1tSKAok0msG1QVWd04rw"
      decimals="-3"
      id="Tc_BcITh5TdaEqAmc0iLRigVA_7_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2403000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_MsltOQqtJ06dRkYgcpe8Cg_8_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5210000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_uqAc0r8iEEeKUQCf8a9KsQ_8_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5270000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_vFASVnr8cUqCX-KnIwTyCw_13_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">6013000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_Iz33vA60P0ufTerx6p_X_g_13_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">4851000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ibio:NotesPayablePppLoanDisclosureTextblock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_IYtO-ucU10eMS_tRAQNArw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;13.&#160;&#160;&#160;Note Payable &#x2013; PPP Loan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On April 16, 2020, the Company received $600,000 related to its filing under the Paycheck Protection Program and Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"). The Company elected to treat the SBA Loans as debt under ASC 470, &#x201c;Debt&#x201d;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On July 21, 2021, iBio was granted forgiveness in repaying the loan. &#160;In accordance with ASC 405-20-40, &#x201c;&lt;i style="font-style:italic;"&gt;Liabilities - Extinguishments of Liabilities &#x2013; Derecognition&lt;/i&gt;&#x201d;, the Company derecognized the liability and accrued interest of approximately $7,000 in the first quarter of Fiscal 2022. &#160;The forgiveness is included in loss from discontinued operations (see Note 3 &#x2013; Discontinued Operations).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:NotesPayablePppLoanDisclosureTextblock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_iLqVWmlH3kmcqy47FvL1gA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14.&#160;&#160;&#160;Finance Lease Obligation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Sublease&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, until November 1, 2021, iBio CDMO leased the Facility as well as certain equipment from College Station under the Sublease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Sublease was terminated on November 1, 2021, when iBio CDMO acquired the Facility and became the tenant under the ground lease for the property upon which the Facility is located. &#160;See Note 15 &#x2013; Operating Lease Obligations for additional information related to the ground lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;General and administrative expenses related to College Station, including rent related to the increases in CPI and real estate taxes, were approximately $189,000 for the three months ended September 30, 2021. Interest expense related to College Station was approximately $608,000 for the three months ended September 30, 2021. Such expenses were classified as part of loss from discontinued operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, the Company assumed three equipment leases that were accounted for as finance leases totaling $813,822 as part of the RubrYc Asset Purchase Agreement. &#160;The monthly rental for the three leases is approximately $14,000 per month and all three expire on August 1, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Mobile Office Trailer&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Commencing April 1, 2021, the Company is leasing a mobile office trailer at a monthly rental of $3,819 through March 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Amortization of ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating cash flows from finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Financing cash flows from finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - noncurrent portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term - finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 1.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate - finance lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 9.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 6.250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the finance lease obligation are due as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on September 30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 369&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 297&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 338&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (303)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <ibio:LessorFinanceLeaseMonthlyRent
      contextRef="Duration_4_1_2021_To_4_1_2021_Cv64n0Mw7E6pyUXZzZXFwA"
      decimals="0"
      id="Narr_WBjNWGXQNkedIIzbpRdNmA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3819</ibio:LessorFinanceLeaseMonthlyRent>
    <ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_HhjxWSFuREmMRh7Mik2Y9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Amortization of ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating cash flows from finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Financing cash flows from finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_RVNRHxBXuE2F1aDdMs82Bw_6_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_erABVk-AsUuZqBuO53ECFw_6_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">2000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_LnYKZO3sjkaKKaDNFsFz8g_7_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">14000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_8xSzUDRkH0eUZrd0tlLaFQ_7_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">14000</us-gaap:LeaseCost>
    <ibio:FinancingCashFlowsFromFinanceLeaseObligation
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_zeWE-E-65k2w-p1MaU1NBA_12_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">10000</ibio:FinancingCashFlowsFromFinanceLeaseObligation>
    <ibio:FinancingCashFlowsFromFinanceLeaseObligation
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_TULBwk5Bd0KuUEu4dnWDjA_12_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">10000</ibio:FinancingCashFlowsFromFinanceLeaseObligation>
    <ibio:ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_-eo3TPstCUKqiHwj815Ftg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - noncurrent portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term - finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 2.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 1.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate - finance lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 9.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 6.250&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ibio:ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_Np5yVVzptUKOiOyw2G82bQ_3_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">875000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_D2q4McnLKEm7-yTXa9Vufg_3_7"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">74000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_9wD6VOzSUEeX_PoNdiWZ_g_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">303000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_MZTZr4S-P0yXOr4j-zrgWg_4_7"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">46000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_7d88KIKxAECrajIjT0lXxw_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">576000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="-3"
      id="Tc_vxRqJYHm7EKbqx7n5Oy03A_5_7"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">30000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      id="Tc_frLcAtpf1EWgY675VrUlog_6_3">P2Y8M26D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      id="Tc_wBGbfYWlWEOb1VpcpgscSA_6_7">P1Y9M3D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="4"
      id="Tc_kS07Dn06T0S3SgL-Rdjlzg_7_3"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.0926</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_6_30_2022_Skb4jZpNh0CpOWVWKHa-1Q"
      decimals="5"
      id="Tc_S6nvC-0HvUObINATWAeS1A_7_7"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.06250</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_pt3HmdDK2E2_Tuf1bKN5AA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the finance lease obligation are due as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on September 30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 303&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 369&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 297&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 338&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (303)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 576&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ"
      decimals="-3"
      id="Tc_x9j9UTlPG0C-F29-8cSTcw_2_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">303000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_WTTx3bX1OkW89C-T4NTf4g"
      decimals="-3"
      id="Tc_7rp4wlpnSk6jJty3A8os-g_2_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">66000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_yfBCRrsTckySn9iuRzytkA_2_9"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">369000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ"
      decimals="-3"
      id="Tc_Yz6n5eiOL02Tw0Sg7yEh6A_3_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">297000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_WTTx3bX1OkW89C-T4NTf4g"
      decimals="-3"
      id="Tc_2jlMUVvMgUC8S5fQJmuCmg_3_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">41000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_ZyNhBA8Dy0GL-rpN1iirCA_3_9"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">338000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ"
      decimals="-3"
      id="Tc_nwYjIydu-kyiPoEdUVdaaw_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">279000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_WTTx3bX1OkW89C-T4NTf4g"
      decimals="-3"
      id="Tc_BE42r9lGbEO3vBcurJCNRA_4_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">14000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_pf4NSDHmcEyU-b81Lj-mCQ_4_9"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">293000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ"
      decimals="-3"
      id="Tc_aQsp1St9CEqGg_PzOvY73w_6_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">879000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_WTTx3bX1OkW89C-T4NTf4g"
      decimals="-3"
      id="Tc_psz533uMVE-fsRC6s1Kriw_6_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">121000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc__zJkYawv_E6AedgTBFGqwA_6_9"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ"
      decimals="-3"
      id="Tc_5xjsVFHHk0SsfNOdChcBuw_7_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">303000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2022_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_pkoTpMzMPU6ePHhlCV9NyQ"
      decimals="-3"
      id="Tc_ukN6d7ejR02OKKdtBTCXwQ_8_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">576000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_AQFOe3J9SESpOOjAvNddQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;15.&#160;&#160;&#160;Operating Lease Obligation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Texas Ground Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;San Diego&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"&gt;On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. &#160;Terms of the lease include the following: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The length of term of the lease is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;88 months&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; from the lease commencement date (as defined).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The lease commencement date was estimated to be on or around January 1, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The monthly rent for the first year of the lease is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$51,223&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and increases approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The lease provides for a base rent abatement for months &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_HTgQ1reF4068PJjjH7wdhg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; through &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_6jE7_kh_EUe3WSMLLFzfcg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; in the first year of the lease.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The landlord is providing a tenant improvement allowance of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$81,860&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; to be used for improvements as specified in the lease.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company is responsible for other expenses such as electric, janitorial, etc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company opened an irrevocable letter of credit in the amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$188,844&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; in favor of the landlord. &#160;The letter of credit expires on October 8, 2022 and renews annually as required.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. &#160;Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease ROU asset in the accompanying balance sheet. &#160;As the Company has already started making improvements to the facility, the rent expense will be recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liability:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the operating lease obligation are due as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on September&#160;30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Imputed Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 464&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 235&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 653&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 674&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,758&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (183)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ibio:LesseeOperatingLeaseMonthlyRent
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ"
      decimals="0"
      id="Narr_AGdLBYd3pUCJ7cZncGs24Q"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">151450</ibio:LesseeOperatingLeaseMonthlyRent>
    <ibio:BaseRentPercentageOfFairMarketValueOfProperty
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_DOnOUjsMWkS6xBtry1JVjQ"
      decimals="3"
      id="Narr_GcMu6DHmLEiLbEaQKugp7g"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.065</ibio:BaseRentPercentageOfFairMarketValueOfProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw"
      decimals="0"
      id="Narr_WOIh7AD_40iabhnMkEwadw"
      unitRef="Unit_Standard_sqft_5KxWaFXlD02dT7QlqBc7JA">11383</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw"
      id="Narr_Tpf-6uuUCkmFq8z98N5t3w">P88M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ibio:LesseeOperatingLeaseMonthlyRent
      contextRef="Duration_9_10_2021_To_9_10_2021_m_dKSYWyjkGt_N2eurcfeg"
      decimals="0"
      id="Narr_2jcRICwwXECh91uMuRc8Jw"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">51223</ibio:LesseeOperatingLeaseMonthlyRent>
    <ibio:LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent
      contextRef="Duration_9_10_2021_To_9_10_2021_m_dKSYWyjkGt_N2eurcfeg"
      decimals="2"
      id="Narr_krXsXSzAzkKoL-3uT7hHEw"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.03</ibio:LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent>
    <us-gaap:TenantImprovements
      contextRef="As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw"
      decimals="0"
      id="Narr_FTE0U7Rb50-eMxw8FqsDvQ"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">81860</us-gaap:TenantImprovements>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_ZxIXPbVKrUyMV_ban-OCAg"
      decimals="0"
      id="Narr_2KISUSa2RkmZsI1oO0jCwA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">188844</us-gaap:GuaranteeObligationsMaximumExposure>
    <ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_mib6xuZba0mZbR7QoXjOOw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liability:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_51Q5MaNkckasbuJs6BriMA_4_2"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">141000</us-gaap:OperatingLeaseCost>
    <ibio:TotalOperatingLeaseCosts
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_7W_5Kno7UEC6GV-1fGqV7A_5_2"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">141000</ibio:TotalOperatingLeaseCosts>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_eV-YETr4bkm_FUNo1VN66A_9_2"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">141000</us-gaap:OperatingLeasePayments>
    <ibio:OperatingCashFlowsFromOperatingLeaseObligation
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_NbK2I9lqJUOaVhkB7BmyIQ_10_2"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3000</ibio:OperatingCashFlowsFromOperatingLeaseObligation>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_vz0xfcdbq0GYxV8vpTltew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the operating lease obligation are due as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on September&#160;30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Imputed Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 183&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 464&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 235&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 653&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 674&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 562&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,638&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,154&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 4,758&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (183)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 3,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_VyPrhH-drUG2nfWuMIcWPw_2_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">183000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearOne
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_SLYwMhQ-J0GnWs1pssB9IA_2_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">281000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearOne>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_FC9aSAUUsEy3tVy__vTHYg_2_9"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">464000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_hWKb0y-fU0WxCzWIT8RDVw_3_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearTwo
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_Ko-axYLDH0ilE56DqOKe_A_3_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">235000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearTwo>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_6vbUxLjIV0ijRK7b2t0IFA_3_9"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">635000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_8A7uI_EdYkatvtPaF1W8Aw_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">449000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearThree
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_aHaWRc_3NE63qAMGmyuqnQ_4_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">204000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearThree>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_DpUcdoE1zUui9qWk0Y6Jlg_4_9"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">653000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_Tmpl1e8JLU-xNxRtY5P7SQ_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">504000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFour
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_xuaXr3x0DU2XHgGDSDW3QA_5_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">170000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFour>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_pKqDoXr8L0e_ia_tLR_Hng_5_9"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">674000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_ADICR2YAtkOMBPt7mt2Pkw_6_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">562000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFive
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_vp9bwSjdqkCn-CxAIGMCdA_6_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">132000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFive>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_ydcebnN0FEqQn4GEyAO7Gg_6_9"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">694000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_-rjVJ080WkOJglf6fPzI7g_7_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1506000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_DCzMNNsOuEWRNiQkT8ASaw_7_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">132000</ibio:LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_L3F74biX9EGbWpRg-TgHrg_7_9"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1638000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_aEfi5Uqu5EahtG8MNgbAcA_9_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3604000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidTotal
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_CZrsSyzQ-UayGRl0CCQOow_9_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1154000</ibio:LesseeOperatingLeaseImputedInterestToBePaidTotal>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_rSV7HAuiF0W84wAd2ktQfg_9_9"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">4758000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_4kxBOhSIG0epOWk2i2QWyg_10_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">183000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-3"
      id="Tc_gI4uNvhR6EeFEWf8q3WVuQ_11_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">3421000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_Z1fqxCq5zkmI2u0LqVq7Vw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;16.&#160;&#160;&#160;Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board of Directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Series 2022 Convertible Preferred Stock (&#x201c;Series 2022 Preferred&#x201d;)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 9, 2022, the Board of Directors of the Company created the Series 2022 Preferred, par value $0.001 per share, out of the Company&#x2019;s 1 million authorized shares of preferred stock. &#160;Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (1:1) shares of the Company's Common Stock on a pre-split basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company issued 1,000 shares of Series 2022 Preferred and received proceeds of $270. &#160;Pursuant to the terms of the preferred stock, the Company&#x2019;s Board of Directors converted the Preferred Stock to 40 shares of Common Stock on July 19, 2022 on a post-split basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;iBio CMO Preferred Tracking Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On February 23, 2017, the Company entered into an exchange agreement with Bryan Capital pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by Bryan Capital and issued one share of a newly created Preferred Tracking Stock, in exchange for 29,990,000 units of limited liability company interests of iBio CDMO held by Bryan Capital at an original issue price of $13 million. After giving effect to the transaction, the Company owned 99.99% and Bryan Capital owned 0.01% of iBio CDMO.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On February 23, 2017, the Board of Directors of the Company created the Preferred Tracking Stock out of the Company&#x2019;s 1 million authorized shares of preferred stock. The Preferred Tracking Stock accrued dividends at the rate of 2% per annum on the original issue price. Accrued dividends were cumulative and were payable if and when declared by the Board of Directors, upon an exchange of the shares of Preferred Tracking Stock and upon a liquidation, winding up or deemed liquidation (such as a merger) of the Company. No dividends were declared through October 31, 2021. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 1, 2021, iBio purchased the iBio CMO Preferred Tracking Stock held by Bryan Capital. No iBio CMO Preferred Tracking Stock remains outstanding. As a result, the iBio CDMO subsidiary and its intellectual property are now wholly owned by iBio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The number of authorized shares of the Company&#x2019;s common stock is 275 million. In addition, the Company has reserved 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the Company&#x2019;s 2020 Omnibus Incentive Plan (the &#x201c;2020 Plan&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Reverse Stock Split&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to effect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio of one-for-twenty &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;five (1:25). On September 22, 2022, the Company's Board of Directors approved the implementation of the reverse stock split of the Company's Common Stock. As a result of the reverse stock split, every twenty five (25) shares of the Company's Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into one (1) share of the Company's common stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a one-for-twenty five (1:25) reverse stock split of the shares of the Company&#x2019;s common stock, either issued or outstanding, effective October 7, 2022. The Company&#x2019;s Common Stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Recent issuances of Common Stock include the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Cantor Fitzgerald Underwriting&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. ("Cantor Fitzgerald") to sell shares of common stock, from time to time, through an &#x201c;at the market offering&#x201d; program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. &#160;Between July 25, 2022, and August 17, 2022, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 175,973 shares of Common Stock. The Company received net proceeds of approximately $1.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;RubrYc Transaction&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 19, 2022, iBio issued 102,354 shares valued at approximately $1,000,000 to RubrYc Therapeutics as part of the payment for purchasing the assets of RubrYc Therapeutics.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Vesting of Restricted Stock Units &#x201c;RSUs&#x201d;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On August 23, 2022, RSUs for 1,057 shares of Common Stock were vested.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Warrant&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt; &lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As discussed above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock of the Company at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw"
      decimals="-6"
      id="Narr_gi74M6zTzkWzoZby0rxxqA"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_ezl_cu4pZEaWF2orMq4slA"
      decimals="INF"
      id="Narr_gwOfpf5r20qSZxR6ZsFW3Q"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">1</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <ibio:NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock
      contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_ezl_cu4pZEaWF2orMq4slA"
      decimals="INF"
      id="Narr_LgBycXa4r0WW8xnz8fwn5w"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">29990000</ibio:NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_ezl_cu4pZEaWF2orMq4slA"
      decimals="-6"
      id="Narr_3gAWvev_0U2YgAfyIMGFXA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">13000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_vBxV47t9JkmztS3TPBPfNQ"
      decimals="4"
      id="Narr_6XmEWK5210W7BB20V79n8w"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.9999</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ibio_EasternAffiliateMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_MyiAUVo2vkGkyCCsfdBIcw"
      decimals="4"
      id="Narr_YNyo6UDWPkKJduPkVX7E7A"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.0001</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_2_23_2017_QxVrYRSL_UiOCiGSWO0CFg"
      decimals="-6"
      id="Narr_FIlCZD2IhkS7lnBFpb5gUg"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_l3TXqFcTd0OMoQ1amXL65A"
      decimals="2"
      id="Narr_S5SU9wBAK0arlCICN4lEvw"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.02</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_h-pYgsijTkKHQ_QNQK-fLg"
      decimals="INF"
      id="Narr_eRGe6HdZJkC9ldMYokCraQ"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">0</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA"
      decimals="INF"
      id="Narr_0WPW4TEuu0mxFazNz5tTFw"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">51583</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA"
      decimals="2"
      id="Narr_-jFZoBEE-UGRxzJhyujjKg"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">33.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_Llf4dd3KVkuMi5naidZAUw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;17.&#160;&#160;&#160;Earnings (Loss) Per Common Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to iBio, Inc. from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,537)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,188)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Preferred stock dividends &#x2013; iBio CMO Preferred Tracking Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (66)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,537)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,254)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,593)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,751)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,130)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,005)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 8,842&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 8,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_UVdxoMmgQkKjhJdoE6VcYg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.85)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_drCJr6G_BkCKj9KtPlTGNA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.60)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Ja0Qe-ca6kSwUGmiTbHIlA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_1FZCwCoI6Emocc2F149ZKA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.43)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-4hgScTO5E-EP-H2wvkN5w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.05)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_OTJhXFjeGU-xhjMC2Fzccw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In Fiscal 2023 and Fiscal 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September&#160;30,&#160;2022 and 2021, shares issuable which could potentially dilute future earnings were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="5" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 923&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 576&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrant issued under the Transaction&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares excluded from the calculation of diluted loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_C2t6XTFi6E2zz1w4n6T8jw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to iBio, Inc. from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,537)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,188)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Preferred stock dividends &#x2013; iBio CMO Preferred Tracking Stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (66)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,537)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,254)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,593)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,751)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,130)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,005)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 8,842&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 8,715&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_UVdxoMmgQkKjhJdoE6VcYg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.85)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_drCJr6G_BkCKj9KtPlTGNA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.60)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Ja0Qe-ca6kSwUGmiTbHIlA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_1FZCwCoI6Emocc2F149ZKA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.43)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-4hgScTO5E-EP-H2wvkN5w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.05)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_OTJhXFjeGU-xhjMC2Fzccw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_bDei4A20w02IDYcQxxAErA_6_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-7537000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_P0GLO56F-U-5kk8WD0vGUw_6_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-5188000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_MYK3Br82VU-6ZSMXf5Et2w_7_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_3KMyINrwwUG40Ql27myoBg_7_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">66000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_l_Ljd7Lh4kSdUx6AxurH3Q_8_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-7537000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_B22WWFXp6062XEejDcFOQA_8_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-5254000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_ShWQSBhdykytX32eGM8ubA_10_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-10593000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_jbKy5nAe20-ayhhguo2wxA_10_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-3751000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_ERP2GzLvl0SZWIqpIzyELg_12_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-18130000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_gYcc-9Qg1UiaCboOBP7UDQ_12_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">-9005000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_uooe1cZxh0yMZ989Ky1aaA_16_3"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8842000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_X3E-n8n8OUiTEgcRPKYQzA_16_6"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">8715000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Tc_uuD2grOrrU2PcHxBO2oL2Q_18_3"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-0.85</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="2"
      id="Tc_n6aBpM8xQE2ShiKw49hPPQ_18_6"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-0.60</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Tc_PXDMP6uNPEmOkI5Y9n1EKw_19_3"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-1.20</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="2"
      id="Tc_PVcGVCroJEyRVUAEFcNRuA_19_6"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-0.43</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Tc_8gLC5PC9Q0uzeJnO9XTvcQ_20_3"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-2.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="2"
      id="Tc_IJmmKb5hbkedNz1SZsbzfA_20_6"
      unitRef="Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw">-1.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_x6lroQbjakCl1abbj70wWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="5" style="padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 923&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 576&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrant issued under the Transaction&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares excluded from the calculation of diluted loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 1,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aLCKc_DsZ0mcPYZ4iThlOg"
      decimals="-3"
      id="Tc_fIP_n67Nok-IOKog8AeHRA_4_2"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">923000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_6yylM16A906KWG6WH1olXw"
      decimals="-3"
      id="Tc_Vzm_lMM3eUe-ZgoiOk7lFA_4_4"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">576000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_gsOXphCp7kqOXBi52mrpig"
      decimals="-3"
      id="Tc_sC5ryBwVFUGJX2CFq6v2Cw_6_2"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">27000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_RW522OwZwE2Q8Rhd-pq6hw"
      decimals="-3"
      id="Tc_Q0VTRwJ8tEa91qegw22JYQ_6_4"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">31000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_Q9iCXIuZzE-pEgIfpLhNGg_7_2"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">1001000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc__LASkG-N_02f9M_JoajCPw_7_4"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">607000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_I_BE__KVUUOvDCdRZt_c-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;18.&lt;/b&gt;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 1,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 706&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 1,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 720&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $96,000 and $101,000 for the three months ended September 30, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;iBio, Inc. 2020 Omnibus Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is 32 million shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors and $1,500,000 for any non-executive chair of our Board of Directors should one be appointed. Notwithstanding the foregoing, the independent members of the Board of Directors may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Vesting of service awards are determined by the Board of Directors and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally three or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock options issued&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the first quarter of Fiscal 2023, the Company granted stock option agreements to various employees to purchase 303,869 shares of the Company's common stock at exercise prices between $6.75 and $9.50 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt;3.21% - 3.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt;115.52 - 116.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt;7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;RSUs &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On August 29, 2022, the Company issued RSUs to acquire 6,954 shares of common stock to various employees at a market value of $7.06 per share. &#160;The RSU&#x2019;s vest over a four-year period. The grant-date fair value of the RSUs totaled approximately $49,000. &#160; &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_ItiboUz-nUOMBLkHzjBhxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 1,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 706&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 1,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0pt 0pt;"&gt; 720&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $96,000 and $101,000 for the three months ended September 30, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_kOWrKqdXuEqZHagsSxnYmQ"
      decimals="-3"
      id="Tc_v-1bGK039k6yZxQzAm6s2g_4_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_U25ZnOgUdEuQ-HzSBdsbxA"
      decimals="-3"
      id="Tc_NfnaRxNFEke92nrgjUZYDw_4_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">14000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_awj1_vQ1DUSHyHXaRL7ufw"
      decimals="-3"
      id="Tc_CQpFpGtE60WmNQOI0t1qeA_5_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1085000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Cd2Z2zMIHkG4C6QpdIGJ0w"
      decimals="-3"
      id="Tc_mxAxXA6FRUq85nTu28tzPw_5_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">706000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="-3"
      id="Tc_Ij59nDR1aUi2c6u90hbM_g_6_3"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_6TbRrwbyUEadqsVyFQoT1g"
      decimals="-3"
      id="Tc_hHavO5xs9kiRpBsT5yceMQ_6_6"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">720000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_MtHCCTglWES6FXBOwD3GbQ"
      decimals="-6"
      id="Narr_7tZvafKPE02HckoQXbLWWQ"
      unitRef="Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ">32000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized
      contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_MtHCCTglWES6FXBOwD3GbQ"
      decimals="0"
      id="Narr_lNjBnLCd50K1MdS4-ugPoA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">500000</ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized>
    <ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized
      contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_QXdJeF316UutTHwstfvd0g"
      decimals="0"
      id="Narr_WY7BQxmP7UCswtSy-psgFg"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">750000</ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized>
    <ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized
      contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_zK_EuxHxJUWase0Bb6jdgw"
      decimals="2"
      id="Narr_OK2MarnSDEOg9vhfd89BZw"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1500000</ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Group_BWwG4VpPrk6DiYudAhyz8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the first quarter of Fiscal 2023, the Company granted stock option agreements to various employees to purchase 303,869 shares of the Company's common stock at exercise prices between $6.75 and $9.50 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the tenth anniversary of the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt;3.21% - 3.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt; 0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt;115.52 - 116.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:79.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.45pt 0.05pt 0pt;"&gt;7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <ibio:GainLossRelatedToLitigationSettlementTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_YKfYzFvQnUulzlth-xylCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;19.&#160;&#160;&#160;Fraunhofer Settlement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 4, 2021, the Company and Fraunhofer USA, Inc. (&#x201c;FhUSA&#x201d;) entered into a Confidential Settlement Agreement and Mutual Release (the &#x201c;Settlement Agreement&#x201d;) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the &#x201c;Lawsuit&#x201d;). The Settlement Agreement, among other things, resolves the Company&#x2019;s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company&#x2019;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Settlement Agreement is not an admission of liability or fault of the parties. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The terms of the Settlement Agreement provide for cash payments to the Company of $28,000,000 as follows: (i) $16,000,000 to be paid no later than May 14, 2021 (which is expected to be paid 100% to cover legal fees and expenses); (ii) &lt;span style="-sec-ix-hidden:Hidden_n27rjvZYL0OlHIzsiufN3A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; payments of $5,100,000 payable by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, &lt;span style="-sec-ix-hidden:Hidden_KLGwyYKoFUWk37Z8Z7W-QA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; payments of $900,000 due on March 1, 2022 and 2023. The license provides for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company&#x2019;s estimated aggregate net cash recovery as a result of the Settlement Agreement will be approximately $10,200,000. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2021, the Company held receivables related to the settlement in the amount of $10,200,000. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in Fiscal 2021. &#160;During the quarter ended March 31, 2022, the Company received the first payment of $5,100,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company would recognize the $1.8 million of license revenue when it determined the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $900,000 payment under the license agreement. As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of September 30, 2022, the Company holds a settlement receivable balance of $5,100,000, which has been pledged to Woodforest - see Note 6 - Significant Transactions, related to the settlement and a trade receivable balance of $900,000 related to the license agreement. &lt;/p&gt;</ibio:GainLossRelatedToLitigationSettlementTextBlock>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_mRyOoO-D5kmgzWk1TetiGg"
      decimals="0"
      id="Narr_JqmQQMX1FUSq2KUYghyJ1w"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">28000000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_fdlqH-ydv0qTOi8QNX4gWA"
      decimals="0"
      id="Narr_NZcpmXanmEGTtyOVmceBZg"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">16000000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <ibio:PercentageOfLegalFeesExpectedToBeReceived
      contextRef="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_97qQQ2NlZkS1QrbYGZ0BWQ"
      decimals="2"
      id="Narr_b-vp_oGvH0qDNmdvDAWAWw"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">1</ibio:PercentageOfLegalFeesExpectedToBeReceived>
    <ibio:SettlementAssetsNonCurrent
      contextRef="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_UYTDkmnuYUKjYhuJvrtFBQ"
      decimals="0"
      id="Narr_toefTnAi2k6v3WJQsLK0Ig"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5100000</ibio:SettlementAssetsNonCurrent>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_6ZrviqcdeEqMylJf6L3J_w"
      decimals="0"
      id="Narr_pIm4L9_EvECQ_roSenQacg"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">900000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <us-gaap:GainContingencyUnrecordedAmount
      contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_DEoVZtJZY0yz9pSSGN9D5w"
      decimals="0"
      id="Narr__g2RCTiAnE-XQNXunVZLzw"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">10200000</us-gaap:GainContingencyUnrecordedAmount>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_6_30_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_LZBHDrN9UUGCxpUjpg5lXA"
      decimals="0"
      id="Narr_nDqrnGho_EOtbTn8bY6wLA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">10200000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_ovqbH7S4FkKWmzhQHgtz3A"
      decimals="0"
      id="Narr_JWVsb1yhlkKgiqEYR4Vilw"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">5100000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_cVkZ8G6vJUqQuiTDjSGGZg"
      decimals="-5"
      id="Narr_tMTCA1usfE67nxjx04ywCg"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">1800000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_cVkZ8G6vJUqQuiTDjSGGZg"
      decimals="0"
      id="Narr_1IxwgpZCzkCeUXE6VHKCbw"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">900000</us-gaap:ProceedsFromLegalSettlements>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_9_30_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_WRviyH3-o0yDEY9X1wSIKQ"
      decimals="0"
      id="Narr_eBEcegN6J0qutX638oghQA"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">900000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_LZCrRaw3AUykqil9MmJrQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;20.&#160;&#160;&#160;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company recorded no income tax expense for the three months ended September&#160;30,&#160;2022 because the estimated annual effective tax rate was zero. As of September 30, 2022, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="0"
      id="Narr_GDoZJrlwkUqt2TcrGS_yFw"
      unitRef="Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Narr_BBFlznZ63EWcXfzXrY0fDw"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_rSLGiQrtT02ig_32YxrCCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;21.&#160;&#160;&#160;Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;COVID-19&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As a result of the pandemic, the Company has at times experienced reduced capacity to provide CDMO services as a result of instituting social distancing at work procedures in our Texas facility, restricting access to essential workers, as well as taking other precautions. In July 2022 after we experienced a rise in COVID-19 cases within our Texas facility, for approximately one week, we mandated only those involved in mission critical manufacturing activities were to be permitted within our Texas facility.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has ascertained that certain risks associated with further COVID-19 developments may adversely impact its operations and liquidity, and its business and share price may also be affected by the COVID-19 pandemic. However, the Company does not anticipate any significant threat to its operations at this point in time. &lt;span style="background:#ffffff;"&gt;The future progression of the pandemic and its effects on the Company&#x2019;s business and operations are uncertain. The Company may face difficulties recruiting or retaining patients in its planned clinical trials if patients are affected by the virus or are fearful of traveling to clinical trial sites because of the outbreak. The Company and its third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to the Company&#x2019;s research and development activities, including, for example, medical and laboratory supplies used in preclinical studies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak. &#160;&lt;/span&gt;Due to the general unknown nature surrounding the crisis, the Company cannot reasonably estimate the potential for any future impacts on its operations or liquidity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The outbreak and spread of COVID-19 and continued progress in various countries around the world, including the United States, has led authorities around the globe to take various extraordinary measures to stem the spread of the disease, such as emergency travel and transportation restrictions, school closures, quarantines and social distancing measures. The outbreak of COVID-19 has had an adverse effect on global markets and may continue to affect the economy in the United States and globally, especially if new strains of SARS-CoV-2 emerge.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;War in Ukraine&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On February 24, 2022, Russia launched an invasion of Ukraine which has resulted in increased volatility in various financial markets and across various sectors. The United States and other countries, along with certain international organizations, have imposed economic sanctions on Russia and certain Russian individuals, banking entities and corporations as a response to the invasion. The extent and duration of the military action, resulting sanctions and future market disruptions in the region are impossible to predict. Moreover, the ongoing effects of the hostilities and sanctions may not be limited to Russia and Russian companies and may spill over to and negatively impact other regional and global economic markets of the world, including Europe and the United States. &#160;Presently, &lt;/span&gt;the Company does not have any existing Russian suppliers or contractors. While it is difficult to estimate the impact of current or future sanctions on the Company&#x2019;s business and financial position, or global supply chains or service provisions that could have an impact on the availability or price of goods and services that the Company requires, the Company is not aware of any company-specific risks related to the war in Ukraine at this time.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Inflation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Although the Company has not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on the Company&#x2019;s operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_aTj3SMstjUK7xwYzmFe3JA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;22.&#160;&#160;&#160;Employee 401(K)&#160;Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Commencing January&#160;1, 2018, the Company established the iBio,&#160;Inc. 401(K)&#160;Plan (the &#x201c;Plan&#x201d;). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a 100% matching contribution that is not in excess of 5% of an eligible employee&#x2019;s compensation. In addition, the Company may make qualified non-elective contributions at its discretion. For the three months ended September&#160;30,&#160;2022 and 2021, employer contributions made to the Plan totaled approximately $104,000 and $33,000, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $71,000 and $33,000 for the three months ended September 30, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Narr_hNQuvsKed0CxvwRnp6YSow"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      decimals="2"
      id="Narr_KbsBlxBowkqYD0EIShe0vg"
      unitRef="Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w"
      id="Tb_wp4-j4uJvkKlzc75q2XPJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;23.&#160;&#160;&#160;Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an interest rate of 5.6% and securitized by certain assets purchased for the San Diego research site.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 10, 2022, as previous disclosed in relation to the Employment Agreement with Thomas F. Isett 3&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;rd&lt;/sup&gt;, the Company&#x2019;s Chief Executive Officer, dated April 30, 2021, the Company granted Mr. Isett RSUs to acquire 200,000 shares of common stock, $0.001 par value per share (the &#x201c;Common Stock&#x201d;), on a post-split basis.&#160; The RSUs vest over a three-year period commencing April 30, 2021 provided the vesting is subject to the following performance conditions: (i) submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application, or alternatively, if the Board approves not to file an IND, (ii) consummation of a disposition of iBio CDMO, LLC, or (iii) outlicensing, with full global rights, any of its investigational product candidates prior to the submission to the FDA an IND application.&#160; The grant-date fair value of the RSUs totaled approximately $296,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 11, 2022, the Company granted Mr. Robert Lutz, the Company&#x2019;s Chief Financial and Business Officer, RSUs to acquire 100,057 shares of the Company&#x2019;s Common Stock in exchange for Mr. Lutz&#x2019; agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#x2019;s 2023 objectives, as defined by the Board of Directors. The grant-date fair value of the RSUs totaled approximately $175,100.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 11, 2022, the Company granted Mr. Martin Brenner, the Company&#x2019;s Chief Scientific Officer, RSUs to acquire 95,348 shares of the Company&#x2019;s Common Stock in exchange for Mr. Brenner&#x2019;s agreement to continue employment with the Company through July 1, 2023. &#160;The RSUs vest the earlier of: (i) July 1, 2023, or (ii) the successful achievement of the Company&#x2019;s 2023 objectives, as defined by the Board of Directors. The grant-date fair value of the RSUs totaled approximately $166,860&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>101
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MGTM] 9Q?"*$.._H&Q>+U\#]02P,$%     @ *XMN57SJ"2Y3!P  ]R$  !@
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M[)F'B4NQGTO_9+(>RLLQ*BT'#61:L@TS1AH#^J5FYZH0"LZJV.5(C'$0 H9
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MR5A4FE$.,XE4511$_KH$)M83+_ >%J[I,M=VP4_&)5G"'/3W<B;-S&]5,EH
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MKR'EB>+;XH/"$U>*I\5A3 G,3!T _U]SKEY/] WJ;U++?P%02P,$%     @
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MP_"B?OA9G!SY)A0-^/RB/C%2N_;) 38^.31G@L>6935Z!K*H"PGS(&$^)"P
M@M7$-3J*:V045SF.Y\4X'N?Y7@QJ?72[7V9_18AG89J'Q<V.3F!&<E>!0<(6
MD# 7$N9!PGQ(6#!2SG!+/VZ-C](:&Z7E?J%9%.=4WLD<],5V4DK:^Q8CJJN6
M(&&+L=(ND\:X[T+6\R!A/B0L,+9$32+V42+VMTGD]&*GDXL1VU4NMG)<0_7"
M!EG1A81YD# ?$A8 P6K2FARE-3%*ZTZ*IR\?KU<H$K?_XMX_;+N0&4E=U00)
M6TS4VRYYLU<;?2 +>I P'Q(6F)NBIA'GJ!''J)$/:4;#)/Y72"21SX32TWD(
MXR1<)K2_9ED_#Q.*5G3)44ZC?28>5:GVZF4LTU5 D+ %),QUE"[H-\3H0=;S
M(6&!<>=K\ID>Y3,URN<=Y85N=(HP9G95!"1L 0ES(6'>5.TA9SIL//O[D"4#
M(%A-/MBJ/$#K(@&)QWF>Q<L]EP,/X@RE=5,H+DTAK>%G+-%5::"T!2C-!:5Y
MH#2_I)F&Q@"J8EUL)X8SODQL<1HE^Y74U8YEAXF,[Y"?L6AG^4'2%J T%Y3F
M@=)\4%I0TAH#\:C%#L"5GXPO-I3OZ,YL7II1G75UWE(N0TX/FCA#;(\:=]N:
MN'XSR-,%88>,FPZUK]DQ$=@<.%0:MJPQ&;=T2&4LXV]REL]W#JBUC+7>LJ,^
M@H.6=4%I'BC-!Z4%4+2ZRBJ'&9LMYI9Y)*)5%JBG7-*,I[UJ>Q)G8N-I\[17
MX_H$-R>3M%%D.!U:S?,>U+K5E+6'(Z=M?*@,7&QV<"^8>=+WHNH48N5TGFNB
MG F9:,Y[2!?3!:5YH#0?E!9 T>KJJ;Q=;#9WGR;RLS#.J58FH"XN*&V!55,8
MXW'3>@.MZ8'2?%!:4-+LMO:H:Z0R:;'9I:UIY)SI;V9UUHMJ*.*)K1E](*NZ
MH#0/E.:#TH+S[5O73&7:8K-K^SU3UF9T9PF!6K58=2CML=4<<2!+>J T'Y06
ME#2[I3GJXJDL6VSV;"\5S]FQ"-3@Q:KUB2VB&8M S5M0F@=*\T%I 12MOHZN
M\GF)V>>=L_2!9L6R8[9&N^,BS(,*.9,3E)4JSRB/Z*Q&]>[:O$M=QR90F@M*
M\T!I/B@M@*+5A5=YOL3L^7ZD.9<.KE#=[=V'G\XNJS#C.J_C5'U$5:@+T)HN
M*,T#I?F@M "*5I?6R>)@LYG;97V%&=595I"T!=&8JT3:&O65Q) U/5":#TH+
MSK5'72Z5U4S,5C/84@MSG<Y:@J0M0&DN47UQ<:%O+E\']9U!:<&9 Z@KJ;*3
MB=E.-JVZ,*=V%@<D;0%*<T%I'M'XUMC!BFT-6C4X7[4ND<JW)F;?^O^9ZC87
M[2PNT$7*H#07E.:!TGQ06D#4.0BC!"OSFYC-[Y:Y;NUTB1G565BJ4ZN\/J6&
MD*EECY2['C5.3F<U+T&ZJ!&Q;&7T '6D-65'SK#M92M26=+$;$E?,"FN[T50
M=YJH[NG4LC3V-&A9%Y3F@=)\4%H 13NH;'#R)K!\]_QMF-W':8X2NA9XZ\5$
M=&1V>)W[L,'9KG@Y>,DX9]OBXX:&*YK) /'[FC'^M"'?-SZ^5#_[#U!+ P04
M    "  KBVY5S^D.4W8)  "A+0  &    'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;*V:;6_CN!''OXK@'HI=8+6VJ <K:1(@F^WB%NC=!<FE15\J$AVS*XL^
MDL[#??H.*<6TQ2'MX/(F\<.(_L]P.+\AI;,G+G[():4J>EZUG3R?+)5:GTZG
MLE[2524_\S7MX)L%%ZM*P5OQ,)5K0:O&7+1JIV0V*Z:KBG63BS/SV;6X..,;
MU;*.7HM(;E:K2KQ\H2U_.I\DD]</;MC#4ND/IA=GZ^J!WE)UM[X6\&ZZ':5A
M*]I)QKM(T,7YY#(YO<KG^@)C\6]&G^3.ZTB[<L_Y#_WF>W,^F6E%M*6UTD-4
M\.^17M&VU2.!CC^&02?;W]07[KY^'?V;<1Z<N:\DO>+M?UBCEN>3<A(U=%%M
M6G7#GWZF@T.Y'J_FK31_HZ?!=C:)ZHU4?#5<# I6K.O_5\]#('8N@''P"\AP
M 1E?D'DN2(<+4N-HK\RX];52U<69X$^1T-8PFGYA8F.N!F]8IZ?Q5@GXEL%U
MZN**=PU,"FTB>"5YRYI*P9M;!?]@MI2,^"*ZJN0R^@8S+J,XNKO]&GWXZ6/T
M4\2ZZ/<EW\BJ:^395($:/>:T'G[Y2__+Q//+:?0+[]121O\$!<W^]5/P8NL*
M>77E"PD.>$O7GZ-T]BDB,T(0/5?'7YX$Y*3;R*9FO-0761VTA0G:0O!5!"M/
M5(IU#WWJ,L6H/,7"U@^;X</J97TJUU5-SR>P;B45CW1R\?>_)<7L'YC/[S38
M7@2R;02RT.@7>QG504EJN403I1^F,,/HNO-X$2=EDL[.IH^[OB!FY4EFK?9$
MYEN1>7":+IO_P2KK4UUQJ$PU[VK6TJC&U&L3_;K6D[O1RP86P=$SF[_GS+[3
M8'M!*[9!*X(S>[NL!(UU^6P@3BM@BJQT5<:<[D?*=V8M(7I][DVM:U3J18A-
M['RK<1[4>+GB0K$_C2Y=Q%BGJNZ!W</45E)2A6;BW-%1S$=279.RQ)666Z7E
MFY0N6%=U-8U:"@&.A 91S!<QI%M >>F&.1TI=TVRI,"EGVREG[Q)NET*;Q)_
MXHK/QNI=&\_*3V:6?;.@^J\4UD;-=@+_# GMESD,MZN!S).13L0HG7G"G.Q@
M.@D'NJ[%QI0;16$]*UVH*'NL=#J#>"A6CQ1F0K]= VV8E%R\1!U7=,<2]2EQ
MY,;)R=BGL-&^3\3Z1-Z4/# 9*[992>U00^]5)&F]$::<HLJ)&^AB+-RU26;$
M(]R2/0EBTQ$.;2,5 F:G7[DZ_6LN/3F4NJMP##K$QI?KEL5)&,;?(4$ZI9-B
MP $J+D-*Q,R1YUKYY%D*)T%>74!/_@#]?$>EZ3A-XJZK%Y/?T%\"64?Y'T>W
M7RZ!R14*G>'7<(F#%ZY)7,SF'D<L&9,#:*1*M:9UUGX("CYM3#.A!'0'J%87
M?HY6UR0N,X]4"\AD'NY0EP!$*D<MC*E^)N8MJ^Y9ZV]GDB" W]K/O-=H^\&P
M#$X.0+BN^48W@3N%-8Y@TAI\I;@PC?-L/&V(T4GJF3:+W"3,W.U*1G6YF(R3
M)!TW,9A97GA6,;% )6&@7@NZKE@3T6?=$M(^C;A:4@%[6:B0L"C\="4N.+/9
MN M C%*2>W1;NI(P71W=,52@;I",:G6!Z&Q7$)OX)/' AUAJD@/4?$W4H3RB
M\A#L%6,V(D9S#].)12,Y@,:A3K]&$E7GX@URM"C'^A S4O@46A"2, A_&[6H
M_+YE#P;EN%@7=K&3E$<#D5@@DC 0KP9B[%9A5)^+L6+<DB(V/GV6<R3,N5^/
MV06C@A&6)>E)/NXY,;N3-/, FECJD0/4&YW+,"BG\IC=.WE7W+W7:/M1L+@C
M8=Q=;T2]K'2I,_WKP6:;N"ASZAU".Y*6GJT/L;PC8=[=T(:NUK;7/JS5A5M*
MG"X6L2+9S+,N4HO ]  "A\!JK?2/#5,OKVI17J<NS\9"$1,HEW-/'Y%:Z*4'
MMI1-PTS9TX=:1YV.I"[1'+$(]$A9>%9M:JF7AJFWEZ^']NFI2[:89/-QA<',
MDH3X KMS\!MFX'7U8OK_!1?1S>9>_+?NM4*!@820S'=2EB+ *T[&1V6(E2]I
M+1/3,!.=8HX5152R2S[BA!DA:)YD'I"GEI!I^.1V7,CMYOO0 ?N[GL.^UVC[
M4; <3L,<OA:\IK098B"KME\B-5^MH&!*Q>L?: R08]DD'S<.B)4OURQ_T_"Y
M[.OJ< XZ;2.&"G;/7>/$J3Z(D>]T-K6L3,.LW*Z.#\/R^*C/V!Y9 V_N7]"\
M0SU CFB3S DY0E&O"Y:A:9BAVH4/#:V%CO1'<*%_I9>Z]NQ3[Y_FU2-D4#<<
M .B#%L%J?0-$?X\ZA>TWR;QTB@!FE^6^0XS,\C8+\_8*EQ]']_2!=1U,"WK'
M"3G)!4J-:RUB-I]G,Y]HB]XLC%Z/:"3FX CM&M0%E[1)7I;CO0EB5I"2>)9Q
M9H&<D6#UO:V7M-FTM#^MZV(C]D#AS8*,?VOA?:_1]@-@*9^%*?]]9PV-;WO<
M_';W>I"FFX"./@U?Q.;N(82L'2ZM8>(9?AB;A4 _A, U2;/2TVQE._=M#YT5
M^UVS57K?-=2#T+YX\, U28N9IP7+;&^0A7?/NQ[L4\8W-?B-:7?C7";C4S[$
MR+>Z+-6S,-7]^GWQQ_4C]U5=_4=#/K.0S\*0_[;3H>LL;S=-WUA6H],K_=E:
M,/ $\HSQYE-D#N(TEX8#P_YSU#N7]LF\&),'L4I+7X+9GB +]P3_VE^_9B[T
M$P-*;/KGDXQ?_ $J#SXSA_?3B$GI.3W,;".0A1N!N\[$=W'L_*#:D9VS>[\6
ML9KGOH<U+.[S,.X'_6M] ZX_$!AV6$I4G:QJ7_N8']YG(R8D]QT(Y);U>9CU
M=QVLY);]"?$U3Y#H9]<>*];JZ,:0-K'NV8\YUL@1X#L^(#8>!RSI\_#6^Z^F
M>NYNLQW9KHDOU7,+Z#P,Z+??B<L/$Q<QR4M?CEC@YF'@^DX)]/:"2;DQ]?^(
M75WNTK3('1>./JW.=QZB"O-V?Q?*U_VY$GVFHF;]GLF6F/5?N4F4'[ZQBYC,
M/2U1;H&<%^%V=[->]\E4M7UCKD\>P)W^25IP%W_B*XCY-S_R]4ZC[<? 0CT/
M0]T<N)BI:Z!,04<(<S;@V12%UWOS:"#ZH7<?WDO*\5U)Q*A(QKDYW7G8=47%
M@WD&6$8&6_W#HMM/M\\97YJG:T>??TE.K_JGA>TP_</+OU0"]HX2&JL%##G[
M/(=<$OWSP/T;Q=?FD=I[KA1?F9=+6C54: /X?L&Y>GVC?V#[5/;%_P%02P,$
M%     @ *XMN5;M6/LXZ"   +Q,  !@   !X;"]W;W)K<VAE971S+W-H965T
M."YX;6R-6&MOV[@2_2N$%UBT0/R(D^T6>0%Y]=; ;1LDV;U8+.X'6AI;1"12
M2U)V?'_]/3.49#M-@P)!+%&<X3S.G!GI;.W\4RB(HGJN2AO.!T6,]<EX'+*"
M*AU&KB:+)POG*QUQZY?C4'O2N0A5Y7@ZF7P85]K8P<69K-WYBS/7Q-)8NO,J
M-%6E_>:*2K<^'QP.NH5[LRPB+XPOSFJ]I >*?]1W'G?C7DMN*K+!.*L\+<X'
MEX<G5\>\7S;\:6@==JX5>S)W[HEO9OGY8,(&44E99 T:/RNZIK)D13#CGU;G
MH#^2!7>O.^V?Q'?X,M>!KEWY'Y/'XGSP<:!R6NBFC/=N_9E:?WYC?9DK@_Q7
MZ[3W:#)061.BJUIA6% 9FW[U<QN''8&//Q*8M@)3L3L=)%;>Z*@OSKQ;*\^[
MH8TOQ%61AG'&<E(>HL=3 [EX\57'QI-R"W75!#P+X6P<H9>?CK-6QU72,?V!
MCB/UQ=E8!'5K<\KWY<>PIS=JVAEU-7U3X0/5(W4T.5#3R73ZAKZCWLDCT7?T
MTTZJOR_G(7I@XK^O^9O4';^NCNOD)-0ZH_,!"B&07]'@XM=?#C],3M\P]K@W
M]O@M[3^9D;=U'([4*SZ;*^,.U,QF(_7NUU\^3J>3TS7)Q>'I@6I7FO!RQ37^
MY1)K>FU-M+</E/,J%M0]OG95K>VF??A>F:"T59<^FH7)C"XA&5&;9DDVH]Z^
MRUDG,,P]RM<J8ZU;Z0CE< WASXSP@[;1S%V^4::J&NMPL->UH3!2C["A/5P5
M&J>JVM3$$6,-K3JHAC(#7C)EIV/H+*K++3>=<JA3>@FB"Q&:?#Z,#E8U2Q6U
M7U(,:HU32:T)!;I1"P $M)4W&>4J@P$432(BFZ/(8[&K-A8ZBM0<P@Y*6MY:
MT;X#=:DM=CO5!%(&1U[.NL#D)F1N15XV1:9KWI>A,HUM2.D\-W;YTZYP\IPP
M:K*UUCY:\GA@=\]DD9Q6X/8:3!W%6 2>FFBRH.ZZ0,^N9M^&AY/#$T'#Y.A4
MW?[KT_UJ-IMM5ZZO[S]N[^YNAH?J<NFL"7&[.K/BAX01YC&\:N^67E<!9H3,
MFSF"K>>(PX$\[>*FR^ D^\$\]RH .M(>^=X)7:=-$E)HP$(.<1'>,4IQJLY7
MFC%J+&X0:D*/BVA@H4,D7#89]NX$1I*ND5=8:9861K+Y.GLJZ=7XC[8NI]!-
M1 ,(UN$L9%3='JMOC5<E&K$D=;@P<^\0=I5AI\EA%]=8)WX@\HR89 $_XVZ&
M-2O)54V-H$K"YQMUXT?J6GNTHT^T+'1IAE<X>&VRIP-UY]T"=)(J\ OE*%^D
M&.'B2,D]?/_# B ^F+CA70\8!XJDT%@MIOQI,AI>%]J(&A9]R$KR+B?T6O7)
M-18N($DC]1D!1D0E_ F0R"-PC<J*G.UT\/Z!=R;&,&_\LDB.KRDEL\2IEKV6
MK&K.:D"1EH241K5H*:LKFGPOA:V9E4-E-LC;PKM*5IK^Z&W:+D.*:BNTPWZ'
MOY_RD2N>6!@P/;1<S?Z&?> "9&3SL%?*N&[E>2?"I),M1GP)P'16B->[UM,"
MWL70K@.T%6>M0&^".L ^(VII293N^]V#$&#YQ#@+9@>BCZB)DC'5B[]T=^$P
MRC!U\,.7[-K1\2L5^P/OZ\:')E4FRH"V15$38IA#D\1C71@$8FL[8Y]Y*P<F
MI/OT)J2J8^^P4((_O& O.;2/K$=ZAK  >DT!<01"+V<H&!3O3<\C=QT%@[$P
MS42JYD QCS,'TH;9A:R0^@L-)A$M$"C9[;+#C Y!F'BA[INY_RO;Y]9W#%8M
MC:5$.EOZ$PAU"C#?V*#3](M-. UMA=17($Y]D.P=HDT_('/<@[D 'K<2X7WJ
M/-_[MFTOE!4V!="$/69#%VM"NNRX];MN-S=6-G3TU^8 X<@=L*E;TD3>TZM'
M2]BUB7@C"5*KB\9SH]]#*Z<,><30HN@9S8.;7@WD+T ]CMM:RW?<S I3IQ0C
MFP&X45R)L9\:VK C KW+S)J-*5NV/%)/M-F&000Q>MTF&]6C>,0&W-HE 'ZB
M+KG2,&<0G-V@WV<PE89(C;=B9Q]9#A!2.^?!37+<Q"X"<],-);DZNAE68,R2
MA1%*N  '%IN>H[K!PE3H"R\"S?%G.0";4FVF=5@8R3 /A1K3%2,#P#SXV<2D
MT&5X0=R!(B.O8FB+)0%QUO-D'<><8X/"A"UI=P?R[5#7M[36(=QO)R14C6!)
M>(62;=R@O<HP4")A%+E'0]"J=IJ,G@F7=Y+WKAMOM^?MVL2[4%I$DJ**8N'R
MU@QNZ"BR;IJ (4)T #X\[X.UC<QTU&+J<Z,>OZA_@TF! \!"9BI,OG"=6UK1
M5'IGI"W3/I :R<P:=BHVT#^-3,RET7-3"GJ3<<CC"H#@@1<-"KM0!D[(9;<2
M7>M;FS:!W&[F?@CF%W'IJ;]WL/5.IJXY=JF 9F-3\^*A./69GE4B7O7;-I:W
MV&%$6[4R*VE0;C'$'U"7@4_5NSMW_9XGE:;F?<> /+^"LANH43[SN[DM@4[&
MZS04)& <[$%N%VEL*4HTC00RU*&Q:.9\O)V.U$-D?:^FLG9KO GDV^QP;Z_,
M_Y)?73X[BC05YXJV":_)2VFQY$A]XY]=//01;2?1O)N%91C<.TH&TX.MJ0"I
M6X?VO2GED-^37DAU#:@[L*,*3TON#!(9EBJ9:=CPG9FS'X]D/&8ULZ\W0XF]
ML T;-'KM-7F\\Q&C(H#M6JHWPR08T_>,?K7_&G29/H)LMZ=/25^ 53 8XK&
MZ&3T^V\#Y=/GF70#1,LGD;F+T55R62!VY'D#GB\<@-/>\ ']-[*+_P-02P,$
M%     @ *XMN572,FL 2"   -1,  !@   !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6R=6&ESVS@2_2LHS;&>*NN.,YGXJ/*1S,YNO/%:R>Y43>T'B&R*F(
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MUT(W)5$E]+W?[I0(Y^O9?'2"EU*T&=<MWEOP%ASKMMTM\/K!6QHS",9V'%)
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MTV&/;[9T;.L0D5^5(SQG],*(!2\[!T?@<QS<ME%8%8_]T=\L[+';8HF.@=X
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MGT[:#6&_&TQ#1^?604SAO$-Q:]PGOP"R;YMJ^'M;?PN)AD<7A(^J"Y)T6I3
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MU<'-^/F;"UK/"_YN]*:./B>$R=3:+_3E+G]U,"* =*&SADY0^&>M;W51T$$
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M=S4,0+>CNB6LJOUXS)2E8>NW)7W=H'8"=+Y4RG:$,[#_7IK_ U!+ P04
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M%6Z'-GH:S17+J6E8AM. JL&@OL=@]O)%?!2=[> ZZKF.=J'_KV?9C70R@.?
MZ <Y-Y1E!G-@J;K' [ 5PH6J&R:7P S5*FW92B,"WK6\H7JT(!R0H6UHF+:@
M"N]UTZ;Z[\PY42]A&5D;[BIO !^H^O+<*UL'"*-Z-*A5R@427,&)+3T,:7H
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M.P/:+Q15STIQ!_23?_8#4$L#!!0    ( "N+;E6YG2M^@@,  %T(   9
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MEM:1/U:T_U$[ ;K?*@JX)YR!X1_%_%]02P,$%     @ *XMN54BS=#W7 @
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M.7]RS56;(RI;(P@QI3'-GGD*##K=2"W>>)6#$66+36&N/^@92!FI0+%K!H
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M+4HJ"U$:J4JFQ?2D=Q8>G@]IO5OPAQ1ST_G/R).)4I]I\"X]Z05$2.0BL83
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M)CA41 MP?ZKP;M,,R$#[">GT7U!+ P04    "  KBVY5 ;H<ZT@'  #H$@
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M[$FAIWCR.)WO*YITZ-XE\RION[@W1SZC@@:8%*,@MW71VX-R.__'Y?;4_WO
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M! 66HE7T8+JON,WGPO/E1KGPA:[W32<1Y*TC4V_!K*"6NO^+S?8>]@!7R3N
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M/@K-*M1G=GG&%T"62"B/K701U0_AM[U$UU*ICK: /,O>' ]$J8H TH.Q@;7
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MC1)S56B@6HZR,$<"25N5<EXHT8*5,(1QIDW6KH$)L"]R@+$!UH+5M0!W6^3
M<! 2(Q:F6N,S*4W' UIU$;3J8E GG VPXK/*E+Y' /L4Z]&;B/"=B=\A7:)X
MD6!J(\"=(@ERE)ZVK*7.@>$@+KH&8LQE0=01)3AQU(L"7"U_ _H(Z\%'D!.D
M_=V9)'WB%O@NRRU*S[W.W0.#ST=0K6#9 2E(Q0(AV#G2*0F(H(5#2"% K$;"
M+PIRM&458Y%9 *\K$Q]#>M0HYD;#,6/Q(0CGO_YQ/9M>/;>B1A.]%=JB1&V,
M)F@6 ><.G9<0L5A6_( PX9M7[;Q9M$5\;+-2$#YX.N/VN6H46+HRR&X'8]"@
M1H"# KLQ!T2\ER+<_MV6*GS#2NV9D&Y**E+^&#()7*\:X+P"MSHD[)=!V"\'
MY?0SFS$4TPK<(#*G3]@?O4E'W +\B)4FQO #)GF ;4#B@.]0 Z3)+>R3DX.F
M=<='-W>W1R?B<G(Y$OYDL@6WSOY9]D>W%$TI8U-8@NQX8QE@(;FS\# ('(0&
MNJ#@P NSD@89Q4!FW8.:E3;Y*;A,L.!9.!2Y;Y1>SUN#:A-<!&]AVVP5]^EJ
M)PAZL?W3F5^Y-,KY7!"](#,HI*0V*%$0\_(*B&%0.BW[;]0@]+%,4OA$Y >K
M KH/5A411$L-HFZ!WF2&-5N4P 1T#D65!1_DB06@Q(WB^23'?\!7>K&ETSPD
MR9:H3\&2(/1A#<3N!?E+<#"JHW2XE9)$L75=E7"6<\Y5XWP=L=*;#@87S0)I
M,F.@T(96 GZ4 (VIK&6'XW>T/A:0QLB2+<U8O%\<A ]--RJCO)>Z0"/35>^-
M+@K1@G-"+L[!7'9,)O&_N^'(BR#Z7R=8L/8>\"D*6H-K,11MU'++K%TT+(X)
MVL2E0MUC. MR_ V<A#.M@$TI("3 #;NP@J$M,$Z@4*A"(\1'J=I90Z>H?^+7
M)M6Y'54(XO],'.L3 5 !ST$6F-*\= 0_[?X&H01EG&CZJGFAE])%0; 4UD:Q
MQ\6P"\0N[$B(=+CL_B0PNG\1RNS 443/8]C%HZH"HLX?]#^(8H:!E%UHQ3&>
M*&4#P:@7IT.&9Y=BGC.@E@OXEW_6K"+-"HR ^*:V4=4.[#YO09<5R'8-SNN9
MN'WSX:-X)S,,?;=@7"$EIACXN?ADJKP%G;G%,(-"X4^Z5FC96;7"0V^4A02)
MOGO=ZB(_A>!$G'U1V:JLB@H$\0M2&@,R3&]0D,<=1Y!8#?2D!I)R,%);1S3'
M(8?-(=X@4DNP%TS4#:028/RJ'*0LV5II,HB!?SGIC@"=4V3H&N1A!5$T)B_X
M[3CQ&,@5B!#PF#6$FKHN#D.3%1#>LN16]O R.*F*Q@-MJ^T:5P\QF&"*]F1!
M&*)"K^>:W<W>0V/QKC(_.+F!T)JL/]GVN/6^?1^E!(P"F-"P8ZJ9[&E<%DWS
MSCF/AK.#]&.AE'98MT$=@Y*.0*$U !PWJK(,G#3K.:EG57B)7%8@9J**PBU6
M\AY3&5C:.,$W'!:2C7/:3%P$DPK"!G]5" _]'+X*"P$C"E#1N4/.G'&(VEIG
M/Y!\# -0]RR% U#>@/_ _ZNYEUW;SI$/C2:\T&]@XD@.J%0+C9'&C27G$VE*
M.< 0^?^6;.!/H"\-V/ "5!]I!7'Z&@P5?-4&JVQKE6&,EQC/#/);0 N]]N](
MES3%I3W /209ZUHF(34'T_ !MH-3>P-.#[!-81ZQ9W82Z0X#P3 *3!;*MD.#
M>.:L<Q(P (<A4@0J85AAM'4^%0T1;%*LR;[(WR&%;K9>Q##)#]["N_L!=HS%
M5Y<N U_2?'F ''WX>^X,<;[#X;Y-EBTX#U(W-&4;P)B#B<P+=<,%I;Q:8XFE
M2>E'T944!89B6+!-N(OBWFC,=QM46.()K=,V%4#M<E%8:Q36H5"#2>)P[1P6
MKH$#ZIYBC;'XS?\,ZFZ02$EMP\5^%.Z[,E(25%%@BSX&HOBL24H8F& R(.I[
MMD(Q8+IZT\#A'2"/=-PW)KMF X/JC*MCC -%D7,4-8(9:"$Y>[<I"YD @9)I
MM(50KV7^5Y/4E<PAR(V[T1$!@)W$A8T$0G\,@*$$^F^\JBQ:U.Z3_>PK5H!B
M_-ELZUC2(S?]3+S3WU5^^@ZB(58"*1;TS4*E 6:* 7#%+(F@M)(3*A#V&D6.
MV<T6L".9[_9V=9:?-TG66MX*%;Y0G6"&[1:0:%MCQ:S8=@$+<FP[IG@?'^OB
M?+<ANS-W'DJ$ V;K6<VID6X*%>1P3])&SIR&B@PIEBO(42$2^)2/0X+M,LM$
M]USP,CWIAEFSD]Y("]+(&$_+CA+O+_=E*5<Y18%35F$*ZZ,*'Q*ON<N@L,NP
M+]W34>=,7S $]6L:CJ/)W*4E "(XL RA0 I] .$%QP#AN)>WQO^T#C\-"UY:
M$A"KJD7W0#I1%ZV-)0("!Q'G<ICW>L$Q9I7=+10<D* ]"!-)ZACTLB5J 0T0
M+,RX[ZLF!C,>!!<0:_3XVXX4Q;1#<R8;\1K"(EBSH0K65:A@70T6GWP,#X$-
M5OO[JE>/VD#<1.M$#03V1F1CFYAH&6S_(:5JN0VL"Y%:$J85V#S=[@:+,K'Y
M"W8O>SMJDJR<'"TP$9AF*PQ:*!=RQ1_)G*P!4O#\9'I(WW[V\=HHPL[.).:W
M<A=1<I\0 ZQ06=IB <M1/^.R).W%^&T-*/B8VT&41MUS!3]@K$RY3DD6*4\0
MC/F7[]2X DBW!,?>S)*N>GF*H5EEOGD0O'QJDPNLQFE7T>9P/U5-=N-D%!-R
MD$85E)%X=2+;A%\9:A>-V-;WI:X]-++D<^= F <ZWFR''!L(.\5/DR$MN0Y:
M<OTP(?\U-L+Z5.7QNZ3ZXKMLVWZ=2<0'38RO&_2&18F"N'X=!M::S=4Q>)U-
M#.;<.NI;;NU.Z ;['H-3(I^!AI%TK=>([94/<V=0>]3:1UU>J[:J\5V51RM?
MI)I70!=76@KVU+ZZI-W,7IWIHN+#5!!?RX5?'XZ1XBZ\0HY$%=,MTBP.<Z-^
M^4SH_TN9'JE'*9TV@K1I>CD=3283>NRGZ61"'\R ACT-&O9T4#=^5=@R[=.I
MASQWN%]2\.\Q0(XIU^(1[9+K)T"8(S[LB+_%[XY..*2P[FE,B2 "U'9%EI]\
MTFFU.,6"Q#%JRFSR_//'K_37]/D)!& 0?;J&/S7Z %XP7LI+@\%=X 'G8:AH
MS2@E8N_"$=]PX_$D'P,Z_+D@#NFLA1P$TBSG_*8S'P-2/,N5.<T5(5]> [&J
M2170;QK7ZU>\,6,O\ZKV\N<(0YD/=D;B<(CBV00'[5[E-85^Y%K65#W!XBF&
M/(;0AH]E59[Z%#2942!/$;XO\\ZZ1)2ICH\R8E@.B#0.[)&WEG">"CAA-206
M*0ZT(6VGIY06-;3EJB252&U@8">6;$O]!YI+SE>0%VDGWT?P8:3"<RJVEBAM
M=Q3"N0@D70I03&C+^ZJX=S;8%<HD3H$ M?%G[BNP#%AD1;J+QYI+9KQ'"+SV
MJV=DYN%D2. S7T.+>42HTBE_%*+7=]Q*[AS55^MSNXS%KXG(2Q)ZL:12J1-Z
MK$-MP1VZZ8%8[^[3(S@YZ)\=[>B>&PX981 :ZS8C4K%3.GAO?3<%0<1HY$[E
MU SK.(%>>/;U&9 /&)'!L][<U<CP,&V24_$4*X+20!8OZR#UI[/)Z>SB=,;I
MX4Z'A3'P^L2?8M=OM]RQATZGJW2@U<B]2&^W8]US\.1.ZW7G1Z)Q+ZL<&& 4
M;%WQA$AD;Q (D^^69[T"AFHC[^X\OW5)/(J[+W$9M79595Z*S&+FZS5*"L8I
M2)>D3[5K$]5WTLIEL+G'F:QU(XL3MR>FY=X \9P&"B.J#^4.&+"$N9AHI?WD
MEC?5G<;X0Y!-JDW[SN#!V$6O$I%!H1E$*)4V0LX9:T.F%L=[@+=<_^+&>9.(
M$LC'&B>NR"H3%1Z+.J,8($R-[RYZ T"% ;_?VWS)L6EJ%"C4[8(UL%GH()5J
MXZ#E?E\Z9I3O/ 71(+IUGTNH[XURNN%\2&>0B*<52U?J(JO@P?/C>MT893="
M\8%YMTKF.Q1[;7_U79D,:^&4;#"8.Q![!NR"VI9D_QY^%DI<<I[RQPV$M--)
MG!:>#"=\TJY& O\5;X'E(%1LN8!$GX$U1I.EP-][9X3_KS;O2)<GEB4/O0*/
M"N3A&4J!,UZF926O6Y.MR 2R(\544"\UEE+6V&0*+9BDD.C=#^<]&1ZM(FAC
M!D:EP#XL)PFC'3D>"8>IK1_.B!-Z"=)T<N<9+-5B! #0KU21N]2@:9 .^#/(
M#G9O**R))3QRX2 A9 #('GG?Y*GCM7]ZSJF0_:-%)[*H0*RRGS]\PIY2BU$=
M3[8N_%@ B.)KLY7E2'Q1WR4&Y3QC P2YOH9]?@';_ DPW$C(@CLKKZZN)U?B
M& ]U"86?-0A9Q3%F$/^%8%_2FNGT>6=,^TL<[K GP2O> 8O?:+6L]BQSW&]Z
M$3;\&!91O"4^QESSQ"4J85Z2B85K,TB2QKT397-9?O.6,:>0.P^UNXM_[C%0
MSL'ELE_C(==];FIK6R["=P5CXWN6W\DV@OC_="G66(+%6.01):>Q^%B*CUE3
MX;+IM*<!-,(H!8MI7D[>:6,;<0,JEONY;EK.$-_X:376N=^J*D>W9R$TIBG6
MO-J4XJ>+\<4'OQ\'F97D( HC<* @; !(Q:>Q_9 IJD:2,X'HY[[B%B-3;8]H
M6 G\]Z</E5G"SK<DZ*^1/]RK*2H>*/%-/X<,\]6U\33637;H[IIQX,M=C B+
M+.8'.4Z]&0?(0EL,62F>!8*>Q^ERYWZ3%A?AP%=DJ([O&K+I2!K/N)&MW#5(
M;LBP"Z4.#< <)PZI:6ZK@H9\\G2&'VF&#RP &"N.Z;FJM;"G/7E&:C(Y?_ZW
M_^_*H?\VB.'N<A+4Y,.4;2Y-V2>(^Q4_B:>CZ^NKY#,(\.75)<CO(7N9R,II
MCX'<!>AB=/7D_,"W#SPD&B8V1[N;39]>]W[7M_T!D[0/X$7?5U\>*TR1KM,+
M(/1Y2NAK(/3079QI<BEI.A@)O"\AGV_"S9(W:HYN-4,??:!._;<VY,\Z64,=
MU4[Q*$QUG@+53ZW$IO M60;:<2&U<3%V)^>"G[@10@,@:H7WV>XI_*W6X(>P
M?7X"66I\&J,_660METI#RE:WX(TRK$)X.'R\H$N^FT<AY1LP-5PJ=.-!<.9:
MMVO+YC;4R'-$V$8"(,PR\Z[*T."#::B(0*.]('1H=AW8(3<,^7K/GF,@L'.R
MU\''#O-A,$:=1>&9_9#7)=XFZ)63!SXKXE_:LI$,>2>81Z?0U(4R=/$"0O-"
M_TF,<:F6*ZFC?SS5$.WP7S@M"5S55+7S1Y V4WS/;/=.%*<UPP0GJB/6(VC6
MK"N<P1JP7#J='*)FO!<W';RQ]@IB#?!;&5O<-^I>%56-_.LE[E_;ZG"MVZ1/
MY,D3OFV\5_;DD,1?WNHMA[^NT#[ZXO6[F[O7(<[$ L+5^>1T.L&K! ]!O$O5
M>%%O.GS/[K.OH^.%N\.-ZL?OXO\CB8AEC:"H!PHO=D?I:?P*1\OI!#R7A?:
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M53;\UKSP;7CIX V_:B\NYS<6?I!FB7Z\4 MX=#*^NCCB>4[_H:EJ>O'>O&K
MY-"?*R4AE,8%\#O.5/@/>$!X%>.K_P!02P,$%     @ *XMN54@P3 *5!0
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M_\ =1PFZ$1J$B(%70ZV>._;C#28FX>39$>B>7Z!*)51K*DJ"#CK=>]3@1^@
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MXWX6$-WVU=:PJO:];*(L=D8_G>&O"&CG@.^G2MF5X398_]R,?P-02P,$%
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M7LZT45@H?[5Y78#VVT$M><YU1F,8>\@.#>H9O,F'=[W(O]AC<K\RN;\/??*
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M<%)HOUVMA.2J>K\W.#RSC(-F1GVB+T5!(IPZA>;D.W3"UZ_Z(^]MD_K_1/9
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M,_5S27!,6%E 7I]3*M8'90.;S:W3_P%02P,$%     @ *XMN59H8?,'Q!0
MQB8  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULO5IM;]LV$/XKA%<,
M"1!$$N67)',,Q%:+=6@Z(T&W#T4_,-+9YD))'DDYZ; ?/U)2),N6Z:C@\B61
M9-YSO$>\XW,VQT\I?Q0K (F>8Y:(Z]Y*RO65XXAP!3$1Y^D:$O7)(N4QD>J6
M+QVQYD"BW"AF#G;=H1,3FO0FX_S9G$_&:28936#.D<CBF/#O4V#ITW7/Z[T\
MN*/+E=0/G,EX399P#_++>L[5G5.A1#2&1- T01P6U[T;[RKP76V0C_B#PI/8
MND8ZE(<T?=0W'Z/KGJMG! Q"J2&(^K>!&3"FD=0\_BY!>Y5/;;A]_8+^(0]>
M!?- !,Q2]B>-Y.JZ=]%#$2Q(QN1=^O0KE $--%Z8,I'_14_%V.&@A\),R#0N
MC=4,8IH4_\ES2<2601\?,,"E =XQ\+T#!GYIX.\:^ <,^J5!/V>F""7G(2"2
M3,8\?4)<CU9H^B(G,[=6X=-$O_=[R=6G5-G)R7WQOE&Z0/=TF= %#4DBT4T8
MIEDB:;)$\Y31D() )Y\)YT2_IE-T$H DE(G3L2/5+#26$Y8>IX5'?,"CCV[3
M1*X$>I]$$#7M'37[*@3\$L(4&P'O87V.?/<,81=C].4^0"?O3DON@*-WR$%B
M13B(EKG.7@_M[4&WX 5FO-^RI&6JAV;88,.O7JB?N_"/O-#?C[_0KY^4+?HH
M(1;?VMYCX:C?[D@7I"NQ)B%<]U3%$< WT)O\_),W=']I(]HF6& )K$%POR*X
M;T*?S'FZH;KL":3*+@K58N:J>B&6BK85-BW0ACF:KL*;B3MV-MO4&/UUI<;D
MKA'OH(IW8(QW]A(@$0)D:X@%P, 0HM%%UQ!-[AHA#JL0AZ\+D5'R0!F5M+58
M3(=[CKVAY[J[P1J==0UVN/<^M4?W0,2C*N*1,>([V$"2@=JYPU05B7\@0C0)
M61;E%UN+VDS(:&]R@^$^'_NC+OI[HP+CA'\PIR\J.BZ,='P")1W.T%S'K.HE
M0^^?UQ!12*103TGXJ"00^BJY8FQ!F(#6<FEVD=NU%4:C6=?58@FL0>)E1>*E
M,<*/B23)DCXP*$H%HO&:4*Y$HFRCZ_)H73PZ(C!.Z ?#]=Q:.KE'RD8<*^FJ
MQ$#X>(;6A*,-86J)G*@,BE+&"!=HK11(OK>?HG_-4F1:>AMMQWONNMX.*^9)
M=5TP1YTVN=F2E9Z1FX!N: 1)A)1B;%OVT])>^S^X ,P^.H=J":W)"*X9P49&
M;F(MP'1UA><0A-"2FR8BXZKD,AK3UB0I,1OE?^"/\'Z1-7OOS%6+WPMLV'B\
M6I]Z1G56;3U?;R%^ /Y-Y<7L1:NKC3@$O?7D/>$=%8_5L%9VK"I4JVB!+;0F
MR[5(]?IOU09X-O7IS"I:8 NMR7(MC3VS-OZ<Z;6I,SDF?^EFH%S(0BUJ0Y<X
M]?8E[%Z9WQ_B[^Q^YLG]:/"U:/;,JOF6)C3.8G.&VM3",ZMH@2VT)GVU O=&
M;Y:AEK1SR;)-M, 66I/E6MA[9MG]@3ZK_;5H7<]0)F"1,;7=+MHUB1G+1]]!
M:;I6SJRJ>%MH3<YJ'>^9A?PM>3Z>V):D=TF?3;3 %EKSV\BZ+<#N6R4VMJGU
M9U;1 EMH39;K!@.;&XQ.B7T$R[\\G-EFT\ZD_1\]"*Y[$&SN0>:J&4ND0$0U
M9I^HDMI"+T)#FIOQ.B] JSV*+;0FEW4?@]_LBW9LM8^QBA;80FNR7/<QV/QM
M^^Z72L=3W8SGN894M]J:V$)K$E>W)MC<FBCB@.E?5S/"T)RG:^#R^W;3_1KY
M;O;1>6%:_17 %EJ3W[K[P<,W2W^K39)5M, 66I/ENDG"YM\INJ>_&<\;&M+?
M:M]C"ZU)7-WW8'.O<CS]7R'RS3XZ+TRK/9(MM":_=8^$+]\L_:VV4E;1 EMH
MS:,,=2OEFW]AZ9S^1_"PH84WFW8^H6"U.W*V#OC$P)?Y02F!\K56')2IGE:'
ML6[R(T@[SZ?>U:PX4E7#%">\;@E?TD0@!@L%Z9Z/U/;*BT-3Q8U,U_DQHH=4
MRC3.+U= (N!Z@/I\D:;RY48[J(ZN3?X#4$L#!!0    ( "N+;E7M"\Y'5P(
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MX9+3=^<,;-^TO>%-%]_]RGCJHKAL:,ZA#0YT7AG2-QBAE7:3,_\%4$L#!!0
M   ( "N+;E6/=9Y5%@,  ,$+   9    >&PO=V]R:W-H965T<R]S:&5E=#4P
M+GAM;+U6;6^;,!#^*Q:KIE;JPDM>VR5(;5BU2FT7->OVH=H'!R[!&MC,=I+V
MW\\VE"4I08F$]@7\<L]S=X\Y<\,UX[]%#"#12YI0,;)B*;-+VQ9A#"D6+98!
M53MSQE,LU90O;)%QP)$!I8GM.4[/3C&AEC\T:Q/N#]E2)H3"A".Q3%/,7Z\A
M8>N1Y5IO"X]D$4N]8/O##"]@"O(IFW ULTN6B*1 !6$4<9B/K"OW,AAH>V/P
M@\!:;(R1SF3&V&\]N8U&EJ,#@@1"J1FP>JU@#$FBB508?PI.JW2I@9OC-_8;
MD[O*988%C%GRDT0R'ED#"T4PQ\M$/K+U5RCRZ6J^D"7"/-&ZL'4L%"Z%9&D!
M5A&DA.9O_%+HL %P.WL 7@'P=@'=/8!V 6@?ZJ%3 #I&F3P5HT. )?:'G*T1
MU]:*30^,F :MTB=4'_M4<K5+%$[Z8T97P"69)8 FG*5$",9?T0.3@!XA!++"
M>NOT 7..]1&=H=, )":).$.?T-,T0*<G9^@$$8J^QVPI,(W$T)8J-.W #HLP
MQGD8WIXPVNB>41D+](5&$&WC;952F9?WEM>U5TOX+90MY+CGR',\IRJ>>O@4
MLA9J.P;N5<"#P^%N33;M\I3:AJ^]A^\J#-F22G%N#D:][ABF BFMT0VAF(:$
M+C:/Z_E.$:!;":GX51']=>ZM4^U-WS27(L,AC"QUE0C@*[#\CQ_<GO.Y2LDF
MR8*&R+94[I0J=^K8_5LJ0;%*]2V'+(4JX6H)CA4N)^L9,GT]K_R+BZ&]VI3C
MO4F[5YIL)=DMD^S6)GE@P3_?0SH#7OGUU#HX5H0FR8*&R+:$[97"]OYKC?::
M5+E)LJ ALBV5^Z7*_=K/]RK5(JL*7:E"W?U3Y,+UW]6,VW6<[<(:UWHY5I"&
MR+8$&92"# Z[M-3ON?+*RN&NLZ&'TW*Z.WK4.CE6CX;(<CWLC>8F!;XP3:)
MIMCR?J!<+?O0*]-^[:R/57^:MY/_:/+F]A[S!5&UFL!<43JMOKI'>-XPYA/)
M,M-"S9A4#9D9QJK'!JX-U/Z<J9(O)MI!V;7[?P%02P,$%     @ *XMN5?I+
M28KZ @  00H  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULK59=;]HP
M%/TK5UDUM5)'OH#2#B(5Z+1.HJK*NCU,>S#)!:S&-K4=:/?K9R<A@PZRM>(%
M;.>>XW.N;^+;70GYH.:(&IY8RE7/F6N]N'!=%<^1$=40"^3FR51(1K29RIFK
M%A))DH-8Z@:>UW89H=R)NOG:K8RZ(M,IY7@K066,$?G<QU2L>H[OK!?NZ&RN
M[8(;=1=DAF/4]XM;:69NQ9)0AEQ1P4'BM.=<^A>#<QN?!WRCN%(;8[!.)D(\
MV,EUTG,\*PA3C+5E(.9OB0-,4TMD9#R6G$ZUI05NCM?LGW+OQLN$*!R(]#M-
M]+SG=!Q(<$JR5-^)U6<L_;0L7RQ2E?_"JHSU'(@SI04KP48!H[SX)T]E'C8
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MH"P U^=2FL? =J7N)Y3]!E!+ P04    "  KBVY5PCZ/0:$"  "R!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6RM55U/VS 4_2M6AB:0@'Q#86DD
M*$,P"0G1P1ZF/;C);6/AV,%V4OCWLYV0!9JR/>PEL7WO.3[W.+Y)UEP\R@)
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MKG3+LL-"_U1 F 0=7W*N7B>F;_6_J?0W4$L#!!0    ( "N+;E5C'9.<8P(
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M"A.@[W/.U<$P";J]G?P!4$L#!!0    ( "N+;E6^?%.GNP(  'H(   9
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MUY\'($R 'L\Y5\\=<S^T'QS)7U!+ P04    "  KBVY5/Y'\AU,"  "?!0
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MD-(;76/ORF8<-($6I>VHK=#8GW:9X00%:1+P?">$/@7F@FXFQW\ 4$L#!!0
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M/<?GW/@ZW6OS: L )$^E5'9*"\1JPIA=%U!R.] 5*+>ST:;DZ$*S9;8RP/,
M*B6+HVC,2BX4S=*P=FNR5-<HA8);0VQ=EMS\N@2I]U,ZI,\+=V);H%]@65KQ
M+2P!'ZI;XR+6L>2B!&6%5L3 9DIGP\D\\?DAX:N O3V8$^]DI?6C#V[R*8V\
M()"P1L_ W;"#.4CIB9R,GRTG[8[TP,/Y,_NGX-UY67$+<RV_B1R+*;V@)(<-
MKR7>Z?TUM'[./=]:2QN^9-_F1I2L:XNZ;,%.02E4,_*GM@X'@.'H!"!N ?%K
M 4D+")5CC;)@:\&19ZG1>V)\MF/SDU";@'9NA/)_<8G&[0J'P^Q&(5=;L9)
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M2XQ4UWN=863MG^]:&ML,?EG:<07*.=CSK;0R>L-UQ#  L]]02P,$%     @
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M-A3&OXJ535.O-)$XD)#; 5)+=;5*[;W597=[,>V%"0>PFMB98T*1]N%W[$"
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MO4M5G)P\2!8\+5DX(US\@MP?*RI?T-$MYAQKC1RC(X=(3$-QC#ZA#A)+S(E
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M6?1L4@-\(7KXJ!W UZ-0A=A* K^)A$7J,@G_0,+_><J;KN08?,N=<9)1^]#
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M& -]?<7U-U(],#=H_@R(_@=02P,$%     @ *XMN520D>,KH @  E@D  !D
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M ;Q8&J[8$?$F7P3L,18B#O/--:,+QK,/I.>7<2R>=S('U0)]\W\!4$L#!!0
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M[Z2Q$^27I;VR0+D$>UY(:<Z!$^@OP?0O4$L#!!0    ( "N+;E68?X4=50(
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M2-0\W_,==#$"31E7'?0!/<U&Z.)M)\+:>&N_B9/*L_O2L^ 5SV90=%%(WJ.
M!$$+/CR.?UGG1_'1<?R[V'01\1WNM^#C$YSW21N.387J,@5UF0*G%_Y_F7[=
MS966YL#];LMQ*=MKE[5-Z%85-(&!9[J, KD!+W[WQN^3CVT9/Z?8Z)QBXS.)
M_5.;L*Y->$R]49OZ""#J:M-6D%*K[[1L$]_$P4UP30B)\*:9ZT.[D/0/[4:'
M=OY-_^K ;MRBUR=ATZX,'C=ZB;TIOE&Y8KDRL2T-2;I7IO_(LON6$RT*UU[F
M0IMFY8:IN;! 6@.SOQ1"[R>V8]578/P74$L#!!0    ( "N+;E7<&KD), ,
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ *XMN59E<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M"  KBVY54B W-[ %  #('@  &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ *XMN57SJ"2Y3!P  ]R$  !@
M             ("!] T  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( "N+;E4H%B^$X (  $$*   8              " @7T5  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  KBVY5?BV6^,,%  "?
M&@  &               @(&3&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ *XMN5</VXN=Z @  +@8  !@              ("!C!X
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( "N+;E51&5B#
M?@<  & _   8              " @3PA  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    "  KBVY5S^D.4W8)  "A+0  &
M@('P*   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ *XMN
M5;M6/LXZ"   +Q,  !@              ("!G#(  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( "N+;E5TC)K $@@  #43   8
M      " @0P[  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "N+;E4?\P]F5 ,  )('   9              "
M@;^!  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ *XMN
M58$'(Q23 P  .PD  !D              ("!2H4  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    "  KBVY52L;V6F0#   %"   &0
M        @($4B0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( "N+;E6YG2M^@@,  %T(   9              " @:^,  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ *XMN54BS=#W7 @  ;08
M !D              ("!:)   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    "  KBVY5>7]*V/L(   Q%@  &0              @(%VDP
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "N+;E7JX$D*
M'@,  (8&   9              " @:B<  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ *XMN5;@.\\)6!@  3A(  !D
M ("!_9\  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  K
MBVY5 ;H<ZT@'  #H$@  &0              @(&*I@  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "N+;E7@T0#%,0H  .P;   9
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M970R-RYX;6Q02P$"% ,4    "  KBVY5/\R9X:L'  #U$0  &0
M    @(%JS@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M "N+;E4)=T1=E ,  % (   9              " @4S6  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ *XMN55.%&XP.!   /PH  !D
M             ("!%]H  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    "  KBVY5;Y*=<5X9  "640  &0              @(%<W@  >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "N+;E5(,$P"E04
M /(2   9              " @?'W  !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ *XMN55XEP:82 P  Q0<  !D              ("!
MO?T  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  KBVY5
MS]CE904#  !T"   &0              @($& 0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( "N+;E6X#TL190,  $8)   9
M      " @4($ 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ *XMN53X2.,RF @  =@8  !D              ("!W@<! 'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  KBVY5UO6:5C0#  #H"
M&0              @(&["@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( "N+;E63"&:QA 0  ,<.   9              " @28. 0!X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ *XMN5=/._CT)
M!   :0L  !D              ("!X1(! 'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    "  KBVY5Z8M18A$$  #X#   &0
M@($A%P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( "N+
M;E59VL^OJ 0  #P+   9              " @6D; 0!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ *XMN59IKU6/H @  ;P@  !D
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M=#0V+GAM;%!+ 0(4 Q0    ( "N+;E6FDOB%*@<  !(O   9
M  " @5DW 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
M*XMN5?4\.92# @  / <  !D              ("!NCX! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    "  KBVY5W,O$Z48"  !%!0  &0
M            @(%T00$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( "N+;E6/=9Y5%@,  ,$+   9              " @?%# 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ *XMN5?I+28KZ @
M00H  !D              ("!/D<! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    "  KBVY5=5.R?H4"  "0!@  &0              @(%O
M2@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( "N+;E7"
M/H]!H0(  +(&   9              " @2M- 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ *XMN56,=DYQC @  PP4  !D
M     ("! U ! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
M"  KBVY5OGQ3I[L"  !Z"   &0              @(&=4@$ >&PO=V]R:W-H
M965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( "N+;E4.KW?+J (  'P(   9
M              " @8]5 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L!
M A0#%     @ *XMN53^1_(=3 @  GP4  !D              ("!;E@! 'AL
M+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  KBVY5E?/<-S4"
M   ;!0  &0              @('X6@$ >&PO=V]R:W-H965T<R]S:&5E=#4X
M+GAM;%!+ 0(4 Q0    ( "N+;E4 0C?=3 ,  +<.   9              "
M@61= 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ *XMN
M5?E<Q>1X P  Q0X  !D              ("!YV ! 'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6Q02P$"% ,4    "  KBVY59U".,3$"   4!0  &0
M        @(&69 $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0
M   ( "N+;E5!WFB+*0(   P%   9              " @?YF 0!X;"]W;W)K
M<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ *XMN50?5X?8) @  , 0
M !D              ("!7FD! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q0
M2P$"% ,4    "  KBVY5 G%"GB($  "=$   &0              @(&>:P$
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( "N+;E7%P+N!
MMP,  *$1   9              " @?=O 0!X;"]W;W)K<VAE971S+W-H965T
M-C4N>&UL4$L! A0#%     @ *XMN52FI?53U P  X1   !D
M ("!Y7,! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    "  K
MBVY5I/A=X]L#  #]$0  &0              @($1> $ >&PO=V]R:W-H965T
M<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( "N+;E41/KIP5 0  -$7   9
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M970W,BYX;6Q02P$"% ,4    "  KBVY5R9"FUR #  #H"P  &0
M    @(&>DP$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    (
M "N+;E6$@Q8=*0(  + $   9              " @?66 0!X;"]W;W)K<VAE
M971S+W-H965T-S0N>&UL4$L! A0#%     @ *XMN5;;/<2 (!P  K$\  !D
M             ("!59D! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"
M% ,4    "  KBVY5T!J0*3 "   0!0  &0              @(&4H $ >&PO
M=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( "N+;E68?X4=50(
M )8%   9              " @?NB 0!X;"]W;W)K<VAE971S+W-H965T-S<N
M>&UL4$L! A0#%     @ *XMN53]R--HF @  "04  !D              ("!
MAZ4! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    "  KBVY5
M+XMRZF\"   .!P  &0              @('DIP$ >&PO=V]R:W-H965T<R]S
M:&5E=#<Y+GAM;%!+ 0(4 Q0    ( "N+;E7<&KD), ,  .X2   -
M      "  8JJ 0!X;"]S='EL97,N>&UL4$L! A0#%     @ *XMN59>*NQS
M    $P(   L              ( !Y:T! %]R96QS+RYR96QS4$L! A0#%
M  @ *XMN5>/"O_?+!0  2#0   \              ( !SJX! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( "N+;E6[2=+?8@(  +0N   :
M  "  <:T 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M "N+;E7=)VL+& (  (4M   3              "  6"W 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !7 %< V!<  *FY 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>111</ContextCount>
  <ElementCount>345</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00205 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00300 - Statement - Condensed Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity</Role>
      <ShortName>Condensed Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Financial Instruments and Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement</Role>
      <ShortName>Financial Instruments and Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Significant Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactions</Role>
      <ShortName>Significant Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Convertible Promissory Note Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable</Role>
      <ShortName>Convertible Promissory Note Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Investments in Debt and Equity Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecurities</Role>
      <ShortName>Investments in Debt and Equity Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Finance Lease ROU Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets</Role>
      <ShortName>Finance Lease ROU Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Operating Lease ROU Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets</Role>
      <ShortName>Operating Lease ROU Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Note Payable - PPP Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureNotePayablePppLoan</Role>
      <ShortName>Note Payable - PPP Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Finance Lease Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation</Role>
      <ShortName>Finance Lease Obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Operating Lease Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation</Role>
      <ShortName>Operating Lease Obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Earnings (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare</Role>
      <ShortName>Earnings (Loss) Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>11901 - Disclosure - Fraunhofer Settlement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFraunhoferSettlement</Role>
      <ShortName>Fraunhofer Settlement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>12001 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>12101 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureContingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>12201 - Disclosure - Employee 401(K) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEmployee401KPlan</Role>
      <ShortName>Employee 401(K) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>12301 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>20402 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDiscontinuedOperations</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Significant Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables</Role>
      <ShortName>Significant Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSignificantTransactions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Investments in Debt and Equity Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesTables</Role>
      <ShortName>Investments in Debt and Equity Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecurities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Finance Lease ROU Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables</Role>
      <ShortName>Finance Lease ROU Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Finance Lease Obligation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables</Role>
      <ShortName>Finance Lease Obligation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Operating Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</Role>
      <ShortName>Operating Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>31703 - Disclosure - Earnings (Loss) Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables</Role>
      <ShortName>Earnings (Loss) Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>31803 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Basis of Presentation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails</Role>
      <ShortName>Basis of Presentation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureBasisOfPresentation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Discontinued Operations (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails</Role>
      <ShortName>Discontinued Operations (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Summary of Significant Accounting Policies - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Significant Transactions (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails</Role>
      <ShortName>Significant Transactions (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails</Role>
      <ShortName>Significant Transactions (Summary of Asset Acquisition) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Significant Transactions - Amended Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsAmendedCreditAgreementDetails</Role>
      <ShortName>Significant Transactions - Amended Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Convertible Promissory Note Receivable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails</Role>
      <ShortName>Convertible Promissory Note Receivable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Investments in Debt and Equity Securities (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails</Role>
      <ShortName>Investments in Debt and Equity Securities (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Investments in Debt and Equity Securities (Components of Investments in Debt Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails</Role>
      <ShortName>Investments in Debt and Equity Securities (Components of Investments in Debt Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Investments in Debt and Equity Securities (Debt Securities, Contractual Maturity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails</Role>
      <ShortName>Investments in Debt and Equity Securities (Debt Securities, Contractual Maturity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails</Role>
      <ShortName>Finance Lease ROU Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails</Role>
      <ShortName>Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails</Role>
      <ShortName>Operating Lease ROU Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Fixed Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails</Role>
      <ShortName>Fixed Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFixedAssets</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails</Role>
      <ShortName>Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFixedAssets</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails</Role>
      <ShortName>Intangible Assets (Carrying Value and Accumulated Amortization) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Intangible Assets (Estimated Annual Amortization Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets (Estimated Annual Amortization Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Note Payable - PPP Loan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureNotePayablePppLoanNarrativeDetails</Role>
      <ShortName>Note Payable - PPP Loan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureNotePayablePppLoan</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Finance Lease Obligation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails</Role>
      <ShortName>Finance Lease Obligation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41403 - Disclosure - Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails</Role>
      <ShortName>Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41404 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails</Role>
      <ShortName>Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Operating Lease Obligation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails</Role>
      <ShortName>Operating Lease Obligation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41502 - Disclosure - Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails</Role>
      <ShortName>Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41503 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails</Role>
      <ShortName>Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Share-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41802 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation (Share Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>41805 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Share-Based Compensation (Fair Value of Options Granted) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails</Role>
      <ShortName>Fraunhofer Settlement (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFraunhoferSettlement</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>42001 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails</Role>
      <ShortName>Employee 401(K) Plan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEmployee401KPlan</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>42301 - Disclosure - Subsequent Events (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ibio-20220930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9941002 - Disclosure - Operating Lease ROU Assets (Category the net carrying values of operating lease ROU) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsCategoryNetCarryingValuesOfOperatingLeaseRouDetails</Role>
      <ShortName>Operating Lease ROU Assets (Category the net carrying values of operating lease ROU) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets</ParentRole>
      <Position>79</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 32 fact(s) appearing in ix:hidden were eligible for transformation: ibio:BaseRentAbatementInFirstYearPeriod, ibio:CashPaymentsReceivablesRelatedToLitigationSettlement, ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm, ibio:StockIssuedDuringPeriodValueCapitalRaise, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare, us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare, us-gaap:InvestmentMaturityDate, us-gaap:LeasePracticalExpedientsPackage, us-gaap:PreferredStockSharesOutstanding, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:SettlementAssetsCurrent, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  ibio-20220930x10q.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="ibio-20220930x10q.htm">ibio-20220930x10q.htm</File>
    <File>ibio-20220930.xsd</File>
    <File>ibio-20220930_cal.xml</File>
    <File>ibio-20220930_def.xml</File>
    <File>ibio-20220930_lab.xml</File>
    <File>ibio-20220930_pre.xml</File>
    <File>ibio-20220930xex10d2.htm</File>
    <File>ibio-20220930xex10d3.htm</File>
    <File>ibio-20220930xex10d4.htm</File>
    <File>ibio-20220930xex31d1.htm</File>
    <File>ibio-20220930xex31d2.htm</File>
    <File>ibio-20220930xex32d1.htm</File>
    <File>ibio-20220930xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ibio-20220930x10q001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="478">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>107
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ibio-20220930x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "contextCount": 111,
   "dts": {
    "calculationLink": {
     "local": [
      "ibio-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ibio-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ibio-20220930x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ibio-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ibio-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ibio-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 531,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 29,
    "http://www.ibioinc.com/20220930": 5,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 39
   },
   "keyCustom": 93,
   "keyStandard": 252,
   "memberCustom": 29,
   "memberStandard": 21,
   "nsprefix": "ibio",
   "nsuri": "http://www.ibioinc.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document And Entity Information",
     "role": "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Discontinued Operations",
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Financial Instruments and Fair Value Measurement",
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement",
     "shortName": "Financial Instruments and Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:SignificantTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Significant Transactions",
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactions",
     "shortName": "Significant Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:SignificantTransactionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Convertible Promissory Note Receivable",
     "role": "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable",
     "shortName": "Convertible Promissory Note Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Investments in Debt and Equity Securities",
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecurities",
     "shortName": "Investments in Debt and Equity Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Finance Lease ROU Assets",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets",
     "shortName": "Finance Lease ROU Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Operating Lease ROU Assets",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets",
     "shortName": "Operating Lease ROU Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Fixed Assets",
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssets",
     "shortName": "Fixed Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Intangible Assets",
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:NotesPayablePppLoanDisclosureTextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Note Payable - PPP Loan",
     "role": "http://www.ibioinc.com/role/DisclosureNotePayablePppLoan",
     "shortName": "Note Payable - PPP Loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:NotesPayablePppLoanDisclosureTextblock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Finance Lease Obligation",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation",
     "shortName": "Finance Lease Obligation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Operating Lease Obligation",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation",
     "shortName": "Operating Lease Obligation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Stockholders' Equity",
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - Earnings (Loss) Per Common Share",
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare",
     "shortName": "Earnings (Loss) Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11801 - Disclosure - Share-Based Compensation",
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:GainLossRelatedToLitigationSettlementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11901 - Disclosure - Fraunhofer Settlement",
     "role": "http://www.ibioinc.com/role/DisclosureFraunhoferSettlement",
     "shortName": "Fraunhofer Settlement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:GainLossRelatedToLitigationSettlementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "12001 - Disclosure - Income Taxes",
     "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "12101 - Disclosure - Contingencies",
     "role": "http://www.ibioinc.com/role/DisclosureContingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "12201 - Disclosure - Employee 401(K) Plan",
     "role": "http://www.ibioinc.com/role/DisclosureEmployee401KPlan",
     "shortName": "Employee 401(K) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_IqSumpNCE0i4cjreMDVcuw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "12301 - Disclosure - Subsequent Events",
     "role": "http://www.ibioinc.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20402 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Discontinued Operations (Tables)",
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_vIjz2QvLhkmSRzd2SRXhOA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Significant Transactions (Tables)",
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
     "shortName": "Significant Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_vIjz2QvLhkmSRzd2SRXhOA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Investments in Debt and Equity Securities (Tables)",
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesTables",
     "shortName": "Investments in Debt and Equity Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Finance Lease ROU Assets (Tables)",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables",
     "shortName": "Finance Lease ROU Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31403 - Disclosure - Finance Lease Obligation (Tables)",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables",
     "shortName": "Finance Lease Obligation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31503 - Disclosure - Operating Lease Obligations (Tables)",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables",
     "shortName": "Operating Lease Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31703 - Disclosure - Earnings (Loss) Per Common Share (Tables)",
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables",
     "shortName": "Earnings (Loss) Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31803 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ibio:CashAndCashEquivalentsPlusDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Basis of Presentation (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
     "shortName": "Basis of Presentation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ibio:CashAndCashEquivalentsPlusDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ibio:EmployeeReductionExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Discontinued Operations (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
     "shortName": "Discontinued Operations (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ibio:EmployeeReductionExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProvisionForLossOnContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProvisionForLossOnContracts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Summary of Significant Accounting Policies - Revenue (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ibio:DeferredFinancingCostsAmortizationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Significant Transactions (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
     "shortName": "Significant Transactions (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_KrEDvp2NX0iab3cqmohmHA",
      "decimals": "0",
      "lang": null,
      "name": "ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_8_23_2021_To_8_23_2021_ITw1i6YR9UyPpE1bDlnljA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
     "shortName": "Significant Transactions (Summary of Asset Acquisition) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_8_23_2021_To_8_23_2021_ITw1i6YR9UyPpE1bDlnljA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - Significant Transactions - Amended Credit Agreement (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsAmendedCreditAgreementDetails",
     "shortName": "Significant Transactions - Amended Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Convertible Promissory Note Receivable (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails",
     "shortName": "Convertible Promissory Note Receivable (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_RpRam_Iq8kC7AtGMNktNbw",
      "decimals": "-5",
      "lang": null,
      "name": "ibio:LoansReceivableAmountInvested",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Investments in Debt and Equity Securities (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails",
     "shortName": "Investments in Debt and Equity Securities (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_srt_RangeAxis_srt_MinimumMember_-6_SwUpb2EmaZh5-_vBL1Q",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:InvestmentInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Investments in Debt and Equity Securities (Components of Investments in Debt Securities) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails",
     "shortName": "Investments in Debt and Equity Securities (Components of Investments in Debt Securities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Investments in Debt and Equity Securities (Debt Securities, Contractual Maturity) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails",
     "shortName": "Investments in Debt and Equity Securities (Debt Securities, Contractual Maturity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
     "shortName": "Finance Lease ROU Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails",
     "shortName": "Finance Lease ROU Assets (Summary of Finance Lease ROU) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unitRef": "Unit_Standard_sqft_5KxWaFXlD02dT7QlqBc7JA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails",
     "shortName": "Operating Lease ROU Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Fixed Assets (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails",
     "shortName": "Fixed Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
     "shortName": "Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Intangible Assets (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
     "shortName": "Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2N7RXo2_pUetdE_cG5cZ6w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Condensed Consolidated Statements of Equity",
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity",
     "shortName": "Condensed Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2N7RXo2_pUetdE_cG5cZ6w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
     "shortName": "Intangible Assets (Carrying Value and Accumulated Amortization) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Intangible Assets (Estimated Annual Amortization Expense) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails",
     "shortName": "Intangible Assets (Estimated Annual Amortization Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NotesPayableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Note Payable - PPP Loan (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureNotePayablePppLoanNarrativeDetails",
     "shortName": "Note Payable - PPP Loan (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_4_1_2021_To_4_1_2021_Cv64n0Mw7E6pyUXZzZXFwA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ibio:LessorFinanceLeaseMonthlyRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Finance Lease Obligation (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails",
     "shortName": "Finance Lease Obligation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_4_1_2021_To_4_1_2021_Cv64n0Mw7E6pyUXZzZXFwA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ibio:LessorFinanceLeaseMonthlyRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41403 - Disclosure - Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
     "shortName": "Finance Lease Obligation (Finance Lease Cost and Other Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41404 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
     "shortName": "Finance Lease Obligation (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unitRef": "Unit_Standard_sqft_5KxWaFXlD02dT7QlqBc7JA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Operating Lease Obligation (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
     "shortName": "Operating Lease Obligation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_10_2021_0-wtIntoAU27qUl5ncXZcw",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41502 - Disclosure - Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails",
     "shortName": "Operating Lease Obligation (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41503 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails",
     "shortName": "Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_2_23_2017_QxVrYRSL_UiOCiGSWO0CFg",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - Stockholders' Equity (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_2_23_2017_QxVrYRSL_UiOCiGSWO0CFg",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
     "shortName": "Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_MtHCCTglWES6FXBOwD3GbQ",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41801 - Disclosure - Share-Based Compensation (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_MtHCCTglWES6FXBOwD3GbQ",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_AVRUwjn5-k-vxpma50I6CQ",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41802 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation (Share Based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41805 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails",
     "shortName": "Share-Based Compensation (Fair Value of Options Granted) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SettlementAssetsCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
     "shortName": "Fraunhofer Settlement (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_6_30_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_LZBHDrN9UUGCxpUjpg5lXA",
      "decimals": "0",
      "lang": null,
      "name": "ibio:CashPaymentsReceivablesRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "42001 - Disclosure - Income Taxes (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
     "shortName": "Employee 401(K) Plan (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_ixUVRkEHxkO_OhFbouCuvw",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "42301 - Disclosure - Subsequent Events (Narrative) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
     "shortName": "Subsequent Events (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "As_Of_9_30_2022_uELtsK8WUk6VRL9a7V5sxw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_toc5kWKGu02J2pKUs-6wtA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9941002 - Disclosure - Operating Lease ROU Assets (Category the net carrying values of operating lease ROU) (Details)",
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsCategoryNetCarryingValuesOfOperatingLeaseRouDetails",
     "shortName": "Operating Lease ROU Assets (Category the net carrying values of operating lease ROU) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of Business",
     "role": "http://www.ibioinc.com/role/DisclosureNatureOfBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Basis of Presentation",
     "role": "http://www.ibioinc.com/role/DisclosureBasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibio-20220930x10q.htm",
      "contextRef": "Duration_7_1_2022_To_9_30_2022_38EMMn8xBESSlSzV2K1A7w",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 52,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document And Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued interest receivable on convertible promissory note receivable.",
        "label": "Accrued Interest Receivable on Convertible Promissory Note Receivable",
        "negatedLabel": "Accrued interest receivable on convertible promissory note receivable"
       }
      }
     },
     "localname": "AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]",
        "label": "After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]"
       }
      }
     },
     "localname": "AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_AssetAcquisitionIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Intangible Assets [Member]",
        "label": "Asset Acquisition Intangible Assets [Member]"
       }
      }
     },
     "localname": "AssetAcquisitionIntangibleAssetsMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_AssetAcquisitionPrepaidExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Prepaid Expenses [Member]",
        "label": "Asset Acquisition Prepaid Expenses [Member]"
       }
      }
     },
     "localname": "AssetAcquisitionPrepaidExpensesMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_BaseRentAbatementInFirstYearPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base rent abatement period in the first year.",
        "label": "Base Rent Abatement In the First Year, Period",
        "terseLabel": "Base rent abatement period in the first year"
       }
      }
     },
     "localname": "BaseRentAbatementInFirstYearPeriod",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ibio_BaseRentPercentageOfFairMarketValueOfProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of base rent payable on percentage of fair Market Value of the Property.",
        "label": "Base Rent, Percentage of Fair Market Value of Property",
        "terseLabel": "Percentage of base rent"
       }
      }
     },
     "localname": "BaseRentPercentageOfFairMarketValueOfProperty",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_BasisOfPresentationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Basis of Presentation.",
        "label": "Basis of Presentation [Abstract]"
       }
      }
     },
     "localname": "BasisOfPresentationAbstract",
     "nsuri": "http://www.ibioinc.com/20220930",
     "xbrltype": "stringItemType"
    },
    "ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid for capital expenditures incurred for intangible assets during the previous year.",
        "label": "Capital Expenditure Incurred For Intangible Assets Paid",
        "terseLabel": "Fixed assets included in accounts payable in prior period, paid in current period"
       }
      }
     },
     "localname": "CapitalExpenditureIncurredForIntangibleAssetsPaid",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CashAndCashEquivalentsPlusDebtSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents plus debt securities",
        "label": "Cash and cash equivalents plus debt securities",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPlusDebtSecurities",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash Paid For Amounts Included In Measurement Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash Paid For Amounts Included In Measurement Operating Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement lease liability:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_CashPaymentsReceivablesRelatedToLitigationSettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments receivables related to litigation settlement.",
        "label": "Cash Payments Receivables Related to Litigation Settlement",
        "terseLabel": "Cash payments receivables related to litigation settlement"
       }
      }
     },
     "localname": "CashPaymentsReceivablesRelatedToLitigationSettlement",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CollaborationAndLicenseAgreementAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement, agreement term",
        "label": "Collaboration and license agreement, agreement term",
        "terseLabel": "Collaboration and license agreement, agreement term"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementAgreementTerm",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement, royalty payment term",
        "label": "Collaboration and License Agreement, Royalty payment term",
        "terseLabel": "Collaboration and license agreement, royalty payment term"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementRoyaltyPaymentTerm",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ibio_CollaborationOptionAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration, Option and License Agreement [Member]",
        "label": "Collaboration, Option and License Agreement [Member]"
       }
      }
     },
     "localname": "CollaborationOptionAndLicenseAgreementMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_CollegeStationInvestorsLlcAndBryanCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to College Station Investors LLC And Bryan Capital.",
        "label": "College Station Investors LLC And Bryan Capital [Member]"
       }
      }
     },
     "localname": "CollegeStationInvestorsLlcAndBryanCapitalMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_CommonStockIssuedInRubrycTransactionInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of common stock issued in the RubrYc transaction.",
        "label": "Common Stock Issued In RubrYc Transaction (In Shares)",
        "terseLabel": "Common stock issued - RubrYc transaction (in shares)"
       }
      }
     },
     "localname": "CommonStockIssuedInRubrycTransactionInShares",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_CommonStockIssuedInRubrycTransactionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of common stock issued in the RubrYc transaction.",
        "label": "Common Stock Issued In RubrYc Transaction, Value",
        "terseLabel": "Common stock issued - RubrYc transaction",
        "verboseLabel": "RubrYc asset acquisition by issuance of common stock"
       }
      }
     },
     "localname": "CommonStockIssuedInRubrycTransactionValue",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CompanyPurchasingCardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Company purchasing card.",
        "label": "Company Purchasing Card [Member]"
       }
      }
     },
     "localname": "CompanyPurchasingCardMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ContractAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contract assets.",
        "label": "Contract Assets [Policy Text Block]",
        "terseLabel": "Contract Assets"
       }
      }
     },
     "localname": "ContractAssetsPolicyTextBlock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_ContractLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contract liabilities.",
        "label": "Contract Liabilities [Policy Text Block]",
        "terseLabel": "Contract Liabilities"
       }
      }
     },
     "localname": "ContractLiabilitiesPolicyTextBlock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of convertible Promissory Note Receivable and Accrued Interest.",
        "label": "Convertible Promissory Note Receivable and Accrued Interest",
        "terseLabel": "Convertible promissory note receivable and accrued interest"
       }
      }
     },
     "localname": "ConvertiblePromissoryNoteReceivableAndAccruedInterest",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CreditAgreementThresholdLimitUnrestrictedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold limit of unrestricted cash to be maintained.",
        "label": "Credit Agreement, Threshold Limit, Unrestricted Cash",
        "terseLabel": "Unrestricted cash"
       }
      }
     },
     "localname": "CreditAgreementThresholdLimitUnrestrictedCash",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current liabilities related to assets held for sale.",
        "label": "Current Liabilities Related To Assets Held For Sale",
        "terseLabel": "Current liabilities related to assets held for sale"
       }
      }
     },
     "localname": "CurrentLiabilitiesRelatedToAssetsHeldForSale",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DeferredFinancingCostsAmortizationExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of loan and debt issuance costs.",
        "label": "Deferred Financing Costs, Amortization Expense",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinancingCostsAmortizationExpense",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DiscontinuedOperationsMiscellaneousExpensesIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miscellaneous expenses (income) attributable to discontinued operations.",
        "label": "Discontinued Operations, Miscellaneous Expenses (Income)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DiscontinuedOperationsMiscellaneousExpensesIncome",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses attributable to discontinued operations.",
        "label": "Discontinued Operations, Research And Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DiscontinuedOperationsResearchAndDevelopmentExpenses",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of finance lease ROU assets attributable to discontinued operations.",
        "label": "Disposal Group, Amortization Of Finance Lease Right Of Use Assets",
        "terseLabel": "Amortization of finance lease ROU assets"
       }
      }
     },
     "localname": "DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current operating lease obligations attributable to discontinued operations.",
        "label": "Disposal Group, Current Liabilities, Operating Lease Obligations",
        "terseLabel": "Operating lease obligation"
       }
      }
     },
     "localname": "DisposalGroupCurrentLiabilitiesOperatingLeaseObligations",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed asset charges incurred but not yet paid attributable to discontinued operations.",
        "label": "Disposal Group, Fixed Assets Incurred But Not Yet Paid In Current Period",
        "terseLabel": "Fixed assets included in accounts payable in prior period, paid in current period"
       }
      }
     },
     "localname": "DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupGainOnDebtForgiveness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on forgiveness of debt to discontinued operations.",
        "label": "Disposal Group, Gain On Debt Forgiveness",
        "terseLabel": "Forgiveness of note payable and accrued interest - SBA loan"
       }
      }
     },
     "localname": "DisposalGroupGainOnDebtForgiveness",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupInterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense to related party from discontinued operations.",
        "label": "Disposal Group, Interest Expense, Related Party",
        "negatedLabel": "Interest expense - related party"
       }
      }
     },
     "localname": "DisposalGroupInterestExpenseRelatedParty",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupNoncurrentOperatingLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent operating lease obligations attributable to discontinued operations.",
        "label": "Disposal Group, Noncurrent Operating Lease Obligations",
        "terseLabel": "Operating lease obligation"
       }
      }
     },
     "localname": "DisposalGroupNoncurrentOperatingLeaseObligations",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current operating lease ROU assets attributable to discontinued operations.",
        "label": "Disposal Group, Operating Lease Right Of Use Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DisposalGroupOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent operating lease ROU assets attributable to discontinued operations.",
        "label": "Disposal Group, Operating Lease Right Of Use Assets, Noncurrent",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DisposalGroupOperatingLeaseRightOfUseAssetsNoncurrent",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_EarningsLossPerCommonShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Loss Per Common Share [Line Items]"
       }
      }
     },
     "localname": "EarningsLossPerCommonShareLineItems",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_EarningsLossPerCommonShareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Loss Per Common Share [Table]"
       }
      }
     },
     "localname": "EarningsLossPerCommonShareTable",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_EasternAffiliateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Eastern affiliate.",
        "label": "Eastern Affiliate [Member]"
       }
      }
     },
     "localname": "EasternAffiliateMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_EmployeeReductionExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected amount of expenses to be incurred due to employee reductions.",
        "label": "Employee Reduction Expenses",
        "terseLabel": "Expected employee reduction charges"
       }
      }
     },
     "localname": "EmployeeReductionExpenses",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration transferred for equity interest acquired under the equity agreement.",
        "label": "Equity Agreement, Consideration Transferred Equity Interests Acquired",
        "terseLabel": "Cash consideration for equity interest acquired"
       }
      }
     },
     "localname": "EquityAgreementConsiderationTransferredEquityInterestsAcquired",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity agreement, percentage of equity interest issued or issuable.",
        "label": "Equity Agreement, Percentage of Equity Interest Issued or Issuable",
        "terseLabel": "Percentage of equity interest"
       }
      }
     },
     "localname": "EquityAgreementPercentageOfEquityInterestIssuedOrIssuable",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_EquityAgreementWarrantsIssuedOrIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued or issuable under the equity agreement.",
        "label": "Equity Agreement, Warrants Issued or Issuable",
        "terseLabel": "Warrants issuable"
       }
      }
     },
     "localname": "EquityAgreementWarrantsIssuedOrIssuable",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_ExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Agreement [Member]",
        "label": "Exchange Agreement [Member]"
       }
      }
     },
     "localname": "ExchangeAgreementMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_FacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for facility.",
        "label": "Facility [Member]"
       }
      }
     },
     "localname": "FacilityMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_FairMarketValueOfProperty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair market value of the property.",
        "label": "Fair Market Value of Property",
        "terseLabel": "Fair market value of property"
       }
      }
     },
     "localname": "FairMarketValueOfProperty",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_FinanceLeaseObligationOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Finance Lease Obligation, Other Information [Abstract]",
        "terseLabel": "Other Information"
       }
      }
     },
     "localname": "FinanceLeaseObligationOtherInformationAbstract",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Finance Lease ROU [Abstract]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetDisclosureAbstract",
     "nsuri": "http://www.ibioinc.com/20220930",
     "xbrltype": "stringItemType"
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finance Lease, Right Of Use Asset, Disclosure [Line Items]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetDisclosureLineItems",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about activity in the balance of lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right Of Use Asset, Disclosure [Table]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetDisclosureTable",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right Of Use Asset, Disclosure [Text Block]",
        "terseLabel": "Finance Lease ROU Assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetDisclosureTextBlock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_FinanceLeaseRightOfUseAssetGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of lessee's right to use underlying asset under finance lease, before accumulated amortization.",
        "label": "Finance Lease, Right Of Use Asset, Gross",
        "terseLabel": "ROU, gross"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetGross",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_FinancingCashFlowsFromFinanceLeaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for finance lease obligations.",
        "label": "Financing Cash Flows From Finance Lease Obligation",
        "terseLabel": "Financing cash flows from finance lease obligation"
       }
      }
     },
     "localname": "FinancingCashFlowsFromFinanceLeaseObligation",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_ForgivenessOfNotePayableAndAccruedInterestSbaLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness of note payable and accrued interest - SBA loan",
        "label": "Forgiveness of note payable and accrued interest - SBA loan",
        "negatedLabel": "Forgiveness of note payable and accrued interest - SBA loan"
       }
      }
     },
     "localname": "ForgivenessOfNotePayableAndAccruedInterestSbaLoan",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_GainLossRelatedToLitigationSettlementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure on gain (Loss) related to litigation settlement.",
        "label": "Gain Loss Related To Litigation Settlement [Text Block]",
        "terseLabel": "Fraunhofer Settlement"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementTextBlock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I Bio Inc Versus Fraunhofer United States of America Incorporated [Member].",
        "label": "iBio, Inc. v. Fraunhofer USA, Inc. [Member]"
       }
      }
     },
     "localname": "IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_IbioCdmoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Bioprocessing (iBio CDMO) [Member]"
       }
      }
     },
     "localname": "IbioCdmoMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_IbioCmoPreferredTrackingStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to IBio CMO Preferred Tracking Stock.",
        "label": "IBio CMO Preferred Tracking Stock"
       }
      }
     },
     "localname": "IbioCmoPreferredTrackingStockMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_IbioInc.2020OmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for iBio, Inc. 2020 Omnibus Equity Incentive Plan.",
        "label": "2020 Omnibus Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "IbioInc.2020OmnibusEquityIncentivePlanMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ImmuneOncologyAntibodiesRtx003Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immune-Oncology Antibodies (RTX-003) [Member]",
        "label": "Immune-Oncology Antibodies (RTX-003) [Member]"
       }
      }
     },
     "localname": "ImmuneOncologyAntibodiesRtx003Member",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_IncreaseDecreaeInOperatingLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increae (decrease) in operating lease obligations for new leases during the period.",
        "label": "Increase (Decreae) In Operating Lease Obligations",
        "terseLabel": "Increase in operating lease obligation for new lease"
       }
      }
     },
     "localname": "IncreaseDecreaeInOperatingLeaseObligations",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in finance lease obligations for new leases incurred during the period.",
        "label": "Increase (Decrease) In Finance Lease Obligations For New Leases",
        "terseLabel": "Increase in finance lease obligation for new leases"
       }
      }
     },
     "localname": "IncreaseDecreaseInFinanceLeaseObligationsForNewLeases",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_IncreaseDecreaseInInventoryReserve": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in inventory valuation reserve during the period.",
        "label": "Increase (Decrease) In Inventory Reserve",
        "terseLabel": "Inventory reserve"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventoryReserve",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_InterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to interest portion of the obligation.",
        "label": "Interest [Member]"
       }
      }
     },
     "localname": "InterestMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_IrrevocableLetterOfCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Irrevocable letter of credit",
        "label": "Irrevocable letter of credit",
        "terseLabel": "Irrevocable letter of credit"
       }
      }
     },
     "localname": "IrrevocableLetterOfCredit",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LeaseIncentiveForConstructionInProgress": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease incentive for construction in progress",
        "label": "Lease incentive for construction in progress",
        "terseLabel": "Lease incentive for construction in progress"
       }
      }
     },
     "localname": "LeaseIncentiveForConstructionInProgress",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease, Annual percentage increase in base rent",
        "label": "Lessee Operating Lease, Annual percentage increase in base rent",
        "verboseLabel": "Annual percentage increase in base rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Total",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Total",
        "totalLabel": "Imputed Interest, Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidTotal",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearFive",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 3.0,
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four.",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearFour",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 4.0,
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year One.",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearOne",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 5.0,
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearThree",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 6.0,
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearTwo",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Imputed Interest Payment, Due [Abstract]",
        "label": "Operating Lease Obligation, Imputed Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Principal And Imputed Interest",
        "label": "Lessee Operating Lease Liability Principal And Imputed Interest",
        "totalLabel": "Principal and imputed interest, Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]",
        "terseLabel": "Operating Lease Obligation, Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five",
        "totalLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five",
        "totalLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 3.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four",
        "totalLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 4.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One",
        "totalLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 5.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three",
        "totalLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 6.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two",
        "totalLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LesseeOperatingLeaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of rent payable monthly by the lessee under the operating lease.",
        "label": "Lessee, Operating Lease Monthly Rent",
        "terseLabel": "Operating lease monthly rent payable"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRent",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LessorFinanceLeaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of rent receivable monthly by the lessor under the finance lease.",
        "label": "Lessor, Finance Lease Monthly Rent",
        "terseLabel": "Mobile office trailer monthly rent"
       }
      }
     },
     "localname": "LessorFinanceLeaseMonthlyRent",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LetterOfCreditSanDiegoLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to letter of credit for sandiego lease.",
        "label": "Letter Of Credit - San Diego Lease [Member]"
       }
      }
     },
     "localname": "LetterOfCreditSanDiegoLeaseMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_LetterOfCreditTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to letter of credit term loan.",
        "label": "Letter Of Credit - Term Loan [Member]"
       }
      }
     },
     "localname": "LetterOfCreditTermLoanMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_LoansReceivableAmountInvested": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the face amount of notes receivable invested.",
        "label": "Loans Receivable, Amount Invested",
        "terseLabel": "Amount invested"
       }
      }
     },
     "localname": "LoansReceivableAmountInvested",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_LoansReceivableFixedRatesOfInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fixed rate of interest on notes.",
        "label": "Loans Receivable, Fixed Rates of Interest",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LoansReceivableFixedRatesOfInterest",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_NoBiosimilarProductHasBeenApprovedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Biosimilar Product has been Approved [Member]",
        "label": "No Biosimilar Product has been Approved [Member]"
       }
      }
     },
     "localname": "NoBiosimilarProductHasBeenApprovedMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_NonCashSettlementOfRevenueContract": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash Settlement of revenue contract",
        "label": "Non cash Settlement of revenue contract",
        "verboseLabel": "Settlement of revenue contract"
       }
      }
     },
     "localname": "NonCashSettlementOfRevenueContract",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase in Right Of Use Assets under the ASU 842, for which no cash outflow was incurred.",
        "label": "Non Cash Transaction Increase In Right Of Use Assets And Liabilities",
        "terseLabel": "Increase in operating lease ROU assets for new lease - net of lease incentive"
       }
      }
     },
     "localname": "NonCashTransactionIncreaseInRightOfUseAssetsAndLiabilities",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_NoncurrentLiabilitiesRelatedToAssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent liabilities related to assets held for sale.",
        "label": "Noncurrent Liabilities Related To Assets Held For Sale",
        "terseLabel": "Noncurrent liabilities related to assets held for sale"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesRelatedToAssetsHeldForSale",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_NotesPayablePppLoanDisclosureTextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of notes payable PPP loan.",
        "label": "Notes Payable Ppp Loan Disclosure Text Block",
        "verboseLabel": "Note Payable - PPP Loan"
       }
      }
     },
     "localname": "NotesPayablePppLoanDisclosureTextblock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureNotePayablePppLoan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock.",
        "label": "Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock",
        "terseLabel": "Number of LLC interest units exchanged for each share of preferred tracking stock"
       }
      }
     },
     "localname": "NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_NumberOfMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to number of major customers.",
        "label": "Number of Major Customers",
        "terseLabel": "Number of major customers"
       }
      }
     },
     "localname": "NumberOfMajorCustomers",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ibio_OperatingCashFlowsFromOperatingLeaseObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating cash flows from operating lease obligation.",
        "label": "Operating Cash Flows From Operating Lease Obligation",
        "terseLabel": "Operating cash flows from operating lease obligation"
       }
      }
     },
     "localname": "OperatingCashFlowsFromOperatingLeaseObligation",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_OperatingLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Operating Lease Costs [Abstract]",
        "terseLabel": "Operating lease cost:"
       }
      }
     },
     "localname": "OperatingLeaseCostsAbstract",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_OperatingLeaseObligationOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Lease Obligation Other Information [Abstract]",
        "verboseLabel": "Other information:"
       }
      }
     },
     "localname": "OperatingLeaseObligationOtherInformationAbstract",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset Disclosure [Text Block]",
        "terseLabel": "Operating Lease ROU Assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetDisclosureTextBlock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_PercentageOfLegalFeesExpectedToBeReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of legal fees expected to be received.",
        "label": "Percentage Of Legal Fees Expected to be Received",
        "terseLabel": "Percentage of legal fees expected to be received"
       }
      }
     },
     "localname": "PercentageOfLegalFeesExpectedToBeReceived",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ibio_PreferredTrackingStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "iBio CMO Preferred Tracking Stock [Member]"
       }
      }
     },
     "localname": "PreferredTrackingStockMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_PrincipalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to principal portion of the obligation.",
        "label": "Principal [Member]"
       }
      }
     },
     "localname": "PrincipalMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ProceedsFromIssuanceOfPreferredAndCommonStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Preferred And Common Stock",
        "terseLabel": "Proceeds from sales of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredAndCommonStock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from options exercised included in prepaid expenses and other current assets.",
        "label": "Proceeds from options exercised included in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "ProceedsFromOptionsExercisedIncludedInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.",
        "label": "Purchase Price For Property, Termination of Sublease And Equity Interest",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.",
        "label": "Purchase Price For Property, Termination of Sublease And Equity Interest, Cash Payment",
        "terseLabel": "Cash payment"
       }
      }
     },
     "localname": "PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_RightOfUseAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of accounting policy for right-of-use assets.",
        "label": "Right Of Use Assets Policy [Policy Text Block]",
        "terseLabel": "Right-of-Use Assets"
       }
      }
     },
     "localname": "RightOfUseAssetsPolicyPolicyTextBlock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_RubrycTheraputicsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RubrYc Theraputics, Inc. [Member]",
        "label": "RubrYc Theraputics, Inc. [Member]"
       }
      }
     },
     "localname": "RubrycTheraputicsInc.Member",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ScenarioOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for scenario one in which the value of maximum award in calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors.",
        "label": "Scenario One [Member]"
       }
      }
     },
     "localname": "ScenarioOneMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ScenarioPlanExpectedLegalFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Plan, Expected Legal Fees [Member].",
        "label": "Scenario Plan Expected Legal Fees [Member]"
       }
      }
     },
     "localname": "ScenarioPlanExpectedLegalFeesMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ScenarioPlanExpectedPaymentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Plan Expected Payment One [Member].",
        "label": "Scenario Plan Expected Payment One [Member]"
       }
      }
     },
     "localname": "ScenarioPlanExpectedPaymentOneMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ScenarioPlanExpectedPaymentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Plan Expected Payment Two [Member].",
        "label": "Scenario Plan Expected Payment Two [Member]"
       }
      }
     },
     "localname": "ScenarioPlanExpectedPaymentTwoMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ScenarioTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents Preferred tracking stock exchanged for units.",
        "label": "Scenario Two [Member]"
       }
      }
     },
     "localname": "ScenarioTwoMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.",
        "label": "Schedule Of Components Of Lease Expense And Supplemental Balance Sheet Information Related To Finance Lease Obligation [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation",
        "label": "Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation [Table Text Block]",
        "terseLabel": "Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to schedule of finance lease right of use assets and obligation and weighted average information.",
        "label": "Schedule of Finance Lease Right of use Assets and Obligation and Weighted average Information [Table Text Block]",
        "terseLabel": "Schedule of finance lease and weighted average information"
       }
      }
     },
     "localname": "ScheduleOfFinanceLeaseRightOfUseAssetsAndObligationAndWeightedAverageInformationTableTextBlock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_SecuredTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to secured term loan.",
        "label": "Secured Term Loan"
       }
      }
     },
     "localname": "SecuredTermLoanMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_Series2PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 Preferred Stock [Member]",
        "label": "Series A-2 Preferred Stock [Member]"
       }
      }
     },
     "localname": "Series2PreferredStockMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_SettlementAssetsNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement receivables, Non current portion.",
        "label": "Settlement Assets Non Current",
        "terseLabel": "Settlement receivable - noncurrent portion"
       }
      }
     },
     "localname": "SettlementAssetsNonCurrent",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_SettlementOfRevenueContract": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of revenue contract.",
        "label": "Settlement of revenue contract",
        "negatedLabel": "Settlement of revenue contract"
       }
      }
     },
     "localname": "SettlementOfRevenueContract",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized",
        "terseLabel": "Maximum value of all awards awarded under the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_SignificantTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Transactions [Abstract]",
        "label": "Significant Transactions [Abstract]"
       }
      }
     },
     "localname": "SignificantTransactionsAbstract",
     "nsuri": "http://www.ibioinc.com/20220930",
     "xbrltype": "stringItemType"
    },
    "ibio_SignificantTransactionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Transactions [Text Block]",
        "label": "Significant Transactions [Text Block]",
        "verboseLabel": "Significant Transactions"
       }
      }
     },
     "localname": "SignificantTransactionsTextBlock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_StockIssuedDuringPeriodSharesCapitalRaise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new shares raised during the period.",
        "label": "Stock Issued During Period, Shares, Capital Raise",
        "terseLabel": "Capital raise (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCapitalRaise",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_StockIssuedDuringPeriodValueCapitalRaise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of capital raise during the period.",
        "label": "Stock Issued During Period, Value, Capital Raise",
        "terseLabel": "Capital raise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCapitalRaise",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement [Member]",
        "label": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ibio_StockPurchaseAgreementNumberOfSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement, number of shares purchased",
        "label": "Stock purchase agreement, number of shares purchased",
        "terseLabel": "Stock purchase agreement, number of shares purchased"
       }
      }
     },
     "localname": "StockPurchaseAgreementNumberOfSharesPurchased",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_StockPurchaseAgreementValueOfSharesPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement, value of shares purchased",
        "label": "Stock purchase agreement, value of shares purchased"
       }
      }
     },
     "localname": "StockPurchaseAgreementValueOfSharesPurchased",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_StockPurchaseAgreementValueOfSharesToBePurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement, value of shares to be purchased",
        "label": "Stock purchase agreement, value of shares to be purchased",
        "terseLabel": "Stock purchase agreement, value of shares to be purchased",
        "verboseLabel": "Unpaid portion of RubrYc transaction"
       }
      }
     },
     "localname": "StockPurchaseAgreementValueOfSharesToBePurchased",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_StockholdersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityLineItems",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_StockholdersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Table]"
       }
      }
     },
     "localname": "StockholdersEquityTable",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.",
        "label": "Summary Of Gross Carrying Value And Accumulated Amortization Of Finance Lease, Right Of Use Assets [Table Text Block]",
        "terseLabel": "Summary of the gross carrying value and accumulated amortization of finance lease ROU"
       }
      }
     },
     "localname": "SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ibio_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ibio_TotalOperatingLeaseCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total operating lease costs.",
        "label": "Total Operating Lease Costs",
        "terseLabel": "Total lease cost"
       }
      }
     },
     "localname": "TotalOperatingLeaseCosts",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_UnconsolidatedGainLossAttributableToStockholders": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unconsolidated net gain (loss) attributable to stockholders.",
        "label": "Unconsolidated Gain (Loss) Attributable To Stockholders",
        "totalLabel": "Net loss available to iBio, Inc. stockholders"
       }
      }
     },
     "localname": "UnconsolidatedGainLossAttributableToStockholders",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid fixed assets included in accounts payable, attributable to discontinued operations.",
        "label": "Unpaid Fixed Assets Attributable To Discontinued Operations",
        "terseLabel": "Unpaid fixed assets included in accounts payable"
       }
      }
     },
     "localname": "UnpaidFixedAssetsAttributableToDiscontinuedOperations",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_UnpaidFixedAssetsIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unpaid fixed assets included in accounts payable.",
        "label": "Unpaid Fixed Assets Included In Accounts Payable",
        "terseLabel": "Unpaid fixed assets included in accounts payable"
       }
      }
     },
     "localname": "UnpaidFixedAssetsIncludedInAccountsPayable",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued for the final payment of rent due under sublease.",
        "label": "Warrants Issued for Final Payment of Sublease Rent",
        "terseLabel": "Shares issued under the Warrant"
       }
      }
     },
     "localname": "WarrantsIssuedForFinalPaymentOfSubleaseRent",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of warrants issued for the final payment of rent due under sublease.",
        "label": "Warrants Issued for Final Payment of Sublease Rent, Value",
        "terseLabel": "Fair value of the warrant"
       }
      }
     },
     "localname": "WarrantsIssuedForFinalPaymentOfSubleaseRentValue",
     "nsuri": "http://www.ibioinc.com/20220930",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r63",
      "r65",
      "r118",
      "r119",
      "r270",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r269",
      "r289",
      "r337",
      "r339",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r533",
      "r535",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r269",
      "r289",
      "r337",
      "r339",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r533",
      "r535",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r186",
      "r245",
      "r246",
      "r318",
      "r321",
      "r488",
      "r532",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r186",
      "r245",
      "r246",
      "r318",
      "r321",
      "r488",
      "r532",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r237",
      "r244",
      "r245",
      "r246",
      "r247",
      "r269",
      "r289",
      "r323",
      "r337",
      "r339",
      "r370",
      "r371",
      "r372",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r533",
      "r535",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r237",
      "r244",
      "r245",
      "r246",
      "r247",
      "r269",
      "r289",
      "r323",
      "r337",
      "r339",
      "r370",
      "r371",
      "r372",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r533",
      "r535",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r64",
      "r65",
      "r118",
      "r119",
      "r270",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r130",
      "r135",
      "r243",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r130",
      "r135",
      "r243",
      "r338",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r52",
      "r474"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r189",
      "r190"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "verboseLabel": "Accounts receivable - trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r45",
      "r69",
      "r70",
      "r71",
      "r520",
      "r540",
      "r541"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r68",
      "r71",
      "r76",
      "r77",
      "r78",
      "r122",
      "r123",
      "r124",
      "r420",
      "r468",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Loss [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r379",
      "r380",
      "r381",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r342",
      "r384",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile consolidated net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Allocated Share-based Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r89",
      "r103",
      "r282",
      "r444"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of premiums on debt securities",
        "verboseLabel": "Amortization of premiums on debt securities"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r103",
      "r216",
      "r223"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "verboseLabel": "Area of lab and office"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Purchase price allocated"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of asset acquisition.",
        "label": "Asset Acquisition [Table Text Block]",
        "terseLabel": "Summary of Purchase Price Allocation of Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r36",
      "r115",
      "r175",
      "r178",
      "r184",
      "r209",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r415",
      "r421",
      "r436",
      "r472",
      "r474",
      "r504",
      "r519"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r30",
      "r50",
      "r115",
      "r209",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r415",
      "r421",
      "r436",
      "r472",
      "r474"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "auth_ref": [
      "r226",
      "r474"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.",
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Current assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r19",
      "r21",
      "r25",
      "r228",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]",
        "terseLabel": "Other assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r200",
      "r211"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Adjusted cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss",
        "terseLabel": "Unrealized loss on available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r204"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after Two Years, Fair Value",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Premium on Purchased Options [Policy Text Block]",
        "verboseLabel": "Investments in Debt Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesPurchasedOptionsPricePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpenditureDiscontinuedOperations": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital expenditure attributable to discontinued operations.",
        "label": "Capital Expenditure, Discontinued Operations",
        "terseLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "CapitalExpenditureDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r29",
      "r33",
      "r105"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r98",
      "r105",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - end",
        "periodStartLabel": "Cash, cash equivalents - beginning"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r98",
      "r437"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "verboseLabel": "Amount in excess of insured limit"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r112",
      "r115",
      "r139",
      "r140",
      "r141",
      "r144",
      "r146",
      "r155",
      "r156",
      "r157",
      "r209",
      "r255",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r287",
      "r288",
      "r292",
      "r296",
      "r302",
      "r436",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants, exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants issued",
        "verboseLabel": "Warrants to purchase shares of Common Stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r249",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total number of shares of common stock reserved"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "verboseLabel": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r42",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, Shares, Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r42",
      "r474"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Value of common stock issued",
        "verboseLabel": "Common stock - $0.001 par value; 275,000,000 shares authorized at September 30, 2022 and June 30, 2022; 9,006,582 and 8,727,158 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee 401(K) Plan [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r73",
      "r75",
      "r83",
      "r414",
      "r425",
      "r511",
      "r529"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r188",
      "r434",
      "r435",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r188",
      "r434",
      "r435",
      "r542",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r188",
      "r434",
      "r435",
      "r542",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r161",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r188",
      "r434",
      "r435",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r308",
      "r309",
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, Net, Current",
        "verboseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized included in contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r164",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r114",
      "r120",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r446",
      "r505",
      "r506",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r266",
      "r283",
      "r284",
      "r445",
      "r446",
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Secured term loan"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r57",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r58",
      "r114",
      "r120",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecurities2Details": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading), classified as current.",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair value",
        "totalLabel": "Fair value",
        "verboseLabel": "Investments in debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesComponentsOfInvestmentsInDebtSecuritiesDetails",
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesDebtSecuritiesContractualMaturityDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r103",
      "r229"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation of fixed assets"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "auth_ref": [
      "r18",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.",
        "label": "Depreciation and Amortization, Discontinued Operations",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r344",
      "r345",
      "r376",
      "r377",
      "r378",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation [Member]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease ROU Assets [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r19",
      "r21",
      "r25",
      "r227",
      "r233"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Noncurrent assets held for sale",
        "verboseLabel": "Total other assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r17",
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": {
     "auth_ref": [
      "r17",
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)",
        "terseLabel": "Gross profit"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "auth_ref": [
      "r8",
      "r9",
      "r17",
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "negatedLabel": "Interest expense - term note payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r19",
      "r228",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "terseLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "negatedLabel": "Total other expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r19",
      "r228",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r19",
      "r227",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r17",
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]",
        "terseLabel": "Results of operations for discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r27",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsPreferredStockStock": {
     "auth_ref": [
      "r304",
      "r516"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.",
        "label": "Dividends, Preferred Stock, Stock",
        "negatedLabel": "Preferred stock dividends- iBio CDMO Tracking Stock",
        "negatedNetLabel": "Preferred stock dividends - iBio CMO Preferred Tracking Stock"
       }
      }
     },
     "localname": "DividendsPreferredStockStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Common Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r84",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r136",
      "r139",
      "r144",
      "r145",
      "r146",
      "r150",
      "r151",
      "r431",
      "r432",
      "r512",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - total",
        "verboseLabel": "Per share amount basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic and diluted denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r84",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r139",
      "r144",
      "r145",
      "r146",
      "r150",
      "r151",
      "r431",
      "r432",
      "r512",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - total",
        "verboseLabel": "Per share amount diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (Loss) Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "verboseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "verboseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r76",
      "r77",
      "r78",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r154",
      "r210",
      "r302",
      "r304",
      "r379",
      "r380",
      "r381",
      "r393",
      "r394",
      "r430",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r468",
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Fair Value Measurement [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r452",
      "r458",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Finance lease obligations - current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Payments Under the Finance Lease Obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "presentationGuidance": "Finance lease obligation - non-current portion",
        "terseLabel": "Finance lease obligations - net of current portion",
        "verboseLabel": "Finance lease obligation - net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r453",
      "r460"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of finance lease obligation"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Finance lease right-of-use assets, net of accumulated amortization",
        "totalLabel": "Net finance lease ROU",
        "verboseLabel": "Finance lease ROU assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r452",
      "r458"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r452",
      "r458",
      "r466"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "presentationGuidance": "Amortization of ROU assets",
        "terseLabel": "Amortization of finance lease right-of-use assets",
        "verboseLabel": "Amortization of finance lease ROU assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r463",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - Finance lease obligation"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r462",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - finance lease"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialStandbyLetterOfCreditMember": {
     "auth_ref": [
      "r250",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation if defined events occur or fail to occur.",
        "label": "Letter of Credit"
       }
      }
     },
     "localname": "FinancialStandbyLetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r34",
      "r222"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-Lived Intangible Assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r217",
      "r218",
      "r222",
      "r224",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r222",
      "r490"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite-Lived Intangible Assets, gross carrying value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r217",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r222",
      "r489"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Total",
        "totalLabel": "Total definite lived intangible assets, net of accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsEstimatedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainContingencyUnrecordedAmount": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.",
        "label": "Gain Contingency, Unrecorded Amount",
        "terseLabel": "Estimated net cash recovery"
       }
      }
     },
     "localname": "GainContingencyUnrecordedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fraunhofer Settlement [Abstract]"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative (related party of $0 and $189)"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Intangible asset impairment"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of guarantee.",
        "label": "Guarantor Obligations, Nature [Axis]"
       }
      }
     },
     "localname": "GuaranteeObligationsByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.",
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "verboseLabel": "Irrevocable letter of credit"
       }
      }
     },
     "localname": "GuaranteeObligationsMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees.",
        "label": "Guarantor Obligations, Nature [Domain]"
       }
      }
     },
     "localname": "GuaranteeObligationsNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r86",
      "r104",
      "r127",
      "r128",
      "r129",
      "r130",
      "r142",
      "r146",
      "r413"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net loss attributable to iBio, Inc.",
        "totalLabel": "Net loss attributable to iBio, Inc. from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r411",
      "r414"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r115",
      "r125",
      "r175",
      "r177",
      "r180",
      "r183",
      "r185",
      "r209",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r414",
      "r432",
      "r436"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Consolidated Gain (Loss) From Continuing Operations",
        "totalLabel": "Consolidated net loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r79",
      "r84",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r139",
      "r144",
      "r145",
      "r432",
      "r508",
      "r509",
      "r512",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r79",
      "r84",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r139",
      "r144",
      "r145",
      "r146",
      "r432",
      "r512",
      "r525",
      "r528",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r10",
      "r22",
      "r25",
      "r399",
      "r526"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ibio_UnconsolidatedGainLossAttributableToStockholders",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r81",
      "r84",
      "r140",
      "r144",
      "r145",
      "r512",
      "r526",
      "r528",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r140",
      "r144",
      "r145",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r232",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r116",
      "r390",
      "r391",
      "r392",
      "r395",
      "r397",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r117",
      "r133",
      "r134",
      "r174",
      "r388",
      "r396",
      "r398",
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable - trade"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r102",
      "r485"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory.",
        "label": "Increase (Decrease) in Finished Goods and Work in Process Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r102",
      "r460"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses - noncurrent"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r215",
      "r220"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Total net intangible assets",
        "verboseLabel": "Intangible assets, net of accumulated amortization"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r95",
      "r100",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Net",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r49",
      "r110",
      "r153",
      "r212",
      "r213",
      "r214",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r88",
      "r173"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentInterestRate": {
     "auth_ref": [
      "r203",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of interest on investment.",
        "label": "Interest Rate",
        "verboseLabel": "Debt securities, interest rate"
       }
      }
     },
     "localname": "InvestmentInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_InvestmentMaturityDate": {
     "auth_ref": [
      "r202",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity date of investment, in YYYY-MM-DD format.",
        "label": "Investment Maturity Date",
        "verboseLabel": "Debt securities, maturity date"
       }
      }
     },
     "localname": "InvestmentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Schedule of fair value of available-for-sale debt securities, by contractual maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r207",
      "r503",
      "r514",
      "r543",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Investments in Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r464",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFinanceLeaseCostAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasePracticalExpedientsPackage": {
     "auth_ref": [
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.",
        "label": "Lease, Practical Expedients, Package [true false]"
       }
      }
     },
     "localname": "LeasePracticalExpedientsPackage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Obligation [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Finance Lease Obligation"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Future Minimum Payments under the Operating Lease Obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 1.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "order": 2.0,
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Operating Lease Obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r54",
      "r115",
      "r179",
      "r209",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r416",
      "r421",
      "r422",
      "r436",
      "r472",
      "r473"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r48",
      "r115",
      "r209",
      "r436",
      "r474",
      "r507",
      "r522"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r56",
      "r115",
      "r209",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r416",
      "r421",
      "r422",
      "r436",
      "r472",
      "r473",
      "r474"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndMaintenanceMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and process of preserving asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Maintenance [Member]"
       }
      }
     },
     "localname": "LicenseAndMaintenanceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation settlement, amount awarded from other party",
        "terseLabel": "Settlement income"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "Convertible Promissory Note Receivable"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r158",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r98",
      "r101",
      "r104"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r72",
      "r74",
      "r78",
      "r82",
      "r104",
      "r115",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r133",
      "r134",
      "r142",
      "r175",
      "r177",
      "r180",
      "r183",
      "r185",
      "r209",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r432",
      "r436",
      "r510",
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Basic and diluted numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r72",
      "r74",
      "r78",
      "r133",
      "r134",
      "r418",
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r136",
      "r137",
      "r143",
      "r146",
      "r175",
      "r177",
      "r180",
      "r183",
      "r185"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ibio_UnconsolidatedGainLossAttributableToStockholders",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss available to iBio, Inc. stockholders",
        "totalLabel": "Net loss attributable to iBio, Inc. stockholders from continuing operations"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Investing noncash transactions:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r304",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Abstract]"
       }
      }
     },
     "localname": "NotesPayableAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Term note payable - net of deferred financing costs",
        "verboseLabel": "Note payable PPP loan"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureNotePayablePppLoanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsAmendedCreditAgreementDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Convertible Promissory Note Receivable [Member]"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r175",
      "r177",
      "r180",
      "r183",
      "r185"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r459",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Obligation, Principal"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "verboseLabel": "Operating lease obligation - current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r451"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease obligation - net of current portion",
        "verboseLabel": "Long-term portion of minimum lease obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r454",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease ROU assets",
        "verboseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsCategoryNetCarryingValuesOfOperatingLeaseRouDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "verboseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r28",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r66",
      "r67",
      "r69"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Other comprehensive loss - unrealized loss on debt securities",
        "verboseLabel": "Unrealized loss on available-for-sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Investing and Financing Items [Abstract]",
        "verboseLabel": "Schedule of non-cash activities:"
       }
      }
     },
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents and Licenses [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r90",
      "r92",
      "r199"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of debt securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Payment for RubrYc asset acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r96",
      "r208"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "negatedLabel": "Purchase of equity security"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Employee 401(K) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "verboseLabel": "Preferential dividend rate percentage"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsPerShareDeclared": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding.",
        "label": "Preferred Stock, Dividends Per Share, Declared"
       }
      }
     },
     "localname": "PreferredStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r41",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred Stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r41",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r41",
      "r474"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Series 2022 Convertible Preferred Stock - $.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of September 30, 2022 and June 30, 2022, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "verboseLabel": "Prepaid expenses - noncurrent"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for the settlement of litigation during the current period.",
        "label": "Proceeds from Legal Settlements",
        "terseLabel": "Settlement payment received"
       }
      }
     },
     "localname": "ProceedsFromLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r90",
      "r91",
      "r199"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "verboseLabel": "Redemption of debt securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r25",
      "r72",
      "r74",
      "r78",
      "r97",
      "r115",
      "r125",
      "r133",
      "r134",
      "r175",
      "r177",
      "r180",
      "r183",
      "r185",
      "r209",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r414",
      "r417",
      "r419",
      "r424",
      "r425",
      "r432",
      "r436",
      "r513"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Consolidated net loss",
        "disclosureGuidance": "Net loss including portion attributable to noncontrolling interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Consolidated net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r236",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r231",
      "r474",
      "r515",
      "r523"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Net fixed assets",
        "verboseLabel": "Fixed assets, net of accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r231",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsSummaryOfFinanceLeaseRouDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Fixed assets, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForLossOnContracts": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative provision for contract losses not offset against related costs accumulated on the balance sheet.",
        "label": "Provision for Loss on Contracts",
        "verboseLabel": "Provisions for contract loss"
       }
      }
     },
     "localname": "ProvisionForLossOnContracts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Receivable [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r327",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "verboseLabel": "Operating expenses general and administrative, related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r327",
      "r469",
      "r471",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r387",
      "r487",
      "r552"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r33",
      "r105",
      "r108"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Collateral held"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r35",
      "r108",
      "r544"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r44",
      "r304",
      "r474",
      "r521",
      "r539",
      "r541"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r210",
      "r379",
      "r380",
      "r381",
      "r393",
      "r394",
      "r430",
      "r536",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r165",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r80",
      "r115",
      "r171",
      "r172",
      "r176",
      "r181",
      "r182",
      "r186",
      "r187",
      "r188",
      "r209",
      "r255",
      "r256",
      "r257",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r436",
      "r513"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRevenueDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r461",
      "r466"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Increase in finance lease ROU assets for new leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of shares, net of issuance cost"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The scenario under which facts represent plans as distinct from actual.",
        "label": "Scenario, Plan [Member]"
       }
      }
     },
     "localname": "ScenarioPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureConvertiblePromissoryNoteReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of components of investments in debt securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of of total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r3",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r20",
      "r23",
      "r24",
      "r25",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of discontinued operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings (loss) Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r374",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r217",
      "r221",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r217",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "verboseLabel": "Schedule of Category the gross carrying value and accumulated amortization of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r341",
      "r343",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "verboseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair value of options granted using the Black-Scholes option pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "verboseLabel": "Security deposits"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettlementAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.",
        "label": "Settlement Assets, Current",
        "verboseLabel": "Settlement receivable - current portion"
       }
      }
     },
     "localname": "SettlementAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation.",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r348",
      "r367",
      "r368",
      "r369",
      "r370",
      "r373",
      "r382",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Share-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r109",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r112",
      "r115",
      "r139",
      "r140",
      "r141",
      "r144",
      "r146",
      "r155",
      "r156",
      "r157",
      "r209",
      "r255",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r287",
      "r288",
      "r292",
      "r296",
      "r302",
      "r436",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r61",
      "r76",
      "r77",
      "r78",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r134",
      "r154",
      "r210",
      "r302",
      "r304",
      "r379",
      "r380",
      "r381",
      "r393",
      "r394",
      "r430",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r468",
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "verboseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "verboseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r154",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtAndEquitySecuritiesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r41",
      "r42",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r60",
      "r277",
      "r302",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Conversion of preferred stock to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r41",
      "r42",
      "r302",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Vesting of RSU's (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r42",
      "r302",
      "r304",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Stock Options, Exercised",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r302",
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r42",
      "r46",
      "r47",
      "r115",
      "r196",
      "r209",
      "r436",
      "r474"
     ],
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total iBio, Inc. Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "iBio, Inc. Stockholders' Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r77",
      "r115",
      "r122",
      "r123",
      "r124",
      "r126",
      "r132",
      "r209",
      "r210",
      "r304",
      "r379",
      "r380",
      "r381",
      "r393",
      "r394",
      "r411",
      "r412",
      "r423",
      "r430",
      "r436",
      "r438",
      "r439",
      "r443",
      "r468",
      "r537",
      "r538"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Member]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r113",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r304",
      "r306",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, shares received per share tendered"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossParenthetical"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r475",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r524"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "verboseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r159",
      "r160",
      "r162",
      "r163",
      "r167",
      "r168",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r138",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r136",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126982154&loc=d3e400-110220"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2510-110228"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907419&loc=d3e10037-110241"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e12803-110250"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "35",
   "Topic": "605",
   "URI": "https://asc.fasb.org/extlink&oid=126916656&loc=d3e57777-111642"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=6435544&loc=d3e41834-113960"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r553": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r554": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r555": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r556": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r557": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r558": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r559": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>108
<FILENAME>0001558370-22-017874-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-017874-xbrl.zip
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M'&9+L;P\:.R4-H;R H<1XY<T^GT.K23PU=M6SW*+(YSWA[F7M"X3J >$-)I
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M4S&]3,)XO+S5-KJX7)EF;+$JBJG6L$K1^5]E]=0GWS8NV' 1KE2233]3J%C
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M.CH]W4,0E,"SB!=SQW"X@_H+-#UC1>:E1P<9?\Z12;II^_&/G&/__*KU\<+
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MP-$?ESD5UQT/P 9$1O2Z]A5X R;RDJL&;##=VYPZ"JN5JYPLQ[8LFPI:Z:_
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M?EGQKI^[OH;(?UY(3W[]/U!+ P04    "  KBVY5?#$&<CXO  !2M ( %0
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MFR:W/+V6,@A"3NZ#\3*HKLLMSSILCT0I,::+1^C9FJ'*&6I8UH>1.IJ0#?O
M(XGK; PSV5O7XH-Y-=%0?UWZ('8IWB\QR3=?5\D3+'/AFB_HT@I\>/MFU+G
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MF-[1'>&B_5R<#O1?O\FC_2$&6OQOSQG=J8>.L^Q[P/\^H4_P[8'WGX#WM_\
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MZA0_X@G0'<V++-H6E*<I/S$M,2JJ'AQ'9X?8E]57![NZ)IL9Z>E* \Z3W>#
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M& FGF-V67U&]GO;"(ESE;6XP#HDG0R(K<)]II0HW8'A*W.7!H,:MBZ_(NNS
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M\.;DX!"B?KX\)\<D9$8-ARWG]Y_)/_W]CQM>8_/E.=H^,Y47RU)Z+/CYS9<
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M$ XOB,%E7L;IEZN$13=[KH(#UX6LL7%"?$?AY,#>$G7U<-Z)K_[R)F&+:GK
M)Q(!]%>?9A1P6[51@WY6%0&<AYZN$B8XS0LX_OU$=>;4@\)Z>E3);/MIT18(
MPM.ABO$513\"BE<&\!Z[6 _QVG#+[9$O%;VRLZKD@U/!N5V:/05)]#=N0G T
MF<91* PR"=E"FE<QR\VNO+ 7Q/?L+U2\ZS)PZ70>VDAW4>><F-85U3D(KW]S
M=3ZN^SO.@%<!L8U9U9#:L%JMTY.+<W2S*R]3]"\WF0"1>FQI66[UTNI!K=\S
M2\."02T:4/+K _U:D'?LL_^&]7RE._^56L^89W@7Y%'.>T36IJ?QQL/@")D
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MP#T9<=)7]''XT&D(&"EI962]E:]20JZ?JC*PH6[0+VO]$JDI7JU4OB1T>SA
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M?G^&S@-'%;KTT(]_)C1%8(6 2&_9L57I2"^98D+2"(*ROT3%\\4Q+](][!-
MAJ$ R94(U@MX8T1M/X[G0@'AW3QW]GJ*61(!O4R?Q+,,_EG>4I+.6.I4\27Z
M6IGMR 8!H9#)2H2Z;LD(C5.F9,'20/5J(-PT7-P]"-V'YM3;DJYH0IVO7(<T
M1JH*I^Y\B&W)<TFR@,56?0PBZF*V)BQ$VQT6IF? >A1<*Q[B:YHIQPUU)'MV
MEJ\V!0G3,\N>12;$)B*BNX-=%&S$P&P?8A2BWSM$"8[4.,3 B[9K2-4K!-L0
MID@"L#CG]D'^#'4'['_@DOM+$$/2TLX +'&1SNI=!&N=TML@KG\^;\]5W\<R
M)%$( _^0T/W;Z$T5<].3D0M^1_,BB[;\*AK['<72SJNW#B_3[)[QUCRS><NF
M\1GNB=T<(";*;QFKYC3G2%HXECA)<-DR1Q%:W5(G<*ENB-P0V)":^!D+9L_R
M@*=),[J/CGNX35./0,HA5K-LBTJW.2=F_G=K9[@R .=]:7:R6SSUX'BO7YO8
M[[Y>K8)%>7U:SXA2:SBX?PO?6$F0#A%RRE0+5NKW](7&*7\FYL-7J" T+UQ6
MF%C'!=9"M<\(!M$0#@8L>5+DR 4FCYHD7%(B^V<X\\LZ8XJQ\U!>&<A:9!DM
M$1$2C4XBU;E&*RR<=*,#:\KW+$.+K"-_U/(LW9W!HY8HAPA3I.R_3)E[XP;F
M$0X^32.<7^\%VH63]NB>O1-H$6[:XOKS/J"=ZAG?!O1OI9THK<]O W;_VQC#
MCJ#CW2-L9H$MWV%3$_'I*383AXZOL6U4?_+-1.>:"C_>:6MZ;LFWTT2.B$NX
M9<XG>J'@D,PF.XH24JW_>*%;MP#<R:Q_/V LCYI>:X^]7FN;,@]:FG1)CR^W
M_H2PZTT'TLU@SG@F6NI%^6\7&0VC OZE.P0R86#=_!T4HGW35PN.<+-W@!=5
M34:#00!P0P12^1^^6<Y$$7/>M[(1$,5,/M$OYW7N@(7:"?OGEM_6M,H:C2>#
M8U!CQ96MS)7&ZJ8WCL'^LXCT"VGHD#8A_ZQQ)JGAHD12Q"=RE>='V#GJ9@ G
M-MT^T_ 8TYO=^R@_I'D0_Y*EQP,+L[?Q,61,0C$B[\IQA&--6GH:T=7IO@@*
M<1$[B.&9MOMG2F%'?1Z&O"P]B)M2QN';JAB<(,7&>)/>BJW79V/]V!Q+1E55
M+Q^?" 9@'UZR0&0>2,,$^?6!OR"+[@G]F<2*$XAT0GG6TGI49#>JKOSB']+>
M ]H1P79>+J*J_8X-!4278<^>45&U=8L>&OA,(K/_5Z0%<W9;7LP(_Y?03C%C
MUA0S;K&*&1\8[9O=>98Q043/\:^1KL^ !A;I#K:)\=:=:Q7@^G>L]5PH]K0Q
MPT[!G;]0(N%PK9'_6]RY+IZ#A+21?@7R.$U:)/Z@$=XGML U?WE@_\J#+5^G
MQ(,JNAI#5RI();'CA&T5P[J16+\,=@Q_B^CT^W0?1,F<SQKPQP&KHM7SIXQR
M%I2*:0&/4,1C(T!=NV,"QBG9&>9(_9YC71]-:B3M TW+EN.L(<&4NK7C8W;:
M/C"+"@['(MK"EN0[O7X;P3%JU(;9;RK3]+!(]6A##/4S90SCW[=$0N&;Y.^0
M='L% =:)2.#D^WS+HN^<;[BM]J)#2$CQAI4HK?#"B+%^-&'!3K_G#B 1"<N;
M?>,H<>Z/^WV0G6"/6*\"_*8,.8^Y!8"$[,>>V,B9'?V]'^C$DFRC. JL[6LZ
M6>SLS[3I4.>#QM%$S!!-8=B80.E?D)/NA9$V\;7<@<7=N!5F9ION#VG"LTCL
MOZ+V!;H0+M#E^!?H2I8NXB#/HUU$PW>GJD/$,8@_!@4P>'H?%-3*6TPCB7<1
M;^HT="_KC:6'<J%O&K/&JZ(-3?)X(A)54I$E0-<CQ[# A,A.81=$&7D)XJ.X
MO-)WGAW'L(%YVTKSMB]'GS.[(N*<F]TO69KG%T&6G:+DZ<_ )!Q_;=G^Z<B?
MJ#O?IUD1_4V4R>TNHP2.R7@OC>Z%$*.S6&M0C#S/6E/9)(N6'A$IX[2.6,H+
M9D7PR&AG\D4SN%-6L)^>@!NR+=DI#1DRHT'#$0DDEL#*Q66T(I4NHY%C$M*,
M[ 2[) 9^5[Z@AC7#U:[J9D?XR*0:FO"QR7G"2X_JV92'!Z22 =&%:$-4=^6P
M=YU>S"^<;([5V)9>DKN;S\@[6C8I44&OHQ?:NV;AN(EUH(2];W466KU5M2:#
MN#MUY-$880E:9YQ8_PJ11Y'F,N)?,(-^2IG]CS;^J)FS8.X6H%+]1KT[OMEQ
M9U=V$&"^\?YX.(B'C(-8KL6Z2M@RO!<UY]6;R;*[O'F,R_>3+<)/'$8P0E+,
M*6_"5 PND$)7/%%=PMEV>DJL]%3PQUU$+G%('@6+) <>F8>HF93?D >/TXX<
MTIK;M8-;C[Y![9U9D-IP __%J56=7GC@*[-$2IX(9XI(7,E/V[?"8=*PYDD0
M[.-WZ.5FEU;^1190TT8!WLRH1V?_\1<* &RKP<*2X(E*$^NR4BXS(NJ2N.0D
M*M:^)8;#7N26DTEQ0^G A"F/4!HKA"89 0NA683+##&7LZTM@^1Y&/BSE(<!
M8V\,E?_GEY))$@@NY;'0EK$59[FSF9)6ESMY L^;";QI3^!?NA,H+UV>+4M(
M\]I6S"&M0\F^R#-3]8H_56<?5ED7)PHXV9810LI9%@?TU;,KSKPI&@BU,JTU
MD4US>(=MS3,*>RQ@9_21K2/[XY[<!B=Q@OF9)^HANM-%VCZG1\H[;LD3?H+$
MEI7?0XK$;=J72Y+8\8$=02((B[ YK-D;W!Z^LM3(JYUW]-7+P^_13DD%[BFI
MWJS/L5S.]-A0>V;&!;6C*&$^3C1*Z/ZC14YDD!XS&L&C]I&CC@*CAK\6AXGS
M38 N$#[6@;!GMMTXT ]!!EF@_)9F56^W: M]RJ/X"*[1K53 D1IVN< HX=4E
M TZD$,L&1O!I#$ J>H01))SBAG":HF.]H(H>-:PX#V_B-,^_-4X']EV7I(A"
MX"1ZD2KW/WR%?B\T%.\7[P_'HJRNZLZ4P^V7V0;"=A1S3YGFALQ,HV#>F9E5
M!/,M&FDH^?Y,-1B!CTFDX=3NRD/?]/HF$3N(V1_B]$399&4O$6SS5$UJFPN(
M-[OR>?6_T9")$*4,+B\<FMC-/AZV?UMH C6ATKR#80932TAB#C/*$4DY)-%W
ME6Y?N&U&)F)HPL?VT/N]_DE%]H;-C)4;T?,O01;RUASEVX5042^F,<^/>_$W
MQYW>/(-@^[TYITKM[.88 ='#S<>^T0)E@RL'(GRD#1$M9<K!-J0>CDCC>>C%
M5IJXR];=R+2<CJ<L2&#;?<QY@<\S99,2;'\[8YA,C+R$(X<LV@+ /@UI/..1
MK.:!Y/B8PQNH392I2NW;XR(<>KH*5I]2VB+B'"NZ<:=_NKO7"?+ 2 Q=VU_V
MY.[UBV8^"5M,/OCC/LA^HP7WK.AM%YR[#;\[.?4SYIY7X]57&QVKF<.JD]ON
M^[#*T @M(E:4:[YNY#@]S):?K.LHH5>,NJ[[[ZH<_%Z-O#?)ZQIZ/?SOT-@[
MLBG:QP 'I&9ATRDZX7UH:SZ(Q BT2AGC+H CPEF:LZ5GE8BY8_L;WGBW+*I1
M[A0,P A;@T'6Z[V %A(G^!]@IZ=K\/.VO -]3/C5AK+@+(="ID>HPF>Q8L8@
M0K8K97^B57HMJX98^V%I9QDKCFN$JKP+(\8?_87Z$T^VST'VA!3$MUS>I[10
M^KJ.,Y5<U?ECSCLZ:;SP;-1QUN>9)T=>>V<BO?JZ.BO? T'R\*+'(5JK;&L=
M_;4:#BGSN.QDW='\&(L:X^8Q'GXEWJ>'>EIS8 ZI[N@+97^PF4Q+0AZX#2>1
MM1["B@JN,W!@<0:[+^EY8-=3Y"Y_]=XR^0GJS0Y>"<_OTSB</B]]BM[;JFX2
M1AIMEYS/UJOF=08S%O4.; 7CI G0]MZD+2<#P$"R)RY9KI#,-ROG#?YNLW07
M%=?L7]-GJD?0>QO73,%($^]0\]G"E:S.8."B-:8@3-X Z6^]-W"[N1"2'3C8
MC.DV=;*1Q?J4:3P<*[YG,4.<'F"O8,K$C:.#D*2;(G"=OQM#!">U-YY3U0:0
M(_%4<MB@-;F_H"BRZ/$HCHN+5+<Q7#GS-^,4:'+AL#\HYP:ZD4GT,'.&*WQZ
M[T,,FK!_Q?P(9A\E$20XH,R]%'<&WSTT@/\AB-T4C0U)S-2]#E%L6)\C9!'C
ME =T\DB5\_ _@ADU5;+@00O/=[=2W^2=S8_T*7KO.'23,-)3=,GY[!K4O,[@
M"YHKXJ_%]"VGXH$_%I[6XE%-6.2;I5\E;+)H7LQFZ#V"WMNY9@I&FGF'FL]6
MKF1UEC-$07<9&_])S$%"GZ"OS$Q6;C<5M6!5]Z$SPOZP)TE:4'((3K MG#=U
M(?/?XK!LJW,;9,5)LS>RQ,5)43@))J<EK!#14A$.W UK5Y'6/:L.@"?N*7N3
M<Y@B:]^IM%W&INX;Q:FL[4$6^9QG[:^YE*/X)8B2FP1N1EPR>=EF(Z&]LP=K
M+&SG8!1&[1:4*!XX! -?_9TC@ZV:K*0)U*!4"' "QF_D^)1]'"=DUP=PH6\2
M MA$0L?)+(Z3Z;+]I>3 H'I?)X.O%57.X8S<OSLG<1K,V2Y6G1C]R/Y*8\8N
M38]YE0\5U5+VV54C$6]..RQ$'3CJ,%#PZ9QCD,V>AK8PFI.--Q%'^O95'7&X
M2Z\]WVA/RX=Z6@2UF<]8[0.0682^*9YIYGLB@C,Y7[JQ1<W[%(1*^+%I1HF4
MS\F'/I]SI!>!Z"M*.UA,0IE8Y(*]EJ2B?#OL_;C+#1,'\-[B+:=HI!,8H.ZS
M7[!B?097T;X\*(UDN.6PBIV)-V9N=BX5E' 5+2D&[&L.PCAV-=^4R/8TG>KJ
M=C07RS/8CV!E0TKZZ'>#%IN:2D#Q,-C/OJ^]5\D+XS;-3B7?<YR-="EZO[KJ
M)F'TF5Z;G,_KIYK764[U2L*US7M_=F\Y%S784BGY=OO][G-R@PG((73L)+V=
M>.ILO1G7@[2]#8/:-:.I!Q%OS-S=?*X?F/0USS91]*YCZ3X*(=Z*O-F1S_5;
MD=@)_E%RWG0^+7]$]"S=G36/B/H>*MQFH&?%Z98)!EU<H+D:KWJ>+708'L'[
M4,)VDD:&%D/D?0XU['B?(?2H!F+_@J'X25H]V.L)1T;.5X7&Q::-V G%N9XP
M?J<U^];M]24DYDU$O*($Q%*)A]>6;3"F^;>M7,-KL>Y/:;)=*@.IHOUJ;%X_
M,1/-OT_X-7@"'=<S.H5FB->8D+2>(''.^4HRDMJPIQ%WP=A*'N3U;C;Z4S7W
M?J,9X55N.;KL+[_K:$9\O1N/P5F;>>\Q/5FJ]1E3"/F=0%7;_G@JWB=5![52
M6N5_SQE69Y]FD6O%\UNS2^]K!K9Z7CFB2U1QS$8=Z>WQ>2>G]1[Y/*37?Z-\
M3KYGB'LD?OPI[UAVDBHIXV:44=LJF_BF'$L6J.4'FU?3AT^&G6AA1SDC!%<'
M.@Z$/(AUG+FU/DU.&\S7$.Q,GXBN+ZLFIN6QND&01!8[X)D^ ]V8IU&!5Q7J
M6&>,YQS@=04\=KGC^:B_FK!GP2QRRX]XE$I>?*JNT^3IC+>R6",":M@:'_E8
MT<".>!P$54<Z%@0\B'"LN71)Y+RRX&;\''3=E#0G'H<RX^7U+(3Y1 MX(/0V
M2U^BD(;O3I]S&EXE2G\Z=(-M)"V<P&22X'(,,HK0ZN'&!"[[;HL6A+\J6U&#
M%^;> $$2)=_J'Y3#O5CVGAXRNHTX,]#)<I]F1?0W_I_J6= =/+G303IX'2MP
MZVS5E<CZQZ?C..PO1!(=T:Q5HK31:372X><2,E/UO?&YPEZ9R9O=993 _=-Q
M-T)<2&$'P>YBJV-A>SH>A,2NS/844R8 G81V@L2K/.6</!G=$+DU.3<[4I+T
M]X;):NJ $EA<!(>H"&+>QR*,BF-&G>()>W2<,,)5/#EZL,5=/6AP8ZQ_)"'0
MB83O680P4<!;QM SWYZ"L7V%IX#Q# PVVVR[ ?=4<]@YLXA'^!#V;_X^]="^
MU!X?:2_J*F!K_VF+O/Z>TXTS97H,MIDU 1Z6UR3$V^3HV>FI4C;2):6\##K)
M _&*]F)9Z$NP:K'H7I6/>;\[%I_2XM]I<1M$X555.W!+LRCM/M$X SWLP'SD
M!*BC<T=B'H3HHSCN-_QLUH;JW?'F;7@6ED,+4')B/QX8R=<0K,\S+=V(74R3
M($LJNH01)HPR8:0)T&:_U&?Z@CQVX#Z[DG#MB(\A3Q5".]CTF+ _5CUBV=\.
MC%!&#IS>1J@-^VMU)'!03LL$G_@Y@2$D.<\E'7U(K2+Y*800O. DD6OW-XH*
MCM^;P&I/EP6M5DQL5.F-ITYO@3EI.3F9''E(_=@<H6L#RO:)1:-10:^C%SCP
M*1C[$>-$B/[N]#'XCS2[B!GOYU\C78K"B0+.%FJ$D/(FR@%]]6V4,V^*!1@H
MG'$2I*%1V>KCB7 RA--A&RI&">>,SB!J(^BG8$_?I_L@ZCK[T52\4UF3L)9J
MJR+AD^KJ^7-4WTU+>8$8^560P]'AVZ!@P4C^D>X?:::9EPX,COXI&96UJP6P
MNNXH1N^G*04,SPM=1UO1M/Y7@8+S]>'9FSBFV^(8Q-7M4:,JF!!P]&)8!%E)
M]-"K:\P0*\HWBBJ$^K[S OJ39X6D.^R_&KUA__'7.\83581?G=_6U08E8_#A
M6S^L]HT5H_9?L8;?9P]?;#Z>TL)[OR)]P+[M=GY:_R,:K;+\C+.OX0,?\B.+
M,O;'O?93=GY?_V,J&:P^9^O'53^H8F3%JSL<9GW7^C'X:OZH[=\1/JJ*P?JC
MRC^N^U'[(_<_JH#!C;<N8'J30J1I[J+\MW>G=S39/N^#[#=#1F,8#:G8PE*<
M5I'% ,[ZQ156#/6+*F0T GBD1L-,2O3%J;@R9B&&T7Q1,;4X9A5KXWB@8BJ&
M'%4,,VMP1U]H<J27[%,Q)GF]P%^BXOGBF!?IGF;&+:0E+HZZ.0DFZYP5XNJ*
MY\!5/[ 5N-XMF ]L.+>ULL'PQ8?UA!A8(2MP#SQ7AQ<;IP487BV)P)#;:BAC
M>*)$?2&,2M2 XRM1EQ=[)<)<]"JOV1/'N-P-8B&IDYTP+94RHZRO5C;\*/JS
M""RBT+$I2YVF8N?^N&?AVNEF=Q\])=$NVD)31W'.'B5/MVD<;2.:7T<)Y=67
MJA( 9Q((53HCQ:SK<QSQ5].U\<SU%*^D G==)#JD(40J2N17H"4*AI%.!>&J
M;,[LXC+-KM,\OTFJ\%$7=ADQD$X,AX5HG1_JP=<_31SB1=7[56"079H1P"'L
MWS76(I5++S1[3,WEYA,$R;DDVQ*<Q P;*WKL;9SX63Y<4C=VQ+;"1(LF;87J
M1)5#:!C1I1U/JBA3Z-87ADHJW+(__89\H@L_5V-A/S,(AWG74,%]U1[I5.87
M[N@V9:OAWVCWTL98(OX8U+"H0[:EI^"%F0VQ9VUQ-:$-J=).#2VD*XESR%L)
MD]6 K8+;9G%K&GGAM :$F\FWP H+2ODUS#""4J7;8/M;\$0U4S2(A=3$STZ8
M5F<^,\KZ[?9L^.DWA@,L> JAQ",-(ONK0"6_%AE3R%T0YQ1M;Z%^W^!S3G?'
M^#K:Z?3-"A-MKV$K5&?/,82&L?>PXTG[_H3F#0Z!3X  XG9DI&SRK; -.0I1
M8H4HR)7G@T9DA^I;C;G9C&SP/*HFMU V0PGY\H8T&!M-$$V2)A#28-O2+VD:
M?HGBF+F#CC!7^T,097O]!M\.%<>67,22;<D&;W5;LF>JIW 5*E^-NK9$&G0<
M2YH@6->22*25914[NG\.,OJ.1:#A1;J'WFRBWUN608$L</7NU(#<!B?XT_F7
M( LO&==_#N(CR'W<'_@-1HA<MP4-WT?0LC$)[X)"MZ"M,"Z.!:\VH;+Y+S[H
MZKYC)8GZYSU ].P1J!)Y9"(-#9<99;AR>,+'WQ#@@' 6B,3#AE1<D(H- GS@
M>#"LZ:U%SY82W6(_@2[\*:+QJ 83,_21RY\_)U&2'S,*+3V/^F,0%216=S@M
MT^U&<#TPA)YO&AX4[=WR9[8IJ&") $8[L;#F6_P(>5#Z=4OAP')'*AGB:!_-
M^6CEIR,4=MSLQ#W>,IVKK+;002(459B9KFLGU& XS4M,O"BRXP?&!+\26SQ#
M.YU=FNW%&@E9FH#M,I,G:$*2<*J@'WM^>7I;$5ZY#8F3=)]JILL;WQ4\0A>1
MD8QW9ANIU#POL@C61? L;)\$_P-YNY<@!M51_]50(#R%(%91^M0I:%>JCZ6&
M4+X^C56%QZD(BB<!("? _R&A8U8JCQ-XX+K%%)*O2>%-ES/&TWLE2F^N>=7K
M^H2":DVH=4V+ M::"Q;'1<4#S?;7:9 H==0"'B'LLA&@#KY,P#@AV#!'XP.Q
MF-.&T&#+J1/Q#!FCOW(D-D)(@0+EMP*)G!' (X"X1.5WF\7[('D?T:>4G]';
M&H,2"=TB#*)HS$*!X8-M:-F:T4"@AC5GKA?&$0\ H%J*O<@*<V'(A&.7;S<L
M8#201@N24]G0G4WJ19"%>G,Q@B,8B@7[M8D88'&,8Y AQ1%48P<9C0.(JYD1
M@(F4Q,BAID:VC-S*RN\N4L5W@T( !_D6+ O;.O%>+TIL_T'>#IF?&YB)-EX^
M=[:)Z6: )Q-&R1G/Q+4FR]S=0$"];G]+W?U;>W>-^J[>T.[JO&#FGIV8W?/C
MF9%[M!X5/_?1&F%=MLX=$M[MEI7\C<H++7L79/"<=1Y!+](8ENDLB,DSYLEA
ME_DDO'].,[Z1$R^,0*2B?X/*GH WZ]* B .+CP;;AQ7&R)KU,@(6Q\F(E\TE
M0LN86UH$\= QYB1!'V $LN7B\G=RJ+0(@K19XW/@=YR:+;8;X'4*O!WQS>Z^
M2+>F1F0&>*0:J2$!6K5-.N#U:Y+,G/2MAG>+3G>$ Z+V4I$8-K=040 B.6,M
MRRVGVX-:W[EJ6!A4A_F3^/<TBVC^XRV#H?".#A](GX<Q@F.THQAFOVD]H8?%
MR<,,,M0O->08Y/SL1U)C5;JAR5LLFW=9181):486!C^FHO?+S:%\F+KLR7[^
ME%'NG$UY1Q=\E$2DNX!29M(>&2M5Z<JA>B=4D=@0041NS4]J.DA&Y(F0BW4[
MOLW2\+@M;C)F^R^,'4U/>378^KV/3>Q6+9!5,*MV0M8SH+JM":!BYR6@U^Y&
M7[+ =U:"@UP94P[ HNF"GO&.0O0!,;1"QX6=:LP?9%[M]\>$WB3;-$Z?3N=)
M$3VF(8L"[HJO3"3]ZFN'A[#JN@A4K[8V2#BKK#UG_9-!CGI6X9(&F;RY>_BW
M,X;_+=*RBB758EZT3B;<LR4]R*)4LY!JX-;WGD:&*\^I!%K5:QHXZ&]?2I"U
M5]!JW,])?J#;:!?14+N"&F 1=&"(\5H/=(#KZH*9"ZT^P+V<&F.)-?13^BY*
M\V@?Q4%6+MO_,\C?49J<'PY9^D(-U3/VN!B77QP%:Z[#6"(B79!QXJY_-R,E
M#3ZIXK3G(">/C 2I:" MK<C"+>9E+^"B&LT.05:<X,E&S0*K!EO?MYK8K=RJ
M"F95CZIG0)'%:$#+)S-7?C6-EF5L3=JER[YVU77 17AQS56P^CTV6\1U7VMS
MX\I&T>9?L2$G1Y_HO5@CQ$%RFN77\99MS]]EIR"Y" Y1$<3F]+,3":0,] @Q
M6TEH!WR\/+0SD^.KR\OA2#D>J0<DU]<7;#<:$CXF*0==O=AVCLEPE'&^8""G
MV^^>TI?O0QJ)M8#]HUD&V'_\]9H^!?$'MN<O3HH(0 FQKN$9F 2[4OR\FGO6
MCJVX>/ $K2LYV%P+_?"W%>,I5_'^S^M_515[U2>5?UOU>_8'[GW,ZC,ND#QF
M_^=BG]:'Q0]9L/V-^<F!2@4K-(S4L;TX3>9X& <I<6S+V/BE\(KM%,G%QQNI
M6J :190-K+SXC1=Y4!*4.J_W]+&X2O(BXU_:4!*H L2I\]*S+-=Y]:%6K_/2
ML=!O\\0 20.)6??7YEF[XQT&]T$WU/O:(5AD/1G<O7:T9;/8#O:>;J%)T_#5
M?@T@2D&@@66I%% !A54$J&5E_**9"Z)HM_9=A"IAFSOZ,RIP>;F3WF;1EEZF
M6=46',:*$E%OM;L_/O+[VF6;\.)T!;DAMA=523:5(H))S#,)M>U,(X=C9'/P
MK+GX424BR0%H\S8 8)M-BWSXKZ(9!ZJYX4_5:+SV)F5_R4A0Y3)S$NQ3L&0&
M!SG*B)879^ /E//&C%\PMW9KM$6FLB)*.%7"R$H3^-">O'KBSLM7!]AD5.01
M.JZMIEK>N$6X+56V.)U_0EK$7YVS5$S-3'Y3HOP:76B/?77KJD/9%AF\Z/]V
MK/-.\%P^MKS460[VZCRNFR;.Z'2A$_3'(/N-%OS>]LVNXELEHP$8P2D.LEX[
M.2TDCM,:8*?_'@OT8=]S!/+"V[&73N50XJWL$T;Q+Q#*=O*,_PH'P51GF?^#
MAO\)M@AMVN^8XMS2#)X&#YX8:T[VZ4@ P69'B5C;L1,VCFV/8%'7F9PI&3S+
M0*#I!WC^ -Y:$4F5DC2 [%3&)8<D*SN'.28 :) [GD2\;0GKFR>90]BVA/47
MG]&OB%!#JDE*\BBDXE;>0Q8DN3CW:4<D^?F6_7?6>Q=W%HH(GF>>2:A=T31R
M.+YI#IY5;^HV5$C1D.%[H\[NA00E,7),&(Z\P:EW0RO[JT4FI=R<U%39[J0U
M31+A[D8F)Q5M!'^VC(; SF7;DM^D&LLYOK\$\#).D5_E^9&&-QG\+RRJ%C.A
M1\5W94-BZ7R6#L\+YV1FKJ=C%3B).#QA^A65&-ZZ&D<1^SZE%OJJ%KJB@>\[
MIGQ E03SN0$Y6&M[LA&.P848OJMP%UWG/.PI>>%.7-G565_06%][&]9=S?I^
M"-?9S#4!DOMI;UPZ88R7/FGR)-R:OKD'A5&7P98:'\/3@_M0&-5G7U\8U< B
M%T9U&1DNC (,Y&?R'$6X[U;N>*#KE>G".Y7\KGS86*>5U&8"/MB#C8AZ"S%A
M(]O,,&O#5E2O-$!D0P09:5'"Z9,\6<Y:+'A8EKP)\BK0^';.2X#\38UZ77Q@
MP/ES&H?7\.[EYZ3I#0M[=]7"ZD@ XP+@&!&;ZW\NV$B7_]Q9[%?T5$CBQ5,(
M:HX2IN@<7*3DD1*HXH5:3KKZ(QHSR%F^(2,%KXWDG XTRI#DOE!T1%XA7)U#
MU,_=[S?GI:<LHR\,G@7([7=]5,(8@#$N. VQWEQKTD$B768RL]-?/QKXWG-0
M*]])\IUSLS$NR?Z:O;++S-I-=A<]/1?54[P\HH^@U.PBB&,:OCM5&;@24/OZ
MP52JJ%VXITZ&HF7W6))8_;VG\:MO!E["0\:'(VQ(\Y)S0YT(\N3QU*2O*XR5
MGZ9>=EX:X;^TSR:PMOS+B%E_1!8EUK6Q^7/ A #9+]+]/DT0+Y(JI?[PE6VI
MHK)6L_ZQ%O6MRPP.T_+(X=D*/NCFA@CYX=SLN'1Q:17%LERY@?'3BXV<@ IN
M0V@EKRAW/S"/QHU[QDU%^Z#P,LTNHR2(RV+HIF3Z3G.QPPD=8>,Q0KQZ*^*
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MXV/(MJDL4@Y( 3'@=^3AF<$W, $+#UF0'$*P' H.*%!E^[WR6H@4?^=YRD:
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MT(+].O8SP.($?8,,]90B^3Y8-X9S9[&;-^(XN%TXI@C1] S#Z=[8YUWC:52
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M>/T0V<R)IMA$ "Y1/.UTP9&%OM&V*#,H_(#U[OZS46T&<+"N/5H(TKX!:4!
MN PYR(WB7F2%4U;PBYK]!2HJ]4'QM:FRT@K-JPU*3QR+3<HU3L6E-4/.FY5K
MY!K,B1'C^3X]:L]39Z+M4]@U<F)FW&\(PIX$<*.XMMY#5-1%X8%$'PH.5&DO
M,0I.>=#VF89'7FQ1IKIH"!S3).<LGV<9E#E!H6#^[M3 E \LGG\)LE"5>%J
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MS+\>5D>!=1X_)\V@:Z>5?A>3AM"G8JV)^UAFY^MT?1#'(E6?B_]A$W5,0N;
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M&!?1V*[(P.BX_WS9 +K,G-NV*Y_YRQ7ZR.?P"@:^5]J\89_]]Z]W8<!&W 0
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M: 9(4%5]WY[.!1W0_D"JB$ 4A<HV+3=_$/#K?Z9J#1)1%&_;<1D#\B0&5V]
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M8PO:*4C=E"X\S_E"9Z7\3/E&1>R-)Y-Q3RK;2;##F$K94GC4NJZ>$>WIXC)
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MAOL) :3Z#@40S9DVM>(.A2FRW0EKPJ#<^1!P(,BUMC(]K>>=J[GEJRAO2LU
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MZ0:TP9A&KR"X]Q9^L*H1I')2WC33)V[Q-_C[)%Z%C,#*#:'W\[KU!7:G4-Z
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MA8CID\&IWLJJLP"MM'!MN_0:MWM->J$.ACSW'*0BW.E5078O3-= L<7 %"#
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MBHA0E3NLTORI2JVL0@ 2/K(:I(NRG4S..WTTVC]XTD2HRK-F/CQEW&VUB']
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M+$3>2NA;Y /(:&P'8OD+*WH%I3[K_3[=68]L:)F+B&,WZ,U;MAC?0'3O(7P
M+%'.H"O;&F<!>)K(SWUQCK3-\=8TO6/T#LD+F3JT],;XJG6=&CS:08;?T3@,
MB.NUC(F:[&HM2=K^3>/NFJQXCU(1."C2I2BRD\GDI*,#A@J$2#/:-,2T6'\=
M#=V H*NB -_0FHMC_Y_]G&<\W89=V2%TA)84+I5!P4@%[YW7(E*\+.$M8F)Q
MT<9[:W"1I*:+9_M=:(%BDQ@4@AHSWHL2HM]Q8%CHNW".K=\7&WI$5%$4P)<X
M2N9,?K94Q;7+TA@$3-1Q;E9B?^6'-6)?)4]LA3[&P47F$"3/F892Z2TCX'>
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M<C)X98EGE#5)AZ\-=[;BL677*<6[G,ITFN6$$.O0SF)/VA:JV>?2I0X-4NA
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MR&)RF%[$;X'.#N\W)+0=NP>^"#CDP>LOWJ:O8T_SE6)[A)?H/IO.>^EV.ET
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M].:R9M:P#*WJHU57)=K 57*!C&)<$\<]$OP+;-T6BSTKK;QN%GM5Q_D)*ED
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M"9WPRA'%B"BN$Y'&OK7_[UWSDHE*$D4"@<<I><A'94#S<3$1XP$U) 1"P&5
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MC. *$938_EQD/,VQ&U1L>AI8@S2*TT@@-,'(T]991BVL'?D+_1C[FZ3(^\T
M=ZSX.<X6RG'^$M&Q7OFC, #.OV^8RW=PB5"Y8?H=+E\.5(O1TT7 8M5L%\,2
MB>6,#[G\R[G\$RP-&4B(:/!Y '6@)$&>]OLJ^\1M([5X\-L(Q!IV\ ='A\(
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M0-.B(K GS;2L3CFUPJ4PQIHDH$#S&S,>EV9A3"3D]H]U9ORAW'XQV^5D;N=
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M,U-N+->=8*NKPZ&M\/$U(MEO6.Z8MXA<,#;ZRY4A5N)0\-8C*1>UP>[(X()
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ME'^2T?_AGC?6?X5;;[C96IX3$M7YWU10,?YF:(]:>T/W#5*]_:NNFN!["&C
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M9HJZ%[&A:]D1 1C7M=6YYPIS'0RMMF5&J[,M70^'U"+1 8Y[ &.636,QKW/
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ML'@&%L] U;A\Q/;.5 -F-MU\&L)M%L^\>OK^!+!F1H95( Y_VE4U<W\4>."
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MK'>")NRU!T,N#CY'/@K\-&X,-I;N E:9:X"QNX+)M 6\N\<-XC.XD;IJI2O
MACM/M;E[ IR\;"FFP)?@[M(DN7N9N'L"G#Q?^QJ5XMZS,D^>(@:%XOJ$ E(
M8B44"D@!J!90*"Y?)99Z IR\N@QJQ?4)!;REZ QE1%>F$["RZMY1X7;=[5LH
M/2H(NF"*(",X&4O.#,#*C8^<,P3Z;7]V%QTDP>*)"Q9/$*MM1K*\N0Y@]<3G
M"Y/.2[6+)VI!Y;H&Y?H(C/_K?+F^=Z8?,)'Q3S-JKD!0/IE4XT0->1V>&?4Y
M?VF2B(9LMBM#(-$:5>S]FE?#.'Q'_N,LOO!CPS('KB5J3PE\7*V'Y(>]NH+B
MO"K+!M5DYMT_3^"+6PL['<]UHK6%]#^0@U,>"Z36L4H$UZ$,#,QJG8!P>SQ&
M\O3#C_PW%*7@]1;I2MR#>]'50\QG\_;2CB_1HQ>6'O+(V<^D9HJZ%[&A:]D1
M 1C7M=6YYT;-/X96VS*CU=F6KH=#:N$Z0WAR#X"27*!G'6_06+$!"OANM4-Z
M^:H?@1*&A:@$$0DB$D2D*T2D]R\+:V<#K%[($RNTP:)ZNU6;HL/&GS?,.QDZ
M6=-A#V4+59HUR)RTS2U:PG8=FTS1E6!X'OU&9>&E8&<]8TVAIIX:HCY9B)@N
MB$I0XNBE#G\)4)_N[IGKM%=->UAKLL4\;BUW.#+(#Y3+@]5OBRVZ=G.:XW;3
M'FJ,E[;>4P)O&35/(^/>GCA.G+"Y)X2L+]>&WAY@?;(N% +6$2I!C6*N,.T,
MIU54R(TU>H1W\(7]YQ5=IT>G,K+=9,NZYG.X[)*=G,Z+R$:)T"DJ(<6S^#>4
M@C6DT/$[ TC=5[3[CV&*;;I.@QYS&C7J-_-";D0ZVQ0@S%M@Z:P)<=G@@YI&
MS<5EA:>F#56(G;6HQC1+?R,H^IHNQ/M3Z,B?]4 5$N"."7 ]):90)B !8'W(
MY60BI3FOYQ2**\EYA4(!*0"Q$@H%I !4BQ21! I%6DM,ST: ZRDQA5IQ/JVX
M[^5?3XGI&74BI26F$!6@N_W7)(F/*?X9GXV<8!G1'7VJ'+RFW)N9[__RTET5
M__STCSY9$42'06_F.O_E+3Z(^!**BR[MORD!T=IW2$5$2[?L[\^'>F__JJLF
M^.Z9$K"CGQ)_CE_R/6XL&[YUN+ !R+3"-RZ<#!M^2?JU<#:#HSCV[W_.3T2(
M4W)-B(_7>)&2<Q(A4[Q($!2?S1& SXLYE,=Q<3Y'49R2<1"^\Y_"\S>&(M^2
M^%Q6S?H [7AF@QQWC "P/H_Q&/5VZ&(@#5;%F@.T8+=FUXY9SFL]G\=YC'@[
MM.8..WC/GHHH0)%*K3DCO9;?BX8FGNKTRKR^Z6^G:+$RZQ+S087M(SY/\/C;
MD6) K"W6<#H<'KC"9,"T>$U5PI'TVY&YT;K"D-Z49HMKG*?K]7Q+KT7/3,Z4
MKXMKM]&N#5'@KXIE>>:;K183#4W,U.#J>KUA,#IJ8*9FZB1:1W;1^['\VZ%4
M*QA@LE+RT$9W:<A@WBR9A5ZTJ,2J]%*;FGK]C8D6UX2(R4(5ZZ][?#:Y?M#-
MS1I#EZ]PB-;2G#P/0%=BPI'DVY$(0BZ*;9_B6+S=D<=&K;JAG6AD@E)(;=70
M;-Q6T+7:\39B;H>A6C020]\.1856A6DN4)(K%N61,5P-J-4BFFB2J")-;L;!
MEG2T-15HPJ8_1TN>$@U-"E5!G&WH_+;#!H6\Z#N[OH-VXJ$)HJ+XNI*S5T5,
MPW/>K)[E^KJ%1W--$G6]&AFLH?,66]R- S!MU;?,)"9J@E;!J(?LBEJGJPG<
MAJ/4XK*[U'H\R2<(T)A0*[8HZ%L.Y$=V'3<6_FS%A",3ZT?F-N/TM_Q0 W-E
MWF5W[*Y65,*1B;>#>7<S$QOY&HM7-G@C2XP$C_##D0E"@<Z :>!L@40K%,[/
MN;FHE/1H9))3$P2M:;.",=$&HHLUE]PP.\I'KT]R:L>L5;RD#%=:Q78"N]1$
MO+45K3[)J:G=P#VET)$UT.I.BVM[2TIF/#3!*64A>*#&-]=H8U=1!I)9K#AV
M-($DIPA!X\I"090UW,FJY3ZR#M:+>&B"5MQ 7VBV)3BA5#O]);];=9?E'I]+
M<DI?=8))9:=568#[A2Q)$6NVZ8<C$^OG[,7<DX=] 37F770A!9I*KZ-G)I9?
M:U?*4X52&YQ04]<:N^L61)6)6GAC": (I;W2T;M]%F&G#&/V/,F:1J^/4CM_
M'8H[ >&V1ZL=A["%C4 J]>U4B]Z/)Q:E]? RWU;[.0W'3%'-!<RNWE>BH8E5
MR=I\J@M;K,L:LKP-YD-B1LP8GDY2JD=/-V4.*:OH.MNN>W8S1WJAI-))2N$+
MW5C:ZC30#):29 G,>+'8"T<F*)6WU76/I:L<2^4V!9GO6H+8C48FT,<JEOI*
MGB-VFKJ:\#M:88.A$XU,TC2[:5GV<L;-M$ =&>-R=F33JVBB29JVY\+:&;#=
M+0IF97XRK.>JK9#[] &:#K2<P3L(7]0HUEE5JP*V'.CQT,3Z<W@1-9?8HH&N
MU^N&ARV=3I9F^'R2IIY;XF>[KCAC*Z@_G]6=U69H*E&RSMN16$LOSX?NV&0%
MH3)I,X7R8DGTPI$)F@:5'5?'<T6?ZVP79;[ UVJ]9O3V!$U7)5%99<?D0*.R
M]&:CUWI4KQX],TG3EK'34;,PPME!( _TGCZM;-SHH5'AQ!OL&XI]I<&X)-I!
MUZ",L$U^LHR&)FDZJS36_1:MUKDU;8Z"D3R@_7RT_"1-&4(RJ[TMQ7)@[@3%
M7E;<>7HO1+0D4=WU>.@803/+(<Q8+8^&XVZ[&@]-/+4RK4H$32YH%NDZK=&0
M&(_YT$X(AR;(6BK*+NA/)FO44#MF-KL9-6TN?FJ"KKMMJV(,\@V20V;*ND6U
MLW6A[4=#DX15K%VY4F:$K*9NVLL)PC8*@1;/($G9^JQKC^UEKL.-T4Y1P$6C
M6;29>&Q"LMU::3?H%1 "[;1+JSX_G"E#3HENW$XJMF]9A0*N>:PP-,OU(&!4
M5XXOYT[0B]R"T434S946HH#GS98-=3>.GYJ 8'95984J%5!:* 95H1GPU3'N
M1T,3I/7D-2;4^7&?[;2G:IDL#95ZLQ<-36Y8C4*K*NKK9H$-BOE)EO,K7)F(
M)YO<L9@YA;!"4&AR075>4('=*EE&/(7DEC6O3J:TK@U03A!E:=GK$GY[M']N
M8L^JZ)N:@37HO(:(2U04D1[C^/%SDYM66:9F"Y; &QS"FY552S(:;2)>V\NN
M%3M_SY;]4[9BZ,SHPLH!WY]_>.TN4*&YO]A[0H:P1>)D/_/%)T9T(+NOG60D
M=F;C3YYB;"CZWY%'X=K/;WUZ&K;W-#Z7,8?E'JEWHW62NCGP?"M\IJQ;_K.7
M\OP[$KG[W^<V$#3$#XGPKY7EQ"5GWVV@AT[:!KQYYI/S$[_X>:@P#UTXSP5O
M%GJQ  GVA6A N+27?_\V7/1NL 3R!?(%\N5U<!%]-[P*^7(Q?7DW(QOR!?(%
M\N4UCF'O9A1 OD!]@7SY15\@6]+'%J@ND"^0+Q#&KIPM4%T@7R!?((Q=.5N@
MNJ23+Q]4#T"V7(8M]"/U;K(RY N$,<B7US"&0AQ+(5\^JD.!?($X!OD"S;&4
MLX5^S$&^I) O$,8@7R!?/L\7ZI&&YMCI^/+%7I$?9KZ>O&%JYA<BG*L(^;PE
MN(ERT%0VVX4T^6(VY3W2Y*-M%=($TN0S&7SW2!,H)U\^*TT921*=&Z#<0%U*
M#4VN2Y>@F$":I(8F4'7N3$Q$2X\^_,\#_O"'],E_$,@Z]HTKGR'/[UM,/?QX
M=:W<2[\G*"'';X7Z?A; /=+D[)T@KX F4'<NU$;XNDCRT:GO/=($J@ZDR3%.
M&J^8)O"4#YYH09K 4SZXG4":P%.^=-$$R@D,KT(Q@32!J@/%Y#(G$[G'_&GI
M<^R3B7!V42*NH,.#"7AT=4! .NX"V% VX*$5/+2"&V_*: (/K>"A%50=2!-X
M: 4/K:[E@.;,?@KYIWX*1CWF0G(\723R?$7@:IN);S?,/%^0>#V.3-<&,K!M
M(/V_?V 4^J^!:XG:5?DU9Y:<[!]+#OE(T[<D.47+,"PS R4&!LV>H$10):1F
M0EF \;$('%8V6 #343< 2L0))()^O"IPN-9<_VL1A_QC_K01CB/+0]LRHZOU
M;$O7PUE&(K$W0*%@7 T%8!@C)32!88P4A#$^6O,!>#N*BX#?DD\Y6 @V<*[%
M0+@4RZE;8CEC6)[IWC#+_R+)ZG:X#!7[D^&>VV'YS2LV9'DBZB.L5/=Z<N8N
MPO-]).]V>-ZT'(CK'P;J;H??)2"KH@IQ_>-@W.WPO!9]'3B0Z>]OYKF;8OK0
M2FSE?Q9HF@NBIMBA,2A]_X<H B#+E^1]0= %4P09P<E8<J;NZ4$&^Y;!41P[
M6I3IO N^AF@T),KA&N_SJ\8K@+ C;7]-)/R1)!.AVFCE&'Z\<QDH!Q<GRD<0
M^5]'J\.&\GWO\KV/8Z9?#/ZM;L.)FV5;$*/"OXQGJFX?R/]YX,(?^($KF))@
M2[P3QS%Y9M3G_*5)(AJRV:X,@41K5+'WD(F.M,,WQU]D'+XC\Q1/H'QD7?">
M@RB"L(J>Y0(C-,[8M1?2/LJ4L<SP5X?9JL[+J'UV79Q<UP+&'-@\WL[U)Q;.
MKSC@2BPO5DAQ1OD/&0F(JB'HSG\>$.(A(UNV(;C_>5"W[G?3,R3+??K[0\84
MC)"J3R_XOH_(=CS7B=86TC^T>T.VAB/"IZC2?QZ&(L][W:%2V:QT#K MFE5S
MNTEGQO D3S_\H+_E,/+?__R5;->*B*E7HTMM$U_S)XZT<=P28'"#$A\J,:F-
M&Q4/Q>OXJL$Y".6[S'6A1?3H1>@8 MO9SZ1FBKH7L:%KV1$!&->UU;GG"G,=
M#*U?TWN>XP<'("8[WTU&Q9:YTE2C;9&,5":S626$& Q[^)&'^ +Q!>++Y?'E
M9S^$*,F[9CX=]#QA3:6*D'V[FA>X(C#J(3&P@0B4]&%-CT3SY6:1Y[A*75^-
M*\2B2NUZ$=9D'W[@-/X-IRB(..>L4KX'P-G?6I\NQ$DL-/,_Z<*;G]GB<:>-
M7\H)0C2P#/"$/4VF;8Q[GK7E$%')EEI;>[,64H ](=G#5Q\ H6)>0OEM$[>X
M8C"@R_1HO-@AD4^%Y1Y^4$0"?_X7 M I6XS< P+M&X= !/H* O6!*Z@FD%C!
M-D.Z.$]PDQW41[U&OCGE!H7B0/=)25=7:88;JES NK8SGVKX9BV;/6SH8)L(
M;G#TX0>6([Y1> YB#C1ZCF[TY"Z]TJN#G,/*_1S/V0FBW2_4/+8QU76:+]L-
MO\.D&'B60G-1S('A!NWH;5-O3,$XRT?.%DY$P ,Q!X9VC@TZ^Q*O=('.)6([
ME5X^BY;E?!D="#DZMULBF&NF "O>0@1!] >"CJD6VU$ZS%80&UK#B&T3*H0(
ME/Y&4O0[\9C4E;U= Q3<3"\?2(&_23PZ8QWLQW;8I4D""\8A!<Y^;P14BZL0
M"B@34"9@;PVH)ZF4$D@!J"=03ZY;3V"W]M]D3$ ]@7H";P1)UXT@4%&N05&@
MGESZ^@^H)^G7$^B@I*!)YMD4Y19:%[!;8(NJ Z+&!4YT*)NQ5M&9J .+]&'G
M MBYX&V6!:SLOKF\HM03!;8]@')P@U6&7VA[4/)L(7H4G^.Q?3K:T.+S1ZMK
M7BW]J>,R!9W#S85'[T8]84OU_BZWK>8X'I#"B4<9;2%9+6G?'"'^8V=O8CW;
M7M*A/+9@ZB!6;6FB%;6.+8;C54,CF9  ],./9$$/5+D;VX^NR\6[%F2"&Q34
MELN3Z5JTY<@9Y4?=Q-]O'H 0WF2@8.L6:H!E?;GK#-=FX^@;^DC0/?#9_9S'
M?!D+C1T6K0QQIKM=.XY<4"):9!]^Y)*E*]>LCFE6O@M4RUTA1*6QOP#<T2]U
M0 [5Y0J+X:&ZP,TEG51*8QTWU!;H+J:43/=:@?R!OT@-YWW;GP<<*TAK9Q24
M>]80^\NN*7_IX[4G"[[,!C.91>H#:5;M-^;#012SC6J/W_7Q4E=V_%':0!S,
M1N9"2(B0:<8*F$[,K&LHI_UH;>_>8+&_YN/YLH_Y5=0/?^[JDB->,WCB:N!4
M;.;W):!WGM=W\DI>*-+G%>E35TU!?MX81'V]^]#1=U4HL5!BH<1>E9.:XD--
M1EIZCAO-R1E:OWES[.7%3E[QE8_7!^$BG)#I V!O5!'L/>4^$"W%C)\2.\T'
M_.,@6P(+H3U:HR _VXF]+J[3K,_3\1DH'5V6=ZI#T#O"E5.7:ET<5DY>R0MW
MPG-+[(FK<"\NLB>OJ84B"T'VR"![XNI6*+'0W3BNR)Z\SO0*_(TC'XI=P$?P
MS-JT3W0E7UL;N=ILQ=@E:M4+?83H#.U]'^$6RG$YTP;A7'= RNB6XV1"B9'
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M/7L8+TS/?IA&5S]!I2MM'Q*RS_K^!!*U)XSHORA^QRS^!(CN"SZT0WCX.>C
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M9G9M2P2.\ZSB*CATK6@;U[(#JE=U-:&CH,UP5;-VM"?L+_'XAA&G2?*X-JR
MT "AX2H-P[^ AAFM,Y-10_#9->%LM_9VUR(*,32$YB)))6N58/;7[69_/=F+
M71NL!%7*@'V9\_[DSW(7P,Z(GFU'66'PI@X8%+B&H,#U)71]$?J?=/6Y9\%3
M9X)P#^A$^OIRT7Q(G/!5A^)^ZLX%6*';8HNUBD,T\\/6LL/P.+[O<@)O$X8J
M#E7\LM;=WZIX;\X06@M;B"@^G>4[36]"]W>QBD?W@> D+$J]NXA@PL)#,J$
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M^C>S2A)B\-#=QF"L&_>L[89"JB'SR<RGLK) N9N6,55E(I\MNC;>511P'_E
MQ5_B,7-M9]8>/[KR.";'GM+..-V\,,#&T)LKA,1)+K6;#:N#!HL(&R)L.'2W
M\P.P86'4KH9*MO'0)5*JVY;B^?F\0K$!CYR<))*[O-CL *'ABW.C?CP6GIRH
MDO_!41O'9#&B2OZ18D2*$2G&L3-81TI8L3>@)\HIFC&S.<4R)IRJ3XF]QD*]
MWTU8![C"47[, >;'?#Y0B^0[DN]CEN^#CON_3IB?IF]HNI8T$K&NF:%P,ADX
MG$TDU_JJF5!'&[D<_J0<XIFGSY?P]%R60E-<X%W']K61EQY=U2+YJ:AJ>.J]
M;%@=42.=0.V+@ +;KD#NB+ER(U_(\85[[<*\=A-.OS;K)X0/N?L\TI8(0CXE
MA&P2ZY][R^G/@42:.O%AO)$<CA<W-Z1_]I :772&""1X</(DD=TLC?,5CTX>
M*5?$W,XVD<G$I-*_0[_S %?V>&+HPY^!KW?V:K>92/26'"+;9<N87(F.IZVT
MHB6S"7E=+HB:9C>4YXW"%H-P-4P+%4<6>F/R>-FI7@^SQ5(-# *]6"%Q$N=W
M6"KW2RM(!!%?#R)V[!WN""*&>?V\F8RGS:[:K\UM]6K6G3?R"!'49TSN!B(B
MIO( F4IT& E$'L["=QF_XF6M$<L0L0R?VM-\,U%9HKJ^M [E:5W=8B',ME"[
MS7?ZEV.W8+I)V;V/=?.M?B(1T9,1<!S&I!PB<!P]/?E&^#A+W+8?Y'-5*E5N
MRN[8N<A(Y[T\PD>:UG;,[*;63T1*'A IF8?7T5IMG&-PJ@Z"/E0A/HEN</W,
M',01I?I\82>P&FAC<(GC.H+'.F<7%S?Q;HUO"()I5E+-VW81',#DASB !ZK4
MQZ'#AS\#>]?]H_?CWH  25,N9&(])<Z+22>K-\:]S-"B"$!)PFPZ.L?XE<XQ
M;DEP5-0YD=_;G_L<WON^7;SHH-8Q&X,=;SRO&X.FA25NG$53$W4GK\L8Y)O8
M9(M5X!O-V'TW?W_+3^ZZ\:20B-U/[B"RI[<VQ$^26V[QB6YM."(H./Q)B2!D
M#_[DKT!(*?_0O+OM=E7^HKF0W&QG:CJS(4(((P?C$3GXE>JS>8XEDR@40:[M
M#JP[B3F6G(@"9E,F\=CIA;TZE/LK,_1I3$I4B6EO+NJ9:ZLZ 4"PZ\1I*'@X
MWOM&WF)AXM6:*;4[@RI?F*7F!4U6KC*563]!KYE(YW9SZ_=!0TN$)(<Q0P>/
M))\O@_+-NQZ_AB$M9_Y4ZK>E ?_XV&P7*N>5>:<_1 R)[KCXBORGKPWAR8G*
M57TEZB-B02-5B%0A4H6#4(7/QF8=*7GUVY<+F%Z186ZPX+Y[-PW\M;7(VQ<I
MA?5%R:^HG/@G3KC[G6KB55_%5ZJ)KT>?;NO,EH3+JLIW^(5+'E)FXD*>01?I
M-NOF'NNQHT,$!E\,#(YMQ_27T.#9NP6>KLOSBV2>-'G2NJTGQGFE4M>&" OI
M;_^D3H3D;K(O(DYJGYS41[G=45@>A>6'')9_OMJLD6)$BA$I1L1>'2I[Q=ZP
M?M. HNJB+D4W#7S"HUU'=#SS\X%:)-^1?!^S?!\T"W!L0?^K^=)>:3AFLFU1
M8T?R)&,R,7"*#&G\!0.8KW,D[_!MP2'NW!_)%A.LGK%2'+)JVR[X[*2A-"VB
M$,LB,I:&I&#002S8PB6G^84UO7EHE$IDGGZ4<L7N75/-]Y/T!@+A1$@)48&O
M(Z9$#G]2(@#917KTNV#'PR/)/BA"UBQ=I,Q%K3L>M3*](6+'1R1'?PY%^;IG
M^&AI".20"*<16F-V -T5HR-\4>)"E+CP67Q,/W&AS#3Y$A6Y::FZI)JBYI^M
MV6(:M-MZ4[YKUA:E@I5VKAM.O':9G/63]/H!8;.P>'3T[B@0X/!G*$*.#TYY
M^E7DR$KI6:?P^+3@+ZZ+%Y?%?H^OZ4-$#G JL]DHL^D+D9SOG%<?_G3;]B;W
M=7,^#HPR_4I.[,&-_J"8C[UDYY=]<'@Q.[]^4\_>Z7=N9AR[><C*I4HAFU-:
M_63"HTZ3$76Z=^HT I(#!9)C<W-_"4F>S>R_;\7O1K>6KG4;+:7AE$O->E&8
M(:3LVOG]'(#RE=A4W[[NZ7S] :Y^E,$493!%\AW)=R3?GY?-^CKD%7L#4E+@
M,EIT!U35*3UUPD@JO'!S"@Z@[M@<^+:<16S'4B6'R/3[+Q@K'A@+=40 >5CY
M,Q\?_.V61L+(#_^OM-3H=J#,M,*@+J]^$&K9A-DS(%1D&%'TL +^K;FX**6Y
M-!+U(6F+#BDI"I&<EP+(\_.43NIN[:I[H4YNSPO93*V3R/>3M#"_$#_)9*/*
M_/MGI2)@.1I@V2VK=#C $G^ZR0^:S:O\N%)NC!\>YZJNC5L(+%BN/WF2RB8C
M=NK+L5.%-WNS7(P;$'B.CENNQQ[$1_E_'V-[#G=[8^?[I'F[WU#ZZ<"C[8P'
MR8=[LS[B"V:C=].[.!=C0FL_AF=;);,[4KJ.S87A6!R,JNG[>BY7ZX)?2FOQ
MQ[,GZ<QF.?YC1XD(%")0V"4H"/U**Y?DRTJNS'?$3#;S]! 3'#U_.*#@%B[R
MEU,ATQ7OW#.S/.K=7ADS! 7P*3.9DR2_Z5,>.S_ZA;/]?L.E)/#I%V0O#HPG
M787<!$"N;+@#C1R">?GW!R;8?/S(#\#:+$E5MW3IV!?97G><OFE?YL3,3<J>
M[XE4W6)M%M/DV5ES5DF/.T+RH5J8.9EY%JQ-AE*CJ9-L=O/&P2^(+1&41%"R
M9R@1^K7KG)26LM5JJ7%UTQC-V\G8<'(X4)*_+)T1Z8G,>;*XDYLYX6[XR%,H
M <<U'3\!;8G./;^'+_NW(X(*[""+X\&U'559A&?NQ:&P=D%4&7\[4$9=C[H>
M=3WJ>M3UJ.O'VG4)_"1BK?;\>D0X49*,";QV@9M^NN' \T4+/M8Y%7XPM$2-
M,T6+E@IQ1L0FX$:*KJQ2@L?0H?\V^XLRN")^[!W;A!_:#GQ #Q&?[FL]]KT"
MS_?LK8Z6K$[_^2_\Q_^=I!'10C]T]%-6;5,3%S^H![8F;''A%&N]3."3$7/O
M,J<X>B_&X?G_8(="SUUY6$PBFO;S)6+2?\*.!16/%W/\\O_@E>G0O(3^^S__
M+SR:I0<>DPS-L'[X(5IH^KQYB5.7?$AB XN(XYBHP.M_B-I,7-C>6+/9TWC2
MW[;X$81Y">Q3ZC2;_0^W_!/G9&/-)N(\%IHV+P"(:41Q?K!?^1_1N,[_S+!5
MC$M^6$03'75*UE;,6W#',+>N[4[BBL1R'?XK<B,+(\-_73<*6V$0_X;P"")
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M+;;I=5_2&, @J%RO^I)1H!V5_]J)"3F\D1^45=F-K[EZ$P)8D88/ _1R^D8
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MM@H1F8F70*V3(?/AEA<_4K_"""KKL'::![RT&6"BX5H22QH:T4-?GB/EES$
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MOM&GD( [G=%YT2AJC\[9'4)*\P$.^AA#^4BXHT.D!^>K7AKZ,.80:[(;4OG
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M88#FK-QJ!!-@>IZ3C\OXL17&^S4-#+3N!_==_8MY1# C.O;+!US:_@2^W]H
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M:2F"[X]DVQ1LNMP9&R8&8VKZ@IQ3)'P($7#C[JJIK:Q>8^*(B9O*<#'(5$?
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M)P.T01DB%;#*?"5Q6IA?4G$?X]%M#&.3V3$<F#72('C_K$W_I!BQR'VDH5'
MPQT2_3C*47,@9YB+V[=@7CB061.^5<) I=LC3!Y200>ET%@Z6(P=JE,WT,?R
M>^RQ82D;CP\4,E\(OJ.9/V4B0' UXVF6I?MU[H@F?+0KD9?L+QZM8Z/_=A:I
MP/;GW"#L7*!5!+'\-?.=<OPC48P-9T1F/<)R0LC08CR*B4 3BF\!WPCXH4E+
M  HAO<'0#UL1;RBNC]>$^.E&K EL*;K(\ S?RK!@[K0&W<!NS)(>0(I(D!GD
M8&/A2!<1F4'6GLA"1#Z0CO/(53A< X+*X,>B )H0>,S!HO[D##9$7:3Q16_<
M T6#/&\:.(<9H5AKD]\U'!,T<&Q\?JW8WEQ&N>F"87)FB +. 7WJ^'V<3,Q$
M=S29SQ](/1/F@>T#-GG0&$X?"\?+-+']Y3F,-!AZ"F$O"M"&6"[S )-5+I @
M8BO26&<Y!*2;#%/%C'K?@(B& (8X!"@@F.C#J9!GP0,+6P L.0=X,Q46!*%C
MU(V-L85LC%</[Y6&WWMK[Z=)F.6&P('02,/XD;6MKQK&LW3Q<)6^[77*S]?)
MUJQAMQ8?"DGT<XON5H_29]0UY?\W_&H$68_D3SA8OVYSS*AA$!^/XEGB-<PW
M266C7G8/B!/R9V*Z^?[(BHGB7TPXHHP1@@7V-HN.<I#A*T\2BQ)&K+&"F41>
M:$UFZ3L>](K?-#\;XL-$6RI 2),6,.W%:/]1?- K9SNU@)%UH-,$!DAZ."72
M"CB*<.#^6>,IR<$I07@=R\BE"<:&FY$;'+*?A>S7QLKPG $,TQ:94KCZ&^@1
M(RD[+O9M=RX:QFL#E&1;S&A!%&X7$4V:9BPIK-( . YHBN1?R51=E<)S8FO
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M-8X!V4Y#U0[&0(+9W>PK>R#NY/LC^I02)%_RG<Z@="=?]85<C@@A]&RTG=C
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MEOVWP9XWW8I$;;X4R3DD*YL0XJG]8$"N\ =W.7RCIY,+T[0 NT&VV(UJV];
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M@G$>!#/QI"6,@6@KH#9$?*FIR+M=&V+:L.Y9G%;%EJWK"@927LGP"J)>:PR
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MK2D>C]U'DV%QS,UC+UFW-Q46[@T"(:C[)!,2(@B$B-['0Y$( B7B]V0T)$0
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M8'"-#0 .@*CJ/$^*2]&.R$NIKK%BIRORO.,6<J<3[WF90L2Y*L0) >:& 28
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MD#\#SI^W[,2_J.ZHJ:,(;J/KZ8V$-MQSX+\VQ3B:#_\[2N+%S<0S.=TNO<S
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MU.$N#*77,%2(0B$*?0J%UL$E"$(&,'5--27$&8C)W-@A6.A 19:?:0MCQ&M
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M9]5(=I$N%BI9$576189)-!3YZSG>@B;R89@CF!;-81Q8B@(8J%4RS\X::JS
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MVIN/7@Y$1T*PIS8\+*#:B$]:_)G.+U&TFY"&[F=CH*(=4'C$!M F."RZ*/*
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MFZV.Z<'HF9GQ+=O<6T.@-AL*CH?C;IH"DAJT<YB=H2C$$V\YH+%),0=(W0R
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M.'#J7^O?WYV\NGK9/&A_'#LG+U]7-R Q1C>=F[\Z[>.S3]]V6_Y%4M^-OW_
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M6&]388^/Q'-GSGA08)Y[PU'4=BKU]<ZMW>".W4^@;$$/06::,[T\1LI@[?9
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MA>29<;<W9H_/3D?(&>6!A_!VI@%EO';7]D@RH)FC-6E)HF,.;82B$AAI$\Z
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MX8!$>; 0=D^HU1P;X2DJ2=^524' ODF/+)<0FF1$KW96R$<I*J#O5@&]5U1
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MP ]N'$?=)!P,^<4G,L8J)WVP'XAY"$[[>>(:?5C5))0VN.8\,ZJ441$<F?-
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M^.XWA!O!>1Y4<9HZ!8$4O97-:C,CW2O]J$4&7$Y=Z " 6KZ[!E[6:T^YV=T
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M+8.G5HYP#A\_@EK*T$0_#NW$'P;8SVRG)0,!5;X,$ ((['#/0!K%4CCKB<[
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MCH=)T0'-^I5#?EE6S-\K6#)#<\,^#X#;0<80.\#Y<H4LSG!?"-4@WT#C1=&
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MI:2R#2X-C\B^V!P$& )64-LVNY&P2W+YYC:89$ 4729DZ+[M*DJ3*H9H) [
M1!!.;E+C[_6]-E+O.D71]BKMC)"L*2&Y2'*<!5W$!G^;Q-^72:AC'=Y!+MA7
ME6A:7,G3T?*$P,5:.X8\F7MO0UQ0.ETU\B.X *X.ER5_G0XQRR 8BU2F$QF;
M[ZE0S5XG0"2\$PT%*)<5.P0"8(>>2Y#W+ K,JQ3K/)6TK>'$)0Z6"I?->TF\
MW@I(%B$F7XDG)/=IUG)WNF#*6.7'&**VTRK5"H:X#T.\LT&)^]9^*'Q?HLPO
MX(ESPG3#!.!B/MAKE1K-W1]E [D8?4'!"BNP0KM=VFT_*"O\,-U+YZ!NU]M[
M.ZWJY:[H@W/0J]<ONZ#*+OL[U;V>W=K;Z^YT9YR#]M'-$)X11Y>-G9W=G?;&
MG8*V5.'\IUI=9=4Z.EX$%D)+TQI!(GH,+I$-&YD8L2GX0A9!(P[54Y6A+M.
M.E4TQUA7MZC46RI]J%V_\8U%XPPLA48BO^= UJ)O0_GL!5^CXS#[I4%>1K[/
MXIY&<TJ@$<PSWA)-:"R(5!2H_EW&B-=S1DJ9P/-O!2G1W]M=6& 2"^WH/"Y:
MR9)0UCHC6?DUO3HY/#QZ?WEV^GD6Q2:;A5Q(6O5*O5Y0UMTIZSY[O M.>JW8
MY!_89,J79^LE?@%A^<AP5_(IW<Q3LD%LJ1I93[X/0$-V)532KR8^'D$CF#:&
M^>=*&_CSR(;-4^NAB'JA2W6_64*]CWB8!?K<MC-8WZ;?PU]844#\DW9[;7NK
M9,<_:7,?(^;SJY@8#[++>[?+BT:E]@L8"7.*;'\V+;U&MK+58\J1Z)7AUX@5
M_5RP_9BIL^8A([>N@'^6([S?) CH,(['T?-GSR:3206>5QD$U\\Z86^((;IG
MPAG8X3/'CNUGM6:]NE.O/H,MJM6:\(]F;;=:WVGO[CV+KYM[C69[[U+<-,JU
MRC >/4!U\JWER =(0=A_P:-$3WPUQL9(?Y7DB#^_5RE9N0O>B7" 0=O<QZ<3
M7X31T!U3KF/!CSHCX3N96.>RQ3QQ]3^%8R%PM>MCQ!/V7X0T9C .K(Q_ &RO
M$F>+YJ'R#W$H*N4&G33J>YX.2<%7.%+Q9 PTRZ0<_/\[>RIO0:'=VJZRJW?K
MM=H+ZQCSC>"F\*=PYN5&JUIO/-7"W,X+=%5C72 ?SR ?[Q;(QYF*F@+Y> 'R
ML4'\-=59O\DP>F&BW6ZBW2,2L;U6VH-LV(]NSZ]L MZZ/X5SM()S5"_8KF"[
M?Z3G5=T#:QP]K]WF7FV7/*_ZACROU9RA6<_L7OY1_;']HV/1#>'6RDEJ/HR3
M5 CVPJ0J9'MA4FTKYS4JC8+M"K;[1YI4C49KITG!['9=FE2;"F:OQZ2:6XW,
M0S?F&E.[Y3?WLZ5>)[Z0MRC,J,*,*N3Y3[D_!>>M8$8U"[9;L;Q[[^[EW06[
M_D+F5[79;NW5Z]7JWMX>F%^C>KVYL]=T:NLUP,X1<--APTMPMR\V5)/YM#_U
M[$GT4)&KVGI-+]O'*)95;W/KVW++JUIN-6KU5F%Y/6B=YZ/*N$)U%*IC6_:U
MD! K6(BM@LU_'-ZJX/Q_I-'(?T6CL5IMUY_!NH(R_KM6K>[<@-WH_!R!.U=:
ME-;*QJ2ULAUIW=N$/.W%"!-B[; %:>6-1ZN(V!5VXS9O=*%0?HFM+N3(G:U+
M>/U?I6_HIR+10AK\<N9E<R\U+ZM[M3:8E[7J^NS+3A2)V/J0P(KM2!C(E0P1
M>2[&L<2VD@$^M!C1F).SFTT#DX*:23?\TD-0I= >BP1H-+J/^8D"9EWV9_J.
M]5IA@A8FZ,^XT872^26VNI CJYB@]?\NQ$$A#K9RJ]=K@QH&9*/*!N3:FC4N
M1#B2,^,,ZY'SVYY FW+&DMS[,4NRL, *"VS[-KH0N;_$5A=R9!4+K%%88(4X
MV,ZMWK@%UEB7!?9VOI6E)I@LM+)*]/DYK.[0%8, /HO&B"K?I'D>A9556%G;
MM]&%6/TEMKJ0(ZM86<W_*<RL0AYLYU9OW,QJKLO,FCO_SNK@#,^9M.G,',%;
M8EUR0B -VBL,K\+PVKZ-+@3M+['5A1RY>P=%K5(K[*ZBN?T^]+1>6VF1==2H
M;:)/02*&?*#)NFY/E6F! ;1@'#%6GT6)S?,&SQ)/0GG4&G:YUB3SJ-9R\*^R
MY<&HZM(579T>=434]AI-FOMG.\$8#;&Q<>MS' P8^+)/MEK7][/#KNV+J'QZ
MXXFINE6]6JT;IIA5R- "(:00HAL7H@5HR(\8-$7%5,&+/[=!LP$0VL4&S8?0
M]7ONV/:,">:%4?,KT7UAU!2"M#!JMF3OYAHU]2)*4_#B3VW4U'^^*$UMU_I4
M.:\<5++V1ZW1JM[-4MFKM@M+I4B%_3P;7>2]BKS7+[#G=[.HBC!1P?O;P/N;
M+2X"P^RGC#:MW3@KQ&P112H\UP(\?ULVZM:*ZEKEY/UYP7JY'7-],%GBY]5*
M8SPSY!C_5^9O%.U9!7.N$%8Z\3W7%Y;<NK_VS]YBOU4,:ES\=\'%A?XL].?&
M6;10J3^D4L\/7A7<6'#C RM,TI07]DW@!Z.I=703"Y]P^\Y[0S&R"]59J,Z"
M63?/K(7J_"'5>=!Y6W!CP8UK4IT'MM=+/(HT%_JST)\%QVZ>8PO]^4/Z\_#H
MN.#&@AO7I#\/1=_UW4)]%NJS8-CM8-A"??Z0^GS;V2^XL>#&-:G/MW97>,(I
M=&>A.PMNW3RW%KKSAW3GA[.C@AL+;ER3[OP0B@@(<4'L5BUPR,7%[<H.K_P?
MSLE%H]0Z-[IHEB@:I7Z!/;^3^F\6G%]P_J9-AH, ML8:VP-AG2"1VCUJVSZT
M8YOGESY!*&+89QZ,ZOK4V&,:&D[02Q"\^&E.##R+[:XG-BS =C5EZ;.MWYV(
M'/?ZQQ=?J<ZLP?@$B8+^"7^7EE>M4ML3HQ?C(*(TP?-08+K]6FBY6?T7OK"Q
MN*[=NQJ$0>([Y5[@!>%S15SJCN.;.;>C1U?:\"@I85J5JN*$YW[@"[W#EIW$
M@56UJOC<9_!@]><CL/Y_L]UO_GE,<WEQYB^28(6.9GU"9_?N]/+8BYH,W5B4
MX9.>>#X.17D2VF/XS?]8%G8 VL"<V.T'AQQQ!YX;6;+=T7)]!_L#81_C='CR
M__??__W_6T,;^+V+L.+!R(WQ%_"EW>L!'6!_ <]#/HG%R&I7:T^Z3Y_4JD_Q
M]F=B(.M <'AR99W[L"7'<<=EV);K_.]OESM.H]JVV]7+5MVN7C:;.ZU+N[I3
MOW2Z>_7^KMUSNO6]W[@CDJ\X/WGYOG/QZ>SH_+)6VVGNUN2WC^_24,,."DI+
MOG4W\TC9?MH-/ >^3)?YGV?=A]SXI2(_OT2SA14U5"B^)6Y(J/K1G5'2^,*!
M&\4AWFIH1Y:3>%.K9R<1<0XP5,@=M?"8KK B6!Q\ 2S@PF.Z8FA[?60LO!%(
M8Q'*'Q#/)3Y<1/<#<3H,0GA1AX49:4HMS-E: $'NV>-(/%=_,;>G#>\L9?O(
MOH'?P@'Z6J>0E8(B6WW A@E](FT,_HUA=,C?X"=9-3,3&*C=.2S0@CO,-V^L
M:F4W[0W+:3/C.6B<]+U@HOA+_9LDW_-N*.RK\@3V:XYVR]Y3?V]WP?Q*8JG]
M9M[65&YW-2%_A==<Q7%;Y7T?003?(RZXX173N Y>-D^@O8^[7.SZBBM^<J8E
M^2+7A!G X)^>)^P0%%L\?.&XT=BSI\_IISG[O5ZKM+,V^TZE/L-DQGTS-ROW
MA.>]R&T;WSEWAT?6]/6FT9_+F];8XZTRY0/^^7__SYW\#6/_Y,;4Z>0'HLQ2
MS.[#\Y_;WL2>1LH#WZW4F]KOT YQ Q?5JNSN_LM*_YK*+F,UJ &-?<MH.+XJ
MJ^/D9[>(4L,_FW>X#TVP= 8-@R-LB2OR7Q>G!W-]$_S[\MG:9%6 <7/ YD$T
M [JQA/SSFSIOM[;;;/D99-3/)U5_).&[X:4?@OO[?#:Z</<_C<%<31[,M?+)
MY>*,&!NZ4SQP+1OT+'JF9HD=5WB<F-7X3Y1D'T47[U1:< D& 774"AE/69MS
M]N"W/T('!% ROF>Z8,OH?OM77)SD&D[RD=:X $7U/]W0>O9'BN0U^X-'/Y"?
MA/@+-?5KJZFS -XOMMXF\?>?\I!_/G52[/BZ5\Q*8 :ML=C]M:QX&5XF#F!)
MO^_T>D'BQ["X!4?TL)GP+4F+W3,A7]N>;.J]%E6$#/,APV;U$4*&9DB(XW69
MF%#F(W15&M6Y<<;KP'46A!G3+$@W<*;PGV$\\O[X?U!+ P04    "  KBVY5
M .)?:1WF  "?3 $ &    &EB:6\M,C R,C Y,S!X,3!Q,# Q+FIP9^R\9UQ4
MV98^?$B"Y)RC9!&0++% )(M(3@(J(DE 0'(H 0$E"@@H"(CDG'.2+"(@&8I<
M(!FM(A90X2U[YO:];=\[W3V__\S[8>Z!S0?.V7L]ZWG67GNM4S_ S&"6 4IM
M=2UU  <7 '"P7P!F#E %\'!Q?WQC+WSL-P$1 0$^/@$Q(>$%(E)B4E(28A(2
M,G)J2C)R*G(2$DIZ2BH:6CHZ.E(*!D9Z6D9J6CK:'XO@X&'GX!-<)""X2$M&
M0D;[ER_,!X"*".<07P(/YQ* 2X6#1X6#Z0$XL#@)<'ZY@/^\<'"Q&"\0$ETD
M)L$^4$<)X.+@X>'BX_U C;T;A+T/X%,14'.)J5R@T;]'>,F=5CPD(9N(^WI5
M)YW!*(Q'XKY'Z$5B>@9&)F9>/GX!P<N24M(RUV3E5&^HJ6MH:FD;&AF;F)J9
M6]@^L'MH[^#HY/G$R]O'U\\_[%EX1.3S%U&)2:^24U)?OTE[GY.;EU]06%1<
M75-;5]_0V-3<U=W3V]?_<>#3V/C$Y-3TS"QD!;JZ]G5]8W-K&[Y_<'AT?((X
M/?OA%PZ A_.WZY_Z187U"Q<?'P^?\(=?.+@^/QZ@PB?@$KM K:)/>,^=YI)X
M"!'M]83LJLZ+W!(&,+K['J/$]#R2*[SP'Z[]XMF?<RSTO^79KX[]W2\(0(J'
M@Q4/CPH  2O!_.!.M6!9A#/4-%HRFH+6O-?V7LD"Q++O28")$//-[1P^A;>
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M>OIOBAX+@<7*@OLX/BU]_3:7E-DTXK_\O?VR\_02/0M42(LTF!<]:J7%&Z?
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M,EN5:)G4:XXP?X^([K>^ &_QM>PY8_L>Q3==.Y,]);IWJ49&/]HRW_>^N<L
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MN)\VF+H5OECGF(^(HSLHEXR(DW<G_:0AWHT4YX>+?E:RH]O(JC4-DW*+7*1
M&+[;$7MO#=GR69,4O\B5(MWV,,[L[>/1YI>?N@N5FK*-6BJOF=^!$PN\KY?
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M<RS>,$JTD&8BT%+P&>)GDH:@ZPEX:NW+MX()OTAU4"#N!^G<# UP9EFBW9:
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M5%'C. YA"NUXGB9OC;#O>FQMX>3O^H(BF>=FRU=AJM,4K7OSS^BY2%SU/U2
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MG&0_KZ % ZD#BXN%CBJX2'3D6=:61(2!Z4?)6 ,^&JWZN!D$X*]K SLK*UG
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M6U:D_I5>7X!N(JA0^F$<F'U 9+7W0$X:LQ0NT.!*9G^Q7)F7A@T838IJ\1J
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M+T)4XN E&T&%4''L5JM$O'I]QL#E2H7)IFCX#54\J\^CN>^B&:]"CI2/$$3
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MEY$V7)8(.;?>>RVFU/Q-JY3I:=W'="5(LFJ-?*@1KA0KV!J>,TX$&E@L2"*
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ME'QYQ=$/U/G]6L]7R/-CQ70Q\9WIDB;&RXE-\NO&ZA*?C1A<*=&Q5Y2N7.'
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M-#K@\EEJ8&.-W4\CT:D_PD $'*NEUXN%%HM4\1->AZXY;.'GR3M_PNAG8.J
MI,[#O:&R@(V?,5+["1BX6NO01B;I$U_YJ9\PNOLC,$(]6!(=I"_>T%W^$2.F
M'X'9]")1(?[_--U&P&:QR'K:^AJ,:>3>/CW.?U!G-'-<K/WTK:F+S]SGA>;E
M21]N=(5E%<[YV=_H"K&EH#AX;75$[,^&TO\! .#W !1%H2F:M.CPHI@O+75H
M354%N=O!$9WJUAS%9R/UHQX*34%92;^]Q28V$]9(H-$788I.E"W\1DL([@CW
M0FBVU,F?-PQM65)F,=X&A[2"6=1HWJKKP^X1 4BE/\$8_UTJW]3^B8#=(0)>
M%B3/0@@+.SB)HCO8<?ACB>"[%T,YA*)98'O])ND!8NJ)J((]_E_2;L\?S0)1
M7TW65BV_(3#=)O\V&15_: 6Q?YL!PT/@P&Q09#O>D@A0+@\@ KQ'H(<+-C^^
MR*\*7H?746R7L]3LO]ZVPTNR_(FUR)_:@^I/#DOX77NT@#'K"#:2Y2I\0P2,
MNP+QQL"?7BRNFN+SUY0."@-7";/>R22F//8'4VK\J67\_^#$<[]I&6PB7A[>
M MT4L@+MC+;^ONCV_?->S2NHX'XW]'\OK'[[2C@^:,>_\_7_!*JT9?M7W01M
MSVX=V]I+"&PQO([XN*MU<+& [CF"NY;## -O*%\?&]]]/S]XMWZ4?3?HV@G:
M$P$4.7?!PJ/0!G5Y"V=;89%)[Q/"H7>B=]C86 D'=S (/)-,\Q@SIC,FHV&R
M\+25Y/#E)U.Q:C!'82MZQN"6&P:@@1'DKNY8P+XAU>C!Y_W@OZ$HIH X=W#X
M88)G-W2M)HH@&O7C\Y;K1<*#G3>$P<8=J*-BYU^J$UPK@5MW"K3'7 K<7YWZ
M?27R^^<#X\^@>.]Y4-G[NO&1KA+$7RN=>G$B(#@>UT4(M*4@[%<2 >CY?_)"
MUY%N!NQ!M_)$S'7GTO+:W]&JX8F$D_I39Y"N@4YGZS[&3@ /:.N$)J/P3)Y7
MA\I8GWB9O=&8G.0]QAZ8-8L^UN5ZCUQ@AR.?_36MZ4WYL4Y"!.ACY6,W_1I'
MPP&@$HDW_\+ N^ZYI$/ROQJ.?3-2<[6T]]>S#$1FO5 ]O(SONAY)6</)\JVZ
M=!W_0UKXZG^I\?=UXR?9\L):QZEO8WO[YCN#GWVMAIHF#%JN<*MQ[@W]U)9@
MJV\(B%[QK/_MX^D0/]B>4V0-_O]G)NZ_#=WV/H*XI8D%P@4W[AD[>&WEL56,
MD^>$CY7]1?EP6&-]P"%#R6/=>=%KOL=OGT!,@38;?7G_GT3J_QS=Y+@^['A#
M=50C]+2ABJ?W;$=V9QA"M?YN;##GJXL@]I5_(S7X#U*-<8LW\9S8F*,!!XD.
MW:00%E)#'DD$_"LV^2^E._T[NI4X74EL-'6Y5L6LP,B&I;RX9K@+ZC+?=30F
M5GY7-E^ %\NDD[H/7(DPBR,">#CJB8#-L9L"Y$T(DNNQJTASF%T4=9 /SMK:
M_;!/(J(-\UMV$73%X.#\ OAN$VA-D@0%L!_[##[1@=?:E,_93L-])0+(%.D7
MT_B*BXW!3=KJIY/3K?E.R^R%KQ2?4'YWK%C]$1F%3;G0&]P%K-9MW  F'ZDH
MW4LPM'WTA=]*B^9HYDS">2+ FD]79;5L?:T9RNHVC(:M0,S$_&M)^)ZJ%<(D
M/S,RC'@TKO5\:>?4$:!3[0W;B2</J?,_>>A$+>>CM9B\)'%+4UK!)A(81S=R
M+>S+$ARB<<\H*47F4ZR%:N;19\WK!^LEP@]ITE.&.M)ZMEH"T5Q"S>PVB[+2
M.9;YULOKJA4ZE[)Z6-0$%KG4V71U[EUJN$=WMJKK-%X?$Q6(%T?3F&PT5]/"
M;#-O#+I6Z'J$BS=;.Y<R!3U^3,8GUW>BB;'*;5KW):%AO.H@966%XXBG%KV;
M/Z6N?#Z-P?+4<!!S,(9*HV3P[4%VPGKO&*&-< 9L*GI6W\Q24[8+)'2$DAIT
M1("\ZB"F7D'?RP/',UGH CUEE=0:BBAYF&Q2UOOTT>,/:5=;GWP08J24,SSY
M=3^G>\AT<BT*1HTW1%MB9H.Q5(VHEOKG[WJ7I9+=BYXI8D[E)_"915-P+:%7
MZ+2>$YJ@)9:!$U095O6* Y*V=$T5VP!#387,K")3ZSO'C^M$F(VF3'Z%,GM?
MPL9MV^',WN&9!C83,(,QDS4*O+<3YK3ZG8;U5L[WG@N2P(ZH" )ZBIEIHMT;
M.I4DR;ZZS2XUW?72PGD>3YP2H5+NF4O V,C2II^L6RT^S=5>7J!';];@@J+C
M3#M.T\7@Y8!SGAA51.\88^>"-L,T((-]EDD;#_S/1:Y<%2%G&+E!=C1G## =
MNAN&-+DXJ,CC!M\^BY5YH408&7#Z8K"ZJGJ'.E8Z5#V./)L(J/,[6*S8Y\<#
M,14O%$5]N@D7!R4]C<$/N.7[G6K,H*QI<E9'KJWRJAV[\^FSS'NVAR_HCO@J
MOAHB2."H&L<82K"W/TQIT2W4<]0-;QN;+&D'BCR]U-?QLGSHTU%\UF;A"0(O
M[K;6B0;T6ZQBI)?X99739=NX^M;S.R>2'X^^7W4Y>64Z6G:H?;P8VB!&J8:U
MFPKXDCD\MC#&B;V%TO'+'E,]7];+D\1:5'1Z\'Q[\ZRZ@$@I+;/:;:%/]9?G
M=?98&H H1(,L)R332L?D2C=,JZQTE[?8,[O/_&53YG-N,Q8R>S)^)K*=U,06
M1# J*F(68PN/P,LYHK_J925Q&F2)>!0<U[_%4V%.>Z/E:KJ/M)<BE MX#!XI
M+^]EPF':'?2.;EC%3,XK=;C"++6R\TJSU_"^E1<UQA*I]77G05RC!TUV2+[;
MW0([2063P8L5@XD:KB?#_"[OHE3'FE_%ZGW@3TK>_H#CFD $ S^XA@Q?PQS$
M1^9,YI_8,@8]N''?I-F;*>1,]:4I]WB8\.?;A@Y=!H ])(%!1&@?ND^U?[MK
MWVYYW);P9:-O!60Y7O)E?:/F\5JBBWC:I20QK^MOK:O+4]\:+[JX5*>]G?4.
M;;?N.5^]/N24=H\Q$97#;W69,VEWO=$E<7NKKVB.C&:ML?;=/%NBMJJ]8G*S
M'FX@^. ]U!)P49\BA(^W$OQ>]=)N-(@=L 5EP-OB/"=6)*;N#LD[3HZ>;QG#
M;BX\%9.ZP7NM^A9+!5\%0^Z9E_M(^=!Y_!6T,6\+^[GLDG2;!(_.&+<TB[J#
MYTORC&*W,M_Q!%.DPU\2 >:P  +KH \?W@6;7?AVV ;5AB7DYQ@H;#ZR*/'S
M*G=@J%=F<3GW[:I(&=E^1H&73!+X^=CE@WQ)Z G4":<#NN4D0GQF(Z(R:'7J
MEK6%7E]&<,+%9M7CZF_HW+#!I, P"$Q7AML$,>*5,*W!98DGKP?EY#?87:;9
M45>SOZH0LF3\I>RS3#G6R+ ]KD$P.%+OJT1U3+02)[V:!PZT#<'H1@Y// W(
M5<* )ULCM$*%S0:VQ.B7T@2MQ:3<GS+=6!]YVC=^-(&W8T39S$I>M\*G)>T8
M5A<)I<$AD7O3LN=A&89+L1T9\]6BQ:@,*TRUD/IC<ZM,P7<\PGFZ/.:MIM%T
MZ?-_;B+_OF6K^-L&[AT*RA_2/_/]?BS:WO_; C(:7&:Y(@!]##[AYJD7U3AD
M(E8SN)7KI&&KV+LB,M(A>..3JT3T,^VG(!3G$./DVG!:+Q'P$<HL1>/XT6,H
MT,L"L]BZLE<1*'4EDT%>D\T-=:6?6?"C<RNG\_%*&$XP*,D9'D0$G)2<J:_L
M,UA#TR8?&=/_Q.!&I79YG,/%N5-IB]D,/;[</-GU;7];$[>3J[^X-Q=:JXFF
MHQMIRW.+:MI!V-17KZ--V5D^DMUG](MZ-_'PR%@@$7",!G:[#W^E"'\=IX!&
MD'R:H<]GNYJ?:=)L^5/ZBLM_3KYUHR&(DFU["6R*E-!B4.<HB*FD+LKA\9M7
M6A7:,$,#5X0PXTWC[VG],' D:@86[L,#2>/L*Q4"T5CM5E:Q!)X%ROJM[UJH
MSU5/Z/9K+XP#Y:DF[8+2N#'2R1.%VEI]I1I"(L^FFA)=Q4="IJZIR\.$9GA/
MNBO,DQ$![ B;_?$ *"O^U$0'+-BCC!"%CE =OAG<1 1 0CD>5+VNNJ[,-FZ#
M;\+7?5P *]-"IF##:U18NFTK/E_HI"G*^?(*V(SVGU?:_J>G+6;_87MT#K'2
MAGV\TSK.YDS#]EM^4N>3P@GM]==7N9\\A[I5=&S>70/+ZN82^@@<59B*5@2'
M@5'^A<1["2M44(:;7LV\PS11C;5UJK/D/,\\TOP1#A^5F3"E4UH0L4_X8>8+
MMVM'=FJD61I02#<E_!WAE'EU-\GMVD\?4]+M*Y>ZG1=2:+.+KS&4V)ZZ8<CQ
MGGZ.NW(3;@9DP L7U=-*D]6>.X =1*,^)4U]GJGM<]_V6AF=FVSMJ'GD-YB[
MJ"C8<ZP\OP!9V"HRLQ8TV<.H&<F6X)1J%GK^6;.R^\-K1A>?I'ZTI;C,:U)X
M,*_@LKG@C5\K\^L+5O=(H7OA!7R'L]EK[%T=4W'PM*:9%L_2JBS(K]*UOJ-!
M^QQ@;U,@>ZG#U%MN1.U8<T%,ZS8;@Y+\VY"V!U1^%6QR+^3#R;]XN.-B;',7
M8X&X&ZM/['(P7])>'R^S[ZLJJ;P:Y#Q"?B.]L9CEJM:7-"6I7C=+]';(FT7[
M#@>XPFJF-7.H>H$[0\6PQ0OC5") 8O6AOUXF]<2E8YT7!<^9E)IBC/%$0 >!
M\F:\C%B8UM)GC,S[ZO!V[D$G<0%K<F5DAW9WN5H[W2./;LG]8MZSO1,AAN9N
M@007PB*V;9MSJ, *=-I5WTUT7'?HZ5SDF,)-!:-;YM'MQ4&GA'/B!)"<Y)6B
M6C?C#'"M4E\0(9,5V&/CB=*!V5^M<[.OG^J@][-8QQT, \X?:Z$\NNYHX&DS
M,E(+@WFZ[.Z=6EY X<<'X./3;OM*9U-81[B:+]X)J'0&@I^68BV>/7*_7CHK
MT&*B=:$\M_/*Y8]SD1"4,YC=#=(L&QGG(/;"K*_S=5Y#GM:Y+Z7+3S<@-B6L
MVSR?ZRUJ_(%6CSZN+MT@N=XK=L[0HRU[S:/U 4^D6/H+Z%[/\%165<9!,L(U
M7L908.ERI$!Z>;UE,G.(Q_M076!QX'C=@?6L&_R;Y;X,2C[$IZO&,G6F_,M8
M\H?P?4NIBLGQ8R:XQ-O]4B>*-H>I.%A"KZQ*R34\]9L6/J5T9CJU<%?WG196
M12FN(::5*:&G*>F(M9E*K.>V(C3Q0U3TB?(&KX[9U=&XU*Q0M#R'>[:1&WDS
M.]=LF77FF(FQ7A?Y.%^+C%YXS6ZHS!D\,G<V?_C^2XX9ZU'W!6\H8-O^GD;2
M'BL*[@<O!971*'MJ6$:.BA;ZMS\VQ'W;)G^*#5)C:^.+V;FQ**Z7GS-:UU-N
MJ!%4Q?60OBH:^M$!UEL7AQRG=P*?7!C<$PFJHX;G&*I-VR2>UI8J3:2!TB!S
MHSCP67I[T51<3;2ON[5"N-DC=TS\A^ZOKTDQ%<=OR:6JW;OQL@7XI3P4+;X-
M$[C$*^!\9=C?[=XSO=#VG0 H21T'"WW3=MDI<-.LR]J)W=7!:#B(4JY/1J2^
METT!:![I=&$X=;1)M2;EQ? )!2U..D>3NGRW_=O8HVD\P>K8DVZJZW-W@N;V
MU7FK \70-ZZ97VJM?V [T1$TV<%@;R_DV01C+%6P66N*^8(>K.U;W5S20RU>
M?EIHM_HTHUC<[FK^AYZ4>+?9CV=6*>0':C6OVXTB6CO:1STW]Q.+@S=\3'PL
M_:0*.IY6T%#GDW/EBX<_-YOG8.4?EM2T$ZFZ*WE/65]%(.;DJG9W>*1:G6?P
M"X* E6QB$#RP=/N#DO/;!E.[3,F*]63+!]>[HIL,S[?H.)QE4 >Y"@^TXLVQ
M"L%A8DXU7YT?]&_Q<B)L]WE'."3E@I G.\E5]8X82.TR3=F]J79>O*U^D\9D
MNO/EH^1[57-.=Z^[I#3\XYT'8T0 YK98F&YU1'W9A(CR1!=-"MBN#UE^RTI/
M.%>AN/VCR[DZR"H[?H84N-GB;!9WT$%UA8(Q%F;9K%P8AWI=XTS0-3.<[OR
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MF(^H'7?/D?F,N6=#\C[P.B=5,YB2^$K+V\.K4,VBUS+10>A&-H^D^E>+ 1J
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M/!00IF,[ %$L&$7EG*WAO8&?FY$]<]L,[-*QEZ!G?$%7<8 L3Y"+HP$<IF@
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MOXT;_>>3Z"9XK['.(XX374T'Y10E#A:LU;><2^@[,67I@$U7!CWRX)Q,G>,
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MI0UP98(%<G9^WCOQ#GL75\>?CP^[5TT4$ UBB@9X-D'1.+L $=%,);1)S-
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M25EZXQK+#Y;)>7(MZ,>T!?2-U*3FS'<H,C@@).^<&4@O!QRL 1B%9&H8?7O
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M:XSAXTN).GJ5?,K@Z?;[K=T=701FLO>#.,9?X(JUFH^%H#*1>R9#S1B>1H6
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M1-X.4=8@.2=&E[#(JGH'^.4)W5)*.?QN%"68 (JBB9$P!B*,B-BAPMG4"-U
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MR)7VW90;-)=O+.T-LHRR!?PZY?H%EIKH,C2E\ZA QAS3)=A@:338H_,\UW7
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MSOUAWX6$J"!!>^2UJ!*P=''9G.(9K8MJJQ-6/Y)-UW19&%PV0L"F9:!I(Q0
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MM>G&'R823/*&TEPI&Y:2A:4W+_ON86K"=9+.O$]AD@4C 4^>4*O,#@HR;!L
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MW0HBWB&_GS=_W*RY)HL\MD**=WNY*\Z*2HI'AM!LUG#2PR+3W&JB[0A^N*$
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M=KSF:6!_CB"<4.0I%]X9 7@H<!Q+IAB.&)PPICL65HWOM3Q)V4'H,&E[H.3
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M/+L+KG$S<]1@X#^/"31O^TO->+4-,(:&U8P_K]QJVI:U4T+3F/V_Z]O-S#L
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M.WH@2V,FE9OGTR\3BA',GRR_3$:"-AX:F8S1E@50,L:I,U8WD0PW0\W:YFH
MR\63&]=O9^'+Z6. .;!Y:=0O!Q=$M3@3[<<1Y0FY7G+TCLXCBW%%D.0 O!C8
M>M'FB*9P2+5#'7AP[##B0[IFF&PCK!!PEN6B=*]C/O/C\YG?[IW//'OY\N+]
MQ>M7[R9GKUY.SGYZ?_[V#'\^J SGOWO1[-M4 O#+%,T&1],+IGL!%&WP!#*@
M7#AYP20I^4F<)8[<B. VP$E[!:#*K <!EPDJ3-;E1ZK$T#T?L)-&5^:'--0
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ML,1(Q407*_#6""!J@!C<VY/X=IB?7T;.7  =&)9'$PU,P?C$3A3G*HT^;,1
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M+^5>Z@<,*HHF49W%^P-#XJRMIE1S_S(U@//?K_R6Z4E5]L%C2/W3- V([>W
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M[^^>J/6'>%%L/J_Q=+[T;P,\!<G^JC)BK!_EWRGZPT-=R>A\CA:"-*#I\7
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M-]VXP8DHN6/3;$+Q+U"-.&:D[C C=1#2O^_":6J34=%:5\X^OSP#+65,(:O
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M%Z)?Z8 8:4DIDV$.);A*,>I5&FJGVW1XM]88@._O]YF!?VJSHM$?QM^9FXQ
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M60EK2S'YX$"QI'9;(,NI-QW]$!'G7PU>:T4G<#B& H7*[4TLVND6B&."*[,
M>3._F#^X?G)=+C=<D"<J,GB13*43)3'-0 #D0; V![&KM-Y#$ EMXCY:+3 X
M7&O7)"9&,;]M6Z/&KG_;XUEZUJC.%I>6LN2?98@M(U:!]/V'O4O=@#6JQ];]
M%8CGH#-6=DGQ+GZ!59=SD\4M##<\QJUW&+<^/82X=4QLC,"M@S:_?SL:G*<9
M&AS1CO!#@Q[@LH<C0M?X_U;1>Z#K5H#KF_D+%__[5?77.-!&](^&V1_;GJKP
M3FM7<KVJTM)EAFW@3"!E9=N7Y"4,/NF4M5%KC3LN&PH;VK8V/[4F;=?P>7ZH
MR+)-6U'1ZG^*JJ*>*\"$V47W_8CZ=NYI,]VL@WF4?MR4\Y(*T-E7\TF#.M?>
MXY?^YWA0IF4V?"%F():P??S=FGXZ\XHD)-SY7C'#@^W(%(*.(R&^8!4%J6GF
M5+1"-S?"&JB45JAFC[_!J!/RO6HL#*1B$^) %!]DBM>A4!0OXY/]VN_?ZC S
MID' (J"OE<AK&:I7<+%VO=;BDZ;C':GGR;=H(ACEB.LTQYR8DM#ADMMQ,\,3
MMV.3:+YUP'D6QA=U,E5Y20(:O0#LS#"M$)?22\7R%YAA _W#%GPI(7\WW')M
MV0?0$CEG_&0ULH6,&L/6\4$:'+0L8=@METD.9#O^A#:/!/,$.L0OMF$JXCY2
M&D$"=N]FSZ@OQ3;L(GY!FL& +-0H,,2],,S 25WHMG]X44GG-<\41*"#]J(!
MER>YS.Z?Q+4D02HF_; ->R6 %E(%&,&9Z=*Y!?-UGY9N(D;NZ(_?H3_^[!#\
M<;)HR(HG_NA'5I*$Q22+?1G1,Z@;E#.(!$""Z\=B*]@$-D>X#+.-B',1&OP3
M'9&DW<Q'UKCYU;@'118#48@@T<0F$NUK=CUBHE-O!U=K &J332(KPM5@?]7J
M$AG(E>+"$F#<1F]A2RQ  F&31ZP$,N!=Q0Q4-&J&6Y$]S(!QR4"6JJ 9>#**
M 1D&[)JUPZUC_L:\R:'+'[,920IJ=@55]]#VHKP:G>NQZJ*8L3F<-TLVFBM+
M/A$A&"4%(<7[$GS#%A=,\"_I-YFZ&^?K_&35QA^A!*F\@8BQ2J6R, ^/IQCW
M-X:#FFJG0,]#(1'^E;LQLXP5BO(3ZOUEY9V'!#9SZ<_0$A)&,=DO/A.Q7$D#
M45I.NQ6P,))YS!)QV'X A%\1L_._'%*$D/(R9I>[U"E52$3"H4VD4+!%-W,&
M?$V;YD.'I5-_)V8**0%(;?1Y[$N*"9W">Q\2.J^ :M'OOHH:# #C:(Q;-KG%
M[Y73#.'OZE4MD-\89QTWS3RNA-_6L>X] <1ZB-H0%*]G%73VL;[XPEX;MF!@
M<0)Y6RVI/_[SZ3Y<(.2"2&R&DWX\Q^_P'']^".<XI_K=5[I<WX*87D5BA'NE
MTH*GSF%$FEN#Q1F9$ZF:7[K:M=2(ZI?9?7NFA-ME2>F4W,VJ]7+3.3=[9)F]
MM2$]WRP2G0XDRT0A5<#L$HH VW4'G2O4R"G5"VY[Z8/5QSL[#G;(JA/R=TIE
M^SF:;E56@'#,/T0QWI(B)R/?+5 Q01!+S:42XN0&0LK"'S5M<3]*MM,-'Z&:
M70GR]5W49'+R^/3DAZC%HIC\U-27"X<YE;-^";CTV>3M^<7[8G)1SQYZJSEY
MZ0^'&PB__')9"ZON1R3"4'\LVX!2>H=E61DZ/OXP0/?\D95OV//SMB6N F%B
M(!0(Z,$ B5AW5:TG[68)AZ;%S<=3,3EY%DT$9.(PZ:(GP",$5;43[Z64C/E'
M<DT2BY]]^KMCS3%:OMY<"@.:[@CVL(C1$Y<=)4OOI*\I-/6PAN'RCVIP2B8\
M6G7:4Y0^4]13E'V2_9N+[ #\^TJ[BTSFFZG?#)/=%\@"/$=;2]9U67UPN!9P
MH:<QU[ %3WK@FD%,QF]Y:("LJ(-AU OGDYD^.V]4CQ;OFCL)<#=#=HFQ5,S?
MFN\LZ\2MOTM7Z;\.F_3DZR,VZ8A-^N+8I/^N>.2;0XA'7L^(B97D^UX2*Z8-
M0R*"S^#O:I#MSP._S:B20UW^E)P('+!BJ#,:1R.%EB#$DT,<QTF%L5*;9A:P
M8Q7UN]1!X2"< *^F>T\2+$$OYE3C$LB>@O>6].EY=X'*0DM.;+6.5;Z&J1HY
M0KT+O-@0%KQ#]P63INPWF%JK)9U%TDXZ'9&*H;FL_9(SBF4=<8?(SX$"+(LZ
M"KS<.NF8VB-2U&&B*O!N:Z=!Y9?-=3.C=*<FFQ#SG\KO7&K+#W./^GWX .2
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MET(8^3,P1$Q+L]KM9UBS 54U=_-!4[8B2<<<O<'4W>;Y<0[&7^APCJI7T6E
M_A=#+?WKO:[:?J-ME3^;9%>L)0:?8*^%W;"X BR+8^IJMR";&Z_^ KU4<$A1
MD+<T=A0TM0VJK(T_F1C3 .6!E3K4R9)"9N2NF Q*,A<L\# 3$K"Q%16V*D=
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M39]/'0ECRVHHT\'N-)M1JZ'1P:[ 7D[F/A:!WOWE5EE0>%1PRVC]\=+C\$C
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MI5M,7(<97OR[55*DWN$O3R%625 C^$SU!K]TLK\/VW!R?A;K^2JA@ (%;.%
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MWS4[<6"VSK<''E/T!BXQTY_!P5O?4MNO"R>YOF967F=<*NE*F#HVXRQM2%I
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M:K,<&A2L[;]51C)IE,^V=K=>BH;DZY-4>P?WSZR$*PO7QK:SVWNEE4RPZ;%
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MA&_C$WPX";Z5O:XJBCS$2R7Y=CHK_1NL])=+6^D?3T_^U=\_C_9/CL]/3X[
M"->&^YM(F>6G?\I?=9;Y75KF+]?#,M<%8?M@'!1C:9,;;<=-M"NBQAK0)S%3
MT2R_ET5F3>"24HD>T4:#6.&OPLGE2S"_,6@PA=LDT\PJ'JI.42((K K$F76H
MO)I=$.6:'/<;F"(D&-S9X3V2#PNEK;+91"G9#%KQ$$$YP2J4#/BUR=!;*!V/
M=6-QN&<,_+E9QDS!0K@5! Y$DQID$TS>"QO+QL'-R)%Y'9@$E0U-G\3:BVQ
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M$[&-Q1:Y!7Y 5M*-*-2X4HGF$L<F9"A76)G+Y'42ON)1^374K56F%]@P,"7
M9CI.IU?P/#1@U+57%GDV@&MU'&UP@#PSU-I\VT7*D"VII3!4C7CDX51.7D(+
M/=(;0 S'AWB3XC.UAZG73($"2S[14;2KXJ;Q674N=?--2_!>F48!3&)'Y>CF
M@Q.E?B^32RQV(30#?(+V=DY-RP"KS>5D4&&%_XYE]QBD(&Z D:IF\"/VA\FU
M:KJAWQ1,-.:M@F_G1>YA.S?<RT'@X+VX9^YE1S=M-S_7$N(>B,!'YRRH5^F)
MRTB-4,'&FD&..I%5[1IK#>OD^#5%T,#2/]N$S;Q"OB2T797:G,+7S5T1!C13
MH5(EP/;C^6VW:_,*U?8<N#!-^\9>FLT -=C8!&YJF%(.Z-K-2>AO:8L6B[0(
MWF^:@7ITDMS7#!Y#MI"=HUJU*?K2LB@>KG8HJ:MH=IQ6T94S$GXECFV3X3WA
M,)_QKF<5S0.Z\59!='DZT;7<X!].F0Y[J DIU8<[1-:W([*>;7>(K Z1M<:(
MK-N*.Y%9-*A=G&[NDAH.&?K0N8>F@^02ZC;Q4 ]BBBJ@"?)U9HN"]$,HOZ1]
M2=O?Q)I!.K^)][.(_XDR)LV#I=T+$UY!@X*Z*M\@&2'I.JQQ4_^BWR78JDX-
M8EB 1:)LJFL@3JF09"N#_]9%-D[K2M '(F!JT!+/2JBOAQ@KD%K&$)XKT?W3
M_GII*GZXT)!,/M^K'6"P2=V>4.V8"^_1W%K\*E,7M]';=&N5J8M!['O?. ((
M5*4BMQSVAXB9X.TF/XKSOSEUKP<'T1B?6##YC\S%DJ/5G=5*5 =*$I6#1G=^
M]8]?LM\X[[;I>YB25I(H@!MWN9^6A+]Q!1L!/CAF8='*#CK!;9&$K$GHSJ.5
M.4YNH/VA?3/%I: Z$AB2(=X2-Y=H"?FW< 2#.&@$J47H%&4+K%2,#VWH +7E
ML=3XF$T=QL"$)$0598/B*+D@B"4POB!% 5N%L6LK2@,Q%B%E-$6KNM#T/\#U
M0RVH('$<N\4/NJ\7RAOTON+)&8/-K($]5  R:</G\'[I=M,8[] D2/S6-@DQ
M44(;KR# "7)$8+1D8;V*TAVX$FJUZ.VHPBDRK=0,=!NGRG93VP_&EO684$5:
MS GLC=-NVH09\#VH L>IT7H ;F)OIK)<Y$L,6#=\PCB2M$D'L'&V4;<K(TWZ
M3IUBB#VU+2H&F%R /*Y&GLBOED1C&:\YX:61 ^;R4N$&I^#6T:>D/0NT&S"
MA%G3/Z>@R0=0G <;,R353T>$[&&G!%"K.$?9.$;]-XE!+-D9;-;#,)TDU.P4
M@WAI13*B5\"35ZP"I*BBK0+T:3PTJ&G SD534&3.2C]?.3@#HE@3!81N<8FN
MOZ='R2'H'FW*T^:&5] Z8"X*$ V[,@^J@06F39/(LC!;LDDXO-[:?>DUT>J
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MW>SH;<66=WZT?S[$TDZ'6.H02P^.6/JY[L]GZW!_?A#<KVAL@BYU#.DK["R
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M@@9LI%$(6&X[*%)*I04"%AM396 83]WLCN9XY?Q/ G_/BJ%H/ZZ+\1:? #7
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MKQ+ ]2N!2L >K\A(XA[V!K)\@>]%;/TE4V"(8GYC5XG:AD9;(\2K4 !K/-?
M%^\%E7E#97 4PP=*&3X+9%FBC1J;CMR>SQ4;95.Z5)6B5Q^ M/#\O#".6/N"
MWUP5R"T@^@HGF'YGE1;<$+_PHI\8 (R%A<,AF^39:,YZ990R+DFX7<8YA(]
MG7GC U=).4$N.R*E%H4O2 8@$09C=(-C4XV=$83K!GQE]2\-PL12$-_ME.BJ
M0$'>;9[H9@,OA67A7-DCEA-N@_\SRZZ3<8JMI";P>J:6&8_32X-)(#KZ@MP,
M033S5<<I=JFATHBE)[9%>9)*(;9<"@1$Y0TT[K3D5L "&W,85YJH9*UIF!.J
M67F=,86BVM#,,G6DB7HN4U1EN= ?H8[7?G?U9.X>!4U*RQI%PM>2J$J!;1<Z
M&)20_<U%T5>0_5,\:7&R80LR"]V%>X<7[EH4$(78_H\3: 7?8R  )FC!5+P,
MX]F#W*&RZQ;PVMHF'WDR,3WM-=; 1 O#G0=0B2O%@CW^1J/L"_X66V@EW&A$
M*V-D\]#(<T 1EAEWYN#?(:H=?K?HG2XD!0N*&_7-#191@*F4?I&2K=C6F$V<
M_X*7@^I3'YUF S#-J>'H>*Q.B.E(VOY=6 PH-*J)D<C V*:S"W6(,Z+1TL%1
MI3<@82Y5,\.?O&TQB4&Z$:!^T30[T_DY79B@P[WZ[J)@**RWUD=8D^[R=W5V
M_%VJE;6H@]D'6R$MX;:N6D*;W(N'4\5#LO#LMZS1C;1P7!:C)#0;D4/H50.#
MF6^>9;ZFV_=(BT%_$6E_%R:JHQF>(ZQY+(L\&PB?N4X'5[E:L$ME-*=;EUMQ
M=)TET8%Z'RA+>_8J9;V-D_*VA[#U;!#:P8\W>HGH::)GS6;[35KK3LN%4L89
M0,WL(RQDTL&5.F;56UA>9R\"8>BZN*3.C8GI)^S$#&#EQE15KI3B@7#G1\D7
M1J^*20+H-!IE9-@J,UYS_!';*6^K&),'UO<0?ZC]K7VKX71Z$/RS61XA@SI@
MTNFDN]1):U$3M%_DHVQ(9"@>*"C8#454@IH*::C-,!+E@C*S' L/V$^#0A1=
MEA9NR2:IU)MI5JL., VO/NAV(AN(R<A7AQ0=G<[/:3HEW=+V7:QY&M3CN?L)
M>\#!C@&39PQVP^)'L>O)V!YP@0AV)!U!CMJX!1RC#*L=DS%0(5["?_#]6,*G
M1#_/N1=#-1O7"+P"WQ1UW\Z+-WE*B@UV3OO%3"@JNBTG3GFE7B5858#A1LD-
M_%/KB#!!VLK]S)?H9\)2M/=YPMY9U50--3-=I,!5IQWC0*^IF>&"TNNL&+L!
M+7 @+\MD>M7AJ[X'7_6LPU=U^*H.7[5:0V,M:M$.@->ZF$Z$Z<G7/MH<J[,L
M7^[^^!N^M1:0NK/9A3K\"$>[G?3!<#U4]"VP.;@]IVS.N1SG0K-WK?!E8ZJ&
MH-1$HTDD1VW :!/E?.)39-@FEC;&VJ!@:9&M!28@/,'M3HG&LD-(J)9 F6PP
M%TJAZ-F;7@WXKC&0X4PK+]]3:SKM!9RTX6)JIXS)XYJQP?+BAM'^VN6\X'6O
M=*AR'\KE\Z@'&1AJWA6P:+V8*!+_4-R"J@K'@YFUM0Z(B;&O,S]-IAUNB!1H
MGW1VQ2:J]Y!.M]RM;ED+ .$^Q5P&6G"4'E!N54U![Q.4OL,)N#=IH\%7*]L7
MJYE&-)F#<N3I#.2+;6]JGP\*B%;4$9_;9^DHL,D':U_1/@Y>1!H!#B9V@J@H
M69S!Z1PJB8N5\^5,/$'J[CA*Z\$6T]'#,0"ZSR\#$["&V3%+-]:+4J-=\W(H
M%@XJ4H,I8*YXFU2@3NRCD=(E%=.&991SM%.ZAI['&6>GJ9$ZY.W*C!I"^;GK
MQH+HP?Q.;*5^U=&"GL]*I7&W>"R;IF8!=&/ $(+T./IS0.Y HL.]!8AD!,BR
MYGZU^[+(@%/3K\"M>A=B%KMW&ZM8*3LM6:89<EU.)D!RQ&7B)B&>CD#/5W0E
M3:9 EHB[*,:C6=>0;(UVR0">;(/ZN,G6%B9F@PL;1=+V6W!'[]]2?-NFEP76
MZ(>)[,QYD0/7U/P IE!>F1MJ#4NAK9[*=?AEK*LG=7@FN1#M5$Y%G#R4W<L+
M&UX@KAHW,F0YB9O--)A)F%@[&_3!;73KIK<&%85?I7)-B%.*7L]O@W2"!) @
M4;V -A@BX\H+NXT$A3"\1A0=W%Q!HD]0\3<H^2B9Z-_=NLI[JK4U3%RH:=\>
M:LQ.I.J V2Z_3O,,5PQ_F1=S8ED9#!*PH,AP\^7&#WLY BBV#B$FS1RGZ2=@
M^5@EVH [3,*.'R4WF@"&ILT;#A)B5L"02)OL+&!/#$D+_/*RA%W(TTME%^C)
M0FQ?*?%(K3;G'EU*2N Y(TQ5;/M!,$6K,@*QF407SK]+PV@MRL>/B^C?.G89
ML'E<B*!N_F)J=_$XZ#85($$6?HI6B,MEU%)'3M5)5J42!XL3444MJR$XL4@P
MQ48\$1P61^6,](PZG=I+@/'C+67+8"\@9A@@L%2'K,:;E0!NL0=[0TR;47<&
MS&9A;_-V')OABG< ;0M+IN( >"V^%;U&W-+PW-C5_/[U8.K <$=,CS!GBRD;
MTAW[NSOV>VM1U+_O4C+!G@-U[PR87([ :@CH@@G2A3&"2..&L,,6<-# /R;J
M6M;0&S8;Y%OP,N&7W&2EH4%7HEP13Q];=\8H^$;CV<S @FK=&]PY]$P4V+BW
MPXB;#=(E^D?'<)OEYG#.\>Q>I>.AX"HGDB@D7DN':E"T3GCT2[1***)D*0?L
MW<N\6H3PT#3E7I!I2";[G-&D8\,0R"DZAR1]);FWGO*/!["[-O&VDO>^LJAL
M']WLZOMD+BI7;XF6+0A#<H0P]TB56(3,ST:T^!@Y]QL*;4S4VDAH)D456S]Z
M#T'L'(Q<WA_F&)I' O5FPM @,/5#Y\R,\RM MV9AN]OA#F^'M8C#GP/O%02W
M:+L_F,:*@5N!#I(.#[GJ)]#GK2PNRV12H?>:<^R;&C>"6_@9K9[:?3WV>0/$
MZ@ C#Q!.PIRO$W(3T0\=$8EU>#YTJ&/W#JB3SV[:/]'Q.GJF-R0#H2 (K5X>
M/,I +FK\)WWVV&LT!PYLT@*GRZWZ]+*Y20.'>M8;@WQM>9GDV=]FN6S5OON=
MIQH%@SCXNF8/#[W]S 9<SHC<E'>*KGTP2=.00?HK4L(!Q75)(1,#'+9<TU-(
MAZOOE=%U>@47@AI7-JTBY6Y"(TX)@GU##'&:?']HOF$"I&^8"BZ#Z-1$VZA,
ME)KE\!YH5: N>^AWB-4.-!5.CYC=\1=T4!2 -DK4;0OON-XT6X0[8S=5IUE,
M'$[FEQ(U;DA4AX= FP;/O][$6P"B3XB.I*>73U$$BQ+U-> C,(ZZ8? \%/EY
MJH8UW,1T50ZL>7!\[/C@"N%WIV^()>A:+9AZT3C[&]V!<?H%I1PFJ$Y -JJI
MU95YQFJK&'X^6,OS#M;2P5HZ6,MJ;:NUR$-2JO$,RE:5-N]-I[.2VS1@UXN0
MXQVL#4*[!K/IU" ;'LMI&[1V*'0_-!4S_4E:0C!X'KVG6Q>#]6B=:%I9#+RA
M8^*U I/AZI5B-E]L[6R1+Y=<4'JM=I->N@T9NRXVO6K[@_UZO_Y)Z,BPD$,/
MW_9F1*$-,0C4%F^OS*K/7N3?-#!:D%10!H0HQ4*3!M-0,LB'.0(= W21U]4,
MC.\L%=GIT.!'3>R%FN[FFX=;_]UO7G\45' *<K<^"SV<S-($P<>]M9:<5_W\
M.BL+;<#37QWTL1.!<AH!XK96EMP\D/Z&O\.$-F3Q&<'%(1'%X"*[+9YVP$R1
MGOI#;M/>IK\@ 0RVGKQ )Z40'!L#,ENY$Q>4=I@B(ZUVVT)[[,0Z* \!T5 (
MOZ$S=:!4X@,NQC,ELU<I1Z0@TSM%%\DMUKQ5?MEA0[$YP2>@.&J DWN_B$.A
M[Z6S>56GDTJ$-P$<D@[]\V0@5 3-FB98'YD ;9O.8>M&0X:J3CF7@;''D=I!
MC4<9X\TDRK35TWQ0G_&EK=*$7&M5N]UG\0JAZ^,!=_4Y[>JRZL>[UDYG8W8[
M3TU:Z[Z3L8MF\\+T4G80-:B[!/ZBEKU:^6Z!>@F6!/!A8[7C5 #'/80YP3_&
M9IU82"(-$8?P)M34)BA8(LV'51R(.R*J 25L=F#K$\ET"Z?54IHN9%CLI[&>
M%W,O2>$'H &$,Y30TXK/=\7G6[,@B-IGM*,H6D<ZYW,J2B3ER88EQ*9*L,QS
M?="QT)N3)(FN<))#<%0+]+]4;F5-_,K^\$RCCO79FF]Q !^%'[J&49(7792D
MBY(\IBC)(=)%'@-OX1_ 3GGR+@Y6&J(OSY@M%_$O:_FQVCIAQB6P 4=9"=D^
ML&4L,TV%?#4)^.R"8]ZOP<;%K:G+'9\?DD/(L"?3*OU5_T.N",R63PEL =?M
M.H<CF=6%>S;P-X[DTMF0<HM+#:-Y.D[FQ8R_).4RPDU04H!J0NUO;4X^CVB'
M1*T>&D$#SHY!,N;]4^+.3WS^WU(\>21:5(7$B0=#XF4T+FZTR.J?G]Z4R?17
M.N,W:@5O/7OF[[I)Z1LXAJL_A>*#ZH]?=2;Y?^OA<HN]]>I9M]ZK6^^]EUO/
MNP5?Y8)O;7<*9:4*9>=EM]ZK7._7.]UZKU2!/WO1+?@=+?@O=0FV(JZ\,FFK
M::*,R+TGM^["LU=;>Z^,=\:NX,[T2X0YJ4C[D.V[= _+HQG;*85U5_?3/0R4
MPLG-_W7&_96[\?SYFNT&4=N+O;@;48/#]L S^R9W?7VE\7NF\^U"^ICW\3LE
M>;637(3\/^L=1P>'_?<GT>'QV<?#TW[T+(Z.CO8!51'_XZ+\+0$2/>*F0@QC
M.K3U>9C=3?)Y)]^.?*_/[F9OLR*.#O,!@F3\_11-*!^I9'=J^-&(Z5UHVN\*
M6][#I-[.?XW"N["[Q"[LK9_]_$OU2_0OZ*4W2(">??#Y1SXRWQM&64>!>KF&
M G5:7$1'L_KO[HYYY >FNV,>X(ZY7PVW./-T#].!)@]?&9VA=,U:J;7NCGRX
M._)^I[,XDK\N!P+"WVMU(+H[_@<Y\-T=W]WQWSN=P[KRW)C'>,?W9O554:J_
M<1\J@.S^R">_N^K7\ERLW56_?Y6EH^B=J:\'L.5;S9QX H5O:=F9 8]<&?P4
M9D GCS_,=!YIK';EL=@/T($GC]Z6*9 1=\?BD1^+3DUW\OB8IM/Y$'<2+GS\
M3D1W#_U0Y[Z[ASIY?$S3Z>ZA+I9E8UEG0-549\"7&HY?_8*5M[IJ8DV$PPQ#
MD\OE19ZZ=?H+7_.MHX='_:C\"2\[_H2./^'!^!-< >6)/0CG8O]__7[X]O \
MVME2_^_I#J#'[X=/)CAEN9??,8V5<LVLY39^/.U_.#SKG]W?_BU!^?&]U]N]
M;0MJ_A>6IRB;7$95.?CG$S6\XNGN]N[N]NN][2_IEYWMX=[V]K.MOZ:7P+)1
M__/)>^A3G@V>^%>PP^^JM?_SUUMX R"QA]6GK/RWM_9 D3<4C%M2^NSEME*\
M-,Y5LIB]N!L:IP<P46X]9W>O2=;9W-G9;9@[#26_*F7X=*<SLSHS:WW,K 9C
MW1K87+LKM+G68_Y4+1[]<7+Z/Z.C_OEY__1!S19_4<Z!=8S9R/Z +A!':0U]
MN; [+[7ZQKXG:3G1'>4TH79$XNRT"7<Z#,/OLEQ]&)J6,'6R[-G)))-^G]>V
M(:G?IA7P5%.S6FYV EU,KLHB5SMV"0&:,7,G#X= (\K-F;*JFJ6F'VEHG+;-
MLAI5!>W;<^AE!ER4P%O)#X#FF=R&6'0"3@;U+!DO?*R>6P\;('.WULIT40_,
M%LB[==>LHM0TMC@';GUF">.XO1E3:4[2A!96[4]ZC>VG7,9<0S)'[)QM(U"_
M3>HZ&5P1)^<#J8\O5TH;UU)]X/ZJJ2P>/72;!$H\:#(;B^;32ZY]VWHW/_U5
MBQ]\PCV1FMZN$.6U]QV]''9>A?3K_31RX KPG2W2HG0?+^P!R-PI3%5]%AT>
M'YX?]HZB_9/CL_/33_OGAR?'ZI?1^>_]:"T\RQ^MY88ZN.O0<,/P;\+)D]TU
M1"/7BLDXL1.&Z$J+W,N-QI MC??\*R8V?>2INX+?] \O*'DO#M-J4&87T"62
M=(E1PZMIUHAO0P[\'>RYL:#[YBK&XVW<S'3S#/5"\!:S01+OL/XCF:K3Q) N
MBDJPBYO&"^H[PW2LUJ!TGVB[/":B30-VX+:M$:N9JTGP$+W<>@Y)AV9FZ<EO
M+__QB_K*;[Z$WD:SKD=R*%:@!ZU0N%.%:%%:T90&A9X0"K*V$.22OS%-4^/H
MJKA)U1>P@[FF4D\'T&2,FTK ;*+ZIHB@Z4;Z):O00"R+@GK]P;JK$4?0ZX%^
MJ78#^U0BN[]F^V=F^&%1E!4)G" .YU[)554,,B0,QXU',VUPE>27:65;H_#[
M@4\<CI5:8,LWKB:D#BATQ@AT13X_M MG#5-O9>RSN+TUM1Q(B*#WZ6"L!AEC
M<S6E3L?9YQ3ZON4I-,;%WBM*TT[4#$IET**A<5D4W/65^R_#PP;J6 P7=AJY
M;7Q^.\8+S?(^*&#C$OLTD.6L5O_8?18K*SBK)MD@AMG0P1AG(^!_'Z70PY[T
MVPPZ;RA1!2L'IF"6_$/_8Y0A>3MZ#:GRJ/-+Z"G_)8.V@4KCFXYZSG%"57J)
M+0#,IY1P8SM%^"K*1*1\[6;W4OAJ;Z*6<Y"P-CC(*M-D.^H-ZFACE8JK=]!S
MU!4K!U+R&[8[S#2IJ?]VF2@-JQLVH50VYL?-,;&]8+7YV"U';9*LT'+<7=IR
M9,_]\,/'TY-_]S_TC\\[N_!.6[&MAUVXZ,IL;<(&].S0+75,MRAT'!7?3\R5
MFU3<BZSZE1_3ATG-GY[DZK*&%J5PJ(_5**/?U8!+K,K[HK3_ ;"P*T6W\5^O
M=N+7+[:WMK<WHXU5FUX?DB_99#81-D1O4LR@_Z]5:['UQ=]E(S5T9UK.5)YO
MQ]NO:2K8$T9]<:+DWM@C(VKZ8BWA);K^K'Q-CM1@S-NEF>#H^H3[$JL/)G#B
MRNA_9UOI5JQ6)RO]_4>9L *@+*S<6;>]G?C52URW_Z^Y8 WW@1?M$'1X-GG
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MXL/W.GQXAP]_<'QXN\URF>9I20V&N?4R4ZI)* %ESM5'!W,W+"V5&R0R]5U
MMY=28D-J5@NE4%,E[,DEAS#&H/G4[X>4@)LDX)!S/V1UZ4U2R%<!P[ %?NHW
M'X;O,"\2&RQ[;F)J09$/,J3>A5&"+0I%9<K$9+P"H@0<)A6>ELL41Z1_>#M#
M*^DO4ZH(5F\@[K_HOW:VXVW)QDY%9"9 KMXH"A^9PR:?(SIV3D%6Z)F<VQ8A
M<#M[Y5F&7<O,7K<Y\"+;E&76J4ZX6HER4P):#-P8CRGA16!UU8OSU%\2;6;
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M8_IJ-,RI3P=]"E6!FM%E J0_8B_5AW0IV@1:;R3Z9L)U!)T!01[U'&7AS4;
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M1581Z2DR:I39 *J&RFB2 A0??\K3=%C%5FO(SO+2[ 0TWB7V_ZEO4BUHS;6
MSRXY3&S?-=1@'.IV$4L[$PM:-*#'KTY"[ 6\S1"W4K&25@]G5UCC H^F#5GQ
M[I'SJ&?',5:H^\C2\5!Z9CPP+&A?4MW$;:O/X1X-->%>5_X;F8'%ZSYG<&W+
MCR)0%0M7,:4?36IJ4% W-J:O1U8<,N4S79F(2*DO2I'_+4J>.#P)&Z,\CFR0
MJ06&I]Z 1%RG3K<!B2"I"FJZI.1?PK+0XV =K0&'S7[?2U5I%J5SA6+U%&EU
M&P#4!5L(_RG*/!4'JM%\*E@EL1#P@RN+JR#[$10<D.&>)V,-S)NDZJX$KADX
M-(0=R;E<0HC_<AGNDHY(.J[2FROV^J0KYI>$^B<P++J>IRLM'A28A>?VA@%(
M7WU((3HV!MS8;*H6\1(2Y@S_44\IKBDD-TPORJRRA>CF#? YWP'M:17"PW,0
MGFL6#[=#;.DRT1HA7VDHY!6.6L;EU\=(>/SYTX=H7.9%G$\='I] W L[[V&!
M/6)C/\#UDD=ORQ2U&'3#J[E>UJ,$"B536AIBMM2I*OL]5AY/G8TA&XI*N@G1
MUN83@IF1M8)K26NM3-@3,^UCDQ#27)M;PD%K'UIW!N[N##P$XU?C=F\_!6X'
M2GL./H))'+U38O;W QX"'6K][B-@<YC= 5CQ 7@0MB*T1;GK=55A2@9J3<*[
M+<\#$S.B#W$#2$:UDEC-,Z2<9IE"-B('MYG[A2%U -<0Y+/)!9&A:/HZKX:
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M9N"-$WO:"O2D^8=?P"4@'8*,/I->5J( J5OR"@O&'[T??O3#6R>A87V3:-@
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M;@ %:)]]),A3BUI)^=8ISM:N (\U%MF/#,W6W&L76^A22U'= NA(?,"W$[#
ME8=E;D7:'<?KTL1->(R"PD:Y_PGKH6":L#"0W@7#%M?$%D]6LL6IXWY'@=\@
M0@]\_*O 'P'5(D8+W6-OL-)M7.'?"NV,*(I3%Q0R']6\*1%N=!=JET4@;AVD
MI88R)96+-[<Q&IJ7H<L9-3]]&]&)<C>P*A&*  ^AIC#-[,I^GB<CI6= />^J
MGMVQM@HF0GKVI1:KJ ,][;!\TA1)7F7H8'/RF<R6M.-@F4!Z4A"CJZS@(&1]
M#+$NA9V\@II$XS.6X%IROI:V)J,Y?Q2R6QD8(>9U%\7?F5;Q([!W).0L10&!
MB_'1"8I!![@B2]$)*RT8"EPQG9(O!!A^YG)DHN2:7"?];3C26MO< PIXFMP#
MDWOP G(/7J".\GY>1T'NWL!F\IA[ET@'@#2YR \4>D,4.%KXBQ]C0'>*/K%<
M^?90PP%=E6-U%(PK!95D8+&H%FN_8,4IIJT_\EPMBB(69<U"MQ!*'EQ;%@\;
ME.WI^NCH$)X7B 8K3^@)2=A3*-7P2NR\X!QR(U2QT>TP;RT6/#Y%"5CPB*!)
M9;3L=5'PAP5Z4CGDAZXE,'<;UIV3C*UA=!<4+550CQQ 99948M#H,56^N&D6
M3]&K+_,LX BP3YS=B3[9I@+T&<$#T%D?P2. KPDCO$Z@$S?)AFC>YCDAY/^X
M@T<E$=!&7#398E3@R?_E:\\=[JU@L.$32/@ O:'A'$U1'A7,5K#WL@!]I;EK
M\-:/@G*@-<ZPG;;VP41Q*/"<<ER6]<LQQTCAWP1=_?&M0_;JG*^]D5NM:$8#
MQX"5BJ3H\' =@JPY ^L\ Q^;5OD0G/D)V([QC73R>AFR9="5$W$G?1(E!CL-
MLLF0_&&S)!5JT@29$$,*%DR0W7KHP%&1(Z!^Y'3D5I DV2CB62<+T)G2GAI^
M%I\_21\)4SF<$;1!W2 K\7SJVLH$J^XE6H9SE H59H*=.1E<CX$!@7$,<I?\
M&PY^XOGL 9:>9$-S:\L\VK\O]2@"CA9$#F<[T!RBJJ1'O0)]6O%W4!UB4.NL
MT/$#3JMQ8W&7$-N!7RAP(JD65092!I&C1Y&GK<AX=D=D&RN/'*CB8*V.' XD
ME/0+K7NH"(.BMX>E+?W&26\>\OAQ=(>\N\$BX6'W5[,)9;!/6>$J^0/6)>.&
ME,&HP[_2)(?UT^;).4Q^&32'X0 O3CLB\SM#IQ)R\2D%7.[@%.&Y<S%;#S82
M-"RD0 P(D?86LK12OL7 _\X"@%.=\"#F\25RBLI &[Z+#S./&G%"CM;<4@-F
M3! J DMER3!,"QF5Y,"00;KF?1$GXCMS\&=AG,4.!N !JD*@6^'6A_.0-XFA
M*YE$D6(I3:P:#IY[LF9[TBW!WK,T\V;X @$J!^]2[@4#J.A^$^2AT4>"WD?>
M-]8D7)[W4TT>*B0,\7LR (")8:V/G54S*5MYTLVMG),T<=PQ1N\M.AE>X<"2
M&,R*;O2<2DKI%7YX"P>4.5_UN>S?EZ\HJ)JCV'%EBAZ(N$1,X9S&B@?H&[0&
M)_,[D36I: $;8=)F\?A4+4S?I(C)"MO*D-NZR*V:*S;'J8F:8DXB\HFW5I#6
MJ,22*AY<,B]$#!I[""SJQD&K-RRP<C\<!<YD0OD'G$TT1#10#"S(?,RW'<.+
M0+=J%.T6)%%,G<&O)=\KI$YJ35$:$)3$::AF;513S46;HYI'N4J(QCBO N[R
M\*>Q<%(93W+\.$^YIN\JUJ^,6]4DY//L<%W-JEC$(1K,'UCQ@J,G4\[(Q";F
M,453+<2$P8PTXS#Z@>E;R ](R]8'>PF+R9_,F4_175EP\/O(8^;S.^G=J(#G
M^00C4)-0N<<74$: +U/%BZE5FC$MJUU!,N,T<]:+?=Q^Y%%8D^+E0ZY>XH\H
MHN,1.F3(13=7(9.2+T-:BCHK3_I;L"I!T!V2CV6YPV4"U[HZ[,3>T=CQ_*AA
M3<=1&-W$SG3<*%@A_&JP198JY>3L*87 \&64;-G(*RX 6]]G 1))H@.\F+8&
M!CW&',S)6]O)JP;NYQ V)-M))1;1$40J\\,BO9;E<RZ>Y<FAXHO0GY!G<NC'
M: 0X?V9.[&<3(F$=K$<Z0L)?$GG%N]V9&[!AR]1V*\"6"$P6^!J)HAJ/[T08
M!OA>RB+C3+&XH ?-,51T>/#U)6HH>IS)H$BCV&'W72$/I"'3D[P;25'*0>U/
M..NG46&PR(4FDPB-7^G#UJZ!3I0BS5*ZE4KV0C_U343:Y#7&V%%W (->VC)6
MX RQ0C2*9V^T,9^GK% *F>\"*R/_'Q@WB<I 5C*AM&5<NU(W1E'$T9-A+*@F
MTT6I@3X)X:"'!<=:1BYZKMGGIXJNANAYT6FS95-+N:(;VE>CU!8PGY&A^Y0N
M7QW+3.F]G#)!NC"8ZS'IP.APQ"*T+)2I4R[F4 4.>JG<R&-I":#$1\'?L:Z<
MC M5I>8\KNL\5B.7@R)M+0[EP.NSD8/.H,+Q67[:%/]UM&N'KY)$[8<N9<G#
MV9*>2:DEE*A<T]Z(-0+\L9]-T(VW5!\@#6A6T+W(QQ;%>=AFN0:&6?IA,:L'
M]##0;$1X@ZT.9U,AW0 RJQ\Q[Z0ZRT<G?R>@*K$J@QH90&DV]1-.!%= RZ%)
M?"9Q L%YUG]F*+Q")W8Q:,SJ6!H-\: IG0A3@+B"(J$%>J12J36H[X=./.37
MP[M\+##!L;93?4$H3SRQGR'\[&0E TC\F%)IU,_'C %L,J*&3CA*R\_SFRK\
M3%(+*Y8(%P=+T-%!RQPNEEFL.OY=NAOE@HZY,YM';@O<U[KQ.:$YQ&)-+OM*
M-U;K9?*<MI'G=&CRG$R>D\ESVJ*Z4$T3N2>61$55GN#ZJJD(\@2*HG]5QKTH
M/T+*]G]GWLVD(EX:K&JFT0_,PY5N$LIAQ3O0$9L)F13"TI/#F=E-HM(N\N(Q
M<D&P8X739E'4X ^EQ [9;P0>GRSIX6$TT;61UL>%[H(5Q;6Y?A%$:&"5G6^J
M3)C,"EDDCE5 GKAS@N_P9Q -AS[_G,68=(./2\A"\6-DRXUBQC^0=NH/LR"/
M>Y]B#5]HV>134-J<3G$:6<F$S5JELX$*ZV6R]8PR.&6I"=_$5FTAZ!X-.>K*
M&@\Y+QJ%]#G4D^'^B2RJ8A70X?8Q"RK;J\TK#.FNK6'!O3D<=PY8 DA.;AIC
MTN2LP2D#"P,$3.*Q8*LD3Y+D9DSE5$GDL:&L+@=; D/; DQ^+-HKF2CEBBD=
M556. WIE=1V<Q52DN%B,8L>7%;)8)C&9IK(?@^,AXE4').Q.9 AL?02VLC\1
M-W,AP0;<!;A>,B:<W8#=AV97P:=*[GQ_/H-H00Q2&=SR3@Y!:J>7#E_F7CML
MOY)?S\L81C]4&QZTZAQRK_HC5>TI'^'GQ8FAD^I6"6"QHX] NA\0;=03@;@;
MO8/]1/&LDM:3%V#"[F05*]:?T@-D/M \E."9?; -SWQQ VK(*= ",,S0=[0I
M/*<9! YU?=+>*NL&4[5"W72"7^@$Q:I:>F]#OY3]6MA70%^= W3B>+)@%B,;
MV<V89-KL#<HF9NQ*/)7=(UQ@)OV4I6+;I%1:J[K;2&^X.:YK.ZXKLQ**'?14
M_3$*A)$?BV*Q/6'XUG$SF;891W"\X'#,>4.7]8=2B@J3Y81];*@[N2;A:7VX
MKN82V-J@T6IKL6 #1"48'/]V0G2J(_.CU,.\@#ZCP(-RA99=;APM( ]?P2AR
M*/?=#\1<-:LL-J="P+F4T46OQ!MRBTK*<<D\X[P'1*4["A9!QM;>$'@DM<HC
MER+IZ.30Y#QWS>'5]2R$U#9>\SX>TH1D8=,00\_KHN<%72B<NY"Z(A5KXV5X
M+$<5J(..RYW@6#A+PL-DXOGF3(]*L-$%("X8:J!_8J07 .HQ%7M"9SICK&SA
M@C!&EE&LN5%,KG"Q!)OW@0OB' _.%.#<@ 6:4B%])Y>D&/W#WC)>[$SSV" *
M?*7SPZEUA1^0#]O_D1(?ETN:RZI.I@[F!3M!) .*0.6 VU3$\Z=/-I@:!1GV
M['-E!/$M+]RQ_LR<@,P-C%DTI+!G=1\P$T^0<Z38^2H86N0,S?.+T1#U;E56
MB^P6M*A6N2.; 984S)!</KFVF4.V@"(W4GZ<7/%,LI!1*9N(_%K%FC-$&BPL
M6IL^10$*3W.EYD:D*]O,D5H9:)U1$H:+XI3. V<:8]^N*O&KG?K5N+5/D%#M
M.BG5VK$HBUK"2 .P$J@J)D#HOXLN",,"U\8"YQ)7J($+J%?(<-!ND#E%.I%(
MIQ<U9*<;[HSJ8&>L4: : 7@8@Z0;M+VMJS&D[ZF0B%3@MAQ+)/LJF1/RI1@M
MT:8\44-5/Y=K'\6\":IZB](T$/3>V!5!X9U8'$+&6F[82;^:W*D?& -_C20W
MUZ:BT#.V:##H3FM%/;_"OOP0X\+*T*4&$*+83H)*6^B/"3(9[A 6F=S3]6-U
M45FX] K[2;$@<+X-351*@JO(MCFRH'0(*N4#M!9\%W*,<R=ZT^?WRE'.Y+M(
M!-5EP.WP_L)-%Q@Q!]D"@K,OM:-WQ_O'S9.\W3$7"RY]>NX283FG4SVD<U*&
M@;#]%_(_U0:,+_:Y["G)4+>G*A_5-(>+%6'IAD371J)S==^RR@K$"'8+=+^'
MT5T@O!N1+*PU(PT&-/,(1-0-.RJXBQA5H-UDJ!3+0K=<N%"74\SZFH#>0IJP
MBDT,0>T;^7.M#);E@"XZ&VKE29*1PXO[71?[=>E83:FQ8;%%M>X]4"K.)GL8
MK,^(VSQQ!1+[$(DG-W1#?]T[3)9%-J3'W%79V'[L<0$FZ82Z6A=38*EU+2D0
MJN>MKK'7T1WR U9;%<N>L7G2-6GA:=&*XF+C:,J=)\DT28KXTH@I@&912Z-"
M'I4J""XC802&&JD1$@L<%$Z^,PU1Q[6\P:1^J^S]WLA+(V6CR9O8F2AU6Q,@
M+Q_!9_)V=BQOY\CD[9B\G2?/VUDNU75+!I#H;BR871;X9"$LI:.M#4ZPQ/!3
M,,I"5Z6&HE7FQVXVP:8UK,PXH96%LM/"?RB?6LF#V;P;M,&.& [+XB*(A<O:
M0Y">7$^HQ6^B';CY\ =N(L$W4CM#=1N9BX5.%NBP"76E-3J+8LZ]U3&)&W2_
MI=3:4Z /)2 '#G;7IAYW+G#R&)-P%I?.Y[%LF>50F'<A!4(4EZ00<GZ4"R*
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MH JHR]6^RZINJ$"#ZS*P9A.KY,#Z"Z09[*!*-%'31U2]'K6C>V+$OM-X794
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M^F]M^(_.<*G= -KE2%V*Q&UK$,<X2K6H+:!B2"A@W0;6 N"_ >7.";\GUAY
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M%0! N%^5/==)+3&TM2[:JK;!DDX+13BJ/4^,9.,D+(4:2#-)!NPI95F"C9N
M457$"3P@KC@HX.( S+B011-VLL?B"[A5:Y0)EU9@QT$D8JDQ%\C16&/K+@2K
M-D*CL@^J_ 4ULLOM=\V!6Q>XWU>-7^#=$_AC#,"6O:#X',!ITEI!@U0WV_-\
M69+=4V58SHK;L?1J0EZ2ZIV%QA>.[UEW8ZSHR["/5QQE-^/=4CE(V;!0*$KK
M9Q% 2N!$N?E?.[5'HU:M_R1^6' 2<?:%7VC%IA0M$$%#4>@2,YQI3ZP5"I1B
M.#%#NCU$2,J8*AXL/2@_>0G02T+-5_ <ZZ?Y+'A]++$=.5D@92 1G"Z'!($I
M3W1CB8F8PNV!?RL;J<^HTXM+^]!OBL6-$[.EI]]5W%?AO8;FUD1S'RLTUXFP
MDR(6FR+:<HX\B:BKHD,UNEBWNW>T_]KRG!D7K7JWU#,'"2>,K$0 XT-*T\_P
M!$635:&J1NEBK5Y3I\'SVES<^U7FHAF*A\X:/%K1J*$:9\;8B@FPXR?< 56,
M!+7;!B4Y&HT2@<TBH[BA&$SAN,L(:9+73#<L-W#\2:(\/4,G\1/9M99^:>0U
MVU6^X=PX*#,UP1B"6!M!5(,>[9$*$%.( ?2'J50AJ/F7$Z<AH&;L3QN6P*X'
M>6,KH!,X\$0H5,#?2M)H.A6!=<I1*Y>\@=BG8>P$(R0[9=0!K0UGN4L_*1;R
M)TP5Q35Y&>A0JBT:.A84?:)] .SFSPQ#9CXW<O5 0JHV$<!3\FB:I<OU"[8E
MN2PHVX>UV"P=1SQ0)Y+;8^XFA=B*C>JG$Y2X!YKN7; ("K@U?MU_],J3R%#Z
MVBA]08PBYW%JU,!4A*QZ2(Y3Y48J:P*4)2?\'F?3%+LWQ(!96+P36X%SISGJ
M=4BBKH\3$C3;HWD)3X?5YX#(JI-Z4&[4P>=ID0#*3YKR3E)'#I^4%M)(T&P=
M"4 Q-D_GT19XD#&J'Q!N4=X!@> =V.0[PTF?>(6<^,,M1<C1B53D _O*$C$?
MT/!#-\B0T!K G5+2B[%Q64HG'P5A!'<M>Q]U0\M?QWEYR'4CX&&J2PZ%6'[X
M[GSSPZ(K32 3RX<9D?\,5D]N-723>=B03=]PR[VT-40MJ2I8-R*4_=H:\+XP
M&\%QRF*,W\7"22?D*<@PG@><,G80%4AW4<(=)3W=O2VBP2-U:EFRH^G#F*^X
MM<SA Y,Y;#*'GRQS^/[.6)HI-B1+1)[CA#<B1D9)/?T;A>E%."I1];OU@:$A
M4V.QCR)\&&5I,?9LZ5"TRFEC.>]X_W9<:C19^$&WNP+Y<^M'@:/B$WA'1>[
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M09,)<SR*DIBU)*;,.9&-[!FUE?;E)8 )I#0:;UI3H836\VL4_&< !'AP!UX
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MWWOQ6&EQJB;B/!O+].\!/X&_6A7QX.\'U%K'_Z>@(^BS5#_*39G$0Y@%3NV
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MQF.5AHJ\\BNJOZ+ZAWD1)V*/2?Y..]1OD4?#6@"7$T?OW%WT1P48,[CD1S$
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MOZH4[90+*<U3B4"!!N+MJ^%T!$.;DWJ*+5(.) SHTT"$QC)J!#?4@0PV_LF
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M> "T")2&VT39&<1)ZAS%A4(OA)649LO4.IY;UWI"BN-S78Z)(W150&^<#-"
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M,C R,C Y,S!X97@S,60Q+FAT;>U<;6_;.!+^*]P4NTT 6[+\DCBR&Z!-4UR
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M\X;;L>BOF89S$+Z6D'\;6UJ8*\2TU)MW0=(>,<"):B27!LA2@0(@ 3.N+;4
M*99;/5BU7)&2)K%Q92$ GBH/6(%'JR(]>)(#00%;M!0\L?? =!EIGG"J.$Z
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MLK.LRH7W79C .TU5\<>>N1>+'L"E, 64<5PJ!(-&OG6/UDQJ ^WX5!+HTK"
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MW7+;MA)^%=2=GM@SDBA*\D\HQS.)XTPSD[\FRISI)4B"(HY!@@5 R>K3GUV
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M-6(9>T +%\FT S#X+V0H"-0&VK-X2V6VL+91L!;^'+"V-IVY@F[K$Z&U00Z
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M&-OPYQW:Z#:,>:QCN\N+$+>NS?M&!4Q  38&Y)B2G&8,]_G8'QT-A\,W@_[
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MRJ. <+CK6#%-(-0*Z$SRN([TCWJ#4;.GN;*^Y;SN)T+L;XZ<_!]02P,$%
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M<$8*8W++R!(<D:I'X:H!_5A/2Y?H<\87$-89\334E#1JC+S;4\JJ)!P'C-0
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M(ZG\;D-_63+X!U!+ 0(4 Q0    ( "N+;E40S?K<_AD  %4_ 0 1
M      "  0    !I8FEO+3(P,C(P.3,P+GAS9%!+ 0(4 Q0    ( "N+;E4$
M#2WP9!,  ,4_ 0 5              "  2T:  !I8FEO+3(P,C(P.3,P7V-A
M;"YX;6Q02P$"% ,4    "  KBVY5?#$&<CXO  !2M ( %0
M@ '$+0  :6)I;RTR,#(R,#DS,%]D968N>&UL4$L! A0#%     @ *XMN54(.
MN;F@?0  '!T' !4              ( !-5T  &EB:6\M,C R,C Y,S!?;&%B
M+GAM;%!+ 0(4 Q0    ( "N+;E6F+0GL^%H  *HC!@ 5              "
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M,3!D,BYH=&U02P$"% ,4    "  KBVY5@EZ='Y:K 0"^S0P &
M    @ &]1P0 :6)I;RTR,#(R,#DS,'AE>#$P9#,N:'1M4$L! A0#%     @
M*XMN54$#'\[W+   ?CD! !@              ( !B?,% &EB:6\M,C R,C Y
M,S!X97@Q,&0T+FAT;5!+ 0(4 Q0    ( "N+;E7\-W )N@D  %9&   8
M          "  ;8@!@!I8FEO+3(P,C(P.3,P>&5X,S%D,2YH=&U02P$"% ,4
M    "  KBVY56+%:P7D)  !(10  &               @ &F*@8 :6)I;RTR
M,#(R,#DS,'AE>#,Q9#(N:'1M4$L! A0#%     @ *XMN5>AY([JD!0  'B(
M !@              ( !530& &EB:6\M,C R,C Y,S!X97@S,F0Q+FAT;5!+
M 0(4 Q0    ( "N+;E56E.@$R 4   $:   8              "  2\Z!@!I
M8FEO+3(P,C(P.3,P>&5X,S)D,BYH=&U02P4&      X #@"^ P  +4 &

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
